PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	GOODWIN, SR; FRIEDMAN, WA; BELLEFLEUR, M				GOODWIN, SR; FRIEDMAN, WA; BELLEFLEUR, M			IS IT TIME TO USE EVOKED-POTENTIALS TO PREDICT OUTCOME IN COMATOSE CHILDREN AND ADULTS	CRITICAL CARE MEDICINE			English	Article						ANOXIA; COMA; DROWNING; ENCEPHALITIS; TRAUMA; EVOKED POTENTIALS; HEAD INJURY; MORTALITY; VEGETATIVE; PATIENT OUTCOME ASSESSMENT; PEDIATRICS; NEUROLOGY	AUDITORY BRAIN-STEM; SEVERE HEAD-INJURY; PROGNOSTIC UTILITY; TRAUMATIC COMA; RESPONSES; DEATH; LATENCY; PRESSURE; DAMAGE; SEPS	Objective: To determine the value of multimodality-evoked potential recordings in predicting outcome in comatose children. Design: Prospective series and literature review. Setting: Pediatric ICU in a university hospital. Patients: Forty-one children with a Glasgow Coma Scale score of < 8, who were admitted to the pediatric ICU between 1984 and 1989. Interventions: Forty-one patients underwent brainstem auditory-evoked potential testing within 72 hrs of admission. Of these patients, 37 also had somatosensory-evoked potential testing at the same time. Four patients did not receive somatosensory-evoked potential testing for various nonmedical reasons. Measurements and Main Results: Multimodality-evoked potential recordings were used to predict outcome in these comatose children. Outcomes were categorized as bad (death or chronic vegetative state) or good (all other outcomes). Survivor outcomes were determined at discharge and on subsequent follow-up visits from 1 to 3 yrs later. There were no false pessimistic predictions, and two false optimistic predictions in this series. A comprehensive literature review of coma outcome prediction, using multimodality-evoked potential recordings, revealed 20 series with 982 additional patients in whom the predictive errors of false optimism and false pessimism could be determined. Five cases of false pessimism and 99 cases of false optimism were identified in the 982 additional patients. If neonates are excluded, the false pessimism number is reduced to three. Conclusions: A bad outcome can be reliably predicted using multimodality-evoked potential recordings with little chance of a false pessimistic prediction. The acceptable error of false optimism occurs frequently, since patients often die of progressive neurologic and nonneurologic problems that may or may not be present at the time of the evoked potential recordings. Thus, in comatose children, multimodality-evoked potential recordings are a useful adjunct to clinical examination and other diagnostic aids in predicting outcome and in making decisions regarding the degree of intervention to offer.	UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32611; UNIV FLORIDA,COLL MED,DEPT NEUROSURG,GAINESVILLE,FL 32611	GOODWIN, SR (corresponding author), UNIV FLORIDA,COLL MED,DEPT ANESTHESIOL,GAINESVILLE,FL 32611, USA.						AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ALLMAN FD, 1986, AM J DIS CHILD, V40, P571; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; ASHWAL S, 1987, PEDIATR NEUROL, V3, P69, DOI 10.1016/0887-8994(87)90030-0; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DEAR PRF, 1985, ARCH DIS CHILD, V60, P17, DOI 10.1136/adc.60.1.17; DELATORRE JC, 1978, EXP NEUROL, V60, P304, DOI 10.1016/0014-4886(78)90085-7; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; EDGREN E, 1983, CRIT CARE MED, V11, P4, DOI 10.1097/00003246-198301000-00002; ELWANY S, 1988, J LARYNGOL OTOL, V102, P755, DOI 10.1017/S0022215100106383; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; FRANK LM, 1985, NEUROLOGY, V35, P931, DOI 10.1212/WNL.35.6.931; Friedman W A, 1988, Clin Neurosurg, V34, P187; FRIEDMAN WA, 1985, J NEUROSURG, V62, P552, DOI 10.3171/jns.1985.62.4.0552; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HANSOTIA P, 1981, NEUROLOGY, V31, P83, DOI 10.1212/WNL.31.1.83; HUME AL, 1979, ANN NEUROL, V5, P379, DOI 10.1002/ana.410050412; JAIN S, 1984, ACTA NEUROL SCAND, V69, P163, DOI 10.1111/j.1600-0404.1984.tb07795.x; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JOHNSTON B, 1984, ACTA NEUROL SCAND, V69, P417, DOI 10.1111/j.1600-0404.1984.tb07825.x; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KAGA K, 1985, ANN NEUROL, V18, P360, DOI 10.1002/ana.410180318; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KASTE M, 1981, J NEUROSURG, V55, P511, DOI 10.3171/jns.1981.55.4.0511; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MARSH RR, 1984, OTOLARYNG HEAD NECK, V92, P685, DOI 10.1177/019459988409200616; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARA T, 1988, AM J DIS CHILD, V142, P173, DOI 10.1001/archpedi.1988.02150020075032; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATALONI S, 1988, RESUSCITATION, V16, P127, DOI 10.1016/0300-9572(88)90077-9; NEWLON PG, 1983, NEUROSURGERY, V12, P613, DOI 10.1227/00006123-198306000-00003; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; STARR A, 1976, BRAIN, V99, P543, DOI 10.1093/brain/99.3.543; STEINHART CM, 1985, CRIT CARE MED, V13, P560, DOI 10.1097/00003246-198507000-00010; STOCKARD JJ, 1978, ANN NEUROL, V3, P368, DOI 10.1002/ana.410030416; TAYLOR MJ, 1983, NEW ENGL J MED, V309, P1169, DOI 10.1056/NEJM198311103091908; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; TSUBOKAWA T, 1980, J NEUROL NEUROSUR PS, V43, P1005, DOI 10.1136/jnnp.43.11.1005; VAPALAHTI M, 1986, ANN CLIN RES, V18, P37; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	50	55	55	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	1991	19	4					518	524		10.1097/00003246-199104000-00011			7	Critical Care Medicine	General & Internal Medicine	FH611	WOS:A1991FH61100011	2019138				2021-06-18	
J	LEVIN, HS; WILLIAMS, DH; VALASTRO, M; EISENBERG, HM; CROFFORD, MJ; HANDEL, SF				LEVIN, HS; WILLIAMS, DH; VALASTRO, M; EISENBERG, HM; CROFFORD, MJ; HANDEL, SF			CORPUS CALLOSAL ATROPHY FOLLOWING CLOSED HEAD-INJURY - DETECTION WITH MAGNETIC-RESONANCE-IMAGING	JOURNAL OF NEUROSURGERY			English	Article									LA GUARDIA HOSP,DEPT RADIOL,FOREST HILLS,NY; NMR ASSOCIATES,HOUSTON,TX	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BYNE W, 1988, BEHAV NEUROSCI, V102, P222, DOI 10.1037/0735-7044.102.2.222; DELACOSTE MC, 1988, BRAIN BEHAV EVOLUT, V31, P318, DOI 10.1159/000116598; DELACOSTEUTAMSING C, 1982, SCIENCE, V216, P1431, DOI 10.1126/science.7089533; DIETEMANN JL, 1988, NEURORADIOLOGY, V30, P478, DOI 10.1007/BF00339686; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LHERMITTE J, 1929, REV NEUROL, V37, P703; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; REINARZ SJ, 1988, AM J ROENTGENOL, V151, P791, DOI 10.2214/ajr.151.4.791; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SCHOTT B, 1969, REV NEUROL-FRANCE, V120, P359; SIMON JH, 1987, AM J NEURORADIOL, V8, P599; SIMON JH, 1986, RADIOLOGY, V160, P363, DOI 10.1148/radiology.160.2.3726114; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, PATHOLOGY TRAUMA, P166; TEASDALE G, 1974, LANCET, V2, P81	19	55	55	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1990	73	1					77	81		10.3171/jns.1990.73.1.0077			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DL088	WOS:A1990DL08800012	2352026				2021-06-18	
J	SHUM, DHK; MCFARLAND, K; BAIN, JD; HUMPHREYS, MS				SHUM, DHK; MCFARLAND, K; BAIN, JD; HUMPHREYS, MS			EFFECTS OF CLOSED-HEAD INJURY ON ATTENTIONAL PROCESSES - AN INFORMATION-PROCESSING STAGE ANALYSIS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV QUEENSLAND,DEPT PSYCHOL,ST LUCIA,QLD 4067,AUSTRALIA			Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			BENYISHAY Y, 1983, REHABILITATION HEAD, P167; BOND MR, 1983, REHABILITATION HEAD, P97; Brooks N., 1984, CLOSED HEAD INJURY P; DODD DH, 1973, PSYCHOL BULL, V79, P391, DOI 10.1037/h0034347; FROWEIN HW, 1981, ACTA PSYCHOL, V47, P105, DOI 10.1016/0001-6918(81)90002-0; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Keppel G., 1982, DESIGN ANAL RES HDB, V2nd; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Meier M. J., 1987, NEUROPSYCHOLOGICAL R; Miller E, 1970, Cortex, V6, P121; MULDER G, 1983, J CHILD PSYCHOL PSYC, V24, P19, DOI 10.1111/j.1469-7610.1983.tb00100.x; NETTLEBECK T, 1981, INT REV RES MENT RET, P61; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; SANDERS AF, 1982, ACTA PSYCHOL, V51, P41, DOI 10.1016/0001-6918(82)90018-X; SANDERS AF, 1980, TUTORIALS MOTOR BEHA, P331, DOI DOI 10.1016/S0166-4115(08)61955-X; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Tabachnick BG, 1983, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452	25	55	55	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1990	12	2					247	264		10.1080/01688639008400971			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DB328	WOS:A1990DB32800006	2341554				2021-06-18	
J	CICERONE, KD; WOOD, JC				CICERONE, KD; WOOD, JC			PLANNING DISORDER AFTER CLOSED HEAD-INJURY - A CASE-STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article										CICERONE, KD (corresponding author), ROBERT WOOD JOHNSON JR LIFESTYLE INST,DEPT COGNIT REHABIL,EDISON,NJ 08820, USA.						AYRES AJ, 1980, SO CALIFORNIA SENSOR; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; HEPPNER PP, 1983, INNOVATIONS CLIN PRA, V2, P73; HUMPHREY LL, 1982, J CONSULT CLIN PSYCH, V50, P624, DOI 10.1037/0022-006X.50.5.624; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kazdin A. E., 1982, SINGLE CASE RES DESI; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Luria A.R., 1981, LANGUAGE COGNITION; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; Meichebaum D., 1979, COGNITIVE BEHAVIORAL, P11; MEICHENBAUM D, 1980, HELPING PEOPLE CHANG, P390; MEICHENBAUM DH, 1971, J ABNORM PSYCHOL, V77, P115, DOI 10.1037/h0030773; Miller GA., 1960, PLANS STRUCTURE BEHA; ODDY M, 1984, CLOSED HEAD INJURY P, P108; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; ZIHL J, 1979, J NEUROL NEUROSUR PS, V42, P312, DOI 10.1136/jnnp.42.4.312	19	55	55	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1987	68	2					111	115					5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	G0247	WOS:A1987G024700009	3813856				2021-06-18	
J	Tiedt, S; Duering, M; Barro, C; Kaya, AG; Boeck, J; Bode, FJ; Klein, M; Dorn, F; Gesierich, B; Kellert, L; Ertl-Wagner, B; Goertler, MW; Petzold, GC; Kuhle, J; Wollenweber, FA; Peters, N; Dichgans, M				Tiedt, Steffen; Duering, Marco; Barro, Christian; Kaya, Asli Gizem; Boeck, Julia; Bode, Felix J.; Klein, Matthias; Dorn, Franziska; Gesierich, Benno; Kellert, Lars; Ertl-Wagner, Birgit; Goertler, Michael W.; Petzold, Gabor C.; Kuhle, Jens; Wollenweber, Frank A.; Peters, Nils; Dichgans, Martin			Serum neurofilament light A biomarker of neuroaxonal injury after ischemic stroke	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INFARCT VOLUME; MARKER; REMOTE; BLOOD; DIAGNOSIS; LESION; CHAIN; NEURODEGENERATION; RECURRENCE	Objective To explore the utility of serum neurofilament light chain (NfL) as a biomarker for primary and secondary neuroaxonal injury after ischemic stroke (IS) and study its value for the prediction of clinical outcome. Methods We used an ultrasensitive single-molecule array assay to measure serum NfL levels in healthy controls (n = 30) and 2 independent cohorts of patients with IS: (1) with serial serum sampling at hospital arrival (n = 196), at days 2, 3, and 7 (n = 89), and up to 6 months post stroke; and (2) with standardized MRI at baseline and at 6 months post stroke, and with cross-sectional serum sampling at 6 months (n = 95). We determined the temporal profile of serum NfL levels, their association with imaging markers of neuroaxonal injury, and with clinical outcome. Results Patients with IS had higher serum NfL levels compared with healthy controls starting from admission until 6 months post stroke. Serum NfL levels peaked at day 7 (211.2 pg/mL [104.7-442.6], median [IQR]) and correlated with infarct volumes (day 7: partial r = 0.736, p = 1.5 x 10(-15)). Six months post stroke, patients with recurrent ischemic lesions on MRI (n = 19) had higher serum NfL levels compared to those without new lesions (n = 76, p = 0.002). Serum NfL levels 6 months post stroke further correlated with a quantitative measure of secondary neurodegeneration obtained from diffusion tensor imaging MRI (r = 0.361, p = 0.001). Serum NfL levels 7 days post stroke independently predicted modified Rankin Scale scores 3 months post stroke (cumulative odds ratio [95% confidence interval] = 2.35 [1.60-3.45]; p = 1.24 x 10(-05)). Conclusion Serum NfL holds promise as a biomarker for monitoring primary and secondary neuroaxonal injury after IS and for predicting functional outcome.	[Tiedt, Steffen; Duering, Marco; Kaya, Asli Gizem; Boeck, Julia; Gesierich, Benno; Wollenweber, Frank A.; Dichgans, Martin] Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Univ Hosp, Munich, Germany; [Tiedt, Steffen] Ludwig Maximilians Univ Munchen, Grad Sch Syst Neurosci, Munich, Germany; [Tiedt, Steffen; Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Med, Univ Hosp Basel, Basel, Switzerland; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Biomed, Univ Hosp Basel, Basel, Switzerland; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Clin Res, Univ Hosp Basel, Basel, Switzerland; [Bode, Felix J.; Petzold, Gabor C.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Bode, Felix J.; Petzold, Gabor C.] Univ Hosp Bonn, Dept Neurol, Bonn, Germany; [Klein, Matthias; Kellert, Lars] Ludwig Maximilians Univ Munchen, Dept Neurol, Univ Hosp, Munich, Germany; [Dorn, Franziska] Ludwig Maximilians Univ Munchen, Dept Neuroradiol, Univ Hosp, Munich, Germany; [Ertl-Wagner, Birgit] Ludwig Maximilians Univ Munchen, Dept Radiol, Univ Hosp, Munich, Germany; [Goertler, Michael W.] Univ Magdeburg, Univ Hosp, Dept Neurol, Magdeburg, Germany; [Goertler, Michael W.] German Ctr Neurodegenerat Dis DZNE, Magdeburg, Germany; [Peters, Nils] Univ Hosp Basel, Stroke Ctr, Basel, Switzerland; [Peters, Nils] Univ Hosp Basel, Dept Neurol, Basel, Switzerland; [Dichgans, Martin] German Ctr Neurodegenerat Dis DZNE, Munich, Germany	Dichgans, M (corresponding author), Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Univ Hosp, Munich, Germany.; Dichgans, M (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.; Dichgans, M (corresponding author), German Ctr Neurodegenerat Dis DZNE, Munich, Germany.	martin.dichgans@med.uni-muenchen.de	Klein, Matthias/F-4118-2017; Duering, Marco/AAE-6949-2021; Dorn, Franziska/AAA-7754-2020; Barro, Christian/AAO-3567-2021; Ertl-Wagner, Birgit/AAD-5708-2020	Klein, Matthias/0000-0001-9064-6865; Dorn, Franziska/0000-0001-9093-8307; Barro, Christian/0000-0002-7795-7383; Ertl-Wagner, Birgit/0000-0002-7896-7049; Wollenweber, Frank Arne/0000-0002-9375-405X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC 1123]; German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF); European UnionEuropean Commission [66688, 667375, Health-F2-2013-601456]; Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain)Leducq Foundation; Vascular Dementia Research Foundation; Jackstaedt Foundation; Josef-Hackl-Stiftung; Swiss National Research FoundationSwiss National Science Foundation (SNSF) [320030_160221]; Alzheimer Forschung Initiative e.V. [16018CB]; German Research FoundationGerman Research Foundation (DFG) [DFG DU1626/1-1]; Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology [SyNergy]); Neurology Research Pool (University Hospital Basel)	M. Dichgans was supported by grants from the Deutsche Forschungsgemeinschaft (CRC 1123 [B3] and Munich Cluster for Systems Neurology [SyNergy]), the German Federal Ministry of Education and Research (BMBF, e:Med programme e: AtheroSysMed), the FP7/2007-2103 European Union project CVgenes@target (grant agreement no. Health-F2-2013-601456), the European Union Horizon2020 projects SVDs@target (grant agreement no. 66688) and CoSTREAM (grant agreement no. 667375), the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain), the Vascular Dementia Research Foundation, and the Jackstaedt Foundation. S.T. was supported by the Josef-Hackl-Stiftung and by a grant from the Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology [SyNergy]). J.K. was supported by the Swiss National Research Foundation (320030_160221). N.P. was supported by the Neurology Research Pool (University Hospital Basel). M. Duering was supported by grants from the Alzheimer Forschung Initiative e.V. (#16018CB) and the German Research Foundation (DFG DU1626/1-1).	Ahmad O, 2012, CEREBROVASC DIS, V33, P47, DOI 10.1159/000332810; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Baird AE, 2001, LANCET, V357, P2095, DOI 10.1016/S0140-6736(00)05183-7; Baykara E, 2016, ANN NEUROL, V80, P581, DOI 10.1002/ana.24758; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Christensen R.H.B., 2015, Ordinal-Regression Models for Ordinal Data. R package version 2015., P6; Conklin J, 2014, ANN NEUROL, V76, P899, DOI 10.1002/ana.24285; De Marchis GM, 2018, EUR J NEUROL, V25, P562, DOI 10.1111/ene.13554; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Duering M, 2017, BRAIN, V140, P1818, DOI 10.1093/brain/awx135; Duering M, 2015, NEUROLOGY, V84, P1685, DOI 10.1212/WNL.0000000000001502; Duering M, 2012, NEUROLOGY, V79, P2025, DOI 10.1212/WNL.0b013e3182749f39; Eastwood JD, 2003, AM J NEURORADIOL, V24, P680; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Gattringer T, 2017, NEUROLOGY, V89, P2108, DOI 10.1212/WNL.0000000000004645; Hansson O, 2017, NEUROLOGY, V88, P930, DOI 10.1212/WNL.0000000000003680; Hopyan J, 2010, RADIOLOGY, V255, P142, DOI 10.1148/radiol.09091021; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kang DW, 2009, STROKE, V40, P1653, DOI 10.1161/STROKEAHA.108.539429; Kang DW, 2003, ANN NEUROL, V54, P66, DOI 10.1002/ana.10592; Kang DW, 2004, NEUROLOGY, V63, P2261, DOI 10.1212/01.WNL.0000147295.50029.67; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kellner E, 2016, MAGN RESON MED, V76, P1574, DOI 10.1002/mrm.26054; Kluge MG, 2017, GLIA, V65, P1885, DOI 10.1002/glia.23201; Kuchcinski G, 2017, BRAIN, V140, P1932, DOI 10.1093/brain/awx114; Kuhle J, 2017, NEUROLOGY, V88, P826, DOI 10.1212/WNL.0000000000003653; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; R Core Team, 2017, R LANG ENV STAT COMP; Rost NS, 2012, STROKE, V43, P441, DOI 10.1161/STROKEAHA.111.629212; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schulz UGR, 2007, J NEUROL, V254, P375, DOI 10.1007/s00415-006-0381-y; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Singh P, 2011, J NEUROL SCI, V304, P117, DOI 10.1016/j.jns.2011.01.025; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steinacker P, 2017, NEUROLOGY, V88, P961, DOI 10.1212/WNL.0000000000003688; Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307; Tiedt S, 2017, CIRC RES, V121, P970, DOI 10.1161/CIRCRESAHA.117.311572; Traenka C, 2015, CEREBROVASC DIS, V40, P222, DOI 10.1159/000440774; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Vogt G, 2012, STROKE, V43, P1266, DOI 10.1161/STROKEAHA.111.646570; Winbeck K, 2002, STROKE, V33, P2459, DOI 10.1161/01.STR.0000029828.51413.82; Wollenweber FA, 2014, INT J STROKE, V9, P387, DOI 10.1111/ijs.12092; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang J, 2012, STROKE, V43, P1700, DOI 10.1161/STROKEAHA.111.632448; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zhang ZX, 2002, J COMP NEUROL, V450, P144, DOI 10.1002/cne.10306	50	54	55	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 2	2018	91	14					E1338	E1347		10.1212/WNL.0000000000006282			10	Clinical Neurology	Neurosciences & Neurology	HD4LD	WOS:000452498100008	30217937	Green Published			2021-06-18	
J	Johnson, VE; Weber, MT; Xiao, R; Cullen, DK; Meaney, DF; Stewart, W; Smith, DH				Johnson, Victoria E.; Weber, Maura T.; Xiao, Rui; Cullen, D. Kacy; Meaney, David F.; Stewart, William; Smith, Douglas H.			Mechanical disruption of the blood-brain barrier following experimental concussion	ACTA NEUROPATHOLOGICA			English	Article						Mild traumatic brain injury; Concussion; Blood-brain barrier; Fibrinogen; Gliosis; Biomechanics	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CHRONIC TRAUMATIC ENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; WHITE-MATTER INJURY; ICE HOCKEY PLAYERS; MULTIPLE-SCLEROSIS; IMMUNOHISTOCHEMICAL LOCALIZATION; CORTICAL CONTUSION	Although concussion is now recognized as a major health issue, its non-lethal nature has limited characterization of the underlying pathophysiology. In particular, potential neuropathological changes have typically been inferred from non-invasive techniques or post-mortem examinations of severe traumatic brain injury (TBI). Here, we used a swine model of head rotational acceleration based on human concussion to examine blood-brain barrier (BBB) integrity after injury in association with diffuse axonal injury and glial responses. We then determined the potential clinical relevance of the swine concussion findings through comparisons with pathological changes in human severe TBI, where post-mortem examinations are possible. At 6-72 h post-injury in swine, we observed multifocal disruption of the BBB, demonstrated by extravasation of serum proteins, fibrinogen and immunoglobulin-G, in the absence of hemorrhage or other focal pathology. BBB disruption was observed in a stereotyped distribution consistent with biomechanical insult. Specifically, extravasated serum proteins were frequently observed at interfaces between regions of tissue with differing material properties, including the gray-white boundary, periventricular and subpial regions. In addition, there was substantial overlap of BBB disruption with regions of axonal pathology in the white matter. Acute perivascular cellular uptake of blood-borne proteins was observed to be prominent in astrocytes (GFAP-positive) and neurons (MAP-2-positive), but not microglia (IBA1-positive). Parallel examination of human severe TBI revealed similar patterns of serum extravasation and glial uptake of serum proteins, but to a much greater extent than in the swine model, attributed to the higher injury severity. These data suggest that BBB disruption represents a new and important pathological feature of concussion.	[Johnson, Victoria E.; Weber, Maura T.; Cullen, D. Kacy; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA; [Xiao, Rui] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Cullen, D. Kacy; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19103 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland; [Cullen, D. Kacy] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@pennmedicine.upenn.edu		Meaney, David/0000-0002-0954-4122; Stewart, William/0000-0003-2199-2582	Department of DefenseUnited States Department of Defense [W81XWH-13-1-0052]; National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS038104]; Department of Veterans AffairsUS Department of Veterans Affairs [I01RX001097]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS038104, R01NS092398] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001097] Funding Source: NIH RePORTER	The authors thank Kathryn Wofford for assistant with kinematic measurements. Research reported in this publication was supported by the Department of Defense Grant W81XWH-13-1-0052, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R01NS092398, R01NS094003 and R01NS038104, and the Department of Veterans Affairs under Merit Review number I01RX001097.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams RA, 2004, MOL INTERV, V4, P163; Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Alvarez JI, 2015, NEUROBIOL DIS, V74, P14, DOI 10.1016/j.nbd.2014.09.016; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bridges LR, 2014, J NEUROPATH EXP NEUR, V73, P1026, DOI 10.1097/NEN.0000000000000124; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Graham D.I., 2002, GREENFIELDS NEUROPAT; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hsiao TW, 2013, ACTA BIOMATER, V9, P7200, DOI 10.1016/j.actbio.2013.02.047; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P270, DOI 10.1093/jnen/nlx007; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; KWON EE, 1994, J NEUROPATH EXP NEUR, V53, P625, DOI 10.1097/00005072-199411000-00010; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LIU HM, 1989, ACTA NEUROPATHOL, V78, P16, DOI 10.1007/BF00687397; Liu JYW, 2012, BRAIN, V135, P3115, DOI 10.1093/brain/aws147; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Patton DA, 2015, J APPL BIOMECH, V31, P264, DOI 10.1123/jab.2014-0223; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryu JK, 2009, J CELL MOL MED, V13, P2911, DOI 10.1111/j.1582-4934.2008.00434.x; Ryu JK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9164; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shreiber D. I, 1997, 973335 SAE, DOI [10.4271/973335, DOI 10.4271/973335]; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; STRICH SJ, 1961, LANCET, V2, P443; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Tomimoto H, 1996, STROKE, V27, P2069, DOI 10.1161/01.STR.27.11.2069; Veksler R, 2014, ARCH MED RES, V45, P646, DOI 10.1016/j.arcmed.2014.11.016; Viggars AP, 2011, NEUROSCI LETT, V505, P25, DOI 10.1016/j.neulet.2011.09.049; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830	95	54	54	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2018	135	5					711	726		10.1007/s00401-018-1824-0			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	GD1VF	WOS:000430288700005	29460006	Green Accepted			2021-06-18	
J	Cai, W; Yang, T; Liu, H; Han, LJ; Zhang, K; Hu, XM; Zhang, XJ; Yin, KJ; Gao, YQ; Bennett, MVL; Leak, RK; Chen, J				Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Gao, Yanqin; Bennett, Michael V. L.; Leak, Rehana K.; Chen, Jun			Peroxisome proliferator-activated receptor gamma (PPAR gamma): A master gatekeeper in CNS injury and repair	PROGRESS IN NEUROBIOLOGY			English	Article						Thiazolidinedione; Nrf2; Stroke; Traumatic brain injury; Inflammation; Remyelination	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; INSULIN-RESISTANCE INTERVENTION; PIOGLITAZONE CLINICAL-TRIAL; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; ADULT HIPPOCAMPAL NEUROGENESIS; VASCULAR COGNITIVE IMPAIRMENT; TYPE-2 DIABETES-MELLITUS; OBSERVATIONAL FOLLOW-UP	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a widely expressed ligand-modulated transcription factor that governs the expression of genes involved in inflammation, redox equilibrium, trophic factor production, insulin sensitivity, and the metabolism of lipids and glucose. Synthetic PPAR gamma agonists (e.g. thiazolidinediones) are used to treat Type II diabetes and have the potential to limit the risk of developing brain injuries such as stroke by mitigating the influence of comorbidities. If brain injury develops, PPAR gamma serves as a master gatekeeper of cytoprotective stress responses, improving the chances of cellular survival and recovery of homeostatic equilibrium. In the acute injury phase, PPAR gamma directly restricts tissue damage by inhibiting the NFKI3 pathway to mitigate inflammation and stimulating the Nrf2/ARE axis to neutralize oxidative stress. During the chronic phase of acute brain injuries, PPAR gamma activation in injured cells culminates in the repair of gray and white matter, preservation of the blood brain barrier, reconstruction of the neurovascular unit, resolution of inflammation, and long-term functional recovery. Thus, PPAR gamma lies at the apex of cell fate decisions and exerts profound effects on the chronic progression of acute injury conditions. Here, we review the therapeutic potential of PPAR gamma in stroke and brain trauma and highlight the novel role of PPAR gamma in long-term tissue repair. We describe its structure and function and identify the genes that it targets. PPAR gamma regulation of inflammation, metabolism, cell fate (proliferation/differentiation/maturation/survival), and many other processes also has relevance to other neurological diseases. Therefore, PPAR gamma is an attractive target for therapies against a number of progressive neurological disorders. (C) 2018 Elsevier Ltd. All rights reserved.	[Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Chen, Jun] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA; [Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Leak, Rehana K.] Duquesne Univ, Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA	Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Leak, RK (corresponding author), Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA.	leakr@duq.edu; chenj2@upmc.edu	Yang, Tuo/J-5620-2019; Zhang, Xuejing/J-8857-2018; Leak, Rehana K/I-2607-2019	Zhang, Xuejing/0000-0003-2994-5502; Leak, Rehana K/0000-0003-2817-7417	National Institutes of Health/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS095029, NS095671, NS045048, NS092618, R15NS093539]; VA Merit Review awardsUS Department of Veterans Affairs [I01BX003377, 1I01BX002495]; Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81529002, 81371306, 81571285]; VA Senior Research Career Scientist Award; Richard King Mellon Endowed Chair; UPMC Endowed Professorship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095671, R01NS095029, R01NS092618, R15NS093539, R01NS045048, R01NS086820, R01NS091175] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002495, I01BX003377] Funding Source: NIH RePORTER	W.C. and T.Y. contributed equally to this article. This work was supported by National Institutes of Health/NINDS grants NS095029 (to J.C., R.K.L., and M.V.L.B.), NS095671 (to J.C.), NS045048 (to J.C.), NS092618 (to X.H.), and R15NS093539 (to R.K.L.), the VA Merit Review awards (I01BX003377 and 1I01BX002495 to J.C.), and grants from the Chinese Natural Science Foundation grants 81529002, 81371306, and 81571285, and (to Y.G. and J.C.). J.C. is a recipient of the VA Senior Research Career Scientist Award, and the Richard King Mellon Endowed Chair and UPMC Endowed Professorship.	Abou Kheir W, 2005, J CELL SCI, V118, P5369, DOI 10.1242/jcs.02638; Abraham HMA, 2016, J CEREBR BLOOD F MET, V36, P132, DOI 10.1038/jcbfm.2015.121; Agostini M, 2006, CELL METAB, V4, P303, DOI 10.1016/j.cmet.2006.09.003; Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Allahtavakoli M, 2009, BRAIN RES, V1271, P121, DOI 10.1016/j.brainres.2009.03.040; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060; Appel S, 2005, BLOOD, V106, P3888, DOI 10.1182/blood-2004-12-4709; Arbo BD, 2016, PROG NEUROBIOL, V144, P27, DOI 10.1016/j.pneurobio.2016.03.010; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attwell D, 2016, J CEREBR BLOOD F MET, V36, P451, DOI 10.1177/0271678X15610340; Auclair M, 2013, ARTERIOSCL THROM VAS, V33, P829, DOI 10.1161/ATVBAHA.112.300962; Azoulay L, 2010, PHARMACOEPIDEM DR S, V19, P343, DOI 10.1002/pds.1883; Bach RG, 2013, CIRCULATION, V128, P785, DOI 10.1161/CIRCULATIONAHA.112.000678; Bagshaw SM, 2008, RENAL FAILURE, V30, P581, DOI 10.1080/08860220802134649; Ballesteros I, 2014, J LEUKOCYTE BIOL, V95, P587, DOI 10.1189/jlb.0613326; Barnabe-Heider F, 2010, CELL STEM CELL, V7, P470, DOI 10.1016/j.stem.2010.07.014; Barroso I, 1999, NATURE, V402, P880; Bath PM, 2016, INT J STROKE, V11, P741, DOI 10.1177/1747493016660099; Bauer S, 2005, NEUROSCIENCE, V130, P75, DOI 10.1016/j.neuroscience.2004.08.047; Baylis C, 2003, J PHARMACOL EXP THER, V307, P854, DOI 10.1124/jpet.103.055616; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Bernardo A, 2009, J NEUROPATH EXP NEUR, V68, P797, DOI 10.1097/NEN.0b013e3181aba2c1; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Bevers MB, 2017, J CEREBR BLOOD F MET, V37, P2577, DOI 10.1177/0271678X16671730; Beyer AM, 2008, HYPERTENSION, V51, P867, DOI 10.1161/HYPERTENSIONAHA.107.103648; Bhatt DL, 2007, AM HEART J, V154, P137, DOI 10.1016/j.ahj.2007.03.029; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; BLAKEMORE WF, 1974, NATURE, V249, P577, DOI 10.1038/249577a0; Blanco M, 2005, STROKE, V36, P1189, DOI 10.1161/01.STR.0000166054.55993.e5; Boekhoff TMA, 2012, J NEUROTRAUM, V29, P1000, DOI 10.1089/neu.2011.1821; BORHANI NO, 1965, AM J PUBLIC HEALTH N, V55, P673, DOI 10.2105/AJPH.55.5.673; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Bruemmer D, 2003, EUR J PHARMACOL, V466, P225, DOI 10.1016/S0014-2999(03)01556-5; Butt AM, 2006, GLIA, V54, P666, DOI 10.1002/glia.20424; Canton J, 2013, NAT REV IMMUNOL, V13, P621, DOI 10.1038/nri3515; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chaitanya GV, 2011, BRAIN PATHOL, V21, P16, DOI 10.1111/j.1750-3639.2010.00426.x; Chang CZ, 2015, J VASC RES, V52, P12, DOI 10.1159/000381099; Chang KL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09000; Charbonnel B, 2004, DIABETES CARE, V27, P1647, DOI 10.2337/diacare.27.7.1647; Chen H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.544; Chen QW, 2017, TRANSL STROKE RES, V8, P362, DOI 10.1007/s12975-017-0521-y; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chinetti G, 2001, NAT MED, V7, P53; Ching J, 2015, ONCOTARGET, V6, P21301, DOI 10.18632/oncotarget.4019; Chistiakov DA, 2016, J CELL MOL MED, V20, P17, DOI 10.1111/jcmm.12689; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Choi YS, 2008, GLIA, V56, P791, DOI 10.1002/glia.20653; Chu K, 2006, BRAIN RES, V1093, P208, DOI 10.1016/j.brainres.2006.03.114; Chung BH, 2005, AM J TRANSPLANT, V5, P1856, DOI 10.1111/j.1600-6143.2005.00979.x; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clarkson BD, 2012, ADV EXP MED BIOL, V946, P309, DOI 10.1007/978-1-4614-0106-3_18; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Compe E, 2005, MOL CELL BIOL, V25, P6065, DOI 10.1128/MCB.25.14.6065-6076.2005; Conti AC, 1998, J NEUROSCI, V18, P5663; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; Cunard R, 2004, J IMMUNOL, V172, P7530, DOI 10.4049/jimmunol.172.12.7530; Curb JD, 2004, AM J EPIDEMIOL, V160, P150, DOI 10.1093/aje/kwh177; da Rocha  LF, 2013, PPAR RES, V2013, DOI 10.1155/2013/519724; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; De Nuccio C, 2011, J NEUROPATH EXP NEUR, V70, P900, DOI 10.1097/NEN.0b013e3182309ab1; de Wit NM, 2017, NEUROBIOL DIS, V107, P57, DOI 10.1016/j.nbd.2016.09.015; Dekkers JF, 2012, TRENDS MOL MED, V18, P283, DOI 10.1016/j.molmed.2012.03.004; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Dhawan V., 2014, STUDIES RESP DISORDE, P27; Di Sanzo M, 2017, CURR PHARM BIOTECHNO, V18, P194, DOI 10.2174/1389201018666170224105600; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doetsch F, 1997, J NEUROSCI, V17, P5046; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Duan HM, 2016, SCI CHINA LIFE SCI, V59, P1313, DOI 10.1007/s11427-016-0205-2; Duan SZ, 2008, CIRC RES, V102, P283, DOI 10.1161/CIRCRESAHA.107.164384; Duarte JV, 2015, J CEREBR BLOOD F MET, V35, P1671, DOI 10.1038/jcbfm.2015.106; Dustin ML, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0034-2016; Duvanel CB, 2003, J NEUROSCI RES, V71, P246, DOI 10.1002/jnr.10471; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Elder CP, 2004, SPINAL CORD, V42, P711, DOI 10.1038/sj.sc.3101652; Elmelund M, 2017, NEUROUROL URODYNAM, V36, P1607, DOI 10.1002/nau.23163; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Erdmann E, 2016, DIABETES OBES METAB, V18, P266, DOI 10.1111/dom.12608; Erdmann E, 2014, DIABETES OBES METAB, V16, P63, DOI 10.1111/dom.12180; Erdmann E, 2010, J DIABETES, V2, P212, DOI 10.1111/j.1753-0407.2010.00082.x; Ericsson H, 2004, DRUG METAB DISPOS, V32, P923; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Fang H, 2014, J IMMUNOL, V192, P5984, DOI 10.4049/jimmunol.1400054; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; FDA, 2015, FDA DRUG SAF COMM FD; FEDDERSEN RM, 1989, BIOTECHNIQUES, V7, P44; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; Ferguson LB, 2014, NEUROPHARMACOLOGY, V86, P397, DOI 10.1016/j.neuropharm.2014.06.024; Finch ER, 2017, BLOOD, V129, P1802, DOI 10.1182/blood-2016-08-736405; Floyd ZE, 2008, METABOLISM, V57, pS32, DOI 10.1016/j.metabol.2008.04.006; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Food and Drug Administration (FDA), 2013, FDA DRUG SAF COMM FD; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; GAETANI P, 1990, STROKE, V21, P328, DOI 10.1161/01.STR.21.2.328; Galeffi F, 2016, J CEREBR BLOOD F MET, V36, P696, DOI 10.1177/0271678X15624699; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Garcia-Bueno B, 2007, NEUROPSYCHOPHARMACOL, V32, P1251, DOI 10.1038/sj.npp.1301252; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Gold M, 2010, DEMENT GERIATR COGN, V30, P131, DOI 10.1159/000318845; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Gough PJ, 2006, J CLIN INVEST, V116, P59, DOI 10.1172/JCI25074; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920; Grau AJ, 2010, NAT REV NEUROL, V6, P681, DOI 10.1038/nrneurol.2010.163; Greene M. E., 1995, Gene Expression, V4, P281; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Griggs RB, 2015, PAIN, V156, P469, DOI 10.1097/01.j.pain.0000460333.79127.be; Grommes C, 2013, CANCER CHEMOTH PHARM, V71, P929, DOI 10.1007/s00280-013-2084-2; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17; Guan LQM, 2000, PLANT J, V22, P87, DOI 10.1046/j.1365-313x.2000.00723.x; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013; Habib ZA, 2009, PHARMACOEPIDEM DR S, V18, P437, DOI 10.1002/pds.1722; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Halabi CM, 2008, CELL METAB, V7, P215, DOI 10.1016/j.cmet.2007.12.008; Hamblin M, 2009, ANTIOXID REDOX SIGN, V11, P1415, DOI [10.1089/ars.2008.2280, 10.1089/ARS.2008.2280]; Hamming AM, 2016, J CEREBR BLOOD F MET, V36, P1224, DOI 10.1177/0271678X15619189; Han LJ, 2015, STROKE, V46, P2628, DOI 10.1161/STROKEAHA.115.010091; HARRISON B M, 1975, Proceedings of the Australian Association of Neurologists, V12, P117; HAWKINS CP, 1991, BRAIN, V114, P801, DOI 10.1093/brain/114.2.801; He F, 2008, OBESITY, V16, P1735, DOI 10.1038/oby.2008.269; Heinaniemi M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r147; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; Hills NK, 2014, NEUROLOGY, V83, P890, DOI 10.1212/WNL.0000000000000752; Hills NK, 2012, ANN NEUROL, V72, P850, DOI 10.1002/ana.23688; Hind WH, 2015, BRIT J PHARMACOL, V172, P3015, DOI 10.1111/bph.13106; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Hovelmeyer N, 2005, J IMMUNOL, V175, P5875, DOI 10.4049/jimmunol.175.9.5875; HOWARD G, 1995, STROKE, V26, P1153, DOI 10.1161/01.STR.26.7.1153; Hsiao FY, 2009, DRUG SAFETY, V32, P675, DOI 10.2165/00002018-200932080-00006; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huria T, 2015, J CEREBR BLOOD F MET, V35, P543, DOI 10.1038/jcbfm.2014.227; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Huxley RR, 2011, CIRCULATION, V124, P2056, DOI 10.1161/CIRCULATIONAHA.111.028373; Iankova I, 2006, MOL ENDOCRINOL, V20, P1494, DOI 10.1210/me.2005-0222; Ibrahim WNW, 2013, TOXICOL APPL PHARM, V269, P51, DOI 10.1016/j.taap.2013.03.003; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Imamoto E, 2004, BIOFACTORS, V20, P37, DOI 10.1002/biof.5520200104; Inzucchi SE, 2016, J DIABETES, V8, P607, DOI 10.1111/1753-0407.12399; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Iwai S, 2008, DRUG DISCOV THER, V2, P353; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Jana M, 2012, J BIOL CHEM, V287, P34134, DOI 10.1074/jbc.M112.398552; Janani C, 2015, DIABETES METAB SYND, V9, P46, DOI 10.1016/j.dsx.2014.09.015; Jeffery ND, 1997, BRAIN, V120, P27, DOI 10.1093/brain/120.1.27; Jennewein C, 2008, J IMMUNOL, V181, P5646, DOI 10.4049/jimmunol.181.8.5646; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jia HB, 2013, NEUROSCI LETT, V543, P130, DOI 10.1016/j.neulet.2013.03.046; Jiang XY, 2016, TRANSL STROKE RES, V7, P548, DOI 10.1007/s12975-016-0502-6; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Joseph MJE, 2016, TRANSL STROKE RES, V7, P192, DOI 10.1007/s12975-015-0445-3; Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Kanakasabai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050500; Kane CJM, 2011, BRAIN BEHAV IMMUN, V25, pS137, DOI 10.1016/j.bbi.2011.02.016; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kaplan JM, 2005, SHOCK, V24, P59, DOI 10.1097/01.shk.0000167108.88376.f2; Katzan I, 2007, NAT CLIN PRACT NEURO, V3, P486, DOI 10.1038/ncpneuro0562; Kaundal RK, 2010, DRUG NEWS PERSPECT, V23, P241, DOI 10.1358/dnp.2010.23.4.1437710; Kawabori M, 2015, CURR MED CHEM, V22, P1258, DOI 10.2174/0929867322666150209154036; Kernan WN, 2016, NEW ENGL J MED, V374, P1321, DOI 10.1056/NEJMoa1506930; Khandoudi N, 2002, DIABETES, V51, P1507, DOI 10.2337/diabetes.51.5.1507; Kielian T, 2008, J IMMUNOL, V180, P5004, DOI 10.4049/jimmunol.180.7.5004; Kim TH, 2013, YONSEI MED J, V54, P545, DOI 10.3349/ymj.2013.54.3.545; Kivisakk P, 2009, ANN NEUROL, V65, P457, DOI 10.1002/ana.21379; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199; Kumari R, 2010, J CEREBR BLOOD F MET, V30, P352, DOI 10.1038/jcbfm.2009.221; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lalloyer F, 2010, ARTERIOSCL THROM VAS, V30, P894, DOI 10.1161/ATVBAHA.108.179689; Lan LF, 2015, CNS NEUROSCI THER, V21, P410, DOI 10.1111/cns.12374; Lee J, 2007, NEUROCHEM RES, V32, P635, DOI 10.1007/s11064-006-9138-3; Lee TM, 2003, AM J PHYSIOL-HEART C, V285, pH1650, DOI 10.1152/ajpheart.00407.2002; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Lee-Liu D, 2013, GENESIS, V51, P529, DOI 10.1002/dvg.22406; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leisewitz AV, 2008, J CELL PHYSIOL, V217, P367, DOI 10.1002/jcp.21509; Lemay DG, 2006, J LIPID RES, V47, P1583, DOI 10.1194/jlr.M500504-JLR200; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li XW, 2015, AM J PATHOL, V185, P230, DOI 10.1016/j.ajpath.2014.09.016; Li XG, 2013, J INT MED RES, V41, P153, DOI 10.1177/0300060513476601; Liebetanz D, 2006, EXP NEUROL, V202, P217, DOI 10.1016/j.expneurol.2006.05.032; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Lin TN, 2006, ARTERIOSCL THROM VAS, V26, P481, DOI 10.1161/01.ATV.0000201933.53964.5b; Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086; Lindvall O., 2015, COLD SPRING HARB PER, V7; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu HR, 2004, CARDIOVASC RES, V62, P135, DOI 10.1016/j.cardiores.2003.12.027; Liu J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010693.pub3; Liu SH, 2010, CELL MOL LIFE SCI, V67, P1465, DOI 10.1007/s00018-009-0255-4; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Losy J, 2005, FOLIA NEUROPATHOL, V43, P97; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu CJ, 2013, CEREBROVASC DIS, V36, P145, DOI 10.1159/000353679; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Luzzati F, 2006, J NEUROSCI, V26, P609, DOI 10.1523/JNEUROSCI.4371-05.2006; Lygate CA, 2003, CARDIOVASC RES, V58, P632, DOI 10.1016/S0008-6363(03)00289-X; Mahaffey KW, 2013, AM HEART J, V166, P240, DOI 10.1016/j.ahj.2013.05.004; Majai G, 2007, EUR J IMMUNOL, V37, P1343, DOI 10.1002/eji.200636398; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Mandrekar-Colucci S, 2013, ASN NEURO, V5, DOI 10.1042/AN20130030; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; MCGUIRE EJ, 1981, J UROLOGY, V126, P205, DOI 10.1016/S0022-5347(17)54449-3; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; McTigue DM, 2008, PPAR RES, V2008, DOI 10.1155/2008/517162; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Migaud M, 2010, EUR J NEUROSCI, V32, P2042, DOI 10.1111/j.1460-9568.2010.07521.x; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Ming XD, 2015, LIFE SCI, V136, P36, DOI 10.1016/j.lfs.2015.06.015; Miron VE, 2007, GLIA, V55, P130, DOI 10.1002/glia.20441; Miron VE, 2009, AM J PATHOL, V174, P1880, DOI 10.2353/ajpath.2009.080947; Molina-Holgado E, 2010, J NEUROCHEM, V114, P1277, DOI 10.1111/j.1471-4159.2010.06849.x; Molshatzki N, 2011, CEREBROVASC DIS, V31, P271, DOI 10.1159/000322155; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Mracsko E, 2014, J NEUROSCI, V34, P16784, DOI 10.1523/JNEUROSCI.1867-14.2014; Mughal MM, 2011, EXPERT REV CARDIOVAS, V9, P1315, DOI [10.1586/erc.11.120, 10.1586/ERC.11.120]; Mukohda Masashi, 2016, American journal of physiology. Heart and circulatory physiology, V310, pH39, DOI 10.1152/ajpheart.00490.2015; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Neschen S, 2007, DIABETES, V56, P1034, DOI 10.2337/db06-1206; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Niino M, 2001, J NEUROIMMUNOL, V116, P40, DOI 10.1016/S0165-5728(01)00285-5; Nissen SE, 2010, ARCH INTERN MED, V170, P1191, DOI 10.1001/archinternmed.2010.207; Okada T, 2006, DIABETES, V55, P1666, DOI 10.2337/db05-1285; Ormerod BK, 2013, BRAIN BEHAV IMMUN, V29, P28, DOI 10.1016/j.bbi.2012.10.017; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Ou ZS, 2006, BRAIN RES, V1096, P196, DOI 10.1016/j.brainres.2006.04.062; Ouyang YB, 2014, ADV NEUROBIOL, V11, P171, DOI 10.1007/978-3-319-08894-5_9; Owens J, 1997, NUCL MED COMMUN, V18, P149, DOI 10.1097/00006231-199702000-00010; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Padilla J., 2000, J IMMUNOL, V165; Paintlia AS, 2010, GLIA, V58, P1669, DOI 10.1002/glia.21039; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pan HC, 2013, EUR J IMMUNOL, V43, P2854, DOI 10.1002/eji.201343301; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Park BV, 2015, CELL MOL IMMUNOL, V12, P533, DOI 10.1038/cmi.2015.21; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park EY, 2004, CANCER RES, V64, P3701, DOI 10.1158/0008-5472.CAN-03-3924; Park KS, 2004, EXP CELL RES, V297, P424, DOI 10.1016/j.yexcr.2004.03.034; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Patel PC, 2008, MOL BIOL CELL, V19, P4628, DOI 10.1091/mbc.E08-02-0223; Patel SN, 2004, J INFECT DIS, V189, P204, DOI 10.1086/380764; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-20; Pedersen WA, 2006, EXP NEUROL, V199, P265, DOI 10.1016/j.expneurol.2006.01.018; Pennypacker KR, 2015, J CEREBR BLOOD F MET, V35, P186, DOI 10.1038/jcbfm.2014.212; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pierce AA, 2010, J NEUROSCI, V30, P723, DOI 10.1523/JNEUROSCI.2479-09.2010; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Polvani S, 2012, PPAR RES, V2012, DOI 10.1155/2012/641087; Pourcet B, 2010, J BIOL CHEM, V285, P5983, DOI 10.1074/jbc.M109.078311; Puyal J, 2013, PROG NEUROBIOL, V105, P24, DOI 10.1016/j.pneurobio.2013.03.002; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Qureshi Al, 2017, J CEREB BLOOD FLOW M; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Redondo-Castro E, 2013, EUR J NEUROSCI, V38, P3786, DOI 10.1111/ejn.12382; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Riyahi TY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027311; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rohatagi S, 2008, J CLIN PHARMACOL, V48, P1420, DOI 10.1177/0091270008323260; Rolland M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005547; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Rosenberg GA, 2016, J CEREBR BLOOD F MET, V36, P4, DOI 10.1177/0271678X15609542; Rosenberg GA, 2009, STROKE, V40, pS20, DOI 10.1161/STROKEAHA.108.533133; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; ROSS GD, 1992, J LEUKOCYTE BIOL, V51, P109; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Rowat A, 2014, INT J STROKE, V9, P633, DOI 10.1111/ijs.12264; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Samaha FF, 2006, ARTERIOSCL THROM VAS, V26, P624, DOI 10.1161/01.ATV.0000200136.56716.30; Sarafidis PA, 2006, AM J HYPERTENS, V19, P646, DOI 10.1016/j.amjhyper.2005.12.017; Sarafidis PA, 2010, AM J KIDNEY DIS, V55, P835, DOI 10.1053/j.ajkd.2009.11.013; Sasaki Makoto, 2005, BMC Physiol, V5, P3, DOI 10.1186/1472-6793-5-3; Sauer S, 2015, TRENDS PHARMACOL SCI, V36, P688, DOI 10.1016/j.tips.2015.06.010; Scheen AJ, 2012, DIABETES RES CLIN PR, V98, P175, DOI 10.1016/j.diabres.2012.09.001; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Schousboe A, 2005, NEUROTOX RES, V8, P221, DOI 10.1007/BF03033975; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shao DL, 1998, NATURE, V396, P377; Sharma SK, 2016, J THORAC DIS, V8, P1406, DOI 10.21037/jtd.2016.05.22; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shaya Fadia T, 2009, P T, V34, P490; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Shereen A, 2011, J CEREBR BLOOD F MET, V31, P1155, DOI 10.1038/jcbfm.2010.212; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Shi YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10523; Shi YJ, 2016, TRANSL STROKE RES, V7, P89, DOI 10.1007/s12975-016-0447-9; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shiomi T, 2002, CIRCULATION, V106, P3126, DOI 10.1161/01.CIR.0000039346.31538.2C; Siddiqui AM, 2006, CRIT CARE MED, V34, P1874, DOI 10.1097/01.CCM.0000221921.71300.BF; Sidell RJ, 2002, DIABETES, V51, P1110, DOI 10.2337/diabetes.51.4.1110; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Sim FJ, 2008, GLIA, V56, P954, DOI 10.1002/glia.20669; SIMONI J, 1990, BIOMATER ARTIF CELL, V18, P189, DOI 10.3109/10731199009117301; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Soares HD, 1995, J NEUROSCI, V15, P8223; Staessen JA, 2003, JAMA-J AM MED ASSOC, V289, P2420, DOI 10.1001/jama.289.18.2420; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Storer PD, 2005, J NEUROSCI RES, V80, P66, DOI 10.1002/jnr.20413; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Sugawara A, 2001, ENDOCRINOLOGY, V142, P3125, DOI 10.1210/en.142.7.3125; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Sundararajan S, 2004, DRUG NEWS PERSPECT, V17, P229, DOI 10.1358/dnp.2004.17.4.829049; Taheri M, 2015, PHARMACOL REP, V67, P1103, DOI 10.1016/j.pharep.2015.04.011; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tanaka R, 2015, J ATHEROSCLER THROMB, V22, P1305, DOI 10.5551/jat.30007; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Terasaki Y, 2014, CURR MED CHEM, V21, P2035, DOI 10.2174/0929867321666131228223400; Tesfamariam B, 2007, VASC PHARMACOL, V46, P229, DOI 10.1016/j.vph.2006.11.005; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Tholance Y, 2015, ACS CHEM NEUROSCI, V6, P1902, DOI 10.1021/acschemneuro.5b00299; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Tsai YS, 2009, P NATL ACAD SCI USA, V106, P19084, DOI 10.1073/pnas.0909657106; Trang T, 2011, NEURON GLIA BIOL, V7, P99, DOI 10.1017/S1740925X12000087; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; Urra X, 2009, CURR MOL MED, V9, P195, DOI 10.2174/156652409787581574; Uruno A, 2011, J MOL ENDOCRINOL, V46, P37, DOI 10.1677/JME-10-0088; Vallarino C, 2013, CLIN DRUG INVEST, V33, P621, DOI 10.1007/s40261-013-0106-9; Vanasse A, 2009, DIABETES VASC DIS RE, V6, P87, DOI 10.1177/1479164109336047; Vattulainen-Collanus S, 2016, J CELL SCI, V129, P693, DOI 10.1242/jcs.169011; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Verrier E, 2004, CIRC RES, V94, P1515, DOI 10.1161/01.RES.0000130527.92537.06; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Viola HM, 2013, CLIN EXP PHARMACOL P, V40, P295, DOI 10.1111/1440-1681.12072; Viscoli CM, 2014, AM HEART J, V168, P823, DOI 10.1016/j.ahj.2014.07.016; Von Knethen A, 2001, FASEB J, V15, P535, DOI 10.1096/fj.00-0187com; Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200; Wahl LM, 1997, TRANSPL IMMUNOL, V5, P173, DOI 10.1016/S0966-3274(97)80033-0; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang CY, 2014, ANTIOXID REDOX SIGN, V21, P2208, DOI 10.1089/ars.2014.5845; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang HE, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-9; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Wang SH, 2009, MOL CELL ENDOCRINOL, V307, P176, DOI 10.1016/j.mce.2009.02.012; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; Wang YD, 2017, J MOL NEUROSCI, V62, P199, DOI 10.1007/s12031-017-0931-z; Wang YT, 2012, CURR DRUG TARGETS, V13, P166, DOI 10.2174/138945012799201603; Wang Y, 2016, PROG NEUROBIOL, V141, P45, DOI [10.1016/j.pneurobio.2016.04.00, 10.1016/j.pneurobio.2016.04.005]; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Warden A, 2016, SCI REP-UK, V6, DOI 10.1038/srep27618; Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014; Wartenberg KE, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/830614; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Wilcox R, 2007, STROKE, V38, P865, DOI 10.1161/01.STR.0000257974.06317.49; Willmot M, 2004, HYPERTENSION, V43, P18, DOI 10.1161/01.HYP.0000105052.65787.35; Wilson HM, 2010, J CELL MOL MED, V14, P2055, DOI 10.1111/j.1582-4934.2010.01121.x; Winkelmayer WC, 2008, ARCH INTERN MED, V168, P2368, DOI 10.1001/archinte.168.21.2368; Wohlfert EA, 2007, J IMMUNOL, V178, P4129, DOI 10.4049/jimmunol.178.7.4129; Wolinski P, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/727189; Woo MS, 2016, J BIOL CHEM, V291, P23654, DOI 10.1074/jbc.M116.750018; Wu GF, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0287-3; Wu JS, 2016, MOL NEUROBIOL, V53, P3626, DOI 10.1007/s12035-015-9294-z; Wu JS, 2009, CIRCULATION, V119, P1124, DOI 10.1161/CIRCULATIONAHA.108.812537; Xiang ZM, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-18; Xu R., 2016, J NEUROSURG, P1; Xu Y, 2003, DIABETES, V52, P1187, DOI 10.2337/diabetes.52.5.1187; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yamanaka M, 2012, J NEUROSCI, V32, P17321, DOI 10.1523/JNEUROSCI.1569-12.2012; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yang HC, 2009, J AM SOC NEPHROL, V20, P2380, DOI 10.1681/ASN.2008111138; Yang JC, 2009, CLIN SCI, V116, P17, DOI 10.1042/CS20070462; Yang T, 2016, SPR SER TRANSL STROK, P377, DOI 10.1007/978-3-319-32337-4_18; Yang T, 2017, AGEING RES REV, V34, P15, DOI 10.1016/j.arr.2016.09.007; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966; Yessoufou A, 2010, SWISS MED WKLY, V140, P4, DOI 10.4414/smw.2010.13071; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Yin KJ, 2014, NEUROCHEM INT, V77, P9, DOI 10.1016/j.neuint.2014.03.013; Yin KJ, 2013, BRAIN, V136, P1274, DOI 10.1093/brain/awt002; Yin KJ, 2010, J NEUROSCI, V30, P6398, DOI 10.1523/JNEUROSCI.0780-10.2010; Yoo HY, 1999, GENE, V234, P87, DOI 10.1016/S0378-1119(99)00176-6; Yoshihara D, 2011, AM J PHYSIOL-RENAL, V300, pF465, DOI 10.1152/ajprenal.00460.2010; Yoshii H, 2014, J ATHEROSCLER THROMB, V21, P563; Yu Y, 2015, HYPERTENSION, V66, P403, DOI 10.1161/HYPERTENSIONAHA.115.05726; Yue TL, 2001, CIRCULATION, V104, P2588, DOI 10.1161/hc4601.099403; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112; Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood-2004-02-0664; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9; Zhao XR, 2015, CNS NEUROSCI THER, V21, P357, DOI 10.1111/cns.12350; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233; Zhao XR, 2015, J NEUROCHEM, V133, P144, DOI 10.1111/jnc.12974; Zhao XR, 2009, J NEUROSCI, V29, P6186, DOI 10.1523/JNEUROSCI.5857-08.2009; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158; Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015; Zhao X., 2014, IMMUNOLOGICAL MECH T, P301; Zhou K, 2017, J CEREBR BLOOD F MET, V37, P967, DOI 10.1177/0271678X16648712; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Vincent ZA, 2007, BBA-MOL CELL BIOL L, V1771, P915, DOI 10.1016/j.bbalip.2007.01.007; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x; Zuo YQ, 2012, NEPHROL DIAL TRANSPL, V27, P174, DOI 10.1093/ndt/gfr240	506	54	57	6	31	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	APR-MAY	2018	163				SI		27	58		10.1016/j.pneurobio.2017.10.002			32	Neurosciences	Neurosciences & Neurology	GK5OM	WOS:000436224400003	29032144	Green Accepted			2021-06-18	
J	Wang, MH; Ding, FF; Deng, SY; Guo, XQ; Wang, W; Iliff, JJ; Nedergaard, M				Wang, Minghuan; Ding, Fengfei; Deng, SaiYue; Guo, Xuequn; Wang, Wei; Iliff, Jeffrey J.; Nedergaard, Maiken			Focal Solute Trapping and Global Glymphatic Pathway Impairment in a Murine Model of Multiple Microinfarcts	JOURNAL OF NEUROSCIENCE			English	Article						glymphatic; microinfarct; vascular dementia	CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; CONTRAST-ENHANCED MRI; VASCULAR DEMENTIA; CORTICAL MICROINFARCTS; INTERSTITIAL FLUID; CLEARANCE; DISEASE; LESIONS; SYSTEM	Microinfarcts occur commonly in the aging brain as a consequence of diffuse embolic events and are associated with the development of vascular dementia and Alzheimer's disease. However, the manner in which disperse microscopic lesions reduce global cognitive function and increase the risk for Alzheimer's disease is unclear. The glymphatic system, which is a brain-wide perivascular network that supports the recirculation of CSF through the brain parenchyma, facilitates the clearance of interstitial solutes including amyloid beta and tau. We investigated whether glymphatic pathway function is impaired in a murine model of multiple microinfarcts induced by intraarterial injection of cholesterol crystals. The analysis showed that multiple microinfarcts markedly impaired global influx of CSF along the glymphatic pathway. Although suppression of global glymphatic function was transient, resolving within 2 weeks of injury, CSF tracers also accumulated within tissue associated with microinfarcts. The effect of diffuse microinfarcts on global glymphatic pathway function was exacerbated in the mice aged 12 months compared with the 2-to 3-month-old mice. These findings indicate that glymphatic function is focally disrupted around microinfarcts and that the aging brain is more vulnerable to this disruption than the young brain. These observations suggest that microlesions may trap proteins and other interstitial solutes within the brain parenchyma, increasing the risk of amyloid plaque formation.	[Wang, Minghuan; Ding, Fengfei; Iliff, Jeffrey J.; Nedergaard, Maiken] Univ Rochester, Div Glial Dis & Therapeut, Dept Neurosurg, Med Ctr,Ctr Translat Neuromed, Rochester, NY 14642 USA; [Wang, Minghuan; Ding, Fengfei; Deng, SaiYue; Guo, Xuequn; Wang, Wei] Huazhong Univ Sci & Technol, Tongii Hosp, Dept Neurol, Tongii Med Coll, Wuhan 430030, Peoples R China; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA; [Nedergaard, Maiken] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Basic & Translat Neurosci, DK-2200 Copenhagen, Denmark	Nedergaard, M (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Ctr Basic & Translat Neurosci, DK-2200 Copenhagen, Denmark.; Iliff, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd Mail Code L458, Portland, OR 97239 USA.; Nedergaard, M (corresponding author), Univ Rochester, Ctr Translat Neuromed, Med Ctr, Box 645,575 Elmwood Ave, Rochester, NY 14642 USA.	iliffj@ohsu.edu; Nedergaard@URMC.Rochester.edu		Nedergaard, Maiken/0000-0001-6502-6031	National Institute of Neurological DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Stroke-National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); American Heart AssociationAmerican Heart Association; Leducq FoundationLeducq Foundation; European UnionEuropean Commission [666881]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089709, R01NS078167, R01NS100366, R01NS078304, R01NS075177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048769] Funding Source: NIH RePORTER; Lundbeck FoundationLundbeckfonden [R155-2016-552] Funding Source: researchfish; Novo Nordisk FondenNovo Nordisk Foundation [NNF13OC0004258] Funding Source: researchfish	This work was supported by the National Institute of Neurological Disorders and Stroke-National Institutes of Health, the American Heart Association, the Leducq Foundation, and the European Union's Horizon 2020 Research and Innovation Programme (Grant 666881, SVDs@ target). We thank Yonghong Liao for expert technical support.	Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; Esiri MM, 1997, J NEUROL NEUROSUR PS, V63, P749, DOI 10.1136/jnnp.63.6.749; Gaberel T, 2014, STROKE, V45, P3092, DOI 10.1161/STROKEAHA.114.006617; Haglund M, 2006, INT J GERIATR PSYCH, V21, P681, DOI 10.1002/gps.1550; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kovari E, 2013, NEUROPATH APPL NEURO, V39, P498, DOI 10.1111/nan.12003; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Simon MJ, 2016, BBA-MOL BASIS DIS, V1862, P442, DOI 10.1016/j.bbadis.2015.10.014; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Sonnen JA, 2011, ARCH NEUROL-CHICAGO, V68, P1049, DOI 10.1001/archneurol.2011.157; Vinters HV, 2000, J NEUROPATH EXP NEUR, V59, P931, DOI 10.1093/jnen/59.11.931; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	20	54	57	1	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 11	2017	37	11					2870	2877		10.1523/JNEUROSCI.2112-16.2017			8	Neurosciences	Neurosciences & Neurology	EQ1CX	WOS:000397808000008	28188218	Green Published, Bronze			2021-06-18	
J	Winkler, EA; Minter, D; Yue, JK; Manley, GT				Winkler, Ethan A.; Minter, Daniel; Yue, John K.; Manley, Geoffrey T.			Cerebral Edema in Traumatic Brain Injury Pathophysiology and Prospective Therapeutic Targets	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Cerebral edema; Traumatic brain injury; Pathophysiology; Therapeutic targets; Blood-brain barrier	LIGHT-CHAIN KINASE; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; NONSELECTIVE CATION CHANNEL; OSMOTIC WATER PERMEABILITY; ADULT-RAT BRAIN; ISCHEMIC-STROKE; BARRIER DISRUPTION; SUBSTANCE-P; INTRACRANIAL HYPERTENSION	Traumatic brain injury is a heterogeneous disorder resulting from an external force applied to the head. The development of cerebral edema plays a central role in the evolution of injury following brain trauma and is closely associated with neurologic outcomes. Recent advances in the understanding of the molecular and cellular pathways contributing to the posttraumatic development of cerebral edema have led to the identification of multiple prospective therapeutic targets. The authors summarize the pathogenic mechanisms underlying cerebral edema and highlight the molecular pathways that may be therapeutically targeted to mitigate cerebral edema and associated sequelae following traumatic brain injury.	[Winkler, Ethan A.; Yue, John K.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Minter, Daniel; Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M779, San Francisco, CA 94143 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Ameli PA, 2014, J NEUROSCI RES, V92, P1091, DOI 10.1002/jnr.23407; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Filippidis AS, 2014, J NEUROTRAUM, V31, P1258, DOI 10.1089/neu.2013.3063; Filippini G., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001331; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; HALL JM, 1995, NEUROCHEM INT, V26, P17, DOI 10.1016/0197-0186(94)00115-B; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hirose T, 2013, NEUROL MED-CHIR, V53, P609; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; Hudak AM, 2014, BRAIN INJURY, V28, P1602, DOI 10.3109/02699052.2014.936039; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ishmael JE, 2008, ACTA HISTOCHEM, V110, P172, DOI 10.1016/j.acthis.2007.08.005; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jia F, 2014, J NEUROTRAUM, V31, P1225, DOI 10.1089/neu.2013.3230; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Kim DJ, 2012, J NEUROTRAUM, V29, P1354, DOI 10.1089/neu.2011.2018; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Krieg SM, 2015, J NEUROTRAUM, V32, P221, DOI 10.1089/neu.2013.3274; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee M, 2015, ACS CHEM NEUROSCI, V6, P1658, DOI 10.1021/acschemneuro.5b00140; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mahmoodpoor A, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Mori K, 2002, J NEUROTRAUM, V19, P1261, DOI 10.1089/08977150260338047; Mysiorek C, 2009, CURR NEUROVASC RES, V6, P181, DOI 10.2174/156720209788970081; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Oshio K, 2003, ACT NEUR S, V86, P525; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Ramirez SH, 2009, J CEREBR BLOOD F MET, V29, P1933, DOI 10.1038/jcbfm.2009.112; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rossi JL, 2013, J NEUROTRAUM, V30, P1672, DOI 10.1089/neu.2013.2898; Rungta RL, 2015, CELL, V161, P610, DOI 10.1016/j.cell.2015.03.029; Ryken TC, 2010, J NEURO-ONCOL, V96, P103, DOI 10.1007/s11060-009-0057-4; Salvador E, 2014, CELL TISSUE RES, V355, P597, DOI 10.1007/s00441-013-1762-z; Sandercock PAG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000064.pub2; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shohami E, 2014, CNS NEUROL DISORD-DR, V13, P567, DOI 10.2174/18715273113126660196; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Storkebaum E, 2011, NAT NEUROSCI, V14, P1390, DOI 10.1038/nn.2947; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tang XQ, 2014, NEUROL RES, V36, P118, DOI 10.1179/1743132813Y.0000000266; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Turner RJ, 2011, BRAIN RES, V1393, P84, DOI 10.1016/j.brainres.2011.03.066; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Watanabe M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00371; Winkler EA, 2014, BRAIN PATHOL, V24, P371, DOI 10.1111/bpa.12152; Winkler EA, 2014, P NATL ACAD SCI USA, V111, pE1035, DOI 10.1073/pnas.1401595111; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhu DH, 2010, BLOOD, V115, P4963, DOI 10.1182/blood-2010-01-262386; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	144	54	60	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					473	+		10.1016/j.nec.2016.05.008			17	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800009	27637397				2021-06-18	
J	Thelin, EP; Jeppsson, E; Frostell, A; Svensson, M; Mondello, S; Bellander, BM; Nelson, DW				Thelin, Eric Peter; Jeppsson, Emma; Frostell, Arvid; Svensson, Mikael; Mondello, Stefania; Bellander, Bo-Michael; Nelson, David W.			Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity	CRITICAL CARE			English	Article						Traumatic brain injury; Biomarkers; S100B; Neuron-specific enolase; Outcome	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; GLASGOW COMA SCALE; SERUM S100B; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; HEAD-INJURY; S-100-BETA PROTEIN; PROGNOSTIC VALUE; PREDICTIVE-VALUE	Background: In order to improve assessment and outcome prediction in patients suffering from traumatic brain injury (TBI), cerebral protein levels in serum have been suggested as biomarkers of injury. However, despite much investigation, biomarkers have yet to reach broad clinical utility in TBI. This study is a 9-year follow-up and clinical experience of the two most studied proteins, neuron-specific enolase (NSE) and S100B, in a neuro-intensive care TBI population. Our aims were to investigate to what extent NSE and S100B, independently and in combination, could predict outcome, assess injury severity, and to investigate if the biomarker levels were influenced by extracranial factors. Methods: All patients treated at the neuro-intensive care unit at Karolinska University Hospital, Stockholm, Sweden between 2005 and 2013 with at least three measurements of serum S100B and NSE (sampled twice daily) were retrospectively included. In total, 417 patients fulfilled the criteria. Parameters were extracted from the computerized hospital charts. Glasgow Outcome Score (GOS) was used to assess long-term functional outcome. Univariate, and multivariate, regression models toward outcome and what explained the high levels of the biomarkers were performed. Nagelkerke's pseudo-R-2 was used to illustrate the explained variance of the different models. A sliding window assessed biomarker correlation to outcome and multitrauma over time. Results: S100B was found a better predictor of outcome as compared to NSE (area under the curve (AUC) samples, the first 48 hours had Nagelkerke's pseudo-R2 values of 0.132 and 0.038, respectively), where the information content of S100B peaks at approximately 1 day after trauma. In contrast, although both biomarkers were independently correlated to outcome, NSE had limited additional predictive capabilities in the presence of S100B in multivariate models, due to covariance between the two biomarkers (correlation coefficient 0.673 for AUC 48 hours). Moreover, NSE was to a greater extent correlated to multitrauma the first 48 hours following injury, whereas the effect of extracerebral trauma on S100B levels appears limited to the first 12 hours. Conclusions: While both biomarkers are independently correlated to long-term functional outcome, S100B is found a more accurate outcome predictor and possibly a more clinically useful biomarker than NSE for TBI patients.	[Thelin, Eric Peter; Jeppsson, Emma; Frostell, Arvid; Svensson, Mikael; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Nelson, David W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden	Thelin, EP (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	eric.thelin@ki.se	Mondello, Stefania/A-1813-2012; Viani, Rafael/V-1196-2018; Svensson, Mikael/F-8662-2012; Thelin, Eric Peter/K-2144-2012	Mondello, Stefania/0000-0002-8587-3614; Svensson, Mikael/0000-0003-1179-7003; Thelin, Eric Peter/0000-0002-2338-4364	Karolinska InstitutetKarolinska Institutet; Stockholm CountyStockholm County Council; SENSUS Region Mellansverige	The study was founded by grants from the Karolinska Institutet and the Stockholm County (ALF funding) as well as funding from SENSUS Region Mellansverige. The funding bodies had no role in the design of the study, interpretation of the data or in the presentation results.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Beaudeux JL, 2000, CLIN CHEM, V46, P989; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Committee on Trauma-American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Gonzalez-Mao MC, 2011, CLIN LAB, V57, P587; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Karaoguz R, 2008, INT HEART J, V49, P553, DOI 10.1536/ihj.49.553; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; R Development Core Team, 2008, R LANGUAGE ENV STAT; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Sogut O, 2010, J INT MED RES, V38, P1708, DOI 10.1177/147323001003800516; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; TEASDALE G, 1974, LANCET, V2, P81; Thelin E. P., 2015, EUR J TRAUMA EMERG S; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127	88	54	59	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	SEP 8	2016	20								285	10.1186/s13054-016-1450-y			15	Critical Care Medicine	General & Internal Medicine	DV2AN	WOS:000382723300001	27604350	DOAJ Gold, Green Published			2021-06-18	
J	Kwon, EJ; Skalak, M; Lo Bu, R; Bhatia, SN				Kwon, Ester J.; Skalak, Matthew; Lo Bu, Riana; Bhatia, Sangeeta N.			Neuron-Targeted Nanoparticle for siRNA Delivery to Traumatic Brain Injuries	ACS NANO			English	Article						traumatic brain injury; nucleic acid delivery; nanoparticle; peptide; neuron targeting	FOCUSED ULTRASOUND; GENE DELIVERY; CELL-DEATH; BLOOD; BARRIER; EXPRESSION; RECEPTOR; TUMORS; RATS; NEUROPROTECTION	Traumatic brain injuries (TBIs) affect 2.5 million Americans per year, and survivors of TBI can develop long-term impairments in physical, cognitive, and psychosocial functions. Currently, there are no treatments available to stop the long-term effects of TBI. Although the primary injury can only be prevented, there is an opportunity for intervention during the secondary injury, which persists over the course of hours to years after the initial injury. One promising strategy is to modulate destructive pathways using nucleic acid therapeutics, which can downregulate "undruggable" targets considered difficult to inhibit with small molecules; however, the delivery of these materials to the central nervous system is challenging. We engineered a neuron-targeting nanoparticle which can mediate intracellular trafficking of siRNA cargo and achieve silencing of mRNA and protein levels in cultured cells. We hypothesized that, soon after an injury, nanoparticles in the bloodstream may be able to infiltrate brain tissue in the vicinity of areas with a compromised blood brain barrier (BBB). We find that, when administered systemically into animals with brain injuries, neuron-targeted nanoparticles can accumulate into the tissue adjacent to the injured site and downregulate a therapeutic candidate.	[Kwon, Ester J.; Skalak, Matthew; Lo Bu, Riana; Bhatia, Sangeeta N.] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Harvard MIT Div Hlth Sci & Technol, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Bhatia, Sangeeta N.] Harvard Med Sch, Boston, MA 02115 USA; [Bhatia, Sangeeta N.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02139 USA; [Bhatia, Sangeeta N.] Howard Hughes Med Inst, Cambridge, MA 02139 USA	Bhatia, SN (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), MIT, Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Bhatia, SN (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Bhatia, SN (corresponding author), Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02139 USA.; Bhatia, SN (corresponding author), Howard Hughes Med Inst, Cambridge, MA 02139 USA.	sbhatia@mit.edu		Kwon, Ester/0000-0002-6335-9681	Marie D. & Pierre Casimir-Lambert Fund; Koch Institute from the National Cancer Institute (Swanson Biotechnology Center) [P30-CA14051]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30-ES002109]; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [HR0011-13-2-0017]; Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1F32CA177094-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014051, F32CA177094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES002109] Funding Source: NIH RePORTER	We thank the Koch Institute Swanson Biotechnology Center (MIT) for assistance with TEM imaging, specifically Dr. Dong Soo Yun, and tissue sectioning, specifically Michael Brown and Kathleen Cormier. We thank Dr. Heather Fleming (MIT) for critical reading and editing of the manuscript. This work was supported in part by the Marie D. & Pierre Casimir-Lambert Fund, and a Koch Institute Support Grant P30-CA14051 from the National Cancer Institute (Swanson Biotechnology Center) and a Core Center Grant P30-ES002109 from the National Institute of Environmental Health Sciences. This work was also supported by the Defense Advanced Research Projects Agency under Cooperative Agreement HR0011-13-2-0017. The content of the information within this document does not necessarily reflect the position or the policy of the government. E.J.K. acknowledges support from the Ruth L. Kirschstein National Research Service Award (1F32CA177094-01). S.N.B. is an HHMI Investigator.	Al-Jamal KT, 2011, P NATL ACAD SCI USA, V108, P10952, DOI 10.1073/pnas.1100930108; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bharali DJ, 2005, P NATL ACAD SCI USA, V102, P11539, DOI 10.1073/pnas.0504926102; Boeckle S, 2005, J GENE MED, V7, P1335, DOI 10.1002/jgm.783; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/NNANO.2012.45, 10.1038/nnano.2012.45]; Cheng JJ, 2006, J MED CHEM, V49, P6522, DOI 10.1021/jm060736s; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi CHJ, 2010, P NATL ACAD SCI USA, V107, P1235, DOI 10.1073/pnas.0914140107; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; El Badawy AM, 2010, ENVIRON SCI TECHNOL, V44, P1260, DOI 10.1021/es902240k; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; HANHAM CA, 1993, J VIROL, V67, P530, DOI 10.1128/JVI.67.1.530-542.1993; Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kwon EJ, 2010, BIOMATERIALS, V31, P2417, DOI 10.1016/j.biomaterials.2009.11.086; Lafon M, 2005, J NEUROVIROL, V11, P82, DOI 10.1080/13550280590900427; Lee J, 2016, J CONTROL RELEASE, V223, P197, DOI 10.1016/j.jconrel.2015.12.051; Lin KY, 2014, NANO TODAY, V9, P550, DOI 10.1016/j.nantod.2014.09.001; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062905; Liu YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep17543; Mulik RS, 2016, BIOMATERIALS, V83, P257, DOI 10.1016/j.biomaterials.2016.01.021; Nance E, 2014, J CONTROL RELEASE, V189, P123, DOI 10.1016/j.jconrel.2014.06.031; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Price L., 2016, TRANSLATIONAL RES TR; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ren Y, 2012, ACS NANO, V6, P8620, DOI 10.1021/nn301975s; Ren Y, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003778; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rungta RL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.65; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101; Schnell MJ, 2010, NAT REV MICROBIOL, V8, P51, DOI 10.1038/nrmicro2260; Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep22595; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	45	54	56	2	78	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	AUG	2016	10	8					7926	7933		10.1021/acsnano.6b03858			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	DU1HP	WOS:000381959100077	27429164	Green Accepted			2021-06-18	
J	Mishra, V; Skotak, M; Schuetz, H; Heller, A; Haorah, J; Chandra, N				Mishra, Vikas; Skotak, Maciej; Schuetz, Heather; Heller, Abi; Haorah, James; Chandra, Namas			Primary blast causes mild, moderate, severe and lethal TBI with increasing blast overpressures: Experimental rat injury model	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; ACETYL-L-CARNITINE; OXIDATIVE STRESS; SHOCK-WAVE; BARRIER DYSFUNCTION; INDUCED NEUROTRAUMA; ANESTHETIZED RAT; COMBAT VETERANS; NERVOUS-SYSTEM; SHELL SHOCK	Injury severity in blast induced Traumatic Brain Injury (bTBI) increases with blast overpressure (BOP) and impulse in dose-dependent manner. Pure primary blast waves were simulated in compressed gas shock-tubes in discrete increments. Present work demonstrates 24 hour survival of rats in 0-450 kPa (0-800 Pa.s impulse) range at 10 discrete levels (60, 100, 130, 160, 190, 230, 250, 290, 350 and 420 kPa) and determines the mortality rate as a non-linear function of BOP. Using logistic regression model, predicted mortality rate (PMR) function was calculated, and used to establish TBI severities. We determined a BOP of 145 kPa as upper mild TBI threshold (5% PMR). Also we determined 146-220 kPa and 221-290 kPa levels as moderate and severe TBI based on 35%, and 70% PMR, respectively, while BOP above 290 kPa is lethal. Since there are no standards for animal bTBI injury severity, these thresholds need further refinements using histopathology, immunohistochemistry and behavior. Further, we specifically investigated mild TBI range (0-145 kPa) using physiological (heart rate), pathological (lung injury), immuno-histochemical (oxidative/nitrosative and blood-brain barrier markers) as well as blood borne biomarkers. With these additional data, we conclude that mild bTBI occurs in rats when the BOP is in the range of 85-145 kPa.	[Mishra, Vikas; Skotak, Maciej; Haorah, James; Chandra, Namas] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA; [Schuetz, Heather; Heller, Abi] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA	Haorah, J; Chandra, N (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA.	james.haorah@njit.edu; namas.chandra@njit.edu	Skotak, Maciej/H-4769-2019	Skotak, Maciej/0000-0003-2584-7294	NIH/NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [1R21AA022734-01A1]; U.S. Army Medical Research and Materiel Command grantU.S. Army Medical Research & Materiel Command (USAMRMC) [14059001 (W81XWH-15-1-0303)]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA022734] Funding Source: NIH RePORTER	This work was supported by NIH/NIAAA grants 1R21AA022734-01A1 to JH, and the U.S. Army Medical Research and Materiel Command grant Log No. 14059001 (W81XWH-15-1-0303) to NC. Authors declare no conflicts of interest.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alikunju S, 2011, BRAIN BEHAV IMMUN, V25, pS129, DOI 10.1016/j.bbi.2011.01.007; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Borkholder D. A., 2014, INT STAT OF THE SCI; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chandra N., 2015, BRAIN NEUROTRAUMA MO, P199; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039353; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clifton G. L., 2007, J CEREB BLOOD FLOW M, V11, P114; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; DePalma R. G., 2011, P NATO RTO MP HFM 20; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Haorah J, 2011, FREE RADICAL BIO MED, V51, P1601, DOI 10.1016/j.freeradbiomed.2011.06.020; Haorah J, 2008, FREE RADICAL BIO MED, V45, P1542, DOI 10.1016/j.freeradbiomed.2008.08.030; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Hyde D, 2004, CONVENTIONAL WEAPONS; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kinney G. F., 1985, EXPLOSIVE SHOCKS AIR, V1; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Ohnishi M, 2001, EXP PHYSIOL, V86, P357, DOI 10.1113/eph8602145; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rump TJ, 2010, FREE RADICAL BIO MED, V49, P1494, DOI 10.1016/j.freeradbiomed.2010.08.011; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Sawdon M, 2002, EXP PHYSIOL, V87, P683, DOI 10.1113/eph8702432; Selvan V, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4024132; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Southard E. E., 1919, CASE HIST SERIES, V905-982; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Sundaramurthy A, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00253; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025; Zhang JK, 1996, J TRAUMA, V40, pS77	89	54	58	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 7	2016	6								26992	10.1038/srep26992			14	Multidisciplinary Sciences	Science & Technology - Other Topics	DO1QF	WOS:000377552500001	27270403	DOAJ Gold, Green Published			2021-06-18	
J	David, CN; Frias, ES; Szu, JI; Vieira, PA; Hubbard, JA; Lovelace, J; Michael, M; Worth, D; McGovern, KE; Ethell, IM; Stanley, BG; Korzus, E; Fiacco, TA; Binder, DK; Wilson, EH				David, Clement N.; Frias, Elma S.; Szu, Jenny I.; Vieira, Philip A.; Hubbard, Jacqueline A.; Lovelace, Jonathan; Michael, Marena; Worth, Danielle; McGovern, Kathryn E.; Ethell, Iryna M.; Stanley, B. Glenn; Korzus, Edward; Fiacco, Todd A.; Binder, Devin K.; Wilson, Emma H.			GLT-1-Dependent Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite Toxoplasma gondii	PLOS PATHOGENS			English	Article							TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; REPRODUCING INCREASED DOPAMINE; AMYOTROPHIC-LATERAL-SCLEROSIS; TYROSINE-HYDROXYLASE ACTIVITY; ISCHEMIC CORTICAL PENUMBRA; REGULATED ANION CHANNELS; NF-KAPPA-B; ALZHEIMERS-DISEASE; TRANSPORTER GLT-1	The immune privileged nature of the CNS can make it vulnerable to chronic and latent infections. Little is known about the effects of lifelong brain infections, and thus inflammation, on the neurological health of the host. Toxoplasma gondii is a parasite that can infect any mammalian nucleated cell with average worldwide seroprevalence rates of 30%. Infection by Toxoplasma is characterized by the lifelong presence of parasitic cysts within neurons in the brain, requiring a competent immune system to prevent parasite reactivation and encephalitis. In the immunocompetent individual, Toxoplasma infection is largely asymptomatic, however many recent studies suggest a strong correlation with certain neurodegenerative and psychiatric disorders. Here, we demonstrate a significant reduction in the primary astrocytic glutamate transporter, GLT-1, following infection with Toxoplasma. Using microdialysis of the murine frontal cortex over the course of infection, a significant increase in extracellular concentrations of glutamate is observed. Consistent with glutamate dysregulation, analysis of neurons reveal changes in morphology including a reduction in dendritic spines, VGlut1 and NeuN immunoreactivity. Furthermore, behavioral testing and EEG recordings point to significant changes in neuronal output. Finally, these changes in neuronal connectivity are dependent on infection-induced downregulation of GLT-1 as treatment with the beta-lactam antibiotic ceftriaxone, rescues extracellular glutamate concentrations, neuronal pathology and function. Altogether, these data demonstrate that following an infection with T. gondii, the delicate regulation of glutamate by astrocytes is disrupted and accounts for a range of deficits observed in chronic infection.	[David, Clement N.; Frias, Elma S.; Szu, Jenny I.; Hubbard, Jacqueline A.; Michael, Marena; Worth, Danielle; McGovern, Kathryn E.; Ethell, Iryna M.; Binder, Devin K.; Wilson, Emma H.] Univ Calif Riverside, Sch Med, Div Biomed Sci, Riverside, CA 92521 USA; [Vieira, Philip A.; Lovelace, Jonathan; Stanley, B. Glenn; Korzus, Edward] Univ Calif Riverside, Dept Psychol, Riverside, CA 92521 USA; [Fiacco, Todd A.] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA	Wilson, EH (corresponding author), Univ Calif Riverside, Sch Med, Div Biomed Sci, Riverside, CA 92521 USA.	emmaw@ucr.edu		McGovern, Kathryn/0000-0001-8770-2619; Vieira, Philip/0000-0003-0792-2836; Hubbard, Jacqueline/0000-0003-4092-7153	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS067231, NS072298]; UCR's Academic Senate and Office of Research; UCR's Graduate Division;  [NS082570];  [NS081243];  [R01MH106617]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH106617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072298, R21NS071160] Funding Source: NIH RePORTER	Funding to EHW was provided by NIH (NS067231; NS072298) and UCR's Academic Senate and Office of Research, to DKB by (NS082570; NS081243), to CND by UCR's Graduate Division, and to EK (R01MH106617). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032489; Babiloni C, 2015, INT J PSYCHOPHYSIOL; Barger SW, 2007, J NEUROCHEM, V101, P1205, DOI 10.1111/j.1471-4159.2007.04487.x; Berenreiterova M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028925; Brooks JM, 2015, MBIO, V6, DOI 10.1128/mBio.01428-15; BYLSMA FW, 1994, NEUROPSYCHOLOGIA, V32, P137, DOI 10.1016/0028-3932(94)90001-9; Cabral CM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005447; Carbone M, 2012, NEUROCHEM INT, V60, P31, DOI 10.1016/j.neuint.2011.10.017; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dass SAH, 2014, MOL ECOL, V23, P6114, DOI 10.1111/mec.12888; Dellacasa-Lindberg I, 2007, MICROBES INFECT, V9, P1291, DOI 10.1016/j.micinf.2007.06.003; Dickerson F, 2014, BIPOLAR DISORD, V16, P129, DOI 10.1111/bdi.12123; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; DURING MJ, 1993, LANCET, V341, P1607; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Fagard R, 1999, PARASITOLOGY, V15; FERGUSON DJP, 1994, PARASITOL RES, V80, P493, DOI 10.1007/BF00932696; FERGUSON DJP, 1987, VIRCHOWS ARCH A, V411, P39, DOI 10.1007/BF00734512; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; Flegr J, 2013, TRENDS PARASITOL, V29, P156, DOI 10.1016/j.pt.2013.01.007; Flegr J, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-72; Fontana AC, 2015, J NEUROTRAUMA; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Gale SD, 2015, PARASITOLOGY, V142, P557, DOI 10.1017/S0031182014001577; GAZZINELLI R, 1992, J IMMUNOL, V149, P175; Gegelashvili G, 1997, J NEUROCHEM, V69, P2612; Ghosh M, 2011, J NEUROSCI, V31, P9159, DOI 10.1523/JNEUROSCI.0302-11.2011; Giraudon P, 2009, REV NEUROL-FRANCE, V165, P789, DOI 10.1016/j.neurol.2009.07.004; Gonsette RE, 2008, J NEUROL SCI, V274, P48, DOI 10.1016/j.jns.2008.06.029; Gonzalez LE, 2007, BEHAV BRAIN RES, V177, P70, DOI 10.1016/j.bbr.2006.11.012; Gupta RK, 2014, NEUROCHEM RES, V39, P150, DOI 10.1007/s11064-013-1200-3; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; Halpain S, 2000, TRENDS NEUROSCI, V23, P141, DOI 10.1016/S0166-2236(00)01576-9; Hermes G, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-48; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; Honjo K, 2009, ALZHEIMERS DEMENT, V5, P348, DOI 10.1016/j.jalz.2008.12.001; HUNTER CA, 1992, LAB INVEST, V67, P635; Hyzinski-Garcia MC, 2011, J NEUROCHEM, V118, P140, DOI 10.1111/j.1471-4159.2011.07289.x; Ji YF, 2013, GLIA, V61, P1959, DOI 10.1002/glia.22566; John B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000505; Kam JWY, 2013, J PSYCHIATR RES, V47, P1893, DOI 10.1016/j.jpsychires.2013.09.009; Kannan G, 2013, NEUROBIOL DIS, V57, P5, DOI 10.1016/j.nbd.2013.05.012; Kimelberg HK, 2006, GLIA, V54, P747, DOI 10.1002/glia.20423; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Kiryk A, 2008, NEUROTOX RES, V13, P19, DOI 10.1007/BF03033364; Kusbeci OY, 2011, ALZ DIS ASSOC DIS, V25, P1, DOI 10.1097/WAD.0b013e3181f73bc2; Lafferty KD, 2013, J EXP BIOL, V216, P56, DOI 10.1242/jeb.073668; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee M, 2013, NEUROSCIENCE, V229, P164, DOI 10.1016/j.neuroscience.2012.10.033; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Maragakis NJ, 2004, ANN NEUROL, V55, P469, DOI 10.1002/ana.20003; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; McConkey GA, 2015, INFECT IMMUN, V83, P3334, DOI 10.1128/IAI.00605-15; Mendy A, 2015, PARASITOLOGY, V142, P1221, DOI 10.1017/S0031182015000505; Mendy A, 2015, BRAIN BEHAV IMMUN, V45, P36, DOI 10.1016/j.bbi.2014.12.006; Mesci P, 2015, BRAIN, V138, P53, DOI 10.1093/brain/awu312; Miman O, 2010, NEUROSCI LETT, V475, P129, DOI 10.1016/j.neulet.2010.03.057; Miranda AS, 2010, BRAZ J MED BIOL RES, V43, P1173, DOI 10.1590/S0100-879X2010007500130; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Morel L, 2013, J BIOL CHEM, V288, P7105, DOI 10.1074/jbc.M112.410944; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; Parlog A, 2014, DIS MODEL MECH, V7, P459, DOI 10.1242/dmm.014183; Parpura V, 2004, NEUROCHEM INT, V45, P259, DOI 10.1016/j.neuint.2003.12.011; PIANI D, 1994, J IMMUNOL, V152, P3578; Promeneur D, 2013, P NATL ACAD SCI USA, V110, P1035, DOI 10.1073/pnas.1220566110; Raju K, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa4312; Rao PSS, 2014, ALCOHOL ALCOHOLISM, V49, P390, DOI 10.1093/alcalc/agu019; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Schallier A, 2011, J ALZHEIMERS DIS, V24, P287, DOI 10.3233/JAD-2011-101005; Selemon LD, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.115; Soni N, 2014, PHARMACOL BIOCHEM BE, V127, P70, DOI 10.1016/j.pbb.2014.10.001; Strack A, 2002, ACTA NEUROPATHOL, V103, P458, DOI 10.1007/s00401-001-0491-7; Takahashi K, 2015, J EXP MED, V212, P319, DOI 10.1084/jem.20140413; Takaki J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-275; Tauber S C, 2008, Curr Mol Pharmacol, V1, P68; Torrey EF, 2012, SCHIZOPHRENIA BULL, V38, P642, DOI 10.1093/schbul/sbs043; Underhill SM, 2015, J NEUROSCI, V35, P5260, DOI 10.1523/JNEUROSCI.4365-14.2015; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vyas A, 2007, P NATL ACAD SCI USA, V104, P6442, DOI 10.1073/pnas.0608310104; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang ZT, 2015, INFECT IMMUN, V83, P1039, DOI 10.1128/IAI.02465-14; Wang ZT, 2015, INFECT IMMUN, V83, P3336, DOI 10.1128/IAI.00642-15; Watts E, 2015, MBIO, V6, DOI 10.1128/mBio.01155-15; Webster JP, 2006, P R SOC B, V273, P1023, DOI 10.1098/rspb.2005.3413; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson EH, 2005, J NEUROIMMUNOL, V165, P63, DOI 10.1016/j.jneuroim.2005.04.018; Wilson EH, 2004, INT J PARASITOL, V34, P543, DOI 10.1016/j.ijpara.2003.12.010; Wilson EH, 2009, IMMUNITY, V30, P300, DOI 10.1016/j.immuni.2008.12.013; Yamada T, 2006, NEUROCHEM RES, V31, P49, DOI 10.1007/s11064-005-9077-4; Yolken RH, 2001, CLIN INFECT DIS, V32, P842, DOI 10.1086/319221; Zhang YH, 2008, EXP NEUROL, V210, P514, DOI 10.1016/j.expneurol.2007.11.027	95	54	56	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7366	1553-7374		PLOS PATHOG	PLoS Pathog.	JUN	2016	12	6							e1005643	10.1371/journal.ppat.1005643			29	Microbiology; Parasitology; Virology	Microbiology; Parasitology; Virology	DQ6WD	WOS:000379345300016	27281462	DOAJ Gold, Green Published			2021-06-18	
J	Winston, CN; Noel, A; Neustadtl, A; Parsadanian, M; Barton, DJ; Chellappa, D; Wilkins, TE; Alikhani, AD; Zapple, DN; Villapol, S; Planel, E; Burns, MP				Winston, Charisse N.; Noel, Anastasia; Neustadtl, Aidan; Parsadanian, Maia; Barton, David J.; Chellappa, Deepa; Wilkins, Tiffany E.; Alikhani, Andrew D.; Zapple, David N.; Villapol, Sonia; Planel, Emmanuel; Burns, Mark P.			Dendritic Spine Loss and Chronic White Matter Inflammation in a Mouse Model of Highly Repetitive Head Trauma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BRAIN-INJURY CAUSES; AMYLOID-BETA ACCUMULATION; ALZHEIMERS-DISEASE; AXONAL INJURY; OPTIC-NERVE; TRANSGENIC MODEL; MEMORY DEFICITS; RAT MODEL; MILD; TAU	Mild traumatic brain injury (mTBI) is an emerging risk for chronic behavioral, cognitive, and neurodegenerative conditions. Athletes absorb several hundred mTBIs each year; however, rodent models of repeat mTBI (rmTBI) are often Limited to impacts in the single digits. Herein, we describe the effects of 30 rmTBIs, examining structural and pathological changes in mice up to 365 days after injury. We found that single mTBI causes a brief loss of consciousness and a transient reduction in dendritic spines, reflecting a loss of excitatory synapses. Single mTBI does not cause axonal injury, neuroinflammation, or cell death in the gray or white matter. Thirty rmTBIs with a 1-day interval between each mTBI do not cause dendritic spine loss; however, when the interinjury interval is increased to 7 days, dendritic spine Loss is reinstated. Thirty rmTBIs cause white matter pathology characterized by positive silver and Ruoro-Jade B staining, and microglial proliferation and activation. This pathology continues to develop through 60 days, and is still apparent at 365 days, after injury. However, rmTBIs did not increase beta-amyloid Levels or tau phosphorylation in the 3xTg-AD mouse model of Alzheimer disease. Our data reveal that single mTBI causes a transient loss of synapses, but that rmTBIs habituate to repetitive injury within a short time period. rmTBI causes the development of progressive white matter pathology that continues for months after the final impact.	[Winston, Charisse N.; Neustadtl, Aidan; Parsadanian, Maia; Barton, David J.; Chellappa, Deepa; Wilkins, Tiffany E.; Alikhani, Andrew D.; Zapple, David N.; Villapol, Sonia; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC 20057 USA; [Noel, Anastasia; Planel, Emmanuel] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada; [Planel, Emmanuel] CHU Quebec, Res Ctr, Neurosci, Quebec City, PQ, Canada	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, New Res Bldg WP22a,3970 Reservoir Rd NW, Washington, DC 20057 USA.; Planel, E (corresponding author), CHUL, RC-9800,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	emmanuel@planel.org; mpb37@georgetown.edu	Villapol, Sonia/D-1949-2014; Barton, David J/C-9282-2011	Barton, David J/0000-0003-0976-0383; Villapol, Sonia/0000-0002-6174-4113; alikhani, ahmad/0000-0001-9857-8844; Burns, Mark P/0000-0003-4750-2000	Georgetown University's Neural Injury and Plasticity Training Program [T32NS041218]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS067417]; Promote Diversity in Health-Related Research supplement; Alzheimer Society of Canada; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-106423, PCN-102993]; Fonds de Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec [16205, 20048]; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [354722]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS081068, T32NS041218, R03NS067417] Funding Source: NIH RePORTER	Supported by Georgetown University's Neural Injury and Plasticity Training Program grant T32NS041218, supported by the NIH (C.N.W.; principal investigators Dr. Jean Wrathall and Dr. Kathleen Maguire-Zeiss); the National Institute of Neurological Disorders and Stroke grant R01 NS067417 (M.P.B.); a Promote Diversity in Health-Related Research supplement (M.P.B.); a donation from K.P.B. Corporation (M.P.B.); Alzheimer Society of Canada postdoctoral awards (An.N.); the Canadian Institute of Health Research grants MOP-106423 and PCN-102993 (E.P.); Fonds de Recherche en Sante du Quebec grants 16205 and 20048 (E.P.); and the Natural Sciences and Engineering Research Council of Canada grant 354722 (E.P.).	Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bretteville A, 2008, J ALZHEIMERS DIS, V14, P431; BRION JP, 1993, J NEUROCHEM, V61, P2071, DOI 10.1111/j.1471-4159.1993.tb07444.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Duff K, 2005, NAT MED, V11, P826, DOI 10.1038/nm0805-826; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Petry FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094251; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Xu LY, 2015, EXP NEUROL, V273, P168, DOI 10.1016/j.expneurol.2015.08.014	62	54	54	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	MAR	2016	186	3					552	567		10.1016/j.ajpath.2015.11.006			16	Pathology	Pathology	DE9WY	WOS:000370991800011	26857506	Green Published, Bronze			2021-06-18	
J	Unden, L; Calcagnile, O; Unden, J; Reinstrup, P; Bazarian, J				Unden, Linda; Calcagnile, Olga; Unden, Johan; Reinstrup, Peter; Bazarian, Jeff			Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults	BMC MEDICINE			English	Article						Biomarkers; Brain injury; Computed tomography; Decision rule; Guidelines; Head injury; Management; Mild traumatic brain injury; S100B/S100/S100BB; Traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; S100B; RULE; QUESTIONNAIRE; EPIDEMIOLOGY	Background: Acute management of traumatic brain injury (TBI), in particular mild TBI, focuses on the detection of the 5-7 % who may be harboring potentially life-threatening intracranial hemorrhage (IH) using CT scanning. Guidelines intending to reduce unnecessary head CT scans using available clinical variables to detect those at high IH risk have shown varying results. Recently, the Scandinavian Neurotrauma Committee (SNC) derived a new set of high-IH risk variables for adults with TBI using an evidence-based literature review. Unlike previous guidelines, the SNC guideline incorporates serum values of the brain protein S100B with clinical variables. Methods: We performed a nested cohort study of adults with mild TBI presenting to six emergency departments in New York and Pennsylvania within 6 h of injury. Patients were managed according to existing guidelines for CT selection. All patients underwent head CT scanning and serum S100B measurement, as well as prospective collection of clinical variables, as a requirement of the parent study. Using the SNC guidelines, S100B values and clinical variables were applied to these subjects, classifying each into one of five pre-defined severity categories, as well as predicting the need for head CT scanning to identify IH. This classification was then compared to actual head CT results to determine guideline sensitivity and specificity. Results: In total, 662 adults (mean age 42 years, range 18-96; 258 females, 549 Caucasians) were available for analysis; 36 (5 %) had IH on head CT scan. The SNC guidelines had a sensitivity of 97 % (95 % CI, 84-100 %) and a specificity of 34 % (95 % CI, 30-37 %) for the detection of IH on head CT. Application of the SNC guidelines would have resulted in a CT reduction of 32 % (211/662 patients). One patient with low-risk mild TBI and a S100B level under 0.10 mu g/L had a traumatic CT abnormality and would have been discharged with strict adherence to the guidelines. However, this patient did not need any intervention for the injury and had a good outcome. Conclusion: Using the SNC guideline could save approximately one third of CT scans in a pre-selected cohort of mild TBI patients with little or no impact on patient outcome.	[Unden, Linda] Lund Univ, S-20185 Lund, Sweden; [Calcagnile, Olga] Hallands Hosp, Dept Pediat Med, S-30185 Halmstad, Sweden; [Unden, Johan] Lund Univ, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden; [Reinstrup, Peter] Skane Univ Hosp, Dept Neuroanesthesia, S-20185 Lund, Sweden; [Reinstrup, Peter] Lund Univ, S-20185 Lund, Sweden; [Bazarian, Jeff] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA	Unden, J (corresponding author), Lund Univ, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com					Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Choi SJ, 2014, PEDIATR EMERG CARE, V30, P479, DOI 10.1097/PEC.0000000000000165; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kelly JC, 2010, IRISH J MED SCI, V179, P557, DOI 10.1007/s11845-010-0499-x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Unden J, 2009, SCAND J CLIN LAB INV, V69, P13, DOI 10.1080/00365510802651833	25	54	54	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1741-7015			BMC MED	BMC Med.	DEC 9	2015	13								292	10.1186/s12916-015-0533-y			9	Medicine, General & Internal	General & Internal Medicine	CY1KT	WOS:000366165800001	26645914	DOAJ Gold, Green Published			2021-06-18	
J	Mez, J; Solomon, TM; Daneshvar, DH; Murphy, L; Kiernan, PT; Montenigro, PH; Kriegel, J; Abdolmohammadi, B; Fry, B; Babcock, KJ; Adams, JW; Bourlas, AP; Papadopoulos, Z; McHale, L; Ardaugh, BM; Martin, BR; Dixon, D; Nowinski, CJ; Chaisson, C; Alvarez, VE; Tripodis, Y; Stein, TD; Goldstein, LE; Katz, DI; Kowall, NW; Cantu, RC; Stern, RA; McKee, AC				Mez, Jesse; Solomon, Todd M.; Daneshvar, Daniel H.; Murphy, Lauren; Kiernan, Patrick T.; Montenigro, Philip H.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; McHale, Lisa; Ardaugh, Brent M.; Martin, Brett R.; Dixon, Diane; Nowinski, Christopher J.; Chaisson, Christine; Alvarez, Victor E.; Tripodis, Yorghos; Stein, Thor D.; Goldstein, Lee E.; Katz, Douglas I.; Kowall, Neil W.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.			Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study	ALZHEIMERS RESEARCH & THERAPY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; ALZHEIMERS ASSOCIATION WORKGROUPS; RESEARCH DIAGNOSTIC-CRITERIA; 21ST-CENTURY BRAIN BANKING; MILD COGNITIVE IMPAIRMENT; FOOTBALL-LEAGUE PLAYER; NATIONAL-INSTITUTE; NEUROPATHOLOGIC ASSESSMENT; COLUMBIA-UNIVERSITY; PARKINSON-DISEASE	Introduction: Chronic traumatic encephalopathy (CTE) is a progressive neurodegeneration associated with repetitive head impacts. Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) is a U01 project recently funded by the National Institute of Neurological Disorders and Stroke and the National Institute of Biomedical Imaging and Bioengineering. The goal of the UNITE project is to examine the neuropathology and clinical presentation of brain donors designated as "at risk" for the development of CTE based on prior athletic or military exposure. Here, we present the rationale and methodology for UNITE. Methods: Over the course of 4 years, we will analyze the brains and spinal cords of 300 deceased subjects who had a history of repetitive head impacts sustained during participation in contact sports at the professional or collegiate level or during military service. Clinical data are collected through medical record review and retrospective structured and unstructured family interviews conducted by a behavioral neurologist or neuropsychologist. Blinded to the clinical data, a neuropathologist conducts a comprehensive assessment for neurodegenerative disease, including CTE, using published criteria. At a clinicopathological conference, a panel of physicians and neuropsychologists, blinded to the neuropathological data, reaches a clinical consensus diagnosis using published criteria, including proposed clinical research criteria for CTE. Results: We will investigate the validity of these clinical criteria and sources of error by using recently validated neuropathological criteria as a gold standard for CTE diagnosis. We also will use statistical modeling to identify diagnostic features that best predict CTE pathology. Conclusions: The UNITE study is a novel and methodologically rigorous means of assessing clinicopathological correlation in CTE. Our findings will be critical for developing future iterations of CTE clinical diagnostic criteria.	[Mez, Jesse; Solomon, Todd M.; Daneshvar, Daniel H.; Murphy, Lauren; Kiernan, Patrick T.; Montenigro, Philip H.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; Alvarez, Victor E.; Stein, Thor D.; Goldstein, Lee E.; Kowall, Neil W.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Mez, Jesse; Murphy, Lauren; Kiernan, Patrick T.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; Goldstein, Lee E.; Katz, Douglas I.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; McHale, Lisa; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Ardaugh, Brent M.; Martin, Brett R.; Dixon, Diane; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Alvarez, Victor E.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] VA Boston Healthcare Syst, US Dept Vet Affairs, Jamaica Plain, MA 02130 USA; [Alvarez, Victor E.; Stein, Thor D.; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA; [Alvarez, Victor E.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA 02184 USA; [Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA	McKee, AC (corresponding author), Boston Univ, Sch Med, Alzheimers Dis Ctr, 72 East Concord St,B-7800, Boston, MA 02118 USA.	amckee@bu.edu	Kowall, Neil/M-5378-2019; , Bob/ABA-8507-2020	Kowall, Neil/0000-0002-6624-0213; Papadopoulos, Zachary/0000-0001-5681-1388; Daneshvar, Daniel/0000-0003-3691-9513; Stein, Thor/0000-0001-6954-4477; Montenigro, Philip/0000-0003-4442-9207; Tripodis, Yorghos/0000-0003-2190-7608	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1UO1NS086659-01, R01 NS078337, R56 NS078337]; U.S. Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; U.S. Department of Veterans Affairs, the Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS); Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute on Aging Boston University Alzheimer's Disease Center [P30AG13846]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP grant) [13267017]; National Institute on Aging Boston University Framingham Heart Study [R01 AG1649]; National Operating Committee on Standards for Athletic Equipment; Sports Legacy Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337, U01NS086659, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, K23AG046377] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA, USA). We also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the VA Boston Healthcare System, and the individuals and families whose participation and contributions made this work possible. This work was supported by the National Institute of Neurological Disorders and Stroke (grants 1UO1NS086659-01, R01 NS078337, R56 NS078337), the U.S. Department of Defense (grant W81XWH-13-2-0064), the U.S. Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS), the Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (grant B6796-C), the National Institute on Aging Boston University Alzheimer's Disease Center (grant P30AG13846; supplement 0572063345-5), the Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP grant 13267017), the National Institute on Aging Boston University Framingham Heart Study (grant R01 AG1649), the National Operating Committee on Standards for Athletic Equipment, and the Sports Legacy Institute. This work was also supported by unrestricted gifts from the Andlinger Family Foundation, the WWE, and the NFL.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Berk RA, 2008, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-77501-2_1; Bertens LCM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001531; Bigio EH, 2008, J NEUROPATH EXP NEUR, V67, P635, DOI 10.1097/NEN.0b013e31817d751c; BLACKER D, 1994, ARCH NEUROL-CHICAGO, V51, P1198, DOI 10.1001/archneur.1994.00540240042014; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2008, NEUROLOGY, V70, P1916, DOI 10.1212/01.wnl.0000312279.49272.9f; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Cleveland Clinic Canada, 2009, HEAD INT QUEST; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIC, V2nd, P232; Del Tredici K, 2002, J NEUROPATH EXP NEUR, V61, P413, DOI 10.1093/jnen/61.5.413; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; First M., 1995, STRUCTURED CLIN INTE; Gabel MJ, 2004, J HEALTH ECON, V23, P543, DOI 10.1016/j.jhealeco.2003.10.004; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Kraemer HC, 2014, ANNU REV CLIN PSYCHO, V10, P111, DOI 10.1146/annurev-clinpsy-032813-153739; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Love S., 2008, GREENFIELDS NEUROPAT, V8th; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P417; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; McNair M, 1983, ASSESSMENT GERIATRIC, P137; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Roth R.M., 2005, BEHAV RATING INVENTO; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shen H, 2015, NATURE, V518, P466, DOI 10.1038/518466a; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Walker MP, 2000, BRIT J PSYCHIAT, V177, P252, DOI 10.1192/bjp.177.3.252; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	78	54	54	1	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.	OCT 12	2015	7								62	10.1186/s13195-015-0148-8			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CT2KD	WOS:000362629500001	26455775	DOAJ Gold, Green Published			2021-06-18	
J	Gao, WW; Zhao, ZL; Yu, GJ; Zhou, ZW; Zhou, Y; Hu, TT; Jiang, RC; Zhang, JN				Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Hu, Tingting; Jiang, Rongcai; Zhang, Jianning			VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-kappa B signaling pathway in experimental traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Nuclear factor-kappa B (NF-kappa B); Inflammatory cytokine; Blood brain barrier	TOLL-LIKE RECEPTORS; RAT MODEL; NEURONAL APOPTOSIS; IMMUNE-SYSTEM; LESION SIZE; MOUSE MODEL; CNS; EXPRESSION; GROWTH; CELLS	Acute traumatic brain injury (TBI) tends to cause the over-activation of inflammatory response and disruption of blood brain barrier (BBB), associating with long-term cognitive and behavioral dysfunction. Vascular endothelial growth inhibitor (VEGI), as a suppressor in the angiogenesis specifically by inducing apoptosis in proliferating endothelial cells, has been applied to different diseases, especially the tumors. But rare study had been done in the field of brain injury. So in this study, we investigated the effects and mechanisms associated with VEGI-induced neuroprotection following CNS injury in mice TBI models. We demonstrated that the VEGI treatment reduced the contusion brain tissue loss, the permeation of inflammatory cells (MPO+) and the activation of microglia (Iba-1(+)). The treatment upregulated the tight junction proteins (CLN5, ZO-1 and OCLN), which are vital importance for the integrity of the blood brain barrier (BBB), the B-cell lymphoma 2 (Bcl-2) cell survival factors, while down-regulated the expression of TLR4, NF-kappa B and inflammatory cytokines (IL-1 beta, TNF-alpha, iNOS). The treatment also decreased the expression of reactive astrocytes (GFAP(+)), as well as the VEGF, and lowered the permeability of Evens Blue (EB). These findings suggested that the VEGI-treatment could alleviate the post-traumatic excessive inflammatory response, and maintain the stability of blood vessels, remitting the secondary brain damage. (C) 2015 Published by Elsevier B.V.	[Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Gao, Weiwei; Zhao, Zilong; Yu, Gongjie; Zhou, Ziwei; Zhou, Yuan; Jiang, Rongcai; Zhang, Jianning] Minist Educ & Tianjin City, Key Lab Postneurotrauma Neurorepair & Regenerat C, Tianjin 300052, Peoples R China; [Hu, Tingting] Tianjin Med Univ, Gen Hosp, Dept Nursing, Tianjin 300052, Peoples R China	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Minist Educ, 154 Anshan Rd, Tianjin 300052, Peoples R China.	hongw1980@hotmail.com; ZilongZ@psbc.org; yugongjie@hotmail.com; 1985zhouziwei@163.com; zy963000@126.com; tingtinghu91@hotmail.com; jianghope@gmail.com; jianningzhang@hotmail.com	Zhao, Zilong/AAZ-2196-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81330029]	We acknowledge Wei-yun Cui, Li Liu and Lei Zhou for their excellent technical support. The work is supported by the National Natural Science Foundation of China (Grants 81271361 and 81330029).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Barclay L.A., 2015, MOL CELL; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Cao GD, 2002, J NEUROSCI, V22, P5423; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Conway Kevin P, 2007, Int Wound J, V4, P55, DOI 10.1111/j.1742-481X.2006.00295.x; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Li YN, 2014, J NEUROCHEM, V129, P120, DOI 10.1111/jnc.12611; Liu B, 2015, INT J BIOL SCI, V11, P353, DOI 10.7150/ijbs.9813; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Ryu JK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-18; Smith CC, 2015, ALCOHOL CLIN EXP RES, V39, P36, DOI 10.1111/acer.12606; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xu LX, 2014, INT J BIOCHEM CELL B, V55, P109, DOI 10.1016/j.biocel.2014.08.015; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yuksel H, 2013, NEUROL SCI, V34, P1941, DOI 10.1007/s10072-013-1411-z; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073	40	54	55	0	30	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 5	2015	1622						230	239		10.1016/j.brainres.2015.04.035			10	Neurosciences	Neurosciences & Neurology	CS4OC	WOS:000362054100022	26080076				2021-06-18	
J	Dennis, EL; Ellis, MU; Marion, SD; Jin, Y; Moran, L; Olsen, A; Kernan, C; Babikian, T; Mink, R; Babbitt, C; Johnson, J; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Ellis, Monica U.; Marion, Sarah D.; Jin, Yan; Moran, Lisa; Olsen, Alexander; Kernan, Claudia; Babikian, Talin; Mink, Richard; Babbitt, Christopher; Johnson, Jeffrey; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			Callosal Function in Pediatric Traumatic Brain Injury Linked to Disrupted White Matter Integrity	JOURNAL OF NEUROSCIENCE			English	Article						corpus callosum; DTI; ERP; interhemispheric transfer time; traumatic brain injury	POTENTIAL INTERHEMISPHERIC TRANSMISSION; CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; TRANSFER TIME; RADIAL DIFFUSIVITY; EVOKED-POTENTIALS; VISUAL PROCESSES; AXONAL INJURY; DISCONNECTION; INFORMATION	Traumatic brain injury (TBI) often results in traumatic axonal injury and white matter (WM) damage, particularly to the corpus callosum (CC). Damage to the CC can lead to impaired performance on neurocognitive tasks, but there is a high degree of heterogeneity in impairment following TBI. Here we examined the relation between CC microstructure and function in pediatric TBI. We used high angular resolution diffusion-weighted imaging (DWI) to evaluate the structural integrity of the CC in humans following brain injury in a sample of 32 children (23 males and 9 females) with moderate-to-severe TBI (msTBI) at 1-5 months postinjury, compared with well matched healthy control children. We assessed CC function through interhemispheric transfer time (IHTT) as measured using event-related potentials (ERPs), and related this to DWI measures of WM integrity. Finally, the relation between DWI and IHTT results was supported by additional results of neurocognitive performance assessed using a single composite performance scale. Half of the msTBI participants (16 participants) had significantly slower IHTTs than the control group. This slow IHTT group demonstrated lower CC integrity (lower fractional anisotropy and higher mean diffusivity) and poorer neurocognitive functioning than both the control group and the msTBI group with normal IHTTs. Lower fractional anisotropy-a common sign of impaired WM-and slower IHTTs also predicted poor neurocognitive function. This study reveals that there is a subset of pediatric msTBI patients during the post-acute phase of injury who have markedly impaired CC functioning and structural integrity that is associated with poor neurocognitive functioning.	[Dennis, Emily L.; Jin, Yan; Thompson, Paul M.] Univ So Calif, Keck Sch Med, Mary & Mark Stevens Inst Neuroimaging & Informat, Imaging Genet Ctr, Marina Del Rey, CA 90292 USA; [Ellis, Monica U.; Moran, Lisa; Olsen, Alexander; Kernan, Claudia; Babikian, Talin; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Ellis, Monica U.; Marion, Sarah D.] Fuller Theol Seminary, Sch Psychol, Pasadena, CA 91101 USA; [Olsen, Alexander] Norwegian Univ Sci & Technol, Dept Psychol, NO-7491 Trondheim, Norway; [Olsen, Alexander] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, NO-7030 Trondheim, Norway; [Mink, Richard] Harbor UCLA Med Ctr, Torrance, CA 90502 USA; [Mink, Richard] Los Angeles BioMed Res Inst, Dept Pediat, Torrance, CA 90502 USA; [Babbitt, Christopher] Miller Childrens Hosp, Long Beach, CA 90806 USA; [Johnson, Jeffrey] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA 90033 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA; [Thompson, Paul M.] Univ So Calif, Dept Neurol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Pediat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Psychiat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Radiol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Engn, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Thompson, PM (corresponding author), Univ So Calif, Keck Sch Med, 2001 N Soto St, Los Angeles, CA 90033 USA.	pthomp@usc.edu	Thompson, Paul M/C-4194-2018; Jin, Yan/N-5037-2016; Olsen, Alexander/P-5235-2019; Dennis, Emily/AAD-5223-2021	Thompson, Paul M/0000-0002-4720-8867; Jin, Yan/0000-0001-9392-5552; Olsen, Alexander/0000-0001-8691-3860; 	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061504]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403, R01 EB008432, R01 AG040060, R01 NS080655]; UCLA Brain Injury Research Center [NS027544, NS05489]; Child Neurology Foundation; Jonathan Drown Foundation; Staglin IMHRO Center for Cognitive Neuroscience; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB008432, U54EB020403, P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080655, R01NS027544, K99NS096116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant R01 HD061504). E.L.D., Y.J., and P.M.T. are also supported by the National Institutes of Health Grants U54 EB020403, R01 EB008432, R01 AG040060, and R01 NS080655 to P.M.T., C.C.G. is supported by the UCLA Brain Injury Research Center (Grants NS027544 and NS05489), the Child Neurology Foundation, and the Jonathan Drown Foundation. Scanning was supported by the Staglin IMHRO Center for Cognitive Neuroscience. We thank Alma Martinez and Alma Ramirez for assisting with participant recruitment and study coordination. Finally, we thank the participants and their families for contributing their time to this study.	ANDREASSI JL, 1975, PSYCHOPHYSIOLOGY, V12, P541, DOI 10.1111/j.1469-8986.1975.tb00043.x; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bartzokis G, 2010, NEUROBIOL AGING, V31, P1554, DOI 10.1016/j.neurobiolaging.2008.08.015; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; BROWN WS, 1993, NEUROPSYCHOLOGIA, V31, P1267, DOI 10.1016/0028-3932(93)90097-J; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; DAMASIO AR, 1980, J NEUROL NEUROSUR PS, V43, P351, DOI 10.1136/jnnp.43.4.351; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Ellis M. U., 2015, J NEUROTRAU IN PRESS; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; GAZZANIGA MS, 1973, NEUROLOGY, V23, P1126, DOI 10.1212/WNL.23.10.1126; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jin Y, 2011, 2011 IEEE INT S BIOM; Jin Y, 2013, 2013 IEEE 10 INT S B; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Yan, 2012, Multimodal Brain Image Anal (2012), V7509, P147, DOI 10.1007/978-3-642-33530-3_12; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Kochunov P, 2012, NEUROBIOL AGING, V33, P9, DOI 10.1016/j.neurobiolaging.2010.01.014; Larson EB, 1997, NEUROPSYCHOLOGIA, V35, P573; LASSONDE M, 1988, BEHAV BRAIN RES, V30, P165, DOI 10.1016/0166-4328(88)90146-5; LEDLOW A, 1978, ANN NEUROL, V3, P525, DOI 10.1002/ana.410030613; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LINDENBERG R, 1955, AM J PATHOL, V31, P297; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; RUGG MD, 1985, J NEUROL NEUROSUR PS, V48, P367, DOI 10.1136/jnnp.48.4.367; SARON CD, 1989, BEHAV NEUROSCI, V103, P1115, DOI 10.1037/0735-7044.103.5.1115; SAUERWEIN H, 1983, NEUROPSYCHOLOGIA, V21, P167, DOI 10.1016/0028-3932(83)90084-2; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; SUGISHITA M, 1987, NEUROPSYCHOLOGIA, V25, P329, DOI 10.1016/0028-3932(87)90022-4; Thomason ME, 2011, ANNU REV CLIN PSYCHO, V7, P63, DOI 10.1146/annurev-clinpsy-032210-104507; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Wechsler D., 2003, WECHSLER INTELLIGENC; Westerhausen R, 2006, NEUROSCI LETT, V409, P140, DOI 10.1016/j.neulet.2006.09.028; Whitford TJ, 2011, NEUROIMAGE, V54, P2318, DOI 10.1016/j.neuroimage.2010.10.048; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	55	54	55	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 15	2015	35	28					10202	10211		10.1523/JNEUROSCI.1595-15.2015			10	Neurosciences	Neurosciences & Neurology	CN3BO	WOS:000358298500010	26180196	Green Published, Bronze			2021-06-18	
J	Di Battista, AP; Buonora, JE; Rhind, SG; Hutchison, MG; Baker, AJ; Rizoli, SB; Diaz-Arrastia, R; Mueller, GP				Di Battista, Alex P.; Buonora, John E.; Rhind, Shawn G.; Hutchison, Michael G.; Baker, Andrew J.; Rizoli, Sandro B.; Diaz-Arrastia, Ramon; Mueller, Gregory P.			Blood biomarkers in moderate-to-severe traumatic brain injury: potential utility of a multi-marker approach in characterizing outcome	FRONTIERS IN NEUROLOGY			English	Article						s100B; GFAP; NSE; BDNF; MCP-1; ICAM-5; PRDX-6	NEURON-SPECIFIC ENOLASE; NEUROTROPHIC FACTOR; PROGNOSTIC VALUE; S100B LEVELS; SERUM; HEAD; PROTEIN; MCP-1; NEUROINFLAMMATION; INFLAMMATION	Background: Blood biomarkers are valuable tools for elucidating complex cellular and molecular mechanisms underlying traumatic brain injury (TBI). Profiling distinct classes of biomarkers could aid in the identification and characterization of initial injury and secondary pathological processes. This study characterized the prognostic performance of a recently developed multi-marker panel of circulating biomarkers that reflect specific pathogenic mechanisms including neuroinflammation, oxidative damage, and neuroregeneration, in moderate-to-severe TBI patients. Materials and methods: Peripheral blood was drawn from 85 isolated TBI patients (n = 60 severe, n = 25 moderate) at hospital admission, 6-, 12-, and 24-h post-injury. Mortality and neurological outcome were assessed using the extended Glasgow Outcome Scale. A multiplex platform was designed on MULTI-SPOT plates to simultaneously analyze human plasma levels of s100 calcium binding protein beta (s100B), glial fibrillary acidic protein (GFAP), neuron specific enolase (NSF), brain-derived neurotrophic factor (BDNF), monocyte chemoattractant protein (MCP)-1, intercellular adhesion molecule (ICAM)-5, and peroxiredoxin (PRDX)-6. Multivariable logistic regression and area under the receiver-operating characteristic curve (AUC) were used to evaluate both individual and combined predictive abilities of these markers for 6-month neurological outcome and mortality after TBI. Results: Unfavorable neurological outcome was associated with elevations in s100B, GFAP, and MCP-1. Mortality was related to differences in six of the seven markers analyzed. Combined admission concentrations of s100B, GFAP, and MCP-1 were able to discriminate favorable versus unfavorable outcome (AUC = 0.83), and survival versus death (AUG = 0.87), although not significantly better than s100B alone (AUG = 0.82 and 0.86, respectively). Conclusion: The multi-marker panel of TBI-related biomarkers performed well in discriminating unfavorable and favorable outcomes in the acute period after moderateto-severe TBI. However, the combination of these biomarkers did not outperform s100B alone.	[Di Battista, Alex P.; Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M3K 2C9, Canada; [Di Battista, Alex P.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Di Battista, Alex P.; Baker, Andrew J.; Rizoli, Sandro B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Buonora, John E.; Mueller, Gregory P.] Univ Hlth Sci, Uniformed Serv, Dept Anat Physiol & Genet, Bethesda, MD USA; [Buonora, John E.] US Army, Grad Program Anesthesia Nursing, Ft Sam Houston, TX USA; [Rhind, Shawn G.; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, David L Maclntosh Sport Med Clin, Toronto, ON, Canada; [Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Dept Surg & Crit Care Med, Toronto, ON, Canada; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Di Battista, AP (corresponding author), Univ Toronto, Inst Med Sci, Fac Med, 1133 Sheppard Ave West, Toronto, ON M3K 2C9, Canada.	alex.dibattista@mail.utoronto.ca		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833	Defence Research and Development Canada Technology Investment Fund Programme; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Tr-Service Nursing Research Program [HT9404-12-1-T513]	The authors gratefully acknowledge the technical assistance of Ms. Maria Shiu and Mr. Shahid Hassan. This research was funded by the Defence Research and Development Canada Technology Investment Fund Programme, the Center for Neuroscience and Regenerative Medicine, and the Tr-Service Nursing Research Program, Grant #HT9404-12-1-T513.	Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Denes A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00382; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Finnie JW, 2014, VET RES COMMUN, V38, P297, DOI 10.1007/s11259-014-9616-z; Gaddam Samson Sujit Kumar, 2015, Handb Clin Neurol, V127, P205, DOI 10.1016/B978-0-444-52892-6.00014-3; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Guo H, 2000, ANN NEUROL, V48, P590, DOI 10.1002/1531-8249(200010)48:4<590::AID-ANA5>3.3.CO;2-Z; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Mondello Stefania, 2015, Handb Clin Neurol, V127, P245, DOI 10.1016/B978-0-444-52892-6.00016-7; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Tulsawani R, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-125; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2013, PROC SPIE, V8723, DOI 10.1117/12.2020030; Wolf H, 2015, J NEUROTRAUM, V32, P23, DOI 10.1089/neu.2013.3202; Yang HP, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/368938; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	49	54	54	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAY 26	2015	6								110	10.3389/fneur.2015.00110			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU9DC	WOS:000363842300002	26074866	DOAJ Gold, Green Published			2021-06-18	
J	Saxena, M; Young, P; Pilcher, D; Bailey, M; Harrison, D; Bellomo, R; Finfer, S; Beasley, R; Hyam, J; Menon, D; Rowan, K; Myburgh, J				Saxena, Manoj; Young, Paul; Pilcher, David; Bailey, Michael; Harrison, David; Bellomo, Rinaldo; Finfer, Simon; Beasley, Richard; Hyam, Jonathan; Menon, David; Rowan, Kathryn; Myburgh, John			Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection	INTENSIVE CARE MEDICINE			English	Article						Temperature; Mortality; Stroke; Traumatic brain injury; Meningitis; Encephalitis	BODY-TEMPERATURE; BACTERIAL-MENINGITIS; RISK PREDICTION; BRAIN-INJURY; FEVER; HYPERTHERMIA; CARE; NORMOTHERMIA; MANAGEMENT; SEVERITY	Fever suppression may be beneficial for patients with traumatic brain injury (TBI) and stroke, but for patients with meningitis or encephalitis [central nervous system (CNS) infection], the febrile response may be advantageous. To evaluate the relationship between peak temperature in the first 24 h of intensive care unit (ICU) admission and all-cause hospital mortality for acute neurological diseases. Retrospective cohort design from 2005 to 2013, including 934,159 admissions to 148 ICUs in Australia and New Zealand (ANZ) and 908,775 admissions to 236 ICUs in the UK. There were 53,942 (5.8 %) patients in ANZ and 56,696 (6.2 %) patients in the UK with a diagnosis of TBI, stroke or CNS infection. For both the ANZ (P = 0.02) and UK (P < 0.0001) cohorts there was a significant interaction between early peak temperature and CNS infection, indicating that the nature of the relationship between in-hospital mortality and peak temperature differed between TBI/stroke and CNS infection. For patients with CNS infection, elevated peak temperature was not associated with an increased risk of death, relative to the risk at 37-37.4 A degrees C (normothermia). For patients with stroke and TBI, peak temperature below 37 A degrees C and above 39 A degrees C was associated with an increased risk of death, compared to normothermia. The relationship between peak temperature in the first 24 h after ICU admission and in-hospital mortality differs for TBI/stroke compared to CNS infection. For CNS infection, increased temperature is not associated with increased risk of death.	[Saxena, Manoj; Finfer, Simon; Myburgh, John] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia; [Saxena, Manoj; Myburgh, John] Univ New S Wales, St George Hosp Clin Sch, Sydney, NSW, Australia; [Young, Paul] Wellington Reg Hosp, Intens Care Unit, Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Young, Paul; Beasley, Richard] Med Res Inst New Zealand, Wellington, New Zealand; [Pilcher, David; Bailey, Michael; Bellomo, Rinaldo] Australian & New Zealand Intens Care Soc Ctr Outc, Melbourne, Vic, Australia; [Pilcher, David] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Pilcher, David] Alfred Hosp, Dept Intens Care, Prahran, Vic 3181, Australia; [Harrison, David; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, London, England; [Finfer, Simon] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Hyam, Jonathan] Natl Hosp Neurol & Neurosurg, Victor Horsely Dept Neurosurg, London WC1N 3BG, England; [Menon, David] Univ Cambridge, Div Anaesthesia, Cambridge, England	Saxena, M (corresponding author), George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.	m.saxena@unsw.edu.au	Beasley, Richard/AAH-3908-2019; Harrison, David A/O-4355-2018; Bailey, Michael J/A-4499-2012	Beasley, Richard/0000-0003-0337-406X; Harrison, David A/0000-0002-9002-9098; Bailey, Michael J/0000-0002-5551-1401; Finfer, Simon/0000-0002-2785-5864; Young, Paul/0000-0002-3428-3083; Pilcher, David/0000-0002-8939-7985; Saxena, Manoj/0000-0002-0385-6731; Bellomo, Rinaldo/0000-0002-1650-8939			Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Blanford S, 1998, ECOL ENTOMOL, V23, P9, DOI 10.1046/j.1365-2311.1998.00104.x; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chaudhuri A, 2008, EUR J NEUROL, V15, P649, DOI 10.1111/j.1468-1331.2008.02193.x; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; de Jonge RCJ, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-232; den Hertog HM, 2011, J NEUROL, V258, P302, DOI 10.1007/s00415-010-5756-4; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Diringer MN, 2004, CRIT CARE MED, V32, P2170; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Frank B, 2013, ACTA NEUROL SCAND, V128, P172, DOI 10.1111/ane.12094; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Harrison DA, 2005, CRIT CARE, V9; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Hensch PS, 1935, JAMA-J AM MED ASSOC, V104, P1779; Jorgensen HS, 2001, CEREBROVASC DIS, V11, P207, DOI 10.1159/000047640; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KLUGER MJ, 1979, AM ZOOL, V19, P295; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Kushimoto S, 2013, CRIT CARE, V17, DOI 10.1186/cc13106; Lee BH, 2012, CRIT CARE, V16, DOI 10.1186/cc11211; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Mackowiak PA, 1998, ARCH INTERN MED, V158, P1870, DOI 10.1001/archinte.158.17.1870; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Moench M., 1926, J LAB CLIN MED, V57, P665; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Paul E, 2013, J CRIT CARE, V28, P935, DOI 10.1016/j.jcrc.2013.07.058; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Sacho RH, 2008, BRIT J NEUROSURG, V22, P497, DOI 10.1080/02688690802245558; Saxena M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006811.pub3; Saxena M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006811.pub2; Saxena MK, 2013, CRIT CARE RESUSC, V15, P110; Seguin P, 2012, CRIT CARE, V16, DOI 10.1186/cc11465; Starks PT, 2000, NATURWISSENSCHAFTEN, V87, P229, DOI 10.1007/s001140050709; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Stow PJ, 2006, J CRIT CARE, V21, P133, DOI 10.1016/j.jcrc.2005.11.010; SYDENHAM E, 2009, COCHRANE DATABASE SY; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Young PJ, 2011, MED J AUSTRALIA, V195, P458, DOI 10.5694/mja11.10502; Young PJ, 2012, INTENS CARE MED, V38, P437, DOI 10.1007/s00134-012-2478-3	52	54	56	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2015	41	5					823	832		10.1007/s00134-015-3676-6			10	Critical Care Medicine	General & Internal Medicine	CH2FR	WOS:000353841600008	25643903	Green Published, Other Gold			2021-06-18	
J	McMahon, PJ; Panczykowski, DM; Yue, JK; Puccio, AM; Inoue, T; Sorani, MD; Lingsma, HF; Maas, AIR; Valadka, AB; Yuh, EL; Mukherjee, P; Manley, GT; Okonkwo, DO; Casey, SS; Cheong, M; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Hricik, AJ; Lawless, K; Menon, D; Schnyer, DM; Vassar, MJ				McMahon, Paul J.; Panczykowski, David M.; Yue, John K.; Puccio, Ava M.; Inoue, Tomoo; Sorani, Marco D.; Lingsma, Hester F.; Maas, Andrew I. R.; Valadka, Alex B.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.; Okonkwo, David O.; Casey, Scott S.; Cheong, Maxwell; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Hricik, Allison J.; Lawless, Kerri; Menon, David; Schnyer, David M.; Vassar, Mary J.		TRACK-TBI Investigators Including	Measurement of the Glial Fibrillary Acidic Protein and Its Breakdown Products GFAP-BDP Biomarker for the Detection of Traumatic Brain Injury Compared to Computed Tomography and Magnetic Resonance Imaging	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; imaging; traumatic brain injury	COMMON DATA ELEMENTS; NEW-ORLEANS CRITERIA; MINOR HEAD-INJURY; NEUROSURGICAL INTERVENTION; TRANSFORMING RESEARCH; INTRACRANIAL LESIONS; CLINICAL KNOWLEDGE; DECISION-MAKING; SERUM; MILD	Glial fibrillary acidic protein and its breakdown products (GFAP-BDP) are brain-specific proteins released into serum as part of the pathophysiological response after traumatic brain injury (TBI). We performed a multi-center trial to validate and characterize the use of GFAP-BDP levels in the diagnosis of intracranial injury in a broad population of patients with a positive clinical screen for head injury. This multi-center, prospective, cohort study included patients 16-93 years of age presenting to three level 1 trauma centers with suspected TBI (loss of consciousness, post-trauma amnesia, and so on). Serum GFAP-BDP levels were drawn within 24 h and analyzed, in a blinded fashion, using sandwich enzyme-linked immunosorbent assay. The ability of GFAP-BDP to predict intracranial injury on admission computed tomography (CT) as well as delayed magnetic resonance imaging was analyzed by multiple regression and assessed by the area under the receiver operating characteristic curve (AUC). Utility of GFAP-BDP to predict injury and reduce unnecessary CT scans was assessed utilizing decision curve analysis. A total of 215 patients were included, of which 83% suffered mild TBI, 4% moderate, and 12% severe; mean age was 42.1 +/- 18 years. Evidence of intracranial injury was present in 51% of the sample (median Rotterdam Score, 2; interquartile range, 2). GFAP-BDP demonstrated very good predictive ability (AUC=0.87) and demonstrated significant discrimination of injury severity (odds ratio, 1.45; 95% confidence interval, 1.29-1.64). Use of GFAP-BDP yielded a net benefit above clinical screening alone and a net reduction in unnecessary scans by 12-30%. Used in conjunction with other clinical information, rapid measurement of GFAP-BDP is useful in establishing or excluding the diagnosis of radiographically apparent intracranial injury throughout the spectrum of TBI. As an adjunct to current screening practices, GFAP-BDP may help avoid unnecessary CT scans without sacrificing sensitivity (Registry: ClinicalTrials.gov Identifier: NCT01565551).	[McMahon, Paul J.; Panczykowski, David M.; Puccio, Ava M.; Okonkwo, David O.; Hricik, Allison J.; Lawless, Kerri] Univ Pittsburgh Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Yue, John K.; Inoue, Tomoo; Sorani, Marco D.; Manley, Geoffrey T.; Casey, Scott S.; Cooper, Shelly R.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yuh, Esther L.; Mukherjee, Pratik; Cheong, Maxwell] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Menon, David] Univ Cambridge, Devis Anesthesia, Cambridge, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh Med Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Cooper, Shelly/0000-0003-0026-6688; Mukherjee, Pratik/0000-0001-7473-7409	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RC2 NS069409]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was funded by the National Institutes of Health (grant no.: 1RC2 NS069409).	Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hunink MGM, 2005, RADIOLOGY, V235, P375, DOI 10.1148/radiol.2352040727; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Lee YB, 2000, BRAIN RES, V864, P220, DOI 10.1016/S0006-8993(00)02180-6; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	23	54	56	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					527	533		10.1089/neu.2014.3635			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900002	25264814	Green Published			2021-06-18	
J	Vargas, G; Rabinowitz, A; Meyer, J; Arnett, PA				Vargas, Gray; Rabinowitz, Amanda; Meyer, Jessica; Arnett, Peter A.			Predictors and Prevalence of Postconcussion Depression Symptoms in Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; depressive symptoms; sports	TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; COGNITIVE RESERVE; MILD; CONCUSSION; ASSOCIATION; IMPAIRMENT; DISORDERS	Context: Depression is common after concussion and is associated with functional outcome and quality of life after injury. However, few baseline predictors of postconcussion depressive symptoms (PCDS) have been found. Objective: To describe the prevalence of depressive symptoms in a collegiate athlete sample at baseline and postconcussion, compare these levels of symptoms and change in symptoms with those of a control group with no reported concussions in the past year, and examine the baseline predictors for PCDS. Design: Case-control study. Setting: Undergraduate institution. Patients or Other Participants: Participants were 84 collegiate athletes (65 men, 19 women) with concussion and 42 individuals (23 men, 21 women) with no history of recent concussion who served as controls. Main Outcome Measure(s): The Beck Depression Inventory-Fast Screen was administered to the concussion group at baseline and postconcussion and to the control group at 2 time points. Results: Seventeen athletes (20%) showed a reliable increase in depression, and more athletes reported clinically important depression postconcussion than at baseline. Only 2 participants (5%) in the control group showed a reliable increase in depression. Concussed athletes were more likely to show a reliable increase in depression symptoms than control participants (chi(2)(1) = 5.2, P = .02). We also found several predictors of PCDS in the athletes, including baseline depression symptoms (r = 0.37, P < .001), baseline postconcussion symptoms (r = 0.25, P = .03), estimated premorbid intelligence (full-scale IQ; r = -0.29, P = .009), and age of first participation in organized sport (r = 0.34, P = .002). For the control group, predictors of depression symptoms at time 2 were number of previous head injuries (r = 0.31, P = .05) and baseline depression symptoms (r = 0.80, P < .001). Conclusions: A large proportion of athletes showed a reliable increase in depression after concussion, and we identified several baseline predictors. Given that depression affects quality of life and recovery from concussion, more research is necessary to better understand why certain athletes show an increase in PCDS and how these can be better predicted and prevented.	[Vargas, Gray] Alfred I DuPont Hosp Children, Dept Behav Hlth, Wilmington, DE 19803 USA; [Rabinowitz, Amanda] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Meyer, Jessica; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA	Vargas, G (corresponding author), Alfred I DuPont Hosp Children, Dept Behav Hlth, 1600 Rockland Rd, Wilmington, DE 19803 USA.	grayvargas@gmail.com					Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Barnett JH, 2006, PSYCHOL MED, V36, P1053, DOI 10.1017/S0033291706007501; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Steer RA, 1999, GEN HOSP PSYCHIAT, V21, P106, DOI 10.1016/S0163-8343(98)00070-X; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271	30	54	55	0	19	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2015	50	3					250	255		10.4085/1062-6050-50.3.02			6	Sport Sciences	Sport Sciences	CQ8AM	WOS:000360828300003	25643158	Green Published, Bronze			2021-06-18	
J	Narayana, PA; Yu, XT; Hasan, KM; Wilde, EA; Levin, HS; Hunter, JV; Miller, ER; Patel, VKS; Robertson, CS; McCarthy, JJ				Narayana, Ponnada A.; Yu, Xintian; Hasan, Khader M.; Wilde, Elisabeth A.; Levin, Harvey S.; Hunter, Jill V.; Miller, Emmy R.; Patel, Vipul Kumar S.; Robertson, Claudia S.; McCarthy, James J.			Multi-modal MRI of mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; Orthopedic injury; Magnetic resonance imaging; Diffusion tensor imaging; Magnetic resonance spectroscopic imaging; Magnetization transfer ratio; Tensor based morphometry	MAGNETIC-RESONANCE-SPECTROSCOPY; TENSOR-BASED MORPHOMETRY; WHITE-MATTER INTEGRITY; MULTIPLE-SCLEROSIS; AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; CONCUSSION; ABNORMALITIES; MODERATE	Multi-modal magnetic resonance imaging (MRI) that included high resolution structural imaging, diffusion tensor imaging (DTI), magnetization transfer ratio (MTR) imaging, and magnetic resonance spectroscopic imaging (MRSI) were performed in mild traumatic brain injury (mTBI) patients with negative computed tomographic scans and in an orthopedic-injured (OI) group without concomitant injury to the brain. The OI group served as a comparison group tot mTBI. MRI scans were performed both in the acute phase of injury (similar to 24 h) and at follow-up (similar to 90 days). DTI data was analyzed using tract based spatial statistics (TBSS). Global and regional atrophies were calculated using tensor-based morphometry (TBM). MTR values were calculated using the standard method. MRSI was analyzed using LC Model. At the initial scan, the mean diffusivity (MD) was significantly higher in the mTBI cohort relative to the comparison group in several white matter (WM) regions that included internal capsule, external capsule, superior corona radiata, anterior corona radiata, posterior corona radiata, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, forceps major and forceps minor of the corpus callosum, superior longitudinal fasciculus, and corticospinal tract in the right hemisphere. TBSS analysis failed to detect significant differences in any DTI measures between the initial and follow-up scans either in the mTBI or OI group. No significant differences were found in MRSI, MTR or morphometry between the mTBI and OI cohorts either at the initial or follow-up scans with or without family wise error (ME) correction. Our study suggests that a number of WM tracts are affected in mTBI in the acute phase of injury and that these changes disappear by 90 clays. This study also suggests that none of the MRI-modalities used in this study, with the exception of DTI, is sensitive in detecting changes in the acute phase of mTBI. (C) 2014 The Authors. Published by Elsevier Inc.	[Narayana, Ponnada A.; Yu, Xintian; Hasan, Khader M.; Patel, Vipul Kumar S.] Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Robertson, Claudia S.] Baylor Coll Med, Neurosurg, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Emergency Med, Houston, TX 77030 USA	Narayana, PA (corresponding author), Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Imaging, Houston, TX 77030 USA.	ponnada.a.narayana@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		Congressionally Directed Medical Research Program of the Department of Defense [W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, W81XWH-08-2-0131]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER	This study was funded by the Congressionally Directed Medical Research Program of the Department of Defense (W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, and W81XWH-08-2-0131). The funding agency played no role in the study design, data collection, analysis and interpretation of data, writing of this manuscript and its submission for publication. The funding agency is not responsible for the contents of this article. One of the authors (PAN) gratefully acknowledges the support by the endowment provided by the Chair in Biomedical Engineering.	Assistant Secretary of Defense for Health Affairs, 2007, TRAUM BRAIN INJ DEF; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; Chenevert TL, 2011, J MAGN RESON IMAGING, V34, P983, DOI 10.1002/jmri.22363; Chumbley JR, 2009, NEUROIMAGE, V44, P62, DOI 10.1016/j.neuroimage.2008.05.021; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fox WC, 2013, NEUROL RES, V35, P223, DOI 10.1179/1743132813Y.0000000162; Garcia M, 2012, NEUROIMAGE, V59, P202, DOI 10.1016/j.neuroimage.2011.07.038; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunsche S, 2001, RADIOLOGY, V221, P550, DOI 10.1148/radiol.2212001823; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, NEUROLOGY, V53, pS3; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mottershead JP, 2003, J NEUROL, V250, P1293, DOI 10.1007/s00415-003-0192-3; Narayana PA, 2005, J NEUROIMAGING, V15, p46S, DOI 10.1177/1051228405284200; Narayana PA, 2013, NEUROIMAGE-CLIN, V2, P120, DOI 10.1016/j.nicl.2012.11.009; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K., 2010, ATLAS HUMAN WHITE MA; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pike GB, 2000, RADIOLOGY, V215, P824, DOI 10.1148/radiology.215.3.r00jn02824; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sajja BR, 2009, NEUROIMAG CLIN N AM, V19, P45, DOI 10.1016/j.nic.2008.08.002; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tao GZ, 2009, J NEUROL SCI, V282, P39, DOI 10.1016/j.jns.2008.12.035; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	76	54	55	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						87	97		10.1016/j.nicl.2014.07.010			11	Neuroimaging	Neurosciences & Neurology	DI0GE	WOS:000373172600011	25610770	DOAJ Gold, Green Published			2021-06-18	
J	Scholten, AC; Haagsma, JA; Panneman, MJM; van Beeck, EF; Polinder, S				Scholten, Annemieke C.; Haagsma, Juanita A.; Panneman, Martien J. M.; van Beeck, Ed F.; Polinder, Suzanne			Traumatic Brain Injury in the Netherlands: Incidence, Costs and Disability-Adjusted Life Years	PLOS ONE			English	Article							QUALITY-OF-LIFE; HEAD-INJURIES; ECONOMIC BURDEN; HEALTH; WORK; PREVENTION; DISORDERS; MORTALITY; DISEASES; OUTCOMES	Objective: Traumatic brain injury (TBI) is a major cause of death and disability, leading to great personal suffering and huge costs to society. Integrated knowledge on epidemiology, economic consequences and disease burden of TBI is scarce but essential for optimizing healthcare policy and preventing TBI. This study aimed to estimate incidence, cost-of-illness and disability-adjusted life years (DALYs) of TBI in the Netherlands. Methods: This study included data on all TBI patients who were treated at an Emergency Department (ED - National Injury Surveillance System), hospitalized (National Medical Registration), or died due to their injuries in the Netherlands between 2010-2012. Direct healthcare costs and indirect costs were determined using the incidence-based Dutch Burden of Injury Model. Disease burden was assessed by calculating years of life lost (YLL) owing to premature death, years lived with disability (YLD) and DALYs. Incidence, costs and disease burden were stratified by age and gender. Results: TBI incidence was 213.6 per 100,000 person years. Total costs were (sic)314.6 (USD $433.8) million per year and disease burden resulted in 171,200 DALYs (on average 7.1 DALYs per case). Men had highest mean costs per case ((sic)19,540 versus (sic)14,940), driven by indirect costs. 0-24-year-olds had high incidence and disease burden but low economic costs, whereas 25-64-year-olds had relatively low incidence but high economic costs. Patients aged 65+ had highest incidence, leading to considerable direct healthcare costs. 0-24-year-olds, men aged 25-64 years, traffic injury victims (especially bicyclists) and home and leisure injury victims (especially 0-5-year-old and elderly fallers) are identified as risk groups in TBI. Conclusions: The economic and health consequences of TBI are substantial. The integrated approach of assessing incidence, costs and disease burden enables detection of important risk groups in TBI, development of prevention programs that target these risk groups and assessment of the benefits of these programs.	[Scholten, Annemieke C.; Haagsma, Juanita A.; van Beeck, Ed F.; Polinder, Suzanne] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Panneman, Martien J. M.] Consumer & Safety Inst, Res Dept, Amsterdam, Netherlands	Scholten, AC (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.	a.scholten@erasmusmc.nl					Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; [Anonymous], 2014, US INFLATION CALCULA; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Consumer and Safety Institute, 2011, FACT SHEET BIC ACC; Consumer and Safety Institute, 2011, FACT SHEET SPORTS IN; Consumer and Safety Institute, 2013, FACT SHEET TRAUM BRA; Consumer and Safety Institute, 2012, FACT SHEET SPORTS IN; Consumer Safety Institute, 2005, DUTCH BURD INJ MOD; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Eurostat, 2014, HICP INFL RAT; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Gommer A, 2010, YEARS LIFE LOST MORB; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Haagsma JA, 2012, B WORLD HEALTH ORGAN, V90, P513, DOI 10.2471/BLT.11.095109; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Hoang Hanh T M, 2008, Cost Eff Resour Alloc, V6, P17, DOI 10.1186/1478-7547-6-17; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Meerding WJ, 2006, EUR J PUBLIC HEALTH, V16, P271, DOI 10.1093/eurpub/ckl006; Meerding WJ, 2010, INT J INJ CONTROL SA, V17, P13, DOI 10.1080/17457300903523237; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mulder S, 2002, INJURY PREV, V8, P74, DOI 10.1136/ip.8.1.74; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Nielen M, 2014, INCIDENCE PREVALENCE; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2004, SURVEILLANCE BASED A; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Rivara FP, 1998, ANNU REV PUBL HEALTH, V19, P293, DOI 10.1146/annurev.publhealth.19.1.293; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Schulman J, 2002, INJ PREV, V8, P47, DOI 10.1136/ip.8.1.47; Statistics Netherlands (CBS), 2014, POP DAT; Statistics Netherlands (CBS), 2014, MOB NETH; Statistics Netherlands (CBS), 2014, CONS PRIC INFL 1963; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Thurman DJ., 1995, GUIDELINES SURVEILLA; Van der Stegen R, 2009, DISCRIPTION METHODS; World Health Organization, 2004, WORLD REPORT ROAD TR; World Health Organization, 2006, NEUR DIS PUBL HLTH C	63	54	54	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2014	9	10							e110905	10.1371/journal.pone.0110905			10	Multidisciplinary Sciences	Science & Technology - Other Topics	AS0BL	WOS:000343943500064	25343447	DOAJ Gold, Green Published			2021-06-18	
J	Loane, D; Stoica, B; Tchantchou, F; Kumar, A; Barrett, J; Akintola, T; Xue, F; Conn, P; Faden, A				Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Xue, Fengtian; Conn, P. Jeffrey; Faden, Alan I.			Novel mGluR5 Positive Allosteric Modulator Improves Functional Recovery, Attenuates Neurodegeneration, and Alters Microglial Polarization after Experimental Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; Metabotropic glutamate receptor 5; Positive allosteric modulator; Neuroprotection; Functional recovery; Microglial activation	METABOTROPIC GLUTAMATE RECEPTORS; IN-VIVO ACTIVITY; ALTERNATIVE ACTIVATION; CELL-DEATH; NEURONAL APOPTOSIS; SUBTYPE 5; INFLAMMATION; ANTAGONISTS; INHIBITION; TARGETS	Traumatic brain injury (TBI) causes microglial activation and related neurotoxicity that contributes to chronic neurodegeneration and loss of neurological function. Selective activation of metabotropic glutamate receptor 5 (mGluR5) by the orthosteric agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), is neuroprotective in experimental models of TBI, and has potent anti-inflammatory effects in vitro. However, the therapeutic potential of CHPG is limited due to its relatively weak potency and brain permeability. Highly potent, selective and brain penetrant mGluR5 positive allosteric modulators (PAMs) have been developed and show promise as therapeutic agents. We evaluated the therapeutic potential of a novel mGluR5 PAM, VU0360172, after controlled cortical impact (CCI) in mice. Vehicle, VU0360172, or VU0360172 plus mGluR5 antagonist (MTEP), were administered systemically to CCI mice at 3 h post-injury; lesion volume, hippocampal neurodegeneration, microglial activation, and functional recovery were assessed through 28 days post-injury. Anti-inflammatory effects of VU0360172 were also examined in vitro using BV2 and primary microglia. VU0360172 treatment significantly reduced the lesion, attenuated hippocampal neurodegeneration, and improved motor function recovery after CCI. Effects were mediated by mGluR5 as co-administration of MTEP blocked the protective effects of VU0360172. VU0360172 significantly reduced CD68 and NOX2 expression in activated microglia in the cortex at 28 days post-injury, and also suppressed pro-inflammatory signaling pathways in BV2 and primary microglia. In addition, VU0360172 treatment shifted the balance between M1/M2 microglial activation states towards an M2 pro-repair phenotype. This study demonstrates that VU0360172 confers neuroprotection after experimental TBI, and suggests that mGluR5 PAMs may be promising therapeutic agents for head injury.	[Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Hlth Sci Facil HSFII 2, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Xue, Fengtian] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA	Faden, A (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Hlth Sci Facil HSFII 2, S247,20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Barrett, James/0000-0002-0924-9449; Loane, David/0000-0003-0393-3503; Henry, Rebecca/0000-0001-8548-1170; Faden, Alan I./0000-0003-0128-2348	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313]; UMB Pilot & Exploratory Interdisciplinary Research (IDR) Award; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R37NS031373] Funding Source: NIH RePORTER	We thank Marie Hanscom for expert technical assistance. This work was supported by a grant from the NIH/NINDS to AIF (5R01NS037313), and by a 2013 UMB Pilot & Exploratory Interdisciplinary Research (IDR) Award to B.S. and F.X.	Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Ayala JE, 2009, NEUROPSYCHOPHARMACOL, V34, P2057, DOI 10.1038/npp.2009.30; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760; de Paulis T, 2006, J MED CHEM, V49, P3332, DOI 10.1021/jm051252j; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gass JT, 2009, BIOL PSYCHIAT, V65, P717, DOI 10.1016/j.biopsych.2008.11.001; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gravius A, 2008, J NEURAL TRANSM, V115, P1609, DOI 10.1007/s00702-008-0098-4; Homayoun H, 2004, NEUROPSYCHOPHARMACOL, V29, P1259, DOI 10.1038/sj.npp.1300417; Homayoun H, 2010, EUR J PHARMACOL, V639, P33, DOI 10.1016/j.ejphar.2009.12.042; Kinney GG, 2005, J PHARMACOL EXP THER, V313, P199, DOI 10.1124/jpet.104.079244; Kinney GG, 2003, J PHARMACOL EXP THER, V306, P116, DOI 10.1124/jpet.103.048702; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lecourtier L, 2007, BIOL PSYCHIAT, V62, P739, DOI 10.1016/j.biopsych.2006.12.003; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane David J, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P136; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Nickols HH, 2014, NEUROBIOL DIS, V61, P55, DOI 10.1016/j.nbd.2013.09.013; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Noetzel MJ, 2012, MOL PHARMACOL, V81, P120, DOI 10.1124/mol.111.075184; Olive MF, 2010, EUR J PHARMACOL, V639, P47, DOI 10.1016/j.ejphar.2010.01.029; Piers TM, 2011, NEUROSCI LETT, V505, P140, DOI 10.1016/j.neulet.2011.10.007; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Rodriguez AL, 2010, MOL PHARMACOL, V78, P1105, DOI 10.1124/mol.110.067207; Szydlowska K, 2007, EUR J PHARMACOL, V554, P18, DOI 10.1016/j.ejphar.2006.09.061; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Xue FT, 2014, CNS NEUROL DISORD-DR, V13, P558, DOI 10.2174/18715273113126660199; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhu PM, 2004, J NEUROSCI RES, V77, P525, DOI 10.1002/jnr.20175	46	54	56	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	OCT	2014	11	4					857	869		10.1007/s13311-014-0298-6			13	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AS3AI	WOS:000344147100015	25096154	Green Published			2021-06-18	
J	Zhao, JB; Chen, Z; Xi, GH; Keep, RF; Hua, Y				Zhao, Jinbing; Chen, Zhi; Xi, Guohua; Keep, Richard F.; Hua, Ya			Deferoxamine Attenuates Acute Hydrocephalus After Traumatic Brain Injury in Rats	TRANSLATIONAL STROKE RESEARCH			English	Article						Deferoxamine; Hydrocephalus; Lateral fluid percussion; Traumatic brain injury	INTRACEREBRAL HEMORRHAGE; POSTTRAUMATIC HYDROCEPHALUS; SUBARACHNOID HEMORRHAGE; COMPLEMENT ACTIVATION; IRON; MODEL; DIAGNOSIS; ATROPHY; EDEMA	Acute post-traumatic ventricular dilation and hydrocephalus are relatively frequent consequences of traumatic brain injury (TBI). Several recent studies have indicated that high iron levels in brain may relate to hydrocephalus development after intracranial hemorrhage. However, the role of iron in the development of post-traumatic hydrocephalus is still unclear. This study was to determine whether or not iron has a role in hydrocephalus development after TBI. TBI was induced by lateral fluid-percussion in male Sprague-Dawley rats. Some rats had intraventricular injection of iron. Acute hydrocephalus was measured by magnetic resonance T2-weighted imaging and brain hemorrhage was determined by T2* gradient-echo sequence imaging and brain hemoglobin levels. The effect of deferoxamine on TBI-induced hydrocephalus was examined. TBI resulted in acute hydrocephalus at 24 h (lateral ventricle volume: 24.1 +/- 3.0 vs. 9.9 +/- 0.2 mm(3) in sham group). Intraventricular injection of iron also caused hydrocephalus (25.7 +/- 3.4 vs. 9.0 +/- 0.6 mm(3) in saline group). Deferoxamine treatment attenuated TBI-induced hydrocephalus and heme oxygenase-1 upregulation. In conclusion, iron may contribute to acute hydrocephalus after TBI.	[Zhao, Jinbing; Chen, Zhi; Xi, Guohua; Keep, Richard F.; Hua, Ya] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA	Hua, Y (corresponding author), Univ Michigan, Dept Neurosurg, R5018 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	yahua@umich.edu		Keep, Richard/0000-0001-6441-5334; Chen, Zhi/0000-0002-8404-4937	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-073595, NS-079157, NS-084049]; NSFCNational Natural Science Foundation of China (NSFC) [81301049, 30872675]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073595, R21NS084049, R01NS079157] Funding Source: NIH RePORTER	This study was supported by grants NS-073595, NS-079157 and NS-084049 from the National Institutes of Health (NIH) and grants 81301049 and 30872675 from NSFC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and NSFC.	Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen B, 2010, STROKE, V41, P2348, DOI 10.1161/STROKEAHA.110.584920; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; de Backer ME, 2010, AM J NEURORADIOL, V31, P1577, DOI 10.3174/ajnr.A2264; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Guo FY, 2012, TRANSL STROKE RES, V3, P130, DOI 10.1007/s12975-011-0106-0; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Hua Y, 2006, J NEUROSURG, V104, P305, DOI 10.3171/jns.2006.104.2.305; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; IWANOWSKI L, 1960, J NEUROPATH EXP NEUR, V19, P433, DOI 10.1097/00005072-196007000-00010; Jin H, 2013, TRANSL STROKE RES, V4, P130, DOI 10.1007/s12975-012-0232-3; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KJELLIN KG, 1967, ACTA NEUROL SCAND, V43, P299, DOI 10.1111/j.1600-0404.1967.tb05735.x; Kuker W, 2000, ACTA RADIOL, V41, P544, DOI 10.1034/j.1600-0455.2000.041006544.x; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lee JY, 2010, J CEREBR BLOOD F MET, V30, P1793, DOI 10.1038/jcbfm.2010.137; Linfante I, 1999, STROKE, V30, P2263, DOI 10.1161/01.STR.30.11.2263; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Losowska-Kaniewska D, 2007, Adv Med Sci, V52 Suppl 1, P176; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674; Nahed BV, 2007, J NEUROSURG, V107, P236, DOI 10.3171/PED-07/09/236; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Okauchi M, 2010, STROKE, V41, P375, DOI 10.1161/STROKEAHA.109.569830; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Rouault TA, 2009, METAB BRAIN DIS, V24, P673, DOI 10.1007/s11011-009-9169-y; Suzuki H, 2003, STROKE, V34, P2796, DOI 10.1161/01.STR.0000103743.62248.12; Suzuki H, 2006, J NEUROL, V253, P1170, DOI 10.1007/s00415-006-0184-1; TAKAGI H, 1981, SURG NEUROL, V16, P103, DOI 10.1016/0090-3019(81)90106-3; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Wan S, 2006, ACTA NEUROCHIR SUPPL, V96, P199; Wu G, 2010, TRANSL STROKE RES, V1, P31, DOI 10.1007/s12975-009-0008-6; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yoshimoto Y, 1996, AM J NEURORADIOL, V17, P1183; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1	50	54	55	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	OCT	2014	5	5					586	594		10.1007/s12975-014-0353-y			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AN1VV	WOS:000340373000008	24935175	Green Accepted			2021-06-18	
J	Carlson, SW; Madathil, SK; Sama, DM; Gao, X; Chen, JH; Saatman, KE				Carlson, Shaun W.; Madathil, Sindhu K.; Sama, Diana M.; Gao, Xiang; Chen, Jinhui; Saatman, Kathryn E.			Conditional Overexpression of Insulin-Like Growth Factor-1 Enhances Hippocampal Neurogenesis and Restores Immature Neuron Dendritic Processes After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Cellular proliferation; Controlled cortical impact; Dendrites; Doublecortin; Hippocampus; IGF-1; Neuronal differentiation; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; DENTATE GYRUS; ADULT NEUROGENESIS; COGNITIVE RECOVERY; CELL-PROLIFERATION; IGF-I; PATTERN SEPARATION; GRANULE CELLS; MICE; RATS	Traumatic brain injury (TBI) is associated with neuronal damage or neuronal death in the hippocampus, a region critical for cognitive function. Immature neurons within the hippocampal neurogenic niche are particularly susceptible to TBI. Therapeutic strategies that protect immature hippocampal neurons or enhance posttraumatic neurogenesis may be advantageous for promoting functional recovery after TBI. Insulin-like growth factor-1 (IGF-1) promotes neurogenesis in the adult brain, but its effects on neurogenesis after TBI are unknown. We used an astrocyte-specific conditional IGF-1-overexpressing mouse model to supplement IGF-1 in regions of neuronal damage and reactive astrocytosis after controlled cortical impact injury. Although early loss of immature neurons was not significantly attenuated, overexpression of IGF-1 resulted in a marked increase in immature neuron density in the subgranular zone at 10 days after injury. This delayed increase seemed to be driven by enhanced neuron differentiation rather than by increased cellular proliferation. In wild-type mice, dendrites of immature neurons exhibited significant decreases in total length and number of bifurcations at 10 days after injury versus neurons in sham-injured mice. In contrast, the morphology of immature neuron dendrites in brain-injured IGF1-overexpressing mice was equivalent to that in sham controls. These data provide compelling evidence that IGF-1 promotes neurogenesis after TBI.	[Carlson, Shaun W.; Madathil, Sindhu K.; Sama, Diana M.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Carlson, Shaun W.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Dept Neurol Surg, Stark Neurosci Res Inst, Indianapolis, IN 46204 USA	Saatman, KE (corresponding author), Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012	Carlson, Shaun/0000-0002-1413-5075	Kentucky Spinal Cord and Head Injury Research Trust [KSCHIRT 7-20]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS072302, P30 NS051220, R21 NS072631]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R21NS072631, F32NS083182, R01NS072302] Funding Source: NIH RePORTER	This study was supported by Kentucky Spinal Cord and Head Injury Research Trust Grant No. KSCHIRT 7-20 (Kathryn E. Saatman) and National Institutes of Health Grant Nos. R01 NS072302 (Kathryn E. Saatman), P30 NS051220 (Kathryn E. Saatman), and R21 NS072631 (Jinhui Chen).	Aberg MAI, 2000, J NEUROSCI, V20, P2896; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Aberg ND, 2003, J NEUROSCI RES, V74, P12, DOI 10.1002/jnr.10734; Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042; Brooker GJF, 2000, J NEUROSCI RES, V59, P332, DOI 10.1002/(SICI)1097-4547(20000201)59:3<332::AID-JNR6>3.0.CO;2-2; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cai WK, 2012, J NEUROSCI, V32, P9887, DOI 10.1523/JNEUROSCI.0375-12.2012; Cheng CM, 2003, J NEUROSCI RES, V73, P1, DOI 10.1002/jnr.10634; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Liquitaya-Montiel A, 2012, CNS NEUROL DISORD-DR, V11, P818, DOI 10.2174/1871527311201070818; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; McCurdy RD, 2005, EUR J NEUROSCI, V22, P1581, DOI 10.1111/j.1460-9568.2005.04355.x; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Niblock MM, 2000, J NEUROSCI, V20, P4165; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; TORRESALEMAN I, 1989, INT J DEV NEUROSCI, V7, P195, DOI 10.1016/0736-5748(89)90069-5; Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016; Trejo JL, 2001, J NEUROSCI, V21, P1628; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801	78	54	58	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2014	73	8					734	746		10.1097/NEN.0000000000000092			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AL8KF	WOS:000339386600001	25003234	Green Accepted, Bronze			2021-06-18	
J	Zweckberger, K; Hackenberg, K; Jung, CS; Hertle, DN; Kiening, KL; Unterberg, AW; Sakowitz, OW				Zweckberger, K.; Hackenberg, K.; Jung, C. S.; Hertle, D. N.; Kiening, K. L.; Unterberg, A. W.; Sakowitz, O. W.			GLIBENCLAMIDE REDUCES SECONDARY BRAIN DAMAGE AFTER EXPERIMENTAL TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						traumatic brain injury; glibenclamide; secondary brain damage; brain edema; cerebral metabolism; epileptic seizures	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; SULFONYLUREA RECEPTOR 1; ISCHEMIC-STROKE; SUBARACHNOID HEMORRHAGE; GLUTAMATE RELEASE; ANEURYSM SURGERY; CEREBRAL EDEMA; MICRODIALYSIS; MODEL	Following traumatic brain injury (TBI) SUR1-regulated NCCa-ATP (SUR1/TRPM4) channels are transcriptionally up-regulated in ischemic astrocytes, neurons, and capillaries. ATP depletion results in depolarization and opening of the channel leading to cytotoxic edema. Glibenclamide is an inhibitor of SUR-1 and, thus, might prevent cytotoxic edema and secondary brain damage following TBI. Anesthetized adult Sprague Dawley rats underwent parietal craniotomy and were subjected to controlled cortical impact injury (CCI). Glibenclamide was administered as a bolus injection 15 min after CCI injury and continuously via osmotic pumps throughout 7 days. In an acute trial (180 min) mean arterial blood pressure, heart rate, intracranial pressure, encephalographic activity, and cerebral metabolism were monitored. Brain water content was assessed gravimetrically 24 h after CCI injury and contusion volumes were measured by MRI scanning technique at 8 h, 24 h, 72 h, and 7 d post injury. Throughout the entire time of observation neurological function was quantified using the "beam-walking" test. Glibenclamide-treated animals showed a significant reduction in the development of brain tissue water content(80.47% +/- 0.37% (glibenclamide) vs. 80.83% +/- 0.44% (control); p < 0.05; n = 14). Contusion sizes increased continuously within 72 h following CCI injury, but glibenclamide-treated animals had significantly smaller volumes at any time-points, like 172.53 +/- 38.74 mm(3) (gliben-clamide) vs. 299.20 +/- 64.02 mm(3) (control) (p < 0.01; n = 10; 24h) or 211.10 +/- 41.03 mm(3) (glibenclamide) vs. 309.76 +/- 19.45 mm(3) (control) (p < 0.05; n = 10; 72 h), respectively. An effect on acute parameters, however, could not be detected, most likely because of the up-regulation of the channel within 3-6 h after injury. Furthermore, there was no significant effect on motor function assessed by the beam-walking test throughout 7 days. In accordance to these results and the available literature, glibenclamide seems to have promising potency in the treatment of TBI. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Zweckberger, K.; Hackenberg, K.; Jung, C. S.; Hertle, D. N.; Kiening, K. L.; Unterberg, A. W.; Sakowitz, O. W.] Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany	Zweckberger, K (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	klaus.zweckberger@med.uni-heidelberg.de					Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BTF-Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, P1; Buckingham SC, 2011, NAT MED, V17, P1269, DOI 10.1038/nm.2453; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Cremer CM, 2009, NEUROSCIENCE, V163, P490, DOI 10.1016/j.neuroscience.2009.03.068; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJ, 2000, NEUROSURGERY, V46, P201; Kang N, 2005, J NEUROPHYSIOL, V94, P4121, DOI 10.1152/jn.00448.2005; Kett-White R, 2002, ACT NEUR S, V81, P363; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Marks JA, 2012, J TRAUMA ACUTE CARE, V73, P351, DOI 10.1097/TA.0b013e3182592f76; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Sakowitz OW, 2002, ACT NEUR S, V81, P221; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2007, BBA-MOL BASIS DIS, V1772, P947, DOI 10.1016/j.bbadis.2007.03.004; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Vazquez-Lopez A, 2005, NEUROSCI LETT, V388, P81, DOI 10.1016/j.neulet.2005.06.063; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	36	54	55	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 11	2014	272						199	206		10.1016/j.neuroscience.2014.04.040			8	Neurosciences	Neurosciences & Neurology	AJ0IY	WOS:000337335400019	24792709				2021-06-18	
J	Taylor, SE; Morganti-Kossmann, C; Lifshitz, J; Ziebell, JM				Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.			Rod Microglia: A Morphological Definition	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CELL-DEATH; RAT; ACTIVATION; MOUSE; PHYSIOLOGY; RESPONSES; SENSOR; MICE; CNS	Brain microglial morphology relates to function, with ramified microglia surveying the micro-environment and amoeboid microglia engulfing debris. One subgroup of microglia, rod microglia, have been observed in a number of pathological conditions, however neither a function nor specific morphology has been defined. Historically, rod microglia have been described intermittently as cells with a sausage-shaped soma and long, thin processes, which align adjacent to neurons. More recently, our group has described rod microglia aligning end-to-end with one another to form trains adjacent to neuronal processes. Confusion in the literature regarding rod microglia arises from some reports referring to the sausage-shaped cell body, while ignoring the spatial distribution of processes. Here, we systematically define the morphological characteristics of rod microglia that form after diffuse brain injury in the rat, which differ morphologically from the spurious rod microglia found in uninjured sham. Rod microglia in the diffuse-injured rat brain show a ratio of 1.79 +/- 0.03 cell length: cell width at day 1 post-injury, which increases to 3.35 +/- 0.05 at day 7, compared to sham (1.17 +/- 0.02). The soma length: width differs only at day 7 post-injury (2.92 +/- 0.07 length: width), compared to sham (2.49 +/- 0.05). Further analysis indicated that rod microglia may not elongate in cell length but rather narrow in cell width, and retract planar (side) processes. These morphological characteristics serve as a tool for distinguishing rod microglia from other morphologies. The function of rod microglia remains enigmatic; based on morphology we propose origins and functions for rod microglia after acute neurological insult, which may provide biomarkers or therapeutic targets.	[Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85006 USA; [Taylor, Samuel E.; Morganti-Kossmann, Cristina; Lifshitz, Jonathan; Ziebell, Jenna M.] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA; [Taylor, Samuel E.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; [Lifshitz, Jonathan] Phoenix VA Healthcare Syst, Phoenix, AZ USA; [Lifshitz, Jonathan] Arizona State Univ, Dept Psychol, Neurosci Program, Tempe, AZ 85287 USA	Ziebell, JM (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85006 USA.	jmziebell@email.arizona.edu	Ziebell, Jenna/Y-4496-2019	Ziebell, Jenna/0000-0003-2497-4347; Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052]; Mission Support Fund at Phoenix Children's Hospital; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052] Funding Source: NIH RePORTER	Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052 and the Mission Support Fund at Phoenix Children's Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carthew HL, 2012, NEUROSCIENCE, V214, P78, DOI 10.1016/j.neuroscience.2012.04.028; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; GRAEBER MB, 1994, NEUROPATH APPL NEURO, V20, P178; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2011, J NEUROPATH EXP NEUR, V70, P481, DOI 10.1097/NEN.0b013e31821db3aa; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Learoyd AE, 2012, BEHAV BRAIN RES, V226, P197, DOI 10.1016/j.bbr.2011.09.016; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Spielmeyer W., 1922, HISTOPATHOLOGIE NERV; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Taylor SE, 2013, CURRENT PROTOCOLS ES; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tremblay ME, 2011, NEURON GLIA BIOL, V7, P67, DOI 10.1017/S1740925X12000038; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wierzba-Bobrowicz T, 2002, FOLIA NEUROPATHOL, V40, P125; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	39	54	57	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2014	9	5							e97096	10.1371/journal.pone.0097096			9	Multidisciplinary Sciences	Science & Technology - Other Topics	AI3UI	WOS:000336789500034	24830807	DOAJ Gold, Green Published			2021-06-18	
J	Cui, CM; Cui, Y; Gao, JL; Sun, LQ; Wang, YC; Wang, KJ; Li, R; Tian, YX; Song, SX; Cui, JZ				Cui, Changmeng; Cui, Ying; Gao, Junling; Sun, Liqian; Wang, Yongchao; Wang, Kaijie; Li, Ran; Tian, Yanxia; Song, Sixin; Cui, Jianzhong			Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						TBI; Glutamate excitotoxicity; GLT-1; Ceftriaxone; Autophagy; Functional recovery	GLUTAMATE TRANSPORTER EXPRESSION; CELL-DEATH; AUTOPHAGY; ISCHEMIA; CONTRIBUTES; DEFICITS; MICE	Traumatic brain injury (TBI) is a leading cause of mortality and disability in children and young adults worldwide. Neurologic impairment is caused by both immediate brain tissue disruption and post-injury cellular and molecular events that worsen the primary neurologic insult. The beta-lactam antibiotic ceftriaxone (CTX) has been reported to induce neuroprotection in animal models of diverse neurologic diseases via up-regulation of GLT-1. However, no studies have addressed the neuroprotective role of CTX in the setting of TBI, and whether the mechanism is involved in the modulation of neuronal autophagy remains totally unclear. The present study was designed to determine the hypothesis that administration of CTX could significantly enhance functional recovery in a rat model of TBI and whether CTX treatment could up-regulate GLT-1 expression and suppress post-TBI neuronal autophagy. The results demonstrated that daily treatment with CTX attenuated TBI-induced brain edema and cognitive function deficits in rats. GLT-1 is down-regulated following TBI and this phenomenon can be reversed by treatment of CTX. In addition, we also found that CTX significantly reduced autophagy marker protein, LC3 II, in hippocampus compared to the TBI group. These results suggest that CTX might provide a new therapeutic strategy for TBI and this protection might be associated with up-regulation of GLT-1 and suppression of neuronal autophagy.	[Cui, Changmeng; Cui, Jianzhong] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Peoples R China; [Cui, Ying; Sun, Liqian; Wang, Kaijie; Cui, Jianzhong] Tangshan Workers Hosp, Tangshan 063000, Peoples R China; [Gao, Junling; Wang, Yongchao; Li, Ran; Tian, Yanxia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Peoples R China; [Song, Sixin] Taishan Med Univ, Dept Neurosurg, Affiliated Hosp, Taishan 271000, Peoples R China	Cui, CM (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei, ChinaNatural Science Foundation of Hebei Province [H2012401071]	This research was supported by the Natural Science Foundation of Hebei, China, Grant Number H2012401071.	Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Chu CT, 2008, AM J PATHOL, V172, P284, DOI 10.2353/ajpath.2008.071064; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Ketheeswaranathan P, 2011, BRAIN RES, V1418, P93, DOI 10.1016/j.brainres.2011.08.029; Kim K, 2011, J CELL PHYSIOL, V226, P2484, DOI 10.1002/jcp.22609; Lai Y, 2007, J CEREB BLOOD FLOW M, V28, P540; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Maragakis NJ, 2004, GLIA, V45, P133, DOI 10.1002/glia.10310; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mimura K, 2011, REPROD SCI, V18, P1193, DOI 10.1177/1933719111410710; NAU R, 1993, ANTIMICROB AGENTS CH, V37, P1518, DOI 10.1128/AAC.37.7.1518; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Rasmussen B, 2011, DRUG ALCOHOL DEPEN, V118, P484, DOI 10.1016/j.drugalcdep.2011.03.022; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Shacka JJ, 2007, NEUROSCI LETT, V414, P57, DOI 10.1016/j.neulet.2006.12.025; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0	24	54	58	0	8	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2014	35	5					695	700		10.1007/s10072-013-1585-4			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AI4BJ	WOS:000336810100008	24277205				2021-06-18	
J	Mychasiuk, R; Farran, A; Esser, MJ				Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.			Assessment of an Experimental Rodent Model of Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						sex differences; executive function; concussion; childhood; behavior	ELEVATED PLUS-MAZE; COGNITIVE DEFICITS; PROFESSIONAL FOOTBALL; EXECUTIVE FUNCTION; ANIMAL-MODEL; CONCUSSION; VULNERABILITY; CONSEQUENCES; BIOMECHANICS; AQUAPORIN-4	Childhood is one the highest risk periods for experiencing a mild traumatic brain injury (mTBI) from sports-related concussions, motor vehicle accidents, and falls. In addition, many children experience lingering symptomology (post-concussion syndrome) from these closed head injuries. Although the negative sequel of mTBI has been described, a clinically reliable animal model of mild pediatric brain injury has not. The purpose of this study was to examine the validity of a modified weight-drop technique as a model for the induction of mTBI/concussion in juvenile rats following a single impact. Male and female rats (P30) were exposed to a single mTBI or a sham injury followed by a behavioral test battery. Juvenile rats who experienced a single mTBI displayed significant motor/balance impairments when tested on the beam walking task and in the open field, as well as deficits of executive functioning as measured with the novel context mismatch task and the probe trial of the Morris water task. In addition, both male and female rats showed depression-like behavior in the forced swim task, with male rats also exhibiting decreased anxiety-related behaviors in the elevated plus maze. The results from this study suggest that the modified weight-drop technique induces a clinically relevant behavioral phenotype in juvenile rats, and may provide researchers with a reliable animal model of mTBI/concussion from which clinical therapeutic strategies could be developed.	[Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg Room 277 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca	Meijer, Anna/K-5118-2016		Department of Pediatrics at the University of Calgary; Alberta Children's Hospital Foundation (ACHF); Alberta Children's Hospital Research Institute (ACHRI); ACHF	The authors thank Irene Ma, Rose Tobias, and Dr. Jong Rho for their technical and organizational assistance. Funding for this study was provided to Dr. Esser by the Department of Pediatrics at the University of Calgary, the Alberta Children's Hospital Foundation (ACHF), and the Alberta Children's Hospital Research Institute (ACHRI). Dr. Mychasiuk's postdoctoral fellowship was funded by ACHF.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kolb B., 2008, FUNDAMENTALS HUMAN N; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Whishaw I. Q., 2005, BEHAV LAB RAT HDB TE; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	51	54	55	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					749	757		10.1089/neu.2013.3132			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200006	24283269				2021-06-18	
J	Joseph, B; Friese, RS; Sadoun, M; Aziz, H; Kulvatunyou, N; Pandit, V; Wynne, J; Tang, A; O'Keeffe, T; Rhee, P				Joseph, Bellal; Friese, Randall S.; Sadoun, Moutamn; Aziz, Hassan; Kulvatunyou, Narong; Pandit, Viraj; Wynne, Julie; Tang, Andrew; O'Keeffe, Terence; Rhee, Peter			The BIG (brain injury guidelines) project: Defining the management of traumatic brain injury by acute care surgeons	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; guidelines for management of traumatic brain injury; neurosurgical consultation; acute care surgeons; repeat head computed tomography	COMPUTED-TOMOGRAPHY; HEAD-INJURY; PREDICTION; UTILITY; CT	BACKGROUND It is becoming a standard practice that any positive identification of a radiographic intracranial injury requires transfer of the patient to a trauma center for observation and repeat head computed tomography (RHCT). The purpose of this study was to define guidelinesbased on each patient's history, physical examination, and initial head CT findingsregarding which patients require a period of observation, RHCT, or neurosurgical consultation. METHODS In our retrospective cohort analysis, we reviewed the records of 3,803 blunt traumatic brain injury patients during a 4-year period. We classified patients according to neurologic examination results, use of intoxicants, anticoagulation status, and initial head CT findings. We then developed brain injury guidelines (BIG) based on the individual patient's need for observation or hospitalization, RHCT, or neurosurgical consultation. RESULTS A total of 1,232 patients had an abnormal head CT finding. In the BIG 1 category, no patients worsened clinically or radiographically or required any intervention. BIG 2 category had radiographic worsening in 2.6% of the patients. All patients who required neurosurgical intervention (13%) were in BIG 3. There was excellent agreement between assigned BIG and verified BIG. statistic is equal to 0.98. CONCLUSION We have proposed BIG based on patient's history, neurologic examination, and findings of initial head CT scan. These guidelines must be used as supplement to good clinical examination while managing patients with traumatic brain injury. Prospective validation of the BIG is warranted before its widespread implementation. LEVEL OF EVIDENCE Epidemiologic study, level III.	[Joseph, Bellal; Friese, Randall S.; Sadoun, Moutamn; Aziz, Hassan; Kulvatunyou, Narong; Pandit, Viraj; Wynne, Julie; Tang, Andrew; O'Keeffe, Terence; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Huynh T, 2006, AM SURGEON, V72, P1162; Joseph B, 2014, REPEAT HEAD COMPUTED; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; Langlois JA., TRAUMATIC BRAIN INJU; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; RHODES M, 1993, J TRAUMA, V35, P384, DOI 10.1097/00005373-199309000-00009; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tang AL, 2010, SCAND J SURG, V99, P61, DOI 10.1177/145749691009900202; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	22	54	54	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					965	969		10.1097/TA.0000000000000161			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500016	24662858				2021-06-18	
J	Jung, SY; Kim, DY; Yune, TY; Shin, DH; Baek, SB; Kim, CJ				Jung, Sun-Young; Kim, Dae-Young; Yune, Tae Young; Shin, Dong-Hoon; Baek, Sang-Bin; Kim, Chang-Ju			Treadmill exercise reduces spinal cord injury-induced apoptosis by activating the PI3K/Akt pathway in rats	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						spinal cord injury; treadmill exercise; motor function; apoptosis; neurotrophic factors	TRAUMATIC BRAIN-INJURY; DEATH; EXPRESSION; RECOVERY; SURVIVAL; BCL-2; HEMISECTION; PLASTICITY; ISCHEMIA; PROMOTES	Apoptosis occurring secondary to spinal cord injury (SCI) causes further neural damage and functional loss. In this study, a rat model was used to investigate the effect of treadmill exercise on SCI-induced apoptosis and expression of neurotrophic factors. To produce SCI, a contusion injury (10 g x 25 mm) was applied subsequent to laminectomy at the T9-T10 level. Following SCI, treadmill exercise was performed for six weeks. Hindlimb motor function was evaluated with a grid-walking test. The expression of neurotrophic factors and the level of apoptosis at the site of SCI were determined by western blotting. SCI reduced hindlimb motor function and suppressed expression of neurotrophin (NT)-3 and insulin-like growth factor (IGF)-1. Expression of phosphatidylinositol 3-kinase (PI3K), the ratio of phosphorylated Akt to Akt (pAkt/Akt) and the ratio of B-cell lymphoma 2 (Bcl-2) to Bax (Bcl-2/Bax) were decreased, and cleaved caspase-3 expression was increased by SCI. Treadmill exercise enhanced hindlimb motor function and increased expression of nerve growth factor (NGF), NT-3 and IGF-1 in the SCI rats. Treadmill exercise increased PI3K expression, the pAkt/Akt and the Bcl-2/Bax ratios, and suppressed cleaved caspase-3 expression in the injured spinal cord. This study demonstrated that treadmill exercise promotes the recovery of motor function by suppressing apoptosis in the injured spinal cord. The beneficial effect of exercise may be attributed to the increase in expression of neurotrophic factors via activation of the PI3K/Akt pathway.	[Jung, Sun-Young; Kim, Dae-Young; Kim, Chang-Ju] Kyung Hee Univ, Dept Physiol, Coll Med, Seoul 130701, South Korea; [Yune, Tae Young] Kyung Hee Univ, Dept Biochem & Mol Biol, Coll Med, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Shin, Dong-Hoon] Korea Univ, Grad Sch Life Sci & Biotechnol, Dept Food & Biotechnol, Seoul 136701, South Korea; [Baek, Sang-Bin] Univ Ulsan, Gangneung Asan Hosp, Dept Psychiat, Kangnung 210711, South Korea	Kim, CJ (corresponding author), Kyung Hee Univ, Dept Physiol, Coll Med, 26 Kyungheedae Ro, Seoul 130701, South Korea.	changju@khu.ac.kr	Kim, Chang Ju/M-4216-2017	Kim, Chang Ju/0000-0003-4749-5795	Kyung Hee University [KHU 20100848]	This study was supported by the 2010 Research Fund from Kyung Hee University (grant no. KHU 20100848).	Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan G, 2010, J IMMUNOL, V184, P3213, DOI 10.4049/jimmunol.0903025; Chao OY, 2012, NEUROSCIENCE, V202, P318, DOI 10.1016/j.neuroscience.2011.11.016; Chen MJ, 2005, MOL BRAIN RES, V135, P181, DOI 10.1016/j.molbrainres.2004.12.001; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Leon RD, 2006, J NEUROTRAUM, V23, P1147, DOI 10.1089/neu.2006.23.1147; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Goldshmit Y, 2008, J NEUROTRAUM, V25, P449, DOI 10.1089/neu.2007.0392; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002; Hennigan A, 2007, BIOCHEM SOC T, V35, P424, DOI 10.1042/BST0350424; Hwang L, 2013, INT J MOL MED, V31, P1047, DOI 10.3892/ijmm.2013.1301; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li Y, 2013, J BIOMED RES, V27, P43, DOI 10.7555/JBR.27.20120051; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Lobner D, 2002, BRAIN RES, V954, P42, DOI 10.1016/S0006-8993(02)03337-1; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Pierchala BA, 2004, J BIOL CHEM, V279, P27986, DOI 10.1074/jbc.M312237200; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Schorey JS, 2003, CELL MICROBIOL, V5, P133, DOI 10.1046/j.1462-5822.2003.00263.x; Shin DY, 2012, INT J MOL SCI, V13, P14158, DOI 10.3390/ijms131114158; Sung YH, 2012, LIFE SCI, V91, P1309, DOI 10.1016/j.lfs.2012.10.003; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Tillerson JL, 2003, NEUROSCIENCE, V119, P899, DOI 10.1016/S0306-4522(03)00096-4; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Upadhyay D, 2003, AM J RESP CELL MOL, V29, P180, DOI 10.1165/rcmb.2002-0269OC; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Yang Dongmei, 2012, World J Neurosci, V2, P74; Yao RQ, 2012, NEUROCHEM RES, V37, P2777, DOI 10.1007/s11064-012-0871-5; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Ying Z, 2003, BRAIN RES, V987, P93, DOI 10.1016/S0006-8993(03)03258-X; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	44	54	64	0	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	MAR	2014	7	3					587	593		10.3892/etm.2013.1451			7	Medicine, Research & Experimental	Research & Experimental Medicine	AC7GG	WOS:000332695500011	24520250	Green Published, Bronze			2021-06-18	
J	Angelucci, F; Ricci, V; Gelfo, F; Martinotti, G; Brunetti, M; Sepede, G; Signorelli, M; Aguglia, E; Pettorruso, M; Vellante, F; Di Giannantonio, M; Caltagirone, C				Angelucci, Francesco; Ricci, Valerio; Gelfo, Francesca; Martinotti, Giovanni; Brunetti, Marcella; Sepede, Gianna; Signorelli, Maria; Aguglia, Eugenio; Pettorruso, Mauro; Vellante, Federica; Di Giannantonio, Massimo; Caltagirone, Carlo			BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure	BRAIN AND COGNITION			English	Article						Post-traumatic stress disorder; Trauma exposure; BDNF; ELISA	ADMINISTERED PTSD SCALE; NERVE GROWTH-FACTOR; FACTOR VAL66MET POLYMORPHISM; NEUROTROPHIC FACTOR BDNF; DOPAMINERGIC-NEURONS; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; SEXUAL-ABUSE; HUMAN BRAIN; SCHIZOPHRENIA	Post-traumatic stress disorder (PTSD) is a syndrome resulting from exposure to a severe traumatic event that poses threatened death or injury and produces intense fear and helplessness. The neural structures implicated in PTSD development belong to the limbic system, an important region for emotional processing. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that serves as survival factor for selected populations of central nervous system (CNS) neurons and plays a role in the limbic system by regulating synaptic plasticity, memory processes and behavior. Impaired BDNF production in the brain can lead to a variety of CNS dysfunctions including symptoms associated with PTSD. However, so far fewer studies have investigated this neurotrophin in patients with PTSD. Furthermore, given the multiple role of BDNF in various CNS disorders, it cannot be excluded that traumatic events per se may influence neurotrophin levels, without a direct association to the PTSD syndrome. To elucidate these issues, in this study we analyzed BDNF serum levels in two groups of subjects: patients with trauma exposure who developed PTSD, and subjects with trauma exposure who did not develop PTSD. We found that BDNF serum levels were lower in PTSD patients as compared to related control subjects. Thus, these data suggest that BDNF might be involved in pathophysiology of PTSD and consequently therapeutic approaches aimed at restoring BDNF serum levels may be beneficial to this pathology. (C) 2013 Elsevier Inc. All rights reserved.	[Angelucci, Francesco; Ricci, Valerio; Gelfo, Francesca; Caltagirone, Carlo] IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, I-00179 Rome, Italy; [Martinotti, Giovanni; Brunetti, Marcella; Sepede, Gianna; Vellante, Federica; Di Giannantonio, Massimo] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [Signorelli, Maria; Aguglia, Eugenio] Univ Catania, Dept Psychiat, I-95124 Catania, Italy; [Pettorruso, Mauro] Univ Cattolica Sacro Cuore, Dept Neurosci, Rome, Italy	Angelucci, F (corresponding author), IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, I-00179 Rome, Italy.	f.angelucci@hsantalucia.it	Signorelli, Maria S/A-7422-2016; Signorelli, Maria/E-6155-2010; Sepede, Gianna/AAE-8711-2019; Pettorruso, Mauro/D-3620-2017; Ricci, Valerio/AAL-7972-2021; De Berardis, Domenico/F-9343-2018; Signorelli, Maria/E-6155-2010	Signorelli, Maria S/0000-0002-6941-9454; Signorelli, Maria/0000-0002-6941-9454; Pettorruso, Mauro/0000-0002-4164-3040; De Berardis, Domenico/0000-0003-4415-5058; Signorelli, Maria/0000-0001-5835-4176; aguglia, eugenio/0000-0003-2146-7737	Italian Ministry of HealthMinistry of Health, Italy	Supported by Italian Ministry of Health.	ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andero R, 2012, GENES BRAIN BEHAV, V11, P503, DOI 10.1111/j.1601-183X.2012.00801.x; Angelucci F, 2005, EUR NEUROPSYCHOPHARM, V15, P311, DOI 10.1016/j.euroneuro.2004.11.005; Angelucci F, 2004, PROG BRAIN RES, V146, P151, DOI 10.1016/S0079-6123(03)46011-1; Angelucci F, 2003, INT J NEUROPSYCHOPH, V6, P225, DOI 10.1017/S1461145703003468; BECK KD, 1994, PROG NEUROBIOL, V44, P497, DOI 10.1016/0301-0082(94)90009-4; Berger W, 2010, PROG NEURO-PSYCHOPH, V34, P1279, DOI 10.1016/j.pnpbp.2010.07.008; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bonne O, 2011, J CLIN PSYCHIAT, V72, P1124, DOI 10.4088/JCP.09m05106blu; Bremner J. Douglas, 2006, CNS & Neurological Disorders-Drug Targets, V5, P503; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Chao L., 2013, PSYCHIAT RES; Choi SW, 2011, PSYCHIAT RES, V186, P427, DOI 10.1016/j.psychres.2010.07.028; Cohen H, 2012, NEUROPSYCHOPHARMACOL, V37, P350, DOI 10.1038/npp.2011.230; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Croce N, 2013, MOL CELL BIOCHEM, V376, P189, DOI 10.1007/s11010-013-1567-0; Croce N, 2011, NEURODEGENER DIS, V8, P300, DOI 10.1159/000323468; Cunha ABM, 2006, NEUROSCI LETT, V398, P215, DOI 10.1016/j.neulet.2005.12.085; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Dennis NA, 2011, HIPPOCAMPUS, V21, P980, DOI 10.1002/hipo.20809; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Elfving B, 2010, J NEUROSCI METH, V187, P73, DOI 10.1016/j.jneumeth.2009.12.017; Felmingham KL, 2013, BIOL PSYCHIAT, V3223, P1034; First MB., 1997, STRUCTURED CLIN INTE; Gelfo F, 2012, CNS NEUROSCI THER, V18, P487, DOI 10.1111/j.1755-5949.2012.00314.x; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Gil-Bea FJ, 2011, HIPPOCAMPUS, V21, P999, DOI 10.1002/hipo.20812; Gonul AS, 2011, WORLD J BIOL PSYCHIA, V12, P110, DOI 10.3109/15622975.2010.507786; Hajcak G, 2009, GENES BRAIN BEHAV, V8, P80, DOI 10.1111/j.1601-183X.2008.00447.x; Hauck S, 2010, PROG NEURO-PSYCHOPH, V34, P459, DOI 10.1016/j.pnpbp.2010.01.010; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; Hemmings SMJ, 2013, PROG NEURO-PSYCHOPH, V40, P273, DOI 10.1016/j.pnpbp.2012.10.011; HOVENS JE, 1994, J CLIN PSYCHOL, V50, P325, DOI 10.1002/1097-4679(199405)50:3<325::AID-JCLP2270500304>3.0.CO;2-M; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Johansen JP, 2011, CELL, V147, P509, DOI 10.1016/j.cell.2011.10.009; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kuczewski N, 2010, EUR J NEUROSCI, V32, P1239, DOI 10.1111/j.1460-9568.2010.07378.x; Laske C, 2011, INT J NEUROPSYCHOPH, V14, P399, DOI 10.1017/S1461145710001008; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Lonsdorf TB, 2010, BEHAV NEUROSCI, V124, P9, DOI 10.1037/a0018261; Martinotti G, 2012, J BIOL REG HOMEOS AG, V26, P347; Martinotti G, 2011, J ECT, V27, pE44, DOI 10.1097/YCT.0b013e318205e1c0; Nathan PJ, 2011, CURR OPIN PHARMACOL, V11, P540, DOI 10.1016/j.coph.2011.06.008; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rasmusson AM, 2002, NEUROPSYCHOPHARMACOL, V27, P133, DOI 10.1016/S0893-133X(02)00286-5; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Stevens J.S., 2013, J PSYCHIAT RES; Teixeira AL, 2010, BIOMARK MED, V4, P871, DOI 10.2217/BMM.10.111; van Wingen G, 2010, NEUROIMAGE, V50, P1212, DOI 10.1016/j.neuroimage.2010.01.058; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Zhang HP, 2006, AM J MED GENET B, V141B, P387, DOI 10.1002/ajmg.b.30332; Zhang XY, 2012, PSYCHOPHARMACOLOGY, V222, P277, DOI 10.1007/s00213-012-2643-y; Zhen YF, 2013, PSYCHOPHARMACOLOGY, V227, P93, DOI 10.1007/s00213-012-2942-3	59	54	58	0	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	FEB	2014	84	1					118	122		10.1016/j.bandc.2013.11.012			5	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	295AM	WOS:000330089000013	24362070				2021-06-18	
J	Ditillo, M; Pandit, V; Rhee, P; Aziz, H; Hadeed, S; Bhattacharya, B; Friese, RS; Davis, K; Joseph, B				Ditillo, Michael; Pandit, Viraj; Rhee, Peter; Aziz, Hassan; Hadeed, Steven; Bhattacharya, Bishwajit; Friese, Randall S.; Davis, Kimberly; Joseph, Bellal			Morbid obesity predisposes trauma patients to worse outcomes: A National Trauma Data Bank analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Obesity; trauma; adverse outcomes in obese patients; mortality in obese patients; obesity and trauma	INDEPENDENT RISK-FACTOR; BLUNT TRAUMA; INJURED PATIENTS; MORTALITY	BACKGROUND: One third of US adults are obese. The impact of obesity on outcomes after blunt traumatic injury has been studied with discrepant results. The aim of our study was to evaluate outcomes in morbidly obese patients after blunt trauma. We hypothesized that morbidly obese patients have adverse outcomes as compared with nonobese patients after blunt traumatic injury. METHODS: We performed a retrospective analysis of all blunt trauma patients (>= 18 years) using the National Trauma Data Bank for years 2007 to 2010. Patients with recorded comorbidity of morbid obesity (body mass index >= 40) were identified. Patients transferred, dead on arrival, and with isolated traumatic brain injury were excluded. Propensity score matching was used to match morbidly obese patients to non-morbidly obese patients (body mass index < 40) in a 1: 1 ratio based on age, sex, Injury Severity Score (ISS), Glasgow Coma Scale (GCS), and systolic blood pressure on presentation. The primary outcome was mortality, and the secondary outcome was hospital complications. RESULTS: A total of 32,780 patients (morbidly obese, 16,390; nonobese, 16,390) were included in the study. Morbidly obese patients were more likely to have in-hospital complications (odds ratio [OR], 1.8, 95% confidence interval [CI], 1.6-1.9), longer hospital stay (OR, 1.2; 95% CI, 1.1-1.3), and longer intensive care unit stay (OR, 1.15; 95% CI, 1.09-1.2). The overall mortality rate was 2.8% (n = 851). Mortality was higher in morbidly obese patients compared with the nonobese patients (3.0 vs. 2.2; OR, 1.4; 95% CI, 1.1-1.5). CONCLUSION: In a cohort of matched patients, morbid obesity is a risk factor for the development of in-hospital complications and mortality after blunt traumatic injury. The results of our study call for attention through focused injury prevention efforts. Future studies are needed to help define the consequences of obesity that influence outcomes. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Pandit, Viraj; Rhee, Peter; Aziz, Hassan; Hadeed, Steven; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, Tucson, AZ 85724 USA; [Ditillo, Michael; Bhattacharya, Bishwajit; Davis, Kimberly] Yale New Haven Med Ctr, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, New Haven, CT 06504 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Ditillo, Michael/AAI-6259-2020	Bhattacharya, Bishwajit/0000-0002-7118-7621			Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P613; Brown Carlos V R, 2006, World J Emerg Surg, V1, P27, DOI 10.1186/1749-7922-1-27; Brown CVR, 2005, J TRAUMA, V59, P1048, DOI 10.1097/01.ta.0000189047.65630.c5; Byrnes MC, 2005, J TRAUMA, V58, P232, DOI 10.1097/01.TA.0000152081.67588.10; CHOBAN PS, 1991, J TRAUMA, V31, P1253, DOI 10.1097/00005373-199109000-00009; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fryar CD., PREVALENCE OVERWEIGH; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kisat M, 2013, SURG INFECT, V14, P62, DOI 10.1089/sur.2012.009; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Winfield RD, 2013, J AM COLL SURGEONS, V216, P1193, DOI 10.1016/j.jamcollsurg.2013.01.055	12	54	54	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					176	179		10.1097/TA.0b013e3182ab0d7c			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200033	24368375				2021-06-18	
J	Ji, SB; Ghadyani, H; Bolander, RP; Beckwith, JG; Ford, JC; McAllister, TW; Flashman, LA; Paulsen, KD; Ernstrom, K; Jain, S; Raman, R; Zhang, LY; Greenwald, RM				Ji, Songbai; Ghadyani, Hamidreza; Bolander, Richard P.; Beckwith, Jonathan G.; Ford, James C.; McAllister, Thomas W.; Flashman, Laura A.; Paulsen, Keith D.; Ernstrom, Karin; Jain, Sonia; Raman, Rema; Zhang, Liying; Greenwald, Richard M.			Parametric Comparisons of Intracranial Mechanical Responses from Three Validated Finite Element Models of the Human Head	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Sports-related concussion; Injury threshold; Finite element model; Head impact exposure	TRAUMATIC BRAIN-INJURY; FOOTBALL; PREDICTION; IMPACTS; BIOMECHANICS; GENERATION; KINEMATICS; SIMON	A number of human head finite element (FE) models have been developed from different research groups over the years to study the mechanisms of traumatic brain injury. These models can vary substantially in model features and parameters, making it important to evaluate whether simulation results from one model are readily comparable with another, and whether response-based injury thresholds established from a specific model can be generalized when a different model is employed. The purpose of this study is to parametrically compare regional brain mechanical responses from three validated head FE models to test the hypothesis that regional brain responses are dependent on the specific head model employed as well as the region of interest (ROI). The Dartmouth Scaled and Normalized Model (DSNM), the Simulated Injury Monitor (SIMon), and the Wayne State University Head Injury Model (WSUHIM) were selected for comparisons. For model input, 144 unique kinematic conditions were created to represent the range of head impacts sustained by male collegiate hockey players during play. These impacts encompass the 50th, 95th, and 99th percentile peak linear and rotational accelerations at 16 impact locations around the head. Five mechanical variables (strain, strain rate, strain 9 strain rate, stress, and pressure) in seven ROIs reported from the FE models were compared using Generalized Estimating Equation statistical models. Highly significant differences existed among FE models for nearly all output variables and ROIs. The WSUHIM produced substantially higher peak values for almost all output variables regardless of the ROI compared to the DSNM and SIMon models (p < 0.05). DSNM also produced significantly different stress and pressure compared with SIMon for all ROIs (p < 0.05), but such differences were not consistent across ROIs for other variables. Regardless of FE model, most output variables were highly correlated with linear and rotational peak accelerations. The significant disparities in regional brain responses across head models regardless of the output variables strongly suggest that model-predicted brain responses from one study should not be extended to other studies in which a different model is utilized. Consequently, response-based injury tolerance thresholds from a specific model should not be generalized to other studies either in which a different model is used. However, the similar relationships between regional responses and the linear/rotational peak accelerations suggest that each FE model can be used independently to assess regional brain responses to impact simulations in order to perform statistical correlations with medical images and/or well-selected experiments with documented injury findings.	[Ji, Songbai; Ghadyani, Hamidreza; Paulsen, Keith D.; Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg, Lebanon, NH USA; [Bolander, Richard P.; Beckwith, Jonathan G.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Ford, James C.; McAllister, Thomas W.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Ernstrom, Karin; Jain, Sonia; Raman, Rema] UCSD, Biostat Res Ctr, Dept Family & Prevent Med, La Jolla, CA USA; [Raman, Rema] UCSD, Dept Neurosci, La Jolla, CA USA; [Zhang, Liying] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA	Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	songbai.ji@dartmouth.edu	Ford, James/AAF-7039-2020; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	National Operating Committee on Standards for Athletic Equipment [NOCSAE 07-04, 14-19]; National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; Riddell, Inc. (Chicago, IL); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD040743, R01HD048638] Funding Source: NIH RePORTER	We would like to thank Dr. Erik Takhounts for providing support with the SIMon model. This work was supported by the National Operating Committee on Standards for Athletic Equipment (NOCSAE 07-04, 14-19) and by the National Institute for Child Health and Human Development at the National Institutes of Health (R01HD048638). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Danelson KA, 2008, STAPP CAR C, V52, P59; Franklyn Melanie, 2005, Stapp Car Crash J, V49, P1; Gadd C. W., 1966, 10 STAPP CAR CRASH C; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Horgan T.J., 2005, FINITE ELEMENT MODEL; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; King A., 2003, P IRCOBI C LISB PORT; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Nahum AM, 1977, P STAPP CAR CRASH CO; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J, 2000, 44 STAPP CAR CRASH C; Post A, 2012, TRAUMA, V14, P327, DOI 10.1177/1460408612446573; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Takhounts EG, 2008, STAPP CAR C, V52, P1; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; Versace J., 1971, 15 STAPP CAR CRASH C; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Yang King H, 2006, Stapp Car Crash J, V50, P429; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; Zhang L, 2011, IRCOBI IMP BIOM, V74, P315; Zhang L., 2004, SAE T; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	42	54	56	1	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2014	42	1					11	24		10.1007/s10439-013-0907-2			14	Engineering, Biomedical	Engineering	AB7MV	WOS:000331975400002	24077860	Green Accepted			2021-06-18	
J	Lei, BL; Dawson, HN; Roulhac-Wilson, B; Wang, HC; Laskowitz, DT; James, ML				Lei, Beilei; Dawson, Hana N.; Roulhac-Wilson, Briana; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.			Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage	JOURNAL OF NEUROINFLAMMATION			English	Article						Intracerebral hemorrhage; Microglia; Tumor necrosis factor alpha antagonism; Murine model; Cytokine; Remicade	TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; FUNCTIONAL RECOVERY; APOLIPOPROTEIN-E; RAT MODEL; EDEMA; INHIBITION; BARRIER; INFLAMMATION; ATTENUATION	Background: Intracerebral hemorrhage (ICH) is a devastating stroke subtype characterized by a prominent neuroinflammatory response. Antagonism of pro-inflammatory cytokines by specific antibodies represents a compelling therapeutic strategy to improve neurological outcome in patients after ICH. To test this hypothesis, the tumor necrosis factor alpha (TNF-alpha) antibody CNTO5048 was administered to mice after ICH induction, and histological and functional endpoints were assessed. Methods: Using 10 to 12-week-old C57BL/6J male mice, ICH was induced by collagenase injection into the left basal ganglia. Brain TNF-alpha concentration, microglia activation/macrophage recruitment, hematoma volume, cerebral edema, and rotorod latency were assessed in mice treated with the TNF-alpha antibody, CNTO5048, or vehicle. Results: After ICH induction, mice treated with CNTO5048 demonstrated reduction in microglial activation/ macrophage recruitment compared to vehicle-treated animals, as assessed by unbiased stereology (P = 0.049). This reduction in F4/80-positive cells was associated with a reduction in cleaved caspase-3 (P = 0.046) and cerebral edema (P = 0.026) despite similar hematoma volumes, when compared to mice treated with vehicle control. Treatment with CNTO5048 after ICH induction was associated with a reduction in functional deficit when compared to mice treated with vehicle control, as assessed by rotorod latencies (P = 0.024). Conclusions: Post-injury treatment with the TNF-alpha antibody CNTO5048 results in less neuroinflammation and improved functional outcomes in a murine model of ICH.	[Lei, Beilei; Roulhac-Wilson, Briana; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.] Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; [Lei, Beilei; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Dawson, Hana N.; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.] Dept Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	James, ML (corresponding author), Multidisciplinary Neuroprotect Labs, 132 Sands Bldg, Durham, NC 27710 USA.	michael.james@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210	American Heart Association Scientist Development GrantAmerican Heart Association	Funding for this study was provided by an American Heart Association Scientist Development Grant (MLJ). CNTO5048 was provided by Janssen. The authors would like to acknowledge Kathy Gage for her editorial assistance.	Albers GW, 2011, STROKE, V42, P2645, DOI 10.1161/STROKEAHA.111.618850; [Anonymous], 1998, REM INFL PACK INS; Arima H, 2012, STROKE, V43, P2236, DOI 10.1161/STROKEAHA.112.651422; Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Hernandez-Romero MC, 2012, NEUROTOXICOLOGY, V33, P347, DOI 10.1016/j.neuro.2012.01.018; Castellanos Mar, 2007, Cerebrovasc Dis, V24 Suppl 1, P7, DOI 10.1159/000107374; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hua Y, 2006, NEUROSURGERY, V58, P542, DOI 10.1227/01.NEU.0000197333.55473.AD; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; James ML, 2012, ANESTHESIOLOGY, V116, P1299, DOI 10.1097/ALN.0b013e318253a02a; James ML, 2010, J NEUROTRAUM, V27, P217, DOI 10.1089/neu.2009.1022; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Lin J, 2008, CLIN IMMUNOL, V126, P13, DOI 10.1016/j.clim.2007.08.012; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; Mendelow AD, 2005, LANCET, V365, P387; Morgan T, 2008, ACTA NEUROCHIR SUPPL, V105, P147; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Niemann JT, 2010, CRIT CARE MED, V38, P1162, DOI 10.1097/CCM.0b013e3181d44324; Onda A, 2004, SPINE, V29, P1857, DOI 10.1097/01.brs.0000137054.08788.b2; Perez la de Ossa N, 2010, STROKE, V41, P810; Qureshi AI, 2010, ARCH NEUROL-CHICAGO, V67, P570, DOI 10.1001/archneurol.2010.61; Reed SD, 2001, NEUROLOGY, V57, P305, DOI 10.1212/WNL.57.2.305; Rodriguez-Yanez M, 2008, CURR OPIN NEUROL, V21, P353, DOI 10.1097/WCO.0b013e3282ffafbf; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P175, DOI 10.1111/j.1749-6632.2009.05327.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sun W, 2012, J CLIN NEUROSCI, V19, P1096, DOI 10.1016/j.jocn.2011.11.020; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wang XK, 2004, MOL PHARMACOL, V65, P890, DOI 10.1124/mol.65.4.890; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Watters O, 2011, J NEUROIMMUNOL, V234, P27, DOI 10.1016/j.jneuroim.2011.01.008; Wu J, 2008, ACTA NEUROCHIR SUPPL, V105, P59; Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097	47	54	56	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 20	2013	10								103	10.1186/1742-2094-10-103			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	207EQ	WOS:000323580600001	23962089	DOAJ Gold, Green Published			2021-06-18	
J	Madathil, SK; Carlson, SW; Brelsfoard, JM; Ye, P; D'Ercole, AJ; Saatman, KE				Madathil, Sindhu K.; Carlson, Shaun W.; Brelsfoard, Jennifer M.; Ye, Ping; D'Ercole, A. Joseph; Saatman, Kathryn E.			Astrocyte-Specific Overexpression of Insulin-Like Growth Factor-1 Protects Hippocampal Neurons and Reduces Behavioral Deficits following Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; IGF-I; FLUID-PERCUSSION; GLIAL SCAR; OLIGODENDROCYTE DEVELOPMENT; CASPASE-3 ACTIVATION; REACTIVE ASTROCYTES	Traumatic brain injury (TBI) survivors often suffer from long-lasting cognitive impairment that stems from hippocampal injury. Systemic administration of insulin-like growth factor-1 (IGF-1), a polypeptide growth factor known to play vital roles in neuronal survival, has been shown to attenuate posttraumatic cognitive and motor dysfunction. However, its neuroprotective effects in TBI have not been examined. To this end, moderate or severe contusion brain injury was induced in mice with conditional (postnatal) overexpression of IGF-1 using the controlled cortical impact (CCI) injury model. CCI brain injury produces robust reactive astrocytosis in regions of neuronal damage such as the hippocampus. We exploited this regional astrocytosis by linking expression of hIGF-1 to the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter, effectively targeting IGF-1 delivery to vulnerable neurons. Following brain injury, IGF-1Tg mice exhibited a progressive increase in hippocampal IGF-1 levels which was coupled with enhanced hippocampal reactive astrocytosis and significantly greater GFAP levels relative to WT mice. IGF-1 overexpression stimulated Akt phosphorylation and reduced acute (1 and 3d) hippocampal neurodegeneration, culminating in greater neuron survival at 10d after CCI injury. Hippocampal neuroprotection achieved by IGF-1 overexpression was accompanied by improved motor and cognitive function in brain-injured mice. These data provide strong support for the therapeutic efficacy of increased brain levels of IGF-1 in the setting of TBI.	[Madathil, Sindhu K.; Carlson, Shaun W.; Brelsfoard, Jennifer M.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40508 USA; [Ye, Ping; D'Ercole, A. Joseph] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA	Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40508 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012	Carlson, Shaun/0000-0002-1413-5075	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS058484, NS072302, NS051220]; Kentucky Spinal Cord and Head Injury Research Trust [KSCHIRT 7-20]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072302] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) NS058484, NS072302, and NS051220, and KSCHIRT 7-20 Kentucky Spinal Cord and Head Injury Research Trust fellowship to SKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; Benito M, 1996, INT J BIOCHEM CELL B, V28, P499, DOI 10.1016/1357-2725(95)00168-9; Brywe KG, 2005, EUR J NEUROSCI, V21, P1489, DOI 10.1111/j.1460-9568.2005.03982.x; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Cao Y, 2003, J CEREBR BLOOD F MET, V23, P739, DOI 10.1097/01.WCB.0000067720.12805.6F; Cheng BX, 2011, MOL CELL NEUROSCI, V47, P181, DOI 10.1016/j.mcn.2011.04.002; CHERNAUSEK SD, 1993, J NEUROSCI RES, V34, P189, DOI 10.1002/jnr.490340206; Conte V., 2003, EUR J TRAUMA, V29, P335; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Delaney CL, 1999, J NEUROBIOL, V41, P540, DOI 10.1002/(SICI)1097-4695(199912)41:4<540::AID-NEU9>3.0.CO;2-P; Delaney CL, 2001, J NEUROPATH EXP NEUR, V60, P147, DOI 10.1093/jnen/60.2.147; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fletcher L, 2009, J NEUROSURG, V111, P164, DOI 10.3171/2009.2.JNS081199; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukunaga K, 2003, J PHARMACOL SCI, V92, P317; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Giralt A, 2010, GENE THER, V17, P1294, DOI 10.1038/gt.2010.71; Giralt A, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-71; Goddard DR, 1999, J NEUROSCI RES, V57, P74, DOI 10.1002/(SICI)1097-4547(19990701)57:1<74::AID-JNR8>3.0.CO;2-O; Guan J, 2001, NEUROSCIENCE, V105, P299, DOI 10.1016/S0306-4522(01)00145-2; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Horwood JM, 2006, EUR J NEUROSCI, V23, P3375, DOI 10.1111/j.1460-9568.2006.04859.x; Hunsaker MR, 2008, BEHAV BRAIN RES, V188, P310, DOI 10.1016/j.bbr.2007.11.015; Karpova A, 2006, NEUROSCIENCE, V137, P833, DOI 10.1016/j.neuroscience.2005.10.012; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kesner RP, 2007, PROG BRAIN RES, V163, P567, DOI 10.1016/S0079-6123(07)63030-1; Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje; Lin SY, 2011, BRAIN RES, V1385, P246, DOI 10.1016/j.brainres.2011.02.013; Liu XF, 2001, NEUROSCI LETT, V308, P91, DOI 10.1016/S0304-3940(01)01982-6; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; McMorris FA, 1996, BRAIN PATHOL, V6, P313, DOI 10.1111/j.1750-3639.1996.tb00858.x; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Takadera T, 1999, J NEUROCHEM, V73, P548, DOI 10.1046/j.1471-4159.1999.0730548.x; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zheng WH, 2000, ADV RES NEURODEGENER, V8, P261; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801; Zhu W, 2009, J CEREBR BLOOD F MET, V29, P1528, DOI 10.1038/jcbfm.2009.75	74	54	54	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2013	8	6							e67204	10.1371/journal.pone.0067204			14	Multidisciplinary Sciences	Science & Technology - Other Topics	174IX	WOS:000321150000044	23826235	DOAJ Gold, Green Published			2021-06-18	
J	Moreau, OK; Cortet-Rudelli, C; Yollin, E; Merlen, E; Daveluy, W; Rousseaux, M				Moreau, Odile Kozlowski; Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie; Daveluy, Walter; Rousseaux, Marc			Growth Hormone Replacement Therapy in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						activities of daily living; cognitive disorders; hormone replacement therapy; pituitary hormone deficiency; quality of life; traumatic brain injury	QUALITY-OF-LIFE; GH-DEFICIENT ADULTS; ANTERIOR-PITUITARY FUNCTION; HEALTHY OLDER-ADULTS; COGNITIVE FUNCTION; FACTOR-I; REPORTED OUTCOMES; SPATIAL MEMORY; KIMS DATABASE; HEAD-INJURY	In patients with severe traumatic brain injury (TBI), a growth hormone deficiency (GHD) is frequent and may contribute to the cognitive sequelae and reduction in quality of life (QoL). Recent studies have suggested that GH replacement therapy (GHRT) can improve processing speed and memory. The aim of the study was to analyze the efficacy of GHRT on cognition, activities of daily living (ADL), and QoL and the factors that predicted and contributed to these effects. We included patients at least 1 year after their TBI and assessed pituitary functions (with stimulation tests), cognition (attention, memory, and executive function), participation in ADL and QoL. GHD was treated for at least 1 year in 23 patients, who were compared with 27 non-treated patients. Other deficiencies were also treated. Measurements were performed at baseline and 1 year later. An analysis of variance of the factors group and session (p <= 0.05) showed that most cognitive parameters had improved at 1 year (evidencing a session effect). A stronger effect of GHRT (i. e. a group x session interaction) was found for Rey Osterrieth complex figure recall and 2/6 domains in the QoL questionnaire ("personal'' and "functional''). Trends (p <= 0.07) were also found for spatial orientation and immediate recall in the verbal memory test. Greatest improvements were associated with lower performance before treatment. The magnitude of the improvements in ADL and QoL was moderately correlated with the improvement in cognition. In conclusion, replacement therapy can improve cognition and QoL in patients with TBI who have GHD, especially in those with severe disabilities.	[Moreau, Odile Kozlowski; Daveluy, Walter; Rousseaux, Marc] Swynghedauw Hosp, Neurol Rehabil Unit, Lille, France; [Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie] CHRU Lille, Huriez Hosp, Endocrinol Unit, F-59037 Lille, France; [Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie] Univ Lille Nord France, Lille, France	Rousseaux, M (corresponding author), CHRU Lille, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France.	marc.rousseaux@chru-lille.fr					Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Abrams P, 2008, EUR J ENDOCRINOL, V159, P825, DOI 10.1530/EJE-08-0448; Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Auernhammer CJ, 2007, PITUITARY, V10, P1, DOI 10.1007/s11102-007-0001-6; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baker LD, 2012, ARCH NEUROL-CHICAGO, V69, P1420, DOI 10.1001/archneurol.2012.1970; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks N., 1994, EVALUATION TRAUMATIC, V1994, P1; Burman P, 1996, CLIN ENDOCRINOL, V44, P319, DOI 10.1046/j.1365-2265.1996.617439.x; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Chrisoulidou A, 1998, BAILLIERE CLIN ENDOC, V12, P261, DOI 10.1016/S0950-351X(98)80022-0; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; FEHMWOLFSDORF G, 1991, PEPTIDES, V12, P1399, DOI 10.1016/0196-9781(91)90226-F; Ghigo E, 2008, GROWTH HORM IGF RES, V18, P1, DOI 10.1016/j.ghir.2007.07.004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Lasaite Lina, 2004, Medicina (Kaunas), V40, P740; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; LOBIE PE, 1993, DEV BRAIN RES, V74, P225, DOI 10.1016/0165-3806(93)90008-X; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.1007/BF03350340, 10.3275/7045]; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Nieves-Martinez E, 2010, J ENDOCRINOL, V204, P31, DOI 10.1677/JOE-09-0323; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Radcliffe DJ, 2004, PHARMACOECONOMICS, V22, P499, DOI 10.2165/00019053-200422080-00003; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rosilio M, 2004, J CLIN ENDOCR METAB, V89, P1684, DOI 10.1210/jc.2003-030134; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Schneider HJ, 2011, CLIN ENDOCRINOL, V75, P825, DOI 10.1111/j.1365-2265.2011.04137.x; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; STABLER B, 1992, CLIN ENDOCRINOL, V36, P467, DOI 10.1111/j.1365-2265.1992.tb02247.x; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Stouthart PJHM, 2003, PSYCHONEUROENDOCRINO, V28, P612, DOI 10.1016/S0306-4530(02)00045-8; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Svensson J, 2007, GROWTH HORM IGF RES, V17, P67, DOI 10.1016/j.ghir.2006.11.002; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tazopoulou E, 2005, ACTA NEUROPSYCHOL, V1, P13; Thornton PL, 2000, J GERONTOL A-BIOL, V55, pB106; van Dam P Sylze, 2006, Treat Endocrinol, V5, P159; van Dam PS, 2004, EUR J PHARMACOL, V490, P87, DOI 10.1016/j.ejphar.2004.02.047; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Van der Linden M., 2004, EVALUATION TROUBLES; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vitiello MV, 2006, NEUROBIOL AGING, V27, P318, DOI 10.1016/j.neurobiolaging.2005.01.010; Webb S M, 2008, J Endocrinol Invest, V31, P52; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; ZIMMERMANN P, 1994, TEST ATTENTIONAL PER	63	54	55	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					998	1006		10.1089/neu.2012.2705			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300010	23323993				2021-06-18	
J	Schmidt, J; Fleming, J; Ownsworth, T; Lannin, NA				Schmidt, Julia; Fleming, Jennifer; Ownsworth, Tamara; Lannin, Natasha A.			Video Feedback on Functional Task Performance Improves Self-awareness After Traumatic Brain Injury: A Randomized Controlled Trial	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						cognition; rehabilitation; occupational therapy; neuropsychology	INTERVENTIONS; DEFICITS; REHABILITATION; SAMPLE; ADULTS; SKILLS	Background. Feedback is used in rehabilitation to improve self-awareness in people with traumatic brain injury (TBI), but there have been no comparisons of the different methods of providing feedback. Objective. To compare the effect of different methods of feedback on impaired self-awareness after TBI. Method. This was a randomized, assessor-blinded trial with concealed allocation. A total of 54 participants with TBI and impaired self-awareness (85% male) were recruited from inpatient and community rehabilitation settings. Participants performed a meal preparation task on 4 occasions and were randomly assigned to 1 of 3 feedback intervention groups: video plus verbal feedback, verbal feedback, or experiential feedback. The primary outcome was improvement in online awareness measured by the number of errors made during task completion. Secondary outcomes included level of intellectual awareness, self-perception of rehabilitation, and emotional status. Results. Receiving video plus verbal feedback reduced the number of errors more than verbal feedback alone (mean difference = 19.7 errors; 95% confidence interval [CI] = 9.2-30.1) and experiential feedback alone (mean difference = 12.4 errors; 95% CI = 1.8-23.0). Conclusion. The results suggest that the video plus verbal feedback approach used in this study was effective in improving self-awareness in people with TBI. The results also provide evidence that improvement in self-awareness was not accompanied by deterioration in emotional status.	[Schmidt, Julia] Royal Rehabil Ctr, Sydney, NSW, Australia; [Schmidt, Julia; Fleming, Jennifer] Univ Queensland, Brisbane, Qld 4072, Australia; [Schmidt, Julia; Fleming, Jennifer] Metro South Hlth Serv Dist, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Ownsworth, Tamara] Griffith Univ, Brisbane, Qld 4111, Australia; [Lannin, Natasha A.] Alfred Hlth, Melbourne, Vic, Australia; [Lannin, Natasha A.] La Trobe Univ, Melbourne, Vic, Australia; [Lannin, Natasha A.] Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia	Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Lannin, Natasha A/A-4195-2013	Lannin, Natasha A/0000-0002-2066-8345; Schmidt, Julia/0000-0003-2004-4871; Ownsworth, Tamara/0000-0003-1835-7094	Occupational Therapists Board of Queensland; Wenkart Foundation, Australia; Cerebral Palsy Alliance, Australia	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This trial has been partially funded through a grant awarded by the Occupational Therapists Board of Queensland. At the time of this study, JS was supported by a fellowship provided by the Wenkart Foundation, Australia, and NAL was supported by the Balnaves Fellowship provided by the Cerebral Palsy Alliance, Australia. There are no industrial links or affiliations of authors involved in this study, and there are no conflicts of interest.	Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Alexy WD, 1983, COGNITIVE REHABILITA, V1, P8; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming J, 2009, INTERNATIONAL HANDBOOK OF OCCUPATIONAL THERAPY INTERVENTIONS, P225, DOI 10.1007/978-0-387-75424-6_20; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; MCNAUGHTON SS, 1987, PAUSE PROMPT PRAISE; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2009, 6 S NEUR REH AUG 3 4; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Pocock SJ, 1983, CLIN TRIALS PRACTICA; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Schlund MW, 1999, BRAIN INJURY, V13, P375, DOI 10.1080/026990599121566; Schmidt J, 2012, AUST OCCUP THER J, V59, P138, DOI 10.1111/j.1440-1630.2012.00998.x; Schmidt J, 2011, J REHABIL MED, V43, P673, DOI 10.2340/16501977-0846; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, AWARENESS QUESTIONNA; Tabachnick B., 2001, USING MULTIVARIATE S; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; Wilson BA, 1996, BEHAV ASSESSMENT DYS	30	54	54	0	32	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2013	27	4					316	324		10.1177/1545968312469838			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	136JX	WOS:000318359300004	23270921				2021-06-18	
J	Pineda, JA; Leonard, JR; Mazotas, IG; Noetzel, M; Limbrick, DD; Keller, MS; Gill, J; Doctor, A				Pineda, Jose A.; Leonard, Jeffrey R.; Mazotas, Ioanna G.; Noetzel, Michael; Limbrick, David D.; Keller, Martin S.; Gill, Jeff; Doctor, Allan			Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study	LANCET NEUROLOGY			English	Article							SEVERE HEAD-INJURY; INTENSIVE-CARE; CHILDREN; MORTALITY; EXPERIENCE; MANAGEMENT; RECOMMENDATIONS; VALIDITY; IMPACT; SCALE	Background Outcomes after traumatic brain injury are worsened by secondary insults; modern intensive-care units address such challenges through use of best-practice pathways. Organisation of intensive-care units has an important role in pathway effectiveness. We aimed to assess the effect of a paediatric neurocritical care programme (PNCP) on outcomes for children with severe traumatic brain injury. Methods We undertook a retrospective cohort study of 123 paediatric patients with severe traumatic brain injury (Glasgow coma scale scores <= 8, without gunshot or abusive head trauma, cardiac arrest, or Glasgow coma scale scores of 3 with fixed and dilated pupils) admitted to the paediatric intensive-care unit of the St Louis Children's Hospital (St Louis, MO, USA) between July 15, 1999, and Jan 15, 2012. The primary outcome was rate of categorised hospital discharge disposition before and after implementation of a PNCP on Sept 17, 2005. We developed an ordered probit statistical model to assess adjusted outcome as a function of initial injury severity. We assessed care-team behaviour by comparing timing of invasive neuromonitoring and scored intensity of therapies targeting intracranial hypertension. Findings Characteristics of treated patients (aged 3-219 months) were much the same between treatment periods. Before PNCP implementation, 33 (52%) of 63 patients had unfavourable disposition at hospital discharge (death or admission to an inpatient facility) and 30 (48%) had a favourable disposition (home with or without treatment); after PNCP implementation, 20 (33%) of 60 patients had unfavourable disposition and 40 (67%) had favourable disposition (p=0.01). Seven (11%) patients died before PNCP implementation compared with two (3%) deaths after implementation. The probit model indicated that outcome improved across the spectrum of Glasgow coma scale scores after resuscitation (p=0.02); this improvement progressed with increasing injury severity. Kaplan-Meier analysis suggested that neuromonitoring was started earlier and maintained longer after implementation of the PNCP (p=0.03). Therapeutic intensity scores were increased for the first 3 days of treatment after PNCP implementation (p=0.0298 for day 1, 1)=0.0292 for day 2, and p=0.0471 for day 3). The probit model suggested that increasing age (p=0.03), paediatric risk of mortality III scores (p=0.0003), and injury severity scores (p=0.02) were reliably associated with increased probability of unfavourable outcomes whereas white race (p=0.01), use of intracranial pressure monitoring (p=0.001), and increasing Glasgow coma scale scores after resuscitation (p=0.04) were associated with increased probability of favourable outcomes. Interpretation Outcomes for children with traumatic brain injury can be improved by altering the care system in a way that stably implements a cooperative programme of accepted best practice.	[Pineda, Jose A.; Doctor, Allan] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Pineda, Jose A.; Noetzel, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Mazotas, Ioanna G.; Keller, Martin S.; Gill, Jeff] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Leonard, Jeffrey R.; Limbrick, David D.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; [Leonard, Jeffrey R.; Limbrick, David D.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Gill, Jeff] Washington Univ, Sch Med, Dept Polit Sci, St Louis, MO 63110 USA; [Gill, Jeff] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA; [Doctor, Allan] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Pineda, JA (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, Campus Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.	pineda_j@kids.wustl.edu	Pineda, Jose/W-2806-2019	Doctor, Allan/0000-0002-6096-6400	St Louis Children's Hospital; Sean Glanvill Foundations	Funding St Louis Children's Hospital and the Sean Glanvill Foundations.	Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Bell MJ, 2009, NEUROCRIT CARE, V10, P4, DOI 10.1007/s12028-008-9061-3; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Cuschieri J, 2012, ANN SURG, V255, P993, DOI 10.1097/SLA.0b013e31824f1ebc; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Dougherty D, 2008, JAMA-J AM MED ASSOC, V299, P2319, DOI 10.1001/jama.299.19.2319; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Forsyth RJ, 2008, PEDIATR CRIT CARE ME, V9, P8, DOI 10.1097/01.PCC.0000298759.78616.3A; Glass HC, 2010, NEUROCRIT CARE, V12, P421, DOI 10.1007/s12028-009-9324-7; Guerguerian AM, 2009, CURR OPIN PEDIATR, V21, P737, DOI 10.1097/MOP.0b013e328332d11c; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Keller JM, 2012, J ORTHOP TRAUMA, V26, pE161, DOI 10.1097/BOT.0b013e3182324460; Knopf L, 2012, NEUROCRIT CARE, V16, P63, DOI 10.1007/s12028-011-9620-x; Logani S, 2011, CRIT CARE RES PRACT, V2011, DOI 10.1155/2011/170814; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Randolph AG, 2002, J EVAL CLIN PRACT, V8, P1; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Scaife ER, 2010, CURR OPIN PEDIATR, V22, P339, DOI 10.1097/MOP.0b013e3283395f2b; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Society of Critical Care Medicine, 2003, Crit Care Med, V31, pS407; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Sutton Gigi, 2011, J Healthc Qual, V33, P10, DOI 10.1111/j.1945-1474.2011.00138.x; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Wetzel RC, 2011, PEDIATR ANESTH, V21, P787, DOI 10.1111/j.1460-9592.2011.03595.x	35	54	55	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					45	52		10.1016/S1474-4422(12)70269-7			8	Clinical Neurology	Neurosciences & Neurology	055PR	WOS:000312429400019	23200264				2021-06-18	
J	Starkey, ML; Bleul, C; Zorner, B; Lindau, NT; Mueggler, T; Rudin, M; Schwab, ME				Starkey, Michelle Louise; Bleul, Christiane; Zoerner, Bjoern; Lindau, Nicolas Thomas; Mueggler, Thomas; Rudin, Markus; Schwab, Martin Ernst			Back seat driving: hindlimb corticospinal neurons assume forelimb control following ischaemic stroke	BRAIN			English	Article						stroke; functional recovery; plasticity; sprouting; movement control	INDUCED MOVEMENT THERAPY; FOCAL CEREBRAL-ISCHEMIA; PRIMARY MOTOR CORTEX; SPINAL-CORD INJURY; IN-VIVO; FUNCTIONAL REORGANIZATION; SOMATOSENSORY STIMULATION; CORTICAL REORGANIZATION; ELECTRICAL-STIMULATION; BRAIN REORGANIZATION	Whereas large injuries to the brain lead to considerable irreversible functional impairments, smaller strokes or traumatic lesions are often associated with good recovery. This recovery occurs spontaneously, and there is ample evidence from preclinical studies to suggest that adjacent undamaged areas (also known as peri-infarct regions) of the cortex 'take over' control of the disrupted functions. In rodents, sprouting of axons and dendrites has been observed in this region following stroke, while reduced inhibition from horizontal or callosal connections, or plastic changes in subcortical connections, could also occur. The exact mechanisms underlying functional recovery after small- to medium-sized strokes remain undetermined but are of utmost importance for understanding the human situation and for designing effective treatments and rehabilitation strategies. In the present study, we selectively destroyed large parts of the forelimb motor and premotor cortex of adult rats with an ischaemic injury. A behavioural test requiring highly skilled, cortically controlled forelimb movements showed that some animals recovered well from this lesion whereas others did not. To investigate the reasons behind these differences, we used anterograde and retrograde tracing techniques and intracortical microstimulation. Retrograde tracing from the cervical spinal cord showed a correlation between the number of cervically projecting corticospinal neurons present in the hindlimb sensory-motor cortex and good behavioural recovery. Anterograde tracing from the hindlimb sensory-motor cortex also showed a positive correlation between the degree of functional recovery and the sprouting of neurons from this region into the cervical spinal cord. Finally, intracortical microstimulation confirmed the positive correlation between rewiring of the hindlimb sensory-motor cortex and the degree of forelimb motor recovery. In conclusion, these experiments suggest that following stroke to the forelimb motor cortex, cells in the hindlimb sensory-motor area reorganize and become functionally connected to the cervical spinal cord. These new connections, probably in collaboration with surviving forelimb neurons and more complex indirect connections via the brainstem, play an important role for the recovery of cortically controlled behaviours like skilled forelimb reaching.	[Starkey, Michelle Louise; Bleul, Christiane; Zoerner, Bjoern; Lindau, Nicolas Thomas; Schwab, Martin Ernst] Univ Zurich, Brain Res Inst, Dept Hlth Sci & Technol, CH-8057 Zurich, Switzerland; [Mueggler, Thomas; Rudin, Markus] ETH, Anim Imaging Ctr, CH-8093 Zurich, Switzerland	Starkey, ML (corresponding author), Balgrist Univ Hosp, Forchstr 340, CH-8008 Zurich, Switzerland.	mstarkey@paralab.balgrist.ch	Schwab, Martin E/B-6818-2016; Mueggler, Thomas/AAC-7998-2020		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [3100AO-122527/1]; National Centre for Competence in Research 'Neural Plasticity and Repair' of the Swiss National Science Foundation; European UnionEuropean Commission [201024, 202213]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [223524]; Spinal Cord Consortium of the Christopher and Dana Reeve Foundation	Swiss National Science Foundation (Grant number 3100AO-122527/1); the National Centre for Competence in Research 'Neural Plasticity and Repair' of the Swiss National Science Foundation; The European Union's Seventh Framework Programme FP7/2007-2013 (Grant numbers 201024 and 202213) (European Stroke Network, www.europeanstrokenetwork.info/); The European Commission under the 7th Framework Programme-HEALTH-Collaborative Project Plasticise (www.plasticise.eu) (Grant number 223524) and The Spinal Cord Consortium of the Christopher and Dana Reeve Foundation.	Adesnik H, 2010, NATURE, V464, P1155, DOI 10.1038/nature08935; Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Brown AW, 2010, SEMIN NEUROL, V30, P511, DOI 10.1055/s-0030-1268867; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Brown CE, 2010, J CEREBR BLOOD F MET, V30, P783, DOI 10.1038/jcbfm.2009.241; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Brus-Ramer M, 2007, J NEUROSCI, V27, P13793, DOI 10.1523/JNEUROSCI.3489-07.2007; Carmel JB, 2010, J NEUROSCI, V30, P10918, DOI 10.1523/JNEUROSCI.1435-10.2010; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Cicinelli P, 1997, MUSCLE NERVE, V20, P535, DOI 10.1002/(SICI)1097-4598(199705)20:5<535::AID-MUS1>3.0.CO;2-A; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2011, PROG BRAIN RES, V192, P273, DOI 10.1016/B978-0-444-53355-5.00015-4; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Enright LE, 2007, J CEREBR BLOOD F MET, V27, P1185, DOI 10.1038/sj.jcbfm.9600428; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fouad K, 2001, CURR BIOL, V11, P1766, DOI 10.1016/S0960-9822(01)00535-8; Gharbawie OA, 2005, NEUROSCIENCE, V130, P601, DOI 10.1016/j.neuroscience.2004.10.010; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Gilmour G, 2004, BEHAV BRAIN RES, V150, P171, DOI 10.1016/j.bbr.2003.07.006; Green JB, 1999, NEUROLOGY, V53, P736, DOI 10.1212/WNL.53.4.736; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; Hewlett KA, 2006, NEUROSCIENCE, V141, P27, DOI 10.1016/j.neuroscience.2006.03.071; Hoffman LR, 2007, PHYS THER, V87, P208, DOI 10.2522/ptj.20050365; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; KLINE J, 1984, PHYSIOL BEHAV, V33, P301, DOI 10.1016/0031-9384(84)90116-1; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Li SL, 2006, NEUROBIOL DIS, V23, P362, DOI 10.1016/j.nbd.2006.03.011; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, ACTA NEUROL SCAND, V101, P321, DOI 10.1034/j.1600-0404.2000.90337a.x; Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Martin JH, 1999, EXP BRAIN RES, V125, P184, DOI 10.1007/s002210050673; Martin JH, 2004, J NEUROSCI, V24, P2122, DOI 10.1523/JNEUROSCI.4616-03.2004; Mostany R, 2011, J NEUROSCI, V31, P1734, DOI 10.1523/JNEUROSCI.4386-10.2011; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NEAFSEY EJ, 1982, BRAIN RES, V232, P151, DOI 10.1016/0006-8993(82)90617-5; Schaechter JD, 2012, NEUROREHAB NEURAL RE, V26, P325, DOI 10.1177/1545968311421613; Starkey ML, 2011, EXP NEUROL, V232, P81, DOI 10.1016/j.expneurol.2011.08.006; Stinear C, 2010, LANCET NEUROL, V9, P1228, DOI 10.1016/S1474-4422(10)70247-7; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; Traversa R, 1997, STROKE, V28, P110, DOI 10.1161/01.STR.28.1.110; Wang L, 2011, P NATL ACAD SCI USA, V108, P2545, DOI 10.1073/pnas.1014335108; Ward NS, 2007, EUR J NEUROSCI, V25, P1865, DOI 10.1111/j.1460-9568.2007.05434.x; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Weishaupt N, 2010, J NEUROTRAUM, V27, P1387, DOI 10.1089/neu.2010.1346; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1990, BEHAV BRAIN RES, V41, P49, DOI 10.1016/0166-4328(90)90053-H; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Winship IR, 2008, J NEUROSCI, V28, P6592, DOI 10.1523/JNEUROSCI.0622-08.2008; Wu CWH, 1999, J NEUROSCI, V19, P7679, DOI 10.1523/JNEUROSCI.19-17-07679.1999; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000; Zhang SX, 2007, PLOS BIOL, V5, P1152, DOI 10.1371/journal.pbio.0050119; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zorner B, 2010, NAT METHODS, V7, P701, DOI 10.1038/nmeth.1484	75	54	55	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2012	135		11				3265	3281		10.1093/brain/aws270			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	044SV	WOS:000311644800014	23169918	Green Published, Green Accepted, Bronze			2021-06-18	
J	Crowe, LM; Catroppa, C; Babl, FE; Rosenfeld, JV; Anderson, V				Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Rosenfeld, Jeffrey V.; Anderson, Vicki			Timing of Traumatic Brain Injury in Childhood and Intellectual Outcome	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; IQ; outcome; plasticity; traumatic brain injury	CLOSED HEAD-INJURY; DEVELOPMENTAL-CHANGES; YOUNG-CHILDREN; FUNCTIONAL RECOVERY; FRONTAL-CORTEX; PLASTICITY; AGE; LANGUAGE; INFANTS; PERFORMANCE	Objective Typically, studies on outcomes after traumatic brain injury (TBI) have investigated whether a younger age at injury is associated with poorer recovery by comparing 2 age groups rather than participants injured across childhood. This study extended previous research by examining whether the influence of age on recovery fits an early vulnerability or critical developmental periods model. Methods Children with a TBI (n = 181) were categorized into 4 age-at-injury groups-infant, preschool, middle childhood, and late childhood-and were evaluated at least 2-years post-TBI on IQ. Results Overall, the middle childhood group had lower IQ scores across all domains. Infant and preschool groups performed below the late childhood group on nonverbal and processing speed domains. Conclusions Contrary to expectations, children injured in middle childhood demonstrated the poorest outcomes; this age potentially coincides with a critical period of brain and cognitive development.	[Crowe, Louise M.] Royal Childrens Hosp, Dept Child Neuropsychol Crit Care & Neurosci, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Crowe, Louise M.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Babl, Franz E.] Royal Childrens Hosp, Emergency Dept, Parkville, Vic 3052, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia	Crowe, LM (corresponding author), Royal Childrens Hosp, Dept Child Neuropsychol Crit Care & Neurosci, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au	Rosenfeld, Jeffrey V/B-7249-2011	Crowe, Louise/0000-0003-4619-9708			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; Case ME, 2008, BRAIN PATHOL, V18, P562, DOI 10.1111/j.1750-3639.2008.00202.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Daniel A., 1983, POWER PRESTIGE OCCUP; DENNIS M, 1976, BRAIN LANG, V3, P404, DOI 10.1016/0093-934X(76)90036-5; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ennis Elaine, 2004, Pediatr Rehabil, V7, P205, DOI 10.1080/13638490410001703316; ESCALONA SK, 1982, PEDIATRICS, V70, P670; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Gerring J., 2012, J NEUROTRAUMA; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hertz-Pannier L, 2002, BRAIN, V125, P361, DOI 10.1093/brain/awf020; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; HUTTENLOCHER PR, 1997, DEV PREFRONTAL CORTE, P69; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P, 1988, ICPS FAMILY FUNCTION; Paul R., 2006, LANGUAGE DISORDERS I; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Spencer-Smith M, 2009, DEV NEUROREHABIL, V12, P279, DOI 10.3109/17518420903090701; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Teuber H., 1971, NEUROPSYCHOLOGIA, V17, P557; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wechsler, 2002, WECHSLER PRESCHOOL P; Wechsler D, 1991, MANUAL WECHSLER SCAL; Wechsler D, 1989, MANUAL PRESCHOOL PRI; YULE W, 1982, PERS INDIV DIFFER, V3, P65, DOI 10.1016/0191-8869(82)90075-7	56	54	55	0	25	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2012	37	7					745	754		10.1093/jpepsy/jss070			10	Psychology, Developmental	Psychology	981KC	WOS:000306965500005	22669504				2021-06-18	
J	Fogelberg, DJ; Hoffman, JM; Dikmen, S; Temkin, NR; Bell, KR				Fogelberg, Donald J.; Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy R.; Bell, Kathleen R.			Association of Sleep and Co-Occurring Psychological Conditions at 1 Year After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Comorbidity; Rehabilitation; Sleep	CHRONIC INSOMNIA; QUALITY INDEX; DEPRIVATION; DISTURBANCE; PAIN; PERFORMANCE; DEPRESSION; DISORDER; THERAPY; SCALE	Fogelberg DJ, Hoffman JM, Dikmen S. Temkin NR, Bell KR. Association of sleep and co-occurring psychological conditions at 1 year after traumatic brain injury. Arch Phys Med Rehabil 2012;93: 1313-8. Objectives: To compare individuals' sleep 1 year after traumatic brain injury (TBI) with that of a healthy comparison group, and examine the relationship between sleep, co-occurring conditions, and functional status in those with TBI. Design occurred at 1 year after TBI. Setting: Inpatient acute rehabilitation for TBI and community follow-up at 1 year postinjury. Participants: Individuals with TBI (N = 174) were recruited from consecutive admissions to an inpatient rehabilitation unit and enrolled into the TBI Model Systems study. Participant mean age was 38, and mean Glasgow Coma Scale score on admission was 9.3. Seventy-eight percent of the sample were men. Interventions: None. Main Outcome Measures: Sleep was assessed with the Pittsburgh Seep Quality Index (PSQI). Depression, anxiety, and pain were measured with the Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 Scale, and an analog pain rating scale, respectively. Results: Participants with TBI reported significantly greater sleep difficulties than the healthy comparison group. Forty-four percent of participants with TBI reported significant sleep problem; (PSQI>5). Participants with 1 or more co-occurring conditions (depression, pain, or anxiety) had significantly worse sleep than those without such a condition. The highest level of sleep problems was reported by participants with multiple co-occurring conditions. Sleep problems were also associated with poor functional status. Conclusions: Sleep difficulties are a frequent problem at 1 year after TBI, and often co-occur with depression, anxiety, and pain. Assessment and treatment of sleep difficulties should be included in clinical practice. Future research on the potential causal relationship among co-occurring conditions may assist in additional intervention planning.	[Fogelberg, Donald J.; Hoffman, Jeanne M.; Dikmen, Sureyya; Temkin, Nancy R.; Bell, Kathleen R.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Fogelberg, DJ (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	fogelber@uw.edu		Bell, Kathleen/0000-0002-0928-2046; Fogelberg, Donald/0000-0002-8188-4252	National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems [HI33A070032]	Supported by the National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems (grant no. HI33A070032).	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Baker FC, 1999, J PSYCHOSOM RES, V47, P335, DOI 10.1016/S0022-3999(99)00017-3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; Corrigan J., 2000, SATISFACTION LIFE SC; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Hamilton B., 1987, REHABILITATION OUTCO; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Harrison Y, 2000, J EXP PSYCHOL-APPL, V6, P236, DOI 10.1037//1076-898X.6.3.236; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Jensen MP, 2011, HDB PAIN ASSESSMENT; Johnson EO, 1998, SLEEP, V21, P178, DOI 10.1093/sleep/21.2.178; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lautenbacher S, 2006, SLEEP MED REV, V10, P357, DOI 10.1016/j.smrv.2005.08.001; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roehrs T, 2006, SLEEP, V29, P145, DOI 10.1093/sleep/29.2.145; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Venkatraman V, 2007, SLEEP, V30, P603, DOI 10.1093/sleep/30.5.603; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wright J., 2000, DISABILITY RATING SC; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	44	54	54	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1313	1318		10.1016/j.apmr.2012.04.031			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700003	22840828				2021-06-18	
J	Corrigan, F; Vink, R; Blumbergs, PC; Masters, CL; Cappai, R; van den Heuvel, C				Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; Masters, Colin L.; Cappai, Roberto; van den Heuvel, Corinna			sAPPa rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						amyloid precursor protein; sAPPa; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; HEAD-INJURY; HIPPOCAMPAL-NEURONS; NEURITE OUTGROWTH; SECRETED FORMS; BETA-PROTEIN; RISK-FACTOR; NEUTROPHIL INFILTRATION	J. Neurochem. (2012) 122, 208220. Abstract The amyloid precursor protein (APP) is thought to be neuroprotective following traumatic brain injury (TBI), although definitive evidence at moderate to severe levels of injury is lacking. In the current study, we investigated histological and functional outcomes in APP-/- mice compared with APP+/+ mice following a moderate focal injury, and whether administration of sAPPa restored the outcomes in knockout animals back to the wildtype state. Following moderate controlled cortical impact injury, APP-/- mice demonstrated greater impairment in motor and cognitive outcome as determined by the ledged beam and Barnes Maze tests respectively (p < 0.05). This corresponded with the degree of neuronal damage, with APP-/- mice having significantly greater lesion volume (25.0 +/- 1.6 vs. 20.3 +/- 1.6%, p < 0.01) and hippocampal damage, with less remaining CA neurons (839 +/- 245 vs. 1353 +/- 142 and 1401 +/- 263). This was also associated with an impaired neuroreparative response, with decreased GAP-43 immunoreactivity within the cortex around the lesion edge compared with APP+/+ mice. The deficits observed in the APP-/- mice related to a lack of sAPPa, as treatment with exogenously added sAPPa post-injury improved APP-/- mice histological and functional outcome to the point that they were no longer significantly different to APP+/+ mice (p < 0.05). This study shows that endogenous APP is potentially protective at moderate levels of TBI, and that this neuroprotective activity is related to the presence of sAPPa. Importantly, it indicates that the mechanism of action of exogenously added sAPPa is independent of the presence of endogenous APP.	[Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia; [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Melbourne, Vic 3010, Australia; [Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia	van den Heuvel, C (corresponding author), Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Cappai, Roberto/0000-0002-9505-8496; Corrigan, Frances/0000-0001-6150-8893; , Corinna/0000-0003-0664-8935	Brain Foundation; Neurosurgical Research Foundation	We thank Prof. Hui Zheng for providing the APP knockout mice and Dr Mark Habgood (University of Melbourne), Dr Jenna Zeibell and Jim Manavis for expert technical assistance. We thank Dr. Chi Pham (The University of Melbourne) for purifying the sAPP alpha. We also thank the staff within the IMVS animal care facility. This work was funded, in part, by grants from the Brain Foundation and the Neurosurgical Research Foundation. RC is a National Health and Medical Research Council Senior Research Fellow. No authors have a conflict of interest to declare.	AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen UL, 2009, BIOCHEM BIOPH RES CO, V378, P57, DOI 10.1016/j.bbrc.2008.10.173; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Copanaki E, 2010, MOL CELL NEUROSCI, V44, P386, DOI 10.1016/j.mcn.2010.04.007; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Koopmans G, 2003, PHYSIOL BEHAV, V79, P683, DOI 10.1016/S0031-9384(03)00171-9; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Markakis EA, 1999, J COMP NEUROL, V406, P449; Mattson MP, 1997, PHYSIOL REV, V77, P1081; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Paxinos G., 2007, MOUSE BRAIN STEREOTA, P137; Phinney AL, 1999, NEUROSCIENCE, V90, P1207, DOI 10.1016/S0306-4522(98)00645-9; QIU WQ, 1995, J NEUROSCI, V15, P2157; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Senechal Y, 2008, BEHAV BRAIN RES, V186, P126, DOI 10.1016/j.bbr.2007.08.003; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	79	54	57	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2012	122	1					208	220		10.1111/j.1471-4159.2012.07761.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	956BG	WOS:000305064100020	22519988				2021-06-18	
J	Gao, JB; Hu, J; Tung, WW				Gao, Jianbo; Hu, Jing; Tung, Wen-wen			Entropy measures for biological signal analyses	NONLINEAR DYNAMICS			English	Article						Approximate entropy; Sample entropy; Scale-dependent Lyapunov exponent; Seizure detection	TIME-SERIES; APPROXIMATE ENTROPY; KOLMOGOROV-ENTROPY; INFORMATION-THEORY; POSTURAL-CONTROL; NOISE; CHAOS; PREDICTABILITY; CONCUSSION; COMPLEXITY	Entropies are among the most popular and promising complexity measures for biological signal analyses. Various types of entropy measures exist, including Shannon entropy, Kolmogorov entropy, approximate entropy (ApEn), sample entropy (SampEn), multiscale entropy (MSE), and so on. A fundamental question is which entropy should be chosen for a specific biological application. To solve this issue, we focus on scaling laws of different entropy measures and introduce an ensemble forecasting framework to find the connections among them. One critical component of the ensemble forecasting framework is the scale-dependent Lyapunov exponent (SDLE), whose scaling behavior is found to be the richest among all the entropy measures. In fact, SDLE contains all the essential information of other entropy measures, and can act as a unifying multiscale complexity measure. Furthermore, SDLE has a unique scale separation property to aptly deal with nonstationarity and characterize high-dimensional and intermittent chaos. Therefore, SDLE can often be the first choice for exploratory studies in biology. The effectiveness of SDLE and the ensemble forecasting framework is illustrated by considering epileptic seizure detection from EEG.	[Gao, Jianbo] PMB Intelligence LLC, W Lafayette, IN 47996 USA; [Gao, Jianbo] Wright State Univ, Dayton, OH 45435 USA; [Hu, Jing] Affymetrix Inc, Santa Clara, CA 95051 USA; [Tung, Wen-wen] Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA	Gao, JB (corresponding author), PMB Intelligence LLC, POB 2077, W Lafayette, IN 47996 USA.	jbgao.pmb@gmail.com			Div Of Civil, Mechanical, & Manufact InnNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1031958] Funding Source: National Science Foundation		Abramov R, 2005, J ATMOS SCI, V62, P65, DOI 10.1175/JAS-3373.1; Adeli H, 2007, IEEE T BIO-MED ENG, V54, P205, DOI 10.1109/TBME.2006.886855; Andrzejak RG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.061907; ATMANSPACHER H, 1987, FOUND PHYS, V17, P939, DOI 10.1007/BF00734321; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cao YH, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.046217; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cellucci CJ, 1997, CHAOS, V7, P414, DOI 10.1063/1.166214; COHEN A, 1985, PHYS REV A, V31, P1872, DOI 10.1103/PhysRevA.31.1872; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Cover T.M., 1991, ELEMENTS INFORM THEO; ECKMANN JP, 1985, REV MOD PHYS, V57, P617, DOI 10.1103/RevModPhys.57.617; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gao JB, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.066204; Gao J.B., EUROPHYS LETT UNPUB; Gao J.B., CHAOS SOLIT IN PRESS; Gao J.B., 2007, MULTISCALE ANAL COMP; Gao JB, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016117; GAO JB, 1994, PHYS REV E, V49, P3807, DOI 10.1103/PhysRevE.49.3807; Gao JB, 1999, INT J MOD PHYS B, V13, P3283, DOI 10.1142/S0217979299003027; GAO JB, 1993, PHYS LETT A, V181, P153, DOI 10.1016/0375-9601(93)90913-K; Gao JB, 1999, PHYS REV LETT, V82, P1132, DOI 10.1103/PhysRevLett.82.1132; Gao JB, 2013, QUANT FINANC, V13, P265, DOI 10.1080/14697688.2011.580774; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gao JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024331; Gao JB, 2011, COGN NEURODYNAMICS, V5, P171, DOI 10.1007/s11571-011-9151-3; Gao JB, 2010, IEEE SIGNAL PROC LET, V17, P237, DOI 10.1109/LSP.2009.2037773; Gao JB, 2009, CHINESE ANN MATH B, V30, P569, DOI 10.1007/s11401-009-0108-3; GASPARD P, 1993, PHYS REP, V235, P291, DOI 10.1016/0370-1573(93)90012-3; GRASSBERGER P, 1983, PHYS REV A, V28, P2591, DOI 10.1103/PhysRevA.28.2591; Haven K, 2005, J COMPUT PHYS, V206, P334, DOI 10.1016/j.jcp.2004.12.008; Hu J, 2004, CHAOS SOLITON FRACT, V22, P807, DOI 10.1016/j.chaos.2004.02.061; Hu J, 2006, IEEE T BIO-MED ENG, V53, P2606, DOI 10.1109/TBME.2006.883825; Hu J, 2010, ANN BIOMED ENG, V38, P854, DOI 10.1007/s10439-009-9863-2; Hu J, 2009, CHAOS, V19, DOI 10.1063/1.3152007; Hu J, 2009, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2009/02/P02066; Hwang SK, 2000, PHYS REV E, V61, P5162, DOI 10.1103/PhysRevE.61.5162; KENNEL MB, 1992, PHYS REV A, V45, P3403, DOI 10.1103/PhysRevA.45.3403; Kleeman R, 2002, J ATMOS SCI, V59, P2057, DOI 10.1175/1520-0469(2002)059<2057:MDPUUR>2.0.CO;2; LEMPEL A, 1976, IEEE T INFORM THEORY, V22, P75, DOI 10.1109/TIT.1976.1055501; LIEBERT W, 1991, EUROPHYS LETT, V14, P521, DOI 10.1209/0295-5075/14/6/004; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PACKARD NH, 1980, PHYS REV LETT, V45, P712, DOI 10.1103/PhysRevLett.45.712; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; SAUER T, 1991, J STAT PHYS, V65, P579, DOI 10.1007/BF01053745; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Takens F., 1981, DYNAMICAL SYSTEMS TU, P366; Tung WW, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.046210	51	54	55	1	44	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0924-090X	1573-269X		NONLINEAR DYNAM	Nonlinear Dyn.	MAY	2012	68	3			SI		431	444		10.1007/s11071-011-0281-2			14	Engineering, Mechanical; Mechanics	Engineering; Mechanics	921MT	WOS:000302482400008					2021-06-18	
J	Toblin, RL; Riviere, LA; Thomas, JL; Adler, AB; Kok, BC; Hoge, CW				Toblin, Robin L.; Riviere, Lyndon A.; Thomas, Jeffrey L.; Adler, Amy B.; Kok, Brian C.; Hoge, Charles W.			Grief and physical health outcomes in US soldiers returning from combat	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Military; Grief; Epidemiology; Somatic symptoms; Occupational functioning	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SELF-REPORTED SYMPTOMS; COMPLICATED GRIEF; GULF-WAR; IRAQ WAR; DEPRESSION; COMORBIDITY; PREVALENCE; PERSONNEL	Background: Few studies have measured the burden of physical health problems after Iraq/Afghanistan deployment, except in association with post-traumatic stress disorder (PTSD) or mild traumatic brain injury (mTBI). Grief, a correlate of health problems in the general population, has not been systematically examined. We aimed to identify the prevalence of post-deployment physical health problems and their association with difficulty coping with grief. Methods: Infantry soldiers (n=1522) completed anonymous surveys using validated instruments six months following deployment in November-December 2008. Multiple logistic regression was used to assess the association of difficulty coping with grief and physical health. Results: The most frequent physical health symptoms reported were: sleep problems (32.8%), musculoskeletal pain (32.7%), fatigue (32.3%), and back pain (28.1%). Difficulty coping with grief over the death of someone close affected 21.3%. There was a dose-response relationship between level of difficulty coping with grief and principal physical health outcomes (ps<.002). Controlling for demographics, combat experiences, injuries, PTSD, depression, and other factors, grief significantly and uniquely contributed to a high somatic symptom score (adjusted odds ratio (AOR)=3.6), poor general health (AOR=2.0), missed work (AOR=1.7), medical utilization (AOR=1.5), difficulty carrying a heavy load (AOR=1.7), and difficulty performing physical training (AOR=1.6; all 95% confidence intervals > 1). Limitations: Data are cross-sectional and grief was measured with one item. Conclusions: Over 20% of soldiers reported difficulty coping with grief. This difficulty was significantly associated with physical health outcomes and occupational impairment Clinicians should be aware of the unique role grief plays in post-deployment physical health when treating patients. Published by Elsevier B.V.	[Toblin, Robin L.; Riviere, Lyndon A.; Thomas, Jeffrey L.; Kok, Brian C.; Hoge, Charles W.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Mil Psychiat Branch, Silver Spring, MD 20910 USA; [Adler, Amy B.] US Army Med Res Unit Europe, D-69126 Heidelberg, Germany	Toblin, RL (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Mil Psychiat Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	robin.l.toblin@us.army.mil			U.S. Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC)	We accomplished this work entirely using internal funding supplied by the U.S. Army Medical Research and Materiel Command (MRMC). MRMC's Research Area Directorate III: Interventions to Enhance Psychological Resilience and Prevent Psychiatric Casualties is the funding mechanism. MRMC did not have any role in writing the manuscript or the decision to submit it for publication and did not pay us to write the article.	Adler AB, 2008, MIL MED, V173, P10, DOI 10.7205/MILMED.173.1.10; Bartone P. T., 1990, J TRAUMA STRESS, V3, P523; Boelen PA, 2010, J AFFECT DISORDERS, V125, P374, DOI 10.1016/j.jad.2010.01.076; Bonanno GA, 2007, J ABNORM PSYCHOL, V116, P342, DOI 10.1037/0021-843X.116.2.342; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Committee on Gulf War and Health Institute of Medicine, 2010, GULF WAR HLTH, V8; Engel CC, 1999, J OCCUP ENVIRON MED, V41, P384, DOI 10.1097/00043764-199905000-00006; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Gray GC, 2002, AM J EPIDEMIOL, V155, P1033, DOI 10.1093/aje/155.11.1033; Hardison Heather Gaines, 2005, Behav Sleep Med, V3, P99, DOI 10.1207/s15402010bsm0302_4; Hoge C., 2010, ONCE WARRIOR ALWAYS; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Maciejewski PK, 2007, JAMA-J AM MED ASSOC, V297, P716, DOI 10.1001/jama.297.7.716; Mancini AD, 2011, RESILIENCE MENTAL HL, P189; Neria Y, 2007, J TRAUMA STRESS, V20, P251, DOI 10.1002/jts.20223; Papa A, 2008, PSYCHIAT ANN, V38, P686, DOI 10.3928/00485713-20081001-07; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Stroebe M, 2007, LANCET, V370, P1960, DOI 10.1016/S0140-6736(07)61816-9; Sung SC, 2011, J AFFECT DISORDERS, V134, P453, DOI 10.1016/j.jad.2011.05.017; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U.S. Department of Defense, 2011, CAS STAT REP SIT; Wittouck C, 2011, CLIN PSYCHOL REV, V31, P69, DOI 10.1016/j.cpr.2010.09.005	32	54	55	0	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	FEB	2012	136	3					469	475		10.1016/j.jad.2011.10.048			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	915AT	WOS:000301996000035	22154707				2021-06-18	
J	Panczykowski, DM; Puccio, AM; Scruggs, BJ; Bauer, JS; Hricik, AJ; Beers, SR; Okonkwo, DO				Panczykowski, David M.; Puccio, Ava M.; Scruggs, Bobby J.; Bauer, Joshua S.; Hricik, Allison J.; Beers, Sue R.; Okonkwo, David O.			Prospective Independent Validation of IMPACT Modeling as a Prognostic Tool in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; outcome measures; traumatic brain injury	HEAD-INJURY; PREDICTORS; VARIABLES; TRIALS; DESIGN; TREE	Clinical trials in traumatic brain injury (TBI) have been fraught with failure due in part to heterogeneity in pathology and insensitive outcome measurements. The International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic model has been purposed as a means of risk adjustment and outcome prediction for use in trial design and analysis. The purpose of this study was to evaluate the performance of the IMPACT model in predicting 6-month functional outcome and mortality using prospectively collected data at a large, Level 1 neurotrauma center. This population-based cohort study included all TBI patients >= 14 years of age admitted with a Glasgow Coma Scale (GCS) score of <= 8 (severe TBI) to the University of Pittsburgh Medical Center between July 1994 and May 2009. Clinical data were prospectively collected and linked to 6-month functional outcome (Glasgow Outcome Scale [GOS]) and mortality. The discriminatory power and calibration of the three iterations of the IMPACT model (core, extended, and lab) were assessed using multiple regression analyses and indicated by the area under the receiver operating characteristic curve (AUC). A sample of 587 patients was available for analysis; the mean age was 37.8 +/- 17 years. The median 6-month GOS was 3 (IQR 3); 6-month mortality was 41%. The prognostic models were composed of age, motor score, and pupillary reactivity (core model), Marshall grade on head CT and secondary insults (extended), and laboratory values (lab); all of these displayed good prediction ability for unfavorable outcome and mortality (unfavorable outcome AUC=0.76, 0.79, 0.76; mortality AUC=0.78, 0.83, 0.83, respectively). All model iterations displayed adequate calibration for predicting unfavorable outcome and mortality. Prospective, independent validation supports the IMPACT prognostic model's prediction of patient 6-month functional status and mortality after severe TBI. The IMPACT prognostic model is an effective instrument to assist TBI study design and analysis.	[Panczykowski, David M.; Puccio, Ava M.; Scruggs, Bobby J.; Bauer, Joshua S.; Hricik, Allison J.; Beers, Sue R.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA	Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu					Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAIN TRAUM FD, 1996, J NEUROTRAUM, V13, P641; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Edwards P, 2005, LANCET, V365, P1957; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1976, LANCET, V1, P1031; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71	23	54	54	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					47	52		10.1089/neu.2010.1482			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300004	21933014				2021-06-18	
S	Sarkamo, T; Soto, D			Annals NY Acad Sci	Sarkamo, Teppo; Soto, David			Music listening after stroke: beneficial effects and potential neural mechanisms	NEUROSCIENCES AND MUSIC IV: LEARNING AND MEMORY	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Neurosciences and Music-IV - Learning and Memory	JUN 09-12, 2011	Univ Edinburgh, Edinburgh, SCOTLAND	Mariani Fdn, Inst Mus Human & Social Dev	Univ Edinburgh	music listening; stroke; emotion; cognition; rehabilitation; neuroplasticity	TRAUMATIC BRAIN-INJURY; RAT AUDITORY-CORTEX; MELODIC INTONATION THERAPY; NMDA-RECEPTOR ANTAGONIST; WORKING-MEMORY PERFORMANCE; EARLY-ONSET STIMULATION; HEALTHY OLDER-ADULTS; SHORT-TERM-MEMORY; MISMATCH NEGATIVITY; EMOTIONAL RESPONSES	Music is an enjoyable leisure activity that also engages many emotional, cognitive, and motor processes in the brain. Here, we will first review previous literature on the emotional and cognitive effects of music listening in healthy persons and various clinical groups. Then we will present findings about the short-and long-term effects of music listening on the recovery of cognitive function in stroke patients and the underlying neural mechanisms of these music effects. First, our results indicate that listening to pleasant music can have a short-term facilitating effect on visual awareness in patients with visual neglect, which is associated with functional coupling between emotional and attentional brain regions. Second, daily music listening can improve auditory and verbal memory, focused attention, and mood as well as induce structural gray matter changes in the early poststroke stage. The psychological and neural mechanisms potentially underlying the rehabilitating effect of music after stroke are discussed.	[Sarkamo, Teppo] Univ Helsinki, Inst Behav Sci, Cognit Brain Res Unit, FI-00014 Helsinki, Finland; [Sarkamo, Teppo] Univ Jyvaskyla, Finnish Ctr Excellence Interdisciplinary Mus Res, Jyvaskyla, Finland; [Soto, David] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Neurosci, London, England	Sarkamo, T (corresponding author), Univ Helsinki, Inst Behav Sci, Cognit Brain Res Unit, Siltavuorenpenger 1 B,POB 9, FI-00014 Helsinki, Finland.	teppo.sarkamo@helsinki.fi	Soto, David/R-3711-2019	Soto, David/0000-0003-0205-7513; Sarkamo, Teppo/0000-0002-1470-4530	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802212] Funding Source: Medline		Abikoff H, 1996, J LEARN DISABIL, V29, P238, DOI 10.1177/002221949602900302; Ahveninen J, 1999, ALCOHOL CLIN EXP RES, V23, P1507, DOI 10.1097/00000374-199909000-00013; ALBERT ML, 1973, ARCH NEUROL-CHICAGO, V29, P130, DOI 10.1001/archneur.1973.00490260074018; Altenmuller E, 2009, ANN NY ACAD SCI, V1169, P395, DOI 10.1111/j.1749-6632.2009.04580.x; Amunts K, 1997, HUM BRAIN MAPP, V5, P206, DOI 10.1002/(SICI)1097-0193(1997)5:3<206::AID-HBM5>3.0.CO;2-7; Angelucci F, 2007, NEUROSCI LETT, V429, P152, DOI 10.1016/j.neulet.2007.10.005; Angelucci F, 2007, BEHAV PHARMACOL, V18, P491, DOI 10.1097/FBP.0b013e3282d28f50; Antic S, 2008, COLLEGIUM ANTROPOL, V32, P19; Ashburner J, 2009, MAGN RESON IMAGING, V27, P1163, DOI 10.1016/j.mri.2009.01.006; Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; ASTROM M, 1993, STROKE, V24, P52, DOI 10.1161/01.STR.24.1.52; Ayotte J, 2000, BRAIN, V123, P1926, DOI 10.1093/brain/123.9.1926; Baldeweg T, 2004, SCHIZOPHR RES, V69, P203, DOI 10.1016/j.schres.2003.09.009; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Baumgartner T, 2006, INT J PSYCHOPHYSIOL, V60, P34, DOI 10.1016/j.ijpsycho.2005.04.007; Beh HC, 1999, ERGONOMICS, V42, P1087, DOI 10.1080/001401399185153; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Bi CX, 2006, BRAIN RES, V1110, P30, DOI 10.1016/j.brainres.2006.06.056; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Bose M, 2010, SYNAPSE, V64, P97, DOI 10.1002/syn.20710; Boyle R, 1996, Q J EXP PSYCHOL-A, V49, P398, DOI 10.1080/027249896392702; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Brown S, 2007, BRAIN COGNITION, V63, P59, DOI 10.1016/j.bandc.2006.08.006; Chabris CF, 1999, NATURE, V400, P826, DOI 10.1038/23608; Chaudhury S, 2009, INT J DEV NEUROSCI, V27, P583, DOI 10.1016/j.ijdevneu.2009.06.004; Chikahisa S, 2006, BEHAV BRAIN RES, V169, P312, DOI 10.1016/j.bbr.2006.01.021; CLARK DM, 1985, J PERS SOC PSYCHOL, V48, P1595, DOI 10.1037/0022-3514.48.6.1595; Cohen A., 2002, PSYCHOMUSICOLOGY J R, V18, P89, DOI [10.1037/h0094049, DOI 10.1037/H0094049]; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; Driver J, 2001, COGNITION, V79, P39, DOI 10.1016/S0010-0277(00)00124-4; Engineer ND, 2004, J NEUROPHYSIOL, V92, P73, DOI 10.1152/jn.00059.2004; Escoffier N, 2010, ACTA PSYCHOL, V135, P12, DOI 10.1016/j.actpsy.2010.04.005; Feduccia AA, 2008, BRAIN RES BULL, V77, P189, DOI 10.1016/j.brainresbull.2008.07.007; Forsblom A., 2010, MUSIC MED, V2, P229, DOI DOI 10.1177/1943862110378110; Forsblom A, 2009, ANN NY ACAD SCI, V1169, P426, DOI 10.1111/j.1749-6632.2009.04776.x; Foster NA, 2001, EXP AGING RES, V27, P215, DOI 10.1080/036107301300208664; Franceschini R, 2001, BIOMED PHARMACOTHER, V55, P458, DOI 10.1016/S0753-3322(01)00086-5; Franowicz JS, 1998, PSYCHOPHARMACOLOGY, V136, P8, DOI 10.1007/s002130050533; Fukui H, 2003, NEUROENDOCRINOL LETT, V24, P173; Gaab N, 2003, NEUROIMAGE, V19, P1417, DOI 10.1016/S1053-8119(03)00224-6; Gaser C, 2003, J NEUROSCI, V23, P9240; Gosselin N, 2006, BRAIN, V129, P2585, DOI 10.1093/brain/awl240; Grahn JA, 2007, J COGNITIVE NEUROSCI, V19, P893, DOI 10.1162/jocn.2007.19.5.893; Greene CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011739; Griffiths TD, 1999, NEUROREPORT, V10, P3825, DOI 10.1097/00001756-199912160-00019; Griffiths TD, 2004, J NEUROL NEUROSUR PS, V75, P344; Groussard M, 2010, NEUROIMAGE, V49, P2764, DOI 10.1016/j.neuroimage.2009.10.039; Hallam S, 2002, EDUC STUD, V28, P111, DOI 10.1080/03055690220124551; Hays T., 2005, PSYCHOL MUSIC, V33, P437, DOI 10.1177/0305735605056160; HOMMEL M, 1990, ARCH NEUROL-CHICAGO, V47, P573, DOI 10.1001/archneur.1990.00530050097018; Hyde KL, 2008, NEUROPSYCHOLOGIA, V46, P632, DOI 10.1016/j.neuropsychologia.2007.09.004; Hyde KL, 2007, J NEUROSCI, V27, P13028, DOI 10.1523/JNEUROSCI.3039-07.2007; Hyde KL, 2006, BRAIN, V129, P2562, DOI 10.1093/brain/awl204; Hyde KL, 2009, J NEUROSCI, V29, P3019, DOI 10.1523/JNEUROSCI.5118-08.2009; Ilvonen TM, 2003, STROKE, V34, P1746, DOI 10.1161/01.STR.0000078836.26328.3B; Irish M, 2006, DEMENT GERIATR COGN, V22, P108, DOI 10.1159/000093487; ISEN AM, 1987, J PERS SOC PSYCHOL, V52, P1122, DOI 10.1037/0022-3514.52.6.1122; ISEN AM, 1985, J EXP PSYCHOL GEN, V114, P388, DOI 10.1037/0096-3445.114.3.388; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; James CE, 2008, NEUROIMAGE, V42, P1597, DOI 10.1016/j.neuroimage.2008.06.025; Janata P, 2002, SCIENCE, V298, P2167, DOI 10.1126/science.1076262; Janata P, 2002, COGN AFFECT BEHAV NE, V2, P121, DOI 10.3758/CABN.2.2.121; Janata P, 2009, CEREB CORTEX, V19, P2579, DOI 10.1093/cercor/bhp008; Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962; Jeong SH, 2007, APPL NURS RES, V20, P125, DOI 10.1016/j.apnr.2007.04.005; Johnsrude IS, 2000, BRAIN, V123, P155, DOI 10.1093/brain/123.1.155; Juslin PN, 2004, J NEW MUSIC RES, V33, P217, DOI 10.1080/0929821042000317813; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Khalfa S, 2003, ANN NY ACAD SCI, V999, P374, DOI 10.1196/annals.1284.045; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Knab AM, 2010, INT J BIOL SCI, V6, P133; Koelsch S, 2006, HUM BRAIN MAPP, V27, P239, DOI 10.1002/hbm.20180; Koelsch S, 2005, TRENDS COGN SCI, V9, P578, DOI 10.1016/j.tics.2005.10.001; Koelsch S, 2005, NEUROIMAGE, V25, P1068, DOI 10.1016/j.neuroimage.2004.12.050; Koelsch S, 2010, TRENDS COGN SCI, V14, P131, DOI 10.1016/j.tics.2010.01.002; Korostenskaja M, 2007, BRAIN RES BULL, V72, P275, DOI 10.1016/j.brainresbull.2007.01.007; Kreisel SH, 2006, CEREBROVASC DIS, V21, P6, DOI 10.1159/000089588; Kreutz G, 2004, J BEHAV MED, V27, P623, DOI 10.1007/s10865-004-0006-9; Krumhansl CL, 1997, CAN J EXP PSYCHOL, V51, P336, DOI 10.1037/1196-1961.51.4.336; Kujala T, 2001, P NATL ACAD SCI USA, V98, P10509, DOI 10.1073/pnas.181589198; Lee BK, 2007, ARCH GEN PSYCHIAT, V64, P810, DOI 10.1001/archpsyc.64.7.810; Levitin DJ, 2003, NEUROIMAGE, V20, P2142, DOI 10.1016/j.neuroimage.2003.08.016; Ligeois-Chauvel C, 1998, BRAIN, V121, P1853, DOI 10.1093/brain/121.10.1853; Lundqvist LO, 2009, PSYCHOL MUSIC, V37, P61, DOI 10.1177/0305735607086048; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Maess B, 2001, NAT NEUROSCI, V4, P540; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; Malhotra PA, 2006, ANN NEUROL, V59, P186, DOI 10.1002/ana.20701; Mammarella N, 2007, AGING CLIN EXP RES, V19, P394; Matteis M, 1997, J NEUROL SCI, V149, P57, DOI 10.1016/S0022-510X(97)05375-6; McDermott J, 2005, MUSIC PERCEPT, V23, P29, DOI 10.1525/mp.2005.23.1.29; Mehta MA, 2006, CURR PHARM DESIGN, V12, P2487, DOI 10.2174/138161206777698891; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; Merriam, 1964, ANTHR MUSIC; Mikkola K, 2007, CLIN NEUROPHYSIOL, V118, P1494, DOI 10.1016/j.clinph.2007.04.012; Milner B, 1962, INTERHEMISPHER RELAT, P177; Mitterschiffthaler MT, 2007, HUM BRAIN MAPP, V28, P1150, DOI 10.1002/hbm.20337; Mutschler I, 2009, NEUROSCI LETT, V457, P66, DOI 10.1016/j.neulet.2009.03.101; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Nettl B, 2000, ORIGINS OF MUSIC, P463; Nichols JA, 2007, NEUROSCIENCE, V145, P832, DOI 10.1016/j.neuroscience.2006.12.061; Nieoullon A, 2002, PROG NEUROBIOL, V67, P53, DOI 10.1016/S0301-0082(02)00011-4; Nilsson U, 2009, HEART LUNG, V38, P201, DOI 10.1016/j.hrtlng.2008.07.008; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Norton A, 2009, ANN NY ACAD SCI, V1169, P431, DOI 10.1111/j.1749-6632.2009.04859.x; Nys GMS, 2006, J NEUROL SCI, V247, P149, DOI 10.1016/j.jns.2006.04.005; Omar R, 2011, NEUROIMAGE, V56, P1814, DOI 10.1016/j.neuroimage.2011.03.002; Panksepp J, 2002, BEHAV PROCESS, V60, P133, DOI 10.1016/S0376-6357(02)00080-3; Patterson RD, 2002, NEURON, V36, P767, DOI 10.1016/S0896-6273(02)01060-7; Percaccio CR, 2005, J NEUROPHYSIOL, V94, P3590, DOI 10.1152/jn.00433.2005; PERETZ I, 1990, BRAIN, V113, P1185, DOI 10.1093/brain/113.4.1185; Peretz I, 2009, ANN NY ACAD SCI, V1169, P256, DOI 10.1111/j.1749-6632.2009.04557.x; Plailly J, 2007, CEREB CORTEX, V17, P2650, DOI 10.1093/cercor/bhl173; Platel H, 2003, NEUROIMAGE, V20, P244, DOI 10.1016/S1053-8119(03)00287-8; Popescu M, 2004, NEUROIMAGE, V21, P1622, DOI 10.1016/j.neuroimage.2003.11.002; Racette A, 2007, MEM COGNITION, V35, P242, DOI 10.3758/BF03193445; Racette A, 2006, BRAIN, V129, P2571, DOI 10.1093/brain/awl250; Radley JJ, 2005, AGEING RES REV, V4, P271, DOI 10.1016/j.arr.2005.03.004; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; Rasquin S, 2005, CEREBROVASC DIS, V19, P309, DOI 10.1159/000084499; RAUSCHER FH, 1993, NATURE, V365, P611, DOI 10.1038/365611a0; Rickard Nikki S, 2005, Behav Cogn Neurosci Rev, V4, P235, DOI 10.1177/1534582305285869; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; ROBIN DA, 1990, BRAIN LANG, V39, P539, DOI 10.1016/0093-934X(90)90161-9; Rowe G, 2007, P NATL ACAD SCI USA, V104, P383, DOI 10.1073/pnas.0605198104; Saarikallio S., 2007, PSYCHOL MUSIC, V35, P88, DOI [10.1177/0305735607068889, DOI 10.1177/0305735607068889]; Saarikallio S, 2011, PSYCHOL MUSIC, V39, P307, DOI 10.1177/0305735610374894; Sacks O, 2006, BRAIN, V129, P2528, DOI 10.1093/brain/awl234; SALAME P, 1989, Q J EXP PSYCHOL-A, V41, P107, DOI 10.1080/14640748908402355; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; SAMSON S, 1988, BRAIN COGNITION, V7, P348, DOI 10.1016/0278-2626(88)90008-5; Sandmann P., 2009, BEHAV BRAIN FUNC, V6, P1; Sarkamo T., 2011, THESIS U HELSINKI FI; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Sarkamo T, 2010, J COGNITIVE NEUROSCI, V22, P2716, DOI 10.1162/jocn.2009.21376; Satoh M, 2006, AM J NEURORADIOL, V27, P1101; Schauer M, 2003, CLIN REHABIL, V17, P713, DOI 10.1191/0269215503cr668oa; Schellenberg E. G., 2007, PSYCHOL MUSIC, V35, p5?19, DOI DOI 10.1177/0305735607068885; SCHLAUG G, 1995, NEUROPSYCHOLOGIA, V33, P1047, DOI 10.1016/0028-3932(95)00045-5; Schlaug G, 2008, MUSIC PERCEPT, V25, P315, DOI 10.1525/MP.2008.25.4.315; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Schneider N, 2001, NEURORADIOLOGY, V43, P472, DOI 10.1007/s002340000522; Schneider S, 2007, J NEUROL, V254, P1339, DOI 10.1007/s00415-006-0523-2; Schneider S, 2010, MUSIC PERCEPT, V27, P271, DOI 10.1525/MP.2010.27.4.271; Schon D, 2008, COGNITION, V106, P975, DOI 10.1016/j.cognition.2007.03.005; Schonwiesner M, 2005, EUR J NEUROSCI, V22, P1521, DOI 10.1111/j.1460-9568.2005.04315.x; Schuppert M, 2000, BRAIN, V123, P546, DOI 10.1093/brain/123.3.546; SHAPIRO BE, 1981, NEUROPSYCHOLOGIA, V19, P161, DOI 10.1016/0028-3932(81)90101-9; Simmons-Stern NR, 2010, NEUROPSYCHOLOGIA, V48, P3164, DOI 10.1016/j.neuropsychologia.2010.04.033; Singh-Curry V, 2010, CLIN REHABIL, V24, P675, DOI 10.1177/0269215509357851; Sloboda J.A., 2001, MUSIC EMOTION THEORY, P415; Sluming V, 2002, NEUROIMAGE, V17, P1613, DOI 10.1006/nimg.2002.1288; Smith A, 1996, NATURE, V380, P291, DOI 10.1038/380291a0; Soto D, 2009, P NATL ACAD SCI USA, V106, P6011, DOI 10.1073/pnas.0811681106; SPARKS R, 1974, Cortex, V10, P303; Stewart L, 2006, BRAIN, V129, P2533, DOI 10.1093/brain/awl171; Straube T, 2008, NEUROPSYCHOLOGIA, V46, P1505, DOI 10.1016/j.neuropsychologia.2008.01.008; Suda M, 2008, NEUROREPORT, V19, P75, DOI 10.1097/WNR.0b013e3282f3476f; Sutoo D, 2004, BRAIN RES, V1016, P255, DOI 10.1016/j.brainres.2004.05.018; Tervaniemi M, 2001, ANN NY ACAD SCI, V930, P259, DOI 10.1111/j.1749-6632.2001.tb05737.x; Thaut AH, 2007, NEUROREHAB NEURAL RE, V21, P455, DOI 10.1177/1545968307300523; Thaut MH, 1997, J NEUROL SCI, V151, P207, DOI 10.1016/S0022-510X(97)00146-9; Thaut MH, 2005, ANN NY ACAD SCI, V1060, P243, DOI 10.1196/annals.1360.017; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Thompson RG, 2005, EXP AGING RES, V31, P91, DOI 10.1080/03610730590882819; Thompson WF, 2001, PSYCHOL SCI, V12, P248, DOI 10.1111/1467-9280.00345; Tikhonravov D, 2008, BRAIN RES, V1203, P97, DOI 10.1016/j.brainres.2008.02.006; Tillmann B, 2003, COGNITIVE BRAIN RES, V16, P145, DOI 10.1016/S0926-6410(02)00245-8; Toyomaki A, 2008, PROG NEURO-PSYCHOPH, V32, P95, DOI 10.1016/j.pnpbp.2007.07.020; Trainor L, 2008, NATURE, V453, P598, DOI 10.1038/453598a; Trehub SE, 2003, NAT NEUROSCI, V6, P669, DOI 10.1038/nn1084; Umbricht D, 2002, BIOL PSYCHIAT, V51, P400, DOI 10.1016/S0006-3223(01)01242-2; Vollmer-Haase J, 1998, NEUROPSYCHOLOGIA, V36, P857, DOI 10.1016/S0028-3932(98)00024-4; WALLACE WT, 1994, J EXP PSYCHOL LEARN, V20, P1471, DOI 10.1037/0278-7393.20.6.1471; Warren JD, 2005, NEUROIMAGE, V24, P1052, DOI 10.1016/j.neuroimage.2004.10.031; Wilson SJ, 2006, MUSIC PERCEPT, V24, P23, DOI 10.1525/mp.2006.24.1.23; WOOD JV, 1990, J PERS SOC PSYCHOL, V58, P899, DOI 10.1037/0022-3514.58.5.899; Xu F, 2007, NEUROSCI LETT, V420, P179, DOI 10.1016/j.neulet.2007.05.005; Xu JH, 2009, BEHAV BRAIN RES, V196, P49, DOI 10.1016/j.bbr.2008.07.018; Zatorre R, 2005, NATURE, V434, P312, DOI 10.1038/434312a; ZATORRE RJ, 1994, J NEUROSCI, V14, P1908, DOI 10.1523/jneurosci.14-04-01908.1994; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946; Zentner M, 2008, EMOTION, V8, P494, DOI 10.1037/1528-3542.8.4.494	189	54	56	1	121	BLACKWELL SCIENCE PUBL	OXFORD	OSNEY MEAD, OXFORD OX2 0EL, ENGLAND	0077-8923		978-1-57331-841-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2012	1252						266	281		10.1111/j.1749-6632.2011.06405.x			16	Multidisciplinary Sciences; Neurosciences; Psychology	Science & Technology - Other Topics; Neurosciences & Neurology; Psychology	BAU07	WOS:000305518900036	22524369				2021-06-18	
J	Johnson, VE; Stewart, W; Trojanowski, JQ; Smith, DH				Johnson, Victoria E.; Stewart, William; Trojanowski, John Q.; Smith, Douglas H.			Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans	ACTA NEUROPATHOLOGICA			English	Article						TDP-43; 43 kDa transactive response (TAR) DNA binding protein; Traumatic brain injury; Head injury; Diffuse axonal injury; DAI; Neurodegeneration; Dementia; Alzheimer's disease; Long-term survival; Single versus repetitive TBI	TAR-DNA-BINDING; FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; NUCLEAR FACTOR TDP-43; SEVERE HEAD-INJURY; PROTEIN MISFOLDING DISEASES; FOOTBALL-LEAGUE PLAYER; DIFFUSE AXONAL INJURY; BETA-AMYLOID PROTEIN; ALZHEIMERS-DISEASE	The pathologic phosphorylation and sub-cellular translocation of neuronal transactive response-DNA binding protein (TDP-43) was identified as the major disease protein in frontotemporal lobar degeneration (FTLD) with ubiquitinated inclusions, now termed FTLD-TDP, and amyotrophic lateral sclerosis (ALS). More recently, TDP-43 proteinopathy has been reported in dementia pugilistica or chronic traumatic encephalopathy caused by repetitive traumatic brain injury (TBI). While a single TBI has been linked to the development of Alzheimer's disease and an increased frequency of neurofibrillary tangles, TDP-43 proteinopathy has not been examined with survival following a single TBI. Using immunohistochemistry specific for both pathological phosphorylated TDP-43 (p-TDP-43) and phosphorylation-independent TDP-43 (pi-TDP-43), we examined acute (n = 23: Survival < 2 weeks) and long-term (n = 39; 1-47 years survival) survivors of a single TBI versus age-matched controls (n = 47). Multiple regions were examined including the hippocampus, medial temporal lobe, cingulate gyrus, superior frontal gyrus and brainstem. No association was found between a history of single TBI and abnormally phosphorylated TDP-43 (p-TDP-43) inclusions. Specifically, just 3 of 62 TBI cases displayed p-TDP-43 pathology versus 2 of 47 control cases. However, while aggregates of p-TDP-43 were not increased acutely or long-term following TBI, immunoreactivity to phosphorylation-independent TDP-43 was commonly increased in the cytoplasm following TBI with both acute and long-term survival. Moreover, while single TBI can induce multiple long-term neurodegenerative changes, the absence of TDP-43 proteinopathy may indicate a fundamental difference in the processes induced following single TBI from those of repetitive TBI.	[Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Johnson, Victoria E.; Stewart, William] Univ Glasgow, Div Clin Neurosci, Glasgow, Lanark, Scotland; [Stewart, William] So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Trojanowski, John Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Sch Med, Alzheimers Dis Core Ctr, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu		Stewart, William/0000-0003-2199-2582	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, AG10124, AG17546, NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124, R03AG038911, R01AG017546] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants NS038104, AG10124, AG17546 and NS056202. We would also like to thank Ms. Janice E. Stewart for her technical assistance with immunohistochemical staining procedures.	Abhyankar MM, 2007, J BIOL CHEM, V282, P36143, DOI 10.1074/jbc.M705811200; Acharya KK, 2006, DEV BIOL, V295, P781, DOI 10.1016/j.ydbio.2006.04.443; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; Arai T, 2009, ACTA NEUROPATHOL, V117, P125, DOI 10.1007/s00401-008-0480-1; Ayala YM, 2006, FEBS LETT, V580, P1339, DOI 10.1016/j.febslet.2006.01.052; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buratti E, 2004, AM J HUM GENET, V74, P1322, DOI 10.1086/420978; Buratti E, 2001, J BIOL CHEM, V276, P36337, DOI 10.1074/jbc.M104236200; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; Buratti E, 2008, FRONT BIOSCI-LANDMRK, V13, P867, DOI 10.2741/2727; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Geser F, 2010, ARCH NEUROL-CHICAGO, V67, P1238, DOI 10.1001/archneurol.2010.254; Geser F, 2009, J NEUROL, V256, P1205, DOI 10.1007/s00415-009-5069-7; Geser F, 2009, ARCH NEUROL-CHICAGO, V66, P180, DOI 10.1001/archneurol.2008.558; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; Higashi S, 2007, BRAIN RES, V1184, P284, DOI 10.1016/j.brainres.2007.09.048; Hu WT, 2008, ACTA NEUROPATHOL, V116, P215, DOI 10.1007/s00401-008-0400-4; Huber A., 1993, J NEUROTRAUMA S1, V10, pS180; Igaz LM, 2008, AM J PATHOL, V173, P182, DOI 10.2353/ajpath.2008.080003; IGNATIUS SH, 1995, J VIROL, V69, P3584, DOI 10.1128/JVI.69.6.3584-3596.1995; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Inukai Y, 2008, FEBS LETT, V582, P2899, DOI 10.1016/j.febslet.2008.07.027; Johnson VE, 2011, BRAIN PATHO IN PRESS; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kanazawa M, 2011, J NEUROCHEM, V116, P957, DOI 10.1111/j.1471-4159.2010.06860.x; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kwong LK, 2008, NEUROSIGNALS, V16, P41, DOI 10.1159/000109758; Lee EB, 2011, NAT REV NEU IN PRESS; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; McDonald KK, 2011, HUM MOL GENET, V20, P1400, DOI 10.1093/hmg/ddr021; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mercado PA, 2005, NUCLEIC ACIDS RES, V33, P6000, DOI 10.1093/nar/gki897; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakashima-Yasuda H, 2007, ACTA NEUROPATHOL, V114, P221, DOI 10.1007/s00401-007-0261-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neumann M, 2007, ARCH NEUROL-CHICAGO, V64, P1388, DOI 10.1001/archneur.64.10.1388; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Neumann M, 2009, ACTA NEUROPATHOL, V117, P137, DOI 10.1007/s00401-008-0477-9; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schwab C, 2008, J NEUROPATH EXP NEUR, V67, P1159, DOI 10.1097/NEN.0b013e31818e8951; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2008, J NEUROPATH EXP NEUR, V67, P555, DOI 10.1097/NEN.0b013e31817713b5; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wang HY, 2004, GENOMICS, V83, P130, DOI 10.1016/S0888-7543(03)00214-3; Wang IF, 2008, TRENDS MOL MED, V14, P479, DOI 10.1016/j.molmed.2008.09.001	75	54	55	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	DEC	2011	122	6					715	726		10.1007/s00401-011-0909-9			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	854CC	WOS:000297471200006	22101322	Green Accepted			2021-06-18	
J	Wang, LZ; Cheung, JTM; Pu, F; Li, DY; Zhang, M; Fan, YB				Wang, Lizhen; Cheung, Jason Tak-Man; Pu, Fang; Li, Deyu; Zhang, Ming; Fan, Yubo			Why Do Woodpeckers Resist Head Impact Injury: A Biomechanical Investigation	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CANCELLOUS BONE; ARCHITECTURE; DENSITY; BEHAVIOR; HISTORY; TISSUE; SPORT; SKULL; MASS	Head injury is a leading cause of morbidity and death in both industrialized and developing countries. It is estimated that brain injuries account for 15% of the burden of fatalities and disabilities, and represent the leading cause of death in young adults. Brain injury may be caused by an impact or a sudden change in the linear and/or angular velocity of the head. However, the woodpecker does not experience any head injury at the high speed of 6-7 m/s with a deceleration of 1000 g when it drums a tree trunk. It is still not known how woodpeckers protect their brain from impact injury. In order to investigate this, two synchronous high-speed video systems were used to observe the pecking process, and the force sensor was used to measure the peck force. The mechanical properties and macro/micro morphological structure in woodpecker's head were investigated using a mechanical testing system and micro-CT scanning. Finite element (FE) models of the woodpecker's head were established to study the dynamic intracranial responses. The result showed that macro/micro morphology of cranial bone and beak can be recognized as a major contributor to non-impact-injuries. This biomechanical analysis makes it possible to visualize events during woodpecker pecking and may inspire new approaches to prevention and treatment of human head injury.	[Wang, Lizhen; Pu, Fang; Li, Deyu; Fan, Yubo] Beihang Univ, Key Lab Biomech & Mechanobiol, Minist Educ, Sch Biol Sci & Med Engn, Beijing, Peoples R China; [Wang, Lizhen; Zhang, Ming] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China; [Cheung, Jason Tak-Man] Li Ning Sports Sci Res Ctr, Beijing, Peoples R China	Wang, LZ (corresponding author), Beihang Univ, Key Lab Biomech & Mechanobiol, Minist Educ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.	ming.zhang@polyu.edu.hk; yubofan@buaa.edu.cn	Zhang, Ming/F-8331-2011	Zhang, Ming/0000-0002-6027-4594	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [10925208, 11120101001]; Hong Kong Polytechnic UniversityHong Kong Polytechnic University [G-U624]; National Key Lab of Virtual Reality Technology	This project was funded by National Natural Science Foundation of China under the Grant 10925208, 11120101001 (http://www.nsfc.gov.cn/Portal0/default124.htm) and by the Hong Kong Polytechnic University under the grant G-U624 (http://www.polyu.edu.hk/cpa/polyu/index.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to acknowledge the support from the National Key Lab of Virtual Reality Technology.	BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BOCK WJ, 1964, J MORPHOL, V114, P1, DOI 10.1002/jmor.1051140102; Bock WJ, 1999, OSTRICH, V70, P23, DOI 10.1080/00306525.1999.9639746; BOCK WJ, 1966, AUK, V83, P10, DOI 10.2307/4082976; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; CARTER DR, 1987, J BIOMECH, V20, P785, DOI 10.1016/0021-9290(87)90058-3; Corporation LST, 2006, LS DYNA KEYW US MAN; COWIN SC, 1986, J BIOMECH ENG-T ASME, V108, P83, DOI 10.1115/1.3138584; Cowin SC, 1998, J BIOMECH, V31, P759, DOI 10.1016/S0021-9290(98)00078-5; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; Giesen EBW, 2001, J BIOMECH, V34, P799, DOI 10.1016/S0021-9290(01)00030-6; Holbourn AHS, 1943, LANCET, V2, P438; HOSEY RR, 1982, HOMEOMORPHIC FINITE, P379; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; Kabel J, 1999, BONE, V25, P481, DOI 10.1016/S8756-3282(99)00190-8; King AI, 2003, IRCOBI C LISB PORT; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Linde F, 1988, Eng Med, V17, P23; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MAY PRA, 1976, LANCET, V1, P454; MAY PRA, 1979, ARCH NEUROL-CHICAGO, V36, P370, DOI 10.1001/archneur.1979.00500420080011; MLIKOVSKY J, 1989, Vestnik Ceskoslovenske Spolecnosti Zoologicke, V53, P252; Oda J, 2006, JSME INT J A-SOLID M, V49, P390, DOI 10.1299/jsmea.49.390; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; RICE JC, 1988, J BIOMECH, V21, P155, DOI 10.1016/0021-9290(88)90008-5; ROESLER H, 1987, J BIOMECH, V20, P1025, DOI 10.1016/0021-9290(87)90020-0; Ruan J. S., 1994, IMPACT BIOMECHANICS; Ruimerman R, 2001, COMPUTER METHODS BIO, V4, P433, DOI DOI 10.1080/10255840108908019; Schwab IR, 2002, BRIT J OPHTHALMOL, V86, P843, DOI 10.1136/bjo.86.8.843; SPRING LOWELL W., 1965, CONDOR, V67, P457, DOI 10.2307/1365612; Stalnaker R.L., 1969, MECH PROPERTIES HEAD; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Yang King H, 2006, Stapp Car Crash J, V50, P429; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024	39	54	62	4	105	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2011	6	10							e26490	10.1371/journal.pone.0026490			8	Multidisciplinary Sciences	Science & Technology - Other Topics	841NR	WOS:000296519600022	22046293	DOAJ Gold, Green Published			2021-06-18	
J	Guo, W; Wang, H; Zou, SP; Gu, M; Watanabe, M; Wei, F; Dubner, R; Huang, GTJ; Ren, K				Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Watanabe, Mineo; Wei, Feng; Dubner, Ronald; Huang, George T. -J.; Ren, Ke			Bone Marrow Stromal Cells Produce Long-Term Pain Relief in Rat Models of Persistent Pain	STEM CELLS			English	Article						Adult stem cells; Bone marrow stromal cells; Cellular therapy; Neuropathy; Rat model; Stem cell transplantation	MESENCHYMAL STEM-CELLS; SCIATIC-NERVE CONSTRICTION; TRIGEMINAL NEUROPATHIC PAIN; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; THERAPEUTIC BENEFIT; CEREBRAL-ISCHEMIA; RHEUMATOID-ARTHRITIS; GROWTH-FACTORS; TRANSPLANTATION	Chronic pain conditions are difficult to treat and are major health problems. Bone marrow stromal cells (BMSCs) have generated considerable interest as a candidate for cell-based therapy. BMSCs are readily accessible and are easy to isolate and expand ex vivo. Clinical studies show that direct injection of BMSCs does not produce unwanted side effects and is well tolerated and safe. Here, we show that a single systemic (intravenous) or local injection (into the lesion site) of rat primary BMSCs reversed pain hypersensitivity in rats after injury and that the effect lasted until the conclusion of the study at 22 weeks. The pain hypersensitivity was rekindled by naloxone hydrochloride, an opioid receptor antagonist that acts peripherally and centrally, when tested at 1-5 weeks after BMSC infusion. In contrast, naloxone methiodide, a peripherally acting opioid receptor antagonist, only rekindled hyperalgesia in the first 3 weeks of BMSC treatment. Focal downregulation of brainstem mu opioid receptors by RNA interference (RNAi) reversed the effect of BMSCs, when RNAi was introduced at 5-but not 1-week after BMSC transplantation. Thus, BMSCs produced long-term relief of pain and this effect involved activation of peripheral and central opioid receptors in distinct time domains. The findings prompt studies to elucidate the cellular mechanisms of the BMSC-induced pain relieving effect and translate these observations into clinical settings. STEM CELLS 2011; 29: 1294-1303	[Huang, George T. -J.] Boston Univ, Dept Endodont, Henry M Goldman Sch Dent Med, Boston, MA 02118 USA; [Huang, George T. -J.] Boston Univ, Dept Mol & Cell Biol, Henry M Goldman Sch Dent Med, Boston, MA 02118 USA; [Watanabe, Mineo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral Biol, Div Mol Med Sci, Hiroshima, Japan; [Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Wei, Feng; Dubner, Ronald; Ren, Ke] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA; [Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Wei, Feng; Dubner, Ronald; Ren, Ke] Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA	Huang, GTJ (corresponding author), Boston Univ, Dept Endodont, Henry M Goldman Sch Dent Med, 100 E Newton St G-705, Boston, MA 02118 USA.	gtjhuang@bu.edu; kren@umaryland.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DE11964, DE018573, NS060735, NS059028, DE019156]; Japanese Ministry of Education, Science and CultureMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22592039]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE019156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE011964, R01DE018573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059028, R01NS060735] Funding Source: NIH RePORTER	This work was supported by Grants DE11964, DE018573, NS060735, NS059028, and DE019156 from the NIH. M.W. is supported by Grant-in-Aid for Scientific Research (22592039) from the Japanese Ministry of Education, Science and Culture.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Bouffi C, 2009, RHEUMATOLOGY, V48, P1185, DOI 10.1093/rheumatology/kep162; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Carr CA, 2008, AM J PHYSIOL-HEART C, V295, pH533, DOI 10.1152/ajpheart.00094.2008; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Christensen D, 1999, PAIN, V83, P433, DOI 10.1016/S0304-3959(99)00126-8; Coronel MF, 2009, NEUROPEPTIDES, V43, P125, DOI 10.1016/j.npep.2008.12.003; Coronel MF, 2006, NEUROSCI LETT, V405, P5, DOI 10.1016/j.neulet.2006.06.018; Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Djouad F, 2009, NAT REV RHEUMATOL, V5, P392, DOI 10.1038/nrrheum.2009.104; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Guo W, 2006, J NEUROSCI, V26, P126, DOI 10.1523/JNEUROSCI.3686-05.2006; Guo W, 2004, J NEUROSCI, V24, P9161, DOI 10.1523/JNEUROSCI.3422-04.2004; Guo W, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-40; Harden RN, 2004, ANESTH ANALG, V99, P1478, DOI 10.1213/01.ANE.0000132549.25154.ED; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Holzer U, 2010, SCAND J RHEUMATOL, V39, P88, DOI 10.3109/03009740903096622; Horwitz EM, 2009, ISR MED ASSOC J, V11, P209; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867; Jessop DS, 2010, ANN NY ACAD SCI, V1193, P117, DOI 10.1111/j.1749-6632.2009.05294.x; Kajii TS, 2005, J OROFAC PAIN, V19, P41; Klass M, 2007, ANESTH ANALG, V104, P944, DOI 10.1213/01.ane.0000258021.03211.d0; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Liechty KW, 2000, NAT MED, V6, P1282; Machelska H, 2007, NEUROPEPTIDES, V41, P355, DOI 10.1016/j.npep.2007.06.001; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Maestroni GJM, 1998, EXP HEMATOL, V26, P1172; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mao F, 2010, INFLAMM RES, V59, P219, DOI 10.1007/s00011-009-0090-y; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Meunier A, 2005, MOL THER, V11, P608, DOI 10.1016/j.ymthe.2004.12.011; Musolino PL, 2007, NEUROSCI LETT, V418, P97, DOI 10.1016/j.neulet.2007.03.001; Niikura K, 2010, TRENDS PHARMACOL SCI, V31, P299, DOI 10.1016/j.tips.2010.04.003; Noel D, 2007, LEUKEMIA LYMPHOMA, V48, P1283, DOI 10.1080/10428190701361869; Pavlichenko N, 2008, BRAIN RES, V1233, P203, DOI 10.1016/j.brainres.2008.06.123; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031-9384(99)00136-5; REN K, 2008, SENSES COMPREHENSIVE, V5, P723; Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Shibata T, 2008, DIABETES, V57, P3099, DOI 10.2337/db08-0031; Siniscalco D, 2010, CELL MOL LIFE SCI, V67, P655, DOI 10.1007/s00018-009-0202-4; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; Wang J, 2009, BRAIN RES, V1262, P7, DOI 10.1016/j.brainres.2009.01.056; Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008; Wei F, 2010, J NEUROSCI, V30, P8624, DOI 10.1523/JNEUROSCI.5389-09.2010; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	60	54	58	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	AUG	2011	29	8					1294	1303		10.1002/stem.667			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	797NF	WOS:000293133900013	21630378	Green Accepted			2021-06-18	
J	Wu, AG; Ying, Z; Schubert, D; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Schubert, David; Gomez-Pinilla, Fernando			Brain and Spinal Cord Interaction: A Dietary Curcumin Derivative Counteracts Locomotor and Cognitive Deficits After Brain Trauma	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; hippocampus; learning; BDNF; curcumin derivative	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; SYNAPSIN-I; INJURY; EXERCISE; RAT; MEMORY	Background. In addition to cognitive dysfunction, locomotor deficits are prevalent in traumatic brain injured (TBI) patients; however, it is unclear how a concussive injury can affect spinal cord centers. Moreover, there are no current efficient treatments that can counteract the broad pathology associated with TBI. Objective. The authors have investigated potential molecular basis for the disruptive effects of TBI on spinal cord and hippocampus and the neuroprotection of a curcumin derivative to reduce the effects of experimental TBI. Methods. The authors performed fluid percussion injury (FPI) and then rats were exposed to dietary supplementation of the curcumin derivative (CNB-001; 500 ppm). The curry spice curcumin has protective capacity in animal models of neurodegenerative diseases, and the curcumin derivative has enhanced brain absorption and biological activity. Results. The results show that FPI in rats, in addition to reducing learning ability, reduced locomotor performance. Behavioral deficits were accompanied by reductions in molecular systems important for synaptic plasticity underlying behavioral plasticity in the brain and spinal cord. The post-TBI dietary supplementation of the curcumin derivative normalized levels of BDNF, and its downstream effectors on synaptic plasticity (CREB, synapsin I) and neuronal signaling (CaMKII), as well as levels of oxidative stress-related molecules (SOD, Sir2). Conclusions. These studies define a mechanism by which TBI can compromise centers related to cognitive processing and locomotion. The findings also show the influence of the curcumin derivative on synaptic plasticity events in the brain and spinal cord and emphasize the therapeutic potential of this noninvasive dietary intervention for TBI.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Schubert, David] Salk Inst Biol Studies, La Jolla, CA USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC1 NS068473, R01 NS056413]; Craig H Neilsen Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC1NS068473, R01NS056413] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This study was supported by NIH award RC1 NS068473 and R01 NS056413 and Craig H Neilsen Foundation.	Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bolton MM, 2000, PROG BRAIN RES, V128, P203; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; BROCK TO, 1987, J NEUROSCI, V7, P931; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gomez-Pinilla F, 2007, NEUROSCIENCE, V148, P893, DOI 10.1016/j.neuroscience.2007.05.051; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Liu YB, 2008, J NEUROCHEM, V105, P1336, DOI 10.1111/j.1471-4159.2008.05236.x; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WANG T, 1995, J NEUROSCI, V15, P4796; Williams G, 2010, NEUROREHAB NEURAL RE, V24, P550, DOI 10.1177/1545968309357925; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	50	54	56	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2011	25	4					332	342		10.1177/1545968310397706			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	742KJ	WOS:000288940900004	21343524	Green Accepted			2021-06-18	
J	Bernick, KB; Prevost, TP; Suresh, S; Socrate, S				Bernick, Kristin B.; Prevost, Thibault P.; Suresh, Subra; Socrate, Simona			Biomechanics of single cortical neurons	ACTA BIOMATERIALIA			English	Article						Atomic force microscopy; Neuron; Cell mechanics; Constitutive modeling; Finite elements	ATOMIC-FORCE MICROSCOPY; TRAUMATIC BRAIN-INJURY; VISCOELASTIC PROPERTIES; MECHANICAL-PROPERTIES; ARTICULAR CHONDROCYTES; CELL STIFFNESS; HEAD-INJURIES; CANCER-CELLS; MODEL; TISSUE	This study presents experimental results and computational analysis of the large strain dynamic behavior of single neurons in vitro with the objective of formulating a novel quantitative framework for the biomechanics of cortical neurons. Relying on the atomic force microscopy (AFM) technique, novel testing protocols are developed to enable the characterization of neural soma deformability over a range of indentation rates spanning three orders of magnitude, 10, 1, and 0.1 mu m s(-1). Modified spherical AFM probes were utilized to compress the cell bodies of neonatal rat cortical neurons in load, unload, reload and relaxation conditions. The cell response showed marked hysteretic features, strong non-linearities, and substantial time/rate dependencies. The rheological data were complemented with geometrical measurements of cell body morphology, i.e. cross-diameter and height estimates. A constitutive model, validated by the present experiments, is proposed to quantify the mechanical behavior of cortical neurons. The model aimed to correlate empirical findings with measurable degrees of (hyper)elastic resilience and viscosity at the cell level. The proposed formulation, predicated upon previous constitutive model developments undertaken at the cortical tissue level, was implemented in a three-dimensional finite element framework. The simulated cell response was calibrated to the experimental measurements under the selected test conditions, providing a novel single cell model that could form the basis for further refinements. (C) 2010 Acts Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Socrate, Simona] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Bernick, Kristin B.; Suresh, Subra] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Socrate, S (corresponding author), MIT, Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office through the MIT Institute for Soldier Nanotechnologies [DAAD-19-02-D0002]; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; National Science FoundationNational Science Foundation (NSF); National Institutes of Health Molecular, Cell, and Tissue BiomechanicsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT AllianceSingapore-MIT Alliance for Research & Technology Centre; Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB006348] Funding Source: NIH RePORTER	This work was supported by the US Army Research Office through the MIT Institute for Soldier Nanotechnologies (DAAD-19-02-D0002) and the Joint Improvised Explosive Devices Defeat Organization (W911NF-07-1-0035), the National Science Foundation Graduate Research Fellowship Program, the National Institutes of Health Molecular, Cell, and Tissue Biomechanics Training Grant, the Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France), the Computational Systems Biology Programme of the Singapore-MIT Alliance, and the Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology. The authors are grateful to Professor Sebastian Seung (Massachusetts Institute of Technology, Cambridge, MA) for providing cortical tissue, Professor Patricia Carvalho (Instituto Superior Tecnico, Lisbon, Portugal) for imaging SEM samples, and Dr Shelten Yuen and Daniel Rudoy (Harvard University, Cambridge, MA) for providing the MATLAB routine employed in the determination of the cell-cantilever contact point.	ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brewer GJ, 2007, NAT PROTOC, V2, P1490, DOI 10.1038/nprot.2007.207; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Costa KD, 2006, J BIOMECH ENG-T ASME, V128, P176, DOI 10.1115/1.2165690; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Darling EM, 2006, OSTEOARTHR CARTILAGE, V14, P571, DOI 10.1016/j.joca.2005.12.003; Desprat N, 2005, BIOPHYS J, V88, P2224, DOI 10.1529/biophysj.104.050278; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; EVANS E, 1984, BLOOD, V64, P1028; Fernandez P, 2006, BIOPHYS J, V90, P3796, DOI 10.1529/biophysj.105.072215; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Franz CM, 2008, CELL MOL BIOENG, V1, P289, DOI 10.1007/s12195-008-0037-3; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103; Guck J, 2001, BIOPHYS J, V81, P767, DOI 10.1016/S0006-3495(01)75740-2; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; Guilak F, 2000, J BIOMECH, V33, P1663, DOI 10.1016/S0021-9290(00)00105-6; Gurtin ME, 1981, INTRO CONTINUUM MECH; Henon S, 1999, BIOPHYS J, V76, P1145, DOI 10.1016/S0006-3495(99)77279-6; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holzapfel G., 2000, NONLINEAR SOLID MECH; Karcher H, 2003, BIOPHYS J, V85, P3336, DOI 10.1016/S0006-3495(03)74753-5; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lam WA, 2007, BLOOD, V109, P3505, DOI 10.1182/blood-2006-08-043570; LEE EH, 1969, J APPL MECH, V36, P1, DOI 10.1115/1.3564580; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Li QS, 2008, BIOCHEM BIOPH RES CO, V374, P609, DOI 10.1016/j.bbrc.2008.07.078; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lulevich V, 2006, LANGMUIR, V22, P8151, DOI 10.1021/la060561p; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massiera G, 2007, BIOPHYS J, V93, P3703, DOI 10.1529/biophysj.107.111641; Matei GA, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2336115; Mathur AB, 2001, J BIOMECH, V34, P1545, DOI 10.1016/S0021-9290(01)00149-X; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McGarry J G, 2004, Eur Cell Mater, V7, P27; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Merryman WD, 2006, AM J PHYSIOL-HEART C, V290, pH224, DOI 10.1152/ajpheart.00521.2005; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Mills JP, 2007, P NATL ACAD SCI USA, V104, P9213, DOI 10.1073/pnas.0703433104; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Radmacher M, 1996, BIOPHYS J, V70, P556, DOI 10.1016/S0006-3495(96)79602-9; Radmacher M, 2007, METHOD CELL BIOL, V83, P347, DOI 10.1016/S0091-679X(07)83015-9; RAND RP, 1964, BIOPHYS J, V4, P115, DOI 10.1016/S0006-3495(64)86773-4; Rudoy D, 2010, J R STAT SOC C-APPL, V59, P573; SATO M, 1990, J BIOMECH ENG-T ASME, V112, P263, DOI 10.1115/1.2891183; SCHMIDSCHONBEIN GW, 1981, BIOPHYS J, V36, P243, DOI 10.1016/S0006-3495(81)84726-1; Shin D, 1999, J ORTHOP RES, V17, P880, DOI 10.1002/jor.1100170613; Spagnoli C, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2534889; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Suresh S, 2005, ACTA BIOMATER, V1, P15, DOI 10.1016/j.actbio.2004.09.001; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagawa H, 1997, CIRC RES, V80, P281, DOI 10.1161/01.RES.80.2.281; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Trepat X, 2004, AM J PHYSIOL-LUNG C, V287, pL1025, DOI 10.1152/ajplung.00077.2004; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; Unnikrishnan GU, 2007, J BIOMECH ENG-T ASME, V129, P315, DOI 10.1115/1.2720908; Van Vliet KJ, 2003, ACTA MATER, V51, P5881, DOI 10.1016/j.actamat.2003.09.001; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	70	54	55	0	50	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	MAR	2011	7	3					1210	1219		10.1016/j.actbio.2010.10.018			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	725KP	WOS:000287643900032	20971217	Green Accepted, Green Published			2021-06-18	
J	Li, J; Li, XY; Feng, DF; Gu, L				Li, Jia; Li, Xue-Yuan; Feng, Dong-Fu; Gu, Lei			Quantitative evaluation of microscopic injury with diffusion tensor imaging in a rat model of diffuse axonal injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						anisotropy; diffusivity; electron microscopy; immunohistochemistry; region of interest	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; WHITE-MATTER INJURY; IN-VIVO; AMYLOID-BETA; OPTIC-NERVE; MOUSE MODEL; DAMAGE; ACCUMULATION; DIAGNOSIS	Diffuse axonal injury (DAI) is the predominant effect of severe traumatic brain injury and contributes significantly to neurological deficits. However, it is difficult to diagnose or characterize non-invasively with conventional imaging. Our study provides significant validation of a visual and statistical diffusion tensor imaging (DTI) technique as compared with pathological and electron microscopic study in a rat DAI model at multiple predilection sites and time points following trauma. Two DTI parameters, fractional anisotropy (FA) and axial diffusivity (AD), were significantly reduced from 12 h to 5 days post-trauma, corresponding to pathological axonal injury. At 7 days post-trauma, FA remained decreased, whereas AD pseudo-normalized and radial diffusivity increased. The temporal alterations in DTI parameters were observed in multiple predilection sites, and the extent of the changes in these parameters correlated significantly with the severity of histologically visualized axonal injury, as assessed by integrated optical density of immunochemically stained injured axons with quantitative stereology. Although anatomical T2-weighted magnetic resonance images showed no abnormal signals in microscopic lesions, we detected and characterized axonal injury directly by DTI at each time point. These results demonstrate that DTI has significant potential as a non-invasive tool with which to quantitatively diagnose and evaluate microstructural injury in the experimental and clinical assessment of DAI. This method can assist in accurate evaluation of the extent of axonal injury, detection of severe predilection foci, determination of approximate time of injury, and monitoring of the pathogenic condition at the early post-injury stage.	[Li, Jia; Li, Xue-Yuan; Feng, Dong-Fu; Gu, Lei] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Peoples Hosp 3, Shanghai 201900, Peoples R China; [Feng, Dong-Fu] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China	Feng, DF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Peoples Hosp 3, 280 Mo He Rd, Shanghai 201900, Peoples R China.	feng_df@yahoo.com			Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [064119639]; Shanghai Jiao Tong University School of Medicine [09XJ21072]; Shanghai Jiao Tong University [YG08PETMS19]	This study was supported by grants from the Shanghai Committee of Science and Technology (No. 064119639), the Shanghai Jiao Tong University School of Medicine (No. 09XJ21072) and the Medicine-Engineering Combination Project of Shanghai Jiao Tong University (No. YG08PETMS19).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Chan KC, 2009, J MAGN RESON IMAGING, V29, P1013, DOI 10.1002/jmri.21736; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chua CO, 2009, STROKE, V40, P3369, DOI 10.1161/STROKEAHA.109.549212; DASILVA AFM, 2003, NEUROSURG FOCUS, V15, P1; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Dijkhuizen RM, 2003, J CEREBR BLOOD F MET, V23, P1383, DOI 10.1097/01.WCB.0000100341.78607.EB; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Hannila I, 2009, OSTEOARTHR CARTILAGE, V17, P1570, DOI 10.1016/j.joca.2009.05.011; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Jang SH, 2009, NEUROREHABILITATION, V25, P229, DOI 10.3233/NRE-2009-0519; Lespessailles E, 2007, CALCIFIED TISSUE INT, V80, P97, DOI 10.1007/s00223-006-0216-y; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lima RR, 2008, INFLAMMATION, V31, P24, DOI 10.1007/s10753-007-9046-y; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Ma TG, 2001, ANAL BIOCHEM, V296, P18, DOI 10.1006/abio.2001.5208; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 2007, NEUROSURG FOCUS, V15, P1; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MCNAMARA G, 1995, MVPMATH PROGRAM IMAG; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Muller MJ, 2006, AM J NEURORADIOL, V27, P440; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; SKANDSEN T, 2009, J NEUROSURG, V23, P1; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Sykova E, 2004, NEUROSCIENCE, V129, P861, DOI 10.1016/j.neuroscience.2004.06.077; Szaleczky E, 2000, ANAL CELL PATHOL, V20, P131, DOI 10.1155/2000/830906; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Thuen M, 2009, J MAGN RESON IMAGING, V29, P39, DOI 10.1002/jmri.21606; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Wang CJ, 2009, APPL IMMUNOHISTO M M, V17, P530, DOI 10.1097/PAI.0b013e3181a13bf2; Wang S, 2009, AM J NEURORADIOL, V30, P1907, DOI 10.3174/ajnr.A1697; Wang SL, 2008, STROKE, V39, P2348, DOI 10.1161/STROKEAHA.107.509927; Wang-Tilz Y, 2006, EPILEPSIA, V47, P233, DOI 10.1111/j.1528-1167.2006.00414.x; Wexler EJ, 2002, J NEUROSCI METH, V113, P51, DOI 10.1016/S0165-0270(01)00476-9; Wood RI, 1999, J NEUROBIOL, V39, P359, DOI 10.1002/(SICI)1097-4695(19990605)39:3<359::AID-NEU3>3.0.CO;2-W; Xavier LL, 2005, BRAIN RES PROTOC, V16, P58, DOI 10.1016/j.brainresprot.2005.10.002; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	62	54	60	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2011	33	5					933	945		10.1111/j.1460-9568.2010.07573.x			13	Neurosciences	Neurosciences & Neurology	727MN	WOS:000287804500013	21385236				2021-06-18	
J	Jacobs, B; Beems, T; van der Vliet, TM; Diaz-Arrastia, RR; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; van der Vliet, Ton M.; Diaz-Arrastia, Ramon R.; Borm, George F.; Vos, Pieter E.			Computed Tomography and Outcome in Moderate and Severe Traumatic Brain Injury: Hematoma Volume and Midline Shift Revisited	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; hematoma; midline shift; outcome; severe traumatic brain injury	SEVERE HEAD-INJURY; COMA DATA-BANK; ADMISSION CHARACTERISTICS; PROGNOSTIC MODELS; CLASSIFICATION; PREDICTION; VALIDATION; HEMORRHAGE; IMPACT; LESION	Intracranial lesion volume and midline shift are powerful outcome predictors in moderate and severe traumatic brain injury (TBI), and therefore they are used in TBI and computed tomography (CT) classification schemes, like the Traumatic Coma Data Bank (TCDB) classification. In this study we aimed to explore the prognostic value of lesion volume and midline shift in moderate and severe TBI as measured from acute cranial CT scans. Also, we wanted to determine interrater reliability for the evaluation of these CT abnormalities. We included all consecutive moderate and severe TBI patients admitted to our hospital who were aged >= 16 years, over an 8-year period, as part of the prospective Radboud University Brain Injury Cohort Study. Six months post-trauma we assessed outcomes using the Glasgow Outcome Scale-Extended (GOS-E). We analyzed 605 patients and found an association of both lesion volume and midline shift with outcome; increases were associated with a higher frequency of patients with an unfavorable outcome or death. A cut-off value, such as that used in the TCDB CT classification (lesion volume 25 mL and midline shift 5 mm), was not found. The average interrater difference in volume measurement was 6.8 mL, and it was 0.2 mm for the determination of degree of shift. Using lesion volume and midline shift as continuous variables in prognostic models might be preferable over the use of threshold values, although an association of these variables with outcome in relation to other CT abnormalities was not tested. The data provided here will be useful for stratification of patients enrolled in clinical trials of neuroprotective therapies.	[Jacobs, Bram; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] Radboud Univ Nijmegen, Dept Radiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Borm, George F.] Radboud Univ Nijmegen, Dept Epidemiol Biostat & HTA, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Diaz-Arrastia, Ramon R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	Vos, PE (corresponding author), Radboud Univ Nijmegen, Dept Neurol 935, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012	Diaz-Arrastia, Ramon/0000-0001-6051-3594			*AAAM, 2001, ABBR INJ SCAL 1990 R; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P597; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOKSEY M, 1993, BRIT J NEUROSURG, V7, P611, DOI 10.3109/02688699308995090; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; EIDE PK, 1992, ACTA NEUROL SCAND, V86, P194, DOI 10.1111/j.1600-0404.1992.tb05065.x; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2000, J NEUROL NEUROSUR PS, V68, P14, DOI 10.1136/jnnp.68.1.14; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	51	54	54	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					203	215		10.1089/neu.2010.1558			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700004	21294647				2021-06-18	
J	Paterniti, I; Mazzon, E; Gil, C; Impellizzeri, D; Palomo, V; Redondo, M; Perez, DI; Esposito, E; Martinez, A; Cuzzocrea, S				Paterniti, Irene; Mazzon, Emanuela; Gil, Carmen; Impellizzeri, Daniela; Palomo, Valle; Redondo, Myriam; Perez, Daniel I.; Esposito, Emanuela; Martinez, Ana; Cuzzocrea, Salvatore			PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; CELL-DEATH; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; MESSENGER-RNA; EXPRESSION; APOPTOSIS; PHOSPHODIESTERASES; NEURONS	Background: Primary traumatic mechanical injury to the spinal cord (SCI) causes the death of a number of neurons that to date can neither be recovered nor regenerated. During the last years our group has been involved in the design, synthesis and evaluation of PDE7 inhibitors as new innovative drugs for several neurological disorders. Our working hypothesis is based on two different facts. Firstly, neuroinflammation is modulated by cAMP levels, thus the key role for phosphodiesterases (PDEs), which hydrolyze cAMP, is undoubtedly demonstrated. On the other hand, PDE7 is expressed simultaneously on leukocytes and on the brain, highlighting the potential crucial role of PDE7 as drug target for neuroinflammation. Methodology/Principal Findings: Here we present two chemically diverse families of PDE7 inhibitors, designed using computational techniques such as virtual screening and neuronal networks. We report their biological profile and their efficacy in an experimental SCI model induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy. We have selected two candidates, namely S14 and VP1.15, as PDE7 inhibitors. These compounds increase cAMP production both in macrophage and neuronal cell lines. Regarding drug-like properties, compounds were able to cross the blood brain barrier using parallel artificial membranes (PAMPA) methodology. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, and production of a range of inflammatory mediators, tissue damage, and apoptosis. Treatment of the mice with S14 and VP1.15, two PDE7 inhibitors, significantly reduced the degree of spinal cord inflammation, tissue injury (histological score), and TNF-alpha, IL-6, COX-2 and iNOS expression. Conclusions/Significance: All these data together led us to propose PDE7 inhibitors, and specifically S14 and VP1.15, as potential drug candidates to be further studied for the treatment of SCI.	[Paterniti, Irene; Impellizzeri, Daniela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Mazzon, Emanuela; Esposito, Emanuela; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Gil, Carmen; Palomo, Valle; Redondo, Myriam; Perez, Daniel I.; Martinez, Ana] CSIC, Inst Quim Med, E-28006 Madrid, Spain	Paterniti, I (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	salvator@unime.it	Gil, Carmen/J-8932-2014; Martinez, Ana/L-6414-2014; Perez Fernandez, Daniel Ignacio/L-6245-2014; Mazzon, Emanuela/AAL-4334-2020; Palomo Ruiz, Maria del Valle/N-2932-2016	Gil, Carmen/0000-0002-3882-6081; Martinez, Ana/0000-0002-2707-8110; Perez Fernandez, Daniel Ignacio/0000-0003-1774-4471; mazzon, emanuela/0000-0002-5073-717X; Palomo Ruiz, Maria del Valle/0000-0002-1473-4086; Impellizzeri, Daniela/0000-0001-9492-3161	MICINNSpanish GovernmentEuropean Commission; ISCiiiInstituto de Salud Carlos III [SAF2009-13015-CO2-01, RD0060/0015]	The financial support of MICINN and ISCiii (projects no. SAF2009-13015-CO2-01 and RD0060/0015, programs SAF and RETICS respectively) are acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0; Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Castano T, 2009, CHEMMEDCHEM, V4, P866, DOI 10.1002/cmdc.200900043; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; Castro A, 2008, EUR J MED CHEM, V43, P1349, DOI 10.1016/j.ejmech.2007.10.027; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Choi SH, 2003, NEUROBIOL DIS, V14, P181, DOI 10.1016/S0969-9961(03)00085-8; Choi SH, 2003, J NEUROSCI, V23, P5877; Combs CK, 2001, J NEUROSCI, V21, P1179; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Crivori P, 2000, J MED CHEM, V43, P2204, DOI 10.1021/jm990968+; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; de Castro R, 2004, EXP NEUROL, V190, P414, DOI 10.1016/j.expneurol.2004.05.046; Di L, 2003, EUR J MED CHEM, V38, P223, DOI 10.1016/S0223-5234(03)00012-6; Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1; Essayan DM, 1999, BIOCHEM PHARMACOL, V57, P965, DOI 10.1016/S0006-2952(98)00331-1; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Giembycz MA, 2005, CURR OPIN PHARMACOL, V5, P238, DOI 10.1016/j.coph.2005.04.001; Gil C, 2009, J NEUROCHEM, V110, P119; Gil C, 2008, EXPERT OPIN THER PAT, V18, P1127, DOI 10.1517/13543776.18.10.1127; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; Hong GY, 2010, J SURG RES, V159, P565, DOI 10.1016/j.jss.2008.12.018; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lee R, 2002, CELL SIGNAL, V14, P277, DOI 10.1016/S0898-6568(01)00250-9; Levy M L, 1999, Neurosurg Focus, V6, pe11; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003; Maegele M, 2005, CRIT CARE MED, V33, P1136, DOI 10.1097/01.CCM.0000163269.42524.50; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; MARTINEZ AC, 2009, 5 IMINO SUBSTITUTED; Menniti FS, 2006, NAT REV DRUG DISCOV, V5, P660, DOI 10.1038/nrd2058; Mullane K, 1989, Prog Clin Biol Res, V301, P39; Nakata A, 2002, CLIN EXP IMMUNOL, V128, P460, DOI 10.1046/j.1365-2249.2002.01856.x; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Redondo M, 2009, DRUG FUTURE, V34, P142; Reyes-Irisarri E, 2005, NEUROSCIENCE, V132, P1173, DOI 10.1016/j.neuroscience.2005.01.050; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Spina D, 2003, DRUGS, V63, P2575, DOI 10.2165/00003495-200363230-00002; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; vanAsperen J, 1997, J PHARM SCI, V86, P881, DOI 10.1021/js9701364; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Yang GC, 2003, J IMMUNOL, V171, P6414, DOI 10.4049/jimmunol.171.12.6414	65	54	57	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e15937	10.1371/journal.pone.0015937			15	Multidisciplinary Sciences	Science & Technology - Other Topics	714UK	WOS:000286834300030	21297958	DOAJ Gold, Green Published			2021-06-18	
J	Courtney, MW; Courtney, AC				Courtney, Michael W.; Courtney, Amy C.			Working toward exposure thresholds for blast-induced traumatic brain injury: Thoracic and acceleration mechanisms	NEUROIMAGE			English	Article						Blast injury; Traumatic brain injury; TBI; Behind armor blunt trauma; Blast wave; Ballistic pressure wave	PRESSURE WAVE INJURIES; CENTRAL-NERVOUS-SYSTEM; MISSILE EXTREMITY IMPACT; ARMOR BLUNT TRAUMA; INDUCED NEUROTRAUMA; HUMAN TORSO; VELOCITY; SHOCK; INVOLVEMENT; LIGHT	Research in blast-induced lung injury resulted in exposure thresholds that are useful in understanding and protecting humans from such injury. Because traumatic brain injury (TBI) due to blast exposure has become a prominent medical and military problem, similar thresholds should be identified that can put available research results in context and guide future research toward protecting war fighters as well as diagnosis and treatment. At least three mechanical mechanisms by which the blast wave may result in brain injury have been proposed-a thoracic mechanism, head acceleration, and direct cranial transmission. These mechanisms need not be mutually exclusive. In this study, likely regions of interest for the first two mechanisms based on blast characteristics (positive pulse duration and peak effective overpressure) are developed using available data from blast experiments and related studies, including behind-armor blunt trauma and ballistic pressure wave studies. These related studies are appropriate to include because blast-like pressure waves are produced that result in neurological effects like those caused by blast. Results suggest that injury thresholds for each mechanism are dependent on blast conditions, and that under some conditions, more than one mechanismmay contribute. There is a subset of blast conditions likely to result in TBI due to head acceleration and/or a thoracic mechanism without concomitant lung injury. These results can be used to guide experimental designs and compare additional data as they become available. Additional data are needed before actual probabilities or severity of TBI for a given exposure can be described. (C) 2010 Elsevier Inc. All rights reserved.	[Courtney, Michael W.] USAF Acad, Colorado Springs, CO 80840 USA; [Courtney, Amy C.] Force Protect Ind Inc, Ladson, SC 29456 USA	Courtney, MW (corresponding author), BTG Res, POB 62541, Colorado Springs, CO 80962 USA.	Michael.Courtney@usafa.edua; amy_courtney@post.harvard.edu		Courtney, Amy/0000-0002-1925-8736			Alley M., 2009, THESIS PURDUE U W LA; Axelsson H, 1996, J TRAUMA, V40, pS31, DOI 10.1097/00005373-199603001-00006; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; Bowen LG, 1968, 2113 DEF AT SUPP AG; Cannon L, 2001, J R Army Med Corps, V147, P87; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cooper GJ, 1996, J TRAUMA, V40, pS105, DOI 10.1097/00005373-199603001-00024; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney A, 2007, BRAIN INJURY, V21, P657, DOI 10.1080/02699050701481571; Cripps NPJ, 1996, J TRAUMA, V40, pS206, DOI 10.1097/00005373-199603001-00045; Drobin D, 2007, J TRAUMA, V63, P405, DOI 10.1097/01.ta.0000236015.68105.48; Dubos Rene, 1950, L PASTEUR FREE LANCE; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Gibson LJ, 2006, J ZOOL, V270, P462, DOI 10.1111/j.1469-7998.2006.00166.x; GORANSSON AM, 1988, J TRAUMA, V28, pS204; GRYTH D, 2007, THESIS KAROLINSKA I; Gryth D, 2008, J TRAUMA, V64, P1420, DOI 10.1097/TA.0b013e318054e247; Gryth D, 2007, MIL MED, V172, P1110, DOI 10.7205/MILMED.172.10.1110; HARVEY EN, 1947, J EXP MED, V85, P321, DOI 10.1084/jem.85.3.321; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; JOHNSON DL, 1994, 942 US ARM AER RES L; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; KRAJSA J, 2009, THESIS MASARYK U BRN; Krave U, 2005, EUR J NEUROSCI, V21, P2876, DOI 10.1111/j.1460-9568.2005.04115.x; Lee M, 1997, J FLUID STRUCT, V11, P819, DOI 10.1006/jfls.1997.0103; Liu G, 2008, COMBUST EXPLO SHOCK+, V44, P213, DOI 10.1007/s10573-008-0028-7; Merkle AC, 2008, J TRAUMA, V64, P1555, DOI 10.1097/TA.0b013e318160ff3a; Moore DF, 2008, FUTUR NEUROL, V3, P243, DOI 10.2217/14796708.3.3.243; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; NYEIN M, 2008, P 26 ARM SCI C DEC 1; ONO K, 1980, SAE PUBLICATION; PARVIN SJ, 2007, LETHAL PHYS INJURY M; PRICE GR, 2005, CURRENT STATUS RATIN; Roberts JC, 2007, J BIOMECH, V40, P125, DOI 10.1016/j.jbiomech.2005.11.003; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Singerm E, 2008, TECHNOL REV, V111, P52; STUHMILLER JH, 1994, HLTH HAZARDS ASSESSM; STUHMILLER JH, 1998, RTO HFM SPEC M MOD A; SUNESON A, 1988, J TRAUMA, V28, pS197, DOI 10.1097/00005373-198801001-00041; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; SUNESON A, 1990, J TRAUMA, V30, P281, DOI 10.1097/00005373-199003000-00006; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Wang Q, 2004, J TRAUMA, V56, P604, DOI 10.1097/01.TA.0000058122.57737.0E; WRIGHT HC, 1950, 50639 ROYAL NAV; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; YELVERTON JT, 1973, DNA3114T; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	65	54	56	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN	2011	54			1			S55	S61		10.1016/j.neuroimage.2010.05.025			7	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	813ZF	WOS:000294408600008	20483376				2021-06-18	
J	Wishart, HA; Roth, RM; Saykin, AJ; Rhodes, CH; Tsongalis, GJ; Pattin, KA; Moore, JH; McAllister, TW				Wishart, Heather A.; Roth, Robert M.; Saykin, Andrew J.; Rhodes, C. Harker; Tsongalis, Gregory J.; Pattin, Kristine A.; Moore, Jason H.; McAllister, Thomas W.			COMT Va158Met Genotype and Individual Differences in Executive Function in Healthy Adults	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognition; Neuropsychological tests; Executive control; Catechol-O-methyltransferase; Polymorphism; Epistasis	CATECHOL-O-METHYLTRANSFERASE; VAL(108/158) MET GENOTYPE; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; VAL(158)MET POLYMORPHISM; MOLECULAR-GENETICS; KINASE GENE; DOPAMINE; COGNITION; HIPPOCAMPAL	The Val158Met polymorphism of the catechol-O-methyltransferase (COMT) gene may be related to individual differences in cognition, likely via modulation of prefrontal dopamine catabolism. However, the available studies have yielded mixed results, possibly in part because they do not consistently account for other genes that affect cognition. We hypothesized that COMT Met allele homozygosity, which is associated with higher levels of prefrontal dopamine, would predict better executive function as measured using standard neuropsychological testing, and that other candidate genes might interact with COMT to modulate this effect. Participants were 95 healthy, right-handed adults who underwent genotyping and cognitive testing. COMT genotype predicted executive ability as measured by the Trail-Making Test, even after covarying for demographics and Apolipoprotein E (APOE), brain-derived neurotrophic factor (BDNF), and ankyrin repeat and kinase domain containing 1 (ANKK 1) genotype. There was a COMT-ANKK 1 interaction in which individuals having both the COMT Val allele and the ANKK 1 T allele showed the poorest performance. This study suggests the heterogeneity in COMT effects reported in the literature may be due in part to gene gene interactions that influence central dopaminergic systems. (JINS, 2011, 17, 174-180)	[Wishart, Heather A.] Dartmouth Med Sch, DHMC, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03756 USA; [Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN USA; [Rhodes, C. Harker; Tsongalis, Gregory J.] Dartmouth Med Sch, Dept Pathol, Lebanon, NH 03756 USA; [Pattin, Kristine A.; Moore, Jason H.] Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA	Wishart, HA (corresponding author), Dartmouth Med Sch, DHMC, Dept Psychiat, Neuropsychol Program, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	wishart@dartmouth.edu	; Saykin, Andrew/A-1318-2007	Moore, Jason/0000-0002-5015-1099; Saykin, Andrew/0000-0002-1376-8532	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS045830, R03NS056228, R01NS40472]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG3248, PP1214]; Hitchcock Foundation; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771]; National Institute on Disability and Rehabilitation Research [H133670031, H133G000136]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176]; Ira DeCamp Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA101318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS056228, R01NS040472, K23NS045830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER	Supported in part by the National Institute of Neurological Disorders and Stroke (K23NS045830, R03NS056228, R01NS40472), National Multiple Sclerosis Society (RG3248, PP1214), Hitchcock Foundation, National Institute on Aging (R01AG019771), National Institute on Disability and Rehabilitation Research (H133670031, H133G000136), National Institute of Child Health and Development (R01HD048176) and Ira DeCamp Foundation. No conflicts exist.	Barnett JH, 2008, BIOL PSYCHIAT, V64, P137, DOI 10.1016/j.biopsych.2008.01.005; BARNETT JH, 2009, BIOL PSYCHIAT, V65, pE3; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542; Bookheimer S, 2009, ANNU REV CLIN PSYCHO, V5, P343, DOI 10.1146/annurev.clinpsy.032408.153625; Briand LA, 2007, PROG NEUROBIOL, V83, P69, DOI 10.1016/j.pneurobio.2007.06.007; Cerasa A, 2008, NEUROREPORT, V19, P405, DOI 10.1097/WNR.0b013e3282f5f784; Colzato LS, 2010, NEUROPSYCHOLOGIA, V48, P2764, DOI 10.1016/j.neuropsychologia.2010.04.023; Cowansage Kiriana K, 2010, Curr Mol Pharmacol, V3, P12; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Delis DC, 2001, DELISKAPLAN EXECUTIV; Dickinson D, 2009, NEUROSCIENCE, V164, P72, DOI 10.1016/j.neuroscience.2009.05.014; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Funke B, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-19; Goldberg TE, 2003, ARCH GEN PSYCHIAT, V60, P889, DOI 10.1001/archpsyc.60.9.889; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Koch W, 2002, CLIN CHEM LAB MED, V40, P1123, DOI 10.1515/CCLM.2002.197; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Meyer-Lindenberg A, 2006, MOL PSYCHIATR, V11, P867, DOI 10.1038/sj.mp.4001860; Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Parasuraman R, 2002, NEUROPSYCHOLOGY, V16, P254, DOI 10.1037//0894-4105.16.2.254; Ponce G, 2009, NEUROTOX RES, V16, P50, DOI 10.1007/s12640-009-9046-9; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reitz C, 2009, NEUROSCIENCE, V164, P174, DOI 10.1016/j.neuroscience.2009.04.006; Reuter M, 2006, INT J NEUROPSYCHOPH, V9, P155, DOI 10.1017/S1461145705005419; Reuter M, 2005, BEHAV BRAIN RES, V164, P93, DOI 10.1016/j.bbr.2005.06.002; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Savitz J, 2006, BRAIN RES REV, V51, P125, DOI 10.1016/j.brainresrev.2005.10.006; Stelzel C, 2009, EUR J NEUROSCI, V29, P1056, DOI 10.1111/j.1460-9568.2009.06647.x; Tan HY, 2007, P NATL ACAD SCI USA, V104, P12536, DOI 10.1073/pnas.0610125104; Tunbridge EM, 2006, BIOL PSYCHIAT, V60, P141, DOI 10.1016/j.biopsych.2005.10.024; Xu HY, 2007, SCHIZOPHR RES, V90, P104, DOI 10.1016/j.schres.2006.10.001; Zinkstok J, 2006, NEUROSCI LETT, V405, P34, DOI 10.1016/j.neulet.2006.06.034	38	54	54	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2011	17	1					174	180		10.1017/S1355617710001402			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	702KX	WOS:000285894700019	21144101	Green Accepted			2021-06-18	
J	Dudley, RR; Aziz, I; Bonnici, A; Saluja, RS; Lamoureux, J; Kalmovitch, B; Gursahaney, A; Razek, T; Maleki, M; Marcoux, J				Dudley, Roy R.; Aziz, Ishtiaque; Bonnici, Andre; Saluja, Rajeet S.; Lamoureux, Julie; Kalmovitch, Boaz; Gursahaney, Ash; Razek, Tarek; Maleki, Mohammad; Marcoux, Judith			Early Venous Thromboembolic Event Prophylaxis in Traumatic Brain Injury with Low-Molecular-Weight Heparin: Risks and Benefits	JOURNAL OF NEUROTRAUMA			English	Article						dalteparin; enoxaparin; low-molecular-weight heparin; traumatic brain injury; venous thromboembolic event	DEEP-VEIN THROMBOSIS; SPINAL-CORD-INJURY; MAJOR TRAUMA; ENOXAPARIN; PREVENTION; DALTEPARIN; HEMORRHAGE	Traumatic brain injury (TBI) patients are known to be at high risk for venous thromboembolic events (VTEs). The Brain Trauma Foundation Guidelines (2007) state that low-molecular-weight heparin or unfractionated heparin should be used to prevent VTE complications, but suggest that there is an increased risk of expansion of intracranial hemorrhages (ICH) with VTE prophylaxis. In addition, it is unclear which treatment regimen (i.e., medication, dose, and timing) provides the best risk: benefit ratio in TBI patients. We reviewed all moderate-to-severe TBI patients admitted over a 5-year period to: (1) examine the occurrence of VTEs and their timing; (2) examine the symptomatic expansion of ICH while on VTE prophylaxis; and (3) compare the efficacy of two prophylactic agents: enoxaparin and dalteparin. Two-hundred eighty-seven patients were included. VTE prophylaxis was started 48-72 h post-trauma in all individuals who had no confounding coagulopathy, when two consecutive computed tomography (CT) scans revealed hemorrhage stability. VTEs occurred in 7.3% of treated patients, mostly within 2 weeks after trauma. Proximal VTEs occurred in 3.1% of treated patients. No significant difference in VTE rates was seen between enoxaparin (7.0%) and dalteparin (7.5%; p = 0.868). Moreover, the group treated with dalteparin was more severely injured (higher Injury Severity Score [p = 0.002]), had lower Glasgow Coma Scale (GCS) scores (p = 0.003), and had more inferior vena cava (IVC) filters placed (p = 0.007). The two groups did not show significant differences in the development of VTE when controlled for ISS and IVC filters (p = 0.819). Importantly, only one patient suffered a symptomatic expansion of ICH while on VTE prophylaxis, at 15 days post-trauma. These results suggest that current regimens of VTE prophylaxis used in our TBI population provide a relatively high level of protection against VTEs, and an extremely low risk of expanding ICH. They also suggest that there was no difference in VTE between dalteparin- and enoxaparin-treated patients.	[Maleki, Mohammad; Marcoux, Judith] McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; [Aziz, Ishtiaque] McGill Univ, Fac Sci, Dept Biochem, Montreal, PQ H3G 1A4, Canada; [Bonnici, Andre] McGill Univ, Fac Pharm, Montreal, PQ H3G 1A4, Canada; [Dudley, Roy R.; Aziz, Ishtiaque; Saluja, Rajeet S.] McGill Univ, Ctr Hlth, Montreal Neurol Hosp, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Univ Montreal, Montreal, PQ, Canada; [Kalmovitch, Boaz] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Kalmovitch, Boaz] E Wolfson Med Ctr, Dept Surg, Holon, Israel; [Gursahaney, Ash] McGill Univ, Ctr Hlth, Clin Serv, Montreal, PQ H3G 1A4, Canada; [Gursahaney, Ash] McGill Univ, Div Crit Care, Dept Med, Montreal, PQ H3G 1A4, Canada; [Razek, Tarek] McGill Univ, Ctr Hlth, Trauma Program, Montreal, PQ H3G 1A4, Canada	Marcoux, J (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Neurosurg, 1650 Cedar Ave,Room L7-524, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca		Lamoureux, Julie/0000-0002-4986-2504			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Chiou-Tan FY, 2003, AM J PHYS MED REHAB, V82, P678, DOI 10.1097/01.PHM.0000083671.27501.47; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Hess Dean R, 2004, Respir Care, V49, P1171; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim KS, 2009, NEUROCRIT CARE, V11, P28, DOI 10.1007/s12028-009-9201-4; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Slavik RS, 2007, J TRAUMA, V62, P1075, DOI 10.1097/TA.0b013e31804fa177; SMITH RM, 1994, INJURY, V25, P551, DOI 10.1016/0020-1383(94)90099-X; TEASDALE G, 1974, LANCET, V2, P81	19	54	57	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2165	2172		10.1089/neu.2010.1366			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400006	20939698				2021-06-18	
J	Wang, GH; Zhang, XG; Jiang, ZL; Li, X; Peng, LL; Li, YC; Wang, Y				Wang, Guo-Hua; Zhang, Xiang-Gen; Jiang, Zheng-Lin; Li, Xia; Peng, Liang-Liang; Li, Yong-Cai; Wang, Yong			Neuroprotective Effects of Hyperbaric Oxygen Treatment on Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; hyperbaric oxygen; neuroprotective effect; secondary brain damage; time window; traumatic brain injury	SEVERE HEAD-INJURY; EXPERIMENTAL ANIMAL-MODELS; INTRACRANIAL-PRESSURE; CEREBRAL OXYGENATION; MITOCHONDRIAL-FUNCTION; THERAPY; APOPTOSIS; METABOLISM; CONTUSIONS; HYPEROXIA	This study was designed to evaluate the potential benefits of hyperbaric oxygen (HBO) in the treatment of traumatic brain injury (TBI). The right cerebral cortex of rats was injured by the impact of a 20-g object dropped from a predetermined height. The rats received HBO treatment at 3 ATA for 60 min after TBI. Neurological behavior score, brain water content, neuronal loss in the hippocampus, and cell apoptosis in brain tissue surrounding the primary injury site were examined to determine brain damage severity. Three and six hours after TBI, HBO-treated rats displayed a significant reduction in brain damage. However, by 12 h after TBI, the efficacy of HBO treatment was considerably attenuated. Furthermore, at 24, 48, and 72 h after TBI, the HBO treatment did not show any notable effects. In contrast, multiple HBO treatments (three or five times in all), even when started 48 h after TBI, remarkably reduced neurology deficit scores and the loss of neuronal numbers in the hippocampus. Although multiple treatments started at 48 h significantly improved neurological behaviors and reduced brain injury, the overall beneficial effects were substantially weaker than those seen after a single treatment at 6 h. These results suggest that: (1) HBO treatment could alleviate brain damage after TBI; (2) a single treatment with HBO has a time limitation of 12 h post-TBI; and (3) multiple HBO treatments have the possibility to extend the post-TBI delivery time window. Therefore, our results clearly suggest the validity of HBO therapy for the treatment of TBI.	[Wang, Guo-Hua; Zhang, Xiang-Gen; Jiang, Zheng-Lin; Li, Xia; Peng, Liang-Liang] Nantong Univ, Inst Naut Med, Dept Neuropharmacol, Nantong 226001, Jiangsu, Peoples R China; [Li, Yong-Cai; Wang, Yong] First Hosp Nantong, Dept Neurosurg, Nantong, Jiangsu, Peoples R China; [Zhang, Xiang-Gen] Shanghai Salvage Corp, Shanghai, Peoples R China	Jiang, ZL (corresponding author), Nantong Univ, Inst Naut Med, Dept Neuropharmacol, 19 Qixiu Rd, Nantong 226001, Jiangsu, Peoples R China.	jiangzl@ntu.edu.cn		Wang, Guohua/0000-0002-4810-8534	Administration of Science and Technology of Nantong, Jiangsu Province, China [S5031]	The authors wish to thank Dr. Temugin Berta for help revising the manuscript, and Dr. Yong-Jing Gao for constructive suggestions about the writing of the manuscript. This study was supported by a grant from the Administration of Science and Technology of Nantong (project no. S5031), Jiangsu Province, China.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; BLENKARN GD, 1969, J PHARMACOL EXP THER, V166, P346; Calvert JW, 2007, NEUROL RES, V29, P132, DOI 10.1179/016164107X174156; Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Conti AC, 1998, J NEUROSCI, V18, P5663; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Golarai G, 2001, J NEUROSCI, V21, P8523; Goldman RJ, 2009, PM&R, V1, P471, DOI 10.1016/j.pmrj.2009.03.012; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hampson N, 2003, UNDERSEA HYPERBAR M, V30, P147; Kleen M, 1999, Minerva Anestesiol, V65, P393; KOHSHI K, 1991, Neurologia Medico-Chirurgica, V31, P575, DOI 10.2176/nmc.31.575; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Liu Zhan, 2006, Chin J Traumatol, V9, P168; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nemoto EM, 2007, NEUROL RES, V29, P116, DOI 10.1179/016164107X174138; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Oppel L, 2003, BRAIN INJURY, V17, P225, DOI 10.1080/0269905021000030814; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119; Qin Z, 2008, ACTA NEUROCHIR SUPPL, V105, P113; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rogatsky GG, 2005, BRAIN RES, V1047, P131, DOI 10.1016/j.brainres.2005.02.049; Rogatsky GG, 2003, NEUROL RES, V25, P95, DOI 10.1179/016164103101201003; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHEFFIELD PJ, 1976, AVIAT SPACE ENVIR MD, V47, P759; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sukoff MH, 2001, J NEUROSURG, V95, P544; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Yin DL, 2005, NEUROCRIT CARE, V2, P206, DOI 10.1385/NCC:2:2:206; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	55	54	68	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1733	1743		10.1089/neu.2009.1175			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500018	20568957				2021-06-18	
J	Oni, MB; Wilde, EA; Bigler, ED; McCauley, SR; Wu, TC; Yallampalli, R; Chu, ZL; Li, XQ; Hunter, JV; Vasquez, AC; Levin, HS				Oni, Margaret B.; Wilde, Elisabeth A.; Bigler, Erin D.; McCauley, Stephen R.; Wu, Trevor C.; Yallampalli, Ragini; Chu, Zili; Li, Xiaoqi; Hunter, Jill V.; Vasquez, Ana C.; Levin, Harvey S.			Diffusion Tensor Imaging Analysis of Frontal Lobes in Pediatric Traumatic Brain Injury	JOURNAL OF CHILD NEUROLOGY			English	Article						frontal lobe; traumatic brain injury; diffusion tensor imaging; outcome; Glasgow Coma Scale; Glasgow Outcome Scale	AXONAL INJURY; PRACTICAL SCALE; HEAD-INJURY; CHILDREN; MODERATE; PREDICTORS; DISABILITY; EXPERIENCE; CHILDHOOD; SEVERITY	This study examined the use of diffusion tensor imaging in detecting white matter changes in the frontal lobes following pediatric traumatic brain injury. A total of 46 children (ages 8-16 years) with moderate to severe traumatic brain injury and 47 children with orthopedic injury underwent 1.5 Tesla magnetic resonance imaging (MRI) at 3 months postinjury. Conventional MRI studies were obtained along with diffusion tensor imaging. Diffusion tensor imaging metrics, including fractional anisotropy, apparent diffusion coefficient, and radial diffusivity, were compared between the groups. Significant group differences were identified, implicating frontal white matter alterations in the injury group that were predictive of later Glasgow Outcome Scale ratings; however, focal lesions were not related to the Glasgow Outcome Scale ratings. Injury severity was also significantly associated with diffusion tensor imaging metrics. Diffusion tensor imaging holds great promise as an index of white matter integrity in traumatic brain injury and as a potential biomarker reflective of outcome.	[Wilde, Elisabeth A.; McCauley, Stephen R.; Yallampalli, Ragini; Li, Xiaoqi; Vasquez, Ana C.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat Hematol & Oncol, Houston, TX 77030 USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Inst Brain, Salt Lake City, UT USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS021889]; TIRR Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	Dr Oni and Dr Wilde are both first authors and contributed equally to this work. We would like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We acknowledge the contribution of Stacey K. Martin for assistance in manuscript preparation. We also wish to thank Ms Lori Cook and Drs Sandra B. Chapman and Gillian Hotz. We would also like to thank the patients and their families for their involvement in this study. Participants in this study were recruited from Children's Medical Center Dallas (Dallas, Texas), Parkland Memorial Hospital (Dallas, Texas), Cook Children's Medical Center (Fort Worth, Texas), Baylor Institute for Rehabilitation (Dallas, Texas), Our Children's House at Baylor (Dallas, Texas), Texas Children's Hospital (Houston, Texas), Jackson Memorial Hospital (Miami, Florida), and Miami Children's Hospital (Miami, Florida). Imaging was performed at the Texas Children's Hospital (Houston, Texas) and the Mary Nell and Ralph B. Rogers Magnetic Resonance Center at the University of Texas Southwestern Medical Center (Dallas, Texas) and Miami Children's Hospital (Miami, Florida). Image analysis was performed at the Baylor College of Medicine/Texas Children's Hospital Diagnostic Imaging Laboratory in Houston, Texas. Portions of this study were presented at the 2009 International Neuropsychological Society meeting, Atlanta, Georgia.; The authors disclosed receipt of the following financial support for the research and/or authorship of this article: this research was supported by grant NS021889 awarded to Harvey S. Levin by the National Institutes of Health.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carli P, 2004, LANCET, V363, P584, DOI 10.1016/S0140-6736(04)15626-2; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; JENNETT B, 1975, LANCET, V1, P480; Ker K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a865; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lazar M, 2006, AM J NEURORADIOL, V27, P1258; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; TEASDALE G, 1974, LANCET, V2, P81; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yung A, 2007, PEDIATR RES, V61, P732, DOI 10.1203/pdr.0b013e31805365db	49	54	54	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	AUG	2010	25	8					976	984		10.1177/0883073809356034			9	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	625PS	WOS:000279908100006	20332386	Green Accepted			2021-06-18	
J	Klose, M; Brennum, J; Poulsgaard, L; Kosteljanetz, M; Wagner, A; Feldt-Rasmussen, U				Klose, Marianne; Brennum, Jannick; Poulsgaard, Lars; Kosteljanetz, Michael; Wagner, Aase; Feldt-Rasmussen, Ulla			Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage	CLINICAL ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; ANTERIOR-PITUITARY FUNCTION; LONG-TERM; NEUROENDOCRINE DYSFUNCTION; GROWTH-HORMONE; ACUTE-PHASE; THYROID-FUNCTION; GH DEFICIENCY; FREE CORTISOL; SEPTIC SHOCK	Objective Aneurysmal subarachnoid haemorrhage (SAH) has recently been reported as a common cause of chronic hypopituitarism, and introduction of routine neuroendocrine screening has been advocated. We aimed at estimating the risk of hypopituitarism after SAH using strict criteria including confirmatory testing in case of suggested insufficiency. Design Cross-sectional evaluation with a nested prospective subgroup. Patients and measurements Endocrine evaluation was performed at a median of 14 months (range 11-26) post-SAH in 62 patients with SAH and 30 healthy controls. Twenty-six patients were followed prospectively (median 7 days, and 12 months post-SAH). Endocrine evaluation included baseline evaluation, which was combined with an insulin tolerance test (ITT) or, if contraindicated, GHRH + arginine tests and a standard ACTH test at evaluation 1-2 years post-SAH. Pituitary insufficiencies were confirmed by re-evaluation. Results Early post-SAH hormone alterations mimicking central hypogonadism were present in 58% of the patients and associated with a worse clinical state (P < 0.05). One to 2 years post-SAH, initial neuroendocrine evaluation identified seven patients (11%) with abnormal results; three had free T4 and TSH suggestive of central hypothyroidism, three men had testosterone below 10 nm, and one had an insufficient GH and cortisol response to the ITT. None of these abnormalities was confirmed upon confirmatory testing. Conclusion In the largest reported cohort of patients with SAH to date, with early and late endocrine evaluation, none of the patients had chronic hypopituitarism. Based on these findings, the introduction of routine neuroendocrine screening is not justified, and the data suggest the importance of using strict diagnostic criteria in patients with a low pretest probability of hypopituitarism.	[Klose, Marianne; Feldt-Rasmussen, Ulla] Copenhagen Univ Hosp, Dept Med Endocrinol, Rigshosp, DK-2100 Copenhagen, Denmark; [Brennum, Jannick; Poulsgaard, Lars; Kosteljanetz, Michael] Copenhagen Univ Hosp, Dept Neurosurg, Rigshosp, DK-2100 Copenhagen, Denmark; [Wagner, Aase] Copenhagen Univ Hosp, Dept Radiol, Rigshosp, DK-2100 Copenhagen, Denmark	Klose, M (corresponding author), Copenhagen Univ Hosp, Dept Med Endocrinol, Rigshosp, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Feldt-Rasmussen, Ulla/AAB-9218-2021	Feldt-Rasmussen, Ulla/0000-0002-5903-3355; Brennum, Jannick/0000-0002-7961-0156	Novo NordiskNovo Nordisk; A.P. Moller Foundation for the Advancement of Medical Science,; King Christian the 10th Foundation; Copenhagen University, Denmark; PfizerPfizer	The study was supported by an unrestricted grant from Novo Nordisk, A.P. Moller Foundation for the Advancement of Medical Science, and King Christian the 10th Foundation. M Klose was supported by a fellowship from Copenhagen University, Denmark.; MK has received lecture fees from Novo Nordisk and Pfizer, LP, MKo, AW and JB have nothing to declare. UFR has received lecture fees from Novo Nordisk and Pfizer, and an unrestricted grant from Novo Nordisk for the present study.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Andersen S, 2003, THYROID, V13, P1069, DOI 10.1089/105072503770867237; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Beishuizen A, 2001, INTENS CARE MED, V27, P1584, DOI 10.1007/s001340101073; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Cansu A, 2006, EPILEPSIA, V47, P1855, DOI 10.1111/j.1528-1167.2006.00821.x; Darzy KH, 2003, J CLIN ENDOCR METAB, V88, P95, DOI 10.1210/jc.2002-021094; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HARRIS EK, 1970, CLIN CHEM, V16, P1022; Herzog AG, 2005, CURR OPIN NEUROL, V18, P167, DOI 10.1097/01.wco.0000162859.42218.fd; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Isojarvi JIT, 2001, EPILEPSIA, V42, P930, DOI 10.1046/j.1528-1157.2001.042007930.x; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2007, J CLIN ENDOCR METAB, V92, P1326, DOI 10.1210/jc.2006-1791; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; OSTERMAN PO, 1975, ACTA NEUROL SCAND, V52, P56, DOI 10.1111/j.1600-0404.1975.tb02827.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Vestergaard P, 1997, HORM METAB RES, V29, P106, DOI 10.1055/s-2007-979000	33	54	56	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	JUL	2010	73	1					95	101		10.1111/j.1365-2265.2010.03791.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	612QR	WOS:000278917100015	20105184				2021-06-18	
J	Tian, HL; Chen, H; Wu, BS; Cao, HL; Xu, T; Hu, J; Wang, G; Gao, WW; Lin, ZK; Chen, SW				Tian, Heng-Li; Chen, Hao; Wu, Bing-Shan; Cao, He-Li; Xu, Tao; Hu, Jin; Wang, Gan; Gao, Wen-Wei; Lin, Zai-Kai; Chen, Shi-Wen			D-dimer as a predictor of progressive hemorrhagic injury in patients with traumatic brain injury: analysis of 194 cases	NEUROSURGICAL REVIEW			English	Article						Coagulation; D-dimer; Fibrinolysis; Progressive hemorrhagic injury; Traumatic brain injury	POSTTRAUMATIC CEREBRAL INFARCTION; RECOMBINANT FACTOR-VIIA; HEAD TRAUMA; COMPUTED-TOMOGRAPHY; COAGULOPATHY; BLUNT; THROMBOCYTOPENIA; MODERATE; UTILITY; LESIONS	This study sought to describe and evaluate any relationship between D-dimer values and progressive hemorrhagic injury (PHI) after traumatic brain injury (TBI). In patients with TBI, plasma D-dimer was measured while a computed tomography (CT) scan was conducted as soon as the patient was admitted to the emergency department. A series of other clinical and laboratory parameters were also measured and recorded. A logistic multiple regression analysis was used to identify risk factors for PHI. A cohort of 194 patients with TBI was evaluated in this clinical study. Eighty-one (41.8%) patients suffered PHI as determined by a second CT scan. The plasma D-dimer level was higher in patients who demonstrated PHI compared with those who did not (P < 0.001. Using a receiver-operator characteristic curve to predict the possibility by measuring the D-dimer level, a value of 5.00 mg/L was considered the cutoff point, with a sensitivity of 72.8% and a specificity of 78.8%. Eight-four patients had D-dimer levels higher than the cut point value (5.0 mg/L); PHI was seen in 71.4% of these patients and in 19.1% of the other patients (P < 0.01). Factors with P < 0.2 on bivariate analysis were included in a stepwise logistic regression analysis to identify independent risk factors for TBI coagulopathy. Logistic regression analysis showed that the D-dimer value was a predictor of PHI, and the odds ratio (OR) was 1.341 with per milligram per liter (P = 0.020). The stepwise logistic regression also identified that time from injury to the first CT shorter than 2 h (OR = 2.118, P = 0.047), PLT counts lesser than 100 x 109/L (OR = 7.853, P = 0.018), and Fg lower than 2.0 g/L (OR = 3.001, P = 0.012) were risk factors for the development of PHI. When D-dimer values were dichotomized at 5 mg/L, time from injury to the first CT scan was no longer a risk factor statistically while the OR value of D-dimer to the occurrence of PHI elevated to 11.850(P < 0.001). The level of plasma D-dimer after TBI can be a useful prognostic factor for PHI and should be considered in the clinical management of patients in combination with neuroimaging and other data.	[Tian, Heng-Li; Chen, Hao; Wu, Bing-Shan; Cao, He-Li; Xu, Tao; Hu, Jin; Wang, Gan; Gao, Wen-Wei; Lin, Zai-Kai] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China; [Chen, Shi-Wen] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Radiol, Shanghai 200233, Peoples R China	Wu, BS (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, 600 Yishan Rd, Shanghai 200233, Peoples R China.	wubingshan@gmail.com					*ASS ADV AUT MED, 1990, ABBR INJ SCAL; Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuo JR, 2007, EUR J NEUROL, V14, P1073, DOI 10.1111/j.1468-1331.2007.01908.x; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Rathbun SW, 2004, CHEST, V125, P851, DOI 10.1378/chest.125.3.851; ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TALVING P, 2008, J TRAUMA, V66, P61; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Williams MT, 2003, CRIT CARE CLIN, V19, P185, DOI 10.1016/S0749-0704(02)00048-9; Zaaroor M, 2008, ACTA NEUROCHIR, V150, P663, DOI 10.1007/s00701-008-1593-y	32	54	64	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2010	33	3					359	365		10.1007/s10143-010-0251-z			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	612MN	WOS:000278902900021	20349100				2021-06-18	
J	Wang, JP; Jiang, C; Liu, CL; Li, X; Chen, NN; Hao, YJ				Wang, Jianping; Jiang, Chao; Liu, Chunling; Li, Xin; Chen, Ningning; Hao, Yujin			Neuroprotective effects of progesterone following stroke in aged rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Progesterone; Infarct volume; Brain water content; Functional deficits; Aged rats	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; INFARCT VOLUME; ISCHEMIA; OCCLUSION; EDEMA; EXPRESSION; RECOVERY	Recent studies indicate that progesterone (PROG) protects against animal brain injury, including ischemic stroke, in various animal models. However, there are insufficient studies about PROG in other various groups such as ovariectomized females and aged animals. This study was designed to examine the efficacy of PROG on infarct volume, brain water content and functional outcome after cerebral ischemia in aged rats. Thirty-six male aged Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO) with the intraluminal filament technique and sham operation. After induction of pMCAO, the rats received an initial intraperitoneal injection of PROG (8 mg/kg) or vehicle at 1 h post-occlusion followed by subcutaneous injections at 6, 24 and 48 h. Functional deficits were tested with Zea Longa and Rotarod test at 24, 48 and 72 h after pMCAO. The rats were killed 72 h after surgery and infarct volume were determined with 2,3,5-triphenyltetrazolium chloride (TTC) staining and digital image analysis. Brain water content was determined by the dry-wet weight method. PROG-treated rats showed a substantial reduction in the volume of the infarction (% contralateral hemisphere) and brain water content compared to vehicle-treated rats. In addition, there was a significant improvement in ability to remain on an accelerating rotarod and increased Zea Longa scores observed in the pMCAO rats treated with PROG compared to vehicle. These findings point to the response of aged adult rats to PROG in cerebral ischemia, and suggest that such response need to be considered in the development of neuroprotective agents for stroke. (C) 2010 Elsevier B.V. All rights reserved.	[Wang, Jianping; Jiang, Chao] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China; [Liu, Chunling; Li, Xin; Chen, Ningning; Hao, Yujin] Zhengzhou Univ, Affiliated Hosp 2, Dept Neurol, Zhengzhou 450014, Henan, Peoples R China	Wang, JP (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 5, Kangfu Rd, Zhengzhou 450052, Henan, Peoples R China.	jcmd666@126.com			Medical Science and Technology Research Programs of Henan Province [WKJ2007-2-031]	This work was supported by grants from Medical Science and Technology Research Programs of Henan Province (WKJ2007-2-031).	ARNOLD KG, 1981, AGE AGEING, V10, P5, DOI 10.1093/ageing/10.1.5; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Buga AM, 2009, ROM J MORPHOL EMBRYO, V50, P559; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GINSBERG MD, 1988, NEUROCHEM PATHOL, V9, P171; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOYER S, 1987, GERONTOLOGY, V33, P203, DOI 10.1159/000212877; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MIZOI K, 1986, Neurological Research, V8, P75; Pitkanen A, 2003, IDRUGS, V6, P200; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; Tatlisumak T, 2000, J NEUROL SCI, V178, P107, DOI 10.1016/S0022-510X(00)00380-4; Vandromme M, 2008, CRIT CARE, V12, DOI 10.1186/cc6899; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; YAO H, 1991, STROKE, V22, P1414, DOI 10.1161/01.STR.22.11.1414	28	54	58	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAY 1	2010	209	1					119	122		10.1016/j.bbr.2010.01.026			4	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	582FW	WOS:000276582900017	20109497				2021-06-18	
J	Meric, E; Gunduz, A; Turedi, S; Cakir, E; Yandi, M				Meric, Emine; Gunduz, Abdulkadir; Turedi, Suleyman; Cakir, Ertugrul; Yandi, Mustafa			THE PROGNOSTIC VALUE OF NEURON-SPECIFIC ENOLASE IN HEAD TRAUMA PATIENTS	JOURNAL OF EMERGENCY MEDICINE			English	Article						head trauma; neuron-specific enolase; prognosis	SERUM; BRAIN; MARKER; INJURY	In recent years, in addition to neurological examination and neuroradiologic examinations, attempts have been made to assess the severity of post-traumatic brain injury and to obtain an early idea of patient prognosis using biochemical markers with a high degree of brain tissue specificity. One such enzyme is neuron-specific enolase (NSE). This study investigates the correlation between serum NSE levels, Glasgow Coma Score, and prognosis measured by Glasgow Outcome Scores in head trauma patients. This was a prospective study conducted with 80 trauma patients presenting to the Emergency Department. Patients were divided into four groups. The first group consisted of patients with general body trauma, but no head trauma. The second group had minor head trauma. The third group had moderate head trauma, and the fourth group had severe head trauma. The relationship between subjects' admission NSE levels and admission and discharge Glasgow Coma Scores (GCS) and Glasgow Outcome Scores (GOS) 1 month later was examined. A receiver operating characteristic (ROC) analysis was performed using a serum NSE cutoff level of 20.52 ng/mL and a GOS of 3 or less as the definition of poor neurologic outcome. There was a significant difference in the NSE levels between group 1 (general trauma) and group 3 (moderate head trauma). There was also a statistically significant difference in NSE levels between group 1 (general trauma) and group 4 (severe head trauma) (p < 0.05). There was a statistically significant inverse relationship between NSE levels and GOS as determined within groups 3 (moderate) and 4 (severe head trauma) (p < 0.05). When NSE levels were compared with admission GCS, it was found that GCS fell as NSE levels rose. There was no significant correlation between NSE and GCS within groups 3 (moderate) or 4 (severe). There was a statistically significant correlation within group 2 (mild) (p < 0.05). By ROC analysis, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in the study patients. The area under the curve was 0.931. This study shows that initial serum NSE levels in moderate and severe head trauma patients correlate inversely with GOS 1 month later, but only within the moderate and severe head trauma groups. However, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in all of the study patients. This derived cutoff value now needs to be prospectively validated. (C) 2010 Elsevier Inc.	[Gunduz, Abdulkadir; Turedi, Suleyman] Karadeniz Tech Univ, Fac Med, Dept Emergency Med, TR-61080 Trabzon, Turkey; [Meric, Emine] Ordu Gen Hosp, Dept Emergency Med, Ordu, Turkey; [Cakir, Ertugrul] Karadeniz Tech Univ, Fac Med, Dept Neurosurg, TR-61080 Trabzon, Turkey; [Yandi, Mustafa] Karadeniz Tech Univ, Fac Med, Dept Gen Surg, TR-61080 Trabzon, Turkey	Turedi, S (corresponding author), Karadeniz Tech Univ, Tip Fak, Farabi Hastanesi, Acil Tip Anabilim Dali, TR-61080 Trabzon, Turkey.		Gunduz, Abdulkadir/AAW-7072-2020	Turedi, Suleyman/0000-0002-6500-3961			BAKAY RA, 1996, NEUROSURGERY, V18, P376; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HECK CN, 1996, EPILEPSY Q, V37, P606; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; KUROIWA T, 1993, SHINKEI GEKA, V21, P1021; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	15	54	63	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	APR	2010	38	3					297	301		10.1016/j.jemermed.2007.11.032			5	Emergency Medicine	Emergency Medicine	581ZI	WOS:000276564200004	18499387				2021-06-18	
J	McIntosh, AS; McCrory, P; Finch, CF; Wolfe, R				McIntosh, A. S.; McCrory, P.; Finch, C. F.; Wolfe, R.			Head, face and neck injury in youth rugby: incidence and risk factors	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PROSPECTIVE COHORT; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; PERFORMANCE PROJECT; FOOTBALL PLAYERS; SPINAL-CORD; UNION; CONCUSSION; SPORTS	Objectives: In this study, the incidence of head, neck and facial injuries in youth rugby was determined, and the associated risk factors were assessed. Design: Data were extracted from a cluster randomised controlled trial of headgear with the football teams as the unit of randomisation. No effect was observed for headgear use on injury rates, and the data were pooled. Setting: General school and club-based community competitive youth rugby in the 2002 and 2003 seasons. Participants: Young male rugby union football players participating in under-13, under 15, under 18 and under 21 years competitions. Eighty-two teams participated in year 1 and 87 in year 2. Main outcome measures: Injury rates for all body regions combined, head, neck and face calculated for game and missed game injuries. Results: 554 head, face and neck injuries were recorded within a total of 28 902 h of rugby game exposure. Level of play and player position were related to injury risk. Younger players had the lowest rates of injury; forwards, especially the front row had the highest rate of neck injury; and inside backs had the highest rate of injuries causing the player to miss a game. Contact events, including the scrum and tackle, were the main events leading to injury. Conclusion: Injury prevention must focus on the tackle and scrum elements of a youth rugby game.	[McIntosh, A. S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Finch, C. F.] Univ Ballarat, Sch Human Movement & Sport Sci, Ballarat, Vic, Australia; [Wolfe, R.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019	Wolfe, Rory/0000-0002-2126-1045; McCrory, Paul/0000-0003-4850-0568	International Rugby Board (IRB); NHMRCNational Health and Medical Research Council of Australia	This project was funded by the International Rugby Board (IRB). CF was funded by an NHMRC Principal Research Fellowship. The investigators were solely responsible for decisions regarding the design and conduct of the study, as well as collection, management, analysis and interpretation of the data. The authors prepared this manuscript, and it was sent to the IRB for approval. All authors and researchers are independent of the International Rugby Board, and the project was conducted independently. Statistical analyses were conducted in part by Dr Rory Wolfe from Monash University. Dr J P Best and Associate Professor D Chalmers were investigators on the randomised controlled trial of headgear. The authors would like to thank the following research assistants on the project: Ms M Romiti, Dr D Twomey, Mr C French and Mr T Savage. Thanks go to Mr John Searl from the Australian Rugby Union who liaised with the ARU and rugby clubs. Many other people contributed to the execution of the project-for example, primary data collectors, club/school personnel, team staff and medical personnel. We gratefully acknowledge their contributions.	Agel J, 2007, J ATHL TRAINING, V42, P270; Agel J, 2007, J ATHL TRAINING, V42, P241; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Browne GJ, 2006, BRIT J SPORT MED, V40, P68, DOI 10.1136/bjsm.2005.020636; Carmody DJ, 2005, MED J AUSTRALIA, V182, P561, DOI 10.5694/j.1326-5377.2005.tb06814.x; Checkoway H., 2004, RES METHODS OCCUPATI; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2007, CLIN J SPORT MED, V17, P10, DOI 10.1097/JSM.0b013e31802e9c28; GARRAWAY M, 1995, LANCET, V345, P1485; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; MCINTOSH AS, 2004, 7 WORLD C INJ PREV S; MCINTOSH AS, 2005, P AUSTR C SCI MED SP; Murray, 1998, DESIGN ANAL GROUP RA; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Quarrie KL, 2002, SPORTS MED, V32, P633, DOI 10.2165/00007256-200232100-00003; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; Sparks J P, 1981, Br J Sports Med, V15, P30	33	54	54	0	36	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	MAR	2010	44	3					188	193		10.1136/bjsm.2007.041400			6	Sport Sciences	Sport Sciences	569IR	WOS:000275590300007	18385188	Bronze			2021-06-18	
J	Itoh, T; Satou, T; Nishida, S; Tsubaki, M; Imano, M; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Nishida, Shozo; Tsubaki, Masahiro; Imano, Motohiro; Hashimoto, Shigeo; Ito, Hiroyuki			Edaravone Protects Against Apoptotic Neuronal Cell Death and Improves Cerebral Function After Traumatic Brain Injury in Rats	NEUROCHEMICAL RESEARCH			English	Article						Edaravone; Traumatic brain injury; Neuroprotection; Apoptosis; Oxidative stress	CENTRAL-NERVOUS-SYSTEM; RADICAL SCAVENGER; OXYGEN RADICALS; ISCHEMIA; ACTIVATION; MCI-186; PATHWAY; DAMAGE; PROLIFERATION; ACCUMULATION	Edaravone is a novel free radical scavenger used clinically in patients with acute cerebral infarction; however, it has not been assessed in traumatic brain injury (TBI). We investigated the effects of edaravone on cerebral function and morphology following TBI. Rats received TBI with a pneumatic controlled injury device. Edaravone (3 mg/kg) or physiological saline was administered intravenously following TBI. Numbers of 8-OHdG-, 4-HNE-, and ssDNA-positive cells around the damaged area after TBI were significantly decreased in the edaravone group compared with the saline group (P < 0.01). There was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the edaravone group compared with the saline group (P < 0.01). Edaravone administration following TBI inhibited free radical-induced neuronal degeneration and apoptotic cell death around the damaged area. In summary, edaravone treatment improved cerebral dysfunction following TBI, suggesting its potential as an effective clinical therapy.	[Itoh, Tatsuki; Satou, Takao; Ito, Hiroyuki] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; [Satou, Takao] Kinki Univ Hosp, Div Hosp Pathol, Sch Med, Osaka, Japan; [Satou, Takao] Kinki Univ, Div Sports Med, Inst Life Sci, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan	Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21500803, 20500472] Funding Source: KAKEN		Arai T, 2008, J PHARMACOL EXP THER, V324, P529, DOI 10.1124/jpet.107.131391; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Elvander E, 2004, NEUROSCIENCE, V126, P541, DOI 10.1016/j.neuroscience.2004.03.058; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Han Ning, 2008, Neurosci Bull, V24, P351, DOI 10.1007/s12264-008-0711-4; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Mizuno A, 1998, GEN PHARMACOL-VASC S, V30, P575, DOI 10.1016/S0306-3623(97)00311-X; NISHI H, 1989, STROKE, V20, P1236, DOI 10.1161/01.STR.20.9.1236; Niyaz M, 2007, J NEUROSCI RES, V85, P2933, DOI 10.1002/jnr.21412; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Takizawa Y, 2009, PEDIATR RES, V65, P636, DOI 10.1203/PDR.0b013e3181a16a9f; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang XY, 2001, BIOL NEONATE, V79, P172; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; Weissman L, 2007, NEUROSCIENCE, V145, P1318, DOI 10.1016/j.neuroscience.2006.08.061; Wen J, 2006, BIOL PHARM BULL, V29, P713, DOI 10.1248/bpb.29.713; Wu T, 2006, BIOL PHARM BULL, V29, P1613, DOI 10.1248/bpb.29.1613; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Yamamoto T, 1997, BRAIN RES, V762, P240, DOI 10.1016/S0006-8993(97)00490-3; Yasuoka N, 2004, DEV BRAIN RES, V151, P129, DOI 10.1016/j.devbrainres.2004.04.006; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06	34	54	59	1	8	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	FEB	2010	35	2					348	355		10.1007/s11064-009-0061-2			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	544UP	WOS:000273685100018	19768539				2021-06-18	
J	Walker, WC; Ketchum, JM; Marwitz, JH; Chen, T; Hammond, F; Sherer, M; Meythaler, J				Walker, W. C.; Ketchum, J. M.; Marwitz, J. H.; Chen, T.; Hammond, F.; Sherer, M.; Meythaler, J.			A multicentre study on the clinical utility of post-traumatic amnesia duration in predicting global outcome after moderate-severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; GALVESTON ORIENTATION; PRACTICAL SCALE; REHABILITATION; LOG	Background: Past research shows that post-traumatic amnesia (PTA) duration is a particularly robust traumatic brain injury (TBI) outcome predictor, but low specificity limits its clinical utility. Objectives: The current study assessed the relationship between PTA duration and probability thresholds for Glasgow Outcome Scale (GOS) levels. Methods: Data were prospectively collected in this multicentre observational study. The cohort was a consecutive sample of rehabilitation patients enrolled in the National Institute on Disability and Rehabilitation Research funded TBI Model Systems (n=1332) that had documented finite PTA duration greater than 24 h, and 1-year and 2-year GOS. Results: The cohort had proportionally more Good Recovery (44% vs 39%) and less Severe Disability (19% vs 23%) at year 2 than at year 1. Longer PTA resulted in an incremental decline in probability of Good Recovery and a corresponding increase in probability of Severe Disability. When PTA ended within 4 weeks, Severe Disability was unlikely (< 15% chance) at year 1, and Good Recovery was the most likely GOS at year 2. When PTA lasted beyond 8 weeks, Good Recovery was highly unlikely (< 10% chance) at year 1, and Severe Disability was equal to or more likely than Moderate Disability at year 2. Conclusions: Two PTA durations, 4 weeks and 8 weeks, emerged as particularly salient GOS probability thresholds that may aid prognostication after TBI.	[Walker, W. C.; Marwitz, J. H.; Chen, T.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, J. M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Hammond, F.] Carolinas Rehabil, Charlotte, NC USA; [Sherer, M.] TIRR Mem Hermann, Houston, TX USA; [Meythaler, J.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980661, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu	Walker, William C/N-3162-2014; Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A070036, H133A070042, H133A070043]	Supported by grants H133A070036 (VCU TBI Model System), H133A070042 (Carolinas TBI Model System), H133A070043 (Texas TBI Model System of TIRR) from the National Institute on Disability and Rehabilitation Research, United States Department of Education.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kothari S., 2006, BRAIN INJURY MED PRI, P529; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	15	54	54	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN 10	2010	81	1					87	89		10.1136/jnnp.2008.161570			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	533WF	WOS:000272855400021	20019222				2021-06-18	
S	Bruce, ML		Barchas, JD; Difede, J		Bruce, Martha L.			Suicide risk and prevention in veteran populations	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	suicide; veterans; military	TRAUMATIC BRAIN-INJURY; VIETNAM VETERANS; INTEGRATED CARE; VA PATIENTS; FOLLOW-UP; PRISM-E; DEPRESSION; MORTALITY; OUTCOMES; PERIODS	Rates of suicide among veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) rose significantly from 2005 to 2007, adding to existing concerns about veteran suicide risk by the Department of Veterans Affairs. This paper summarizes the available data about risk and rates of suicide in veterans, including the choice of appropriate comparison groups and the identification of risk factors. The data suggest that taking into account the selection bias of who enters the military (known as the healthy soldier effect), rates of suicide in veterans are higher than expected, especially among activity duty OEF/OIF veterans and even more so among those who experienced injuries and trauma. Thus, the experiences of war and the downstream sequelae, in particular the individuals' psychological reactions and societal responses, lead to suicide risk. This paper describes the VA's response to these data in developing and implementing suicide prevention interventions.	Weill Cornell Med Coll, Dept Psychiat, Westchester Div, White Plains, NY 10605 USA	Bruce, ML (corresponding author), Weill Cornell Med Coll, Dept Psychiat, Westchester Div, 21 Bloomingdale Rd, White Plains, NY 10605 USA.	mbruce@med.cornell.edu					Blue Ribbon Work Group on Suicide Prevention in the Veteran Population, 2008, REP BLUE RIBB WORK G; Boehmer TKC, 2004, ARCH INTERN MED, V164, P1908, DOI 10.1001/archinte.164.17.1908; Breiding MJ, 2006, INJURY PREV, V12, P49, DOI 10.1136/ip.2006.012591; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Bullman TA, 1996, AM J PUBLIC HEALTH, V86, P662, DOI 10.2105/AJPH.86.5.662; CLIFTON E, 2010, SUICIDE RATE SURGED; Cukor J, 2009, CLIN PSYCHOL REV, V29, P715, DOI 10.1016/j.cpr.2009.09.001; Desai RA, 2008, MIL MED, V173, P721, DOI 10.7205/MILMED.173.8.721; Difede J, 2009, INT REV PSYCHIATR, V21, P559, DOI 10.3109/09540260903344081; Gibbons RD, 2007, AM J PSYCHIAT, V164, P1044, DOI 10.1176/appi.ajp.164.7.1044; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; HEFLING K, 2010, HUFFINGTON POST 0111, P18; Institute of Medicine, 1994, RED RISKS MENT DIS F; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 2009, ANN EPIDEMIOL, V19, P757, DOI 10.1016/j.annepidem.2009.05.004; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Krahn DD, 2006, PSYCHIAT SERV, V57, P946, DOI 10.1176/appi.ps.57.7.946; Matthieu MM, 2009, MIL MED, V174, P1123, DOI 10.7205/MILMED-D-00-1109; Matthieu MM, 2008, ARCH SUICIDE RES, V12, P148, DOI 10.1080/13811110701857491; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McLaughlin R, 2008, ANN EPIDEMIOL, V18, P928, DOI 10.1016/j.annepidem.2008.09.002; Mills PD, 2008, JT COMM J QUAL PATIE, V34, P482, DOI 10.1016/S1553-7250(08)34061-6; National Institute of Mental Health, 2006, SUIC US STAT PREV; Oslin DW, 2006, PSYCHIAT SERV, V57, P954, DOI 10.1176/appi.ps.57.7.954; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pietrzak RH, 2009, PSYCHIAT SERV, V60, P1118, DOI 10.1176/ps.2009.60.8.1118; *US DEP HHS, 2001, NAT STRAT SUIC PREV; *US DEP VET AFF, 2010, SUIC PREV; Valenstein M, 2009, PSYCHIAT SERV, V60, P439, DOI 10.1176/appi.ps.60.4.439; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	32	54	54	0	14	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						98	103		10.1111/j.1749-6632.2010.05697.x			6	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000013	20955331				2021-06-18	
J	Larson, EB; Zollman, FS				Larson, Eric B.; Zollman, Felise S.			The Effect of Sleep Medications on Cognitive Recovery From Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition disorders; hypnotics and sedatives; sleep initiation and maintenance disorders	DOSE-RESPONSE; ZOLPIDEM; TRAZODONE; INSOMNIA; MEMORY; TRIAZOLAM; EFFICACY; DRUGS; IMPAIRMENT; ZOPICLONE	Objective: To summarize the literature on the available pharmacotherapy for insomnia and the adverse cognitive effects of those options in persons with traumatic brain injury (TBI). Design: Ovid/MEDLINE databases were searched by using the following key words: "brain injury," "sleep initiation and maintenance disorders," "hypnotics and sedatives," "benzodiazepines," "trazodone," and "neuronal plasticity." Results: The reviewed literature consistently reported that benzodiazepines and atypical gamma-aminobutyric acid (GABA) agonists result in cognitive impairment when plasma levels are at their peak. Evidence of residual effects on cognition was reported for benzodiazepines but was seen less often in atypical GABA agonists. However, evidence has also been presented that GABA agonists have adverse effects on neuroplasticity, raising concerns about their use in patients recovering from TBI. Conclusions: Use of benzodiazepines in TBI has been discouraged and some authors also advocate caution in prescribingatypical GABA agonists. Alternate treatments including trazodone and a newer class of agents, melatonin agonists, are highlighted, along with the limited data available addressing the use of these medications in TBI. Finally, suggestions are offered for further research, especially on topic related to neural plasticity and functional recovery.	[Larson, Eric B.; Zollman, Felise S.] Rehabil Inst Chicago, Brain Injury Rehabil & Med Program, Chicago, IL 60611 USA; [Larson, Eric B.; Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA	Larson, EB (corresponding author), Rehabil Inst Chicago, Brain Injury Rehabil & Med Program, 345 E Super St, Chicago, IL 60611 USA.	elarson@ric.org	Larson, Eric/AAD-9567-2021; Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	US Department of Education, National Institute on Disability and Rehabilitation ResearchUS Department of Education [HI33N060014]	This study was supported by the US Department of Education, National Institute on Disability and Rehabilitation Research, grant HI33N060014 through the Midwest Regional Traumatic Brain Injury Model System: Innovative Approaches to Improve Cognition, Function, and Community Living. We thank Laura Wasek for her assistance in this project.	ALLEN D, 1993, EUR J CLIN PHARMACOL, V45, P313; Barker MJ, 2005, J INT NEUROPSYCH SOC, V11, P281, DOI 10.1017/S1355617705050332; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; BARRON J, 1985, AM J MENT DEF, V90, P124; BEER B, 1994, J CLIN PHARMACOL, V34, P335, DOI 10.1002/j.1552-4604.1994.tb02002.x; BILLIARD M, 1987, SLEEP, V10, P27, DOI 10.1093/sleep/10.suppl_1.27; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CUNNINGHAM LA, 1994, J CLIN PSYCHOPHARM, V14, P99; CURRAN HV, 1988, PSYCHOPHARMACOLOGY, V95, P520; Danjou P, 1999, BRIT J CLIN PHARMACO, V48, P367; Dujardin K, 1998, PHARMACOPSYCHIATRY, V31, P14, DOI 10.1055/s-2007-979289; Erman M, 2006, SLEEP MED, V7, P17, DOI 10.1016/j.sleep.2005.09.004; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUDGE JL, 1990, J AFFECT DISORDERS, V18, P275, DOI 10.1016/0165-0327(90)90079-N; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; Greenblatt DJ, 2004, CLIN PHARMACOL THER, V76, P467, DOI 10.1016/j.clpt.2004.07.009; Greenblatt DJ, 1998, CLIN PHARMACOL THER, V64, P553, DOI 10.1016/S0009-9236(98)90139-4; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; GREENBLATT DJ, 1993, CLIN PHARMACOKINET, V24, P453, DOI 10.2165/00003088-199324060-00003; Isawa S, 2000, Nihon Shinkei Seishin Yakurigaku Zasshi, V20, P61; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Lenhart SE, 2001, ANN PHARMACOTHER, V35, P1449; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mendelson WB, 2004, SLEEP MED REV, V8, P7, DOI 10.1016/S1087-0792(03)00042-X; Meythaler J. M., 2006, BRAIN INJURY MED PRI, P1023; MONTGOMERY I, 1983, BRIT J CLIN PHARMACO, V16, P139, DOI 10.1111/j.1365-2125.1983.tb04977.x; Mort JR, 2002, CNS DRUGS, V16, P99, DOI 10.2165/00023210-200216020-00003; MOSKOWITZ RW, 1986, SEMIN ARTHRITIS RHEU, V15, P1, DOI 10.1016/S0049-0172(86)80001-4; MOURET J, 1988, PSYCHOPHARMACOLOGY, V95, pS37; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; NIERENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Pompeia S, 2004, PSYCHOPHARMACOLOGY, V174, P327, DOI 10.1007/s00213-003-1760-z; RAKEL RE, 1987, PSYCHOPATHOLOGY, V20, P57, DOI 10.1159/000284524; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rush CR, 1996, J CLIN PSYCHOPHARM, V16, P146, DOI 10.1097/00004714-199604000-00007; Saletu-Zyhlarz GM, 2002, PROG NEURO-PSYCHOPH, V26, P249, DOI 10.1016/S0278-5846(01)00262-7; Saletu-Zyhlarz GM, 2001, NEUROPSYCHOBIOLOGY, V44, P139, DOI 10.1159/000054934; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHARF MB, 1990, J CLIN PSYCHIAT, V51, P13; Seibi J, 2008, SLEEP, V31, P1381; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Stewart SA, 2005, J CLIN PSYCHIAT, V66, P9; TATA PR, 1994, PSYCHOL MED, V24, P203, DOI 10.1017/S0033291700026969; Terzano MG, 2003, DRUG SAFETY, V26, P261, DOI 10.2165/00002018-200326040-00004; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Troy SM, 2000, J CLIN PSYCHOPHARM, V20, P328, DOI 10.1097/00004714-200006000-00007; VANBEMMEL AL, 1992, PSYCHOPHARMACOLOGY, V107, P569, DOI 10.1007/BF02245272; Vermeeren A, 1998, HUM PSYCHOPHARM CLIN, V13, pS98, DOI 10.1002/(SICI)1099-1077(1998110)13:2+<S98::AID-HUP54>3.3.CO;2-T; Verster JC, 2004, CNS DRUG REV, V10, P45; Waldron-Perrine B, 2008, REHABIL PSYCHOL, V53, P426, DOI 10.1037/a0013530; Walsh JK, 1998, HUM PSYCHOPHARM CLIN, V13, P191, DOI 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X; WALSH KW, 1985, UNDERSTANDING BRAIN, P234; Wan H, 2004, EUR J NEUROSCI, V20, P2214, DOI 10.1111/j.1460-9568.2004.03688.x; Wang-Weigand S, 2007, SLEEP, V30, pA244; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 1955, WAIS MANUAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WESENSTEN NJ, 1995, PSYCHOPHARMACOLOGY, V121, P242, DOI 10.1007/BF02245635; WESENSTEN NJ, 1995, EUR J CLIN PHARMACOL, V48, P115; Wiegand MH, 2008, DRUGS, V68, P2411, DOI 10.2165/0003495-200868170-00001; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012	74	54	56	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					61	67		10.1097/HTR.0b013e3181c1d1e1			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800008	20051895				2021-06-18	
J	Claassen, J				Claassen, Jan			How I Treat Patients with EEG Patterns on the Ictal-Interictal Continuum in the Neuro ICU	NEUROCRITICAL CARE			English	Article						Continuous EEG; Ictal-interictal continuum; Intensive care unit; Non-convulsive seizures; Non-convulsive status epilepticus	PARTIAL STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; GENERALIZED STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; DIFFUSION ABNORMALITIES; NONCONVULSIVE SEIZURES; DISCHARGES; ENOLASE	Refractory status epilepticus (RSE) is associated with a high risk of poor outcome and treated by most neurointensivists with continuous intravenous antiepileptic medications (cIV-AEDs). Continuous EEG monitoring has allowed us to unveil a number of epileptiform patterns of less certain significance. These have been labeled ictal to interictal continuum (IIC), many of which are associated with poor outcome. It is unclear to which extent individual patterns are epiphenomena or lead to additional brain injury. The treatment of these patterns is highly controversial and guidelines how to manage them are non existent. In this review of a challenging case, I will discuss a number of approaches to determine the ictal nature of the IIC in an effort to minimize neuronal injury from epileptiform brain activity on the one hand and from the treatment on the other hand. Ultimately it will be most important to replace the dichotomy of ictal versus non-ictal patterns by differentiating between harmful and non-harmful patterns.	[Claassen, Jan] Columbia Univ, Dept Neurol, Div Neurocrit Care, New York, NY 10032 USA; [Claassen, Jan] Columbia Univ, Dept Neurol, Comprehens Epilepsy Ctr, New York, NY 10032 USA	Claassen, J (corresponding author), Columbia Univ, Dept Neurol, Div Neurocrit Care, Milstein Hosp Bldg,177 Ft Washington Ave,Milstein, New York, NY 10032 USA.	jc1439@columbia.edu	Viani, Rafael/V-1196-2018; Claassen, Jan/AAA-5451-2020		National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR024156]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This publication was made possible by Grant Number UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at the NCRR Website. Information on Re-engineering the Clinical Research Enterprise can be obtained from the NIH Roadmap website. I would like to thank Stephan A. Mayer, Lawrence J. Hirsch, and J. Michael Schmidt for their support, guidance, and review of this manuscript.	Assal F, 2001, SEIZURE-EUR J EPILEP, V10, P260, DOI 10.1053/seiz.2000.0506; Bozkurt MF, 2002, CLIN ELECTROENCEPHAL, V33, P171, DOI 10.1177/155005940203300407; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DURING MJ, 1993, LANCET, V341, P1607; Engelhorn T, 2007, NEUROSCI LETT, V417, P275, DOI 10.1016/j.neulet.2007.02.072; Engelhorn T, 2005, AM J NEURORADIOL, V26, P1563; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Fushimi M, 2003, ACTA NEUROL SCAND, V108, P55, DOI 10.1034/j.1600-0404.2003.00084.x; Gerber PA, 2008, J CLIN NEUROPHYSIOL, V25, P241, DOI 10.1097/WNP.0b013e318182ed67; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Katramados AM, 2009, EPILEPSIA, V50, P265, DOI 10.1111/j.1528-1167.2008.01736.x; Kimiwada T, 2006, EPILEPSIA, V47, P167, DOI 10.1111/j.1528-1167.2006.00383.x; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Morales-Villagran A, 2008, J NEUROSCI METH, V168, P48, DOI 10.1016/j.jneumeth.2007.09.005; RABINOWICZ AL, 1995, EPILEPSIA, V36, P475, DOI 10.1111/j.1528-1157.1995.tb00489.x; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Szabo K, 2005, BRAIN, V128, P1369, DOI 10.1093/brain/awh454; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WARACH S, 1994, AM J NEURORADIOL, V15, P965; Waziri A, 2009, ANN NEUROL, V66, P366, DOI 10.1002/ana.21721; WESTMORELAND BF, 1986, ARCH NEUROL-CHICAGO, V43, P494, DOI 10.1001/archneur.1986.00520050066024	36	54	57	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2009	11	3					437	444		10.1007/s12028-009-9295-8			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	521SH	WOS:000271943800023	19851892				2021-06-18	
J	Wang, JA; Lin, W; Morris, T; Banderali, U; Juranka, PF; Morris, CE				Wang, Jun A.; Lin, Wei; Morris, Terence; Banderali, Umberto; Juranka, Peter F.; Morris, Catherine E.			Membrane trauma and Na+ leak from Nav1.6 channels	AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY			English	Article						sodium dye; stretch; shear; bleb	INJURY IN-VITRO; SODIUM-CHANNEL; SKELETAL-MUSCLE; FUNCTIONAL-ANALYSIS; SLOW INACTIVATION; MOLECULAR-CLONING; LIPID RAFTS; HUMAN HEART; VOLTAGE; TETRODOTOXIN	Wang JA, Lin W, Morris T, Banderali U, Juranka PF, Morris CE. Membrane trauma and Na+ leak from Nav1.6 channels. Am J Physiol Cell Physiol 297: C823-C834, 2009. First published August 5, 2009; doi: 10.1152/ajpcell.00505.2008.-During brain trauma, white matter experiences shear and stretch forces that, without severing axons, nevertheless trigger their secondary degeneration. In central nervous system (CNS) trauma models, voltage-gated sodium channel (Nav) blockers are neuroprotective. This, plus the rapid tetrodotoxin-sensitive Ca2+ overload of stretch-traumatized axons, points to "leaky" Nav channels as a pivotal early lesion in brain trauma. Direct effects of mechanical trauma on neuronal Nav channels have not, however, been tested. Here, we monitor immediate responses of recombinant neuronal Nav channels to stretch, using patch-clamp and Na+-dye approaches. Trauma constituted either bleb-inducing aspiration of cell-attached oocyte patches or abrupt uniaxial stretch of cells on an extensible substrate. Nav1.6 channel transient current displayed irreversible hyperpolarizing shifts of steady-state inactivation [availability(V)] and of activation [g(V)] and, thus, of window current. Left shift increased progressively with trauma intensity. For moderately intense patch trauma, a similar to 20-mV hyperpolarizing shift was registered. Nav1.6 voltage sensors evidently see lower energy barriers posttrauma, probably because of the different bilayer mechanics of blebbed versus intact membrane. Na+ dye-loaded human embryonic kidney (HEK) cells stably transfected with alpha Nav1.6 were subjected to traumatic brain injury-like stretch. Cytoplasmic Na+ levels abruptly increased and the trauma-induced influx had a significant tetrodotoxin-sensitive component. Nav1.6 channel responses to cell and membrane trauma are therefore consistent with the hypothesis that mechanically induced Nav channel leak is a primary lesion in traumatic brain injury. Nav1.6 is the CNS node of Ranvier Nav isoform. When, during head trauma, nodes experienced bleb-inducing membrane damage of varying intensities, nodal Nav1.6 channels should immediately "leak" over a broadly left-smeared window current range.	[Wang, Jun A.; Lin, Wei; Morris, Terence; Banderali, Umberto; Juranka, Peter F.; Morris, Catherine E.] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8M5, Canada	Morris, CE (corresponding author), Ottawa Hosp, Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	cmorris@uottawa.ca		Morris, Catherine/0000-0002-7401-6545	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada	This work was supported by a grant to C.E. Morris from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada.	Andersen OS, 2007, ANNU REV BIOPH BIOM, V36, P107, DOI 10.1146/annurev.biophys.36.040306.132643; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Baptiste DC, 2008, EXPERT OPIN EMERG DR, V13, P63, DOI [10.1517/14728214.13.1.63, 10.1517/14728214.13.1.63 ]; Bement WM, 2007, CURR OPIN CELL BIOL, V19, P95, DOI 10.1016/j.ceb.2006.12.001; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BLANCHARD CE, 1985, J NEUROCYTOL, V14, P1053, DOI 10.1007/BF01224812; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Davies A, 2006, J NEUROSCI, V26, P8748, DOI 10.1523/JNEUROSCI.2764-06.2006; Duprat F, 2000, MOL PHARMACOL, V57, P906; Fayaz I, 2000, J NEUROSCI METH, V102, P69, DOI 10.1016/S0165-0270(00)00282-X; FIELDS RD, 1988, BRAIN RES, V443, P231, DOI 10.1016/0006-8993(88)91617-4; FLEIG A, 1994, PFLUG ARCH EUR J PHY, V427, P399, DOI 10.1007/BF00374253; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gottlieb P, 2008, PFLUG ARCH EUR J PHY, V455, P1097, DOI 10.1007/s00424-007-0359-3; Hamill OP, 1997, ANNU REV PHYSIOL, V59, P621, DOI 10.1146/annurev.physiol.59.1.621; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Laitko U, 2004, J GEN PHYSIOL, V123, P135, DOI 10.1085/jgp.200308965; Laitko U, 2006, J GEN PHYSIOL, V127, P687, DOI 10.1085/jgp.200509394; Lundbaek JA, 2004, J GEN PHYSIOL, V123, P599, DOI 10.1085/jgp.200308996; Maguy A, 2006, CARDIOVASC RES, V69, P798, DOI 10.1016/j.cardiores.2005.11.013; MAKITA N, 1994, J BIOL CHEM, V269, P7571; Makita N, 1996, CIRC RES, V78, P244, DOI 10.1161/01.RES.78.2.244; Mantegazza M, 2005, J NEUROSCI, V25, P3341, DOI 10.1523/JNEUROSCI.0104-05.2005; Mathie A, 2007, CURR OPIN INVEST DR, V8, P555; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; Meier SD, 2006, J NEUROSCI METH, V155, P251, DOI 10.1016/j.jneumeth.2006.01.009; Moran O, 2003, NEUROSCI LETT, V336, P175, DOI 10.1016/S0304-3940(02)01284-3; Morris CE, 2007, BIOPHYS J, V93, P822, DOI 10.1529/biophysj.106.101246; Morris CE, 2007, CURR TOP MEMBR, V59, P297, DOI 10.1016/S1063-5823(06)59011-8; Morris Catherine E., 2006, V322, P315; Patra M, 2005, EUR BIOPHYS J BIOPHY, V35, P79, DOI 10.1007/s00249-005-0011-0; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Qin N, 2003, EUR J BIOCHEM, V270, P4762, DOI 10.1046/j.1432-1033.2003.03878.x; Rajagopalan L, 2007, J BIOL CHEM, V282, P36659, DOI 10.1074/jbc.M705078200; Rosenberg LJ, 2005, GLIA, V49, P107, DOI 10.1002/glia.20096; Schmidt D, 2008, P NATL ACAD SCI USA, V105, P19276, DOI 10.1073/pnas.0810187105; Shcherbatko A, 1999, BIOPHYS J, V77, P1945, DOI 10.1016/S0006-3495(99)77036-0; Sheetz MP, 2006, ANNU REV BIOPH BIOM, V35, P417, DOI 10.1146/annurev.biophys.35.040405.102017; Shirahata E, 2006, J NEUROPHYSIOL, V96, P1347, DOI 10.1152/jn.01264.2005; SMALL DL, 1994, AM J PHYSIOL, V267, pC598; Smith MR, 1998, J NEUROSCI, V18, P6093; Stadnicka A, 1999, ANESTHESIOLOGY, V90, P1671, DOI 10.1097/00000542-199906000-00024; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Swartz KJ, 2008, NATURE, V456, P891, DOI 10.1038/nature07620; Tabarean IV, 1999, BIOPHYS J, V77, P758, DOI 10.1016/S0006-3495(99)76930-4; Teng YD, 1997, J NEUROSCI, V17, P4359; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Villalba-Galea CA, 2008, P NATL ACAD SCI USA, V105, P17600, DOI 10.1073/pnas.0807387105; WAN X, 1995, J MEMBRANE BIOL, V145, P21; Wan XD, 1999, AM J PHYSIOL-CELL PH, V276, pC318; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Welch NC, 2008, NEUROPHARMACOLOGY, V55, P1165, DOI 10.1016/j.neuropharm.2008.07.015; Wiggins P, 2005, BIOPHYS J, V88, P880, DOI 10.1529/biophysj.104.047431; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiao YF, 2006, AM J PHYSIOL-CELL PH, V290, pC362, DOI 10.1152/ajpcell.00296.2005; Yu FH, 2005, PHARMACOL REV, V57, P387, DOI 10.1124/pr.57.4.13; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P117, DOI 10.1111/j.1469-7793.2000.t01-1-00117.x	65	54	54	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6143	1522-1563		AM J PHYSIOL-CELL PH	Am. J. Physiol.-Cell Physiol.	OCT	2009	297	4					C823	C834		10.1152/ajpcell.00505.2008			12	Cell Biology; Physiology	Cell Biology; Physiology	501KY	WOS:000270381900005	19657055	Green Published			2021-06-18	
J	Tisdall, MM; Taylor, C; Tachtsidis, I; Leung, TS; Elwell, CE; Smith, M				Tisdall, Martin M.; Taylor, Christopher; Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin			The Effect on Cerebral Tissue Oxygenation Index of Changes in the Concentrations of Inspired Oxygen and End-Tidal Carbon Dioxide in Healthy Adult Volunteers	ANESTHESIA AND ANALGESIA			English	Article							NEAR-INFRARED SPECTROSCOPY; JUGULAR VENOUS OXIMETRY; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; OPTICAL PATHLENGTH; BLOOD-VOLUME; NIRO 300; ARTERIAL; THRESHOLDS; SATURATION	BACKGROUND: A variety of near-infrared spectroscopy devices can be used to make noninvasive measurements of cerebral tissue oxygen saturation (ScO2). The ScO2 measured by the NIRO 300 spectrometer (Hamamatsu Photonics, Japan) is called the cerebral tissue oxygenation index (TOI) and is an assessment of the balance between cerebral oxygen delivery and utilization. We designed this study to investigate the effect of systemic and intracranial physiological changes on TOI. METHODS: Fifteen healthy volunteers were studied during isocapneic hyperoxia and hypoxemia, and normoxic hypercapnea and hypocapnea. Absolute cerebral TOI and changes in oxy- and deoxyhemoglobin concentrations were measured using a a NIRO 300 spectrometer. Changes in arterial oxygen saturation (Sao(2)), ETco(2), heart rate, mean arterial blood pressure (MBP), and middle cerebral artery blood flow velocity (V-mca) were also measured during these physiological challenges. Changes in cerebral blood volume (CBV) were subsequently calculated from changes in total cerebral hemoglobin concentration. RESULTS: Baseline TOI was 67.3% with an interquartile range (IQR) of 65.2%-71.9%. Hypoxemia was associated with a median decrease in TOI of 7.1% (IQR -9.1% to -5.4'%) from baseline (P < 0.0001) and hyperoxia with a median increase of 2.3% (IQR 2.0%-2.5%) (P < 0.0001). Hypocapnea caused a reduction in TOI of 2.1% (IQR -3.3%, to -1.3%) from baseline (P < 0.0001) and hypercapnea an increase of 2.6% (IQR 1.40/-3.7%) (P < 0.0001). Changes in Sao(2) (P < 0.0001), ETco(2) (P < 0.0001), CBV (P = 0.0003), and MBP (P = 0.03) were significant variables affecting TOI. Changes in V-mca (P = 0.7) and heart rate (P = 0.2) were not significant factors. CONCLUSION: TOI is an easy-to-monitor variable that provides real-time, multisite, and noninvasive assessment of the balance between cerebral oxygen delivery and utilization. However, TOI is a complex variable that is affected by Sao(2) and ETco(2), and, to a lesser extent, by MBP and CBV. Clinicians need to be aware of the systemic and cerebral physiological changes that can affect TOI to interpret changes in this variable during clinical monitoring. (Anesth Analg 2009:109:906-13)	[Tisdall, Martin M.; Taylor, Christopher; Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, London WC1N 3BG, England; [Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin] UCL, Dept Med Phys & Bioengn, London, England	Smith, M (corresponding author), Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, Box 30,Queen Sq, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Smith, Martin/B-2616-2009; Tachtsidis, Ilias/N-2747-2018	Tachtsidis, Ilias/0000-0002-8125-0313; Tisdall, Martin/0000-0001-8880-8386; Elwell, Clare/0000-0002-7281-7234	Wellcome TrustWellcome TrustEuropean Commission [075608]; Engineering Physical Science Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [GR/N14248/01]; Hamamatsu Photonics; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR); Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/G005036/1, GR/N14248/01] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish	Supported by the Wellcome Trust (Grant no. 075608) (to MT), the Engineering Physical Science Research Council (Grant no. GR/N14248/01) (to IT), and Hamamatsu Photonics, KK (to TL). This work was undertaken at University College London Hospitals and partially funded by the Department of Health's NIHR Biomedical Research Centres funding scheme. The work was also made possible in part by a donation in memory of Karolyn Margaret Jones.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; An HY, 2002, MAGNET RESON MED, V48, P583, DOI 10.1002/mrm.10257; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; Dash RK, 2004, ANN BIOMED ENG, V32, P1676, DOI 10.1007/s10439-004-7821-6; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; GREENBERG JH, 1978, CIRC RES, V43, P324, DOI 10.1161/01.RES.43.2.324; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 1997, ANESTH ANALG, V85, P817, DOI 10.1097/00000539-199710000-00018; HARE G, 2007, CAN J ANAESTH, V50, P1061; Ito H, 2005, J CEREBR BLOOD F MET, V25, P852, DOI 10.1038/sj.jcbfm.9600076; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Okada E, 2003, APPL OPTICS, V42, P2915, DOI 10.1364/AO.42.002915; Owen-Reece H, 1999, BRIT J ANAESTH, V82, P418, DOI 10.1093/bja/82.3.418; Quaresima V, 2000, J BIOMED OPT, V5, P201, DOI 10.1117/1.429987; Rasmussen P, 2007, J CEREBR BLOOD F MET, V27, P1082, DOI 10.1038/sj.jcbfm.9600416; Schell RM, 2000, ANESTH ANALG, V90, P559, DOI 10.1097/00000539-200003000-00012; Siegel S., 1988, NONPARAMETRIC STAT B; Smith M, 2008, NEUROSURG CLIN N AM, V19, P489, DOI 10.1016/j.nec.2008.07.008; Sorensen LC, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2357730; Suzuki S, 1999, P SOC PHOTO-OPT INS, V3597, P582, DOI 10.1117/12.356862; Tachtsidis I, 2008, ADV EXP MED BIOL, V614, P389, DOI 10.1007/978-0-387-74911-2_43; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; WHITESELL R, 1981, ANESTH ANALG, V60, P508	31	54	55	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2009	109	3					906	913		10.1213/ane.0b013e3181aedcdc			8	Anesthesiology	Anesthesiology	488EB	WOS:000269330800035	19690266	Green Accepted			2021-06-18	
J	Park, S; Ahn, J; Gee, AO; Kuntz, AF; Esterhai, JL				Park, SangDo; Ahn, Jaimo; Gee, Albert O.; Kuntz, Andrew F.; Esterhai, John L.			Compartment Syndrome in Tibial Fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						compartment syndrome; tibial fractures; risk factors; age; tibia; fasciotomy	RISK; SKIN; AGE	Objectives: Compartment syndrome is a devastating complication of tibial fractures. The purpose of this study was to investigate the rate of clinically determined compartment syndrome requiring surgical intervention in tibial fractures by anatomical region and to identify the associated patient and injury factors. Design: Retrospective cohort. Setting: University level I trauma center. Patients/Participants: Acute tibial fractures in 414 patients from January 1, 2004 through October 31, 2006. Methods: Tibial fractures in 414 patients met the inclusion and exclusion criteria. The fractures were classified into 3 groups (proximal, diaphyseal, and distal) based on the anatomic location of the fractures (AO/OTA fractures 41, 42, and 43, respectively). To determine the patient and injury factors associated with the development of compartment syndrome in tibia] fractures, the following data were obtained: patient age and sex, mechanism of injury, presence of associated fractures, presence of concomitant head/chest/abdominal/pelvic injury, blood pressure upon admission, open versus closed fracture (Gustilo-Anderson classification if open), status of the fibula, and AO/OTA classification of the tibial fracture. Main Outcome Measures: Rate of clinically determined compartment syndrome requiring fasciotomy by anatomical region of the tibia. Results: The rate of compartment syndrome was highest in the diaphyseal group (8.1 %, P < 0.05) followed by proximal (1.6%) and distal (1.4%) groups. The diaphyseal group was further analyzed according to patient and injury factors. Patients who developed compartment syndrome were significantly younger (27.5 years +/- 11.7 SD versus 39.0 years +/- 16.7 SD, P = 0.003, Student t test) than those who did not develop compartment syndrome. The mean arterial pressures upon admission of the patients who developed compartment syndrome were also found to be slightly higher (107 versus 98.5 mm Hg, P = 0.039, Student t test) but not significantly so after Bonferrom adjustment. In multivariate regression analysis, decreasing age remained the only statistically significant independent predictor for the development of compartment syndrome (P = 0.006, regression coefficient = -0.0589) in diaphyseal tibial fractures. Conclusions: Tibial fractures of the diaphysis are more frequently associated with development of compartment syndrome than proximal or distal tibial fractures. More specifically, young patients with diaphyseal fractures are at risk for developing this complication and warrant increased vigilance and suspicion for compartment syndrome. A prospective study with sufficient power is needed to further identify risk factors associated with compartment syndrome in tibial fractures.	[Park, SangDo; Ahn, Jaimo; Gee, Albert O.; Kuntz, Andrew F.; Esterhai, John L.] Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	Park, S (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein Paavil,3400 Spruce St, Philadelphia, PA 19104 USA.	sangdo.park@uphs.upenn.edu		Kuntz, Andrew/0000-0003-3053-5500			Barei DP, 2004, J ORTHOP TRAUMA, V18, P649, DOI 10.1097/00005131-200411000-00001; BLICK SS, 1986, J BONE JOINT SURG AM, V68A, P1348, DOI 10.2106/00004623-198668090-00007; BOURNE RB, 1989, CLIN ORTHOP RELAT R, P97; DELEE JC, 1981, CLIN ORTHOP RELAT R, P175; Egol KA, 2005, J ORTHOP TRAUMA, V19, P448, DOI 10.1097/01.bot.0000171881.11205.80; HALPERN AA, 1980, J TRAUMA, V20, P786, DOI 10.1097/00005373-198009000-00013; LEVY AS, 1994, J ORTHOP TRAUMA, V8, P154, DOI 10.1097/00005131-199404000-00013; LOVELL CR, 1987, BRIT J DERMATOL, V117, P419, DOI 10.1111/j.1365-2133.1987.tb04921.x; McQueen MM, 1996, J BONE JOINT SURG BR, V78B, P95; McQueen MM, 2000, J BONE JOINT SURG BR, V82B, P200, DOI 10.1302/0301-620X.82B2 .9799; Torp S, 1975, STRUCTURE FIBROUS BI, V26, P197; TURNIPSEED WD, 1995, J VASC SURG, V21, P810, DOI 10.1016/S0741-5214(05)80012-6; Varani J, 2006, AM J PATHOL, V168, P1861, DOI 10.2353/ajpath.2006.051302; Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P	14	54	55	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	AUG	2009	23	7					514	518		10.1097/BOT.0b013e3181a2815a			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	477TV	WOS:000268542700005	19633461				2021-06-18	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, Armin; Pech, Katrin; Kakulas, Byron A.; Martin, Didier; Schoenen, Jean; Noth, Johannes; Brook, Gary A.			NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury	BMC NEUROLOGY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; CELL-ADHESION MOLECULES; PROTEIN-TYROSINE-PHOSPHATASE; PDGF ALPHA-RECEPTOR; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; NEURITE OUTGROWTH; CNS INJURY; GLIAL SCAR; RAT-BRAIN	Background: A major class of axon growth-repulsive molecules associated with CNS scar tissue is the family of chondroitin sulphate proteoglycans (CSPGs). Experimental spinal cord injury (SCI) has demonstrated rapid re-expression of CSPGs at and around the lesion site. The pharmacological digestion of CSPGs in such lesion models results in substantially enhanced axonal regeneration and a significant functional recovery. The potential therapeutic relevance of interfering with CSPG expression or function following experimental injuries seems clear, however, the spatio-temporal pattern of expression of individual members of the CSPG family following human spinal cord injury is only poorly defined. In the present correlative investigation, the expression pattern of CSPG family members NG2, neurocan, versican and phosphacan was studied in the human spinal cord. Methods: An immunohistochemical investigation in post mortem samples of control and lesioned human spinal cords was performed. All patients with traumatic SCI had been clinically diagnosed as having "complete" injuries and presented lesions of the maceration type. Results: In sections from control spinal cord, NG2 immunoreactivity was restricted to stellate-shaped cells corresponding to oligodendrocyte precursor cells. The distribution patterns of phosphacan, neurocan and versican in control human spinal cord parenchyma were similar, with a fine reticular pattern being observed in white matter (but also located in gray matter for phosphacan). Neurocan staining was also associated with blood vessel walls. Furthermore, phosphacan, neurocan and versican were present in the myelin sheaths of ventral and dorsal nerve roots axons. After human SCI, NG2 and phosphacan were both detected in the evolving astroglial scar. Neurocan and versican were detected exclusively in the lesion epicentre, being associated with infiltrating Schwann cells in the myelin sheaths of invading peripheral nerve fibres from lesioned dorsal roots. Conclusion: NG2 and phosphacan were both present in the evolving astroglial scar and, therefore, might play an important role in the blockade of successful CNS regeneration. Neurocan and versican, however, were located at the lesion epicentre, associated with Schwann cell myelin on regenerating peripheral nerve fibres, a distribution that was unlikely to contribute to failed CNS axon regeneration. The present data points to the importance of such correlative investigations for demonstrating the clinical relevance of experimental data.	[Buss, Armin; Pech, Katrin; Noth, Johannes] Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neurol, Aachen, Germany; [Kakulas, Byron A.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; [Martin, Didier] Univ Liege, Sart Tilman Hosp, Dept Neurosurg, B-4000 Liege, Belgium; [Schoenen, Jean] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Schoenen, Jean] Univ Liege, Dept Neuroanat, B-4000 Liege, Belgium; [Brook, Gary A.] Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neuropathol, Aachen, Germany	Buss, A (corresponding author), Univ Aachen, Sch Med, Rhein Westfal TH Aachen, Dept Neurol, Pauwelsstr 30, Aachen, Germany.	arminbuss@hotmail.com; pech13@gmx.de; bkakulas@cyllene.uwa.edu.au; didier.martin@chu.ulg.ac.be; jschoenen@ulg.ac.be; jnoth@ukaachen.de; gbrook@ukaachen.de	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; MARTIN, Didier/0000-0001-7325-4958	Deutsche Stiftung Querschnittsl hmung (DSQ)	The authors thank S. Lecouturier for excellent technical assistance and Prof. B. Stallcup for technical discussion. This work was supported by a grant from the Deutsche Stiftung Querschnittsl hmung (DSQ).	Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brook GA, 1998, J NEUROSCI RES, V53, P51, DOI 10.1002/(SICI)1097-4547(19980701)53:1<51::AID-JNR6>3.0.CO;2-I; Bruce JH, 2000, J NEUROTRAUM, V17, P781, DOI 10.1089/neu.2000.17.781; Buss A, 2008, SPINAL CORD, V46, P364, DOI 10.1038/sj.sc.3102148; Buss A, 2007, BRAIN, V130, P940, DOI 10.1093/brain/awl374; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Condic ML, 2002, NEUROREPORT, V13, pA37, DOI 10.1097/00001756-200203040-00002; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Garwood J, 1999, J NEUROSCI, V19, P3888; Grimpe B, 2002, PROG BRAIN RES, V137, P333; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Maeda N, 1996, DEVELOPMENT, V122, P647; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; McKeon RJ, 1999, J NEUROSCI, V19, P10778; McTigue DM, 2006, J NEUROPATH EXP NEUR, V65, P406, DOI 10.1097/01.jnen.0000218447.32320.52; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILLER B, 1995, J COMP NEUROL, V355, P615, DOI 10.1002/cne.903550410; Moon LDF, 2002, NEUROSCIENCE, V109, P101, DOI 10.1016/S0306-4522(01)00457-2; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Pearlman A L, 1996, Prog Brain Res, V108, P117; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Schwab ME, 1996, PHYSIOL REV, V76, P319; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tan AM, 2006, J NEUROSCI, V26, P4729, DOI 10.1523/JNEUROSCI.3900-05.2006; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690	37	54	59	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JUL 15	2009	9								32	10.1186/1471-2377-9-32			15	Clinical Neurology	Neurosciences & Neurology	491DH	WOS:000269557100001	19604403	DOAJ Gold, Green Published			2021-06-18	
J	Huska, D; Hubalek, J; Adam, V; Vajtr, D; Horna, A; Trnkova, L; Havel, L; Kizek, R				Huska, Dalibor; Hubalek, Jaromir; Adam, Vojtech; Vajtr, David; Horna, Ales; Trnkova, Libuse; Havel, Ladislav; Kizek, Rene			Automated nucleic acids isolation using paramagnetic microparticles coupled with electrochemical detection	TALANTA			English	Article						mRNA; Isolation; Magnetic particle and bead; Cyclic voltammetry; Square wave voltammetry; Brain tissue; Maize plants; Cadmium	TRAUMATIC BRAIN-INJURY; ELIMINATION VOLTAMMETRY; MAGNETIC PARTICLES; DNA HYBRIDIZATION; OSZILLOGRAPHISCHE POLAROGRAPHIE; CARBON ELECTRODES; GENOMIC DNA; NANOPARTICLES; EXTRACTION; OLIGONUCLEOTIDES	Easy, efficient and low demanding separation of mRNA from biological material is needed to study gene expression and to use in chip technologies. It is common knowledge that each mRNA molecule contains sequence of 25 adenines. This feature can be used for binding mRNA on the surface of the particles coated by thymine chains. The present work reports on suggesting and optimizing of mRNA separation and detection from biological material via paramagnetic microparticles coupled with electrochemical detection. Primarily we optimized cyclic and square wave voltammetric conditions to detect poly(A),which was used as standard to mimic behaviour of mRNA. Under the optimized square wave voltammetric conditions (frequency 280 Hz, accumulation time 200 s, supporting electrolyte and its temperature: acetate buffer 4.6 and 35 degrees C) we estimated detection limit down to 1 ng of poly(A) per ml. To enhance effectiveness and repeatability of isolation of nucleic acid automated approach for rinsing and hybridizing was proposed. We optimized the whole procedure and experimental conditions. Using automated way of isolation and under optimized conditions the yield of poly(A) (isolated concentration of poly(A)/given concentration of poly(A)*100) was approximately 75%. The suggested and optimized method for poly(A) isolation and detection was utilized for the analysis of brain tissues of patients with traumatic brain injury. The total amount of isolated mRNA varied from 40 to 760 g of mRNA per g of brain tissue. The isolation of mRNA from six samples per run was not longer than 2.5 h. Moreover, we applied the optimized procedure on fully automated pipetting instrument to isolate mRNA. The instrument was successfully tested on the analysis of extracts from roots of maize plants treated with cadmium(II) ions. (C) 2009 Elsevier B.V. All rights reserved.	[Huska, Dalibor; Adam, Vojtech; Kizek, Rene] Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, CZ-61300 Brno, Czech Republic; [Huska, Dalibor; Havel, Ladislav] Mendel Univ Agr & Forestry Brno, Dept Plant Biol, CZ-61300 Brno, Czech Republic; [Hubalek, Jaromir] Brno Univ Technol, Fac Elect Engn & Commun, Dept Microelect, CZ-60200 Brno, Czech Republic; [Adam, Vojtech] Mendel Univ Agr & Forestry Brno, Fac Agron, Dept Anim Nutr & Forage Prod, CZ-61300 Brno, Czech Republic; [Vajtr, David] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, CZ-15006 Prague 5, Czech Republic; [Horna, Ales] Tomas Bata Univ, Fac Technol, CZ-76272 Zlin, Czech Republic; [Trnkova, Libuse] Masaryk Univ, Fac Sci, Dept Chem, CZ-61137 Brno, Czech Republic	Kizek, R (corresponding author), Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Zemedelska 1, CZ-61300 Brno, Czech Republic.	kizek@sci.muni.cz	Huska, Dalibor/M-8285-2019; Adam, Vojtech/D-7686-2012; Huska, Dalibor/J-9493-2018; Horna, Ales/H-6388-2012; Kizek, Rene/D-7748-2012; Hubalek, Jaromir/D-7753-2012; Havel, Ladislav/C-8954-2012	Huska, Dalibor/0000-0003-3852-8751; Adam, Vojtech/0000-0002-8527-286X; Hubalek, Jaromir/0000-0002-7496-2558; Kizek, Rene/0000-0002-0467-6169; Havel, Ladislav/0000-0003-3378-2785	GACRGrant Agency of the Czech Republic [102/08/1546, KAN208130801]	Financial support from the grant GACR 102/08/1546 and KAN208130801 is highly acknowledged.	Abreu FC, 2002, BIOSENS BIOELECTRON, V17, P913, DOI 10.1016/S0956-5663(02)00082-9; Archer MJ, 2006, ANAL BIOCHEM, V355, P285, DOI 10.1016/j.ab.2006.05.005; Becker C, 2007, J MAGN MAGN MATER, V311, P234, DOI 10.1016/j.jmmm.2006.11.203; Brett AMO, 2003, ELECTROCHEM COMMUN, V5, P178, DOI 10.1016/S1388-2481(03)00014-6; Cao ZJ, 2006, ANAL CHIM ACTA, V557, P152, DOI 10.1016/j.aca.2005.10.048; Cler L, 2006, MOL CELL PROBE, V20, P191, DOI 10.1016/j.mcp.2005.12.003; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Diculescu VC, 2005, SENSORS-BASEL, V5, P377, DOI 10.3390/s5060377; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Fojta M, 2003, ELECTROANAL, V15, P431, DOI 10.1002/elan.200390050; Fojta M, 2002, TALANTA, V56, P867, DOI 10.1016/S0039-9140(01)00660-9; Gijs MAM, 2004, MICROFLUID NANOFLUID, V1, P22, DOI 10.1007/s10404-004-0010-y; Heer R, 2007, J MAGN MAGN MATER, V311, P244, DOI 10.1016/j.jmmm.2006.10.1154; Hsing IM, 2007, ELECTROANAL, V19, P755, DOI 10.1002/elan.200603785; Jaffrezic-Renault N, 2007, SENSORS-BASEL, V7, P589, DOI 10.3390/s7040589; Ki JS, 2007, J BIOSCI BIOENG, V103, P242, DOI 10.1263/jbb.103.242; Kinoshita T, 2007, J MAGN MAGN MATER, V311, P255, DOI 10.1016/j.jmmm.2006.10.1161; Kizek R, 2002, BIOELECTROCHEMISTRY, V55, P119, DOI 10.1016/S1567-5394(01)00139-6; Korbut O, 2003, SENSORS-BASEL, V3, P1, DOI 10.3390/s30100001; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; Lagae L, 2005, IEE P-CIRC DEV SYST, V152, P393, DOI 10.1049/ip-cds:20050022; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; Lund-Olesen T, 2007, J MAGN MAGN MATER, V311, P396, DOI 10.1016/j.jmmm.2006.10.1171; Lunov O, 2007, J MAGN MAGN MATER, V311, P162, DOI 10.1016/j.jmmm.2006.10.1172; Matsunaga T, 1996, ANAL CHEM, V68, P3551, DOI 10.1021/ac9603690; Mikelova R, 2007, ELECTROANAL, V19, P348, DOI 10.1002/elan.200603739; Minc N, 2004, ANAL CHEM, V76, P3770, DOI 10.1021/ac035246b; Mykhaylyk O, 2007, J MAGN MAGN MATER, V311, P275, DOI 10.1016/j.jmmm.2006.10.1178; Ngomsik AF, 2005, CR CHIM, V8, P963, DOI 10.1016/j.crci.2005.01.001; Nikitin PI, 2007, J MAGN MAGN MATER, V311, P445, DOI 10.1016/j.jmmm.2006.10.1180; PALECEK E, 1958, NATURWISSENSCHAFTEN, V45, P186, DOI 10.1007/BF00621332; Palecek E, 2002, TALANTA, V56, P919, DOI 10.1016/S0039-9140(01)00666-X; Palecek E, 2002, ANAL CHIM ACTA, V469, P73, DOI 10.1016/S0003-2670(01)01605-1; PALECEK E, 1960, BIOCHEMISTRY-MOSCOW+, V25, P619; PALECEK E, 1960, COLLECT CZECH CHEM C, V25, P2283; Palecek E, 2007, TALANTA, V74, P276, DOI 10.1016/j.talanta.2007.08.020; Pichl L, 2005, TRANSFUSION, V45, P1106, DOI 10.1111/j.1537-2995.2005.04356.x; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Revyakin A, 2005, NAT METHODS, V2, P127, DOI 10.1038/nmeth0205-127; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Tomschik M, 1999, J ELECTROANAL CHEM, V476, P71, DOI 10.1016/S0022-0728(99)00369-1; Trnkova L, 2006, ELECTROANAL, V18, P662, DOI 10.1002/elan.200503447; Trnkova L, 2005, SENSORS-BASEL, V5, P448, DOI 10.3390/s5060448; Trnkova L, 2004, BIOELECTROCHEMISTRY, V63, P25, DOI 10.1016/j.bioelechem.2003.09.012; Trnkova L, 2000, ELECTROANAL, V12, P905, DOI 10.1002/1521-4109(200008)12:12<905::AID-ELAN905>3.0.CO;2-R; Trnkova L, 2002, BIOELECTROCHEMISTRY, V55, P131, DOI 10.1016/S1567-5394(01)00145-1; Vajtr D, 2007, CESK SLOV NEUROL N, V70, P515; Wang J, 2001, ANALYST, V126, P2020, DOI 10.1039/b106343j; Xu CJ, 2007, POLYM INT, V56, P821, DOI 10.1002/pi.2251; Yeung SW, 2006, BIOSENS BIOELECTRON, V21, P989, DOI 10.1016/j.bios.2005.03.008; Yu CH, 2007, J PHYS CHEM C, V111, P7879, DOI 10.1021/jp071289a	51	54	56	1	42	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	JUL 15	2009	79	2					402	411		10.1016/j.talanta.2009.04.007			10	Chemistry, Analytical	Chemistry	473OK	WOS:000268216900046	19559897				2021-06-18	
J	Prins, ML; Hovda, DA				Prins, Mayumi L.; Hovda, David A.			The Effects of Age and Ketogenic Diet on Local Cerebral Metabolic Rates of Glucose after Controlled Cortical Impact Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						age; metabolism; pediatric brain injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; EMISSION-TOMOGRAPHY; FLUID PERCUSSION; LUMPED CONSTANT; ADULT RATS; CONTUSION; HYPERGLYCEMIA; MICRODIALYSIS	Previous studies from our laboratory have shown the neuroprotective potential of ketones after TBI in the juvenile brain. It is our premise that acutely after TBI, glucose may not be the optimum fuel and decreasing metabolism of glucose in the presence of an alternative substrate will improve cellular metabolism and recovery. The current study addresses whether TBI will induce age-related differences in the cerebral metabolic rates for glucose (CMRglc) after cortical controlled impact (CCI) and whether ketone metabolism will further decrease CMRglc after injury. Postnatal day 35 (PND35; n-48) and PND70 (n-42) rats were given either sham or CCI injury and placed on either a standard or a ketogenic (KG) diet. CMRglc studies using C-14-2deoxy-d-glucose autoradiography were conducted on days 1, 3, or 7 post-injury. PND35 and PND70 standard-fed CCI-injured rats exhibited no significant neocortical differences in CMRglc magnitude or time course compared to controls. Measurement of contusion volume also indicated no age differences in response to TBI. However, PND35 subcortical structures showed earlier metabolic recovery compared to controls than PND70. Ketosis induced by the KG diet was shown to affect CMRglc in an age-dependent manner after TBI. The presence of ketones after injury further reduced CMRglc in PND35 and normalized CMRglc in PND70 rats at 7 days bilaterally after injury. The changes in CMRglc seen in PND35 TBI rats on the KG diet were associated with decreased contusion volume. These results suggest that conditions of reduced glucose utilization and increased alternative substrate metabolism may be preferable acutely after TBI in the younger rat.	[Prins, Mayumi L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Prins, ML (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Semel Room 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	 [NS052406];  [NS27544];  [NS37363]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037363, R01NS027544, R01NS052406] Funding Source: NIH RePORTER	This work was supported by NS052406, NS27544, and NS37363.	Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; AlMudallal AS, 1995, NEUROLOGY, V45, P2261, DOI 10.1212/WNL.45.12.2261; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartolucci EJ, 2007, IEEE IND APPL MAG, V13, P24, DOI 10.1109/MIA.2007.322272; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; CHEREL Y, 1988, METABOLISM, V37, P1033, DOI 10.1016/0026-0495(88)90063-7; Cherian L, 2004, J NEUROTRAUM, V21, P1196; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; CORDDRY DH, 1982, J NEUROCHEM, V38, P1637, DOI 10.1111/j.1471-4159.1982.tb06644.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; FEISE G, 1977, BRAIN RES, V126, P263, DOI 10.1016/0006-8993(77)90725-9; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1999, CRIT CARE MED, V27, P2063; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HIRT D, 2007, BRAIN B, V51; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jablonka J, 2006, ACTA NEUROBIOL EXP, V66, P261; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; MILLER AL, 1986, METAB BRAIN DIS, V1, P53, DOI 10.1007/BF00998477; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NEHLIG A, 1988, J NEUROSCI, V8, P2321; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Randle P J, 1966, Recent Prog Horm Res, V22, P1; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SCHUIER F, 1990, J CEREBR BLOOD F MET, V10, P765, DOI 10.1038/jcbfm.1990.134; Scremin OU, 2007, BRAIN RES, V1141, P235, DOI 10.1016/j.brainres.2007.01.006; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TAKEI H, 1986, J NEUROCHEM, V46, P931, DOI 10.1111/j.1471-4159.1986.tb13059.x; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VESPA P, 2006, CRIT CARE MED, V34, P400; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812	51	54	54	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1083	1093		10.1089/neu.2008.0769			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500014	19226210	Green Published			2021-06-18	
J	Kocsis, JD; Tessler, A				Kocsis, Jeffery D.; Tessler, Alan			Pathology of blast-related brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						barotrauma; blast injury; blast overpressure; blast-related; brain injury; blast underpressure; central nervous system; closed head injury; improvised explosive devices; neuropathology; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; INDUCED NEUROTRAUMA; INVOLVEMENT	Blasts are responsible for about two-thirds of the combat injuries in Operation Iraqi Freedom and Operation Enduring Freedom, which include at least 1,200 traumatic brain injuries. Blasts inflict damage to the brain directly and by causing injuries to other organs, resulting in air emboli, hypoxia, and shock. Direct injuries to the brain result from rapid shifts in air pressure (primary blast injury), from impacts with munitions fragments and other objects propelled by the explosion (secondary blast injury), and from collisions with objects and rapid acceleration of individuals propelled by the explosion (tertiary blast injury). Tertiary injury can occur from a building or other structure collapsing and from an individual being thrown by the blast wind. The pathological consequences of secondary and tertiary blast injuries are very likely to be similar to those of other types of mechanical trauma seen in civilian life. The damage attributable to the specific effects of a blast, however, has received little study, although it has been assumed to include the focal and diffuse lesions characteristic of closed head injuries. Available clinical studies of blast injuries show focal damage similar to that found in other types of closed head injuries but have not determined whether diffuse axonal injury also occurs. In this article, we will try to reach a better understanding of the specific pathology of blast-related brain injury by reviewing the available experimental studies and the autopsy reports of victims of terrorist attacks and military casualties dating back to World War I.	[Kocsis, Jeffery D.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Kocsis, Jeffery D.] Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA; [Kocsis, Jeffery D.] Dept Vet Affairs VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT USA; [Tessler, Alan] Philadelphia VA Med Ctr, Dept Neurol, Philadelphia, PA USA	Kocsis, JD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr 127A, VA CT Healthcare Syst, West Haven, CT 06516 USA.	jeffery.kocsis@yale.edu			Department of Veterans AffairsUS Department of Veterans Affairs	This material was supported by the Department of Veterans Affairs.	Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; COHEN H, 1946, ARCH PATHOL, V42, P12; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Guy R J, 2000, J R Nav Med Serv, V86, P27; HIRSCH AE, 1972, J NEUROSURG, V37, P95, DOI 10.3171/jns.1972.37.1.0095; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Macleod AD, 2004, J ROY SOC MED, V97, P86, DOI 10.1258/jrsm.97.2.86; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott FW, 1916, LANCET, V1, P441; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *WAR OFF COMM ENQ, 1922, REP WAR OFF COMM ENQ; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014	24	54	56	0	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					667	671		10.1682/JRRD.2008.08.0100			5	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100004	20104396	Bronze			2021-06-18	
J	Maassen, GH; Bossema, E; Brand, N				Maassen, Gerard H.; Bossema, Ercolie; Brand, Nico			Reliable change and practice effects: Outcomes of various indices compared	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Reliable change index; Practice effects; Standard error of measurement of the difference; Standard error of prediction; Regression-based index	CLINICALLY SIGNIFICANT CHANGE; SPORT CONCUSSION; PSYCHOTHERAPY; REGRESSION; JACOBSON; ERROR	In this article the outcomes of three indices for the assessment of reliable change (RCIs) are compared: the null hypothesis method of Chelune, Naugle, Luders, Sedlak, and Awad (1993), the regression-based method of McSweeny, Naugle, Chelune, and Luders (1993), and a recently proposed adjustment to the latter procedure (Maassen, 2003). Simulated data demonstrated the importance of using large control samples. The regression-based method proved to be the most lenient in designating individuals as reliably changed, resulting in the most correct and the most incorrect designations. The adjusted procedure resulted in fewer correct designations and the lowest numbers of incorrect designations. Real-world data showed the same patterns.	[Maassen, Gerard H.; Bossema, Ercolie; Brand, Nico] Univ Utrecht, Utrecht, Netherlands	Maassen, GH (corresponding author), POB 80-140, NL-3508 TC Utrecht, Netherlands.	g.h.maassen@uu.nl					Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bossema ER, 2005, J VASC SURG, V41, P775, DOI 10.1016/j.jvs.2004.12.057; BRAND AN, 1992, J AFFECT DISORDERS, V25, P77, DOI 10.1016/0165-0327(92)90095-N; BRAND N, 1990, EUROPEAN PERSPECTIVE, V2, P321; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Hageman WJJM, 1999, BEHAV RES THER, V37, P1169; HAGEMAN WJJM, 1993, BEHAV RES THER, V31, P693, DOI 10.1016/0005-7967(93)90122-B; HSU LM, 1989, BEHAV ASSESS, V11, P459; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maassen GH, 2006, BRIT J SPORT MED, V40, P829, DOI 10.1136/bjsm.2005.023713; Maassen GH, 2000, J CLIN EXP NEUROPSYC, V22, P622, DOI 10.1076/1380-3395(200010)22:5;1-9;FT622; Maassen GH, 2000, PSYCHOMETRIKA, V65, P187, DOI 10.1007/BF02294373; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; MAASSEN GH, 2003, NEDERLANDS TIJDSCHRI, V58, P69; McNemar Q., 1962, PSYCHOL STAT; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Wald F.D., 1990, NEDERLANDS TIJDSCHRI, V45, P86; Zegers F. E., 1994, ULTIMATE RELIABLE CH	25	54	54	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					339	352	PII 794906104	10.1080/13803390802169059			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100008	18618359				2021-06-18	
J	Nakase-Richardson, R; Sepehri, A; Sherer, M; Yablon, SA; Evans, C; Mani, T				Nakase-Richardson, Risa; Sepehri, Arash; Sherer, Mark; Yablon, Stuart A.; Evans, Clea; Mani, Tanja			Classification Schema of Posttraumatic Amnesia Duration-Based Injury Severity Relative to 1-Year Outcome: Analysis of Individuals with Moderate and Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Classification; Rehabilitation	HEAD-INJURY; BATTERY	Objective: Early investigations classified traumatic brain injury (TBI) severity according to posttraumatic amnesia (PTA) duration, designating "greater than 7 days" as the most severe. PTA durations of more than 7 days are common in neurorehabilitation populations. Moreover, no study has derived a PTA severity schema anchored to late outcome. The purpose of this study was to develop a PTA severity classification schema. Design: Prospective observational study. Setting: Rehabilitation hospital. Participants: Sample included TBI Model System participants (N=280) with known or imputed PTA duration during acute hospitalization and 1-year productivity status. Participants were primarily male (70%), median age of 27 years; and the most common mechanism of injury was motor vehicle collisions (79%). For study purposes, 4 injury severity groups were identified by observing differences in productivity associated with different PTA durations. Interventions: None. Main Outcome Measure: Productivity status at 1 year postinjury. Results: Fisher exact test comparisons revealed significant differences among 3 of the groups. Most individuals with PTA fewer than 14 days had favorable 1-year outcome (68% productive), whereas worse outcomes were associated with PTA more than 28 days (18% productive). Conclusions: If validated by other investigators, the proposed schema will be useful in determining prognosis for late functional status based on PTA duration.	[Nakase-Richardson, Risa] James A Haley Vet Hosp, Psychol Serv, James A Haley Vet Affairs Med Ctr, Tampa, FL 33612 USA; [Sepehri, Arash; Yablon, Stuart A.; Evans, Clea; Mani, Tanja] Methodist Rehabil Ctr, Jackson, MS USA; [Sepehri, Arash; Yablon, Stuart A.; Evans, Clea; Mani, Tanja] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA	Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, Psychol Serv, James A Haley Vet Affairs Med Ctr, 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Risa.Richardson@va.gov			National Institute on Disability Rehabilitation and Research [H133A020514]	Supported by the National Institute on Disability Rehabilitation and Research (grant no. H133A020514).	BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Jennett B, 1981, MANAGEMENT HEAD INJU; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1954, BRIT MED BULL, V10, P65, DOI 10.1093/oxfordjournals.bmb.a069376; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Symonds CP, 1943, LANCET, V1, P7; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	25	54	54	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2009	90	1					17	19		10.1016/j.apmr.2008.06.030			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	397IY	WOS:000262657600003	19154824				2021-06-18	
J	Stovner, LJ; Schrader, H; Mickeviciene, D; Surkiene, D; Sand, T				Stovner, L. J.; Schrader, H.; Mickeviciene, D.; Surkiene, D.; Sand, T.			Headache after concussion	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cohort study; concussion; headache; migraine; prognosis	LATE WHIPLASH SYNDROME; FREQUENT HEADACHE; MILD HEAD; INJURY; EPIDEMIOLOGY; EXPECTATION; PREVALENCE; PAIN; MIGRAINE; COHORT	Chronic post-traumatic headache attributed to mild head injury is a somewhat disputed headache diagnosis. A main object of this study was to assess the validity of this diagnosis by studying the headache pattern of concussed patients that participated in one historic (n = 131) and one prospective cohort (n = 217) study. Head injury patients were recruited from two hospitals in Kaunas, Lithuania. Controls were recruited amongst patients with minor orthopaedic traumas not involving the head and neck. When data from the two studies were pooled, no difference in any headache category (diagnosis, attack frequency, symptoms) was found one or more years after the trauma, except that photophobia was somewhat more prevalent amongst the concussed patients. In both injury groups, the existence of pre-traumatic headache was a predictor of post-traumatic headache, although pre-traumatic headache seems to have been underreported amongst the concussed patients. There was a significant negative correlation between the duration of unconsciousness and the headache. This negative correlation, and the lack of specificity indicates that headache occurring 3 months or more after concussion is not caused by the head or brain injury. Rather it may represent an episode of one of the primary headaches, possibly induced by the stress of the situation.	[Stovner, L. J.; Schrader, H.] Norwegian Univ Sci & Technol, Norwegian Natl Headache Ctr, Dept Neurosci, N-7034 Trondheim, Norway; [Stovner, L. J.; Schrader, H.; Sand, T.] St Olavs Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway; [Mickeviciene, D.; Surkiene, D.] Kaunas Univ Med, Dept Neurol, Kaunas, Lithuania	Stovner, LJ (corresponding author), Univ Trondheim Hosp, Norwegian Natl Headache Ctr, N-7006 Trondheim, Norway.	lars.stovner@ntnu.no	Stovner, Lars Jacob/D-5025-2014	Schrader, Harald/0000-0001-9975-1960			ALVES WM, 1990, NEUROLOGICAL SURG, P2219; Boardman HF, 2003, CEPHALALGIA, V23, P129, DOI 10.1046/j.1468-2982.2003.00468.x; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DROTTNING M, 1995, NORD J PSYCHIAT, V49, P293, DOI 10.3109/08039489509011919; Ferrari R, 2001, J NEUROL NEUROSUR PS, V70, P722, DOI 10.1136/jnnp.70.6.722; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Ferrari Robert, 2002, Med Sci Monit, V8, pCR728; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haas DC, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-17; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hagen K, 2002, CEPHALALGIA, V22, P672, DOI 10.1046/j.1468-2982.2002.00413.x; Hasvold T, 1996, SCAND J PRIM HEALTH, V14, P92, DOI 10.3109/02813439608997077; KATSARAVA ZK, 2008, 17 INT HEAD RES SEM; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Long C J, 1983, Psychiatr Med, V1, P35; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; PAVLIC GO, 2008, 17 INT HEAD RES SEM; RASMUSSEN BK, 1995, CEPHALALGIA, V15, P45; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P115; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Schrader H, 2006, EUR J NEUROL, V13, P1226, DOI 10.1111/j.1468-1331.2006.01481.x; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; STOVNER LJ, 2005, HEADACHES, P17	35	54	56	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JAN	2009	16	1					112	120		10.1111/j.1468-1331.2008.02363.x			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	381GG	WOS:000261523100029	19087157				2021-06-18	
J	Guseva, MV; Hopkins, DM; Scheff, SW; Pauly, JR				Guseva, Maria V.; Hopkins, Deann M.; Scheff, Stephen W.; Pauly, James R.			Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						acetylcholine; alpha 7 nAChR; bungarotoxin; dietary supplementation; Morris water maze; neuroprotection; nicotinic	RECEPTOR ALPHA-7 SUBUNIT; NICOTINIC RECEPTORS; PERIPHERAL BENZODIAZEPINE; BINDING-SITES; ACETYLCHOLINE-RECEPTORS; MICROGLIAL ACTIVATION; HIPPOCAMPAL ALPHA-7; SELECTIVE AGONIST; EVOKED RELEASE; NEURODEGENERATION	Novel pharmacological approaches that safely and effectively lessen the degree of neurological impairment following traumatic brain injury (TBI) are sorely needed. Non-invasive approaches that could be used over an extended periods of time might be particularly useful. Previous studies from our lab have hypothesized that TBI-induced decreases in hippocampal and cortical alpha 7 neuronal nicotinic cholinergic receptor (nAChR) expression might contribute to cognitive impairment that follows brain injury. The purpose of this study was to determine whether the low-potency, but selective alpha 7 nAChR agonist choline might be a useful treatment for improvement of neurological outcome in a rat model of TBI. Male Sprague-Dawley rats were exposed to control or choline-supplemented diets for 2 weeks prior to experimental brain injury (1.5-mm cortical contusion injury) and throughout the recovery phase. Dietary choline supplementation resulted in a modest degree of improvement in spatial memory as assessed in the Morris water maze test. In addition, choline treatment resulted in significant cortical tissue sparing, reduced brain inflammation, and normalized some TBI-induced deficits in nAChR expression. The results of this study suggest that alpha 7 nAChR agonists may be useful drugs to enhance recovery following brain injury.	[Guseva, Maria V.; Hopkins, Deann M.; Pauly, James R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Guseva, Maria V.; Hopkins, Deann M.; Scheff, Stephen W.; Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.	jpauly@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS42196, NS39828]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS039828] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant NS42196 to J.R.P. and grant NS39828 to S.W.S.).	Albuquerque EX, 1998, J PHYSIOLOGY-PARIS, V92, P309, DOI 10.1016/S0928-4257(98)80039-9; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Berg DK, 2002, J NEUROBIOL, V53, P512, DOI 10.1002/neu.10116; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; Cacabelos R, 1996, ANN NY ACAD SCI, V777, P399, DOI 10.1111/j.1749-6632.1996.tb34452.x; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; COUTCHER JB, 1992, J PHARMACOL EXP THER, V262, P1128; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; Fayuk D, 2004, MOL PHARMACOL, V66, P658, DOI 10.1124/mol.104.000042; FREEDMAN R, 1994, HARVARD REV PSYCHIAT, V2, P179, DOI 10.3109/10673229409017136; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-00028; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Guseva MV, 2006, PHARMACOL BIOCHEM BE, V84, P26, DOI 10.1016/j.pbb.2006.04.002; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hazell AS, 1999, NEUROSCI LETT, V271, P5, DOI 10.1016/S0304-3940(99)00489-9; Jonnala RR, 2003, SYNAPSE, V47, P262, DOI 10.1002/syn.10176; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kuhlmann AC, 1999, TOXICOL SCI, V48, P107, DOI 10.1093/toxsci/48.1.107; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7; MARKS MJ, 1986, MOL PHARMACOL, V30, P427; Marrero MB, 2004, J PHARMACOL EXP THER, V309, P16, DOI 10.1124/jpet.103.061655; McIntosh TK, 1996, LAB INVEST, V74, P315; MORLEY BJ, 1977, NATURE, V266, P848, DOI 10.1038/266848a0; Mulholland PJ, 2004, DEV BRAIN RES, V153, P203, DOI 10.1016/j.devbrainres.2004.08.008; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; Nott A, 2006, BRAIN RES, V1081, P72, DOI 10.1016/j.brainres.2006.01.052; Park CH, 1996, GLIA, V16, P65, DOI 10.1002/(SICI)1098-1136(199601)16:1<65::AID-GLIA7>3.0.CO;2-A; Parnetti L, 2007, J NEUROL SCI, V257, P264, DOI 10.1016/j.jns.2007.01.043; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; RINNE JO, 1991, BRAIN RES, V547, P167; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Tribollet E, 2004, NEUROSCIENCE, V124, P405, DOI 10.1016/j.neuroscience.2003.09.028; van Kampen M, 2004, PSYCHOPHARMACOLOGY, V172, P375, DOI 10.1007/s00213-003-1668-7; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Zeisel SH, 2006, NUTR REV, V64, P197, DOI [10.1301/nr.2006.janr.197-203, 10.1111/j.1753-4887.2006.tb00202.x]	56	54	61	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					975	983		10.1089/neu.2008.0516			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700003	18665805	Green Published			2021-06-18	
J	Turkstra, LS				Turkstra, Lyn S.			(Conversation-based assessment of social cognition in adults with traumatic brain injury	BRAIN INJURY			English	Article						social cognition; theory of mind; brain injury; pragmatic language; inference	CLOSED-HEAD-INJURY; WORKING-MEMORY CAPACITY; FALSE-BELIEF TASK; INDIVIDUAL-DIFFERENCES; LOBE CONTRIBUTIONS; ASPERGER-SYNDROME; ELICITATION TASK; MIND; DISCOURSE; CHILDREN	Primary objective: The purpose of this study was to characterize performance of individuals with traumatic brain injury (TBI) on a novel video-based test, the Video Social Inference Test (VSIT). The VSIT was designed to capture social inference processes that would be engaged in daily conversations. The test required both initial social inferences and also predictions or explanations of subsequent behaviours. Research design: Between-groups comparison. Methods: Adults with TBI (n=19) and typical controls matched for age and sex (n=19) completed the VSIT, as well as a working memory test and the Eyes Test, a widely-used picture-based test of social cognition. Results: VSIT scores were lower in the TBI group and higher than on the Eyes Test. Participants in both groups had lower scores when required to predict or explain future behaviours based on an initial social inference. Conclusions and implications: The results suggest that conversation-based stimuli may yield unique and useful information about social cognition beyond the laboratory.	[Turkstra, Lyn S.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53706 USA	Turkstra, LS (corresponding author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu					Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Apperly IA, 2007, COGNITION, V103, P300, DOI 10.1016/j.cognition.2006.04.012; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2001, J DEV LEARNING DISOR, V5, P47, DOI DOI 10.1111/J.1467-7687.2008.00720.X; Baron-Cohen S., 1995, MIND BLINDNESS ESSAY; Barrett L, 2007, PHILOS T R SOC B, V362, P561, DOI 10.1098/rstb.2006.1995; Beaumont RB, 2008, J AUTISM DEV DISORD, V38, P249, DOI 10.1007/s10803-007-0384-2; Beer JS, 2006, BRAIN RES, V1079, P98, DOI 10.1016/j.brainres.2006.01.002; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosacki SL, 2000, J EDUC PSYCHOL, V92, P709, DOI 10.1037//0022-0663.92.4.709; Bowie CR, 2005, PSYCHIAT CLIN N AM, V28, P613, DOI 10.1016/j.psc.2005.05.004; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Campbell T, 1997, J SPEECH LANG HEAR R, V40, P519, DOI 10.1044/jslhr.4003.519; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Daneman M, 1996, PSYCHON B REV, V3, P422, DOI 10.3758/BF03214546; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DODGE KA, 1986, MONOGR SOC RES CHILD, V51, P1; DODGE KA, 1994, CHILD DEV, V65, P1385, DOI 10.2307/1131505; Dziobek I, 2006, J AUTISM DEV DISORD, V36, P623, DOI 10.1007/s10803-006-0107-0; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GAULIN CA, 1994, PERCEPT MOTOR SKILL, V79, P55, DOI 10.2466/pms.1994.79.1.55; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heavey L, 2000, J AUTISM DEV DISORD, V30, P225, DOI 10.1023/A:1005544518785; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hill RW, 1998, ASSESSMENT, V5, P67, DOI 10.1177/107319119800500109; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Knickmeyer R, 2006, HORM BEHAV, V49, P282, DOI 10.1016/j.yhbeh.2005.08.010; Langbein John H., 2006, TRAUMATIC BRAIN INJU, P1; Lehman MT, 1998, APHASIOLOGY, V12, P771, DOI 10.1080/02687039808249572; MACCOBY EE, 1988, DEV PSYCHOL, V24, P755, DOI 10.1037/0012-1649.24.6.755; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; MCDONALD S, 2005, BRAIN IMPAIR, V6, P58; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McKinnon MC, 2007, COGNITION, V102, P179, DOI 10.1016/j.cognition.2005.12.011; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Mutter B, 2006, PERCEPT MOTOR SKILL, V102, P819, DOI 10.2466/PMS.102.3.819-835; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Saltzman-Benaiah J, 2007, CLIN NEUROPSYCHOL, V21, P294, DOI 10.1080/13854040500473760; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Simon JA, 2001, COGNITIVE NEUROPSYCH, V18, P1, DOI 10.1080/02643290126042; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; STRONACH ST, 2007, IN PRESS APHASIOLOGY; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1998, APHASIOLOGY, V12, P421, DOI 10.1080/02687039808249541; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; VANLEER E, 1999, J COMMUNICATIION DIS, V32, P348; Walker S, 2005, J GENET PSYCHOL, V166, P297, DOI 10.3200/GNTP.166.3.297-312; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Weismer SE, 1999, J SPEECH LANG HEAR R, V42, P1249, DOI 10.1044/jslhr.4205.1249; WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P239, DOI 10.2466/pms.1974.38.1.239; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	80	54	55	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2008	22	5					397	409		10.1080/02699050802027059			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500005	18415720				2021-06-18	
J	Forsberg, JA; Elster, EA; Andersen, RC; Nylen, E; Brown, TS; Rose, MW; Stojadinovic, A; Becker, KL; McGuigan, FX				Forsberg, Jonathan Agner; Elster, Eric A.; Andersen, Romney C.; Nylen, Eric; Brown, Trevor S.; Rose, Matthew W.; Stojadinovic, Alexander; Becker, Kenneth L.; McGuigan, Francis Xavier			Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							OPERATION-IRAQI-FREEDOM; VACUUM-ASSISTED CLOSURE; ORTHOPEDIC INJURIES; DIAGNOSTIC-VALUE; PRESSURE ULCERS; TOTAL HIP; SEPSIS; INFECTION; SERUM; TRAUMA	Background: Despite technological advances in the treatment of severe extremity trauma, the timing of wound closure remains the subjective clinical decision of the treating surgeon. Traditional serum markers are poor predictors of wound-healing. The objective of this study was to evaluate the cytokine and chemokine profiles of severe extremity wounds prior to closure to determine if wound effluent markers can be used to predict healing. Methods: Serum and effluent (exudate) samples were collected prospectively from adult volunteers with multiple high-energy penetrating extremity wounds sustained during military combat. Samples were collected prior to definitive wound closure or flap coverage. Wounds were followed clinically for six weeks. The primary clinical outcome measures were wound-healing and dehiscence. Control serum samples were collected from normal age and sex-matched adult volunteers. All samples were analyzed for the following cytokines and chemokines: procalcitonin; eotaxin; granulocyte macrophage colony stimulating factor; interferon (IFN)-gamma; interieukin (IL)-1 through 8, 10, 12, 13, and 15; IFN-gamma inducible protein-10; monocyte chemotactic protein-1; macrophage inflammatory protein-la; the protein regulated on activation, normal T expressed and secreted (RANTES); and tumor necrosis factor (TNF)-alpha. Results: Fifty wounds were analyzed in twenty patients. Four of the fifty wounds dehisced. An increased rate of wound dehiscence was observed in patients with a concomitant closed head injury as well as in those with an associated arterial injury of the affected limb (p < 0.05). Among the serum chemokines and cytokines, only serum procalcitonin levels correlated with wound dehiscence (p < 0.05). Effluent analysis showed that, compared with wounds that healed, wounds that dehisced were associated with elevated procalcitonin, decreased RANTES protein, and decreased IL-13 concentrations (p < 0.05). No wound with an effluent procalcitonin concentration of < 220 pg/mL, an IL-13 concentration of > 12 pg/mL, or a RANTES protein concentration of > 1000 pg/mL failed to heal. Conclusions: Effluent procalcitonin, IL-13, and RANTES protein levels as well as serum procalcitonin levels correlate with wound dehiscence following closure of severe open extremity wounds. These preliminary results indicate that effluent biomarker analysis may be an objective means of determining the timing of traumatic wound closure.	[Forsberg, Jonathan Agner; Elster, Eric A.; Andersen, Romney C.; Nylen, Eric; Brown, Trevor S.; Rose, Matthew W.; Stojadinovic, Alexander; Becker, Kenneth L.; McGuigan, Francis Xavier] Natl Naval Med Ctr, Dept Orthopaed Surg, Bethesda, MD 20889 USA	Forsberg, JA (corresponding author), Natl Naval Med Ctr, Dept Orthopaed Surg, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	onathan.forsberg@med.navy.mil	Forsberg, Jonathan/K-2116-2012; Elster, Eric A/G-2332-2010; Brown, Trevor/F-7392-2015	Stojadinovic, Alexander/0000-0002-2829-8967; Brown, Trevor/0000-0001-7042-785X; Elster, Eric/0000-0002-0981-2748			Arkader R, 2004, J CARDIOTHOR VASC AN, V18, P160, DOI 10.1053/j.jvca.2004.01.021; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; BASSIM CW, 2007, ANN M INT ASS DENT R; BATINICA J, 1995, MIL MED, V160, P124; Batty CG, 1999, MIL MED, V164, P336; Becker KL, 2004, J CLIN ENDOCR METAB, V89, P1512, DOI 10.1210/jc.2002-021444; BETTIN D, 1989, Z ORTHOP GRENZGEB, V127, P518, DOI 10.1055/s-2008-1044718; Bouza E, 2006, DIAGN MICR INFEC DIS, V56, P345, DOI 10.1016/j.diagmicrobio.2006.06.012; BREIDENBACH WC, 1995, PLAST RECONSTR SURG, V95, P860, DOI 10.1097/00006534-199595050-00015; Bucalo Brian, 1993, Wound Repair and Regeneration, V1, P181, DOI 10.1046/j.1524-475X.1993.10308.x; Centers for Disease Control and Prevention (CDC), 2004, MMWR MORB MORTAL WKL, V53, P1063; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CHESNEY RW, 1983, J LAB CLIN MED, V101, P576; Covey CDC, 2002, J BONE JOINT SURG AM, V84A, P1221, DOI 10.2106/00004623-200207000-00022; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Davis KA, 2005, EMERG INFECT DIS, V11, P1218, DOI 10.3201/1108.050103; Di Cesare PE, 2005, J BONE JOINT SURG AM, V87A, P1921, DOI 10.2106/JBJS.D.01803; Drugea I, 2003, METH MOLEC MED, V78, P359; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Gofrit ON, 1997, MIL MED, V162, P24; GUNBY P, 1991, JAMA-J AM MED ASSOC, V266, P619, DOI 10.1001/jama.266.5.619; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; Haaker R, 2004, ORTHOPADE, V33, P431, DOI 10.1007/s00132-003-0624-x; HACK CE, 1989, BLOOD, V74, P1704; Harris I R, 1995, Exp Dermatol, V4, P342, DOI 10.1111/j.1600-0625.1995.tb00058.x; Islinger RB, 2000, MIL MED, V165, P463; Joseph E, 2000, WOUNDS, V12, P60; KATZ MH, 1991, J AM ACAD DERMATOL, V25, P1054, DOI 10.1016/0190-9622(91)70306-M; Kingsley Andrew, 2003, Ostomy Wound Manage, V49, P1; Krizek TJ, 1967, SURG FORUM, V18, P518; Ladwig GP, 2002, WOUND REPAIR REGEN, V10, P26, DOI 10.1046/j.1524-475X.2002.10903.x; LIAPPIS AP, 2007, ANN M END SOC JUN TO; Lin DL, 2004, J ORTHOP TRAUMA, V18, P300; LONDON PS, 1983, J BONE JOINT SURG BR, V65, P507; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; Mast Bruce A., 1996, Wound Repair and Regeneration, V4, P411, DOI 10.1046/j.1524-475X.1996.40404.x; Morgenthaler NG, 2003, HORM METAB RES, V35, P290; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; Nudelman R, 1983, Adv Pediatr, V30, P517; Nwomeh BC, 1998, CLIN PLAST SURG, V25, P341; Nylen E, 2003, CLIN INFECT DIS, V36, P823, DOI 10.1086/368088; Nylen ES, 1998, CRIT CARE MED, V26, P1001, DOI 10.1097/00003246-199806000-00015; Nylen ES, 2001, BEST PRACT RES CL EN, V15, P553, DOI 10.1053/beem.2001.0169; Pallister I, 2005, J AM ACAD ORTHOP SUR, V13, P93, DOI 10.5435/00124635-200503000-00002; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Pinzur MS, 2003, J BONE JOINT SURG AM, V85A, P1667, DOI 10.2106/00004623-200309000-00003; Robbins Graham M, 2002, J Am Acad Orthop Surg, V10, P86; Robson M C, 1968, Surg Forum, V19, P501; Robson M C, 1970, J Surg Oncol, V2, P379, DOI 10.1002/jso.2930020410; ROBSON MC, 1969, MIL MED, V134, P19; Song K M, 2001, J Am Acad Orthop Surg, V9, P166; Southwood LL, 2003, AM J VET RES, V64, P727, DOI 10.2460/ajvr.2003.64.727; SPALDING TJW, 1991, BRIT J SURG, V78, P1102, DOI 10.1002/bjs.1800780921; Spangehl MJ, 1999, J BONE JOINT SURG AM, V81A, P672, DOI 10.2106/00004623-199905000-00008; Stechmiller JK, 2006, WOUND REPAIR REGEN, V14, P371, DOI 10.1111/j.1743-6109.2006.00134.x; Szalay L, 2003, SHOCK, V20, P245, DOI 10.1097/00024382-200309000-00008; Uzzan B, 2006, CRIT CARE MED, V34, P1996, DOI 10.1097/01.CCM.0000226413.54364.36; VANDEUREN M, 1992, J PATHOL, V168, P349, DOI 10.1002/path.1711680403; Viallon A, 2000, INTENS CARE MED, V26, P1082, DOI 10.1007/s001340051321; Yager DR, 1999, WOUND REPAIR REGEN, V7, P433, DOI 10.1046/j.1524-475X.1999.00433.x; Yamaguchi M, 2003, J CELL BIOCHEM, V89, P356, DOI 10.1002/jcb.10510; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806; Zorrilla P, 2004, CLIN ORTHOP RELAT R, P304, DOI 10.1097/01.blo.0000126231.32385.dd	64	54	54	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAR	2008	90A	3					580	588		10.2106/JBJS.G.00265			9	Orthopedics; Surgery	Orthopedics; Surgery	273QJ	WOS:000253946500015	18310708				2021-06-18	
J	Kelly, P; Farrant, B				Kelly, Patrick; Farrant, Bridget			Shaken baby syndrome in New Zealand, 2000-2002	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						child abuse; shaken baby syndrome; subdural hematoma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NONACCIDENTAL HEAD-INJURY; YOUNG-CHILDREN; SUBDURAL HEMATOMAS; IMPACT SYNDROME; RISK-FACTORS; INFANT; NEUROPATHOLOGY; HEMORRHAGES; PATTERNS	Aim: To describe the epidemiology of subdural haemorrhage (SDH) in New Zealand infants. Methods: Prospective enrolment of all cases of infantile SDH from 2000 to 2002. Retrospective analysis of national discharge and death data for the same period. Results: Seventy-seven cases of infantile SDH were identified prospectively, and a further 49 cases retrospectively. Of these 126 cases, 92 resulted from non-birth-related trauma. Forty-eight of these were attributed to abuse and 28 to accidental injury. Sixteen cases were undetermined. The 'minimum' annual incidence of inflicted infantile SDH in New Zealand is 14.7 per 100 000 (95% confidence interval(CI) 10.8-19.4), and the 'maximum' 19.6 per 100 000 (95% CI 15.1-25.0). Among Maori, the 'minimum' is 32.5 per 100 000 (95% CI 21.4-47.3), and the 'maximum' 38.5 per 100 000 (95% CI 26.3-54.4). Conclusions: The epidemiology of infantile subdural haemorrhage in New Zealand is similar to that described elsewhere. Non-accidental head injury is a significant child health issue in New Zealand, and the incidence is particularly high among Maori.	[Kelly, Patrick] Starship Childrens Hosp, Child Abuse Assessment Unit, Auckland 1, New Zealand; [Farrant, Bridget] Univ Auckland, Dept Paediat, Auckland, New Zealand	Kelly, P (corresponding author), Starship Childrens Hosp, Child Abuse Assessment Unit, Pk Rd,Private Bag 92024, Auckland 1, New Zealand.	patrickk@adhb.govt.nz					AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BECROFT DMO, 1989, NEW ZEAL MED J, V102, P207; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Campbell-Stokes PL, 2005, DIABETOLOGIA, V48, P643, DOI 10.1007/s00125-005-1697-3; CRAIG E, 2005, HLTH STATUS CHILDREN, P94; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; FRASIER LD, 1997, EC CONSEQUENCES SHAK; FROMM S, 2001, PREVENT CHILD ABUSE; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GOULD MS, 1995, CHILD MALTREATMENT C; Harding B, 2004, BMJ-BRIT MED J, V328, P720, DOI 10.1136/bmj.328.7442.720; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HOWARD MA, 1993, BRIT J NEUROSURG, V7, P355, DOI 10.3109/02688699309103489; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly Patrick, 2004, N Z Med J, V117, pU1047; King WJ, 2003, CAN MED ASSOC J, V168, P155; LANTZ PE, 2002, BMJ-BRIT MED J, V328, P754; LENTNER C, 1984, GEIGY SCI TABLES, V2; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; *MIN HLTH, 1998, OUR CHILDR HLTH KEY, P151; *MIN HLTH, 1998, FAM VIOL GUID HLTH S; Minns RA, 2004, BRIT MED J, V328, P766, DOI 10.1136/bmj.328.7442.766; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Punt J, 2004, Pediatr Rehabil, V7, P173, DOI 10.1080/13638490410001711515; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schnitzer PG, 2005, PEDIATRICS, V116, pE687, DOI 10.1542/peds.2005-0296; Sinal SH, 2000, CHILD ABUSE NEGLECT, V24, P1241, DOI 10.1016/S0145-2134(00)00177-0; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3	46	54	54	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1034-4810	1440-1754		J PAEDIATR CHILD H	J. Paediatr. Child Health	MAR	2008	44	3					99	107		10.1111/j.1440-1754.2007.01234.x			9	Pediatrics	Pediatrics	269DJ	WOS:000253629400004	18086144				2021-06-18	
J	Maiya, B; Newcombe, V; Nortje, J; Bradley, P; Bernard, F; Chatfield, D; Outtrim, J; Hutchinson, P; Matta, B; Antoun, N; Menon, D				Maiya, Balachandra; Newcombe, Virginia; Nortje, Jurgens; Bradley, Peter; Bernard, Francis; Chatfield, Dot; Outtrim, Joanne; Hutchinson, Peter; Matta, Basil; Antoun, Nagui; Menon, David			Magnetic resonance imaging changes in the pituitary gland following acute traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hypopituitarism; magnetic resonance imaging	HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; HYPOGONADISM	Objective: The objective was to study the anatomical changes in the pituitary gland following acute moderate or severe traumatic brain injury (TBI). Design: Retrospective, observational, case-control study. Setting: Neurosciences Critical Care Unit of a university hospital. Patients: Forty-one patients with moderate or severe TBI who underwent magnetic resonance imaging (MRI) during the acute phase (less than seven days) of TBI. MRI scans of 43 normal healthy volunteers were used as controls. Interventions: None. Measurements and main results: Patient demographics, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Injury Severity Score (ISS), post-resuscitation Glasgow Coma Score (GCS), Glasgow Outcome Score (GOS), mean intracranial pressure (ICP), mean cerebral perfusion pressure (CPP), computed tomography (CT) data, pituitary gland volumes and structural lesions in the pituitary on MRI scans. The pituitary glands were significantly enlarged in the TBI group (the median and interquartile range were as follows: cases 672mm(3) (range 601-783mm3) and controls 552mm(3) (range 445-620mm(3)); p value<0.0001). APACHE II, GCS, GOS and ICP were not significantly correlated with the pituitary volume. Twelve of the 41 cases (30%) demonstrated focal changes in the pituitary gland (haemorrhage/haemorrhagic infarction (n=5), swollen gland with bulging superior margin (n=5), heterogeneous signal intensities in the anterior lobe (n=2) and partial transection of the infundibular stalk (n=1). Conclusions: Acute TBI is associated with pituitary gland enlargement with specific lesions, which are seen in approximately 30% of patients. MRI of the pituitary may provide useful information about the mechanisms involved in post-traumatic hypopituitarism.	[Maiya, Balachandra; Newcombe, Virginia; Nortje, Jurgens; Bradley, Peter; Chatfield, Dot; Outtrim, Joanne; Hutchinson, Peter; Matta, Basil; Menon, David] Univ Cambridge, Fdn Hosp NHS Trust, Div Anaesthesia, Cambridge CB2 2QQ, England; [Bernard, Francis] Univ Montreal, Sacred Heart Hosp, Montreal, PQ, Canada; [Antoun, Nagui] Univ Cambridge, Fdn Hosp NHS Trust, Dept Radiol, Cambridge CB2 2QQ, England	Maiya, B (corresponding author), Univ Cambridge, Fdn Hosp NHS Trust, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 2QQ, England.	bm331@cam.ac.uk		Outtrim, Joanne/0000-0001-8118-6430; Newcombe, Virginia/0000-0001-6044-9035	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0600986, G0001237] Funding Source: Medline		ADAMS JH, 1966, J NEUROL NEUROSUR PS, V29, P545, DOI 10.1136/jnnp.29.6.545; ADAMS JH, 1966, LANCET, V1, P263; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; BASAVARAJU N, 1989, J AM GERIATR SOC, V37, P49, DOI 10.1111/j.1532-5415.1989.tb01568.x; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; Chang YC, 2006, J FORMOS MED ASSOC, V105, P172, DOI 10.1016/S0929-6646(09)60341-7; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Cryan E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL P. M., 1956, QUART JOUR EXPTL PHYSIOL, V41, P215; DANIEL PM, 1959, LANCET, V2, P927; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LAVALLEE G, 1995, AM J NEURORADIOL, V16, P1939; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rollero A, 1998, NEUROPSYCHOBIOLOGY, V38, P73, DOI 10.1159/000026520; Sassi RB, 2001, BIOL PSYCHIAT, V50, P271, DOI 10.1016/S0006-3223(01)01086-1; SHEEHAN HL, 1949, Q J MED, V18, P319; Sosin DM, 1996, BRAIN INJURY, V10, P47; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	31	54	57	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					468	475		10.1007/s00134-007-0902-x			8	Critical Care Medicine	General & Internal Medicine	263EQ	WOS:000253200800012	18046535				2021-06-18	
J	Newton, A; Ratchford, A; Khan, I				Newton, Alastair; Ratchford, Andrew; Khan, Ifly			Incidence of adverse events during prehospital rapid sequence intubation: A review of one year on the London helicopter emergency medical service	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	3rd Mediterranean Emergency Medicine Congress	SEP 01-05, 2005	Nice, FRANCE			prehospital; rapid sequence intubation; complications; airway; hypoxia; hypotension	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; HYPOXIA; HYPOTENSION; INDUCTION; FIELD	Background To establish the incidence of hypoxemia and hypotension during prehospital rapid sequence intubation (RSI) in trauma patients attended by the London Helicopter Emergency Medical Service (HEMS) and to compare it with historical control data from published studies of both hospital and prehospital RSI. Methods: A retrospective observational study during a 12-month period of London HEMS. All mission reports from the period March 1, 2003 to February 28, 2004 were reviewed and all intubations involving the use of drugs were included in the analysis. Measurements of oxygen saturation (SPO2) and systolic blood pressure (SBP) were obtained from the printed record produced by the portable monitor. Results: During the 12-month period 244 RSIs were performed. Completed SpO(2), data were available on 175 patients (71.7%), and of those 32 (18.3%) experienced hypoxemia (SpO(2), < 90%, or > 10% fall if initial SpO(2), < 90%). Completed SBP data were available for 192 patients (79.1%), and of those 25 (13%) experienced hypotension (SBP < 90 mm Hg or > 10 mm. Hg fall if initial SBP < 90 mm Hg). No patients developed both hypoxemia and hypotension. Conclusions. Rates of hypoxemia and hypotension during prehospital RSI performed by London HEMS are relatively low. They are less than that found in previous studies of prehospital RSI and are similar to those reported in studies of in-hospital emergency RSI undertaken in the emergency department or ward setting. We therefore conclude that prehospital RSI has an acceptably low complication rate when performed by appropriately trained personnel.	[Newton, Alastair] St Thomas Hosp, Emergency Dept, London SE1 7EH, England; [Ratchford, Andrew] Mona Vale Hosp, Emergency Dept, Sydney, NSW, Australia; [Khan, Ifly] Royal London Hosp, London E1 1BB, England	Newton, A (corresponding author), St Thomas Hosp, Emergency Dept, London SE1 7EH, England.	alastair.newton@gstt.nhs.uk					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Graham CA, 2004, J TRAUMA, V56, P1123, DOI 10.1097/01.TA.0000109066.62811.8A; Graham CA, 1997, J ACCID EMERG MED, V14, P219; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Omert L, 2001, J TRAUMA, V51, P1065, DOI 10.1097/00005373-200112000-00007; Reid C, 2004, EMERG MED J, V21, P296, DOI 10.1136/emj.2003.007344; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wang H E, 2001, Prehosp Emerg Care, V5, P40, DOI 10.1080/10903120190940317; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	17	54	55	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					487	492		10.1097/TA.0b013e31802e7476			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	264KV	WOS:000253287100047	18301219				2021-06-18	
J	Ashman, TA; Cantor, JB; Gordon, WA; Spielman, L; Egan, M; Ginsberg, A; Engmann, C; Dijkers, M; Flanagan, S				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Egan, Matthew; Ginsberg, Annika; Engmann, Clara; Dijkers, Marcel; Flanagan, Steven			Objective measurement of fatigue following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive performance; fatigue; mental fatigue; traumatic brain injury	SPATIAL WORKING-MEMORY; CLOSED-HEAD-INJURY; RHEUMATOID-ARTHRITIS; SUSTAINED ATTENTION; MULTIPLE-SCLEROSIS; CANCER-PATIENTS; MENTAL EFFORT; METHYLPHENIDATE; INVENTORY; VIGILANCE	Objectives: To quantify posttraumatic brain injury (post-TBI) mental fatigue objectively by documenting changes in performance on neuropsychological tests as a result of sustained mental effort and to examine the relationship between objectively measured mental fatigue and self-reported situational and day-to-day fatigue. Participants: The study included 202 community-dwelling individuals with mild-severe TBI and 73 noninjured controls. Measures: Measures included Cambridge Neuropsychological Test Automated Battery, Global Fatigue Index, and situational fatigue rating. Method: Subjects were administered a 30-minute computerized neuropsychological test battery 3 times. The second and third administrations of the battery were separated by approximately 2 hours of interviews and administration of self-report measures. Results: The neuropsychological test scores were factor analyzed, yielding 3 subscales: speed, accuracy, and executive function. Situational fatigue and day-to-day fatigue were significantly higher in individual with TBI group than in individuals without TBI and were associated with speed subscale scores. Individuals with TBI evidenced a significant decline in performance on the accuracy subscale score. These declines in performance related to sustained mental effort were not associated with subjective fatigue in the TBI group. While practice effects on the speed and accuracy scores were observed in non-brain-injured individuals, they were not evidenced in individuals with TBI. Conclusions: Findings were largely consistent with previous literature and indicated that while subjective fatigue is associated with poor performance in individuals with TBI, it is not associated with objective decline in performance of mental tasks.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Spielman, Lisa; Egan, Matthew; Ginsberg, Annika; Engmann, Clara; Dijkers, Marcel; Flanagan, Steven] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustav Levy Pl,Box 1240, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Flanagan, Steven/0000-0001-9005-5897; Dijkers, Marcel/0000-0002-8362-5596			Aistars J, 1987, Oncol Nurs Forum, V14, P25; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; BELZA BL, 1995, J RHEUMATOL, V22, P639; BELZA BL, 1993, NURS RES, V42, P93; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kirsh KL, 2001, J PAIN SYMPTOM MANAG, V22, P931, DOI 10.1016/S0885-3924(01)00350-5; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luria A. R., 1963, RESTORATION FUNCTION; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Mehta MA, 2000, J NEUROSCI, V20; MELAMED S, 1985, SCAND J REHABIL MED, P16; MORRIS RG, 1986, COGNITIVE NEUROCHEMI, P21; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Riekkinen M, 1999, NEUROSCIENCE, V92, P975, DOI 10.1016/S0306-4522(99)00070-6; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schwartz A L, 1998, Oncol Nurs Forum, V25, P711; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Schwid SR, 2002, J REHABIL RES DEV, V39, P211; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Mens-Verhulst J, 1997, WOMEN HEALTH, V26, P51; Van Mens-Verhulst J, 1998, SOC SCI MED, V47, P621, DOI 10.1016/S0277-9536(98)00116-6; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	41	54	54	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2008	23	1					33	40		10.1097/01.HTR.0000308719.70288.22			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	256HS	WOS:000252719800007	18219233				2021-06-18	
J	Zehtabchi, S; Soghoian, S; Liu, YJ; Carmody, K; Shah, L; Whittaker, B; Sinert, R				Zehtabchi, Shahriar; Soghoian, Samara; Liu, Yiju; Carmody, Kristin; Shah, Lekha; Whittaker, Brian; Sinert, Richard			The association of coagulopathy and traumatic brain injury in patients with isolated head injury	RESUSCITATION			English	Article						coagulation; brain injury; international normalized ratio; trauma	ACTIVATED FACTOR-VII; MORTALITY PREDICTION; COAGULATION; SCORE	The emergence of prothrombotic agents (e.g. activated factor VII) to treat traumatic brain injury (TBI) requires a better understanding of the association of coagulopathy with isolated head injury (IHI). Objective: To investigate the association of IHI and coagulopathy. Methods: Prospective, observational study in an urban level I trauma center. Inclusion criteria: Adult (>= 13 years of age) patients with IHI. Exclusion criteria: patients with known coagulopathies or on anticoagulant therapy. Predictor Variables: TBI (head abbreviated injury severity score >2, or brain hematoma on CT scan), age, gender, mechanism of injury, Glasgow Coma Score (GCS), and loss of consciousness (LOC). Outcome variables: coagulopathy defined as etevated International Normalized Ratio (INR>1.3) or activated partial thromboplastin time (PTT) greater than 34s. We divided IHI subjects into two groups of patients with and without TBI. Statistical Analysis: Fisher's exact test and Mann-Whitney U were used to compare data where appropriate (alpha: 0.05, two-tailed). Results: From July 2005 to December 2006, 276 patients with IHI were studied. The median age was 35 years (interquartile range: 25-52) with a 79% male predominance and 88% blunt trauma. Eight percent (95% Cl, 5-12%) of patients had coagulopathy. The rate of coagulopathy in TBI patients (17%) was significantly higher than non-TBI patients (6%) (11% difference, 95% Cl, 3-20%]. The relative risk of coagutopathy in TBI patients was 2.9 (95% Cl, 1.3-6.6). Conclusion: Coagulopathy as defined by elevated INR and/or PTT is associated with TBI after isolated head injury. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Zehtabchi, Shahriar; Soghoian, Samara; Liu, Yiju; Carmody, Kristin; Shah, Lekha; Whittaker, Brian; Sinert, Richard] Suny Downstate Med Ctr, Dept Emergency Med, Brooklyn, NY 11203 USA	Zehtabchi, S (corresponding author), Suny Downstate Med Ctr, Dept Emergency Med, Box 1228,450 Clarkson Ave, Brooklyn, NY 11203 USA.	szehtabchi@yahoo.com		Soghoian, Samara/0000-0002-8767-6681; Carmody, Kristin/0000-0003-1223-5280; zehtabchi, shahriar/0000-0002-6427-986X			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; May AK, 1997, AM SURGEON, V63, P233; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; Schurr MJ, 2004, J TRAUMA, V57, P718; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; 1999, WHO TECH REP SER, V889, P64	20	54	62	1	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	JAN	2008	76	1					52	56		10.1016/j.resuscitation.2007.06.024			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	263GB	WOS:000253204500011	17706857				2021-06-18	
J	Kraus, MF; Little, DM; Donnell, AJ; Reilly, JL; Simonian, N; Sweeney, JA				Kraus, Marilyn F.; Little, Deborah M.; Donnell, Alison J.; Reilly, James L.; Simonian, Narina; Sweeney, John A.			Oculomotor function in chronic traumatic brain injury	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						traumatic brain injury; visually guided saccades; antisaccades; executive function; prefrontal cortex	SACCADIC EYE-MOVEMENTS; CLOSED-HEAD-INJURY; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; WORKING-MEMORY; AXONAL INJURY; MILD; TASK; SCHIZOPHRENIA; CONCUSSION	Objective: To characterize oculomotor function using visually guided saccade and antisaccade (AS) tasks in chronic traumatic brain injury (TBI) and assess the relationship to neuropsychologic testing. Background: TBI causes dysfunction of prefrontal cortex, in part by disrupting cortical and subcortical pathways, resulting in specific cognitive impairments. Oculomotor function tests provide a method of assessing the integrity of these pathways. Methods: Twenty mild TBI (MTBI), 17 moderate to severe TBI (M/STBI), and 19 healthy controls underwent oculomotor and neuropsychologic testing. Results: On the visually guided saccade task, the M/STBI showed longer latencies and reduced accuracy. On the AS task, which is more dependent on prefrontal cortex function, both patient groups committed more prosaccade errors than controls. On neuropsychologic testing, only the M/STBI patients were significantly impaired. Correlations were found between AS and neuropsychologic performance. Conclusions: The M/STBI group was impaired on both oculomotor tasks and neuropsychologic testing, consistent with more global neuropathology. The MTBI group showed impaired performance primarily on the AS task, consistent with prefrontal system dysfunction. Hence, oculomotor testing is sensitive to the range of neuropathology in chronic TBI. and importantly, may be more sensitive to neuropathology in MTBI.	Univ Illinois, Coll Med, Ctr Cognit Med, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Neurol, Chicago, IL 60612 USA; Univ Illinois, Dept Ophthalmol & Psychol, Chicago, IL 60612 USA	Kraus, MF (corresponding author), Univ Illinois, Coll Med, Ctr Cognit Med, Dept Psychiat, Chicago, IL 60612 USA.	mkraus@psych.uic.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH068787] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH068787] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basso MR, 2003, J CLIN EXP NEUROPSYC, V25, P893, DOI 10.1076/jcen.25.7.893.16489; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bearden CE, 2004, AM J PSYCHIAT, V161, P1700, DOI 10.1176/appi.ajp.161.9.1700; Becker W., 1989, NEUROBIOLOGY SACCADI, P13; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A, 1989, MULTILINGUAL APHASIA; Benton A., 1976, MULTILINGUAL APHASIA; Berman RA, 1999, HUM BRAIN MAPP, V8, P209, DOI 10.1002/(SICI)1097-0193(1999)8:4<209::AID-HBM5>3.0.CO;2-0; Bozikas VP, 2004, COMPR PSYCHIAT, V45, P392, DOI 10.1016/j.comppsych.2004.03.006; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; Chey J, 2002, PSYCHIAT RES, V110, P259, DOI 10.1016/S0165-1781(02)00105-1; CONNERS D, 2000, CONNERS CONTINOUS PE; Crevits L, 2005, NEUROPSYCHOBIOLOGY, V51, P39, DOI 10.1159/000082854; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Culbertson W. C., 2001, TOWER LONDON DREXEL; Delis DC, 2000, CALIFORNIA VERBAL LE; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLASS I, 1995, BRAIN INJURY, V9, P769, DOI 10.3109/02699059509008233; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Golden CJ, 2002, STROOP COLOR WORD TE; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GUITTON D, 1985, EXP BRAIN RES, V58, P455; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jefferson AL, 2006, ARCH CLIN NEUROPSYCH, V21, P311, DOI 10.1016/j.acn.2006.03.007; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KLOVE H, 1964, CLIN NEUROPSYCHOLOGY; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Little DM, 2000, PSYCHOL AGING, V15, P9, DOI 10.1037//0882-7974.15.1.9; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; Matthews C, 1964, INSTRUCTION MANUAL A; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; MIRANDA M, 2007, IN PRESS J ATTEN DIS; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Pierrot-Deseilligny C, 2005, ANN NY ACAD SCI, V1039, P239, DOI 10.1196/annals.1325.023; Ploner CJ, 2005, BIOL PSYCHIAT, V57, P1159, DOI 10.1016/j.biopsych.2005.02.017; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PSYCHOLOGICAL C, 2001, WECHSLER TEST ADULT; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruff R. M., 1988, RUFF FIGURAL FLUENCY; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Snitz BE, 2006, SCHIZOPHRENIA BULL, V32, P179, DOI 10.1093/schbul/sbi048; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TOMBAUCH T, 1996, TEST MEMORY MALINGER; TOMBAUCH T, 1997, TEST MEMORY MALINGER; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wechsler D, 1997, WMS 3 ADM SCORING MA	59	54	54	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2007	20	3					170	178		10.1097/WNN.0b013e318142badb			9	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	214NQ	WOS:000249745600006	17846516				2021-06-18	
J	Register-Mihalik, J; Guskiewicz, KM; Mann, JD; Shields, EW				Register-Mihalik, Johna; Guskiewicz, Kevin M.; Mann, John Douglas; Shields, Edgar W.			The effects of headache on clinical measures of neurocognitive function	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						headache; concussion; balance; cognition	SPORT-RELATED CONCUSSION; POSTURAL STABILITY; FOOTBALL PLAYERS; MANAGEMENT; COLLEGIATE; MIGRAINE	Objective: To examine effects of preseason baseline headache and posttraumatic headache (PTH) on neurocognitive function. Design: Retrospective repeated measures study with headache groups formed regarding baseline headache score (0 = negative headache; 1-6 = positive headache) and day I postinjury headache score (0 = no headache; 1-2 = mild headache; 3-6 = moderate-severe headache). Setting: Clinical athletic training setting and sports medicine research laboratory. Participants: High-school and collegiate athletes with a concussion. Independent Variables: Preseason baseline headache, PTH, test-day. Main Outcome Measures: A Graded Symptom Checklist (GSC) was used to assess symptoms. The Automated Neuropsychological Assessment Metrics (ANAM) and the Standardized Assessment of Concussion (SAC) were used to assess neuropsychological function and mental status. The Balance Error Scoring System (BESS) was used to assess postural stability. Results: Both baseline headache groups displayed a higher symptom endorsement and higher symptom severity at day I postinjury and improved by day 7 postinjury. The positive headache group reported an even greater increase in symptom severity and presence (P < 0.05). ANAM revealed deficits in both groups I day postinjury. All PTH headache groups displayed a difference in symptom number and severity with the increase being magnified by headache severity (P < 0.05). Individuals reporting moderate-severe PTH displayed increased deficits subacutely but improved by 5-7 days postinjury on overall neuropsychological performance, reaction time, and working memory (P < 0.05). Deficits were observed for all ANAM measures except simple reaction time I (SRT 1) and match to sample subacutely and improved over time (P < 0.05). The SAC yielded an interaction (P < 0.05) for baseline headache. The BESS yielded no significant findings. Conclusions: Clinicians should consider headache when assessing concussion and during preseason baseline assessments because headache may affect symptom presence and other clinical measures of concussion.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sports Sci, Chapel Hill, NC 27599 USA; Univ N Carolina Hosp, Dept Neurol, Chapel Hill, NC USA	Register-Mihalik, J (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sports Sci, CB 8700,Fetzer Gymnasium,S Rd, Chapel Hill, NC 27599 USA.	johnakay@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743			Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HOOKER WD, 1986, ARCH NEUROL-CHICAGO, V43, P709, DOI 10.1001/archneur.1986.00520070065020; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MCCREA M, 2000, STANDARD ASSESSMENT; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2005, J ATHL TRAINING, V40, P139; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19	18	54	55	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2007	17	4					282	288		10.1097/JSM.0b013e31804ca68a			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	188VX	WOS:000247948500009	17620782				2021-06-18	
J	Maegele, M; Engel, D; Bouillon, B; Lefering, R; Fach, H; Raum, M; Buchheister, B; Schaefer, U; Klug, N; Neugebauer, E				Maegele, M.; Engel, D.; Bouillon, B.; Lefering, R.; Fach, H.; Raum, M.; Buchheister, B.; Schaefer, U.; Klug, N.; Neugebauer, E.			Incidence and outcome of traumatic brain injury in an urban area in western Europe over 10 years	EUROPEAN SURGICAL RESEARCH			English	Article						traumatic brain injury; incidence; traumatic brain injury, outcome; urban area in western Europe	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; FINNISH PATIENTS 5; UNITED-STATES; PRACTICAL SCALE; DATA-BANK; SCORE; MORTALITY; MANAGEMENT; MODERATE	Introduction: Valid epidemiological data on incidence and outcome of traumatic brain injury (TBI) show great variability. A study on incidence, severity and outcome of TBI was conducted in an urban area of one million inhabitants. Materials and Methods: 130,000 prehospital emergencies were screened for TBI. Inclusion criteria: Glasgow Coma Scale (GCS) score <= 8 and/or Abbreviated Injury Scale for head injuries (AIS head) score 6 2 with confirmed TBI via appropriate diagnostics. Results: Annual incidence was 7.3/100,000. Overall mortality rate was 45.8%: 182 (28%) were prehospital deaths, 116 (17.8%) patients died in hospital. Two hundred and fourteen of 352 (60.8%) surviving patients were sufficiently rehabilitated at discharge [Glasgow Outcome Scale (GOS) score = 1], but 138 patients (39.2%) survived with persisting deficits. GOS was associated with initial GCS and AIS head. Conclusion: The incidence of TBI was lower compared to the literature. The overall mortality was high, especially prehospital and early in-hospital mortality rates. Copyright (c) 2007 S. Karger AG, Basel.	Univ Witten Herdecke, Inst Res Operat Med, Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, D-51109 Cologne, Germany; Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Surg, D-51109 Cologne, Germany; Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany; Univ Cologne, Dept Neurosurg, Cologne, Germany; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANNONI JM, 1991, SCHWEIZ MED WSCHR, V121, P207; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; BOUILLON B, 1990, THEOR SURG, V5, P36; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; *BTF, 2000, J NEUROTRAUM, V17, P457; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FEARNSIDE FR, 1997, HEAD INJURY; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HARTWIG E, 1993, UNFALLCHIRURG, V96, P564; Hoffmann B, 2002, ACT NEUR S, V79, P33; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1992, HEAD INJURY, P1; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MacKenzie E J, 1989, Md Med J, V38, P725; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; MOECKE H, 1994, ANASTH INTENSIVMED, V31, P96; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROY PD, 1987, CAN J SURG, V30, P17; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	73	54	56	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-312X	1421-9921		EUR SURG RES	Eur. Surg. Res.		2007	39	6					372	379		10.1159/000107097			8	Surgery	Surgery	214FW	WOS:000249722400007	17690556				2021-06-18	
J	Bianchini, KJ; Curtis, KL; Greve, KW				Bianchini, Kevin J.; Curtis, Kelly L.; Greve, Kevin W.			Compensation and malingering in traumatic brain injury: A dose-response relationship?	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	23rd Annual Meeting of the National-Academy-of-Neuropsychology	2003	Dallas, TX	Natl Acad Neuropsychol			FAKE-BAD SCALE; RELIABLE DIGIT SPAN; MILD HEAD-INJURY; LABORATORY-INDUCED PAIN; NEUROCOGNITIVE DYSFUNCTION; SYMPTOM EXAGGERATION; COGNITIVELY INTACT; NORMATIVE DATA; CLINICAL-USE; MMPI-2	The purpose of this study was to determine if there is a dose-response relationship between potential monetary compensation and failure on psychological indicators of malingering in traumatic brain injury. 332 traumatic brain injury patients were divided into three groups based on incentive to perform poorly on neuropsychological testing: no incentive; limited incentive as provided by State law; high incentive as provided by Federal law. The rate of failure on five well-validated malingering indicators across these groups was examined. Cases handled under Federal workers compensation laws showed considerably higher rates of failure and diagnosable malingering than cases handled under State law. The findings indicate that monetary compensation associated with workers compensation claims is a major motive for exaggeration and malingering of problems attributed to work-related brain injuries. The clinician's index of suspicion regarding exaggeration and malingering of symptoms and deficits should be much higher in the context of Federal workers compensation claims, particularly in patients who have suffered only mild traumatic brain injury.	Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bianchini K, 2005, ARCH CLIN NEUROPSYCH, V20, P365, DOI 10.1016/j.acn.2004.09.003; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; BUTCHER JN, 1989, MMPI2 MANUAL ADM SCO; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Denney RL, 1996, ARCH CLIN NEUROPSYCH, V11, P589, DOI 10.1016/0887-6177(95)00042-9; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eaton DL, 2001, CASARETT DOULLS TOXI, P11; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; GRAHAM JR, 1990, MMPI2 ASSESSING PERS; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Hennekens CH, 1987, EPIDEMIOLOGY MED; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Price J R, 1997, Appl Neuropsychol, V4, P75, DOI 10.1207/s15324826an0401_10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	66	54	54	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					831	847		10.1080/13854040600875203			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000017	16980265				2021-06-18	
J	Williams, AJ; Ling, GSF; Tortella, FC				Williams, Anthony J.; Ling, Geoffrey S. F.; Tortella, Frank C.			Severity level and injury track determine outcome following a penetrating ballistic-like brain injury in the rat	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; ballistic; penetrating; gunshot wound; rat	CRANIOCEREBRAL GUNSHOT WOUNDS; COMBAT CASUALTY CARE; HEAD-INJURY; MULTIVARIATE-ANALYSIS; WARFARE	Penetrating ballistic brain injury (PBBI) is a high-energy transfer wound causing direct damage to the cerebrum. Outcome is directly related to the ballistic's anatomical path and degree of energy transfer. In this study we evaluated differences in outcome induced by altering the 'projectile' paths and severity levels of a simulated bullet wound using a newly characterized rat model of PBBI. Severity levels (5, 10, and 15%) were compared across three distinct injury paths: (1) unilateral 'frontal', (2) 'bilateral' hemispheric, and (3) unilateral 'caudal' (including cerebellum/midbrain). Outcome was assessed by differences in mortality rate and motor dysfunction (e.g. neurological and balance beam deficits). Results indicated that outcome was dependent not only on the severity level of PBBI (P < 0.00 1, r = 0.535) but also brain regions injured (P < 0.00 1, r = 0.398). A unilateral caudal injury was associated with the highest degree of mortality (up to 100%) and motor dysfunction (64-100% disability). Bilateral hemispheric injuries were also potentially fatal, while the best outcomes were associated with a unilateral frontal injury (no mortality and 14-39% motor disability). These data closely resemble clinical reports of ballistic wounds to the head and further validate the rat PBBI model with the ultimate intent to investigate novel therapeutic approaches for diagnosis and treatment of the neuropathological damage associated with PBBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Williams, AJ (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave,Bldg 503,Room 2A40, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil					BELLAMY RF, 1984, MIL MED, V149, P55; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Hinsley DE, 2005, BRIT J SURG, V92, P637, DOI 10.1002/bjs.4911; Holcomb JB, 2005, J TRAUMA, V59, P990, DOI 10.1097/01.ta.0000188010.65920.26; Hotz GA, 2000, BRAIN INJURY, V14, P649; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; Sapsford W, 2003, J R Army Med Corps, V149, P5; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; Vajkoczy P, 1999, CLIN NEUROL NEUROSUR, V101, P175, DOI 10.1016/S0303-8467(99)00033-5; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	18	54	55	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	NOV 20	2006	408	3					183	188		10.1016/j.neulet.2006.08.086			6	Neurosciences	Neurosciences & Neurology	104LB	WOS:000241958800006	17030434				2021-06-18	
J	Nishio, Y; Koda, M; Kamada, T; Someya, Y; Yoshinaga, K; Okada, S; Harada, H; Okawa, A; Moriya, H; Yamazaki, M				Nishio, Yutaka; Koda, Masao; Kamada, Takahito; Someya, Yukio; Yoshinaga, Katsunori; Okada, Seiji; Harada, Hideki; Okawa, Akihiko; Moriya, Hideshige; Yamazaki, Masashi			The use of hemopoietic stem cells derived from human umbilical cord blood to promote restoration of spinal cord tissue and recovery of hindlimb function in adult rats	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; human umbilical cord blood; hemopoiesis; stem cell; transplantation; rat	MARROW STROMAL CELL; TRAUMATIC BRAIN-INJURY; PROGENITOR CELLS; TRANSPLANTATION; EXPRESSION; STROKE; MODEL; DIFFERENTIATION; NEUROGENESIS; REGENERATION	Object. The use of human umbilical cord blood (HUCB) cells has been reported to improve functional recovery in cases of central nervous system injuries such as stroke, traumatic brain injury, and spinal cord injury (SCI). The authors investigated the effects of hemopoietic stem cells that were derived from HUCB and transplanted into the injured spinal cords of rats. Methods. One week after injury, an HUCB fraction enriched in CD34-positive cells was transplanted into the experimental group. In control animals, vehicle (Matrigel) was transplanted. Recovery of motor functions was assessed using the Basso-Beattie-Bresnahan Locomotor Scale, and immunohistochemical examinations were performed. Cells from HUCB that were CD34 positive improved functional recovery, reduced the area of the cystic cavity at the site of injury, increased the volume of residual white matter, and promoted the regeneration or sparing of axons in the injured spinal cord. Immunohistochemical examination revealed that transplanted CD34-positive cells survived in the host spinal cord for at least 3 weeks after transplantation but had disappeared by 5 weeks. The transplanted cells were not positive for neural markers, but they were positive for hemopoietic markers. There was no evidence of an immune reaction at the site of injury in either group. Conclusions. These results suggest that transplantation of a CD34-positive fraction from HUCB may have therapeutic effects for SCI. The results of this study provide important preclinical data regarding HUCB stem cell-based therapy for SCI.	Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Tougane Chiba Prefecture Hosp, Chiba, Japan; Narashino Daiiti Hosp, Chiba, Japan; Chiba Univ Hosp, Div Rehabl Med, Chiba, Japan; Kumamoto Univ, Div Hemopoiesis, Ctr Acquired Immunodeficiency Syndrome Res, Kumamoto, Japan	Yamazaki, M (corresponding author), Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Tougane Chiba Prefecture Hosp, Chiba, Japan.	masashiy@faculty.Chiba-u.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17659460] Funding Source: KAKEN		Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Broxmeyer H E, 1996, Cancer Treat Res, V84, P139; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; Buzanska L, 2002, J CELL SCI, V115, P2131; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Chung K, 2001, BRAIN RES, V895, P204, DOI 10.1016/S0006-8993(01)02092-3; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Joshi SS, 2000, CLIN CANCER RES, V6, P4351; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Koda M, 2005, NEUROREPORT, V16, P1763, DOI 10.1097/01.wnr.0000183329.05994.d7; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Newman MB, 2004, EXPERT OPIN BIOL TH, V4, P121, DOI 10.1517/14712598.4.8.1351; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; PAHWA RN, 1994, P NATL ACAD SCI USA, V91, P4485, DOI 10.1073/pnas.91.10.4485; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Takami T, 2002, J NEUROSCI, V22, P6670; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451; Zhao ZM, 2004, CELL TRANSPLANT, V13, P113, DOI 10.3727/000000004773301780; Zhao Zong-mao, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P484	36	54	72	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	NOV	2006	5	5					424	433		10.3171/spi.2006.5.5.424			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	100OO	WOS:000241678600007	17120892				2021-06-18	
J	Marx, CE; Shampine, LJ; Khisti, RT; Trost, WT; Bradford, DW; Grobin, AC; Massing, MW; Madison, RD; Butterfield, MI; Lieberman, JA; Morrow, AL				Marx, Christine E.; Shampine, Lawrence J.; Khisti, Rahul T.; Trost, William T.; Bradford, Daniel W.; Grobin, A. Chistina; Massing, Mark W.; Madison, Roger D.; Butterfield, Marian I.; Lieberman, Jeffrey A.; Morrow, A. Leslie			Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						olanzapine; fluoxetine; antipsychotic; neuroactive steroid; pregnenolone; allopregnanolone; deoxycorticosterone; neurosteroid	NEUROACTIVE STEROID ALLOPREGNANOLONE; TRAUMATIC BRAIN-INJURY; OLANZAPINE/FLUOXETINE COMBINATION; MAJOR DEPRESSION; CELL-DEATH; PROGESTERONE; MEMORY; SULFATE; NEUROSTEROIDS; MICE	Olanzapine and fluoxetine elevate the GABAergic neuroactive steroid allopregnanolone to physiologically relevant concentrations in rodent cerebral cortex. It is unknown if these agents also alter pregnenolone or deoxycorticosterone. Since olanzapine and fluoxetine in combination have clinical utility and may demonstrate synergistic effects, we investigated neuroactive steroid alterations following olanzapine, fluoxetine or coadministration. Male rats received IP vehicle, olanzapine, fluoxetine or the combination of both agents in higher-dose (0, 10, 20 or 10/20 mg/kg, respectively) and lower-dose (0, 5, 10 or 5110 mg/kg, respectively) experiments. Pregnenolone and allopregnanolone levels in hippocampus were determined by gas chromatography/mass spectrometry. Peripheral deoxycorticosterone and other steroid levels were determined by radioimmunoassay. Olanzapine, fluoxetine or the combination increased hippocampal pregnenolone and serum deoxycorticosterone in both higher- and lower-dose experiments, and elevated hippocampal allopregnanolone in higher-dose conditions. No synergistic effects on pregnenolone or allopregnanolone were observed following olanzapine and fluoxetine coadministration compared to either compound alone. Pregnenolone and its sulfate enhance learning and memory in rodent models, and therefore pregnenolone elevations may be relevant to cognitive changes in psychotic and affective disorders. Since pregnenolone decreases have been linked to depression, it is possible that olanzapine- and fluoxetine-induced pregnenolone elevations may contribute to the antidepressant actions of these agents. Published by Elsevier Inc.	Duke Univ, Med Ctr, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Mental Hlth Serv, Durham, NC USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA	Marx, CE (corresponding author), Duke Univ, Med Ctr, 508 Fulton St,Line 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Lieberman, Jeffrey/AAY-8239-2020		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH065080] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 65080] Funding Source: Medline		Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; CORYA SA, 2006, DEPRESS ANXIETY, P1; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; GEORGE MS, 1994, BIOL PSYCHIAT, V35, P775, DOI 10.1016/0006-3223(94)91139-8; Griffin LD, 1999, P NATL ACAD SCI USA, V96, P13512, DOI 10.1073/pnas.96.23.13512; Keefe RSE, 2004, AM J PSYCHIAT, V161, P985, DOI 10.1176/appi.ajp.161.6.985; Khisti RT, 2005, BRAIN RES, V1049, P104, DOI 10.1016/j.brainres.2005.05.007; Khisti RT, 2000, BRAIN RES, V865, P291, DOI 10.1016/S0006-8993(00)02373-8; Koch S, 2004, NEUROPHARMACOLOGY, V46, P232, DOI 10.1016/j.neuropharm.2003.09.001; Kodamo M, 2004, BIOL PSYCHIAT, V56, P570, DOI 10.1016/j.biopsych.2004.07.008; Lewis DA, 2004, PSYCHOPHARMACOLOGY, V174, P143, DOI 10.1007/s00213-003-1673-x; Lewis DA, 2004, ANN NY ACAD SCI, V1021, P64, DOI 10.1196/annals.1308.008; Maragnoli ME, 2004, BIOL PSYCHIAT, V55, P1095, DOI 10.1016/j.biopsych.2004.02.003; Marx CE, 2000, BIOL PSYCHIAT, V47, P1000, DOI 10.1016/S0006-3223(99)00305-4; Marx CE, 2003, NEUROPSYCHOPHARMACOL, V28, P1, DOI 10.1038/sj.npp.1300015; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; MORROW AL, 1990, MOL PHARMACOL, V37, P263; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schule C, 2006, MOL PSYCHIATR, V11, P261, DOI 10.1038/sj.mp.4001782; Schumacher M, 2001, BRAIN RES REV, V37, P343, DOI 10.1016/S0165-0173(01)00139-4; Seager MA, 2004, BIOL PSYCHIAT, V55, P1103, DOI 10.1016/j.biopsych.2004.02.012; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Sharma T, 2003, PSYCHOPHARMACOLOGY, V169, P398, DOI 10.1007/s00213-003-1506-y; Shelton RC, 2001, AM J PSYCHIAT, V158, P131, DOI 10.1176/appi.ajp.158.1.131; Shelton RC, 2005, J CLIN PSYCHIAT, V66, P1289, DOI 10.4088/JCP.v66n1012; Tohen M, 2003, ARCH GEN PSYCHIAT, V60, P1079, DOI 10.1001/archpsyc.60.11.1079; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P13451, DOI 10.1021/bi026109w; Ugale RR, 2004, NEUROPSYCHOPHARMACOL, V29, P1597, DOI 10.1038/sj.npp.1300460; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N; WIELAND S, 1995, PSYCHOPHARMACOLOGY, V118, P65, DOI 10.1007/BF02245251; Zhang W, 2000, NEUROPSYCHOPHARMACOL, V23, P250, DOI 10.1016/S0893-133X(00)00119-6	46	54	57	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	AUG	2006	84	4					609	617		10.1016/j.pbb.2006.07.032			9	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	101ZI	WOS:000241779800006	16996120				2021-06-18	
J	Schonberger, M; Humle, F; Teasdale, TW				Schonberger, M; Humle, F; Teasdale, TW			The development of the therapeutic working alliance, patients' awareness and their compliance during the process of brain injury rehabilitation	BRAIN INJURY			English	Article						therapeutic working alliance; awareness; compliance; acquired brain injury; rehabilitation; process research	HEAD-INJURY; SELF-AWARENESS; DEFICITS	Purpose: To examine the development and interaction of the therapeutic alliance, patients' compliance and awareness during the process of brain injury rehabilitation and the role of demographic and injury related variables in this process. Subjects were 86 patients who underwent a holistic neuropsychological outpatient rehabilitation programme. Patients had suffered a traumatic brain injury (n = 27), a cerebrovascular accident (n = 49) or another neurological insult (n = 10). Measures: The therapeutic alliance between clients and their primary therapists, clients' awareness and their compliance were rated four times during the 14-week rehabilitation programme. The therapeutic alliance was rated by both clients and therapist using the Working Alliance Inventory (WAI), awareness and compliance were rated by the therapists. Results: The development of the process measures over time is described in the article. Clients' and therapists' perspectives on their alliance tended to converge over time. Clients' experience of their emotional bond with their therapist added as much to the prediction of clients' awareness as the localization of their brain injury. Clients' awareness was related to their compliance and mediated the impact of the therapeutic alliance on their compliance. Discussion: A good working alliance is the basis of successful rehabilitative work. The article discusses therapeutic implications of the results.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark; Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen, Denmark	Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CONSTANTINO MJ, 2002, WORKING ALLIANCE FLA, P81; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; Hatcher RL, 1999, PSYCHOTHER RES, V9, P405, DOI 10.1080/10503309912331332831; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lambert M.J., 2002, PSYCHOTHERAPY RELATI, P17; Lewis L., 1991, AWARENESS DEFICIT BR, P223; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; SCHONBERGER M, 2005, IN PRESS NEUROPSYCHO; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Tracey T. J., 1989, PSYCHOL ASSESS, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207]; VOLMER T, 1998, COMPLIANCE SELBSTMAN, P45	28	54	55	0	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2006	20	4					445	454		10.1080/02699050600664772			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700009	16716990				2021-06-18	
J	Da Dalt, L; Marchi, AG; Laudizi, L; Crichiutti, G; Messi, G; Pavanello, L; Valent, F; Barbone, F				Da Dalt, L; Marchi, AG; Laudizi, L; Crichiutti, G; Messi, G; Pavanello, L; Valent, F; Barbone, F			Predictors of intracranial injuries in children after blunt head trauma	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						closed head trauma; childhood; intracranial injury; clinical assessment	PEDIATRIC-PATIENTS; BRAIN-INJURIES; CONSCIOUSNESS; MANAGEMENT; CT; HOSPITALIZATION; YOUNGER; CANCER; RISKS	This study was conducted to determine if clinical features can predict the risk of intracranial injury (ICI) in pediatric closed head trauma. We enrolled 3,806 children under 16 years consecutively referred for acute closed head trauma to the paediatric emergency room of five Italian children's hospitals. Relevant outcomes were death and diagnosis of ICI. Clinical symptoms and signs were evaluated as possible outcome predictors. Children were also classified into five groups according to their clinical presentation. The association of ICI with signs and symptoms and the appropriateness of the five-group classification in predicting the likelihood of ICI were evaluated by logistic regression analyses. ICI was diagnosed in 22 children; 2 of them died. The risk of fatal and nonfatal ICI was 0.5 and 5.2 per 1,000 children with closed head trauma respectively. Significant associations were found between ICI and loss ofThis study was conducted to determine if clinical features can predict the risk of intracranial injury (ICI) in pediatric closed head trauma. We enrolled 3,806 children under 16 years consecutively referred for acute closed head trauma to the paediatric emergency room of five Italian children's hospitals. Relevant outcomes were death and diagnosis of ICI. Clinical symptoms and signs were evaluated as possible outcome predictors. Children were also classified into five groups according to their clinical presentation. The association of ICI with signs and symptoms and the appropriateness of the five-group classification in predicting the likelihood of ICI were evaluated by logistic regression analyses. ICI was diagnosed in 22 children; 2 of them died. The risk of fatal and nonfatal ICI was 0.5 and 5.2 per 1,000 children with closed head trauma respectively. Significant associations were found between ICI and loss of consciousness, prolonged headache, persistent drowsiness, abnormal mental status, focal neurological signs, signs of skull fracture in non-frontal areas and signs of basal skull fracture. The five-group classification of children allowed an excellent prediction in terms of likelihood of ICI (ROC area 0.972). Conclusions: Selection of children with closed head trauma based on different combinations of signs and symptoms allows for early identification of subjects at different risk for ICI. In patients with minor head injuries, the absence of loss of consciousness, drowsiness, amnesia, prolonged headache, clinical evidence of basal or non-frontal skull fracture identified 100% of children without lesions. Validation of our results with a larger sample of patients with ICI would be highly desirable.	Univ Padua, Dipartimento Pediat, I-35128 Padua, Italy; IRCCS, Burlo Garofolo Trieste, Trieste, Italy; Univ Modena, Pediat Clin, I-41100 Modena, Italy; Univ Udine, Pediat Clin, I-33100 Udine, Italy; Univ Udine, Cattedra Igiene & Epidemiol, I-33100 Udine, Italy	Da Dalt, L (corresponding author), Univ Padua, Dipartimento Pediat, Via Giustiniani 3, I-35128 Padua, Italy.	dadalt@pediatria.unipd.it	Valent, Francesca/J-4759-2016	Valent, Francesca/0000-0002-4071-0897; Barbone, Fabio/0000-0003-1337-5111			Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; BEGG CB, 1991, STAT MED, V10, P1887, DOI 10.1002/sim.4780101205; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown FD, 2000, J ACCID EMERG MED, V17, P268; DAVIES RL, 1995, PEDIATRICS, V95, P345; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunning J, 2004, ARCH DIS CHILD, V89, P763, DOI 10.1136/adc.2003.042523; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; FERNANDEZ JB, 1998, ESP PEDIAT, V48, P122; Glasgow JFT, 2000, ARCH DIS CHILD, V82, P333, DOI 10.1136/adc.82.4.333; Greenes DS, 2003, ANN EMERG MED, V42, P515, DOI 10.1067/S0196-0644(03)00631-0; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Holmes JF, 2004, ANN EMERG MED, V43, P706, DOI 10.1016/j.annemergmed.2003.11.008; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; *ISTAT, 2000, CAUS MORT; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; Jan MMS, 1997, J PEDIATR-US, V130, P134, DOI 10.1016/S0022-3476(97)70322-6; Kuppermann N, 2004, ARCH DIS CHILD, V89, P593, DOI 10.1136/adc.2003.046821; Langlois J., 2001, TRAUMATIC BRAIN INJU, P1; Le Hors-Albouze H, 2003, ARCH PEDIATRIE, V10, P82, DOI 10.1016/S0929-693X(03)00232-X; Murgio A, 2001, CHILD NERV SYST, V17, P257, DOI 10.1007/s003810000403; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; ROSENTHAL BW, 1989, J PEDIATR-US, V115, P346, DOI 10.1016/S0022-3476(89)80830-3; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014	35	54	54	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0340-6199	1432-1076		EUR J PEDIATR	Eur. J. Pediatr.	MAR	2006	165	3					142	148		10.1007/s00431-005-0019-6			7	Pediatrics	Pediatrics	009RC	WOS:000235129000002	16311740				2021-06-18	
J	Coats, B; Margulies, SS				Coats, Brittany; Margulies, Susan S.			Material properties of porcine parietal cortex	JOURNAL OF BIOMECHANICS			English	Article						gray matter; material properties; porcine; brain	BRAIN	Computational models of the head can be used to simulate events associated with traumatic brain injury and to design protective equipment and environments. Accurate material property descriptions of biological tissues are crucial to the development of computational models that mimic human responses. Recent finite element models of adult head injury assign distinct homogeneous properties to white and gray matter regions within the brain, based on limited regional data. However, white matter is usually considered homogeneous, despite recent reports of significant mechanical property differences between corpus callosum and corona radiata. In this study, we extend our investigation of homogeneity to gray matter by measuring stiffness of cerebral cortex and comparing it to thalamus from our previous work. Using a parallel plate shear-testing device, we performed a sequence of stress relaxation tests at 2.5%, 5%, 10%, 20%, 30%, 40%, and then 50% strain. Force and displacement were measured and used to determine the stiffness in two different porcine cortical gray matter regions. While no significant difference was found between the two cortical regions, cortical gray matter was significantly less stiff than previously reported values of porcine thalamic gray matter (p < 0.01) and human cortical gray matter (p < 0.001). These data indicate that while intraregional gray matter may be considered homogenous, there exists heterogeneity between differing regions of the brain. The assumption of gray matter homogeneity should be carefully considered in future finite element models of the head. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Coats, Brittany/A-4523-2009		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39679] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER		Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bonovas PM, 2001, PHYSIOL MEAS, V22, P65, DOI 10.1088/0967-3334/22/1/309; King A.I., 2003, IRCOBI C LISB PORT, P1; Miller RT, 1998, P 42 STAPP CAR CRASH; *NCIPC, 2001, INJ FACT BOOK 2001 2; OGDEN RW, 1984, NONLINEAR ELASTIC DE; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; SHUCK L, 1972, J BASIC ENG, P905; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhou C, 1995, P 39 STAPP CAR CRASH	10	54	54	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.		2006	39	13					2521	2525		10.1016/j.jbiomech.2005.07.020			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	094MG	WOS:000241242900020	16153652				2021-06-18	
J	Laskowitz, DT; Fillit, H; Yeung, N; Toku, K; Vitek, MP				Laskowitz, D. T.; Fillit, H.; Yeung, N.; Toku, K.; Vitek, M. P.			Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease	ACTA NEUROLOGICA SCANDINAVICA			English	Article; Proceedings Paper	Conference on Cholesterol, Alzheimers Disease and Statins (CAS)	APR 14-15, 2005	Stockholm, SWEDEN	Swedish Fdn Old Servants, Int Task Force Prevent Coronary Heart Dis		apolipoprotein E; inflammation; peptides; neuroprotection	GLOBAL CEREBRAL-ISCHEMIA; E-MIMETIC PEPTIDES; E-DEFICIENT MICE; APOE GENOTYPE; MICROGLIAL ACTIVATION; NEURONAL DAMAGE; TYPE-4 ALLELE; PROTEIN; BINDING; RISK	The apolipoprotein E4 isoform (apoE4) was initially identified as a susceptibility gene for the development of Alzheimer's disease, and has also recently been associated with poor outcome after acute traumatic and ischemic brain injury. One mechanism by which apoE may influence outcome in acute and chronic neurological disease is by downregulating glial activation and the neuroinflammatory response. Because it does not readily cross the blood-brain barrier (BBB), the apoE holoprotein has limited therapeutic potential. However, smaller peptides derived from the receptor binding region of apoE have been developed that mimic the functional anti-inflammatory and neuroprotective effects of the intact apoE protein. These apoE-derived therapeutic peptides cross the BBB and have been demonstrated to improve functional and histological outcomes in murine models of brain injury. Thus, the development of apoE-derived peptides represent a novel therapeutic strategy for the treatment of acute and chronic neurological disease.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Inst Study Aging, New York, NY USA; Cognosci Inc, Res Triangle Pk, NC USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS4487, 5R44 NS 043954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS043954] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Andersen OM, 2003, CHEMBIOCHEM, V4, P1137, DOI 10.1002/cbic.200300580; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; AVILA EM, 1982, J BIOL CHEM, V257, P5900; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Croy JE, 2004, BIOCHEMISTRY-US, V43, P7328, DOI 10.1021/bi036208p; CURTISS LK, 1981, J IMMUNOL, V126, P1382; de Bont N, 1999, J LIPID RES, V40, P680; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GALLO G, 1994, AM J PATHOL, V145, P526; GURUNATH R, 1994, BIOCHEM BIOPH RES CO, V202, P241, DOI 10.1006/bbrc.1994.1918; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hu JR, 1998, J NEUROCHEM, V71, P1626; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLONS JC, 2000, NEUROSURGERY, V47, P2000	43	54	59	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.		2006	114			185			15	20		10.1111/j.1600-0404.2006.00680.x			6	Clinical Neurology	Neurosciences & Neurology	069HX	WOS:000239438100004	16866906				2021-06-18	
J	Mullis, BH; Dahners, LE				Mullis, BH; Dahners, LE			Hip arthroscopy to remove loose bodies after traumatic dislocation	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						hip dislocation; hip arthroscopy; loose bodies; acetabulum; femoral head	POSTERIOR DISLOCATION; FRACTURE; BODY; JOINT	Objectives: This study was designed to review the incidence of arthroscopically detected intra-articular loose bodies found in patients after traumatic hip dislocation or small acetabular wall fracture which would not otherwise be treated without surgery. Design: Retrospective review Setting: Level 1 academic trauma center. Patients: Thirty-six patients who sustained traumatic hip injuries and subsequently had 39 hip arthroscopies between November 1997 and January 2004 were reviewed. Intervention: All patients had standard AP pelvis x-rays and CT scans performed. At our institution, patients with hip dislocations or acetabular wall fractures not otherwise requiring Surgery are routinely offered hip arthroscopy to remove loose bodies. The radiographs were reviewed to determine incidence of loose bodies or nonconcentric reduction before hip arthroscopy. Chart review provided incidence of loose bodies found during arthroscopy. Main Outcome Measurements: Comparison was made between radiographic data obtained preoperatively and operative findings. Results: Loose bodies were found in the hips of 33 of 36 patient (92%) who were arthroscoped. Loose bodies were found in 7 of 9 cases (78%) in which standard radiographic Studies (AP pelvis x-rays and CT scan) found no loose bodies and a concentric reduction. Conclusions: Loose bodies are routinely present after closed treatment of hip dislocations or wall fractures not otherwise requiring surgery, even when radiographs are negative. Hip arthroscopy may be indicated for loose body removal when open treatment is not otherwise necessary.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Florida Orthopaed Inst, Dept Orthopaed, Tampa, FL USA	Dahners, LE (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055,Room 3153, Chapel Hill, NC 27599 USA.	led@med.unc.edu	MULLIS, BRIAN/Q-3123-2019				BAIRD RA, 1982, RADIOLOGY, V145, P661, DOI 10.1148/radiology.145.3.7146393; Bartlett CS, 1998, J ORTHOP TRAUMA, V12, P294, DOI 10.1097/00005131-199805000-00014; Dahners LE, 1997, J ORTHOP TRAUMA, V11, P374, DOI 10.1097/00005131-199707000-00014; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; ERIKSSON E, 1986, ORTHOPEDICS, V9, P169; EVANS CH, 1984, ARTHRITIS RHEUM, V27, P200, DOI 10.1002/art.1780270212; FRICK SL, 1995, J ORTHOP TRAUMA, V9, P388, DOI 10.1097/00005131-199505000-00005; Glick J M, 1987, Arthroscopy, V3, P4, DOI 10.1016/S0749-8063(87)80003-8; Kashiwagi N, 2001, ARTHROSCOPY, V17, P67, DOI 10.1053/jars.2001.8024; KEENE GS, 1994, INJURY, V25, P507, DOI 10.1016/0020-1383(94)90090-6; LEVIN PE, 1998, SKELETAL TRAUMA FRAC, P1713; Routt ML, 2005, J ORTHOP TRAUMA, V19, P223; Sampson TG, 2001, CLIN SPORT MED, V20, P831, DOI 10.1016/S0278-5919(05)70288-X; Svoboda SJ, 2003, ARTHROSCOPY, V19, P777, DOI 10.1016/S0749-8063(03)00696-0; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548; Yamamoto Y, 2003, ARTHROSCOPY, V19, P269, DOI 10.1053/jars.2003.50033	18	54	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	JAN	2006	20	1					22	26		10.1097/01.bot.0000188038.66582.ed			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	014QP	WOS:000235495200005	16424806				2021-06-18	
J	Skold, MK; Risling, M; Holmin, S				Skold, MK; Risling, M; Holmin, S			Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						glial fibrillary acidic protein; microtubuli-associated protein 2; neuron-specific enolase; rat; S100 beta	FOCAL CEREBRAL-ISCHEMIA; INTRACEREBRAL INFLAMMATORY RESPONSE; STIMULATES AXONAL OUTGROWTH; VEGF MESSENGER-RNA; RAT-BRAIN; FACTOR EXPRESSION; SPINAL-CORD; PERMEABILITY FACTOR; IN-VITRO; NEUROBIOCHEMICAL MARKERS	Angiogenesis following traumatic brain injuries (TBIs) may be of importance for post-traumatic reparative processes and the development of secondary injuries. We have previously shown expression of vascular endothelial growth factor (VEGF), a major regulator of endothelial cell proliferation, angiogenesis and vascular permeability, and VEGF receptors (VEGFR1 and 2) after TBI in rat. In the present work we tried to further elucidate the role of VEGF after TBI by performing specific VEGFR2 activity inhibition. In rats subjected to VEGFR2 blockage we report an increased haemorrhagic area (P < 0.05), early increase in serum levels of neural injury marker neuron-specific enolase (P < 0.05) and glial injury marker S100 beta (P < 0.05), and increased numbers of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labelling- (TUNEL-) and FluoroJade B- (P < 0.05) positive cells, all increases preceding the known VEGF/VEGFR vascular response in brain trauma. An increase in lesion area, as measured by decreased microtubuli-associated protein 2 expression (P < 0.05) and increased glial fibrillary acidic protein reactivity (P < 0.05), could also be demonstrated. In addition, vascular density, as measured by von Willebrandt factor-positive cells, was decreased (P < 0.05). No differences in post-traumatic inflammatory response, as measured by stainings for macrophages, granulocytes and intracellular adhesion molecules, were shown between the groups. Taken together, our findings point towards VEGF/VEGFR2 up-regulation after TBI as being an important endogenous cytoprotective mechanism in TBI. The possible importance of VEGF on the vascular, neuronal and glial compartments of the neurovascular unit after TBI is discussed.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Def Med, FOI, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Trauma Res, S-17177 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Neurosci, Sect Clin CNS Res, Stockholm, Sweden	Skold, MK (corresponding author), Karolinska Inst, Dept Neurosci, Retzius Vag 8,B1-5, S-17177 Stockholm, Sweden.	Mattias.Skold@neuro.ki.se	SkAld, Mattias/AAJ-8253-2020	Holmin, Staffan/0000-0002-1628-1615			Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367; Fong TAT, 1999, CANCER RES, V59, P99; Gelaw B, 2001, SURGERY, V130, P497, DOI 10.1067/msy.2001.115833; Gerber HP, 1999, DEVELOPMENT, V126, P1149; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; Goldman CK, 1997, NEUROSURGERY, V40, P1269, DOI 10.1097/00006123-199706000-00029; Guan Wei, 2003, Chin J Traumatol, V6, P218; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOLMIN S, 1997, INFLAMMATION BRAIN C; ImperatoKalmar EL, 1997, EXP NEUROL, V145, P322, DOI 10.1006/exnr.1997.6449; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, NEUROSCIENCE, V100, P713, DOI 10.1016/S0306-4522(00)00331-6; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022; Kish PE, 2001, J NEURO-ONCOL, V53, P243, DOI 10.1023/A:1012222522359; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Krum JM, 1998, EXP NEUROL, V154, P57, DOI 10.1006/exnr.1998.6930; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Manoonkitiwongsa PS, 2004, J CEREBR BLOOD F MET, V24, P693, DOI 10.1097/01.WCB.0000126236.54306.21; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marchi N, 2003, J NEUROSCI, V23, P1949; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Matsuzaki H, 2001, FASEB J, V15, P1218; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Proescholdt MA, 2002, J NEUROPATH EXP NEUR, V61, P914, DOI 10.1093/jnen/61.10.914; Provias J, 1997, NEUROSURGERY, V40, P1016, DOI 10.1097/00006123-199705000-00027; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Risau W, 1998, PATHOL BIOL, V46, P171; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rosenstein JM, 2003, J NEUROSCI, V23, P11036; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schaller B, 2004, J CEREBR BLOOD F MET, V24, P351, DOI 10.1097/00004647-200404000-00001; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Skold MK, 2004, EXP NEUROL, V188, P20, DOI 10.1016/j.expneurol.2004.03.024; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sorci G, 1998, BBA-MOL CELL RES, V1448, P277, DOI 10.1016/S0167-4889(98)00134-7; Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takamoto Takeshi, 2001, Kobe Journal of Medical Sciences, V47, P181; Ulger H, 2002, ANAT HISTOL EMBRYOL, V31, P31, DOI 10.1046/j.1439-0264.2002.00357.x; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; West H, 2005, DEVELOPMENT, V132, P1855, DOI 10.1242/dev.01732; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	97	54	58	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2006	23	1					21	34		10.1111/j.1460-9568.2005.04527.x			14	Neurosciences	Neurosciences & Neurology	008PG	WOS:000235052400003	16420412				2021-06-18	
J	von Gertten, C; Morales, AF; Holmin, S; Mathiesen, T; Nordqvist, ACS				von Gertten, C; Morales, AF; Holmin, S; Mathiesen, T; Nordqvist, ACS			Genomic responses in rat cerebral cortex after traumatic brain injury	BMC NEUROSCIENCE			English	Article							BINDING-PROTEIN-DELTA; GENE-EXPRESSION; PROTHYMOSIN-ALPHA; MICROARRAY ANALYSIS; ALTERED EXPRESSION; GROWTH-FACTOR; GLIAL-CELLS; OSTEOPONTIN; HIPPOCAMPUS; CD44	Background: Traumatic brain injury (TBI) initiates a complex sequence of destructive and neuroprotective cellular responses. The initial mechanical injury is followed by an extended time period of secondary brain damage. Due to the complicated pathological picture a better understanding of the molecular events occurring during this secondary phase of injury is needed. This study was aimed at analysing gene expression patterns following cerebral cortical contusion in rat using high throughput microarray technology with the goal of identifying genes involved in an early and in a more delayed phase of trauma, as genomic responses behind secondary mechanisms likely are time-dependent. Results: Among the upregulated genes 1 day post injury, were transcription factors and genes involved in metabolism, e. g. STAT-3, C/EBP-delta and cytochrome p450. At 4 days post injury we observed increased gene expression of inflammatory factors, proteases and their inhibitors, like cathepsins, alpha-2-macroglobulin and C1q. Notably, genes with biological function clustered to immune response were significantly upregulated 4 days after injury, which was not found following 1 day. Osteopontin and one of its receptors, CD-44, were both upregulated showing a local mRNA- and immunoreactivity pattern in and around the injury site. Fewer genes had decreased expression both 1 and 4 days post injury and included genes implicated in transport, metabolism, signalling, and extra cellular matrix formation, e. g. vitronectin, neuroserpin and angiotensinogen. Conclusion: The different patterns of gene expression, with little overlap in genes, 1 and 4 days post injury showed time dependence in genomic responses to trauma. An early induction of factors involved in transcription could lead to the later inflammatory response with strongly upregulated CD-44 and osteopontin expression. An increased knowledge of genes regulating the pathological mechanisms in trauma will help to find future treatment targets. Since trauma is a risk factor for development of neurodegenerative disease, this knowledge may also reduce late negative effects.	Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Sect Clin CNS Res, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Mol Med, Stockholm, Sweden	von Gertten, C (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Sect Clin CNS Res, SE-17176 Stockholm, Sweden.	Christina.von.Gertten@cns.ki.se; Amilcar.Flores@molmed.ki.se; Staffan.Holmin@karolinska.se; Tiit.Mathiesen@karolinska.se; Anki.Nordqvist@cns.ki.se		Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Boan F, 2001, CYTOGENET CELL GENET, V93, P171, DOI 10.1159/000056980; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flores-Morales A, 2001, ENDOCRINOLOGY, V142, P3163, DOI 10.1210/en.142.7.3163; Gao CJ, 2003, BIOCHEM BIOPH RES CO, V309, P120, DOI 10.1016/S0006-291X(03)01534-1; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002-0235; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Kim MD, 2004, J NEUROIMMUNOL, V151, P78, DOI 10.1016/j.jneuroim.2004.02.014; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KURY P, 2004, FASEB J, V29, P29; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Marshall J, 2003, NEURON, V39, P625, DOI 10.1016/S0896-6273(03)00496-3; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Niquet J, 1996, GLIA, V16, P359, DOI 10.1002/(SICI)1098-1136(199604)16:4<359::AID-GLIA8>3.0.CO;2-V; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang XK, 2002, J NEUROCHEM, V83, P1172, DOI 10.1046/j.1471-4159.2002.01225.x; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Won JS, 2003, J NEUROSCI, V23, P7470; Yang CH, 2004, EXP CELL RES, V298, P197, DOI 10.1016/j.yexcr.2004.04.008; Zalewska T, 2003, BRAIN RES, V977, P62, DOI 10.1016/S0006-8993(03)02742-2	49	54	55	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	NOV 30	2005	6								69	10.1186/1471-2202-6-69			11	Neurosciences	Neurosciences & Neurology	992PV	WOS:000233897100001	16318630	DOAJ Gold, Green Published			2021-06-18	
J	Bledsoe, GH; Li, GH; Levy, F				Bledsoe, GH; Li, GH; Levy, F			Injury risk in professional boxing	SOUTHERN MEDICAL JOURNAL			English	Article						boxing; head injury; professional sports	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; DEMENTIA-PUGILISTICA; BOXERS; CONCUSSION; SPORTS	Objective: Although a popular endeavor, boxing has fallen under increased scrutiny because of its association with traumatic brain injury. However, few studies have investigated the overall epidemiology of boxing injuries from representative samples, and no study has ever documented the incidence of injuries in female boxers. This study is a review of professional boxing data from the state of Nevada from September 2001 through March 2003. Materials and Methods: Medical and outcome data for all professional boxing matches occurring in Nevada between September 2001 and March 2003 (n = 524 matches) were analyzed on the basis of a pair-matched, case-control design. Cases were boxers who received an injury during the boxing matches. Boxers who were not injured served as control subjects. Both conditional and unconditional logistic regression models were used to assess risk factors for injury. Results: The overall incidence rate of injury was 17.1 per 100 boxer-matches, or 3.4 per 100 boxer-rounds. Facial laceration accounted for 51% of all injuries, followed by hand injury (17%), eye injury (14%), and nose injury (5%). Male boxers were significantly more likely than female boxers to receive injuries (3.6 versus 1.2 per 100 boxer-rounds, P = 0.01). Male boxing matches also ended in knockouts and technical knockouts more often than did female matches (P < 0.001). The risk of injury for those who lost the matches was nearly twice the risk for the winners. Those who lost by knockout had double the risk of injury compared with those who lost by other means. Neither age nor weight was significantly associated with the risk of injury. Conclusions: The injury rate in professional boxing matches is high, particularly among male boxers. Superficial facial lacerations are the most common injury reported. Male boxers have a higher rate of knockout and technical knockouts than female boxers. Further research is necessary to determine the outcomes of injury, particularly the long-term neurologic outcome differences between sexes.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21287 USA	Bledsoe, GH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 600 N Wolfe St,Marburg B-186, Baltimore, MD 21287 USA.	gbledso1@jhmi.edu					ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Bents RT, 2003, MED SCI SPORT EXER, V35, P1645, DOI 10.1249/01.MSS.0000089340.89660.EB; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; Constantoyannis C, 2004, BRIT J SPORT MED, V38, P78, DOI 10.1136/bjsm.2002.001123; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Hazar M, 2002, BRIT J SPORT MED, V36, P428, DOI 10.1136/bjsm.36.6.428; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; NOBLE C, 1987, AM J SPORT MED, V15, P342, DOI 10.1177/036354658701500408; Ooi A, 2003, EUR J CARDIO-THORAC, V24, P1043, DOI 10.1016/S1010-7940(03)00579-7; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Powell JW, 2001, J ATHL TRAINING, V36, P307; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Ross RT, 1999, MIL MED, V164, P68; Unterharnscheidt F, 1995, Rev Neurol, V23, P847; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F, 1995, Rev Neurol, V23, P1013; Unterharnscheidt F, 1995, Rev Neurol, V23, P833; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	31	54	57	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	OCT	2005	98	10					994	998		10.1097/01.smj.0000182498.19288.e2			5	Medicine, General & Internal	General & Internal Medicine	982RC	WOS:000233178300009	16295814				2021-06-18	
J	Lange, RT; Iverson, GL; Zakrzewski, MJ; Ethel-King, PE; Franzen, MD				Lange, RT; Iverson, GL; Zakrzewski, MJ; Ethel-King, PE; Franzen, MD			Interpreting the trail making test following traumatic brain injury: Comparison of traditional time scores and derived indices	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	109th Annual Convention of the American-Psychological-Association	AUG 24-28, 2001	SAN FRANCISCO, CA	Amer Psychol Assoc			DRUG-ABUSE; SAMPLE; AGE; PERFORMANCE; DEPRESSION; IMPAIRMENT; ETHNICITY; DEMENTIA; UTILITY; SEX	The purpose of this study was to examine the clinical application of traditional time scores and various derived indices from the Trail Making Test (THT) in a sample of 571 patients with acute traumatic brain injury (TBI). Participants were classified into four injury severity groups. A clear linear relation between injury severity and THT performance was demonstrated, with the more severely brain injured patients performing more poorly on most measures. Hierarchical logistic regression analysis of THT time scores across binary extreme groups based on injury severity resulted in high classification rates for patients with very mild TBI (93.0% correctly classified) and low classification rates for patients with moderate to severe TBI (50.0% correctly classified). However, TMT derived indices did not provide a unique contribution to test interpretation beyond what is already available from Part A and B separately.	Riverview Hosp, Coquitlam, BC V3C 4J2, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Lange, RT (corresponding author), Riverview Hosp, 124 ADMIN Bldg,2601 Lougheed Highway, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Basso MR, 2003, J CLIN EXP NEUROPSYC, V25, P893, DOI 10.1076/jcen.25.7.893.16489; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; GRANT I, 1987, J CLIN PSYCHIAT, V48, P319; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; Heilbronner R L, 1991, Arch Clin Neuropsychol, V6, P251, DOI 10.1016/0887-6177(91)90002-Q; Horton AM, 2003, INT J NEUROSCI, V113, P595, DOI 10.1080/00207450390162317; Horton AM, 2003, ARCH CLIN NEUROPSYCH, V18, P49, DOI 10.1016/S0887-6177(01)00183-4; Horton AM, 2002, INT J NEUROSCI, V112, P429, DOI 10.1080/00207450290025563; Horton AM, 2002, INT J NEUROSCI, V112, P1075, DOI 10.1080/00207450290026067; Horton AM, 2002, INT J NEUROSCI, V112, P565, DOI 10.1080/00207450290025653; Horton AM, 2002, INT J NEUROSCI, V112, P225, DOI 10.1080/00207450212021; Horton AM, 2001, INT J NEUROSCI, V110, P173, DOI 10.3109/00207450108986544; Horton AM, 2001, INT J NEUROSCI, V111, P123, DOI 10.3109/00207450108986557; Horton AM, 2001, INT J NEUROSCI, V111, P101, DOI 10.3109/00207450108986555; Horton AM, 2001, INT J NEUROSCI, V109, P281, DOI 10.3109/00207450108986539; Horton AM, 2001, INT J NEUROSCI, V108, P281, DOI 10.3109/00207450108986518; Kim MS, 2003, PSYCHIAT RES-NEUROIM, V123, P109, DOI 10.1016/S0925-4927(03)00045-3; KLESGES RC, 1984, J CLIN NEUROPSYCHOLO, V1, P29; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; McCaffrey R J, 1989, Arch Clin Neuropsychol, V4, P393, DOI 10.1016/0887-6177(89)90030-9; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R. M., 1992, TRAIL MAKING TEST MA; REITAN RM, 1959, J NERV MENT DIS, V129, P257, DOI 10.1097/00005053-195909000-00006; Reitan RM., 1985, HALSTEAD REITAN NEUR; Roberts C, 2003, INT J NEUROSCI, V113, P747, DOI 10.1080/00207450390200062; Roberts C, 2002, INT J NEUROSCI, V112, P337, DOI 10.1080/00207450212031; Roberts C, 2002, INT J NEUROSCI, V112, P985, DOI 10.1080/00207450290025987; Roberts C, 2002, INT J NEUROSCI, V112, P575, DOI 10.1080/00207450290025662; Roberts C, 2001, INT J NEUROSCI, V110, P99, DOI 10.3109/00207450108994225; Roberts C, 2001, INT J NEUROSCI, V109, P273, DOI 10.3109/00207450108986538; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sellers A. H., 1992, PSYCHOTHERAPY PRIVAT, V11, P47; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; *US WAR DEP ADJ GE, 1994, MAN ARM IND TEST	52	54	54	2	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2005	27	7					897	906		10.1080/1380339049091290			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	970GN	WOS:000232293400010	16183622				2021-06-18	
J	Petzold, GC; Windmuller, O; Haack, S; Major, S; Buchheim, K; Megow, D; Gabriel, S; Lehmann, TN; Drenckhahn, C; Peters, O; Meierkord, H; Heinemann, U; Dirnagl, U; Dreier, JP				Petzold, GC; Windmuller, O; Haack, S; Major, S; Buchheim, K; Megow, D; Gabriel, S; Lehmann, TN; Drenckhahn, C; Peters, O; Meierkord, H; Heinemann, U; Dirnagl, U; Dreier, JP			Increased extracellular K+ concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia	STROKE			English	Article						brain injuries; N-methyl-D-aspartate; spreading cortical depression; stroke; subarachnoid hemorrhage; trauma	FOCAL CEREBRAL-ISCHEMIA; SUBARACHNOID SPACE; PERIINFARCT DEPOLARIZATIONS; ANOXIC DEPOLARIZATION; INTRACRANIAL-PRESSURE; RATS; INJURY; BRAIN; HEMORRHAGE; CORTEX	Background and Purpose - Spreading depression (SD)-like depolarizations may augment neuronal damage in neurovascular disorders such as stroke and traumatic brain injury. Spreading ischemia ( SI), a particularly malignant variant of SD-like depolarization, is characterized by inverse coupling between the spreading depolarization wave and cerebral blood flow. SI has been implicated in particular in the pathophysiology of subarachnoid hemorrhage. Under physiological conditions, SD is blocked by N-methyl-D-aspartate receptor ( NMDAR) antagonists. However, because both SD-like depolarizations and SI occur in presence of an increased extracellular K+ concentration ([K+](o)), we tested whether this increase in baseline [K+](o) would reduce the efficacy of NMDAR antagonists. Methods - Cranial window preparations, laser Doppler flowmetry, and K+-sensitive/reference microelectrodes were used to record SD, SD-like depolarizations, and SI in rats in vivo; microelectrodes and intrinsic optical signal measurements were used to record SD and SD-like depolarizations in human and rat brain slices. Results - In vivo, the noncompetitive NMDAR antagonist dizocilpine (MK-801) blocked SD propagation under physiological conditions, but did not block SD-like depolarizations or SI under high baseline [K+](o). Similar results were found in human and rat neocortical slices with both MK-801 and the competitive NMDAR antagonist D-2-amino-5-phosphonovaleric acid. Conclusions - Our data suggest that elevated baseline [K+](o) reduces the efficacy of NMDAR antagonists on SD-like depolarizations and SI. In conditions of moderate energy depletion, as in the ischemic penumbra, or after subarachnoid hemorrhage, NMDAR inhibition may not be sufficient to block these depolarizations.	Charite Univ Med Berlin, Dept Neurol, D-10117 Berlin, Germany; Charite Univ Med Berlin, Dept Expt Neurol, Berlin, Germany; Charite Univ Med Berlin, Johannes Muller Inst Physiol, Berlin, Germany; Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; Charite Univ Med Berlin, Dept Psychiat, Berlin, Germany	Dreier, JP (corresponding author), Charite Univ Med Berlin, Dept Neurol, Schumannstr 20-21, D-10117 Berlin, Germany.	jens.dreier@charite.de	Major, Sebastian/I-1838-2019	Major, Sebastian/0000-0003-0970-1308; Dreier, Jens/0000-0001-7459-2828; Dirnagl, Ulrich/0000-0003-0755-6119; Peters, Oliver/0000-0003-0568-2998; Megow, Dirk/0000-0002-7659-0524			Anderson TR, 2002, J NEUROPHYSIOL, V88, P2713, DOI 10.1152/jn.00321.2002; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; AYATA C, 2004, MK 801 PREVENTS EXPA; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; CHI OZ, 1991, CIRC RES, V69, P414, DOI 10.1161/01.RES.69.2.414; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; Dreier JP, 2002, ANN NEUROL, V52, P825, DOI 10.1002/ana.10383; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Gabriel S, 1998, NEUROSCI LETT, V249, P91, DOI 10.1016/S0304-3940(98)00420-0; Hartings JA, 2003, J NEUROSCI, V23, P11602; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; LAURITZEN M, 1988, BRAIN RES, V475, P317, DOI 10.1016/0006-8993(88)90620-8; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; MIES G, 1994, J CEREBR BLOOD F MET, V14, P802, DOI 10.1038/jcbfm.1994.100; Muller M, 2000, J NEUROPHYSIOL, V84, P1869, DOI 10.1152/jn.2000.84.4.1869; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Ohta O., 1983, VASCULAR NEUROEFFECT, P353; Petzold GC, 2003, ANN NEUROL, V54, P591, DOI 10.1002/ana.10723; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214	28	54	55	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUN	2005	36	6					1270	1277		10.1161/01.STR.0000166023.51307.e0			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	929EL	WOS:000229324800038	15879337	Bronze			2021-06-18	
J	Kazemi, M; Shearer, H; Choung, YS				Kazemi, M; Shearer, H; Choung, YS			Pre-competition habits and injuries in Taekwondo athletes	BMC MUSCULOSKELETAL DISORDERS			English	Article							RAPID WEIGHT-LOSS; PERFORMANCE; WRESTLERS; ANXIETY	Background: Over the past decade, there has been heightened interest in injury rates sustained by martial arts athletes, and more specifically, Taekwondo athletes. Despite this interest, there is a paucity of research on pre-competition habits and training of these athletes. The purpose of this pilot study was to assess training characteristics, competition preparation habits, and injury profiles of Taekwondo athletes. Methods: A retrospective survey of Canadian male and female Taekwondo athletes competing in a national tournament was conducted. Competitors at a Canadian national level tournament were given a comprehensive survey prior to competition. Items on training characteristics, diet, and injuries sustained during training and competition were included. Questionnaires were distributed to 60 athletes. Results: A response rate of 46.7% was achieved. Of those that responded, 54% dieted prior to competition, and 36% dieted and exercised pre-competition. Sixty-four percent of the athletes practised between 4 - 6 times per week, with 54% practicing 2 hours per session. Lower limb injuries were the most common (46.5%), followed by upper extremity (18%), back (10%), and head (3.6%). The majority of injuries consisted of sprains/strains (45%), followed by contusions, fractures, and concussions. More injuries occurred during training, including 59% of first injuries. Conclusion: More research needs to be conducted to further illustrate the need for appropriate regulations on weight cycling and injury prevention.	Canadian Mem Chiropract Coll, Toronto, ON, Canada	Kazemi, M (corresponding author), Canadian Mem Chiropract Coll, Toronto, ON, Canada.	mkazemi@cmcc.ca; hshearer@cmcc.ca; masterchoung@rogers.com					Alderman BL, 2004, MED SCI SPORT EXER, V36, P249, DOI 10.1249/01.MSS.0000113668.03443.66; [Anonymous], 2005, STEDMANS MED DICT HL; Birrer RB, 1996, AM J SPORT MED, V24, pS72, DOI 10.1177/036354659602406S21; Buschbacher R M, 1999, Phys Med Rehabil Clin N Am, V10, P35; Chapman C, 1997, PERCEPT MOTOR SKILL, V85, P1275, DOI 10.2466/pms.1997.85.3f.1275; Feehan M, 1995, BRIT J SPORT MED, V29, P258, DOI 10.1136/bjsm.29.4.258; Filaire E, 2001, INT J SPORTS MED, V22, P454, DOI 10.1055/s-2001-16244; FINKENBERG ME, 1992, PERCEPT MOTOR SKILL, V75, P239, DOI 10.2466/PMS.75.4.239-243; FOGELHOLM GM, 1993, MED SCI SPORT EXER, V25, P371, DOI 10.1249/00005768-199303000-00012; Hall CJ, 2001, BRIT J SPORT MED, V35, P390, DOI 10.1136/bjsm.35.6.390; Kazemi M, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-22; KOH JO, 2002, BOUNDARIES, V1, P79; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Smith M, 2001, INT J SPORT NUTR EXE, V11, P238, DOI 10.1123/ijsnem.11.2.238; WASLEN PE, 1993, CLIN J SPORT MED, V3, P235; Wenos DL, 1998, PERCEPT MOTOR SKILL, V87, P975, DOI 10.2466/pms.1998.87.3.975; WORRELL TW, 1994, SPORTS MED, V17, P338, DOI 10.2165/00007256-199417050-00006; Zemper E D, 1989, Br J Sports Med, V23, P161	18	54	57	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2474			BMC MUSCULOSKEL DIS	BMC Musculoskelet. Disord.	MAY 27	2005	6								26	10.1186/1471-2474-6-26			9	Orthopedics; Rheumatology	Orthopedics; Rheumatology	942VZ	WOS:000230312300001	15921510	DOAJ Gold, Green Published			2021-06-18	
J	Thompson, J; Sebastianelli, W; Slobounov, S				Thompson, J; Sebastianelli, W; Slobounov, S			EEG and postural correlates of mild traumatic brain injury in athletes	NEUROSCIENCE LETTERS			English	Article						electroencephalogram (EEG); mild traumatic brain injury (MTBI); posture; balance	PERFORMANCE; COLLEGIATE; MRI	Mild traumatic brain injury (MTBI), or concussion, is one of the least understood injuries facing the neuroscience and sports medicine community today. The notion of transient dysfunction and rapid symptom resolution is misleading since symptom resolution is not indicative of injury resolution. Our working hypothesis is that there are residual postural and EEG abnormalities in concussed individuals that could be reliably assessed using appropriate research methodology. This paper presents combined postural and electroencephalographic (EEG) findings suggesting the persistent functional deficits in athletes suffering from MTBI. Twelve concussed athletes and twelve normal controls participated in the study. There was a decrease in EEG power in all bandwidths studied in concussed subjects, especially in standing postures. This was accompanied by sustained postural instability especially under the no vision testing condition. Overall, this study demonstrated the presence of long-term functional abnormalities in individuals suffering from mild traumatic brain injury. (c) 2004 Published by Elsevier Ireland Ltd.	Penn State Univ, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, 19 Recreat Hall,Univ Pk, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; BEATTY J, 1974, SCIENCE, V183, P871, DOI 10.1126/science.183.4127.871; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; COLLINS D, 1999, J SPORT EXEC PSY, V12, P223; CREWS DJ, 1993, MED SCI SPORT EXER, V25, P116, DOI 10.1249/00005768-199301000-00016; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GEVINS AS, 1979, SCIENCE, V203, P665, DOI 10.1126/science.760212; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HOFFMAN DA, 1995, J NEUROTHERAPY, V2, P149; HOOVEY ZB, 1972, ELECTROEN CLIN NEURO, V32, P337, DOI 10.1016/0013-4694(72)90001-6; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Ouchi Y, 1999, BRAIN, V122, P329, DOI 10.1093/brain/122.2.329; Randolph C, 2001, J ATHL TRAINING, V36, P288; Saitou K, 1996, ELECTROEN CLIN NEURO, V98, P449, DOI 10.1016/0013-4694(96)95004-X; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov SM, 1997, J MOTOR BEHAV, V29, P263, DOI 10.1080/00222899709600841; SLOBUNOV S, IN PRESS CLIN NEUROP; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VOLLER B, 1999, BRAIN INJURY, V15, P95	29	54	55	2	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 4	2005	377	3					158	163		10.1016/j.neulet.2004.11.090			6	Neurosciences	Neurosciences & Neurology	907WY	WOS:000227750000004	15755518				2021-06-18	
J	Chen, X; Li, Y; Kline, AE; Dixon, CE; Zafonte, RD; Wagner, AK				Chen, X; Li, Y; Kline, AE; Dixon, CE; Zafonte, RD; Wagner, AK			Gender and environmental brain-derived neurotrophic effects on regional factor expression after experimental traumatic brain injury	NEUROSCIENCE			English	Article						traumatic brain injury; brain-derived neurotrophic factor; environmental enrichment; frontal cortex; hippocampus; gender	BDNF MESSENGER-RNA; RAT-BRAIN; COGNITIVE FUNCTION; PREFRONTAL CORTEX; RESPONSE ELEMENT; GENE-EXPRESSION; SPATIAL MEMORY; FEMALE RATS; ENRICHMENT; HIPPOCAMPUS	Alterations in brain-derived neurotrophic factor expression have been reported in multiple brain regions acutely after traumatic brain injury, however neither injury nor post-injury environmental enrichment has been shown to affect hippocampal brain-derived neurotrophic factor gene expression in male rats chronically post-injury. Studies have demonstrated hormone-related neuroprotection for female rats after traumatic brain injury, and estrogen and exercise both influence brain-derived neurotrophic factor levels. Despite recent studies suggesting that exposure post-traumatic brain injury to environmental enrichment improves cognitive recovery in male rats, we have shown that environmental enrichment mediated improvements with spatial learning are gender specific and only positively affect males. Therefore the purpose of this study was to evaluate the effect of gender and environmental enrichment on chronic post-injury cortical and hippocampal brain-derived neurotrophic factor protein expression. Sprague-Dawley male and cycling female rats were placed into environmental enrichment or standard housing after controlled cortical impact or sham surgery. Four weeks post-surgery, hippocampal and frontal cortex brain-derived neurotrophic factor expression were examined using Western blot. Results revealed significant increases in brain-derived neurotrophic factor expression in the frontal cortex ipsilateral to injury for males (P=0.03). Environmental enrichment did not augment this effect. Neither environmental enrichment nor injury significantly affected cortical brain-derived neurotrophic factor expression for females. In the hippocampus ipsilateral to injury brain-derived neurotrophic factor expression for both males and females was half (49% and 51% respectively) of that observed in shams housed in the standard environment. For injured males, there was a trend in this region for environmental enrichment to restore brain-derived neurotrophic factor levels to sham values. However, there were robust increases in hippocampal brain-derived neurotrophic factor expression ipsilateral to the injury for injured females in environmental enrichment compared with both sham and injured females placed in standard housing (P <= 0.005). In the hippocampus contralateral to injury, there were also significant injury related increases in brain-derived neurotrophic factor expression for females (P <= 0.05) that were not further augmented by environmental enrichment. These results show significant, region-specific gender differences in brain-derived neurotrophic factor expression with both injury and environmental enrichment that may be important for recovery. However, these data do not support a critical role for brain-derived neurotrophic factor in environmental enrichment mediated improvements with spatial learning. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD41399, K08HD40833] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833, R03HD041399] Funding Source: NIH RePORTER		Altar CA, 1998, TRENDS NEUROSCI, V21, P433, DOI 10.1016/S0166-2236(98)01273-9; Belz EE, 2003, PHARMACOL BIOCHEM BE, V76, P481, DOI 10.1016/j.pbb.2003.09.005; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BONTKE CF, 1996, PHYS MED REHABILITAT, P1027; Conner JM, 1997, J NEUROSCI, V17, P2295; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; de Oliveira RWD, 2003, PSYCHOPHARMACOLOGY, V170, P51, DOI 10.1007/s00213-003-1511-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; Gillespie LN, 2003, CLIN EXP PHARMACOL P, V30, P724, DOI 10.1046/j.1440-1681.2003.03909.x; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Lee I, 2003, J NEUROSCI, V23, P1517; Lu B, 1997, REV NEUROSCIENCE, V8, P1; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Singh M, 1999, J NEUROSCI, V19, P1179; Sobreviela T, 1996, J COMP NEUROL, V375, P417; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Torasdotter M, 1996, NEUROSCI LETT, V218, P107, DOI 10.1016/S0304-3940(96)13127-X; Turner CA, 2003, PHYSIOL BEHAV, V80, P259, DOI 10.1016/j.physbeh.2003.07.008; Vafaei AA, 2004, BEHAV BRAIN RES, V149, P61, DOI 10.1016/S0166-4328(03)00209-2; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhou Y, 1996, ENDOCRINOLOGY, V137, P2163, DOI 10.1210/en.137.5.2163	38	54	57	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	135	1					11	17		10.1016/j.neuroscience.2005.05.041			7	Neurosciences	Neurosciences & Neurology	965GP	WOS:000231938900002	16084663				2021-06-18	
J	Bahloul, M; Chelly, H; Ben Hmida, M; Ben Hamida, C; Ksibi, H; Kallel, H; Chaari, A; Kassis, M; Rekik, N; Bouaziz, M				Bahloul, M; Chelly, H; Ben Hmida, M; Ben Hamida, C; Ksibi, H; Kallel, H; Chaari, A; Kassis, M; Rekik, N; Bouaziz, M			Prognosis of traumatic head injury in South Tunisia: A multivariate analysis of 437 cases	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						trauma; acute head injury; adult patients; intensive care unit; multivariate analysis; prognosis; motor vehicle crash	COMA DATA-BANK; BRAIN-INJURY; DIABETES-INSIPIDUS; INAPPROPRIATE SECRETION; SECONDARY INSULTS; PRACTICAL SCALE; SEVERITY SCORE; BLOOD-GLUCOSE; HYPERGLYCEMIA; DIAGNOSIS	Background: This study aimed to determine predictive factors of mortality after posttraumatic brain injury. Methods: A retrospective study conducted over a 3-year period (1997-1999) involved 437 adult patients with head injury admitted to the intensive care unit of a university hospital in Sfax, Tunisia. Basic demographic, clinical, biologic, and radiologic data were recorded at admission and during the intensive care unit stay. Results: This study included 393 men (90%) and 44 women with a mean age of 36 +/- 17 years. Traffic accidents were the main cause of trauma (85.6%). In 58% of the cases, the injury was serious (Glasgow Coma Score, <8). The mean simplified acute physiology score was 39 +/- 15, and the mean Injury Severity Score was 34.5 +/- 17. Of the 437 patients, 127 (29.1%) died. According to multivariate analysis, the factors that correlated with a poor prognosis were age older than 40 years (p < 0.01), simplified acute physiology score exceeding 40 (p < 0.001), Glasgow Coma Score lower than 7 (p = 0.03), intracranial mass lesion (p = 0.02), a cerebral herniation (p < 0.001), diabetes insipidus (p < 0.001), and blood sugar level higher than 10 mmol/L (p < 0. 001). Conclusions: In Tunisia, head injury is a frequent cause of hospitalization, comprising 14.4% of all adult admissions. It is observed most often among young patients involved in traffic accidents. The short-term prognosis is poor, with a high (29%) mortality rate, and determined by demographic, clinical, radiologic, and biologic factors. Prevention is highly advised.	Habib Bourguiba Univ Hosp, Dept Intens Care, Sfax 3029, Tunisia; Hedi Chaker Univ Hosp, Dept Nephrol, Sfax, Tunisia; Hedi Chaker Univ Hosp, Dept Epidemiol, Sfax, Tunisia	Bahloul, M (corresponding author), Habib Bourguiba Univ Hosp, Dept Intens Care, Sfax 3029, Tunisia.	bahloulmab@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULL JP, 1978, INJURY, V9, P184, DOI 10.1016/0020-1383(78)90004-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; DUROCHER A, 1988, INTENS CARE MED, V14, P39, DOI 10.1007/BF00254120; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fukuda T, 1996, NEUROL SURG TOKYO, V24, P723; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; GAILLARD M, 1989, ANN PEDIATR-PARIS, V36, P194; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GREGER NG, 1986, AM J DIS CHILD, V140, P551, DOI 10.1001/archpedi.1986.02140200061028; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HICKS IR, 1994, INJURY, V25, P545, DOI 10.1016/0020-1383(94)90098-1; Hill DA, 1997, J TRAUMA, V42, P62, DOI 10.1097/00005373-199701000-00011; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KARUS JF, 1996, NEUROL CLIN, V14, P435; KERN KB, 1984, J TRAUMA, V24, P69, DOI 10.1097/00005373-198401000-00012; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NOTMAN DD, 1980, J TRAUMA, V20, P599, DOI 10.1097/00005373-198007000-00009; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PFENNINGER EG, 1991, ACTA ANAESTH SCAND, V35, P148, DOI 10.1111/j.1399-6576.1991.tb03263.x; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Raggueneau J L, 1988, Agressologie, V29, P433; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; *TUN NAT GUARD, TUN NAT GUARD STAT D; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; *US DEP HHS, 1994, AHCPR PUBL, P12; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	53	54	54	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2004	57	2					255	261		10.1097/01.TA.0000083004.35231.1E			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	859YG	WOS:000224303700010	15345970				2021-06-18	
J	Kazemi, M; Pieter, W				Kazemi, M; Pieter, W			Injuries at a Canadian National Taekwondo championships: a prospective study	BMC MUSCULOSKELETAL DISORDERS			English	Article							SACROILIAC JOINT; INHIBITION; PAIN	Background: The purpose of this prospective study was to assess the injury rates in male and female adult Canadian Taekwondo athletes relative to total number of injuries, type and body part injured. Methods: Subjects ( 219 males, 99 females) participated in the 1997 Canadian National Taekwondo Championships in Toronto, Canada. Injuries were recorded on an injury form to documents any injury seen and treatment provided by the health care team. These data were later used for this study. The injury form describes the athlete and nature, site, severity and mechanism of the injury. Results: The overall rate of injuries was 62.9/1,000 athlete-exposures (A-E). The males (79.9/1,000 A-E) sustained significantly more injuries than the females (25.3/1,000 A-E). The lower extremities were the most commonly injured body region in the men (32.0/1,000 A-E), followed by the head and neck (18.3/1,000 A-E). Injuries to the spine ( neck, upper back, low back and coccyx) were the third most often injured body region in males (13.8/1,000 A-E). All injuries to the women were sustained to the lower extremities. The most common type of injury in women was the contusion (15.2/1,000 A-E). However, men's most common type of injury was the sprain (22.8/1,000 A-E) followed by joint dysfunction (13.7/1,000 A-E). Concussions were only reported in males (6.9/1,000 A-E). Compared to international counterparts, the Canadian men and women recorded lower total injury rates. However, the males incurred more cerebral concussions than their American colleagues (4.7/1,000 A-E). Conclusions: Similar to what was found in previous studies, the current investigation seems to suggest that areas of particular concern for preventive measures involve the head and neck as well as the lower extremities. This is the first paper to identify spinal joint dysfunction.	Canadian Mem Chiropract Coll, Dept Clin Studies, Toronto, ON, Canada; Univ Sci Malaysia, Sch Hlth Sci, Kelantan, Malaysia	Kazemi, M (corresponding author), Canadian Mem Chiropract Coll, Dept Clin Studies, Toronto, ON, Canada.	mkazemi@cmcc.ca; yshin516@yahoo.com					BARRAULT D, 1983, SYMB, V15, P144; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; *CO MED SOC, 1991, REP SPORTS MED COMM; Dah C, 1989, CINESIOLOGIE, V28, P153; Greenwald P, 1996, IARC SCI PUBL, P13; HALDEMAN S, 1992, PRINCIPLES PRACTICE, P623; Harrison DE, 1997, J MANIP PHYSIOL THER, V20, P607; Hillman S., 1993, AUS J SCI MED SPORT, V25, P73; James G, 2003, BIOL SPORT, V20, P25; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; KNUSTSON GA, 1999, J MANIP PHYSIOL THER, V22, P491; Kokmeyer DJ, 2002, J MANIP PHYSIOL THER, V25, P42, DOI 10.1067/mmt.2002.120418; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Maigne J Y, 2001, Spine (Phila Pa 1976), V26, pE479, DOI 10.1097/00007632-200110150-00024; Maigne JY, 2001, SPINE, V26, pE484; McKeag DB, 1993, PRIMARY CARE SPORTS, P63; MCLATCHIE GR, 1976, BR J ACC SURG, V8, P132; Phillips JS, 2001, SA J PHYS, V57, P32; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1995, P 38 WORLD C P GAIN, P165; Pieter W, 1997, P 2 ANN C EUR COLL S; Pieter W., 2001, ACTA KINESIOLOGIAE U, V6, P102; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1999, P 5 IOC WORLD C SPOR; PIETER W, 2000, P 1 WORLD C COMB SPO; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; Suter E, 2000, J MANIP PHYSIOL THER, V23, P76, DOI 10.1016/S0161-4754(00)90071-X; Suter E, 1999, J MANIP PHYSIOL THER, V22, P149, DOI 10.1016/S0161-4754(99)70128-4; Taylor P, 1990, J CAN CHIROPRACT ASS, V34, P82; Toussaint R, 1999, J MANIP PHYSIOL THER, V22, P134, DOI 10.1016/S0161-4754(99)70125-9; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; Zemper E D, 1989, Br J Sports Med, V23, P161	33	54	57	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2474			BMC MUSCULOSKEL DIS	BMC Musculoskelet. Disord.	JUL 27	2004	5								22	10.1186/1471-2474-5-22			8	Orthopedics; Rheumatology	Orthopedics; Rheumatology	844AK	WOS:000223129000001	15279679	DOAJ Gold, Green Published			2021-06-18	
J	Ponsford, J; Facem, PC; Willmott, C; Rothwell, A; Kelly, AM; Nelms, R; Ng, KT				Ponsford, J; Facem, PC; Willmott, C; Rothwell, A; Kelly, AM; Nelms, R; Ng, KT			Use of the Westmead PTA scale to monitor recovery of memory after mild head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE ORIENTATION; GALVESTON ORIENTATION; CONCUSSION; REHABILITATION; PREDICTORS; DURATION; LOG	Study objective: Duration of post-traumatic amnesia (PTA) is an important index of severity of head injury. Retrospective assessment of PTA duration is arguably unreliable. Existing objective measures of PTA duration are designed for use over a 24-hour timeframe and, therefore, are not useful for assessing PTA following mild head injury (MHI). A revised version of the Westmead PTA scale was developed for assessing patients with MHI in the Emergency Department (ED) at hourly intervals. The objective of this study was the field testing of this scale in EDs and assessment of validity and reliability of test items. Methods: The scale contained 12 items, assessing orientation, memory for a face and name in a photograph and three pictures of objects. This revised scale, administered by nursing staff, was completed at least four times at hourly intervals by 147 adults with MHI in the ED and again at follow-up 1 week later. It was also completed by 109 demographically similar controls. Results were compared with Glasgow Coma scores and retrospective estimates of PTA duration based on patient report and medical records. Results: Thirty-six per cent of MHI participants made errors on the scale in the ED, a significantly greater proportion than in MHI or controls at follow-up. Removal of the items 5 (day of week) and 9 (recall of name of face in photograph) improved the validity of the measure significantly. Scores correlated significantly with Glasgow Coma Scale scores and estimated duration of PTA. Conclusion: The Westmead Scale (minus items 5 and 9) is a valid measure of PTA duration in adult patients with MHI in ED. Its use will allow for more appropriate timing of discharge and accurate prognostic information.	Monash Univ, Clayton, Vic 3168, Australia; Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic, Australia; Alfred Hosp, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; Julia Farr Serv S Australia, Adelaide, SA, Australia; Western Hosp, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, 30 Erin St, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; [Anonymous], 1942, Proc R Soc Med, V35, P601; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BERROL S, 1992, REHABILITATION POST, P1; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brooks D N, 1979, Int Rehabil Med, V1, P160; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dowler RN, 2000, BRAIN INJURY, V14, P117, DOI 10.1080/026990500120781; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Greenwood R, 1997, LANCET, V349, P1041, DOI 10.1016/S0140-6736(05)62288-X; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KAY T, 1992, REHABILITATION POST, P109; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kraus J. F., 1999, REHABILITATION ADULT, P3; LEININGER B, 1992, REHABILITATION POST; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; NELSON HE, 1991, NATL ADULT READINT T; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD J, 2002, 1 JOINT S NAT INT NE; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rey A, 1964, EXAMEN CLIN PSYCHOL; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; Symonds CP, 1943, LANCET, V1, P7; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	52	54	55	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2004	18	6					603	614		10.1080/02699050310001646152			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	811DX	WOS:000220753700007	15204340				2021-06-18	
J	Wisniewski, JF; Guskiewicz, K; Trope, M; Sigurdsson, A				Wisniewski, JF; Guskiewicz, K; Trope, M; Sigurdsson, A			Incidence of cerebral concussions associated with type of mouthguard used in college football	DENTAL TRAUMATOLOGY			English	Article						cerebral; brain concussions; concussions; college football; American football; football		Controversy exists among sports dentists as to whether or not a 'custom made' mouthguard is more effective in reducing the incidence of cerebral concussion than the boil-and-bite 'non-custom made' mouthguard. While members on each side remain steadfast in their opinion, not a single epidemiological study has been conducted to investigate the effect of type of mouthguard worn on the incidence of cerebral concussion. The aim of this study was to determine if there was a difference between the type of mouthguard worn and the incidence of cerebral concussions among National Collegiate Athletic Association (NCAA) Division I-A football players. During the 15-week 2001 college football season, trainers entered, via an interactive web site, weekly data for each game and practice sessions for the preceding week. Eighty-seven (76%) out of a possible 114 Division I teams participated. A total of 506 297 athletic exposures were recorded; 369 brain concussions were reported. The incidence of cerebral concussions per 1000 exposures was 0.73. Utilizing a risk ratio with a 95% confidence interval, no statistical difference occurred in the incidence of cerebral concussions between football players wearing custom made versus non-custom made mouthguards (0.990,1.750). In this study, there was no advantage of wearing a custom made mouthguard over a boil-and-bite mouthguard to reduce the risk of cerebral concussion in football players.	Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA; Dent Hlth Associates, Cary, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Trope, M (corresponding author), Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA.	martin_trope@dentistry.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130			Blignaut J B, 1987, Br J Sports Med, V21, P5; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; FINKBEINER BL, 1995, COMPREHENSIVE DENT A, P1035; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Kerr L, 1983, Clin Sports Med, V2, P115; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; PADILLA R, 1996, J CALIF DENT ASSOC, V24, P346; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; WINTERS JE, 2002, J ATHL TRAINING, V36, P339; WOODMANSEY KF, 1999, GEN DENT, V1, P64	13	54	56	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	JUN	2004	20	3					143	149		10.1111/j.1600-4469.2004.00259.x			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	821CF	WOS:000221436600004	15144445				2021-06-18	
J	Kalpakjian, CZ; Lam, CS; Toussaint, LL; Merbitz, NKH				Kalpakjian, CZ; Lam, CS; Toussaint, LL; Merbitz, NKH			Describing quality of life and psychosocial outcomes after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						quality of life; psychosocial outcomes; tramatic brain injury; assessment instruments	COMMUNITY INTEGRATION QUESTIONNAIRE; SPINAL-CORD; SATISFACTION; REHABILITATION; IMPAIRMENT; DISABILITY	Objective: To describe the quality of life (QOL) and psychosocial outcomes of a sample of adults with traumatic brain injury in 50 community dwelling adults with traumatic brain injury and examine the associations among these variables. Design: Cross-sectional. Results: Mean QOL rating was low average. Standardized measures had acceptable internal reliability and normal distributions in this sample. Subjects had significantly lower QOL and social support, higher negative affect, and similar positive affect and spirituality compared with standardization and other nondisabled samples. They also had a significantly higher level of community integration than other traumatic brain injury samples. Regression analyses suggested that social support, community integration, and positive affect make a unique and significant contribution to the QOL variance with R-2 of 0.492. The addition of spirituality reduced their respective unique variance, reducing positive affect to nonsignificant levels due to their high intercorrelation. Conclusions: Findings suggest that this sample experiences a wide range of QOL. Factors significantly associated with good QOL include community integration, positive affect, and social support; demographic variables had virtually no association with QOL. Evaluation of the sample's response to standardized scales not designed for a traumatic brain injury population support their use in similar QOL investigations.	Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; IIT, Inst Psychol, Chicago, IL 60616 USA; Idaho State Univ, Dept Psychol, Pocatello, ID 83209 USA	Kalpakjian, CZ (corresponding author), Univ Michigan Hosp, Dept Phys Med & Rehabil, Box 0491,300 N Ingalls, Ann Arbor, MI 48109 USA.			Kalpakjian, Claire/0000-0001-6652-1245			Ashley MJ, 1997, BRAIN INJURY, V11, P677; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown M, 1999, MT SINAI J MED, V66, P160; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Dawson DR, 2000, BRAIN COGNITION, V44, P35; ELLIOTT TR, 1992, PSYCHOL HEALTH, V7, P55, DOI 10.1080/08870449208404295; Frisch M. B, 1994, QUALITY LIFE INVENTO; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Hatch RL, 1998, J FAM PRACTICE, V46, P476; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Holosko M, 1989, CANADIAN J REHABILIT, V2, P145; Kim J, 2000, REHABIL PSYCHOL, V45, P365, DOI 10.1037/0090-5550.45.4.365; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; MANCINI JA, 1992, J GERONTOL, V47, pP14, DOI 10.1093/geronj/47.1.P14; McColl MA, 2000, DISABIL REHABIL, V22, P555, DOI 10.1080/096382800416805; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pargament KI., 1997, PSYCHOL RELIG; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355	31	54	55	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2004	83	4					255	265		10.1097/01.PHM.0000118033.07952.8C			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	804VJ	WOS:000220325900001	15024324				2021-06-18	
J	Sifri, ZC; Livingston, DH; Lavery, RF; Homnick, AT; Mosenthal, AC; Mohr, AM; Hauser, CJ				Sifri, ZC; Livingston, DH; Lavery, RF; Homnick, AT; Mosenthal, AC; Mohr, AM; Hauser, CJ			Value of repeat cranial computed axial tomography scanning in patients with minimal head injury	AMERICAN JOURNAL OF SURGERY			English	Article						cranial computed axial tomography scan; neurological status; neurosurgical intervention; traumatic brain injury	CT SCANS; UTILITY; MANAGEMENT; ADMISSION; MODERATE	Background: Patients with minimal head injury (MHI) and a cranial computed axial tomography (CAT) scan positive for the presence of intracranial injury routinely undergo a repeat CAT scan within 24 hours after injury. The value of this repeat cranial CAT scan is unclear in those patients who are neurologically normal or improving. Methods: A retrospective analysis of all adult patients admitted to a level-1 trauma center with MHI and a positive cranial CAT scan during a 32-month period was performed. The need for neurosurgical intervention after repeat CAT scan in patients with a persistently normal or improved neurological examination was recorded. Results: One hundred fifty-one patients had a persistently normal or improved neurological examination, but none of these patients required neurosurgical intervention after the repeat cranial CAT scan. Conclusions: A persistently normal or improving neurological examination in a patient with MHI appears to exclude the need for neurosurgical intervention and thus a repeat cranial CAT scan. (C) 2004 Excerpta Medica, Inc. All rights reserved.	Univ Med & Dent New Jersey, Dept Surg, Div Trauma, Newark, NJ 07103 USA	Livingston, DH (corresponding author), Univ Med & Dent New Jersey, Dept Surg, Div Trauma, M-243,150 Bergen St, Newark, NJ 07103 USA.	livingst@umdnj.edu	Hauser, Carl J./Y-1189-2019; Mohr, Alicia M/E-3016-2015	Mohr, Alicia/0000-0003-1732-1313; Hauser, Carl/0000-0003-3167-1846			Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MORAN SG, 1994, AM SURGEON, V60, P533; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; VALADKA AB, 2000, TRAUMA, P377	14	54	55	0	1	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	MAR	2004	187	3					338	342		10.1016/j.amjsurg.2003.12.015			5	Surgery	Surgery	801PL	WOS:000220107700005	15006561				2021-06-18	
J	Nakase-Thompson, R; Sherer, M; Yablon, SA; Nick, TG; Trzepacz, PT				Nakase-Thompson, R; Sherer, M; Yablon, SA; Nick, TG; Trzepacz, PT			Acute confusion following traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; GALVESTON ORIENTATION; DIAGNOSTIC-CRITERIA; DELIRIUM; SCALE; RECOVERY; VALIDATION; SURVIVORS; BEHAVIOR	Primary objective: To determine the incidence, duration and symptoms associated with acute confusion/ delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions. Research design: Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions. Methods and procedures: Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium. Main outcomes and results: Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Delirium Diagnostic Criteria ( DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation. Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test ( GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status. Conclusions: Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI. Use of a single measure ( e. g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion.	Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Lilly Res Labs, Indianapolis, IN USA	Nakase-Thompson, R (corresponding author), Methodist Rehabil Ctr, Dept Neuropsychol, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.		Trzepacz, Paula/AAQ-3330-2021				American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P124; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fladby T, 1999, J GERIATR PSYCH NEUR, V12, P16, DOI 10.1177/089198879901200105; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1993, HEAD INJURY, P525; LEVIN HS, 1992, J NEUROTRAUM, V9, P359; MCEVOY JP, 1981, ANN INTERN MED, V95, P212, DOI 10.7326/0003-4819-95-2-212; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; OCONNOR M, 1987, MED J AUSTRALIA, V147, P481, DOI 10.5694/j.1326-5377.1987.tb133639.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sessler CN, 1992, CHEST, V102, p191S; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C. P, 1937, P ROY SOC MED, V30, P33; SYMONDS CP, 1943, LANCET, P7; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Trzepacz Paula T., 1994, P189; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1994, PSYCHOSOMATICS, V35, P374, DOI 10.1016/S0033-3182(94)71759-X; TRZEPACZ PT, 2002, AM PSYCHIAT PUBLISHI, P525; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	42	54	56	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					131	142		10.1080/0269905031000149542			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000003	14660226				2021-06-18	
J	Walker, N; Mellick, D; Brooks, CA; Whiteneck, GG				Walker, N; Mellick, D; Brooks, CA; Whiteneck, GG			Measuring participation across impairment groups using the Craig handicap assessment reporting technique	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						disability; outcomes research; handicap; surveys; reliability; validity	AGREEMENT	Objective: To assess the efficacy, across a range of disability groups, of the Craig Handicap Assessment and Reporting Technique (CHART), a measure of societal participation. Design: Cross-sectional analysis survey methodology. A total of 1110 community-based, nonhospitalized Coloradans with spinal cord injury, traumatic brain injury, multiple sclerosis, stroke, burn, or amputation were interviewed twice, 2 wks apart, using the CHART and a single administration of the FIM(TM). Results: Across all impairment groups, the intraclass correlation for the total score and the subscales of CHART-R were high. In addition, the CHART-R discriminated among the impairment categories in a direction that parallels increasing disability. Conclusions: CHART may be an appropriate measure of handicap for a range of physical or cognitive impairments.	Craig Hosp, Dept Res, Englewood, CO 80110 USA	Mellick, D (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80110 USA.						BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; GRANGER CV, 1997, ASSESSING MED REHABI, P103; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1997, INT CLASS IMP ACT PA; World Health Organization, 1993, INT CLASS IMP DIS HA	11	54	54	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	DEC	2003	82	12					936	941		10.1097/01.PHM.0000098041.42394.9A			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	744ZM	WOS:000186662800005	14627930				2021-06-18	
J	Yan, P; Liu, NK; Kim, GM; Xu, JM; Xu, J; Li, Q; Hsu, CY; Xu, XM				Yan, P; Liu, NK; Kim, GM; Xu, JM; Xu, J; Li, Q; Hsu, CY; Xu, XM			Expression of the type 1 and type 2 receptors for tumor necrosis factor after traumatic spinal cord injury in adult rats	EXPERIMENTAL NEUROLOGY			English	Article						glucocorticoids; inflammation; rat; spinal cord injury; TNF-alpha; TNF receptor	KAPPA-B ACTIVATION; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; BRAIN-INJURY; TNF RECEPTOR; CELL-DEATH; MESSENGER-RNA; FUNCTIONAL RECOVERY; MOLECULAR-CLONING; CYTOKINES	Posttraumatic inflammation has been implicated in secondary tissue damage after spinal cord injury (SCI). Tumor necrosis factor-alpha (TNF-alpha) is a key inflammatory mediator that is increasingly expressed after SCI. The effect of TNF-alpha is mediated through its receptors TNFR1 (p55) and TNFR2 (p75). However, whether these two receptors are expressed after SCI has not been demonstrated. In the present study, the temporo-spatial expression of TNFR1 and TNFR2 was examined in rats that had received a 10 g impact injury dropped at a height of 12.5 mm using the New York University impact device. In sham operates, no detectable TNFR1 or TNFR2 immunoreactivity (IR) was observed. In contused spinal cord, TNFR1 protein expression and immunoreactivity (IR) were detected as early as 15 min postinjury, reached its peak at 8 h, and declined markedly after 1 and 3 days postinjury. The temporal pattern of TNFR2 expression was similar to that of TNFR1 but its expression peaked at 4 h postinjury. During peak expression, TNFR1- and TNFR2-IR were most intense at the site of injury and decreased gradually from the injury epicenter. TNFR1- and TNFR2-positive cells included neurons, astrocytes, and oligodendrocytes. Methylprednisolone (NIP), a synthetic glucocorticoid, partially inhibited the injury-induced expression of TNFR1 and TNFR2, an effect which could be reversed by RU486, an antagonist of glucocorticoid receptors. We suggest that the expression of TNFR1 and TNFR2 after SCI may contribute to posttraumatic inflammatory responses of TNF-alpha. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; St Louis Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Xu, XM (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR Rm 616, Louisville, KY 40292 USA.			Xu, Xiao-ming/0000-0002-7229-0081; Hsu, Chung Y./0000-0002-5632-2733	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037230, R01NS036350] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37230, NS36350] Funding Source: Medline		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; ARZT E, 1994, ENDOCRINOLOGY, V134, P672, DOI 10.1210/en.134.2.672; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 1998, J NEUROSCI, V18, P3251; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRENNER T, 1994, BRAIN RES, V641, P51, DOI 10.1016/0006-8993(94)91814-7; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Goodman J. W., 1991, Optics & Photonics News, V2, P11; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Haridas V, 1998, J IMMUNOL, V160, P3152; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; HEYDERMAN RS, 1995, INFLAMM RES, V44, P275, DOI 10.1007/BF02032568; HOLETS VR, 1987, BRAIN RES, V408, P141, DOI 10.1016/0006-8993(87)90366-0; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; HSU CY, 2001, TRAUMATIC CNS INJURY, P118; Kahn MA, 1999, J NEUROIMMUNOL, V95, P19, DOI 10.1016/S0165-5728(98)00258-6; Kim GM, 2001, J NEUROSCI, V21, P6617; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lin RH, 1997, J IMMUNOL, V158, P598; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLERGRAZIANO CL, 1994, SHOCK, V1, P317, DOI 10.1097/00024382-199405000-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Okuyama M, 2000, ARTERIOSCL THROM VAS, V20, P1506, DOI 10.1161/01.ATV.20.6.1506; PERRETTI M, 1994, PHARMACOL RES, V30, P53, DOI 10.1016/1043-6618(94)80087-1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Steer JH, 1998, ANN RHEUM DIS, V57, P732, DOI 10.1136/ard.57.12.732; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANFURTH AM, 1995, CLIN DIAGN LAB IMMUN, V2, P689, DOI 10.1128/CDLI.2.6.689-692.1995; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.ge.19.120185.001233; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yan P, 1999, J NEUROSCI, V19, P9355; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041	62	54	57	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	OCT	2003	183	2					286	297		10.1016/S0014-4886(03)00135-3			12	Neurosciences	Neurosciences & Neurology	728PB	WOS:000185724600006	14552870				2021-06-18	
J	Sakoh, M; Gjedde, A				Sakoh, M; Gjedde, A			Neuroprotection in hypothermia linked to redistribution of oxygen in brain	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						cerebral blood flow; cerebral metabolic rate of oxygen	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; ACUTE STROKE; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; ARTERY OCCLUSION; POSTISCHEMIC HYPOTHERMIA; GLUCOSE-METABOLISM; FOCAL ISCHEMIA; CANINE BRAIN	Hypothermia improves the outcome of acute ischemic stroke, traumatic injury, and inflammation of brain tissue. We tested the hypothesis that hypothermia reduces the energy metabolism of brain tissue to a level that is commensurate with the prevailing blood flow and hence allows adequate distribution of oxygen to the entire tissue. To determine the effect of 32degreesC hypothermia on brain tissue, we measured the sequential changes of physiological variables by means of PET in pigs. Cerebral blood flow and oxygen consumption (cerebral metabolic rate of oxygen) declined to 50% of the baseline in 3 and 5 h, respectively, thus elevating the oxygen extraction fraction to 140% of the baseline at 3 h. The results are consistent with the claim that cooling of the brain to 32degreesC couples both energy metabolism and blood flow to a lower rate of work of the entire tissue.	Aarhus Univ Hosp, PET Ctr, DK-8000 Aarhus, Denmark; Aarhus Univ, Ctr Functionally Integrat Neurosci, DK-8000 Aarhus, Denmark; Ehime Univ, Sch Med, Dept Neurol Surg, Matsuyama, Ehime 7910295, Japan	Gjedde, A (corresponding author), Aarhus Univ Hosp, PET Ctr, 44 Norrebrogade, DK-8000 Aarhus, Denmark.	albert@gjedde.nu	Gjedde, Albert/I-2452-2019; Gjedde, Albert/U-3751-2019	Gjedde, Albert/0000-0002-3756-7401			Angstwurm K, 2000, J CEREBR BLOOD F MET, V20, P834, DOI 10.1097/00004647-200005000-00010; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Aubert A, 2002, NEUROIMAGE, V17, P1162, DOI 10.1006/nimg.2002.1224; Bacher A, 1998, ANESTHESIOLOGY, V88, P403, DOI 10.1097/00000542-199802000-00019; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Canevari L, 1999, BRAIN RES, V817, P241, DOI 10.1016/S0006-8993(98)01278-5; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Clifton G, 2000, J NEUROSURG, V93, P718; COETZEE A, 1990, SCAND J CLIN LAB INV, V50, P149, DOI 10.3109/00365519009087504; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; Danielsen E, 1998, SCAND J LAB ANIM SCI, V25, P127; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Gjedde A, 1978, Ugeskr Laeger, V140, P1408; Gjedde A, 2002, NEUROIMAGE, V17, P1876, DOI 10.1006/nimg.2002.1272; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; GJEDDE A, 2002, BRAIN ACTIVATION CBF, P223; GJEDDE A, 1991, A BENZON S, V31, P177; Gjedde Albert, 1997, P23; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; GUTIERREZ G, 1986, J APPL PHYSIOL, V60, P751; Heiss WD, 1997, J CEREBR BLOOD F MET, V17, P388, DOI 10.1097/00004647-199704000-00004; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Henderson RD, 2001, J NEUROSURG, V95, P964, DOI 10.3171/jns.2001.95.6.0964; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Hyder F, 1998, J APPL PHYSIOL, V85, P554; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; Iwama T, 1997, J NEUROSURG, V87, P440, DOI 10.3171/jns.1997.87.3.0440; JIANG Q, 1994, J CEREBR BLOOD F MET, V14, P732, DOI 10.1038/jcbfm.1994.94; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; KASSISSIA IG, 1995, CIRC RES, V77, P1201, DOI 10.1161/01.RES.77.6.1201; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MICHENFELDER JD, 1977, STROKE, V8, P87, DOI 10.1161/01.STR.8.1.87; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Mori K, 1999, NEUROL RES, V21, P585, DOI 10.1080/01616412.1999.11740981; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Ohta S, 1996, J CEREBR BLOOD F MET, V16, P765, DOI 10.1097/00004647-199609000-00002; Ooboshi H, 2000, BRAIN RES, V884, P23, DOI 10.1016/S0006-8993(00)02861-4; Poulsen PH, 1997, J NEUROSCI METH, V77, P199, DOI 10.1016/S0165-0270(97)00127-1; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Sakoh M, 2000, STROKE, V31, P1958, DOI 10.1161/01.STR.31.8.1958; Sakoh M, 2000, J NEUROSURG, V93, P647, DOI 10.3171/jns.2000.93.4.0647; Schwab M, 1998, ACTA NEUROBIOL EXP, V58, P29; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; SESSLER DI, 1995, J NEUROSURG ANESTH, V7, P38, DOI 10.1097/00008506-199501000-00008; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TOUZANI O, 1995, STROKE, V26, P2112, DOI 10.1161/01.STR.26.11.2112; Ueda T, 1999, J CEREBR BLOOD F MET, V19, P99, DOI 10.1097/00004647-199901000-00011; Vafaee MS, 2000, J CEREBR BLOOD F MET, V20, P747, DOI 10.1097/00004647-200004000-00012; VALABREGUE R, IN PRESS J CEREB BLO; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	62	54	56	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	JUL	2003	285	1					H17	H25		10.1152/ajpheart.01112.2002			9	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	687AX	WOS:000183354600003	12793975				2021-06-18	
J	Ruchhjoltz, S; Waydhas, C; Schroeder, T; Piepenbrink, K; Kuhl, H; Nast-Kolb, D				Ruchhjoltz, S; Waydhas, C; Schroeder, T; Piepenbrink, K; Kuhl, H; Nast-Kolb, D			The value of computed tomography in the early treatment of seriously injured patients	CHIRURG			German	Article						computed tomography; multiple severe trauma; clinical management; emergency room diagnostic; missed injuries	CHEST TRAUMA; MANAGEMENT	Background. The availability of newer,faster computed tomography (CT) technology has engendered discussion about whole-body CT-scanning for primary radiological diagnostics of seriously injured patients. Method. Within a quality management system,the scaled, priority-oriented scheme of conventional radiological and CT-diagnostics used in each institution was analysed and compared with the possible benefit of whole-body CT-scanning. Every patient with severe trauma admitted directly from the scene of an accident, underwent basic radiological and sonographic diagnostics in the emergency room (ER). According to the findings, patients in a stable vital condition had CT-scans when indicated by the guidelines of the particular institution. Results. From 5/1998 until 12/2000, a total of 832 patients were treated in the ER. Of those, 480 patients (average ISS 20) were admitted directly from the scene of the accident. Basic radiological - sonographic diagnostics (radiographs of cervical spine, chest, and abdomen, as well as abdominal sonography) took 15+/-8 min. Twenty-two (5%) of the patients in hemorrhagic shock needed emergency operations after 57+/-43 min. The remaining patients underwent further radiological diagnostics (spine, extremities etc.) after 44+/-27 min. In 79% (379) of patients, CT was indicated. Cranial CT for traumatic brain injury prevailed clearly with 74% of cases. Spine (24%), chest (18%),abdomen (5%) and pelvis (5%) were indicated comparatively less frequently. The incidence of delayed diagnoses (after ICU-admission) was 4% (22). In 2% (nine) of patients the lesions possibly could have been detected by a primary CT-scan. In the three cases with thoracic lesions, there was a deviation from the indication guidelines for thoracic CT as normally used in the institution. There were three cases of delayed diagnoses in both the cerebral (small contusion haematomas) region and the abdominal region. The abdominal lesions were detected by sonographic control examinations. No patient died because of a delayed diagnosis. The average X-ray dose was five times lower with the scaled diagnostic management comprising indicated CT when compared to the doses calculated for routine whole-body CT. Conclusion. While 74% of patients had cranial CT, only 25% needed CT for the trunk regions. Delayed diagnoses were rare and without severe consequences for the patient. Considering the five times higher X-ray doses combined with the possible time loss in patients with unstable conditions, primary whole-body CT-scanning should not be performed routinely when serious injury is suspected.	Univ Essen Gesamthsch Klinikum, Klin & Poliklin Unfallchirurg, D-45122 Essen, Germany; Univ Essen Gesamthsch Klinikum, Zent Inst Rontgendiagnost, D-45122 Essen, Germany; Univ Essen Gesamthsch Klinikum, Abt Anasthesiol & Intens Med, D-45122 Essen, Germany	Ruchhjoltz, S (corresponding author), Univ Essen Gesamthsch Klinikum, Klin & Poliklin Unfallchirurg, Hufelandstr 55, D-45122 Essen, Germany.						BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blostein PA, 1997, J TRAUMA, V43, P13, DOI 10.1097/00005373-199707000-00006; Fosse JP, 1997, PRESSE MED, V26, P1232; Healey MA, 1996, J TRAUMA, V40, P875, DOI 10.1097/00005373-199606000-00004; Nast-Kolb D, 1998, UNFALLCHIRURG, V101, P82, DOI 10.1007/s001130050239; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; Ruchholtz S, 2001, UNFALLCHIRURG, V104, P927, DOI 10.1007/s001130170033; Shanmuganathan K, 1999, RADIOLOGY, V212, P423, DOI 10.1148/radiology.212.2.r99au18423; Trupka A, 1997, J TRAUMA, V43, P405, DOI 10.1097/00005373-199709000-00003	9	54	55	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0009-4722			CHIRURG	Chirurg	OCT	2002	73	10					1005	1012		10.1007/s00104-002-0429-1			8	Surgery	Surgery	616XY	WOS:000179329800006	12395159				2021-06-18	
J	Kochanek, PM; Hendrich, KS; Dixon, CE; Schiding, JK; Williams, DS; Ho, C				Kochanek, PM; Hendrich, KS; Dixon, CE; Schiding, JK; Williams, DS; Ho, C			Cerebral blood flow at one year after controlled cortical impact in rats: Assessment by magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						atrophy; dementia; perfusion; spin-lattice relaxation; traumatic brain injury	SPIN-LABELED MRI; BRAIN INJURY; ARTERIAL WATER; PERFUSION; AGE; TRAUMA; REACTIVITY; LESION	Progressive tissue loss and delayed cognitive deficits are seen in rats during the initial year after experimental traumatic brain injury (TBI). As much as 10% of parenchymal volume is lost even in the contralateral hemisphere by 1 year after controlled cortical impact (CCI) in rats. Progressive declines in cerebral blood flow (CBF) are also associated with advanced age and neurodegenerative diseases. Surprisingly, the long-term effects of TBI on CBF remain undefined. CBF was quantified by continuous arterial spin-labeled magnetic resonance imaging (MRI) and measurements of spin-lattice relaxation time in a slice through the plane of injury at 1 year after experimental TBI produced by CCI (n = 4) or sham surgery (n = 4) in rats. CBF was quantified in six regions of interest (ROIs) that were anatomically identified on the control images in each hemisphere and included a medial cortical segment (contusion-enriched, beneath the impact site, on the ipsilateral side) cortex, hippocampus, thalamus, amygdala/pyriform cortex, and hemisphere. At 1 year after injury, CBF was dramatically (96%) reduced in structures within the large cystic lesion that was seen in three of four rats and variably included cortex and hippocampus. Overall, there was an 80% reduction in CBF in the ipsilateral medial cortical segment comparing CCI and sham groups. Similarly, 52% and 67% reductions were seen in CBF in the cortical and hippocampal ROIs ipsilateral to impact (CCI vs. sham), respectively. These are regions both with marked CBF disturbances early after injury and that ultimately suffer considerable tissue loss over the 1-year interval. However, at 1 year after CCI, CBF was not different from sham in other ROIs, including ipsilateral thalamus, or either contralateral hippocampus or hemisphere. We conclude that, at 1 year after CCI, CBF is reduced in anatomic structures at or near the impact site, including injured cortex and hippocampus, and this translates into a reduction in hemispheric CBF. However, despite both significant occult tissue loss ipsilateral and contralateral to the injury and delayed cognitive deficits, widespread reductions in CBF are not observed. This suggests the possibility of remodeling or repackaging of the brain that preserves CBF outside of the cystic lesion.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Dept Crit Care Med, Pittsburgh, PA USA; Dept Anesthesiol, Pittsburgh, PA USA; Dept Pediat, Pittsburgh, PA USA; Dept Neurosurg, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	Kochanekpm@ccm.upmc.edu	Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P01NS030318, P20NS030318, R01NS038087] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41-RR03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38087, NS 30318] Funding Source: Medline		BERMAN RF, 1988, NEUROBIOL AGING, V9, P691, DOI 10.1016/S0197-4580(88)80134-9; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CAO WH, 1989, NEUROSCI LETT, V107, P135, DOI 10.1016/0304-3940(89)90805-7; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donaldson HH, 1931, J COMP NEUROL, V53, P263, DOI 10.1002/cne.900530202; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Friel KM, 2000, NEUROREHAB NEURAL RE, V14, P187, DOI 10.1177/154596830001400304; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOCHANEK PM, 1997, J NEUROTRAUM, V14, P783; LARTAUD I, 1993, AM J PHYSIOL, V264, pH851; Liepert J, 1999, CURR OPIN NEUROL, V12, P709, DOI 10.1097/00019052-199912000-00009; NAMBA H, 1991, NEUROSCI RES, V12, P463, DOI 10.1016/0168-0102(91)90079-E; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nobili F, 2001, DEMENT GERIATR COGN, V12, P89, DOI 10.1159/000051241; Otsuka H, 2000, J NEUROSURG, V93, P298, DOI 10.3171/jns.2000.93.2.0298; PIERCE JES, 1995, J NEUROTRAUM, V12, P964; Rapoport S I, 1982, Exp Brain Res, VSuppl 5, P86; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; Scremin OU, 1996, LIFE SCI, V58, P2011, DOI 10.1016/0024-3205(96)00192-0; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sonntag WE, 1997, ENDOCRINOLOGY, V138, P3515, DOI 10.1210/en.138.8.3515; Sorger D, 1999, NUCL MED BIOL, V26, P9, DOI 10.1016/S0969-8051(98)00059-6; STRUPP JP, 1996, NEUROIMAGE, V3, P607; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Uchida S, 2000, NEUROSCI LETT, V294, P109, DOI 10.1016/S0304-3940(00)01556-1; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	41	54	55	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1029	1037		10.1089/089771502760341947			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900004	12482116				2021-06-18	
J	Bein, T; Kuhr, LP; Bele, S; Ploner, F; Keyl, C; Taeger, K				Bein, T; Kuhr, LP; Bele, S; Ploner, F; Keyl, C; Taeger, K			Lung recruitment maneuver in patients with cerebral injury: effects on intracranial pressure and cerebral metabolism	INTENSIVE CARE MEDICINE			English	Article						volume recruitment; brain injury; jugular venous oxygen saturation	SEVERE HEAD-INJURY; CONTINUOUS ROTATIONAL THERAPY; TRAUMATIC BRAIN INJURY; UNILATERAL MEASUREMENTS; OXYGEN-METABOLISM; JUGULAR BULB; VENTILATION; ARDS	Objective: To investigate the effects of a lung recruitment maneuver on intracranial pressure (ICP) and cerebral metabolism in patients with acute cerebral injury and respiratory failure. Design: Prospective investigation. Setting: Ten-bed intensive care unit of a university hospital. Patients: Eleven patients with acute traumatic or non-traumatic cerebral lesions, who were on mechanical ventilation with acute lung injury. Interventions: Hemodynamics, ICP, cerebral perfusion pressure (CPP), jugular venous oxygen saturation (SJO(2)), and arterial minus jugular venous lactate content difference (AJDL) were measured before, during and after a volume recruitment maneuver (VRM), which included a 30-s progressive increase in peak pressure up to 60 cmH(2)O and a sustained pressure at the same level for the next 30 s. Results: At the end of VRM, ICP was elevated (16+/-5 mmHg vs 13+/-5 mmHg before VRM, P<0.05) and mean arterial pressure was reduced (75+/-10 vs 86+/-9 mmHg, P<0.01), which resulted in a decrease of CPP (60+/-10 vs 72+/-8 mmHg, P<0.01). SJO(2) deteriorated at the end of the procedure (59+/-7 vs 69+/-6%, P<0.05), AJDL was not altered. In the following period all parameters returned to normal values. An improvement in arterial oxygenation was observed at the end, but not in the period after the maneuver. Conclusions: Our VRM reduced cerebral hemodynamics and metabolism. We conclude that our VRM with high peak pressure effects only a marginal improvement in oxygenation but causes deterioration of cerebral hemodynamics. We therefore cannot recommend this technique for the ventilatory management of brain-injured patients.	Univ Hosp, Dept Anesthesia, D-93042 Regensburg, Germany; Univ Hosp, Dept Neurosurg, D-93042 Regensburg, Germany	Bein, T (corresponding author), Univ Hosp, Dept Anesthesia, D-93042 Regensburg, Germany.						Albert RK, 2000, CLIN CHEST MED, V21, P511, DOI 10.1016/S0272-5231(05)70162-3; Bein T, 1998, INTENS CARE MED, V24, P132, DOI 10.1007/s001340050534; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bohm SH, 1998, YB INTENSIVE CARE EM, P430; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRATTON SL, 1997, NEUROSURGERY, V41, P1214; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; Foti G, 2000, INTENS CARE MED, V26, P501, DOI 10.1007/s001340051196; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Lapinsky SE, 1999, INTENS CARE MED, V25, P1297, DOI 10.1007/s001340050104; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Metz C, 1998, ACT NEUR S, V71, P324; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Paolin A, 1998, J TRAUMA, V44, P495, DOI 10.1097/00005373-199803000-00012; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; TILLETT JM, 1993, CRIT CARE MED, V21, P1005, DOI 10.1097/00003246-199307000-00014; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878	20	54	66	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	2002	28	5					554	558		10.1007/s00134-002-1273-y			5	Critical Care Medicine	General & Internal Medicine	558XP	WOS:000175993300005	12029401				2021-06-18	
J	Aksenova, M; Butterfield, DA; Zhang, SX; Underwood, M; Geddes, JW				Aksenova, M; Butterfield, DA; Zhang, SX; Underwood, M; Geddes, JW			Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury	JOURNAL OF NEUROTRAUMA			English	Article						creatine kinase; oxidative stress; protein oxidation; spinal cord injury	LIPID-PEROXIDATION PRODUCT; TRAUMATIC BRAIN INJURY; ENERGY-METABOLISM; VITAMIN-E; ALZHEIMERS-DISEASE; COMPRESSION TRAUMA; METHYLPREDNISOLONE; RATS; INACTIVATION; INHIBITION	Traumatic injury to the spinal cord triggers several secondary effects, including oxidative stress and compromised energy metabolism, which play a major role in biochemical and pathological changes in spinal cord tissue. Free radical generation and lipid peroxidation have been shown to be early events subsequent to spinal cord injury. In the present study, we demonstrated that protein oxidation increases in rat spinal cord tissue after experimental injury. As early as 1 h after injury, the level of protein carbonyls at the injury epicenter was significantly higher than in control (169%, p < 0.05) and increased gradually over the next 4 weeks to 1260% of control level. Both caudal and rostral parts of the injured spinal cord demonstrated a mild increase of protein carbonyls by 4 weeks postinjury (135-138%, p < 0.05). Immunocytochemical analysis of protein carbonyls in the spinal cord cross-sections showed increased protein carbonyl immunoreactivity in the epicenter section compared to rostral and caudal sections of the same animal or control laminectomy animals. Increased protein carbonyl formation in damaged spinal cord tissue was associated with changes in activity and expression of an oxidative sensitive enzyme, creatine kinase BB, which plays an important role in the maintenance of ATP level in the CNS tissue. Damage to CK function in the CNS may severely aggravate the impairment of energy metabolism. The results of our study indicate that events associated with oxidative damage are triggered immediately after spinal cord trauma but continue to occur over the subsequent 4 weeks. These results suggest that antioxidant therapeutic strategies may be beneficial to lessen the consequences of the injury and potentially improve the restoration of neurological function.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Kentucky, Dept Pharmacol, Lexington, KY 40506 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA; Univ Kentucky, Ctr Membrane Sci, Lexington, KY 40506 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40506 USA	Butterfield, DA (corresponding author), Univ Kentucky, Dept Chem, 121 Chem Phys Bldg, Lexington, KY 40506 USA.	dabcns@uky.edu; jgeddes@uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-10836, AG-05119] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER		Aksenov M, 2000, J NEUROCHEM, V74, P2520, DOI 10.1046/j.1471-4159.2000.0742520.x; Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Aksenova MV, 1999, DEMENT GERIATR COGN, V10, P158, DOI 10.1159/000017098; ANDERSON DK, 1980, J NEUROSURG, V52, P387, DOI 10.3171/jns.1980.52.3.0387; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.biochem.54.1.831; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BURBAEVA GS, 1992, DEMENTIA, V3, P91, DOI 10.1159/000107000; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; BUTTERFIELD DA, 1997, ADV CELL AGING GERON, V2, P161; Chung I, 1998, NEUROSCIENCE, V86, P1101, DOI 10.1016/S0306-4522(98)00103-1; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; Goldberg AL, 1997, MOL BIOL REP, V24, P69, DOI 10.1023/A:1006860828265; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL ED, 1989, CRIT CARE CLIN, V5, P793; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL NC, 1995, NEUROSCIENCE, V69, P591, DOI 10.1016/0306-4522(95)00289-U; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; IWASA K, 1989, FREE RADICAL BIO MED, V6, P599, DOI 10.1016/0891-5849(89)90067-1; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Koufen P, 2000, BBA-MOL BASIS DIS, V1501, P44, DOI 10.1016/S0925-4439(00)00005-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MILLER K, 1993, AM J PHYSIOL, V265, pC1544; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; Mu XJ, 2000, BRAIN RES, V870, P66, DOI 10.1016/S0006-8993(00)02402-1; NORBY HK, 1982, ACTANEUROCHIR WIEN, V65, P93; Pocernich CB, 2001, NEUROCHEM INT, V39, P141, DOI 10.1016/S0197-0186(01)00012-2; PREHN JHM, 1992, J CEREB BLOOD FLOW M, V12, P378; SANCHEZRODRIGUEZ VF, 1995, AM J FOREN MED PATH, V16, P210, DOI 10.1097/00000433-199509000-00004; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; Springer JE, 1997, J NEUROCHEM, V68, P2469; Subramaniam R, 1997, J NEUROCHEM, V69, P1161; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; THOMAS C, 1994, FREE RADICAL RES, V21, P387, DOI 10.3109/10715769409056591; TOMIMOTO H, 1993, ACTA NEUROPATHOL, V86, P447; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; WANG WP, 1994, CHINESE MED J-PEKING, V107, P205; Yatin SM, 1999, NEUROCHEM RES, V24, P427, DOI 10.1023/A:1020997903147; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; ZHANG Y, 1993, SURG NEUROL, V39, P297, DOI 10.1016/0090-3019(93)90009-P; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	66	54	55	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2002	19	4					491	502		10.1089/08977150252932433			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	542XP	WOS:000175071200009	11990354				2021-06-18	
J	Jackson, H; Philp, E; Nuttall, RL; Diller, L				Jackson, H; Philp, E; Nuttall, RL; Diller, L			Traumatic brain injury: A hidden consequence for battered women	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article							HEAD-INJURY; CONSCIOUSNESS; DISORDERS; VIOLENCE	The inability of substantial numbers of battered women to terminate or extricate themselves from violent relationships is of grave concern to clinical practitioners. Despite professional intervention, many victims of domestic violence return to the batterer and to repetitive battering, demonstrating that, for these women, traditional psychosocial interventions are ineffective. In a sample of 53 battered women, 92% reported having received blows to the head in the course of their battering; 40% reported loss of consciousness. Correlations between frequency of being hit in the head and severity of cognitive symptoms were significant, strongly suggesting that battered women should be routinely screened for traumatic brain injury and postconcussive syndrome. Development of treatment strategies to address the potentially damaging sequelae of head trauma in this population is essential.	Columbia Univ, Sch Social Work, New York, NY 10025 USA; Columbia Univ, New York, NY 10027 USA; Boston Coll, Lynch Sch Educ, Chestnut Hill, MA 02167 USA; NYU, Med Ctr, New York, NY USA	Jackson, H (corresponding author), Columbia Univ, Sch Social Work, 622 W 113th St, New York, NY 10025 USA.	maj3@columbia.edu					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barnett OW., 1997, FAMILY VIOLENCE LIFE; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BROWNE A, 1993, AM PSYCHOL, V48, P1077, DOI 10.1037/0003-066X.48.10.1077; CLAERHOUT S, 1982, AM J COMMUN PSYCHOL, V10, P605, DOI 10.1007/BF00894147; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DILLER L, 1992, NEUROPSYCHOLOGICAL R; EBY K, 1995, WOMENS HLTH CARE INT, V16, P563; FERRANT SL, 1992, DISS ABSTR INT B, V530, P6; GELLES RJ, 1990, PHYSICAL VIOLENCE AM; Gronwall D, 1989, MILD HEAD INJURY, P153; KAY R, 1992, NEUROPSYCHOLOGY, V4, P371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KAY T, 1992, PACIF COAST BRAIN IN; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; Kubzansky LD, 1997, CIRCULATION, V95, P818; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Loseke D.R., 1992, BATTERED WOMAN SHELT; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; Pelcovitz D, 1997, J TRAUMA STRESS, V10, P3, DOI 10.1002/jts.2490100103; Picard N., 1999, HELPS; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; SATO RA, 1992, J FAM VIOLENCE, V7, P229, DOI 10.1007/BF00979030; Silver JM., 1994, NEUROPSYCHIATRY TRAU; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; SOUTHERN JP, 1990, LANCET, V336, P1425, DOI 10.1016/0140-6736(90)93114-5; STARK E, 1996, COMMUNICATION    JAN; STRAUS M, 1990, MANUAL CONFLICT TACT; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; Sutherland C, 1998, Womens Health, V4, P41; TEASDALE G, 1974, LANCET, V2, P81; Walker L., 1978, VICTIMOLOGY, V2, P525, DOI DOI 10.1521/JSCP.23.4.445.40311; WALKER LE, 1991, PSYCHOTHER, V28, P21, DOI 10.1037/0033-3204.28.1.21; WALKER LEA, 1994, CURRENT CONTROVERSIE, P133; WILT SA, 1997, FEMALE HOMICIDE VICT	42	54	54	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	FEB	2002	33	1					39	45		10.1037//0735-7028.33.1.39			7	Psychology, Multidisciplinary	Psychology	514QJ	WOS:000173452300006					2021-06-18	
J	Soustiel, JF; Shik, V; Shreiber, R; Tavor, Y; Goldsher, D				Soustiel, JF; Shik, V; Shreiber, R; Tavor, Y; Goldsher, D			Basilar vasospasm diagnosis - Investigation of a modified "Lindegaard index" based on imaging studies and blood velocity measurements of the basilar artery	STROKE			English	Article						basilar artery; cerebral angiography; subarachnoid hemorrhage; tomography, x-ray computed; ultrasonography, Doppler, transcranial; vasospasm	TRANSCRANIAL DOPPLER ULTRASOUND; SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CEREBRAL VASOSPASM; FLOW VELOCITIES; VERTEBROBASILAR VASOSPASM; CEREBROVASCULAR SPASM; ULTRASONOGRAPHY; HEMODYNAMICS; HYPEREMIA	Background and Purpose-Numerous studies have shown that cerebral vasospasm is one of the leading causes of death and neurological disability after subarachnoid hemorrhage. Most of these studies, however, have focused on anterior circulation vessels. Since the introduction of the transcranial Doppler (TCD), increasing attention has been given to basilar artery (BA) vasospasm, especially in traumatic subarachnoid hemorrhage. As shown for the anterior circulation, however, the significance of elevated flow velocities (FVs) in the posterior vessels may be ambiguous, so vasospasm may not be reliably differentiated from hyperemia. The purpose of the present study was to evaluate the potential additional value of an intracranial/extracranial FV ratio in the posterior circulation to cope with this shortcoming of the TCD in the diagnosis of BA vasospasm. Methods-FV in the extracranial vertebral artery (VA) was measured in 20 healthy volunteers. Normative values of all intracranial/extracranial VA FV ratio (IVA/EVA) and a BA/extracranial VA FV ratio (BA/EVA) were calculated. Thirty-four patients with subarachnoid hemorrhage were then evaluated with TCD and CT angiography (CTA). The value of the IVA/EVA and BA/EVA ratios in the diagnosis and assessment of vertebrobasilar vasospasm was investigated. Results-The extracranial VA could be insonated in all subjects at depths ranging from 45 to 55 mm. The average FV for the extracranial VA was 26 cm/s. The ratios between intracranial and extracranial VA FVs were 1.6 on both sides, whereas the ratio between the BA FVs and the mean extracranial VA FVs was slightly higher at 1.7. Fourteen patients (41.2%) had CTA evidence of BA vasospasm. Vasospasm was severe in 7 patients, moderate in 1, and mild in the remaining. An FV threshold of 80 cm/s was indicative of BA vasospasm in 92.8% with 3 false-positive results that could be related to vertebrobasilar hyperemia. Comparative analysis between CTA and TCD findings showed that BA/EVA was >2 in all patients with BA vasospasm (100% sensitivity) and <2 in all but I patient without BA vasospasm (95% specificity). Furthermore, the BA/EVA ratio showed a close correlation with BA diameter (r=-0.8139, P<0.0001) and was >3 in all patients with severe vasospasm. Conclusions-The results of the present study showed that the BA/EVA ratio may contribute to all improved discrimination between BA vasospasm and vertebrobasilar hyperemia and enhance the accuracy and reliability of TCD in the diagnosis of BA vasospasm. Our data further suggest that the BA/EVA ratio may provide an approximation of vasospasm severity and help in identifying patients who are likely to suffer from heinodynamically significant vasospasm.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neuroradiol, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, POB 9602, IL-31096 Haifa, Israel.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Aaslid R, 1999, ACT NEUR S, V72, P47; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ECHLIN FA, 1965, J NEUROSURG, V23, P1, DOI 10.3171/jns.1965.23.1.0001; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fujioka KA., 1992, TRANSCRANIAL DOPPLER, P9; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MOORE WS, 1979, J SURG RES, V26, P1, DOI 10.1016/0022-4804(79)90071-4; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; Soustiel JF, 1998, NEUROSURGERY, V43, P282, DOI 10.1097/00006123-199808000-00061; Soustiel JF, 2001, STROKE, V32, P629, DOI 10.1161/01.STR.32.3.629; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	23	54	56	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JAN	2002	33	1					72	77		10.1161/hs0102.100484			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	509KV	WOS:000173147700016	11779892	Bronze			2021-06-18	
J	van Santbrink, H; Schouten, JW; Steyerberg, EW; Avezaat, CJJ; Maas, AIR				van Santbrink, H; Schouten, JW; Steyerberg, EW; Avezaat, CJJ; Maas, AIR			Serial transcranial Doppler measurements in Traumatic Brain Injury with special focus on the early posttraumatic period	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; transcranial Doppler Sonography; prognosis; outcome; brain tissue PO2	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ARTERIAL SPASM; ULTRASOUND; VELOCITY; VASOSPASM; PRESSURE; TOMOGRAPHY; OXYGEN	Background. Cerebral ischemia is considered a key factor in the development of secondary damage after Traumatic Brain Injury (TBI). Studies on Cerebral Blood Flow (CBF) have documented decreased flow in over 50% of patients with TBI, studied in the acute phase. Transcranial Doppler (TCD) sonography is a non-invasive technique, permitting frequent or continuous measurements of blood flow velocity in the basal cerebral arteries. Objectives. To investigate the potential of TCD to detect decreased blood flow velocity in the early phase after TBI; To investigate whether flow velocity differs between hemispheres in patients with focal lesions versus those with more diffuse injuries; To investigate if decreased blood flow velocity is indicative of cerebral ischemia, as evidenced by measurements of brain tissue pO(2) Methods. TCD examinations were performed in 57 patients with severe TBI (GCS less than or equal to 8) daily over a period of 10 days, with particular attention focused on the first 72 hours, during which period examinations were performed more frequently. A low flow velocity state (LFVS) was defined as a flow velocity less than or equal to 35 cm/sec in one or both MCA's within 72 hours after trauma. PbrO(2) was measured in 33 patients with an intraparenchymal Clark type electrode (Licox). Patients were differentiated into those with primarily unilateral pathology on the admission CT scan versus those with primarily more diffuse or bilateral pathology. Outcome was evaluated at six months after injury, according to the Glasgow Outcome Scale (GOS). Results. A low flow velocity state was observed in 63% of patients studied. Decreased flow was most pronounced during the first eight hours after injury and was accompanied by high pulsatility indices, especially at the side of the lesion. Flow velocity increased significantly after this time period. Initial Vmca values had a strong correlation with ipsilateral measured PbrO(2) values (R = 0.73). The occurrence of a LFVS was associated with poorer outcome (odds ratio 3.9). Conclusions. TCD studies show reduction of cerebral blood flow velocity in the acute phase after traumatic brain injury. Decreased flow velocity is most pronounced ipsilateral to focal pathology. A low flow velocity state is probably due to high peripheral resistance, and is indicative of ischemia, as demonstrated by the association with decreased PbrO(2). A low flow velocity state is of prognostic value and identifies patients at increased risk for ischemia. Early TCD studies are recommended in TBI.	Erasmus MC, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Sci, Dept Publ Hlth, NL-3015 GD Rotterdam, Netherlands	Maas, AIR (corresponding author), Erasmus MC, Dept Neurosurg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.		Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122			AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRINK WA, 2000, NEUROSURGERY, V46, P868; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CHAN KH, 1992, NEUROSURGERY, V30, P697; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROLIMUND P, 1988, LANCET          0521, P1173; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Muizelaar JP, 1997, STROKE, V28, P1998, DOI 10.1161/01.STR.28.10.1998; RINGELSTEIN EB, 1990, ULTRASOUND MED BIOL, V16, P745, DOI 10.1016/0301-5629(90)90039-F; ROMNER B, 1991, British Journal of Neurosurgery, V5, P31, DOI 10.3109/02688699108998444; SAUNDERS FW, 1988, SURG NEUROL, V29, P401, DOI 10.1016/0090-3019(88)90049-3; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; SHIGEMORI M, 1990, ACTA NEUROCHIR, V107, P5, DOI 10.1007/BF01402605; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VANSANTBRINK H, 1994, SERIAL TRANSCRANIAL, P585; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	29	54	57	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2002	144	11					1141	1149		10.1007/s00701-002-1012-8			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	616KZ	WOS:000179304100003	12434170				2021-06-18	
J	Hessmann, MH; Rommens, PM				Hessmann, MH; Rommens, PM			Osteosynthesis techniques in proximal humeral fractures	CHIRURG			German	Article						fracture; humerus; fixation; shoulder	SURGICAL NECK FRACTURES; ELDERLY PATIENTS; FIXATION; INTRAMEDULLARY; HEAD; REPLACEMENT; REDUCTION; PEOPLE; 3-PART	Although proximal humeral fractures are common injuries, there is no generally accepted strategy as to how unstable and displaced two- to four-part fractures should be managed. Surgical therapy is in a conflicting situation between the requirement for anatomical fracture reduction and stable fixation, on the one hand, and the necesscity for minimal intraoperative damage to the soft tissue and arterial vascularization of the humeral head in order to avoid avascular necrosis on the other. Whereas minimally invasive procedures using closed or percutaneous reduction and fixation techniques are advantageous for protection of the arterial blood supply of the proximal humerus, plate fixation provides superior fixation stability. Plate fixation seems to be associated with a reduced risk of avascular necrosis when indirect reduction techniques are used. Poor results in the operative management of humeral head fractures are often seen in association with malunion. There is therefore a tendency towards the use of implants with angular stability in order to reduce the risk for secondary loss of reduction during functional after-treatment. Innovative new plates and intramedullary nails that provide superior stability of fixation of the humeral head fragment have been actually introduced into clinical practice. Together with the specific patient and fracture characteristics, the final result of operative management, however, remains mainly related to the knowledge and operative skills of the trauma or orthopaedic surgeon who deals with these proximal humeral fractures.	Johannes Gutenberg Univ Mainz, Klin & Poliklin Unfallchirurg, D-55101 Mainz, Germany	Hessmann, MH (corresponding author), Johannes Gutenberg Univ Mainz, Klin & Poliklin Unfallchirurg, Langenbeckstr 1, D-55101 Mainz, Germany.	Hessmann@unfall.klinik.uni-mainz.de					Adedapo AO, 2001, INJURY, V32, P115, DOI 10.1016/S0020-1383(00)00154-6; BARTSCH S, 2001, AKTUELLE TRAUMATOL, V31, P64; BENGNER U, 1988, CLIN ORTHOP RELAT R, V231, P179; Beredjiklian PK, 1998, J BONE JOINT SURG AM, V80A, P1484, DOI 10.2106/00004623-199810000-00010; Bernard J, 2000, INJURY, V31, P789, DOI 10.1016/S0020-1383(00)00150-9; BLUM J, 2000, HEFTE UNFALLCHIRURG, V279; BONNEVIALLE P, 1996, OPERAT ORTHOP TRAUMA, V8, P243; Boss A, 1997, UNFALLCHIRURG, V100, P867, DOI 10.1007/s001130050206; Chen CY, 1998, J TRAUMA, V45, P1039, DOI 10.1097/00005373-199812000-00011; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Damanakis K, 1996, UNFALLCHIRURG, V99, P561; DARDER A, 1993, J ORTHOP TRAUMA, V7, P497, DOI 10.1097/00005131-199312000-00002; ESSER RD, 1994, CLIN ORTHOP RELAT R, V299, P244; GERBER C, 1990, J BONE JOINT SURG AM, V72A, P1486, DOI 10.2106/00004623-199072100-00009; GOTZEN L, 1996, SWISS SURG S2, V3, P27; HABERMEYER P, 1992, ORTHOPADE, V21, P148; HAWKINS RJ, 1987, CLIN ORTHOP RELAT R, V223, P77; Hessmann M, 1999, INJURY, V30, P453, DOI 10.1016/S0020-1383(99)00111-4; HESSMANN MH, 1996, LANGENBECK ARCH CHIR, V381, P907; Hoffmann R, 1998, ZBL CHIR, V123, P1232; JABERG H, 1992, J BONE JOINT SURG AM, V74A, P508, DOI 10.2106/00004623-199274040-00006; JAKOB RP, 1991, J BONE JOINT SURG BR, V73, P295; JAKOB RP, 1983, SURG SHOULDER, P330; Kannus P, 1996, BRIT MED J, V313, P1051; KASPERCZYK WJ, 1993, UNFALLCHIRURG, V96, P422; Ko JY, 1996, CLIN ORTHOP RELAT R, P225, DOI 10.1097/00003086-199606000-00028; KOCIALKOWSKI A, 1990, INJURY, V21, P209, DOI 10.1016/0020-1383(90)90003-D; KOFOED H, 1983, CLIN ORTHOP RELAT R, P175; Koval KJ, 1996, J TRAUMA, V40, P778, DOI 10.1097/00005373-199605000-00017; KRISTIANSEN B, 1989, ARCH ORTHOP TRAUM SU, V108, P339, DOI 10.1007/BF00932441; Kuner E H, 1987, Unfallchirurgie, V13, P64, DOI 10.1007/BF02585983; LEE CK, 1981, J TRAUMA, V21, P788, DOI 10.1097/00005373-198109000-00006; Lill H, 1997, UNFALLCHIRURG, V100, P186, DOI 10.1007/s001130050109; LIND T, 1989, ARCH ORTHOP TRAUM SU, V108, P285, DOI 10.1007/BF00932316; LYONS FA, 1990, J BONE JOINT SURG AM, V72A, P1262, DOI 10.2106/00004623-199072080-00023; Matsuda M, 1999, ACTA ORTHOP SCAND, V70, P283, DOI 10.3109/17453679908997808; MEISSNER A, 1987, Aktuelle Traumatologie, V17, P204; MODA SK, 1990, J BONE JOINT SURG BR, V72, P1050; NEER CS, 1982, J BONE JOINT SURG AM, V64, P319, DOI 10.2106/00004623-198264030-00001; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; NEUMANN K, 1988, UNFALLCHIRURG, V91, P451; REES J, 1998, CLIN ORTHOP RELAT R, V353, P18; Resch H, 1997, J BONE JOINT SURG BR, V79B, P295, DOI 10.1302/0301-620X.79B2.6958; Ruch DS, 2000, J ORTHOP TRAUMA, V14, P36, DOI 10.1097/00005131-200001000-00008; SAVOIE FH, 1989, ORTHOPEDICS, V12, P65; Schai P, 1993, Z Unfallchir Versicherungsmed, V86, P27; SEIDEL H, 1995, DYNAMISCHE OSTEOSYNT, pS209; Skutek M, 1998, ARCH ORTHOP TRAUM SU, V117, P252, DOI 10.1007/s004020050239; Speck M, 1996, Swiss Surg, P51; SZYSKOWITZ R, 1987, HEFTE UNFALLHEILKD, V186, P165; Togninalli D, 1998, SWISS SURG, V4, P193; Wachtl SW, 2000, ARCH ORTHOP TRAUM SU, V120, P171, DOI 10.1007/s004020050037; Wheeler DL, 1997, J ORTHOP TRAUMA, V11, P363, DOI 10.1097/00005131-199707000-00012; Williams GR, 1997, J SHOULDER ELB SURG, V6, P423, DOI 10.1016/S1058-2746(97)70048-X; Wurm M, 1999, TRAUMA BERUFSKRANKH, V1, P370; ZIFKO B, 1992, ORTHOPADE, V21, P115	57	54	55	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0009-4722	1433-0385		CHIRURG	Chirurg	NOV	2001	72	11					1235	+		10.1007/s001040170026			11	Surgery	Surgery	497CJ	WOS:000172434900003	11766645				2021-06-18	
J	Vink, R; Mullins, PGM; Temple, MD; Bao, WL; Faden, AI				Vink, R; Mullins, PGM; Temple, MD; Bao, WL; Faden, AI			Small shifts in craniotomy position in the lateral fluid percussion injury model are associated with differential lesion development	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; lesions; magnetic resonance imaging; neurotrauma	TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; MAGNETIC-RESONANCE; HEAD-INJURY; RAT; SPECTROSCOPY; DYSFUNCTION; METABOLISM; DISRUPTION; DECLINE	Previous studies have shown that location and direction of injury may affect outcome in experimental models of traumatic brain injury. Significant variability in outcome data has also been noted in studies using the lateral fluid percussion brain injury model (FPI) in rats. In recent studies from our laboratory, we observed considerable variability in localization and severity of tissue damage as a function of small changes in craniotomy position. To further address this issue, we examined the relationship between craniotomy position and brain lesion size/location in rats subjected to moderate FPI (2.28 +/- 0.18 atmospheres). With placement of a 5-mm craniotomy adjacent to the sagittal suture, there was both ipsilateral and contralateral damage as detected at 3 weeks posttrauma using T-2-weighted magnetic resonance imaging (MRI). The MRI lesions were generally restricted to the hippocampus and subcortical layers. Shifting of the craniotomy site laterally was associated with increased ipsilateral tissue damage and a greater cortical component that correlated with distance from the sagittal suture. In contrast, the contralateral MRI lesion did not change significantly in size or location unless the center of the craniotomy was placed more than 3.5 mm from the sagittal suture, under which condition contralateral damage could no longer be detected. Ipsilateral tissue damage as determined from the MRI scans was linearly correlated to motor outcome but not with cognitive outcome as assessed by the Morris Water Maze. We conclude that craniotomy position is critical in determining extent and location of tissue injury produced during the lateral FPI model in rats. Addressing such potential variability is essential for studies that address either injury mechanisms or therapeutic treatments.	Georgetown Univ, Sch Med, Dept Neurosci, Seattle, WA USA	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Mullins, Paul/0000-0002-1339-6361	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1988, J NEUROTRAUM, V5, P99; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FLOYD CL, 1997, J NEUROTRAUM, V14, P766; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Golding EM, 1996, MAGNET RESON MED, V35, P174, DOI 10.1002/mrm.1910350208; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Qian Liang, 1996, Bulletin of Tokyo Medical and Dental University, V43, P53; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757	35	54	58	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					839	847		10.1089/089771501316919201			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600010	11526990				2021-06-18	
J	Marshall, SW; Spencer, RJ				Marshall, SW; Spencer, RJ			Concussion in rugby: The hidden epidemic	JOURNAL OF ATHLETIC TRAINING			English	Article						injury; epidemiology	INJURIES; UNION; PLAYERS; SEASON; SCHOOL	Objective: To determine the incidence of concussion in high school rugby players and compare the findings with the relevant published literature. Design and Setting: Prospective data collection in one US high school rugby program. Subjects: Two teams followed for 3 years. Measurements: Injury rate, injury severity, and time withheld from competition. Results: Seventeen concussions were recorded, accounting for 25% of all reported injuries. The incidence rate for concussion was 3.8 per 1000 athlete-exposures (95% confidence interval, 2.0-5.7) or 11.3 per 100 player-seasons (95% confidence interval, 5.9-16.7). Of the 17 concussions, 14 were Cantu grade 1, 2 were grade 2, and 1 was grade 3. Concussions accounted for 25% of all days lost from rugby participation due to injury. Conclusions: The incidence of concussion in this study was higher than previously reported in other studies. Methodologic limitations and administrative rules that required suspension for injured players may have suppressed reporting in previous epidemiologic studies. The incidence of concussion in rugby is probably much higher than previously suggested.	Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Highland High Sch, Salt Lake City, UT USA	Marshall, SW (corresponding author), Univ N Carolina, Injury Prevent Res Ctr, CB 7505 Chase Hall, Chapel Hill, NC 27599 USA.			Marshall, Stephen/0000-0002-2664-9233			Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; CLARK DR, 1990, S AFR MED J, V77, P559; DALLEY DR, 1992, NZ J SPORTS MED, V20, P2; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; GARRAWAY M, 1995, LANCET, V345, P1485; Hughes DC, 1994, CLIN J SPORT MED, V4, P249, DOI 10.1097/00042752-199410000-00007; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; NATHAN M, 1983, S AFR MED J, V64, P132; ROUX CE, 1987, S AFR MED J, V71, P307; SUGERMAN S, 1985, AUST J SPORTS MED EX, V15, P5; Wetzler MJ, 1996, AM J SPORT MED, V24, P454, DOI 10.1177/036354659602400408; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	14	54	55	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					334	338					5	Sport Sciences	Sport Sciences	557NC	WOS:000175913800020	12937506				2021-06-18	
J	Leski, ML; Bao, F; Wu, LQ; Qian, H; Sun, DC; Liu, DX				Leski, ML; Bao, F; Wu, LQ; Qian, H; Sun, DC; Liu, DX			Protein and DNA oxidation in spinal injury: Neurofilaments - An oxidation target	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						protein oxidation; DNA oxidation; protein degradation; neurofilament; spinal cord injury; protein carbonyl content; 8-hydroxy-2-deoxyguanosine; Mn (III) tetrakis (4-benzoic acid) porphyrin; nitro-L-arginine; immunohistochemical staining; HPLC analysis; free radicals	HYDROXYL RADICAL PRODUCTION; METAL-CATALYZED OXIDATION; TRAUMATIC BRAIN INJURY; ACID PORPHYRIN MNTBAP; CORD INJURY; SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; IN-VIVO; PEROXYNITRITE PRODUCTION; LIQUID-CHROMATOGRAPHY	This study measured the time courses of protein and DNA oxidation following spinal cord injury (SCI) in rats and characterized oxidative degradation of proteins. Protein carbonyl content-a marker of protein oxidation-significantly increased at 3-9 h postinjury and the ratio 8-hydroxy-2-deoxyguanosine/deoxyguanosine-an indicator of DNA oxidation-was significantly higher at 3-6 h postinjury in the injured cords than in the sham controls. This suggests that oxidative modification of proteins and DNA contributes to secondary damage in SCI. Densities of selected bands on coomassie-stained gels indicated that most proteins were degraded. Neurofilament protein (NFP) was particularly evaluated immunohistochemically; its light chain (NFP-68) was gradually degraded in nerve fibers, neuron bodies, and large dendrites following SCI. A mixture of Mn (III) tetrakis (4-benzoic acid) porphyrin (10 mg/kg)-a novel SOD mimetic-and nitro-L-arginine (1 mg/kg)-an inhibitor of nitric oxide synthase-injected intraperitoneally, increased NFP-68 immunoreactivity and the numbers of NFP-positive nerve fibers post-SCI, correlating NFP degradation in SCI to free radical-triggered oxidative damage for the first time. Therefore, blockage of protein and DNA oxidation in the secondary injury stage may improve long-term recovery-important information for development of the SCI therapies. (C) 2001 Elsevier Science Inc.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd,RT 0653, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035119, R29NS034048] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 34048, NS 35119] Funding Source: Medline		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; AMICI A, 1989, J BIOL CHEM, V264, P3341; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ARUOMA OI, 1989, J BIOL CHEM, V264, P13024; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELAND FA, 1979, J CHROMATOGR, V174, P177, DOI 10.1016/S0021-9673(00)87048-X; BIRNBOIM HC, 1988, ANN NY ACAD SCI, V551, P83, DOI 10.1111/j.1749-6632.1988.tb22322.x; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; CROSS CE, 1992, FREE RADICAL RES COM, V15, P347, DOI 10.3109/10715769209049150; Cuzzocrea S, 1999, BRIT J PHARMACOL, V128, P1241, DOI 10.1038/sj.bjp.0702826; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; FLOYD RA, 1990, ANAL BIOCHEM, V188, P155, DOI 10.1016/0003-2697(90)90544-J; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; FLOYD RA, 1988, ARCH BIOCHEM BIOPHYS, V262, P266, DOI 10.1016/0003-9861(88)90188-9; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Grune T, 1997, FASEB J, V11, P526; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; Haghighi SS, 1996, NEUROL RES, V18, P509; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; HALLIWELL B, 1987, FASEB J, V1, P358; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; IKEDA Y, 1989, Neurological Research, V11, P213; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; Keller JN, 1998, J NEUROSCI, V18, P687; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Morin B, 1998, BIOCHEM J, V330, P1059, DOI 10.1042/bj3301059; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSTMANTUR R, 1994, J NEUROTRAUM, V11, P533; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; VLIET A, 1994, FEBS LETT, V339, P89; vonEuler M, 1997, ACTA NEUROPATHOL, V94, P232, DOI 10.1007/s004010050698; YAGHMAI A, 1992, J NEUROPATHOL EXP NE, V23, P63; Yang MH, 1996, FREE RADICAL BIO MED, V20, P225, DOI 10.1016/0891-5849(95)02039-X; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	69	54	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR 15	2001	30	6					613	624		10.1016/S0891-5849(00)00500-1			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	412BZ	WOS:000167535300004	11295359				2021-06-18	
J	Grados, MA; Slomine, BS; Gerring, JP; Vasa, R; Bryan, N; Denckla, MB				Grados, MA; Slomine, BS; Gerring, JP; Vasa, R; Bryan, N; Denckla, MB			Depth of lesion model in children and adolescents with moderate to severe traumatic brain injury: use of SPGR MRI to predict severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; magnetic resonance imaging; Glasgow coma scale; lesion depth	CLOSED-HEAD-INJURY; AXONAL INJURY; IMAGING FINDINGS; STEM; MEMORY; SCALE; COMA; SCHIZOPHRENIA; CONSCIOUSNESS; SURVIVAL	Objectives-The utility of a depth of lesion classification using an SPGR MRI sequence in children with moderate to severe traumatic brain injury (TBI) was examined. Clinical and depth of lesion classification measures of TBI severity were used to predict neurological and functional outcome after TBI. Methods-One hundred and six children, aged 4 to 19, with moderate to severe TBI admitted to a rehabilitation unit had an SPGR MRI sequence obtained 3 months after TBI. Acquired images were analyzed for location, number, and size of lesions. The Glasgow coma scale (GCS) was the clinical indicator of severity. The deepest lesion present was used for depth of lesion classification. Speed of injury was inferred from the type of injury. The disability rating scale at the time of discharge from the rehabilitation unit (DRS1) and at 1 year follow up (DRS2) were functional outcome measures. Results-The depth of lesion classification was significantly correlated with GCS Severity, number of lesions, and both functional measures, DRS1 and DRS2. This result was more robust for time 1, probably due to the greater number of psychosocial factors impacting on functioning at time 2. Lesion volume was not correlated with the depth of lesion model. In multivariate models, depth of lesion was most predictive of DRS1, whereas GCS was most predictive of DRS2. Conclusions-A depth of lesion classification of TBI severity may have clinical utility in predicting functional outcome in children and adolescents with moderate to severe TBI.	Kennedy Krieger Inst, Dept Psychiat, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Hosp Univ Penn, Dept Radiol, Philadelphia, PA USA	Grados, MA (corresponding author), Kennedy Krieger Inst, Dept Psychiat, 4th Floor,1750 E Fairmount, Baltimore, MD 21224 USA.	mjgrados@mail.jhmi.edu		Grados, Marco/0000-0002-6189-6264	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1RR00052] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; Aylward EH, 1997, PSYCHIAT RES-NEUROIM, V75, P23, DOI 10.1016/S0925-4927(97)00026-7; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; Cassidy John W., 1994, P43; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Colletti PM, 1996, COMPUT MED IMAG GRAP, V20, P491, DOI 10.1016/S0895-6111(96)00045-6; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Friston KJ, 1996, BRIT MED BULL, V52, P644; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; *ISG TECHN, 1995, ALL SOFTW; JENKINS A, 1986, LANCET, V2, P445; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KIM RC, 1985, SURG NEUROL, V23, P525, DOI 10.1016/0090-3019(85)90250-2; KRIEGER D, 1993, CRIT CARE MED, V21, P1944, DOI 10.1097/00003246-199312000-00024; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paradiso S, 1997, NEUROPSY NEUROPSY BE, V10, P1; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Rand S, 1992, Top Magn Reson Imaging, V4, P7; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SALLOWAY S, 1997, NEUROPSYCHIATRY LIMB; SHOGRY MEC, 1992, J COMPUT ASSIST TOMO, V16, P48, DOI 10.1097/00004728-199201000-00009; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; *STAT CORP, 1999, STAT 6 0; STRICH SJ, 1961, LANCET, V2, P443; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Torres IJ, 1997, BIOL PSYCHIAT, V42, P1087, DOI 10.1016/S0006-3223(97)00024-3; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	46	54	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2001	70	3					350	358		10.1136/jnnp.70.3.350			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	405MG	WOS:000167163100013	11181858	Green Published, Bronze			2021-06-18	
J	Gozzoli, V; Schottker, P; Suter, PM; Ricou, B				Gozzoli, V; Schottker, P; Suter, PM; Ricou, B			Is it worth treating fever in intensive care unit patients? Preliminary results from a randomized trial of the effect of external cooling	ARCHIVES OF INTERNAL MEDICINE			English	Article							ORGAN FAILURE; SEPSIS	Background: Antipyresis is a common clinical practice in intensive care, although it is unknown if fever is harmful, beneficial, or a negligible adverse effect of infection and inflammation. Methods: In a randomized study, rectal temperature and discomfort were assessed in 38 surgical intensive care unit patients without neurotrauma or severe hypoxemia and with fever (temperature greater than or equal to 38.5 degreesC) and systemic inflammatory response syndrome. Eighteen patients received external cooling while 20 received no antipyretic treatment. Results: Temperature and discomfort decreased similarly in both groups after 24 hours. No significant differences in recurrence of fever, incidence of infection, antibiotic therapy, intensive care unit and hospital length of stay, or mortality were noted between the groups. Conclusions: These results suggest that the systematic suppression of fever may not be useful in patients without severe cranial trauma or significant hypoxemia. Letting fever take its natural course does not seem to harm patients with systemic inflammatory response syndrome or influence the discomfort level and may save costs.	Univ Hosp Geneva, Div Surg Intens Care, Dept Anaesthesiol Pharmacol & Surg Intens Care, CH-1211 Geneva 14, Switzerland	Ricou, B (corresponding author), Univ Hosp Geneva, Div Surg Intens Care, Dept Anaesthesiol Pharmacol & Surg Intens Care, CH-1211 Geneva 14, Switzerland.						BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Kluger MJ, 1998, ANN NY ACAD SCI, V856, P224, DOI 10.1111/j.1749-6632.1998.tb08329.x; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Poblete B, 1997, BRIT J ANAESTH, V78, P123; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	6	54	54	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9926			ARCH INTERN MED	Arch. Intern. Med.	JAN 8	2001	161	1					121	123		10.1001/archinte.161.1.121			3	Medicine, General & Internal	General & Internal Medicine	387LN	WOS:000166124200015	11146708				2021-06-18	
J	Berthier, ML; Kulisevsky, J; Gironell, A; Lopez, OL				Berthier, ML; Kulisevsky, J; Gironell, A; Lopez, OL			Obsessive-compulsive disorder and traumatic brain injury: Behavioral, cognitive, and neuroimaging findings	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article; Proceedings Paper	49th Annual Meeting of the American-Academy-of-Neurology	APR 12-19, 1997	BOSTON, MASSACHUSETTS	Amer Acad Neurol			POSTTRAUMATIC-STRESS-DISORDER; CLOSED-HEAD-INJURY; EMISSION TOMOGRAPHY; ANOREXIA-NERVOSA; EVENT SCALE; BLOOD-FLOW; SLOWNESS; SECONDARY; ADOLESCENCE; CATATONIA	Objective: The goal of this study was to evaluate behavior and cognition in a consecutive series of patients who developed obsessive-compulsive disorder (OCD) after suffering a traumatic brain injury (TBI). Background: Because OCD is a rare sequelae of TBI, the phenomenology of obsessions and compulsions, the comorbid psychiatric disorders, the performance on cognitive tests, and the neural correlates have not been well characterized. Methods: Ten adult patients who met DSM-IV diagnostic criteria for OCD after suffering either mild (6 cases), moderate (2 cases), or severe (2 cases) TBI were studied using structured psychiatric rating scales (i.e., Yale-Brown Obsessive Compulsive Scale), cognitive tests, and magnetic resonance imaging (MRI). Results: Global severity of OCD ranged from moderate to severe, and all patients had multiple obsessions and compulsions. There was a high frequency of aggressive, contamination, need for symmetry/exactness, somatic, and sexual obsessions as well as cleaning/washing, checking, and repeating compulsions. Unusual features such as obsessional slowness (3 cases) and compulsive exercising (3 cases) were also documented. Comorbid psychiatric diagnoses were common and included posttraumatic stress disorder, anxiety with panic attacks, depression, and intermittent explosive disorder. Compared with 10 age-matched normal controls, the OCD group had poor performance on tests of general intelligence, attention, learning, memory, word-retrieval, and executive functions; these cognitive deficits were more pervasive among patients displaying obsessional slowness. All OCD patients with mild TBI had normal MRI scans, whereas focal contusions in the frontotemporal cortices, subcortical structures (caudate nucleus), or both were found in OCD patients with moderate and severe TBI. Conclusions: Posttraumatic OCD has a relatively specific pattern of symptoms even in patients with mild TBI and is associated with a variety of other psychiatric disorders, particularly non-OCD anxiety. The patterns of cognitive deficits and MRI findings suggest dysfunction of frontal-subcortical circuits.	Univ Malaga, Fac Med, Dept Med & Dermatol, E-29071 Malaga, Spain; Autonomous Univ Barcelona, St Pau Hosp, Dept Neurol, Barcelona, Spain; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA	Berthier, ML (corresponding author), Univ Malaga, Fac Med, Dept Med & Dermatol, Campus Univ Teatinos, E-29071 Malaga, Spain.			Gironell, Alexandre/0000-0003-2109-9030			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association Committee on Nomenclature and Statistics, 1994, DIAGN STAT MAN MENT; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Berthier M L, 1998, Depress Anxiety, V8, P43, DOI 10.1002/(SICI)1520-6394(1998)8:1<43::AID-DA9>3.0.CO;2-6; Berthier ML, 1996, NEUROLOGY, V47, P353, DOI 10.1212/WNL.47.2.353; BOLL TJ, 1981, HDB CLIN NEUROPSYCHO; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Cooper J, 1970, Psychol Med, V1, P48; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DAVIDOFF DA, 1993, COGN REHABIL; DAVIS C, 1994, PSYCHOL MED, V24, P957, DOI 10.1017/S0033291700029044; Depue RA, 1999, BEHAV BRAIN SCI, V22, P491; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Epstein Richard S., 1994, P285; Fahn S, 1982, Adv Neurol, V35, P349; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FISHER CM, 1989, ARCH NEUROL-CHICAGO, V46, P798, DOI 10.1001/archneur.1989.00520430094024; FLAMENT MF, 1988, J AM ACAD CHILD PSY, V27, P764, DOI 10.1097/00004583-198811000-00018; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; GOODMAN WK, 1992, PSYCHIAT CLIN N AM, V15, P861; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLDEN NL, 1990, BRIT J PSYCHIAT, V157, P1, DOI 10.1192/bjp.157.1.1; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HYMAS N, 1991, BRAIN, V114, P2203, DOI 10.1093/brain/114.5.2203; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Kant R, 1996, BRAIN INJURY, V10, P55; Kaplan E., 1983, BOSTON NAMING TEST; Krauss JK, 1997, MOVEMENT DISORD, V12, P776, DOI 10.1002/mds.870120527; Leckman JF, 1997, AM J PSYCHIAT, V154, P911; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lopez OL, 1997, NEUROPSY NEUROPSY BE, V10, P120; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; Michael AJ, 1988, J ANXIETY DISORD, V4, P353, DOI DOI 10.1016/0887-6185(88)90030-8; Money J., 1976, STANDARDIZED ROAD MA; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OTTO MW, 1992, PSYCHIAT CLIN N AM, V15, P825; RATNASURIYA RH, 1991, BRIT J PSYCHIAT, V159, P273, DOI 10.1192/bjp.159.2.273; ROGERS D, 1991, J NEUROPSYCH CLIN N, V3, P334; ROTHENBERG A, 1990, PSYCHIAT CLIN N AM, V13, P469; SAWLE GV, 1991, BRAIN, V114, P2191, DOI 10.1093/brain/114.5.2191; SHTASEL DL, 1991, ARCH GEN PSYCHIAT, V48, P1022; Spitzer RL, 1985, STRUCTURED CLIN INTE; Spreen O., 1991, COMPENDIUM NEUROPSYC; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; TEASDALE GM, 1976, LANCET, V2, P1031; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; VEALE D, 1993, BRIT J PSYCHIAT, V162, P198, DOI 10.1192/bjp.162.2.198; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407	60	54	59	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JAN	2001	14	1					23	31					9	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	405WP	WOS:000167183800003	11234906				2021-06-18	
J	Horsburgh, K; McCulloch, J; Nilsen, M; Roses, AD; Nicoll, JAR				Horsburgh, K; McCulloch, J; Nilsen, M; Roses, AD; Nicoll, JAR			Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; genotype; injury; trauma	TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; E-DEFICIENT MICE; E EPSILON-4 ALLELE; HEAD-INJURY; ALZHEIMER-DISEASE; FOCAL ISCHEMIA; E GENOTYPE; RAT; EXPRESSION	Apolipoprotein E (apoE, protein; APOE, gene) is expressed as three isoforms in humans (E2, E3, E4). The APOE-epsilon4 allele is associated with a poor outcome in patients after head injury of which ischaemic brain damage is a contributor of mortality and morbidity. The aim of the study was to determine whether mice expressing human APOE-epsilon4 displayed more extensive ischaemic neuronal damage 72 h after transient global ischaemia compared with mice which express human APOE-epsilon3. APOE-epsilon3 and -epsilon4 transgenic mice, under the control of a human promoter, were used which express human APOE in neurons and glia. Ischaemic neuronal damage in the CA1 pyramidal cell layer in the APOE-epsilon4 transgenic mice was significantly greater than in the APOE-epsilon3 mice after global ischaemia (36.4 +/- 8.9%, 18.2 +/- 7.3%; P < 0.05). This was associated with more extensive neuronal apoE immunoreactivity in the CA1 pyramidal cell layer in the APOE-<epsilon>4 transgenic mice compared with APOE-epsilon3 transgenic mice. In contrast, in the caudate nucleus, there were similar levels of ischaemic neuronal damage in the APOE-epsilon3 and -epsilon4 transgenic mice (39.2 +/- 10.1%; 44.6 +/- 8.4%, P = 0.32). In the caudate, similar numbers of neurons were immunostained for apoE in the APOE-epsilon3 and -epsilon4 transgenic mice. The present study demonstrated that the APOE-epsilon4 allele is associated with an increased vulnerability of a specific brain region to the effects of global ischaemia, which is closely associated with an increase in neuronal apoE. The data extend previous work and are consistent with an association of the APOE-epsilon4 allele with a poor outcome after acute brain injury in humans.	Univ Glasgow, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow, Lanark, Scotland; Glaxo Wellcome Res & Dev Ltd, Res Triangle Pk, NC USA	Horsburgh, K (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.		; Nicoll, James/I-9253-2017	Horsburgh, Karen/0000-0002-9620-3691; Nicoll, James/0000-0002-9444-7246			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BERTRAND P, 1995, MOL BRAIN RES, V33, P174, DOI 10.1016/0169-328X(95)00097-C; Buttini M, 1999, J NEUROSCI, V19, P4867; Cambon K, 2000, NEUROSCIENCE, V97, P685, DOI 10.1016/S0306-4522(00)00065-8; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; GILL R, 1992, BRAIN RES, V580, P35, DOI 10.1016/0006-8993(92)90924-X; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; HORSBURGH K, 1999, J CEREB BLOOD FLO S1, V19, P589; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Masliah E, 1996, APOLIPOPROTEIN E ALZ, P59; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NELLGARD B, 1992, J CEREBR BLOOD F MET, V12, P2, DOI 10.1038/jcbfm.1992.2; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9	43	54	56	0	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2000	12	12					4309	4317		10.1046/j.1460-9568.2000.01339.x			9	Neurosciences	Neurosciences & Neurology	387FV	WOS:000166113000014	11122341				2021-06-18	
J	Herrmann, M; Curio, N; Petz, T; Synowitz, H; Wagner, S; Bartels, C; Wallesch, CW				Herrmann, M; Curio, N; Petz, T; Synowitz, H; Wagner, S; Bartels, C; Wallesch, CW			Coping with illness after brain diseases - a comparison between patients with malignant brain tumors, stroke, Parkinson's disease and traumatic brain injury	DISABILITY AND REHABILITATION			English	Article							PRIMARY SUPPORT PERSONS; HEAD-INJURY; DEPRESSION; IMPAIRMENT	Purpose : This study investigates coping styles in patients suffering from different brain disorders (malignant brain tumors, stroke, Parkinson's disease and traumatic brain injury). Method: In a combined analysis of four prospective studies we investigated 21 patients with malignant glioma at the end radiochemotherapy, 30 patients one year after ischemic stroke, 54 patients suffering from various stages of Parkinson's disease, and 58 patients 6 to 8.5 months after traumatic brain injury. The assessment of coping with illness was based on the Freiburg Questionnaire on Coping with illness.(1) Results : With few exceptions, coping styles did not differ across the various brain pathologies. Differences occurred with respect to 'active, problem-oriented coping' (decreased in stroke patients), and coping by search for religious relief or quest for sense (increased in patients with Parkinson's disease). Conclusion : Differences in coping styles could be mainly related to age and social factors. Individual coping strategies seem only to be little related to the type of brain pathology.	Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, Magdeburg, Germany	Herrmann, M (corresponding author), Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, Magdeburg, Germany.		Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			Angeleri F, 1997, J CLIN PSYCHIAT, V58, P261, DOI 10.4088/JCP.v58n0605; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; CASAS MS, 1989, J REHABIL, V55, P37; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Ehmann T S, 1990, J Geriatr Psychiatry Neurol, V3, P85, DOI 10.1177/089198879000300206; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; FALLER H, 1994, PSYCHOTHER PSYCH MED, V44, P207; Field D, 1983, Int Rehabil Med, V5, P96; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; Herrmann M, 1997, DISABIL REHABIL, V19, P6, DOI 10.3109/09638289709166439; HERRMANN M, 1993, J NEUROL NEUROSUR PS, V56, P672, DOI 10.1136/jnnp.56.6.672; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HERRMANN M, 1995, TOP STROKE REHABIL, V2, P5; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; KARNOFSKY DA, 1951, ARCH INTERN MED, V87, P477, DOI 10.1001/archinte.1951.03810040002001; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; MAHONEY F I, 1965, Md State Med J, V14, P61; MULLER A, 1998, NEUROLOGICAL REHABIL, V4, P71; Muthny FA., 1989, ERFAHRUNGEN FREIBURG, P86; Muthny FA., 1989, FREIBURGER FRAGEBOGE; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1997, NEUROLOGICAL REHABIL, P423; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; RIDLEY B, 1989, SOC SCI MED, V29, P555, DOI 10.1016/0277-9536(89)90201-3; SCHULZ R, 1988, PSYCHOL AGING, V3, P131, DOI 10.1037/0882-7974.3.2.131; SINYOR D, 1986, STROKE, V17, P1102, DOI 10.1161/01.STR.17.6.1102; STARKSTEIN SE, 1992, TXB NEUROPSYCHIATRY, P449; TOMPKINS CA, 1988, J CONSULT CLIN PSYCH, V56, P502, DOI 10.1037/0022-006X.56.4.502	30	54	54	0	7	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	AUG	2000	22	12					539	546		10.1080/096382800416788			8	Rehabilitation	Rehabilitation	352QC	WOS:000089228500002	11005743				2021-06-18	
J	Stern, SA; Zink, BJ; Mertz, M; Wang, X; Dronen, SC				Stern, SA; Zink, BJ; Mertz, M; Wang, X; Dronen, SC			Effect of initially limited resuscitation in a combined model of fluid-percussion brain injury and severe uncontrolled hemorrhagic shock	JOURNAL OF NEUROSURGERY			English	Article						brain injury; hemorrhage; shock; resuscitation; cerebral blood flow; pig	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; VASCULAR INJURY; VOLUME; ISOFLURANE; EPIDEMIOLOGY; MANAGEMENT; DISABILITY	Object. Studies of isolated uncontrolled hemorrhage have indicated that initial limited resuscitation improves survival. Limited rt suscitation has not been studied in combined traumatic brain injury and uncontrolled hemorrhage. In this study the authors evaluated the effects of limited resuscitation on outcome in combined fluid-percussion injury (FPI) and uncontrolled hemorrhage. Methods. Twenty-four swine weighing 17 to 24 kg each underwent FPI (3 arm) and hemorrhage to a mean arterial pressure (MAP) of 30 mm Hg in the presence of a 4-mm aortic tear. Group I (nine animals) was initially resuscitated to a goal MAP of 60 mm Hg; Group II (nine animals) was resuscitated to a goal MAP of 80 mm Hg; and Group III (control; six animals) was not resuscitated. After 60 minutes, the aortic hemorrhage was controlled and the animals were resuscitated to baseline physiological parameters and observed for 150 minutes. Mortality rates were 11%, 50%, and 100% for Groups I, TT, and III, respectively (Fisher's exact test; p = 0.002). The total hemorrhage volume was greater in Group II (69 +/- 32 ml/kg), as compared with Group I (41 +/- 18 ml/kg) and Group III (37 +/- 3 ml/kg) according to analysis of variance (p < 0.05). In surviving animals, cerebral perfusion pressure, cerebral blood flow (CBF), cerebral venous O-2 saturation (ScvO(2)), and cerebral metabolic rate of O-2 did not differ among groups. Although CBF was approximately 50% of baseline during the period of limited resuscitation in Group I, ScvO(2) remained greater than 60%, and arteriovenous O-2 differences remained within normal limits. Conclusions. In this model of FPI and uncontrolled hemorrhage, early aggressive resuscitation, which is currently recommended, resulted in increased hemorrhage and failure to optimize cerebrovascular parameters. In addition, a 60-minute period of moderate hypotension (MAP = 60 mm Hg) was well tolerated and did not compromise cerebrovascular hemodynamics, as evidenced by physiological parameters that remained within the limits of cerebral autoregulation.	Univ Michigan, Med Ctr, Dept Emergency Med, Ann Arbor, MI 48109 USA	Stern, SA (corresponding author), Univ Michigan, Med Ctr, Dept Emergency Med, TC-B1354-0303,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.						BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chestnut R. M., 1996, NEUROTRAUMA, P445; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dixon CE, 1996, NEUROTRAUMA, P1337; DRONEN SC, 1993, AM J EMERG MED, V11, P331, DOI 10.1016/0735-6757(93)90162-5; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; GROSSLIGHT K, 1985, ANESTHESIOLOGY, V63, P533, DOI 10.1097/00000542-198511000-00011; GUNNAR W, 1988, SURGERY, V103, P398; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; *JOINT SECT TRAUM, 1995, GUID MAN SEV HEAD IN; JONES RR, 1993, WORLD WATCH, V6, P4; Kelly DF, 1996, NEUROTRAUMA, P71; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MURR R, 1993, ANESTH ANALG, V77, P898; *NAT SAF COUNC, 1984, ACC FACTS; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P5; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; STERN SA, 1995, ACAD EMERG MED, V2, P89, DOI 10.1111/j.1553-2712.1995.tb03167.x; TRANMER BI, 1989, NEUROSURGERY, V25, P173, DOI 10.1227/00006123-198908000-00004; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; *US DEP HHS, 1992, MONTHL VIT STAT REP, V43, P1; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	51	54	62	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2000	93	2					305	314		10.3171/jns.2000.93.2.0305			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	338HY	WOS:000088414500019	10930018				2021-06-18	
J	Connolly, JF; D'Arcy, RCN				Connolly, JF; D'Arcy, RCN			Innovations in neuropsychological assessment using event-related brain potentials	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						event-related potentials; assessment; language; stroke; traumatic brain injury; neuropsychology	RECEPTIVE VOCABULARY; SPOKEN SENTENCES; CEREBRAL-PALSY; APHASIA; WORDS; DETERMINANTS; STROKE; P300	Historically, clinicians have utilized evoked potentials for evaluating sensory functions and neuropsychological tests for evaluating cognitive functions. However, the clinical implementation of event-related brain potentials (ERPs), an on-line index of cognitive processing, remains to be developed fully. We describe a new method for assessing language functions using neuropsychological tests that are formatted for computer presentation with simultaneous ERP recordings. From its inception, there have been two major objectives of this ERP language assessment research. Practically, we have sought to develop assessment techniques that would enable clinicians to evaluate the language functions of individuals with limited behavioral and communicative abilities. Conceptually, we have endeavored to increase the precision of neuropsychological testing through the development of measures that are sensitive to readily identifiable and objective neural responses. This article summarizes the issues central to the development of ERP assessment techniques, reviews recent normative studies with healthy individuals, and suggests some future avenues of research in this area. (C) 2000 Elsevier Science B.V. All rights reserved.	Dalhousie Univ, Dept Psychol, Cognit Clin Neurosci Unit, Life Sci Ctr, Halifax, NS B3H 4J1, Canada; Dalhousie Univ, Div Psychiat, Dept Med, Halifax, NS B3H 4J1, Canada	Connolly, JF (corresponding author), Dalhousie Univ, Dept Psychol, Cognit Clin Neurosci Unit, Life Sci Ctr, Halifax, NS B3H 4J1, Canada.			Connolly, John/0000-0001-8869-5369			BATSHAW ML, 1981, CHILDREN HANDICAPS M; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Byrne JM, 1995, CHILD NEUROPSYCHOL, V1, P211, DOI 10.1080/09297049508400226; BYRNE JM, 1995, J CLIN EXP NEUROPSYC, V17, P9, DOI 10.1080/13803399508406576; Byrne JM, 1999, DEV MED CHILD NEUROL, V41, P740, DOI 10.1017/S0012162299001504; CHIAPPA K, 1997, EVOKED POTENTIALS CL; Coltheart, 1992, PSYCHOLINGUISTIC ASS; CONNOLLY JF, 1992, BRAIN LANG, V43, P1, DOI 10.1016/0093-934X(92)90018-A; Connolly JF, 1999, J CLIN EXP NEUROPSYC, V21, P444, DOI 10.1076/jcen.21.4.444.879; CONNOLLY JF, 1995, J CLIN EXP NEUROPSYC, V17, P548, DOI 10.1080/01688639508405145; CONNOLLY JF, 1990, BRAIN LANG, V39, P302, DOI 10.1016/0093-934X(90)90016-A; Connolly JF, 1999, ARCH PHYS MED REHAB, V80, P1309, DOI 10.1016/S0003-9993(99)90035-7; CONNOLLY JF, 1995, ELECTROEN CLIN NEURO, V94, P276, DOI 10.1016/0013-4694(95)98479-R; CONNOLLY JF, 1994, J COGNITIVE NEUROSCI, V6, P256, DOI 10.1162/jocn.1994.6.3.256; CONNOLLY JF, 2000, UNPUB EVENT RELATED; D'Arcy RCN, 2000, CLIN NEUROPHYSIOL, V111, P40, DOI 10.1016/S1388-2457(99)00210-2; D'Arcy RCN, 1999, NEUROPSYCHOLOGIA, V37, P1477, DOI 10.1016/S0028-3932(99)00057-3; DARCY RCN, 2000, IN PRESS J INT NEURO; DARCY RCN, 1998, THESIS; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; Dunn L., 1981, PEABODY PICTURE VOCA; Enderby P, 1987, Int Rehabil Med, V8, P162; Golden CJ, 1978, DIAGNOSIS REHABILITA; HAGOORT P, 1993, LANG COGNITIVE PROC, V8, P337; Ingles JL, 1996, CORTEX, V32, P199, DOI 10.1016/S0010-9452(96)80047-5; Kaplan E., 1991, WAISR NEUROPSYCHOLOG; KEARSLEY R, 1979, INFANTS RISK ASSESSM; KUTAS M, 1980, BIOL PSYCHOL, V11, P99, DOI 10.1016/0301-0511(80)90046-0; KUTAS M, 1994, HDB PSYCHOLINGUISTIC, P83, DOI DOI 10.1016/8978-012369374-7/50018-3; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mangina CA, 2000, INT J PSYCHOPHYSIOL, V35, P11; MANGINA CA, 2000, INT J PSYCHOPHYSIOL; MATARAZZO JD, 1992, AM PSYCHOL, V47, P1007, DOI 10.1037/0003-066X.47.8.1007; MCCARTY SM, 1986, DEV MED CHILD NEUROL, V28, P364; MORSE PA, 1992, CLIN SYNDROMES ADULT, P86; NAATANEN R, 1992, EAR HEARING, V16, P6; NELSON KB, 1989, PEDIAT NEUROLOGY PRI, P363; Osterhout L, 1996, J COGNITIVE NEUROSCI, V8, P507, DOI 10.1162/jocn.1996.8.6.507; PANETH N, 1986, NEW ENGL J MED, V315, P124, DOI 10.1056/NEJM198607103150209; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Rugg Michael D., 1995, P789; Sattler JM, 1988, ASSESSMENT CHILDREN; STANLEY F, 1984, EPIDEMIOLOGY CEREBRA; WADE DT, 1986, J NEUROL NEUROSUR PS, V49, P11, DOI 10.1136/jnnp.49.1.11; WECHSLER D, 1991, WECHSLER INTELLIGENC, pR3; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; ZELAZO PR, 1979, INFANTS RISK ASSESSM	51	54	54	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760			INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	JUL	2000	37	1					31	47		10.1016/S0167-8760(00)00093-3			17	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	326ZG	WOS:000087766700004	10828373				2021-06-18	
J	Haji-Michael, PG; Vincent, JL; Degaute, JP; van de Borne, P				Haji-Michael, PG; Vincent, JL; Degaute, JP; van de Borne, P			Power spectral analysis of cardiovascular variability in critically ill neurosurgical patients	CRITICAL CARE MEDICINE			English	Article						heart rate variability; autonomic nervous system; outcome; neurosurgery; spectral analysis; critical illness; baroreflex sensitivity; head injury; death; brain damage	HEART-RATE-VARIABILITY; TRAUMATIC BRAIN INJURY; BAROREFLEX SENSITIVITY; MYOCARDIAL-INFARCTION; AUTONOMIC DYSFUNCTION; BLOOD-PRESSURE; PREDICTION; FAILURE; HUMANS; REFLEX	Objective: Patients with brain damage exhibit a number of changes in heart rate and cardiovascular control. The aim of this study was to relate changes in autonomic cardiovascular control seen in critically ill neurosurgical patients to the quality of subsequent outcome and survival. Design: Prospective, longitudinal, outcome study. Setting: Intensive care department of a university teaching hospital. Patients: A total of 29- consecutive neurosurgical patients admitted for greater than or equal to 2 days to the intensive care department with a Glasgow Coma Scale score <13 who needed electrocardiographic and invasive arterial monitoring, Interventions: Sampling of the electrocardiogram, respiratory rate, and arterial pressure into a personal computer was carried out for greater than or equal to 60 mins, Power spectral analysis was then applied to the data by using a fast Fourier transformation. Arterial baroreflex sensitivity was determined as the gain of the transfer function between systolic arterial blood pressure and electrocardiograph R-R interval (RRI) variability. All surviving patients were followed up at 3 months postadmission to measure quality of outcome. Measurements and Main Results: There were reductions in the total power (p < .01) of RRI variability in those who subsequently died compared with those who survived, This was significant for very low frequency (p < .001) and low-frequency (LF) (p < .05) but not high-frequency (HF) bands (p = .11), Blood pressure variability, however, did not change between groups. Baroreflex sensitivity was 8.7 +/- 2.2 msecs/mm Hg for patients with a good later outcome and 4.4 +/- 1.5 msecs/mm Hg for patients who subsequently died (p = .03), Patients who recovered to a good quality outcome also had a raised LF/HF ratio in RRI (p = .05), Conclusion: A reduction in the total power variability of RRI and a lowered LF/HF ratio of the RRI are associated with a poor quality recovery or death after neurosurgical illness. A reduction in the baroreflex was specifically associated with death in this patient group.	Erasme Univ Hosp, Dept Cardiol, Hypertens Clin, B-1070 Brussels, Belgium; Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium	van de Borne, P (corresponding author), Erasme Univ Hosp, Dept Cardiol, Hypertens Clin, 808 Lennik Rd, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951			ALBENTOSA M, 1994, AQUACULTURE, V126, P315, DOI 10.1016/0044-8486(94)90048-5; ANDERSON ID, 1990, J TRAUMA, V30, P974, DOI 10.1097/00005373-199008000-00005; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; DEFERRARI GM, 1995, AM HEART J, V130, P473, DOI 10.1016/0002-8703(95)90354-2; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grimm DR, 1997, AM J PHYSIOL-HEART C, V272, pH835; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HNATKOVA K, 1994, COMPUT METH PROG BIO, V42, P147, DOI 10.1016/0169-2607(94)90125-2; HOWELL SJ, 1995, BRIT J ANAESTH, V74, P168, DOI 10.1093/bja/74.2.168; INOUE K, 1995, J AUTONOM NERV SYST, V54, P225, DOI 10.1016/0165-1838(95)00012-M; INOUE K, 1990, AM J PHYSIOL, V258, pH1722; JENNETT B, 1975, LANCET, V1, P480; KAREMAKER JM, 1985, PSYCHOPHYSIOLOGY CAR, P55; Kimura T, 1996, ANESTHESIOLOGY, V84, P1068, DOI 10.1097/00000542-199605000-00008; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; La Rovere MT, 1998, LANCET, V351, P478; LACQUANITI LG, 1993, INT J CLIN MONIT COM, V10, P181, DOI 10.1007/BF01246453; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LOWENSOHN RI, 1977, LANCET, V1, P626; MALIK M, 1993, AM J CARDIOL, V72, P821, DOI 10.1016/0002-9149(93)91070-X; MUHLNICKEL V, 1989, ANAESTHESIOL REANIM, V14, P71; MULDER LJM, 1987, COMPUTERS PSYCHOL ME, P30; Parati G, 1997, J HYPERTENS, V15, P1621, DOI 10.1097/00004872-199715120-00063; PARATI G, 1988, HYPERTENSION, V12, P214, DOI 10.1161/01.HYP.12.2.214; PIEPOLI M, 1995, CLIN SCI, V89, P155, DOI 10.1042/cs0890155; PORGES SW, 1980, PSYCHOL BULL, V88, P580, DOI 10.1037/0033-2909.88.3.580; RaeGrant AD, 1996, J TRAUMA, V40, P401, DOI 10.1097/00005373-199603000-00013; ROBBE HWJ, 1987, HYPERTENSION, V10, P538, DOI 10.1161/01.HYP.10.5.538; Rompelman O., 1980, Study of heart-rate variability, P59; ROMPELMAN O, 1986, AUTOMEDICA, V6, P192; SIMPSON DM, 1988, J GERONTOL, V43, pM21, DOI 10.1093/geronj/43.1.M21; Svigelj V, 1996, ACTA NEUROL SCAND, V94, P120, DOI 10.1111/j.1600-0404.1996.tb07041.x; VANDEBORNE P, 1994, AM J PHYSIOL, V266, pH548; vandeBorne P, 1997, CIRCULATION, V95, P1449; Watkins LL, 1996, HYPERTENSION, V28, P238, DOI 10.1161/01.HYP.28.2.238; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011	41	54	56	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2000	28	7					2578	2583		10.1097/00003246-200007000-00066			6	Critical Care Medicine	General & Internal Medicine	336QW	WOS:000088315300060	10921598				2021-06-18	
J	Keeling, KL; Hicks, RR; Mahesh, J; Billings, BB; Kotwall, GJ				Keeling, KL; Hicks, RR; Mahesh, J; Billings, BB; Kotwall, GJ			Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system	JOURNAL OF NEUROIMMUNOLOGY			English	Article						myeloperoxidase; brain trauma; head injury; inflammation; complement	MICROTUBULE-ASSOCIATED PROTEIN-2; CONTROLLED CORTICAL IMPACT; POLYMORPHONUCLEAR LEUKOCYTES; MYELOPEROXIDASE ACTIVITY; ADHESION MOLECULES; ALZHEIMERS-DISEASE; HEAD-INJURY; FACTOR-B; INFLAMMATION; TISSUE	Traumatic brain injury can lead to locally destructive secondary events mediated by several inflammatory components. Following lateral fluid-percussion (FP) brain injury in rats, we examined cortical and hippocampal sections for neutrophil infiltration and accumulation of complement component C3. Neutrophil influx into the brain after injury was detected by an improved myeloperoxidase (MPO) microassay and manual cell counting, while C3 accumulation was detected using immunocytochemistry. MPO levels were elevated in the injured cortical tissue, whereas C3 immunoreactivity was increased in both injured cortical and ipsilateral hippocampal sections. These results show that the FP model of head injury leads to an intense local inflammatory reaction and subsequent tissue destruction. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA; Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA	Kotwall, GJ (corresponding author), Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40292 USA.						ALBELDA SM, 1994, FASEB J, V8, P504; ANDREWS PC, 1982, ANAL BIOCHEM, V127, P346, DOI 10.1016/0003-2697(82)90185-3; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BECKER P, 1987, ANAESTHESIST, V36, P301; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BOKISCH VA, 1975, P NATL ACAD SCI USA, V72, P1989, DOI 10.1073/pnas.72.6.1989; BOWMAN CM, 1983, AM REV RESPIR DIS, V128, P469, DOI 10.1164/arrd.1983.128.3.469; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRETZ U, 1974, J CELL BIOL, V63, P251, DOI 10.1083/jcb.63.1.251; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Daly J, 1998, NEUROBIOL AGING, V19, P619, DOI 10.1016/S0197-4580(98)00100-6; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hudome S, 1997, PEDIATR RES, V41, P607, DOI 10.1203/00006450-199705000-00002; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kuebler WM, 1996, INT J MICROCIRC, V16, P89, DOI 10.1159/000179155; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MercerJones MA, 1997, SHOCK, V8, P193, DOI 10.1097/00024382-199709000-00007; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; ROTHER K, 1988, COMPLEMENT SYSTEM; SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179, DOI 10.1016/0160-5402(90)90061-O; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; SPIEGEL K, 1997, NEUROINFLAMMATION ME, P129; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; SUZUKI K, 1983, ANAL BIOCHEM, V132, P345, DOI 10.1016/0003-2697(83)90019-2; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TONNESEN MG, 1988, MOL CELLULAR BIOL WO, P149; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; YUAN X-Q, 1990, Journal of Neurotrauma, V7, P141, DOI 10.1089/neu.1990.7.141	57	54	54	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	JUN 1	2000	105	1					20	30		10.1016/S0165-5728(00)00183-1			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	310HV	WOS:000086821200003	10713360				2021-06-18	
J	Chen, E; Hornig, S; Shepherd, SM; Hollander, JE				Chen, E; Hornig, S; Shepherd, SM; Hollander, JE			Primary closure of mammalian bites	ACADEMIC EMERGENCY MEDICINE			English	Article						lacerations; wounds, mammalian bites; dog; cat; human; infection	RISK-FACTORS; WOUNDS; INFECTION; ANTIBIOTICS; EMERGENCY; LACERATIONS; APPEARANCE; MANAGEMENT; INJURIES; CHILDREN	Objective: Suturing of bite wounds remains controversial. The authors evaluated the incidence of wound infection in 145 mammalian bite wounds treated with primary closure. Methods: Consecutive patients with bite wounds receiving primary closure at a university hospital ED had structured closed-question data sheets completed at the time of wound management and suture removal. Infection was determined at the time of suture removal using a previously validated definition. Data included demographics medical history time from injury to evaluation wound characteristics and location details of wound cleansing methods, debridement, foreign body removal, and wound closure methods use of antibiotics and follow-up wound evaluation. Proportions and 95% confidence intervals were calculated. Results: One hundred forty-five mammalian bite patients were enrolled: 88 dog, 45 cat, and 12 human bites. Patients had a mean (+/-SD) age of 21 +/- 20 years; 58% were male; 86% were white; and they presented a mean (+/-SD) of 1.8 +/- 1.2 hours after injury. Bites occurred on the head and neck (57%), upper extremity (36%), and lower extremity (6%). Wounds had a mean length and width of 2.5 cm and 4.8 mm, respectively. Twelve percent involved structures deep to subcutaneous tissue. After primary wound closure, wound infections occurred in eight patients (5.5%; 95% confidence interval = 1.8% to 9.2%). Conclusions: The data suggest that carefully selected mammalian bite wounds can be sutured with approximately a 6% rate of infection. This infection rate may be acceptable in lacerations where cosmesis is a primary concern.	Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA	Hollander, JE (corresponding author), Hosp Univ Penn, Dept Emergency Med, Ground Floor,3400 Spruce St,Ravdin Bldg, Philadelphia, PA 19104 USA.		Shepherd, Suzanne M./G-9137-2014	Hollander, Judd/0000-0002-1318-2785			AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; CALLAHAM M, 1980, ANN EMERG MED, V9, P410, DOI 10.1016/S0196-0644(80)80153-3; CALLAHAM M, 1988, ANN EMERG MED, V17, P1321, DOI 10.1016/S0196-0644(88)80359-7; CALLAHAM ML, 1978, JACEP-J AM COLL EMER, V7, P83, DOI 10.1016/S0361-1124(78)80063-X; CUMMINGS P, 1994, ANN EMERG MED, V23, P535, DOI 10.1016/S0196-0644(94)70073-7; Dire D J, 1994, Acad Emerg Med, V1, P258; Dire Daniel J., 1992, Emergency Medicine Clinics of North America, V10, P719; DIRE DJ, 1990, ANN EMERG MED, V19, P704, DOI 10.1016/S0196-0644(05)82484-9; DIRE DJ, 1995, ACAD EMERG MED, V2, P4, DOI 10.1111/j.1553-2712.1995.tb03070.x; DIRE DJ, 1991, ANN EMERG MED, V20, P973, DOI 10.1016/S0196-0644(05)82975-0; EARLEY MJ, 1984, BRIT J PLAST SURG, V37, P458, DOI 10.1016/0007-1226(84)90130-9; Galvin J R, 1976, JACEP, V5, P332, DOI 10.1016/S0361-1124(76)80056-1; GOLDSTEIN EJC, 1992, CLIN INFECT DIS, V14, P633, DOI 10.1093/clinids/14.3.633; GOSNOLD JK, 1977, PRACTITIONER, V218, P584; GUY RJ, 1986, ANN PLAS SURG, V17, P45, DOI 10.1097/00000637-198607000-00009; Hollander JE, 1997, ACAD EMERG MED, V4, P225, DOI 10.1111/j.1553-2712.1997.tb03747.x; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P983, DOI 10.1111/j.1553-2712.1995.tb03126.x; HOLLANDER JE, 1995, ANN EMERG MED, V25, P675, DOI 10.1016/S0196-0644(95)70183-4; LACKMANN GM, 1992, J CRANIO MAXILL SURG, V20, P81, DOI 10.1016/S1010-5182(05)80472-X; LEUNG AKC, 1992, PEDIATR EMERG CARE, V8, P255, DOI 10.1097/00006565-199210000-00001; LINDSEY D, 1987, J TRAUMA, V27, P45, DOI 10.1097/00005373-198701000-00008; MAIMARIS C, 1988, ARCH EMERG MED, V5, P156; Rest J G, 1985, Emerg Med Clin North Am, V3, P117; RUTHERFORD WH, 1980, ANN EMERG MED, V9, P350, DOI 10.1016/S0196-0644(80)80110-7; SINGER AJ, 1995, AM J EMERG MED, V13, P265, DOI 10.1016/0735-6757(95)90197-3; Singer AJ, 1997, ACAD EMERG MED, V4, P133, DOI 10.1111/j.1553-2712.1997.tb03720.x; THOMSON HG, 1973, J TRAUMA, V13, P20, DOI 10.1097/00005373-197301000-00004; Weiss HB, 1998, JAMA-J AM MED ASSOC, V279, P51, DOI 10.1001/jama.279.1.51; WILEY JF, 1990, CLIN PEDIATR, V29, P283, DOI 10.1177/000992289002900506; ZUBOWICZ VN, 1991, PLAST RECONSTR SURG, V88, P111, DOI 10.1097/00006534-199107000-00019	30	54	58	0	2	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	FEB	2000	7	2					157	161		10.1111/j.1553-2712.2000.tb00519.x			5	Emergency Medicine	Emergency Medicine	293XN	WOS:000085880700008	10691074	Bronze			2021-06-18	
J	Ruff, RM; Jurica, P				Ruff, RM; Jurica, P			In search of a unified definition for mild traumatic brain injury	BRAIN INJURY			English	Article								Discrepant criteria are utilized by various disciplines for the diagnosis of mild traumatic brain injury (TBI). This study evaluates 76 patients, all of whom were diagnosed as having sustained a mild TBI according to the diagnostic criteria set forth by the American Congress of Rehabilitation Medicine (ACRM); yet only 34% of these patients were classified as having a concussion according to DSM-IV. A unified definition is proposed which is comprised of grades: Type I for ACRM, Type III for DSM-IV, and Type II to bridge the two discrepant definitions. An examination of the patients, subdivided into the three types, revealed no significant differences for (1) number of subjective complaints, (2) neurocognitive performances, and (3) pre-existing emotional risk factors. Thus, the proposed gradation unifies the definitions across the heterogeneity of mild TBI. However, further research is indicated for their clinical validation.	Univ Calif San Francisco, Dept Neurosurg & Psychiat, San Francisco, CA 94143 USA; San Francisco Clin Neurosci, San Francisco, CA USA	Ruff, RM (corresponding author), 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baser C A, 1987, Arch Clin Neuropsychol, V2, P13, DOI 10.1016/0887-6177(87)90031-X; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CAMPBELL DT, 1974, PHILOS K POPP 1, V14, P416; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MILLON T, 1987, MANUAL MCMI II; MILLON T, 1994, MCMI 3 MANUAL; Popper K. R., 1972, OBJECTIVE KNOWLEDGE; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUFF RM, 1991, HDB CLIN TRIALS NEUR, P89; TEASDALE G, 1974, LANCET, V2, P81; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	14	54	55	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1999	13	12					943	952					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600001	10628500				2021-06-18	
J	Sagara, Y; Hendler, S; Khoh-Reiter, S; Gillenwater, G; Carlo, D; Schubert, D; Chang, J				Sagara, Y; Hendler, S; Khoh-Reiter, S; Gillenwater, G; Carlo, D; Schubert, D; Chang, J			Propofol hemisuccinate protects neuronal cells from oxidative injury	JOURNAL OF NEUROCHEMISTRY			English	Article						oxidative injury; glutamate; propofol; neurotrauma; neuronal cells; antioxidant	SPINAL-CORD INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; GLUTAMATE TOXICITY; TIRILAZAD MESYLATE; ALPHA-TOCOPHEROL; VITAMIN-E; BRAIN SYNAPTOSOMES; COMPRESSION INJURY; CONTROLLED TRIAL	Oxidative stress contributes to the neuronal death observed in neurodegenerative disorders and neurotrauma. Some antioxidants for CNS injuries, however, have yet to show mitigating effects in clinical trials, possibly due to the impermeability of antioxidants across the blood-brain barrier (BBB). Propofol (2,6-diisopropylphenol), the active ingredient of a commonly used anesthetic, acts as an antioxidant, but it is insoluble in water. Therefore, we synthesized its water-soluble prodrug, propofol hemisuccinate sodium salt (PHS), and tested for its protective efficacy in neuronal death caused by non-receptor-mediated, oxidative glutamate toxicity. Glutamate induces apoptotic death in rat cortical neurons and the mouse hippocampal cell line HT-22 by blocking cystine uptake and causing the depletion of intracellular glutathione, resulting in the accumulation of reactive oxygen species (ROS). PHS has minimal toxicity and protects both cortical neurons and MT-22 cells from glutamate. The mechanism of protection is attributable to the antioxidative property of PHS because PHS decreases the ROS accumulation caused by glutamate. Furthermore, PHS protects MT-22 cells from oxidative injury induced by homocysteic acid, buthionine sulfoximine, and hydrogen peroxide. For comparison, we also tested alpha-tocopherol succinate (TS) and methylprednisolone succinate (MPS) in the glutamate assay. Although TS is protective against glutamate at lower concentrations than PHS, TS is toxic to HT-22 cells. In contrast, MPS is nontoxic but also nonprotective against glutamate. Taken together, PHS, a water-soluble prodrug of propofol, is a candidate drug to treat CNS injuries owing to its antioxidative properties, low toxicity, and permeability across the BBB.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Vyrex Corp, La Jolla, CA USA; Immune Response Corp, Carlsbad, CA USA	Sagara, Y (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5PO1NS28121, F32NS10032, R01NS09658] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS028121, F32NS010032, R01NS009658] Funding Source: NIH RePORTER		Abe K, 1996, J NEUROCHEM, V67, P2074; Bagenholm R, 1997, BRAIN RES, V773, P132, DOI 10.1016/S0006-8993(97)00776-2; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bao YP, 1998, BRIT J ANAESTH, V81, P584, DOI 10.1093/bja/81.4.584; BASS DA, 1983, J IMMUNOL, V130, P1910; BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; De la Cruz JP, 1998, ANESTH ANALG, V87, P1141, DOI 10.1097/00000539-199811000-00031; ERIKSSON O, 1992, BIOCHEM PHARMACOL, V44, P391, DOI 10.1016/0006-2952(92)90026-F; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; GRIFFITH OW, 1983, J BIOL CHEM, V258, P1591; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HALL ED, 1992, J NEUROTRAUM, V9, pS165; HALL ED, 1995, J NEUROTRAUM, V12, P245, DOI 10.1089/neu.1995.12.245; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1987, FASEB J, V1, P358; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Katoh D, 1996, SPINAL CORD, V34, P234, DOI 10.1038/sc.1996.43; Kokita N, 1996, ANESTHESIOLOGY, V84, P117, DOI 10.1097/00000542-199601000-00014; KVAM C, 1993, BIOCHEM BIOPH RES CO, V193, P927, DOI 10.1006/bbrc.1993.1714; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Li GL, 1997, FREE RADICAL RES, V27, P187, DOI 10.3109/10715769709097851; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MACHLIN LJ, 1982, ANN NY ACAD SCI, V393, P48, DOI 10.1111/j.1749-6632.1982.tb31231.x; Maher P, 1996, J NEUROSCI, V16, P6394; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MAY PC, 1985, J NEUROL SCI, V70, P101, DOI 10.1016/0022-510X(85)90192-3; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MUSACCHIO E, 1991, PHARMACOL TOXICOL, V69, P75, DOI 10.1111/j.1600-0773.1991.tb00414.x; OKA A, 1993, J NEUROSCI, V13, P1441; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; RATAN RR, 1994, J NEUROSCI, V14, P4385; Sagara Y, 1998, J NEUROCHEM, V71, P1002, DOI 10.1046/j.1471-4159.1998.71031002.x; Sagara Y, 1998, J NEUROSCI, V18, P6662; Sagara Y, 1998, FREE RADICAL BIO MED, V24, P1375, DOI 10.1016/S0891-5849(97)00457-7; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VOGT M, 1963, P NATL ACAD SCI USA, V49, P171, DOI 10.1073/pnas.49.2.171; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x	58	54	77	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	1999	73	6					2524	2530		10.1046/j.1471-4159.1999.0732524.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	256JX	WOS:000083723100035	10582614				2021-06-18	
J	Bramlett, HM; Green, EJ; Dietrich, WD				Bramlett, HM; Green, EJ; Dietrich, WD			Exacerbation of cortical and hippocampal CA1 damage due to posttraumatic hypoxia following moderate fluid-percussion brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						brain injury; hypoxia; secondary injury; fluid-percussion injury; rat	CEREBRAL BLOOD-FLOW; AMINO-ACIDS; IMPACT INJURY; HEAD-INJURY; ISCHEMIA; HYPOTHERMIA; MILD; VULNERABILITY; EXPRESSION; DISRUPTION	Object. Patients with head injuries often experience respiratory distress that results in a secondary hypoxic insult. The present experiment was designed to assess the 'histopathological consequences of a secondary hypoxic insult by using an established rodent model of traumatic brain injury (TBI). Methods. Intubated anesthetized rats were subjected to moderate (1.94-2.18 atm) parasagittal fluid-percussion injury (FPI) to the brain. Following the TBI, the animals were maintained for 30 minutes by using either hypoxic (TBI-HY group, nine animals) or normoxic (TBI-NO, 10 animals) gas levels. Sham-operated animals also underwent ail manipulations except for the FPI (sham-HY group, seven animals, and sham-NO group, seven animals). Three days after TBI the rats were killed, and quantitative histopathological evaluation was undertaken. Cortical contusion volumes were dramatically increased in the TBI-HY group compared with the TBI-NO group (p < 0.03). Qualitative assessment of cortical and subcortical structures demonstrated significant damage within the hippocampal areas, CAI and CA2, of TBI-HY animals compared with the TBI-NO animals (both p < 0.03). There was also a significant increase in the frequency of damaged neuronal profiles within the middle and medial sectors of the CA1 hippocampus (p < 0.03) due to the hypoxic insult. Conclusions. The results of this study demonstrate that a secondary hypoxic insult following parasagittal FPI exacerbates contusion and neuronal pathological conditions. These findings emphasize the need to control for secondary hypoxic insults after experimental and human head injury.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Dept Psychol, Miami, FL 33101 USA; Univ Miami, Neurotrauma Res Ctr, Miami, FL 33101 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, POB 016960,Mail Locator R-48, Miami, FL 33101 USA.	ddietrich@miamiproject.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dings J, 1998, NEUROL RES, V20, pS71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PHILLIS JW, 1993, REGULATION CEREBRAL, P249; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Zilles K., 1985, CORTEX RAT STEREOTAX	35	54	54	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	1999	91	4					653	659		10.3171/jns.1999.91.4.0653			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	239HV	WOS:000082763400018	10507388				2021-06-18	
J	Zou, LL; Huang, L; Hayes, RL; Black, C; Qiu, YH; Perez-Polo, JR; Le, W; Clifton, GL; Yang, K				Zou, LL; Huang, L; Hayes, RL; Black, C; Qiu, YH; Perez-Polo, JR; Le, W; Clifton, GL; Yang, K			Liposome-mediated NGF gene transfection following neuronal injury: potential therapeutic applications	GENE THERAPY			English	Article						liposomes; NGF; gene therapy; neuronal injury; ChAT; CNS	NERVE GROWTH-FACTOR; SEPTOHIPPOCAMPAL CELL-CULTURES; TRAUMATIC BRAIN INJURY; NUCLEUS BASALIS MAGNOCELLULARIS; SEPTAL CHOLINERGIC NEURONS; FIMBRIA-FORNIX TRANSECTION; IN-VIVO; NEUROTROPHIC FACTOR; CATIONIC LIPOSOMES; HIPPOCAMPAL-NEURONS	We have systematically investigated the therapeutic potential of cationic liposome-mediated neurotrophic gene transfer for treatment of CNS injury. Following determination of optimal transfection conditions, we examined the effects of dimethylaminoethane-carbamoyl-cholesterol (DC-Chol) liposome-mediated NGF cDNA transfection in injured and uninjured primary septo-hippocampal cell cultures and rat brains. In in vitro studies, we detected an increase of NGF mRNA in cultures 1 day after transfection. Subsequent ELISA and PC12 cell biological assays confirmed that cultured cells secreted soluble active NGF into the media from day 2 after gene transfection. Further experiments showed that such NGF gene transfection reduced the loss of choline acetyltransferase (ChAT) activity in cultures following calcium-dependent depolarization injury. In in vivo studies, following intraventricular injections of NGF cDNA complexed with DC-Chol liposomes, ELISA detected nine- to 12-fold increases of NGF in rat CSF. Further studies showed that liposome/NGF cDNA complexes could attenuate the loss of cholinergic neuronal immunostaining in the rat septum after traumatic brain injury (TBI). Since deficits in cholinergic neurotransmission are a major consequence of TBI, our studies demonstrate for the first time that DC-Chol liposome-mediated NGF gene transfection may have therapeutic potential for treatment of brain injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77550 USA	Yang, K (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.		Perez-Polo, Jose R./B-6250-2009		NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA064654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS035502] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 64654] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21458, R01-NS35502] Funding Source: Medline		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BATCHELOR PE, 1989, J COMP NEUROL, V284, P187, DOI 10.1002/cne.902840204; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CastelBarthe MN, 1996, NEUROBIOL DIS, V3, P76, DOI 10.1006/nbdi.1996.0008; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; DEKKER AJ, 1992, BRAIN RES, V584, P55, DOI 10.1016/0006-8993(92)90877-C; DEKKER AJ, 1994, NEUROSCIENCE, V60, P299, DOI 10.1016/0306-4522(94)90244-5; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DORAN SE, 1995, NEUROSURGERY, V36, P965, DOI 10.1227/00006123-199505000-00012; Fasbender A, 1997, GENE THER, V4, P716, DOI 10.1038/sj.gt.3300459; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISCHER W, 1991, EXP NEUROL, V113, P93, DOI 10.1016/0014-4886(91)90167-B; FISCHER W, 1991, J NEUROSCI, V11, P1889; Frick KM, 1997, J NEUROSCI, V17, P2543; Gao X, 1995, GENE THER, V2, P710; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGG T, 1993, EXP NEUROL, V119, P37, DOI 10.1006/exnr.1993.1005; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HEFTI F, 1986, J NEUROSCI, V6, P2155; Imaoka T, 1998, HUM GENE THER, V9, P1093, DOI 10.1089/hum.1998.9.7-1093; Iwamoto Y, 1996, NEUROREPORT, V7, P609, DOI 10.1097/00001756-199601310-00056; Karpati G, 1996, TRENDS NEUROSCI, V19, P49; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; Le WD, 1996, NEUROREPORT, V7, P710, DOI 10.1097/00001756-199602290-00007; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; MartinezSerrano A, 1996, EUR J NEUROSCI, V8, P727, DOI 10.1111/j.1460-9568.1996.tb01258.x; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Qiu YH, 1998, J NEUROSCI RES, V52, P192, DOI 10.1002/(SICI)1097-4547(19980415)52:2<192::AID-JNR7>3.3.CO;2-1; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; RONER S, 1996, J NEUROSCI RES, V45, P40; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; RYLETT RJ, 1993, J NEUROSCI, V13, P3956; SCALI C, 1994, NEUROSCI LETT, V170, P117, DOI 10.1016/0304-3940(94)90253-4; SINSON G, 1995, J NEUROCHEM, V65, P2209; SINSON G, 1996, J NEUROSURG, V84, P665; SUHR ST, 1993, ARCH NEUROL-CHICAGO, V50, P1252, DOI 10.1001/archneur.1993.00540110122012; Thorsell A, 1996, REGUL PEPTIDES, V61, P205, DOI 10.1016/0167-0115(95)00161-1; Tuszynski MH, 1996, GENE THER, V3, P305; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; Yang GY, 1997, BRAIN RES, V751, P181, DOI 10.1016/S0006-8993(96)01277-2; Yang K, 1996, MOL BRAIN RES, V43, P13, DOI 10.1016/S0169-328X(96)00142-8; Yang K, 1997, J NEUROTRAUM, V14, P281, DOI 10.1089/neu.1997.14.281; YANG K, 1994, NEUROSCI LETT, V182, P287, DOI 10.1016/0304-3940(94)90818-4; YANG K, 1994, NEUROSCI LETT, V182, P291, DOI 10.1016/0304-3940(94)90819-2; YANG K, 1995, PARADIGMS NEURAL INJ, P290; Yang KY, 1997, NEUROREPORT, V8, P2355, DOI 10.1097/00001756-199707070-00050; Yoon SO, 1996, P NATL ACAD SCI USA, V93, P11974, DOI 10.1073/pnas.93.21.11974; Zhang LX, 1997, NEUROSCIENCE, V77, P15, DOI 10.1016/S0306-4522(96)00420-4; ZHANG LX, 1992, NEUROREPORT, V3, P700; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	64	54	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0969-7128			GENE THER	Gene Ther.	JUN	1999	6	6					994	1005		10.1038/sj.gt.3300936			12	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	204JA	WOS:000080759700007	10455401	Bronze			2021-06-18	
J	Morris, GF; Juul, N; Marshall, SB; Benedict, B; Marshall, LF				Morris, GF; Juul, N; Marshall, SB; Benedict, B; Marshall, LF		Executive Comm Int Selfotel Trial	Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries	NEUROSURGERY			English	Article						Glasgow Outcome Scale; human clinical trials; outcome measures; pupillary abnormality; severe head injury; traumatic brain injury	SEVERE HEAD-INJURY	OBJECTIVE: A recently improved understanding of the pathophysiological features of head injuries has led to the development of new drug therapies. Accurate human clinical trials remain necessary to document the efficacy and safety of new agents. It would be helpful to decrease the time from drug development to clinical use and general availability for drugs found to be effective. Conversely, ineffective agents could be abandoned in a timely fashion. RATIONALE: A new endpoint measure, defined as neuroworsening (NW), is an objective observable event that is identifiable during hospitalization. This may enable the efficacy of drugs to be demonstrated or disproved much earlier than with 6-month outcome assessments. The prospective, double-blind, multicenter trial of the N-methyl-D-aspartate receptor antagonist Selfotel was used to acquire data on the efficacy of NW in predicting neurological outcomes. The 6-month Glasgow Outcome Scale scores, which were the primary endpoints of that trial, were compared with the frequency of NW. NW was an observable event that could be objectively defined after head injuries. Patients who suffered one or more episodes of NW demonstrated significantly higher morbidity and mortality rates than did patients who did not. CONCLUSION: Future trials should consider the use of NW as an outcome measure that can be included with more traditional measures in the study design. If the strong correlation demonstrated between NW and 6-month Glasgow Outcome Scale scores can be prospectively demonstrated in a successful trial, the time to approval of future agents could be decreased.	Univ Calif San Diego, Ctr Med, Div Neurosurg, San Diego, CA 92103 USA; Aalborg Hosp, Dept Neuroanesthesia & Neurointens Care, Aalborg, Denmark	Marshall, LF (corresponding author), Univ Calif San Diego, Ctr Med, Div Neurosurg, 200 W Arbor Dr, San Diego, CA 92103 USA.						CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1989, J NEUROSURG S, V75, pS28; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	11	54	55	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	1998	43	6					1369	1372		10.1097/00006123-199812000-00063			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	141LP	WOS:000077145700056	9848851				2021-06-18	
J	Thatcher, RW; Biver, C; McAlaster, R; Salazar, A				Thatcher, RW; Biver, C; McAlaster, R; Salazar, A			Biophysical linkage between MRI and EEG coherence in closed head injury	NEUROIMAGE			English	Article						EEG coherence; MRI; H-1 proton relaxation times; cognition; traumatic brain injury	MAGNETIC-RESONANCE IMAGES; RELAXATION-TIMES; BRAIN; TISSUE; NMR; SEGMENTATION; DEPENDENCE; SEQUENCES; MODEL; T1	Using conventional MRI procedures, nuclear magnetic resonance (NMR) of brain water proton (H-1) T2 relaxation times and EEG coherence were obtained from two independent groups of closed head injured (CHI) patients and a group of normal control subjects. Statistically significant intercorrelations were observed between III T2 relaxation times of the cortical gray and white matter and EEG coherence. The analyses showed that lengthened H-1 T2 relaxation times of the cortical gray and white matter were related to: (1) decreased EEG coherence between short interelectrode distances (e.g., 7 cm) and increased EEG coherence between long interelectrode distances (e.g., 28 cm), (2) differences in EEG frequency in which T2 relaxation time was most strongly related to the gray matter in the delta and theta frequencies in CHI patients, and (3) increased T2 relaxation time and decreased short-distance EEG; coherence were related to reduced cognitive function. The results were interpreted in terms of reduced integrity of protein/lipid neural membranes and the efficiency and effectiveness of short- and long-distance neural synchronization following traumatic brain injury. (C) 1998 Academic Press.	VA Med Ctr, Res & Dev Serv, Bay Pines, FL 33744 USA; Univ S Florida, Coll Med, Dept Neurol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Radiol, Tampa, FL 33612 USA; Def & Vet Head Injury Program, Washington, DC USA	Thatcher, RW (corresponding author), VA Med Ctr, Res & Dev Serv, Bay Pines, FL 33744 USA.						Bendat J.S., 1980, ENG APPL CORRELATION; BENSAID AM, 1994, P SOC PHOTO-OPT INS, V2167, P454, DOI 10.1117/12.175079; BERRYMAN AA, 1981, POPULATION SYSTEMS G; BEZDEK JC, 1993, MED PHYS, V20, P1033, DOI 10.1118/1.597000; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; BOTTOMLEY PA, 1987, MED PHYS, V14, P1, DOI 10.1118/1.596111; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; BRAITENBERG V, 1978, ARCHITECTECTONICS CE; Braitenberg V., 1991, ANATOMY CORTEX STAT; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; Cohen J., 1983, APPL MULTIPLE REGRES; DANIEL JC, 1997, DEFENSE VETERANS HEA; DARWIN RH, 1986, RADIOLOGY, V160, P375, DOI 10.1148/radiology.160.2.3726116; DECERTAINES JD, 1993, MAGN RESON IMAGING, V11, P841, DOI 10.1016/0730-725X(93)90201-N; DIXON RL, 1982, MED PHYS, V9, P807, DOI 10.1118/1.595189; FEIN G, 1988, ELECTROEN CLIN NEURO, V69, P581, DOI 10.1016/0013-4694(88)90171-X; FULLERTON GD, 1992, MAGNETIC RESONANCE I, P88; HENRIKSEN O, 1993, MAG RESON IMAG, V11, P811; HICKEY DS, 1986, BRIT J RADIOL, V59, P565, DOI 10.1259/0007-1285-59-702-565; KJOS BO, 1985, AM J ROENTGENOL, V144, P1165, DOI 10.2214/ajr.144.6.1165; KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210; MILLS CM, 1984, RADIOLOGY, V150, P87, DOI 10.1148/radiology.150.1.6689792; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; NICHOLSON C, 1980, NEUROSCI RES PROGRAM, V18, P181; Nunez P., 1981, ELECT FIELDS BRAIN; Nunez P. L., 1995, NEOCORTICAL DYNAMICS; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Otnes R. K., 1972, DIGITAL TIME SERIES; PASCUALMARQUI RD, 1988, INT J NEUROSCI, V40, P89, DOI 10.3109/00207458808985730; Petsche H, 1996, INT J PSYCHOPHYSIOL, V24, P145, DOI 10.1016/S0167-8760(96)00050-5; RAPPELSBERGER P, 1989, Brain Topography, V2, P63, DOI 10.1007/BF01128844; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHOENIGER JS, 1994, J MAGN RESON SER B, V103, P261, DOI 10.1006/jmrb.1994.1039; SZAFER A, 1995, MAGNET RESON MED, V33, P687; Thatcher R W, 1995, J Neuroimaging, V5, P35; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; THATCHER RW, 1994, DEV PSYCHOPATHOL, V6, P565, DOI 10.1017/S0954579400004697; THATCHER RW, 1986, ELECTROEN CLIN NEURO, V64, P123, DOI 10.1016/0013-4694(86)90107-0; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224; THATCHER RW, 1998, DYNAMICAL SYSTEMS DE; VANBAAL C, 1997, THESIS VRIJE U NETHE; VELLEMAN PF, 1995, DATA DESK VERSION 5; Wehrli F. W, 1992, MAGNETIC RESONANCE I, P3; Wright JJ, 1997, BIOL CYBERN, V76, P181, DOI 10.1007/s004220050331	47	54	55	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	NOV	1998	8	4					307	326		10.1006/nimg.1998.0365			20	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	144GV	WOS:000077306700001	9811550				2021-06-18	
J	Inci, S; Ozcan, OE; Kilinc, K				Inci, S; Ozcan, OE; Kilinc, K			Time-level relationship for lipid peroxidation and the protective effect of alpha-tocopherol in experimental mild and severe brain injury	NEUROSURGERY			English	Article						brain injury; lipid peroxidation; alpha-tocopherol	CENTRAL-NERVOUS-SYSTEM; OXYGEN FREE-RADICALS; DIETARY VITAMIN-E; BLOOD-FLOW; EDEMA; RAT; ANTIOXIDANT; DAMAGE; SUPPLEMENTATION; MALONALDEHYDE	OBJECTIVE: Oxygen free radical-mediated lipid peroxidation has been proposed to be one of the major mechanisms of secondary damage in traumatic brain injury. The first purpose of this study was to establish the time-level relationship for lipid peroxidation in injured brain tissue. The second purpose was to examine the protective effect of alpha-tocopherol against lipid peroxidation. METHODS: For this study, 65 guinea pigs in five groups were studied. Five of the animals were identified as a control group, and the remaining 60 animals were divided equally into four groups (Groups A, B, C, and D). Mild injury (200 g x cm) (Groups A and C) and severe injury (1000 g x cm) (Croups B and D) were produced by the method of Feeney et al. alpha-Tocopherol (100 mg/kg) was administered intraperitoneally before brain injury in Groups C and D, Five animals from each group were killed immediately after trauma, five after 1 hour, and the remaining five animals after 36 hours. Lipid peroxidation in traumatized brain tissues was assessed using the thiobarbituric acid method. RESULTS: In all groups with traumatic brain injuries, levels of malondialdehyde, a lipid peroxidation product, were higher than in the control group. The amount of lipid peroxidation was increased by the severity of the trauma. alpha-Tocopherol significantly suppressed the rise in lipid peroxide levels in traumatized brain tissues. CONCLUSION: This study demonstrates that lipid peroxidation is increased by the severity of trauma and that cy-tocopherol has a protective effect against oxygen free radical-mediated lipid peroxidation in mild and severe brain injury.	Univ Hacettepe, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey; Univ Hacettepe, Sch Med, Dept Biochem, TR-06100 Ankara, Turkey	Inci, S (corresponding author), Emek Mahallesi 4,Cadde 70-8, TR-06510 Ankara, Turkey.						ACOSTA D, 1987, EXP NEUROL, V97, P607, DOI 10.1016/0014-4886(87)90117-8; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; BURTON GW, 1980, J AM CHEM SOC, V102, P7791, DOI 10.1021/ja00546a032; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; CHAN PH, 1978, SCIENCE, V201, P358, DOI 10.1126/science.663662; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; COHEN G, 1984, NEUROTOXICOLOGY, V5, P77; DEAN RT, 1987, BIOCHEM BIOPH RES CO, V148, P1277, DOI 10.1016/S0006-291X(87)80271-1; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; ESTERBAUER H, 1993, BRIT MED BULL, V49, P566, DOI 10.1093/oxfordjournals.bmb.a072631; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FAND J, 1981, ARCH INT PHARMACOD T, V250, P4; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GOSSSAMPSON MA, 1987, NEUROPATH APPL NEURO, V13, P289, DOI 10.1111/j.1365-2990.1987.tb00068.x; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; HALL ED, 1993, RES P ARNMD, V71, P81; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P201; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HOLLEY AE, 1993, BRIT MED BULL, V49, P494, DOI 10.1093/oxfordjournals.bmb.a072626; IKEDA Y, 1990, ACT NEUR S, V51, P74; IKEDA Y, 1989, Neurological Research, V11, P213; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KANTOS HA, 1986, CENT NERV SYST TRAUM, V3, P257; KANTOS HA, 1986, J NEUROSURG, V64, P803; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; LONG DM, 1972, STEROIDS BRAIN EDEMA, P87; LUCY JA, 1972, ANN NY ACAD SCI, V203, P4, DOI 10.1111/j.1749-6632.1972.tb27849.x; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MEYDANI M, 1988, LIPIDS, V23, P405, DOI 10.1007/BF02535510; MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557; MIKI M, 1987, ARCH BIOCHEM BIOPHYS, V258, P373, DOI 10.1016/0003-9861(87)90358-4; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; SHIN SM, 1994, BRAIN RES, V653, P45, DOI 10.1016/0006-8993(94)90370-0; SUZUKI R, 1983, ACTA NEUROPATHOL, V60, P207, DOI 10.1007/BF00691868; TAKENAKA Y, 1991, ARCH BIOCHEM BIOPHYS, V285, P344, DOI 10.1016/0003-9861(91)90370-X; Tappel A L, 1978, Adv Exp Med Biol, V97, P111; TAPPEL AL, 1968, GERIATRICS, V23, P97; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VATASSERY GT, 1984, J NEUROCHEM, V43, P409, DOI 10.1111/j.1471-4159.1984.tb00916.x; WINROW VR, 1993, BRIT MED BULL, V49, P506, DOI 10.1093/oxfordjournals.bmb.a072627; Witting LA, 1980, FREE RADICAL BIO MED, V4, P295; YAO T, 1994, AM J PHYSIOL, V267, pG476; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZELESKA MM, 1985, NEUROCHEM RES, V10, P397	57	54	55	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1998	43	2					330	335		10.1097/00006123-199808000-00095			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	103VX	WOS:000074979500086	9696087				2021-06-18	
J	Sliwinski, M; Gordon, WA; Bogdany, J				Sliwinski, M; Gordon, WA; Bogdany, J			The Beck Depression Inventory: Is it a suitable measure of depression for individuals with traumatic brain injury?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MILD HEAD TRAUMA; POSTSTROKE DEPRESSION; SYMPTOMS	Objective: This study examined the relationship between Beck Depression inventory (BDI) scores and current diagnosis of depression, based on The Structured Clinical interview for DSM-IV Diagnosis (SCID). Design: Correlation. Setting: Community-based sample. Participants: 100 individuals with traumatic brain injury (TBI) participated in this study, 25 of whom were diagnosed as depressed and 75 as not depressed at the time of interview. Main Outcome Measures: BDI scores, number of symptoms reported on a symptom checklist and DSM-IV diagnosis of depression. Results: BDI symptoms correlated significantly with the SCID diagnosis of depression (r = .30) but were more strongly related (r = .67) to the number of non-depression-related problems reported, using the TIRR Symptom Checklist, a list of symptoms frequently found post TBI. The BDI had low sensitivity for discriminating depressed from nondepressed individuals (sensitivity = 36% when specificity was set at 80%). These results suggest that for individuals with TBI, high BDI scores may reflect hyperreactivity to post-TDI symptoms to a greater extent than clinical depression. Conclusions: Further study is needed to (1) understand the physiological! functional, and psychosocial factors that are associated with depression in individuals with TBI; (2) provide the basis for developing better measures of depression; and (3) understand how depression is experienced after TBI.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA	Gordon, WA (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.						Beck A.T., 1987, BECK DEPRESSION INVE; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M.B., 1996, STRUCTURED CLIN INTE; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; GORDON WA, 1991, REHABIL PSYCHOL, V36, P71, DOI 10.1037/h0079078; Gordon WA, 1997, ARCH PHYS MED REHAB, V78, P658, DOI 10.1016/S0003-9993(97)90433-0; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; RUTHERFORD WH, 1977, LANCET, V1, P1; Stein PN, 1996, CLIN NEUROPSYCHOL, V10, P141, DOI 10.1080/13854049608406674; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	16	54	55	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					40	46		10.1097/00001199-199808000-00004			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000004	9651238				2021-06-18	
J	Williams, SE; Ris, MD; Ayyangar, R; Schefft, BK; Berch, D				Williams, SE; Ris, MD; Ayyangar, R; Schefft, BK; Berch, D			Recovery in pediatric brain injury: Is psychostimulant medication beneficial?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; MULTIMETHOD CLINICAL PROTOCOL; ATTENTION DEFICIT DISORDER; INTELLECTUAL ABILITY; CHILDREN; METHYLPHENIDATE; SEQUELAE; HYPERACTIVITY; PERFORMANCE; APPROPRIATE	Objective: To assess the effects of methylphenidate on attention, memory, behavior, processing speed, and psychomotor skills of children with closed head injuries. Design: Double-blind, placebo-controlled, crossover design. Setting: An outpatient facility of a children's hospital medical center. Patients: Ten pediatric subjects identified through chart review. Subjects met baseline scores for hyperactivity (Conner's Hyperactivity Index greater than or equal to 60) and intellectual functioning (Verbal Intelligence Quotient greater than or equal to 70) and achieved minimal scores on two psychometric tests. Ail subjects evidenced head injury by focal lesions on computed tomography scan and/or sequelae reported at the time of injury. Severity of injury ranged from mild to severe. All subjects were medically stable at the time of testing. Mean time post injury was 2 years, 8 months. Intervention: Administration of methylphenidate and placebo. Main Outcome Measures: Percentage change in scores was calculated to assess differences between baseline and end of methylphenidate/placebo trials. Results: No significant differences between methylphenidate and placebo on measures assessing behavior, attention, memory, and processing speed. Conclusions: The results of the study call into question the effectiveness of methylphenidate in the pediatric head injury population.	Stanford Univ, Med Ctr, Sch Med, Div Child Psychiat,Dept Psychiat, Stanford, CA 94305 USA; Univ Cincinnati, Coll Med, Neuropsychol Program, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Phys Med & Rehabil, Cincinnati, OH USA; Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA	Williams, SE (corresponding author), Stanford Univ, Med Ctr, Sch Med, Div Child Psychiat,Dept Psychiat, 401 Quarry Rd, Stanford, CA 94305 USA.	sharonw@leland.Stanford.edu					ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARKLEY RA, 1977, J CHILD PSYCHOL PSYC, V18, P137, DOI 10.1111/j.1469-7610.1977.tb00425.x; BARKLEY RA, 1988, J CLIN CHILD PSYCHOL, V17, P14, DOI 10.1207/s15374424jccp1701_3; Barkley RA, 1990, ATTENTION DEFICIT HY; BARKLEY RA, 1991, COMPREHENSIVE MENTAL, V1, P27; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Beery K., 1989, DEV TEST VISUAL MOTO; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUMAGHIM JT, 1987, PSYCHOPHYSIOLOGY, V24, P361, DOI 10.1111/j.1469-8986.1987.tb00310.x; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Conners C. K., 1989, CONNERS RATING SCALE; DENCKLA M B, 1974, Cortex, V10, P186; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1987, J HEAD TRAUMA REHAB, V1, P34; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FISCHER M, 1991, J CLIN CHILD PSYCHOL, V20, P232, DOI 10.1207/s15374424jccp2003_2; Fletcher J, 1987, NEUROBEHAVIORAL RECO; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANKOWSKI KF, 1985, CENTRAL NERVOUS SYST; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; HANNAY HJ, 1988, J CLIN EXPT NEUROPSY, V11, P444; Hayes R. L., 1992, J HEAD TRAUMA REHAB, V7, P16; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLORMAN R, 1990, PSYCHOPHYSIOLOGY, V27, P328, DOI 10.1111/j.1469-8986.1990.tb00391.x; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MATTES JA, 1980, COMPR PSYCHIAT, V21, P358, DOI 10.1016/0010-440X(80)90017-6; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; NEUCHTERLEIN KH, 1983, J ABNORM PSYCHOL, V92, P4; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P1878; Reitan RM., 1969, MANUAL ADM NEUROPSYC; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; SWANSON JM, 1985, PSYCHOPHARMACOL BULL, V21, P887; SYKES DH, 1971, J CHILD PSYCHOL PSYC, V12, P129, DOI 10.1111/j.1469-7610.1971.tb01056.x; TIFFIN J, 1948, INSTRUCTIONS NORMATI; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZAMETKIN AJ, 1987, J AM ACAD CHILD PSY, V26, P676, DOI 10.1097/00004583-198709000-00011	44	54	54	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1998	13	3					73	81		10.1097/00001199-199806000-00007			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZT046	WOS:000074042200007	9582180				2021-06-18	
J	Bleiberg, J; Halpern, EL; Reeves, D; Daniel, JC				Bleiberg, J; Halpern, EL; Reeves, D; Daniel, JC			Future directions for the neuropsychological assessment of sports concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						computerized neuropsychological testing; concussion; reaction time	MILD HEAD-INJURY; REACTION-TIME; ATTENTION DEFICITS; PERFORMANCE	This article argues in favor of using newly developed computerized, complex reaction time (RT)-based neuropsychological procedures for the study of sports-related concussion. Recent studies show that by using these complex RT procedures, significant differences between concussed and control samples can be observed. The magnitude of RT differences is 110 ms or less, levels that are not meaningfully measured with stopwatch-based procedures. RT-based procedures also have the advantage of permitting analysis of variability of RT, and several recent studies have shown that brain dysfunction is accompanied by erratic and inconsistent RT. A currently ongoing sports concussion study using measures of complex RT and variability of RT is described.	Natl Rehabil Hosp, Assist Technol Res Ctr, Psychol Serv, Medlant Res Inst, Washington, DC 20010 USA; Nutr Rehabil Ctr, Assist Technol Ctr, Psychol Serv, Washington, DC USA; Naval Med Ctr, Dept Clin Invest, San Diego, CA USA; USN, Med Ctr, Dept Pediat, San Diego, CA 92152 USA	Bleiberg, J (corresponding author), Natl Rehabil Hosp, Assist Technol Res Ctr, Psychol Serv, Medlant Res Inst, 102 Irving St NW, Washington, DC 20010 USA.			Bleiberg, Joseph/0000-0003-0867-5494			Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; HEAD H, 1926, APHASTA KINDRED DISO; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; REEVES D, 1989, 891 UTCPAB W REED AR; SEGALOWITZ S, 1997, J INT NEUROPSYCHOL S, V3, P35; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; VANZOMEREN AH, 1989, MILD HEAD INJURY	19	54	54	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1998	13	2					36	44		10.1097/00001199-199804000-00006			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF451	WOS:000072898800006	9575255				2021-06-18	
J	Chen, Y; Shohami, E; Constantini, S; Weinstock, M				Chen, Y; Shohami, E; Constantini, S; Weinstock, M			Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; cholinergic activity; closed-head injury; mecamylamine; mice; scopolamine; spatial memory	CEREBRAL BLOOD-FLOW; ALZHEIMERS-DISEASE; RAT; IMPAIRMENT; PERFORMANCE; METABOLISM; ISCHEMIA; TRAUMA; ANTAGONIST; FOREBRAIN	The effects of Rivastigmine, a novel centrally-acting anticholinesterase agent, were evaluated on cerebral edema, neurological and motor deficits, and impairment of spatial memory induced in mice by closed-head injury (CHI), Severe injury was induced in the left hemisphere of mice under ether anesthesia. Rivastigmine (1 or 2 mg/kg) or saline (10 ml/kg) was injected SC 5 min later, Rivastigmine (2 mg/kg) reduced cerebral edema by at least 50% (p < 0.01), 24 h after CHI and accelerated the recovery of motor function 7 and 14 days after CHI. Control mice (n = 24), previously trained to find the goal platform in a Morris water maze failed to recall or relearn its position for at least 11 days post-injury, Those given a single injection of Rivastigmine (2 mg/kg) regained their pre-test latencies by the third day after CHI, The neuroprotective effects of Rivastigmine on brain edema, neurological and motor function, and performace in the Morris water maze were completely antagonized by simultaneous SC injection of either scopolamine (0.5 mg/kg) or mecamylamine (2.5 mg/kg). The antagonists alone had no significant effect on any of these parameters, These data show that the reduction by Rivastigmine of the immediate and long-term sequelae of brain injury are mediated by increased cholinergic activity at both muscarinic and nicotinic receptors.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Sourasky Tel Aviv Med Ctr, Div Pediat Neurosurg, Tel Aviv, Israel	Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.						ANAND R, 1996, J DRUG DEV CLIN PR, V8, P1; BROOKS D N, 1975, Cortex, V11, P329; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHEN Y, 1998, IN PRESS BRAIN RES; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1996, J NEUROTRAUM, V13, P615; Dunnett S B, 1990, Neuroreport, V1, P61, DOI 10.1097/00001756-199009000-00017; ENZ A, 1989, KLIN PHARM, V2, P271; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN ED, 1987, BEHAV NEURAL BIOL, V48, P206, DOI 10.1016/S0163-1047(87)90752-7; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SADOSHIMA S, 1995, J CEREBR BLOOD F MET, V15, P845, DOI 10.1038/jcbfm.1995.105; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCREMIN OU, 1989, STROKE, V20, P92, DOI 10.1161/01.STR.20.1.92; SCREMIN OU, 1993, J CEREBR BLOOD F MET, V13, P702, DOI 10.1038/jcbfm.1993.89; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1993, J ANESTH ANALG, V71, P141; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TANAKA K, 1994, NEUROCHEM RES, V19, P117, DOI 10.1007/BF00966804; TANAKA K, 1995, NEUROCHEM RES, V20, P663, DOI 10.1007/BF01705533; TSUJIMOTO S, 1993, ACTA NEUROCHIR, V124, P127, DOI 10.1007/BF01401134; VOGELS OJM, 1990, NEUROBIOL AGING, V11, P3, DOI 10.1016/0197-4580(90)90056-6; WEINSTOCK M, 1994, J NEURAL TRANSM-SUPP, P219; Weinstock M., 1986, ADV BEHAV BIOL, P539; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Yamaguchi T, 1996, NEUROPHARMACOLOGY, V35, P329, DOI 10.1016/0028-3908(95)00171-9; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	43	54	60	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1998	15	4					231	237		10.1089/neu.1998.15.231			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZF401	WOS:000072893800001	9555969				2021-06-18	
J	Chapman, SB; Levin, HS; Wanek, A; Weyrauch, J; Kufera, J				Chapman, SB; Levin, HS; Wanek, A; Weyrauch, J; Kufera, J			Discourse after closed head injury in young children	BRAIN AND LANGUAGE			English	Article							NARRATIVE DISCOURSE; COGNITIVE SEQUELAE; BRAIN INJURY; ADOLESCENTS; APHASIA; CHILDHOOD; COMPREHENSION; HEMISPHERE; RECOVERY; DEFICITS	This study examined narrative discourse in 23 children, ages 6 to 8 years, who sustained a severe closed head injury (CHI) at least 1 year prior to assessment. Narratives were analyzed at multiple levels using language and information structure measures. Results revealed significant discourse impairments in the CHI group on all measures of information structure, whereas differences in the linguistic domain failed to reach significance. In addition, effects of age at injury and lateralization of lesion on discourse were considered. Although no significant differences were found according to age at injury, a consistent pattern of generally poorer discourse scores was found for the early injured group (<5 years). With regard to lesion focus, the group findings were unimpressive. However, preliminary examination of individual CHI cases with relatively large lateralized lesions suggested that the late injured children may show the language-brain patterns reported in brain-injured adults, whereas early injured children may not. (C) 1998 Academic Press.	Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA; Univ Maryland, Med Syst, Div Neurol Surg, Baltimore, MD 21201 USA	Chapman, SB (corresponding author), Univ Texas, Callier Ctr Commun Disorders, 1966 Inwood Rd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Applebee A., 1978, CHILDS CONCEPT STORY; ARAM DM, 1985, J CLIN EXP NEUROPSYC, V7, P55, DOI 10.1080/01688638508401242; ARAM DM, 1986, BRAIN LANG, V27, P75, DOI 10.1016/0093-934X(86)90006-4; ARAM DM, 1987, BRAIN LANG, V31, P61, DOI 10.1016/0093-934X(87)90061-7; BAMBERG M, 1991, J CHILD LANG, V18, P689, DOI 10.1017/S0305000900011314; BOND S, 1986, THESIS U TEXAS DALLA; BOTVIN GJ, 1977, DEV PSYCHOL, V13, P377, DOI 10.1037/0012-1649.13.4.377; BYRNES JP, 1988, CHILD STUDY J, V18, P101; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1989, BRAIN LANG, V36, P651, DOI 10.1016/0093-934X(89)90092-8; DELIS D, 1987, CALIFORNIA VERBAL LE; DENNIS M, 1994, BRAIN LANG, V46, P129, DOI 10.1006/brln.1994.1008; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1976, BRAIN LANG, V3, P404, DOI 10.1016/0093-934X(76)90036-5; DENNIS M, 1980, LANGUAGE DEV APHASIA, P45; DENNIS M, 1980, BIOL STUDIES MENTAL, P159; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Ehrlich JS, 1994, DISCOURSE ANAL APPL, P149; EWINGCOBBS I, 1985, SPEECH LANGUAGE EVAL, P97; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; FLETCHER JM, 1988, J CLIN EXP NEUROPSYC, V10, P495, DOI 10.1080/01688638808408255; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Frederiksen C.H., 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Goldman PS, 1974, PLASTICITY RECOVERY; Greenough W.T., 1986, DEV NEUROPSYCHOBIOLO, P387; Guttmann E, 1942, BRAIN, V65, P205, DOI 10.1093/brain/65.2.205; Halliday Michael A. K., 1976, COHESION ENGLISH; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HUNT KW, 1965, 4 NAT COUNC TEACH EN; JOANETTE Y, 1990, DISCOURSE ABILITY BR, P131, DOI DOI 10.1007/978-1-4612-3262-9_6; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; KOLB B, 1989, AM PSYCHOL, V44, P1203, DOI 10.1037/0003-066X.44.9.1203; Labov William., 1972, LANGUAGE INNER CITY; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MENDOLSOHN D, 1992, CHILD NERV SYST, V8, P45; NEWMAN JE, 1986, TOP LANG DISORD, V7, P31, DOI 10.1097/00011363-198612000-00006; SMITH A, 1984, EARLY BRAIN DAMATE, V1; STJAMESROBERTS I, 1979, ADV CHILD DEV BEHAV, P253; TEASDALE G, 1974, LANCET, V2, P81; THAL DJ, 1991, BRAIN LANG, V40, P491, DOI 10.1016/0093-934X(91)90145-Q; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; VANDIJK R, 1985, HDB DISCOURSE ANAL; WECHSLER D, 1974, WECHSLER INTLELLIGEN; Westby C. E., 1984, LANGUAGE LEARNING DI, P103; WOODS BT, 1979, ANN NEUROL, V6, P405, DOI 10.1002/ana.410060505	57	54	56	1	7	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	FEB 15	1998	61	3					420	449		10.1006/brln.1997.1885			30	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	ZK818	WOS:000073366800006	9570872				2021-06-18	
J	Ivanhoe, CB; Lai, JM; Francisco, GE				Ivanhoe, CB; Lai, JM; Francisco, GE			Bruxism after brain injury: Successful treatment with botulinum toxin-A	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MUSCLE	Bruxism, the rhythmic grinding of teeth-usually during sleep-is not an infrequent complication of traumatic brain injury. Its prevalence in the general population is 21%, but its incidence after brain injury is unknown. Untreated, bruxism causes masseter hypertrophy, headache, temporomandibular joint destruction, and total dental wear. We report a case of complete resolution of postanoxic bruxism after treatment with botulinum toxin-A (BTX-A). The patient was a 28-year-old man with no history of bruxism who sustained an anoxic brain injury secondary to cardiac arrest of unknown etiology. On admission to our rehabilitation unit 2 months after the injury, the patient presented with severe bruxism and heavy dental wear. The patient was injected with a total of 200 units of BTX-A to each masseter and temporalis, There was total resolution of bruxism 2 days after injection, with no complications. On fellow-up 3 months after injection, the patient remained free of bruxism. We propose that botulinum toxin be considered as a treatment for bruxism secondary to anoxic brain injury. Further studies regarding muscle selection and medication dosage are warranted to elucidate the toxin's efficacy in this condition. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PHYS MED & REHABIL,HOUSTON,TX	Ivanhoe, CB (corresponding author), TIRR,BRAIN INJURY PROGRAM,1333 MOURSUND,HOUSTON,TX 77030, USA.						GORDON K, 1993, J CHILD NEUROL, V8, P154, DOI 10.1177/088307389300800208; GUI D, 1994, LANCET, V344, P1127, DOI 10.1016/S0140-6736(94)90633-5; HORN AKE, 1993, EXP BRAIN RES, V96, P39, DOI 10.1007/BF00230437; KAUFMAN DM, 1994, J NEUROPSYCH CLIN N, V6, P50; MERELLO M, 1994, MOVEMENT DISORD, V9, P104, DOI 10.1002/mds.870090118; MILLER SC, 1947, AM J ORTHOD ORAL SUR, V33, P675; PASRICHA PJ, 1994, ANN INTERN MED, V121, P590, DOI 10.7326/0003-4819-121-8-199410150-00006; PRATAPCHAND R, 1985, CLIN NEUROL NEUROSUR, V87, P113, DOI 10.1016/0303-8467(85)90107-6; REDDING GR, 1966, J DENT RES, V45, P1198; SCOTT AB, 1980, SURG J PEDIAT OPHTHA, V17, P210; SHAARI CM, 1991, LARYNGOSCOPE, V101, P960; SMYTH AG, 1994, BRIT J ORAL MAX SURG, V32, P29, DOI 10.1016/0266-4356(94)90169-4	12	54	56	0	9	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1997	78	11					1272	1273		10.1016/S0003-9993(97)90343-9			2	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YE945	WOS:A1997YE94500018	9365360				2021-06-18	
J	Maxeiner, H				Maxeiner, H			Detection of ruptured cerebral bridging veins at autopsy	FORENSIC SCIENCE INTERNATIONAL			English	Article						subdural bleeding; head injury; bridging veins; postmortem X-ray	SUBDURAL-HEMATOMA	Subdural hematomas (SDH) are a frequent autopsy finding in victims of closed head injuries. About 2/3 of the cases in our own massive SDH series had brain contusions as a cause of bleeding. In about 1/3 of the cases, SDH resulted from ruptured vessels of the brain surface in the absence of contusions. Our experience has shown that such an ''isolated'' SDH may be expected in about 5% of fatal blunt head injuries. A technique is presented to detect bridging vein leakage before there is any risk of artificial damage. After sawing through the skull in the fronto-occipital plane and cutting through the upper half of the brain together with the calvarium, approximately 5-10 ml of barium sulfate are instilled into the superior sagittal sinus by a balloon catheter at low pressure, and X-rays are taken. If there is extravasation, the rupture is visible before further preparation. (C) 1997 Elsevier Science Ireland Ltd.		Maxeiner, H (corresponding author), FREE UNIV BERLIN,MED CTR BENJAMIN FRANKLIN,INST FORENS MED,HITTORFSSTR 18,D-14195 BERLIN,GERMANY.						AVIS SP, 1993, AM J FOREN MED PATH, V14, P130, DOI 10.1097/00000433-199306000-00005; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; KRAULAND W, 1982, VERLETZUNGEN INTRAKR; KRAULAND W, 1961, QUELLEN AKUTEN CHRON; Leth P, 1997, FORENSIC SCI INT, V85, P65, DOI 10.1016/S0379-0738(96)02082-8; OLEARY PM, 1986, ANN EMERG MED, V15, P944, DOI 10.1016/S0196-0644(86)80682-5; Rothschild M A, 1990, Beitr Gerichtl Med, V48, P223; Voigt G E, 1968, Dtsch Z Gesamte Gerichtl Med, V64, P9, DOI 10.1007/BF00585127; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121	9	54	57	0	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	SEP 19	1997	89	1-2					103	110		10.1016/S0379-0738(97)00124-2			8	Medicine, Legal	Legal Medicine	XV942	WOS:A1997XV94200012	9306669				2021-06-18	
J	Lamb, RG; Harper, CC; McKinney, JS; Rzigalinski, BA; Ellis, EF				Lamb, RG; Harper, CC; McKinney, JS; Rzigalinski, BA; Ellis, EF			Alterations in phosphatidylcholine metabolism of stretch-injured cultured rat astrocytes	JOURNAL OF NEUROCHEMISTRY			English	Article						cultured astrocytes; stretch-induced cell injury; phosphatidylcholine biosynthesis; phospholipase activity; phosphocholine cytidylyltransferase activity; oxyradical scavengers; antioxidants	EXPERIMENTAL BRAIN INJURY; ARACHIDONIC-ACID; PHOSPHOLIPASE-C; HEAD-INJURY; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; LIPID-PEROXIDATION; LIVER; SUPEROXIDE; CTP; MECHANISMS	The primary objective of this study was to determine the influence of stretch-induced cell injury on the metabolism of cellular phosphatidylcholine (PC). Neonatal rat astrocytes were grown to confluency in Silastic-bottomed tissue culture wells in medium that was usually supplemented with 10 mu M unlabeled arachidonate. Cell injury was produced by stretching (5-10 mm) the Silastic membrane with a 50-ms pulse of compressed air. Stretch-induced cell injury increased the incorporation of [H-3]choline into PC in an incubation time- and stretch magnitude-dependent manner. PC biosynthesis was increased three- to fourfold between 1.5 and 4.5 h after injury and returned to control levels by 24 h postinjury. Stretch-induced cell injury also increased the activity of several enzymes involved in the hydrolysis [phospholipase A(2) (EC 3.1.1.4) and C (PLC; EC 3.1.4.3)] and biosynthesis [phosphocholine cytidylyltransferase (PCT; EC 2.7.7.15)] of PC, Stretch-induced increases in PC biosynthesis and PCT activity correlated well (r = 0.983) and were significantly reduced by pretreating (1 h) the cells with an iron chelator (deferoxamine) or scavengers of reactive oxygen species such as superoxide dismutase and catalase, The stretch-dependent increase in PC biosynthesis was also reduced by antioxidants (vitamin E, vitamin E succinate, vitamin E phosphate, melatonin, and n-acetylcysteine), Arachidonate-enriched cells were more susceptible to stretch-induced injury because lactate dehydrogenase release and PC biosynthesis were significantly less in non-arachidonate-enriched cells. In summary, the data suggest that stretch-induced cell injury is (a) a result of an increase in the cellular level of hydroxyl radicals produced by an iron-catalyzed Haber-Weiss reaction, (b) due in part to the interaction of oxyradicals with the polyunsaturated fatty acids of cellular phospholipids such as PC, and (c) reversible as long as the cell's membrane repair functions (PC hydrolysis and biosynthesis) are sufficient to repair injured membranes. These results suggest that stretch-induced cell injury in vitro may mimic in part experimental traumatic brain injury in vivo because alterations in cellular PC biosynthesis and PLC activity are similar in both models, Therefore, this in vitro model of stretch-induced injury may supplement or be a reasonable alternative to some in vivo models of brain injury for determining the mechanisms by which traumatic cell injury results in cell dysfunction.		Lamb, RG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 980613,MCV STN,RICHMOND,VA 23298, USA.				NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA 08758] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008758, R55AA008758] Funding Source: NIH RePORTER		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHAN PH, 1988, J NEUROCHEM, V50, P1185, DOI 10.1111/j.1471-4159.1988.tb10591.x; COLEMAN JB, 1988, TOXICOL APPL PHARM, V95, P200, DOI 10.1016/0041-008X(88)90156-1; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GAMACHE DA, 1988, BIOCHIM BIOPHYS ACTA, V958, P116, DOI 10.1016/0005-2760(88)90252-4; Haber F., 1934, P ROY SOC          A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/rspa.1934.0221]; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HUBAND S, 1995, FASEB J, V9, pA957; ISHIDATE K, 1980, BIOCHIM BIOPHYS ACTA, V620, P49; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LAMB RG, 1982, TOXICOL APPL PHARM, V63, P216, DOI 10.1016/0041-008X(82)90044-8; LAMB RG, 1994, HEPATOLOGY, V19, P174, DOI 10.1016/0270-9139(94)90069-8; LAMB RG, 1970, J BIOL CHEM, V245, P3075; Lamb RG, 1988, LIVER DRUGS EXPT PHA, P53; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; REYNOLDS ES, 1980, TOXIC INJURY LIVER B, P541; RZIGALINSKI BA, 1994, BBA-MOL CELL RES, V1223, P219, DOI 10.1016/0167-4889(94)90229-1; SANGHERA JS, 1990, BIOCHIM BIOPHYS ACTA, V1042, P380, DOI 10.1016/0005-2760(90)90168-W; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SPECTOR AA, 1985, J LIPID RES, V26, P1015; TAVLIN SJ, 1995, J NEUROPHYSIOL, V74, P2767; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEY HE, 1993, TOXICOL APPL PHARM, V120, P72, DOI 10.1006/taap.1993.1088; WHITE BC, 1993, ANN EMERG MED, V22, P970, DOI 10.1016/S0196-0644(05)82737-4; YAO ZM, 1990, J BIOL CHEM, V265, P4326; YOUNES M, 1988, LIVER DRUGS EXPT PHA, P31	37	54	57	2	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	MAY	1997	68	5					1904	1910					7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	WU248	WOS:A1997WU24800015	9109516				2021-06-18	
J	Donders, J; Warschausky, S				Donders, J; Warschausky, S			WISC-III factor index score patterns after traumatic head injury in children	CHILD NEUROPSYCHOLOGY			English	Article							ADOLESCENTS	Four subtypes of Wechsler Intelligence Scale for Children-Third Edition (WISC-III) factor index score patterns were identified by means of two-stage cluster analysis in a sample of 153 children with traumatic head injury (THI). Three of these subtypes were differentiated primarily by level of performance, and bore close resemblance to clusters known to be prevalent in the WISC-III standardization sample. One subtype displayed an uncommon pattern of performance, characterized by selective impairment on the Perceptual Organization and Processing Speed factor indexes, which may be clinically significant in children with THI. Support for the reliability and validity of the subtypes is provided. It is concluded that the WISC-III is a useful tool in the evaluation of sequelae of THI in children.	UNIV MICHIGAN,ANN ARBOR,MI 48109	Donders, J (corresponding author), MARY FREE BED HOSP,235 WEALTHY SE,GRAND RAPIDS,MI 49503, USA.						BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bouchard T.J., 1985, HDB INTELLIGENCE THE, P391; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; DONDERS J, 1993, CLIN NEUROPSYCHOL, V7, P430, DOI 10.1080/13854049308401533; DONDERS J, 1995, ASSESSMENT, V2, P219; DONDERS J, 1996, HDB PEDIAT PSYCHOL P; Everitt B. S., 1980, CLUSTER ANAL; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; Fuerst DR, 1995, CHILD NEUROPSYCHOL, V1, P38, DOI 10.1080/09297049508401341; Kaufman A.S., 1994, INTELLIGENT TESTING; KAUFMAN AS, 1993, J SCHOOL PSYCHOL, V31, P345, DOI 10.1016/0022-4405(93)90019-F; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LITTLE SG, 1992, SCHOOL PSYCHOL QUART, V7, P136; MCDERMOTT PA, 1989, PSYCHOL ASSESSMENT J, V1, P292; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; ROID GH, 1993, J PSYCHOEDUC ASSESS, P6; Rourke BP, 1989, NONVERBAL LEARNING D; ROURKE BP, 1996, ASSESSMENT, V3, P277; *SAS, 1990, SAS STAT US GUID VER, V1; SATTLER JM, 1992, ASSESSMENT CHILDRENS; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC	28	54	55	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	APR	1997	3	1					71	78		10.1080/09297049708401369			8	Clinical Neurology	Neurosciences & Neurology	XE553	WOS:A1997XE55300006					2021-06-18	
J	May, AK; Young, JS; Butler, K; Bassam, D; Brady, W				May, AK; Young, JS; Butler, K; Bassam, D; Brady, W			Coagulopathy in severe closed head injury: Is empiric therapy warranted?	AMERICAN SURGEON			English	Article; Proceedings Paper	64th Annual Scientific Meeting and Postgraduate Course Program, Southeastern-Surgical-Congress	FEB 04-07, 1996	TAMPA, FL	SE Surg Congress			DISSEMINATED INTRAVASCULAR COAGULATION; DISORDERS	Closed head injuries account for a significant portion of the morbidity and mortality following blunt trauma. Severe closed head injuries can be complicated by the development of a coagulopathy that may worsen blood loss and delay invasive neurosurgical procedures. Awaiting the results of coagulation studies prior to initiating treatment of such a coagulopathy introduces an inherent delay that may allow worsening of the coagulation disturbance and negatively influence outcome. This study was undertaken to see if a subgroup of patients with severe closed head injuries had a high probability of developing a coagulopathy and would warrant empiric treatment with fresh frozen plasma. The records of adult patients admitted to our trauma center with a Glasgow coma score (GCS) of less than or equal to 8 and an extracranial abbreviated injury score of less than or equal to 2 during a 9-month period were reviewed. Patients with penetrating trauma or whose altered level of consciousness was due to sedation or shock were excluded. The presence of coagulation abnormalities was determined according to prothrombin time and partial thromboplastin time obtained on admission. The time to invasive neurosurgical procedures for both coagulopathic and noncoagulopathic patients was determined as well as the mean number of hospital days, intensive care unit days, and the mortality for each group. Eighty-one per cent of the patients with a GCS less than or equal to 6 were coagulopathic on admission, and all patients with a GCS of 3 or 4 were coagulopathic. In contrast, no patient with a score of 7 or 8 was coagulopathic. The coagulopathic patients tended to have a higher mortality than the noncoagulopathic patients (53 versus 22%) as well as longer intensive care unit and hospital stays. The mean time to neurosurgical intervention for the coagulopathic group was 226.0+/-190.9 minutes versus 84.8+/-38.4 minutes for the noncoagulopathic patients. We conclude that patients with closed head injuries who present with a GCS of 6 or less are candidates for empiric treatment for coagulopathy. Such treatment will negate the delay of awaiting coagulation studies. Whether or not such therapy shortens the interval between admission and neurosurgical procedures or alters outcome will require prospective study.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT EMERGENCY MED,CHARLOTTESVILLE,VA 22908							ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PONDAAG W, 1978, ADV NEUROSURG, V6, P159; PRESTON FE, 1974, J NEUROL NEUROSUR PS, V37, P241, DOI 10.1136/jnnp.37.3.241; ROSEMAN B, 1985, ORAL SURG ORAL MED O, V59, P551, DOI 10.1016/0030-4220(85)90179-3; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567	16	54	57	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	MAR	1997	63	3					233	236					4	Surgery	Surgery	WK405	WOS:A1997WK40500013	9036890				2021-06-18	
J	Haseler, LJ; Arcinue, E; Danielsen, ER; Bluml, S; Ross, BD				Haseler, LJ; Arcinue, E; Danielsen, ER; Bluml, S; Ross, BD			Evidence from proton magnetic resonance spectroscopy for a metabolic cascade of neuronal damage in shaken baby syndrome	PEDIATRICS			English	Article						shaken baby syndrome; traumatic brain injury; neuronal injury; magnetic resonance imaging; magnetic resonance spectroscopy	HUMAN BRAIN; INFANT; INJURY; CHILDREN; SHAKING; SYSTEM; WATER	Objective. The purpose of this study was to use proton magnetic resonance spectroscopy (MRS) as a metabolic assay to describe biochemical changes during the evolution of neuronal injury in infants after shaken baby syndrome (SBS), that explain the disparity between apparent physical injury and the neurological deficit after SBS. Methodology. Three infants [6 months (A), 5 weeks (B), 7 months (C)] with SBS were examined repeatedly using localized quantitative proton MRS. Examinations were performed on days 7 and 13 (A), on days 1, 3, 5,and 12 (B), and on days 7 and 19 (C) posttrauma. Long-term follow-up examinations were performed 5 months posttrauma (A) and 4.6 months posttrauma (B). Data were compared to control data from 52 neurologically normal infants presented in a previous study. Results. Spectra from parietal white matter obtained at approximately the same time after injury (5 to 7 days) showed markedly different patterns of abnormality. Infant A shows near normal levels of the neuronal marker N-acetyl aspartate, creatine, and phosphocreatine, although infant C shows absent N-acetyl aspartate, almost absent creatine and phosphocreatine, and a great excess of lactate/lipid and lipid. Analysis of the time course in infant B appears to connect these variations as markers of the severity of head injury suffered in the abuse, indicating a progression of biochemical abnormality. The principal cerebral metabolites detected by MRS that remain normal up to 24 hours fall precipitately to similar to 40% of normal within 5 to 12 days, with lactate/lipid and lipid levels more than doubling concentration between days 5 and 12. Conclusions. A strong impression is gained of MRS as a prognostic marker because infant A recovered although infants B and C remained in a state consistent with compromised neurological capacity. Loss of integrity of the proton MR spectrum appears to signal irreversible neurological damage and occurs at a time when clinical and neurological status gives no indication of long-term outcome. These results suggest the value of sequential MRS in the management of SBS.	HUNTINGTON MED RES INST, PASADENA, CA USA; CALTECH, DEPT CHEM, PASADENA, CA 91125 USA; HUNTINGTON MEM HOSP, PEDIAT INTENS CARE UNIT, PASADENA, CA USA; SCHULTE RES FDN, SANTA BARBARA, CA USA				Bluml, Stefan/0000-0003-2124-797X; Haseler, Luke/0000-0003-1607-4402			AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; ERNST T, 1993, P SOC MAGNETIC RESON, P323; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HASELER LJ, 1995, P 3 SOC MAGNETIC RES, V1, P381; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LEADBEATTER S, 1995, BRIT MED J, V310, P1600, DOI 10.1136/bmj.310.6994.1600; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; NIXON RA, 1993, ANN NY ACAD SCI, V679, P87, DOI 10.1111/j.1749-6632.1993.tb18291.x; ROSS BD, 1996, IN PRESS MRI CENTRAL; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; 1995, J PEDIAT NEUROBIOL N, V26, P285	19	54	56	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	1997	99	1					4	14		10.1542/peds.99.1.4			11	Pediatrics	Pediatrics	WB350	WOS:A1997WB35000002	8989330				2021-06-18	
J	Wroblewski, BA; Joseph, AB; Cornblatt, RR				Wroblewski, BA; Joseph, AB; Cornblatt, RR			Antidepressant pharmacotherapy and the treatment of depression in patients with severe traumatic brain injury: A controlled, prospective study	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							CLOSED HEAD-INJURY; FLUOXETINE; POPULATION; SEIZURES; MOOD	Background: Untreated or poorly treated depression in patients who suffer from traumatic brain injury can result in greater functional disability and prolonged or ineffective hospital and rehabilitation stays. Literature available on the pharmacologic treatment of depression after traumatic brain injury is scarce. This study investigated in a controlled and prospective manner the use of desipramine, a tricyclic antidepressant, in a series of patients with severe traumatic brain injury. Method: Ten patients with severe traumatic brain injury and long-standing depression, as diagnosed by DSM-III-R criteria, were admitted to the study because of the intention to be treated with antidepressants. They were randomly assigned to blindly start on either desipramine treatment (N = 6) or placebo lead-in (N = 4), Patients starting with desipramine stayed on that drug; patients starting with placebo lead-in were blindly crossed over to desipramine after 1 month if there was no significant improvement demonstrated by DSM-III-R criteria, All rating clinicians, physicians, and patients were blind to actual treatment and any ratings data, DSM-III-R evaluations were done monthly. An affect/mood scale was done every 2 weeks. Results: Of all patients evaluable using the DSM-III-R, 6 (86%) of 7 demonstrated resolution of depression and depressed mood during desipramine treatment. (Three received desipramine throughout the study; 3 others started taking placebo and crossed over to desipramine.) One patient refused evaluation on DSM-III-R throughout; 2 patients, both on desipramine, dropped out because of adverse effects (seizure, mania). In addition, there was statistically significant (p = .001) improvement over time and different rates of improvement over time in the treated and untreated groups for the affect/mood scale data. Conclusion: Results from this small study, utilizing a blinded, placebo lead-in design appear to (1) demonstrate the clinically significant effectiveness of desipramine in treating long-standing depression in a series of patients with severe traumatic brain injury, as rated with DSM-III-R criteria; (2) show statistically significant improvement on the affect/mood scale data, favoring the treated versus untreated (placebo lead-in) group.	ASCO HEALTHCARE,WESTBOROUGH,MA; MIDDLESEX HOSP,CTR NEUROBEHAV REHABIL,WALTHAM,MA; HARVARD UNIV,SCH MED,BOSTON,MA; MCLEAN HOSP,BELMONT,MA 02178	Wroblewski, BA (corresponding author), MASSACHUSETTS COLL PHARM ALLIED HLTH SCI,GREENERY REHABIL CTR,99 CHESTNUT HILL AVE,BOSTON,MA 02135, USA.						BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; BOYESON MG, 1991, NEUROREHABILITATION, V1, P33; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; DIVAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Gualtari CT, 1991, BRAIN INJURY, V5, P219; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KETTER TA, 1991, J CLIN PSYCHOPHARM, V11, P198; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVINE R, 1994, J CLIN PSYCHOPHARM, V14, P145, DOI 10.1097/00004714-199404000-00011; LIPSEY JR, 1984, LANCET, V1, P297; MALKMUS D, 1980, REHABILITATION HEAD; PRESKORN SH, 1991, J CLIN PSYCHIAT, V52, P23; PRESKORN SH, 1991, J CLIN PSYCHIAT, V52, P353; QUITKIN FM, 1991, AM J PSYCHIAT, V148, P197; QUITKIN FM, 1991, AM J PSYCHIAT, V148, P193; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273	25	54	55	0	1	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	DEC	1996	57	12					582	587		10.4088/JCP.v57n1206			8	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	WD707	WOS:A1996WD70700006	9010122				2021-06-18	
J	Cherian, L; Robertson, CS; Goodman, JC				Cherian, L; Robertson, CS; Goodman, JC			Secondary insults increase injury after controlled cortical impact in rats	JOURNAL OF NEUROTRAUMA			English	Article						cortical impact injury; secondary ischemia; secondary insults; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; ENERGY PHOSPHATE-METABOLISM; FLUID-PERCUSSION INJURY; SEVERE HEAD-INJURY; OXYGEN DELIVERY; CATS; RESPONSES; HYPOXIA; HYPOTENSION	Secondary ischemic insults are common after severe head injury and contribute to poor neurological outcome. To study the increased vulnerability of the traumatized brain to secondary insults, bilateral carotid occlusion was produced after a controlled cortical impact injury in rats. The injury produced by either the impact injury or the bilateral carotid occlusion was mild to moderate when studied individually. The 1 and 3 m/sec impact injuries alone caused no detectable contusion at the impact side and minimal neuronal loss in the hippocampus. The 5 m/sec impact injury alone resulted in a small contusion with a median volume of 5.4 mm(3). The 40-min period of bilateral carotid occlusion alone caused no cortical injury and no neuronal loss in the CA1 region of the hippocampus. When the 40 min of bilateral carotid occlusion was produced 1 h after the impact injury, there was an increase in the damage produced. The contusion volume was significantly larger after the 3 and 5 m/sec impact injuries and the hippocampal neuronal loss was significantly greater after the 1 and 3 m/sec impact injuries. When varying durations of bilateral carotid occlusion were produced 1 h after a 3 m/sec impact injury, contusion volume was significantly larger after bilateral carotid occlusion duration of 40 min, and CA1 neuronal loss was significantly greater after bilateral carotid occlusion durations of 30 and 40 min. When 40 min of bilateral carotid occlusion was produced at different time intervals after a 3 m/sec injury, the increased contusion volume was maximal when bilateral carotid occlusion occurred at 4 h after the impact injury, and the increased neuronal loss in the CA3 region of the hippocampus was maximal when bilateral carotid occlusion occurred at 1 h after the impact injury. By 24 h after the impact injury, 40 min of bilateral carotid occlusion had minimal consequences, similar to the effect in sham-injured animals. These results mimic the clinical situation where secondary insults of a severity that would not cause permanent neurological damage in a normal person are associated with a marked worsening of neurological outcome after head injury and where the injured brain is most susceptible to secondary insults in the first few hours after injury.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030	Cherian, L (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR SUPP, V59, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137	30	54	55	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1996	13	7					371	383		10.1089/neu.1996.13.371			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VB732	WOS:A1996VB73200003	8863193				2021-06-18	
J	Yoles, E; Belkin, M; Schwartz, M				Yoles, E; Belkin, M; Schwartz, M			HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy	JOURNAL OF NEUROTRAUMA			English	Article						tetrahydrocannabinol; crush injury; optic nerve; metabolism; electrophysiology	TRAUMATIC BRAIN INJURY; EXPERIMENTAL HEAD-INJURY; CNS WHITE MATTER; ANOXIC INJURY; CEREBRAL-CORTEX; GRADED CRUSH; RAT; METABOLISM; CAT; RECEPTOR	HU-211 is a novel synthetic analog of tetrahydrocannabinol that was recently shown in animal models to be nonpsychotropic. In this study we show that HU-211 can potentially be used as a neuroprotective compound in the CNS. Using a calibrated crush injury of adult rat optic nerve, we show that HU-211 can reduce injury-induced metabolic and electrophysiological deficits. Energy metabolism was monitored by measuring the intramitochondrial nicotine-amine adenine dinucleotide redox state hourly for 6 h after injury and treatment. Electrophysiological activity was assessed by compound action potential and visual evoked potential response. Beneficial effects were dose-dependent, being optimal at 7 mg/kg, administered intraperitoneally. The time window during which treatment was effective was found to be from the time of injury for at least 5 h, with treatment most effective at the time of injury. These results strongly suggest that HU-211, given immediately after CNS injury at the optimal dosage, may possess neuroprotective activities.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; TEL AVIV UNIV, SHEBA MED CTR, SACKLER FAC MED, GOLDSCHLEGER EYE RES INST, TEL HASHOMER, ISRAEL			Belkin, Michael/AAK-4728-2020				ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; BRAY GM, 1991, ANN NY ACAD SCI, V633, P214; CHANCE B, 1965, NATURE, V206, P257, DOI 10.1038/206257a0; CHANCE B, 1966, 3 P INT C HYP MED, P15; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; DUBOC D, 1990, TRANSPLANTATION, V50, P751; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARBER JL, 1990, ENVIRON HEALTH PERSP, V84, P107, DOI 10.2307/3430711; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAYEVSKY A, 1984, BRAIN RES REV, V7, P49, DOI 10.1016/0165-0173(84)90029-8; MAYEVSKY A, 1982, SCIENCE, V217, P527; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MINEZAKI K K, 1990, Heart and Vessels, V5, P193, DOI 10.1007/BF02058689; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; OSBAKKEN M, 1991, CARDIOVASC RES, V25, P749, DOI 10.1093/cvr/25.9.749; QUIGLEY HA, 1995, OPHTHAL VIS SCI, V36, P774; RANSOM BR, 1990, STROKE, V21, P52; RANSOM BR, 1990, NEUROLOGY, V40, P1399, DOI 10.1212/WNL.40.9.1399; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; STYS PK, 1992, J NEUROSCI, V12, P430; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yoles E., 1991, Journal of Basic and Clinical Physiology and Pharmacology, V2, P297; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZALISH M, 1993, RETINA-J RET VIT DIS, V13, P145, DOI 10.1097/00006982-199313020-00010; ZIVIN JA, 1991, SCI AM, V265, P36	43	54	56	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1996	13	1					49	57		10.1089/neu.1996.13.49			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TW167	WOS:A1996TW16700007	8714863				2021-06-18	
J	Stein, SC; Spettell, CM				Stein, SC; Spettell, CM			Delayed and progressive brain injury in children and adolescents with head trauma	PEDIATRIC NEUROSURGERY			English	Article						head injury; CT scanning; children; delayed brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; COMA DATA-BANK; YOUNG-ADULTS; SEVERITY; EXPERIENCE; HEMATOMAS; PRESSURE; LESIONS; SCALE	We performed serial CT scans on 351 children and adolescents with serious closed-head injury. Delayed or progressive lesions were encountered in 145 (41%). The occurrence of such delayed cerebral injuries correlated with the severity of the initial head trauma, with the presence of major extracranial injury and with studies of coagulopathy on admission. The presence of delayed cerebral injury had a profound influence on survival and recovery from head trauma, especially when the initial severity of the head injury was taken into account. We conclude that serial CT scans provide a reliable means of diagnosing and following the progress of delayed cerebral injury in the pediatric population.	UNIV MED & DENT NEW JERSEY,COOPER HOSP,MED CTR,DEPT SURG,NEWARK,NJ; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103; THOMAS JEFFERSON UNIV,DEPT RADIOL,PHILADELPHIA,PA 19107							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Atluru V, 1986, Pediatr Neurol, V2, P297, DOI 10.1016/0887-8994(86)90024-X; Baracchini-Muratorio G, 1985, J Neurosurg Sci, V29, P305; Berkson J, 1944, J AM STAT ASSOC, V39, P357, DOI 10.2307/2280041; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BURGER MS, 1985, J NEUROSURG, V62, P194; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; COSTEFF H, 1990, J NEUROSURG, V73, P648; DALENS B, 1981, ACTA NEUROL SCAND, V64, P81; DALENS B, 1983, J PEDIATR, V101, P166; DHARKER SR, 1993, NEUROSURGERY, V33, P863; DOSSANTOS ALM, 1994, PEDIATR NEUROSURG, V21, P50; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; DUHAIME AC, 1994, PEDIATR NEUROSURG, V21, P117, DOI 10.1159/000120825; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Gennarelli T A, 1993, Acta Neurochir Suppl (Wien), V57, P49; Gjerris F, 1986, Acta Neurochir Suppl (Wien), V36, P155; GRAEBER JE, 1978, LANCET, V2, P285; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HUNEIDI AHS, 1992, ANN ROY COLL SURG, V74, P345; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LUERSSEN TG, 1994, PEDIAT NEUROSURGERY, P266; MCGAULEY JL, 1975, J NEUROSURG, V43, P374, DOI 10.3171/jns.1975.43.3.0374; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Nelson C M, 1983, J Neurosurg Nurs, V15, P72; NOAH ZL, 1992, CRIT CARE CLIN, V8, P59; Papo I, 1982, J Neurosurg Sci, V26, P193; Parmelee D X, 1989, Psychiatr Med, V7, P11; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; PFENNINGER J, 1984, EUR J PEDIATR SURG, V39, P223; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Schafermeyer Robert, 1993, Emergency Medicine Clinics of North America, V11, P187; SCHELLER J, 1992, DEV MED CHILD NEUROL, V34, P836; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHAPIRO K, 1994, PEDIATR NEUROSURG, V21, P123; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1990, J PEDIATR SURG, V58, P236; Tseng Sheng-Hong, 1992, Journal of the Formosan Medical Association, V91, P585; WALKER ML, 1984, CHILD BRAIN, V11, P387; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015; 1971, JAMA-J AM MED ASSOC, V215, P277	66	54	54	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	DEC	1995	23	6					299	304		10.1159/000120975			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	UJ892	WOS:A1995UJ89200005	8743998				2021-06-18	
J	ROBERTSON, CS; GOPINATH, SP; CHANCE, B				ROBERTSON, CS; GOPINATH, SP; CHANCE, B			A NEW APPLICATION FOR NEAR-INFRARED SPECTROSCOPY - DETECTION OF DELAYED INTRACRANIAL HEMATOMAS AFTER HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, DC	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		DELAYED INTRACRANIAL HEMATOMA; NEAR INFRARED SPECTROSCOPY; SECONDARY INSULTS	CEREBRAL BLOOD-VOLUME; TRAUMATIC INTRACEREBRAL HEMATOMA; XE-133 CLEARANCE; PRETERM INFANTS; EARLY DIAGNOSIS; CYTOCHROME AA3; CT SCAN; BRAIN; OXYGENATION; TOMOGRAPHY	Clinical studies have documented the importance of secondary brain insults in determining neurologic outcome after head injury, Delayed intracranial hematomas are one of the most easily remediable causes of secondary injury if identified early, but can cause significant disability or death if not promptly recognized and treated, Early identification and treatment of these lesions that appear or enlarge after the initial CT scan may improve neurological outcome. Serial examinations using near-infrared spectroscopy (NIRS) to detect the development of delayed hematomas were obtained in 167 patients. The difference in absorbance of light (Delta OD) at 760 nm between the normal and the hematoma side was measured serially during the first 3 days after injury, Twenty-seven (16%) of the patients developed some type of late hematoma: an intracerebral hematoma in 8 patients, an extracerebral hematoma in 6 patients, and a postoperative hematoma in 13 patients, Eighteen of the delayed hematomas caused significant mass effect and required surgical evacuation, The hematomas appeared between 2 and 72 h after admission. In 24 of the 27 patients, a significant increase (>0.3) in the Delta OD occurred prior to an increase in intracranial pressure or a change in the neurological examination, or a change on CT scan. Early diagnosis using NIBS may allow early treatment and reduce secondary injury caused by delayed hematomas.	UNIV PENN,PHILADELPHIA,PA 19104	ROBERTSON, CS (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616, R01NS027346] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27346, P01-NS27616] Funding Source: Medline		ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; ANDREWS BT, 1988, CONT NEUROSURG, V10, P6; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; BRAZY JE, 1988, J PEDIATR-US, V112, P457, DOI 10.1016/S0022-3476(88)80336-6; BRAZY JE, 1985, PEDIATRICS, V75, P217; BRAZY JE, 1986, J PEDIATR-US, V108, P983, DOI 10.1016/S0022-3476(86)80944-1; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CHANCE B, 1989, PHOTON MIGRATION IN TISSUES, P121; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHEONG WF, 1994, IEEE J QUANTUM ELECT, V26, P2166; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CONTANT CF, 1993, J NEUROTRAUMA S1, V10, pS57; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; EDWARDS AD, 1988, J PHYSL, V410, pP50; Ferrari M, 1986, Adv Exp Med Biol, V200, P203; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FUKAMACHI A, 1985, ACTA NEUROCHIR, V74, P35, DOI 10.1007/BF01413274; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gentleman D, 1989, Br J Neurosurg, V3, P367, DOI 10.3109/02688698909002817; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; GOPINATH SP, 1993, J NEUROSURG, V79, P43, DOI 10.3171/jns.1993.79.1.0043; GOPINATH SP, 1995, NEUROCHEMICAL MONITO, P160; GOPINATH SP, 1995, IN PRESS NEUROTRAUMA; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KURTH CD, 1992, ANESTHESIOLOGY, V77, P656, DOI 10.1097/00000542-199210000-00007; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LIVERA LN, 1991, ARCH DIS CHILD-FETAL, V66, P376, DOI 10.1136/adc.66.4_Spec_No.376; LOBATO RD, 1988, J NEUROSURG, V6, P48; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MCCORMICK PW, 1991, STROKE, V22, P596, DOI 10.1161/01.STR.22.5.596; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Millikan GA, 1942, REV SCI INSTRUM, V13, P434, DOI 10.1063/1.1769941; NIKOKA S, 1990, PEDIATR RES, V28, P54; NINCHOJI T, 1984, ACTA NEUROCHIR, V71, P69, DOI 10.1007/BF01401152; PATTERSON MS, 1989, APPL OPTICS, V28, P2331, DOI 10.1364/AO.28.002331; PEEBLES DM, 1992, AM J OBSTET GYNECOL, V166, P1369, DOI 10.1016/0002-9378(92)91606-B; PEEBLES DM, 1991, LANCET, V338, P254, DOI 10.1016/0140-6736(91)90396-7; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; PRYDS O, 1990, PEDIATR RES, V27, P445, DOI 10.1203/00006450-199005000-00006; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; SAKAI H, 1986, INTRACRANIAL PRESSUR, V6, P6522; SAWADA Y, 1984, J NEUROL NEUROSUR PS, V47, P1125, DOI 10.1136/jnnp.47.10.1125; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1985, NEW ENGL J MED, V304, P1511; SHAH AR, 1992, J PEDIATR, V126, P769; SKOV L, 1991, PEDIATR RES, V30, P570, DOI 10.1203/00006450-199112000-00016; SWEET RC, 1978, NEUROSURGERY, V3, P16, DOI 10.1227/00006123-197807000-00003; WYATT JS, 1990, J APPL PHYSIOL, V68, P1086; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006; ZIMMERMAN RA, 1977, J COMPUT ASSIST TOMO, V1, P271	57	54	57	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					591	600		10.1089/neu.1995.12.591			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000010	8683610				2021-06-18	
J	DUVDEVANI, R; ROOF, RL; FULOP, Z; HOFFMAN, SW; STEIN, DG				DUVDEVANI, R; ROOF, RL; FULOP, Z; HOFFMAN, SW; STEIN, DG			BLOOD-BRAIN-BARRIER BREAKDOWN AND EDEMA FORMATION FOLLOWING FRONTAL CORTICAL CONTUSION - DOES HORMONAL STATUS PLAY A ROLE	JOURNAL OF NEUROTRAUMA			English	Article							CLOSED-HEAD-INJURY; CEREBRAL EDEMA; VASCULAR DISRUPTION; COLD INJURY; RAT; DEXAMETHASONE; PERMEABILITY; PEROXIDASE; MOUSE	The present experiment was designed to evaluate and correlate the time course of blood-brain barrier (BBB) integrity and cerebral edema in adult male rats given medial frontal cortex contusions. The effect of sex hormones on BBB integrity in the same injury model was also examined, because previous work has shown that progesterone can reduce cerebral edema (Roof et al., 1993). BBB breakdown was assessed by Evans blue extravasation and albumin immunostaining while edema formation was measured by the wet weight dry weight technique. These processes were examined beginning 2 h and continuing up to 10 days after injury. Our findings show that medial frontal contusion in rats produces changes in cerebral water content and opening of the BBB that endures at least 7 days postinjury. Although pseudopregnancy has been shown to reduce cerebral edema at day 1 postinjury, we did not find any evidence that this hormonal state is associated with BBB repair.	RUTGERS STATE UNIV,INST ANIM BEHAV,BRAIN RES LAB,NEWARK,NJ 07102			Stein, Donald/AAJ-5139-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR208836-01] Funding Source: Medline		Asdell SA, 1946, PATTERNS MAMMALIAN R; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BODSCH W, 1982, BRAIN RES, V249, P111, DOI 10.1016/0006-8993(82)90175-5; COLE DJ, 1991, ACTA NEUROPATHOL, V82, P266, DOI 10.1007/BF00308811; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Fulop Z., 1992, Society for Neuroscience Abstracts, V18, P178; GALLYAS F, 1970, ACTA NEUROPATHOL, V16, P35, DOI 10.1007/BF00686961; GAMACHE DA, 1986, J NEUROSURG, V65, P686, DOI 10.3171/jns.1986.65.5.0686; GREENWOOD J, 1991, NEURORADIOLOGY, V33, P95, DOI 10.1007/BF00588242; GUERIN C, 1992, ANN NEUROL, V31, P481, DOI 10.1002/ana.410310504; HEDLEYWHYTE ET, 1986, ANN NEUROL, V19, P373, DOI 10.1002/ana.410190411; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KLATZO I, 1980, BRAIN EDEMA, P359; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MITCHELL J, 1979, ACTA NEUROPATHOL, V46, P45, DOI 10.1007/BF00684803; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; POLLAY M, 1985, NEUROSURGERY, P322; REID AC, 1983, ANN NEUROL, V13, P28, DOI 10.1002/ana.410130107; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TODD NV, 1990, ACT NEUR S, V51, P296; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; ZIYLAN YZ, 1988, J NEUROCHEM, V51, P1338, DOI 10.1111/j.1471-4159.1988.tb01094.x; ZUCCARELLO M, 1989, STROKE, V20, P367, DOI 10.1161/01.STR.20.3.367	36	54	56	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	1995	12	1					65	75		10.1089/neu.1995.12.65			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QN638	WOS:A1995QN63800005	7783233				2021-06-18	
J	MARMAROU, A				MARMAROU, A			TRAUMATIC BRAIN EDEMA - AN OVERVIEW	ACTA NEUROCHIRURGICA			English	Article						VASOGENIC EDEMA; TRAUMATIC EDEMA; MRI; RESOLUTION	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; PRIMARY ASTROCYTE CULTURES; COMPUTED-TOMOGRAPHY; EXTRACELLULAR POTASSIUM; INTRACRANIAL-PRESSURE; COMPRESSION; CLEARANCE; BARRIER; CIRCULATION	This article provides a brief summary of concepts describing the formation and resolution of traumatic brain edema. Recent laboratory and clinical data are reviewed targeted toward resolving the contribution of edema to the swelling process. These data, indicate that blood volume is reduced in areas of ischemia following traumatic injury and edema volume is increased. Thus, edema is the major contributor to the swelling process in diffuse injury. As clinical MRI studies have not revealed barrier compromise in the presence of swelling, it is considered that other forms of edema, primarily ischemic and neurotoxic, make a substantial contribution to the edema volume.		MARMAROU, A (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, BOX 508, MCV STN, RICHMOND, VA 23298 USA.						BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, INTRACRANIAL PRESSUR, V8; CLUBB RJ, 1980, J NEUROSURG, V52, P189, DOI 10.3171/jns.1980.52.2.0189; CSERR HF, 1981, AM J PHYSIOL, V240, pF319; CSERR HF, 1977, EXP EYE RES, V25, P461, DOI 10.1016/S0014-4835(77)80041-9; CZERNICKI Z, 1977, ACTA NEUROCHIR, V36, P181, DOI 10.1007/BF01405390; EISENBERG H, 1988, APR ANN M AM ASS NEU; Flexner LB, 1933, Q REV BIOL, V8, P397, DOI 10.1086/394447; FODA M, 1993, IN PRESS J NEUROSURG; Go KG, 1991, CEREBRAL PATHOPHYSIO; His W., 1865, Z WISS ZOOL, V15, P127; ISHII S, 1966, HEAD INJURY, P276; JAKOBSSON DE, 1990, NEUROL RES, V12, P153; JAKOBSSON KE, 1990, ACTA NEUROCHIR, V104, P126, DOI 10.1007/BF01842830; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KETTENMANN H, 1985, J NEUROSCI, V5, P3295; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KLATZO I, 1960, J NEUROPATH EXP NEUR, V19, P475, DOI 10.1097/00005072-196010000-00001; Klatzo I, 1980, Adv Neurol, V28, P359; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; LANGFITT TW, 1965, NEUROLOGY, V15, P761, DOI 10.1212/WNL.15.8.761; LOWELL HM, 1971, J NEUROSURG, V34, P760, DOI 10.3171/jns.1971.34.6.0760; MARMAROU A, 1988, 7TH INT S INT PRESS; MARMAROU A, 1991, IN PRESS ICP CRANIOS; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Milhorat T, 1983, NEUROBIOLOGY CEREBRO, P1; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1973, J NEUROSURG, V39, P186, DOI 10.3171/jns.1973.39.2.0186; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OHATA K, 1990, ACTA NEUROPATHOL, V81, P162, DOI 10.1007/BF00334505; OHATA K, 1992, J NEUROSURG, V77, P387, DOI 10.3171/jns.1992.77.3.0387; PENN RD, 1982, HEAD INJURY, P233; Ponten U, 1986, Acta Radiol Suppl, V369, P360; REULEN HJ, 1978, J NEUROSURG, V48, P754, DOI 10.3171/jns.1978.48.5.0754; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; SAKAMOTO H, 1986, INTRACRANIAL PRESSUR, V6, P166; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SCHROEDER M, 1993, LOCAL CEREBRAL BLOOD; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Wood JH., 1980, NEUROBIOLOGY CEREBRO, P1; YAMAGUCHI M, 1976, STROKE, V7, P77, DOI 10.1161/01.STR.7.1.77; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	51	54	58	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			421	424					4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600114	7976607				2021-06-18	
J	RAO, N; KILGORE, KM				RAO, N; KILGORE, KM			PREDICTING RETURN TO WORK IN TRAUMATIC BRAIN INJURY USING ASSESSMENT SCALES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; RECOVERY	This study compared two frequently used brain injury assessment scales with a comprehensive functional scale in their capability to predict return to work in a traumatic brain injured population. Fifty-seven consecutive admissions to an inpatient brain injury program were rated at admission and discharge using the following scales: Patient Evaluation and Conference System (PECS), Disability Rating Scale, and Levels of Cognitive Functioning Scale. Their relative accuracy in predicting return to work or school up to 26 months after the injury was assessed using hierarchical logistic regression analysis. In each analysis, return to work/school was the dependent variable. The independent variables were initial status and discharge status on each rating scale. Overall these scales predicted return to work with 73.5% to 84.4% accuracy. Total PECS and PECS Cognition scores were the most accurate predictors. Analysis of incorrect predictions revealed the importance of additionally tracking the social factors of substance abuse, family/community support and financial need to return to work.	MARIANJOY REHABIL HOSP,WHEATON,IL							BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAMPBELL DT, 1963, EXPT QUASI-EXPT DESI; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cohen J., 1983, APPL MULTIPLE REGRES; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hagan C., 1982, COGNITIVE REHABILITA, P131; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; MILLER RG, 1966, SIMULTANEOUS STATIST; NORUSIS MJ, 1990, SPSS PC PLUS ADV STA; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; SILVERSTEIN B, 1991, ARCH PHYS MED REHAB, V72, P631; SILVERSTEIN B, 1989, IMPLEMENTING PATIENT	19	54	54	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1992	73	10					911	916					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	JU061	WOS:A1992JU06100004	1417465				2021-06-18	
J	ROWE, MJ; CARLSON, C				ROWE, MJ; CARLSON, C			BRAIN-STEM AUDITORY EVOKED-POTENTIALS IN POST-CONCUSSION DIZZINESS	ARCHIVES OF NEUROLOGY			English	Article									UNIV CALIF IRVINE,DEPT NEUROL,IRVINE,CA 92664	ROWE, MJ (corresponding author), MEMORIAL HOSP,MED CTR,ELECTRODIAGNOST LAB,LONG BEACH,CA 90801, USA.						BALLINGER JJ, 1969, DISEASES NOSE THROAT, P753; BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GAY JR, 1953, JAMA-J AM MED ASSOC, V152, P1698, DOI 10.1001/jama.1953.03690180020006; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; HOWE JR, 1975, NEUROLOGY, V25, P286, DOI 10.1212/WNL.25.3.286; MAKISHIMA K, 1975, ARCH OTOLARYNGOL, V101, P426; MCLAURIN RL, 1973, NEUROLOGICAL SURGERY, V2, P1023; MITCHELL BE, 1973, LANCET, V2, P213; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; ROWE MJ, 1978, ELECTROEN CLIN NEURO, V44, P459, DOI 10.1016/0013-4694(78)90030-5; RUTHERFORD WH, 1977, LANCET, V1, P1; STARR A, 1976, ELECTROEN CLIN NEURO, V41, P595, DOI 10.1016/0013-4694(76)90005-5; STARR A, 1975, ARCH NEUROL-CHICAGO, V32, P761, DOI 10.1001/archneur.1975.00490530083009; STOCKARD JJ, 1977, NEUROLOGY, V27, P316, DOI 10.1212/WNL.27.4.316; SYMUNDS C, 1962, LANCET, V1, P1; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; TOGLIA JU, 1976, NEUROLOGY, V26, P808, DOI 10.1212/WNL.26.9.808; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154	21	54	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1980	37	11					679	683		10.1001/archneur.1980.00500600027002			5	Clinical Neurology	Neurosciences & Neurology	KR819	WOS:A1980KR81900001	7436806				2021-06-18	
J	Munji, RN; Soung, AL; Weiner, GA; Sohet, F; Semple, BD; Trivedi, A; Gimlin, K; Kotoda, M; Korai, M; Aydin, S; Batugal, A; Cabangcala, AC; Schupp, PG; Oldham, MC; Hashimoto, T; Noble-Haeusslein, LJ; Daneman, R				Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Semple, Bridgette Deanne; Trivedi, Alpa; Gimlin, Kayleen; Kotoda, Masakazu; Korai, Masaaki; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Schupp, Patrick Georg; Oldham, Michael Clark; Hashimoto, Tomoki; Noble-Haeusslein, Linda J.; Daneman, Richard			Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module	NATURE NEUROSCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; P-SELECTIN; VASCULAR DEVELOPMENT; IN-VITRO; EXPRESSION; ICAM-1; CELLS; CNS; LIPOCALIN-2; INTEGRITY	Blood vessels in the CNS form a specialized and critical structure, the blood-brain barrier (BBB). We present a resource to understand the molecular mechanisms that regulate BBB function in health and dysfunction during disease. Using endothelial cell enrichment and RNA sequencing, we analyzed the gene expression of endothelial cells in mice, comparing brain endothelial cells with peripheral endothelial cells. We also assessed the regulation of CNS endothelial gene expression in models of stroke, multiple sclerosis, traumatic brain injury and seizure, each having profound BBB disruption. We found that although each is caused by a distinct trigger, they exhibit strikingly similar endothelial gene expression changes during BBB disruption, comprising a core BBB dysfunction module that shifts the CNS endothelial cells into a peripheral endothelial cell-like state. The identification of a common pathway for BBB dysfunction suggests that targeting therapeutic agents to limit it may be effective across multiple neurological disorders.	[Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Daneman, Richard] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; [Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Daneman, Richard] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Semple, Bridgette Deanne; Trivedi, Alpa; Gimlin, Kayleen; Schupp, Patrick Georg; Oldham, Michael Clark; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Kotoda, Masakazu; Korai, Masaaki; Hashimoto, Tomoki] Barrow Neurol Inst, Barrow Aneurysm & AVM Res Ctr, Dept Neurosurg & Neurobiol, Phoenix, AZ 85013 USA	Daneman, R (corresponding author), Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA.; Daneman, R (corresponding author), Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.	Rdaneman@ucsd.edu		Korai, Masaaki/0000-0002-5326-3467; Aydin, Sidar/0000-0001-7791-7931; Soung, Allison/0000-0002-1590-6038	National Institutes of Health (NIH)/National Institue of Neurological Disorders and Stroke (NINDS) [R01 NS091281-01A1]; National Multiple Sclerosis Society Pilot Grant; Takeda Pharmaceuticals New Frontier Science Program; UCSF Department of Clinical Pharmacology and Therapeutics NIH T32 grant [GM007546]; UCSF Department of Anesthesia and Perioperative Care NIH T32 grant [GM008440]; NIH/National Institue of Mental Health [R01 MH113896]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050159, NS077767, R01NS055876, R01NS082280]; Barrow Neurological Foundation grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008440, T32GM007546, T32GM007198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH113896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091281, R01NS082280, R01NS077767] Funding Source: NIH RePORTER	We would like to thank N. Lescano and A. Schroeder and the Parnassus Flow Cytometry Core, T. Rambaldo and the UCSD Veterans Hospital Flow Cytometry Core, R. Chadwick and the Gladstone Genomics Core, A. Williams and The Gladstone Bioinformatics Core and K. Jepsen and the UCSD Institute for Genomics Medicine Genomics Center. R.D. is funded by the National Institutes of Health (NIH)/National Institue of Neurological Disorders and Stroke (NINDS) (grant no. R01 NS091281-01A1), a National Multiple Sclerosis Society Pilot Grant and Takeda Pharmaceuticals New Frontier Science Program. R.N.M. was funded by the UCSF Department of Clinical Pharmacology and Therapeutics (grant no. GM007546) and the Department of Anesthesia and Perioperative Care (grant no. GM008440) NIH T32 grants. M.C.O. is funded by the NIH/National Institue of Mental Health (grant no. R01 MH113896). L.J.N.-H. is funded by the NIH/NINDS (grant nos. R01 NS050159 and NS077767). T.H. is funded by the NIH/NINDS (grant nos. R01NS055876 and R01NS082280) and the Barrow Neurological Foundation grant.	Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Akamatsu Y, 2015, J NEUROSCI, V35, P3851, DOI 10.1523/JNEUROSCI.3838-14.2015; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Cheng BH, 2012, PEPTIDES, V37, P171, DOI 10.1016/j.peptides.2012.07.012; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Doring A, 2007, J IMMUNOL, V179, P8470, DOI 10.4049/jimmunol.179.12.8470; Ferreira AC, 2015, PROG NEUROBIOL, V131, P120, DOI 10.1016/j.pneurobio.2015.06.005; Henninger DD, 1997, J IMMUNOL, V158, P1825; Huang J, 2000, STROKE, V31, P3047, DOI 10.1161/01.STR.31.12.3047; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jin AY, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-12; Keuschnigg J, 2009, BLOOD, V114, P478, DOI 10.1182/blood-2008-11-188763; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Love S, 2001, NEUROPATH APPL NEURO, V27, P465, DOI 10.1046/j.1365-2990.2001.00356.x; Lui JH, 2014, NATURE, V515, P264, DOI 10.1038/nature13973; Lyck R, 2003, BLOOD, V102, P3675, DOI 10.1182/blood-2003-02-0358; Ma S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001469; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Oldham MC, 2008, NAT NEUROSCI, V11, P1271, DOI 10.1038/nn.2207; Pinzon-Daza ML, 2014, J CEREBR BLOOD F MET, V34, P1258, DOI 10.1038/jcbfm.2014.100; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Troletti CD, 2016, BBA-MOL BASIS DIS, V1862, P452, DOI 10.1016/j.bbadis.2015.10.010; Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042; Weidenfeller C, 2007, J NEUROCHEM, V101, P555, DOI 10.1111/j.1471-4159.2006.04394.x; Xing CH, 2014, STROKE, V45, P2085, DOI 10.1161/STROKEAHA.114.005733; Zhou T, 2019, NAT NEUROSCI, V22, P421, DOI 10.1038/s41593-018-0324-9; Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018; Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	47	53	53	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2019	22	11					1892	+		10.1038/s41593-019-0497-x			13	Neurosciences	Neurosciences & Neurology	JI3VI	WOS:000493396600016	31611708	Green Accepted	Y	N	2021-06-18	
J	Kenny, EM; Fidan, E; Yang, Q; Anthonymuthu, TS; New, LA; Meyer, EA; Wang, H; Kochanek, PM; Dixon, CE; Kagan, VE; Bayir, H				Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Wang, Hong; Kochanek, Patrick M.; Dixon, C. Edward; Kagan, Valerian E.; Bayir, Hulya			Ferroptosis Contributes to Neuronal Death and Functional Outcome After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						baicalein; cell death; ferroptosis; lipid oxidation; lipoxygenase; traumatic brain injury	CONTROLLED CORTICAL IMPACT; POLYUNSATURATED FATTY-ACIDS; GLUTATHIONE-PEROXIDASE 4; OXIDATIVE STRESS; CELL-DEATH; COGNITIVE DEFICITS; LIPID-PEROXIDATION; UNITED-STATES; BAICALEIN; 12/15-LIPOXYGENASE	Objectives: Traumatic brain injury triggers multiple cell death pathways, possibly including ferroptosis-a recently described cell death pathway that results from accumulation of 15-lipoxygenase-mediated lipid oxidation products, specifically oxidized phosphatidylethanolamine containing arachidonic or adrenic acid. This study aimed to investigate whether ferroptosis contributed to the pathogenesis of in vitro and in vivo traumatic brain injury, and whether inhibition of 15-lipoxygenase provided neuroprotection. Design: Cell culture study and randomized controlled animal study. Setting: University research laboratory. Subjects: HT22 neuronal cell line and adult male C57BL/6 mice. Interventions: HT22 cells were subjected to pharmacologic induction of ferroptosis or mechanical stretch injury with and without administration of inhibitors of ferroptosis. Mice were subjected to sham or controlled cortical impact injury. Injured mice were randomized to receive vehicle or baicalein (12/15-lipoxygenase inhibitor) at 10-15 minutes postinjury. Measurements and Main Results: Pharmacologic inducers of ferroptosis and mechanical stretch injury resulted in cell death that was rescued by prototypical antiferroptotic agents including baicalein. Liquid chromatography tandem-mass spectrometry revealed the abundance of arachidonic/adrenic-phosphatidylethanolamine compared with other arachidonic/adrenic acid-containing phospholipids in the brain. Controlled cortical impact resulted in accumulation of oxidized phosphatidylethanolamine, increased expression of 15-lipoxygenase and acyl-CoA synthetase long-chain family member 4 (enzyme that generates substrate for the esterification of arachidonic/adrenic acid into phosphatidylethanolamine), and depletion of glutathione in the ipsilateral cortex. Postinjury administration of baicalein attenuated oxidation of arachidonic/adrenic acid-containing-phosphatidylethanolamine, decreased the number of terminal deoxynucleotidyl transferase dUTP nick-end labeling positive cells in the hippocampus, and improved spatial memory acquisition versus vehicle. Conclusions: Biomarkers of ferroptotic death were increased after traumatic brain injury. Baicalein decreased ferroptotic phosphatidylethanolamine oxidation and improved outcome after controlled cortical impact, suggesting that 15-lipoxygenase pathway might be a valuable therapeutic target after traumatic brain injury. (Crit Care Med 2019; 47:410-418)	[Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Bayir, Hulya] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Kochanek, Patrick M.; Dixon, C. Edward; Bayir, Hulya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Wang, Hong] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; [Kagan, Valerian E.; Bayir, Hulya] IM Sechenov Moscow State Med Univ, Inst Regenerat Med, Lab Nav Redox Lipid, Moscow, Russia; [Bayir, Hulya] UPMC Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA	Bayir, H (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA.; Bayir, H (corresponding author), IM Sechenov Moscow State Med Univ, Inst Regenerat Med, Lab Nav Redox Lipid, Moscow, Russia.; Bayir, H (corresponding author), UPMC Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu	Anthonymuthu, Tamil/I-5534-2019	Wang, Hong/0000-0003-0477-2908; Kagan, Valerian E./0000-0002-7245-1885	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, NS076511, AI068021, NS079061]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076511, R01NS061817, R01NS079061] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants (NS061817, NS076511, AI068021, and NS079061).	An CR, 2016, TRANSL STROKE RES, V7, P512, DOI 10.1007/s12975-016-0483-5; Angeli JPF, 2017, TRENDS PHARMACOL SCI, V38, P489, DOI 10.1016/j.tips.2017.02.005; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Coronado VG, 2012, BRAIN INJURY MED PRI, P84100; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gascon S, 2016, CELL STEM CELL, V18, P396, DOI 10.1016/j.stem.2015.12.003; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Hafting T, 2005, NATURE, V436, P801, DOI 10.1038/nature03721; Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Im HI, 2005, J PHARMACOL SCI, V98, P185, DOI 10.1254/jphs.SC0050014; Jameson JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104094; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jin G, 2008, STROKE, V39, P2538, DOI 10.1161/STROKEAHA.108.514927; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn H, 2015, BBA-MOL CELL BIOL L, V1851, P308, DOI 10.1016/j.bbalip.2014.10.002; Lapchak PA, 2007, NEUROSCIENCE, V150, P585, DOI 10.1016/j.neuroscience.2007.09.033; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lin YL, 2011, J ETHNOPHARMACOL, V138, P373, DOI 10.1016/j.jep.2011.09.014; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; MOSER E, 1993, J NEUROSCI, V13, P3916; Platt SR, 2007, VET J, V173, P278, DOI 10.1016/j.tvjl.2005.11.007; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tonnus W, 2017, IMMUNOL REV, V277, P128, DOI 10.1111/imr.12551; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5; Vorhees CV, 2014, ILAR J, V55, P310, DOI 10.1093/ilar/ilu013; Wei N, 2017, NEUROCHEM RES, V42, P1345, DOI 10.1007/s11064-017-2179-y; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zille M, 2017, STROKE, V48, P1033, DOI 10.1161/STROKEAHA.116.015609	60	53	56	8	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2019	47	3					410	418		10.1097/CCM.0000000000003555			9	Critical Care Medicine	General & Internal Medicine	HL6ZT	WOS:000458886600027	30531185	Green Accepted	Y	N	2021-06-18	
J	Zhang, J; Liu, XJ; Xu, WJ; Luo, WH; Li, M; Chu, FB; Xu, L; Cao, AY; Guan, JS; Tang, SM; Duan, XJ				Zhang, Jing; Liu, Xiaojun; Xu, Wenjing; Luo, Wenhan; Li, Ming; Chu, Fangbing; Xu, Lu; Cao, Anyuan; Guan, Jisong; Tang, Shiming; Duan, Xiaojie			Stretchable Transparent Electrode Arrays for Simultaneous Electrical and Optical Interrogation of Neural Circuits in Vivo	NANO LETTERS			English	Article						Stretchable electronics; transparent electrode; neural electrode array; brain activity mapping; optogenetics; calcium imaging; traumatic brain injury; nanobio interface; carbon nanotube	WALLED CARBON NANOTUBES; LARGE-AREA; BRAIN; OPTOGENETICS; GRAPHENE; NEURONS; ACCELERATION; BIOMECHANICS; DEFORMATION; STIMULATION	Recent developments of transparent electrode arrays provide a unique capability for simultaneous optical and electrical interrogation of neural circuits in the brain. However, none of these electrode arrays possess the stretchability highly desired for interfacing with mechanically active neural systems, such as the brain under injury, the spinal cord, and the peripheral nervous system (PNS). Here, we report a stretchable transparent electrode array from carbon nanotube (CNT) web-like thin films that retains excellent electrochemical performance and broad-band optical transparency under stretching and is highly durable under cyclic stretching deformation. We show that the CNT electrodes record well-defined neuronal response signals with negligible light-induced artifacts from cortical surfaces under optogenetic stimulation. Simultaneous two-photon calcium imaging through the transparent CNT electrodes from cortical surfaces of GCaMP-expressing mice with epilepsy shows individual activated neurons in brain regions from which the concurrent electrical recording is taken, thus providing complementary cellular information in addition to the high-temporal-resolution electrical recording. Notably, the studies on rats show that the CNT electrodes remain operational during and after brain contusion that involves the rapid deformation of both the electrode array and brain tissue. This enables real-time, continuous electrophysiological monitoring of cortical activity under traumatic brain injury. These results highlight the potential application of the stretchable transparent CNT electrode arrays in combining electrical and optical modalities to study neural circuits, especially under mechanically active conditions, which could potentially provide important new insights into the local circuit dynamics of the spinal cord and PNS as well as the mechanism underlying traumatic injuries of the nervous system.	[Zhang, Jing; Liu, Xiaojun; Chu, Fangbing; Duan, Xiaojie] Peking Univ, Coll Engn, Dept Biomed Engn, Beijing 100871, Peoples R China; [Zhang, Jing; Luo, Wenhan; Li, Ming; Tang, Shiming] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China; [Zhang, Jing; Luo, Wenhan; Li, Ming; Tang, Shiming; Duan, Xiaojie] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Zhang, Jing; Liu, Xiaojun; Chu, Fangbing; Duan, Xiaojie] Peking Univ, Ctr Nanochem, Beijing Sci & Engn Ctr Nanocarbons, Beijing 100871, Peoples R China; [Xu, Wenjing; Xu, Lu; Cao, Anyuan] Peking Univ, Dept Mat Sci & Engn, Coll Engn, Beijing 100871, Peoples R China; [Li, Ming; Tang, Shiming] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Luo, Wenhan; Guan, Jisong] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Guan, Jisong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China	Duan, XJ (corresponding author), Peking Univ, Coll Engn, Dept Biomed Engn, Beijing 100871, Peoples R China.; Duan, XJ (corresponding author), Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.; Duan, XJ (corresponding author), Peking Univ, Ctr Nanochem, Beijing Sci & Engn Ctr Nanocarbons, Beijing 100871, Peoples R China.	xjduan@pku.edu.cn		Luo, Wenhan/0000-0001-5202-8855; Guan, Ji-Song/0000-0001-5219-0289; Li, Ming/0000-0001-5173-1602	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21422301, 91648207, 21373013]; National Basic Research Program of ChinaNational Basic Research Program of China [2016YFA0200103, 2014CB932500]; China's 1000 Young Talent Award program; Microelectronics Research Center at Peking University	We thank the Microelectronics Research Center at Peking University for the microfabrication facility and support, the Animal Resources Center at Peking University for animal housing and care, and the Core Facilities at the School of Life Sciences, Peking University, for assistance with two-photon imaging. This work was supported by grants from the National Natural Science Foundation of China (grant nos. 21422301, 91648207, and 21373013), the National Basic Research Program of China (grant nos. 2016YFA0200103 and 2014CB932500), and China's 1000 Young Talent Award program.	Anikeeva P, 2012, NAT NEUROSCI, V15, P163, DOI 10.1038/nn.2992; [Anonymous], 2007, J NEUROSCI, V27, P14231; Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Berciaud S, 2007, NANO LETT, V7, P1203, DOI 10.1021/nl062933k; Canales A, 2015, NAT BIOTECHNOL, V33, P277, DOI 10.1038/nbt.3093; Cardin JA, 2010, NAT PROTOC, V5, P247, DOI 10.1038/nprot.2009.228; Carlson GC, 2008, NAT PROTOC, V3, P249, DOI 10.1038/nprot.2007.539; Carriero G, 2010, J NEUROPHYSIOL, V103, P2728, DOI 10.1152/jn.00862.2009; Carvalho-de-Souza JL, 2015, NEURON, V86, P207, DOI 10.1016/j.neuron.2015.02.033; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen Q, 2012, NEURON, V76, P297, DOI 10.1016/j.neuron.2012.07.011; Chen T, 2014, ACS NANO, V8, P1039, DOI 10.1021/nn405939w; Cheng A, 2011, NAT METHODS, V8, P139, DOI 10.1038/NMETH.1552; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; Dresselhaus MS, 2001, CARBON NANOTUBES SYN; Ghezzi D, 2013, NAT PHOTONICS, V7, P400, DOI [10.1038/nphoton.2013.34, 10.1038/NPHOTON.2013.34]; Goncalves JT, 2013, NAT NEUROSCI, V16, P903, DOI 10.1038/nn.3415; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Harrison DE, 1999, J MANIP PHYSIOL THER, V22, P227, DOI 10.1016/S0161-4754(99)70049-7; Honda K, 2004, J PHOTOCH PHOTOBIO A, V166, P63, DOI 10.1016/j.jphotochem.2004.04.027; Jiang YW, 2016, NAT MATER, V15, P1023, DOI 10.1038/NMAT4673; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Kim K, 2015, NANOSCALE, V7, P14577, DOI 10.1039/c5nr04341g; Kim KH, 2011, ADV MATER, V23, P2865, DOI 10.1002/adma.201100310; Kim TI, 2013, SCIENCE, V340, P211, DOI 10.1126/science.1232437; Kuzum D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6259; Lacour SP, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.63; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Laxpati Nealen G, 2014, Front Neuroeng, V7, P40, DOI 10.3389/fneng.2014.00040; Ledochowitsch P, 2015, J NEUROSCI METH, V256, P220, DOI 10.1016/j.jneumeth.2015.07.028; Lee J, 2015, NAT METHODS, V12, P1157, DOI 10.1038/nmeth.3620; Li Z, 2010, J MATER CHEM, V20, P7236, DOI 10.1039/c0jm01361g; Lipomi DJ, 2011, NAT NANOTECHNOL, V6, P788, DOI [10.1038/nnano.2011.184, 10.1038/NNANO.2011.184]; Liu KH, 2012, NAT NANOTECHNOL, V7, P325, DOI [10.1038/nnano.2012.52, 10.1038/NNANO.2012.52]; Mayevsky A., 2003, J NEUROTRAUM, V20, P1315; Minev IR, 2015, SCIENCE, V347, P159, DOI 10.1126/science.1260318; Montgomery KL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7577; Nikolenko V, 2007, NAT METHODS, V4, P943, DOI 10.1038/NMETH1105; Packer AM, 2013, NAT NEUROSCI, V16, P805, DOI 10.1038/nn.3427; Park DW, 2016, NAT PROTOC, V11, P2201, DOI 10.1038/nprot.2016.127; Park DW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6258; Park S, 2017, NAT NEUROSCI, V20, P612, DOI 10.1038/nn.4510; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scanziani M, 2009, NATURE, V461, P930, DOI 10.1038/nature08540; Topp KS, 2006, PHYS THER, V86, P92, DOI 10.1093/ptj/86.1.92; Wang GF, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.019; Wu H, 2013, NAT NANOTECHNOL, V8, P421, DOI [10.1038/NNANO.2013.84, 10.1038/nnano.2013.84]; Yang L, 2017, NANO LETT, V17, P71, DOI 10.1021/acs.nanolett.6b03356; Zang JF, 2013, NAT MATER, V12, P321, DOI [10.1038/NMAT3542, 10.1038/nmat3542]; Zhang JY, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/055007; Zhao SY, 2016, NANO LETT, V16, P7731, DOI 10.1021/acs.nanolett.6b03829	52	53	57	13	135	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	MAY	2018	18	5					2903	2911		10.1021/acs.nanolett.8b00087			9	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	GF6QT	WOS:000432093200023	29608857				2021-06-18	
J	Chandran, R; Mehta, SL; Vemuganti, R				Chandran, Raghavendar; Mehta, Suresh L.; Vemuganti, Raghu			Non-coding RNAs and neuroprotection after acute CNS injuries	NEUROCHEMISTRY INTERNATIONAL			English	Article						Non-coding RNA; microRNA; lncRNA; piRNA; Ischemic stroke; Hemorrhagic stroke; Traumatic brain injury; Spinal cord injury	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; IMPROVES FUNCTIONAL RECOVERY; NEURONAL CELL-DEATH; MAGUK PROTEIN CASK; MICRORNA EXPRESSION; DOWN-REGULATION; CIRCULATING MICRORNAS; MIRNA EXPRESSION	Accumulating evidence indicates that various classes of non-coding RNAs (ncRNAs) including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs) and long non-coding RNAs (lncRNAs) play important roles in normal state as well as the diseases of the CNS. Interestingly, ncRNAs have been shown to interact with messenger RNA, DNA and proteins, and these interactions could induce epigenetic modifications and control transcription and translation, thereby adding a new layer of genomic regulation. The ncRNA expression profiles are known to be altered after acute CNS injuries including stroke, traumatic brain injury and spinal cord injury that are major contributors of morbidity and mortality worldwide. Hence, a better understanding of the functional significance of ncRNAs following CNS injuries could help in developing potential therapeutic strategies to minimize the neuronal damage in those conditions. The potential of ncRNAs in blood and CSF as biomarkers for diagnosis and/or prognosis of acute CNS injuries has also gained importance in the recent years. This review highlighted the current progress in the understanding of the role of ncRNAs in initiation and progression of secondary neuronal damage and their application as biomarkers after acute CNS injuries. (C) 2017 Elsevier Ltd. All rights reserved.	[Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660,600 Highland Ave, Madison, WI 53792 USA; William S Middleton Vet Hosp, Madison, WI USA	Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660,600 Highland Ave, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu	Chandran, Raghavendar/AAB-9402-2019	Chandran, Raghavendar/0000-0002-7915-2810	American Heart AssociationAmerican Heart Association [15IRG23050015]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS095192]; Veterans AdministrationUS Department of Veterans Affairs [BX001638]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS095192, R21NS082957, R03NS083007] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002985] Funding Source: NIH RePORTER	The authors are supported by grants from American Heart Association (15IRG23050015), National Institute of Health (NS095192) and Veterans Administration (BX001638).	Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barker RA, 2016, NEUROPATH APPL NEURO, V42, P6, DOI 10.1111/nan.12303; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bracko O, 2014, J CEREBR BLOOD F MET, V34, P1522, DOI 10.1038/jcbfm.2014.112; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Busch DJ, 2012, J COMP NEUROL, V520, P1751, DOI 10.1002/cne.23011; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Cabin DE, 2002, J NEUROSCI, V22, P8797; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Cao L, 2012, BRAIN RES BULL, V88, P525, DOI 10.1016/j.brainresbull.2012.05.009; Chao HW, 2008, J CELL BIOL, V182, P141, DOI 10.1083/jcb.200712094; Chen F, 2015, TRANSL STROKE RES, V6, P478, DOI 10.1007/s12975-015-0429-3; Chen GQ, 2015, MOL MED REP, V12, P2465, DOI 10.3892/mmr.2015.3670; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Dharap A, 2013, ASN NEURO, V5, P283, DOI 10.1042/AN20130029; Dharap A, 2012, STROKE, V43, P2800, DOI 10.1161/STROKEAHA.112.669465; Dharap A, 2011, STROKE, V42, P1105, DOI 10.1161/STROKEAHA.110.598391; Dharap A, 2010, J NEUROCHEM, V113, P1685, DOI 10.1111/j.1471-4159.2010.06735.x; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Duan XM, 2014, J DIABETES COMPLICAT, V28, P705, DOI 10.1016/j.jdiacomp.2014.04.012; Feng NP, 2015, NEUROSCI LETT, V591, P1, DOI 10.1016/j.neulet.2015.02.002; Feng Y, 2015, CELL MOL BIOL, V61, P24; Funk K, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-32; Gan CS, 2012, GENET MOL RES, V11, P147, DOI 10.4238/2012.January.27.1; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gilbert O, 2014, ATHEROSCLEROSIS, V232, P305, DOI 10.1016/j.atherosclerosis.2013.11.028; Gubern C, 2013, FEBS J, V280, P6233, DOI 10.1111/febs.12546; Guo D, 2013, STROKE, V44, P1739, DOI 10.1161/STROKEAHA.111.000835; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hachisuka S, 2014, SPINAL CORD, V52, P596, DOI 10.1038/sc.2014.86; Halic M, 2009, CELL, V138, P1058, DOI 10.1016/j.cell.2009.08.030; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hsueh YP, 2006, CURR MED CHEM, V13, P1915, DOI 10.2174/092986706777585040; Hu JZ, 2015, BRAIN RES, V1608, P191, DOI 10.1016/j.brainres.2015.02.036; Hu T, 2015, J MOL NEUROSCI, V57, P114, DOI 10.1007/s12031-015-0584-8; Huang S, 2016, NEUROSCI LETT, V615, P102, DOI 10.1016/j.neulet.2016.01.028; Hunsberger JG, 2012, AM J TRANSL RES, V4, P316; Hwang JY, 2014, J MOL BIOL, V426, P3454, DOI 10.1016/j.jmb.2014.07.032; Iwasaki YW, 2015, ANNU REV BIOCHEM, V84, P405, DOI 10.1146/annurev-biochem-060614-034258; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Jiang Y, 2015, J NEUROCHEM, V134, P173, DOI 10.1111/jnc.13097; Jickling GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099283; Jin HW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-296; Keasey MP, 2016, J MOL NEUROSCI, V59, P404, DOI 10.1007/s12031-016-0740-9; Kim JH, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/634289; Koronowski KB, 2015, STROKE, V46, P2293, DOI 10.1161/STROKEAHA.115.009876; Kostandy BB, 2012, NEUROL SCI, V33, P223, DOI 10.1007/s10072-011-0828-5; Krings T, 2011, NAT REV NEUROL, V7, P547, DOI 10.1038/nrneurol.2011.136; Kumar A, 2016, BRAIN RES BULL, V122, P35, DOI 10.1016/j.brainresbull.2016.02.016; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Lee YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045836; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Leung LY, 2014, CLIN CHIM ACTA, V433, P139, DOI 10.1016/j.cca.2014.03.007; Li LJ, 2014, MOL MED REP, V10, P527, DOI 10.3892/mmr.2014.2172; Li PX, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000972; Li YA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13316; Liu CY, 2015, INT J MOL SCI, V16, P24302, DOI 10.3390/ijms161024302; Liu CY, 2012, J NEUROCHEM, V120, P830, DOI 10.1111/j.1471-4159.2011.07624.x; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; Liu D, 2015, CELL MOL NEUROBIOL, V35, P483, DOI 10.1007/s10571-014-0142-x; Liu DZ, 2016, J CEREBR BLOOD F MET, V36, P1374, DOI 10.1177/0271678X15610786; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu DH, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0188-x; Liu L., 2014, ADV DIFFER EQU, V217, P9, DOI DOI 10.1371/J0URNAL.P0NE.0103948; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu P., 2015, J CEREBRAL CIRCULATI, V46, P513, DOI DOI 10.1161/STR0KEAHA.114.007482; Liu XJ, 2015, INT J CLIN EXP PATHO, V8, P3811; Liu YZ, 2016, SPINE, V41, P97, DOI 10.1097/BRS.0000000000001323; Liu ZH, 2015, J NEUROSCI, V35, P12733, DOI 10.1523/JNEUROSCI.0605-15.2015; Long GW, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-178; Lopez MS, 2016, J CEREBR BLOOD F MET, V36, P1644, DOI 10.1177/0271678X16656202; Lou YL, 2012, MOL CELL BIOCHEM, V370, P45, DOI 10.1007/s11010-012-1396-6; Louw AM, 2016, NANOMED-NANOTECHNOL, V12, P643, DOI 10.1016/j.nano.2015.10.011; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Lusardi TA, 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014.00011, 10.3389/fnmol.2014.00011]; Lusardi TA, 2010, J CEREBR BLOOD F MET, V30, P744, DOI 10.1038/jcbfm.2009.253; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Matsuura I, 2008, J NEUROCHEM, V105, P1471, DOI 10.1111/j.1471-4159.2008.05251.x; Mehta SL, 2015, J NEUROSCI, V35, P16443, DOI 10.1523/JNEUROSCI.2943-15.2015; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Meng FJ, 2016, J NEUROSURG ANESTH, V28, P195, DOI 10.1097/ANA.0000000000000204; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Miao W, 2015, BRAZ J MED BIOL RES, V48, P433, DOI [10.1590/1414-431X20144012, 10.1590/1414-431x20144012]; Moon JM, 2013, J CEREBR BLOOD F MET, V33, P1976, DOI 10.1038/jcbfm.2013.157; Muller AH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1341-7; Myers J, 2007, AM J PHYS MED REHAB, V86, P142, DOI 10.1097/PHM.0b013e31802f0247; Nelson PT, 2010, J ALZHEIMERS DIS, V21, P75, DOI 10.3233/JAD-2010-091603; Neo WH, 2014, J BIOL CHEM, V289, P20788, DOI 10.1074/jbc.M113.525493; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Noh KM, 2012, P NATL ACAD SCI USA, V109, pE962, DOI 10.1073/pnas.1121568109; O'Donnell KA, 2007, CELL, V129, P37, DOI 10.1016/j.cell.2007.03.028; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Pandi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058039; Peng ZF, 2013, J NEUROSCI RES, V91, P1349, DOI 10.1002/jnr.23255; Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473; Qu Y, 2014, NEUROBIOL DIS, V63, P184, DOI 10.1016/j.nbd.2013.11.023; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Raval AP, 2006, NEUROSCIENCE, V141, P1721, DOI 10.1016/j.neuroscience.2006.05.016; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reid G, 2011, CRIT REV ONCOL HEMAT, V80, P193, DOI 10.1016/j.critrevonc.2010.11.004; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schmidt-Kastner R, 2002, MOL BRAIN RES, V108, P81, DOI 10.1016/S0169-328X(02)00516-8; Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5; Schober K, 2015, INT J LEGAL MED, V129, P701, DOI 10.1007/s00414-014-1129-3; Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Sepramaniam S, 2014, INT J MOL SCI, V15, P1418, DOI 10.3390/ijms15011418; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Sharp FR, 2011, J CEREBR BLOOD F MET, V31, P1513, DOI 10.1038/jcbfm.2011.45; Shi Hong, 2010, Front Biosci (Elite Ed), V2, P1304; Shi H, 2013, CNS NEUROL DISORD-DR, V12, P381, DOI 10.2174/1871527311312030011; Shin JH, 2014, BBA-GENE REGUL MECH, V1839, P826, DOI 10.1016/j.bbagrm.2014.06.019; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Sisalli MJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00115; Smith SD, 2011, RADIOL CLIN N AM, V49, P27, DOI 10.1016/j.rcl.2010.07.011; Sorensen SS, 2014, TRANSL STROKE RES, V5, P711, DOI 10.1007/s12975-014-0364-8; Stetler RA, 2014, PROG NEUROBIOL, V114, P58, DOI 10.1016/j.pneurobio.2013.11.005; Sun M, 2015, CELL TRANSPLANT, V24, P367, DOI 10.3727/096368915X686869; Sun YY, 2015, CELL MOL NEUROBIOL, V35, P1117, DOI 10.1007/s10571-015-0205-7; Taheri S, 2016, J NEUROTRAUM, V33, P1818, DOI 10.1089/neu.2015.4281; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tan JR, 2011, CURR MOL MED, V11, P76; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Tao J, 2015, NEUROSCIENCE, V305, P1, DOI 10.1016/j.neuroscience.2015.07.064; Tao Z, 2015, J NEUROL SCI, V355, P113, DOI 10.1016/j.jns.2015.05.036; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Thompson JW, 2013, NEUROTHERAPEUTICS, V10, P789, DOI 10.1007/s13311-013-0202-9; Tripathi AK, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-39; Tsai PC, 2013, J VASC RES, V50, P346, DOI 10.1159/000351767; Varga ZV, 2013, J MOL CELL CARDIOL, V62, P111, DOI 10.1016/j.yjmcc.2013.05.009; Vartanian KB, 2015, J CEREBR BLOOD F MET, V35, P257, DOI 10.1038/jcbfm.2014.193; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Wade JT, 2014, NAT REV MICROBIOL, V12, P647, DOI 10.1038/nrmicro3316; Wang Hailian, 2011, Front Biosci (Elite Ed), V3, P604; Wang J, 2015, BRAIN RES, V1624, P314, DOI 10.1016/j.brainres.2015.07.052; Wang MD, 2016, MOL NEUROBIOL, V53, P1310, DOI 10.1007/s12035-015-9099-0; Wang P, 2014, NEUROCHEM RES, V39, P1279, DOI 10.1007/s11064-014-1310-6; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; Wang Y, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-77; Wang Y, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/276540; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wei N., 2015, MOL NEUROBIOL, V11, P11; Weng HC, 2011, BIOMED RES-TOKYO, V32, P135, DOI 10.2220/biomedres.32.135; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Xu Q., 2016, CELL DEATH DIS, V7, P1; Yan W, 2016, CELL MOL BIOL, V62, P38; Yang SS, 2016, CARDIOVASC TOXICOL, V16, P213, DOI 10.1007/s12012-015-9329-8; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Yang ZB, 2016, INTERNAL MED, V55, P1279, DOI 10.2169/internalmedicine.55.5925; Yang ZB, 2014, CLIN SCI, V127, P679, DOI 10.1042/CS20140084; Yin KJ, 2010, J NEUROSCI, V30, P6398, DOI 10.1523/JNEUROSCI.0780-10.2010; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Yin ZS, 2008, NEUROL RES, V30, P480, DOI 10.1179/174313208X284133; Yuan LY, 2015, STROKE, V46; Zeng L, 2014, GENE THER, V21, P37, DOI 10.1038/gt.2013.55; Zeng L, 2011, FRONT BIOSCI ELITE E, V3, P1265, DOI DOI 10.2741/330; Zeng LL, 2013, EUR NEUROL, V69, P68, DOI 10.1159/000342896; Zeng X, 2014, EUR J PAIN, V18, P1323, DOI 10.1002/j.1532-2149.2014.493.x; Zhang J, 2016, EXP NEUROL, V277, P162, DOI 10.1016/j.expneurol.2015.12.014; Zhang L, 2012, ARTERIOSCL THROM VAS, V32, P1856, DOI 10.1161/ATVBAHA.112.252619; Zhang N, 2012, INDIAN J MED RES, V135, P287; Zhang Y, 2016, J AFFECT DISORDERS, V193, P51, DOI 10.1016/j.jad.2015.12.061; Zhao CN, 2013, SCI REP-UK, V3, DOI 10.1038/srep01329; Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504; Zhao Y, 2015, NEURAL REGEN RES, V10, P1147, DOI 10.4103/1673-5374.156983; Zheng BJ, 2015, MOL MED REP, V12, P967, DOI 10.3892/mmr.2015.3474; Zheng HW, 2012, CNS NEUROSCI THER, V18, P1003, DOI 10.1111/cns.12019; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002; Zhou JS, 2014, MOL MED REP, V10, P971, DOI 10.3892/mmr.2014.2245; Zhu F, 2014, J MOL NEUROSCI, V52, P148, DOI 10.1007/s12031-013-0155-9; Zhu YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121608	191	53	56	1	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		12	22		10.1016/j.neuint.2017.01.015			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600003	28131900	Green Accepted			2021-06-18	
J	Sundman, MH; Chen, NK; Subbian, V; Chou, YH				Sundman, Mark H.; Chen, Nan-kuei; Subbian, Vignesh; Chou, Ying-hui			The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Gut-brain axis; Traumatic Brain Injury; Concussion; Gut; Microbiota; Chronic Traumatic Encephalopathy; Neurodegenerative disease; Neuroinflammation; Microglia; Intestinal dysfunction	CAUSES CHRONIC NEUROINFLAMMATION; VAGUS NERVE-STIMULATION; C-REACTIVE PROTEIN; BACTERIAL TRANSLOCATION; MICROGLIAL ACTIVATION; SYSTEMIC INFLAMMATION; DOCOSAHEXAENOIC ACID; ALZHEIMERS-DISEASE; SICKNESS BEHAVIOR; IMMUNE ACTIVATION	As head injuries and their sequelae have become an increasingly salient matter of public health, experts in the field have made great progress elucidating the biological processes occurring within the brain at the moment of injury and throughout the recovery thereafter. Given the extraordinary rate at which our collective knowledge of neurotrauma has grown, new insights may be revealed by examining the existing literature across disciplines with a new perspective. This article will aim to expand the scope of this rapidly evolving field of research beyond the confines of the central nervous system (CNS). Specifically, we will examine the extent to which the bidirectional influence of the gut-brain axis modulates the complex biological processes occurring at the time of traumatic brain injury (TBI) and over the days, months, and years that follow. In addition to local enteric signals originating in the gut, it is well accepted that gastrointestinal (GI) physiology is highly regulated by innervation from the CNS. Conversely, emerging data suggests that the function and health of the CNS is modulated by the interaction between 1) neurotransmitters, immune signaling, hormones, and neuropeptides produced in the gut, 2) the composition of the gut microbiota, and 3) integrity of the intestinal wall serving as a barrier to the external environment. Specific to TBI, existing pre-clinical data indicates that head injuries can cause structural and functional damage to the GI tract, but research directly investigating the neuronal consequences of this intestinal damage is lacking. Despite this void, the proposed mechanisms emanating from a damaged gut are closely implicated in the inflammatory processes known to promote neuropathology in the brain following TBI, which suggests the gut-brain axis may be a therapeutic target to reduce the risk of Chronic Traumatic Encephalopathy and other neurodegenerative diseases following TBI. To better appreciate how various peripheral influences are implicated in the health of the CNS following TBI, this paper will also review the secondary biological injury mechanisms and the dynamic pathophysiological response to neurotrauma. Together, this review article will attempt to connect the dots to reveal novel insights into the bidirectional influence of the gut-brain axis and propose a conceptual model relevant to the recovery from TBI and subsequent risk for future neurological conditions. (C) 2017 Elsevier Inc. All rights reserved.	[Sundman, Mark H.; Chou, Ying-hui] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; [Chen, Nan-kuei; Subbian, Vignesh] Univ Arizona, Dept Biomed Engn, Tucson, AZ USA; [Subbian, Vignesh] Univ Arizona, Dept Syst & Ind Engn, Tucson, AZ 85721 USA; [Chou, Ying-hui] Univ Arizona, Cognit Sci Program, Tucson, AZ USA; [Chou, Ying-hui] Univ Arizona, Arizona Ctr Aging, Tucson, AZ USA	Sundman, MH (corresponding author), 1503 East Univ Blvd,POB 210068, Tucson, AZ 85719 USA.	marksundman@email.arizona.edu	Chen, Nan-kuei/E-7791-2016	Chen, Nan-kuei/0000-0001-6564-4219; Subbian, Vignesh/0000-0001-9974-8382	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER		Aamodt S, 2007, NAT NEUROSCI, V10, P1349, DOI 10.1038/nn1107-1349; Anrather J, 2016, NEUROTHERAPEUTICS, V13, P661, DOI 10.1007/s13311-016-0483-x; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Arrieta MC, 2006, GUT, V55, DOI 10.1136/gut.2005.085373; Asti A, 2014, J ALZHEIMERS DIS, V39, P169, DOI 10.3233/JAD-131394; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Balzan S, 2007, J GASTROEN HEPATOL, V22, P464, DOI 10.1111/j.1440-1746.2007.04933.x; Bansal V., 2009, J NEUROTRAUM, V26; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bengmark S, 2013, PHARMACOL RES, V69, P87, DOI 10.1016/j.phrs.2012.09.002; Bested AC, 2013, GUT PATHOG, V5, DOI 10.1186/1757-4749-5-3; Bickford PC, 2017, EXP GERONTOL, V94, P4, DOI 10.1016/j.exger.2017.01.027; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Blaser M, 2013, NAT REV MICROBIOL, V11, P213, DOI 10.1038/nrmicro2973; Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a; BLUTHE RM, 1994, CR ACAD SCI III-VIE, V317, P499; Borovikova LV, 2000, NATURE, V405, P458; Bramlett H., 2014, J NEUROTRAUM, P1; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Carr J, 2007, TRAUMA, V9, P21, DOI 10.1177/1460408607082845; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chen ZH, 2016, J NEUROCHEM, V136, P10, DOI [10.1111/jnc.13062, 10.1080/17512786.2015.1063079]; Cheng YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091530; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Coughlin J.M., 2016, JAMA NEUROL, V6, P193; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crapser J, 2016, AGING-US, V8, P1049, DOI 10.18632/aging.100952; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Croisier E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-14; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; D'Mello C, 2015, J NEUROSCI, V35, P10821, DOI 10.1523/JNEUROSCI.0575-15.2015; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davenport E.M, 2016, CONCUSSION; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Punder K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00223; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Dinan T.G, 2017, NAT REV GASTROENTERO; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; DiSabato DJ, 2016, J NEUROCHEM, V139, P136, DOI 10.1111/jnc.13607; Distrutti E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106503; Divyashri G, 2015, J MED MICROBIOL, V64, P1527, DOI 10.1099/jmm.0.000184; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Ehrhart J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0350-4; El-Tawil A.M, 2012, INFLAMM BOWEL DIS, V18; Elali A, 2016, BRAIN BEHAV IMMUN, V55, P138, DOI 10.1016/j.bbi.2015.07.021; Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668; Erny D, 2017, IMMUNOLOGY, V150, P7, DOI 10.1111/imm.12645; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Farhadi A, 2003, J GASTROEN HEPATOL, V18, P479, DOI 10.1046/j.1440-1746.2003.03032.x; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Forsyth CB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028032; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghaisas S, 2016, PHARMACOL THERAPEUT, V158, P52, DOI 10.1016/j.pharmthera.2015.11.012; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gimeno D, 2009, PSYCHOL MED, V39, P413, DOI 10.1017/S0033291708003723; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Haar CV, 2016, BRAIN RES, V1640, P114, DOI 10.1016/j.brainres.2015.12.030; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Hannestad J, 2012, NEUROIMAGE, V63, P232, DOI 10.1016/j.neuroimage.2012.06.055; Hill JM, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00009; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hornig M, 2013, CURR OPIN RHEUMATOL, V25, P488, DOI 10.1097/BOR.0b013e32836208de; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Hsieh CY, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12327; Hu X, 2016, SCI CHINA LIFE SCI, V59, P1006, DOI 10.1007/s11427-016-5083-9; Hu YC, 2013, J SURG RES, V184, P1022, DOI 10.1016/j.jss.2013.04.005; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Kekkonen RA, 2008, WORLD J GASTROENTERO, V14, P2029, DOI 10.3748/wjg.14.2029; Kelly JR, 2016, J PSYCHIATR RES, V82, P109, DOI 10.1016/j.jpsychires.2016.07.019; Kelly JR, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00392; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kharrazian D, 2015, ALTERN THER HEALTH M, V21, P28; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Kitazawa M, 2004, ANN NY ACAD SCI, V1035, P85, DOI 10.1196/annals.1332.006; Klingelhoefer L, 2015, NAT REV NEUROL, V11, P625, DOI 10.1038/nrneurol.2015.197; Koerte I.K., 2013, JAMA-J AM MED ASSOC, V308, P1; Koerte I.K., 2015, J NEUROTRAUMA, V1293; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lamprecht M, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-45; Lasselin J, 2016, BRAIN BEHAV IMMUN, V57, P30, DOI 10.1016/j.bbi.2016.01.003; Layer A.M., 2016, NAT MED, V13, P720; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Leonard B, 2012, NEUROSCI BIOBEHAV R, V36, P764, DOI 10.1016/j.neubiorev.2011.12.005; Levy G, 2012, J TRAUMA ACUTE CARE, V73, P338, DOI 10.1097/TA.0b013e31825debd3; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maes M, 2013, ACTA PSYCHIAT SCAND, V127, P344, DOI 10.1111/j.1600-0447.2012.01908.x; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P117; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Michielan A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/628157; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mobley AR, 2014, NUTRIENTS, V6, P2540, DOI 10.3390/nu6072540; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mohamadshahi M, 2014, BIOIMPACTS, V4, P83, DOI 10.5681/bi.2014.007; Montiel-Castro AJ, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00070; Morley Wendy A, 2014, Surg Neurol Int, V5, P97, DOI 10.4103/2152-7806.134731; Moser D.M.Y. Adam, 2008, COMPUTER LONG BEACH, V23, P1, DOI DOI 10.1038/JID.2014.371; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Neren D, 2016, NEUROCRIT CARE, V24, P308, DOI 10.1007/s12028-015-0203-0; Nevin KG, 2004, CLIN BIOCHEM, V37, P830, DOI 10.1016/j.clinbiochem.2004.04.010; Noble EE, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00009; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Ohland CL, 2010, AM J PHYSIOL-GASTR L, V298, pG807, DOI 10.1152/ajpgi.00243.2009; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Ostman EM, 2001, AM J CLIN NUTR, V74, P96; Palin K, 2008, NEUROBIOL DIS, V30, P19, DOI 10.1016/j.nbd.2007.11.012; Parachikova A, 2007, NEUROBIOL AGING, V28, P1821, DOI 10.1016/j.neurobiolaging.2006.08.014; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raftery T, 2015, UNITED EUR GASTROENT, V3, P294, DOI 10.1177/2050640615572176; Rajkumar H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/348959; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reddy BL, 2015, J MOL MICROB BIOTECH, V25, P51, DOI 10.1159/000375303; Redelmeier D.A., 2016, CMAJ, V188, P1; Rodes L, 2013, J MICROBIOL BIOTECHN, V23, P518, DOI 10.4014/jmb.1205.05018; Rogers GB, 2016, MOL PSYCHIATR, V21, P738, DOI 10.1038/mp.2016.50; Romijn JA, 2008, CURR OPIN CLIN NUTR, V11, P518, DOI 10.1097/MCO.0b013e328302c9b0; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sampson TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/j.chom.2015.04.011; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Santos A, 2008, BASIC CLIN PHARMACOL, V103, P247, DOI 10.1111/j.1742-7843.2008.00272.x; Savignac HM, 2016, BRAIN BEHAV IMMUN, V52, P120, DOI 10.1016/j.bbi.2015.10.007; Schaller BJ, 2006, AM J GASTROENTEROL, V101, P1655, DOI 10.1111/j.1572-0241.2006.00540.x; Schedlowski M, 2014, BRAIN BEHAV IMMUN, V35, P1, DOI 10.1016/j.bbi.2013.09.015; Schmidt R, 2002, ANN NEUROL, V52, P168, DOI 10.1002/ana.10265; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Setiawan E, 2015, JAMA PSYCHIAT, V72, P268, DOI 10.1001/jamapsychiatry.2014.2427; Sherry CL, 2010, BRAIN BEHAV IMMUN, V24, P631, DOI 10.1016/j.bbi.2010.01.015; Sherwin E, 2016, CURR OPIN GASTROEN, V32, P96, DOI 10.1097/MOG.0000000000000244; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Slyepchenko A, 2017, PSYCHOTHER PSYCHOSOM, V86, P31, DOI 10.1159/000448957; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song IU, 2009, EUR NEUROL, V62, P99, DOI 10.1159/000222780; Sonnenburg ED, 2014, CELL METAB, V20, P779, DOI 10.1016/j.cmet.2014.07.003; Sonnenburg JL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001626; Stanley D, 2016, NAT MED, V22, P1277, DOI 10.1038/nm.4194; Steenbergen L, 2015, BRAIN BEHAV IMMUN, V48, P258, DOI 10.1016/j.bbi.2015.04.003; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Sun B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128214; Sun J, 2016, BRAIN RES, V1642, P180, DOI 10.1016/j.brainres.2016.03.042; Sundman M H., 2014, J ALZHEIMERS DIS PAR, P4, DOI [10.4172/2161-0460.1000137, DOI 10.4172/2161-0460.1000137]; Swidsinski A, 2012, INTEST RES, V10, P332, DOI 10.5217/ir.2012.10.4.332; Tabbaa M, 2013, NUTRIENTS, V5, P3299, DOI 10.3390/nu5083299; Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da; Tascilar N, 2010, BRATISL MED J, V111, P194; Thayer JF, 2009, NEUROIMAGE, V47, P908, DOI 10.1016/j.neuroimage.2009.05.058; Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Ulluwishewa D, 2011, J NUTR, V141, P769, DOI 10.3945/jn.110.135657; von Bernhardi R, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00124; Vuong H.E., 2017, MICROBIOME HOST BEHA, P21; Wachholz S, 2016, BRAIN BEHAV IMMUN, V55, P105, DOI 10.1016/j.bbi.2015.09.016; Wall R, 2010, LIPIDS, V45, P429, DOI 10.1007/s11745-010-3410-7; Wang W., 2015, ANN TRANSL MED, V3, P1; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Winek K., 2016, J CEREB BLOOD FLOW M; Winek K, 2016, STROKE, V47, P1354, DOI 10.1161/STROKEAHA.115.011800; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Worthmann H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0231-2; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Xu MQ, 2015, WORLD J GASTROENTERO, V21, P102, DOI 10.3748/wjg.v21.i1.102; Yamashiro K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171521; Yin J, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002699; Zhang R, 2009, J NEUROIMMUNOL, V206, P121, DOI 10.1016/j.jneuroim.2008.09.017; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zhou LH, 2015, NEUROPSYCH DIS TREAT, V11, P715, DOI 10.2147/NDT.S61997	214	53	54	4	51	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2017	66						31	44		10.1016/j.bbi.2017.05.009			14	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	FL4YE	WOS:000414236600005	28526435	Green Published			2021-06-18	
J	Albayram, O; Kondo, A; Mannix, R; Smith, C; Tsai, CY; Li, CY; Herbert, MK; Qiu, JH; Monuteaux, M; Driver, J; Yan, S; Gormley, W; Puccio, AM; Okonkwo, DO; Lucke-Wold, B; Bailes, J; Meehan, W; Zeidel, M; Lu, KP; Zhou, XZ				Albayram, Onder; Kondo, Asami; Mannix, Rebekah; Smith, Colin; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Qiu, Jianhua; Monuteaux, Michael; Driver, Jane; Yan, Sandra; Gormley, William; Puccio, Ava M.; Okonkwo, David O.; Lucke-Wold, Brandon; Bailes, Julian; Meehan, William; Zeidel, Mark; Lu, Kun Ping; Zhou, Xiao Zhen			Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae	NATURE COMMUNICATIONS			English	Article							PROLYL ISOMERASE PIN1; CLOSED-HEAD INJURY; CHRONIC TRAUMATIC ENCEPHALOPATHY; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; COGNITIVE DEFICITS; PHOSPHORYLATED TAU; EXPERIMENTAL-MODEL; UNITED-STATES; MOTOR-SKILLS	Traumatic brain injury (TBI) is characterized by acute neurological dysfunction and associated with the development of chronic traumatic encephalopathy (CTE) and Alzheimer's disease. We previously showed that cis phosphorylated tau (cis P-tau), but not the trans form, contributes to tau pathology and functional impairment in an animal model of severe TBI. Here we found that in human samples obtained post TBI due to a variety of causes, cis P-tau is induced in cortical axons and cerebrospinal fluid and positively correlates with axonal injury and clinical outcome. Using mouse models of severe or repetitive TBI, we showed that cis P-tau elimination with a specific neutralizing antibody administered immediately or at delayed time points after injury, attenuates the development of neuropathology and brain dysfunction during acute and chronic phases including CTE-like pathology and dysfunction after repetitive TBI. Thus, cis P-tau contributes to short-term and long-term sequelae after TBI, but is effectively neutralized by cis antibody treatment.	[Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Driver, Jane; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Translat Therapeut, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA; [Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Zeidel, Mark; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA; [Albayram, Onder; Kondo, Asami; Tsai, Cheng-Yu; Li, Chenyu; Herbert, Megan K.; Lu, Kun Ping; Zhou, Xiao Zhen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA; [Mannix, Rebekah; Qiu, Jianhua; Monuteaux, Michael] Harvard Med Sch, Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA; [Smith, Colin] Univ Edinburgh, Dept Neuropathol, 49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland; [Driver, Jane] Harvard Med Sch, VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, 150S Huntington Ave, Boston, MA 02130 USA; [Yan, Sandra; Gormley, William] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, 200 Lothrop St, Pittsburgh, PA 15213 USA; [Lucke-Wold, Brandon] West Virginia Univ, Dept Neurosurg, Hlth Sci Ctr, Suite 4300,POB 9183, Morgantown, WV 26506 USA; [Bailes, Julian] Univ Chicago, Pritzker Sch Med, NorthShore Univ Hlth Syst, Dept Neurosurg, 3rd Floor Kellogg, Evanston, IL 60637 USA; [Meehan, William] Harvard Med Sch, Childrens Hosp Boston, Div Sports Med, Micheli Ctr Sports Injury Prevent, 319 Longwood Ave, Boston, MA 02115 USA	Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Translat Therapeut, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA.; Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.; Lu, KP; Zhou, XZ (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Canc Res Inst, 330 Brookline Ave,CLS 0408, Boston, MA 02215 USA.	klu@bidmc.harvard.edu; zhou@bidmc.harvard.edu	Monuteaux, Michael C/O-5032-2018; Mannix, Rebekah/AAD-8702-2020; Herbert, Megan/AAN-8333-2021; Herbert, Megan/E-6348-2015	Herbert, Megan/0000-0003-1599-4362; Albayram, Onder/0000-0002-2028-1458	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD40128-11A1]; NIH Alzheimer's Association [R01AG029385, R01AG046319, R01CA167677, DVT-14-322623]; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Research UKAlzheimer's Research UK (ARUK); Weston Brain Institute [MCDN-15-368711]; Thome Memorial Foundation in Alzheimer's Disease Drug Discovery Research; NFLPA pilot; BIDMC pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA167677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS096835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046319, R01AG029385] Funding Source: NIH RePORTER	We thank Dr Michael Whalen for his expert advice and comments on the manuscript. O.A. is an Alzheimer's Association Research Fellow. The work is supported by grants from NIH (T32 HD40128-11A1) to R.M., NIH (R01AG029385, R01AG046319, R01CA167677) Alzheimer's Association (DVT-14-322623), Alzheimer's Association, Alzheimer's Research UK and Weston Brain Institute (MCDN-15-368711), Thome Memorial Foundation in Alzheimer's Disease Drug Discovery Research to K.P.L, by NFLPA pilot grants to K.P.L., X.Z.Z, and R.M., and BIDMC pilot grant and gift donations from the Owens Family Foundation to X.Z.Z. and K.P.L.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albayram O, 2016, PFLUG ARCH EUR J PHY, V468, P727, DOI 10.1007/s00424-015-1782-5; Albayram O, 2011, P NATL ACAD SCI USA, V108, P11256, DOI 10.1073/pnas.1016442108; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Chen CH, 2015, NEUROBIOL DIS, V76, P13, DOI 10.1016/j.nbd.2014.12.027; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; DEACON RMJ, 2013, JOVE J VIS EXP MAY; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Giannantoni A, 2011, ARCH PHYS MED REHAB, V92, P1134, DOI 10.1016/j.apmr.2011.02.013; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Iqbal K, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.225; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kallakuri S, 2015, J NEUROSCI RURAL PRA, V6, P481, DOI 10.4103/0976-3147.169767; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Karve Ila P, 2016, Br J Pharmacol, V173, P692, DOI 10.1111/bph.13125; Keller JJ, 2013, NEUROUROL URODYNAM, V32, P354, DOI 10.1002/nau.22309; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kleinbaum DG, 1988, APPL REGRESSION ANAL, P595; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Lu J, 2015, ARCH PHYS MED REHAB, V96, P702, DOI 10.1016/j.apmr.2014.10.026; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2016, JAMA NEUROL, V73, P1356, DOI 10.1001/jamaneurol.2016.2027; Lu PJ, 1999, NATURE, V399, P784; Mannix R, 2016, NAT REV NEUROL, V12, P486, DOI 10.1038/nrneurol.2016.99; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McAteer KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160220; McEwan WA, 2017, P NATL ACAD SCI USA, V114, P574, DOI 10.1073/pnas.1607215114; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nwachuku EL, 2016, CLIN NEUROL NEUROSUR, V149, P1, DOI 10.1016/j.clineuro.2016.06.009; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pallant J., 2013, SPSS SURVIVAL MANUAL; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Pedersen JT, 2015, TRENDS MOL MED, V21, P394, DOI 10.1016/j.molmed.2015.03.003; Pierce JES, 1996, J NEUROSCI, V16, P1083; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rosenmann H, 2006, ARCH NEUROL-CHICAGO, V63, P1459, DOI 10.1001/archneur.63.10.1459; Rosenmann H, 2013, CURR ALZHEIMER RES, V10, P217, DOI 10.2174/1567205011310030001; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Sultana R, 2006, NEUROBIOL AGING, V27, P918, DOI 10.1016/j.neurobiolaging.2005.05.005; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Thrane VR, 2013, NAT MED, V19, P1643, DOI 10.1038/nm.3400; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang YP, 2016, NAT REV NEUROSCI, V17, P5, DOI 10.1038/nrn.2015.1; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu WQ, 2014, AM J PHYSIOL-RENAL, V306, pF1296, DOI 10.1152/ajprenal.00074.2014; Zare-shahabadi A, 2015, REV NEUROSCIENCE, V26, P385, DOI 10.1515/revneuro-2014-0076; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	84	53	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	OCT 17	2017	8								1000	10.1038/s41467-017-01068-4			17	Multidisciplinary Sciences	Science & Technology - Other Topics	FJ9RS	WOS:000413118900003	29042562	DOAJ Gold, Green Published			2021-06-18	
J	Raffiz, M; Abdullah, JM				Raffiz, Mohd; Abdullah, Jafri M.			Optic nerve sheath diameter measurement: a means of detecting raised ICP in adult traumatic and non-traumatic neurosurgical patients	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							INTRACRANIAL-PRESSURE; BRAIN-INJURY; HEAD-INJURY; SONOGRAPHY	Introduction: Bedside ultrasound measurement of optic nerve sheath diameter (ONSD) is emerging as a non-invasive technique to evaluate and predict raised intracranial pressure (ICP). It has been shown in previous literature that ONSD measurement has good correlation with surrogate findings of raised ICP such as clinical and radiological findings suggestive of raised ICP. Objectives: The objective of the study is to find a correlation between sonographic measurements of ONSD value with ICP value measured via the gold standard invasive intracranial ICP catheter, and to find the cut-off value of ONSD measurement in predicting raised ICP, along with its sensitivity and specificity value. Methods: A prospective observational study was performed using convenience sample of 41 adult neurosurgical patients treated in neurosurgical intensive care unit with invasive intracranial pressure monitoring placed in-situ as part of their clinical care. Portable SonoSite ultrasound machine with 7MHz linear probe were used to measure optic nerve sheath diameter using the standard technique. Simultaneous ICP readings were obtained directly from the invasive monitoring. Results: Seventy-five measurements were performed on 41 patients. The non-parametric Spearman correlation test revealed a significant correlation at the 0.01 level between the ICP and ONSD value, with correlation coefficient of 0.820. The receiver operating characteristic curve generated an area under the curve with the value of 0.964, and with standard error of 0.22. From the receiver operating characteristic curve, we found that the ONSD value of 5.205 mm is 95.8% sensitive and 80.4% specific in detecting raised ICP. Conclusions: ONSD value of 5.205 is sensitive and specific in detecting raised ICP. Bedside ultrasound measurement of ONSD is readily learned, and is reproducible and reliable in predicting raised ICP. This non-invasive technique can be a useful adjunct to the current invasive intracranial catheter monitoring, and has wide potential clinical applications in district hospitals, emergency departments and intensive care units. (C) 2016 Elsevier Inc. All rights reserved.	[Raffiz, Mohd] Kuala Lumpur Hosp, Jalan Pahang, Kuala Lumpur 50586, Malaysia; [Abdullah, Jafri M.] Univ Sains Malaysia, Ctr Neurosci Serv & Res, Jalan Sultanah Zainab 2, Kota Baharu, Kelantan, Malaysia; [Abdullah, Jafri M.] Hosp Univ Sains Malaysia, Dept Neurosci, Jalan Hosp USM, Kubang Kerian 16150, Kelantan, Malaysia	Raffiz, M (corresponding author), Kuala Lumpur Hosp, Jalan Pahang, Kuala Lumpur 50586, Malaysia.	raffiz_dr@yahoo.co.uk	Abdullah, J/C-2828-2011	Abdullah, J/0000-0002-0258-7410			Ballantynea S A, 2012, EUROPEAN J ULTRASOUN, V5, P145; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Friedman DI, 2002, NEUROLOGY, V59, P1492, DOI 10.1212/01.WNL.0000029570.69134.1B; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Hartl R, 2013, WORLD NEUROSURG, V79, P599, DOI 10.1016/j.wneu.2013.03.046; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Levitt MR, 2013, WORLD NEUROSURG, V79, P600, DOI 10.1016/j.wneu.2013.03.047; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Mattei TA, 2013, WORLD NEUROSURG, V79, P602, DOI 10.1016/j.wneu.2013.03.048; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040	15	53	54	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2017	35	1					150	153		10.1016/j.ajem.2016.09.044			4	Emergency Medicine	Emergency Medicine	EP5KE	WOS:000397416600030	27852525				2021-06-18	
J	Tator, CH; Davis, HS; Dufort, PA; Tartaglia, MC; Davis, KD; Ebraheem, A; Hiploylee, C				Tator, Charles H.; Davis, Hannah S.; Dufort, Paul A.; Tartaglia, Maria Carmella; Davis, Karen D.; Ebraheem, Ahmed; Hiploylee, Carmen			Postconcussion syndrome: demographics and predictors in 221 patients	JOURNAL OF NEUROSURGERY			English	Article						postconcussion syndrome; concussion; traumatic brain injury; chronic traumatic encephalopathy	TRAUMATIC BRAIN-INJURY; SCHOOL FOOTBALL PLAYERS; MILD HEAD-INJURY; RISK-FACTORS; MINOR HEAD; CONCUSSION; SYMPTOMS; RECOVERY; DISORDER; EPIDEMIOLOGY	OBJECTIVE The objective of this study was to determine the demographics and predictors of postconcussion syndrome (PCS) in a large series of patients using a novel definition of PCS. METHODS The authors conducted a retrospective cohort study of 284 consecutive concussed patients, 221 of whom had PCS on the basis of at least 3 symptoms persisting at least 1 month. This definition of PCS was uniformly employed and is unique in accepting an expanded list of symptoms, in shortening the postconcussion interval to 1 month from 3 months, and in excluding those with focal injuries such as hemorrhages and contusions. RESULTS The 221 cases showed considerable heterogeneity in clinical features of PCS. They averaged 3.3 concussions, with a range of 0 to 12 or more concussions, and 62.4% occurred during sports and recreation. The median duration of PCS was 7 months at the time of examination, with 11.8% lasting more than 2 years, and 23.1% with PCS had only 1 concussion. The average patient age was 27 years (range 10-74 years). The average number of persistent symptoms was 8.1; 26.2% had a previous psychiatric condition, attention-deficit disorder/attention-deficit hyperactivity disorder, a learning disability, or previous migraine headaches. The prevalence of arachnoid cysts and Chiari malformation in PCS exceeded the general population. Additionally, involvement in litigation, presence of extracranial injuries, amnesia and/or loss of consciousness, and female sex were predictive of reporting a high number of symptoms. A prior history of psychiatric conditions or migraines, cause of injury, number of previous concussions, and age did not significantly predict symptom number. Only the number of symptoms reported predicted the duration of PCS. To predict the number of symptoms for those who fulfilled PCS criteria according to the International Classification of Diseases, 10th Revision (ICD-10), and the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), the number of previous concussions was significant. CONCLUSIONS PCS is commonly associated with multiple concussions, but 23.1% in the present series occurred after only 1 concussion. Most patients with PCS had multiple symptoms persisting for months or years. The median duration of PCS was 7 months, with a range up to 26 years. In only 11.3%, the PCS had ended at the time of consultation. Not all predictors commonly cited in the literature align with the findings in this study. This is likely due to differences in the definitions of PCS used in research. These results suggest that the use of ICD-10 and DSM-IV to diagnose PCS may be biased toward those who are vulnerable to concussions or with more severe forms of PCS. It is thus important to redefine PCS based on evidence-based medicine.	[Tator, Charles H.; Davis, Hannah S.; Dufort, Paul A.; Tartaglia, Maria Carmella; Davis, Karen D.; Ebraheem, Ahmed; Hiploylee, Carmen] Toronto Western Hosp, Canadian Concuss Ctr, Toronto, ON, Canada; [Tator, Charles H.; Davis, Karen D.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Tartaglia, Maria Carmella; Davis, Karen D.] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Davis, Karen D.] Toronto Western Hosp, 399 Bathurst St,Rm 4W-422, Toronto, ON M5T 2S8, Canada	Tator, CH (corresponding author), Toronto Western Hosp, 399 Bathurst St,Rm 4W-422, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca			Canadian Concussion Centre at the Toronto Western Hospital - Toronto General and Western Hospital Foundation	Funds for this study were provided by the Canadian Concussion Centre at the Toronto Western Hospital, which is funded by the Toronto General and Western Hospital Foundation.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Meadows J, 2000, J NEUROSURG, V92, P920, DOI 10.3171/jns.2000.92.6.0920; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Speer Marcy C, 2003, J Genet Couns, V12, P297, DOI 10.1023/A:1023948921381; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Wan MJ, 2008, NEUROSURGERY, V63, P748, DOI 10.1227/01.NEU.0000325498.04975.C0; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; World Health Organization, 1992, ICD 10 CLASS MENT BE; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	43	53	55	0	25	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2016	125	5					1206	1216		10.3171/2015.6.JNS15664			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DZ8FK	WOS:000386106100021	26918481	Bronze			2021-06-18	
J	Ko, J; Hemphill, MA; Gabrieli, D; Wu, L; Yelleswarapu, V; Lawrence, G; Pennycooke, W; Singh, A; Meaney, DF; Issadore, D				Ko, Jina; Hemphill, Matthew A.; Gabrieli, David; Wu, Leon; Yelleswarapu, Venkata; Lawrence, Gladys; Pennycooke, Wesley; Singh, Anup; Meaney, Dave F.; Issadore, David			Smartphone-enabled optofluidic exosome diagnostic for concussion recovery	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; MECHANICAL INJURY; AMPA RECEPTORS; IN-VITRO; PROTEIN; QUANTIFICATION; CONSEQUENCES; BIOMARKERS; FLUID	A major impediment to improving the treatment of concussion is our current inability to identify patients that will experience persistent problems after the injury. Recently, brain-derived exosomes, which cross the blood-brain barrier and circulate following injury, have shown great potential as a noninvasive biomarker of brain recovery. However, clinical use of exosomes has been constrained by their small size (30-100 nm) and the extensive sample preparation (>24 hr) needed for traditional exosome measurements. To address these challenges, we developed a smartphone-enabled optofluidic platform to measure brain-derived exosomes. Sample-to-answer on our chip is 1 hour, 10x faster than conventional techniques. The key innovation is an optofluidic device that can detect enzyme amplified exosome biomarkers, and is read out using a smartphone camera. Using this approach, we detected and profiled GluR2+ exosomes in the post-injury state using both in vitro and murine models of concussion.	[Ko, Jina; Hemphill, Matthew A.; Gabrieli, David; Wu, Leon; Yelleswarapu, Venkata; Lawrence, Gladys; Pennycooke, Wesley; Singh, Anup; Meaney, Dave F.; Issadore, David] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Issadore, David] Univ Penn, Sch Engn & Appl Sci, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA; [Meaney, Dave F.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Issadore, D (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.; Issadore, D (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA.	issadore@seas.upenn.edu	Yelleswarapu, Venkata/J-9222-2015	Yelleswarapu, Venkata/0000-0003-3529-2819; Meaney, David/0000-0002-0954-4122	Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21CA182336-01A1, RO1 NS 088176]; Army Research Office [W911NF-10-1-0526]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA182336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER	This work was funded by the Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program, the National Institute of Health: 1R21CA182336-01A1, RO1 NS 088176, and the Army Research Office: W911NF-10-1-0526.	Agoston D. V., 2012, FRONTIERS NEUROLOGY, V3; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Chen Y., 2014, FRONTIERS NEUROLOGY, V5; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Chueh BH, 2007, ANAL CHEM, V79, P3504, DOI 10.1021/ac062118p; Chumo B, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4840575; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Davis JE, 2004, NEUROCHEM RES, V29, P1113, DOI 10.1023/B:NERE.0000023598.04937.83; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dudani JS, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4907807; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Huang JH, 2013, NEUROL RES, V35, P221, DOI 10.1179/1743132813Y.0000000178; Im H, 2014, NAT BIOTECHNOL, V32, P490, DOI 10.1038/nbt.2886; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jeter C. B., 2012, INJURY RES THEORIES, P337; Kanwar SS, 2014, LAB CHIP, V14, P1891, DOI 10.1039/c4lc00136b; Kiesel P., 2007, United States patent, Patent No. [US 7, 248-361, 7248361]; Ko J, 2016, ANALYST, V141, P450, DOI 10.1039/c5an01610j; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Muluneh M, 2014, LAB CHIP, V14, P4638, DOI 10.1039/c4lc00819g; Muluneh M, 2014, ADV HEALTHC MATER, V3, P1078, DOI 10.1002/adhm.201300502; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Patel TP, 2015, J NEUROSCI METH, V243, P26, DOI 10.1016/j.jneumeth.2015.01.020; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Son KJ, 2016, ANALYST, V141, P679, DOI 10.1039/c5an01648g; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Wang J, 2010, LAB CHIP, V10, P3157, DOI [10.1039/c0lc00132e, 10.1039/c01c00132e]; Wang ZX, 2013, LAB CHIP, V13, P2879, DOI 10.1039/c3lc41343h; Xu ZR, 2008, LAB CHIP, V8, P1658, DOI 10.1039/b805774e; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang P, 2016, LAB CHIP, V16, P3033, DOI 10.1039/c6lc00279j	47	53	53	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 8	2016	6								31215	10.1038/srep31215			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DS8BT	WOS:000381008400001	27498963	DOAJ Gold, Green Published			2021-06-18	
J	Doherty, CP; O'Keefe, E; Wallace, E; Loftus, T; Keaney, J; Kealy, J; Humphries, MM; Molloy, MG; Meaney, JF; Farrell, M; Campbell, M				Doherty, Colin P.; O'Keefe, Eoin; Wallace, Eugene; Loftus, Teresa; Keaney, James; Kealy, John; Humphries, Marian M.; Molloy, Michael G.; Meaney, James F.; Farrell, Michael; Campbell, Matthew			Blood-Brain Barrier Dysfunction as a Hallmark Pathology in Chronic Traumatic Encephalopathy	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Blood-brain harrier; Chronic traumatic encephalopathy; Claudin-5; Tight junctions	INJURY	Chronic traumatic encephalopathy (CTE) is a neurodegenerative condition associated with repetitive mild traumatic brain injury. In recent years, attention has focused on emerging evidence linking the development of CTE to concussive injuries in athletes and military personnel; however, the underlying molecular pathobiology of CTE remains unclear. Here, we provide evidence that the blood brain barrier (BBB) is disrupted in regions of dense perivascular p-Tau accumulation in a case of CTE. Immunoreactivity patterns of the BBB-associated tight junction components claudin-5 and zonula occludens-1 were markedly discontinuous or absent in regions of perivascular p-Tau deposition; there was also immunohistochemical evidence of a BBB in these foci. Because the patient was diagnosed premortem clinically as having progressive supranuclear palsy (PSP), we also compromised that the CTE alterations appear to be distinct from those in the brain of a patient with PSP. This report represents the first description of BBB dysfunction in a pathologically proven CTE case and suggests a vascular component in the postconcussion cascade of events that may ultimately lead to development of a progressive degenerative disorder. BBB dysfunction may represent a correlate of neural dysfunction in live subjects suspected of being at risk for development of CTE.	[Doherty, Colin P.; Wallace, Eugene] St James Hosp, Hosp 5, Hlth Care Ctr, Dept Neurol, Dublin, Ireland; [O'Keefe, Eoin; Keaney, James; Kealy, John; Humphries, Marian M.; Campbell, Matthew] Univ Dublin, Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland; [Loftus, Teresa; Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin, Ireland; [Keaney, James] Univ Sch Vet Med, Basseterre, St Kitts & Nevi; [Molloy, Michael G.] Univ Coll Cork, Dept Med, Cork, Ireland; [Meaney, James F.] St James Hosp, Dept Radiol, Dublin, Ireland	Campbell, M (corresponding author), Univ Dublin, Trinity Coll Dublin, Smurfit Inst Genet, Lincoln Pl Gate, Dublin 2, Ireland.	matthew.campbell@tcd.ie	Kealy, John/A-6515-2010	Kealy, John/0000-0002-0503-4379; Meaney, James FM/0000-0003-1596-4972; Doherty, Colin/0000-0002-8869-8567	Science Foundation IrelandScience Foundation IrelandEuropean Commission [12/YI/B2614, 08/IN.I/B2033]; Health Research Board of Ireland; Bright Focus FoundationBrightFocus Foundation; St James' Hospital Research Foundation	This work was supported by grants from Science Foundation Ireland (12/YI/B2614; 08/IN.I/B2033), The Health Research Board of Ireland, the Bright Focus Foundation and St James' Hospital Research Foundation.	Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412; Kon T, 2012, NEUROPATHOLOGY, V32, P267, DOI 10.1111/j.1440-1789.2011.01249.x; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334	16	53	53	0	29	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2016	75	7					656	662		10.1093/jnen/nlw036			7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	DR3BG	WOS:000379777000004	27245243	Green Published, Bronze			2021-06-18	
J	Stanne, TM; Aberg, ND; Nilsson, S; Jood, K; Blomstrand, C; Andreasson, U; Blennow, K; Zetterberg, H; Isgaard, J; Svensson, J; Jern, C				Stanne, Tara M.; Aberg, N. David; Nilsson, Staffan; Jood, Katarina; Blomstrand, Christian; Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik; Isgaard, Jorgen; Svensson, Johan; Jern, Christina			Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke	STROKE			English	Article						brain-derived neurotrophic factor; pathogenesis; risk factors; serum; stroke	RECOVERY; INJURY; BDNF; NGF	Background and Purpose-Brain-derived neurotrophic factor (BDNF) plays important roles in brain plasticity and repair, and it influences stroke outcomes in animal models. Circulating BDNF concentrations are lowered in patients with traumatic brain injury, and low BDNF predicts poor recovery after this injury. We sought to investigate whether circulating concentrations of BDNF are altered in the acute phase of ischemic stroke and whether they are associated with short- or long-term functional outcome. Methods-Serum concentrations of BDNF were measured in the Sahlgrenska Academy Study on Ischemic Stroke. The main outcomes were modified Rankin Scale (mRS) good (mRS score of 0-2) versus poor (mRS score of 3-6) at 3 months and 2 years after stroke, and good (mRS score of 0-2) versus poor (mRS score of 3-5) at 7 years after stroke. Results-Acute concentrations of BDNF were significantly lower in ischemic stroke cases (n=491) compared with controls (n=513). BDNF concentrations were not significantly associated with 3-month outcome. However, patients with BDNF in the lowest tertile had an increased risk of experiencing a poor outcome both at 2-year and 7-year follow-up, and these associations were independent of vascular risk factors and stroke severity (odds ratio, 2.6; confidence intervals, 1.4-4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1-3.9; P=0.028, respectively). Conclusions-Circulating concentrations of BDNF protein are lowered in the acute phase of ischemic stroke, and low levels are associated with poor long-term functional outcome. Further studies are necessary to confirm these associations and to determine the predictive value of BDNF in stroke outcomes.	[Stanne, Tara M.; Jern, Christina] Univ Gothenburg, Sahlgrenska Acad, Dept Med & Clin Genet, Gothenburg, Sweden; [Aberg, N. David; Isgaard, Jorgen; Svensson, Johan] Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Gothenburg, Sweden; [Aberg, N. David; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Ctr Brain Repair & Rehabil, Gothenburg, Sweden; [Jood, Katarina; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden; [Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Nilsson, Staffan] Chalmers, Math Sci, Gothenburg, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, London, England	Stanne, TM (corresponding author), Inst Biomed, Dept Med & Clin Genet, POB 445, SE-40530 Gothenburg, Sweden.	tara.stanne@gu.se	Aberg, N. David/O-4068-2019	Nilsson, Staffan/0000-0003-4748-0446	Swedish Medical Society (Svenska Lakaresallskapet); Swedish Government [ALFGBG-11206, ALFGBG-147771, ALFGBG-148861, ALFGBG-144341]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2013-3595]; Swedish Heart Lung FoundationSwedish Heart-Lung Foundation [20130315]; Swedish Stroke Association; Goteborg Foundation for Neurological Research; Goteborg Medical Society [036/14]	This study was supported by the Swedish Medical Society (Svenska Lakaresallskapet), grants from the Swedish Government (ALFGBG-11206, ALFGBG-147771, ALFGBG-148861, and ALFGBG-144341), the Swedish Research Council (2013-3595), the Swedish Heart Lung Foundation (20130315), the Swedish Stroke Association, the Goteborg Foundation for Neurological Research, and the Goteborg Medical Society (036/14).	Chaldakov GN, 2004, PROG BRAIN RES, V146, P279, DOI 10.1016/S0079-6123(03)46018-4; Golden E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010099; Hope TMH, 2013, NEUROIMAGE-CLIN, V2, P424, DOI 10.1016/j.nicl.2013.03.005; Jood K, 2005, STROKE, V36, P1383, DOI 10.1161/01.STR.0000169944.46025.09; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Li J, 2014, J AFFECT DISORDERS, V168, P373, DOI 10.1016/j.jad.2014.07.011; Manni L, 2005, INT J CARDIOL, V102, P169, DOI 10.1016/j.ijcard.2004.10.041; Pikula A, 2013, STROKE, V44, P2768, DOI 10.1161/STROKEAHA.113.001447; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331	9	53	60	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUL	2016	47	7					1943	1945		10.1161/STROKEAHA.115.012383			3	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	DR4AX	WOS:000379844900058	27301948				2021-06-18	
J	Goswami, R; Dufort, P; Tartaglia, MC; Green, RE; Crawley, A; Tator, CH; Wennberg, R; Mikulis, DJ; Keightley, M; Davis, KD				Goswami, R.; Dufort, P.; Tartaglia, M. C.; Green, R. E.; Crawley, A.; Tator, C. H.; Wennberg, R.; Mikulis, D. J.; Keightley, M.; Davis, Karen D.			Frontotemporal correlates of impulsivity and machine learning in retired professional athletes with a history of multiple concussions	BRAIN STRUCTURE & FUNCTION			English	Article						Concussion; Impulsivity; Uncinate fasciculus; Cortical thickness; Connectivity; Machine learning	TRAUMATIC BRAIN-INJURY; ANTERIOR TEMPORAL-LOBE; SURFACE-BASED ANALYSIS; ORBITOFRONTAL CORTEX; DECISION-MAKING; SUSTAINED ATTENTION; PREFRONTAL CORTEX; LINEAR-MODELS; FRONTAL LOBES; SELECTION	The frontotemporal cortical network is associated with behaviours such as impulsivity and aggression. The health of the uncinate fasciculus (UF) that connects the orbitofrontal cortex (OFC) with the anterior temporal lobe (ATL) may be a crucial determinant of behavioural regulation. Behavioural changes can emerge after repeated concussion and thus we used MRI to examine the UF and connected gray matter as it relates to impulsivity and aggression in retired professional football players who had sustained multiple concussions. Behaviourally, athletes had faster reaction times and an increased error rate on a go/no-go task, and increased aggression and mania compared to controls. MRI revealed that the athletes had (1) cortical thinning of the ATL, (2) negative correlations of OFC thickness with aggression and task errors, indicative of impulsivity, (3) negative correlations of UF axial diffusivity with error rates and aggression, and (4) elevated resting-state functional connectivity between the ATL and OFC. Using machine learning, we found that UF diffusion imaging differentiates athletes from healthy controls with significant classifiers based on UF mean and radial diffusivity showing 79-84 % sensitivity and specificity, and 0.8 areas under the ROC curves. The spatial pattern of classifier weights revealed hot spots at the orbitofrontal and temporal ends of the UF. These data implicate the UF system in the pathological outcomes of repeated concussion as they relate to impulsive behaviour. Furthermore, a support vector machine has potential utility in the general assessment and diagnosis of brain abnormalities following concussion.	[Goswami, R.; Dufort, P.; Tartaglia, M. C.; Green, R. E.; Crawley, A.; Tator, C. H.; Wennberg, R.; Mikulis, D. J.; Keightley, M.; Davis, Karen D.] Toronto Western Hosp, Canadian Sports Concuss Project, Toronto, ON M5T 2S8, Canada; [Goswami, R.; Crawley, A.; Tator, C. H.; Mikulis, D. J.; Davis, Karen D.] Univ Hlth Network, Toronto Western Hosp, Div Brain Imaging & Behav Syst Neurosci, Toronto Western Res Inst, 399 Bathurst St,Room MP14-306, Toronto, ON M5T 2S8, Canada; [Dufort, P.; Crawley, A.; Mikulis, D. J.] Toronto Western Hosp, Dept Med Imaging, Toronto, ON M5T 2S8, Canada; [Dufort, P.; Crawley, A.; Mikulis, D. J.] Univ Toronto, Toronto, ON, Canada; [Tartaglia, M. C.] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; [Tartaglia, M. C.; Wennberg, R.] Krembil Neurosci Ctr, Div Neurol, Toronto, ON, Canada; [Green, R. E.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5T 2S8, Canada; [Crawley, A.; Tator, C. H.; Mikulis, D. J.; Davis, Karen D.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Tator, C. H.] Toronto Western Hosp, Div Neurosurg, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Tator, C. H.; Davis, Karen D.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Keightley, M.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Keightley, M.] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada	Davis, KD (corresponding author), Univ Hlth Network, Toronto Western Hosp, Div Brain Imaging & Behav Syst Neurosci, Toronto Western Res Inst, 399 Bathurst St,Room MP14-306, Toronto, ON M5T 2S8, Canada.	kdavis@uhnres.utoronto.ca	Mikulis, David J/H-5167-2019	Green, Robin/0000-0001-9451-3963; Mikulis, David/0000-0003-3956-0892	Physicians' Services Incorporated (PSI) Foundation; Canadian Sports Concussion Project, Toronto Western Hospital.; Canadian Football League Alumni Association	This research was supported by a Grant from The Physicians' Services Incorporated (PSI) Foundation and funds from the Canadian Sports Concussion Project, Toronto Western Hospital. We are very grateful to Leo Ezerins and the Canadian Football League Alumni Association for their support and aid in recruitment. Thank you to Brenda Colella and Mozhgan Khodadadi for neuropsychological data collection and administrative support, and MRI technologists Eugen Hlasny and Keith Ta for neuroimaging data collection.	Aribisala BS, 2010, LECT NOTES COMPUT SC, V6326, P51; Baldassarre L, 2012, P 2 INT WORKSH PATT; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Berlin HA, 2004, BRAIN, V127, P1108, DOI 10.1093/brain/awh135; Bi YC, 2011, CORTEX, V47, P575, DOI 10.1016/j.cortex.2009.12.002; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boyd Stephen, 2010, Foundations and Trends in Machine Learning, V3, P1, DOI 10.1561/2200000016; Brothers L., 1990, CONCEPTS NEUROSCIENC, V1, P27, DOI DOI 10.7551/MITPRESS/3077.003.0029; Carter L, 2013, BRAIN COGNITION, V82, P35, DOI 10.1016/j.bandc.2013.02.002; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chen YW, 2006, STUD FUZZ SOFT COMP, V207, P315; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DICKMAN SJ, 1990, J PERS SOC PSYCHOL, V58, P95, DOI 10.1037/0022-3514.58.1.95; DREWE E A, 1975, Cortex, V11, P8; EBELING U, 1992, ACTA NEUROCHIR, V115, P143, DOI 10.1007/BF01406373; Efron B., 1994, INTRO BOOTSTRAP; Erpelding N, 2012, PAIN, V153, P1602, DOI 10.1016/j.pain.2012.03.012; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghashghaei H, 2007, NEUROIMAGE, V34, P905, DOI 10.1016/j.neuroimage.2006.09.046; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hastie T., 2001, ELEMENTS STAT LEARNI, DOI [DOI 10.1007/B94608, 10.1007/978-0-387-84858-7, DOI 10.1007/978-0-387-84858-7]; Haufe S, 2014, NEUROIMAGE, V87, P96, DOI 10.1016/j.neuroimage.2013.10.067; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Hoptman MJ, 2002, BIOL PSYCHIAT, V52, P9, DOI 10.1016/S0006-3223(02)01311-2; Hoptman MJ, 2004, NEUROREPORT, V15, P2467, DOI 10.1097/00001756-200411150-00007; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Kahnt T, 2012, J NEUROSCI, V32, P6240, DOI 10.1523/JNEUROSCI.0257-12.2012; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Matsuo K, 2009, HUM BRAIN MAPP, V30, P1188, DOI 10.1002/hbm.20588; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Moayedi M, 2011, NEUROIMAGE, V55, P277, DOI 10.1016/j.neuroimage.2010.12.013; Morey LC., 2007, PERSONALITY ASSESSME; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Pereira F, 2009, NEUROIMAGE, V45, pS199, DOI 10.1016/j.neuroimage.2008.11.007; Piguet O, 2011, LANCET NEUROL, V10, P162, DOI 10.1016/S1474-4422(10)70299-4; Potegal M, 2012, BEHAV BRAIN RES, V231, P386, DOI 10.1016/j.bbr.2011.10.049; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sakai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067391; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schoenbaum G, 2003, NEURON, V39, P855, DOI 10.1016/S0896-6273(03)00474-4; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Snowden JS, 2001, J NEUROL NEUROSUR PS, V70, P323, DOI 10.1136/jnnp.70.3.323; Soloff P, 2008, PSYCHIAT RES-NEUROIM, V164, P223, DOI 10.1016/j.pscychresns.2008.02.003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Strakowski SM, 2009, BIPOLAR DISORD, V11, P41, DOI 10.1111/j.1399-5618.2008.00658.x; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Swann AC, 2007, BIPOLAR DISORD, V9, P206, DOI 10.1111/j.1399-5618.2007.00357.x; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van Tol MJ, 2014, PSYCHOL MED, V44, P2053, DOI 10.1017/S0033291713002742; Vigil-Colet A, 2004, PERS INDIV DIFFER, V37, P1431, DOI 10.1016/j.paid.2004.01.013; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; WEIGER WA, 1988, J PSYCHIAT RES, V22, P85, DOI 10.1016/0022-3956(88)90073-8; Winstanley CA, 2004, J NEUROSCI, V24, P4718, DOI 10.1523/JNEUROSCI.5606-03.2004; Wong C, 2012, BRAIN RES, V1449, P94, DOI 10.1016/j.brainres.2012.02.017; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhou Y, 2013, P ISMRM, V21, P2688; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	91	53	53	0	10	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	MAY	2016	221	4					1911	1925		10.1007/s00429-015-1012-0			15	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	DL3UJ	WOS:000375558600008	25721800	Other Gold, Green Published			2021-06-18	
J	Ryan, NP; van Bijnen, L; Catroppa, C; Beauchamp, MH; Crossley, L; Hearps, S; Anderson, V				Ryan, Nicholas P.; van Bijnen, Loeka; Catroppa, Cathy; Beauchamp, Miriam H.; Crossley, Louise; Hearps, Stephen; Anderson, Vicki			Longitudinal outcome and recovery of social problems after pediatric traumatic brain injury (TBI): Contribution of brain insult and family environment	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Social problems; Pediatrics; Brain injuries; Magnetic resonance imaging; Neurobiology	PROBLEM-SOLVING SKILLS; LONG-TERM OUTCOMES; SELF-REGULATION; HEAD-INJURY; CHILDREN; CHILDHOOD; AGE; COMPETENCE; PREDICTORS; SEVERITY	Pediatric traumatic brain injury (TBI) can result in a range of social impairments, however longitudinal recovery is not well characterized, and clinicians are poorly equipped to identify children at risk for persisting difficulties. Using a longitudinal prospective design, this study aimed to evaluate the contribution of injury and non-injury related risk and resilience factors to longitudinal outcome and recovery of social problems from 12- to 24-months post-TBI. 78 children with TBI (injury age: 5.0-15.0 years) and 40 age and gender-matched typically developing (TD) children underwent magnetic resonance imaging including a susceptibility-weighted imaging (SWI) sequence 2-8 weeks post-injury (M = 39.25, SD = 27.64 days). At 12 and 24-months post-injury, parents completed questionnaires rating their child's social functioning, and environmental factors including socioeconomic status, caregiver mental health and family functioning. Results revealed that longitudinal recovery profiles differed as a function of injury severity, such that among children with severe TBI, social problems significantly increased from 12- to 24-months post injury, and were found to be significantly worse than TD controls and children with mild and moderate TBI. In contrast, children with mild and moderate injuries showed few problems at 12-months post-injury and little change over time. Pre-injury environment and SWI did not significantly contribute to outcome at 24-months, however concurrent caregiver mental health and family functioning explained a large and significant proportion of variance in these outcomes. Overall, this study shows that longitudinal recovery profiles differ as a function of injury severity, with evidence for late-emerging social problems among children with severe TBI. Poorer long-term social outcomes were associated with family dysfunction and poorer caregiver mental health at 24-months post injury, suggesting that efforts to optimize the child's environment and bolster family coping resources may enhance recovery of social problems following pediatric TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Ryan, Nicholas P.; van Bijnen, Loeka; Catroppa, Cathy; Beauchamp, Miriam H.; Crossley, Louise; Hearps, Stephen; Anderson, Vicki] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, CP 6128, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada	Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019; Hearps, Stephen/L-6853-2016	Ryan, Nicholas/0000-0002-0878-8889; 	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Victoria Neurotrauma Initiative, Australia; Victorian Government Operational Infrastructure Support Program	All phases of this study were supported in part by a National Health and Medical Research Council Moving Ahead Seed Grant (Nicholas Ryan, awarded 2014); a National Health and Medical Research Council Senior Practitioner Fellowship (Vicki Anderson; awarded 2014); a grant from the Victoria Neurotrauma Initiative, Australia; and the Victorian Government Operational Infrastructure Support Program. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Achenbach T. M., 2001, ASEBA SCH AGE FORMS; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2012, DEV SOCIAL NEUROSCIE; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coffey C., 1991, Psychopathology and the Brain, V3, P243; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Greenough WT, 1999, CHANGING NERVOUS SYSTEM, P51; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kosty JA, 2013, NEUROL RES, V35, P277, DOI 10.1179/1743132813Y.0000000168; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Levan A, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000040; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2015, NEUROPSYCHOLOGIA, V66, P32, DOI 10.1016/j.neuropsychologia.2014.10.040; Schroeder J., 2011, J DEV DISABIL, V17; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wechsler D., 2011, WASI 2 WECHSLER ABBR; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]; Woods D., 2014, SOCIAL CARE NEURODIS, V5, P51, DOI [10.1108/SCN-01-2013-0002, DOI 10.1108/SCN-01-2013-0002]; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	58	53	53	0	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	APR	2016	49						23	30		10.1016/j.ijdevneu.2015.12.004			8	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	DG3AG	WOS:000371941300004	26739435				2021-06-18	
J	Chesnut, RM; Bleck, TP; Citerio, G; Classen, J; Cooper, DJ; Coplin, WM; Diringer, MN; Grande, PO; Hemphill, JC; Hutchinson, PJ; Le Roux, P; Mayer, SA; Menon, DK; Myburgh, JA; Okonkwo, DO; Robertson, CS; Sahuquillo, J; Stocchetti, N; Sung, G; Temkin, N; Vespa, PM; Videtta, W; Yonas, H				Chesnut, Randall M.; Bleck, Thomas P.; Citerio, Giuseppe; Classen, Jan; Cooper, D. James; Coplin, William M.; Diringer, Michael N.; Graende, Per-Olof; Hemphill, J. Claude, III; Hutchinson, Peter J.; Le Roux, Peter; Mayer, Stephan A.; Menon, David K.; Myburgh, John A.; Okonkwo, David O.; Robertson, Claudia S.; Sahuquillo, Juan; Stocchetti, Nino; Sung, Gene; Temkin, Nancy; Vespa, Paul M.; Videtta, Walter; Yonas, Howard			A Consensus-Based Interpretation of the Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure Trial	JOURNAL OF NEUROTRAUMA			English	Article						BEST TRIP trial; Consensus Development Conference; intracranial pressure; neurocritical care; traumatic brain injury	TRAUMATIC BRAIN-INJURY	Widely-varying published and presented analyses of the Benchmark Evidence From South American Trials: Treatment of Intracranial Pressure (BEST TRIP) randomized controlled trial of intracranial pressure (ICP) monitoring have suggested denying trial generalizability, questioning the need for ICP monitoring in severe traumatic brain injury (sTBI), re-assessing current clinical approaches to monitored ICP, and initiating a general ICP-monitoring moratorium. In response to this dissonance, 23 clinically-active, international opinion leaders in acute-care sTBI management met to draft a consensus statement to interpret this study. A Delphi method-based approach employed iterative pre-meeting polling to codify the group's general opinions, followed by an in-person meeting wherein individual statements were refined. Statements required an agreement threshold of more than 70% by blinded voting for approval. Seven precisely-worded statements resulted, with agreement levels of 83% to 100%. These statements, which should be read in toto to properly reflect the group's consensus positions, conclude that the BEST TRIP trial: 1) studied protocols, not ICP-monitoring per se; 2) applies only to those protocols and specific study groups and should not be generalized to other treatment approaches or patient groups; 3) strongly calls for further research on ICP interpretation and use; 4) should be applied cautiously to regions with much different treatment milieu; 5) did not investigate the utility of treating monitored ICP in the specific patient group with established intracranial hypertension; 6) should not change the practice of those currently monitoring ICP; and 7) provided a protocol, used in non-monitored study patients, that should be considered when treating without ICP monitoring. Consideration of these statements can clarify study interpretation.	[Chesnut, Randall M.; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bleck, Thomas P.] Rush Univ, Med Ctr, Dept Neurol, Chicago, IL 60612 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Dept Hlth Sci, Milan, Italy; [Classen, Jan] Columbia Univ, Div Crit Care Neurol, New York, NY USA; [Classen, Jan] Columbia Univ, Comprehens Epilepsy Ctr, New York, NY USA; [Cooper, D. James] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Coplin, William M.] St Anthony Hosp, Neurosurg Intens Care, Lakewood, CO USA; [Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Graende, Per-Olof] Univ Lund Hosp, Anesthesiol & Intens Care, S-22185 Lund, Sweden; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hutchinson, Peter J.] Addenbrookes Hosp, Div Neurosurg, Cambridge, England; [Hutchinson, Peter J.] Univ Cambridge, Cambridge, England; [Le Roux, Peter] Lankenau Med Ctr, Neurosurg, Wynnewood, PA USA; [Mayer, Stephan A.] Icahn Sch Med Mt Sinai, Inst Crit Care Med, New York, NY 10029 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Myburgh, John A.] Univ New S Wales, Dept Intens Care Med, Sydney, NSW, Australia; [Myburgh, John A.] George Inst Global Hlth, Sydney, NSW, Australia; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA; [Sahuquillo, Juan] Vall dHebron Univ Hosp, Dept Neurol Surg, Barcelona, Spain; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Milan, Italy; [Stocchetti, Nino] Neuro ICU Fdn IRCCS Ca Granda Osped Maggiore Poli, Milan, Italy; [Sung, Gene] Univ So Calif, Dept Neurol, Los Angeles, CA USA; [Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Intens Care Med, Buenos Aires, DF, Argentina; [Yonas, Howard] Univ New Mexico, Dept Neurol Surg, Albuquerque, NM 87131 USA	Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA.	chesnutr@uw.edu	Demchuk, Andrew M/E-1103-2012; Bleck, Thomas/D-3772-2009; Stocchetti, Nino/O-7444-2017; Cooper, D. James/G-7961-2013; Citerio, Giuseppe/B-1839-2015; Diringer, Michael N/C-1165-2008; Sahuquillo, Juan/B-3577-2008; Bleck, Thomas/R-2286-2019	Demchuk, Andrew M/0000-0002-4930-7789; Stocchetti, Nino/0000-0003-3250-6834; Cooper, D. James/0000-0002-5872-9051; Citerio, Giuseppe/0000-0002-5374-3161; Diringer, Michael N/0000-0003-2337-5537; Sahuquillo, Juan/0000-0003-0713-5875; Bleck, Thomas/0000-0002-8267-9787; Hutchinson, Peter/0000-0002-2796-1835; Hemphill, Claude/0000-0003-4019-7525; Chesnut, Randall/0000-0001-6377-3666	University of Washington Department of Neurological Surgery; Brain Trauma Foundation; Integra Lifesciences Corp.; Codman & Shurtleff, Inc.; Neuroptics Inc.; Sophysa USA Inc.; Raumedic Inc.; Orsan Medical Technologies; Moberg Research Inc; Integra LifeSciences; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	This meeting was supported by internal funding from the University of Washington Department of Neurological Surgery, a grant from the Brain Trauma Foundation, and unrestricted grants solicited from the following industrial partners: Integra Lifesciences Corp., Codman & Shurtleff, Inc., Neuroptics Inc., Sophysa USA Inc., Raumedic Inc., Orsan Medical Technologies, and Moberg Research Inc. Industrial support was solicited and accepted under the conditions of allowing silent observation of the meeting without any input, interaction, or involvement in the conference proceedings, analysis of statements, or the writing or editing of any manuscripts resulting from this meeting.; Prof. Chesnut has an Endowed Neurotrauma Professorship from Integra LifeSciences and is a consultant for Orsan Medical and InnerSpace. Prof. Citerio is a consultant for Codman. Dr. Claassen is on the advisory board of Actelion and SAGE for research planning. Dr. Coplin is a consultant for Integra LifeSciences. Prof. Hutchinson is director of Technicam as manufacturer of a cranial access device and has received honoraria from Codman. Dr. LeRoux is a consultant for Integra LifeSciences and Codman and receives research funding from Integra LifeSciences. Prof. Mayer is a consultant for Orsan Medical. Prof. Stocchetti is a consultant for Orsan Medical.	Albuquerque FC, 2013, WORLD NEUROSURG, V79, P598, DOI 10.1016/j.wneu.2013.03.045; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Hartl R, 2013, WORLD NEUROSURG, V79, P599, DOI 10.1016/j.wneu.2013.03.046; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Levitt MR, 2013, WORLD NEUROSURG, V79, P600, DOI 10.1016/j.wneu.2013.03.047; Mattei TA, 2013, WORLD NEUROSURG, V79, P602, DOI 10.1016/j.wneu.2013.03.048; Mukherjee D, 2013, NEW ENGL J MED, V368, P1748, DOI 10.1056/NEJMc1301076; Pilge S, 2013, ANAESTHESIST, V62, P562, DOI 10.1007/s00101-013-2194-6; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Ropper AE, 2013, NEUROSURGERY, V72, pN19, DOI 10.1227/01.neu.0000428424.83867.87; Ropper AH, 2012, NEW ENGL J MED, V367, P2539, DOI 10.1056/NEJMe1212289	13	53	55	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1722	1724		10.1089/neu.2015.3976			3	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500002	26061135				2021-06-18	
J	Smith, DH; Hicks, RR; Johnson, VE; Bergstrom, DA; Cummings, DM; Noble, LJ; Hovda, D; Whalen, M; Ahlers, ST; LaPlaca, M; Tortella, FC; Duhaime, AC; Dixon, CE				Smith, Douglas H.; Hicks, Ramona R.; Johnson, Victoria E.; Bergstrom, Debra A.; Cummings, Diana M.; Noble, Linda J.; Hovda, David; Whalen, Michael; Ahlers, Stephen T.; LaPlaca, Michelle; Tortella, Frank C.; Duhaime, Ann-Christine; Dixon, C. Edward			Pre-Clinical Traumatic Brain Injury Common Data Elements: Toward a Common Language Across Laboratories	JOURNAL OF NEUROTRAUMA			English	Article						common data elements; data dictionary; pre-clinical TBI models; traumatic brain injury	DIFFUSE AXONAL INJURY; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; ACUTE SUBDURAL-HEMATOMA; ADULT-RAT BRAIN; FLUID-PERCUSSION MODEL; LASTING IMPULSE NOISE; ALZHEIMERS-DISEASE; INTRACRANIAL-PRESSURE	Traumatic brain injury (TBI) is a major public health issue exacting a substantial personal and economic burden globally. With the advent of big data approaches to understanding complex systems, there is the potential to greatly accelerate knowledge about mechanisms of injury and how to detect and modify them to improve patient outcomes. High quality, well-defined data are critical to the success of bioinformatics platforms, and a data dictionary of common data elements (CDEs), as well as unique data elements has been created for clinical TBI research. There is no data dictionary, however, for preclinical TBI research despite similar opportunities to accelerate knowledge. To address this gap, a committee of experts was tasked with creating a defined set of data elements to further collaboration across laboratories and enable the merging of data for meta-analysis. The CDEs were subdivided into a Core module for data elements relevant to most, if not all, studies, and Injury-Model-Specific modules for non-generalizable data elements. The purpose of this article is to provide both an overview of TBI models and the CDEs pertinent to these models to facilitate a common language for preclinical TBI research.	[Smith, Douglas H.; Johnson, Victoria E.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Hicks, Ramona R.] One Mind, Seattle, WA USA; [Hicks, Ramona R.; Bergstrom, Debra A.; Cummings, Diana M.] NINDS, NIH, Bethesda, MD 20892 USA; [Noble, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hovda, David] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA; [Whalen, Michael] Massachusetts Gen Hosp, Dept Pediat, Ctr Neurosci, Charlestown, MA USA; [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA; [LaPlaca, Michelle] Georgia Tech, Dept Biomed Engn, Atlanta, GA USA; [LaPlaca, Michelle] Emory Univ, Atlanta, GA 30322 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Duhaime, Ann-Christine] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu			U.S. Department of DefenseUnited States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767] Funding Source: NIH RePORTER	We would like to acknowledge the U.S. Department of Defense and the National Institutes of Health who contributed funding for The Federal Interagency Traumatic Brain Injury Research (FIT-BIR) Informatics System.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Balikci M, 2008, NEUROL RES, V30, P450, DOI 10.1179/016164107X251637; Barbiro-Micahely E, 2001, J NEUROTRAUM, V18, P711, DOI 10.1089/089771501750357654; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BOTEL C, 1994, J EXP ANIM SCI, V36, P78; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dirnagl U, 2010, J CEREBR BLOOD F MET, V30, P1263, DOI 10.1038/jcbfm.2010.51; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Ebmeyer U, 1998, J NEUROTRAUM, V15, P323, DOI 10.1089/neu.1998.15.323; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FITCH W, 1977, J NEUROL NEUROSUR PS, V40, P843, DOI 10.1136/jnnp.40.9.843; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GANZ JC, 1988, ACTA NEUROCHIR, V95, P72, DOI 10.1007/BF01793086; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham D.I., 2002, GREENFIELDS NEUROPAT; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grimmelt AC, 2011, CENT EUR NEUROSURG, V72, P120, DOI 10.1055/s-0031-1271732; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAUERBERG J, 1994, J CEREBR BLOOD F MET, V14, P519, DOI 10.1038/jcbfm.1994.64; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Janda M, 2012, LAB ANIM-UK, V46, P258, DOI 10.1258/la.2011.011149; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; JOHNSTON IH, 1973, J NEUROL NEUROSUR PS, V36, P161, DOI 10.1136/jnnp.36.2.161; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Knight J, 2003, NATURE, V422, P554, DOI 10.1038/422554a; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lemmon VP, 2014, J NEUROTRAUM, V31, P1354, DOI 10.1089/neu.2014.3400; Leung LY, 2014, ANN BIOMED ENG, V42, P1618, DOI 10.1007/s10439-014-1014-8; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; MALKINSON TJ, 1985, BRAIN RES BULL, V15, P321, DOI 10.1016/0361-9230(85)90158-3; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Missios S, 2009, J NEUROTRAUM, V26, P1943, DOI [10.1089/neu.2009.0956, 10.1089/neu.2009-0956]; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mueller CA, 2007, EXP NEUROL, V208, P228, DOI 10.1016/j.expneurol.2007.07.020; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Institute of Neurological Disorders and Stroke, NINDS COMM DAT EL TR; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; NITTA M, 1990, ACTA NEUROCHIR, V104, P30, DOI 10.1007/BF01842890; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Phillips Y. I., 1991, CONVENTIONAL WARFARE; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryan JB, 2003, J HEART LUNG TRANSPL, V22, P922, DOI 10.1016/S1053-2498(02)00558-2; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Sapsford W, 2003, J R Army Med Corps, V149, P5; Sasaki M, 2001, J NEUROTRAUM, V18, P1241, DOI 10.1089/089771501317095278; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHALIT MN, 1974, J NEUROSURG, V40, P594, DOI 10.3171/jns.1974.40.5.0594; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Tsai M L, 1988, Chin J Physiol, V31, P113; TSUCHIDA E, 1995, J NEUROTRAUM, V12, P279, DOI 10.1089/neu.1995.12.279; Wang D, 2010, J NEUROTRAUM, V27, P1489, DOI 10.1089/neu.2009.1057; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang J, 2008, EXP NEUROL, V210, P645, DOI 10.1016/j.expneurol.2007.12.019; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	131	53	53	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1725	1735		10.1089/neu.2014.3861			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500003	26058402	Green Published			2021-06-18	
J	Bossers, SM; Schwarte, LA; Loer, SA; Twisk, JWR; Boer, C; Schober, P				Bossers, Sebastiaan M.; Schwarte, Lothar A.; Loer, Stephan A.; Twisk, Jos W. R.; Boer, Christa; Schober, Patrick			Experience in Prehospital Endotracheal Intubation Significantly Influences Mortality of Patients with Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							RAPID-SEQUENCE INTUBATION; GLASGOW COMA SCALE; HEAD-INJURY; YOUNG-PEOPLE; FOLLOW-UP; IMPACT; MANAGEMENT; MODERATE; OUTCOMES; FIELD	Background Patients with severe traumatic brain injury (TBI) are at high risk for airway obstruction and hypoxia at the accident scene, and routine prehospital endotracheal intubation has been widely advocated. However, the effects on outcome are unclear. We therefore aim to determine effects of prehospital intubation on mortality and hypothesize that such effects may depend on the emergency medical service providers' skill and experience in performing this intervention. Methods and Findings PubMed, Embase and Web of Science were searched without restrictions up to July 2015. Studies comparing effects of prehospital intubation versus non-invasive airway management on mortality in non-paediatric patients with severe TBI were selected for the systematic review. Results were pooled across a subset of studies that met predefined quality criteria. Random effects meta-analysis, stratified by experience, was used to obtain pooled estimates of the effect of prehospital intubation on mortality. Meta-regression was used to formally assess differences between experience groups. Mortality was the main outcome measure, and odds ratios refer to the odds of mortality in patients undergoing prehospital intubation versus odds of mortality in patients who are not intubated in the field. The study was registered at the International Prospective Register of Systematic Reviews (PROSPERO) with number CRD42014015506. The search provided 733 studies, of which 6 studies including data from 4772 patients met inclusion and quality criteria for the meta-analysis. Prehospital intubation by providers with limited experience was associated with an approximately twofold increase in the odds of mortality (OR 2.33, 95% CI 1.61 to 3.38, p<0.001). In contrast, there was no evidence for higher mortality in patients who were intubated by providers with extended level of training (OR 0.75, 95% CI 0.52 to 1.08, p = 0.126). Metaregression confirmed that experience is a significant predictor of mortality (p = 0.009). Conclusions Effects of prehospital endotracheal intubation depend on the experience of prehospital healthcare providers. Intubation by paramedics who are not well skilled to do so markedly increases mortality, suggesting that routine prehospital intubation of TBI patients should be abandoned in emergency medical services in which providers do not have ample training, skill and experience in performing this intervention.	[Bossers, Sebastiaan M.; Schwarte, Lothar A.; Loer, Stephan A.; Boer, Christa; Schober, Patrick] Vrije Univ Amsterdam, Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Schwarte, Lothar A.; Schober, Patrick] Vrije Univ Amsterdam, Med Ctr, Helicopter Emergency Med Serv Lifeliner 1, Amsterdam, Netherlands; [Twisk, Jos W. R.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Boer, Christa] Vrije Univ Amsterdam, Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands	Schober, P (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands.	p.schober@vumc.nl	Bossers, Sebastiaan/AAE-1085-2020; Schober, Patrick/G-7400-2012	Bossers, Sebastiaan/0000-0002-2396-2777; Schober, Patrick/0000-0003-0814-081X; Boer, Christa/0000-0002-7781-6951	Dutch Brain Foundation [F2010(1)-14]	This article was funded by the Dutch Brain Foundation, project number F2010(1)-14 (https://www.hersenstichting.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Blyth A, 2014, BMJ-BRIT MED J, P348; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; BOIDIN MP, 1985, BRIT J ANAESTH, V57, P306, DOI 10.1093/bja/57.3.306; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bukur M, 2011, J SURG RES, V170, pE117, DOI 10.1016/j.jss.2011.04.005; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; Hammell CL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1683; Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Humphries RL, 2008, CURRENT DIAGNOSIS TR, P313; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; Irvin CB, 2010, PREHOSP DISASTER MED, V25, P541, DOI 10.1017/S1049023X00008736; Karamanos E, 2014, PREHOSP DISASTER MED, V29, P32, DOI 10.1017/S1049023X13008947; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; SAFAR P, 1959, J APPL PHYSIOL, V14, P760; Salomone JP, 2008, TRAUMA, P121; SINGBARTL G, 1985, ANASTH INTENSIV NOTF, V20, P251, DOI 10.1055/s-2007-1003119; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tuma M, 2014, CRIT CARE RES PRACT, V2014, DOI 10.1155/2014/135986; Tuominen R, 2012, BRAIN INJURY, V26, P1697, DOI 10.3109/02699052.2012.722256; Vandromme MJ, 2011, J TRAUMA, V71, P1615, DOI 10.1097/TA.0b013e31822a30a1; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2014, EMERG MED J, V31, P186, DOI 10.1136/emermed-2012-202101; Wells GA., NEWCASTLE OTTAWA SCA; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	59	53	54	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2015	10	10							e0141034	10.1371/journal.pone.0141034			26	Multidisciplinary Sciences	Science & Technology - Other Topics	CU1VG	WOS:000363309200054	26496440	DOAJ Gold, Green Published			2021-06-18	
J	Rabinowitz, AR; Li, XQ; McCauley, SR; Wilde, EA; Barnes, A; Hanten, G; Mendez, D; McCarthy, JJ; Levin, HS				Rabinowitz, Amanda R.; Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Mendez, Donna; McCarthy, James J.; Levin, Harvey S.			Prevalence and Predictors of Poor Recovery from Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; human studies; recovery; traumatic brain injury	POST-CONCUSSION SYMPTOMS; SPORTS-RELATED CONCUSSION; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; COGNITIVE RESERVE; OLDER-ADULTS; PRACTICAL SCALE; OUTCOMES; DISORDER; SEX	Although most patients with mild traumatic brain injury (mTBI) recover within 3 months, a subgroup of patients experience persistent symptoms. Yet, the prevalence and predictors of persistent dysfunction in patients with mTBI remain poorly understood. In a longitudinal study, we evaluated predictors of symptomatic and cognitive dysfunction in adolescents and young adults with mTBI, compared with two control groupspatients with orthopedic injuries and healthy uninjured individuals. Outcomes were assessed at 3 months post-injury. Poor symptomatic outcome was defined as exhibiting a symptom score higher than 90% of the orthopedic control (OC) group, and poor cognitive outcome was defined as exhibiting cognitive performance poorer than 90% of the OC group. At 3 months post-injury, more than half of the patients with mTBI (52%) exhibited persistently elevated symptoms, and more than a third (36.4%) exhibited poor cognitive outcome. The rate of high symptom report in mTBI was markedly greater than that of typically developing (13%) and OC (17%) groups; the proportion of those with poor cognitive performance in the mTBI group exceeded that of typically developing controls (15.8%), but was similar to that of the OC group (34.9%). Older age at injury, female sex, and acute symptom report were predictors of poor symptomatic outcome at 3 months. Socioeconomic status was the only significant predictor of poor cognitive outcome at 3 months.	[Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.; Barnes, Amanda; Hanten, Gerri; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Mendez, Donna; McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA	Rabinowitz, AR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Goddard Labs 306, 3710 Hamilton Walk, Philadelphia, PA 19104 USA.	rabinowitz.a@gmail.com	Meijer, Anna/K-5118-2016		P01 [NS056202]; Department of Veterans AffairsUS Department of Veterans Affairs [B6812C]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This project was supported by P01 Grant NS056202 (PI: Douglas Smith, M.D.). H.L., S.M., and E.W. were also supported by the Department of Veterans Affairs Grant B6812C "Neurorehabilitation: Neurons to Networks (N:N2N) Center of Excellence."	Arnold C, 2014, LANCET NEUROL, V13, P136, DOI 10.1016/S1474-4422(13)70287-4; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R.H.B, 1997, BRIEF VISUAL MEMORY; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Derogatis L. R., 1993, BSI BRIEF SYMPTOM IN; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Hanten G, 2013, J NEUROTRAUM, V30, P618, DOI 10.1089/neu.2012.2392; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith A., 1982, SYMBOL DIGIT MODALIT; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	61	53	53	1	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1488	1496		10.1089/neu.2014.3555			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500007	25970233	Green Published			2021-06-18	
J	Shi, H; Hu, XM; Leak, RK; Shi, YJ; An, CR; Suenaga, J; Chen, J; Gao, YQ				Shi, Hong; Hu, Xiaoming; Leak, Rehana K.; Shi, Yejie; An, Chengrui; Suenaga, Jun; Chen, Jun; Gao, Yanqin			Demyelination as a rational therapeutic target for ischemic or traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Demyelination; Oligodendrocyte; Remyelination; Cerebral ischemia; Traumatic brain injury	OLIGODENDROCYTE PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; RECEPTOR/IL-6 FUSION PROTEIN; SPINAL-CORD-INJURY; MITOCHONDRIAL DYSFUNCTION; MULTIPLE-SCLEROSIS	Previous research on stroke and traumatic brain injury (TBI) heavily emphasized pathological alterations in neuronal cells within gray matter. However, recent studies have highlighted the equal importance of white matter integrity in long-term recovery from these conditions. Demyelination is a major component of white matter injury and is characterized by loss of the myelin sheath and oligodendrocyte cell death. Demyelination contributes significantly to long-term sensorimotor and cognitive deficits because the adult brain only has limited capacity for oligodendrocyte regeneration and axonal remyelination. In the current review, we will provide an overview of the major causes of demyelination and oligodendrocyte cell death following acute brain injuries, and discuss the crosstalk between myelin, axons, microglia, and astrocytes during the process of demyelination. Recent discoveries of molecules that regulate the processes of remyelination may provide novel therapeutic targets to restore white matter integrity and improve long-term neurological recovery in stroke or TBI patients. (C) 2015 Elsevier Inc. All rights reserved.	[Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Inst Brain Sci, Shanghai 200032, Peoples R China; [Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China; [Shi, Hong] Tongji Univ, Shanghai Pulm Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China; [Hu, Xiaoming; Shi, Yejie; Suenaga, Jun; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA; [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Hu, Xiaoming; Shi, Yejie; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA	Chen, J (corresponding author), Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, 3500 Terrace St, Pittsburgh, PA 15213 USA.	chenj2@upmc.edu; yqgao@shmu.edu.cn	Gao, Yanqin/I-6790-2016; Shi, Yejie/C-2355-2018; Leak, Rehana K/I-2607-2019	Gao, Yanqin/0000-0002-4915-9819; Shi, Yejie/0000-0001-7502-9201; Leak, Rehana K/0000-0003-2817-7417	Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [14ZR1434600]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171149, 81371306, 81228008]; Shanghai Committee of Science and Technology Research Program [14431907002]; American Heart Association Scientist DevelopmentAmerican Heart Association [13SDG14570025]; Doctoral Training Fund from the Chinese Ministry of EducationMinistry of Education, China [20120071110042]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36736, NS43802, NS45048, NS089534]; Department of Veterans Affairs Research Career Scientist Award and RR D Merit ReviewUS Department of Veterans Affairs [1l01IX000420]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043802, R01NS045048, R01NS089534, R01NS095029, R01NS036736] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000420] Funding Source: NIH RePORTER	This work was supported by the Natural Science Foundation of Shanghai grant 14ZR1434600 (to H.S.), the Natural Science Foundation of China grants 81171149 and 81371306 (to Y.G.), and 81228008 (to J.C.), the Shanghai Committee of Science and Technology Research Program 14431907002 (to Y.G.), the American Heart Association Scientist Development grant 13SDG14570025 (to X.H.), Doctoral Training Fund from the Chinese Ministry of Education 20120071110042 (to J.C.), NIH/NINDS grants NS36736, NS43802, NS45048 and NS089534 (to J.C.), and the Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review 1l01IX000420 (to J.C.).	Al-Saktawi K, 2003, J NEUROSCI RES, V72, P12, DOI 10.1002/jnr.10561; Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; Amaral Ana I, 2013, Front Endocrinol (Lausanne), V4, P54, DOI 10.3389/fendo.2013.00054; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Babayan AH, 2012, J NEUROSCI, V32, P12854, DOI 10.1523/JNEUROSCI.2024-12.2012; Back SA, 2007, J CEREBR BLOOD F MET, V27, P334, DOI 10.1038/sj.jcbfm.9600344; Bakiri Y, 2008, GLIA, V56, P233, DOI 10.1002/glia.20608; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Baxter P, 2014, TRANSL STROKE RES, V5, P136, DOI 10.1007/s12975-013-0283-0; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Bendlin BB, 2010, ALZHEIMERS DEMENT, V6, P394, DOI 10.1016/j.jalz.2009.11.003; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1; Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Butt AM, 2006, GLIA, V54, P666, DOI 10.1002/glia.20424; Caprariello AV, 2012, ANN NEUROL, V72, P395, DOI 10.1002/ana.23606; Carvalho KS, 2013, SEMIN PEDIATR NEUROL, V20, P194, DOI 10.1016/j.spen.2013.09.001; Cayre M, 2013, DEVELOPMENT, V140, P3107, DOI 10.1242/dev.092999; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chen DD, 2014, TRANSL STROKE RES, V5, P156, DOI 10.1007/s12975-013-0320-z; Chew LJ, 2005, GLIA, V52, P127, DOI 10.1002/glia.20232; Chu Min, 2012, Front Biosci (Elite Ed), V4, P1926; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Courtes S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020430; Curatolo L, 1997, CYTOKINE, V9, P734, DOI 10.1006/cyto.1997.0228; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deng YY, 2010, BRAIN PATHOL, V20, P909, DOI 10.1111/j.1750-3639.2010.00387.x; Deng YY, 2008, BRAIN PATHOL, V18, P387, DOI 10.1111/j.1750-3639.2008.00138.x; Deoni SCL, 2011, J NEUROSCI, V31, P784, DOI 10.1523/JNEUROSCI.2106-10.2011; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Domercq M, 2005, GLIA, V52, P36, DOI 10.1002/glia.20221; Domercq M, 2013, GLIA, V61, P383, DOI 10.1002/glia.22441; Douaud G, 2011, NEUROIMAGE, V55, P880, DOI 10.1016/j.neuroimage.2010.12.008; Duncan ID, 2009, P NATL ACAD SCI USA, V106, P6832, DOI 10.1073/pnas.0812500106; Edgar JM, 2010, EMBO MOL MED, V2, P42, DOI 10.1002/emmm.200900057; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; El Waly B, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00145; Emery B, 2010, SCIENCE, V330, P779, DOI 10.1126/science.1190927; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fern RF, 2014, GLIA, V62, P1780, DOI 10.1002/glia.22722; Fischer R, 2014, GLIA, V62, P272, DOI 10.1002/glia.22605; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Gillum RF, 2011, STROKE, V42, P3294, DOI 10.1161/STROKEAHA.111.625343; Girard C, 2005, J NEUROSCI, V25, P7924, DOI 10.1523/JNEUROSCI.4890-04.2005; Gold BT, 2012, BBA-MOL BASIS DIS, V1822, P416, DOI 10.1016/j.bbadis.2011.07.009; Gold BT, 2010, NEUROIMAGE, V52, P1487, DOI 10.1016/j.neuroimage.2010.05.036; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hovelmeyer N, 2005, J IMMUNOL, V175, P5875, DOI 10.4049/jimmunol.175.9.5875; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hu YZ, 2011, HUM BRAIN MAPP, V32, P10, DOI 10.1002/hbm.20996; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jepson S, 2012, J BIOL CHEM, V287, P22184, DOI 10.1074/jbc.M112.366179; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karimi-Abdolrezaee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037589; Kassmann CM, 2014, BIOCHIMIE, V98, P111, DOI 10.1016/j.biochi.2013.09.020; Kaur C, 2009, PROG NEUROBIOL, V87, P264, DOI 10.1016/j.pneurobio.2009.01.003; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim S, 2011, J NEUROCHEM, V116, P53, DOI 10.1111/j.1471-4159.2010.07084.x; Kleinsimlinghaus K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00277; Kolodziejczyk Karolina, 2010, F1000 Biol Rep, V2, P57, DOI 10.3410/B2-57; Kong YH, 2014, INTERD T GERONT GERI, V39, P86, DOI 10.1159/000358901; Kostic M, 2013, REV NEUROSCIENCE, V24, P71, DOI 10.1515/revneuro-2012-0062; Kouhsar SS, 2011, BRAIN RES, V1392, P93, DOI 10.1016/j.brainres.2011.03.038; Koutsoudaki PN, 2010, NEUROSCIENCE, V171, P235, DOI 10.1016/j.neuroscience.2010.08.070; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lara-Ramirez R, 2008, NEUROSCIENCE, V152, P601, DOI 10.1016/j.neuroscience.2008.01.014; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Li JR, 2008, J NEUROSCI, V28, P5321, DOI 10.1523/JNEUROSCI.3995-07.2008; Li WW, 2005, J NEUROIMMUNOL, V158, P58, DOI 10.1016/j.jneuroim.2004.08.011; Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086; Lisak RP, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-4; Long P, 2014, SCIENCE, V346, P298, DOI 10.1126/science.1261127; Mahad D, 2008, NEUROPATH APPL NEURO, V34, P577, DOI 10.1111/j.1365-2990.2008.00987.x; Maier O, 2013, BIOCHEM BIOPH RES CO, V440, P336, DOI 10.1016/j.bbrc.2013.09.083; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mato S, 2013, GLIA, V61, P750, DOI 10.1002/glia.22470; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Matute C, 2011, J ANAT, V219, P53, DOI 10.1111/j.1469-7580.2010.01339.x; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McKenzie IA, 2014, SCIENCE, V346, P318, DOI 10.1126/science.1254960; McLaughlin B, 2013, TRANSL STROKE RES, V4, P104, DOI 10.1007/s12975-012-0240-3; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 1998, J NEUROSCI, V18, P5354; Menichella DM, 2006, J NEUROSCI, V26, P10984, DOI 10.1523/JNEUROSCI.0304-06.2006; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Mi S, 2013, CNS DRUGS, V27, P493, DOI 10.1007/s40263-013-0068-8; Mi S, 2009, ANN NEUROL, V65, P304, DOI 10.1002/ana.21581; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Miron VE, 2011, BBA-MOL BASIS DIS, V1812, P184, DOI 10.1016/j.bbadis.2010.09.010; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Morrison BM, 2013, TRENDS CELL BIOL, V23, P644, DOI 10.1016/j.tcb.2013.07.007; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Orthmann-Murphy JL, 2007, J NEUROSCI, V27, P13949, DOI 10.1523/JNEUROSCI.3395-07.2007; Owens K, 2013, TRANSL STROKE RES, V4, P618, DOI 10.1007/s12975-013-0278-x; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pham LDD, 2012, GLIA, V60, P875, DOI 10.1002/glia.22320; Piaton G, 2011, BRAIN, V134, P1156, DOI 10.1093/brain/awr022; Pizzi M, 2004, MOL CELL NEUROSCI, V25, P301, DOI 10.1016/j.mcn.2003.10.022; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plemel JR, 2014, PROG NEUROBIOL, V117, P54, DOI 10.1016/j.pneurobio.2014.02.006; Pusic AD, 2014, J NEUROIMMUNOL, V266, P12, DOI 10.1016/j.jneuroim.2013.10.014; Rash JE, 2010, NEUROSCIENCE, V168, P982, DOI 10.1016/j.neuroscience.2009.10.028; Richardson WD, 2011, NEURON, V70, P661, DOI 10.1016/j.neuron.2011.05.013; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Rodgers JM, 2015, GLIA, V63, P768, DOI 10.1002/glia.22783; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ruiz A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.31; Saab AS, 2013, CURR OPIN NEUROBIOL, V23, P1065, DOI 10.1016/j.conb.2013.09.008; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Scafidi J, 2014, NATURE, V506, P230, DOI 10.1038/nature12880; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; See JM, 2009, J NEUROPATH EXP NEUR, V68, P595, DOI 10.1097/NEN.0b013e3181a66ad9; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Shereen A, 2011, J CEREBR BLOOD F MET, V31, P1155, DOI 10.1038/jcbfm.2010.212; Shibata M, 2007, STROKE, V38, P2826, DOI 10.1161/STROKEAHA.107.490151; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Siebert JR, 2011, EXP NEUROL, V231, P19, DOI 10.1016/j.expneurol.2011.05.002; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Smith CD, 2010, NEUROBIOL AGING, V31, P1122, DOI 10.1016/j.neurobiolaging.2008.08.006; Song MK, 2014, TRANSL STROKE RES, V5, P17, DOI 10.1007/s12975-013-0314-x; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; Syed YA, 2011, J NEUROSCI, V31, P3719, DOI 10.1523/JNEUROSCI.4930-10.2011; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Tong XP, 2009, J CELL BIOL, V186, P113, DOI 10.1083/jcb.200811071; Trapp BD, 2009, LANCET NEUROL, V8, P280, DOI 10.1016/S1474-4422(09)70043-2; Tress O, 2012, J NEUROSCI, V32, P7499, DOI 10.1523/JNEUROSCI.0392-12.2012; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; van Horssen J, 2012, MULT SCLER J, V18, P1058, DOI 10.1177/1352458512452924; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Volpe JJ, 2011, ANN NEUROL, V70, P525, DOI 10.1002/ana.22533; Wake H, 2011, SCIENCE, V333, P1647, DOI 10.1126/science.1206998; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang LW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0215-2; Whittaker MT, 2012, GLIA, V60, P281, DOI 10.1002/glia.21262; Windrem MS, 2008, CELL STEM CELL, V2, P553, DOI 10.1016/j.stem.2008.03.020; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Woodruff RH, 2004, MOL CELL NEUROSCI, V25, P252, DOI 10.1016/j.mcn.2003.10.014; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yoshizaki K, 2008, EXP NEUROL, V210, P585, DOI 10.1016/j.expneurol.2007.12.005; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YT, 2006, J NEUROSCI, V26, P12174, DOI 10.1523/JNEUROSCI.2289-06.2006; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	177	53	56	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		17	25		10.1016/j.expneurol.2015.03.017			9	Neurosciences	Neurosciences & Neurology	CV6AS	WOS:000364353700004	25819104	Green Accepted			2021-06-18	
J	Zehendner, CM; Sebastiani, A; Hugonnet, A; Bischoff, F; Luhmann, HJ; Thal, SC				Zehendner, Christoph M.; Sebastiani, Anne; Hugonnet, Andre; Bischoff, Florian; Luhmann, Heiko J.; Thal, Serge C.			Traumatic brain injury results in rapid pericyte loss followed by reactive pericytosis in the cerebral cortex	SCIENTIFIC REPORTS			English	Article							BARRIER; RECEPTOR; HEALTH; CELLS; KEY	Accumulating evidence suggests a pivotal role of PDGFR beta positive cells, a specific marker for central nervous system (CNS) pericytes, in tissue scarring. Identification of cells that contribute to tissue reorganization in the CNS upon injury is a crucial step to develop novel treatment strategies in regenerative medicine. It has been shown that pericytes contribute to scar formation in the spinal cord. It is further known that ischemia initially triggers pericyte loss in vivo, whilst brain trauma is capable of inducing pericyte detachment from cerebral vessels. These data point towards a significant role of pericytes in CNS injury. The temporal and spatial dynamics of PDGFR beta cells and their responses in traumatic brain injury are poorly understood. Here we show that PDGFR beta positive cells initially decline in the acute phase following experimental traumatic brain injury. However, PDGFR beta positive cells increase significantly in the trauma zone days after brain injury. Using various pericyte markers we identify these cells to be pericytes that are demarcated by reactive gliosis. Our data indicate that brain trauma causes a biphasic response of pericytes in the early phase of brain trauma that may be of relevance for the understanding of pathological cellular responses in traumatic brain injury.	[Zehendner, Christoph M.; Luhmann, Heiko J.] Johannes Gutenberg Univ Mainz, Inst Physiol, Univ Med Ctr, D-55122 Mainz, Germany; [Sebastiani, Anne; Hugonnet, Andre; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, D-55122 Mainz, Germany	Zehendner, CM (corresponding author), Goethe Univ Frankfurt, Inst Cardiovasc Regenerat, Dept Cardiol, ZIM 3, Frankfurt, Germany.	zehendner@med.uni-frankfurt.de; thal@uni-mainz.de	Luhmann, Heiko J./N-8797-2019; Thal, Serge/D-6593-2011	Luhmann, Heiko J./0000-0002-7934-8661; Thal, Serge/0000-0002-1222-8729	Johannes Gutenberg-University of Mainz; ECCPS clinical career grant (DFG)German Research Foundation (DFG); LOEWE Cell and Gene Therapy grant (State of Hesse); Goethe University Frankfurt; DFGGerman Research Foundation (DFG)European Commission [SFB 834]	We thank Beate Krumm for excellent technical assistance. This study was supported by DFG grants to HJL and SCT. CMZ received support from: the Johannes Gutenberg-University of Mainz (Start up grant), ECCPS clinical career grant (DFG), LOEWE Cell and Gene Therapy grant (State of Hesse) and a start up grant from the Goethe University Frankfurt. FB is supported by a scholarship of the DFG (SFB 834). We thank the IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB) in Mainz for confocal image acquisition.	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Birbrair A, 2013, AM J PHYSIOL-CELL PH, V305, pC1098, DOI 10.1152/ajpcell.00171.2013; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Chintalgattu V, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005066; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Fernandez-Klett F, 2013, J CEREBR BLOOD F MET, V33, P428, DOI 10.1038/jcbfm.2012.187; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Karow M, 2013, BIOESSAYS, V35, P771, DOI 10.1002/bies.201300055; Karow M, 2012, CELL STEM CELL, V11, P471, DOI 10.1016/j.stem.2012.07.007; Krueger M, 2010, GLIA, V58, P1, DOI 10.1002/glia.20898; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Shen J, 2012, J CEREBR BLOOD F MET, V32, P353, DOI 10.1038/jcbfm.2011.136; Sixt M, 2001, J CELL BIOL, V153, P933, DOI 10.1083/jcb.153.5.933; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Timaru-Kast R, 2015, J NEUROTRAUM, V32, P1777, DOI 10.1089/neu.2014.3784; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022; Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081637; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	31	53	53	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 3	2015	5								13497	10.1038/srep13497			9	Multidisciplinary Sciences	Science & Technology - Other Topics	CQ3VW	WOS:000360533000001	26333872	DOAJ Gold, Green Published			2021-06-18	
J	Sullivan, S; Eucker, SA; Gabrieli, D; Bradfield, C; Coats, B; Maltese, MR; Lee, J; Smith, C; Margulies, SS				Sullivan, Sarah; Eucker, Stephanie A.; Gabrieli, David; Bradfield, Connor; Coats, Brittany; Maltese, Matthew R.; Lee, Jongho; Smith, Colin; Margulies, Susan S.			White matter tract-oriented deformation predicts traumatic axonal brain injury and reveals rotational direction-specific vulnerabilities	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; Finite element modeling; Porcine; Pediatric; Sports-related head injury; Diffusion tensor imaging	CENTRAL-NERVOUS-SYSTEM; FINITE-ELEMENT MODEL; HEAD-INJURY; MECHANICAL CHARACTERIZATION; PROFESSIONAL FOOTBALL; IN-VITRO; STRAIN; TISSUE; IMPACTS; BIOMECHANICS	A systematic correlation between finite element models (FEMs) and histopathology is needed to define deformation thresholds associated with traumatic brain injury (TBI). In this study, a FEM of a transected piglet brain was used to reverse engineer the range of optimal shear moduli for infant (5 days old, 553-658 Pa) and 4-week-old toddler piglet brain (692-811 Pa) from comparisons with measured in situ tissue strains. The more mature brain modulus was found to have significant strain and strain rate dependencies not observed with the infant brain. Age-appropriate FEMs were then used to simulate experimental TBI in infant () and preadolescent () piglets undergoing a range of rotational head loads. The experimental animals were evaluated for the presence of clinically significant traumatic axonal injury (TAI), which was then correlated with FEM-calculated measures of overall and white matter tract-oriented tissue deformations, and used to identify the metric with the highest sensitivity and specificity for detecting TAI. The best predictors of TAI were the tract-oriented strain (6-7 %), strain rate (38-40 s, and strain times strain rate (1.3-1.8 s values exceeded by 90 % of the brain. These tract-oriented strain and strain rate thresholds for TAI were comparable to those found in isolated axonal stretch studies. Furthermore, we proposed that the higher degree of agreement between tissue distortion aligned with white matter tracts and TAI may be the underlying mechanism responsible for more severe TAI after horizontal and sagittal head rotations in our porcine model of nonimpact TAI than coronal plane rotations.	[Sullivan, Sarah; Gabrieli, David; Bradfield, Connor; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Eucker, Stephanie A.] Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC 27710 USA; [Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; [Maltese, Matthew R.] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Lee, Jongho] Seoul Natl Univ, Dept Elect & Comp Engn, Seoul, South Korea; [Smith, Colin] Univ Edinburgh, Ctr Clin Brain Sci, Acad Dept Neuropathol, Edinburgh, Midlothian, Scotland	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773; Smith, Colin/0000-0002-4507-5132	Department of Transportation-National Highway Transportation and Safety Administration [DTNH 22-07-H-00088]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; American Heart AssociationAmerican Heart Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS039679] Funding Source: NIH RePORTER	We gratefully acknowledge support from the Department of Transportation-National Highway Transportation and Safety Administration (DTNH 22-07-H-00088), the National Institutes of Health (R01 NS39679), and the American Heart Association. We also acknowledge the work of Sohaib Hashmi, Nicole Ibrahim, and Jesse Jiang in the development of the finite element models and DTI image processing.	Anderson Andrew E., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P171, DOI 10.1080/10255840601160484; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chatelin S, 2012, J MECH BEHAV BIOMED, V6, P166, DOI 10.1016/j.jmbbm.2011.09.013; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Eucker S A, 2009, THESIS U PENNSYLVANI; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Fung Y, 1994, 1 COURSE CONTINUUM M; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lamy M, 2013, MED BIOL ENG COMPUT, V51, P353, DOI 10.1007/s11517-012-1004-7; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Maltese MR, 2012, TRAUMATIC BRAIN INJU; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Ogden R.W., 1984, NONLINEAR ELASTIC DE; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Patton DA, 2013, J APPL BIOMECH, V29, P721, DOI 10.1123/jab.29.6.721; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prabhu R, 2011, J MECH BEHAV BIOMED, V4, P1067, DOI 10.1016/j.jmbbm.2011.03.015; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rashid B, 2013, J MECH BEHAV BIOMED, V28, P71, DOI 10.1016/j.jmbbm.2013.07.017; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Sahoo D, 2013, COMPUT METHOD BIOMEC, V16, P198, DOI 10.1080/10255842.2013.815908; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singh A, 2009, J NEUROTRAUM, V26, P627, DOI 10.1089/neu.2008.0621; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Traumatic brain injury in the United States, 2010, EM DEP VIS HOSP DEAT; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang L, 2001, Stapp Car Crash J, V45, P369	62	53	53	1	8	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2015	14	4					877	896		10.1007/s10237-014-0643-z			20	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CL9ZZ	WOS:000357339300014	25547650	Green Accepted			2021-06-18	
J	Trotter, BB; Robinson, ME; Milberg, WP; McGlinchey, RE; Salat, DH				Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.			Military blast exposure, ageing and white matter integrity	BRAIN			English	Article						CNS injury; imaging; concussion; traumatic brain injury; neuropathology; axon degeneration	TRAUMATIC BRAIN-INJURY; REDUCED CORTICAL THICKNESS; AGE-RELATED-CHANGES; DIFFUSION-TENSOR; FRACTIONAL ANISOTROPY; COGNITIVE IMPAIRMENT; HEAD-INJURY; INDUCED NEUROTRAUMA; SPATIAL STATISTICS; ALZHEIMERS-DISEASE	Mild traumatic brain injury, or concussion, is associated with a range of neural changes including altered white matter structure. There is emerging evidence that blast exposure-one of the most pervasive causes of casualties in the recent overseas conflicts in Iraq and Afghanistan-is accompanied by a range of neurobiological events that may result in pathological changes to brain structure and function that occur independently of overt concussion symptoms. The potential effects of brain injury due to blast exposure are of great concern as a history of mild traumatic brain injury has been identified as a risk factor for age-associated neurodegenerative disease. The present study used diffusion tensor imaging to investigate whether military-associated blast exposure influences the association between age and white matter tissue structure integrity in a large sample of veterans of the recent conflicts (n = 190 blast-exposed; 59 without exposure) between the ages of 19 and 62 years. Tract-based spatial statistics revealed a significant blast exposure x age interaction on diffusion parameters with blast-exposed individuals exhibiting a more rapid cross-sectional age trajectory towards reduced tissue integrity. Both distinct and overlapping voxel clusters demonstrating the interaction were observed among the examined diffusion contrast measures (e.g. fractional anisotropy and radial diffusivity). The regions showing the effect on fractional anisotropy included voxels both within and beyond the boundaries of the regions exhibiting a significant negative association between fractional anisotropy and age in the entire cohort. The regional effect was sensitive to the degree of blast exposure, suggesting a 'dose-response' relationship between the number of blast exposures and white matter integrity. Additionally, there was an age-independent negative association between fractional anisotropy and years since most severe blast exposure in a subset of the blast-exposed group, suggesting a specific influence of time since exposure on tissue structure, and this effect was also independent of post-traumatic stress symptoms. Overall, these data suggest that blast exposure may negatively affect brain-ageing trajectories at the microstructural tissue level. Additional work examining longitudinal changes in brain tissue integrity in individuals exposed to military blast forces will be an important future direction to the initial findings presented here.	[Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Translat Res Ctr Traumat Brain Injury & Stress Di, RR&TBI Ctr Excellence, Boston, MA 02130 USA; [Trotter, Benjamin B.; Robinson, Meghan E.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA 02130 USA; [Trotter, Benjamin B.; Robinson, Meghan E.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA; [Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA; [Salat, David H.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA	Salat, DH (corresponding author), VA Boston Healthcare Syst, 182 JP 150 S Huntington Ave, Boston, MA 02130 USA.	salat@nmr.mgh.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR010827]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AT009430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR010827] Funding Source: NIH RePORTER	This work was supported by funding from the Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence; Contract grant number: B9254-C (R.E.M. and W.P.M.) and NIH R01NR010827. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Andersson J.L.R., 2007, TR07JA1 FMRIB; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bartzokis G, 2004, J ALZHEIMERS DIS, V6, pS53; Bartzokis G, 2004, NEUROBIOL AGING, V25, P843, DOI 10.1016/j.neurobiolaging.2003.09.005; Bartzokis G, 2004, NEUROBIOL AGING, V25, P49, DOI 10.1016/j.neurobiolaging.2003.08.001; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fortier CB, 2014, ALCOHOL CLIN EXP RES, V38, P2925, DOI 10.1111/acer.12568; Fortier CB, 2011, ALCOHOL CLIN EXP RES, V35, P2193, DOI 10.1111/j.1530-0277.2011.01576.x; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jacobs HIL, 2013, HUM BRAIN MAPP, V34, P77, DOI 10.1002/hbm.21412; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kochunov P, 2014, PSYCHIAT RES-NEUROIM, V223, P148, DOI 10.1016/j.pscychresns.2014.05.004; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; Leritz EC, 2014, HUM BRAIN MAPP, V35, P1085, DOI 10.1002/hbm.22236; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lippa SM, 2015, J TRAUMA STRESS, V28, P25, DOI 10.1002/jts.21979; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Menke RAL, 2012, ARCH NEUROL-CHICAGO, V69, P1493, DOI 10.1001/archneurol.2012.1122; Molko N, 2002, STROKE, V33, P2902, DOI 10.1161/01.STR.0000041681.25514.22; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Nieuwenhuijsen K, 2003, OCCUP ENVIRON MED, V60, P77; NOMURA Y, 1994, AM J NEURORADIOL, V15, P231; Nusbaum AO, 2001, AM J NEURORADIOL, V22, P136; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Robinson ME, 2015, HUM BRAIN MAPP, V36, P911, DOI 10.1002/hbm.22675; Rosas HD, 2006, MOVEMENT DISORD, V21, P1317, DOI 10.1002/mds.20979; Salat DH, 2006, STROKE, V37, P1759, DOI 10.1161/01.STR.0000227328.86353.a7; Salat DH, 2012, NEUROIMAGE, V59, P181, DOI 10.1016/j.neuroimage.2011.07.033; Salat DH, 2005, ANN NY ACAD SCI, V1064, P37, DOI 10.1196/annals.1340.009; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang SM, 2006, RADIOLOGY, V239, P831, DOI 10.1148/radiol.2393050573; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027	103	53	53	1	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG 1	2015	138		8				2278	2292		10.1093/brain/awv139			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CQ4MJ	WOS:000360578700024	26033970	Green Published			2021-06-18	
J	Magasi, S; Wong, A; Gray, DB; Hammel, J; Baum, C; Wang, CC; Heinemann, AW				Magasi, Susan; Wong, Alex; Gray, David B.; Hammel, Joy; Baum, Carolyn; Wang, Chia-Chiang; Heinemann, Allen W.			Theoretical Foundations for the Measurement of Environmental Factors and Their Impact on Participation Among People With Disabilities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Environment; Patient-centered outcomes; Psychometrics; Rehabilitation; Research; Social participation; Social theory	TRAUMATIC BRAIN-INJURY; SELF-RATED HEALTH; QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; BUILT ENVIRONMENT; MOMENTARY ASSESSMENT; SOCIAL DETERMINANTS; INSIDER PERSPECTIVE; CLINICAL-RESEARCH; COMMUNITY	The ascendance of the World Health Organization's International Classification of Functioning, Disability and Heath (ICF) as the global standard for describing and characterizing aspects of disability has refocused attention on the role that environmental factors (EFs) have on the health and participation of people with disabilities, both as individuals and as a group. There has been a rise in the development of instruments designed to measure EFs alone and in relation to participation. Some instrument developers have used the ICF as a theoretical base for instrument development and to substantiate content validity claims. We contend that this is a misapplication of the ICF. There is a need to step back and reexamine the role that environmental theories can play in developing a conceptually driven approach to measuring the interaction between EFs and participation. For this review, we draw on the fields of social, community, and developmental psychology; disability studies; gerontology; public health; and rehabilitation. We discuss different approaches to the measurement of EFs. We suggest that given the complex nature of EFs and their influence on participation, there is a need for a fresh approach to EF measurement. The thoughtful application of theories and the use of advanced psychometric, measurement, and e-technologies and data visualization methods may enable researchers and clinicians to better quantify, document, and communicate the dynamic interrelationship between EFs and participation and health outcomes for people with disabilities at the individual, group, and population levels. (C) 2015 by the American Congress of Rehabilitation Medicine.	[Magasi, Susan; Hammel, Joy] Univ Illinois, Dept Occupat Therapy, Chicago, IL 60612 USA; [Magasi, Susan; Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Wong, Alex; Gray, David B.; Baum, Carolyn] Washington Univ, Dept Occupat Therapy, St Louis, MO USA; [Gray, David B.; Baum, Carolyn] Washington Univ, Dept Neurol, St Louis, MO USA; [Hammel, Joy] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL USA; [Baum, Carolyn] Univ Illinois, Dept Social Work, Chicago, IL USA; [Wang, Chia-Chiang] SUNY Buffalo, Sch & Educ Psychol, Dept Counseling, Buffalo, NY 14260 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA	Magasi, S (corresponding author), Univ Illinois, Dept Occupat Therapy, 1919 W Taylor St,Rm 327, Chicago, IL 60612 USA.	smagas1@uic.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Wong, Alex/0000-0002-4423-2685	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant [H133B090024]; Craig H. Neilsen Foundation [290474]	Supported in part by The National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant (grant no. H133B090024); and the Craig H. Neilsen Foundation (grant no 290474). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Disability and Rehabilitation Research or the Craig H. Neilsen Foundation.	Adler N, 2010, WOMENS HLTH RES PROG, P11; AERA APA NCME, 1999, STAND ED PSYCH TEST, P10; Alvarelhao J, 2012, J REHABIL MED, V44, P1, DOI 10.2340/16501977-0905; Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Barker RG, 1968, ECOLOGICAL PSYCHOL; Botticello AL, 2014, ANN EPIDEMIOL, V24, P545, DOI 10.1016/j.annepidem.2014.05.003; Bricout JC, 2006, SCAND J DISABIL RES, V8, P1, DOI 10.1080/15017410500335229; Bronfenbrenner U, 1992, 6 THEORIES CHILD DEV, P285; Bronfenbrenner U., 2006, HDB CHILD PSYCHOL, P793; Bronfenbrenner U., 1999, MEASURING ENV LIFE S, P3, DOI [10.1037/10317-001, DOI 10.1037/10317-001]; Brownson RC, 2009, AM J PREV MED, V36, pS99, DOI 10.1016/j.amepre.2009.01.005; Cannuscio C, 2003, ANN INTERN MED, V139, P395, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00003; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D, 2012, NEUROLOGY, V78, P1860, DOI 10.1212/WNL.0b013e318258f744; Cerniauskaite M, 2011, DISABIL REHABIL, V33, P281, DOI 10.3109/09638288.2010.529235; Chen YW, 2014, DISABIL HEALTH J, V7, P361, DOI 10.1016/j.dhjo.2014.04.004; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Clarke P, 2009, MATURITAS, V64, P14, DOI 10.1016/j.maturitas.2009.07.011; Clarke P, 2009, SOC SCI MED, V69, P964, DOI 10.1016/j.socscimed.2009.06.041; Clarke PJ, 2011, SOC SCI MED, V72, P1674, DOI 10.1016/j.socscimed.2011.03.025; Csikszentmihalyi m, 2007, EXPERIENCE SAMPLING; Dashner JL, 2012, 2012 AM OCC THER ASS; Dickinson HO, 2010, ARCH PHYS MED REHAB, V91, P1310, DOI 10.1016/j.apmr.2010.03.012; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers Marcel P J M, 2003, J Allied Health, V32, P38; Dijkers MPJM, 2002, SPINAL CORD, V40, P351, DOI 10.1038/sj.sc.3101310; Escorpizo Reuben, 2011, Am J Phys Med Rehabil, V90, pS66, DOI 10.1097/PHM.0b013e318230fbf9; FEINSTEIN AR, 1987, J CHRON DIS, V40, P635, DOI 10.1016/0021-9681(87)90027-0; Feng J, 2010, HEALTH PLACE, V16, P175, DOI 10.1016/j.healthplace.2009.09.008; Fougeyrollas P, 1997, ICIDH ENV FACTORS IN, V9, P32; Garcia SF, 2015, ARCH PHYS MED REHAB, V96, P596, DOI 10.1016/j.apmr.2014.06.019; George LK, 2005, J GERONTOL B-PSYCHOL, V60, P135; Gilbert KL, 2013, J HEALTH PSYCHOL, V18, P1385, DOI 10.1177/1359105311435983; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; GLAAD, 2013, WE AR TV REP 2012 20; Granholm E, 2008, SCHIZOPHRENIA BULL, V34, P507, DOI 10.1093/schbul/sbm113; Gray DB, 2008, DISABIL REHABIL, V30, P434, DOI 10.1080/09638280701625377; Gray JA, 2012, DISABIL HEALTH J, V5, P87, DOI 10.1016/j.dhjo.2011.12.002; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hammel J, 2006, TOP STROKE REHABIL, V13, P43, DOI 10.1310/5X2G-V1Y1-TBK7-Q27E; Hammel J, 2015, ARCH PHYS MED REHAB, V96, P578, DOI 10.1016/j.apmr.2014.12.008; Heinemann AW, 2015, ARCH PHYS MED REHAB, V96, P589, DOI 10.1016/j.apmr.2013.11.024; Heinemann AW, 2013, ARCH PHYS MED REHAB, V94, P2157, DOI 10.1016/j.apmr.2013.05.017; Heller T, 2011, DISABILITY LIFE COUR; Johnston MV, 2009, CHALLENGE EVIDENCE D; Kawachi I, 1999, AM J PUBLIC HEALTH, V89, P1187, DOI 10.2105/AJPH.89.8.1187; Kim D, 2006, J EPIDEMIOL COMMUN H, V60, P116, DOI 10.1136/jech.2005.038281; Lawton M.P., 1973, PSYCHOL ADULT DEV AG, P619, DOI DOI 10.1037/10044-020; Lawton MP., 1989, COURSE LATER LIFE, P15; Levasseur Melanie, 2007, Can J Occup Ther, V74 Spec No., P233; Lewin K., 1931, ENV FORCES CHILD BEH; Lewin K., 1951, FIELD THEORY SOCIAL; Lounsbury DW, 2009, AM J COMMUN PSYCHOL, V44, P213, DOI 10.1007/s10464-009-9266-4; Magasi S, 2012, QUAL LIFE RES, V21, P739, DOI 10.1007/s11136-011-9990-8; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; NARAYAN D, 2001, CURRENT SOCIOLOGY, V0049; Noreau L, 2010, ARCH PHYS MED REHAB, V91, pS44, DOI 10.1016/j.apmr.2009.10.037; Priestley M, 2001, DISABILITY LIFE COUR; PUTNAM RD, 1995, J DEMOCRACY, V0006; Reed GM, 2005, REHABIL PSYCHOL, V50, P122, DOI 10.1037/0090-5550.50.2.122; Reinhardt JD, 2011, DISABIL REHABIL, V33, P2151, DOI 10.3109/09638288.2011.573053; Reinhardt JD, 2010, TOPICS SPINAL CORD I, V15, P26, DOI DOI 10.1310/SCI1504-26; Rothstein B, 2003, NEW POLIT ECON, V8, P49, DOI 10.1080/1356346032000078723; Rushton G, 2003, ANNU REV PUBL HEALTH, V24, P43, DOI 10.1146/annurev.publhealth.24.012902.140843; Schneidert M, 2003, DISABIL REHABIL, V25, P588, DOI 10.1080/0963828031000137090; Schulz A, 2004, HEALTH EDUC BEHAV, V31, P455, DOI 10.1177/1090198104265598; Schwartz LA, 2014, J PEDIATR PSYCHOL, V39, P588, DOI 10.1093/jpepsy/jsu028; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Szreter S, 2004, INT J EPIDEMIOL, V33, P650, DOI 10.1093/ije/dyh013; Tarlov A., 1996, SOCIAL DETERMINANTS, P71; Trull TJ, 2009, PSYCHOL ASSESSMENT, V21, P457, DOI 10.1037/a0017653; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS44, DOI 10.1016/j.apmr.2011.04.024; U.S. Department of Health and Human Services Food and Drug Administration, 2009, FOOD DRUG ADM GUID I; Vygotsky L., 1978, READINGS DEV CHILDRE, P79, DOI DOI 10.1525/AA.1979.81.4.02A00580; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; WHO, 2011, WORLD REPORT ON DISABILITY, P1; Whyte J, 2008, ARCH PHYS MED REHAB, V89, P203, DOI 10.1016/j.apmr.2007.11.026; Woolcock M, 1998, THEOR SOC, V27, P151, DOI 10.1023/A:1006884930135; World Health Organization, 2001, INNOVATIVE CARE CHRO, P1; Wright B.A., 1983, PHYS DISABILITY PSYC, V2nd edition	84	53	54	0	50	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					569	577		10.1016/j.apmr.2014.12.002			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100001	25813889				2021-06-18	
J	Gatson, JW; Barillas, J; Hynan, LS; Diaz-Arrastia, R; Wolf, SE; Minei, JP				Gatson, Joshua W.; Barillas, Jennifer; Hynan, Linda S.; Diaz-Arrastia, Ramon; Wolf, Steven E.; Minei, Joseph P.			Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; neurofilament-H; serum	MINOR HEAD-INJURY; CEREBRAL CONCUSSION; CEREBROSPINAL-FLUID; AXONAL INJURY; PROTEIN; ACCUMULATION; APOPTOSIS; FOOTBALL; DAMAGE; S100B	Object. In previous studies of traumatic brain injury (TBI), neural biomarkers of injury correlate with injury severity and predict neurological outcome. The object of this paper was to characterize neurofilament-H (NFL-H) as a predictor of injury severity in patients who have suffered mild TBI (mTBI). Thus, the authors hypothesized that phosphorylated NFL-H (pNFL-H) levels are higher in mTBI patients than in healthy controls and identify which subjects experienced a more severe injury such as skull fractures, intracranial hemorrhaging, and/or contusions as detected by CT scans. Methods. In this prospective clinical study, blood (8 ml) was collected from subjects (n = 34) suffering from mTBI (as defined by the American Congress of Rehabilitation and Glasgow Coma Scale scores between 13 and 15) at Parkland Hospital, Dallas, Texas, on Days 1 and 3 after injury). Additional clinical findings from the CT scans were also used to categorize the TBI patients into those with and those without clinical findings on the scans (CT+ and CT groups, respectively). The serum levels of pNFL-H were measured using the enzyme-linked immunosorbent assay. Results. Compared with healthy controls, the mTBI patients exhibited a significant increase in the serum levels of pNFL-H on Days 1 (p = 0.00001) and 3 (p = 0.0001) after TBI. An inverse correlation was observed between pNFL-H serum levels and Glasgow Coma Scale scores, which was significant. Additionally, using receiver operating characteristic curve analysis to compare the mTBI cases with controls to determine sensitivity and specificity, an area under the curve of 100% was achieved for both (p = 0.0001 for both). pNFL-H serum levels were only significantly higher on Day 1 in mTBI patients in the CT+ group (p < 0.008) compared with the CT- group. The area under the curve (82.5%) for the CT+ group versus the CT- group was significant (p = 0.021) with a sensitivity of 87.5% and a specificity of 70%, using a cutoff of 1071 pg/ml of pNFL-H in serum. Conclusions. This study describes the serum profile of pNFL-H in patients suffering from mTBI with and without CT findings on Days 1 and 3 after injury. These results suggest that detection of pNFL-H may be useful in determining which individuals require CT imaging to assess the severity of their injury.	[Gatson, Joshua W.; Barillas, Jennifer; Wolf, Steven E.; Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA	Gatson, JW (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsouthwesterm.edu	Hynan, Linda S/P-6473-2016	Wolf, Steven/0000-0003-2972-3440; Hynan, Linda/0000-0002-4642-7769; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Division of Burn/Trauma/Critical Care; Department of Surgery; UT Southwestern Medical Center, Dallas, Texas	Funding was provided by the Division of Burn/Trauma/Critical Care; Department of Surgery; UT Southwestern Medical Center, Dallas, Texas. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Giza CC, 2001, J ATHL TRAINING, V36, P228; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; MAYEVSKY A, 1974, BRAIN RES, V65, P529, DOI 10.1016/0006-8993(74)90243-1; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Vajtr D, 2012, Soud Lek, V57, P7; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	36	53	57	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2014	121	5					1232	1238		10.3171/2014.7.JNS132474			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AR4AM	WOS:000343530400031	25192482				2021-06-18	
J	Rosenberg, H; McDonald, S; Dethier, M; Kessels, RPC; Westbrook, RF				Rosenberg, Hannah; McDonald, Skye; Dethier, Marie; Kessels, Roy P. C.; Westbrook, R. Frederick			Facial Emotion Recognition Deficits following Moderate-Severe Traumatic Brain Injury (TBI): Re-examining the Valence Effect and the Role of Emotion Intensity	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Emotion recognition; Facial affect; Valence; Positive emotion; Negative emotion	ANXIETY STRESS SCALES; CLOSED-HEAD-INJURY; PERCEPTION DEFICITS; SOCIAL-PERCEPTION; STROKE PATIENTS; EXPRESSIONS; COMMUNICATION; DEPRESSION; DAMAGE; SCHIZOPHRENIA	Many individuals who sustain moderate-severe traumatic brain injuries (TBI) are poor at recognizing emotional expressions, with a greater impairment in recognizing negative (e.g., fear, disgust, sadness, and anger) than positive emotions (e.g., happiness and surprise). It has been questioned whether this "valence effect" might be an artifact of the wide use of static facial emotion stimuli (usually full-blown expressions) which differ in difficulty rather than a real consequence of brain impairment. This study aimed to investigate the valence effect in TBI, while examining emotion recognition across different intensities (low, medium, and high). Method: Twenty-seven individuals with TBI and 28 matched control participants were tested on the Emotion Recognition Task (ERT). The TBI group was more impaired in overall emotion recognition, and less accurate recognizing negative emotions. However, examining the performance across the different intensities indicated that this difference was driven by some emotions (e.g., happiness) being much easier to recognize than others (e.g., fear and surprise). Our findings indicate that individuals with TBI have an overall deficit in facial emotion recognition, and that both people with TBI and control participants found some emotions more difficult than others. These results suggest that conventional measures of facial affect recognition that do not examine variance in the difficulty of emotions may produce erroneous conclusions about differential impairment. They also cast doubt on the notion that dissociable neural pathways underlie the recognition of positive and negative emotions, which are differentially affected by TBI and potentially other neurological or psychiatric disorders.	[Rosenberg, Hannah; McDonald, Skye; Westbrook, R. Frederick] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Dethier, Marie] Univ Liege, Dept Psychol Cognit & Behav, Liege, Belgium; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands; [Kessels, Roy P. C.] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6525 ED Nijmegen, Netherlands; [Kessels, Roy P. C.] Korsakoff Clin, Vincent van Gogh Inst Psychiat, Venray, Netherlands	Rosenberg, H (corresponding author), Univ New S Wales, Sch Psychol, Mathews Bldg, Sydney, NSW 2052, Australia.	hannah.rosenberg@unsw.edu.au	Kessels, Roy P.C./D-1902-2010; McDonald, Skye/G-4118-2014	Kessels, Roy P.C./0000-0001-9500-9793; McDonald, Skye/0000-0003-0723-6094; Westbrook, Fred/0000-0002-6880-9274	Australian Research Council (ARC)Australian Research Council [DP0988689]; NHMRCNational Health and Medical Research Council of Australia	This research was funded by the Australian Research Council (ARC) Discovery Project grant DP0988689 and the NHMRC. The authors have no conflict of interest affecting this manuscript. The authors wish to thank the individuals who participated in this study. The authors are also grateful to Jacob Rosenberg for assistance with data processing and Marios Panayi for statistical advice.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Ammerlaan EJG, 2008, ACTA NEUROBIOL EXP, V68, P214; Anderson AK, 2000, PSYCHOL SCI, V11, P106, DOI 10.1111/1467-9280.00224; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bird KD, 2011, PSYCHOL METHODS, V16, P432, DOI 10.1037/a0024447; Bornhofen C., 2010, READING SMILES OTHER; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Braun M, 2005, BRAIN COGNITION, V58, P193, DOI 10.1016/j.bandc.2004.11.003; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Demaree Heath A, 2005, Behav Cogn Neurosci Rev, V4, P3, DOI 10.1177/1534582305276837; Dethier M., 2013, J INT NEUROPSYCH SOC, V19, P1; Dethier M, 2012, J CLIN EXP NEUROPSYC, V34, P936, DOI 10.1080/13803395.2012.702734; Ekman P., 1976, PICTURES FACIAL AFFE; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fernandez-Duque D, 2005, NEUROPSYCHOLOGIA, V43, P1673, DOI 10.1016/j.neuropsychologia.2005.01.005; Frigerio E, 2002, PSYCHIAT RES, V113, P161, DOI 10.1016/S0165-1781(02)00244-5; George D., 2003, SPSS WINDOWS STEP ST, V4th; Gray John, 2006, Cogn Neuropsychiatry, V11, P505, DOI 10.1080/13546800544000028; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hennenlotter A, 2006, PROG BRAIN RES, V156, P443, DOI 10.1016/S0079-6123(06)56024-8; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessels RPC, 2007, BEHAV NEUROL, V18, P31, DOI 10.1155/2007/868431; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Kohler CG, 2005, AM J GERIAT PSYCHIAT, V13, P926, DOI 10.1176/appi.ajgp.13.11.926; Kreibig SD, 2010, BIOL PSYCHOL, V84, P394, DOI 10.1016/j.biopsycho.2010.03.010; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; Lovibond SH, 1995, MANUAL DEPRESSION AN; Mandal MK, 1998, SCHIZOPHRENIA BULL, V24, P399, DOI 10.1093/oxfordjournals.schbul.a033335; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Montagne B, 2008, EUR PSYCHIAT, V23, P26, DOI 10.1016/j.eurpsy.2007.07.007; Montagne B, 2007, ACTA NEUROPSYCHIATR, V19, P279, DOI 10.1111/j.1601-5215.2007.00235.x; Montagne B, 2007, BRIT J PSYCHOL, V98, P517, DOI 10.1348/000712606X160669; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Montagne Barbara, 2006, Cogn Neuropsychiatry, V11, P389, DOI 10.1080/13546800444000254; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Rosenberg H., 2014, EMOTION PERCEP UNPUB; RUSSELL JA, 1994, PSYCHOL BULL, V115, P102, DOI 10.1037/0033-2909.115.1.102; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Smith MJL, 2010, NEUROPSYCHOLOGIA, V48, P2777, DOI 10.1016/j.neuropsychologia.2010.03.008; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Vuilleumier P, 2002, CURR OPIN PSYCHIATR, V15, P291, DOI 10.1097/00001504-200205000-00011; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Zupan B, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829dded6	62	53	54	2	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2014	20	10					994	1003		10.1017/S1355617714000940			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AW3FN	WOS:000346171700005	25396693				2021-06-18	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Decompressive craniectomy for severe traumatic brain injury: The relationship between surgical complications and the prediction of an unfavourable outcome	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Decompressive craniectomy; Complications; Injury severity	NEUROSURGICAL SITE INFECTIONS; SEVERE HEAD-INJURY; RISK-FACTORS; DELAYED CRANIOPLASTY; SUBDURAL HYGROMA; CEREBRAL EDEMA; HEMICRANIECTOMY; HYDROCEPHALUS; BONE; CRANIOTOMY	Object: To assess the impact that injury severity has on complications in patients who have had a decompressive craniectomy for severe traumatic brain injury (TBI). Methods: This prospective observational cohort study included all patients who underwent a decompressive craniectomy following severe TBI at the two major trauma hospitals in Western Australia from 2004 to 2012. All complications were recorded during this period. The clinical and radiological data of the patients on initial presentation were entered into a web-based model prognostic model, the CRASH (Corticosteroid Randomization After Significant Head injury) collaborators prediction model, to obtain the predicted risk of an unfavourable outcome which was used as a measure of injury severity. Results: Complications after decompressive craniectomy for severe TBI were common. The predicted risk of unfavourable outcome was strongly associated with the development of neurological complications such as herniation of the brain outside the skull bone defects (median predicted risk of unfavourable outcome for herniation 72% vs. 57% without herniation, p = 0.001), subdural effusion (median predicted risk of unfavourable outcome 67% with an effusion vs. 57% for those without an effusion, p = 0.03), hydrocephalus requiring ventriculo-peritoneal shunt (median predicted risk of unfavourable outcome 86% for those with hydrocephalus vs. 59% for those without hydrocephalus, p = 0.001), but not infection (p = 0.251) or resorption of bone flap (p = 0.697) and seizures (0.987). We did not observe any associations between timing of cranioplasty and risk of infection or resorption of bone flap after cranioplasty. Conclusions: Mechanical complications after decompressive craniectomy including herniation of the brain outside the skull bone defects, subdural effusion, and hydrocephalus requiring ventriculoperitoneal shunt were more common in patients with a more severe form of TBI when quantified by the CRASH predicted risk of unfavourable outcome. The CRASH predicted risk of unfavourable outcome represents a useful baseline characteristic of patients in observational and interventional trials involving patients with severe TBI requiring decompressive craniectomy. (C) 2014 Elsevier Ltd. All rights reserved.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Nedlands, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Foster R, 2000, SCHMIDEK SWEET OPERA, P29; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2014, J NEUROSURG; Honeybul S, 2013, BRAIN INJURY, V27, P1732, DOI 10.3109/02699052.2013.830194; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2013, WORLD NEUROSURG, V79, P159, DOI 10.1016/j.wneu.2012.08.012; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; JENNETT B, 1975, LANCET, V1, P480; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lavinio A, 2008, EUR J ANAESTH, V25, P137, DOI 10.1017/S0265021507003298; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Prolo DJ, 1996, NEUROSURGERY, V2, P2783; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	53	53	60	1	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1332	1339		10.1016/j.injury.2014.03.007			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900009	24704150				2021-06-18	
J	Jayakumar, AR; Tong, XY; Ruiz-Cordero, R; Bregy, A; Bethea, JR; Bramlett, HM; Norenberg, MD				Jayakumar, Arumugam R.; Tong, Xiao Y.; Ruiz-Cordero, Roberto; Bregy, Amade; Bethea, John R.; Bramlett, Helen M.; Norenberg, Michael D.			Activation of NF-kappa B Mediates Astrocyte Swelling and Brain Edema in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte swelling; NF-kappa B; traumatic brain injury; transgenic mice	K-CL COTRANSPORTER-1; CULTURED ASTROCYTES; NADPH OXIDASE; OXIDATIVE STRESS; HEPATIC-ENCEPHALOPATHY; IN-VITRO; MECHANISM; CELLS; INFLAMMATION; DISCOVERIES	Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury (TBI). While astrocyte swelling (cytotoxic edema) represents a major component of the brain edema in the early phase of TBI, its mechanisms are unclear. One factor known to be activated by trauma is nuclear factor-kappa B (NF-kappa B). Because this factor has been implicated in the mechanism of cell swelling/brain edema in other neurological conditions, we examined whether NF-kappa B might also be involved in the mediation of post-traumatic astrocyte swelling/brain edema. Here we show an increase in NF-kappa B activation in cultured astrocytes at 1 and 3 h after trauma (fluid percussion injury, FPI), and that BAY 11-7082, an inhibitor of NF-kappa B, significantly blocked the trauma-induced astrocyte swelling. Increased activities of nicotinamide adenine dinucleotide phosphate-oxidase and the Na+, K+, 2Cl(-) cotransporter were also observed in cultured astrocytes after trauma, and BAY 11-7082 reduced these effects. We also examined the role of NF-kappa B in the mechanism of cell swelling by using astrocyte cultures derived from transgenic (Tg) mice with a functional inactivation of astrocytic NF-kappa B. Exposure of cultured astrocytes from wild-type mice to in vitro trauma (3 h) caused a significant increase in cell swelling. By contrast, traumatized astrocyte cultures derived from NF-kappa B Tg mice showed no swelling. We also found increased astrocytic NF-kappa B activation and brain water content in rats after FPI, while BAY 11-7082 significantly reduced such effects. Our findings strongly suggest that activation of astrocytic NF-kappa B represents a key element in the process by which cytotoxic brain edema occurs after TBI.	[Jayakumar, Arumugam R.; Tong, Xiao Y.; Ruiz-Cordero, Roberto; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Bramlett, Helen M.] Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA; [Bregy, Amade; Bethea, John R.; Bramlett, Helen M.] Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu	Ruiz-Cordero, Roberto/AAT-4051-2020	Ruiz-Cordero, Roberto/0000-0002-9747-6069	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. The authors thank Alina Fernandez-Revuelta for the preparation of cell cultures, and Gabriel Gaidosh for assistance with fluorescence imaging.	Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Camandola S, 2007, EXPERT OPIN THER TAR, V11, P123, DOI 10.1517/14728222.11.2.123; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58; Jayakumar AR, 2012, NEUROSCIENCE, V218, P305, DOI 10.1016/j.neuroscience.2012.05.006; Jayakumar AR, 2012, CURR SIGNAL TRANSD T, V7, P35, DOI 10.2174/157436212799278197; Jayakumar AR, 2011, NEUROBIOL DIS, V41, P498, DOI 10.1016/j.nbd.2010.10.021; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2014, J NEUROCHEM, V128, P890, DOI 10.1111/jnc.12516; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jayakumar AR, 2009, J NEUROCHEM, V109, P252, DOI 10.1111/j.1471-4159.2009.05842.x; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Luengo-Blanco M, 2008, BLOOD, V112, P1453, DOI 10.1182/blood-2007-07-099267; Manea A., 2007, Archives of Physiology and Biochemistry, V113, P163, DOI 10.1080/13813450701531235; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Pan DS, 2007, BIOMED ENVIRON SCI, V20, P432; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; Rick FG, 2013, P NATL ACAD SCI USA, V110, P2617, DOI 10.1073/pnas.1222355110; Sathish V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023662; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; Sirabella R, 2009, STROKE, V40, P922, DOI 10.1161/STROKEAHA.108.531962; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939; Valsecchi V, 2013, ADV EXP MED BIOL, V961, P137, DOI 10.1007/978-1-4614-4756-6_12; Yu Y, 2009, CIRCULATION, V119, P2313, DOI 10.1161/CIRCULATIONAHA.108.782458	44	53	56	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1249	1257		10.1089/neu.2013.3169			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000002	24471369	Green Published			2021-06-18	
J	Chen, X; Duan, XS; Xu, LJ; Zhao, JJ; She, ZF; Chen, WW; Zheng, ZJ; Jiang, GD				Chen, X.; Duan, X. -S.; Xu, L. -J.; Zhao, J. -J.; She, Z. -F.; Chen, W. -W.; Zheng, Z. -J.; Jiang, G. -D.			INTERLEUKIN-10 MEDIATES THE NEUROPROTECTION OF HYPERBARIC OXYGEN THERAPY AGAINST TRAUMATIC BRAIN INJURY IN MICE	NEUROSCIENCE			English	Article						interleukin-10; hyperbaric oxygen; traumatic brain injury; apoptosis; inflammation; edema	SPINAL-CORD-INJURY; NEURONAL APOPTOSIS; BARRIER FUNCTION; EDEMA; EXPRESSION; DAMAGE; MATRIX-METALLOPROTEINASE-9; NEUROINFLAMMATION; CASPASES; IMPACT	The aim of present study was to elucidate the role of Interleukin-10 (IL-10) in the neuroprotection of hyperbaric oxygen (HBO) against traumatic brain injury (TBI) in mice. The TBI in mice was induced by controlled cortical impact (CCI). HBO was given for 1 h at 2.0 absolute atmosphere (ATA) in 100% O-2. HBO enhanced the serumal and cerebral IL-10 protein levels in both sham-operated and TBI mice. HBO therapy after TBI reduced lesion volume, attenuated cerebral edema, improved neurological status including motor and cognitive function, inhibited apoptosis evidenced by decreased ratio of cleaved caspase-3 (C3) to pro-C3 and Bax expression and increased bcl-2 expression, and attenuated inflammation marked by reduced expression of IL-1 beta, IL-6, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1) and activity of matrix metalloproteinase-9 (MMP9). In addition, HBO after TBI improved the blood-brain barrier, and upregulated the expression of tight junction proteins including zonula occludens-1 (ZO-1) and claudin-5. IL-10 deficiency aggravated TBI-induced damage in the brain and abrogated the beneficial effects of HBO on neuroinflammation, apoptosis, and edema after TBI. IL-10 deficiency itself had no significant effect on brain water content and neurological status. In conclusion, IL-10 played an important role in the neuroprotection of HBO therapy against TBI in mice. (C) 2014 Published by Elsevier Ltd. on behalf of IBRO.	[Chen, X.; Duan, X. -S.; Xu, L. -J.; She, Z. -F.; Chen, W. -W.; Zheng, Z. -J.; Jiang, G. -D.] 113th Hosp PLA, Dept Hyperbar Oxygen, Ningbo 315040, Zhejiang, Peoples R China; [Zhao, J. -J.] 305th Hosp PLA, Dept Neurol, Beijing, Peoples R China	Jiang, GD (corresponding author), 113th Hosp PLA, Dept Hyperbar Oxygen, 337 Zhongshandong Rd, Ningbo 315040, Zhejiang, Peoples R China.	jianggd2013@hotmail.com					Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cua DJ, 2001, J IMMUNOL, V166, P602, DOI 10.4049/jimmunol.166.1.602; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frenkel D, 2005, J NEUROL SCI, V233, P125, DOI 10.1016/j.jns.2005.03.022; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P145; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu Zhan, 2006, Chin J Traumatol, V9, P168; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Londono D, 2011, J IMMUNOL, V186, P7176, DOI 10.4049/jimmunol.1100060; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Oshima T, 2001, MICROVASC RES, V61, P130, DOI 10.1006/mvre.2000.2288; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Perez-Espejo MA, 2009, NEUROCIRUGIA, V20, P449; Prakash A, 2012, J PEDIATR NEUROSCI, V7, P4, DOI 10.4103/1817-1745.97610; Qian L, 2006, J PHARMACOL EXP THER, V319, P44, DOI 10.1124/jpet.106.106351; Sahni T, 2012, BRIT J NEUROSURG, V26, P202, DOI 10.3109/02688697.2011.626879; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	35	53	58	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						235	243		10.1016/j.neuroscience.2013.11.036			9	Neurosciences	Neurosciences & Neurology	AE8VO	WOS:000334281200023	24291771				2021-06-18	
J	Dunkley, BT; Doesburg, SM; Sedge, PA; Grodecki, RJ; Shek, PN; Pang, EW; Taylor, MJ				Dunkley, B. T.; Doesburg, S. M.; Sedge, P. A.; Grodecki, R. J.; Shek, P. N.; Pang, E. W.; Taylor, M. J.			Resting-state hippocampal connectivity correlates with symptom severity in post-traumatic stress disorder	NEUROIMAGE-CLINICAL			English	Article						Post-traumatic stress disorder; Magnetoencephalography (MEG); Resting-state; Functional connectivity; Neural network	MEDIAL PREFRONTAL CORTEX; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; VIETNAM VETERANS; PREVALENCE; NETWORKS; DYNAMICS; IMAGERY; TRAUMA; INDEX	Post-traumatic stress disorder (PTSD) is a serious mental health injury which can manifest after experiencing a traumatic life event. The disorder is characterized by symptoms of re-experiencing, avoidance, emotional numbing and hyper-arousal. Whilst its aetiology and resultant symptomology are better understood, relatively little is known about the underlying cortical pathophysiology, and in particular whether changes in functional connectivity may be linked to the disorder. Here, we used non-invasive neuroimaging with magnetoencephalography to examine functional connectivity in a resting-state protocol in the combat-related PTSD group (n = 23), and a military control group (n = 21). We identify atypical long-range hyperconnectivity in the high-gamma-band resting-state networks in a combat-related PTSD population compared to soldiers who underwent comparable environmental exposure but did not develop PTSD. Using graph analysis, we demonstrate that apparent network connectivity of relevant brain regions is associated with cognitive-behavioural outcomes. We also show that left hippocampal connectivity in the PTSD group correlates with scores on the well-established PTSD Checklist (PCL). These findings indicate that atypical synchronous neural interactions may underlie the psychological symptoms of PTSD, whilst also having utility as a potential biomarker to aid in the diagnosis and monitoring of the disorder. (C) 2014 The Authors. Published by Elsevier Inc.	[Dunkley, B. T.; Doesburg, S. M.; Taylor, M. J.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Dunkley, B. T.; Doesburg, S. M.; Pang, E. W.; Taylor, M. J.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Doesburg, S. M.; Taylor, M. J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Doesburg, S. M.; Taylor, M. J.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Sedge, P. A.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON, Canada; [Grodecki, R. J.] Canadian Forces Environm Med Estab, Toronto, ON, Canada; [Shek, P. N.] Def Res & Dev Canada, Toronto, ON, Canada; [Pang, E. W.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada	Dunkley, BT (corresponding author), Dept Diagnost Imaging, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ben.dunkley@sickkids.ca		Dunkley, Ben/0000-0001-6173-1171	Defence Research and Development Canada (DRDC) [W7719-135182/001/TOR]; Canadian Forces Health Services	The authors would like to thank Amanda Robertson and Marc Lalancette for help in the data collection, and Daniel Cassel for help with the data analysis pipeline. This work was supported by funding from Defence Research and Development Canada (DRDC) (contract # W7719-135182/001/TOR) and the Canadian Forces Health Services to MJT and EWP.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Fell J, 2001, NAT NEUROSCI, V4, P1259, DOI 10.1038/nn759; Fries P., 2012, TRENDS COGN SCI, V9, P356; Garber BG, 2012, CAN J PSYCHIAT, V57, P736, DOI 10.1177/070674371205701205; Georgopoulos AP, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016011; Gold AL, 2011, PSYCHOL MED, V41, P2563, DOI 10.1017/S0033291711000730; Hall EL, 2013, NEUROIMAGE; Hari R, 2012, NEUROIMAGE, V61, P386, DOI 10.1016/j.neuroimage.2011.11.074; Hiltunen T, 2014, J NEUROSCI, V34, P356, DOI 10.1523/JNEUROSCI.0276-13.2014; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; James LM, 2013, JAMA PSYCHIAT, V70, P410, DOI 10.1001/jamapsychiatry.2013.878; Jin C., 2013, P 4 INT SC WORKSH DA, P1, DOI DOI 10.1109/MWSYM.2013.6697734; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kolassa IT, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-56; Lau TM, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-47; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Luo Q, 2009, CEREB CORTEX, V19, P1896, DOI 10.1093/cercor/bhn216; Mukamel R, 2005, SCIENCE, V309, P951, DOI 10.1126/science.1110913; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Nir Y, 2007, CURR BIOL, V17, P1275, DOI 10.1016/j.cub.2007.06.066; Pagani M, 2010, EUR PSYCHIAT, V25; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shin LM, 2011, AM J PSYCHIAT, V168, P979, DOI 10.1176/appi.ajp.2011.09121812; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Sripada RK, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00672; Tagliazucchi E, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00339; Tewarie P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069318; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; Wang L, 2012, NEURON, V76, P1010, DOI 10.1016/j.neuron.2012.09.033; Wang XJ, 2010, PHYSIOL REV, V90, P1195, DOI 10.1152/physrev.00035.2008; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yin Y, 2011, BRAIN RES, V1411, P98, DOI 10.1016/j.brainres.2011.07.016; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	46	53	53	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						377	384		10.1016/j.nicl.2014.07.017			8	Neuroimaging	Neurosciences & Neurology	CB5LF	WOS:000349667800041	25180157	DOAJ Gold, Green Published			2021-06-18	
J	Eckner, JT; Kutcher, JS; Broglio, SP; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Broglio, Steven P.; Richardson, James K.			Effect of sport-related concussion on clinically measured simple reaction time	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Evaluation; Head injuries	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; RELIABLE CHANGE INDEXES; FOOTBALL PLAYERS; COGNITIVE CHANGE; ASSESSMENT TOOLS; TEST PROTOCOL; RECOVERY; IMPACT; SENSITIVITY	Background Reaction time (RT) is a valuable component of the sport concussion assessment battery. RT is typically measured using computers running specialised software, which limits its applicability in some athletic settings and populations. To address this, we developed a simple clinical test of RT (RTclin) that involves grasping a falling measuring stick. Purpose To determine the effect of concussion on RTclin and its sensitivity and specificity for concussion. Materials and methods Concussed athletes (n=28) and non-concussed control team-mates (n=28) completed RTclin assessments at baseline and within 48h of injury. Repeated measures analysis of variance compared mean baseline and follow-up RTclin values between groups. Sensitivity and specificity were calculated over a range of reliable change confidence levels. Results RTclin differed significantly between groups (p<0.001): there was significant prolongation from baseline to postinjury in the concussed group (p=0.003), with a trend towards improvement in the control group (p=0.058). Sensitivity and specificity were maximised when a critical change value of 0ms was applied (ie, any increase in RTclin from baseline was interpreted as abnormal), which corresponded to a sensitivity of 75%, specificity of 68% and a 65% reliable change confidence level. Conclusions RTclin appears sensitive to the effects of concussion and distinguished concussed and non-concussed athletes with similar sensitivity and specificity to other commonly used concussion assessment tools. Given its simplicity, low cost and minimal time requirement, RTclin should be considered a viable component of the sports medicine provider's multifaceted concussion assessment battery.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Eckner, James T.; Kutcher, Jeffrey S.; Broglio, Steven P.] Univ Michigan, Michigan NeuroSport, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E,Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			Rehabilitation Medicine Scientist Training Program [5K12HD001097]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	Dr Eckner received a K-12 career development award from the Rehabilitation Medicine Scientist Training Program which supported his effort on this project (grant number 5K12HD001097).	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P370, DOI 10.1136/bjsm.37.4.370-a; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eckner JT, 2011, PM&R, V3, P1092, DOI 10.1016/j.pmrj.2011.04.022; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Frerichs RJ, 2005, ARCH CLIN NEUROPSYCH, V20, P321, DOI 10.1016/j.acn.2004.08.002; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	49	53	53	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					112	U175		10.1136/bjsports-2012-091579			8	Sport Sciences	Sport Sciences	276KK	WOS:000328749000012	23314889	Green Accepted			2021-06-18	
J	Dams-O'Connor, K; Cuthbert, JP; Whyte, J; Corrigan, JD; Faul, M; Harrison-Felix, C				Dams-O'Connor, Kristen; Cuthbert, Jeffrey P.; Whyte, John; Corrigan, John D.; Faul, Mark; Harrison-Felix, Cynthia			Traumatic Brain Injury among Older Adults at Level I and II Trauma Centers	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; epidemiology; geriatric brain injury; traumatic brain injury	EMERGENCY-DEPARTMENT VISITS; UNITED-STATES; MORTALITY; AGE; HOSPITALIZATIONS; ASSOCIATION; DISCHARGE; RECOVERY; OUTCOMES; DEATHS	Individuals 65 years of age and over have the highest rates of traumatic brain injury (TBI)-related hospitalizations and deaths, and older adults (defined variably across studies) have particularly poor outcomes after TBI. The factors predicting these outcomes remain poorly understood, and age-specific care guidelines for TBI do not exist. This study provides an overview of TBI in older adults using data from the National Trauma Data Bank (NTDB) gathered between 2007 and 2010, evaluates age group-specific trends in rates of TBI over time using U.S. Census data, and examines whether routinely collected information is able to predict hospital discharge status among older adults with TBI in the NTDB. Results showed a 20-25% increase in trauma center admissions for TBI among the oldest age groups (those >=75 years), relative to the general population, between 2007 and 2010. Older adults (>=65 years) with TBI tended to be white females who have incurred an injury from a fall resulting in a severe Abbreviated Injury Scale (AIS) score of the head. Older adults had more in-hospital procedures, such as neuroimaging and neurosurgery, tended to experience longer hospital stays, and were more likely to require continued medical care than younger adults. Older age, injury severity, and hypotension increased the odds of in-hospital death. The public health burden of TBI among older adults will likely increase as the Baby Boom generation ages. Improved primary and secondary prevention of TBI in this cohort is needed.	[Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Whyte, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Elkins Pk, PA USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kdams13@gmail.com		Faul, Mark/0000-0002-7683-0348; Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD074651] Funding Source: Medline		AANS, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9999; Agency for Healthcare Quality and Research, 2013, H CUPNET HEALTHC COS; AHA, 2011, UND BLOOD PRESS READ; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brewer ES, 2011, J TRAUMA, V70, pE1, DOI 10.1097/TA.0b013e3181e5e286; CDC, 2010, US CENS BRIDG RAC PO; Cefalu CA, 2011, CLIN GERIATR MED, V27, P491, DOI 10.1016/j.cger.2011.07.001; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Chisholm KM, 2010, AM J FOREN MED PATH, V31, P350, DOI 10.1097/PAF.0b013e3181f69c87; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P14; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; Farrer SR, 2007, GROWING OLDER AM HLT; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; Goble S, 2009, J TRAUMA, V67, P637, DOI 10.1097/TA.0b013e3181b84294; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; IBM Corp, 2010, IBM SPSS STAT WIND V; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1111/j.1553-2712.2003.tb01998.x; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Marr A, 2002, CENTRAL NERVOUS SYST; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Neal M., 2005, NATL TRAUMA DATA BAN; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Reistetter TA, 2010, ARCH PHYS MED REHAB, V91, P345, DOI 10.1016/j.apmr.2009.11.010; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryb GE, 2011, J TRAUMA, V71, P742, DOI 10.1097/TA.0b013e31822ba010; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Sasser SM, 2009, GUIDELINES FIELD TRI; Scheetz LJ, 2011, PREHOSP EMERG CARE, V15, P83, DOI 10.3109/10903127.2010.514088; Spaniolas K, 2010, J TRAUMA, V69, P821, DOI 10.1097/TA.0b013e3181efc6c6; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Tri-Analytics, 1997, ICDMAP 90 INJ SEV CO; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269	51	53	53	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2001	2013		10.1089/neu.2013.3047			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500001	23962046	Green Published			2021-06-18	
J	Rachmany, L; Tweedie, D; Rubovitch, V; Yu, QS; Li, YZ; Wang, JY; Pick, CG; Greig, NH				Rachmany, Lital; Tweedie, David; Rubovitch, Vardit; Yu, Qian-Sheng; Li, Yazhou; Wang, Jia-Yi; Pick, Chaim G.; Greig, Nigel H.			Cognitive Impairments Accompanying Rodent Mild Traumatic Brain Injury Involve p53-Dependent Neuronal Cell Death and Are Ameliorated by the Tetrahydrobenzothiazole PFT-alpha	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; OBJECT RECOGNITION MEMORY; FLUORO-JADE-B; CEREBRAL-ISCHEMIA; P53-INDUCED APOPTOSIS; FUNCTIONAL OUTCOMES; GENE-EXPRESSION; HEAD-INJURY; P53; MECHANISMS	With parallels to concussive mild traumatic brain injury (mTBI) occurring in humans, anesthetized mice subjected to a single 30 g weight drop mTBI event to the right parietal cortex exhibited significant diffuse neuronal degeneration that was accompanied by delayed impairments in recognition and spatial memory. To elucidate the involvement of reversible p53-dependent apoptosis in this neuronal loss and associated cognitive deficits, mice were subjected to experimental mTBI followed by the systemic administration of the tetrahydrobenzothiazole p53 inactivator, PFT-alpha, or vehicle. Neuronal loss was quantified immunohistochemically at 72 hr. post-injury by the use of fluoro-Jade B and NeuN within the dentate gyrus on both sides of the brain, and recognition and spatial memory were assessed by novel object recognition and Y-maze paradigms at 7 and 30 days post injury. Systemic administration of a single dose of PFT-alpha 1 hr. post-injury significantly ameliorated both neuronal cell death and cognitive impairments, which were no different from sham control animals. Cellular studies on human SH-SY5Y cells and rat primary neurons challenged with glutamate excitotoxicity and H2O2 induced oxidative stress, confirmed the ability of PFT-alpha and a close analog to protect against these TBI associated mechanisms mediating neuronal loss. These studies suggest that p53-dependent apoptotic mechanisms underpin the neuronal and cognitive losses accompanying mTBI, and that these are potentially reversible by p53 inactivation.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Tweedie, David; Yu, Qian-Sheng; Li, Yazhou; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan	Pick, CG (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il; Greign@grc.nia.nih.gov		Wang, Jia-Yi/0000-0002-9106-3351	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 101-2321-B-038-003, NSC 102-2321-B-038-003]; Sackler School of Medicine, Tel-Aviv University; Israeli Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health (DT,QSY,NHG); (ii) grants from the National Science Council (NSC 101-2321-B-038-003 and NSC 102-2321-B-038-003), Taiwan (JYW); (iii) by the Sackler School of Medicine, Tel-Aviv University, and, in part, by a grant from the Israeli Science Foundation (grant no. 108/09) (LR,VR,CGP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bailey JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021954; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; CHOI DW, 1987, J NEUROSCI, V7, P357; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Eve DJ, 2007, BRAIN RES, V1150, P174, DOI 10.1016/j.brainres.2007.02.088; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Golarai G, 2001, J NEUROSCI, V21, P8523; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gudkov AV, 2007, HUM MOL GENET, V16, pR67, DOI 10.1093/hmg/ddm052; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hong MY, 2012, CHINESE MED J-PEKING, V125, P2019, DOI 10.3760/cma.j.issn.0366-6999.2012.11.032; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Howard DB, 2008, VIROLOGY, V372, P24, DOI 10.1016/j.virol.2007.10.007; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Luo Y, 2009, ANN NEUROL, V65, P520, DOI 10.1002/ana.21592; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nayak SK, 2009, CURR MED CHEM, V16, P2627, DOI 10.2174/092986709788681976; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	87	53	53	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e79837	10.1371/journal.pone.0079837			12	Multidisciplinary Sciences	Science & Technology - Other Topics	261IJ	WOS:000327657900003	24312187	DOAJ Gold, Green Published			2021-06-18	
J	Major, MJ; Fatone, S; Roth, EJ				Major, Matthew J.; Fatone, Stefania; Roth, Elliot J.			Validity and Reliability of the Berg Balance Scale for Community-Dwelling Persons With Lower-Limb Amputation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Amputees; Outcome measures; Postural balance; Rehabilitation	FRENCHAY ACTIVITIES INDEX; 2-MINUTE WALK TEST; INPATIENT REHABILITATION; PSYCHOMETRIC PROPERTIES; PROSTHETIC MOBILITY; STANDING BALANCE; VASCULAR-DISEASE; ELDERLY-PEOPLE; BRAIN-INJURY; STROKE	Objective: To evaluate the validity and reliability of the Berg Balance Scale (BBS) for use in people with lower-limb amputation. Design: Cross-sectional study. Setting: Research laboratory. Participants: Individuals (N=30; age, 54 +/- 12y; 20 men) with unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3) lower-limb amputation of dysvascular (n=7), traumatic (n=14), infectious (n=6), or congenital (n=3) origin. Interventions: Not applicable. Main Outcome Measures: BBS, 2-minute walk test, L test, Prosthesis Evaluation Questionnaire-Mobility Subscale, Activities-specific Balance Confidence Scale, and Frenchay Activities Index; self-reported descriptors were also collected, including frequency of prosthesis use, number of falls in 12 months before the visit, fear of falling, and daily mobility aid use. Results: The BBS had high interrater reliability (intraclass correlation coefficient =.945) and internal consistency (alpha=.827). Relations between the BBS scores and those of other outcome measures were all statistically significant (P <=.001). Significant group differences in BBS scores were observed for fear of falling (P=.008) and mobility aid use (P<.001), but not for multiple (>= 2) falls in the previous 12 months (P=.381). BBS items involving reaching forward, turning 360 degrees, tandem standing, and standing on 1 leg had relatively greater frequencies of lower scores across participants. Conclusions: The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation, but it may not be able to discriminate between individuals with greater or lesser fall risk. Limitations in prosthetic motion and control may be responsible for the challenges experienced on items of lower performance. Future studies would be useful to assess the responsiveness of the BBS to interventions aimed at improving balance in individuals with lower-limb amputation. (C) 2013 by the American Congress of Rehabilitation Medicine	[Major, Matthew J.; Fatone, Stefania] Northwestern Univ, Prosthet Orthot Ctr, Chicago, IL 60611 USA; [Major, Matthew J.; Fatone, Stefania; Roth, Elliot J.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Roth, Elliot J.] Rehabil Inst Chicago, Chicago, IL 60611 USA	Major, MJ (corresponding author), Northwestern Univ, Prosthet Orthot Ctr, 680 N Lake Shore Dr,Suite 1100, Chicago, IL 60611 USA.	Matthew-Major@northwestern.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [3UL1RR025741]; National Institute on Disability and Rehabilitation Research [H133P110013, H133E080009]; David Rubin, MD, Enrichment Fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741] Funding Source: NIH RePORTER	Supported by National Institutes of Health (grant no. 3UL1RR025741), National Institute on Disability and Rehabilitation Research (grant nos. H133P110013 and H133E080009), and the David Rubin, MD, Enrichment Fund. The opinions contained in this article are those of the authors and do not necessarily reflect those of the US Department of Education or Health and Human Services.	Alzayer L, 2009, J NEUROL PHYS THER, V33, P136, DOI 10.1097/NPT.0b013e3181b51307; Andersson AG, 2006, J REHABIL MED, V38, P186, DOI 10.1080/16501970500478023; Askham J, 1990, REV RES FALLS ELDERL; BERG K, 1995, SCAND J REHABIL MED, V27, P27; BERG K, 1989, Physiotherapy Canada, V41, P304; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; BERG KO, 1992, ARCH PHYS MED REHAB, V73, P1073; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Brooks D, 2002, ARCH PHYS MED REHAB, V83, P1562, DOI 10.1053/apmr.2002.34600; Brooks D, 2001, ARCH PHYS MED REHAB, V82, P1478, DOI 10.1053/apmr.2001.25153; Buckley JG, 2002, AM J PHYS MED REHAB, V81, P13, DOI 10.1097/00002060-200201000-00004; Busse ME, 2009, J NEUROL NEUROSUR PS, V80, P88, DOI 10.1136/jnnp.2008.147793; CAMPBELL A J, 1981, Age and Ageing, V10, P264, DOI 10.1093/ageing/10.4.264; Cattaneo D, 2007, DISABIL REHABIL, V29, P1920, DOI 10.1080/09638280701191859; Cattaneo D, 2006, DISABIL REHABIL, V28, P789, DOI 10.1080/09638280500404289; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, DOI [10.4324/9780203771587, DOI 10.1016/B978-0-12-179060-8.50012-8]; Cowley A, 2001, PHYS THER REV, V6, P5; Deathe AB, 2009, DISABIL REHABIL, V31, P1455, DOI 10.1080/09638280802639491; Deathe AB, 2005, PHYS THER, V85, P626, DOI 10.1093/ptj/85.7.626; Dibble Lee E, 2006, J Neurol Phys Ther, V30, P60; Dite W, 2007, ARCH PHYS MED REHAB, V88, P109, DOI 10.1016/j.apmr.2006.10.015; Ditunno JE, 2007, NEUROREHAB NEURAL RE, V21, P539, DOI 10.1177/1545968307301880; Duncan RP, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/237673; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feld JA, 2001, NEUROREHAB NEURAL RE, V15, P239, DOI 10.1177/154596830101500312; Franchignoni F, 2005, PARKINSONISM RELAT D, V11, P427, DOI 10.1016/j.parkreldis.2005.05.005; GEURTS ACH, 1992, SCAND J REHABIL MED, V24, P83; Gosselin S, 2008, J REHABIL MED, V40, P55, DOI 10.2340/16501977-0144; Halsaa KE, 2007, ARCH PHYS MED REHAB, V88, P94, DOI 10.1016/j.apmr.2006.10.016; HERMODSSON Y, 1994, PROSTHET ORTHOT INT, V18, P150; Hislop H, 1995, DANIELS WORTHINGHAMS; Hof AL, 2007, GAIT POSTURE, V25, P250, DOI 10.1016/j.gaitpost.2006.04.013; HOLBROOK M, 1983, AGE AGEING, V12, P166, DOI 10.1093/ageing/12.2.166; Kavounoudias A, 2005, ARCH PHYS MED REHAB, V86, P633, DOI 10.1016/j.apmr.2004.10.030; Kerr GK, 2010, NEUROLOGY, V75, P116, DOI 10.1212/WNL.0b013e3181e7b688; Kulkarni J., 1996, PHYSIOTHERAPY, V82, P130, DOI DOI 10.1016/S0031-9406(05)66968-4]; Landers Merrill R, 2008, J Neurol Phys Ther, V32, P56, DOI 10.1097/NPT.0b013e3181761330; Learmonth YC, 2012, INT J REHABIL RES, V35, P69, DOI 10.1097/MRR.0b013e328350b65f; Leddy AL, 2011, PHYS THER, V91, P102, DOI 10.2522/ptj.20100113; Legro MW, 1998, ARCH PHYS MED REHAB, V79, P931, DOI 10.1016/S0003-9993(98)90090-9; Lemay JF, 2010, SPINAL CORD, V48, P245, DOI 10.1038/sc.2009.119; Lim LIIK, 2005, PARKINSONISM RELAT D, V11, P19, DOI 10.1016/j.parkreldis.2004.06.003; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Major MJ, 2012, J REHABIL RES DEV, V49, P815, DOI 10.1682/JRRD.2011.06.0108; Major MJ, 2013, GAIT POSTURE; Mao HF, 2002, STROKE, V33, P1022, DOI 10.1161/01.STR.0000012516.63191.C5; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Miller WC, 2004, CLIN REHABIL, V18, P414, DOI 10.1191/0269215504cr728oa; Miller WC, 2003, ARCH PHYS MED REHAB, V84, P656, DOI 10.1016/S0003-9993(03)04807-4; Miller WC, 2002, PHYS THER, V82, P856, DOI 10.1093/ptj/82.9.856; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1031, DOI 10.1053/apmr.2001.24295; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1238, DOI 10.1053/apmr.2001.25079; Miller WC, 2001, ARCH PHYS MED REHAB, V82, P1432, DOI 10.1053/apmr.2001.25987; Muir SW, 2008, PHYS THER, V88, P449, DOI 10.2522/ptj.20070251; Nadollek Heidi, 2002, Physiother Res Int, V7, P203, DOI 10.1002/pri.260; Nederhand MJ, 2012, CLIN BIOMECH, V27, P40, DOI 10.1016/j.clinbiomech.2011.07.008; Newstead Ann H, 2005, J Neurol Phys Ther, V29, P18; Nilsagard Y, 2009, CLIN REHABIL, V23, P259, DOI 10.1177/0269215508095087; Norkin CC., 2003, MEASUREMENT JOINT MO, V3rd ed; Norvell DC, 2011, J VASC SURG, V54, P412, DOI 10.1016/j.jvs.2011.01.046; Pauley T, 2006, AM J PHYS MED REHAB, V85, P521, DOI 10.1097/01.phm.0000219119.58965.8c; Pedrinelli A, 2002, PROSTHET ORTHOT INT, V26, P195, DOI 10.1080/03093640208726648; Persson CU, 2011, J REHABIL MED, V43, P348, DOI 10.2340/16501977-0677; Portney LG, 2009, FDN CLIN RES APPL PR; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Quai TM, 2005, CLIN REHABIL, V19, P668, DOI 10.1191/0269215505cr857oa; Qutubuddin AA, 2005, ARCH PHYS MED REHAB, V86, P789, DOI 10.1016/j.apmr.2004.11.005; Rao AK, 2009, GAIT POSTURE, V29, P433, DOI 10.1016/j.gaitpost.2008.11.002; Raya MA, 2010, PROSTHET ORTHOT INT, V34, P73, DOI 10.3109/03093640903585008; Rougier PR, 2009, AM J PHYS MED REHAB, V88, P896, DOI 10.1097/PHM.0b013e3181b331af; Sahin Fusun, 2008, J Geriatr Phys Ther, V31, P32; Sawatzky B, 2007, ARCH PHYS MED REHAB, V88, P1423, DOI 10.1016/j.apmr.2007.08.005; Scalzo PL, 2009, ARQ NEURO-PSIQUIAT, V67, P831, DOI 10.1590/S0004-282X2009000500010; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Thorbahn LDB, 1996, PHYS THER, V76, P576, DOI 10.1093/ptj/76.6.576; Ulger O, 2009, TURK J PHYSIOTHER R, V20, P169; van Velzen JM, 2006, CLIN REHABIL, V20, P999, DOI 10.1177/0269215506070700; Vanicek N, 2009, ARCH PHYS MED REHAB, V90, P1018, DOI 10.1016/j.apmr.2008.12.024; Vincent C, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-68; Viton JM, 2000, PROSTHET ORTHOT INT, V24, P108, DOI 10.1080/03093640008726533; Vrieling AH, 2008, GAIT POSTURE, V28, P222, DOI 10.1016/j.gaitpost.2007.12.002; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E; Wee JY, 2003, ARCH PHYS MED REHAB, V84, P731, DOI 10.1016/S0003-9993(03)04940-7; Wirz M, 2010, NEUROREHAB NEURAL RE, V24, P70, DOI 10.1177/1545968309341059; Yazicioglu K, 2007, AM J PHYS MED REHAB, V86, P800, DOI 10.1097/PHM.0b013e318151fc74	88	53	54	0	60	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2194	2202		10.1016/j.apmr.2013.07.002			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	250KV	WOS:000326852600022	23856150				2021-06-18	
J	Randolph, C; Karantzoulis, S; Guskiewicz, K				Randolph, Christopher; Karantzoulis, Stella; Guskiewicz, Kevin			Prevalence and Characterization of Mild Cognitive Impairment in Retired National Football League Players	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Concussion; Football; Sports; CTE; MCI	CHRONIC TRAUMATIC ENCEPHALOPATHY; RECURRENT CONCUSSION; HEAD IMPACTS; ASSOCIATION; DEMENTIA; DISEASE; AFTERMATH; INJURY; RBANS; SPORT	It has been hypothesized that exposure to repetitive head trauma from contact sports over a long-playing career may eventuate in an increased risk of late-life cognitive impairment. There are currently two competing hypotheses about the possible mechanism underlying such impairment. One is the presence of a unique neurodegenerative disorder known as "chronic traumatic encephalopathy" (CTE). The other is diminished cerebral reserve leading to the earlier clinical expression of age-related neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD). The present study examined informant AD8 inventory data in a sample of 513 retired National Football League (NFL) players. These data were indicative of possible cognitive impairment in 35.1% of this relatively young sample. A comparison of neurocognitive profiles in a subsample of this group to a clinical sample of patients with a diagnosis of MCI due to AD revealed a highly similar profile of impairments. Overall, the data suggest that there may be an increased prevalence of late-life cognitive impairment in retired NFL players, which may reflect diminished cerebral reserve. The findings are considered preliminary, but emphasize the need for larger, controlled studies on this issue.	[Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA; [Karantzoulis, Stella] NYU, Langone Med Ctr, Dept Neurol, New York, NY USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Phys Med & Rehabil, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC USA	Randolph, C (corresponding author), 1 East Erie,Suite 353, Chicago, IL 60611 USA.	crandol@lumc.edu		Guskiewicz, Kevin/0000-0002-8682-2130	Martek Biosciences Corporation	This study was funded in part by Martek Biosciences Corporation. We thank Candice Goerger, Amy Matthews, Karla Thompson, and Daniel Kaufer for their contributions. Dr. Randolph is the author of the RBANS, and receives royalties from sales of this test. The authors have no other conflicts to disclose	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Baron SL, 2012, AM J CARDIOL, V109, P889, DOI 10.1016/j.amjcard.2011.10.050; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; Bennett DA, 2006, NEUROLOGY, V66, P1837, DOI 10.1212/01.wnl.0000219668.47116.e6; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Donnell AJ, 2007, ARCH CLIN NEUROPSYCH, V22, P917, DOI 10.1016/j.acn.2007.06.007; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Galvin JE, 2005, NEUROLOGY, V65, P559, DOI 10.1212/01.wnl.0000172958.95282.2a; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C, 1998, REPEATABLE BATTERY A; Randolph C, 2012, ALZHEIMERS DEMENT, V8, P172; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Roberts RO, 2012, NEUROLOGY, V78, P342, DOI 10.1212/WNL.0b013e3182452862; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Tervo S, 2004, DEMENT GERIATR COGN, V17, P196, DOI 10.1159/000076356; WELSH KA, 1993, NEUROPSY NEUROPSY BE, V6, P103	31	53	53	1	87	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2013	19	8					873	880		10.1017/S1355617713000805			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	209AQ	WOS:000323725800004	23902607				2021-06-18	
J	Shi, HY; Hwang, SL; Lee, KT; Lin, CL				Shi, Hon-Yi; Hwang, Shiuh-Lin; Lee, King-Teh; Lin, Chih-Lung			In-hospital mortality after traumatic brain injury surgery: a nationwide population-based comparison of mortality predictors used in artificial neural network and logistic regression models Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; in-hospital mortality; artificial neural network; logistic regression	UNITED-STATES; HEAD-INJURY; VALIDATION; SURVIVAL; ACCURACY	Object. Most reports compare artificial neural network (ANN) models and logistic regression models in only a single data set, and the essential issue of internal validity (reproducibility) of the models has not been adequately addressed. This study proposes to validate the use of the ANN model for predicting in-hospital mortality after traumatic brain injury (TBI) surgery and to compare the predictive accuracy of ANN with that of the logistic regression model. Methods. The authors of this study retrospectively analyzed 16,956 patients with TBI nationwide who were surgically treated in Taiwan between 1998 and 2009. For every 1000 pairs of ANN and logistic regression models, the area under the receiver operating characteristic curve (AUC), Hosmer-Lemeshow statistics, and accuracy rate were calculated and compared using paired t-tests. A global sensitivity analysis was also performed to assess the relative importance of input parameters in the ANN model and to rank the variables in order of importance. Results. The ANN model outperformed the logistic regression model in terms of accuracy in 95.15% of cases, in terms of Hosmer-Lemeshow statistics in 43.68% of cases, and in terms of the AUC in 89.14% of cases. The global sensitivity analysis of in-hospital mortality also showed that the most influential (sensitive) parameters in the ANN model were surgeon volume followed by hospital volume, Charlson comorbidity index score, length of stay, sex, and age. Conclusions. This work supports the continued use of ANNs for predictive modeling of neurosurgery outcomes. However, further studies are needed to confirm the clinical efficacy of the proposed model. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121130)	[Shi, Hon-Yi; Lee, King-Teh] Kaohsiung Med Univ, Dept Healthcare Adm & Med Informat, Kaohsiung, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ Hosp, Dept Neurosurg, Kaohsiung 80708, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan; [Lee, King-Teh] Kaohsiung Med Univ, Dept Surg, Div Hepatobiliary Surg, Kaohsiung, Taiwan	Lin, CL (corresponding author), Kaohsiung Med Univ Hosp, Dept Neurosurg, 100 Shih Chun 1st Rd, Kaohsiung 80708, Taiwan.	hshi@kmu.edu.tw			National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC99-2314-B-037-069-MY3]	This study was supported by funding from the National Science Council, Taiwan (NSC99-2314-B-037-069-MY3). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bullock MR, 2007, J NEUROTRAUMA S1, V24; Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808; Curry WT, 2005, J NEUROSURG, V102, P977, DOI 10.3171/jns.2005.102.6.0977; Das A, 2003, LANCET, V362, P1261, DOI 10.1016/S0140-6736(03)14568-0; de Jongh MAC, 2010, BRIT J SURG, V97, P1805, DOI 10.1002/bjs.7216; Defillo A, 2010, J NEUROSURG, V113, P399, DOI 10.3171/2009.10.JNS091500; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DiRusso SM, 2000, J TRAUMA, V49, P212, DOI 10.1097/00005373-200008000-00006; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; FORSSTROM JJ, 1995, ANN MED, V27, P509, DOI 10.3109/07853899509002462; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Grossman R, 2011, ANN SURG ONCOL, V18, P521, DOI 10.1245/s10434-010-1299-2; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Hotchkiss JR, 2006, CRIT CARE MED, V34, P1267, DOI 10.1097/01.CCM.0000208148.13721.AE; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Livingston EH, 2010, JAMA-J AM MED ASSOC, V304, P95, DOI 10.1001/jama.2010.905; Nakagawa TA, 2011, CRIT CARE MED, V39, P2139, DOI 10.1097/CCM.0b013e31821f0d4f; Pastorius Benziger Catherine, 2011, Crit Pathw Cardiol, V10, P99, DOI 10.1097/HPC.0b013e318223e375; Rughani AI, 2010, J NEUROSURG, V113, P585, DOI 10.3171/2009.11.JNS09857; Sandberg IW, 2001, NONLINEAR DYNAMICAL; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Segal ME, 2006, J HEAD TRAUMA REHAB, V21, P298, DOI 10.1097/00001199-200607000-00003; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shamim MS, 2011, J NEUROSURG, V115, P1007, DOI 10.3171/2011.7.JNS101829; Shi HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035781; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Terrin N, 2003, J CLIN EPIDEMIOL, V56, P721, DOI 10.1016/S0895-4356(03)00120-3; Tu JV, 1996, J CLIN EPIDEMIOL, V49, P1225, DOI 10.1016/S0895-4356(96)00002-9; WHISNANT JP, 1993, J NEUROSURG, V78, P726, DOI 10.3171/jns.1993.78.5.0726; Zou Jinming, 2008, V458, P15	33	53	54	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					746	752		10.3171/2013.1.JNS121130			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700010	23373802				2021-06-18	
J	Titus, DJ; Sakurai, A; Kang, Y; Furones, C; Jergova, S; Santos, R; Sick, TJ; Atkins, CM				Titus, David J.; Sakurai, Atsushi; Kang, Yuan; Furones, Concepcion; Jergova, Stanislava; Santos, Rosmery; Sick, Thomas J.; Atkins, Coleen M.			Phosphodiesterase Inhibition Rescues Chronic Cognitive Deficits Induced by Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; SPATIAL MEMORY; DORSAL HIPPOCAMPUS; RAT HIPPOCAMPUS; TRANSCRIPTION FACTORS; INDUCED IMPAIRMENTS; PROTEIN-SYNTHESIS; MOUSE MODEL; HEAD-INJURY	Traumatic brain injury (TBI) modulates several cell signaling pathways in the hippocampus critical for memory formation. Previous studies have found that the cAMP-protein kinase A signaling pathway is downregulated after TBI and that treatment with a phosphodiesterase (PDE) 4 inhibitor rolipram rescues the decrease in cAMP. In the present study, we examined the effect of rolipram on TBI-induced cognitive impairments. At 2 weeks after moderate fluid-percussion brain injury or sham surgery, adult male Sprague Dawley rats received vehicle or rolipram (0.03 mg/kg) 30 min before water maze acquisition or cue and contextual fear conditioning. TBI animals treated with rolipram showed a significant improvement in water maze acquisition and retention of both cue and contextual fear conditioning compared with vehicle-treated TBI animals. Cue and contextual fear conditioning significantly increased phosphorylated CREB levels in the hippocampus of sham animals, but not in TBI animals. This deficit in CREB activation during learning was rescued in TBI animals treated with rolipram. Hippocampal long-term potentiation was reduced in TBI animals, and this was also rescued with rolipram treatment. These results indicate that the PDE4 inhibitor rolipram rescues cognitive impairments after TBI, and this may be mediated through increased CREB activation during learning.	[Titus, David J.; Sakurai, Atsushi; Kang, Yuan; Furones, Concepcion; Jergova, Stanislava; Santos, Rosmery; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Sick, Thomas J.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, 1095 NW 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu		Titus, David/0000-0001-7819-734X; Atkins, Coleen/0000-0003-4718-7493	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069721, NS056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS069721] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health Grants NS069721 and NS056072 and the Miami Project to Cure Paralysis. We thank Dr. W. Dalton Dietrich for critical reading of the manuscript.	Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Anderson WW, 2007, J NEUROSCI METH, V162, P346, DOI 10.1016/j.jneumeth.2006.12.018; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; ASANUMA M, 1993, RES COMMUN CHEM PATH, V82, P279; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barad M, 1998, P NATL ACAD SCI USA, V95, P15020, DOI 10.1073/pnas.95.25.15020; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; BOISSARD CG, 1992, NEUROSCIENCE, V48, P807, DOI 10.1016/0306-4522(92)90268-7; Bourtchouladze R, 2003, P NATL ACAD SCI USA, V100, P10518, DOI 10.1073/pnas.1834280100; Bourtchouladze R, 1998, LEARN MEMORY, V5, P365; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown KL, 2011, BEHAV BRAIN RES, V225, P290, DOI 10.1016/j.bbr.2011.07.044; Bruno O, 2009, J MED CHEM, V52, P6546, DOI 10.1021/jm900977c; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chwang WB, 2006, LEARN MEMORY, V13, P322, DOI 10.1101/lm.152906; Clark RE, 2001, HIPPOCAMPUS, V11, P176, DOI 10.1002/hipo.1035; Crain SM, 2008, BRAIN RES, V1231, P16, DOI 10.1016/j.brainres.2008.07.015; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Dlaboga D, 2006, BRAIN RES, V1096, P104, DOI 10.1016/j.brainres.2006.04.032; Egawa T, 1997, JPN J PHARMACOL, V75, P275, DOI 10.1254/jjp.75.275; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Giorgi M, 2004, BEHAV BRAIN RES, V154, P99, DOI 10.1016/j.bbr.2004.01.024; Giralt A, 2011, HUM MOL GENET, V20, P4232, DOI 10.1093/hmg/ddr351; Gong B, 2004, J CLIN INVEST, V114, P1624, DOI 10.1172/JCI200422831; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Imanishi T, 1997, EUR J PHARMACOL, V321, P273, DOI 10.1016/S0014-2999(96)00969-7; Kobori N, 2011, NEUROSCIENCE, V172, P293, DOI 10.1016/j.neuroscience.2010.10.048; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Maren S, 1997, BEHAV BRAIN RES, V88, P261, DOI 10.1016/S0166-4328(97)00088-0; Matus-Amat P, 2004, J NEUROSCI, V24, P2431, DOI 10.1523/JNEUROSCI.1598-03.2004; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; Navakkode S, 2004, J NEUROSCI, V24, P7740, DOI 10.1523/JNEUROSCI.1796-04.2004; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; PHILLIPS RG, 1994, LEARN MEMORY, V1, P34; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Ploski JE, 2008, J NEUROSCI, V28, P12383, DOI 10.1523/JNEUROSCI.1662-08.2008; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Robichaud A, 2002, BRIT J PHARMACOL, V135, P113, DOI 10.1038/sj.bjp.0704457; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; RUDY JW, 1994, BEHAV NEUROSCI, V108, P227, DOI 10.1037/0735-7044.108.2.227; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Runyan JD, 2005, LEARN MEMORY, V12, P232, DOI 10.1101/lm.92405; Rutten K, 2009, NEUROPSYCHOPHARMACOL, V34, P1914, DOI 10.1038/npp.2009.24; Schafe GE, 1999, LEARN MEMORY, V6, P97; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHOFFELMEER ANM, 1985, N-S ARCH PHARMACOL, V330, P74, DOI 10.1007/BF00586712; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van Staveren WCG, 2001, BRAIN RES, V888, P275, DOI 10.1016/S0006-8993(00)03081-X; Vecsey CG, 2009, NATURE, V461, P1122, DOI 10.1038/nature08488; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wiltgen BJ, 2006, J NEUROSCI, V26, P5484, DOI 10.1523/JNEUROSCI.2685-05.2006; WINSKY L, 1987, J PHARMACOL EXP THER, V241, P223; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HT, 2004, NEUROPSYCHOPHARMACOL, V29, P1432, DOI 10.1038/sj.npp.1300440	86	53	58	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 20	2013	33	12					5216	5226		10.1523/JNEUROSCI.5133-12.2013			11	Neurosciences	Neurosciences & Neurology	111XB	WOS:000316553800015	23516287	Green Accepted, Green Published, Bronze			2021-06-18	
J	Esposito, E; Cuzzocrea, S				Esposito, Emanuela; Cuzzocrea, Salvatore			Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Glial cells; N-acylethanolamine; neuroprotection; spinal cord	PERIPHERAL CANNABINOID RECEPTOR; FATTY-ACID AMIDES; MAST-CELLS; N-ACYLETHANOLAMINES; ENDOCANNABINOID SYSTEM; ACUTE-INFLAMMATION; CEREBRAL-ISCHEMIA; GROWTH-FACTOR; CB2 RECEPTOR; EYE TISSUES	The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this N-acylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.	[Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it		Cuzzocrea, Salvatore/0000-0001-6131-3690	PON "RC"Ministry of Education, Universities and Research (MIUR) [01_02512]	This study was partially supported by PON "R&C" 01_02512, 2007-2013.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; ALOE L, 1993, AGENTS ACTIONS, V39, pC145, DOI 10.1007/BF01972748; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Annuzzi G, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-43; Artmann A, 2008, BBA-MOL CELL BIOL L, V1781, P200, DOI 10.1016/j.bbalip.2008.01.006; Balvers MGJ, 2009, J CHROMATOGR B, V877, P1583, DOI 10.1016/j.jchromb.2009.04.010; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Benvenuti F, 1968, Boll Soc Ital Biol Sper, V44, P809; Berger C, 2004, J NEUROCHEM, V88, P1159, DOI 10.1046/j.1471-4159.2003.02244.x; Bischoff SC, 2009, SEMIN IMMUNOPATHOL, V31, P185, DOI 10.1007/s00281-009-0165-4; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; Cerrato S, 2010, VET IMMUNOL IMMUNOP, V133, P9, DOI 10.1016/j.vetimm.2009.06.011; Chapman KD, 2000, CHEM PHYS LIPIDS, V108, P221, DOI 10.1016/S0009-3084(00)00198-5; Chapman KD, 2004, PROG LIPID RES, V43, P302, DOI 10.1016/j.plipres.2004.03.002; Chen J, 2005, BIOCHEM BIOPH RES CO, V330, P1062, DOI 10.1016/j.bbrc.2005.03.095; COBURN AF, 1954, J EXP MED, V100, P425, DOI 10.1084/jem.100.5.425; Conigliaro R, 2011, MINERVA MED, V102, P141; Conti S, 2002, BRIT J PHARMACOL, V135, P181, DOI 10.1038/sj.bjp.0704466; Costa B, 2002, BRIT J PHARMACOL, V137, P413, DOI 10.1038/sj.bjp.0704900; D'Agostino G, 2012, NEUROPSYCHOPHARMACOL, V37, P1784, DOI 10.1038/npp.2012.25; D'Argenio G, 2007, J MOL MED, V85, P523, DOI 10.1007/s00109-007-0192-3; Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50; Eberlein B, 2008, J EUR ACAD DERMATOL, V22, P73, DOI 10.1111/j.1468-3083.2007.02351.x; Eklund KK, 2007, IMMUNOL REV, V217, P38, DOI 10.1111/j.1600-065X.2007.00504.x; Enna S.J., 2009, XPHARM COMPREHENSIVE, P1; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Figueiredo C, 2008, J NEUROCHEM, V107, P73, DOI 10.1111/j.1471-4159.2008.05577.x; Franklin A, 2003, J NEUROSCI, V23, P7767; GANLEY OH, 1958, J LAB CLIN MED, V51, P709; Garcia-Ovejero D, 2009, NEUROBIOL DIS, V33, P57, DOI 10.1016/j.nbd.2008.09.015; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Ghafouri N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027257; Giuffrida A, 1998, FEBS LETT, V422, P373, DOI 10.1016/S0014-5793(98)00046-5; Guida G., 2010, DOLOR, V25, P35; Guindon J, 2006, EUR J PHARMACOL, V550, P68, DOI 10.1016/j.ejphar.2006.08.045; Harvima IT, 2008, ARCH DERMATOL RES, V300, P461, DOI 10.1007/s00403-008-0874-x; Hoareau L, 2009, OBESITY, V17, P431, DOI 10.1038/oby.2008.591; Holdsworth SR, 2008, J AM SOC NEPHROL, V19, P2254, DOI 10.1681/ASN.2008010015; Ito Akihiko, 2008, Journal of Smooth Muscle Research, V44, P83, DOI 10.1540/jsmr.44.83; Izzo AA, 2008, J MOL MED, V86, P89, DOI 10.1007/s00109-007-0248-4; Jacobsson SOP, 2001, BRIT J PHARMACOL, V132, P1743, DOI 10.1038/sj.bjp.0704029; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Jumpertz R, 2011, J CLIN ENDOCR METAB, V96, P787, DOI 10.1210/jc.2010-2028; Kallendrusch S., 2010, P ICRS 2010 20 ANN S; Koch M, 2011, NEUROTOX RES, V19, P330, DOI 10.1007/s12640-010-9166-2; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; Kumar V, 2010, MOL IMMUNOL, V48, P14, DOI 10.1016/j.molimm.2010.07.009; Lambert DM, 1999, CURR MED CHEM, V6, P757; Lambert DM, 2002, CURR MED CHEM, V9, P663, DOI 10.2174/0929867023370707; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; LONG DA, 1956, LANCET, V270, P464; Lundequist A, 2011, CELL MOL LIFE SCI, V68, P965, DOI 10.1007/s00018-010-0587-0; Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; Metz M, 2007, IMMUNOL REV, V217, P304, DOI 10.1111/j.1600-065X.2007.00520.x; Moon TC, 2010, MUCOSAL IMMUNOL, V3, P111, DOI 10.1038/mi.2009.136; Moriconi A, 2010, CURR MED CHEM, V17, P1411, DOI 10.2174/092986710790980069; Muccio GG, 2008, ANAL BIOCHEM, V373, P220, DOI 10.1016/j.ab.2007.09.030; Muccioli GG, 2008, NEUROPHARMACOLOGY, V54, P16, DOI 10.1016/j.neuropharm.2007.05.015; Murillo-Rodniguez E, 2006, LIFE SCI, V79, P30, DOI 10.1016/j.lfs.2005.12.028; Naccarato M, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-47; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; O'Sullivan SE, 2010, IMMUNOBIOLOGY, V215, P611, DOI 10.1016/j.imbio.2009.09.007; Ozalp A, 2009, ANAL BIOCHEM, V395, P68, DOI 10.1016/j.ab.2009.08.005; PERLIK F, 1971, ACTA PHYSIOL HUNG, V39, P395; Petrosino S., 2008, 33rd World Small Animal Veterinary Association Congress, Dublin, Ireland, 20-24 August 2008, P707; Petrosino S, 2010, ALLERGY, V65, P698, DOI 10.1111/j.1398-9995.2009.02254.x; Petrosino S., 2009, HDB NEUROCHEMISTRY M, P75, DOI [10.1007/978-0-387-30378-9_5, DOI 10.1007/978-0-387-30378-9_5]; Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011; Petrosino S, 2010, BIOCHIMIE, V92, P724, DOI 10.1016/j.biochi.2010.01.006; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Re G, 2007, VET J, V173, P21, DOI 10.1016/j.tvjl.2005.10.003; Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401; Sasso O, 2012, PAIN, V153, P33, DOI 10.1016/j.pain.2011.08.010; Sasso O, 2010, EUR NEUROPSYCHOPHARM, V20, P195, DOI 10.1016/j.euroneuro.2009.09.003; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Schreiber D, 2007, ANAL BIOCHEM, V361, P162, DOI 10.1016/j.ab.2006.11.027; Scuderi C, 2011, J CELL MOL MED, V15, P2664, DOI 10.1111/j.1582-4934.2011.01267.x; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Strbian D, 2009, ANN MED, V41, P438, DOI 10.1080/07853890902887303; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Wise LE, 2008, NEUROPHARMACOLOGY, V54, P181, DOI 10.1016/j.neuropharm.2007.06.003	94	53	55	0	6	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2013	12	1					55	61		10.2174/1871527311312010010			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	104MB	WOS:000315996300010	23394520				2021-06-18	
J	Mendez, MF; Owens, EM; Berenji, GR; Peppers, DC; Liang, LJ; Licht, EA				Mendez, Mario F.; Owens, Emily M.; Berenji, Gholam Reza; Peppers, Dominique C.; Liang, Li-Jung; Licht, Eliot A.			Mild traumatic brain injury from primary blast vs. blunt forces: Post-concussion consequences and functional neuroimaging	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast forces; post-concussion; positron emission tomography imaging	PERSISTENT POSTCONCUSSIVE SYMPTOMS; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; OIF/OEF SERVICE MEMBERS; NEUROPSYCHOLOGICAL DEFICITS; WAR VETERANS; HEAD-INJURY; FDG-PET; MECHANISMS; STRESS	INTRODUCTION: Primary blast forces may cause dysfunction from mild traumatic brain injury (mTBI). OBJECTIVE: To investigate the effects of primary blast forces, independent of associated blunt trauma and post-traumatic stress disorder, on sensitive post-concussive measures. METHODS: This study investigated post-concussive symptoms, functional health and well-being, cognition, and positron emission tomography (PET) neuroimaging among 12 Iraq or Afghanistanwar veterans who sustained pure blast-force mTBI, compared to 12 who sustained pure blunt-force mTBI. RESULTS: Both groups had significantly lower scores than published norms on the Rivermead Post-Concussion Questionnaire (RPQ) and the SF36-V Health Survey. Compared to the Blunt Group, the Blast Group had poorer scores on the Paced Auditory Serial Addition Test (PASAT) and greater PET hypometabolism in the right superior parietal region. Only the Blast Group had significant correlations of their RPQ, SF36-V Mental Composite Score, and PASAT scores with specific regional metabolic changes. CONCLUSION: This pilot study suggests that pure blast force mTBI may have greater post-concussive sequelae including deficits in attentional control and regional brain metabolism, compared to blunt mTBI. A disturbance of a right parietal-frontal attentional network is one potential explanation for these findings.	[Mendez, Mario F.; Owens, Emily M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; [Mendez, Mario F.; Licht, Eliot A.] VA Greater Los Angeles Healthcare Ctr, Neurol Sect, Los Angeles, CA 90073 USA; [Berenji, Gholam Reza; Peppers, Dominique C.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA; [Liang, Li-Jung] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA	Mendez, MF (corresponding author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	mmendez@UCLA.edu			Veterans Affairs AdministrationUS Department of Veterans Affairs	No conflicts of interest. This research was made possible by a grant from the Veterans Affairs Administration.	Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Drake AI, 2010, NEUROREHABILITATION, V26, P183, DOI 10.3233/NRE-2010-0554; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Fitzgerald KD, 2005, BIOL PSYCHIAT, V57, P287, DOI 10.1016/j.biopsych.2004.10.038; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kazis LE, 2004, HEALTH CARE FINANC R, V25, P43; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P70; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kozminski M, 2010, J AM OSTEOPATH ASSOC, V110, P514; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silverman DHS, 2011, PSYCHONEUROENDOCRINO, V36, P502, DOI 10.1016/j.psyneuen.2010.08.002; Silverman DHS, 2004, J NUCL MED, V45, P594; Singh JA, 2005, J AM GERIATR SOC, V53, P108, DOI 10.1111/j.1532-5415.2005.53020.x; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Vasquez BP, 2011, NEUROPSYCHOLOGIA, V49, P1741, DOI 10.1016/j.neuropsychologia.2011.02.052; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilson JTL, 2005, ACTA NEUROCHIR SUPPL, V93, P75; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	69	53	53	0	31	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	2					397	407		10.3233/NRE-130861			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	115ZT	WOS:000316851900025	23535805				2021-06-18	
J	Jin, G; Duggan, M; Imam, A; deMoya, MA; Sillesen, M; Hwabejire, J; Jepsen, CH; Liu, BL; Mejaddam, AY; Lu, J; Smith, WM; Velmahos, GC; Socrate, S; Alam, HB				Jin, Guang; Duggan, Michael; Imam, Ayesha; deMoya, Marc A.; Sillesen, Martin; Hwabejire, John; Jepsen, Cecilie H.; Liu, Baoling; Mejaddam, Ali Y.; Lu, Jennifer; Smith, William Michael; Velmahos, George C.; Socrate, Simona; Alam, Hasan B.			Pharmacologic resuscitation for hemorrhagic shock combined with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Brain; trauma; resuscitation; valproic acid; swine	FOCAL CEREBRAL-ISCHEMIA; VALPROIC ACID; FLUID RESUSCITATION; ADHESION MOLECULES; HEAD-INJURY; ACTIVATION; SYSTEM; MODEL; HEMODILUTION; COAGULATION	BACKGROUND: We have previously demonstrated that valproic acid (VPA), a histone deacetylase inhibitor, can improve survival after hemorrhagic shock (HS), protect neurons from hypoxia-induced apoptosis, and attenuate the inflammatory response. We have also shown that administration of 6% hetastarch (Hextend [Hex]) after traumatic brain injury (TBI) decreases brain swelling, without affecting size of the lesion. This study was performed to determine whether addition of VPA to flex would decrease the lesion size in a clinically relevant large animal model of TBI + HS. METHODS: Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters, intracranial pressure, and brain tissue oxygenation. A custom-designed, computer-controlled cortical impact device was used to create a TBI through a 20-mm craniotomy: 15-mm cylindrical tip impactor at 4-m/s velocity, 100-millisecond dwell time, and 12-mm penetration depth. Volume-controlled hemorrhage was started (40% blood volume) concurrent with the TBI. After 2 hours of shock, animals were randomized to one of three resuscitation groups (n = 7 per group) as follows: (1) isotonic sodium chloride solution; (2) 6% hetastarch, Hex; and (3) Hex and VPA 300 mg/kg (Hex + VPA). Volumes of Hex matched the shed blood, whereas that of the isotonic sodium chloride solution was three times the volume. VPA treatment was started after an hour of shock. After 6 hours of postresuscitation monitoring, brains were sectioned into 5-mm slices and stained with 2, 3, 5-Triphenyltetrazolium chloride to quantify the lesion size (mm(3)) and brain swelling (percent change compared with uninjured side). Levels of acetylated histone H3 were determined to quantify acetylation, and myeloperoxidase and interleuldne-1 beta (IL-1 beta) levels were measured as markers of brain inflammation. RESULTS:. Combination of 40% blood loss with cortical impact and a period of shock (2 hours) and resuscitation resulted in a highly reproducible brain injury. Lesion size and brain swelling in the Hex + VPA group (1,989 [156.8] mm(3), and 19% [1.6%], respectively) were significantly smaller than the isotonic sodium chloride solution group (3,335 [287.9] mm(3) and 36% [2.2%], respectively). Hex alone treatment significantly decreased the swelling (27% [1.6%]) without reducing the lesion size. The number of CD11b-positive cells as well as myeloperoxidase and IL-1 levels in the brains were significantly reduced by the VPA treatment. CONCLUSION: In a combined HS and TBI model, treatment with artificial colloid (Hex) improves hemodynamic parameters and reduces swelling, without affecting the actual size of the brain lesion. Addition of VPA effectively reduces both the size of brain lesion and associated swelling by attenuating the inflammatory response. (J Trauma Acute Care Surg. 2012;73: 1461-1470. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Alam, Hasan B.] Univ Michigan Hosp, Taubman Ctr 2920, Dept Surg, Ann Arbor, MI 48109 USA; [Jin, Guang; Duggan, Michael; Imam, Ayesha; deMoya, Marc A.; Hwabejire, John; Jepsen, Cecilie H.; Liu, Baoling; Mejaddam, Ali Y.; Lu, Jennifer; Smith, William Michael; Velmahos, George C.; Alam, Hasan B.] Harvard Univ, Sch Med, Dept Surg,Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02115 USA; [Socrate, Simona] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, Dept Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475			Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Gonzales ER, 2008, J TRAUMA, V65, P554, DOI 10.1097/TA.0b013e31818233ef; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jin G, 2011, ACTA BIOMATER; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Jin G, 2011, SURGERY, V150, P429, DOI 10.1016/j.surg.2011.07.001; Jin G, 2009, EXP NEUROL, V217, P165, DOI 10.1016/j.expneurol.2009.02.004; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kasotakis G, TRAUMATIC BRAIN INJU; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Lheureux PER, 2005, CRIT CARE, V9, P431, DOI 10.1186/cc3742; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; McKeating EG, 1998, BRIT J ANAESTH, V80, P77; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; OHTAKI M, 1993, SURG NEUROL, V40, P196, DOI 10.1016/0090-3019(93)90068-C; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Takano K, 1997, STROKE, V28, P1255, DOI 10.1161/01.STR.28.6.1255; TU YK, 1988, J NEUROSURG, V69, P72, DOI 10.3171/jns.1988.69.1.0072; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; West MA, 2008, J TRAUMA, V64, P870; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	51	53	53	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1461	1470		10.1097/TA.0b013e3182782641			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	058FV	WOS:000312620400017	23188239				2021-06-18	
J	Wade, SL; Walz, NC; Carey, J; McMullen, KM; Cass, J; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.; Cass, Jennifer; Mark, Erin; Yeates, Keith Owen			A Randomized Trial of Teen Online Problem Solving: Efficacy in Improving Caregiver Outcomes After Brain Injury	HEALTH PSYCHOLOGY			English	Article						acquired brain injury; telehealth; adolescent; problem solving; caregiver	PEDIATRIC TRAUMATIC INJURY; FAMILY INTERVENTION; INITIAL YEAR; CHILDREN; PREDICTORS; BEHAVIOR; ADOLESCENTS; ADAPTATION; PROGRAM; BURDEN	Objective: To examine the results of a randomized clinical trial (RCT) of Teen Online Problem Solving (TOPS), an online problem solving therapy model, in increasing problem-solving skills and decreasing depressive symptoms and global distress for caregivers of adolescents with traumatic brain injury (TBI). Method: Families of adolescents aged 11-18 who sustained a moderate to severe TB I between 3 and 19 months earlier were recruited from hospital trauma registries. Participants were assigned to receive a web-based, problem-solving intervention (TOPS, n = 20), or access to online resources pertaining to TBI (Internet Resource Comparison; IRC; n = 21). Parent report of problem solving skills, depressive symptoms, global distress, utilization, and satisfaction were assessed pre- and posttreatment. Groups were compared on follow-up scores after controlling for pretreatment levels. Family income was examined as a potential moderator of treatment efficacy. Improvement in problem solving was examined as a mediator of reductions in depression and distress. Results: Forty-one participants provided consent and completed baseline assessments, with follow-up assessments completed on 35 participants (16 TOPS and 19 IRC). Parents in both groups reported a high level of satisfaction with both interventions. Improvements in problem solving skills and depression were moderated by family income, with caregivers of lower income in TOPS reporting greater improvements. Increases in problem solving partially mediated reductions in global distress. Conclusions: Findings suggest that TOPS may be effective in improving problem solving skills and reducing depressive symptoms for certain subsets of caregivers in families of adolescents with TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; McMullen, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G050239]	This work was supported by grant #H133G050239 from the National Institute of Disability and Rehabilitation Research, U.S. Department of Education. This study is registered at www.clinicaltrials.gov. Clinicaltrials.gov identifier: NCT00409058	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 2005, ARCH PHYS MED REHAB, V86, P175, DOI 10.1016/j.apmr.2004.02.026; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Boschen K., 2005, NEUROREHABILITATION, V19, P363; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; D'Zurilla T. J., 1990, PYCSHOLOGICAL ASSESS, V2, P156, DOI DOI 10.1037/1040-3590.2.2.156; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maruish M.E., 1994, USE PSYCHOL TESTING, P217; Nezu A. M., 2007, SOLVING LIFES PROBLE; Radloff LS, 1977, J APPL PSYCHOL MEASU, V1, P385, DOI DOI 10.1177/014662167700100306; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SILVERBERG SB, 1987, J YOUTH ADOLESCENCE, V16, P293, DOI 10.1007/BF02139096; SILVERBERG SB, 1990, DEV PSYCHOL, V26, P658, DOI 10.1037/0012-1649.26.4.658; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Teasdale G., 1974, LANCET, V304, P248; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	30	53	53	0	16	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0278-6133			HEALTH PSYCHOL	Health Psychol.	NOV	2012	31	6					767	776		10.1037/a0028440			10	Psychology, Clinical; Psychology	Psychology	036IA	WOS:000311018400012	22746261				2021-06-18	
J	Budohoski, KP; Reinhard, M; Aries, MJH; Czosnyka, Z; Smielewski, P; Pickard, JD; Kirkpatrick, PJ; Czosnyka, M				Budohoski, Karol P.; Reinhard, Matthias; Aries, Marcel J. H.; Czosnyka, Zofia; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.; Czosnyka, Marek			Monitoring cerebral autoregulation after head injury. Which component of transcranial Doppler flow velocity is optimal?	NEUROCRITICAL CARE			English	Article						Cerebral autoregulation; Traumatic brain injury; Flow velocity; Transcranial Doppler	TRAUMATIC BRAIN-INJURY; CAROTID-ARTERY STENOSIS; HYPEREMIC RESPONSE TEST; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; BLOOD-FLOW; ULTRASOUND; INDEX; IMPAIRMENT; SONOGRAPHY	Cerebral autoregulation assessed using transcranial Doppler (TCD) mean flow velocity (FV) in response to various physiological challenges is predictive of outcome after traumatic brain injury (TBI). Systolic and diastolic FV have been explored in other diseases. This study aims to evaluate the systolic, mean and diastolic FV for monitoring autoregulation and predicting outcome after TBI. 300 head-injured patients with blood pressure (ABP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), and FV recordings were studied. Autoregulation was calculated as a correlation of slow changes in diastolic, mean and systolic components of FV with CPP (Dx, Mx, Sx, respectively) and ABP (Dxa, Mxa, Sxa, respectively) from 30 consecutive 10 s averaged values. The relationship with age, severity of injury, and dichotomized 6 months outcome was examined. Association with outcome was significant for Mx and Sx. For favorable/unfavorable and death/survival outcomes Sx showed the strongest association (F = 20.11; P = 0.00001 and F = 13.10; P = 0.0003, respectively). Similarly, indices derived from ABP demonstrated the highest discriminatory value when systolic FV was used (F = 12.49; P = 0.0005 and F = 5.32; P = 0.02, respectively). Indices derived from diastolic FV demonstrated significant differences (when calculated using CPP) only when comparing between fatal and non-fatal outcome. Systolic flow indices (Sx and Sxa) demonstrated a stronger association with outcome than the mean flow indices (Mx and Mxa), irrespective of whether CPP or ABP was used for calculation.	[Budohoski, Karol P.; Czosnyka, Zofia; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Reinhard, Matthias] Univ Freiburg, Dept Neurol, Neuroctr, D-79095 Freiburg, Germany; [Aries, Marcel J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland	Budohoski, KP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	kpb26@cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research Brain Repair Centre (Cambridge University Hospitals Foundation Trust) Neuroscience Theme; Fearnside Trust, UK; Marry and Clifford Corbridge Trust of Robinson College, UK; European Federation of Neurological Societies; Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development; National Institute of Health Research Senior Investigator Award; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This project was supported by the National Institute of Health Research Brain Repair Centre (Cambridge University Hospitals Foundation Trust) Neuroscience Theme. KPB received a scholarship from the Fearnside Trust, UK and Marry and Clifford Corbridge Trust of Robinson College, UK. MJHA received a travel grant from the European Federation of Neurological Societies and is supported by the Netherlands Organisation for Health Research and Development. JDP is a recipient of a National Institute of Health Research Senior Investigator Award.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bokkers RPH, 2010, RADIOLOGY, V256, P201, DOI 10.1148/radiol.10091262; Bouzat P, 2011, NEUROSURGERY; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lewis SB, 1999, J CLIN NEUROSCI, V6, P42, DOI 10.1016/S0967-5868(99)90602-1; MENDELOW AD, 1987, J NEUROSURG, V66, P755, DOI 10.3171/jns.1987.66.5.0755; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; OBoyle MK, 1996, AM J ROENTGENOL, V166, P197, DOI 10.2214/ajr.166.1.8571875; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Prevention CfDCa Services UDoHaH, 2010, TRAUMATIC BRAIN INJU; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Reinhard M, 2004, STROKE, V35, P1381, DOI 10.1161/01.STR.0000127533.46914.31; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Rosengarten B, 2002, CEREBROVASC DIS, V13, P230, DOI 10.1159/000057848; Schmidt EA, 2000, ACT NEUR S, V76, P451; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; SMIELEWSKI P, 1995, ULTRASOUND MED BIOL, V21, P599, DOI 10.1016/0301-5629(94)00154-6; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	29	53	53	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2012	17	2					211	218		10.1007/s12028-011-9572-1			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	002QU	WOS:000308548800009	21691895				2021-06-18	
J	Hollis, SJ; Stevenson, MR; McIntosh, AS; Shores, EA; Finch, CF				Hollis, Stephanie J.; Stevenson, Mark R.; McIntosh, Andrew S.; Shores, E. Arthur; Finch, Caroline F.			Compliance with return-to-play regulations following concussion in Australian schoolboy and community rugby union players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY; HEAD; GUIDELINES; MANAGEMENT; SPORT; RISK	Background There is a risk of concussion when playing rugby union. Appropriate management of concussion includes compliance with the return-to-play regulations of the sports body for reducing the likelihood of premature return-to-play by injured players. Purpose To describe the proportion of rugby union players who comply with the sports body's regulations on returning to play postconcussion. Study design Prospective cohort study. Methods 1958 community rugby union players (aged 15-48 years) in Sydney (Australia) were recruited from schoolboy, grade and suburban competitions and followed over >= 1 playing seasons. Club doctors/physiotherapists/coaches or trained injury recorders who attended the game reported players who sustained a concussion. Concussed players were followed up over a 3-month period and the dates when they returned to play (including either a game or training session) were recorded, as well as any return-to-play advice they received. Results 187 players sustained >= 1 concussion throughout the follow-up. The median number of days before players returned to play (competition game play or training) following concussion was 3 (range 1-84). Most players (78%) did not receive return-to-play advice postconcussion, and of those who received correct advice, all failed to comply with the 3-week stand-down regulation. Conclusions The paucity of return-to-play advice received by community rugby union players postconcussion and the high level of non-compliance with return-to-play regulations highlight the need for better dissemination and implementation of the return-to-play regulations and improved understanding of the underlying causes of why players do not adhere to return-toplay practices.	[Hollis, Stephanie J.; Stevenson, Mark R.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Hollis, Stephanie J.] George Inst Global Hlth, Sydney, NSW, Australia; [Stevenson, Mark R.] Monash Univ, Accident Res Ctr, Monash Injury Res Inst, Melbourne, Vic 3004, Australia; [Stevenson, Mark R.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Finch, Caroline F.] Monash Univ, Australian Ctr Res Injury Sport & Its Prevent, Monash Injury Res Inst, Melbourne, Vic 3004, Australia	Hollis, SJ (corresponding author), Univ Sydney, Sydney Med Sch, 25 Nichols Parade, Mt Riverview, NSW 2774, Australia.	shollis@georgeinstitute.org.au	stevenson, mark/AAE-9706-2019; Hollis, Stephanie J/B-5977-2011	stevenson, mark/0000-0003-3166-5876; Shores, Edwin A/0000-0003-1553-5131	International Olympic Committee (IOC); NIH Centres for Disease Prevention and Control; University of Pittsburgh, Pennsylvania, USA; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; scholarship from the New South Wales Sporting Injuries Committee; George Institute for Global Health; School of Public Health, The University of Sydney, Australia	The authors thank the New South Wales Sporting Injuries Committee (NSW SIC) for their continued support of new researchers in sports medicine research in Australia and the Australian Centre for Research into Injury in Sport and its Prevention (ACRISP) as one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee (IOC).; The main funding for the study was provided by the NIH Centres for Disease Prevention and Control, The University of Pittsburgh, Pennsylvania, USA. The primary author received a National Health and Medical Research Council (NHMRC) postgraduate research scholarship during 2 years of PhD candidature, a scholarship from the New South Wales Sporting Injuries Committee and additional financial support from The George Institute for Global Health and the School of Public Health, The University of Sydney, Australia.	Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2009, SPSS STAT SOFTW PROG; Australian Rugby Union, ARU MED SAF REC; Beardmore AL, 2005, PHYS THER SPORT, V6, P24, DOI 10.1016/j.ptsp.2004.04.002; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; International Rugby Board (IRB), REG REL GAM; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kelly JP, 1997, NEUROLOGY, V48, P581; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Twomey D, 2009, J SCI MED SPORT, V12, P452, DOI 10.1016/j.jsams.2008.04.002; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	24	53	55	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2012	46	10					735	740		10.1136/bjsm.2011.085332			6	Sport Sciences	Sport Sciences	985XG	WOS:000307303200013	21705397				2021-06-18	
J	Natale, JE; Joseph, JG; Rogers, AJ; Mahajan, P; Cooper, A; Wisner, DH; Miskin, ML; Hoyle, JD; Atabaki, SM; Dayan, PS; Holmes, JF; Kuppermann, N				Natale, JoAnne E.; Joseph, Jill G.; Rogers, Alexander J.; Mahajan, Prashant; Cooper, Arthur; Wisner, David H.; Miskin, Michelle L.; Hoyle, John D., Jr.; Atabaki, Shireen M.; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		PECARN	Cranial Computed Tomography Use Among Children With Minor Blunt Head Trauma	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							DEPARTMENT WAIT TIMES; EMERGENCY-DEPARTMENT; ETHNIC DISPARITIES; BRAIN-INJURY; HEALTH-CARE; RACE/ETHNICITY; RACE; ASSOCIATION; QUALITY; RISKS	Objective: To determine if patient race/ethnicity is independently associated with cranial computed tomography (CT) use among children with minor blunt head trauma. Design: Secondary analysis of a prospective cohort study. Setting: Pediatric research network of 25 North American emergency departments. Patients: In total, 42 412 children younger than 18 years were seen within 24 hours of minor blunt head trauma. Of these, 39 717 were of documented white non-Hispanic, black non-Hispanic, or Hispanic race/ethnicity. Using a previously validated clinical prediction rule, we classified each child's risk for clinically important traumatic brain injury to describe injury severity. Because no meaningful differences in cranial CT rates were observed between children of black non-Hispanic race/ethnicity vs Hispanic race/ethnicity, we combined these 2 groups. Main Outcome Measure: Cranial CT use in the emergency department, stratified by race/ethnicity. Results: In total, 13 793 children (34.7%) underwent cranial CT. The odds of undergoing cranial CT among children with minor blunt head trauma who were at higher risk for clinically important traumatic brain injury did not differ by race/ethnicity. In adjusted analyses, children of black non-Hispanic or Hispanic race/ethnicity had lower odds of undergoing cranial CT among those who were at intermediate risk (odds ratio, 0.86; 95% CI, 0.78-0.96) or lowest risk (odds ratio, 0.72; 95% CI, 0.65-0.80) for clinically important traumatic brain injury. Regardless of risk for clinically important traumatic brain injury, parental anxiety and request was commonly cited by physicians as an important influence for ordering cranial CT in children of white non-Hispanic race/ethnicity. Conclusions: Disparities may arise from the overuse of cranial CT among patients of nonminority races/ethnicities. Further studies should focus on explaining how medically irrelevant factors, such as patient race/ethnicity, can affect physician decision making, resulting in exposure of children to unnecessary health care risks.	[Natale, JoAnne E.; Kuppermann, Nathan] Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA; [Wisner, David H.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA; [Joseph, Jill G.] Univ Calif Davis, Betty Irene Moore Sch Nursing, Sacramento, CA 95817 USA; [Rogers, Alexander J.] Univ Michigan, Med Ctr, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Rogers, Alexander J.] Univ Michigan, Med Ctr, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; [Mahajan, Prashant] Childrens Hosp Michigan, Dept Pediat, Detroit, MI 48201 USA; [Mahajan, Prashant] Childrens Hosp Michigan, Dept Emergency Med, Detroit, MI 48201 USA; [Hoyle, John D., Jr.] Michigan State Univ, Helen DeVos Childrens Hosp, Dept Emergency Med, E Lansing, MI 48824 USA; [Cooper, Arthur] Columbia Univ, Coll Phys & Surg, Harlem Hosp Ctr, Dept Pediat Surg, New York, NY USA; [Dayan, Peter S.] Columbia Univ, Coll Phys & Surg, Dept Pediat Emergency Med, New York, NY USA; [Miskin, Michelle L.] Data Coordinating Ctr, Pediat Emergency Care Appl Res Network, Salt Lake City, UT USA; [Atabaki, Shireen M.] Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA	Natale, JE (corresponding author), Univ Calif Davis, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	joanne.natale@ucdmc.ucdavis.edu		Tsung, James/0000-0002-4718-8325	Health Resources and Services Administration's Maternal and Child Health Bureau [R40MC02461, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]; Emergency Medical Services for Children; Division of Research, Education, and Training	This work was supported by grant R40MC02461 from the Health Resources and Services Administration's Maternal and Child Health Bureau, Emergency Medical Services for Children, and Division of Research, Education, and Training. The Pediatric Emergency Care Applied Research Network is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the Health Resources and Services Administration's Maternal and Child Health Bureau and Emergency Medical Services for Children.	Akinbami Lara J, 2011, NCHS Data Brief, P1; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Berdahl T, 2010, ACAD PEDIATR, V10, P95, DOI 10.1016/j.acap.2009.12.005; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Chamberlain JM, 2007, PEDIATRICS, V119, pE1319, DOI 10.1542/peds.2006-2309; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Guagliardo MF, 2003, ACAD EMERG MED, V10, P1218, DOI 10.1197/S1069-6563(03)00492-5; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; James CA, 2005, PEDIATRICS, V115, pE310, DOI 10.1542/peds.2004-1541; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Mangione-Smith R, 1999, PEDIATRICS, V103, P711, DOI 10.1542/peds.103.4.711; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; Park CY, 2009, HEALTH SERV RES, V44, P2022, DOI 10.1111/j.1475-6773.2009.01020.x; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Richardson LD, 2003, ACAD EMERG MED, V10, P1184, DOI 10.1197/S1069-6563(03)00487-1; Richardson LP, 2003, ARCH PEDIAT ADOL MED, V157, P984, DOI 10.1001/archpedi.157.10.984; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Takakuwa KM, 2010, AM J ROENTGENOL, V195, P1151, DOI 10.2214/AJR.09.3847; Tamayo-Sarver JH, 2003, AM J PUBLIC HEALTH, V93, P2067, DOI 10.2105/AJPH.93.12.2067; Walsh-Kelly CM, 2008, PEDIATR EMERG CARE, V24, P505, DOI 10.1097/PEC.0b013e318180fdcb; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Wu BU, 2009, AM J GASTROENTEROL, V104, P1668, DOI 10.1038/ajg.2009.189; Yen K, 2003, ANN EMERG MED, V42, P41, DOI 10.1067/mem.2003.230	27	53	53	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	AUG	2012	166	8					732	737					6	Pediatrics	Pediatrics	984KU	WOS:000307189300008	22869404				2021-06-18	
J	O'Connell, KM; Littleton-Kearney, MT; Bridges, E; Bibb, SC				O'Connell, Karen M.; Littleton-Kearney, Marguerite T.; Bridges, Elizabeth; Bibb, Sandra C.			Evaluating the Joint Theater Trauma Registry as a Data Source to Benchmark Casualty Care	MILITARY MEDICINE			English	Article							OPERATION-ENDURING-FREEDOM; SEVERE HEAD-INJURY; BRAIN-INJURY; SECONDARY INSULTS; PROGNOSTIC VALUE; BLOOD-PRESSURE; HYPOTHERMIA; HYPOXIA; IMPACT; DEATH	Just as data from civilian trauma registries have been used to benchmark and evaluate civilian trauma care, data contained within the Joint Theater Trauma Registry (JTTR) present a unique opportunity to benchmark combat care. Using the iterative steps of the benchmarking process, we evaluated data in the JTTR for suitability and established benchmarks for 24-hour mortality in casualties with polytrauma and a moderate or severe blunt traumatic brain injury (TBI). Mortality at 24 hours was greatest in those with polytrauma and a severe blunt TBI. No mortality was seen in casualties with polytrauma and a moderate blunt TBI. Secondary insults after TBI, especially hypothermia and hypoxemia, increased the odds of 24-hour mortality. Data contained in the JTTR were found to be suitable for establishing benchmarks. JTTR data may be useful in establishing benchmarks for other outcomes and types of combat injuries.	[O'Connell, Karen M.; Littleton-Kearney, Marguerite T.; Bibb, Sandra C.] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA; [Bridges, Elizabeth] Univ Washington, Sch Nursing, Seattle, WA 98195 USA	O'Connell, KM (corresponding author), Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				Uniformed Services University of the Health Sciences	Funding for this study was received from the Uniformed Services University of the Health Sciences Intramural Grants.	American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; American College of Surgeons Committee on Trauma, 1999, RES OPT CAR INJ PAT; American Society for Quality, BENCHM; American Trauma Society, TRAUM REG COURS; Arthurs Z, 2006, AM J SURG, V191, P610, DOI 10.1016/j.amjsurg.2006.02.010; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CDC, INJ PREV CONTR TRAUM; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Clarke S P, 2000, Can J Nurs Res, V32, P109; De Jong Marla J, 2008, J Trauma Nurs, V15, P174, DOI 10.1097/01.JTN.0000343322.70334.12; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; DeWitt D S, 1995, New Horiz, V3, P376; Doolan Daniel M, 2009, Res Theory Nurs Pract, V23, P203; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Eastridge BJ, 2010, J TRAUMA, V69, pS5, DOI 10.1097/TA.0b013e3181e421f3; Eastridge Brian J, 2009, Am J Surg, V198, P852, DOI 10.1016/j.amjsurg.2009.04.029; Elf K, 2008, NEUROL RES, V30, P1097, DOI 10.1179/174313208X319125; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hess JR, 2008, TRANSFUSION, V48, P1763, DOI 10.1111/j.1537-2995.2008.01743.x; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; Kowalak JP, 2003, BEST PRACTICES GUIDE; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mcilvoy LH, 2005, AACN ADV CRIT CARE, V16, P488, DOI 10.1097/00044067-200510000-00006; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Nesbitt M, 2010, J TRAUMA, V69, pS162, DOI 10.1097/TA.0b013e3181e45b83; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; U. S. Army Institute of Surgical Research, US ARM I SURG RES JO; United States Army Institute of Surgical Research, JOINT THEAT TRAUM SY, V1; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	41	53	54	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAY	2012	177	5					546	552		10.7205/MILMED-D-11-00422			7	Medicine, General & Internal	General & Internal Medicine	936XK	WOS:000303623100013	22645881	Bronze			2021-06-18	
J	Schatz, P; Moser, RS; Solomon, GS; Ott, SD; Karpf, R				Schatz, Philip; Moser, Rosemarie Scolaro; Solomon, Gary S.; Ott, Summer D.; Karpf, Robin			Prevalence of Invalid Computerized Baseline Neurocognitive Test Results in High School and Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						computerized testing; test validity; concussion testing; traumatic brain injuries	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; TEST-SCORES; PERFORMANCE; RECOVERY; PLAYERS; IMPACT	Context: Limited data are available regarding the prevalence and nature of invalid computerized baseline neurocognitive test data. Objective: To identify the prevalence of invalid baselines on the desktop and online versions of ImPACT and to document the utility of correcting for left-right (L-R) confusion on the desktop version of ImPACT. Design: Cross-sectional study of independent samples of high school (HS) and collegiate athletes who completed the desktop or online versions of ImPACT. Participants or Other Participants: A total of 3769 HS (desktop = 1617, online = 2152) and 2130 collegiate (desktop = 742, online = 1388) athletes completed preseason baseline assessments. Main Outcome Measure(s): Prevalence of 5 ImPACT validity indicators, with correction for L-R confusion (reversing left and right mouse-click responses) on the desktop version, by test version and group. Chi-square analyses were conducted for sex and attentional or learning disorders. Results: At least 1 invalid indicator was present on 11.9% (desktop) versus 6.3% (online) of the HS baselines and 10.2% (desktop) versus 4.1% (online) of collegiate baselines; correcting for L-R confusion (desktop) decreased this overall prevalence to 8.4% (HS) and 7.5% (collegiate). Online Impulse Control scores alone yielded 0.4% (HS) and 0.9% (collegiate) invalid baselines, compared with 9.0% (HS) and 5.4% (collegiate) on the desktop version; correcting for L-R confusion (desktop) decreased the prevalence of invalid Impulse Control scores to 5.4% (HS) and 2.6% (collegiate). Male athletes and HS athletes with attention deficit or learning disorders who took the online version were more likely to have at least 1 invalid indicator. Utility of additional invalidity indicators is reported. Conclusions: The online ImPACT version appeared to yield fewer invalid baseline results than did the desktop version. Identification of L-R confusion reduces the prevalence of invalid baselines (desktop only) and the potency of Impulse Control as a validity indicator. We advise test administrators to be vigilant in identifying invalid baseline results as part of routine concussion management and prevention programs.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Moser, Rosemarie Scolaro] Sports Concuss Ctr New Jersey, Lawrenceville, NJ USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Ott, Summer D.] Methodist Neurol Inst Concuss Ctr, Houston, TX USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu	Solomon, Gary/K-9011-2019	Schatz, Philip/0000-0002-6222-6545			[Anonymous], CONC ID MAN RET TO P; [Anonymous], CONC SPORTS STUD ATH; Bailey CM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P171, DOI 10.1007/0-387-32565-4_8; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; IVERSON G, 2004, J INT NEUROPSYCH SOC, V10, P1; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Larini R, MONTCLAIR HIGH SCH F; Lovell M., IMPACT VERSION 2 0 C; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, IMPACT VERSION 6 0 C; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Mihoces G, 2008, US TODAY        0618; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schwarz A, 2010, NY TIMES        1130; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	34	53	53	0	14	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2012	47	3					289	296		10.4085/1062-6050-47.3.14			8	Sport Sciences	Sport Sciences	953AJ	WOS:000304839000006	22892410	Green Published			2021-06-18	
J	Wang, XL; Vaccari, JPD; Wang, HD; Diaz, P; German, R; Marcillo, AE; Keane, RW				Wang, Xiaoliang; Vaccari, Juan Pablo de Rivero; Wang, Handong; Diaz, Paulo; German, Ramon; Marcillo, Alex E.; Keane, Robert W.			Activation of the Nuclear Factor E2-Related Factor 2/Antioxidant Response Element Pathway Is Neuroprotective after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						antioxidant response element; inflammation; neuroprotection; nuclear factor E2-related factor 2; oxidative stress; SCI	TRANSCRIPTION FACTOR NRF2; TRAUMATIC BRAIN-INJURY; KAPPA-B; INTRACEREBRAL HEMORRHAGE; HEME OXYGENASE-1; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; PROTECTS; MICE; GLUTATHIONE	The activation of oxidative damage, neuroinflammation, and mitochondrial dysfunction has been implicated in secondary pathomechanisms following spinal cord injury (SCI). These pathophysiological processes lead to cell death and are tightly regulated by nuclear factor E2-related factor 2/antioxidant response element (Nrf2/ARE) signaling. Here, we investigated whether activation of Nrf2/ARE is neuroprotective following SCI. Female Fischer rats were subjected to mild thoracic SCI (T8) using the New York University injury device. As early as 30 min after SCI, levels of Nrf2 transcription factor were increased in both nuclear and cytoplasmic fractions of neurons and astrocytes at the lesion site and remained elevated for 3 days. Treatment of injured rats with sulforaphane, an activator of Nrf2/ARE signaling, significantly increased levels of Nrf2 and glutamate-cysteine ligase (GCL), a rate-limiting enzyme for synthesis of glutathione, and decreased levels of inflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) thus leading to a reduction in contusion volume and improvement in coordination. These results show that activation of the Nrf2/ARE pathway following SCI is neuroprotective and that sulforaphane is a viable compound for neurotherapeutic intervention in blocking pathomechanisms following SCI.	[Wang, Xiaoliang; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Wang, Xiaoliang; Wang, Handong] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Vaccari, Juan Pablo de Rivero; Diaz, Paulo; German, Ramon; Marcillo, Alex E.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave,R-430, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS059836]; Craig Neilsen Foundation [124671]; Jinling Hospital of China [2009M014]; China Scholarship CouncilChina Scholarship Council [2009619088]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059836] Funding Source: NIH RePORTER	These studies were supported by National Institutes of Health grant NS059836 and Craig Neilsen Foundation 124671 to R. W. K., grant from Jinling Hospital of China (2009M014), and grant from China Scholarship Council (2009619088). We thank Frank Brand III, Geoffrey Yurcisin, Denise Koivisto, and Ileana Oropesa for technical assistance.	Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bains M., 2011, BIOCH BIOPHYSICA ACT; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Brandenburg LO, 2010, INFLAMM RES, V59, P443, DOI 10.1007/s00011-009-0116-5; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Franklin CC, 2009, MOL ASPECTS MED, V30, P86, DOI 10.1016/j.mam.2008.08.009; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Jin W., 2008, MEDIAT INFLAMM, V725, P174; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Khodagholi F, 2010, MOL CELL BIOCHEM, V337, P39, DOI 10.1007/s11010-009-0284-1; Kotlo KU, 2003, ONCOGENE, V22, P797, DOI 10.1038/sj.onc.1206077; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465; Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017; Lian KC, 2010, TOXICOL APPL PHARM, V245, P21, DOI 10.1016/j.taap.2010.01.003; Lin W, 2008, BIOCHEM PHARMACOL, V76, P967, DOI 10.1016/j.bcp.2008.07.036; Liu XY, 2008, CELL MOL NEUROBIOL, V28, P769, DOI 10.1007/s10571-007-9219-0; Liu Y, 2002, J NEUROTRAUM, V19, P479, DOI 10.1089/08977150252932424; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Mao L., 2010, MEDIAT INFLAMM, V238, P321; Peng ZM, 2010, MOL PHARMACOL, V77, P784, DOI 10.1124/mol.109.061424; Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reddy PVB, 2010, NEUROCHEM INT, V56, P780, DOI 10.1016/j.neuint.2010.02.017; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Soane L, 2010, J NEUROSCI RES, V88, P1355, DOI 10.1002/jnr.22307; Tsvetkov P, 2011, J BIOL CHEM, V286, P8839, DOI 10.1074/jbc.M110.193276; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, NEUROSCI LETT, V465, P226, DOI 10.1016/j.neulet.2009.09.013; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Vargas MR, 2005, J BIOL CHEM, V280, P25571, DOI 10.1074/jbc.M501920200; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009	44	53	58	1	20	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					936	+		10.1089/neu.2011.1922			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900021	21806470	Green Published			2021-06-18	
J	DeVoe, ER; Ross, A				DeVoe, Ellen R.; Ross, Abigail			The Parenting Cycle of Deployment	MILITARY MEDICINE			English	Article							NATIONAL-GUARD SOLDIERS; OPERATION IRAQI FREEDOM; TRAUMATIC BRAIN-INJURY; MILITARY FAMILIES; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION; MENTAL-HEALTH; CHILDREN; STRESS; RISK	Parents of dependent children comprise approximately 42% of Active Duty and National Guard/Reserve military members serving in Operation Iraqi Freedom/Operation Enduring Freedom. Recent estimates indicate that more than two million children have experienced parental deployment since the terrorist attacks on September 11, 2001. This article seeks to characterize the impact of the deployment life cycle on parenting roles among service members and at-home partners/caregivers of dependent children. Specifically, a new conceptual framework is presented for considering the ways in which parenting and co-parenting processes are affected by the demands and transitions inherent in contemporary deployment to a war zone. Although the phase-based emotional cycle of deployment continues to offer an instructive description of the broad challenges faced by military couples, a parenting cycle of deployment model shifts the perspective to the critical and largely ignored processes of parenting in the context of deployment and war, and to the realities faced by parents serving in the U.S. military. Implications for prevention, intervention, and future research related to military families are addressed.	[DeVoe, Ellen R.; Ross, Abigail] Boston Univ, Sch Social Work, Boston, MA 02215 USA	DeVoe, ER (corresponding author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA.				Department of DefenseUnited States Department of Defense [W81XWH-08-1-0230]	The authors thank Ruth Paris, PhD, and Michelle Acker, PsyD, of Strong Families Strong Forces and Joseph Merighi, PhD, of Boston University School of Social Work for their contributions to this manuscript. This work was funded by Department of Defense, Award No. W81XWH-08-1-0230.	American Psychological Association Presidential Task Force on Military Deployment Services for Youth Families and Service Members, 2007, PSYCH NEED US MIL SE; Appleyard K, 2003, INFANT MENT HEALTH J, V24, P111, DOI 10.1002/imhj.10050; Barker LH, 2009, MIL MED, V174, P1033, DOI 10.7205/MILMED-D-04-1108; Barnes VA, 2007, MIL MED, V172, P40, DOI 10.7205/MILMED.172.1.40; BELSKY J, 1984, CHILD DEV, V55, P83, DOI 10.1111/j.1467-8624.1984.tb00275.x; Benedek T, 1946, INSIGHT PERSONALITY, P170; Boss P, 2007, FAM RELAT, V56, P105, DOI 10.1111/j.1741-3729.2007.00444.x; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Brott A, 2009, MILITARY FATHER HAND; Chandra A, 2010, J ADOLESCENT HEALTH, V46, P218, DOI 10.1016/j.jadohealth.2009.10.009; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Cowan CP, 1992, PARTNERS BECOME PARE; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; COZZA SJ, 2007, ZERO 3, V27, P27; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; DeVoe E, 2010, ZER 3 NAT TRAIN I DE; DeVoe ER, 2011, PSYCHOL TRAUMA-US, V3, P1, DOI 10.1037/a0020567; Faber AJ, 2008, J FAM PSYCHOL, V22, P222, DOI 10.1037/0893-3200.22.2.222; Fitzsimons VM, 2009, J SCH NURS, V25, P40, DOI 10.1177/1059840508326733; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Garbarino J, 1996, CHILD DEV, V67, P33, DOI 10.2307/1131684; GARMEZY N, 1983, STRESS COPING DEV CH, P47; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gewirtz AH, 2011, PROF PSYCHOL-RES PR, V42, P56, DOI 10.1037/a0022345; Gewirtz AH, 2011, J FAM PSYCHOL, V25, P29, DOI 10.1037/a0022195; Gewirtz AH, 2010, J CONSULT CLIN PSYCH, V78, P599, DOI 10.1037/a0020571; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Gorman LA, 2010, PSYCHIAT QUART, V81, P1, DOI 10.1007/s11126-009-9116-4; Haas DM, 2005, WOMEN HEALTH ISS, V15, P48, DOI 10.1016/j.whi.2004.12.002; Heltemes KJ, 2011, MIL MED, V176, P132, DOI 10.7205/MILMED-D-09-00238; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; Kelley ML, 2001, J AM ACAD CHILD PSY, V40, P464, DOI 10.1097/00004583-200104000-00016; KOESKE GF, 1990, AM J ORTHOPSYCHIAT, V60, P440, DOI 10.1037/h0079164; Laor N, 1996, ARCH GEN PSYCHIAT, V53, P416, DOI 10.1001/archpsyc.1996.01830050052008; Laor N, 2001, AM J PSYCHIAT, V158, P1020, DOI 10.1176/appi.ajp.158.7.1020; Lapp CA, 2010, J FAM NURS, V16, P45, DOI 10.1177/1074840709357347; LECLERE FB, 1994, J MARRIAGE FAM, V56, P457, DOI 10.2307/353112; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; LOGAN KV, 1987, P MAGAZINE, V113, P43; Luthar S.S., 2006, DEVELOPMENTAL PSYCHO, P739, DOI DOI 10.1002/9780470939406.CH20; MacDermid S., 2005, SITUATED FATHERING F; MacDermid SM, MULTIPLE TRANSITIONS; Maguen S, 2008, MIL MED, V173, P1; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; National Military Family Association, 2005, REP CYCL DEPL SURV A; O'Boyle AL, 2005, SOUTH MED J, V98, P416, DOI 10.1097/01.SMJ.0000152759.37358.81; Office of the Deputy Under Secretary of Defense, 2010, 2008 DEM REP PROF MI; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Padden DL, 2011, MIL MED, V176, P26; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Pincus S. H., 2001, J ARMY MED DEP, V4, P15; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; Renshaw KD, 2008, J FAM PSYCHOL, V22, P586, DOI 10.1037/0893-3200.22.3.586; Renshaw KD, 2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rutter M., 1990, RISK PROTECTIVE FACT; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; Schumer CE, 2007, WAR ANY PRICE TOTAL; Sherman MD, 2009, MY STORY BLOGS 4 MIL; Speziale B, 2010, J SOC WORK DISABIL R, V9, P289, DOI 10.1080/1536710X.2010.523664; Stafford EM, 2003, PEDIATR ANN, V32, P110, DOI 10.3928/0090-4481-20030201-08; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Ternus MP, 2010, J ADOLESCENT HEALTH, V46, P203, DOI 10.1016/j.jadohealth.2009.12.019; Weins TW, 2006, MILITARY LIFE PSYCHO; Wieland D, 2011, PA NURSE, V65, P12; Wieland D, 2011, PA NURSE, V65, P4; Williams D, 2007, ZERO 3, V27, P13	66	53	53	0	31	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	FEB	2012	177	2					184	190		10.7205/MILMED-D-11-00292			7	Medicine, General & Internal	General & Internal Medicine	886KC	WOS:000299852300013	22360065	Bronze			2021-06-18	
J	Guo, QX; Li, HM; Gaddam, SSK; Justice, NJ; Robertson, CS; Zheng, H				Guo, Qinxi; Li, Hongmei; Gaddam, Samson S. K.; Justice, Nicholas J.; Robertson, Claudia S.; Zheng, Hui			Amyloid Precursor Protein Revisited NEURON-SPECIFIC EXPRESSION AND HIGHLY STABLE NATURE OF SOLUBLE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNAS; DYSTROPHIC NEURITES; HIPPOCAMPAL-NEURONS; REACTIVE ASTROCYTES; ASTROGLIAL CELLS; SENILE PLAQUES; GLIAL-CELLS; IN-VIVO	APP processing and amyloid-beta production play a central role in Alzheimer disease pathogenesis. APP has been considered a ubiquitously expressed protein. In addition to amyloid-beta, alpha- or beta-secretase-dependent cleavage of APP also generates soluble secreted APP (APPs alpha or APPs beta, respectively). Interestingly, APPs beta has been shown to be subject to further cleavage to create an N-APP fragment that binds to the DR6 death receptor and mediates axon pruning and degeneration under trophic factor withdrawal conditions. By performing APP immunocytochemical staining, we found that, unexpectedly, many antibodies yielded nonspecific staining in APP-null samples. Screening of a series of antibodies allowed us to identify a rabbit monoclonal antibody Y188 that is highly specific for APP and prompted us to re-examine the expression, localization, and stability of endogenous APP and APPs beta in wild-type and in APPs beta knock-in mice, respectively. In contrast to earlier studies, we found that APP is specifically expressed in neurons and that its expression cannot be detected in major types of glial cells under basal or neuroinflammatory conditions. Both APPs alpha and APPs beta are highly stable in the central nervous system (CNS) and do not undergo further cleavage with or without trophic factor support. Our results clarify several key questions with regard to the fundamental properties of APP and offer critical cellular insights into the pathophysiology of APP.	[Guo, Qinxi; Li, Hongmei; Justice, Nicholas J.; Zheng, Hui] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; [Guo, Qinxi] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Gaddam, Samson S. K.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Zheng, H (corresponding author), Baylor Coll Med, Huffington Ctr Aging, BCM230,1 Baylor Plaza, Houston, TX 77030 USA.	huiz@bcm.edu	Li, Hongmei/L-2595-2013	Li, Hongmei/0000-0002-4952-1734; Guo, Qinxi/0000-0003-4320-6757	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS38660, R01 AG032051, AG033467, NS076117]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076117, P01NS038660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020670, R01AG033467, R01AG032051] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants P01 NS38660 (to C. S. R.) and R01 AG032051, AG033467, and NS076117 (to H. Z.).	Bai Y, 2008, MOL CELL PROTEOMICS, V7, P15, DOI 10.1074/mcp.M700077-MCP200; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BERKENBOSCH F, 1990, J NEUROSCI RES, V25, P431, DOI 10.1002/jnr.490250321; Bitner BR, 2010, J CEREBR BLOOD F MET, V30, P1105, DOI 10.1038/jcbfm.2010.47; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chauvet N, 1997, J COMP NEUROL, V377, P550; Clarner T, 2011, J MOL NEUROSCI, V43, P268, DOI 10.1007/s12031-010-9419-9; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Hoshino T, 2007, BIOCHEM J, V402, P581, DOI 10.1042/BJ20061318; Hsu WC, 2008, J NEURAL TRANSM, V115, P1537, DOI 10.1007/s00702-008-0117-5; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Kaden D, 2009, J CELL SCI, V122, P368, DOI 10.1242/jcs.034058; Kohler C, 2005, NEUROBIOL DIS, V20, P528, DOI 10.1016/j.nbd.2005.04.009; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; Li HM, 2010, P NATL ACAD SCI USA, V107, P17362, DOI 10.1073/pnas.1012568107; Li HM, 2010, J BIOL CHEM, V285, P30598, DOI 10.1074/jbc.M110.137729; Lu DC, 2000, NAT MED, V6, P397; Martins RN, 2001, NEUROSCIENCE, V106, P557, DOI 10.1016/S0306-4522(01)00289-5; Matsui T, 2007, BRAIN RES, V1161, P116, DOI 10.1016/j.brainres.2007.05.050; Moreno-Flores MT, 1998, J NEUROSCI RES, V52, P661, DOI 10.1002/(SICI)1097-4547(19980615)52:6<661::AID-JNR5>3.0.CO;2-6; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Norstrom EM, 2010, J NEUROSCI, V30, P15677, DOI 10.1523/JNEUROSCI.4464-10.2010; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALACIOS G, 1995, EUR J NEUROSCI, V7, P501, DOI 10.1111/j.1460-9568.1995.tb00346.x; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; Palmert M R, 1989, Prog Clin Biol Res, V317, P971; PALMERT MR, 1988, BIOCHEM BIOPH RES CO, V156, P432, DOI 10.1016/S0006-291X(88)80859-3; Pierce JES, 1996, J NEUROSCI, V16, P1083; Shim DJ, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-42; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tran MD, 2011, NEUROSCI LETT, V492, P155, DOI 10.1016/j.neulet.2011.01.078; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Yasuoka K, 2004, J ANAT, V205, P135, DOI 10.1111/j.0021-8782.2004.00320.x; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X; Zheng H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-27; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	49	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2012	287	4					2437	2445		10.1074/jbc.M111.315051			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	892NG	WOS:000300292300018	22144675	Green Published, Other Gold			2021-06-18	
J	Mayers, LB; Redick, TS				Mayers, Lester B.; Redick, Thomas S.			Clinical utility of ImPACT assessment for postconcussion return-to-play counseling: Psychometric issues	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Athlete; Concussion; Neuropsychological testing; Reliability; Validity	TEST-RETEST RELIABILITY; LONG-TERM; NEUROCOGNITIVE PERFORMANCE; CONCUSSION ASSESSMENT; SPORTS CONCUSSION; PROCESSING SPEED; HIGH-SCHOOL; RECOVERY; MANAGEMENT; STATEMENT	Computerized neuropsychological testing is commonly utilized in the management of sport-related concussion. In particular, the Immediate Postconcussion Assessment and Cognitive Testing 2.0 program (ImPACT) is widely used to assess the cognitive functioning of athletes before and after a concussion. We review the evidence for the clinical utility of this program in terms of validity, reliability, and use in return-to-play decisions. We conclude that the empirical evidence does not support the use of ImPACT testing for determining the time of postconcussion return to play.	[Mayers, Lester B.] Pace Univ, Div Sports Med, Athlet Dept, Pleasantville, NY 10570 USA; [Redick, Thomas S.] Indiana Univ Purdue Univ, Div Sci, Columbus, IN USA	Mayers, LB (corresponding author), Pace Univ, Div Sports Med, Athlet Dept, 861 Bedford Rd, Pleasantville, NY 10570 USA.	lmayers@pace.edu	Redick, Thomas S/P-2027-2015				Anastasi A, 1997, PSYCHOL TESTING, V7th; Ashare AB, 2009, ACTA PAEDIATR, V98, P774, DOI 10.1111/j.1651-2227.2009.01300.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brown CN, 2007, J ATHL TRAINING, V42, P515; Campbell D.T, 1963, EXPT QUASIEXPERIMENT; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson G. L., 2003, 23 ANN C NAT AC NEUR; Iverson G.L., 2011, IMMEDIATE POSTCONCUS; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; Mayers LB, 2011, J CLIN EXP NEUROPSYC, V33, P532, DOI 10.1080/13803395.2010.535506; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURPHY K. R., 1998, PSYCHOL TESTING PRIN; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schwarz A, 2009, NY TIMES, pB10; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	45	53	53	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	3					235	242		10.1080/13803395.2011.630655			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	916EE	WOS:000302080100002	22149547				2021-06-18	
J	de Lanerolle, NC; Bandak, F; Kang, DW; Li, AY; Swauger, P; Parks, S; Ling, G; Kim, JH				de Lanerolle, Nihal C.; Bandak, Faris; Kang, Dewey; Li, Alexander Y.; Swauger, Peter; Parks, Steven; Ling, Geoffrey; Kim, Jung H.			Characteristics of an Explosive Blast-Induced Brain Injury in an Experimental Model	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrogliosis; Axonal injury; Blast injury; Blast pressure; Mild traumatic brain injury; Neurotrauma	DIFFUSE AXONAL INJURY; HEAD-INJURY; PRECURSOR; PROTEIN; DAMAGE	Mild traumatic brain injury resulting from exposure to an explosive blast is associated with significant neurobehavioral outcomes in soldiers. Little is known about the neuropathologic consequences of such an insult to the human brain. This study is an attempt to understand the effects of an explosive blast in a large animal gyrencephalic brain blast injury model. Anesthetized Yorkshire swine were exposed to measured explosive blast levels in 3 operationally relevant scenarios: simulated free field (blast tube), high-mobility multipurpose wheeled vehicle surrogate, and building (4-walled structure). Histologic changes in exposed animals up to 2 weeks after blast were compared to a group of naive and sham controls. The overall pathologic changes in all 3 blast scenarios were limited, with very little neuronal injury, fiber tract demyelination, or intracranial hemorrhage observed. However, there were 2 distinct neuropathologic changes observed: increased astrocyte activation and proliferation and periventricular axonal injury detected with beta-amyloid precursor protein immunohistochemistry. We postulate that the increased astrogliosis observed may have a longer-term potential for the exacerbation of brain injury and that the pattern of periventricular axonal injury may be related to a potential for cognitive and mood disorders.	[de Lanerolle, Nihal C.; Kang, Dewey; Li, Alexander Y.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; [Kim, Jung H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Bandak, Faris; Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; FD Neurotechnol Inc, Baltimore, MD USA; [Swauger, Peter; Parks, Steven] ORA Inc, Fredericksburg, VA USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA	de Lanerolle, NC (corresponding author), Yale Univ, Sch Med, Dept Neurosurg, FMB 414,333 Cedar St, New Haven, CT 06520 USA.	nihal.delanerolle@yale.edu			Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	This study was supported by funds from the Defense Advanced Research Projects Agency.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALTSHULER LL, 1995, AM J PSYCHIAT, V152, P1139; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; de Lanerolle NC, 2010, NEUROTHERAPEUTICS, V7, P424, DOI 10.1016/j.nurt.2010.08.002; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ferri A, 2004, FASEB J, V18, P1261, DOI 10.1096/fj.03-1199fje; Friedman A, 2009, EPILEPSY RES, V85, P142, DOI 10.1016/j.eplepsyres.2009.03.005; GANNARELLI TA, 1997, NEUROPATHOL APPL NEU, V22, P509; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HERRMANN LL, 2010, J NEUROL NEUROSUR PS, V79, P619; KAWARABAYASHI T, 1991, BRAIN RES, V552, P1, DOI 10.1016/0006-8993(91)90651-B; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lycke JN, 1998, J NEUROL NEUROSUR PS, V64, P402, DOI 10.1136/jnnp.64.3.402; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; Warden DL, 2005, NEW ENGL J MED, V353, P633; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	28	53	53	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2011	70	11					1046	1057		10.1097/NEN.0b013e318235bef2			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	842DB	WOS:000296567800009	22002430	Bronze			2021-06-18	
J	Schonberger, M; Ponsford, J; Olver, J; Ponsford, M; Wirtz, M				Schoenberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael; Wirtz, Markus			Prediction of functional and employment outcome 1 year after traumatic brain injury: a structural equation modelling approach	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							REHABILITATION; ASSOCIATION; MULTICENTER; DEPRESSION; VALIDATION; DURATION; RETURN; STATE	Background Traumatic brain injury (TBI) can cause lasting functional changes and lead to unemployment. The purpose of this study was to create and test a structural equation model (SEM) of the prediction of functional and employment outcome after TBI. Methods Participants were 949 individuals with predominantly moderate to severe TBI (74% males, median age 25.7 years) who attended a follow-up interview 1 year post-injury. Outcome (employment and mood, cognitive and behavioural changes) was measured using the Structured Outcome Questionnaire. An SEM, based on existing research, was developed, tested and modified. Results A comparative fit index of 0.99 and a root mean square error of approximation of 0.03 supported the fit of the final model. Age, education, pre-injury employment, injury severity and limb injuries were direct predictors of employment outcome. Gender, pre-injury psychiatric disorders and limb injuries were related to employment outcome by their association with mood, cognitive and behavioural changes. Conclusions The results demonstrate the complex interplay between various factors predicting outcome after TBI and provide evidence for the importance of tailoring rehabilitation to the individual's needs. Further research, including other conditions, can build on this model and include additional predictor and outcome measures.	[Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, D-79106 Freiburg, Germany; [Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Schoenberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monashe Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Wirtz, Markus] Univ Educ, Freiburg, Germany	Schonberger, M (corresponding author), Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Engelberger Str 41, D-79106 Freiburg, Germany.	michael.schoenberger@psychologie.uni-freiburg.de	Wirtz, Markus Antonius/AAA-5565-2021	Wirtz, Markus Antonius/0000-0002-9392-0484; Olver, John/0000-0001-7069-1191	Victorian Transport Accident Commission; Victorian Neurotrauma Initiative	The study was funded by the Victorian Transport Accident Commission and the Victorian Neurotrauma Initiative.	ABS, 2001, AUSTR SOC TRENDS; *ABS, 2007, AUSTR SOC TRENDS; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boomsma A, 2000, STRUCT EQU MODELING, V7, P461, DOI 10.1207/S15328007SEM0703_6; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; *ED EMPL OECD COUN, 2008, UNESCO INT I ED PLAN; Ferguson SD, 2009, J PERS DISORD, V23, P230, DOI 10.1521/pedi.2009.23.3.230; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Nightingale EJ, 2007, BRAIN IMPAIR, V8, P101, DOI [10.1375/brim.8.2.101, DOI 10.1375/BRIM.8.2.101]; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; *OECD, 2006, IMPR INC WORK OECD; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Ullman J. B., 2007, USING MULTIVARIATE S; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; World Health Organization (WHO), 2001, WORLD HLTH REP MENT; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	36	53	53	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2011	82	8					936	941		10.1136/jnnp.2010.210021			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	789TE	WOS:000292538400070	21217165				2021-06-18	
J	Mckinlay, A; Bishop, A; Mclellan, T				Mckinlay, A.; Bishop, A.; Mclellan, T.			Public knowledge of 'concussion' and the different terminology used to communicate about mild traumatic brain injury (MTBI)	BRAIN INJURY			English	Article						Mild traumatic brain injury; head injury; concussion	HEAD-INJURY; ADOLESCENTS; CHILDREN	Primary objective: The primary objective was to investigate the public's general knowledge about concussion (mild traumatic brain injury) and to examine whether terminology influenced attributions made about individuals who experience concussion. Design: A random selection of the community was polled to identify public understanding of concussion. To encourage candid responses, a self-report survey method was used. Methods and procedures: One hundred and three members of the general public were asked to indicate if they associated specific attributes with brain injury or head injury, depending on the randomly assigned questionnaire they completed. Participants also completed a questionnaire about their knowledge of concussion and were asked to indicate whether they or someone they knew had experienced an injury to the head. Main outcomes and results: Participants incorrectly evaluated 20% (2/10) of statements regarding concussion knowledge and were relatively uncertain about another 20% (2/10) of statements. Negative attributes were associated more with brain than head injury, although those with prior experience made more positive attributions than those without. Fifty-nine per cent of participants who had experienced a concussion stated they had no brain/head injury. Conclusions: Overall, public knowledge about concussion and different terminology associated with this injury type is substantially inaccurate. More accurate information is required to increase understanding.	[Mckinlay, A.; Bishop, A.; Mclellan, T.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Mckinlay, A.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia	Mckinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		McKinlay, Audrey/0000-0001-9846-8514	Health Research Council of New ZealandHealth Research Council of New Zealand; Accident Compensation Corporation	This research was conducted during the tenure of an ACC Post-Doctoral Research Career Development Award, Awarded to Dr McKinlay from the Health Research Council of New Zealand and the Accident Compensation Corporation.	ANDERSON NH, 1968, J PERS SOC PSYCHOL, V9, P272, DOI 10.1037/h0025907; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Hux D, 1998, BRAIN INJURY, V12, P667; LOVE H, 1997, PRACTICE ISSUES CLIN; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; MCLELLAN T, 2010, J INT NEUROPSYCH SOC, V16, P1; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; PROVVIDENZA CF, 2009, BRIT SPORTS MED, V43, P186; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511	19	53	53	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2011	25	7-8					761	766		10.3109/02699052.2011.579935			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	769RJ	WOS:000291035600012	21619461				2021-06-18	
J	Thomas, M; Haas, TS; Doerer, JJ; Hodges, JS; Aicher, BO; Garberich, RF; Mueller, FO; Cantu, RC; Maron, BJ				Thomas, Mathew; Haas, Tammy S.; Doerer, Joseph J.; Hodges, James S.; Aicher, Brittany O.; Garberich, Ross F.; Mueller, Frederick O.; Cantu, Robert C.; Maron, Barry J.			Epidemiology of Sudden Death in Young, Competitive Athletes Due to Blunt Trauma	PEDIATRICS			English	Article						sudden death; trauma; athletes	BRAIN-INJURY; HIGH-SCHOOL; CONTACT-SPORTS; CONCUSSION; FOOTBALL; MANAGEMENT; COLLEGIATE	BACKGROUND: Sudden deaths of young competitive athletes are highly visible events that have a substantial effect on families and communities. Recent attention has focused predominantly on cardiovascular causes, and less on traumatic organ damage. OBJECTIVE: To define the clinical profile, epidemiology, and frequency of trauma-related deaths in young US athletes. METHODS: We analyzed the 30-year US National Registry of Sudden Death in Young Athletes (1980-2009) by using systematic identification and tracking strategies. RESULTS: Of 1827 deaths of athletes aged 21 years or younger, 261 (14%) were caused by trauma-related injuries, usually involving the head and/ or neck (mean: 16 +/- 2 years; 90% male) in 22 sports. The highest number of events in a single year was 16 (1986), with an average of 9 per year throughout 30 years. The mortality rate was 0.11 in 100 000 participations (95% confidence interval: 0.08-0.15). The largest number of deaths was in football (148 [57%]), including 17 high school athletes who sustained concussions shortly before fatal head trauma ("second-impact syndrome"). Football deaths were more frequent in defensive players, although the single most common position involved was running back (61% of offensive players). CONCLUSIONS: In a large community-based national registry, sudden deaths caused by blunt trauma in young athletes aged 21 years or younger were relatively uncommon with 16 or fewer per year, about fourfold less than cardiovascular deaths. These fatalities were most frequent in football, and an important proportion of deaths after head blows in high school football were associated with a recent history of symptomatic concussion. Pediatrics 2011;128:e1-e8	[Maron, Barry J.] Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, Minneapolis, MN 55407 USA; [Hodges, James S.] Univ Minnesota, Div Biostat, Minneapolis, MN USA; [Mueller, Frederick O.] Natl Ctr Catastroph Sports Injury Res, Chapel Hill, NC USA; [Cantu, Robert C.] Emerson Hosp, Concord, MA USA	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Hypertroph Cardiomyopathy Ctr, 920 E 28th St,Suite 620, Minneapolis, MN 55407 USA.	hcm.maron@mhif.org			Hearst Foundations (New York, NY)	This work was supported by the Hearst Foundations (New York, NY).	[Anonymous], 2010, NY TIMES        1021; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2001, AM J SPORT MED, V29, P50, DOI 10.1177/03635465010290011301; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Epstein D, 2010, SPORTS ILLUSTRA 1101; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GREGORY S, 2010, TIME MAGAZINE   1022; GREGORY S, 2010, TIME MAGAZINE   0128; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; Harris KM, 2006, ANN INTERN MED, V145, P507, DOI 10.7326/0003-4819-145-7-200610030-00008; Heron Melonie, 2009, Natl Vital Stat Rep, V57, P1; Kelly JP, 1997, NEUROLOGY, V48, P581; King P, 2010, SPORTS ILLUSTRA 1101; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Maron BJ, 2010, NEW ENGL J MED, V362, P917, DOI 10.1056/NEJMra0910111; Maron BJ, 2009, CIRCULATION, V119, P1085, DOI 10.1161/CIRCULATIONAHA.108.804617; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1142, DOI 10.1001/jama.287.9.1142; Maron BJ, 2003, NEW ENGL J MED, V349, P1064, DOI 10.1056/NEJMra022783; Maron BJ, 2003, J AM COLL CARDIOL, V41, P974, DOI 10.1016/S0735-1097(02)02976-5; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; *NAT FED HIGH SCH, NFHS PART FIG SEARCH; *NAT LIGHTN SAF I, LIGHTN FAT INJ DAM R; National Collegiate Athletic Association, NCAA SPORTS SPONS PA; PEGULA SM, FATAL OCCUPATIONAL I; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R C, 1964, Clin Neurosurg, V12, P226; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SCHWARZ A, 2009, NY TIMES        1126; SCHWARZ A, 2010, NY TIMES        0420; *US DEP HHS, 2008, MEN VACC INF STAT IN; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; VanCamp SP, 1996, CATASTROPHIC INJURIE, V8	45	53	53	0	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2011	128	1					E1	E8		10.1542/peds.2010-2743			8	Pediatrics	Pediatrics	786IV	WOS:000292299500001	21690117	Bronze			2021-06-18	
J	Zumstein, MA; Moser, M; Mottini, M; Ott, SR; Sadowski-Cron, C; Radanov, BP; Zimmermann, H; Exadaktylos, A				Zumstein, Matthias A.; Moser, Mario; Mottini, Matthias; Ott, Sebastian R.; Sadowski-Cron, Charlotte; Radanov, Bogdan P.; Zimmermann, Heinz; Exadaktylos, Aristomenis			Long-Term Outcome in Patients With Mild Traumatic Brain Injury: A Prospective Observational Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Mild traumatic brain injury; Beltz score; Long-term outcome; Intracranial injury	HEAD-INJURY; COMPUTED-TOMOGRAPHY; CHRONIC PAIN; SEQUELAE; PREVALENCE; VALIDATION; PREDICTION; SYMPTOMS; ADULTS	Background: Mild traumatic brain injury (MTBI) is common; up to 37% of adult men have a history of MTBI. Complaints after MTBI are persistent headaches, memory impairment, depressive mood disorders, and disability. The reported short- and long-term outcomes of patients with MTBI have been inconsistent. We have now investigated long-term clinical and neurocognitive outcomes in patients with MTBI (at admission, and after 1 and 10 years). Methods: Patients of a previous study investigating MTBI short-term outcome were prospectively reassessed after +/-10 year using the same standardized data entry form and validated questionnaire (Beltztest with Beltz Score [BeSc]) for evaluation of Quality of life (QoL) and neurocognitive outcome (higher scores indicate lower QoL). Results: Eighty-six of 176 patients (49%) could be reassessed (n = 75 lost to follow-up; n = 8 second brain trauma; n = 7 death), 10.4 +/- 2 years after initial evaluation. Over time, overall BeSc was significantly increased (5.92 +/- 10.3 [admission] vs. 10.7 +/- 12.8 [1 year] vs. 20.86 +/- 17.1 [10 year]; p < 0.0001); only 54 of 86 patients (62.8%) presented with a normal BeSc. Long-term complaints were fatigue, insomnia, and exhaustion. Ten of eighty-six patients (11.6%) had intracranial injury (ICI) and initial BeSc was almost twofold higher in patients with ICI than in patients without ICI (10.0 +/- 8.4 vs. 5.3 +/- 9.6; p = 0.007). This difference was not seen after 1 year or after 10 years (10.3 +/- 11.6 vs. 10.3 +/- 10.1 and 21.4 +/- 17.3 vs. 16.1 +/- 16.4, respectively). Eight of eighty-six patients (9.3%) lost their jobs because of persistent complaints after MTBI. Conclusion: BeSc deteriorates over time; our data suggest a decline in general health and QoL in a substantial proportion of patients (37.2%) 10 years after MTBI. Patients without ICI appear to have a better long-term outcome with regard to subjective complaints and QoL.	[Ott, Sebastian R.] Univ Hosp Bern, Dept Emergency Med, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, CH-3010 Bern, Switzerland	Ott, SR (corresponding author), Univ Hosp Bern, Dept Emergency Med, Inselspital, CH-3010 Bern, Switzerland.	sebastian.ott@insel.ch	Zumstein, Matthias/AAV-3268-2020				Angst J, 2002, BIPOLAR DISORD, V4, P11, DOI 10.1034/j.1399-5618.4.s1.1.x; *BUND STAT, 1997, SCHWEIZ GES; Coles R R, 1984, J Laryngol Otol Suppl, V9, P7; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; EVANS RW, 1992, NEUROL CLIN, V10, P815; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs A, 1996, J NUCL MED, V37, P1605; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; LEZAK M, 1995, NEUROPHYSIOLOGICAL A; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Pilgramm M, 2004, HNO, V52, P844; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; VONZERSSEN D, 1971, THERAPIEWOCHE, V21, P1908; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; ZERSSEN D, 1976, BESCHWERDELISTE MANU; ZERSSEN DV, 1973, ARCH PSYCHIAT NERVEN, V217, P299, DOI 10.1007/BF02552842	40	53	53	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2011	71	1					120	127		10.1097/TA.0b013e3181f2d670			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	790RR	WOS:000292607400031	21045743				2021-06-18	
J	Brooks, BL; Holdnack, JA; Iverson, GL				Brooks, Brian L.; Holdnack, James A.; Iverson, Grant L.			Advanced Clinical Interpretation of the WAIS-IV and WMS-IV: Prevalence of Low Scores Varies by Level of Intelligence and Years of Education	ASSESSMENT			English	Article						base rates; misdiagnosis; assessment; memory; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEALTHY OLDER-ADULTS; NEUROPSYCHOLOGICAL TEST BATTERIES; BASE RATES; DISCREPANCY SCORES; MEMORY SCORES; PERFORMANCE; IMPAIRMENT; CRITERIA; INDEX	Clinicians can use the base rates of low scores in healthy people to reduce the likelihood of misdiagnosing cognitive impairment. In the present study, base rates were developed for the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) and Wechsler Memory Scale-Fourth Edition (WMS-IV) using 900 healthy adults and validated on 28 patients with moderate or severe traumatic brain injuries (TBIs). Results indicated that healthy people obtain some low scores on the WAIS-IV/WMS-IV, with prevalence rates increasing with fewer years of education and lower predicted intelligence. When applying the base rates information to the clinical sample, the TBI patients were 13 times more likely to be identified as having a low cognitive profile compared with the controls. Using the base rates information is a psychometrically advanced method for establishing criteria to determine low cognitive abilities on the WAIS-IV/WMS-IV.	[Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB, Canada; [Holdnack, James A.] Pearson Assessment, San Antonio, TX USA; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca		Iverson, Grant/0000-0001-7348-9570			Axelrod BN, 2002, INT J NEUROSCI, V112, P1479, DOI 10.1080/00207450290158377; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Brooks BL, 2008, J INT NEUROPSYCH SOC, V14, P463, DOI 10.1017/S1355617708080521; Brooks BL, 2007, J INT NEUROPSYCH SOC, V13, P490, DOI 10.1017/D1355617707070531; Brooks BL, 2010, ARCH CLIN NEUROPSYCH, V25, P14, DOI 10.1093/arclin/acp100; Brooks BL, 2009, ARCH CLIN NEUROPSYCH, V24, P647, DOI 10.1093/arclin/acp061; Brooks BL, 2009, CAN PSYCHOL, V50, P196, DOI 10.1037/a0016066; Brooks BL, 2009, J INT NEUROPSYCH SOC, V15, P613, DOI 10.1017/S1355617709090651; Brooks BL, 2009, DEMENT GERIATR COGN, V27, P439, DOI 10.1159/000215390; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; Ferri J, 2004, NEUROLOGIA, V19, P285; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner R.L., 2008, NEUROPSYCHOLOGY COUR, P243; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson G. L., 2008, NEUROPSYCHOLOGY HDB, P279; IVERSON GL, BLACK BOOK IN PRESS; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Palmer BW, 1998, ARCH CLIN NEUROPSYCH, V13, P503, DOI 10.1016/S0887-6177(97)00037-1; Pearson Assessment, 2009, ADV CLIN SOL WAIS 4; Reitan R.M., 1993, HALSTEADREITAN NEURO; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	26	53	53	0	35	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	JUN	2011	18	2					156	167		10.1177/1073191110385316			12	Psychology, Clinical	Psychology	762XA	WOS:000290514300004	20947705				2021-06-18	
J	Otis, JD; McGlinchey, R; Vasterling, JJ; Kerns, RD				Otis, John D.; McGlinchey, Regina; Vasterling, Jennifer J.; Kerns, Robert D.			Complicating Factors Associated with Mild Traumatic Brain Injury: Impact on Pain and Posttraumatic Stress Disorder Treatment	JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS			English	Article						Pain; Posttraumatic stress disorder; Traumatic brain injury; Polytrauma; Integrated intervention	PERSISTENT POSTCONCUSSIVE SYMPTOMS; COGNITIVE-PROCESSING THERAPY; OPERATIONS ENDURING FREEDOM; POST-CONCUSSION SYMPTOMS; LOW-BACK-PAIN; IRAQI FREEDOM; OIF/OEF VETERANS; HEAD-INJURY; AFGHANISTAN; HEALTH	The nature of combat in Iraq and Afghanistan has resulted in high rates of comorbidity among chronic pain, posttraumatic stress disorder (PTSD), and mild traumatic brain injury (mTBI) in Veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF). Although separate evidence-based psychological treatments have been developed for chronic pain and PTSD, far less is known about how to approach treatment when these conditions co-occur, and especially when they co-occur with mTBI. To provide the best care possible for OEF/OIF Veterans, clinicians need to have a clearer understanding of how to identify these conditions, ways in which these conditions may interact with one another, and ways in which existing evidence-based treatments can be modified to meet the needs of individuals with mTBI. The purpose of the present paper is to review the comorbidity of pain, PTSD, and mTBI in OEF/OIF Veterans, and provide recommendations to clinicians who provide care to Veterans with these conditions. First, we will begin with an overview of the presentation, symptomatology, and treatment of chronic pain and PTSD. The challenges associated with mTBI in OEF/OIF Veterans will be reported and data will be presented on the comorbidity among all three of these conditions in OEF/OIF Veterans. Second, we will present recommendations for providing psychological treatment for chronic pain and PTSD when comorbid with mTBI. Finally, the paper concludes with a discussion of the need for a multidisciplinary treatment approach, as well as a call for continued research to further refine existing treatments for these conditions.	[Otis, John D.] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA; [Vasterling, Jennifer J.] VA Boston Healthcare Syst, Psychol Serv, Boston, MA 02130 USA; [Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Kerns, Robert D.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Otis, John D.; Vasterling, Jennifer J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Otis, John D.] Boston Univ, Dept Psychol, Boston, MA 02215 USA; [McGlinchey, Regina] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Kerns, Robert D.] Yale Univ, Dept Psychiat, West Haven, CT USA; [McGlinchey, Regina] VA Boston Healthcare Syst, Geriatr Educ Clin & Res Ctr, Boston, MA 02130 USA; [McGlinchey, Regina] VA Boston Healthcare Syst, VA RR&D Translat Res Ctr TBI & Stress Disorders T, Boston, MA 02130 USA	Otis, JD (corresponding author), VA Boston Healthcare Syst, Res Serv, 150 S Huntington Ave, Boston, MA 02130 USA.	John.otis@va.gov		Otis, John/0000-0002-5441-7421			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barrow IM, 2006, J TRAUMA, V61, P1142, DOI 10.1097/01.ta.0000241238.70269.c1; Barrow IM, 2006, BRAIN INJURY, V20, P845, DOI 10.1080/02699050600832445; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bilmes L., 2007, SOLDIERS RETURNING I; Bruner E. F., 2006, MILITARY FORCES WHAT; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Buffum MD, 2007, J REHABIL RES DEV, V44, P315, DOI 10.1682/JRRD.2006.06.0064; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CHARD KM, 2010, ISTSS 26 ANN M MONTR; Chibnall JT, 2001, PAIN, V92, P173, DOI 10.1016/S0304-3959(00)00485-1; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; *DEF MANP DAT CTR, GLOB WAR TERR OP IR; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Fisher SE, 2002, J AM GERIATR SOC, V50, P152, DOI 10.1046/j.1532-5415.2002.50021.x; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Haskell SG, 2006, J WOMENS HEALTH, V15, P862, DOI 10.1089/jwh.2006.15.862; HASKELL SG, CLIN J PAIN IN PRESS; HEINRICH RL, 1985, J BEHAV MED, V8, P61, DOI 10.1007/BF00845512; Herr K, 2006, PAIN MANAG NURS, V7, P44, DOI 10.1016/j.pmn.2006.02.003; Hoffman BM, 2007, HEALTH PSYCHOL, V26, P1, DOI 10.1037/0278-6133.26.1.1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; Horgas AL, 2009, J AM GERIATR SOC, V57, P126, DOI 10.1111/j.1532-5415.2008.02071.x; IASP terminology part III: pain terms a current list with definitions and notes on usage, 1994, CLASSIFICATION CHRON, pH; Iverson GI, 2007, POSTCONCUSSION DISOR; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KEANE TM, 1982, J CONSULT CLIN PSYCH, V50, P138, DOI 10.1037/0022-006X.50.1.138; KEANE TM, 1989, BEHAV THER, V20, P245, DOI 10.1016/S0005-7894(89)80072-3; Kerns RD, 2003, J REHABIL RES DEV, V40, P371, DOI 10.1682/JRRD.2003.09.0371; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; King LA, 2008, J REHABIL RES DEV, V45, P395, DOI 10.1682/JRRD.2007.06.0081; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Linton SJ, 2001, PAIN, V90, P83, DOI 10.1016/S0304-3959(00)00390-0; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MCCREA M, 2008, MILD TRAUMATIC BRAIN, P84; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Otis J., 2007, MANAGING CHRONIC PAI; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pautex S, 2006, J AM GERIATR SOC, V54, P1040, DOI 10.1111/j.1532-5415.2006.00766.x; Resick P. A., 1993, COGNITIVE PROCESSING; RESICK PA, 1988, BEHAV THER, V19, P385, DOI 10.1016/S0005-7894(88)80011-X; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Soo C, 2007, COCHRANE DB SYST REV, V3; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *VA CONS C, 2010, PRACT REC TREATM VET; *VADOD EV BAS GUID, EV MAN CONCUSSIONMTB; van Tulder MW, 2000, SPINE, V25, P2688, DOI 10.1097/00007632-200010150-00024; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; *VHA HDB 1160 01, 2008, UN MENT HLTH SERV VA; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1016/S1525-8610(04)70258-3; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wong D, 1998, PEDTR NURS, V14, P9; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	78	53	53	0	13	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1068-9583	1573-3572		J CLIN PSYCHOL MED S	J. Clin. Psychol. Med. Settings	JUN	2011	18	2					145	154		10.1007/s10880-011-9239-2			10	Psychology, Clinical	Psychology	775SQ	WOS:000291484100005	21626354				2021-06-18	
J	Timofeev, I; Czosnyka, M; Carpenter, KLH; Nortje, J; Kirkpatrick, PJ; Al-Rawi, PG; Menon, DK; Pickard, JD; Gupta, AK; Hutchinson, PJ				Timofeev, Ivan; Czosnyka, Marek; Carpenter, Keri L. H.; Nortje, Jurgens; Kirkpatrick, Peter J.; Al-Rawi, Pippa G.; Menon, David K.; Pickard, John D.; Gupta, Arun K.; Hutchinson, Peter J.			Interaction between Brain Chemistry and Physiology after Traumatic Brain Injury: Impact of Autoregulation and Microdialysis Catheter Location	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; brain injury; CPP; ICP; microdialysis	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; INTRACRANIAL-PRESSURE; ENERGY-METABOLISM; INTRACEREBRAL MICRODIALYSIS; REGIONAL OXYGENATION; TISSUE OXYGEN; BLOOD-FLOW; ISCHEMIA	Bedside monitoring of cerebral metabolism in traumatic brain injury (TBI) with microdialysis is gaining wider clinical acceptance. The objective of this study was to examine the relationship between the fundamental physiological neuromonitoring modalities intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain tissue oxygen (PbtO2), and cerebrovascular pressure reactivity index (PRx), and cerebral chemistry assessed with microdialysis, with particular focus on the lactate/pyruvate (LP) ratio as a marker of energy metabolism. Prospectively collected observational neuromonitoring data from 97 patients with TBI, requiring neurointensive care management and invasive cerebral monitoring, were analyzed. A linear mixed model analysis was used to account for individual patient differences. Perilesional tissue chemistry exhibited a significant independent relationship with ICP, PbtO2 and CPP thresholds, with increasing LP ratio in response to decrease in PbtO2 and CPP, and increase in ICP. The relationship between CPP and chemistry depended upon the state of PRx. Within the studied physiological range, tissue chemistry only changed in response to increasing ICP or drop in PbtO2 < 1.33 kPa (10 mmHg). In agreement with previous studies, significantly higher levels of cerebral lactate (p < 0.001), glycerol (p = 0.013), LP ratio (p < 0.001) and lactate/glucose (LG) ratio (p = 0.003) were found in perilesional tissue, compared to "normal" brain tissue (Mann-Whitney test). These differences remained significant following adjustment for the influences of other important physiological parameters (ICP, CPP, PbtO2, PbtCO2, PRx, and brain temperature; mixed linear model), suggesting that they may reflect inherent tissue properties related to the initial injury. Despite inherent biochemical differences between less-injured brain and "perilesional" cerebral tissue, both tissue types exhibited relationships between established physiological variables and biochemistry. Decreases in perfusion and oxygenation were associated with deteriorating neurochemistry and these effects were more pronounced in perilesional tissue and when cerebrovascular reactivity was impaired.	[Timofeev, Ivan; Czosnyka, Marek; Carpenter, Keri L. H.; Kirkpatrick, Peter J.; Al-Rawi, Pippa G.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Div Neurosurg, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Nortje, Jurgens; Menon, David K.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Wolfson Brain Imaging Ctr, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Nortje, Jurgens; Menon, David K.; Gupta, Arun K.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Dept Med, Cambridge CB2 0QQ, England	Timofeev, I (corresponding author), Univ Cambridge, Div Neurosurg, Addenbrookes Hosp, Dept Clin Neurosci, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	it227@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Timofeev, Ivan/0000-0002-1168-0393; Carpenter, Keri/0000-0001-8236-7727	Codman Inc.; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883, G0600986 ID79068]; BP-TNK Kapitza Scholarship; Academy of Medical Sciences/Health Foundation; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001354, G0601025, G0001237, G0001354B, G0600986, G1000183B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We thank Dr. Peter Smielewski for help with digital data capture. Ivan Timofeev received a Codman Inc. grant, The Evelyn Trust grant, the Medical Research Council RESCUEicp trial grant, and a BP-TNK Kapitza Scholarship. Peter Hutchinson received an Academy of Medical Sciences/Health Foundation, Senior Surgical Scientist Fellowship. Dr. Keri Carpenter received support from the Medical Research Council Acute Brain Injury Programme Grant and the National Institute for Health Research Biomedical Research Centre, Cambridge. Study support (Medical Research Council Grant Nos. G9439390 ID 65883 and G0600986 ID79068).	Agren-Wilsson A, 2005, J NEUROL NEUROSUR PS, V76, P1088, DOI 10.1136/jnnp.2004.042838; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1; Bauer R, 2004, INTENS CARE MED, V30, P159, DOI 10.1007/s00134-003-2015-5; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; Chan MTV, 2005, ACT NEUR S, V95, P113; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Eide PK, 2007, ACTA ANAESTH SCAND, V51, P1273, DOI 10.1111/j.1399-6576.2007.01433.x; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hlatky R, 2004, NEUROSURGERY, V55, P1318, DOI 10.1227/01.NEU.0000143029.42638.2C; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kett-White R, 2002, ACT NEUR S, V81, P363; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Poon WS, 2005, ACT NEUR S, V95, P9; Poon WS, 2002, ACT NEUR S, V81, P335; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinert M, 2007, NEUROL RES, V29, P455, DOI 10.1179/016164107X164175; Robertson CS, 1998, NEUROL RES, V20, pS91; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2	47	53	55	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					849	860		10.1089/neu.2010.1656			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600001	21488707	Green Published			2021-06-18	
J	Farahvar, A; Gerber, LM; Chiu, YL; Haertl, R; Carney, N; Ghajar, J				Farahvar, Arash; Gerber, Linda M.; Chiu, Ya-Lin; Haertl, Roger; Carney, Nancy; Ghajar, Jamshid			Response to intracranial hypertension treatment as a predictor of death in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; treatment response; mortality rate; death; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; AGGRESSIVE TREATMENT; MANAGEMENT; OUTCOMES; ICP; AUTOREGULATION; GUIDELINES; TRIAL	Object. The normalization of increased intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI) is assumed to limit secondary brain injury and improve outcome. Despite evidence-based recommendations for monitoring and treatment of elevated ICP, there are few studies that show an association between response to ICP-directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to ICP-lowering therapy on risk of death within the first 2 weeks of injury in patients who sustained TBI and are older than 16 years. Methods. The current study is based on 1426 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) of whom 388 were treated for elevated ICP (> 25 mm Hg) between 2000 and 2008 at 22 trauma centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and hypotension, which are all known early prognostic indicators of death. Treatment of elevated ICP consisted of administration of mannitol, hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting ICP response to treatment and predicting death at 2 weeks were evaluated using logistic regression analyses. Results. Increasing age and fewer hours of elevated ICP on Day I were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to ICP-lowering therapy (p = 0.03), younger age (p <0.0001), fewer hours of elevated ICP (p <0.0001). and absence of arterial hypotension on Day 1 (p = 0.001) significantly predicted reduced risk of death. Conclusions. Patients who responded to ICP-lowering treatment had a 64% lower risk of death at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of death. (DOI: 10.3171/2010.11.JNS101116)	[Haertl, Roger; Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; [Gerber, Linda M.; Chiu, Ya-Lin] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10021 USA; [Farahvar, Arash] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, MN USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Carney, Nancy] Oregon Hlth & Sci Univ, Dept Med Informat & Epidemiol, Portland, OR 97201 USA	Ghajar, J (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, Starr Bldg,Room 651,525 E 68th St,Box 99, New York, NY 10021 USA.	jam@ghajar.net			New York State Department of Health; New York Presbyterian Hospital	The authors would like to thank the New York State Department of Health and the New York Presbyterian Hospital TBI fund for their support.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Akopian G, 2007, AM SURGEON, V73, P447; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BORN JD, 1984, NEUROCHIRURGIE, V30, P329; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; EDDY VA, 1995, AM SURGEON, V61, P24; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FALCAO ALE, 1995, ARQ NEURO-PSIQUIAT, V53, P390, DOI 10.1590/S0004-282X1995000300004; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Lane PL, 2000, CAN J SURG, V43, P442; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; Marmarou A, 2005, ACT NEUR S, V95, P277; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peterson E, 2009, J TRAUMA, V67, P944, DOI 10.1097/TA.0b013e3181ae6e6d; Ratanalert Sanguansin, 1992, Journal of the Medical Association of Thailand, V75, P644; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zhang W, 1997, Zhonghua Wai Ke Za Zhi, V35, P114	38	53	60	1	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2011	114	5					1471	1478		10.3171/2010.11.JNS101116			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	755FW	WOS:000289913900044	21214327				2021-06-18	
J	Jayakumar, AR; Panickar, KS; Curtis, KM; Tong, XY; Moriyama, M; Norenberg, MD				Jayakumar, Arumugam R.; Panickar, Kiran S.; Curtis, Kevin M.; Tong, Xiao Y.; Moriyama, Mitsuaki; Norenberg, Michael D.			Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; bumetanide; cell swelling; Na+-K+-2Cl(-)-cotransporter-1; trauma	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; NA+-K+-2CL(-) COTRANSPORTER; NA+/CA2+ EXCHANGER; OXIDATIVE STRESS; NKCC ACTIVITY; EDEMA; RAT; PHOSPHORYLATION; ACTIVATION	P>Brain edema and associated increased intracranial pressure are major consequences of traumatic brain injury (TBI). An important early component of the edema associated with TBI is astrocyte swelling (cytotoxic edema). Mechanisms for such swelling, however, are poorly understood. Ion channels/transporters/exchangers play a major role in cell volume regulation, and a disturbance in one or more of these systems may result in cell swelling. To examine potential mechanisms in TBI-mediated brain edema, we employed a fluid percussion model of in vitro barotrauma and examined the role of the ion transporter Na+-K+-2Cl(-)-cotransporter 1 (NKCC1) in trauma-induced astrocyte swelling as this transporter has been strongly implicated in the mechanism of cell swelling in various neurological conditions. Cultures exposed to trauma (3, 4, 5 atm pressure) caused a significant increase in NKCC1 activity (21%, 42%, 110%, respectively) at 3 h. At 5 atm pressure, trauma significantly increased NKCC1 activity at 1 h and it remained increased for up to 3 h. Trauma also increased the phosphorylation (activation) of NKCC1 at 1 and 3 h. Inhibition of MAPKs and oxidative/nitrosative stress diminished the trauma-induced NKCC1 phosphorylation as well as its activity. Bumetanide, an inhibitor of NKCC1, significantly reduced the trauma-induced astrocyte swelling (61%). Silencing NKCC1 with siRNA led to a reduction in trauma-induced NKCC1 activity as well as in cell swelling. These findings demonstrate the critical involvement of NKCC1 in the astrocyte swelling following in vitro trauma, and suggest that blocking NKCC1 activity may represent a useful therapeutic strategy for the cytotoxic brain edema associated with the early phase of TBI.	[Jayakumar, Arumugam R.; Panickar, Kiran S.; Tong, Xiao Y.; Moriyama, Mitsuaki; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL USA; [Curtis, Kevin M.; Norenberg, Michael D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL USA; [Jayakumar, Arumugam R.; Curtis, Kevin M.; Norenberg, Michael D.] Res & Educ Inc, S Florida Fdn, Vet Affairs Med Ctr, Miami, FL 33125 USA; [Panickar, Kiran S.] USDA, Beltsville Human Nutr Res Ctr, Diet Genom & Immunol Lab, Beltsville, MD 20705 USA; [Moriyama, Mitsuaki] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835; Curtis, Kevin/0000-0002-7480-1818	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. We thank Alina Fernandez-Revuelta for the preparation of cell cultures.	Abbruscato TJ, 2004, J PHARMACOL EXP THER, V310, P459, DOI 10.1124/jpet.104.066274; Akimova OA, 2006, J BIOL CHEM, V281, P31317, DOI 10.1074/jbc.M602117200; Andersen GO, 2004, AM J PHYSIOL-HEART C, V286, pH1354, DOI 10.1152/ajpheart.00549.2003; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Flatman PW, 2008, CURR OPIN NEPHROL HY, V17, P186, DOI 10.1097/MNH.0b013e3282f5244e; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; GARTY H, 1988, PHYSIOL REV, V68, P309; Gimenez I, 2003, J BIOL CHEM, V278, P26946, DOI 10.1074/jbc.M303435200; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; HALL ED, 1993, RES P ARNMD, V71, P81; HOFFMANN EK, 1985, FED PROC, V44, P2513; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iwamoto T, 2004, J PHARMACOL SCI, V96, P27, DOI 10.1254/jphs.FMJ04002X6; Jayakumar AR, 2008, J NEUROCHEM, V104, P135; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2011, J HEPATOL, V54, P272, DOI 10.1016/j.jhep.2010.06.041; Jayakumar AR, 2010, METAB BRAIN DIS, V25, P31, DOI 10.1007/s11011-010-9180-3; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kintner DB, 2007, AM J PHYSIOL-CELL PH, V292, pC1113, DOI 10.1152/ajpcell.00412.2006; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KRAUS JF, 1996, NEUROTRAUMA, P12; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; LARSEN FS, 2001, LIVER TRANSP, V17, pC22; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; Mongin A. A., 2005, NEUROGLIA, P550; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; Norenberg MD, 2009, METAB BRAIN DIS, V24, P103, DOI 10.1007/s11011-008-9113-6; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Reinert M, 2000, Neurosurg Focus, V8, pe10; Rose CR, 1996, J PHYSIOL-LONDON, V491, P291, DOI 10.1113/jphysiol.1996.sp021216; Russell JM, 2000, PHYSIOL REV, V80, P211; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sugimoto H, 1997, J CEREBR BLOOD F MET, V17, P44, DOI 10.1097/00004647-199701000-00006; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sun DD, 1999, J NEUROPHYSIOL, V81, P1939; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaziri ND, 1999, HYPERTENSION, V34, P1237, DOI 10.1161/01.HYP.34.6.1237; Vitari AC, 2006, BIOCHEM J, V397, P223, DOI 10.1042/BJ20060220; Wong JA, 2001, AM J PHYSIOL-REG I, V281, pR561; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009; Zhao HY, 2004, J PHYSIOL-LONDON, V560, P123, DOI 10.1113/jphysiol.2004.066423; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019	74	53	57	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2011	117	3					437	448		10.1111/j.1471-4159.2011.07211.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	749KJ	WOS:000289464500008	21306384	Bronze			2021-06-18	
J	Bogner, JA; Whiteneck, GG; Corrigan, JD; Lai, JS; Dijkers, MP; Heinemann, AW				Bogner, Jennifer A.; Whiteneck, Gale G.; Corrigan, John D.; Lai, Jin-Shei; Dijkers, Marcel P.; Heinemann, Allen W.			Comparison of Scoring Methods for the Participation Assessment With Recombined Tools-Objective	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Social participation; Psychometrics; Rehabilitation	QUALITY-OF-LIFE; DISABILITY; SATISFACTION; CONFLICT; ISSUES; HEALTH	Bogner JA, Whiteneck GG, Corrigan JD, Lai J-S, Dijkers MP, Heinemann AW. Comparison of scoring methods for the Participation Assessment with Recombined Tools Objective. Arch Phys Med Rehabil 2011;92:552-63. Objective: To develop and compare 2 scoring algorithms for a measure of participation, the Participation Assessment with Recombined Tools Objective (PART-O) based on the assumption that more participation is better versus an alternative that reflects balance in domains of participation. Design: Survey. Setting: Community settings. Participants: Three groups of participants under the age of 65 years were included: (1) persons with spinal cord injury, traumatic brain injury, stroke, and other disorders who are commonly treated in acute rehabilitation settings (n=220), and (2) participants from the general population who did (n=366) or (3) did not (n=284) self-report limitations indicative of a disability who participated in the 2006 Colorado Behavioral Risk Factor Surveillance System (N=870). Interventions: Not applicable. Main Outcome Measure: PART-O. Results: We developed PART-O subscores using a consensus process and then evaluated them empirically. We combined subscores using 2 contrasting algorithms, one using average scores and the other reflecting the amount of participation and variation in participation across 3 domains. The algorithms for the total scores yielded normal distributions in all 3 samples and were equally sensitive to the impact of disability. While strongly correlated, about 30% of the variance of the 2 total scores was not shared. Conclusions: Two scoring algorithms for the PART-O illustrate contrasting perspectives of the construct of participation. The 2 algorithms may be used in future studies to expand our understanding of the construct of participation.	[Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Lai, Jin-Shei] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Bogner, JA (corresponding author), 480 Med Ctr Dr, Columbus, OH 43210 USA.	bogner.1@osu.edu	Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center [H133B040032]; Traumatic Brain Injury Model System [H133A070029]; Craig Hospital [H133A070022]; Mount Sinai School of Medicine [H133A070033]	Supported by National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness grant awarded to the Rehabilitation Institute of Chicago (H133B040032) and Traumatic Brain Injury Model System grants awarded to Ohio State University (H133A070029), Craig Hospital (H133A070022), and Mount Sinai School of Medicine (H133A070033).	Bohle P, 2004, REV SAUDE PUBL, V38, P19, DOI 10.1590/S0034-89102004000700004; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2009, ARCH PHYS MED REHAB, V90, pS36, DOI 10.1016/j.apmr.2009.04.024; *CDCP, 2006, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P711; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Hammig O, 2009, INT J PUBLIC HEALTH, V54, P88, DOI 10.1007/s00038-009-8031-7; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Levasseur M, 2010, QUAL LIFE RES, V19, P665, DOI 10.1007/s11136-010-9633-5; Lund ML, 2009, DISABIL REHABIL, V31, P1592, DOI 10.1080/09638280802638881; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Mortenson WB, 2010, SPINAL CORD, V48, P73, DOI 10.1038/sc.2009.92; Noonan VK, 2009, SPINAL CORD, V47, P435, DOI 10.1038/sc.2008.171; Noonan VK, 2009, DISABIL REHABIL, V31, P1883, DOI 10.1080/09638280902846947; Roos E, 2007, PUBLIC HEALTH NUTR, V10, P222, DOI 10.1017/S1368980007248487; US Census Bureau, 2006 2008 AM COMM SU; van Campen C, 2007, QUAL LIFE RES, V16, P635, DOI 10.1007/s11136-006-9147-3; Wang JL, 2007, AM J IND MED, V50, P143, DOI 10.1002/ajim.20428; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2010, INT CLASS FUNCT DIS	25	53	53	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					552	563		10.1016/j.apmr.2010.11.014			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743VT	WOS:000289047500005	21367397				2021-06-18	
J	Rueda, MAF; Cui, L; Gilchrist, MD				Rueda, M. A. Forero; Cui, L.; Gilchrist, M. D.			Finite element modelling of equestrian helmet impacts exposes the need to address rotational kinematics in future helmet designs	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						head impact; traumatic brain injury (TBI); concussion; sports helmets; horse racing	MULTIBODY DYNAMICS ANALYSIS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FALLS; RECONSTRUCTION; IRELAND	Jockey head injuries, especially concussions, are common in horse racing. Current helmets do help to reduce the severity and incidences of head injury, but the high concussion incidence rates suggest that there may be scope to improve the performance of equestrian helmets. Finite element simulations in ABAQUS/Explicit were used to model a realistic helmet model during standard helmeted rigid headform impacts and helmeted head model University College Dublin Brain Trauma Model (UCDBTM) impacts. Current helmet standards for impact determine helmet performance based solely on linear acceleration. Brain injury-related values (stress and strain) from the UCDBTM showed that a performance improvement based on linear acceleration does not imply the same improvement in head injury-related brain tissue loads. It is recommended that angular kinematics be considered in future equestrian helmet standards, as angular acceleration was seen to correlate with stress and strain in the brain.	[Rueda, M. A. Forero; Cui, L.; Gilchrist, M. D.] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 2, Ireland; [Gilchrist, M. D.] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada	Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 2, Ireland.	michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Cui, Liang/0000-0002-5546-5097	Turf Club of Ireland; Enterprise Ireland; Science Foundation IrelandScience Foundation IrelandEuropean Commission	Financial support for this work has been provided by the Turf Club of Ireland, by Enterprise Ireland and by Science Foundation Ireland.	Aare M., 2003, INT RES COUNC BIOM I, P349; ABAQUS, 2009, ABAQUS AN US MAN V 6; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Andersson T, 1993, 199342 SP SWED NAT T; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Cui L, 2009, MATER DESIGN, V30, P3414, DOI 10.1016/j.matdes.2009.03.044; Cui L, 2009, MAT SCI ENG A-STRUCT, V507, P215, DOI 10.1016/j.msea.2008.12.011; Deck C, 2006, INT J CRASHWORTHINES, V11, P561, DOI 10.1533/ijcr.2006.0149; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Doorly M.C., 2007, THESIS U COLL DUBLIN; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Halldin P, 2001, INT J CRASHWORTHINES, V6, P53, DOI 10.1533/cras.2001.0162; Harrison T.I., 1996, P INT IRCOBI C DUBL, P49; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Mihora D, 2007, INT J CRASHWORTHINES, V12, P211, DOI 10.1080/13588260701440862; Miller R, 1998, SAE T, V107, P2798; Mills NJ, 2006, P I MECH ENG L-J MAT, V220, P167, DOI 10.1243/14644207JMDA100; Mills NJ, 2006, IRCOBI C, P425; Mills NJ, 2003, IRCOBI C; Mills NJ, 1990, BRIT J SPORT MED, V24, P56; NSAI, 2006, 9602006 NSAI IS EN; NSAI, 1997, 13841997 NSAI IS EN; NSAI, 2005, 145722005 NSAI IS EN; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Rueda MAF, 2009, MATER DESIGN, V30, P3405, DOI 10.1016/j.matdes.2009.03.037; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Van Lierde C, 2005, SOLID MECH APPL, V124, P247; Verschueren P, 2009, THESIS KATHOLIEKE U; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/cras.8.6.605.19261; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	53	53	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.		2011	14	12					1021	1031		10.1080/10255842.2010.504922			11	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	880UX	WOS:000299434500001	20665294	Green Accepted			2021-06-18	
J	Chen, HW; Epstein, J; Stern, E				Chen, Haiwen; Epstein, Jane; Stern, Emily			Neural Plasticity After Acquired Brain Injury: Evidence from Functional Neuroimaging	PM&R			English	Article							ACTIVATION	The reorganization of the adult central nervous system after damage is a relatively new area of investigation. Neuroimaging methods, such as functional magnetic resonance imaging, diffusion tensor imaging, and positron emission tomography, have the ability to identify, in vivo, some of the processes involved in these neuroplastic changes and can help with diagnosis, prognosis, and potentially treatment approaches. In this article, traumatic brain injury and stroke are used as examples in which neural plasticity plays an important role in recovery. Basic concepts related to brain remodeling, including spontaneous reorganization and training-induced recovery, as well as characteristics of reorganization in successful recovery, are reviewed. The microscopic and molecular mechanisms that underlie neural plasticity and neurogenesis are briefly described. Finally, exciting future directions for the evaluation, diagnosis, and treatment of severe brain injury are explored, with an emphasis on how neuroimaging can help to inform these new approaches. PM R 2010;2:S306-S312	[Chen, Haiwen; Epstein, Jane; Stern, Emily] Harvard Univ, Funct Neuroimaging Lab, Brigham & Womens Hosp, Sch Med, Chestnut Hill, MA 02467 USA; [Chen, Haiwen] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Stern, E (corresponding author), Harvard Univ, Funct Neuroimaging Lab, Brigham & Womens Hosp, Sch Med, 824 Boylston St, Chestnut Hill, MA 02467 USA.	estern3@partners.org	Stern, Emily/E-6035-2011				Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Butelisch CM, 2001, J PHYSIOL-PARIS, V99, P437; Calautti C, 2001, NEUROREPORT, V12, P3883, DOI 10.1097/00001756-200112210-00005; Calautti C, 2007, NEUROIMAGE, V34, P322, DOI 10.1016/j.neuroimage.2006.08.026; Carey LM, 2007, INT J STROKE, V2, P245, DOI 10.1111/j.1747-4949.2007.00164.x; Carey LM, 2001, NEUROREHAB NEURAL RE, V20, P24; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chanraud S, 2010, NEUROPSYCHOL REV, V20, P209, DOI 10.1007/s11065-010-9129-7; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Corbetta M, 2005, NAT NEUROSCI, V8, P1603, DOI 10.1038/nn1574; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Epstein J, 2006, AM J PSYCHIAT, V163, P1784, DOI 10.1176/appi.ajp.163.10.1784; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Frewen P, 2001, CLIN PSYCHOL REV, V28, P228; Ganasen KA, 2010, PSYCHIAT CLIN N AM, V33, P687, DOI 10.1016/j.psc.2010.04.008; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hodics T, 2006, ARCH PHYS MED REHAB, V87, pS36, DOI 10.1016/j.apmr.2006.09.005; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim YH, 2006, NEUROLOGY, V67, P330, DOI 10.1212/01.wnl.0000225178.85833.0d; Kim YH, 2004, YONSEI MED J, V45, P241, DOI 10.3349/ymj.2004.45.2.241; Kubicki M, 2002, HARVARD REV PSYCHIAT, V10, P324, DOI 10.1093/hrp/10.6.324; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Lauterbach EC, 2010, J NEUROPSYCH CLIN N, V22, P8, DOI 10.1176/appi.neuropsych.22.1.8; Leger A, 2002, NEUROIMAGE, V17, P174, DOI 10.1006/nimg.2002.1238; Levin HS, 2001, BRAIN INJURY, V17, P665; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Marino S, 2011, NEUROCRIT CARE, V2010, P25; Marr RA, 2010, FUTUR NEUROL, V5, P527, DOI 10.2217/FNL.10.33; Meinzer M, 2007, NEUROREHABILITATION, V22, P311; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nighoghossian N, 2001, STROKE, V38, P303; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Pineiro R, 2001, STROKE, V32, P1134, DOI 10.1161/01.STR.32.5.1134; Price CJ, 2001, HDB FUNCTIONAL NEURO, P379; Price CJ, 2001, STROKE, V37, P1749; Protopopescu X, 2008, HIPPOCAMPUS, V18, P985, DOI 10.1002/hipo.20468; Richter M, 2008, BRAIN, V131, P1391, DOI 10.1093/brain/awn043; Root JC, 2009, NEUROREPORT, V20, P429, DOI 10.1097/WNR.0b013e328326a031; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saur D, 2006, BRAIN, V129, P1371, DOI 10.1093/brain/awl090; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Seitz RJ, 1999, RESTOR NEUROL NEUROS, V14, P25; Seitz RJ, 2004, RESTOR NEUROL NEUROS, V22, P207; Stern E, 2001, J CLIN EXP NEUROPSYC, V23, P3, DOI 10.1076/jcen.23.1.3.1222; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Takahashi CD, 2008, BRAIN, V131, P425, DOI 10.1093/brain/awm311; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Triggs WJ, 1999, BIOL PSYCHIAT, V45, P1440, DOI 10.1016/S0006-3223(99)00031-1; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; van der Graaf M, 2001, EUR BIOPHYS J, V39, P527; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Ween JE, 2008, J NEUROIMAGING, V18, P227, DOI 10.1111/j.1552-6569.2007.00180.x; Werring DJ, 1991, J NEUROL NEUROSUR PS, V65, P863; Winward CE, 2007, DISABIL REHABIL, V29, P293, DOI 10.1080/09638280600756489; Yang YH, 2000, NEUROIMAGE, V12, P287, DOI 10.1006/nimg.2000.0625; Zahn R, 2004, COGNITIVE BRAIN RES, V18, P322, DOI 10.1016/j.cogbrainres.2003.10.021	69	53	55	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12		2			S306	S312		10.1016/j.pmrj.2010.10.006			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LT	WOS:000208412600011	21172692				2021-06-18	
J	Reeves, TM; Greer, JE; Vanderveer, AS; Phillips, LL				Reeves, Thomas M.; Greer, John E.; Vanderveer, Andrew S.; Phillips, Linda L.			Proteolysis of Submembrane Cytoskeletal Proteins Ankyrin-G and alpha II-Spectrin Following Diffuse Brain Injury: A Role in White Matter Vulnerability at Nodes of Ranvier	BRAIN PATHOLOGY			English	Article						corpus callosum; membrane cytoskeleton; proteolysis; rat; traumatic axonal injury; traumatic brain injury	TRAUMATIC AXONAL INJURY; CONTROLLED CORTICAL IMPACT; INTRAAXONAL NEUROFILAMENT COMPACTION; HUMAN ERYTHROCYTE ANKYRIN; GATED SODIUM-CHANNELS; RAT-BRAIN; UNMYELINATED AXONS; FLUID PERCUSSION; AXOLEMMAL PERMEABILITY; NEURONAL DEGENERATION	A high membrane-to-cytoplasm ratio makes axons particularly vulnerable to traumatic injury. Posttraumatic shifts in ionic homeostasis promote spectrin cleavage, disrupt ankyrin linkages and destabilize axolemmal proteins. This study contrasted ankyrin-G and alpha II-spectrin degradation in cortex and corpus callosum following diffuse axonal injury produced by fluid percussion insult. Ankyrin-G lysis occurred preferentially in white matter, with acute elevation of all fragments and long-term reduction of a low kD form. Calpain-generated alpha II-spectrin fragments increased in both regions. Caspase-3 lysis of alpha II-spectrin showed a small, acute rise in cortex but was absent in callosum. White matter displayed nodal damage, with horseradish peroxidase permeability into the submyelin space. Ankyrin-G-binding protein neurofascin and spectrin-binding protein ankyrin-B showed acute alterations in expression. These results support ankyrin-G vulnerability in white matter following trauma and suggest that ankyrin-G and alpha II-spectrin proteolysis disrupts Node of Ranvier integrity. The time course of such changes were comparable to previously observed functional deficits in callosal fibers.	[Reeves, Thomas M.; Greer, John E.; Vanderveer, Andrew S.; Phillips, Linda L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, Richmond, VA 23298 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Sch Med, Med Ctr, POB 980709, Richmond, VA 23298 USA.	tmreeves@vcu.edu	Greer, John/K-1008-2012		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057758, NS056247]; Virginia Commonwealth Neurotrauma Initiative [07-302F]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057758, R01NS056247, P30NS047463] Funding Source: NIH RePORTER	The authors wish to thank Lesley Harris, Raiford Black, Nancy Lee and Judy Williamson for their excellent technical assistance in this study. We also acknowledge Dr. Jiepei Zhu for his important contribution to the HRP permeability experiments. These studies were supported by funding from NIH grants NS057758 and NS056247 and from Virginia Commonwealth Neurotrauma Initiative 07-302F. Microscopy was performed at VCU, Department of Anatomy and Neurobiology Microscopy Facility which is supported, in part, with funding from NIH-NINDS Center Core Grant NS047463.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; Bouzidi M, 2002, J BIOL CHEM, V277, P28996, DOI 10.1074/jbc.M201760200; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CROALL DE, 1991, PHYSIOL REV, V71, P813; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; Dzhashiashvili Y, 2007, J CELL BIOL, V177, P857, DOI 10.1083/jcb.200612012; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL TG, 1987, J BIOL CHEM, V262, P10537; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Harada K, 1997, J NEUROCHEM, V69, P371; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hryniewicz-Jankowska A, 2002, FOLIA HISTOCHEM CYTO, V40, P239; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; Inserte J, 2005, CIRC RES, V97, P465, DOI 10.1161/01.RES.0000181170.87738.f3; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Keppel, 1991, DESIGN ANAL RES HDB; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1995, NEUROREPORT, V6, P2545, DOI 10.1097/00001756-199512150-00023; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LI ZP, 1993, J BIOL CHEM, V268, P11489; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maier O, 2006, EXP CELL RES, V312, P500, DOI 10.1016/j.yexcr.2005.11.014; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nishimura K, 2003, J CELL BIOL, V163, P1077, DOI 10.1083/jcb.200303060; Ogawa Y, 2006, J NEUROSCI, V26, P5230, DOI 10.1523/JNEUROSCI.0425-06.2006; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sakaue M, 2003, J NEUROSCI RES, V73, P831, DOI 10.1002/jnr.10715; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603; Yoshida K, 2000, METH MOL B, V144, P267; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	89	53	53	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	NOV	2010	20	6					1055	1068		10.1111/j.1750-3639.2010.00412.x			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	660KS	WOS:000282642100006	20557305	Green Accepted			2021-06-18	
J	Signoretti, S; Vagnozzi, R; Tavazzi, B; Lazzarino, G				Signoretti, Stefano; Vagnozzi, Roberto; Tavazzi, Barbara; Lazzarino, Giuseppe			Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications	NEUROSURGICAL FOCUS			English	Article						mild traumatic brain injury; N-acetylaspartate; concussion; brain energy; metabolism; oxidative stress	MAGNETIC-RESONANCE-SPECTROSCOPY; INCOMPLETE CEREBRAL-ISCHEMIA; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; NITRIC-OXIDE SYNTHASE; L-ASPARTIC ACID; OXIDATIVE STRESS; LIPID-PEROXIDATION; N-ACETYLASPARTATE; HEAD-INJURY	Although numerous studies have been carried out to investigate the pathophysiology of mild traumatic brain injury (mTBI), there are still no standard criteria for the diagnosis and treatment of this peculiar condition. The dominant theory that diffuse axonal injury is the main neuropathological process behind mTBI is being revealed as weak at best or inconclusive, given the current literature and the fact that neuronal injury inherent to mTBI improves, with few lasting clinical sequelae in the vast majority of patients. Clinical and experimental evidence suggests that such a course, rather than being due to cell death, is based on temporal neuronal dysfunction, the inevitable consequence of complex biochemical and neurochemical cascade mechanisms directly and immediately triggered by the traumatic insult. This report is an attempt to summarize data from a long series of experiments conducted in the authors' laboratories and published during the past 12 years, together with an extensive analysis of the available literature, focused on understanding the biochemical damage produced by an mTBI. The overall clinical implications, as well as the metabolic nature of the post-mTBI brain vulnerability, are discussed. Finally, the application of proton MR spectroscopy as a possible tool to monitor the full recovery of brain metabolic functions is emphasized. (DOI: 10.3171/2010.9.FOCUS10183)	[Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, I-00100 Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, I-95124 Catania, Italy	Signoretti, S (corresponding author), San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Circonvallaz Gianicolense 183, I-00100 Rome, Italy.	stefano.signoretti@tiscali.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279	Italian Ministry of University and ResearchMinistry of Education, Universities and Research (MIUR) [2007JBHZ5F]	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was funded by PRIN 2007JBHZ5F grant from the Italian Ministry of University and Research.	Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Baslow MH, 2006, DRUG NEWS PERSPECT, V19, P145, DOI 10.1358/dnp.2006.19.3.985930; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, pXI, DOI 10.1016/S0278-5919(05)70055-7; Cantu RC, 2007, NEUROSURGERY, V60, P963, DOI 10.1227/01.NEU.0000255430.62291.7B; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Donzelli S, 2006, FREE RADICAL BIO MED, V40, P1056, DOI 10.1016/j.freeradbiomed.2005.10.058; Donzelli S, 2006, ANTIOXID REDOX SIGN, V8, P1363, DOI 10.1089/ars.2006.8.1363; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fabbri A, 2010, INJURY, V41, P913, DOI 10.1016/j.injury.2010.03.002; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; HUMPHREY SM, 1987, BASIC RES CARDIOL, V82, P304, DOI 10.1007/BF01906863; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kikugawa K, 2004, BIOL PHARM BULL, V27, P17, DOI 10.1248/bpb.27.17; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1992, FREE RADICAL BIO MED, V13, P489, DOI 10.1016/0891-5849(92)90143-5; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TALLAN HH, 1957, J BIOL CHEM, V224, P41; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Wroblewska B, 2006, ADV EXP MED BIOL, V576, P317; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	97	53	54	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E1	10.3171/2010.9.FOCUS10183			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900002	21039135				2021-06-18	
J	Naylor, JC; Kilts, JD; Hulette, CM; Steffens, DC; Blazer, DG; Ervin, JF; Strauss, JL; Allen, TB; Massing, MW; Payne, VM; Youssef, NA; Shampine, LJ; Marx, CE				Naylor, Jennifer C.; Kilts, Jason D.; Hulette, Christine M.; Steffens, David C.; Blazer, Dan G.; Ervin, John F.; Strauss, Jennifer L.; Allen, Trina B.; Massing, Mark W.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.			Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS			English	Article						Alzheimer's disease; temporal cortex; allopregnanolone; DHEA; pregnenolone; neurosteroid; postmortem	TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPAL-NEURONS; NEUROACTIVE STEROIDS; CELL-DEATH; NEUROSTEROID ALLOPREGNANOLONE; DEHYDROEPIANDROSTERONE DHEA; PROGESTERONE METABOLITE; RECEPTOR AGONISTS; OXIDATIVE STRESS; APOLIPOPROTEIN-E	The neurosteroid allopregnanolone has pronounced neuroprotective actions, increases myelination, and enhances neurogenesis. Evidence suggests that allopregnanolone dysregulation may play a role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Our prior data demonstrate that allopregnanolone is reduced in prefrontal cortex in male patients with AD compared to male cognitively intact control subjects, and inversely correlated with neuropathological disease stage (Braak and Braak). We therefore determined if allopregnanolone levels are also reduced in AD patients compared to control subjects in temporal cortex, utilizing a larger set of samples from both male and female patients. In addition, we investigated if neurosteroids are altered in subjects who are APOE4 allele carriers. Allopregnanolone, dehydroepiandrosterone (DHEA), and pregnenolone levels were determined in temporal cortex postmortem samples by gas chromatography/mass spectrometry, preceded by high performance liquid chromatography (40 subjects with AD/41 cognitively intact control subjects). Allopregnanolone levels are reduced in temporal cortex in patients with AD (median 2.68 ng/g, n = 40) compared to control subjects (median 5.64 ng/g, n = 41), Mann-Whitney p = 0.0002, and inversely correlated with Braak and Braak neuropathological disease stage (Spearman r = -0.38, p = 0.0004). DHEA and pregnenolone are increased in patients with AD compared to control subjects. Patients carrying an APOE4 allele demonstrate reduced allopregnanolone levels in temporal cortex (Mann-Whitney p = 0.04). In summary, our findings indicate that neurosteroids are altered in temporal cortex in patients with AD and related to neuropathological disease stage. In addition, the APOE4 allele is associated with reduced allopregnanolone levels. Neurosteroids may be relevant to the neurobiology and therapeutics of AD. Published by Elsevier B.V.	[Naylor, Jennifer C.; Kilts, Jason D.; Strauss, Jennifer L.; Allen, Trina B.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham VA Med Ctr, Durham, NC 27705 USA; [Naylor, Jennifer C.; Kilts, Jason D.; Strauss, Jennifer L.; Allen, Trina B.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.] Res & Clin Ctr MIRECC, VA Midatlantic Mental Illness, Durham, NC USA; [Hulette, Christine M.; Ervin, John F.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27705 USA	Marx, CE (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham VA Med Ctr, 508 Fulton St,MHSL 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Youssef, Nagy A/F-5869-2019	Youssef, Nagy A/0000-0002-1922-9396	VA Advanced Research Career Development Award; VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC); National Institute of Mental Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 65080]; National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05128, P30: AG028377]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH065080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028377, P50AG005128] Funding Source: NIH RePORTER	This work was supported by the following sources: VA Advanced Research Career Development Award (C.E.M.), VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC), and the National Institute of Mental Health (NIH), K23 MH 65080 (C.E.M.), National Institute on Aging (NIA) P50 AG05128 (C.M.H.), and NIA P30: AG028377 (C.M.H.). Dr. Marx discloses that she is a co-applicant on pending U.S. patent applications for the use of neurosteroids and derivatives for the treatment of central nervous system disorders and for lowering cholesterol. The remaining authors have no potential conflicts of interest to disclose. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health.	Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; AZIZI H, 2009, STEM CELLS DEV; BALES KR, NEUROPHARMA IN PRESS; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2004, NEUROBIOL AGING, V25, P49, DOI 10.1016/j.neurobiolaging.2003.08.001; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Benes FM, 2004, NEUROBIOL AGING, V25, P41, DOI 10.1016/j.neurobiolaging.2003.06.003; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Brown RC, 2000, J NEUROCHEM, V74, P847, DOI 10.1046/j.1471-4159.2000.740847.x; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Calissano P, 2009, Commun Integr Biol, V2, P163; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; COSTA E, 1994, J STEROID BIOCHEM, V49, P385, DOI 10.1016/0960-0760(94)90284-4; Debonnel G, 1996, J ENDOCRINOL, V150, pS33; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Gursoy E, 2001, NEUROCHEM RES, V26, P15, DOI 10.1023/A:1007668213330; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hsu HJ, 2006, NATURE, V439, P480, DOI 10.1038/nature04436; Hulette CM, 1997, ARCH PATHOL LAB MED, V121, P615; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Imamura M, 1998, BIOCHEM BIOPH RES CO, V243, P771, DOI 10.1006/bbrc.1998.8177; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kato-Negishi Midori, 2008, Neuropsychiatr Dis Treat, V4, P209; Kaufman KR, 2010, NEUROSCIENCE, V166, P5, DOI 10.1016/j.neuroscience.2009.11.075; Kim SB, 2003, J CLIN ENDOCR METAB, V88, P5199, DOI 10.1210/jc.2003-030646; Kimonides VG, 1999, NEUROSCIENCE, V89, P429, DOI 10.1016/S0306-4522(98)00347-9; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Kurata K, 2004, J PHARMACOL EXP THER, V311, P237, DOI 10.1124/jpet.104.067629; Leskiewicz M, 2008, J PHYSIOL PHARMACOL, V59, P457; Liao GH, 2009, BRAIN RES, V1270, P140, DOI 10.1016/j.brainres.2009.03.027; Lipton Stuart A., 2005, Current Alzheimer Research, V2, P155, DOI 10.2174/1567205053585846; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; LUCHETTI S, 2009, NEUROBIOL AGING; Martins IJ, 2009, J NEUROCHEM, V111, P1275, DOI 10.1111/j.1471-4159.2009.06408.x; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; MARX CE, 2005, P 44 ANN M AM COLL N, pS79; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Mendelson JH, 2005, NEUROPSYCHOPHARMACOL, V30, P1751, DOI 10.1038/sj.npp.1300753; Meunier J, 2004, NEUROTOXICOL TERATOL, V26, P783, DOI 10.1016/j.ntt.2004.07.003; MORROW AL, 1990, MOL PHARMACOL, V37, P263; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Rohn T.T., 2010, APOPTOSIS; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Sliwinski A, 2004, J NEUROSCI RES, V78, P691, DOI 10.1002/jnr.20332; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Steckelbroeck S, 2004, J BIOL CHEM, V279, P10784, DOI 10.1074/jbc.M313308200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Tamagno E, 2003, NEUROBIOL DIS, V14, P291, DOI 10.1016/S0969-9961(03)00131-1; Treiber-Held S, 2003, J PATHOL, V200, P95, DOI 10.1002/path.1345; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wenk GL, 2006, BEHAV PHARMACOL, V17, P411, DOI 10.1097/00008877-200609000-00007; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yu WX, 2005, J BIOL CHEM, V280, P27296, DOI 10.1074/jbc.M503922200; Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24	100	53	57	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1388-1981	1879-2618		BBA-MOL CELL BIOL L	Biochim. Biophys. Acta Mol. Cell Biol. Lipids	AUG	2010	1801	8			SI		951	959		10.1016/j.bbalip.2010.05.006			9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	620CG	WOS:000279476000027	20488256	Green Accepted			2021-06-18	
J	Weiner, GM; Lacey, MR; Mackenzie, L; Shah, DP; Frangos, SG; Grady, MS; Kofke, A; Levine, J; Schuster, J; Le Roux, PD				Weiner, Gregory M.; Lacey, Michelle R.; Mackenzie, Larami; Shah, Darshak P.; Frangos, Suzanne G.; Grady, M. Sean; Kofke, Andrew; Levine, Joshua; Schuster, James; Le Roux, Peter D.			Decompressive Craniectomy for Elevated Intracranial Pressure and Its Effect on the Cumulative Ischemic Burden and Therapeutic Intensity Levels After Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Craniectomy; Ischemia; Trauma	CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN-PRESSURE; SEVERE HEAD-INJURIES; RANDOMIZED-TRIAL; HYPERTENSION; REACTIVITY; ICP; CLASSIFICATION; EXPERIENCE; MANAGEMENT	BACKGROUND: Increased intracranial pressure (ICP) can cause brain ischemia and compromised brain oxygen (PbtO(2) <= 20 mm Hg) after severe traumatic brain injury (TBI). OBJECTIVE: We examined whether decompressive craniectomy (DC) to treat elevated ICP reduces the cumulative ischemic burden (CIB) of the brain and therapeutic intensity level (TIL). METHODS: Ten severe TBI patients (mean age, 31.4 +/- 14.2 years) who had continuous PbtO(2) monitoring before and after delayed DC were retrospectively identified. Patients were managed according to the guidelines for the management of severe TBI. The CIB was measured as the total time spent between a PbtO2 of 15 to 20, 10 to 15, and 0 to 10 mm Hg. The TIL was calculated every 12 hours. Mixed-effects models were used to estimate changes associated with DC. RESULTS: DC was performed on average 2.8 days after admission. DC was found to immediately reduce ICP (mean [SEM] decrease was 7.86 mm Hg [2.4 mm Hg]; P = .005). TIL, which was positively correlated with ICP (r = 0.46, P <= .001), was reduced within 12 hours after surgery and continued to improve within the postsurgical monitoring period (P <= .001). The duration and severity of CIB were significantly reduced as an effect of DC in this group. The overall mortality rate in the group of 10 patients was lower than predicted at the time of admission (P = .015). CONCLUSION: These results suggest that a DC for increased ICP can reduce the CIB of the brain after severe TBI. We suggest that DC be considered early in a patient's clinical course, particularly when the TIL and ICP are increased.	[Le Roux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg,Sch Med, Philadelphia, PA 19104 USA; [Lacey, Michelle R.] Tulane Univ, Dept Math, New Orleans, LA 70118 USA; [Mackenzie, Larami; Levine, Joshua] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, Andrew; Levine, Joshua] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Le Roux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg,Sch Med, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu		Lacey, Michelle/0000-0002-0926-4593	Integra Neurosciences; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This work was supported by research grants from Integra Neurosciences (the manufacturer of the Licox PbtO<INF>2</INF> monitor) (P. D. L. R.), the Integra Foundation (P. D. L. R.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P. D. L. R.). P. D. L. R. is a member of the Integra Speakers Bureau.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS65; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka Marek, 2007, Neurosurg Focus, V22, pE10; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hollander M., 1999, NONPARAMETRIC STAT M; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jaeger M, 2005, ACT NEUR S, V95, P117; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Pinheiro JC, 2008, MIXED EFFECTS MODELS; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; R Development Core Team, 2008, R LANGUAGE ENV STAT; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL; Rosenfeld JV, 2006, NEUROSURGERY, V59, P467, DOI 10.1227/00006123-200608000-00080; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Schneider GH, 2002, ACT NEUR S, V81, P77; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	69	53	56	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2010	66	6					1111	1118		10.1227/01.NEU.0000369607.71913.3E			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	600RY	WOS:000278006200031	20386136	Bronze			2021-06-18	
J	Mans, RA; Chowdhury, N; Cao, D; McMahon, LL; Li, L				Mans, R. A.; Chowdhury, N.; Cao, D.; McMahon, L. L.; Li, L.			SIMVASTATIN ENHANCES HIPPOCAMPAL LONG-TERM POTENTIATION IN C57BL/6 MICE	NEUROSCIENCE			English	Article						statins; synaptic plasticity; learning and memory; cognitive function; protein phosphorylation; Alzheimer's disease	COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE; CORTICAL-NEURONS; INDUCED INCREASE; CONTROLLED TRIAL; AMYLOID PEPTIDE; STATINS; ATORVASTATIN	Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, and they are widely used to control plasma cholesterol levels and prevent cardiovascular disease. However, emerging evidence indicates that the beneficial effects of statins extend to the CNS. Statins have been shown to improve the outcome of stroke and traumatic brain injury, and statin use has been associated with a reduced prevalence of Alzheimer's disease (AD) and dementia. However, prospective studies with statins in AD have produced mixed results. Recently, we reported that simvastatin, a widely used statin in humans, enhances learning and memory in non-transgenic mice as well as in transgenic mice with AD-like pathology on a mixed genetic background. However, the cellular and molecular mechanisms underlying the beneficial effects of simvastatin on learning and memory remain elusive. The present study was undertaken to investigate the effect of acute simvastatin treatment on hippocampal long-term potentiation (LTP), a cellular model of learning and memory, in brain slices from C57BL/6 mice. Our results demonstrate that a prolonged in vitro simvastatin treatment for 2-4 h, but not a short-term 20-min exposure, significantly increases the magnitude of LTP at CA3-CA1 synapses without altering basal synaptic transmission or the paired-pulse facilitation ratio in hippocampal slices. Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. These findings suggest activation of Akt as a molecular pathway for augmented hippocampal LTP by simvastatin treatment, and implicate enhancement of hippocampal LTP as a potential cellular mechanism underlying the beneficial effects of simvastatin on cognitive function. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mans, R. A.; Chowdhury, N.; Cao, D.; Li, L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Mans, R. A.; McMahon, L. L.; Li, L.] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; [McMahon, L. L.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Li, L (corresponding author), Univ Alabama Birmingham, Dept Med, 1808 7th Ave S,BDB 658, Birmingham, AL 35294 USA.	lili@uab.edu	McMahon, Lori/C-2922-2009	Li, Ling/0000-0002-9245-7387	National Institutes of Health NIA AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-031846]; Neurobiology of Cognition and Cognitive Disorders Training [T32 NS-061788]; Neuroscience Blueprint Core [NS-57098]; anonymous philanthropic foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057098, T32NS061788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031846] Funding Source: NIH RePORTER	We thank Drs. Caroline Smith and Portia McCoy and Hailin Lu for technical support. This work was supported by the National Institutes of Health NIA Award AG-031846 to L. Li, the Neurobiology of Cognition and Cognitive Disorders Training Grant T32 NS-061788, Neuroscience Blueprint Core Grant NS-57098, and a grant from an anonymous philanthropic foundation to L. Li.	Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clarke RM, 2008, J BIOL CHEM, V283, P1808, DOI 10.1074/jbc.M707442200; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/s0140-6736(02)09327-3; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Costa ACS, 2005, NEUROSCI LETT, V382, P317, DOI 10.1016/j.neulet.2005.03.031; Endo A, 2004, ATHEROSCLEROSIS SUPP, V5, P67, DOI 10.1016/j.atherosclerosissup.2004.08.026; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Fassbender K, 2002, NEUROLOGY, V59, P1257, DOI 10.1212/WNL.59.8.1257; Hoffman DA, 2002, P NATL ACAD SCI USA, V99, P7740, DOI 10.1073/pnas.092157999; Hoglund K, 2005, EXP BRAIN RES, V164, P205, DOI 10.1007/s00221-005-2243-8; Hoglund K, 2004, ARCH NEUROL-CHICAGO, V61, P333, DOI 10.1001/archneur.61.3.333; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jones PH, 2003, CLIN CARDIOL, V26, pI15; Kotti T, 2008, P NATL ACAD SCI USA, V105, P11394, DOI 10.1073/pnas.0805556105; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Kuenzi FM, 2000, J NEUROSCI METH, V100, P117, DOI 10.1016/S0165-0270(00)00239-9; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lisman J, 2003, PHILOS T ROY SOC B, V358, P829, DOI 10.1098/rstb.2002.1242; Lu CB, 2001, EXP NEUROL, V170, P180, DOI 10.1006/exnr.2001.7686; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu Y, 2007, EMBO J, V26, P4879, DOI 10.1038/sj.emboj.7601884; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Nakao T, 2007, J PHARMACOL SCI, V105, P334, DOI 10.1254/jphs.FP0070682; Opazo P, 2003, J NEUROSCI, V23, P3679; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Sanna PP, 2002, J NEUROSCI, V22, P3359; SAWADA M, 1975, ANN NY ACAD SCI, V243, P337, DOI 10.1111/j.1749-6632.1975.tb25375.x; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Smith CC, 2005, J NEUROSCI, V25, P7780, DOI 10.1523/JNEUROSCI.0762-05.2005; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Tsvyetlynska NA, 2005, J NEUROPHYSIOL, V94, P3951, DOI 10.1152/jn.00201.2005; Vaughan CJ, 2003, AM J CARDIOL, V91, p23B, DOI 10.1016/S0002-9149(02)03270-8; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Zacco A, 2003, J NEUROSCI, V23, P11104	48	53	55	1	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 17	2010	166	2					435	444		10.1016/j.neuroscience.2009.12.062			10	Neurosciences	Neurosciences & Neurology	560PJ	WOS:000274914300011	20040368	Green Accepted			2021-06-18	
J	Arango-Lasprilla, JC; Quijano, MC; Aponte, M; Cuervo, MT; Nicholls, E; Rogers, HL; Kreutzer, J				Arango-Lasprilla, Juan Carlos; Cristina Quijano, Maria; Aponte, Monica; Teresa Cuervo, Maria; Nicholls, Elizabeth; Lynn Rogers, Heather; Kreutzer, Jeffrey			Family needs in caregivers of individuals with traumatic brain injury from Colombia, South America	BRAIN INJURY			English	Article						Caregivers; family; traumatic brain injury	NEUROSURGICAL TRAUMA; SOCIAL SUPPORT; IMPACT; DEPRESSION; MEMBERS; TBI; INTEGRATION; PREVALENCE; EMPLOYMENT; ATTENTION	Objective: The aim of the present study was to determine the most and least important family needs in a group of family caregivers of individuals with TBI from Cali, Colombia, and to examine which of those needs were more likely to be met and unmet. Design: Cross-sectional descriptive study. Setting: Valle University Hospital in Cali, Colombia. Participants: Twenty-nine family caregivers of individuals with traumatic brain injury. Outcome measure: The Family Needs Questionnaire, a 40-item questionnaire divided into six sub-scales. Results: Health Information, Community Support Network and Professional Support Network sub-scales were the most important needs reported by this group of Colombian TBI family caregivers. The most frequently met needs in the present study fell within Health Information, Involvement with Care and Instrumental Support sub-scales and the most frequently unmet needs fell within the Emotional Support, Instrumental Support and Professional Support sub-scales. Conclusions: Family needs in caregivers of individuals with TBI from Colombia are similar, but more likely to be unmet, than those reported in previous studies. Interventions designed to meet family caregivers' needs in these areas should be implemented in Colombia.	[Arango-Lasprilla, Juan Carlos; Nicholls, Elizabeth; Kreutzer, Jeffrey] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Cristina Quijano, Maria; Aponte, Monica; Teresa Cuervo, Maria] Pontificia Univ Javeriana Cali, Dept Social Sci, Cali, Colombia; [Lynn Rogers, Heather] Univ Antioquia, Grp Rehabil Salud, Medellin, Colombia	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, West Hosp, MCV Campus,3rd Floor,Room 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu		Cuervo Cuesta, Maria teresa/0000-0002-4907-4604; Quijano Martinez, Maria Cristina/0000-0003-3548-1628; Rogers, Heather L./0000-0002-7562-4542	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036]	Supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant no. H133A070036). The authors report no further conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; CAMPBELL CH, 1988, REHABILITATION NURSI, V13, P325; De Silva MJ, 2008, INT J EPIDEMIOL, V38, P1; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engli M, 1993, J Neurosci Nurs, V25, P78; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Firsching R, 2001, WORLD J SURG, V25, P1221; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gamboa AM, 2006, NEUROREHABILITATION, V21, P327; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Izaute M, 2008, BRAIN INJURY, V22, P758, DOI 10.1080/02699050802366002; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathis M, 1984, J Neurosurg Nurs, V16, P36; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Moules S, 1999, BRAIN INJURY, V13, P983; Murray CJL., 1996, GLOBAL HLTH STAT COM; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Raja IA, 2001, WORLD J SURG, V25, P1230; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STEBBINS P, 1999, J REHABIL, V64, P15; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Watanabe Y, 2001, DISABIL REHABIL, V23, P370; Zhao YD, 2001, WORLD J SURG, V25, P1202	49	53	56	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	7-8					1017	1026		10.3109/02699052.2010.490516			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	620MW	WOS:000279505000012	20545455				2021-06-18	
J	Nelson, NW; Hoelzle, JB; Sweet, JJ; Arbisi, PA; Demakis, GJ				Nelson, Nathaniel W.; Hoelzle, James B.; Sweet, Jerry J.; Arbisi, Paul A.; Demakis, George J.			[image omitted] Updated meta-analysis of the MMPI-2 symptom validity scale (FBS): verified utility in forensic practice	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory-2; MMPI-2; Response validity assessment; Forensic neuropsychology	FAKE-BAD-SCALE; POSTTRAUMATIC-STRESS-DISORDER; MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; HENRY-HEILBRONNER INDEX; LEES-HALEY; CLASSIFICATION ACCURACY; CONSTRUCT-VALIDITY; MCMI-II	Clinical research interest in the symptom reporting validity scale currently known as the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Symptom Validity Scale (FBS) has continued to be strong, with multiple new publications annually in peer-reviewed journals that publish psychological and neuropsychological assessment research. Related to this growth in relevant literature, the present study was conducted to update the Nelson, Sweet, and Demakis (2006b) FBS meta-analysis. A total of 83 FBS studies (43 new studies) were identified, and 32 (38.5%) met inclusion criteria. Analyses were conducted on a pooled sample of 2218 over-reporting and 3123 comparison participants. Large omnibus effect sizes were observed for FBS, Obvious-Subtle (O-S), and the Dissimulation Scale-Revised (Dsr2) scales. Moderate effect sizes were observed for the following scales: Back Infrequency (Fb), Gough's F-K, Infrequency (F), Infrequency Psychopathology (Fp), and Dissimulation (Ds2). Moderator analyses illustrate that relative to the F-family scales, FBS exhibited larger effect sizes when (1) effort is known to be insufficient and (2) evaluation is conducted in the context of traumatic brain injury. Overall, current results summarize an extensive literature that continues to support use of FBS in forensic neuropsychology practice.	[Nelson, Nathaniel W.; Hoelzle, James B.; Arbisi, Paul A.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Nelson, Nathaniel W.; Arbisi, Paul A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sweet, Jerry J.] Northshore Univ Hlth Syst, Evanston, IL USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Demakis, George J.] Univ N Carolina, Charlotte, NC USA	Nelson, NW (corresponding author), Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA.	nels5363@umn.edu					Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 2004, CLIN J PAIN, V20, P383, DOI 10.1097/00002508-200411000-00002; Arbisi PA, 2004, ARCH CLIN NEUROPSYCH, V19, P341, DOI 10.1016/j.acn.2003.12.003; Arbisi PA, 2002, PSYCHOL ASSESSMENT, V14, P3, DOI 10.1037//1040-3590.14.1.3; ARNOLD G, 2005, 33 ANN M INT NEUR SO; Bagby RM, 2000, ASSESSMENT, V7, P55, DOI 10.1177/107319110000700104; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Ben-Porath YS, 2009, PSYCHOL INJ LAW, V2, P62, DOI 10.1007/s12207-009-9037-4; Berry D. T. R., 2007, ASSESSMENT MALINGERE, P226; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Binder LM, 2006, CLIN NEUROPSYCHOL, V20, P848, DOI 10.1080/13854040500246927; Blanchard DD, 2003, J PERS ASSESS, V80, P197, DOI 10.1207/S15327752JPA8002_08; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Burandt C. A., 2006, DISS ABSTR INT, V67, P2216; Bury AS, 2002, PSYCHOL ASSESSMENT, V14, P472, DOI 10.1037//1040-3590.14.4.472; Butcher J. N., 2008, PERSONALITY ASSESSME; Butcher JN, 2008, PSYCHOL INJ LAW, V1, P191, DOI 10.1007/s12207-007-9002-z; Butcher JN, 2003, ARCH CLIN NEUROPSYCH, V18, P473, DOI 10.1016/S0887-6177(02)00142-7; BUTCHER JN, 1989, MANUAL ADM SCORING T; CHARLES T, 1999, DISS ABSTR INT, V60, P5221; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cramer KM, 1995, J CLIN PSYCHOL, V51, P831, DOI 10.1002/1097-4679(199511)51:6<831::AID-JCLP2270510616>3.0.CO;2-O; Crawford EF, 2006, J PERS ASSESS, V86, P217, DOI 10.1207/s15327752jpa8602_11; CRAWFORD EF, 2004, DISS ABSTR INT, V65, P2090; CRESPO GS, 2007, REV PSICOLOGIA GEN A, V60, P299; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P1054, DOI 10.1080/13854040701750891; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; Downing SK, 2008, CLIN NEUROPSYCHOL, V22, P680, DOI 10.1080/13854040701562825; DUKARM PD, 2006, DISS ABSTR INT, V67, P3447; Efendov AA, 2008, PSYCHOL ASSESSMENT, V20, P317, DOI 10.1037/a0013870; Elhai JD, 2000, J PERS ASSESS, V75, P449, DOI 10.1207/S15327752JPA7503_06; Elhai JD, 2001, ASSESSMENT, V8, P221, DOI 10.1177/107319110100800210; Eyler VA, 2000, ARCH CLIN NEUROPSYCH, V15, P834, DOI 10.1016/S0887-6177(00)80334-0; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; Frueh BC, 1997, J PERS ASSESS, V68, P369, DOI 10.1207/s15327752jpa6802_8; GERVAIS R, 2005, ANN M NAT AC NEUR TA; Gervais RO, 2007, ARCH CLIN NEUROPSYCH, V22, P873; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; GOUGH H, 1957, CALIFORNIA PSYCHOL I; Gough H.G, 1950, J CONSULT PSYCHOL, V14, P408; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; GREIFFENSTEIN MF, 1996, AM PSYCHOL LAW SOC N; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P337, DOI 10.1016/j.acn.2003.12.005; GRILLO J, 1994, J CLIN PSYCHOL, V50, P651, DOI 10.1002/1097-4679(199407)50:4<651::AID-JCLP2270500424>3.0.CO;2-C; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Hedges L. V., 1981, J EDUC STAT, V6, P107; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; HINOJOSA L, 1993, DISS ABSTR INT, V54, P2203; Horwitz JE, 2006, ARCH CLIN NEUROPSYCH, V21, P551; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; IVERSON GL, 1995, PSYCHOL ASSESSMENT, V7, P118, DOI 10.1037/1040-3590.7.1.118; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; IVERSON GL, 2006, PSYCHOL INJURIES FOR; Lamberty G. J., 2008, UNDERSTANDING SOMATI; Lanyon RI, 2002, J AM ACAD PSYCHIATRY, V30, P400; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P264; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lees-Haley PR, 2004, ARCH CLIN NEUROPSYCH, V19, P333, DOI 10.1016/j.acn.2003.12.004; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEESHALEY PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Lipsey M.W., 2001, PRACTICAL META ANAL; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; Martin William F, 2005, Nutr Metab (Lond), V2, P25, DOI 10.1186/1743-7075-2-25; MCCARTHY J, 2005, 33 ANN M INT NEUR SO; MCCARTHY JR, 2004, DISS ABSTR INT, V65, P3171; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1995, 30 ANN S REC DEV US; MITCHELL CA, 2008, DISS ABSTR INT, V68, P6975; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Nelson NW, 2006, J CLIN EXP NEUROPSYC, V28, P1, DOI 10.1080/13803390490919272; NELSON NW, 2005, AM AC CLIN NEUR MINN; Posthuma AB, 1998, PROF PSYCHOL-RES PR, V29, P437; Rawls KR, 2008, ARCH CLIN NEUROPSYCH, V23, P749; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1995, ASSESSMENT, V2, P81; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rosenthal R., 1994, HDB RES SYNTHESIS, P231; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Salekin R. T., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; SCHMIDT FL, 2003, HDB PSYCHOL, V12; Sellers S, 2006, PSYCHIAT PSYCHOL LAW, V13, P91; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SHEA C, 2006, DISS ABSTR INT, V67, P560; SISUNG JRJ, 2006, DISS ABSTR INT, V66, P6330; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Soetaert DK, 2008, ARCH CLIN NEUROPSYCH, V23, P711; Staudenmayer H, 2007, J PSYCHOSOM RES, V62, P61, DOI 10.1016/j.jpsychores.2006.01.013; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P541, DOI 10.1080/13854040590967135; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P206; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Van Gaasbeek JK, 2001, ARCH CLIN NEUROPSYCH, V16, P813; Vanderslice-Barr J, 2008, ARCH CLIN NEUROPSYCH, V23, P706; WEMAN TJ, 2005, 33 ANN M INT NEUR SO; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Williams CL, 2009, PSYCHOL INJ LAW, V2, P182, DOI 10.1007/s12207-009-9046-3; WYGANT DB, 2008, DISS ABSTR INT, V68, P6975; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	134	53	53	0	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	4					701	724	PII 922247870	10.1080/13854040903482863			24	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	597LR	WOS:000277759300175	20473828				2021-06-18	
J	Xiong, Y; Mahmood, A; Qu, CS; Kazmi, H; Zhang, ZG; Noguchi, CT; Schallert, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Qu, Changsheng; Kazmi, Humaira; Zhang, Zheng Gang; Noguchi, Constance T.; Schallert, Timothy; Chopp, Michael			Erythropoietin Improves Histological and Functional Outcomes after Traumatic Brain Injury in Mice in the Absence of the Neural Erythropoietin Receptor	JOURNAL OF NEUROTRAUMA			English	Article						erythropoietin receptor null; mouse; sensorimotor; spatial learning; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; FOCAL CEREBRAL-ISCHEMIA; IN-VITRO; ENHANCES NEUROGENESIS; NEONATAL STROKE; SPATIAL MEMORY; UP-REGULATION; HEAD-INJURY; RATS; PROTECTS	Erythropoietin (EPO), essential for erythropoiesis, provides neuroprotection. The EPO receptor (EPOR) is expressed in both neural and non-neural cells in the brain. This study was designed to test the hypothesis that EPO provides beneficial therapeutic effects, even in the absence of the neural EPOR. In this study, EPOR-null mice were rescued with selective EpoR expression driven by the endogenous EpoR promoter in hematopoietic tissue, but not in the neural cells. Anesthetized young adult female EPOR-null and wild-type mice were subjected to traumatic brain injury (TBI) induced by controlled cortical impact. EPO (5000 U/kg) or saline was intraperitoneally administered at 6 h and 3 and 7 days post-injury. Sensorimotor and spatial learning functions were assessed. Expression of EPOR and its downstream signal proteins were evaluated by Western blot analysis. Our data demonstrated that EPO treatment significantly reduced cortical tissue damage and hippocampal cell loss, and improved spatial learning following TBI in both the wild-type and EPOR-null mice. EPO treatment significantly improved sensorimotor functional recovery, with better outcomes in the wild-type mice. EPO treatment upregulated anti-apoptotic proteins (p-Akt and Bcl-XL) in the ipsilateral hippocampus and cortex of the injured wild-type and EPOR-null mice. These data demonstrate that EPO significantly provides neuroprotection following TBI, even in the absence of EPOR in the neural cells, suggesting that its therapeutic benefits may be mediated through vascular protection.	[Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Xiong, Ye; Mahmood, Asim; Qu, Changsheng; Kazmi, Humaira] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Noguchi, Constance T.] NIDDKD, Mol Med Branch, NIH, Bethesda, MD 20892 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [RO1 NS62002, PO1 NS42345]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [ZIADK025061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	This work was supported by National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) Health grants RO1 NS62002 and PO1 NS42345, and NIDDK Intramural Research.	Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bianca RDD, 2009, SHOCK, V31, P529, DOI 10.1097/SHK.0b013e31818909c0; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chi OZ, 2008, PHARMACOLOGY, V82, P38, DOI 10.1159/000127839; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Jelkmann W., 2000, Current Pharmaceutical Biotechnology, V1, P11, DOI 10.2174/1389201003379068; Keogh CL, 2007, J PHARMACOL EXP THER, V322, P521, DOI 10.1124/jpet.107.121392; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Mogensen J, 2008, BEHAV BRAIN RES, V186, P215, DOI 10.1016/j.bbr.2007.08.009; Naranda T, 2002, ENDOCRINOLOGY, V143, P2293, DOI 10.1210/en.143.6.2293; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Shafi NI, 2008, J NEUROTRAUM, V25, P257, DOI 10.1089/neu.2007.0347; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; van der Kooij MA, 2008, BRAIN RES REV, V59, P22, DOI 10.1016/j.brainresrev.2008.04.007; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yin W, 2006, NEUROBIOL DIS, V21, P358, DOI 10.1016/j.nbd.2005.07.015; Zhande R, 2007, AM J PHYSIOL-HEART C, V292, pH2467, DOI 10.1152/ajpheart.00649.2006; Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59	51	53	58	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					205	215		10.1089/neu.2009.1001			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200018	19715391	Green Published			2021-06-18	
J	Benzinger, TLS; Brody, D; Cardin, S; Curley, KC; Mintun, MA; Mun, SK; Wong, KH; Wrathall, JR				Benzinger, Tammie L. S.; Brody, David; Cardin, Sylvain; Curley, Kenneth C.; Mintun, Mark A.; Mun, Seong K.; Wong, Kenneth H.; Wrathall, Jean R.		Workshop Sci Organizing Team Prese	Blast-Related Brain Injury: Imaging for Clinical and Research Applications: Report of the 2008 St. Louis Workshop	JOURNAL OF NEUROTRAUMA			English	Article						animal models of blast-related injury; blast physics; blast-related traumatic brain injury; brain imaging; post-traumatic stress disorder	MAGNETIC-RESONANCE-SPECTROSCOPY; WHITE-MATTER; HEAD-INJURY; TEMPORAL WINDOW; VULNERABILITY; ASSOCIATION; CONCUSSION; NIGHTMARES; PROTECTION; MORTALITY	Blast-related traumatic brain injury (bTBI) and post-traumatic stress disorder (PTSD) have been of particular relevance to the military and civilian health care sectors since the onset of the Global War on Terror, and TBI has been called the "signature injury'' of this war. Currently there are many questions about the fundamental nature, diagnosis, and long-term consequences of bTBI and its relationship to PTSD. This workshop was organized to consider these questions and focus on how brain imaging techniques may be used to enhance current diagnosis, research, and treatment of bTBI. The general conclusion was that although the study of blast physics in non-biological systems is mature, few data are presently available on key topics such as blast exposure in combat scenarios, the pathological characteristics of human bTBI, and imaging signatures of bTBI. Addressing these gaps is critical to the success of bTBI research. Foremost among our recommendations is that human autopsy and pathoanatomical data from bTBI patients need to be obtained and disseminated to the military and civilian research communities, and advanced neuroimaging used in studies of acute, subacute, and chronic cases, to determine whether there is a distinct pathoanatomical signature that correlates with long-term functional impairment, including PTSD. These data are also critical for the development of animal models to illuminate fundamental mechanisms of bTBI and provide leads for new treatment approaches. Brain imaging will need to play an increasingly important role as gaps in the scientific knowledge of bTBI and PTSD are addressed through increased coordination, cooperation, and data sharing among the academic and military biomedical research communities.	[Wong, Kenneth H.; Wrathall, Jean R.] Georgetown Univ, Med Ctr, Washington, DC 20057 USA; [Benzinger, Tammie L. S.; Brody, David; Mintun, Mark A.] Washington Univ, Mallinckrodt Inst Radiol, St Louis, MO USA; [Cardin, Sylvain; Curley, Kenneth C.] USA, Med Res & Mat Command, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Mun, Seong K.] Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA; [Curley, Kenneth C.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Inst Res, Silver Spring, MD USA; Naval Med Res Ctr, Silver Spring, MD USA; Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA; Univ Maryland, College Pk, MD 20742 USA; James S McDonnell Fdn, St Louis, MO USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Weill Cornell Med Coll, New York, NY USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Pittsburgh, Pittsburgh, PA USA; St Louis Vet Adm, Med Ctr, St Louis, MO USA; Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; Univ Illinois, Coll Med, Chicago, IL USA; Def & Vet Brain Injury Ctr, Washington, DC USA; Univ Calif San Francisco, San Francisco, CA USA; Virginia Commonwealth Univ, Richmond, VA USA; Vet Adm Puget Sound Hlth Care Syst, Seattle, WA USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; Virginia Hosp Ctr, Arlington, VA USA; Dyn FX Consulting Ltd, Toronto, ON, Canada; Univ Penn, Philadelphia, PA 19104 USA; Banyan Biomarkers Inc, Alachua, FL USA; Wayne State Univ, Detroit, MI USA; [Cardin, Sylvain; Curley, Kenneth C.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA	Wrathall, JR (corresponding author), Georgetown Univ, Med Ctr, 3970 Reservoir Rd,NW, Washington, DC 20057 USA.	Wrathali_@georgetown.edu	Benzinger, Tammie/L-6104-2013; Benzinger, Tammie L. S./ABA-8534-2020; Pancrazio, Joseph/M-3206-2015	Benzinger, Tammie L. S./0000-0002-8114-0552; Pancrazio, Joseph/0000-0001-8276-3690; Kochanek, Patrick/0000-0002-2627-913X; Bayly, Philip/0000-0003-4303-0704; Mukherjee, Pratik/0000-0001-7473-7409; CORBETTA, MAURIZIO/0000-0001-8295-3304			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ASKENASY JJM, 1989, ACTA NEUROL SCAND, V79, P47, DOI 10.1111/j.1600-0404.1989.tb03708.x; Benzinger T., 1950, GERMAN AVIATION MED, V2, P1225; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2008, J TRAUMA, V65, P1140, DOI 10.1097/TA.0b013e3181870a8c; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; Cripps NPJ, 1996, J TRAUMA, V40, pS206, DOI 10.1097/00005373-199603001-00045; Culver J, 2008, J NUCL MED, V49, P169, DOI 10.2967/jnumed.107.043331; CURCIO CK, 2002, 00402 CETO MAR CORPS; Daly CM, 2005, MIL MED, V170, P513, DOI 10.7205/MILMED.170.6.513; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; DESAGA H, 1943, 15 AER RES I GERM AI; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; DOUKAS AG, 1995, ULTRASOUND MED BIOL, V21, P961, DOI 10.1016/0301-5629(95)00027-O; DRAEGER RH, 1945, 1 NAV MED RES I NAT; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; FINE JE, 1998, ARLTR1690; Garner E, 2000, J BIOMECH ENG-T ASME, V122, P166, DOI 10.1115/1.429638; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gouw AA, 2008, BRAIN, V131, P3286, DOI 10.1093/brain/awn265; He BJ, 2007, CURR OPIN NEUROL, V20, P655, DOI 10.1097/WCO.0b013e3282f1c720; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kelly B., 1993, P14 LOS AL NAT LAB; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Peles E, 2001, Harefuah, V140, P381; PHILLIPS Y, 1990, TXB MILITARY MED CON, P221; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; RICHMOND DR, 1992, COMPENDIUM BIOL EFFE; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; STERNBERG HM, 1976, P 6 INT S DET COR CA, V24, P528; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thali Michael J., 2007, Legal Medicine, V9, P100, DOI 10.1016/j.legalmed.2006.11.011; Toth C, 2005, J NEURO-OPHTHALMOL, V25, P1, DOI 10.1097/00041327-200503000-00001; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; VAWTER DL, 1978, J APPL PHYSIOL, V45, P261; VIANO DC, 1988, J BIOMECH, V21, P387, DOI 10.1016/0021-9290(88)90145-5; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Wetherbe M., 1959, TID6056 USAEC DEP CO; WHITE CLAYTON S., 1964, HLTH PHYS, V10, P89, DOI 10.1097/00004032-196403000-00001; WHITE CS, 1961, 1271 DASA DEP DEF; WHITE CS, 1965, CEX654 US AT EN COMM, P20; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG MW, 1945, WAR MED, V8, P73; Zuckerman S, 1940, LANCET, V2, P219	76	53	54	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2127	2144		10.1089/neu.2009.0885			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200001	19508154	Green Published			2021-06-18	
J	Honeybul, S; Ho, KM; Lind, CRP; Corcoran, T; Gillett, GR				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.; Corcoran, Tomas; Gillett, Grant R.			The Retrospective Application of a Prediction Model to Patients Who Have Had a Decompressive Craniectomy for Trauma	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; intracranial hypertension; neurotrauma; outcome	SEVERE HEAD-INJURIES; CEREBRAL-ARTERY INFARCTION; BRAIN-INJURY; RANDOMIZED-TRIAL; INTRACRANIAL HYPERTENSION; SURGICAL DECOMPRESSION; MANAGEMENT; EDEMA; MULTICENTER; VALIDATION	There is currently a resurgence of interest in the use of decompressive craniectomy. As the procedure is used more frequently, there may be an increasing number of patients surviving a severe traumatic brain injury with severe neurological impairment. The aim of this study was to determine if we could predict those cases that fall into this category. We used the web-based prediction model prepared by the CRASH collaborators and applied it to a cohort of patients who had a decompressive craniectomy in 2006 and 2007 at the two major trauma hospitals in Western Australia. All clinical and radiological data were reviewed and entered into the model, and predicted outcome and actual outcome were compared. Our analysis indicated that a significant cut-off point appeared at which the model predicted a 75% risk of an unfavorable outcome at 6 months; 19 of 27 patients with CRASH scores <75% returned to work, whereas none of the 14 patients with higher scores achieved this degree of rehabilitation at 18 months. Statistical analysis of the outcomes in our cohort confirmed that the CRASH model reliably predicted unfavorable outcome. This study demonstrated that our ability to predict poor outcome has improved.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6019, Australia; [Corcoran, Tomas] Univ Western Australia, Dept Anesthesia, Royal Perth Hosp, Perth, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand	Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6019, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010; Lind, Christopher/K-3629-2012	Ho, Kwok M./0000-0002-6705-6004; Lind, Christopher/0000-0001-9991-1725			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Meier U, 2005, ACT NEUR S, V95, P55; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	27	53	54	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2179	2183		10.1089/neu.2009.0989			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200005	19645531				2021-06-18	
J	Statler, KD; Scheerlinck, P; Pouliot, W; Hamilton, M; White, HS; Dudek, FE				Statler, K. D.; Scheerlinck, P.; Pouliot, W.; Hamilton, M.; White, H. S.; Dudek, F. E.			A potential model of pediatric posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Head injury; Controlled cortical impact; Seizures; Immaturity; Development	HEAD-INJURY	Preclinical models of pediatric posttraumatic epilepsy (PTE) are tacking. We hypothesized that traumatic brain injury (TBI), induced by controlled cortical impact, in immature rats would cause etectroencephatographic (EEG) epileptiform activity and behavioral seizures. TBI or sham craniotomy was performed on postnatal day 17. Using video-EEG monitoring 4-11 months post-TBI, most TBI rats (87.5%) showed EEG spiking and one had spontaneous, recurrent seizures. Controls showed neither EEG spikes nor electrographic/behavioral seizures. Late seizures were rare after TBI, but EEG spiking was common and may represent a surrogate for PTE. (C) 2009 Elsevier B.V. All rights reserved.	[Statler, K. D.] Univ Utah, Div Pediat Crit Care, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; [Scheerlinck, P.; Pouliot, W.; Dudek, F. E.] Univ Utah, Sch Med, Dept Physiol, Salt Lake City, UT 84158 USA; [Scheerlinck, P.; Pouliot, W.; Hamilton, M.; White, H. S.; Dudek, F. E.] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA; [Statler, K. D.; Hamilton, M.; White, H. S.] Univ Utah, Dept Pharmacol & Toxicol, Sch Med, Salt Lake City, UT 84112 USA	Statler, KD (corresponding author), Univ Utah, Div Pediat Crit Care, Sch Med, Dept Pediat, POB 581289,295 Chipeta Way, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-HD01410-01, NS045144]; Primary Children's Medical Center Foundation; University of Utah Children's Health Research Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045144] Funding Source: NIH RePORTER	National Institutes of Health (K12-HD01410-01 & NS045144), Primary Children's Medical Center Foundation, and University of Utah Children's Health Research Center. Dr. Statter is a CHRCDA awardee, PCMC Foundation Scholar, and University of Utah PCAT Scholar.	Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0	7	53	53	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	OCT	2009	86	2-3					221	223		10.1016/j.eplepsyres.2009.05.006			3	Clinical Neurology	Neurosciences & Neurology	511FZ	WOS:000271150600014	19520549	Green Accepted			2021-06-18	
J	Classen, S; Levy, C; McCarthy, D; Mann, WC; Lanford, D; Waid-Ebbs, JK				Classen, Sherrilene; Levy, Charles; McCarthy, Dennis; Mann, William C.; Lanford, Desiree; Waid-Ebbs, J. Kay			Traumatic Brain Injury and Driving Assessment: An Evidence-Based Literature Review	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						automobile driving; brain injuries; psychological tests; risk assessment; reproducibility of results	ABILITY; RETURN; FITNESS; TESTS; TBI	OBJECTIVE. We conducted a literature review of assessment tools predicting driving performance for people with traumatic brain injury (TBI). METHOD. Data sources were Web of Science, EBSCOhost, PubMed, and recently published literature from experts and team members not yet catalogued in the databases. We used the American Academy of Neurology's classification criteria to extract data from 13 studies, and we assigned a class (I-IV, with I being the highest level of evidence) to each study. We grouped primary studies into categories of driving assessment (neuropsychological; simulator; off-road; self-report, other report, and postinjury disability status; and comprehensive driving evaluation) and synthesized the predictability of these tools as it relates to driving performance for people with TBI. CONCLUSIONS. To assist clinicians and researchers in making decisions regarding testing the driving performance of people with TBI, we provide recommendations for neuropsychological tests; off-road tests; self-report, other report, and postinjury disability status; and comprehensive driving evaluation.	[Classen, Sherrilene; Mann, William C.; Lanford, Desiree] Univ Florida, Inst Mobil Act & Participat, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Classen, Sherrilene; Mann, William C.; Lanford, Desiree] Univ Florida, Dept Occupat Therapy, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Levy, Charles] N Florida S Georgia Vet Hlth Syst, Phys Med & Rehabil Serv, Gainesville, FL USA; [Levy, Charles] N Florida S Georgia Vet Hlth Syst, TBI PTSD, Gainesville, FL USA; [McCarthy, Dennis] Florida Int Univ, Dept Occupat Therapy, Coll Nursing & Hlth Sci, Miami, FL 33199 USA; [Mann, William C.; Waid-Ebbs, J. Kay] Univ Florida, Rehabil Sci Doctoral Program, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Waid-Ebbs, J. Kay] N Florida S Georgia Vet Hlth Syst, Brain Rehabil Res Ctr, Gainesville, FL USA	Classen, S (corresponding author), Univ Florida, Inst Mobil Act & Participat, Coll Publ Hlth & Hlth Profess, POB 100164, Gainesville, FL 32611 USA.	sclassen@phhp.ufl.edu					American Occupational Therapy Association, 2002, AM J OCCUPATIONAL TH, V62, P625; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Cooper H., 1994, HDB RES SYNTHESIS; Cote Murray J, 2007, Health Care Manag Sci, V10, P253, DOI 10.1007/s10729-007-9018-7; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Edlund W, 2004, CLIN PRACTICE GUIDEL; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; Fisk GD, 1998, BRAIN INJURY, V12, P683; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Innes CRH, 2007, J NEUROL SCI, V260, P188, DOI 10.1016/j.jns.2007.04.052; INNES CR, 2005, 27 ANN INT C IEEE EN; Korner-Bitensky N, 1994, Can J Occup Ther, V61, P141; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Marshall SC, 1999, CAN MED ASSOC J, V160, P1701; McMahon Brian T, 2005, Work, V25, P67; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rizzo M, 1996, NEUROLOGIST, V2, P150; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schneider JJ, 2005, APPL NEUROPSYCHOL, V12, P138, DOI 10.1207/S15324826AN1203_3; Schultheis MT, 2003, REHABIL PSYCHOL, V48, P275, DOI 10.1037/0090-5550.48.4.275; Schultz SM, 2002, J WILDLIFE DIS, V38, P47, DOI 10.7589/0090-3558-38.1.47; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Sundstrom A, 2008, TRANSPORT RES F-TRAF, V11, P1, DOI 10.1016/j.trf.2007.05.002; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yale Steven H, 2003, Clin Med Res, V1, P177	40	53	54	0	7	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5					580	591		10.5014/ajot.63.5.580			12	Rehabilitation	Rehabilitation	493SG	WOS:000269757700008	19785257				2021-06-18	
J	Huang, TT; Solano, J; He, DS; Loutfi, M; Dietrich, WD; Kuluz, JW				Huang, Tingting; Solano, Juan; He, Dansha; Loutfi, Maher; Dietrich, W. Dalton; Kuluz, John W.			Traumatic Injury Activates MAP Kinases in Astrocytes: Mechanisms of Hypothermia and Hyperthermia	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; astrocyte; hyperthermia; hypothermia; MAPKs; SP60025; traumatic brain injury	TRANSIENT FOREBRAIN ISCHEMIA; PERCUSSION BRAIN-INJURY; SPINAL-CORD-INJURY; PROTEIN-KINASE; REACTIVE ASTROCYTES; IN-VITRO; CULTURED ASTROCYTES; SIGNALING CASCADES; ENDOTHELIAL-CELLS; REGULATED KINASE	Hyperthermia is common following traumatic brain injury (TBI) and has been associated with poor neurologic outcome, and hypothermia has emerged as a potentially effective therapy for TBI, although its mechanism is still unclear. In this study we investigated the effects of temperature modulations on astrocyte survival following traumatic injury and the involved MAPK pathways. Trauma was produced by scratch injury of a monolayer of confluent astrocytes in culture, followed by incubation at hypothermia (30 degrees C), normothermia (37 degrees C), or hyperthermia (39 degrees C). The activation of MAPK pathways including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK were measured at 0, 15, 30, 60, and 120 min after traumatic injury followed by temperature modulation. Apoptosis of astrocytes was assessed by quantitation of cleaved caspase-3 expression 24 h after injury. Our findings showed that only JNK activation at 15 min after trauma was reduced by hypothermia, and this was associated with a marked reduction in apoptosis. Hyperthermia activated both ERK and JNK and increased apoptosis. The specific JNK inhibitor, SP60025, markedly reduced JNK-induced apoptosis at normothermia and hyperthermia, and showed a dose-dependent effect. In conclusion, the JNK pathway appears to mediate traumatic injury-induced apoptosis in astrocytes. Prolonged hyperthermia as a secondary insult worsens apoptosis by increasing JNK activation. Hypothermia protects against traumatic injury via early suppression on JNK activation and subsequent prevention of apoptosis. Manipulation of the JNK pathway in astrocytes may represent a therapeutic target for ameliorating the devastating progression of tissue injury and cell death after TBI.	[Huang, Tingting; Solano, Juan; He, Dansha; Kuluz, John W.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Loutfi, Maher] Univ S Alabama, Coll Med, Dept Neurol, Mobile, AL USA	Kuluz, JW (corresponding author), Univ Miami, Sch Med, POB 016960, Miami, FL 33101 USA.	jkuluz@bellsouth.net			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042133, R01 NS089443] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER		Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; ASCHNER M, 1991, NEUROTOXICOLOGY, V12, P505; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen SH, 2008, TOXICOL SCI, V102, P138, DOI 10.1093/toxsci/kfm292; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haseloff RF, 2005, CELL MOL NEUROBIOL, V25, P25, DOI 10.1007/s10571-004-1375-x; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Ikeda H, 2004, J NEUROSCI, V24, P9888, DOI 10.1523/JNEUROSCI.2608-04.2004; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Katano H, 2001, NEUROSCI LETT, V306, P101, DOI 10.1016/S0304-3940(01)01832-8; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Otani N, 2003, ACT NEUR S, V86, P287; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Siddharthan V, 2007, BRAIN RES, V1147, P39, DOI 10.1016/j.brainres.2007.02.029; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; VandeVord PJ, 2008, NEUROSCI LETT, V434, P247, DOI 10.1016/j.neulet.2008.01.056; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023	52	53	62	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1535	1545		10.1089/neu.2008.0743			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200010	19331517	Green Published			2021-06-18	
J	Jiang, C; Wang, JP; Li, X; Liu, CL; Chen, NN; Hao, YJ				Jiang, Chao; Wang, Jianping; Li, Xin; Liu, Chunling; Chen, Ningning; Hao, Yujin			Progesterone exerts neuroprotective effects by inhibiting inflammatory response after stroke	INFLAMMATION RESEARCH			English	Article						Progesterone; Tumor necrosis factor-alpha; Claudin5; Blood-brain barrier	TRAUMATIC BRAIN-INJURY; SPONTANEOUSLY HYPERTENSIVE-RATS; TUMOR-NECROSIS-FACTOR; CEREBRAL-ARTERY OCCLUSION; FACTOR-ALPHA; ISCHEMIA; EXPRESSION; BARRIER; EDEMA; CYTOKINES	We evaluated the inhibitory effects of progesterone (PROG) on inflammatory response and its influence on the structure of blood-brain barrier in a permanent model of stroke. One hundred and twenty adult male Sprague-Dawley rats were used in this study. PROG was dissolved in 22.5% 2-hydroxypropyl-bcyclodextrin and given in a dose of 15 mg/kg by intraperitoneal injection 1 h after permanent occlusion of middle cerebral artery (pMCAO). Additional injections of 15 mg/kg were administered subcutaneously 6, 24, and 48 h after pMCAO. The expression of tumor necrosis factor-alpha (TNF-alpha) and claudin5 was measured by immunohistochemistry and western blot technique. Brain water content was determined by the dry-wet weight method. TNF-alpha were increased, but claudin5 were reduced in vehicle-treated rats after pMCAO. PROG-treated rats showed a substantial reduction in the expression of TNF-alpha compared to vehicle controls. In addition, there was significant increase in the expression of claudin5 in the pMCAO rats treated with PROG compared to vehicle. Examination of the water content of the brain also revealed that administration of PROG significantly attenuated the amount of water compared to vehicle in the ipsilateral hemispheres. These data indicate that PROG is beneficial in this animal model, and may warrant further test in future clinical trials for human stroke.	[Jiang, Chao; Wang, Jianping; Li, Xin; Liu, Chunling; Chen, Ningning; Hao, Yujin] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 2, Zhengzhou 450014, Henan, Peoples R China	Wang, JP (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 2, Zhengzhou 450014, Henan, Peoples R China.	jcmd666@126.com					Begley DJ, 2003, PROG DRUG RES, V61, P39; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dziewulska D, 2003, CLIN NEUROPATHOL, V22, P35; Fisher Mark, 2008, Rev Neurol Dis, V5 Suppl 1, pS4; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hatashita S, 1990, Adv Neurol, V52, P327; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Manicone AM, 2008, SEMIN CELL DEV BIOL, V19, P34, DOI 10.1016/j.semcdb.2007.07.003; Meistrell ME, 1997, SHOCK, V8, P341; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; Tsukita S, 1998, GENES CELLS, V3, P569, DOI 10.1046/j.1365-2443.1998.00212.x; Ueno M, 2004, HISTOCHEM CELL BIOL, V122, P131, DOI 10.1007/s00418-004-0684-y; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vandromme M, 2008, CRIT CARE, V12, DOI 10.1186/cc6899; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	31	53	58	1	7	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	SEP	2009	58	9					619	624		10.1007/s00011-009-0032-8			6	Cell Biology; Immunology	Cell Biology; Immunology	475AJ	WOS:000268326500010	19333725				2021-06-18	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			The effects of a 'home-based' task-oriented exercise programme on motor and balance performance in children with spastic cerebral palsy and severe traumatic brain injury	CLINICAL REHABILITATION			English	Article							RESISTANCE EXERCISE; REHABILITATION; STAND; RELIABILITY	Objectives: To evaluate the feasibility and the ability to recruit and retain children with severe traumatic brain injury or cerebral palsy, and their families, to a simple home-based exercise programme and to assess the immediate and short-term effects of such intervention on reducing impairment and improving function. Study design: Randomized clinical trial. Participants: Twenty children aged 7-13 years, with traumatic brain injury (N = 10) or cerebral palsy (N = 10) who were independent ambulators. Five children from each group were randomly assigned to a control group - regular daily activities, or to an experimental group - regular daily activities plus a home-based task-oriented exercise programme of sit-to-stand and step-up exercise, for six weeks. Outcome measures: Feasibility: The number of participants who completed the programme protocol. Efficacy: Timed Up and Go Test and Functional Reach Test were used as functional balance tests. Maximal isometric strength was assessed by using a hand-held dynamometer; walking performance was assessed by the 10 m walk test, 2-minute walk test and Energy Expenditure Index. Results: Nine children completed all parts of the training programme. At the end of the intervention period an increase of 3 - 4 cm in the mean Functional Reach Test and a reduction of 1.6 +/- 2.1 seconds in the Timed Up and Go Test were noted (P < 0.01) in the experimental group while no changes were noted in the control group. In all other outcomes assessed no significant differences were noted between groups. The positive change in balance performance in the experimental group was maintained during a six-week follow-up period. Conclusions: A home-based task-oriented exercise programme can improve balance performance in children with spastic cerebral palsy or severe traumatic brain injury.	[Katz-Leurer, Michal] Tel Aviv Univ, Sackler Fac Med, Phys Therapy Dept, Sch Hlth Profess, IL-69978 Ramat Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Hosp, Pediat & Adolescent Rehabil Ctr, Jerusalem, Israel	Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Phys Therapy Dept, Sch Hlth Profess, IL-69978 Ramat Aviv, Israel.	michalkz@post.tau.ac.il					Baxter RE, 2003, J ORTHOP SPORT PHYS, V33, P40, DOI 10.2519/jospt.2003.33.1.40; Bodkin Amy Winter, 2003, Pediatr Phys Ther, V15, P247, DOI 10.1097/01.PEP.0000096384.19136.02; Brown DA, 1998, PHYS THER, V78, P934, DOI 10.1093/ptj/78.9.934; Byerly P N, 1994, J Athl Train, V29, P352; Carr J. H., 1998, NEUROLOGICAL REHABIL; DAMIANO DL, 1995, DEV MED CHILD NEUROL, V37, P731, DOI 10.1111/j.1469-8749.1995.tb15019.x; Dite W, 2002, ARCH PHYS MED REHAB, V83, P1566, DOI 10.1053/apmr.2002.35469; Dodd KJ, 2003, DEV MED CHILD NEUROL, V45, P652, DOI 10.1017/S0012162203001221; Donahoe B, 1994, PEDIAT PHYSICAL THER, V6, P189, DOI DOI 10.1097/00001577-199400640-00004; FISHER AC, 1988, PHYSICIAN SPORTSMED, V16, P47, DOI 10.1080/00913847.1988.11709551; Fragala-Pinkham MA, 2005, PHYS THER, V85, P1182, DOI 10.1093/ptj/85.11.1182; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Henry KD, 1999, PHYS THER, V79, P270, DOI 10.1093/ptj/79.3.270; Katz-Leurer M, 2008, PHYSIOTHERAPY, V94, P71, DOI 10.1016/j.physio.2007.04.003; Katz-Leurer Michal, 2008, Pediatr Phys Ther, V20, P254, DOI 10.1097/PEP.0b013e3181820dd8; Katz-Leurer Michal, 2008, Pediatr Phys Ther, V20, P259, DOI 10.1097/PEP.0b013e3181824782; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Liao HF, 2007, ARCH PHYS MED REHAB, V88, P25, DOI 10.1016/j.apmr.2006.10.006; Lin MR, 2004, J AM GERIATR SOC, V52, P1343, DOI 10.1111/j.1532-5415.2004.52366.x; Livingstone MBE, 2000, MED SCI SPORT EXER, V32, P1513, DOI 10.1097/00005768-200008000-00022; Lowes LP, 1996, PEDIAT PHYS THERAPY, V8, P176; MATHIOWETZ V, 1985, OCCUP THER J RES, V5, P24, DOI 10.1177/153944928500500102; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; NICHOLAS F, 2004, PHYSIOTHERAPY, V90, P57; PAI YC, 1991, ARCH PHYS MED REHAB, V72, P881, DOI 10.1016/0003-9993(91)90004-3; Raynor DK, 1998, ADHERENCE TREATMENT, P83; RIDDLE DL, 1989, PHYS THER, V69, P182, DOI 10.1093/ptj/69.3.182; RIOLO L, 1993, PHYS THER, V73, P784, DOI 10.1093/ptj/73.11.784; Rivera JE, 2010, J SPORT REHABIL, V3, DOI 10.1123/jsr.3.2.154; Robertson RJ, 2006, MED SCI SPORT EXER, V38, P158, DOI 10.1249/01.mss.0000190595.03402.66; Schneiders AG, 1998, MAN THER, V3, P147, DOI DOI 10.1016/S1356-689X(98)80005-2; Seven YB, 2008, HUM MOVEMENT SCI, V27, P65, DOI 10.1016/j.humov.2007.11.001; SHUMWAYCOOK A, 1995, MOTOR CONTROL THEORY, P4; TEASDALE G, 1974, LANCET, V2, P81	36	53	57	0	30	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	AUG	2009	23	8					714	724		10.1177/0269215509335293			11	Rehabilitation	Rehabilitation	475UV	WOS:000268388200006	19506005				2021-06-18	
J	Rhodes, JKJ; Sharkey, J; Andrews, PJD				Rhodes, Jonathan K. J.; Sharkey, John; Andrews, Peter J. D.			The Temporal Expression, Cellular Localization, and Inhibition of the Chemokines MIP-2 and MCP-1 after Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						brain; MCP-1/CCL2; MIP-2/CXCL2; trauma	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MACROPHAGE INFLAMMATORY PROTEIN-2; MICROVASCULAR ENDOTHELIAL-CELLS; FACTOR-KAPPA-B; MESSENGER-RNA; AXONAL INJURY; GLIAL-CELLS; CYCLOSPORINE-A	The expression of the neutrophil chemokine macrophage inflammatory protein-2 (MIP-2/CXCL2) and the monocyte chemokine monocyte chemotactic protein-1 (MCP-1/CCL2) have been described in glial cells in vitro but their origin following TBI has not been established. Furthermore, little is known of the modulation of these chemokines. Chemokine expression was investigated in male Sprague-Dawley rats following moderate lateral fluid percussion injury (LFPI). At 0, 4, 8, 12, and 24 h after injury, brains were harvested and MIP-2/CXCL2 and MCP=1/CCL2 levels measured by ELISA. To investigate the inhibition of chemokine expression a second cohort of animals received dexamethasone (1-15 mg/kg), FK506 (1 mg/kg), or vehicle, systemically, immediately after injury. These animals were sacrificed at the time of peak chemokine expression. A third cohort of animals was also sacrificed at the time of peak chemokine expression and immunohistochemistry performed for MIP-2/CXCL2 and MCP-1/CCL2. Following LFPI, chemokines were increased in the ipsilateral hemisphere, MIP-2/CXCL2 peaking at 4 h and MCP-1/CCL2 peaking at 8-12 h post-injury. Dexamethasone significantly reduced cortical MCP-1/CCL2, but not MIP-2/CXCL2 concentrations. FK506 did not inhibit chemokine expression. In undamaged brain, chemokine expression was localized to cells with a neuronal morphology. For MIP-2/CXCL2 this was supported by double staining for the neuronal antigen NeuN. In contused tissue, increased MIP-2/CXCL2 and MCP-1/CCL2 staining was visible in cells with the morphology of degenerating neurons. MIP-2/CXCL2 and MCP-1/CCL2 are increased after injury, and neurons appear to be the source of this expression. Chemokine expression was selectively inhibited by dexamethasone. The implications of this are discussed.	[Rhodes, Jonathan K. J.] Univ Edinburgh, Western Gen Hosp, Dept Anaesthesia, Edinburgh EH4 2XU, Midlothian, Scotland; [Andrews, Peter J. D.] Western Gen Hosp, Intens Care Unit, Edinburgh EH4 2XU, Midlothian, Scotland; [Sharkey, John] Univ Dundee, Ninewells Hosp & Med Sch, Sch Life Sci Res, Translat Med Res Collaborat, Dundee DD1 9SY, Scotland	Rhodes, JKJ (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Anaesthesia, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	J.K.J.Rhodes@sms.ed.ac.uk		Sharkey, John/0000-0001-8288-1857			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; ALDERSON P, 2000, COCHRANE DB SYST REV; Babcock AA, 2003, J NEUROSCI, V23, P7922; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Berman JW, 1996, J IMMUNOL, V156, P3017; Borger P, 2000, TRANSPLANTATION, V69, P1408, DOI 10.1097/00007890-200004150-00034; Butcher SP, 1997, J NEUROSCI, V17, P6939; Che XM, 2001, BRAIN RES, V902, P171, DOI 10.1016/S0006-8993(01)02328-9; COLOTTA F, 1992, J IMMUNOL, V148, P760; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COX G, 1995, J IMMUNOL, V154, P4719; de Haij S, 2002, BRIT J PHARMACOL, V137, P197, DOI 10.1038/sj.bjp.0704866; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; FAN L, 1995, MOL BRAIN RES, V30, P125; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; Gilmour PS, 2004, TOXICOL APPL PHARM, V195, P35, DOI 10.1016/j.taap.2003.10.003; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; Harkness KA, 2003, J NEUROIMMUNOL, V142, P1, DOI 10.1016/S0165-5728(03)00251-0; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Heasman SJ, 2003, J ENDOCRINOL, V178, P29, DOI 10.1677/joe.0.1780029; Held HD, 2001, AM J RESP CRIT CARE, V163, P711, DOI 10.1164/ajrccm.163.3.2003001; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; KAPLAN A, 1995, J DERMATOL SCI, V10, P130, DOI 10.1016/0923-1811(95)00395-9; KIM JS, 1995, J NEUROL SCI, V128, P28, DOI 10.1016/0022-510X(94)00217-C; Kono H, 2004, AM J PHYSIOL-GASTR L, V286, pG1081, DOI 10.1152/ajpgi.00457.2003; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KUBES P, 1991, DIGEST DIS SCI, V36, P1469, DOI 10.1007/BF01296817; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; McCarter JF, 2001, TRANSPL P, V33, P2390, DOI 10.1016/S0041-1345(01)02033-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Minami M, 2003, LIFE SCI, V74, P321, DOI 10.1016/j.lfs.2003.09.019; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Nygardas PT, 2000, EUR J IMMUNOL, V30, P1911, DOI 10.1002/1521-4141(200007)30:7<1911::AID-IMMU1911>3.0.CO;2-E; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Porcheray F, 2005, CLIN EXP IMMUNOL, V142, P481, DOI 10.1111/j.1365-2249.2005.02934.x; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; Saitoh O, 1997, J GASTROENTEROL, V32, P605, DOI 10.1007/BF02934109; Sasakawa Y, 2000, EUR J PHARMACOL, V403, P281, DOI 10.1016/S0014-2999(00)00592-6; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schramm R, 2003, INFECT IMMUN, V71, P2542, DOI 10.1128/IAI.71.5.2542-2547.2003; Schwartz D, 1998, J NEUROL SCI, V155, P13, DOI 10.1016/S0022-510X(97)00268-2; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Soares HD, 1995, J NEUROSCI, V15, P8223; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; SUZUKI S, 1993, TRANSPLANTATION, V55, P1265; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOBLER A, 1992, BLOOD, V79, P45; Tsujikawa A, 1998, STROKE, V29, P1431, DOI 10.1161/01.STR.29.7.1431; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Wakita H, 1998, BRAIN RES, V792, P105, DOI 10.1016/S0006-8993(98)00126-7; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Zawadzka M, 2005, GLIA, V49, P36, DOI 10.1002/glia.20092; Zwijnenburg PJG, 2003, IMMUNOL LETT, V85, P1, DOI 10.1016/S0165-2478(02)00200-6	68	53	54	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					507	525		10.1089/neu.2008.0686			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300004	19210118				2021-06-18	
J	Hanrieder, J; Wetterhall, M; Enblad, P; Hillered, L; Bergquist, J				Hanrieder, Jorg; Wetterhall, Magnus; Enblad, Per; Hillered, Lars; Bergquist, Jonas			Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury (TBI); Ventricular cerebrospinal fluid (CSF); Shotgun proteomics; Protein quantification; Isobaric tag labeling; Matrix assisted laser desorption/ionization time of flight tandem mass spectrometry (MALDI TOF MS/MS)	NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; OUTCOME PREDICTION; SERUM MARKERS; PROTEIN; DAMAGE; ACCUMULATION; STRATEGIES; DISCOVERY	A shotgun proteomic approach based on nanoflow liquid chromatography (nanoLC) in conjunction with matrix assisted laser desorption/ionization time of flight tandem mass spectrometry (MALDI TOF MS/MS) was utilized to quantitatively analyze the protein content of consecutive ventricular cerebrospinal fluid (CSF) samples of severe traumatic brain injury (TBI) patients on an individual basis. CSF was acquired from the lateral ventricle 1-9 days after the TBI incident by canula drain to investigate temporally resolved protein changes in three patients that required intracranial pressure monitoring during neurointensive care. The samples were subjected to at once tryptic digestion followed by isobaric tag labeling before multiplexed peptide separation and MS analysis. By using this approach, we were able to follow characteristic changes in protein concentrations over time allowing new conclusions to be drawn about ongoing pathological processes during TBI. Certain suggested protein-biomarker candidates for TBI, like acute phase reactants (APRs), fibrinogens (FIB), cystatin C (CC) or more brain specific proteins like glial fibrillary acid protein (GFAP) and neuron-specific enolase (NSE) were found to be significantly up-regulated which is in strong consistence with previously reported results. This methodology appears to be a promising tool for studying candidate biomarkers of neurovascular and traumatic brain injuries in the neurointensive care setting. (C) 2008 Elsevier B.V. All rights reserved.	[Hanrieder, Jorg; Wetterhall, Magnus; Bergquist, Jonas] Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, SE-75124 Uppsala, Sweden; [Enblad, Per; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden	Bergquist, J (corresponding author), Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, POB 599, SE-75124 Uppsala, Sweden.	jonas.bergquist@kemi.uu.se	Bergquist, Jonas/C-5894-2015; Hanrieder, Jorg/E-9706-2011	Hillered, Lars/0000-0002-2808-9292; Bergquist, Jonas/0000-0002-4597-041X	Swedish Agency for Innovation SystemsVinnova; Ahlen Foundation; Uppsala University Hospital; Swedish Research Counci; Swedish Research CouncilSwedish Research CouncilEuropean Commission [621-2005-5379, 342-2004-3944, 629-2002-6821, 2004-6210, 2007-3254 LH]	This research was supported by the Uppsala Berzelii Technology Center for Neurodiagnostics, with financing from the Swedish Agency for Innovation Systems, the Ahlen Foundation, Uppsala University Hospital and the Swedish Research Council. The Swedish Research Council (Grants 621-2005-5379, 342-2004-3944 and 629-2002-6821 (JB) 2004-6210 and 2007-3254 LH) is gratefully acknowledged for financial support.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BERGER RP, 2002, PEDIATRICS, P109; Bergquist J, 2002, MASS SPECTROM REV, V21, P2, DOI 10.1002/mas.10016; Brancia FL, 2006, CURR ANAL CHEM, V2, P1, DOI 10.2174/157341106775197367; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Calvo KR, 2005, BIOSCIENCE REP, V25, P107, DOI 10.1007/s10540-005-2851-3; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; KAISER E, 1989, CLIN CHIM ACTA, V183, P13, DOI 10.1016/0009-8981(89)90268-4; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Levy Efrat, 2008, Expert Rev Neurother, V8, P687, DOI 10.1586/14737175.8.5.687; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Mirgorodskaya E, 2005, PROTEOMICS, V5, P399, DOI 10.1002/pmic.200400984; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith RD, 2000, NAT BIOTECHNOL, V18, P1041, DOI 10.1038/80226; Sundelof J, 2008, NEUROLOGY, V71, P1072, DOI 10.1212/01.wnl.0000326894.40353.93; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	44	53	53	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2009	177	2					469	478		10.1016/j.jneumeth.2008.10.038			10	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	407VV	WOS:000263393300027	19263575				2021-06-18	
J	Ottochian, M; Salim, A; Berry, C; Chan, LS; Wilson, MT; Margulies, DR				Ottochian, Marcus; Salim, Ali; Berry, Cherisse; Chan, Linda S.; Wilson, Matthew T.; Margulies, Daniel R.			Severe traumatic brain injury: is there a gender difference in mortality?	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	18th Annual Meeting of the Society-for-Black-Academic-Surgeons	APR 17-20, 2008	Cleveland, OH	Soc Black Acad Surg		Trauma; Traumatic brain injury; Gender; Outcome; Mortality	ESTROGEN; MALES; PROTECTION; FEMALES; RATS	BACKGROUND: Emerging evidence suggests that male and female nervous systems respond differently to traumatic brain injury (TB1). The objective of this study was to examine outcomes between the sexes after TBI. PATIENTS AND METHODS: A retrospective review of all severe TBI patients admitted between January and December 2005 was performed. Isolated severe TBI was defined as a head abbreviated injury score greater than 3 with an abbreviated injury score of 3 or less for other anatomic regions. The population was stratified into age subgroups (<14 y, 14-44 y, 45-54 y, and >= 55 y), Logistic regression was used to identify independent predictors of mortality. RESULTS: A total of 1,807 TBI patients were admitted. The mortality was significantly higher for women (<43.2% vs 36.2%, P < .01) with an adjusted odds ratio Of 1.4 (95%) confidence interval, 1.1-1.9, P < .05). After stratification, only women age 55 and older had a significant difference in mortality (odds ratio, 1.71; 95% confidence interval, 1.11-2.62, P = .02). CONCLUSIONS: Female sex (particularly those age >= 55 y) is associated independently with higher mortality in isolated severe TBI. This increased mortality Of postmenopausal women after isolated TBI may suggest a hormonal influence and warrants further investigation. (C) 2009 Elsevier Inc. All rights reserved.	[Salim, Ali; Berry, Cherisse; Wilson, Matthew T.; Margulies, Daniel R.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Ottochian, Marcus; Chan, Linda S.] Los Angeles Cty Univ So Calif, Med Ctr, Div Trauma, Los Angeles, CA USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020				Amantea D, 2005, PHARMACOL RES, V52, P119, DOI 10.1016/j.phrs.2005.03.002; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10	19	53	53	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	FEB	2009	197	2					155	158		10.1016/j.amjsurg.2008.09.008			4	Surgery	Surgery	408SA	WOS:000263454000005	19185108				2021-06-18	
J	Colantonio, A; Croxford, R; Farooq, S; Laporte, A; Coyte, PC				Colantonio, Angela; Croxford, Ruth; Farooq, Samina; Laporte, Audrey; Coyte, Peter C.			Trends in Hospitalization Associated With Traumatic Brain Injury in a Publicly Insured Population, 1992-2002	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Epidemiology; Hospitalization; Age; Gender	LICENSE; DRIVERS	Background., Traumatic brain injury (TBI) is a leading cause of death and disability in developed countries. We document trends in TBI-related hospitalizations in Ontario, Canada, between April 1992 and March 2002, focusing on relationships between inpatient hospitalization rates, age, sex, cause of injury, severity level, and in-hospital mortality. Methods: Information on all acute hospital separations in Ontario with a diagnosis of TBI was analyzed using logistic regression. Results: Hospitalization rates fell steeply among children and young adults but remained stable among adults aged 66 and older. The proportion of TBI hospitalizations with mild injuries decreased from 75% to 54%, whereas the proportion with moderate injuries increased from 19% to 37%. Adjusting for other risk factors, in-hospital deaths were higher for injuries because of motor vehicle crashes than those because of falls. In-hospital death rates were stable for patients with moderate or severe injuries, but increased over time among those whose injuries were classified as mild, suggesting a trend toward more serious injury within the "mild" classification. Conclusions: Hospitalizations for TBI involve fewer mild injuries over time and are highest in the oldest segment of the population.	[Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Croxford, Ruth] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Farooq, Samina] Univ Toronto, Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Laporte, Audrey; Coyte, Peter C.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 1V7, Canada; [Coyte, Peter C.] CHSRF CIHR Hlth Serv, Toronto, ON, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Toronto Rehabilitation Institute Foundation; Ontario Ministry of Health and Long-term careMinistry of Health and Long-Term Care, Ontario	This research was funded by the Ontario Neurotrauma Foundation and the Toronto Rehabilitation Institute Foundation. The Institute for Clinical Evaluative Sciences and the Toronto Rehabilitation Institute receives funding from the Ontario Ministry of Health and Long-term care.	ASBRIDGE M, DRUGS ED PR IN PRESS; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; *CAN I HLTH INF, 2003, HOSP INJ ADM ONT 200; Center for Disease Control and Prevention, NAT CTR INJ PREV CON; FRAKEL JE, 2006, ARCH PHYS MED REHAB, V87, P57; KINGMA J, 1994, PERCEPT MOTOR SKILL, V78, P915, DOI 10.2466/pms.1994.78.3.915; MACPHERSON AK, 2008, PEDIATRICS, V110, P1; Mann RE, 2002, CAN J PUBLIC HEALTH, V93, P176, DOI 10.1007/BF03404995; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Pickett William, 2004, Chronic Dis Can, V25, P32; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; World Health Organization, 1978, INT CLASS DIS; Zhao JH, 2006, ACCIDENT ANAL PREV, V38, P35, DOI 10.1016/j.aap.2005.06.019; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	16	53	54	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					179	183		10.1097/TA.0b013e3181715d66			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500024	19131822				2021-06-18	
J	Robertson, JVG; Pradon, D; Bensmail, D; Fermanian, C; Bussel, B; Roche, N				Robertson, Johanna V. G.; Pradon, Didier; Bensmail, Djamel; Fermanian, Christophe; Bussel, Bernard; Roche, Nicolas			Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults	GAIT & POSTURE			English	Article						Stiff knee gait; Rectus femoris; Nerve block; Botulinum toxin; Hemiplegic	MOTOR BRANCH-BLOCK; LEGGED GAIT; SWING-PHASE; FLEXION; MUSCLES; SPASTICITY; WALKING; STROKE; PERIOD	Stiff knee gait (SKG) is common in hemiplegic patients. The main focus of treatment is rectus femoris (RF) spasticity. The aims of this study were to evaluate the effect of botulinum toxin injection (BTI) in the RE muscle on peak knee flexion during swing phase and its quantitative and functional impact on gait. We also wished to evaluate the correlation between the effects of nerve block and BTI on peak knee flexion. 10 adult hemiplegic subjects (> 6 months post stroke or traumatic brain injury) with SKG and inappropriate RE EMG activity during mid-swing phase were included. 3D gait analysis, clinical and functional assessments (Timed Up and Go test, 10 m walk test, 6 min walk test and the time taken to ascend and descend a flight of stairs) were performed initially, 30 min after anaesthetic block of the RF nerve and one month post BTI. After BTI, there was a significant increase in knee flexion (8 degrees average) and a tendency towards improvement in gait and functional parameters. The effect of the nerve block on peak knee flexion was significantly correlated with the effect of BTI (11 degrees average increase in peak knee flexion after nerve block). We challenge the relevance of RF nerve blocks in this population when EMG and kinematic data are available. Our results indicate that BTI is an effective treatment for SKG in adult hemiplegic subjects, with a significant increase in peak knee flexion, no reduction in hip flexion and a tendency towards functional improvements. (C) 2008 Elsevier B.V. All rights reserved.	[Robertson, Johanna V. G.] Lab Neurophysiol & Physiol, CNRS UMR 8119, F-75006 Paris, France; [Pradon, Didier; Bensmail, Djamel; Bussel, Bernard] UVSQ, Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France; [Roche, Nicolas] UVSQ, Hop Raymond Poincare, Serv Explorat Fonct, AP HP, F-92380 Garches, France; [Fermanian, Christophe] Hop Ambroise Pare, Unite Rech Clin Paris Ouest, F-92100 Boulogne, France; [Roche, Nicolas] Hop Raymond Poincare, Ctr Invest Clin & Innovat Technol, AP HP, F-92380 Garches, France	Robertson, JVG (corresponding author), Lab Neurophysiol & Physiol, CNRS UMR 8119, 45 Rue St Peres, F-75006 Paris, France.	johanna.robertson@univ-paris5.fr	roche, nicolas/R-6080-2018; Bensmail, Djamel/R-6035-2018	Bensmail, Djamel/0000-0001-9360-9330	Fondation Garches	This project was partially supported by a grant from the 'Fondation Garches'.	BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chantraine F, 2005, ACTA NEUROL BELG, V105, P171; Filipetti P, 2003, NEUROCHIRURGIE, V49, P226; Goldberg SR, 2006, J BIOMECH, V39, P689, DOI 10.1016/j.jbiomech.2005.01.015; Goldberg SR, 2004, J BIOMECH, V37, P1189, DOI 10.1016/j.jbiomech.2003.12.005; Goldberg SR, 2003, J BIOMECH, V36, P1111, DOI 10.1016/S0021-9290(03)00106-4; HOLM S, 1979, SCAND J STAT, V6, P65; Kerrigan DC, 1998, GAIT POSTURE, V7, P117, DOI 10.1016/S0966-6362(97)00040-4; Kerrigan DC, 2001, AM J PHYS MED REHAB, V80, P244, DOI 10.1097/00002060-200104000-00002; Kerrigan DC, 2001, AM J PHYS MED REHAB, V80, P33, DOI 10.1097/00002060-200101000-00009; Kerrigan DCC, 1999, J HEAD TRAUMA REHAB, V14, P136, DOI 10.1097/00001199-199904000-00004; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387; Miller F, 1997, J PEDIATR ORTHOPED, V17, P603, DOI 10.1097/00004694-199709000-00006; Nene A, 1999, GAIT POSTURE, V9, P1, DOI 10.1016/S0966-6362(98)00042-3; PERRY J, 1992, NORMAL PATHOLOGICAL; Piazza SJ, 1996, J BIOMECH, V29, P723, DOI 10.1016/0021-9290(95)00144-1; Riley P O, 1999, IEEE Trans Rehabil Eng, V7, P420, DOI 10.1109/86.808945; Riley PO, 1998, J BIOMECH, V31, P835, DOI 10.1016/S0021-9290(98)00107-9; Sheean GL, 2001, CURR OPIN NEUROL, V14, P771, DOI 10.1097/00019052-200112000-00015; STOQUART GG, 2006, EUR SOC PHYS REH MED; Sung DH, 2003, ARCH PHYS MED REHAB, V84, P1028, DOI 10.1016/S0003-9993(03)00029-7; Sung DH, 2000, ARCH PHYS MED REHAB, V81, P910, DOI 10.1053/apmr.2000.5615; SUTHERLAND DH, 1990, J PEDIATR ORTHOPED, V10, P433; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WINTER DA, 1974, J BIOMECH, V7, P157, DOI 10.1016/0021-9290(74)90056-6	26	53	55	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	JAN	2009	29	1					108	112		10.1016/j.gaitpost.2008.07.005			5	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	396LC	WOS:000262592200020	18771925				2021-06-18	
J	Mauritz, W; Wilbacher, I; Majdan, M; Leitgeb, J; Janciak, I; Brazinova, A; Rusnak, M				Mauritz, Walter; Wilbacher, Ingrid; Majdan, Marek; Leitgeb, Johannes; Janciak, Ivan; Brazinova, Alexandra; Rusnak, Martin			Epidemiology, treatment and outcome of patients after severe traumatic brain injury in European regions with different economic status	EUROPEAN JOURNAL OF PUBLIC HEALTH			English	Article							HEAD-INJURY; MANAGEMENT; TRIAL; CARE; ADMISSIONS; EFFICACY	Background: We hypothesized that the economic status of a region might influence quality of care and outcome of patients with severe brain trauma. Methods: Between January 2001 and December 2005, 13 centres enrolled patients with severe brain trauma. Data on accident, treatment and outcomes were collected prospectively. The regions were classified as high income (Austria, five centres), upper middle income (UMI) (Croatia, Slovakia, six centres) or lower middle income (LMI) (Bosnia, Macedonia, two centres). Data on epidemiology, treatment and outcomes were compared according to this classification. Quality of care was assessed using a new scoring system. Results: A total of 1172 data sets were analysed. Patients from the wealthier regions were significantly older. Low-level falls and traffic accidents contributed to more than two-third of all cases. Violence-related trauma was significantly more frequent in middle income regions. Treatment quality was significantly different; treatment according to guidelines for brain trauma management was provided most frequently for patients from high-income regions. Compared with expected mortality rates, mortality was 6.5 lower in the high-income centres, 2.4 lower in the UMI centres and 13 higher in the LMI centres. Advanced age, poor neurological status, high trauma severity and poor quality of care were associated with significantly lower odds for survival. Conclusions: The association between the economic status and outcome of brain trauma patients was due to the quality of care. Successful implementation of guidelines for brain trauma management requires a well-funded health care system.	[Mauritz, Walter; Wilbacher, Ingrid; Janciak, Ivan; Brazinova, Alexandra; Rusnak, Martin] INRO, A-1080 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Vienna, Austria; [Leitgeb, Johannes] Univ Hosp Vienna, Dept Trauma Surg, Vienna, Austria; [Majdan, Marek; Brazinova, Alexandra; Rusnak, Martin] Trnava Univ, Fac Hlth & Social Serv, Dept Publ Hlth, Trnava, Slovakia	Mauritz, W (corresponding author), INRO, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016; Brazinova, Alexandra/C-4265-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042; Brazinova, Alexandra/0000-0003-0625-256X; Mauritz, Walter/0000-0001-9043-3712			BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Firsching R, 2001, WORLD J SURG, V25, P1221; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Lu J, 2005, ACT NEUR S, V95, P281; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	24	53	59	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1101-1262			EUR J PUBLIC HEALTH	Eur. J. Public Health	DEC	2008	18	6					575	580		10.1093/eurpub/ckn079			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	376FF	WOS:000261168800008	18794186	Bronze			2021-06-18	
J	Lunemann, A; Lunemann, JD; Roberts, S; Messmer, B; da Silva, RB; Raine, CS; Muenz, C				Luenemann, Anna; Luenemann, Jan D.; Roberts, Susanne; Messmer, Brady; da Silva, Rosa Barreira; Raine, Cedric S.; Muenz, Christian			Human NK Cells Kill Resting but Not Activated Microglia via NKG2D-and NKp46-Mediated Recognition	JOURNAL OF IMMUNOLOGY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; HUMAN DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; MULTIPLE-SCLEROSIS; T-CELLS; MEDIATED LYSIS; ADAPTIVE IMMUNITY; GLIAL-CELLS; OLIGODENDROCYTES	Microglia are resident macrophage-like APCs of the CNS. To avoid escalation of inflammatory processes and bystander damage within the CNS, microglia-driven inflammatory responses need to be tightly regulated and both spatially and temporally restricted. Following traumatic, infectious, and autoimmune-mediated brain injury, NK cells have been found in the CNS, but the functional significance of NK cell recruitment and their mechanisms of action during brain inflammation are not well understood. In this study, we investigated whether and by which mechanisms human NK cells might edit resting and activated human microglial cells via killing in vitro. IL-2-activated NK cells efficiently killed both resting allogeneic and autologous microglia in a cell-contact-dependent manner. Activated NK cells rapidly formed synapses with human microglial cells in which perforin had been polarized to the cellular interface. Ab-mediated NKG2D and NKp46 blockade completely prevented the killing of human microglia by activated NK cells. Up-regulation of MHC class I surface expression by TLR4 stimulation protected microglia from NK cell-mediated killing, whereas MHC class I blockade enhanced cytotoxic NK cell activity. These data suggest that brain-infiltrating NK cells might restrict innate and adaptive immune responses within the human CNS via elimination of resting microglia. The Journal of Immunology, 2008, 181: 6170-6177.	[Luenemann, Anna; Luenemann, Jan D.; Roberts, Susanne; Messmer, Brady; da Silva, Rosa Barreira; Muenz, Christian] Rockefeller Univ, Christopher H Browne Ctr Immunol & Immune Dis, Lab Viral Immunobiol, New York, NY 10065 USA; [Raine, Cedric S.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Muenz, C (corresponding author), Univ Zurich, Univ Zurich Hosp, Inst Expt Immunol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	munzc@rockefeller.edu	Lunemann, Jan/G-8729-2011	Lunemann, Jan/0000-0002-3007-708X; Munz, Christian/0000-0001-6419-1940	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA108609, R01CA101741] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA108609, R01 CA101741, R01CA101741, R01 CA108609-04A2, R01CA108609] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [BAA-06-19] Funding Source: Medline		Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aloisi F, 2000, IMMUNOL TODAY, V21, P141, DOI 10.1016/S0167-5699(99)01512-1; Backstrom E, 2007, SCAND J IMMUNOL, V65, P353, DOI 10.1111/j.1365-3083.2007.01912.x; Backstrom E, 2003, EUR J IMMUNOL, V33, P92, DOI 10.1002/immu.200390012; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Byram SC, 2003, BRAIN BEHAV IMMUN, V17, P417, DOI 10.1016/S0889-1591(03)00089-8; Carbone E, 1999, EUR J IMMUNOL, V29, P4022, DOI 10.1002/(SICI)1521-4141(199912)29:12<4022::AID-IMMU4022>3.0.CO;2-O; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; Chiesa MD, 2003, EUR J IMMUNOL, V33, P1657, DOI 10.1002/eji.200323986; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fischer K, 2002, J IMMUNOL METHODS, V259, P159, DOI 10.1016/S0022-1759(01)00507-5; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Hamerman JA, 2004, J IMMUNOL, V172, P2001, DOI 10.4049/jimmunol.172.4.2001; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hansen DS, 2007, J IMMUNOL, V178, P5779, DOI 10.4049/jimmunol.178.9.5779; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Kettenmann H, 2006, NAT NEUROSCI, V9, P1463, DOI 10.1038/nn1206-1463; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LEE SHC, 1992, LAB INVEST, V67, P465; Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Lunemann JD, 2008, BRAIN, V131, P1681, DOI 10.1093/brain/awn132; Matsumoto Y, 1998, EUR J IMMUNOL, V28, P1681, DOI 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moretta A, 2008, CELL DEATH DIFFER, V15, P226, DOI 10.1038/sj.cdd.4402170; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Morse RHA, 2001, J NEUROIMMUNOL, V116, P107, DOI 10.1016/S0165-5728(01)00289-2; Munz C, 2005, BLOOD, V105, P266, DOI 10.1182/blood-2004-06-2492; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Parajuli P, 1999, J LEUKOCYTE BIOL, V65, P764; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Persson CM, 2008, SCAND J IMMUNOL, V67, P30, DOI 10.1111/j.1365-3083.2007.02034.x; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Saikali P, 2007, J NEUROSCI, V27, P1220, DOI 10.1523/JNEUROSCI.4402-06.2007; SATOH J, 1990, J NEUROIMMUNOL, V26, P75, DOI 10.1016/0165-5728(90)90122-4; SATOH J, 1991, J NEUROIMMUNOL, V31, P199, DOI 10.1016/0165-5728(91)90041-5; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Shrikant P, 1996, J IMMUNOL, V157, P1819; Spaggiari GM, 2001, EUR J IMMUNOL, V31, P1656, DOI 10.1002/1521-4141(200106)31:6<1656::AID-IMMU1656>3.0.CO;2-V; Strowig T, 2008, J IMMUNOL, V180, P7785, DOI 10.4049/jimmunol.180.12.7785; TRAUGOTT U, 1984, ANN NY ACAD SCI, V436, P163, DOI 10.1111/j.1749-6632.1984.tb14788.x; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vollmer TL, 2005, J IMMUNOL, V174, P2696, DOI 10.4049/jimmunol.174.5.2696; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Wilkinson RW, 2001, J IMMUNOL METHODS, V258, P183, DOI 10.1016/S0022-1759(01)00474-4; Wilson JL, 1999, J IMMUNOL, V163, P6365; Winkler-Pickett R, 2008, J IMMUNOL, V180, P4495, DOI 10.4049/jimmunol.180.7.4495; Xu W, 2005, J NEUROIMMUNOL, V163, P24, DOI 10.1016/j.jneuroim.2005.02.011; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677	57	53	54	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2008	181	9					6170	6177		10.4049/jimmunol.181.9.6170			8	Immunology	Immunology	368YI	WOS:000260659000042	18941207	Green Accepted, Bronze			2021-06-18	
J	Ma, M; Lindsell, CJ; Rosenberry, CM; Shaw, GJ; Zemlan, FP				Ma, Marek; Lindsell, Christopher J.; Rosenberry, Clark M.; Shaw, George J.; Zemlan, Frank P.			Serum cleaved tau does not predict postconcussion syndrome after mild traumatic brain injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							HEAD-INJURY; PROTEIN; S-100B; QUESTIONNAIRE; RELIABILITY; SF-36	Objectives: Our objective was to determine if the biomarker for axonal injury, serum cleaved tau (C-tau), predicts postconcussion syndrome (PCS) in adults after mild traumatic brain injury (mTBI). Methods: C-tau was measured from blood obtained in the emergency department. Outcome was assessed at 3 months post injury using the Rivermead Postconcussion Symptoms Questionnaire and Acute Medical Outcomes SF-36v2 Health Survey (SF-36). Results: Of 50 patients, there were 15 patients with detectable levels of C-tau, 10 patients with abnormal findings on initial head computed tomography (CT) and 22 patients with PCS. One-third of patients with detectable C-tau and 14.3% of patients without detectable C-tau had abnormal findings on head CT (P = .143). Serum C-tau was not detected more frequently in patients with PCS than those without, neither for all patients (P = .115) nor the subgroup with negative head CT (P = .253). Conclusions: C-tau is a poor predictor of PCS after mTBI regardless of head CT result. (C) 2008 Elsevier Inc. All rights reserved.	[Ma, Marek] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Lindsell, Christopher J.; Rosenberry, Clark M.; Shaw, George J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA; [Zemlan, Frank P.] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA	Ma, M (corresponding author), Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.	mamarek@uphs.upenn.edu		Lindsell, Christopher/0000-0002-3297-2811	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R43-NS46822]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS046822] Funding Source: NIH RePORTER	Research supported by National Institutes of Health grant R43-NS46822 (FPZ).	Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	16	53	54	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	SEP	2008	26	7					763	768		10.1016/j.ajem.2007.10.029			6	Emergency Medicine	Emergency Medicine	352UF	WOS:000259522200005	18774039	Green Accepted			2021-06-18	
J	Wong, DY; Leveque, JC; Brumblay, H; Krebsbach, PH; Hollister, SJ; LaMarca, F				Wong, Darice Y.; Leveque, Jean-Christophe; Brumblay, Hunter; Krebsbach, Paul H.; Hollister, Scott J.; LaMarca, Frank			Macro-architectures in spinal cord scaffold implants influence regeneration	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; in vivo studies; neural injury; polycaprolactone; regeneration; scaffold architecture; traumatic spinal cord injury	PERIPHERAL-NERVE GRAFTS; NEURAL STEM-CELLS; AXONAL REGENERATION; GUIDANCE CHANNELS; POLY(2-HYDROXYETHYL METHACRYLATE); FUNCTIONAL RECOVERY; BRAIN-STEM; INJURY; TRANSECTION; REPAIR	Biomaterial scaffold architecture has not been investigated as a tunable source of influence on spinal cord regeneration. This study compared regeneration in a transected spinal cord within various designed-macro-architecture scaffolds to determine if these architectures alone could enhance regeneration. Three-dimensional (3D) designs were created and molds were built on a 3-D printer. Salt-leached porous poly(epsilon-caprolactone) was cast in five different macro-architectures: cylinder, tube, channel, open-path with core, and open-path without core. The two open-path designs were created in this experiment to compare different supportive aspects of architecture provided by scaffolds and their influence on regeneration. Rats received T8 transections and implanted scaffolds for 1 and 3 months. Overall morphology and orientation of sections were characterized by H&E, luxol fast blue, and cresyl violet staining. Borders between intact gray matter and non-regenerated defect were observed from GFAP immunolabeling. Nerve fibers and regenerating axons were identified with Tuj-1 immunolabeling. The open-path designs allowed extension of myelinated fibers along the length of the defect both exterior to and inside the scaffolds and maintained their original defect length up to 3 months. In contrast, the cylinder, tube, and channel implants had a doubling of defect length from secondary damage and large scar and cyst formation with no neural tissue bridging. The open-path scaffold architectures enhanced spinal cord regeneration compared to the three other designs without the use of biological factors.	[Leveque, Jean-Christophe; Brumblay, Hunter; Hollister, Scott J.; LaMarca, Frank] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA	Hollister, SJ (corresponding author), Univ Michigan, Dept Neurosurg, 1101 Beal Ave,2149 LBME, Ann Arbor, MI 48109 USA.	scottho@umich.edu	Leveque, Jean-Christophe/L-6367-2017; Krebsbach, Paul H./AAC-4765-2021	Leveque, Jean-Christophe/0000-0003-2465-444X; Hollister, Scott/0000-0001-7625-892X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DE-007057-31]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER	Thanks go to Alex Garnepudi for all his assistance. Funding was provided by NIH (training grant T32 DE-007057-31 to D.Y.W.).	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Barnett SC, 2007, NAT CLIN PRACT NEURO, V3, P152, DOI 10.1038/ncpneuro0447; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Carone TW, 2006, J BIOMED MATER RES B, V78B, P274, DOI 10.1002/jbm.b.30483; CLARK P, 1990, DEVELOPMENT, V108, P635; CLARK P, 1991, J CELL SCI, V99, P73; Dinh P, 2007, SPINE, V32, P943, DOI 10.1097/01.brs.0000261408.61303.77; El Maarouf A, 2006, P NATL ACAD SCI USA, V103, P16989, DOI 10.1073/pnas.0608036103; Flynn L, 2003, BIOMATERIALS, V24, P4265, DOI 10.1016/S0142-9612(03)00334-X; Friedman JA, 2002, NEUROSURGERY, V51, P742, DOI 10.1097/00006123-200209000-00024; Fukunaga S, 2004, J ORTHOP SCI, V9, P605, DOI 10.1007/s00776-004-0833-0; Gelain F, 2007, J NANOSCI NANOTECHNO, V7, P424, DOI 10.1166/jnn.2007.154; Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035; Hadlock T, 2006, EXPERT OPIN BIOL TH, V6, P1105, DOI 10.1517/14712598.6.11.1105; Horn EM, 2007, J NEUROSURG-SPINE, V6, P133, DOI 10.3171/spi.2007.6.2.133; HOULE JD, 1994, J NEURAL TRANSP PLAS, V5, P115, DOI 10.1155/NP.1994.115; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Huang YC, 2005, J BIOMED MATER RES B, V74B, P659, DOI 10.1002/jbm.b.30267; Hurtado A, 2006, BIOMATERIALS, V27, P430, DOI 10.1016/j.biomaterials.2005.07.014; Ito Y, 1999, BIOMATERIALS, V20, P2333, DOI 10.1016/S0142-9612(99)00162-3; Jones LL, 2003, J NEUROSCI, V23, P9276; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kuo HS, 2007, BIOCHEM BIOPH RES CO, V357, P1, DOI 10.1016/j.bbrc.2007.02.167; Levi ADO, 2002, J NEUROSURG, V96, P197, DOI 10.3171/spi.2002.96.2.0197; Li XG, 2006, PROG NAT SCI-MATER, V16, P1051; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Miller C, 2002, TISSUE ENG, V8, P367, DOI 10.1089/107632702760184646; MORI S, 1992, BRAIN DEV-JPN, V14, pS109; NOGA BR, 1991, J NEUROSCI, V11, P1691; Nomura H, 2006, J NEUROTRAUM, V23, P496, DOI 10.1089/neu.2006.23.496; Nomura H, 2006, NEUROSURGERY, V59, P183, DOI 10.1227/01.NEU.0000219859.35349.EF; Novikova LN, 2003, CURR OPIN NEUROL, V16, P711, DOI 10.1097/00019052-200312000-00011; Oudega M, 2001, BIOMATERIALS, V22, P1125, DOI 10.1016/S0142-9612(00)00346-X; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Patist CM, 2004, BIOMATERIALS, V25, P1569, DOI 10.1016/S0142-9612(03)00503-9; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Stokols S, 2006, TISSUE ENG, V12, P2777, DOI 10.1089/ten.2006.12.2777; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Tsai EC, 2006, BIOMATERIALS, V27, P519, DOI 10.1016/j.biomaterials.2005.07.025; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Yoshii S, 2004, J BIOMED MATER RES A, V70A, P569, DOI 10.1002/jbm.a.30120; Yoshii S, 2003, SPINE, V28, P2346, DOI 10.1097/01.BRS.0000085302.95413.16; Zhang N, 2005, BRAIN RES REV, V49, P48, DOI 10.1016/j.brainresrev.2004.11.002	49	53	55	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					1027	1037		10.1089/neu.2007.0473			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700009	18721107	Green Published			2021-06-18	
J	Ganesalingam, K; Yeates, KO; Ginn, MS; Taylor, HG; Dietrich, A; Nuss, K; Wright, M				Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Ginn, Melissa Susan; Taylor, H. Gerry; Dietrich, Ann; Nuss, Kathy; Wright, Martha			Family burden and parental distress following mild traumatic brain injury in children and its relationship to post-concussive symptoms	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	35th Annual Meeting of the International-Neuropsychological-Society	FEB 07-10, 2007	Portland, OR	Int Neuropsychol Soc		children; family burden; mild traumatic brain injury; parental distress; post-concussive symptoms	MINOR HEAD TRAUMA; POSTCONCUSSION SYNDROME; NEUROBEHAVIORAL SYMPTOMS; ACADEMIC-PERFORMANCE; BEHAVIOR PROBLEMS; RELIABILITY; PREDICTORS; OUTCOMES	Objective To examine the relationship of mild traumatic brain injuries (TBI) and post-concussive symptoms (PCS) to post injury family burden and parental distress, using data from a prospective, longitudinal study. Methods Participants included 71 children with mild TBI with loss of consciousness (LOC), 110 with mild TBI without LOC, and 97 controls with orthopedic injuries not involving the head (OI), and their parents. Shortly after injury, parents and children completed a PCS interview and questionnaire, and parents rated premorbid family functioning. Parents also rated family burden and parental distress shortly after injury and at 3 months post injury. Results Mild TBI with LOC was associated with greater family burden at 3 months than OI, independent of socioeconomic status and premorbid family functioning. Higher PCS shortly after injury was related to higher ratings of family burden and distress at 3 months. Conclusions Mild TBI are associated with family burden and distress more than mild injuries not involving the head, although PCS may influence post injury family burden and distress more than the injury per se. Clinical implications of the current findings are noted in the Discussion section.	[Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Ginn, Melissa Susan] Nationwide Childrens Hosp, Inst Res, Columbus, OH 43205 USA; [Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathy] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathy] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathy] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Dietrich, Ann; Nuss, Kathy] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA	Ganesalingam, K (corresponding author), Nationwide Childrens Hosp, Inst Res, 700 Childrens Dr, Columbus, OH 43205 USA.	Kalaichelvi.Ganesalingam@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD039834-05, HD39834, K02 HD044099, HD44099, R01 HD039834] Funding Source: Medline		*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; AYR LK, 2005, INT NEUR SOC 34 ANN, P202; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; CASEY R, 1986, PEDIATRICS, V78, P497; CASEY R, 1987, PEDIATRICS, V80, P159; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Kelly JP, 1997, NEUROLOGY, V48, P581; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; *WHO, ICS 10 CLASS MENT BE; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	35	53	53	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUL	2008	33	6					621	629		10.1093/jpepsy/jsm133			9	Psychology, Developmental	Psychology	306XT	WOS:000256282400005	18227110	Bronze, Green Accepted, Green Published			2021-06-18	
J	Choi, I; Park, HK; Chang, JC; Cho, SJ; Choi, SK; Byun, BJ				Choi, Il; Park, Hyung-Ki; Chang, Jae-Chil; Cho, Sung-Jin; Choi, Soon-Kwan; Byun, Bark-Jang			Clinical factors for the development of posttraumatic hydrocephalus after decompressive craniectomy	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						hydrocephalus; craniotomy; craniocerebral trauma	HEMICRANIECTOMY	Objective : Earlier reports have revealed that the incidence of posttraumatic hydrocephalus (PTH) is higher among patients who underwent decompressive craniectomy (DC). The aim of this study was to determine the influencing factors for the development of PTH after DC. Methods : A total of 693 head trauma patients admitted in our hospital between March 2004 and May 2007 were reviewed. Among thee, we analyzed 55 patients with severe traumatic brain injury who underwent DC. We excluded patients who had confounding variables. The 33 patients were finally enrolled in the study and data were collected retrospectively for these patients. The patients were divided into two groups: non-hydrocephalus group (Group I) and hydrocephalus group (Group II). Related factors assessed were individual Glasgow Coma Score (GCS), age, sex, radiological findings, type of operation, re-operation and outcome. Results : Of the 693 patients with head trauma, 28 (4.0%) developed PTH. Fifty-five patients underwent DC and 13 (23.6%) developed PTH. Eleven of the 33 study patients (30.3%) who had no confounding factors were diagnosed with PTH. Significant differences in the type of craniectomy and re-operation were found between Group I and II. Conclusion : It is suggested that the size of DC and repeated operation may promote posttraumatic hydrocephalus in severe head trauma patients who underwent DC.	[Choi, Il; Park, Hyung-Ki; Chang, Jae-Chil; Cho, Sung-Jin; Choi, Soon-Kwan; Byun, Bark-Jang] Soonchunhyang Univ, Coll Med, Dept Neurosurg, Hannam Dong 657, Seoul 140743, South Korea	Park, HK (corresponding author), Soonchunhyang Univ, Coll Med, Dept Neurosurg, Hannam Dong 657, Seoul 140743, South Korea.	phk007@hosp.sch.ac.kr	Choi, IL/ABI-4106-2020	Choi, Il/0000-0003-0120-6564			BEYERL B, 1984, NEUROSURGERY, V15, P257, DOI 10.1227/00006123-198408000-00020; BRET P, 1985, NEUROSURGERY, V16, P44, DOI 10.1227/00006123-198501000-00009; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Dandy WE, 1914, AM J DIS CHILD, V8, P406; Erban P, 2006, CLIN NEUROL NEUROSUR, V108, P384, DOI 10.1016/j.clineuro.2005.06.008; FOLTZ EL, 1956, J NEUROSURG, V13, P546, DOI 10.3171/jns.1956.13.6.0546; FOROGLOU G, 1972, Acta Radiologica Diagnosis, V13, P524; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Loshakov V A, 1993, Zh Vopr Neirokhir Im N N Burdenko, P18; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; PEDERSEN KK, 1973, ACTA NEUROL SCAND, V49, P10; PHILIPPON J, 1976, NEUROCHIRURGIE, V22, P111; Phuenpathom Nakornchai, 1999, Journal of the Medical Association of Thailand, V82, P46; Shin HS, 2000, J KOREAN NEUROSURG S, V29, P1179; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; UPTON ML, 1985, J NEUROSURG, V63, P867, DOI 10.3171/jns.1985.63.6.0867; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yoo DS, 2001, J KOREAN NEUROSURG S, V30, P295; 이진훈, 2003, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V34, P531; 박진열, 2002, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V31, P33	25	53	58	0	0	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	MAY	2008	43	5					227	231		10.3340/jkns.2008.43.5.227			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	320CQ	WOS:000257211700002	19096601	DOAJ Gold, Green Published			2021-06-18	
J	Sanchez-Carrion, R; Gomez, PV; Junque, C; Fernandez-Espejo, D; Falcon, C; Bargallo, N; Roig-Rovira, T; Ensenat-Cantallops, A; Bernabeu, M				Sanchez-Carrion, Rocio; Gomez, Pere Vendrell; Junque, Carme; Fernandez-Espejo, Davinia; Falcon, Carles; Bargallo, Nuria; Roig-Rovira, Teresa; Ensenat-Cantallops, Antonia; Bernabeu, Montserrat			Frontal hypoactivation on functional magnetic resonance imaging in working memory after severe diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; functional MRI; traumatic brain injury; working memory	LANGUAGE-SPECIFIC CORTEX; DUAL-TASK PERFORMANCE; HEAD-INJURY; MS PATIENTS; ACTIVATION; REORGANIZATION; ATTENTION; FMRI; DEFICITS; COMA	Working memory is frequently impaired after traumatic brain injury (TBI). The present study aimed to investigate working memory deficits in patients with diffuse axonal injury and to determine the contribution of cerebral activation dysfunctions to them. Eighteen patients with severe TBI and 14 healthy controls matched for age and gender were included in the study. TBI patients were selected according to signs of diffuse axonal injury on computed tomography (CT) and without any evidence of focal lesions on MRI clinical examination. Functional magnetic resonance (fMRI) was used to assess brain activation during n-back tasks (0-, 2-, and 3-back). Compared to controls, the TBI group showed significant working memory impairment on the Digits Backwards (p = 0.022) and Letter-Number Sequencing subtests from the WAIS-III (p < 0.001) under the 2-back (p = 0.008) and 3-back (p = 0.017) conditions. Both groups engaged bilateral fronto-parietal regions known to be involved in working memory, although patients showed less cerebral activation than did controls. Decreased activation in TBI patients compared to controls was observed mainly in the right superior and middle frontal cortex. The correlation patterns differed between patients and controls: while the control group showed a negative correlation between performance and activation in prefrontal cortex (PFC), TBI patients presented a positive correlation in right parietal and left parahippocampus for the low and high working memory load, respectively. In conclusion, severe TBI patients with diffuse brain damage show a pattern of cerebral hypoactivation in the right middle and superior frontal regions during working memory tasks, and also present an impaired pattern of performance correlations.	[Gomez, Pere Vendrell; Junque, Carme; Fernandez-Espejo, Davinia] Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, E-08036 Barcelona, Spain; [Gomez, Pere Vendrell; Junque, Carme; Fernandez-Espejo, Davinia] Inst Univ Neurorehabiltacio Guttmann, Dept Neuropsychol, Badalona, Spain; [Gomez, Pere Vendrell; Junque, Carme; Falcon, Carles; Bargallo, Nuria] IDIBAPS, Biomed Res Inst August Pi & Sunyer, Barcelona, Spain; [Falcon, Carles; Bargallo, Nuria] Hosp Clin Barcelona, CDI, Dept Radiol, Neuroradiol Sect, Barcelona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabiltacio Guttmann, Head Injury Unit, Badalona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Vendrell, Pere/B-4392-2011; Junque, Carme/B-4400-2011; Bargallo, Nuria/G-6854-2016	Vendrell, Pere/0000-0001-8918-5440; Junque, Carme/0000-0002-6381-3063; Bargallo, Nuria/0000-0001-6284-5402; Fernandez-Espejo, Davinia/0000-0001-5941-7546			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1999, BRAIN COGNITION, V41, P87, DOI 10.1006/brcg.1999.1097; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BERNABEU M, 1999, REHABILITACION TRAUM; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cader S, 2006, BRAIN, V129, P527, DOI 10.1093/brain/awh670; Callicott JH, 2003, AM J PSYCHIAT, V160, P2209, DOI 10.1176/appi.ajp.160.12.2209; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Cohen NJ, 1999, HIPPOCAMPUS, V9, P83, DOI 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Daselaar SM, 2004, NEUROIMAGE, V23, P921, DOI 10.1016/j.neuroimage.2004.07.031; Desmond JE, 2003, NEUROIMAGE, V19, P1510, DOI 10.1016/S1053-8119(03)00102-2; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Forn C, 2006, NEUROIMAGE, V31, P686, DOI 10.1016/j.neuroimage.2005.12.030; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Germano C, 2005, NEUROPSYCHOL REV, V15, P1, DOI 10.1007/s11065-005-3583-7; Gilbert B, 2005, NEUROPSYCHOLOGY, V19, P106, DOI 10.1037/0894-4105.19.1.106; Hampson M, 2006, J NEUROSCI, V26, P13338, DOI 10.1523/JNEUROSCI.3408-06.2006; Higginson CI, 2003, BRAIN COGNITION, V52, P343, DOI 10.1016/S0278-2626(03)00180-5; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Jones JA, 2003, NEUROREPORT, V14, P1129, DOI 10.1097/00001756-200306110-00006; Jonides J, 1998, J NEUROSCI, V18, P5026; Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410; Junque C, 1999, REV NEUROLOGIA, V28, P423, DOI 10.33588/rn.2804.98420; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Lazeron RHC, 2003, J NEUROL SCI, V213, P29, DOI 10.1016/S0022-510X(03)00144-8; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mainero C, 2004, NEUROIMAGE, V21, P858, DOI 10.1016/j.neuroimage.2003.10.004; Mattay VS, 2000, NEUROIMAGE, V12, P268, DOI 10.1006/nimg.2000.0610; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mehta MA, 2000, J NEUROSCI, V20; Na D G, 2000, Korean J Radiol, V1, P19; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Otten LJ, 2001, CURR BIOL, V11, P1528, DOI 10.1016/S0960-9822(01)00454-7; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Pataraia E, 2005, NEUROLOGY, V64, P481, DOI 10.1212/01.WNL.0000150900.71773.E6; Pataraia E, 2004, NEUROLOGY, V63, P1825, DOI 10.1212/01.WNL.0000144180.85779.9A; Penner IK, 2006, J PHYSIOL-PARIS, V99, P455, DOI 10.1016/j.jphysparis.2006.03.008; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Pfefferbaum A, 2001, NEUROIMAGE, V14, P7, DOI 10.1006/nimg.2001.0785; Poldrack Russell A, 2002, Top Magn Reson Imaging, V13, P61, DOI 10.1097/00002142-200202000-00005; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Price CJ, 2001, J COGNITIVE NEUROSCI, V13, P419, DOI 10.1162/08989290152001853; Ranganath C, 2005, CURR OPIN NEUROBIOL, V15, P175, DOI 10.1016/j.conb.2005.03.017; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Riecker A, 2002, NEUROCASE, V8, P417, DOI 10.1076/neur.8.5.417.16181; Rosen HJ, 2000, NEUROLOGY, V55, P1883, DOI 10.1212/WNL.55.12.1883; Rossini P M, 2007, Eura Medicophys, V43, P241; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; TEASDALE G, 1974, LANCET, V2, P81; WECHSLER D, 1999, ESCALA INTENTELIGENC; Wexler BE, 2000, AM J PSYCHIAT, V157, P1694, DOI 10.1176/appi.ajp.157.10.1694; Wishart HA, 2004, NEUROLOGY, V62, P234, DOI 10.1212/01.WNL.0000103238.91536.5F	85	53	53	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					479	494		10.1089/neu.2007.0417			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100005	18363509				2021-06-18	
J	Colantonio, A; Escobar, MD; Chipman, M; McLellan, B; Austin, PC; Mirabella, G; Ratcliff, G				Colantonio, Angela; Escobar, Michael D.; Chipman, Mary; McLellan, Barry; Austin, Peter C.; Mirabella, Giuseppe; Ratcliff, Graham			Predictors of postacute mortality following traumatic brain injury in a seriously injured population	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; mortality; trauma	LONG-TERM SURVIVAL; LIFE EXPECTANCY; DEATH; VETERANS; TRENDS	Background: Traumatic brain injury (TBI) is a primary cause of injury mortality in developed countries but less is known about the impact of TBI on postacute mortality in large study populations. This study investigates the rate and predictors of postacute mortality (1-9 years after the initial injury) of severely injured persons with TBI in the Province of Ontario from April 1, 1993 to March 31, 1995. Method: Cases were identified (n = 2,721) from the Ontario Trauma Registry Comprehensive Data Set based on lead trauma hospitals in the province which also provided data on predictors. Severely injured patients (n = 557) who had lower extremity injuries during the sample time period formed a control population. Results: Poisson regression modeling showed that having a TBI was a significant predictor of premature death controlling for age and injury severity. Age, the number of comorbidities, injury severity, mechanism of injury, and discharge destination were significant predictors in the multivariate analyses for the TBI population. Conclusions: This research quantifies the elevated risk of premature death in the postacute period for seriously injured adults with TBI and identifies factors most associated with highest mortality rates in this population.	[Colantonio, Angela; Escobar, Michael D.; Chipman, Mary; McLellan, Barry; Austin, Peter C.] Univ Toronto, Toronto Rehab Inst, Toronto, ON M5G 1V7, Canada; [McLellan, Barry] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Mirabella, Giuseppe] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Ratcliff, Graham] Clin Neuropsychol Serv, Pittsburgh, PA USA	Colantonio, A (corresponding author), Univ Toronto, Toronto Rehab Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Austin, Peter/0000-0003-3337-233X; Colantonio, Angela/0000-0003-2094-4765; Escobar, Michael/0000-0001-9055-4709			Baguley I, 2000, BRAIN INJURY, V14, P505; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; COPES WS, 1989, P ANN C ASS, P205; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; FAHY TJ, 1967, LANCET, V2, P475; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; *ONT BRAIN INJ ASS, 2001, EST INC TRAUM BRAIN; *ONT TRAUM REG REP, 2003, INJ HOSP INCL 2000 2; Pickett William, 2004, Chronic Dis Can, V25, P32; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001	24	53	53	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					876	882		10.1097/TA.0b013e31804d493e			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	287UN	WOS:000254942100006	18404051				2021-06-18	
J	Esquenazi, A; Mayer, N; Garreta, R				Esquenazi, Alberto; Mayer, Nathaniel; Garreta, Roser			Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spasticity; botulinum toxin type A; gait	UPPER-LIMB SPASTICITY; HEMIPLEGIC GAIT; WALKING SPEED; DOUBLE-BLIND; COORDINATION; INJECTION; ARM; INHIBITION; EXTREMITY; DYSTONIA	Objective: To assess whether walking velocity could be improved in patients with disorders related to upper-motor neuron syndrome (UMNS) by treating elbow flexor spasticity with botulinum toxin type A (BoNTA). Design: This was a prospective, open-label, multicenter, interventional evaluation. The study group of 15 patients (mean age, 51.3 yrs; ten men, five women) were independent ambulators with residual hemiparesis attributable to stroke or traumatic brain injury of at least 18-mo duration. Patients were injected with 120-200 units of BoNTA (BOTOX, Allergan, Inc., Irvine, CA) to the affected biceps, brachialis, and/or brachiora-dialis. Modified Ashworth scores and gait velocity were assessed before and after BoNTA treatment. An untreated control group was employed to assess the potential impact of time on test-retest reliability of the selected temporal spatial gait parameters. Results: The BoNTA group demonstrated a statistically significant increase in walking velocity from 0.56 m/sec before treatment to 0.63 m/sec after treatment (P = 0.037). The mean modified Ashworth score was significantly reduced from 2.6 before BoNTA treatment to 1.4 after treatment (P = 0.00003). Conclusions: Treatment of upper-limb spasticity may be an important adjuvant treatment for patients with gait disturbance related to the UMNS.	Moss Rehab, Philadelphia, PA 19141 USA; [Esquenazi, Alberto; Mayer, Nathaniel] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA; [Garreta, Roser] Hosp Mutua Terrassa, Dept Phys Med & Rehabil, Terrassa, Spain							Abe M, 2001, EXP BRAIN RES, V139, P120, DOI 10.1007/s002210100761; *ALL INC, 2002, BOTOX PACK INS; BOHANNON RW, 1991, PERCEPT MOTOR SKILL, V73, P146, DOI 10.2466/PMS.73.4.146-146; Boroojerdi B, 2003, NEUROLOGY, V61, P1546, DOI 10.1212/01.WNL.0000095965.36574.0F; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Curra A, 2004, MOVEMENT DISORD, V19, pS60, DOI 10.1002/mds.20011; Donker SF, 2001, J MOTOR BEHAV, V33, P86, DOI 10.1080/00222890109601905; Eke-Okoro ST, 1997, CLIN BIOMECH, V12, P516, DOI 10.1016/S0268-0033(97)00050-8; ESQUENAZI A, 2000, PHYS MED REHABILITAT, P242; Gilio F, 2000, ANN NEUROL, V48, P20, DOI 10.1002/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U; Gordon MF, 2004, NEUROLOGY, V63, P1971, DOI 10.1212/01.WNL.0000144349.95487.91; Graham HK, 2001, EUR J NEUROL, V8, P30, DOI 10.1046/j.1468-1331.2001.00036.x; Hirsch MA, 2005, MOVEMENT DISORD, V20, P1014, DOI 10.1002/mds.20499; Kanovsky P, 1998, MOVEMENT DISORD, V13, P108, DOI 10.1002/mds.870130122; Kavanagh J, 2006, EXP BRAIN RES, V172, P454, DOI 10.1007/s00221-006-0353-6; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; Kwakkel G, 2002, PHYS THER, V82, P432, DOI 10.1093/ptj/82.5.432; Mancini F, 2005, NEUROL SCI, V26, P26, DOI 10.1007/s10072-005-0378-9; Mayer Nathaniel H, 2003, Phys Med Rehabil Clin N Am, V14, P855, DOI 10.1016/S1047-9651(03)00093-7; Murray M P, 1967, Phys Ther, V47, P272; PARK CI, 2000, 5 ANN GAIT CLIN MOV; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; vanEmmerik REA, 1996, J BIOMECH, V29, P1175, DOI 10.1016/0021-9290(95)00128-X; VONSCHROEDER HP, 1995, J REHABIL RES DEV, V32, P25; Wagenaar RC, 2000, J BIOMECH, V33, P853, DOI 10.1016/S0021-9290(00)00020-8; WAGENAAR RC, 1992, J BIOMECH, V25, P1007, DOI 10.1016/0021-9290(92)90036-Z; WEBB D, 1994, AM J PHYS ANTHROPOL, V93, P477, DOI 10.1002/ajpa.1330930407; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; Yelnik A, 1999, STROKE, V30, P580, DOI 10.1161/01.STR.30.3.580	30	53	56	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2008	87	4					305	310		10.1097/PHM.0b013e318168d36c			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	279TU	WOS:000254378400008	18437721				2021-06-18	
J	Singh, S; Smith, GA; Fields, SK; McKenzie, LB				Singh, Shubha; Smith, Gary A.; Fields, Sarah K.; McKenzie, Lara B.			Gymnastics-related injuries to children treated in emergency departments in the United States, 1990-2005	PEDIATRICS			English	Article						gymnastics; sports; injury prevention; emergency department; NEISS; children; adolescents	WOMENS GYMNASTICS; FEMALE GYMNASTS; EPIDEMIOLOGY; SPORTS; SCHOOL; ELITE	OBJECTIVE. The objective of this study was to describe the epidemiology of gymnastics-related injuries among children in the United States. METHODS. A retrospective analysis was conducted of data for children 6 through 17 years of age from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission for 1990 through 2005. Sample weights provided by the National Electronic Injury Surveillance System were used to calculate national estimates of gymnastics-related injuries. Injury rates were calculated for the most frequently occurring types of injury using gymnastics participation data. RESULTS. An estimated 425 900 children 6 through 17 years of age were treated in US hospital emergency departments for gymnastics-related injuries during the 16-year period of 1990-2005. The number of injuries averaged 26 600 annually. The number of injuries sustained per 1000 gymnastics participants per year for the pediatric population was 4.8. The number of injuries sustained per 1000 participants per year was greater for the ages 12 to 17 years ( 7.4) than for the ages 6 to 11 years ( 3.6). The place where an injury occurred include school ( 40.0%), a place of recreation or sports ( 39.7%), home ( 14.5%), or on other public property ( 5.8%). The body parts injured were upper extremity ( 42.3%), lower extremity ( 33.8%), head/ neck ( 12.9%), trunk ( 10.4%), and other ( 0.6%). Injury diagnoses were strain/ sprain ( 44.5%), fracture/ dislocation ( 30.4%), abrasion/ contusion ( 15.6%), laceration/ avulsion ( 3.7%), concussion/ closed head injury ( 1.7%), and other ( 4.2%). The majority ( 97.1%) of patients with gymnastics-related injuries were treated and released from the emergency department. CONCLUSIONS. Gymnastics has one of the highest injury rates of all girls' sports. Establishment of a national database for gymnastics-related injuries, including exposure data for direct calculation of injury rates, would permit better identification and monitoring of risk factors for gymnastics-related injuries and aid in the development, implementation, and evaluation of injury prevention strategies based on epidemiologic evidence.	[Smith, Gary A.; McKenzie, Lara B.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educat Serv, Columbus, OH 43210 USA; [Singh, Shubha; Smith, Gary A.; McKenzie, Lara B.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	McKenzie, LB (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	lara.mckenzie@nationwidechildrens.org	McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001			*AM SPORTS DAT INC, 2006, 2006 SUP SPORTS PART, P97; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; CAINE D, 1989, AM J SPORT MED, V17, P811, DOI 10.1177/036354658901700616; Caine D, 2005, MED SPORT SCI, V48, P18, DOI 10.1159/000084282; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; DIXON M, 1993, MED SCI SPORT EXER, V25, P1322; GARRICK JG, 1980, AM J SPORT MED, V8, P261, DOI 10.1177/036354658000800409; *GYM SPORTS RES CT, GYMN INJ; KERR G, 1990, CAN J SPORT SCI, V15, P227; Kessler E., 1999, NEISS SAMPLE DESIGN; KOLT G, 1996, AUSTR PHYSIOTHERAPY, V42, P121; Kolt GS, 1999, BRIT J SPORT MED, V33, P312, DOI 10.1136/bjsm.33.5.312; LINDNER KJ, 1990, CAN J SPORT SCI, V15, P254; LOWRY CB, 1982, AM J SPORT MED, V10, P237, DOI 10.1177/036354658201000409; McDonald A K, 1996, Inj Prev, V2, P77, DOI 10.1136/ip.2.1.77; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; MCLAIN LG, 1989, PEDIATRICS, V84, P446; *NCCSI, 23 NCCSI; Ortega HW, 2004, CLIN PEDIATR, V43, P251, DOI 10.1177/000992280404300306; Ryan J, 1995, PRETTY GIRLS LITTLE; SANDS WA, 1993, AM J SPORT MED, V21, P271, DOI 10.1177/036354659302100218; Sands WA, 2000, SPORTS MED, V30, P359, DOI 10.2165/00007256-200030050-00004; Schroeder T., 2001, NEISS SAMPLE DESIGN; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; Smith GA, 1998, ARCH PEDIAT ADOL MED, V152, P694; *SPSS INC, 2006, SPSS WIND COMP PROGR; Steele V A, 1986, Br J Sports Med, V20, P31; *USA GYMN, 2001, NEW VAULT TABL APP A; WEIKER GG, 1985, CLIN SPORT MED, V4, P39; Weiss H B, 1996, Inj Prev, V2, P166, DOI 10.1136/ip.2.2.166; Weiss H B, 1996, Inj Prev, V2, P61, DOI 10.1136/ip.2.1.61; SPORTS GEAR 101	33	53	55	0	15	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2008	121	4					E954	E960		10.1542/peds.2007-0767			7	Pediatrics	Pediatrics	282OJ	WOS:000254576800076	18381523				2021-06-18	
J	Frye, CA; Walf, AA				Frye, Cheryl A.; Walf, Alicia A.			Effects of progesterone administration and APPswe+PSEN1 Delta e9 mutation for cognitive performance of mid-aged mice	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Alzheimer's disease; allopregnanolone; hippocampus; cortex; learning and memory; neurosteroids	TRAUMATIC BRAIN-INJURY; FAMILIAL ALZHEIMERS-DISEASE; HORMONE REPLACEMENT THERAPY; WILD-TYPE MICE; FEMALE RATS; AMYLOID DEPOSITION; PREFRONTAL CORTEX; INDUCED SEIZURES; KAINIC ACID; CELL-DEATH	Progesterone (P-4) and its metabolite, 5 alpha-pregnan-3 alpha-ol-20-one (3 alpha,5 alpha-THP) have trophic effects and may improve cognitive function. We investigated the role of progestins in a murine model of Alzheimer's Disease (AD) in which transgenic mice co-overexpress a mutant form of amyloid precursor protein (APPswe) and a deletion in presenilin 1 Delta exon 9 (APPswe+PSEN1 Delta e9). We hypothesized that: (1) mice with the APPswe+PSEN1 Delta e9 mutation would have performance deficits compared to wildtype mice and (2) long-term administration of P-4 would enhance cognitive performance and increase brain progestin levels over placebo. Mice were ovariectomized at 6 months of age and administered placebo or P-4 via subcutaneously implanted pellets. Mice were tested between 9 and 12 months of age for cognitive performance in the object placement, water maze, object recognition, and T-maze tasks and for motor behavior in an activity monitor and then tissues were collected for steroid measurement. P-4 administration increased progestin levels in cortex, diencephalon, midbrain, and cerebellum of wildtype and mutant mice, but increases in 3 alpha,5 alpha-THP levels in the hippocampus of APPswe+PSEN1 Delta e9 mutant mice were attenuated compared to that observed in wildtype mice. APPswe+PSEN1 Delta e9 mice showed poorer performance in hippocampus measures (object placement and water maze tasks). In the object recognition and T-maze task, which are mediated by the cortex and hippocampus, P-4 administration improved performance-in both wildtype and APPswe+PSEN1 Delta e9 mutant mice compared to placebo administration. Thus, APPswe+PSEN1 Delta 9, mice have deficits in hippocampal performance and capacity to form 3 alpha,5 alpha-THP in the hippocampus and both wildtype and APPswe+PSEN1 Delta 9 mice show beneficial effects of P-4 in cortical function and similar capacity to form 3 alpha,5 alpha-THP in the cortex. (C) 2007 Elsevier Inc. All rights reserved.	[Frye, Cheryl A.; Walf, Alicia A.] SUNY Albany, Dept Psychol, Albany, NY 12222 USA; [Frye, Cheryl A.] SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; [Frye, Cheryl A.] SUNY Albany, Ctr Res Neurosci, Albany, NY 12222 USA; [Frye, Cheryl A.; Walf, Alicia A.] SUNY Albany, Ctr Life Sci Res, Albany, NY 12222 USA	Frye, CA (corresponding author), SUNY Albany, Dept Psychol, Life Sci Res Bldg 01058,1400 Washington Ave, Albany, NY 12222 USA.	cafrye@albany.edu					Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BROOKMEYER R, 1998, PROJECTIONS ALZHEIME; Buckwalter JG, 1999, PSYCHONEUROENDOCRINO, V24, P69; Burgess BL, 2006, NEUROBIOL DIS, V24, P114, DOI 10.1016/j.nbd.2006.06.007; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; CHENG YJ, 1973, ENDOCRINOLOGY, V93, P1157, DOI 10.1210/endo-93-5-1157; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Crawley JN, 2007, NEUROPEPTIDES, V41, P145, DOI 10.1016/j.npep.2007.02.002; de Wit H, 2001, PSYCHONEUROENDOCRINO, V26, P697, DOI 10.1016/S0306-4530(01)00024-5; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DOHANICH GP, 1994, BEHAV NEUROSCI, V108, P988, DOI 10.1037/0735-7044.108.5.988; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fillit HM, 2002, ARCH INTERN MED, V162, P1934, DOI 10.1001/archinte.162.17.1934; Frick KM, 2003, LEARN MEMORY, V10, P187, DOI 10.1101/lm.50703; Frye CA, 2006, PSYCHOPHARMACOLOGY, V186, P312, DOI 10.1007/s00213-006-0309-3; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 1999, J NEUROENDOCRINOL, V11, P839; Frye CA, 2000, BRAIN RES, V881, P98, DOI 10.1016/S0006-8993(00)02897-3; Frye CA, 1999, PHARMACOL BIOCHEM BE, V62, P315, DOI 10.1016/S0091-3057(98)00182-8; Frye CA, 1998, J NEUROENDOCRINOL, V10, P291, DOI 10.1046/j.1365-2826.1998.00202.x; Frye CA, 2004, BRAIN RES, V1004, P116, DOI 10.1016/j.brainres.2004.01.020; Frye CA, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.5.19.x; Frye CA, 2001, BRAIN RES, V911, P146, DOI 10.1016/S0006-8993(01)02560-4; FRYE CA, 1995, NEUROBIOL LEARN MEM, V64, P83, DOI 10.1006/nlme.1995.1046; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; Frye CA, 2000, PSYCHOBIOLOGY, V28, P550; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Frye CA, 2007, NEUROBIOL LEARN MEM, V88, P208, DOI 10.1016/j.nlm.2007.04.003; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Heikkinen T, 2004, EXP NEUROL, V187, P105, DOI 10.1016/j.expneurol.2004.01.015; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Lalonde R, 2004, NEUROSCI LETT, V369, P156, DOI 10.1016/j.neulet.2004.07.069; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Leskiewicz M, 1997, POL J PHARMACOL, V49, P411; Levin-Allerhand JA, 2002, J ALZHEIMERS DIS, V4, P449; Lonsdale D, 2003, EPILEPSIA, V44, P1494, DOI 10.1111/j.0013-9580.2003.59402.x; Luine VN, 2003, ENDOCRINOLOGY, V144, P2836, DOI 10.1210/en.2003-0004; MALENDOWICZ LK, 1976, ENDOKRINOLOGIE, V67, P26; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Payami H, 1996, NEUROLOGY, V46, P126, DOI 10.1212/WNL.46.1.126; PENNING TM, 1985, J BIOL CHEM, V260, P5266; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P497, DOI 10.1016/0306-4530(92)90008-U; POSER CM, 1986, ACTA NEUROL SCAND, V73, P39, DOI 10.1111/j.1600-0404.1986.tb03239.x; Reddy DS, 2001, EPILEPSIA, V42, P337, DOI 10.1046/j.1528-1157.2001.10200.x; Reiserer RS, 2007, GENES BRAIN BEHAV, V6, P54, DOI 10.1111/j.1601-183X.2006.00221.x; RESKO JA, 1986, BIOL REPROD, V34, P870, DOI 10.1095/biolreprod34.5.870; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P551, DOI 10.1016/j.pbb.2004.03.025; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P505, DOI 10.1016/j.pbb.2004.04.021; RODBARD D, 1974, S RAD REL PROC MED N, P209; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sandstrom NJ, 2001, BEHAV NEUROSCI, V115, P384, DOI 10.1037//0735-7044.115.2.384; Sato T, 2004, BEHAV BRAIN RES, V150, P33, DOI 10.1016/S0166-4328(03)00249-3; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Smith SS, 1998, J NEUROSCI, V18, P5275; Solis-Ortiz S, 2004, PSYCHONEUROENDOCRINO, V29, P1047, DOI 10.1016/j.psyneuen.2003.10.007; Spowart-Manning L, 2004, BEHAV BRAIN RES, V151, P37, DOI 10.1016/j.bbr.2003.08.004; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018; Zheng H, 2002, J NEUROCHEM, V80, P191, DOI 10.1046/j.0022-3042.2001.00690.x	75	53	53	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	JAN	2008	89	1					17	26		10.1016/j.nlm.2007.09.008			10	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Behavioral Sciences; Neurosciences & Neurology; Psychology	246YL	WOS:000252044200002	17988898				2021-06-18	
J	Yeo, JE; Kim, JH; Kang, SK				Yeo, Jee Eun; Kim, Jeong Hwan; Kang, Soo Kyung			Selenium attenuates ROS-mediated apoptotic cell death of injured spinal cord through prevention of mitochondria dysfunction; in vitro and in vivo study	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						apoptotic cell death function recovery; inflammation; myelination; neuroprotection; selenium; spinal cord injury	MAMMALIAN THIOREDOXIN REDUCTASE; TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM INJURY; OXIDATIVE STRESS; PARKINSONS-DISEASE; LIPID-PEROXIDATION; RADICAL HYPOTHESIS; CYTOCHROME-C; RELEASE; BCL-2	The primary objective of this study was to determine the possible apoptotic cell death preventive effects of the antioxidant selenium using an experimental rat spinal cord injury (SCI) model and cultured spinal cord-derived neural progenitor cells (NPCs). Sodium selenite treatment exerted a profound preventive effect on apoptotic cell death, including p-P38, pSAPK/JNK, caspases, and PARP activity, and ameliorated astrogliosis and hypomyelination, which occurs in regions of active cell death in the spinal cords of SCI rats. The foremost protective effect of selenite in SCI would therefore be manifested in the suppression of acute secondary apoptotic cell death. However, selenite does not appear to exert an anti-inflammatory function associated with active microglia and macrophage propagation or infiltration into the lesion site. Selenite-mediated neuroprotection has been linked to selenite's attenuation or inhibition of p38 mitogen-activated protein kinase, pSAPK/JNK, and Bax activation in in vitro and in vivo SCI lesion sites. Selenite also attenuated cell death via the prevention of cytochrome c release, caspase activation, and ROS accumulation in the cytosol. Also, our study showed that selenite administered immediately after SCI significantly diminishes functional deficits. The selenite-treated group recovered hind limb reflexes more rapidly, and a higher percentage of these rats regained responses to a greater degree than was seen in the untreated injured rats. Our data indicate that the therapeutic outcome of selenite is most likely the consequence of its comprehensive apoptotic cell death blocking effects, resulting in the protection of white matter, oligodendrocytes, and neurons, and the inhibition of astrogliosis. The finding that the administration of selenite prevents secondary pathological events in traumatic spinal cord injuries, and promotes the recovery of motor function in an animal model. Its efficacy may facilitate the development of novel drug targets for the treatment of SCI. Copyright (c) 2008 S. Karger AG, Basel.	[Yeo, Jee Eun; Kim, Jeong Hwan; Kang, Soo Kyung] Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea	Kang, SK (corresponding author), Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea.	skkang@pusan.ac.kr					BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; GIULIAN D, 1993, J NEUROSCI, V13, P29; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARMAN D, 1993, FREE RADICALS AGING, P205; HOLSTEGE G, 1991, PROGR BRAIN RES, V87, P307; Imam SZ, 1999, BRAIN RES, V818, P575, DOI 10.1016/S0006-8993(98)01311-0; ITOH N, 1993, J IMMUNOL, V151, P621; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Le Belle JE, 2002, BIODRUGS, V16, P389, DOI 10.2165/00063030-200216060-00001; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Limke TL, 2003, J HEMATOTH STEM CELL, V12, P615, DOI 10.1089/15258160360732641; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; LIU X, 1996, CELL, V86, P145; Marcocci L, 1997, BIOFACTORS, V6, P351, DOI 10.1002/biof.5520060305; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sagara Y, 1998, NEUROTOXICOLOGY, V19, P339; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; TAN S, 1995, J NEUROCHEM, V71, P95; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Whalen MJ, 2000, ACT NEUR S, V76, P61; YU BP, 1994, PHYSIOL REV, V74, P139	45	53	56	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2008	21	1-3					225	238		10.1159/000113764			14	Cell Biology; Physiology	Cell Biology; Physiology	254ME	WOS:000252589900023	18209489	Bronze			2021-06-18	
J	McCaffrey, MA; Mihalik, JP; Crowell, DH; Shields, EW; Guskiewicz, KM				McCaffrey, Meghan A.; Mihalik, Jason P.; Crowell, Dean H.; Shields, Edgar W.; Guskiewicz, Kevin M.			Measurement of head impacts in collegiate football players: Clinical measures of concussion after high- and low-magnitude impacts	NEUROSURGERY			English	Article						biomechanics; helmet; injury threshold; mild traumatic brain injury; subconcussive injury	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; SPORTS; PERFORMANCE; RECOVERY; ACCELERATION	OBJECTIVE: It has been speculated that a theoretical injury threshold of 70 to 75 g may exist for concussions in football players. We aimed to investigate acute balance and neurocognitive performance after head impacts exceeding a theoretical injury threshold in the absence of both self-reported symptoms and a concussion diagnosis 24 hours before testing. METHODS: Forty-three Division I collegiate football players participated in this double-blind, repeated-measures study. Subjects participated in three test sessions (baseline, low impact, and high impact) separated by at least 2 weeks. The Head Impact Telemetry System (Simbex, Lebanon, NH) recorded real-time head impacts sustained during practices and games. The Automated Neuropsychological Assessment Metrics assessed neurocognitive performance. The NeuroCom Sensory Organization Test (NeuroCom International Inc., Clackamas, OR) assessed postural stability. The Graded Symptom Checklist evaluated symptom presence and severity in our participants. RESULTS: After the low-impact test session (< 60 g), we observed improvements in the Math Processing (F-1,F- (26) = 9.797; P = 0.004), Matching to Sample (F-1,F- 26 = 6.504; P 0.017), and Sternberg Procedure (F-1,F- (26) = 5.323; P = 0.030) Automated Neuropsychological Assessment Metrics test modules. Statistically significant differences were also observed after the high-impact test session (> 90g) with improvements in Math Processing (F-1,F- 22 = 16.629; P < 0.001), Procedural Reaction Time (F-1,F- 22 = 14.668; P < 0.001), and the total number of symptoms reported (F-1,F- 22 = 10.267; P = 0.004). Neurocognitive improvements were likely attributed to a learning effect. CONCLUSION: Our findings suggest that sustaining an impact greater than 90 g does not result in acute observable balance and neurocognitive deficits within 24 hours of sustaining the impact. Although previous studies have suggested a theoretical injury threshold, none have been founded on empirical data collected on the playing field in real-time. Future studies should consider the cumulative effects of impacts of varying magnitudes.	[McCaffrey, Meghan A.; Mihalik, Jason P.; Shields, Edgar W.; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Shields, Edgar W.] Univ N Carolina, Campus Hlth Serv, Div Sports Med, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Curriculum Human Movement, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium CB 8700,S Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130	NCIPC CDC HHS [5-R49-CE000196] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196] Funding Source: NIH RePORTER		Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DiMasi FP, 1995, TRANSFORMATION 9 ACC; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mueller F O, 2001, N C Med J, V62, P368; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Woodard J, 2002, J INT NEUROPSYCH SOC, V8, P175; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	28	53	53	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2007	61	6					1236	1243		10.1227/01.neu.0000306102.91506.8b			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	246YN	WOS:000252044400034	18162903				2021-06-18	
J	Dressler, J; Hanisch, U; Kuhlisch, E; Geiger, KD				Dressler, J.; Hanisch, U.; Kuhlisch, E.; Geiger, K. D.			Neuronal and glial apoptosis in human traumatic brain injury	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						apoptosis; traumatic brain injury aging; biostatistics; immunohistochemistry	CELL-DEATH; DNA FRAGMENTATION; WHITE-MATTER; CASPASE; PATHWAYS; MECHANISMS; EXPRESSION; OCCURS	To establish reliable methods to aid the timing of brain damage after traumatic brain injury (TBI), brain tissue from 56 autopsy cases with TBI and known survival times, ranging from a few minutes to 126 days, were tested for apoptotic changes to the neuronal and glial cells. Apoptosis was established using the TdT-inediated dUTP nick end labelling (TUNEL) method of in-situ labelling and immunohistochemical reaction of caspase 3. In addition, cellular reaction and astroglial cell differentiation were investigated using histological and immunohistochemical markers. From a survival time of 120 min up to 12 days, TUNEL-positive apoptotic neuronal cells were frequently detected in the contusion zone. The earliest positive caspase 3 reaction in cortical neurons was evident after a posttraurnatic interval of 80 min. Detection of apoptotic glial cells using the TUNEL technique showed that as in the case of neuronal cells, the earliest positive TUNEL reaction was obtained after 110 min. In cases of survival times of 120 min up to 4 days, apoptotic glial cells could frequently be detected. However, the first caspase 3-positive glial cells appeared 5 h after injury. Cerebral apoptosis was significantly associated with TBI cases as compared to control cases (P < 0.001). The reference histological findings of neutrophilic granulocytes, CD3-positive T-lymphocytes, CD68-positive activated microglial cells/macrophages and TUNEL-positive neuronal cells increases the degree of certainty in determining the probable age of traumatic brain injury to 87.5%.	Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Legale, D-01307 Dresden, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Informat & Biometry, D-01307 Dresden, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Pathol, Dept Neuropathol, D-01307 Dresden, Germany	Dressler, J (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Legale, D-01307 Dresden, Germany.	Jan.Dressler@tu-dresden.de					Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P407, DOI 10.1111/j.1365-2990.1991.tb00740.x; Davison FD, 1995, HISTOCHEM J, V27, P983; Dressler J, 2005, INT J LEGAL MED, V119, P177, DOI 10.1007/s00414-004-0480-1; DRESSLER J, 1998, RECHTSMEDIZIN S1, V8, pA25; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Fisher L, 1993, BIOSTATISTICS METHOD; Fowler J, 2002, CLIN NEUROPATHOL, V21, P156; GEIGER KD, 1997, NEUROMETH, V29, P217; Giffard R, 2004, J BIOENERG BIOMEMBR, V36, P313, DOI 10.1023/B:JOBB.0000041760.23917.e1; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 2006, INT J LEGAL MED, V120, P219, DOI 10.1007/s00414-005-0021-6; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; HUMMEL K, 1972, BIOSTATISTISCHE ABST; Kam PCA, 2000, ANAESTHESIA, V55, P1081, DOI 10.1046/j.1365-2044.2000.01554.x; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; OEHMICHEN M, 2001, BRAIN HYPOXIA ISCHEM; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Padosch SA, 2001, ANAESTHESIST, V50, P905, DOI 10.1007/s00101-001-0247-8; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Schallock K, 1997, CLIN NEUROPATHOL, V16, P133; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Suzuki A, 2001, HISTOL HISTOPATHOL, V16, P583, DOI 10.14670/HH-16.583; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WITESIDE G, 1998, BRAIN RES BRAIN RES, V2, P160; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	37	53	56	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	SEP	2007	121	5					365	375		10.1007/s00414-006-0126-6			11	Medicine, Legal	Legal Medicine	207IM	WOS:000249244800005	17106737				2021-06-18	
J	Hare, GMT; Mazer, CD; Hutchison, JS; McLaren, AT; Liu, E; Rassouli, A; Ai, J; Shaye, RE; Lockwood, JA; Hawkins, CE; Sikich, N; To, K; Baker, AJ				Hare, Gregory M. T.; Mazer, C. David; Hutchison, James S.; McLaren, Anya T.; Liu, Elaine; Rassouli, Alipasha; Ai, Jinglu; Shaye, Rachel E.; Lockwood, Julia A.; Hawkins, Cynthia E.; Sikich, Nancy; To, Kevin; Baker, Andrew J.			Severe hemodilutional anemia increases cerebral tissue injury following acute neurotrauma	JOURNAL OF APPLIED PHYSIOLOGY			English	Article; Proceedings Paper	21st Annual National-Neurotrauma-Society Symposium	NOV 06-07, 2003	BILOXI, MS	Natl Neurotrauma Soc			FLUID PERCUSSION INJURY; TRAUMATIC BRAIN INJURY; OXYGEN-TENSION; CARDIOPULMONARY BYPASS; HEMORRHAGIC-SHOCK; BLOOD-FLOW; HYPOXIA; RAT; EXPRESSION; HYPOXEMIA	Anemia may worsen neurological outcomes following traumatic brain injury (TBI) by undefined mechanisms. We hypothesized that hemodilutional anemia accentuates hypoxic cerebral injury following TBI. Anesthetized rats underwent unilateral TBI or sham injury (n >= 7). Target hemoglobin concentrations between 50 and 70 g/ l were achieved by exchanging 40-50% of the blood volume (1: 1) with pentastarch. The effect of TBI, anemia, and TBI-anemia was assessed by measuring brain tissue oxygen tension (PbrO(2)), regional cerebral blood flow (rCBF), jugular venous oxygen saturation (SjvO(2)), cerebral contusion area, and nuclear staining for programmed cell death. Baseline postinjury PbrO2 values in the TBI and TBI-anemia groups (9.3 +/- 1.3 and 11.3 +/- 4.1 Torr, respectively) were lower than the uninjured controls (18.2 +/- 5.2 Torr, P < 0.05 for both). Hemodilution caused a further reduction in PbrO2 in the TBI-anemia group relative to the TBI group without anemia (7.8 +/- 2.7 vs. 14.8 +/- 3.9 Torr, P < 0.05). The rCBF remained stable after TBI and increased comparably after hemodilution in both anemia and TBI-anemia groups. The SjvO(2) was elevated after TBI (87.4 +/- 8.9%, P < 0.05) and increased further following hemodilution (95.0 +/- 1.6%, P < 0.05). Cerebral contusion area and nuclear counts for programmed cell death were increased following TBI-anemia (4.1 +/- 3.0 mm2 and 686 +/- 192, respectively) relative to TBI alone (1.3 +/- 0.3 mm2 and 404 +/- 133, respectively, P < 0.05 for both). Hemodilutional anemia reduced cerebral PbrO(2) and oxygen extraction and increased cell death following TBI. These results support our hypothesis that acute anemia accentuated hypoxic cerebral injury after neurotrauma.	Univ Toronto, St Michaels Hosp, Dept Anesthesia,Keenan Res Ctr Li Ka Shing Knowle, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Hosp Sick Children, Dept Crit Care Med & Paediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Interdept Div Crit Care, Toronto, ON, Canada; Hosp Sick Children, Div Neuropathol, Dept Lab Med, Toronto, ON M5G 1X8, Canada	Hare, GMT (corresponding author), Univ Toronto, St Michaels Hosp, Dept Anesthesia,Keenan Res Ctr Li Ka Shing Knowle, Cara Phelan Ctr Trauma Res, 30 Bond St, Toronto, ON M5B 1W8, Canada.	hareg@smh.toronto.on.ca	Hare, Greg/AAM-5599-2021; Hawkins, Cynthia/M-2571-2019	AI, JINGLU/0000-0001-7414-0207; Mazer, Cyril David/0000-0003-2566-4308			Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BROWN MM, 1985, BRAIN, V108, P81, DOI 10.1093/brain/108.1.81; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dunn JF, 1999, ADV EXP MED BIOL, V471, P43; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Habib RH, 2003, J THORAC CARDIOV SUR, V125, P1438, DOI 10.1016/S0022-5223(02)73291-1; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Hare GMT, 2003, CAN J ANAESTH, V50, P1061, DOI 10.1007/BF03018375; Hare GMT, 2003, J NEUROTRAUM, V20, P1134; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Homi HM, 2004, ANESTH ANALG, V99, P974, DOI 10.1213/01.ane.0000131504.90754.d0; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUDAK ML, 1986, AM J PHYSIOL, V251, pH63; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kramer MS, 1996, NEUROSURGERY, V38, P355, DOI 10.1097/00006123-199602000-00024; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MAZZONI MC, 1994, AM J PHYSIOL-HEART C, V267, pH1928; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morimoto Y, 2001, J NEUROSURG ANESTH, V13, P33, DOI 10.1097/00008506-200101000-00006; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Nwaigwe CI, 2000, BRAIN RES, V868, P150, DOI 10.1016/S0006-8993(00)02321-0; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rebel A, 2001, AM J PHYSIOL-HEART C, V280, pH2591; Shen H, 2002, ANESTHESIOLOGY, V96, P142, DOI 10.1097/00000542-200201000-00027; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TODD MM, 1994, AM J PHYSIOL-HEART C, V267, pH2025; Tsai AG, 2001, TRANSFUSION, V41, P1290, DOI 10.1046/j.1537-2995.2001.41101290.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van Bommel J, 2002, ANESTHESIOLOGY, V97, P660, DOI 10.1097/00000542-200209000-00021; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	50	53	56	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	SEP	2007	103	3					1021	1029		10.1152/japplphysiol.01315.2006			9	Physiology; Sport Sciences	Physiology; Sport Sciences	204OU	WOS:000249054700040	17556499				2021-06-18	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, Armin; Pech, Katrin; Kakulas, Byron A.; Martin, Didier; Schoenen, Jean; Noth, Johannes; Brook, Gary A.			Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury	BMC NEUROLOGY			English	Article							MULTIPLE-SCLEROSIS LESIONS; HUMAN BRAIN-TUMORS; FUNCTIONAL RECOVERY; TISSUE INHIBITORS; NERVOUS-SYSTEM; FOCAL ISCHEMIA; GELATINASE-A; EXPRESSION; MATRIX-METALLOPROTEINASE-9; REGENERATION	Background: Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that degrade the extracellular matrix and other extracellular proteins. Studies in experimental animals demonstrate that MMPs play a number of roles in the detrimental as well as in the beneficial events after spinal cord injury (SCI). In the present correlative investigation, the expression pattern of several MMPs and their inhibitors has been investigated in the human spinal cord. Methods: An immunohistochemical investigation in post mortem samples of control and lesioned human spinal cords was performed. All patients with traumatic SCI had been clinically diagnosed as having " complete" injuries and presented lesions of the maceration type. Results: In the unlesioned human spinal cord, MMP and TIMP immunoreactivity was scarce. After traumatic SCI, a lesion- induced bi- phasic pattern of raised MMP- 1 levels could be found with an early up- regulation in macrophages within the lesion epicentre and a later induction in peri- lesional activated astrocytes. There was an early and brief induction of MMP- 2 at the lesion core in macrophages. MMP- 9 and - 12 expression peaked at 24 days after injury and both molecules were mostly expressed in macrophages at the lesion epicentre. Whereas MMP- 9 levels rose progressively from 1 week to 3 weeks, there was an isolated peak of MMP- 12 expression at 24 days. The post- traumatic distribution of the MMP inhibitors TIMP- 1, - 2 and - 3 was limited. Only occasional TIMP immuno- positive macrophages could be detected at short survival times. The only clear induction was detected for TIMP- 3 at survival times of 8 months and 1 year in peri- lesional activated astrocytes. Conclusion: The involvement of MMP- 1, - 2, - 9 and - 12 has been demonstrated in the post- traumatic events after human SCI. With an expression pattern corresponding largely to prior experimental studies, they were mainly expressed during the first weeks after injury and were most likely involved in the destructive inflammatory events of protein breakdown and phagocytosis carried out by infiltrating neutrophils and macrophages, as well as being involved in enhanced permeability of the blood spinal cord barrier. Similar to animal investigations, the strong induction of MMPs was not accompanied by an expression of their inhibitors, allowing these proteins to exert their effects in the lesioned spinal cord.	Aachen Univ Hosp, Dept Neurol, Aachen, Germany; Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; Univ Liege, Sart Tilman Hosp, Dept Neurosurg, Liege, Belgium; Univ Liege, Dept Neurol & Neuropathol, Liege, Belgium; Aachen Univ Hosp, Dept Neuropathol, Aachen, Germany	Buss, A (corresponding author), Aachen Univ Hosp, Dept Neurol, Aachen, Germany.	abuss@ukaachen.de; pech13@gmx.de; bkakulas@cyllene.uwa.edu.au; didier.martin@chu.ulg.ac.be; jschoenen@ulg.ac.be; jnoth@ukaachen.de; gary.brook@rwth-aachen.de		MARTIN, Didier/0000-0001-7325-4958			Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P64, DOI 10.1016/j.mcn.2004.08.013; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BUSS A, 2007, BRAIN; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Cossins JA, 1997, ACTA NEUROPATHOL, V94, P590, DOI 10.1007/s004010050754; Dang CM, 2003, PLAST RECONSTR SURG, V111, P2273, DOI 10.1097/01.PRS.0000060102.57809.DA; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; Duchossoy Y, 2001, MOL CELL NEUROSCI, V17, P945, DOI 10.1006/mcne.2001.0986; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; FLEMING JC, 2006, BRAIN; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Lim GP, 1996, J NEUROCHEM, V67, P251; Lorenzl S, 2004, J NEUROL SCI, V218, P39, DOI 10.1016/j.jns.2003.10.015; Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; Noble LJ, 2002, J NEUROSCI, V22, P7526; Peled ZM, 2002, PLAST RECONSTR SURG, V110, P801, DOI 10.1097/01.PRS.0000019915.20203.EC; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; Schwab ME, 1996, PHYSIOL REV, V76, P319; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Vos CMP, 2003, J NEUROIMMUNOL, V138, P106, DOI 10.1016/S0165-5728(03)00036-5; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	33	53	57	0	3	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JUN 26	2007	7								7	10.1186/1471-2377-7-17			12	Clinical Neurology	Neurosciences & Neurology	190XE	WOS:000248093200001	17594482	DOAJ Gold, Green Published			2021-06-18	
J	Stone, TW; Behan, WMH				Stone, Trevor W.; Behan, Wilhelmina M. H.			Interleukin-1 beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: Protection by an adenosine A(2A) receptor antagonist	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						kynurenines; kynurenic acid; quinolinic acid; excitotoxicity; cytokines; interleukin-1 beta; tumor necrosis factor-alpha; TNF-alpha; hippocampus	HIPPOCAMPAL SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; TRANSIENT CEREBRAL-ISCHEMIA; EXCITOTOXIC BRAIN-DAMAGE; CONVERT L-TRYPTOPHAN; TNF-ALPHA; RAT-BRAIN; CELL-DEATH; CEREBROSPINAL-FLUID; INFLAMMATORY CYTOKINES	Quinolinic acid is an agonist at glutamate receptors sensitive to N-methyl-D-aspartate (NMDA). It has been implicated in neural dysfunction associated with infections, trauma, and ischemia, although its neurotoxic potency is relatively low. This study was designed to examine the effects of a combination of quinolinic acid and the proinflammatory cytokines interleukin-1 beta (IL-1 beta) and tumor necrosis factor-a (TNF-alpha). Compounds were administered to the hippocampus of anesthetized male rats, animals being allowed to recover for 7 days before histological analysis of the hippocampus for neuronal damage estimated by counting of intact, healthy neurons. A low dose of quinolinic acid or IL-1 beta produced no damage by itself, but the two together induced a significant loss of pyramidal neurons in the hippocampus. Higher doses produced almost total loss of pyramidal cells. Intrahippocampal TNF-alpha produced no effect alone but significantly reduced the neuronal loss produced by quinolinic acid. The adenosine A(2A) receptor antagonist ZM241385 reduced neuronal loss produced by the combinations of quinolinic acid and IL-1 beta P. The results suggest that simultaneous quinolinic acid and IL-1 P, both being induced by cerebral infection or injury, are synergistic in the production of neuronal damage and could together contribute substantially to traumatic, infective, or ischemic cerebral damage. Antagonism of adenosine A(2A) receptors protects neurons against the combination of quinolinic acid and IL-1 beta. (c) 2007 Wiley-Liss, Inc.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Pathol, Glasgow G12 8QQ, Lanark, Scotland	Stone, TW (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	t.w.stone@bio.gla.ac.uk	Stone, Trevor/M-7904-2015	Stone, Trevor/0000-0002-5532-0031			Alexeev AM, 2001, PHYS LOW-DIMENS STR, V3-4, P1; Allan SM, 2002, J NEUROSCI RES, V67, P428, DOI 10.1002/jnr.10142; Allan SM, 1998, MOL PSYCHIATR, V3, P178, DOI 10.1038/sj.mp.4000351; Angstwurm K, 1998, NEUROSCIENCE, V86, P627, DOI 10.1016/S0306-4522(98)00032-3; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; Behan WMH, 2000, BRIT J PHARMACOL, V129, P1764, DOI 10.1038/sj.bjp.0703250; Behan WMH, 2002, BRIT J PHARMACOL, V135, P1435, DOI 10.1038/sj.bjp.0704613; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Canellada A, 2006, MOL CELL NEUROSCI, V31, P692, DOI 10.1016/j.mcn.2005.12.008; Carlson NG, 1999, J IMMUNOL, V163, P3963; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Chiarugi A, 2001, J NEUROIMMUNOL, V120, P190, DOI 10.1016/S0165-5728(01)00418-0; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CUNHA RA, 1994, BRAIN RES, V649, P208, DOI 10.1016/0006-8993(94)91066-9; De A, 2003, BRAIN RES, V981, P133, DOI 10.1016/S0006-8993(03)02997-4; Dimopoulos N, 2006, NEUROSCI LETT, V398, P118, DOI 10.1016/j.neulet.2005.12.064; Eriksson C, 2000, J NEUROSCI RES, V60, P266, DOI 10.1002/(SICI)1097-4547(20000415)60:2<266::AID-JNR16>3.0.CO;2-P; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; GALARRAGA E, 1990, BRAIN RES, V512, P269, DOI 10.1016/0006-8993(90)90636-P; GAO Y, 1994, LIFE SCI, V55, pPL61, DOI 10.1016/0024-3205(94)00889-2; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grundy RI, 2002, BRAIN RES, V926, P142, DOI 10.1016/S0006-8993(01)03325-X; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Harada N, 2000, J PHARMACOL EXP THER, V294, P1034; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1990, J CEREBR BLOOD F MET, V10, P660, DOI 10.1038/jcbfm.1990.119; HEYES MP, 1990, ANN NEUROL, V27, P666, DOI 10.1002/ana.410270614; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Kerr SJ, 1998, AIDS, V12, P355, DOI 10.1097/00002030-199804000-00003; KHASPEKOV L, 1989, J NEUROSCI RES, V22, P150, DOI 10.1002/jnr.490220207; Koller H, 2001, BRAIN RES, V893, P237, DOI 10.1016/S0006-8993(00)03318-7; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Lukashev DE, 2005, DRUG DEVELOP RES, V64, P172, DOI 10.1002/ddr.10428; Mascarucci P, 1998, NEUROSCIENCE, V86, P1285, DOI 10.1016/S0306-4522(98)00105-5; Meistrell ME, 1997, SHOCK, V8, P341; MOFFETT JR, 1994, CELL TISSUE RES, V278, P461; MOFFETT JR, 1993, BRAIN RES, V623, P337, DOI 10.1016/0006-8993(93)91450-7; Monopoli A, 1998, NEUROREPORT, V9, P3955, DOI 10.1097/00001756-199812010-00034; Ogoshi F, 2005, EXP NEUROL, V193, P384, DOI 10.1016/j.expneurol.2004.12.026; Palmer TM, 1995, MOL PHARMACOL, V48, P970; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pearson VL, 1999, GLIA, V25, P311, DOI 10.1002/(SICI)1098-1136(19990215)25:4<311::AID-GLIA1>3.0.CO;2-E; Pelidou SH, 2002, J NEUROIMMUNOL, V133, P108, DOI 10.1016/S0165-5728(02)00369-7; Pemberton LA, 1997, J INTERF CYTOK RES, V17, P589, DOI 10.1089/jir.1997.17.589; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Platenik J, 2001, FREE RADICAL RES, V34, P445, DOI 10.1080/10715760100300391; Pringle AK, 2001, NEUROSCI LETT, V305, P29, DOI 10.1016/S0304-3940(01)01795-5; Radesater AC, 2003, NEUROTOX RES, V5, P433, DOI 10.1007/BF03033173; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Santamaria A, 2001, NEUROREPORT, V12, P2693, DOI 10.1097/00001756-200108280-00020; Santamaria A, 2001, NEUROREPORT, V12, P871, DOI 10.1097/00001756-200103260-00049; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Sheardown MJ, 1996, DRUG DEVELOP RES, V39, P108; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O; Stipek S, 1997, NEUROCHEM INT, V30, P233, DOI 10.1016/S0197-0186(97)90002-4; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; Stone TW, 2002, ADV EXP MED BIOL, V513, P249; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; STRIJBOS JP, 1995, J NEUROSCI, V15, P3468; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Viviani B, 2003, J NEUROSCI, V23, P8692; VonLubitz DKJE, 1995, EUR J PHARMACOL, V287, P295, DOI 10.1016/0014-2999(95)00498-X; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; Yu ZF, 2002, NEUROBIOL DIS, V11, P199, DOI 10.1006/nbdi.2002.0530; Zhu YY, 2006, NEUROSCI LETT, V393, P122, DOI 10.1016/j.neulet.2005.08.072; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	92	53	56	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR	2007	85	5					1077	1085		10.1002/jnr.21212			9	Neurosciences	Neurosciences & Neurology	157NK	WOS:000245726700015	17304576				2021-06-18	
J	Mossberg, KA; Ayala, D; Baker, T; Heard, J; Masel, B				Mossberg, Kurt A.; Ayala, Danielle; Baker, Tracey; Heard, Justin; Masel, Brent			Aerobic capacity after traumatic brain injury: Comparison with a nondisabled cohort	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Combined Sections Meeting of the American-Physical-Therapy-Association	FEB 01-05, 2006	San Diego, CA	Amer Phys Therapy Assoc		brain injuries; head injuries, closed; physical endurance; rehabilitation	PEAK CARDIORESPIRATORY RESPONSES; PHYSICAL-ACTIVITY; MAXIMAL TREADMILL; OXYGEN UPTAKE; EXERCISE; REHABILITATION; PREVENTION; OUTCOMES; RELIABILITY; EFFICIENCY	Objective: To compare aerobic capacity of people recovering from traumatic brain injury (TBI) with an age- and sex-matched group of nondisabled sedentary people. Design: Descriptive comparative study of peak and submaximal physiologic responses. Setting: Residential postacute treatment center. Participants: Convenience sample of 13 people with TBI and 13 age- and sex-matched nondisabled subjects. All subjects could walk 5.3kph (3.3mph), follow 2-step commands, and comply with testing using the gas collection apparatus. Interventions: Not applicable. Main Outcome Measures: Subjects performed a graded maximal treadmill test during which heart rate, minute ventilation (V-E), oxygen consumption (Vo(2)), carbon dioxide production, and respiratory exchange ratio (RER) were measured every minute until exhaustion. Ventilatory equivalents for oxygen (V-E/Vo(2)) and oxygen pulse were calculated. Results: Subjects recovering from TBI had significantly lower peak responses for heart rate, Vo(2,) V-E, and oxygen pulse TBI (P <.01). Peak RER and V-E/Vo(2) were similar. There were significant differences in subinaximal responses for V-E/Vo(2) and oxygen pulse. Conclusions: Patients with TBI were significantly more deconditioned than a comparable group of sedentary people without disability. Participation in cardiorespiratory fitness programs after TBI should be encouraged to prevent secondary disability.	Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA; Transit Learning Ctr, Galveston, TX USA	Mossberg, KA (corresponding author), Univ Texas, Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046570] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046570] Funding Source: Medline		ASTRAND P, 2003, TXB WORK PHYSLK PHYS; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Booth FW, 2000, J APPL PHYSIOL, V88, P774; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; *CDC, TRAUM BRAIN INJ; Chakravarthy M. V., 2003, EXERCISE; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31; Hillier SL, 1997, BRAIN INJURY, V11, P661; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; *JOINT NAT COMM PR, 1997, DHHS PUBL; Kinne S, 2004, AM J PUBLIC HEALTH, V94, P443, DOI 10.2105/AJPH.94.3.443; LaPier TLK, 1998, PHYS THER, V78, P417, DOI 10.1093/ptj/78.4.417; LUKASKI HC, 1989, J SPORT MED PHYS FIT, V29, P223; McTiernan A, 2004, CANCER INVEST, V22, P68, DOI 10.1081/CNV-120027581; MORAN AJ, 1972, MED J AUSTRALIA, V2, P782, DOI 10.5694/j.1326-5377.1972.tb103537.x; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Pollock ML, 1990, EXERCISE HLTH DIS; SALTIN B, 1967, J APPL PHYSIOL, V23, P353; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Taaffe DR, 2000, J REHABIL RES DEV, V37, P245; TAYLOR HL, 1955, J APPL PHYSIOL, V8, P73; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Whaley MH, 2006, ACSMS GUIDELINES EXE	35	53	53	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2007	88	3					315	320		10.1016/j.apmr.2006.12.006			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	142AU	WOS:000244621600008	17321823				2021-06-18	
J	Fins, JJ; Schiff, ND; Foley, KM				Fins, Joseph J.; Schiff, Nicholas D.; Foley, Kathleen M.			Late recovery from the minimally conscious state - Ethical and policy implications	NEUROLOGY			English	Article							PERSISTENT VEGETATIVE STATE; TRAUMATIC BRAIN-INJURY; SCHIAVO,TERRI; REHABILITATION; DISORDERS; SCHIAVO,THERESA; REIMBURSEMENT; DIAGNOSIS	We consider the ethical and public policy implications of late recovery from the minimally conscious state in light of an Institute of Medicine exploratory meeting convened to discuss current knowledge about disorders of consciousness as well as a recently published study demonstrating axonal regrowth in a patient two decades after traumatic injury. Participants at the meeting (which included the authors) described a lack of research initiatives for basic investigations of patients in these states, the frequent warehousing of patients following a diagnosis of persistent vegetative state that limits their access to appropriate neurologic and diagnostic tests, and the breadth of public confusion about disorders of consciousness. Meeting participants encouraged the Institute to pursue a more formal study to outline both the need for research and the unique opportunities to study consciousness, now available through the use of neuroimaging and related technologies. Areas of initial focus would be to define the epidemiology of the minimally conscious state, elucidate mechanisms of recovery, and identify clinically useful diagnostic and prognostic markers that will aid decision making at the bedside.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Med Eth, Ithaca, NY 14853 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Fins, JJ (corresponding author), New York Presbyterian Weill Cornell Med Ctr, Div Med Eth, 435 E 70 St,Suite 4-J, New York, NY 10021 USA.	jjfins@med.cornell.edu					Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Banja J, 1999, BRAIN INJURY, V13, P745, DOI 10.1080/026990599121142; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Didion J, 2005, NEW YORK REV BOOKS, V52, P60; Fins JJ, 2005, PROG BRAIN RES, V150, P565, DOI 10.1016/S0079-6123(05)50040-2; Fins JJ, 2005, HASTINGS CENT REP, V35, P8, DOI 10.1353/hcr.2005.0038; Fins JJ, 2005, NEW YORK REV BOOKS, V52, P63; Fins JJ, 2004, ARCH NEUROL-CHICAGO, V61, P1354, DOI 10.1001/archneur.61.9.1354; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fins JJ, 2005, HASTINGS CENT REP, V35, P22, DOI 10.1353/hcr.2005.0020; FINS JJ, 2003, NY TIMES MAGAZI 1019, P12; FINS JJ, 2006, PALLIATIVE ETHIC CAR, P48; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 2002, VEGETATIVE STATE; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; OCONNOR A, 2005, NY TIMES        0404, pB1; Quill TE, 2005, NEW ENGL J MED, V352, P1630, DOI 10.1056/NEJMp058062; SCHIFF ND, 2003, CEREBRUM, V5, P7; SMOTHERS R, 1996, NY TIMES        0216; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wilson FC, 2002, NEUROREHABILITATION, V17, P231; Winslade W., 1998, CONFRONTING TRAUMATI; Wolfson J, 2006, DEATH STUD, V30, P113, DOI 10.1080/07481180500455590; Wolfson J, 2005, HASTINGS CENT REP, V35, P16, DOI 10.1353/hcr.2005.0071; ZIMMER C, 2004, NY TIMES MAGAZI 0928, P52	31	53	54	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN 23	2007	68	4					304	307		10.1212/01.wnl.0000252376.43779.96			4	Clinical Neurology	Neurosciences & Neurology	128EA	WOS:000243639800017	17242341				2021-06-18	
J	Alm, PA; Risberg, J				Alm, Per A.; Risberg, Jarl			Stuttering in adults: The acoustic startle response, temperamental traits, and biological factors	JOURNAL OF COMMUNICATION DISORDERS			English	Article							DEFICIT-HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; DOPAMINE ACTIVITY; EARLY-CHILDHOOD; ANTICIPATORY ANXIETY; RAT-BRAIN; PROLACTIN; CHILDREN; ESTROGEN	The purpose of this study was to investigate the relation between stuttering and a range of variables of possible relevance, with the main focus on neuromuscular reactivity, and anxiety. The explorative analysis also included temperament, biochemical variables, heredity, preonset lesions, and altered auditory feedback (AAF). An increased level of neuromuscular reactivity in stuttering adults has previously been reported by [Guitar, B. (2003). Acoustic startle responses and temperament in individuals who stutter. Journal of Speech Language and Hearing Research, 46, 233-240], also indicating a link to anxiety and temperament. The present study included a large number of variables in order to enable analysis of subgroups and relations between variables. Totally 32 stuttering adults were compared with nonstuttering controls. The acoustic startle eyeblink response was used as a measure of neuromuscular reactivity. No significant group difference was found regarding startle, and startle was not significantly correlated with trait anxiety, stuttering severity, or AAF. Startle was mainly related to calcium and prolactin. The stuttering group had significantly higher scores for anxiety and childhood ADHD. Two subgroups of stuttering were found, with high versus low traits of childhood ADHD, characterized by indications of preonset lesions versus heredity for stuttering. The study does not support the view that excessive reactivity is a typical characteristic of stuttering. The increased anxiety is suggested to mainly be an effect of experiences of stuttering. Learning outcomes: As a result of reading this article, the reader will be able to: (a) critically discuss the literature regarding stuttering in relation to acoustic startle, anxiety, and temperament; (b) describe the effect of calcium on neuromuscular reactivity; (c) discuss findings supporting the importance of early neurological incidents in some cases of stuttering, and the relation between such incidents and traits of ADHD or ADD; and (d) discuss the role of genetics in stuttering. (c) 2006 Elsevier Inc. All rights reserved.	Lund Univ, Dept Clin Neurosci, Lund, Sweden; Lund Univ, Dept Psychol, Lund, Sweden	Alm, PA (corresponding author), Harlemans Vag 4A, SE-22730 Lund, Sweden.	per.alm1@yahoo.com					Alm PA, 2004, J FLUENCY DISORD, V29, P123, DOI 10.1016/j.jfludis.2004.02.001; Alm PA, 2004, J COMMUN DISORD, V37, P325, DOI 10.1016/j.jcomdis.2004.03.001; AMBROSE NG, 1993, J SPEECH HEAR RES, V36, P701, DOI 10.1044/jshr.3604.701; Ambrose NG, 1997, J SPEECH LANG HEAR R, V40, P567, DOI 10.1044/jslhr.4003.567; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson JD, 2003, J SPEECH LANG HEAR R, V46, P1221, DOI 10.1044/1092-4388(2003/095); Appelberg B, 2002, PSYCHONEUROENDOCRINO, V27, P661, DOI 10.1016/S0306-4530(01)00067-1; APPELBERG B, 2000, SCHIZOPHR RES, P183; Armario A, 1996, PSYCHONEUROENDOCRINO, V21, P17, DOI 10.1016/0306-4530(95)00048-8; Backman L, 2000, AM J PSYCHIAT, V157, P635; BECKER L, 2000, INTERNET; Ben-Jonathan N, 2001, ENDOCR REV, V22, P724, DOI 10.1210/er.22.6.724; BOHME G, 1968, FOLIA PHONIATR, V20, P239; BOHME G, 1977, STOTTER SYNDROM; BRADY JP, 1991, AM J PSYCHIAT, V148, P1309; Breier A, 1998, AM J PSYCHIAT, V155, P1440, DOI 10.1176/ajp.155.10.1440; BURTIES CA, 1999, TIETZ TXB CLIN CHEM; CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319; CHOKROVERTY S, 1992, ELECTROEN CLIN NEURO, V85, P236, DOI 10.1016/0168-5597(92)90111-N; COSTA D, 1986, ACTIV NERV SUPER, V28, P155; COSTA D, 1986, ACTIV NERV SUPER, V28, P156; COX N, 2000, ASHA LEADER, V5; CRAIG A, 1990, J SPEECH HEAR DISORD, V55, P290, DOI 10.1044/jshd.5502.290; Craig A, 2003, J SPEECH LANG HEAR R, V46, P1197, DOI 10.1044/1092-4388(2003/093); Davis M, 1999, STARTLE MODIFICATION, P95, DOI [10.1017/CB09780511665523.007, DOI 10.1017/CBO9780511665523.007]; Davis S, 2002, EXP NEUROL, V176, P229, DOI 10.1006/exnr.2002.7926; Decker Michael J, 2002, Sleep Breath, V6, P205, DOI 10.1055/s-2002-36531; DEPUE RA, 1994, J PERS SOC PSYCHOL, V67, P485, DOI 10.1037/0022-3514.67.3.485; Drayna D, 1999, AM J HUM GENET, V65, P1473, DOI 10.1086/302625; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; Embrechts M., 2000, P 3 WORLD C FLUENC D, P557; Emiliano ABF, 2004, NEUROPSYCHOPHARMACOL, V29, P833, DOI 10.1038/sj.npp.1300412; Ezrati-Vinacour R, 2004, J FLUENCY DISORD, V29, P135, DOI 10.1016/j.jfludis.2004.02.003; Farde L, 1997, NATURE, V385, P590, DOI 10.1038/385590a0; FOWLIE GM, 1978, J FLUENCY DISORD, V3, P233, DOI 10.1016/0094-730X(78)90023-2; GRILLON C, 1991, PSYCHOPHYSIOLOGY, V28, P588, DOI 10.1111/j.1469-8986.1991.tb01999.x; Guitar B, 2003, J SPEECH LANG HEAR R, V46, P233, DOI 10.1044/1092-4388(2003/018); Guyton AC, 1996, TXB MED PHYSL; Herbst A, 1997, OBSTET GYNECOL, V90, P125, DOI 10.1016/S0029-7844(97)00177-4; HERNANDEZ ML, 1994, J NEURAL TRANSM-GEN, V96, P63, DOI 10.1007/BF01277929; Hill H, 1944, J SPEECH DISORD, V9, P289, DOI 10.1044/jshd.0904.289; HOWARD R, 1992, PSYCHOL MED, V22, P695, DOI 10.1017/S0033291700038137; Ingemarsson I, 1997, BRIT J OBSTET GYNAEC, V104, P1123, DOI 10.1111/j.1471-0528.1997.tb10934.x; Jennings PJ, 1998, BEHAV NEUROSCI, V112, P154, DOI 10.1037/0735-7044.112.1.154; JOBORN H, 1990, CLIN PHYSIOL, V10, P37, DOI 10.1111/j.1475-097X.1990.tb00082.x; KALINOWSKI J, 1993, LANG SPEECH, V36, P1; Kuppers E, 2000, J NEUROCYTOL, V29, P375, DOI 10.1023/A:1007165307652; Lewis KE, 1997, EUR J DISORDER COMM, V32, P441; MALLARD EC, 1995, NEUROSCIENCE, V65, P827, DOI 10.1016/0306-4522(94)00504-X; Mauskop A, 2002, HEADACHE, V42, P242, DOI 10.1046/j.1526-4610.2002.02075.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Messenger M, 2004, J FLUENCY DISORD, V29, P201, DOI 10.1016/j.jfludis.2004.06.002; MILLER S, 1992, J SPEECH HEAR RES, V35, P789, DOI 10.1044/jshr.3504.789; MORRISON J, 1999, PSYCHOL PROBLEMS MAS; MUCCIOLI G, 1991, NEUROENDOCRINOLOGY, V53, P47, DOI 10.1159/000125696; *NIH, 2003, MEDL PLUS; Oliveira MC, 1996, BRAZ J MED BIOL RES, V29, P521; OYLER ME, 1994, THESIS U COLORADO; PASTUSZKO A, 1994, BIOCHEM MED METAB B, V51, P1, DOI 10.1006/bmmb.1994.1001; POULOS MG, 1991, J SPEECH HEAR RES, V34, P5, DOI 10.1044/jshr.3401.05; PUTNAM LE, 1999, STARTLE MODIFICATION, P72, DOI DOI 10.1017/CBO9780511665523.006; Riaz N, 2005, AM J HUM GENET, V76, P647, DOI 10.1086/429226; ROUSEY CG, 1986, J FLUENCY DISORD, V11, P257, DOI 10.1016/0094-730X(86)90013-6; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SCHACHAR R, 2002, CHILD ADOLESCENT PSY, P399; SCHALLING D, 1987, ACTA PSYCHIAT SCAND, V76, P172, DOI 10.1111/j.1600-0447.1987.tb02881.x; SCHEDLOWSKI M, 1992, LIFE SCI, V50, P1201, DOI 10.1016/0024-3205(92)90319-K; SCHILLING A, 1960, HNO, V8, P205; SCHILLING A, 1963, PSYCHOL BEITR, V7, P353; Schleier E, 1991, Otolaryngol Pol, V45, P141; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Shugart YY, 2004, AM J MED GENET A, V124A, P133, DOI 10.1002/ajmg.a.20347; Sobrinho LG, 1998, PSYCHOTHER PSYCHOSOM, V67, P133, DOI 10.1159/000012273; Spielberger C, 1983, STAI MANUAL STATE TR; SWERDLOW NR, 1999, STARTLE MODIFICATION, P114, DOI DOI 10.1017/CBO9780511665523; Taylor R. M., 1996, TAYLOR JOHNSON TEMPE; Thiblin I, 1999, BRIT J PHARMACOL, V126, P1301, DOI 10.1038/sj.bjp.0702412; Thys-Jacobs S, 2000, J AM COLL NUTR, V19, P220, DOI 10.1080/07315724.2000.10718920; Toft PB, 1999, PEDIATR NEUROL, V21, P602, DOI 10.1016/S0887-8994(99)00046-6; Tsang KL, 2000, NEUROLOGY, V54, P2292, DOI 10.1212/WNL.54.12.2292; VANLOON GR, 1983, BRAIN RES BULL, V10, P539, DOI 10.1016/0361-9230(83)90152-1; Victor M., 2001, ADAMS VICTORS PRINCI; Viswanath N, 2004, HUM BIOL, V76, P401, DOI 10.1353/hub.2004.0050; Volkow ND, 1998, AM J PSYCHIAT, V155, P344; Volpe J., 2001, NEUROLOGY NEWBORN, V4th ed.; VRANA SR, 1988, J ABNORM PSYCHOL, V97, P487, DOI 10.1037/0021-843X.97.4.487; WAKABA YY, 1997, P 2 WORLD C FLUENC D, P84; WALKER ST, 1973, PERCEPT MOTOR SKILL, V36, P926, DOI 10.2466/pms.1973.36.3.926; WARD MF, 1993, AM J PSYCHIAT, V150, P885; Watkins RV, 1999, J SPEECH LANG HEAR R, V42, P1125, DOI 10.1044/jslhr.4205.1125; West R, 1939, Q J SPEECH, V25, P23, DOI 10.1080/00335633909380434; Wu JC, 1997, NEUROREPORT, V8, P767, DOI 10.1097/00001756-199702100-00037; Yairi E., 2005, EARLY CHILDHOOD STUT; ZIMMERMANN G, 1980, J SPEECH HEAR RES, V23, P122, DOI 10.1044/jshr.2301.122	96	53	54	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	JAN-FEB	2007	40	1					1	41		10.1016/j.jcomdis.2006.04.001			41	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	128QG	WOS:000243672400001	16814317				2021-06-18	
J	Newsome, MR; Scheibel, RS; Steinberg, JL; Troyanskaya, M; Sharma, RG; Rauch, RA; Li, XQ; Levin, HS				Newsome, Mary R.; Scheibel, Randall S.; Steinberg, Joel L.; Troyanskaya, Maya; Sharma, Rajkumar G.; Rauch, Ronald A.; Li, Xioaqi; Levin, Harvey S.			Working memory brain activation following severe traumatic brain injury	CORTEX			English	Article; Proceedings Paper	2nd International Conference on Working Memory	AUG 17-20, 2004	Kyoto, JAPAN			traumatic brain injury; working memory; fMRI	PREFRONTAL CORTEX; PARAMETRIC MANIPULATION; FUNCTIONAL MRI; TASK; FMRI; MECHANISMS	Functional magnetic resonance imaging (fMRI) has shown that brain activation during performance of working memory (WM) tasks under high memory loads is altered in adults with severe traumatic brain injury (TBI) relative to uninjured subjects (Perlstein et a]., 2004; Scheibel et al., 2003). Our study attempted to equate TBI patients and orthopedically injured (OI) subjects on performance of an N-Back task that used faces as stimuli. To minimize confusion in TBI patients that was revealed in pilot work, we presented the memory conditions in two separate tasks, 0-versus 1-back and 0- versus 2-back. In the 0- versus 1-back task, OI subjects activated bilateral frontal areas more extensively than TBI patients, and TBI patients activated posterior regions more extensively than OI subjects. In the 0- versus 2-back task, there were no significant differences between the groups. Analysis of changes in activation over time on I-back disclosed that OI subjects had decreases in bilateral anterior and posterior regions, while TBI patients showed activation increases in those and other areas over time. In the 2-back condition, both groups showed decreases over time in fusiform and parahippocampal gyri, although the OI group also showed increases over time in frontal, parietal, and temporal areas not seen in the TBI patients. The greatest group differences were found in the 1-back condition, which places low demand on WM. Although the extent of activation in the 2-back condition did not differ between the two groups, deactivation in the 2-back condition was seen in the OI patients only, and both groups' patterns of activation over time varied, suggesting a dissociation between the TBI and OI patients in recruitment of neural areas mediating WM.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA	Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889, NS-42772] Funding Source: Medline		Baddeley A. D., 1986, WORKING MEMORY; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brett M., 2002, 8 INT C FUNCT MAPP H, V16; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen J, 2000, NEUROIMAGE, V11, P378, DOI 10.1006/nimg.2000.0573; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DONALDSON W, 1992, J EXP PSYCHOL GEN, V121, P275, DOI 10.1037/0096-3445.121.3.275; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Fuster J, 1989, PREFRONTAL CORTEX; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; Graham D.I., 2002, GREENFIELDS NEUROPAT; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Mehta MA, 2000, J NEUROSCI, V20; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poldrack RA, 2001, BRAIN, V124, P67, DOI 10.1093/brain/124.1.67; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Proctor A, 2000, BRAIN INJURY, V14, P633; Ranganath C, 2005, CURR OPIN NEUROBIOL, V15, P175, DOI 10.1016/j.conb.2005.03.017; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Zhang JX, 2003, NEUROIMAGE, V20, P1531, DOI 10.1016/j.neuroimage.2003.07.016	39	53	55	0	9	MASSON DIVISIONE PERIODICI	MILANO	VIA MUZIO ATTENDOLO DETTO SFORZA 7-9, 20141 MILANO, ITALY	0010-9452			CORTEX	Cortex	JAN	2007	43	1					95	111		10.1016/S0010-9452(08)70448-9			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	140MI	WOS:000244509000008	17334210				2021-06-18	
J	Powell, T; Ekin-Wood, A; Collin, C				Powell, Trevor; Ekin-Wood, Abigail; Collin, Christine			Post-traumatic growth after head injury: A long-term follow-up	BRAIN INJURY			English	Article						post-traumatic growth; head injury; TBI; follow up; adjustment	TRAUMATIC BRAIN INJURY; SCALE	Primary objective: To investigate the time course of any positive psychological changes after traumatic brain injury (TBI) by comparing questionnaire responses in two groups of TBI survivors, early, 1-3 years post-injury and late, 10-12 years post-injury. Research design: A cross-sectional, between-group design. Method and Procedure: TBI survivors were selected from the Reading Head Injury out-patient records by date of registration, early survivors from 2002-2004 and late survivors from 1993-1996 and sent a battery of postal questionnaires. These included The Post-traumatic Growth Inventory, The Life Satisfaction Checklist and The Hospital Anxiety and Depression Scale. Individuals were also given the opportunity to answer questions about their perception of their condition and to provide free text responses to reflect best and worst advice received, to describe positive and negative changes in themselves and to identify their most useful coping strategies. Results: 61 'early' and 65 'late' people were contacted with study details and 52 consented to the study, receiving questionnaires which provided 23 'early' and 25 'late' responses. There was a significantly greater degree of post-traumatic growth, as measured on 'The Post-traumatic Growth Inventory', reported by the later group (*p = 0.000), but no other significant differences between the groups in terms of all the other variables. Both groups reported greater life satisfaction pre-injury. Conclusion: Measures of Post-traumatic Growth (Relating to Others, Personal Strength, New Possibilities, Appreciation of Life and Spirituality) appear to increase over time after head injury. This is a positive message that clinicians should note and reinforce and could help to shape future adjustment.	Berkshire Healthcare NHS Trust, Erleigh Rd Clin, Reading RG1 5LE, Berks, England; Royal Berkshire Hosp, RBBH NHS Trust, Reading, Berks, England	Powell, T (corresponding author), Berkshire Healthcare NHS Trust, Erleigh Rd Clin, 25 Erleigh Rd, Reading RG1 5LE, Berks, England.	trevor.powell@berkshire.nhs.uk					Affleck G., 1991, INFANTS CRISIS PAREN; ANDERSONPARENTE JK, 1990, COGNITIVE REHABI JAN, P22; Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; [Anonymous], 2003, SPSS PC VERS 14 0 IB; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burt M. R., 1987, J INTERPERS VIOLENCE, V2, P57, DOI [DOI 10.1177/088626087002001004, 10.1177/088626087002001004]; Caplan G., 1964, PRINCIPLES PREVENTIV; COLLINS RL, 1990, SOC COGNITION, V8, P263, DOI 10.1521/soco.1990.8.3.263; Cordova MJ, 2001, HEALTH PSYCHOL, V20, P176, DOI 10.1037//0278-6133.20.3.176; Evers AWM, 2001, J CONSULT CLIN PSYCH, V69, P1026, DOI 10.1037//0022-006X.69.6.1026; Frankl V.E, 1963, MANS SEARCH MEANING; Fromm K, 1996, J BEHAV MED, V19, P221, DOI 10.1007/BF01857767; JENNETT B, 1975, LANCET, V1, P480; JOSEPH S, 1993, J TRAUMA STRESS, V6, P271, DOI 10.1007/BF00974121; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Linley P. A., 2000, J TRAUMA STRESS, V17, P11; MCGRATH J, 2004, 2 EUR POS PSYCH C VE; MCMILLAN JC, 1999, SOC WORK, V44, P468; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Park CL, 1996, J PERS, V64, P71, DOI 10.1111/j.1467-6494.1996.tb00815.x; Polatinsky S, 2000, J TRAUMA STRESS, V13, P709, DOI 10.1023/A:1007870419116; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; SBORDONE RJ, 1990, COMMUNITY INTEGRATIO; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tedeschi R.G., 2006, HDB POSTTRAUMATIC GR; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	53	59	1	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					31	38		10.1080/02699050601106245			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600004	17364517				2021-06-18	
J	Klemen, P; Grmec, S				Klemen, P.; Grmec, S.			Effect of pre-hospital advanced life support with rapid sequence intubation on outcome of severe traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						emergency medical system; pre-hospital trauma care; rapid sequence intubation; severe traumatic brain injury; outcome	SEVERE HEAD-INJURY; NEUROMUSCULAR BLOCKING-AGENTS; TRACHEAL TUBE PLACEMENT; ENDOTRACHEAL INTUBATION; CARE; IMPACT; MANAGEMENT; PHYSICIANS; EFFICACY; MODERATE	Background: The role of pre-hospital trauma care and the effect of pre-hospital rapid sequence intubation (RSI) on patient outcome are still not clear. This study evaluated the impact of pre-hospital trauma care by emergency physicians (EP) on mortality from severe traumatic brain injury (TBI) and a 180-day Glasgow Outcome Scale (GOS). Methods: A 48-month parallel non-controlled cohort study compared a group of 64 patients with severe TBI [Glasgow Coma Scale (GCS) < 9; Injury Severity Score (ISS) > 151 who received pre-hospital advanced life support (ALS) with RSI and were transported to the hospital by EPs (EP group), with a group of 60 patients who did not receive pre-hospital ALS with RSI [emergency medical technicians (EMT) group]. Results: There were no significant statistical differences between the groups in age (P = 0.79), mechanism of injury W = 0.68), gender W = 0.82), initial GCS (P = 0.63), initial SaO(2) in the field (P = 0.63), initial systolic blood pressure in the field (P = 0.47) and on-scene time (P = 0.41). In the EP group, there was significantly better first hour survival (97% vs. 79%, P = 0.02), first day survival (90% vs. 72%, P = 0.02), better functional outcome (GOS 4-5: 53% vs. 33%, P < 0.01; GOS 2-3: 8% vs. 20%, P < 0.01) and shortened hospitalization time in intensive Care unit (ICU) W = 0.03) and other departments (P - 0.04). In total hospital mortality, we detected no differences between both groups [EP group: 40% (95% CI: 34-45%) vs.EMT group 42% (95% CI: 36-47%, P = 0.761, except in a subgroup of patients with GCS 6-8 where there was significantly lower total hospital mortality in the EP group (24% vs. 78%, P < 0.01). Conclusion: After starting the trauma care system with emergency physicians in our region, there was a decrease in the number of deaths on hospital admission, a reduction in hospital mortality in the GCS group 6-8, a change in the temporal distribution of deaths, an improvement in functional neurological outcome and shortened hospitalization time.	Univ Maribor, Ctr Emergency Med Maribor, Fac Med, Maribor 2000, Slovenia	Klemen, P (corresponding author), Univ Maribor, Ctr Emergency Med Maribor, Fac Med, Ulica Talcev 9, Maribor 2000, Slovenia.	petraklemen@email.si					Adnet F, 2001, CRIT CARE, V5, P290; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Deakin C D, 2001, Curr Opin Anaesthesiol, V14, P191, DOI 10.1097/00001503-200104000-00011; di Bartolomeo S, 2003, EUR J EMERG MED, V10, P268, DOI 10.1097/01.mej.0000103466.32882.7b; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Garner A, 2001, INJURY, V32, P455, DOI 10.1016/S0020-1383(01)00013-4; Grmec S, 2004, EMERG MED J, V21, P518, DOI 10.1136/emj.2002.001974; Grmec S, 2002, INTENS CARE MED, V28, P701, DOI 10.1007/s00134-002-1290-x; Hsiao A K, 1993, Prehosp Disaster Med, V8, P229; HUSSAIN LM, 1994, BRIT MED J, V308, P1077, DOI 10.1136/bmj.308.6936.1077; Kwan Irene, 2002, Prehosp Emerg Care, V6, P27, DOI 10.1080/10903120290938733; LANGERON O, 2000, CURR OPIN CRIT CARE, V6, P383; LIBERMAN M, 2000, J TRAUMA, V48, P643; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; MYLES PS, 2000, STAT METHODS ANAESTH, P87; PIEK J, 1999, NEUROTRAUMA MODULE 1, P1; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Schuttler J, 1995, ANAESTHESIST, V44, P850, DOI 10.1007/s001010050221; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Ummenhofer Wolfgang, 2002, Curr Opin Crit Care, V8, P559, DOI 10.1097/00075198-200212000-00013; WINTCHELL RJ, 1997, ARCH SURG-CHICAGO, V132, P592	35	53	53	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2006	50	10					1250	1254		10.1111/J.1399-6576.2006.01039.X			5	Anesthesiology	Anesthesiology	104JL	WOS:000241954600013	17067325				2021-06-18	
J	Gahm, C; Holmin, S; Wiklund, PN; Brundin, L; Mathiesen, T				Gahm, Caroline; Holmin, Staffan; Wiklund, Peter N.; Brundin, Lou; Mathiesen, Tiit			Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; iNOS; L-NIL; neuronal degeneration; nitrotyrosine; traumatic brain injury	PERIVASCULAR TYROSINE NITRATION; DNA-DAMAGE; CELL-DEATH; NEURONAL DEGENERATION; SUPEROXIDE-DISMUTASE; MICE DEFICIENT; FREE-RADICALS; RAT-BRAIN; IN-SITU; INJURY	The inflammatory response is thought to be important for secondary damage following traumatic brain injury (TBI). The inducible nitric oxide synthase (iNOS) isoform is a mediator in inflammatory reactions and may catalyze substantial synthesis of NO in the injured brain. This study was undertaken to analyze neuronal degeneration and survival, cellular apoptosis and formation of nitrotyrosine following treatment with the iNOS-inhibitor L-N-iminoethyl-lysine (L-NIL) in a model of brain contusion. A brain contusion was produced using a weight-drop device in 30 rats. The animals received treatment with L-NIL or NaCl at 15 min and 12 h after the injury and were sacrificed at 24 h or 6 days after trauma. iNOS activity was measured at 24 h post-trauma by the conversion of L-[U-C-14]arginine to L-[U-C-14]citrulline and immunohistochemistry for iNOS. Peroxynitrite formation was indirectly assessed by nitrotyrosine (NT) immunohistochemistry. Neuronal degeneration and survival were assessed by Fluoro-Jade (FJ) and NeuN stainings, and cellular death by TUNEL staining. iNOS activity but not iNOS immunoreactivity was significantly reduced in animals that received L-NIL. Neuronal degeneration (FJ) and NT immunoreactivity were significantly reduced at 24 h. Neuronal survival was unchanged at 24 h but increased at 6 days in L-NIL-treated animals. Cellular apoptosis of ED-1 and NeuN positive cells was significantly reduced following L-NIL treatment at 6 days after trauma. We demonstrated neuroprotection by selective inhibition of iNOS after trauma. L-NIL appeared to protect the injured brain by limiting peroxynitrite formation. Our findings support a putative harmful role of iNOS induction early after TBI.	Karolinska Univ Hosp, Dept Clin Neurosci, Sect Clin CNS Res, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Neurosci, Sect Otorhinolaryngol, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Surg, Urol Sect, S-17176 Stockholm, Sweden; Karolinska Univ Hosp, Ctr Mol Med, Neuroimmunol Unit, S-17176 Stockholm, Sweden	Gahm, C (corresponding author), Karolinska Univ Hosp, Dept Clin Neurosci, Sect Clin CNS Res, S-17176 Stockholm, Sweden.	caroline.gahm@karolinska.se		Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615; Brundin, Lou/0000-0003-4408-7817; Wiklund, Peter/0000-0001-6497-4697			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229, DOI DOI 10.1016/S0076-6879(94)33026-3; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Bryk R, 1998, BIOCHEMISTRY-US, V37, P4844, DOI 10.1021/bi972065t; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Coeroli L, 1998, J NEUROCHEM, V70, P2516; Conti AC, 1998, J NEUROSCI, V18, P5663; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Eguchi Y, 1997, CANCER RES, V57, P1835; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Gahm C, 2005, ACTA NEUROCHIR, V147, P1071, DOI 10.1007/s00701-005-0590-7; Gahm C, 2000, NEUROSURGERY, V46, P169; GANSTER R, 2000, NITRIC OXIDE BIOL PA, V1, P129; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hooper DC, 2000, FASEB J, V14, P691; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; KLEINERT H, 2000, NITRIC OXIDE BIOL PA, V1, P105; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu J, 2003, NEUROSCI LETT, V339, P147, DOI 10.1016/S0304-3940(03)00003-X; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RINK A, 1995, AM J PATHOL, V147, P1575; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; Zhang YW, 2004, CANCER CELL, V6, P5, DOI 10.1016/j.ccr.2004.07.003	59	53	56	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1343	1354		10.1089/neu.2006.23.1343			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900006	16958586				2021-06-18	
J	Houlden, H; Edwards, M; McNeil, J; Greenwood, R				Houlden, H; Edwards, M; McNeil, J; Greenwood, R			Use of the Barthel Index and the Functional Independence Measure during early inpatient rehabilitation after single incident brain injury	CLINICAL REHABILITATION			English	Article							STROKE; DISABILITY; RESPONSIVENESS; SCALES	Objective: To compare the appropriateness and responsiveness of the Barthel Index and the Functional Independence Measure (FIM) during early inpatient rehabilitation after single incident brain injury. Design: Cohort study. Setting: A regional neurological rehabilitation unit. Patients: Two hundred and fifty-nine consecutive patients undergoing inpatient comprehensive neurological rehabilitation following a vascular brain injury due to single cerebral infarction (n = 75), spontaneous intracerebral haemorrhage (n = 34) and subarachnoid haemorrhage (n = 43), and 107 patients who had sustained traumatic brain injury. Measurements: Admission and discharge FIM total, physical and cognitive scores and the Barthel Index were recorded. Appropriateness and responsiveness in the study samples were determined by examining score distributions and floor and ceiling effects, and by an effect size calculation respectively. Non-parametric statistical analysis was used to calculate the significance of the change in scores. Results: In all patient groups there was a significant improvement (Wilcoxon's rank sum, P < 0.0001) in the Barthel Index (mean change score: vascular 3.9, traumatic 3.95) and FIM (mean change score: vascular 17.3, traumatic 17.4) scores during rehabilitation, and similar effect sizes were found for the Barthel Index (effect size: vascular 0.65, traumatic 0.55) and FIM total (effect size: vascular 0.59, traumatic 0.48) and physical scores in all patient groups. In each patient group the cognitive component of the FIM had the smallest effect size (0.35-0.43). Conclusions: All measures were appropriate for younger (less than 65 years of age) patients undergoing early inpatient rehabilitation after single incident vascular or traumatic brain injury. The Barthel Index and the total and physical FIM scores showed similar responsiveness, whilst the cognitive FIM score was least responsive. These findings suggest that none of the FIM scores have any advantage over the Barthel Index in evaluating change in these circumstances.	Homerton Hosp, Reg Neurol Rehabil Unit, London E9 6SR, England	Greenwood, R (corresponding author), Homerton Hosp, Reg Neurol Rehabil Unit, Homerton Row, London E9 6SR, England.	Richard.Greenwood@homerton.nhs.uk	Houlden, Henry/C-1532-2008	Houlden, Henry/0000-0002-2866-7777			Bates BE, 2000, ARCH PHYS MED REHAB, V81, P1468, DOI 10.1053/apmr.2000.17808; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Desrosiers J, 2003, ARCH GERONTOL GERIAT, V37, P157, DOI 10.1016/S0167-4943(03)00044-X; Dromerick AW, 2003, J REHABIL RES DEV, V40, P1, DOI 10.1682/JRRD.2003.01.0001; Edwards MJ, 2003, DISABIL REHABIL, V25, P405, DOI 10.1080/0963828031000062642; Eng JJ, 2002, ARCH PHYS MED REHAB, V83, P483, DOI 10.1053/apmr.2002.31203; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hobart JC, 1996, J NEUROL S2, V243, pS25; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holmes WC, 1997, QUAL LIFE RES, V6, P561, DOI 10.1023/A:1018464200708; Hsueh IP, 2002, J NEUROL NEUROSUR PS, V73, P188, DOI 10.1136/jnnp.73.2.188; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kwon S, 2004, STROKE, V35, P918, DOI 10.1161/01.STR.0000119385.56094.32; MAHONEY F I, 1965, Md State Med J, V14, P61; McMillan T. M., 1993, CLIN REHABIL, V7, P346; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; Novak S., 1996, CLIN REHABIL, V10, P128; O'Connor RJ, 2004, NEUROLOGY, V62, P1842, DOI 10.1212/01.WNL.0000116136.22922.D6; Turner-Stokes L, 1999, CLIN REHABIL, V13, P273, DOI 10.1191/026921599670005973; TURNERSTOKES L, 2003, REHABILITATION FOLLO; van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480; Wade DT, 1992, MEASUREMENT NEUROLOG; Wallace D, 2002, J CLIN EPIDEMIOL, V55, P922, DOI 10.1016/S0895-4356(02)00410-9	25	53	58	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	FEB	2006	20	2					153	159		10.1191/0269215506cr917oa			7	Rehabilitation	Rehabilitation	015DB	WOS:000235531000008	16541936				2021-06-18	
J	Bulut, M; Koksal, O; Dogan, S; Bolca, N; Ozguc, H; Korfali, E; Ilcoll, YO; Parlak, M				Bulut, M; Koksal, O; Dogan, S; Bolca, N; Ozguc, H; Korfali, E; Ilcoll, YO; Parlak, M			Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results	ADVANCES IN THERAPY			English	Article						mild traumatic brain injury; serum tau protein; high risk; cranial CT	MINOR HEAD-INJURY; CEREBROSPINAL-FLUID; COMPUTED-TOMOGRAPHY; NEURONAL DAMAGE; SERIAL S-100; CSF	The objective of this study was to investigate the diagnostic value of serum tau protein in determining the severity of traumatic brain injury in patients with mild traumatic brain injury (mTBI) and high-risk patients. Adult patients who presented to our emergency department (ED) with mTBI over I year were prospectively enrolled. Patients underwent cranial computed tomography (CT) and were subdivided into high- and low-risk groups, according to the probability of resultant intracranial injury. Serum tau levels of 60 patients and 20 healthy volunteers, who served as a control group, were measured. The mean age of the 60 patients (45 males, 15 females) was 32.5 years (range, 15-66 y). Mean Glasgow Coma Scale (GCS) score was 14 +/- 0.6. CT scans demonstrated intracranial injury in 11 patients (18.3%) and depressed fracture in 4 patients (6.7%). Serum tau levels of patients (188 +/- 210 pg/mL), compared with those of controls (86 48 pg/mL), were relatively higher; however, differences were not statistically significant (P = .445).	Uludag Univ, Dept Emergency Med, Sch Med, TR-16059 Bursa, Turkey; Uludag Univ, Dept Radiol, Sch Med, TR-16059 Bursa, Turkey; Uludag Univ, Dept Neurosurg, Sch Med, TR-16059 Bursa, Turkey; Uludag Univ, Dept Gen Surg, Sch Med, TR-16059 Bursa, Turkey; Uludag Univ, Dept Neurosurg, Sch Med, TR-16059 Bursa, Turkey; Uludag Univ, Dept Biochem, Sch Med, TR-16059 Bursa, Turkey	Bulut, M (corresponding author), Uludag Univ, Dept Emergency Med, Sch Med, TR-16059 Bursa, Turkey.		koksal, ozlem/AAK-8332-2020	koksal, ozlem/0000-0003-2271-5659			Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biros MH., 1998, EMERGENCY MED CONCEP, P416; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; GEIJERSTAM JLA, 2004, EMERG MED J, V21, P54; GOTTESFELD SH, 2001, TURK J EMERG MED, V1, P87; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingelson M, 1999, DEMENT GERIATR COGN, V10, P442, DOI 10.1159/000017187; Irazuzta JE, 2001, BRAIN RES, V913, P95, DOI 10.1016/S0006-8993(01)02764-0; McKeating EG, 1998, ACT NEUR S, V71, P117; Mehta PD, 1999, NEUROSCI LETT, V275, P159, DOI 10.1016/S0304-3940(99)00754-5; Neumar RW, 2002, ANN EMERG MED, V39, P342, DOI 10.1067/mem.2002.122007; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sjogren M, 2001, CLIN CHEM, V47, P1776; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Sussmuth SD, 2001, NEUROSCI LETT, V300, P95, DOI 10.1016/S0304-3940(01)01556-7; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zemlan FP, 1999, J NEUROCHEM, V73, P437	27	53	53	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0741-238X	1865-8652		ADV THER	Adv. Ther.	JAN-FEB	2006	23	1					12	22		10.1007/BF02850342			11	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	037AK	WOS:000237118900002	16644603				2021-06-18	
J	Shaw, SE; Morris, DM; Uswatte, G; Mckay, S; Meythaller, JM; Taub, E				Shaw, SE; Morris, DM; Uswatte, G; Mckay, S; Meythaller, JM; Taub, E			Constraint-induced movement therapy for recovery of upper-limb function following traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						behavioral therapy; constraint-induced movement therapy; functional abilities; massed practice; motor function; motor impairment; neurological injury; physical rehabilitation; training; traumatic brain injury	MOTOR FUNCTION-TEST; LEARNED NONUSE; CHRONIC STROKE; CORTICAL REORGANIZATION; FORCED USE; REHABILITATION; PLASTICITY; INTENSITY; DEFICITS; OUTCOMES	A volunteer sample of 22 participants with chronic traumatic brain injury (TBI) (onset > 1 year) and relative hemiplegia that revealed moderate disability in the more-affected upper limb (UL) participated. Constraint-induced (CI) movement therapy (CI therapy) was employed for a 2-week period; treatments included massed practice, shaping of the more-affected UL, behavioral contracts, and other behavioral techniques for affecting transfer to a real-world setting. We used the Wolf Motor Function Test, the Fugl-Meyer Motor Performance Assessment, and the Motor Activity Log to measure outcomes. All outcome measures improved significantly as a result of the intervention. More-adherent participants had more improvement compared with less-adherent participants. These preliminary results suggest that Cl therapy may be effective for improving UL motor function following chronic TBI.	Univ Alabama, Dept Phys Therapy, Birmingham, AL 35294 USA; Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA; Birmingham VA Med Ctr, Dept Vet Affairs, Res Serv, Birmingham, AL USA	Shaw, SE (corresponding author), Univ Alabama, Dept Phys Therapy, RMSB 360,1530 3rd Ave S, Birmingham, AL 35294 USA.	sshaw@uab.edu	Uswatte, Gitendra/C-4913-2009		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 403541-12] Funding Source: Medline		Alon G, 2003, ARCH PHYS MED REHAB, V84, P119, DOI 10.1053/apmr.2003.50073; [Anonymous], 1944, ARMY INDIVIDUAL TEST; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Bauder H, 1999, PSYCHOPHYSIOLOGY, V36, pS31; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benton AL, 1983, MULTILINGUAL APHASIA; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BLEECKER ML, 1988, NEUROLOGY, V38, P1565, DOI 10.1212/WNL.38.10.1565; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cohen J., 1997, STAT POWER ANAL BEHA, P19; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULK GD, 2001, PHYS REHABILITATION, P783; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; McCrea PH, 2002, DISABIL REHABIL, V24, P534, DOI 10.1080/09638280110115393; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; MORGAN WG, 1974, BEHAV THER, V5, P271, DOI 10.1016/S0005-7894(74)80144-9; Morris DM, 1997, NEUROREHABILITATION, V9, P29, DOI 10.3233/NRE-1997-9104; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Page S, 2003, BRAIN INJURY, V17, P675, DOI 10.1080/0269905031000107160; STEVENS J, 2001, APPL MULTIVARIATE ST, P222; Taub E, 2003, J REHABIL MED, V35, P34, DOI 10.1080/16501960310010124; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P475, DOI 10.1037/10361-022; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Taub Edward, 2003, Phys Med Rehabil Clin N Am, V14, pS77, DOI 10.1016/S1047-9651(02)00052-9; Uswatte G, 2005, ARCH PHYS MED REHAB, V86, P1498, DOI 10.1016/j.apmr.2005.01.010; Uswatte G, 2005, REHABIL PSYCHOL, V50, P34, DOI 10.1037/0090-5550.50.1.34; van der Lee JH, 2004, STROKE, V35, P1410, DOI 10.1161/01.STR.0000126900.24964.7e; van Wijck FMJ, 2001, NEUROREHAB NEURAL RE, V15, P23, DOI 10.1177/154596830101500104; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	45	53	58	0	8	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2005	42	6					769	778		10.1682/JRRD.2005.06.0094			10	Rehabilitation	Rehabilitation	047MQ	WOS:000237883800007	16680614	Bronze			2021-06-18	
J	Levenson, CW				Levenson, CW			Trace metal regulation of neuronal apoptosis: From genes to behavior	PHYSIOLOGY & BEHAVIOR			English	Article						zinc; copper; iron; Parkinson's disease; Wilson's disease; motor behavior; trauma; anorexia	SUPPRESSOR PROTEIN P53; CULTURED HUMAN NEURONS; ZINC-DEFICIENCY; PARKINSONS-DISEASE; BRAIN-INJURY; CELL-DEATH; SUBSTANTIA-NIGRA; NEURODEGENERATIVE DISORDERS; INDUCED NEUROTOXICITY; ALZHEIMERS-DISEASE	The genetically programmed form of neuronal death known as apoptosis plays a role in many neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease. Apoptosis is also responsible for neuronal death after traumatic brain and spinal cord injury, stroke, and seizures. The cognitive and behavioral consequences of all of these disorders can be devastating. Unfortunately the mechanisms that regulate neuronal apoptosis are complex. However, it is this very complexity that provides us with a wide array of potential targets for the development of anti-apoptotic strategies. Thus, our lab is currently exploring the molecular and cellular mechanisms responsible for neuronal apoptosis, with a particular focus on the role of the metals copper, zinc, and iron. Each of these metals is essential for normal central nervous system (CNS) development and function. However, imbalances, either excess or deficiency. can result in neuronal apoptosis. In this review, we show the relationship between these metals in neurodegenerative disorders and CNS injury, and the mechanisms that govern neuronal survival and apoptosis. (c) 2005 Elsevier Inc. All rights reserved.	Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA; Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA	Levenson, CW (corresponding author), 237 Biomed Res Facil, Tallahassee, FL 32306 USA.	levenson@neuro.fsu.edu		Levenson, Cathy W/0000-0003-4463-3136			Ahn YH, 1998, EXP NEUROL, V154, P47, DOI 10.1006/exnr.1998.6931; Aldskogius H, 2001, MICROSC RES TECHNIQ, V54, P40, DOI 10.1002/jemt.1119; ANDREWS RCR, 1992, MED HYPOTHESES, V38, P284; Bartzokis G, 1999, ARCH NEUROL-CHICAGO, V56, P569, DOI 10.1001/archneur.56.5.569; Beard J, 2003, J NUTR, V133, P1174; Beard JL, 2002, BEHAV BRAIN RES, V134, P517, DOI 10.1016/S0166-4328(02)00092-X; Berg D, 1999, ULTRASOUND MED BIOL, V25, P901, DOI 10.1016/S0301-5629(99)00046-0; Black MM, 2003, J NUTR, V133, p1473S, DOI 10.1093/jn/133.5.1473S; Blakemore LJ, 2004, NEUROREPORT, V15, P919, DOI 10.1097/00001756-200404090-00037; Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118; Brown KH, 2002, AM J CLIN NUTR, V75, P1062; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Chakravarty I, 2002, NUTR REV, V60, pS53, DOI 10.1301/00296640260130740; Charriaut-Marlangue C, 2004, THERAPIE, V59, P185, DOI 10.2515/therapie:2004035; CONNOR JR, 1992, J NEUROSCI RES, V31, P75, DOI 10.1002/jnr.490310111; Conti AC, 1998, J NEUROSCI, V18, P5663; Costello DJ, 2004, J NEUROL NEUROSUR PS, V75, P631, DOI 10.1136/jnnp.2003.027441; Cruz JAA, 2000, EUR J CLIN NUTR, V54, pS29, DOI 10.1038/sj.ejcn.1600981; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DEXTER DT, 1987, LANCET, V2, P1219; Evans SA, 2004, METABOLISM, V53, P727, DOI 10.1016/j.metabol.2004.01.009; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GORELL JM, 1995, NEUROLOGY, V45, P1138, DOI 10.1212/WNL.45.6.1138; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grossberg GT, 2003, J CLIN PSYCHIAT, V64, P3; He Y, 2003, FREE RADICAL BIO MED, V35, P540, DOI 10.1016/S0891-5849(03)00385-X; HENKIN RI, 1975, ARCH NEUROL-CHICAGO, V32, P745, DOI 10.1001/archneur.1975.00490530067006; Hickey MA, 2003, PROG NEURO-PSYCHOPH, V27, P255, DOI 10.1016/S0278-5846(03)00021-6; Hotz C, 2001, NUTR REV, V59, P80; HUNT DM, 1972, J NEUROCHEM, V19, P2811, DOI 10.1111/j.1471-4159.1972.tb03818.x; Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0; KLUG A, 1995, FASEB J, V9, P597; Koeppen AH, 2001, PEDIATR NEUROL, V25, P148, DOI 10.1016/S0887-8994(01)00269-7; Kreuter M, 2004, ARCH IMMUNOL THER EX, V52, P141; Levenson CW, 2004, EXP NEUROL, V190, P506, DOI 10.1016/j.expneurol.2004.08.014; Levenson CW, 2003, NUTR REV, V61, P311, DOI 10.1301/nr.2003.sept.311-313; Levenson CW, 2000, DEV BRAIN RES, V119, P105, DOI 10.1016/S0165-3806(99)00163-7; Libonati JP, 2000, NUTR NEUROSCI, V3, P425, DOI 10.1080/1028415X.2000.11747342; Lind T, 2003, AM J CLIN NUTR, V77, P883; Logroscino G, 1997, NEUROLOGY, V49, P714, DOI 10.1212/WNL.49.3.714; LOGROSCINO G, 1998, MOVEMENT DISORD, V13, pS13; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; MAES M, 1994, J AFFECT DISORDERS, V31, P135, DOI 10.1016/0165-0327(94)90117-1; Maes M, 1999, J AFFECT DISORDERS, V56, P189, DOI 10.1016/S0165-0327(99)00011-7; Mahmoodi MR, 2001, BIOL TRACE ELEM RES, V81, P93, DOI 10.1385/BTER:81:2:093; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Micheletti A, 2001, SPORTS MED, V31, P577, DOI 10.2165/00007256-200131080-00002; Montine KS, 2002, NEUROTOX RES, V4, P663, DOI 10.1080/1029842021000045435; Narayanan VS, 2001, J NUTR, V131, P1427; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Popescu BO, 2004, J ALZHEIMERS DIS, V6, P123; Prasad AS, 2001, NUTRITION, V17, P67, DOI 10.1016/S0899-9007(00)00469-X; Prasad AS, 2001, NUTRITION, V17, P685, DOI 10.1016/S0899-9007(01)00598-6; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Przedborski S, 2004, NEUROLOGIST, V10, P1, DOI 10.1097/01.nrl.0000106920.84668.37; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Shabanzadeh AP, 2004, NEUROSCI LETT, V356, P69, DOI 10.1016/j.neulet.2003.10.073; Sheline CT, 2002, ANN NEUROL, V52, P195, DOI 10.1002/ana.10276; Skinner JD, 1999, J AM DIET ASSOC, V99, P1514, DOI 10.1016/S0002-8223(99)00371-5; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tapiero H, 2003, BIOMED PHARMACOTHER, V57, P399, DOI 10.1016/S0753-3322(03)00081-7; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; TUCKER DM, 1984, NEUROBIOLOGY ZINC B, V11, P139; Vanlandingham JW, 2003, NUTR NEUROSCI, V6, P39, DOI 10.1080/1028415021000056041; VanLandingham JW, 2002, NEUROMOL MED, V1, P171; Vaquero M P, 2002, J Nutr Health Aging, V6, P147; WEIGAND E, 1978, NUTR METAB, V22, P101; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WIGGLESWORTH JM, 1988, BRAIN IRON NEUROCHEM, P25; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25	82	53	58	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	OCT 15	2005	86	3					399	406		10.1016/j.physbeh.2005.08.010			8	Psychology, Biological; Behavioral Sciences	Psychology; Behavioral Sciences	982FP	WOS:000233143700018	16125208				2021-06-18	
J	Chung, RS; Staal, JA; McCormack, GH; Dickson, TC; Cozens, MA; Chuckowree, JA; Quilty, MC; Vickers, JC				Chung, RS; Staal, JA; McCormack, GH; Dickson, TC; Cozens, MA; Chuckowree, JA; Quilty, MC; Vickers, JC			Mild axonal stretch injury in vitro induces a progressive series of neurofilament alterations ultimately leading to delayed axotomy	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; axotomy; cytoskeleton; diffuse axonal injury; neurofilament; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PHYSICAL INJURY; RAT; CYTOSKELETAL; DAMAGE	We report a new model of transient axonal stretch injury involving pressurized fluid deflection of bundles of axons, resulting in a transient 1-6% increase in original axon length to investigate the slow progression of axonal alterations that are characteristic of diffuse axonal injury (DAI). We found no discernable difference in axon bundle morphology or cytoskeletal neurofilament protein arrangement between unstretched and stretched axonal bundles at 24 h post-injury. However, by 48 h post-injury, there was a stereotypical response of stretched axons involving characteristic neurorilament alterations that bear similarities to in vivo neuronal responses associated with DAI that have been reported previously. For instance, neurofilament protein immunoreactivity (SMI-312) was increased in axons contained within 51% of all injured axon bundles at 48 h compared to surrounding unstretched axon bundles, suggestive of neurofilament compaction. Furthermore, axonal bundle derangement occurred in 25% of injured axon bundles, with individual fibres segregating from each other and becoming undulating and wavy. By 72 h post-stretch, 70% of injured axon bundles underwent secondary axotomy, becoming completely severed at the site of initial stretch injury. While these results suggest a temporal series of stereotypical responses of axons to injury, we were able to distinguish very clear differences between mildly (100-103% increase in original axonal length) injured and strongly injured (106%+) axons. For instance, mildly injured axons developed increased neurofilament immunoreactivtity (SMI-312) within 48 h, and the-marked development of ring-like neurofilament immunoreactive structures within axonal bundles, which were rarely axotomized. Conversely, at more severe strain levels increased neurofilament immunoreactivity was less apparent, while axons often became distorted and disorganised within axonal bundles and eventually became completely disconnected. Almost no ring-like neurorilament structures were observed in these severely injured axonal bundles. This suggests that axons do not respond in a stereotypical manner to a transient stretch insult, and indeed that variable degrees of stretch injury activate different responses within axons, with dramatically different outcomes. Hence, it is possible that the cytoskeletal characteristics that we have used in this study may be useful parameters for discriminating between mildly and severely injured axons following TBI.	Univ Tasmania, Sch Med, NeuroRepair Grp, Hobart, Tas 7001, Australia	Chung, RS (corresponding author), Univ Tasmania, Sch Med, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Vickers, James C/J-7464-2014; Chung, Roger/ABF-8395-2020	Vickers, James C/0000-0001-5671-4879; Chung, Roger/0000-0002-9286-947X; Dickson, Tracey/0000-0002-9196-1661; Chuckowree, Jyoti/0000-0002-1245-1402			Adlard PA, 2000, ACTA NEUROPATHOL, V100, P183, DOI 10.1007/s004019900160; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2003, J NEUROSCI, V23, P3336; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; King CE, 1997, NEUROREPORT, V8, P1663; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611	23	53	57	1	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1081	1091		10.1089/neu.2005.22.1081			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600005	16238485				2021-06-18	
J	Jones, NC; Prior, MJW; Burden-Teh, E; Marsden, CA; Morris, PG; Murphy, S				Jones, NC; Prior, MJW; Burden-Teh, E; Marsden, CA; Morris, PG; Murphy, S			Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						behaviour; interleukin-1 receptor antagonist; magnetic resonance imaging; nitric oxide synthase-2; trauma	CONVERTING-ENZYME; NEURONAL INJURY; FLUORO-JADE; HEAD-INJURY; EXPRESSION; MICE; SYNTHASE; RAT; OVEREXPRESSION; LOCALIZATION	Interleukin (IL)-1 beta plays an important role in the inflammatory response that results from traumatic brain injury and antagonism of the actions of this cytokine can affect outcome. We subjected male mice to aseptic cryogenic injury and assessed recovery through anatomical, histological and functional measures following treatment with recombinant mouse IL-1 receptor antagonist (IL-1ra). A single dose (1 mu g, i.c.v.) at the time of injury reduced lesion volume 3 days later, as assessed by Nissl staining, and also the number (30%) of FluoroJade-positive degenerating neurones. Mice treated with IL-1ra performed better on the beam balance and in the grid test as compared with vehicle-treated animals. Furthermore, IL-1ra-treated animals showed fewer (40%) nitric oxide synthase-2-positive cells in and around the lesion. These data suggest that activation of the IL-1 receptor following trauma contributes to the pathology and that antagonism can reduce both anatomical and functional consequences of neuroinflammation.	Univ Nottingham, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Inst Neurosci, Nottingham NG7 2UH, England; Univ Nottingham, Sir Peter Mansfield MR Ctr, Nottingham NG7 2UH, England	Murphy, S (corresponding author), Univ Nottingham, Inst Cell Signalling, Clifton Blvd, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk	Jones, Nigel C/K-7773-2012	Jones, Nigel/0000-0002-1080-8439; Burden-Teh, Esther/0000-0002-0033-2836	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Colombo JA, 2002, J HISTOCHEM CYTOCHEM, V50, P1135, DOI 10.1177/002215540205000815; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; HONG XY, 1993, PAINT COATINGS IND, V1, P1; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Lopez-Figueroa MO, 2000, BRAIN RES, V852, P239, DOI 10.1016/S0006-8993(99)02241-6; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Oprica M, 2004, ACTA NEUROPATHOL, V108, P69, DOI 10.1007/s00401-004-0868-5; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002	27	53	53	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2005	22	1					72	78		10.1111/j.1460-9568.2005.04221.x			7	Neurosciences	Neurosciences & Neurology	946MW	WOS:000230577400008	16029197				2021-06-18	
J	Ryser, DK; Egger, MJ; Horn, SD; Handrahan, D; Gandhi, P; Bigler, EA				Ryser, DK; Egger, MJ; Horn, SD; Handrahan, D; Gandhi, P; Bigler, EA			Measuring medical complexity during inpatient rehabilitation after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; diaonosis-related groups; rehabilitation; severity of illness index	MIX CLASSIFICATION-SYSTEM; UNIFORM DATA SYSTEM; LENGTH-OF-STAY; SEVERITY; ADMISSIONS; DISABILITY; RECOVERY; CHARGES	Objective: To compare the performance of 3 severity of illness (SOI) indices-the Comprehensive Severity Index (CSI), All Patient Refined Diagnosis Related Groups Severity of Illness, case-mix group (CMG)-and 5 well-known neurologic parameters, as measures of medical complexity. Design: Retrospective chart review. Setting: Inpatient rehabilitation center within a level I trauma center. Participants: Consecutive traumatic brain injury (TBI) admissions (N=212). Intervention: Acute inpatient TBI rehabilitation. CSI and neurologic parameters were scored by chart extraction. SOI was based on diagnosis codes by using 3M PC Grouper software, version 15. Main Outcome Measures: Adjusted R-2 was used to predict rehabilitation charges as a proxy of medical complexity. Results: The highest adjusted R-2 values for single variables predicting charges were: CMG .349, CSI .293, duration of post-traumatic amnesia .260. Adjusted R-2 values for the CMG combined with the CSI, 5 neurologic parameters, and SOI to predict charges were .446, .431, and .365, respectively. Conclusions: The CMG was the best single predictor of rehabilitation charges for TBI. Predictive ability was better when the CMG was combined with the CSI or a combination of the 5 neurologic parameters. A severity index based on objective clinical findings rather than diagnostic codes may have distinct advantages for rehabilitation outcome studies and reimbursement methodology.	Latter Day St Hosp, Neuro Specialty Rehabil Unit, Div PM&R, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Stat Data Ctr, Salt Lake City, UT 84143 USA; Univ Utah, Publ Hlth Programs, Salt Lake City, UT USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Int Sever Informat Syst, Salt Lake City, UT USA	Ryser, DK (corresponding author), Latter Day St Hosp, Neuro Specialty Rehabil Unit, Div PM&R, 8th Ave & C St, Salt Lake City, UT 84143 USA.	lddryser@ihc.com		Egger, Marlene/0000-0001-8886-7837			ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Centers for Medicare & Medicaid Services, 2001, FED REGISTER, V66, P41316; Clayton PD, 2003, METHOD INFORM MED, V42, P1; *CTR MED MED SERV, 2001, FED REGISTER, V66, P41345; *CTR MED MED SERV, 2001, FED REGISTER, V66, P41353; DeJong G, 2004, ARCH PHYS MED REHAB, V85, P678, DOI 10.1016/j.apmr.2003.06.033; Fiedler RC, 1996, AM J PHYS MED REHAB, V75, P125, DOI 10.1097/00002060-199603000-00010; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; IEZZONI L, 1979, ANN INTERN MED, V127, P666; Iezzoni LI, 2002, MILBANK Q, V80, P347, DOI 10.1111/1468-0009.t01-1-00007; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; IEZZONI LI, 1997, RISK ADJUSTMENT MEAS; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; NETER J, 1996, APPL LINEAR STAT MOD, P339; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RYSER DK, 1995, ARCH PHYS MED REHAB, V76, P1042; Stinchcombe AL, 2000, J POLIT PHILOS, V8, P1, DOI 10.1111/1467-9760.00090; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; Stineman MG, 1998, ARCH PHYS MED REHAB, V79, P241, DOI 10.1016/S0003-9993(98)90001-6; Stineman MG, 1997, HEALTH SERV RES, V32, P529; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; STINEMAN MG, 1994, ARCH PHYS MED REHAB, V75, P1277; Stineman MG, 2002, ARCH PHYS MED REHAB, V83, P1802, DOI 10.1053/apmr.2002.36067; STINEMAN MG, 1990, ARCH PHYS MED REHAB, V71, P881; Stineman MG, 1997, HEALTH CARE FINANC R, V19, P87; Stineman MG, 2001, ARCH PHYS MED REHAB, V82, P553, DOI 10.1053/apmr.2001.24088; STINEMAN MG, 1995, ARCH PHYS MED REHAB, V76, P1163, DOI 10.1016/S0003-9993(95)80127-8; Stineman MG, 1997, MED CARE, V35, pJS90, DOI 10.1097/00005650-199706001-00018; Stineman MG, 1997, MED CARE, V35, pJS106; Tooth L, 2001, BRAIN INJURY, V15, P613, DOI 10.1080/02699050010013923; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; Zafonte RD, 1997, BRAIN INJURY, V11, P403	37	53	53	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2005	86	6					1108	1117		10.1016/j.apmr.2004.11.041			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	934EK	WOS:000229689500007	15954048				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			A prospective study of the recovery of attention from acute to 2 years following pediatric traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						head injury; children; attention recovery	CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; CHILDREN; CHILDHOOD; PERFORMANCE; SEQUELAE; DEFICITS; COHORT; SKILLS; SEVERITY	Limited research has investigated specific attentional sequelae following pediatric traumatic brain injury (TBI), such as sustained, selective, and shifting attention, as well as speed of processing. Little is known about the pattern of recovery of these skills or their interaction with ongoing development. The present study examined attentional abilities at acute, 6-, 12-, and 24-month time points postinjury in a group of 71 children who had sustained a mild, moderate, or severe TBI Results indicated that children who sustained a severe TBI generally performed poorest, but showed most recovery over time. The pattern of recovery was dependent on the attentional component being measured. Specifically, deficits were most evident on more complex and timed tasks. While a number of areas showed recovery over time, for some attentional components, difficulties persisted to 24 months postinjury.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au					Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; BETTS J, IN PRESS DEV PSYCHOL; BROUWER WH, 1988, ROAD USER BEHAV THEO, P296; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAIL R, 1986, CHILD DEV, V57, P969, DOI 10.2307/1130372; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kolb B., 1999, COGNITIVE NEUROREHAB, P9; Laurence S., 1978, RECOVERY BRAIN DAMAG, P369; LENNENBERG EH, 1967, BIOL FDN LANGUAGE; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Manly T., 1999, TEST EVERYDAY ATTENT; Maule AJ, 2000, ACTA PSYCHOL, V104, P283, DOI 10.1016/S0001-6918(00)00033-0; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner M, 1990, ANNU REV NEUROSCI, V15, P25; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; ROTHI L, 1983, J CLIN NEUROPSYCHOLO, V3, P73; ROWE JK, 1995, ROWE BEHAV RATING IN; Sparrow S., 1984, VINELAND ADAPTIVE BE; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tabachnick B.G., 1989, USING MULTIVARIATE S; Talland G.A., 1965, DERANGED MEMORY; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1991, MANUAL WECHSLER INTE; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603	53	53	53	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2005	11	1					84	98		10.1017/S1355617705050101			15	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	906CA	WOS:000227616900009	15686611				2021-06-18	
J	Ha, Y; Kim, YS; Cho, JM; Yoon, SH; Park, SR; Yoon, DH; Kim, EY; Park, HC				Ha, Y; Kim, YS; Cho, JM; Yoon, SH; Park, SR; Yoon, DH; Kim, EY; Park, HC			Role of granulocyte-macrophage colony-stimulating factor in preventing apoptosis and improving functional outcome in experimental spinal cord contusion injury	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; granulocyte-macrophage colony-stimulating factor; apoptosis; rat	TRAUMATIC BRAIN INJURY; MARROW STROMAL CELLS; BONE-MARROW; STEM-CELLS; IN-VIVO; GM-CSF; NEURONS; RAT; INTERLEUKIN-3; CYTOKINES	Object. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent hemopoietic cytokine that stimulates stem cell proliferation in the bone marrow and inhibits apoptotic cell death in leukocytes. Its effects in the central nervous system, however, are still unclear. The present study was undertaken to determine if GM-CSF can rescue neuronal cells from apoptosis and improve neurological function in a spinal cord injury (SCI) model. Methods. To study the effect of GM-CSF on apoptotic neuronal death, the authors used a staurosporine-induced neuronal death model in an N2A cell line (in vitro) and in a rat SCI model (in vivo). The N2A cells were preincubated with GM-CSF for 60 minutes before being exposed to staurosporine for 24 hours. To inhibit GM-CSF, N2A cells were pretreated with antibodies against the GM-CSF receptor for 60 minutes. Clip compression was used to induce SCI. Animals were treated with daily doses of GM-CSF (20 mug/day) for 5 days. The number of apoptotic cells in the spinal cord and neurological improvements were assessed. Pretreatment with GM-CSF was found to protect N2A cells significantly from apoptosis, and neutralizing antibodies for the GM-CSF receptors inhibited the rescuing effect of GM-CSF on apoptosis. In the rat SCI model, neurological function improved significantly in the GM-CSF-treated group compared with controls treated with phosphatebuffered saline. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining showed that GM-CSF administration reduced apoptosis in the injured spinal cord. Conclusions. Treatment of SCI with GM-CSF showed beneficial effects. Neuronal protection against apoptosis is viewed as a likely mechanism underlying the therapeutic effect of GM-CSF in SCI.	Inha Univ, Coll Med, Dept Neurosurg, Inchon, South Korea; Inha Univ, Coll Med, Dept Physiol, Inchon, South Korea; Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea	Ha, Y (corresponding author), Inha Univ, Coll Med, Dept Neurosurg, 7-206 Shiheung Dong 3Ga, Inchon, South Korea.	hayoon@inha.ac.kr					Armitage JO, 1998, BLOOD, V92, P4491, DOI 10.1182/blood.V92.12.4491; Be'eri M, 1998, EUR J NEUROSCI, V10, P2707; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; Corti S, 2002, EXP NEUROL, V177, P443, DOI 10.1006/exnr.2002.8004; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; Kannan Y, 2000, NEUROIMMUNOMODULAT, V8, P132, DOI 10.1159/000054273; Kessinger A, 1998, Stem Cells, V16 Suppl 1, P139; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mehler MF, 1997, TRENDS NEUROSCI, V20, P357, DOI 10.1016/S0166-2236(96)01045-4; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Schuster N, 2002, GLIA, V40, P95, DOI 10.1002/glia.10110; TABIRA T, 1995, INT J DEV NEUROSCI, V13, P241, DOI 10.1016/0736-5748(94)00020-4; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Vescovi AL, 2002, NAT MED, V8, P535, DOI 10.1038/nm0602-535a; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098	25	53	57	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JAN	2005	2	1					55	61		10.3171/spi.2005.2.1.0055			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	895OZ	WOS:000226874100011	15658127				2021-06-18	
J	Lu, DY; Mahmood, A; Goussev, A; Qu, CS; Zhang, ZG; Chopp, M				Lu, DY; Mahmood, A; Goussev, A; Qu, CS; Zhang, ZG; Chopp, M			Delayed thrombosis after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						atorvastatin; delayed thrombosis; rat; traumatic brain injury	COA REDUCTASE INHIBITORS; CENTRAL-NERVOUS-SYSTEM; VON-WILLEBRAND-FACTOR; ACUTE HEAD-INJURY; TISSUE FACTOR; INTRAVASCULAR COAGULATION; PLATELET ACTIVATION; CEREBRAL-ISCHEMIA; ATORVASTATIN; EXPRESSION	Secondary thrombosis may contribute to cerebral ischemia caused by traumatic brain injury (TBI). In this study, we sought to investigate the temporal and spatial profiles of intravascular thrombosis and to evaluate the effect of atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitor, on thrombosis after TBI. Young male Wistar rats weighing 350-400 g were subjected to controlled cortical impact injury, and were sacrificed at 1 and 4 h, and 1, 3, 8, and 15 days after TBI (5 rats/time point), respectively. For the evaluation of the effects of atorvastatin on intravascular thrombosis, rats were subjected to TBI, and subsequently atorvastatin (1 mg/kg) was orally administered starting 1 day after TBI and then daily until sacrifice at 3, 8, and 15 days after TBI (5 rats/time point). Before sacrifice of animals, blood was withdrawn and employed for the measurement of von Willibrand factor and platelet activity using enzyme-linked immunoabsorbant assay (ELISA). Brain tissues were prepared for histological analysis. The data show that (1) delayed thrombosis is present in the lesion boundary zone and in the hippocampal CA3 region, starting at 1-4 h, peaking at 1-3 days, and then declining at 8 and 15 days after TBI; (2) intravascular thrombosis also occurs in the other areas of cortex, striatum, and corpus callosum, but with a scattered distribution; (3) delayed thrombi are composed of platelets, fibrin, and vWF; and (4) reduction of the plasma vWF level and platelet activity by atorvastatin decreases delayed thrombosis after TBI. These data suggest that atorvastatin reduces intravascular thrombosis attributed to hemostatic disturbances caused by TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Brand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Atalar E, 2002, INT J CARDIOL, V84, P227, DOI 10.1016/S0167-5273(02)00148-1; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Barron E., 1992, Society for Neuroscience Abstracts, V18, P1492; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; Bourcier T, 2000, ARTERIOSCL THROM VAS, V20, P556, DOI 10.1161/01.ATV.20.2.556; Bruni F, 2003, CLIN EXP MED, V3, P45, DOI 10.1007/s102380300015; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cortellaro M, 2002, THROMB HAEMOSTASIS, V88, P41; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; de Groot PG, 2002, SEMIN THROMB HEMOST, V28, P133, DOI 10.1055/s-2002-27815; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dujovne CA, 2000, AM J CARDIOL, V85, P350, DOI 10.1016/S0002-9149(99)00745-6; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; FURIE B, 1992, NEW ENGL J MED, V326, P800; GADDAM V, J CARDIOVASC PHARM T, V7, P247; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GonzalezDunia D, 1996, J VIROL, V70, P5812, DOI 10.1128/JVI.70.9.5812-5820.1996; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOOTS WK, 1996, NEUROTRAUMA, P673; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Krysiak R, 2003, DRUGS, V63, P1821, DOI 10.2165/00003495-200363170-00005; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laufs U, 2003, ARTERIOSCL THROM VAS, V23, P156, DOI 10.1161/01.ATV.0000051360.79309.4E; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Meisel SR, 2003, CLIN LAB HAEMATOL, V25, P321, DOI 10.1046/j.1365-2257.2003.00544.x; Morikawa Shigeru, 2002, J Atheroscler Thromb, V9, P178; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; Ninomia T, 2000, J CEREBR BLOOD F MET, V20, P998, DOI 10.1097/00004647-200006000-00012; Nordoy A, 2003, J THROMB HAEMOST, V1, P690, DOI 10.1046/j.1538-7836.2003.00140.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; Pokrovskaya EV, 2003, KARDIOLOGIYA, V43, P4; Puccetti L, 2002, EUR J CLIN INVEST, V32, P901, DOI 10.1046/j.1365-2362.2002.01086.x; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Seljeflot I, 2002, ATHEROSCLEROSIS, V162, P179, DOI 10.1016/S0021-9150(01)00696-7; Seljeflot I, 2002, THROMB RES, V105, P285, DOI 10.1016/S0049-3848(02)00034-8; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Shi JM, 2003, BLOOD COAGUL FIBRIN, V14, P575, DOI 10.1097/00001721-200309000-00010; Sinzinger H, 1999, ATHEROSCLEROSIS, V145, P415; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STOLTENBURGDIDI.G, 2000, BRAIN PATHOL, V10, pC13; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Vanhoorelbeke K., 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P125, DOI 10.2174/1568006033481500; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; White CM, 1999, J CLIN PHARMACOL, V39, P111, DOI 10.1177/00912709922007642; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Yamamoto J, 1997, JPN J PHYSIOL, V47, P431, DOI 10.2170/jjphysiol.47.431; ZLOKOVIC BV, 1997, NEUROSURG FOCUS 0602; 1989, LANCET, V2, P957	67	53	56	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1756	1766		10.1089/0897715042664885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400007	15684767				2021-06-18	
J	Bloom, GA; Horton, AS; McCrory, P; Johnston, KM				Bloom, GA; Horton, AS; McCrory, P; Johnston, KM			Sport psychology and concussion: new impacts to explore	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SUPPORT GROUPS; SOCIAL SUPPORT; INJURY; STRESS; PROGRAM		McGill Univ, McGill Sport Med Ctr, Dept Neurosurg Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada; Univ Melbourne, Melbourne, Vic, Australia	Johnston, KM (corresponding author), McGill Univ, McGill Sport Med Ctr, Dept Neurosurg Kinesiol & Phys Educ, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	Karen.Johnston@mcgill.ca	McCrory, Paul/Q-8688-2019				ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; BONNO C, 1987, PREGNANCY LOSS MED T, P225; BREWER BW, 1995, CLIN J SPORT MED, V5, P241, DOI 10.1097/00042752-199510000-00006; Brewer BW., 1991, J APPL SPORT PSYCHOL, V3, P183, DOI [10.1080/10413209108406443, DOI 10.1080/10413209108406443]; Broatch JW, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199612005-00008; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; DEANS G, 1988, BRIT J CANCER, V58, P670, DOI 10.1038/bjc.1988.284; DIPASQUALE JA, 1990, CANCER NURS, V13, P278; Gilbourne D, 1998, J APPL SPORT PSYCHOL, V10, P124, DOI 10.1080/10413209808406381; Gould D, 1997, SPORT PSYCHOL, V11, P361, DOI 10.1123/tsp.11.4.361; Granito Vincent J. Jr., 1995, Journal of Athletic Training, V30, P328; Green SL, 2001, J APPL SPORT PSYCHOL, V13, P40, DOI 10.1080/10413200109339003; Horton A., 2002, MED SCI SPORTS EXERC, V34, P99; Ievleva L., 1991, SPORT PSYCHOL, V5, P25, DOI DOI 10.1123/TSP.5.1.25; KATES N, 1995, CAN J PSYCHIAT, V40, P367, DOI 10.1177/070674379504000702; Lynch GP, 1988, SPORT PSYCHOL, V2, P161; PETIPAS AJ, 1995, SPORT PSYCHOL INTERV, P225; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; Ribble D, 1989, Holist Nurs Pract, V3, P52; Smith AM, 1996, SPORTS MED, V22, P391, DOI 10.2165/00007256-199622060-00006; Taylor J., 1997, PSYCHOL APPROACHES S; Udry E, 1996, J SPORT REHABIL, V5, P151, DOI 10.1123/jsr.5.2.151; Udry E, 1997, J SPORT EXERCISE PSY, V19, P368, DOI 10.1123/jsep.19.4.368; WEISS MR, 1986, ATHLETIC TRAINING, V21, P104; Wiese D. M., 1987, SPORT PSYCHOL, V1, P318, DOI DOI 10.1123/TSP.1.4.318	25	53	53	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT 1	2004	38	5					519	521		10.1136/bjsm.2004.011999			3	Sport Sciences	Sport Sciences	856PE	WOS:000224056300003	15388529	Green Published, Bronze			2021-06-18	
J	Powell, MR; Gfeller, JD; Hendricks, BL; Sharland, M				Powell, MR; Gfeller, JD; Hendricks, BL; Sharland, M			Detecting symptom- and test-coached simulators with the Test of Memory Malingering	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	22nd Annual Meeting of the National-Academy-of-Neuropsychology	OCT   10, 2002	MIAMI, FL	Natl Acad Neuropsychol		symptom validity; effortful; malingering; coaching; assessment; forensics	FEIGNED COGNITIVE IMPAIRMENT; HEAD-INJURY; INCENTIVES; TOMM	The ability of the Test of Memory Malingering (TOMM; Tombaugh, 1996) to detect feigned-memory impairment was explored. The TOMM was administered to three groups: (a) a control group instructed to perform optimally, (b) a symptom-coached group instructed to feign memory problems after being educated about traumatic brain injury symptomatology, and (c) a test-coached group instructed to feign memory problems after being educated about test-taking strategies to avoid detection. The recommended cutoff scores (Tombaugh, 1996) on Trial 2 and the Retention Trial produced overall classification accuracy rates of 96%, with high levels of sensitivity and specificity. Although the symptom-coached group performed more poorly on the TOMM relative to the test-coached group, the test was equally sensitive in detecting suboptimal effort across the different coaching paradigms. (C) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol W 11 B, Rochester, MN 55905 USA; St Louis Univ, St Louis, MO 63103 USA; Univ Wisconsin Marathon Cty, Wausau, WI USA	Powell, MR (corresponding author), Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol W 11 B, 200 1st St SW, Rochester, MN 55905 USA.	powell.matthew@mayo.edu					BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Faust D, 1998, CRIT ISS NE, P1; FELDSTEIN S, 2000, AM J FORESNIC PSYCHO, V18, P57; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gfeller JD, 2001, ARCH CLIN NEUROPSYCH, V16, P848; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reitan RM., 1992, HALSTEAD REITAN NEUR, V2; Rey A, 1964, EXAMEN CLIN PSYCHOL; REYNOLD CR, 1998, DETECTION MALINGERIN; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Smith G. E., 2003, CLIN INTERPRETATION; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams JM, 1998, CRIT ISS NE, P105; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	30	53	54	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					693	702		10.1016/j.acn.2004.04.001			10	Psychology, Clinical; Psychology	Psychology	845PT	WOS:000223257500007	15271412				2021-06-18	
J	Katz, DI; White, DK; Alexander, MP; Klein, RB				Katz, DI; White, DK; Alexander, MP; Klein, RB			Recovery of ambulation after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the American-Physical-Therapy-Association	FEB 13-15, 2003	Tampa, FL	Amer Phys Therapy Assoc		brain injuries; gait disorders; neurologic; recovery of function; rehabilitation	STROKE PATIENTS; COPENHAGEN STROKE; WALKING FUNCTION; HEAD-INJURY; REHABILITATION; GAIT; POSTSTROKE; OUTCOMES; PARESIS; ARM	Objectives: To identify variables that are predictive of independent ambulation after traumatic brain injury (TBI) and to define the time course of recovery. Design: Retrospective review of consecutive admissions of patients with severe TBI over a 32-month period. Setting: Brain injury unit in all acute, inpatient rehabilitation hospital. Participants: Of 264 patients screened, 116 met criteria that included the ability to participate in motor and functional evaluation on admission to acute rehabilitation, and the absence of other neurologic disorders or fractures that affect one's ability to ambulate. Intervention: Inpatient rehabilitation on a specialized TBI unit by an interdisciplinary team. Main Outcome Measures: Recovery of independent ambulation and time to recover independent ambulation. Results: Of eligible patients, 73.3% achieved independent ambulation by latest follow-up (up to 5.1 mo). Patients who achieved independent ambulation were significantly younger (P<.05), had better gait scores on admission (P<.05), and tended to be less severely injured-based on duration of post-traumatic amnesia (PTA: P=.058)-than those who did not ambulate independently. There were no differences in recovery based on neuropathologic profile. Mean time to independent ambulation standard deviation was 5.7+/-4.3 weeks; of those achieving independent ambulation, 82.4% did so by 2 months and 94.1 % by 3 months. If not independent by 3 months postinjury, patients had a 13.9% chance of recovery. Multivariate regression analysis generated prediction models for time to independent ambulation, using admission FIM instrument scores and age (38% of variance); initial gait score, loss of consciousness; and age (40% of variance); or initial gait score and PTA (58% of variance), when restricted to just those patients With diffuse axonal injury. Conclusions: Most patients with severe TBI achieved independent ambulation; the vast majority did so within 3 months postinjury. Functional measures, injury severity measures, and age call help guide prognosis and expectations for time to recover.	Health S Braintree Rehabil Hosp, Braintree, MA 02184 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA USA; Youville Lifecare Rehabil Hosp, Cambridge, MA USA; Boston Univ, Memory Disorders Res Ctr, Boston, MA USA; Boston Univ, Harold Goodglass Aphasia Res Ctr, Boston, MA USA	Katz, DI (corresponding author), Health S Braintree Rehabil Hosp, 250 Pond St, Braintree, MA 02184 USA.	dkatz@bu.edu	White, Daniel Kenta/AAE-8449-2021	Katz, Douglas/0000-0002-7502-8505			Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Friedman P J, 1990, Int Disabil Stud, V12, P119; HAGGARD P, 1995, J NEUROL NEUROSUR PS, V58, P433, DOI 10.1136/jnnp.58.4.433; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; KATZ D, 1999, REHABILITATION ADULT, P89; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; Patel AT, 2000, ARCH PHYS MED REHAB, V81, P1357, DOI 10.1053/apmr.2000.9397; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Richards C, 1996, GAIT POSTURE, V4, P12, DOI 10.1016/0966-6362(96)01063-6; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade D T, 1988, Int Disabil Stud, V10, P64; Wandel A, 2000, ARCH PHYS MED REHAB, V81, P736, DOI 10.1016/S0003-9993(00)90102-3	28	53	54	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2004	85	6					865	869		10.1016/j.apmr.2003.11.020			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	826NK	WOS:000221835600001	15179637				2021-06-18	
J	Sherman, JE; DeVinney, DJ; Sperling, KB				Sherman, JE; DeVinney, DJ; Sperling, KB			Social support and adjustment after spinal cord injury: Influence of past peer-mentoring experiences and current live-in partner	REHABILITATION PSYCHOLOGY			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN INJURY; HEALTH-STATUS; SATISFACTION; COMMUNITY; MORTALITY; OUTCOMES; HANDICAP; IMPACT; PEOPLE	Objective: To compare the impact of 2 types of social support, past peer-mentoring experience (PME) and current live-in partner (LIP), on adjustment after spinal cord injury (SCI). Participants: Sixty-two individuals with SCI (mean age = 42 years; 11.7 years since injury). Design: Cross-sectional survey. PME (yes vs. no) and LIP (yes vs. no) were nearly equally balanced, affording 2 X 2 factorial analyses. Outcome Measures: Craig Handicap Assessment and Reporting Technique, Brief Symptom Inventory, and Satisfaction With Life Scale. Results: PME, which typically concluded over 10 years ago, was associated with higher occupational activity and life satisfaction, whereas having an LIP was associated with greater mobility and economic self-sufficiency. Conclusion: PME positively complements more traditionally studied sources of social support, which is encouraging for the use of PME as a clinical intervention.	Univ Wisconsin Hosp & Clin, Dept Orthoped Surg & Rehabil Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Rehabil Psychol, Madison, WI USA	Sherman, JE (corresponding author), Univ Wisconsin Hosp & Clin, Dept Orthoped Surg & Rehabil Med, 600 N Highland Ave, Madison, WI 53792 USA.	je.sherman@hosp.wisc.edu					ANSON CA, 1993, PARAPLEGIA, V31, P632, DOI 10.1038/sc.1993.102; BERKMAN LF, 1986, AM J EPIDEMIOL, V123, P559, DOI 10.1093/oxfordjournals.aje.a114276; BORKMAN T, 1976, SOC SERV REV, V50, P445, DOI 10.1086/643401; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; Cohen J., 1975, APPL MULTIPLE REGRES; COYNE JC, 1986, J CONSULT CLIN PSYCH, V54, P454, DOI 10.1037/0022-006X.54.4.454; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; Derogatis L, 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers Marcel P., 1995, P185; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dowler R, 2001, J Spinal Cord Med, V24, P87; ELLIOTT TR, 1992, REHABIL PSYCHOL, V37, P241; Frankel H L, 1969, Paraplegia, V7, P179; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HERNANDEZ B, 2001, SCI PSYCHOSOCIAL PRO, V14, P142; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Holicky R, 1999, DISABIL REHABIL, V21, P250; KRAUSE JS, 1991, ARCH PHYS MED REHAB, V72, P91; KRAUSE JS, 1987, REHABIL PSYCHOL, V32, P205; KRAUSE JS, 1992, ARCH PHYS MED REHAB, V73, P558; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P815, DOI 10.1016/S0003-9993(97)90193-3; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Lutz CJ, 2001, J PERS SOC PSYCHOL, V81, P1070, DOI 10.1037/0022-3514.81.6.1070; MCCOLL MA, 1995, SOC SCI MED, V41, P395, DOI 10.1016/0277-9536(94)00338-T; Menter Robert R., 1995, P272; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Post MWM, 1999, PSYCHOL HEALTH, V14, P679, DOI 10.1080/08870449908410757; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P555, DOI 10.1053/apmr.2002.31173; Putzke JD, 2001, ARCH PHYS MED REHAB, V82, P949, DOI 10.1053/apmr.2001.23973; Putzke JD, 2001, J CLIN PSYCHOL MED S, V8, P101, DOI 10.1023/A:1009555910604; Ragins BR, 1999, J APPL PSYCHOL, V84, P529, DOI 10.1037/0021-9010.84.4.529; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; RINTALA DH, 1992, REHABIL PSYCHOL, V37, P155, DOI 10.1037/0090-5550.37.3.155; Scherer MJ, 2001, DISABIL REHABIL, V23, P387; SHERMAN JE, 2001, M AM ASS SPIN CORD I; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TATE DG, 1994, PARAPLEGIA, V32, P473, DOI 10.1038/sc.1994.75; THOITS PA, 1986, J CONSULT CLIN PSYCH, V54, P416, DOI 10.1037/0022-006X.54.4.416; Thoits PA, 2000, HEALTH PSYCHOL, V19, P264, DOI 10.1037//0278-6133.19.3.264; THOITS PA, 1995, J HLTH SOCIAL BEHA S, V36, P53; Vines CL, 2000, SCI PSYCHOSOCIAL PRO, V13, P185; Weinfurt KP., 1995, READING UNDERSTANDIN, P245; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; Whittemore R, 2000, QUAL HEALTH RES, V10, P260, DOI 10.1177/104973200129118408; Winer B.J., 1962, STAT PRINCIPLES EXPT; World Health Organization, 1980, INT CLASS IMP DIS HA; Young J M, 1999, Healthc Manage Forum, V12, P51	53	53	54	1	9	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					140	149		10.1037/0090-5550.49.2.140			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	819BS	WOS:000221288800008					2021-06-18	
J	da Costa, RMEM; de Carvalho, LAV				da Costa, RMEM; de Carvalho, LAV			The acceptance of virtual reality devices for cognitive rehabilitation: a report of positive results with schizophrenia	COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE			English	Article						virtual reality; virtual environment; cognitive rehabilitation; schizophrenia		This study presents a process of virtual environment development supported by a cognitive model that is specific to cognitive deficits of diverse disorders or traumatic brain injury, and evaluates the acceptance of computer devices by a group of schizophrenic patients. The subjects that participated in this experiment accepted to work with computers and immersive glasses and demonstrated a high level of interest in the proposed tasks. No problems of illness have been observed. This experiment indicated that further research projects must be carried out to verify the value of virtual reality technology for cognitive rehabilitation of psychiatric patients. The results of the current study represent a small but necessary step in the realization of that potential. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	UERJ, IME, Dept Informat & Ciencia Compt, BR-20550013 Rio De Janeiro, RJ, Brazil; UFRJ, COPPE, Programa Eng Sistemas & Comp, BR-21945270 Rio De Janeiro, RJ, Brazil	da Costa, RMEM (corresponding author), UERJ, IME, Dept Informat & Ciencia Compt, Rua Sao Francisco Xavier 524 6 Andar,Bl B, BR-20550013 Rio De Janeiro, RJ, Brazil.	rcosta@ime.uerj.br; alfredo@cos.ufrj.br	Costa, Rosa Maria/H-4053-2018	Costa, Rosa Maria/0000-0001-6165-1649			BURDA PC, 1994, COMPUT HUM BEHAV, V10, P359, DOI 10.1016/0747-5632(94)90061-2; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Dautenhahn K., 2000, P 3 INT C DIS VIRT R, P153; DIAMONT JJ, 1989, COGNITIVE REHABILITA; FURLAN JD, 1998, MODELAGEM OBJETOS AT; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Jeste D. V., 1996, NEUROPSYCHIATRY, P325; KIRNER T, 1998, P 2 IEEE INT S APPL; LEWIS CH, 1997, VIRTUAL REALITY NEUR; NINISS H, 2000, P 3 INT C DIS VIRT R, P9; North M., 1998, CLIN PSYCHOL NEUROSC; Pantelidis VS., 1995, VR SCH, V1, P9; Parente R., 1996, RETRAINING COGNITION; PRESSMAN RS, 1997, SOFTWARE ENG; Riva G., 1998, VIRTUAL ENV CLIN PSY; RIZZO A, 2001, APPL VIRTUAL ENV MEN; ROSE FD, 1996, BRIT J THERAPY REHAB, V3; ROUSSOS M, 1997, THESIS U ILLINOIS CH; SCHWARTZKROIN P, 1989, TXB PHYSL, V1, P718; Silverstein SM, 1998, PSYCHIAT QUART, V69, P169, DOI 10.1023/A:1022197109569; Stuart R., 1996, DESIGN VIRTUAL ENV; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876	22	53	55	1	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0169-2607	1872-7565		COMPUT METH PROG BIO	Comput. Meth. Programs Biomed.	MAR	2004	73	3					173	182		10.1016/S0169-2607(03)00066-X			10	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Medical Informatics	Computer Science; Engineering; Medical Informatics	801XX	WOS:000220129700001	14980398				2021-06-18	
J	Slewa-Younan, S; Green, AM; Baguley, IJ; Gurka, JA; Marosszeky, JE				Slewa-Younan, S; Green, AM; Baguley, IJ; Gurka, JA; Marosszeky, JE			Sex differences in injury severity and outcome measures after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; sex differences; treatment outcome	HUMAN CORPUS-CALLOSUM; GENDER-DIFFERENCES; HEAD-INJURY; BLOOD-FLOW; ABILITY; WOMEN; PROGESTERONE; PERFORMANCE; DIMORPHISM; ESTROGEN	Objective: To investigate the effect of a patient's sex on various measures of injury severity and outcome after rehabilitation in a matched sample of patients with traumatic brain injury (TBI). Design: Retrospective data were retrieved from a database that contains information routinely collected on all patients admitted for inpatient rehabilitation. Setting: Inpatient rehabilitation unit of major teaching hospital in Australia. Participants: Fifty-four. women with TBI after a motor vehicle crash (MVC) were identified from the Brain Injury Rehabilitation Database. An equal number of men were then matched for age and years of education. All subjects met the study admission criteria of having being involved in a highspeed MVC. Exclusion criteria included history of a previous head injury, chronic amnesia, psychiatric disturbance, and significant alcohol and/or substance abuse. Interventions: Not applicable. Main Outcome Measures: Differences, by sex, in patient scores on measures of injury severity and outcome after TBI. Results: Men had significantly greater levels of injury severity as indicated by the Glasgow Coma Scale scores (U=994.0, P=.002) and length of posttraumatic amnesia (U=880.0, P=.016) when compared with women. No significant sex differences existed in the outcome measures or in injuries not associated with the central nervous system. Conclusions: Few investigations exist on the effect of patient sex on measures of injury severity and outcome after a TBI. In the present study, men's levels of injury severity were greater than women's despite the same admission criteria (high-speed MVC) being applied to both sexes.	Westmead Hosp, Brain Injury Unit, Wentworthville, NSW 2145, Australia; Univ Sydney, Dept Psychol Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Rehabil Med, Sydney, NSW 2006, Australia; Cumberland Hosp, NSW Inst Psychiat, Parramatta, NSW, Australia	Slewa-Younan, S (corresponding author), Westmead Hosp, Brain Injury Unit, POB 533, Wentworthville, NSW 2145, Australia.	shameran@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			ALLEN LS, 1991, J NEUROSCI, V11, P933; BENBOW CP, 1988, BEHAV BRAIN SCI, V11, P169, DOI 10.1017/S0140525X00049244; CLARKE S, 1989, J COMP NEUROL, V280, P213, DOI 10.1002/cne.902800205; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Delgado AR, 1996, MEM COGNITION, V24, P504, DOI 10.3758/BF03200938; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gerberich SG, 1997, NEUROEPIDEMIOLOGY, V16, P1, DOI 10.1159/000109665; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GUR RE, 1990, SCHIZOPHRENIA BULL, V16, P247, DOI 10.1093/schbul/16.2.247; HOLLOWAY RL, 1993, AM J PHYS ANTHROPOL, V92, P481, DOI 10.1002/ajpa.1330920407; HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53; JENNETT B, 1977, LANCET, V1, P878; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; KAUFMAN AS, 1991, J CLIN PSYCHOL, V47, P801, DOI 10.1002/1097-4679(199111)47:6<801::AID-JCLP2270470611>3.0.CO;2-C; KRAUS JF, 2000, NEUROSURG FOCUS, V8; KULYNYCH JJ, 1994, CEREB CORTEX, V4, P107, DOI 10.1093/cercor/4.2.107; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Rabinowicz T, 1999, J CHILD NEUROL, V14, P98, DOI 10.1177/088307389901400207; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1999, J NEUROTRAUM, V16, P988; SHAYWITZ BA, 1995, NATURE, V373, P561; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tabachnick BG, 2013, USING MULTIVARIATE S; WITELSON SF, 1992, J COMP NEUROL, V323, P326, DOI 10.1002/cne.903230303	26	53	56	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2004	85	3					376	379		10.1016/j.apmr.2003.05.007			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	801AC	WOS:000220067800004	15031820				2021-06-18	
J	Chapman, SB; Sparks, G; Levin, HS; Dennis, M; Roncadin, C; Zhang, LF; Song, J				Chapman, SB; Sparks, G; Levin, HS; Dennis, M; Roncadin, C; Zhang, LF; Song, J			Discourse macrolevel processing after severe pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; WRITTEN LANGUAGE PRODUCTION; DEVELOPMENTAL PLASTICITY; LEARNING-DISABILITIES; TEXT COMPREHENSION; SUMMARIZING TEXTS; PRACTICAL SCALE; CHILDREN; INSTRUCTION; ADOLESCENTS	The purpose of this study was to determine if discourse macrolevel processing abilities differed between children with severe traumatic brain injury (TBI) at least 2 years postinjury and typically developing children. Twenty-three children had sustained a severe TBI either before the age of 8 (n = 10) or after the age of 8 (n = 13). The remaining 32 children composed a control group of typically developing peers. The groups' summaries and interpretive lesson statements were analyzed according to reduction and transformation of narrative text information. Compared to the control group, the TBI group condensed the original text information to a similar extent. However, the TBI group produced significantly less transformed information during their summaries, especially those children who sustained early injuries. The TBI and control groups did not significantly differ in their production of interpretive lesson statements. In terms of related skills, discourse macrolevel summarization ability was significantly related to problem solving but not to lexical or sentence level language skills or memory. Children who sustain a severe TBI early in childhood are at an increased risk for persisting deficits in higher level discourse abilities, results that have implications for academic success and therapeutic practices.	Univ Texas, Ctr BrainHlth, Dallas, TX 75235 USA; Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Bayer Pharmaceut, Dept Biometry, West Haven, CT USA	Chapman, SB (corresponding author), Univ Texas, Ctr BrainHlth, 1966 Inwood Rd, Dallas, TX 75235 USA.	schapman@utdallas.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01 NS 21889-16] Funding Source: Medline		Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN AL, 1983, CHILD DEV, V54, P968, DOI 10.1111/j.1467-8624.1983.tb00518.x; BROWN AL, 1983, J VERB LEARN VERB BE, V22, P1, DOI 10.1016/S0022-5371(83)80002-4; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHAPMAN S, 2001, J HEAD TRAUMA REHAB, V16, P1; CHAPMAN S, IN PRESS J ALZHEIMER; Chapman S. B., 1995, AM J SPEECH-LANG PAT, V4, P124, DOI DOI 10.1044/1058-0360.0404.124; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 1997, APHASIOLOGY, V11, P337, DOI 10.1080/02687039708248475; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHAPMAN SB, 1999, BRAIN DAMAGE BEHAV C; CULHANE KA, 1993, INT NEUR SOC M SAN A; DELIS DC, 1984, UNPUB CALIFORNIA PRO; DELIS DC, 1986, CALIFORNIA VERBAL LE; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1990, DISCOURSE ABILITY BR; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; HIDI S, 1986, REV EDUC RES, V56, P473, DOI 10.2307/1170342; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; JENNETT B, 1975, LANCET, V1, P480; JOHNSON NS, 1983, CHILDRENS LANGUAGE, P315; JOHNSON NS, 1978, THESIS U CALIFORNIA; Kinnunen R., 1995, LEARN INSTR, V5, DOI [10.1016/0959-4752(95)00009-R, DOI 10.1016/0959-4752(95)00009-R]; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kirby John R, 1988, LEARNING STRATEGIES, P229; KIRBY JR, 1985, HUM LEARN, V4, P159; KIRBY JR, 1988, INT C PSYCH SYND AUS; KIRBY JR, 1991, EDUC PSYCHOL, V11, P297, DOI DOI 10.1080/0144341910110306; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MALONE LD, 1992, EXCEPT CHILDREN, V58, P270; Nichelli P, 1995, NEUROREPORT, V6, P2309, DOI 10.1097/00001756-199511270-00010; REVELLE GL, 1985, CHILD DEV, V56, P654; Reyna VF, 1998, J EXP CHILD PSYCHOL, V71, P194, DOI 10.1006/jecp.1998.2472; Semel E. M., 1995, CLIN EVALUATION LANG; STEIN BL, 1992, J READING BEHAV, V24, P217, DOI 10.1080/10862969209547773; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; VANDIJK TA, 1995, DISCOURSE COMPREHENSION, P383; VAURAS M, 1994, J READING BEHAV, V26, P361, DOI 10.1080/10862969409547859; Wechsler D., 2011, WECHLSER ABBREVIATED; Worling DE, 1999, BRAIN LANG, V70, P220, DOI 10.1006/brln.1999.2156; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9; Yorkston KM, 1999, APHASIOLOGY, V13, P691, DOI 10.1080/026870399401803	53	53	53	0	4	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					37	60		10.1207/s15326942dn2501&2_4			24	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	774CG	WOS:000188961700004	14984328				2021-06-18	
J	Cifu, DX; Kreutzer, JS; Kolakowsky-Hayner, SA; Marwitz, JH; Englander, J				Cifu, DX; Kreutzer, JS; Kolakowsky-Hayner, SA; Marwitz, JH; Englander, J			The relationship between therapy intensity and rehabilitative outcomes after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; treatment outcome	STROKE	Objectives: To identify factors relating to the intensity of rehabilitation services received and to ascertain the relation between injury outcomes, demographics, types of therapy, and the intensity of rehabilitation services provided. Design: A multicenter, prospective, nonrandomized study with inpatient rehabilitation data collected between 1989 and 1996. Setting: Three medical centers in the federally sponsored Traumatic Brain Injury Model Systems. In each setting, the continuum of care includes emergency medical services, intensive and acute medical care, and inpatient rehabilitation. Participants: A total of 491 consecutively enrolled patients with a mean age +/- standard deviation of 34.3 +/- 15.88 years recruited from 3 medical centers. To be included in the study, patients must have been at least 16 years of age, have presented to the emergency department within 24 hours of injury, and have received acute care and inpatient rehabilitation. Interventions: Patients received comprehensive medical care along with a combination of rehabilitative therapies, including physical, occupational, psychologic, and speech therapy. Main Outcome Measures: Therapy intensity; levels of functional independence, cognitive function, functional gain, and treatment efficiency, as indicated by the FIM(TM) instrument; rehabilitation length of stay (LOS); and charges. Results: Age predicted the intensity of both psychologic (P < .001) and total therapy (P < .01) services. Acute care LOS was also a significant predictor of psychologic services (P < .01). Only admission motor FIM was relevant in predicting speech services intensity (P < .01). Therapy intensity was predictive of motor functioning at discharge (P < .001). However, therapy intensity did not predict cognitive gain (P < .05). Conclusions: This study is among the first multicenter efforts to examine the potential benefits of individual therapy services. Findings support assertions that increased therapy intensity, particularly physical and psychologic therapies, enhances functional outcomes.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr Traumat Brain Injury & Spinal Cor, Santa Clara, CA USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, 1200 E Broad St,Rm 3-102,Box 980542, Richmond, VA 23298 USA.	jskreutz@hsc.vcu.edu	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BASMAJIAN JV, 1987, ARCH PHYS MED REHAB, V68, P267; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; CAREY LM, 1993, ARCH PHYS MED REHAB, V74, P602, DOI 10.1016/0003-9993(93)90158-7; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Hall KM, 1994, ARCH PHYS MED REHABI, V75, pSC; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HESSE SA, 1994, STROKE, V25, P1999, DOI 10.1161/01.STR.25.10.1999; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Keith RA, 1997, ARCH PHYS MED REHAB, V78, P1298, DOI 10.1016/S0003-9993(97)90300-2; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lorenze EJ, 1962, ARCH PHYS MED, V43, P514; Macdonell R A, 1994, J Stroke Cerebrovasc Dis, V4, P155, DOI 10.1016/S1052-3057(10)80178-8; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; *STAT U NEW YORK, 1995, GUID UN DAT SYST MED; Stern PH, 1971, STROKE, V2, P213, DOI 10.1161/01.STR.2.3.213	25	53	54	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2003	84	10					1441	1448		10.1016/S0003-9993(03)00272-7			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	731JG	WOS:000185880100004	14586910				2021-06-18	
J	Green, P; Rohling, ML; Iverson, GL; Gervais, RO				Green, P; Rohling, ML; Iverson, GL; Gervais, RO			Relationships between olfactory discrimination and head injury severity	BRAIN INJURY			English	Article							WORD MEMORY TEST; POSTTRAUMATIC ANOSMIA; EXAGGERATION	The goal of this study was to examine the relationship between brain injury severity and scores on both an olfactory identification test and on many widely used neuropsychological tests in 367 patients with head injuries of varying levels of severity. It was hypothesized that valid olfactory test scores would correlate highly with injury severity because both the olfactory nerves and the primary olfactory cortices are especially vulnerable to damage in closed head injury. After removing data of doubtful validity from cases failing effort tests, olfactory test scores were related to Glasgow Coma Scale scores (GCS), post-traumatic amnesia and radiological abnormalities more strongly than any of the neuropsychological test scores. Based on the assumption that post-traumatic amnesia is caused by a different mechanism than loss of core consciousness, it was also predicted that there would be no cases with a GCS less than 13 and with no post-traumatic amnesia. As predicted, there were no cases in this group. The results support previous studies showing greater olfactory impairment with increased severity of head injury.	Neurobehav Associates, Edmonton, AB, Canada; Univ S Alabama, Mobile, AL 36688 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Riverview Hosp, Vancouver, BC, Canada	Green, P (corresponding author), 201-17107-107 Ave, Edmonton, AB T5S 1G3, Canada.			Iverson, Grant/0000-0001-7348-9570			Allen L.M., 1997, CARB 97 MANUAL COMPU; ALLEN LM, 1999, CARB WMT MANUALS S; BEERS MH, 1999, MERCK MANUAL DIAGNOS; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Costanzo RM, 1992, J HEAD TRAUMA REHAB, V7, P15, DOI DOI 10.1097/00001199-199203000-00005; COURVILLE CB, 1945, PATHOLOGY NERVOUS SY, P292; Dam~asio A., 1999, FEELING WHAT HAPPENS; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Green P, 2001, NEUROREHABILITATION, V16, P237; Green P, 1998, ARCH CLIN NEUROPSYCH, V13, P138; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 1999, CARB WMT MANUALS S; Green P., 1996, WORD MEMORY TEST USE; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Moore KL., 1999, CLIN ORIENTATED ANAT; Ogawa S, 1999, HETEROCYCLES, V50, P57, DOI 10.3987/COM-98-S(H)42; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P839; SMITH CG, 1961, BASIC NEUROANATOMY; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63	23	53	55	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2003	17	6					479	496		10.1080/0269905031000070242			18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400003	12745704				2021-06-18	
J	Schultke, E; Kendall, E; Kamencic, H; Ghong, Z; Griebel, RW; Juurlink, BHJ				Schultke, E; Kendall, E; Kamencic, H; Ghong, Z; Griebel, RW; Juurlink, BHJ			Quercetin promotes functional recovery following acute spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						functional recovery; iron chelation; MRI; neurotrauma; rat; spinal cord	LIPID-PEROXIDATION; HUMAN-ERYTHROCYTES; OXIDATIVE STRESS; IRON RELEASE; FLAVONOIDS; INHIBITION; APOPTOSIS; ANTIOXIDANT; METHYLPREDNISOLONE; TRAUMA	We tested the hypothesis that quercetin, a potent Fe2+-chelating flavonoid, would decrease secondary damage following spinal cord trauma. MRI studies using the relaxation of the T1 proton signal caused by Fe2+ ions and the dose-dependent reversal of this effect by addition of quercetin in aqueous solution were used to guide us to the dosage of quercetin to be used in animal experimentations. Forty-four male Wistar rats were used in two experimental series to test the hypothesis that administration of quercetin improves recovery of motor function after acute traumatic spinal cord injury. Animals were subjected to laminectomy and subjected to an extradural 40-g force clip compression for 5 see at T7. Quercetin or saline was administered intraperitoneally 1 h after injury and then every 12 hr thereafter. Recovery of motor function was assessed using BBB scores at weekly intervals for 4 weeks. A dose of 2.5 mumoles quercetin/kg body weight did not result in significantly better functional outcome, whereas doses ranging from 5 to 100 mumoles quercetin/kg body weight resulted in a significantly better functional outcome with half or more of the animals walking, although with deficit; in contrast, no animals walked in the group of saline-treated animals. No significant differences in behavioral outcome were seen amongst the doses ranging from 5 to 100 mumol/kg, nor was there a difference if animals were treated for 4 or 10 days. Therapeutic outcome was coincident with more efficient iron clearance, suggesting that one possible mechanism whereby quercetin decreases secondary damage is through iron chelation.	Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Med Imaging, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg, Div Neurosurg, Saskatoon, SK S7N 5E5, Canada	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	juurlink@duke.usask.ca	Schultke, Elisabeth/M-3959-2013	Kendall, Edward/0000-0002-9638-9254			AFANASEV IB, 1989, BIOCHEM PHARMACOL, V38, P1763, DOI 10.1016/0006-2952(89)90410-3; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; BENHUR E, 1993, PHOTOCHEM PHOTOBIOL, V57, P984, DOI 10.1111/j.1751-1097.1993.tb02959.x; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cheng IF, 2000, BIOMETALS, V13, P77, DOI 10.1023/A:1009229429250; Comporti M, 2002, FREE RADICAL BIO MED, V32, P568, DOI 10.1016/S0891-5849(02)00759-1; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Cotelle N, 1996, FREE RADICAL BIO MED, V20, P35, DOI 10.1016/0891-5849(95)02014-4; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cuevas P, 2001, NEUROL RES, V23, P207, DOI 10.1179/016164101101198352; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Fehlings MG, 2001, SPINE, V26, pS99; FEHLINGS MG, 2000, CONT MANAGEMENT SPIN, P35; Fernandez MT, 2002, J INORG BIOCHEM, V92, P105, DOI 10.1016/S0162-0134(02)00511-1; FERRALI M, 1992, BIOCHEM J, V285, P295, DOI 10.1042/bj2850295; FERRANDIZ ML, 1991, AGENTS ACTIONS, V32, P283, DOI 10.1007/BF01980887; Gaetani P, 1998, J NEUROSURG, V89, P748, DOI 10.3171/jns.1998.89.5.0748; Galey J B, 1997, Adv Pharmacol, V38, P167; GRIFFITHS LA, 1972, ANGIOLOGICA, V9, P162; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P263, DOI 10.1042/bj1990263; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Halliwell B, 1989, FREE RADICALS BIOL M; HIDER RC, 1994, ADV EXP MED BIOL, V356, P343; HOLLMAN RC, 1996, FREE RADIC BIOL MED, V21, P232; Horky LL, 1998, J NEUROSURG, V88, P298, DOI 10.3171/jns.1998.88.2.0298; Huk I, 1998, BRIT J SURG, V85, P1080; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; Koszyca B, 2002, J CLIN NEUROSCI, V9, P298, DOI 10.1054/jocn.2001.0969; MALLORY FB, 1961, PATHOLOGICAL TECHNIQ; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; NOCKELS R, 1992, J NEUROTRAUM, V9, pS211; Pelzer LE, 1998, FARMACO, V53, P421, DOI 10.1016/S0014-827X(98)00046-9; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rabchevsky AG, 1999, J NEUROTRAUM, V16, P817, DOI 10.1089/neu.1999.16.817; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; RATTY AK, 1988, BIOCHEM MED METAB B, V39, P69, DOI 10.1016/0885-4505(88)90060-6; Regan RF, 1998, J NEUROTRAUM, V15, P645, DOI 10.1089/neu.1998.15.645; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Romanova D, 2001, NEOPLASMA, V48, P104; SAIJA A, 1995, FREE RADICAL BIO MED, V19, P481, DOI 10.1016/0891-5849(94)00240-K; SCHULTKE E, 2000, SOC NEUR ABSTR, V27, P516; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sestili P, 1998, FREE RADICAL BIO MED, V25, P196, DOI 10.1016/S0891-5849(98)00040-9; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sobottka AM, 2000, ARCH PHARM, V333, P205, DOI 10.1002/1521-4184(20007)333:7<205::AID-ARDP205>3.0.CO;2-Y; SORATA Y, 1984, BIOCHIM BIOPHYS ACTA, V799, P313, DOI 10.1016/0304-4165(84)90276-9; Sugihara N, 1999, FREE RADICAL BIO MED, V27, P1313, DOI 10.1016/S0891-5849(99)00167-7; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; THOMPSON JH, 1966, IRISH J MED SCI, V484, P127; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vasiljeva O V, 2000, Membr Cell Biol, V14, P47; Vymazal J, 1996, MAGN RESON MED, V35, P56, DOI 10.1002/mrm.1910350108; Weidner N, 1999, EXP NEUROL, V160, P40, DOI 10.1006/exnr.1999.7200; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	71	53	56	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					583	591		10.1089/089771503767168500			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900006	12906742				2021-06-18	
J	Nathoo, N; Chetty, R; Van Dellen, JR; Connolly, C; Naidoo, R				Nathoo, N; Chetty, R; Van Dellen, JR; Connolly, C; Naidoo, R			Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: influence of ethnic and regional differences	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; apolipoprotein E; polymorphism; outcome	CEREBRAL AMYLOID ANGIOPATHY; HEAD-INJURY; HIGH-FREQUENCY; INTRACEREBRAL HEMORRHAGE; ALZHEIMER-DISEASE; EPSILON-4 ALLELE; E GENOTYPE; POPULATIONS; ASSOCIATION; STROKE	Object. The presence of the apolipoprotein E-epsilon4 (APOE-epsilon4) allele is reported to be associated with poor outcome after traumatic brain injury (TBI). This study was performed to determine if the presence of the APOE-epsilon4 allele influenced outcome in a cohort of black patients with TBI who had homogeneous neuropathological findings. Methods. Venous blood was collected at the time of admission to determine the APOE genotype in black Zulu-speaking patients who presented with traumatic cerebral contusions. The frequency of the APOE-epsilon4 allele's appearance was correlated with outcome at a minimum of 6 months of follow up. Univariate and multivariate analyses were performed to determine independent risk factors and to control for confounding factors. In 110 black Zulu-speaking patients with traumatic cerebral contusions, genotypes for APOE were analyzed. Eleven of 45 (24.4%) with the APOE-epsilon4 allele experienced a poor outcome, compared with 10 (15.4%) of 65 without this allele (p = 0.34). Both patients with homozygous APOE-epsilon4 alleles experienced a good outcome (Glasgow Outcome Score 5). Univariate and multivariate analysis revealed no significant relationship in patients with the APOE-epsilon4 allele with regard to age, admission Glasgow Comas Scale score, contusion volume, type of neurosurgical management, and outcome. The risk of a poor outcome was, however, greater in patients with the APOE-epsilon4 allele (relative risk 1.59; 95% confidence interval 0.74-3.42). Conclusions. The authors recorded no relationship between APOE-epsilon4 allele status and outcome after TBI in black patients. Given the high regional susceptibility to the APOE gene, further studies, possibly even community-based investigations and studies conducted in other geographic areas, are probably warranted.	Univ Natal, Wentworth Hosp, Nelson R Mandela Sch Med, Dept Neurosurg, Natal, RN, Brazil; Univ Natal, Wentworth Hosp, Nelson R Mandela Sch Med, Dept Pathol, Natal, RN, Brazil; Univ Natal, Wentworth Hosp, Nelson R Mandela Sch Med, Dept Mol Biol, Natal, RN, Brazil; MRC S Africa, Div Biostat, Durban, South Africa; W London Neurosci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Sch Med, London, England	Nathoo, N (corresponding author), Cleveland Clin Fdn, Dept Neurosurg, 9500 Euclid Ave, Cleveland, OH 44195 USA.						ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chikosi AB, 2000, HYPERTENS PREGNANCY, V19, P309, DOI 10.1081/PRG-100101992; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERDES LU, 1992, GENET EPIDEMIOL, V9, P155, DOI 10.1002/gepi.1370090302; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; HIXSON JE, 1990, J LIPID RES, V31, P545; JENNETT B, 1975, LANCET, V1, P480; KAMBOH MI, 1989, DIS MARKERS, V7, P49; KAY AD, 2002, NEUROPATHOL APPL NEU, V28, P152; LECLERCQ PD, 2002, NEUROPATHOL APPL NEU, V28, P161; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Loktionov A, 1999, ATHEROSCLEROSIS, V145, P125, DOI 10.1016/S0021-9150(99)00022-2; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nicoll JAR, 1996, ANN NEUROL, V39, P682, DOI 10.1002/ana.410390521; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SANDHOLZER C, 1995, HUM GENET, V95, P46; SEPEHRNIA B, 1988, AM J HUM GENET, V43, P847; SMITH C, 2002, NEUROPATHOL APPL NEU, V28, P15; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Zekraoui L, 1997, HUM BIOL, V69, P575	33	53	60	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2003	98	2					302	306		10.3171/jns.2003.98.2.0302			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	643RB	WOS:000180873300007	12593615				2021-06-18	
J	Echemendia, RJ; Cantu, RC				Echemendia, RJ; Cantu, RC			Return to play following sports-related mild traumatic brain injury: The role for neuropsychology	APPLIED NEUROPSYCHOLOGY			English	Article						cerebral concussions; return to play; risk-benefit analysis; neuropsychology	HEAD-INJURY; FOOTBALL PLAYERS; CONCUSSION; PERFORMANCE; GUIDELINES	Cerebral concussions frequently occur at all levels of athletic competition. The effects from these concussions can be transient or may lead to chronic, debilitating symptoms. A growing literature has established that neuropsychological tests are useful in detecting the subtle neurocognitive changes that occur following concussions. The identification of these deficits and subsequent recovery of function can be important components in making return-to-play (RTP) decisions. This article describes the emergence of neuropsychology in sports medicine, discusses the context in which RTP decisions are made, outlines factors that are important to RTP decisions, and presents a model that views the RTP decision as a dynamic risk-benefit analysis that involves complex interactions among variables. It is argued that neuropsychology has a unique, but not exclusive, role in the decision making process. Implications for future research are discussed.	Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; Emerson Hosp, Div Neurosurg, Concord, MA USA	Echemendia, RJ (corresponding author), 119 S Burrowes St,Suite 602, State Coll, PA 16801 USA.	RJE2@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P114; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ECHEMENDIA RJ, IN PRESS SPORTS NEUR; Erlanger D, 2001, ARCH CLIN NEUROPSYCH, V16, P740; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; *I MED, 2002, 1OM WORKSH NEUR CONS; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LEE SM, 1955, J CEREBRAL BLOOD FLO, V15, pS722; LIFSHITZ J, 1955, J NEUROTRAUM, V12, P129; LOVELL M, SPORTS NEUROPSYCHOLO; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SUTTON RL, 1994, ACTA NEUROCHRURGICA, V6, P466	25	53	54	1	4	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					48	55		10.1207/S15324826AN1001_7			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900007	12734075				2021-06-18	
J	Turkstra, L; Jones, D; Toler, HL				Turkstra, L; Jones, D; Toler, HL			Brain injury and violent crime	BRAIN INJURY			English	Article							HEAD-INJURY; AGGRESSION; BEHAVIOR	Primary objective : To test the hypothesis that TBI is associated with violent crime, the prevalence and characteristics of traumatic brain injury (TBI) were compared between men convicted of domestic violence and a matched comparison group. Methods and procedures : Participants were 20 African American men convicted of domestic violence and 20 African American men without criminal convictions matched for age and socioeconomic status. Participants completed a questionnaire regarding health and behaviour history. Main outcomes and results : More than half of the participants in both groups had sustained a TBI, although injuries in the offender group were significantly more severe. There were significantly more reports of problems with anger management in the offender group. Conclusions : Published epidemiological data regarding TBI may underestimate the prevalence in urban populations, which may have confounded earlier studies of TBI and domestic violence. The reported prevalence in this sample of defendants suggests implications for the justice system.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA; City Cleveland Hts Municipal Court, Cleveland, OH USA	Turkstra, L (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.						*CDCP, 2000, EP TRAUM BRAIN INJ U; Cohen R A, 1999, Violence Vict, V14, P397; Damasio AR, 1995, ANN NY ACAD SCI, V769, P241, DOI 10.1111/j.1749-6632.1995.tb38142.x; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Filley CM, 2001, NEUROPSY NEUROPSY BE, V14, P1; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2001, BRAIN INJURY, V15, P255; Hartley L. L., 1995, COGNITIVE COMMUNICAT; MUSCAT JE, 1988, AM J PUBLIC HEALTH, V78, P822, DOI 10.2105/AJPH.78.7.822; Mussen P., 1977, ROOTS CARING SHARING; Raine A, 2001, AGGRESSIVE BEHAV, V27, P111, DOI 10.1002/ab.4; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M., 1989, MILD MODERATE HEAD I, P203	17	53	54	1	14	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	1					39	47		10.1080/0269905021000010122			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600003	12519646				2021-06-18	
J	Cruz, J; Minoja, G; Okuchi, K				Cruz, J; Minoja, G; Okuchi, K			Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: A randomized trial	NEUROSURGERY			English	Article						cerebral extraction of oxygen; clinical outcome; head injury; herniation syndrome; intracranial pressure; mannitol	CEREBRAL-BLOOD-FLOW; ACUTE BRAIN-INJURY; OXYGEN-CONSUMPTION; COMATOSE PATIENTS; METABOLIC-RATE; ACUTE ANEMIA; HEAD-INJURY; TRAUMA; HYPERVENTILATION; EXTRACTION	OBJECTIVE: We evaluated long-term clinical outcomes and postoperative physiological findings in acutely comatose patients with nonmissile surgical intraparenchymal temporal lobe hemorrhages and abnormal pupillary widening who received early preoperative high-dose mannitol (HDM) versus conventional dose mannitol treatment in the emergency room. METHODS: One hundred forty-one adult patients with traumatic, nonmissile, acute, intraparenchymal temporal lobe hemorrhages associated with early abnormal pupillary widening were prospectively and randomly assigned to receive emergency preoperative intravenous HDM treatment (approximately 1.4 g/kg; 72 patients) and were compared with a control group that was treated with a lower preoperative mannitol dose (approximately 0.7 g/kg; 69 patients). RESULTS: Early preoperative improvement of abnormal bilateral pupillary widening was significantly more frequent in the study group than in the control group (P < 0.03). The same was true for abnormal unilateral pupillary widening (P< 0.01). Early HDM treatment in the emergency room was also associated with significantly better 6-month clinical outcomes (P < 0.005). The two groups of patients were well matched with respect to diameter of the temporal lobe hemorrhages (approximately 4 cm) as well as timing of clot removal (approximately 2.5 hours after injury). Postoperative physiological findings revealed statistically significant between-group differences, with higher intracranial pressure and lower cerebral extraction of oxygen (global relative cerebral hyperperfusion) in the control group than in the HDM group. Postoperative global brain ischemia (abnormally low arteriojugular lactate difference values) was rare and was found for less than 3% of the patients in both groups. CONCLUSION: Early preoperative HDM administration in the emergency room was associated with improved clinical outcomes for adult comatose patients with acute, nonmissile, intraparenchymal temporal lobe hemorrhages and associated abnormal pupillary widening. Early improvement of bilateral or unilateral pupillary abnormalities and better postoperative control of intracranial hypertension and associated global relative cerebral hyperperfusion seemed to be relevant factors that were related to improved outcomes.	Comprehens Int Ctr Neuroemergencies, BR-04093970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Sao Paulo, Brazil; Univ Insubria, Dept Anesthesiol & Crit Care Med, Varese, Italy; Nara Med Univ, Dept Emergency & Crit Care Med, Nara, Japan	Cruz, J (corresponding author), Comprehens Int Ctr Neuroemergencies, POB Cx Postal 57011, BR-04093970 Sao Paulo, Brazil.						BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J, 2001, NEUROSURGERY, V49, P864; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; LANGFITT TW, 1968, JOHNS HOPKINS MED J, V122, P261; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	30	53	55	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2002	51	3					628	637		10.1097/00006123-200209000-00006			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	592FH	WOS:000177925700007	12188940				2021-06-18	
J	Rhoney, DH; Parker, D; Formea, CM; Yap, C; Coplin, WM				Rhoney, DH; Parker, D; Formea, CM; Yap, C; Coplin, WM			Tolerability of bolus versus continuous gastric feeding in brain-injured patients	NEUROLOGICAL RESEARCH			English	Article						brain injury; nutrition; mechanical ventilation; critical care; enteral nutrition; gastric feeding	CRITICALLY ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; CLOSED-HEAD-INJURY; CARE-UNIT PATIENTS; ENTERAL NUTRITION; RISK-FACTORS; PATIENTS INTOLERANT; CONTROLLED TRIAL; PNEUMONIA; ASPIRATION	Brain injured patients may exhibit altered gastric emptying; thus, some believe post-pyloric feeding to be tolerated better than gastric feeding. Reliable post-pylorus access can be difficult to obtain, so gastric feeding remains the preferred route for administering nutrition. Feeding intolerance may be associated with increased complications and costs. We sought to compare bolus (B) versus continuous (C) gastric feeding in brain injured patients. This retrospective cohort study was carried out at a neurological/neurosurgical intensive care unit at a Level I trauma and tertiary referral center. Our subjects were 152 consecutive patients over two years. Use of B or C feedings was based on clinicians' preferences. Abdominal examination and gastric residuals (>75 mL over four hours) defined feeding intolerance (FI). Putative risks for FI were compared between the groups. Demographic characteristics were similar between groups B (n=86) and C (n=66). Feeding intolerance occurred more often in group B than in group C (60.5% vs. 37.9%, p=0.009). Group C patients achieved 75% of nutritional goals faster than group B patients (median 3.3 vs. 4.6 days; p=0.03). Prokinetic agent use was similar between the groups and did not reduce the time to achieve nutritional goals. There was a trend towards a reduction in the incidence of infections in group C (p=0.05). Independent predictors of FI included: sucralfate (OR 2.3), propofol (OR 2.1), pentobarbital (OR 3.9) or paralytic (OR 3) use; older age (OR 5), days receiving mechanical ventilation (OR 1.2); and admission diagnosis of either intracerebral hemorrhage (OR 2.2) or ischemic stroke (OR 1.9). Continuous gastric feeding is better tolerated than B feedings in patients with acute brain injuries. Use of prokinetic agents did not affect time to achievement of nutritional goals. Use of common medications including sucralfate and propofol were associated with FI.	Wayne State Univ, Coll Pharm, Dept Pharm Practice, Detroit, MI USA; Allied Hlth Profess, Detroit, MI USA; Univ Detroit, Ctr Hlth, Detroit Receiving Hosp, Dept Pharm Serv, Detroit, MI 48221 USA; Univ Detroit, Ctr Hlth, Detroit Receiving Hosp, Dept Dietary Serv, Detroit, MI 48221 USA; Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Neurol, Detroit, MI USA; Wayne State Univ, Sch Med, Detroit Med Ctr, Dept Neurol Surg, Detroit, MI USA	Rhoney, DH (corresponding author), Wayne State Univ, Dept Pharm, 4201 St Antoine, Detroit, MI 48201 USA.			Yap, Christina/0000-0002-6715-2514	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38905] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038905] Funding Source: NIH RePORTER		Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P394, DOI 10.1164/ajrccm.154.2.8756812; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Cerra FB, 1997, CHEST, V111, P769, DOI 10.1378/chest.111.3.769; Chapman MJ, 2000, CRIT CARE MED, V28, P2334, DOI 10.1097/00003246-200007000-00026; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; Davies AR, 2002, CRIT CARE MED, V30, P586, DOI 10.1097/00003246-200203000-00016; Day L, 2001, J Neurosci Nurs, V33, P148; Day L, 2001, J NEUROSCI NURS, V33, P155, DOI [DOI 10.1097/01376517-200106000-00007], 10.1097/ 01376517- 200106000- 00007]; Esparza J, 2001, INTENS CARE MED, V27, P660, DOI 10.1007/s001340100880; FOUNDATION BT, 2000, J NEUROTRAUM, V17, P539; FOX KA, 1995, AM J SURG, V170, P564, DOI 10.1016/S0002-9610(99)80016-6; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JENNETT B, 1975, LANCET, V1, P480; Jolliet P, 1999, CLIN NUTR, V18, P47, DOI 10.1016/S0261-5614(99)80049-1; Klodell CT, 2000, AM J SURG, V179, P168, DOI 10.1016/S0002-9610(00)00297-X; Kocan M J, 1986, J Neurosci Nurs, V18, P333; KUDSK KA, 1996, J CLIN NUTR, V3, P3; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; MacLaren R, 2000, CRIT CARE MED, V28, P438, DOI 10.1097/00003246-200002000-00025; MARIAN M, 1993, SURG GYNECOL OBSTET, V176, P475; MCCLAVE SA, 1992, JPEN-PARENTER ENTER, V16, P99, DOI 10.1177/014860719201600299; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; OLIVARES L, 1974, STROKE, V5, P654, DOI 10.1161/01.STR.5.5.654; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; SOCIETY AT, 1995, AM J RESP CRIT CARE, V153, P1711; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Spain DA, 1999, JPEN-PARENTER ENTER, V23, P288, DOI 10.1177/0148607199023005288; Spilker CA, 1996, CHEST, V110, P243, DOI 10.1378/chest.110.1.243; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TEASDALE G, 1974, LANCET, V2, P81; Yap CW, 2000, NEUROLOGY, V54, pA411; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025; YOUNG B, 1992, J NEUROTRAUMA S, V9, P375; Zaloga GP, 1999, CRIT CARE MED, V27, P259, DOI 10.1097/00003246-199902000-00024	40	53	54	0	3	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	SEP	2002	24	6					613	620		10.1179/016164102101200456			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	606WD	WOS:000178756900017	12238631				2021-06-18	
J	Muessel, MJ; Klein, RM; Wilson, AM; Berman, NEJ				Muessel, MJ; Klein, RM; Wilson, AM; Berman, NEJ			Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules	MOLECULAR BRAIN RESEARCH			English	Article						chemokine; monocyte-chemoattractant protein-1 (MCP-1); microglia; lesion; thalamus; retrograde degeneration; apoptosis	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LATERAL GENICULATE-NUCLEUS; IFN-GAMMA; INDUCED APOPTOSIS; BCL-2 EXPRESSION; INTERFERON-GAMMA; MESSENGER-RNA; FAS LIGAND	The mechanisms regulating retrograde neuronal degeneration and subsequent death of thalamic neurons following cortical injury are not well understood. However, the delay in the onset of retrograde cell death and observed morphological changes are consistent with apoptosis. Our previous studies demonstrated that monocyte chemoattractant protein-1 (MCP-1), a beta-chemokine that attracts cells of monocytic origin to sites of injury, is rapidly and specifically expressed in the lateral geniculate nucleus following visual cortical lesions. To determine the potential role of MCP-1 in retrograde degeneration, the present study examined the effect of genetic deletion of MCP-1 (MCP-1 KO or -/-) or its high affinity receptor CCR2 (CCR2 KO or -/-) on thalamic microglial activation and neuronal cell death following aspiration lesions of the visual cortex in adult mice. Deletion of the MCP-1 gene delayed microglial activation and transiently improved the survival of thalamic neurons. Deletion of the CCR2 receptor resulted in a significant increase in apoptosis as measured by nucleosomal fragmentation after injury compared to wild-type mice, but did not alter neuron survival, suggesting that glial apoptosis is increased in the receptor knockout mice. Investigation of Bcl-2, Bax, Fas, Fas ligand (FasL) and activated caspase-3, key regulators of apoptosis that can be modulated by cytokines, revealed complex alterations of mRNA and protein levels in MCP-/- and CCR2(-/-) mice. As examples, Bcl-2 protein was detected in wild-type, but not in MCP-/- mice. Caspase-3 activity was higher in MCP-/- mice compared to wild-type and CCR2(-/-) mice at 5 days after injury. High levels of activated caspase-3 correlate with the beginning of a period of delayed, but rapid cell death in the thalami of MCP-/- mice. In summary, our data strongly suggest that MCP-1 is involved in early microglial response to axotomy and that modulation of this chemokine could provide a novel strategy for improved neuronal survival following injury to the central nervous system. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA	Berman, NEJ (corresponding author), Univ Kansas, Med Ctr, Dept Anat & Cell Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038282] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD02528] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38282] Funding Source: Medline		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; Aoki T, 1999, CLIN NEUROPATHOL, V18, P51; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Berman JW, 1996, J IMMUNOL, V156, P3017; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; BURNS TM, 1993, GROWTH FACTORS, V9, P253, DOI 10.3109/08977199308991585; Casaccia-Bonnefil P, 2000, GLIA, V29, P124, DOI 10.1002/(SICI)1098-1136(20000115)29:2<124::AID-GLIA5>3.0.CO;2-O; CHAO CC, 1992, J IMMUNOL, V149, P2736; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Combs CK, 1999, J NEUROSCI, V19, P928; Cross AK, 1999, J NEUROSCI RES, V55, P17, DOI 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J; CUNNINGHAM TJ, 1987, ANN NY ACAD SCI, V495, P153, DOI 10.1111/j.1749-6632.1987.tb23673.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; Dorrie J, 1999, LEUKEMIA, V13, P1539, DOI 10.1038/sj.leu.2401479; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fadeel B, 1999, FASEB J, V13, P1647; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; FUENTES ME, 1995, J IMMUNOL, V15, P55769; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110; Giese A, 1998, BRAIN PATHOL, V8, P449; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; GREENLUND LJS, 1995, NEURON, V15, P649, DOI 10.1016/0896-6273(95)90153-1; Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723; Guthrie KM, 1997, J COMP NEUROL, V386, P137; Hadida F, 1999, J IMMUNOL, V163, P1105; Hermann DM, 2000, ACTA NEUROPATHOL, V99, P147, DOI 10.1007/PL00007418; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Hogaboam CM, 2000, AM J PATHOL, V156, P1245, DOI 10.1016/S0002-9440(10)64995-4; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Ivacko J, 1997, J CEREBR BLOOD F MET, V17, P759; Jellinger K. A., 2000, Journal of Neural Transmission Supplement, V60, P21; Kelder W, 1998, ANN NEUROL, V44, P831, DOI 10.1002/ana.410440521; Koczyk D, 2000, INT J DEV NEUROSCI, V18, P591, DOI 10.1016/S0736-5748(99)00111-2; Koshiji M, 1998, CLIN EXP IMMUNOL, V111, P211; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lawrence DA, 2000, TOXICOLOGY, V142, P189, DOI 10.1016/S0300-483X(99)00144-4; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.00216.x; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MartinezPomares L, 1996, IMMUNOBIOLOGY, V195, P407, DOI 10.1016/S0171-2985(96)80012-X; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; McMahon EJ, 2001, J IMMUNOL, V167, P2964, DOI 10.4049/jimmunol.167.5.2964; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Muessel M. J., 2001, Society for Neuroscience Abstracts, V27, P1751; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; OTANI H, 1993, J BIOL CHEM, V268, P22733; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROSE JE, 1949, ELECTROEN CLIN NEURO, V1, P391, DOI 10.1016/0013-4694(49)90059-0; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Rudge J. S., 1993, ASTROCYTES PHARM FUN, P267; Saas P, 1999, J IMMUNOL, V162, P2326; Schultz MJ, 2001, J IMMUNOL, V166, P4059, DOI 10.4049/jimmunol.166.6.4059; Schweickart VL, 2000, J BIOL CHEM, V275, P9550, DOI 10.1074/jbc.275.13.9550; Smith C, 2001, EUR J NEUROSCI, V13, P443, DOI 10.1046/j.1460-9568.2001.01400.x; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; TAKAMIYA Y, 1986, BRAIN RES, V383, P305, DOI 10.1016/0006-8993(86)90029-6; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanabe K, 1999, J BIOL CHEM, V274, P15725, DOI 10.1074/jbc.274.22.15725; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; Vella AT, 1998, P NATL ACAD SCI USA, V95, P3810, DOI 10.1073/pnas.95.7.3810; Wang J, 2000, J CELL SCI, V113, P753; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; White CA, 1998, INT IMMUNOL, V10, P935, DOI 10.1093/intimm/10.7.935; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WONG GHW, 1994, J IMMUNOL, V152, P1751; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	97	53	56	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUN 30	2002	103	1-2					12	27	PII S0169-328X(02)00158-4	10.1016/S0169-328X(02)00158-4			16	Neurosciences	Neurosciences & Neurology	583YV	WOS:000177440400002	12106688				2021-06-18	
J	Adibhatla, RM; Hatcher, JF; Sailor, K; Dempsey, RJ				Adibhatla, RM; Hatcher, JF; Sailor, K; Dempsey, RJ			Polyamines and central nervous system injury: spermine and spermidine decrease following transient focal cerebral ischemia in spontaneously hypertensive rats	BRAIN RESEARCH			English	Article						antioxidant; Fe2+ chelation; hydroxyl radical; putrescine; radical scavenger; spermidine/spermine-N-1-acetyltransferase; transient forebrain ischemia; traumatic brain injury	ORNITHINE-DECARBOXYLASE ACTIVITY; EDEMA FORMATION; LIPID-PEROXIDATION; BRAIN EDEMA; METABOLISM; CITICOLINE; OXIDASE; GERBIL; VOLUME; DAMAGE	Polyamines (putrescine, spermidine and spermine) are ubiquitous cellular components, but their specific role in central nervous system (CNS) injury has yet to be characterized. CNS injury results in increased activities of ornithine decarboxylase and spermidine/spermine-N-1-acetyltransferase, and accumulation of putrescine. The present study determined the polyamine profile in three models of CNS injury, in two different species (gerbil and rat) and two strains of rats (Sprague-Dawley and spontaneously hypertensive): ( 1) transient focal cerebral ischemia in spontaneously hypertensive rats (SHR); (2) traumatic brain injury in Sprague-Dawley rats; and (3) transient forebrain ischemia in gerbils. While there was a significant increase in putrescine in all three models, spermine and spermidine levels were unaltered in forebrain ischemia and traumatic brain injury. However, transient focal cerebral ischemia shows depletion of spermine and spermidine levels in injured hemisphere compared to contralateral region. Exogenous spermine significantly restored the spermine as well as spermidine levels in the ipsilateral hemisphere after transient focal cerebral ischemia, but did not alter putrescine levels or the ratio of spermidine to spermine. The loss of spermine in particular, may have several consequences that contribute to ischemic injury, including destabilization of chromatin, decreased mitochondrial Ca2+ buffering capacity, and increased susceptibility to oxidative stress. Based on our and other studies, we propose a tentative antioxidant mechanism of spermine neuroprotection. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Ctr Clin Canc, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA	Adibhatla, RM (corresponding author), Univ Wisconsin, Ctr Clin Canc, Dept Neurol Surg, H4-330,600 Highland Ave, Madison, WI 53792 USA.	adibhatl@neurosurg.wisc.edu		Sailor, Kurt/0000-0002-9574-6838	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31220, R01 NS 28000] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS028000] Funding Source: NIH RePORTER		Adibhatla RM, 2002, J NEUROCHEM, V80, P12; Adibhatla RM, 2001, STROKE, V32, P2376, DOI 10.1161/hs1001.096010; Babu GN, 2001, NEUROSCI LETT, V300, P17, DOI 10.1016/S0304-3940(01)01538-5; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; BASU HS, 1995, POLYAMINES REGULATIO, V1, P101; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Coert BA, 2000, NEUROSCI LETT, V282, P5, DOI 10.1016/S0304-3940(00)00856-9; Cohen S A, 1998, Guttmacher Rep Public Policy, V1, P1; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; Els T, 2001, STROKE, V32, P43, DOI 10.1161/01.STR.32.1.43; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HALL ED, 1997, PRIMER CEREBROVASCUL, P200; Henley CM, 1997, J NEUROCHEM, V69, P259; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; Kauppinen RA, 1995, PROG NEUROBIOL, V47, P545, DOI 10.1016/0301-0082(95)00037-2; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11426, DOI 10.1073/pnas.89.23.11426; KHAN AU, 1992, P NATL ACAD SCI USA, V89, P11428, DOI 10.1073/pnas.89.23.11428; KITADA M, 1981, RES COMMUN CHEM PATH, V33, P487; Lee Y, 1998, J BIOL CHEM, V273, P19490, DOI 10.1074/jbc.273.31.19490; LOVAAS E, 1991, FREE RADICAL BIO MED, V11, P455, DOI 10.1016/0891-5849(91)90061-7; LOVAAS E, 1995, MED HYPOTHESES, V45, P59, DOI 10.1016/0306-9877(95)90204-X; Lovaas E, 1997, Adv Pharmacol, V38, P119; Marzabadi MR, 1996, FREE RADICAL BIO MED, V21, P375, DOI 10.1016/0891-5849(96)00038-X; Morgan DML, 1998, BIOCHEM SOC T, V26, P586, DOI 10.1042/bst0260586; PASCHEN W, 1990, NEUROSCI LETT, V110, P232, DOI 10.1016/0304-3940(90)90817-S; PASCHEN W, 1987, NEUROCHEM PATHOL, V7, P143, DOI 10.1007/BF02834214; PASCHEN W, 1992, MOL CHEM NEUROPATHOL, V16, P241, DOI 10.1007/BF03159973; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; PASCHEN W, 1987, J NEUROCHEM, V49, P35, DOI 10.1111/j.1471-4159.1987.tb03390.x; PEGG AE, 1982, AM J PHYSIOL, V243, pC212; Rao AM, 1998, NEUROSCI LETT, V256, P65, DOI 10.1016/S0304-3940(98)00780-0; Rao AM, 2000, J NEUROCHEM, V74, P1106; RAO AM, 1995, J NEUROCHEM, V65, P2639; RAO AM, 1999, RRD NEUROCHEMISTRY 2, V2, P517; SAUER D, 1992, NEUROSCI LETT, V141, P131, DOI 10.1016/0304-3940(92)90878-B; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; Seiler N, 2000, NEUROCHEM RES, V25, P471, DOI 10.1023/A:1007508008731; SHIN WW, 1985, J NEUROCHEM, V44, P1056, DOI 10.1111/j.1471-4159.1985.tb08724.x; SHOCKLEY RP, 1988, BRAIN RES, V454, P170, DOI 10.1016/0006-8993(88)90816-5; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TADOLINI B, 1988, BIOCHEM J, V249, P33, DOI 10.1042/bj2490033; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; Ying WH, 1999, J NEUROCHEM, V73, P1549, DOI 10.1046/j.1471-4159.1999.0731549.x	50	53	60	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 31	2002	938	1-2					81	86	PII S0006-8993(02)02447-2	10.1016/S0006-8993(02)02447-2			6	Neurosciences	Neurosciences & Neurology	563RV	WOS:000176270100011	12031538				2021-06-18	
J	Magee, WL; Davidson, JW				Magee, WL; Davidson, JW			The effect of music therapy on mood states in neurological patients: A pilot study	JOURNAL OF MUSIC THERAPY			English	Article							RHYTHMIC AUDITORY-STIMULATION; TRAUMATIC BRAIN INJURY; PARKINSONS-DISEASE; GAIT; STROKE; INSTRUCTION; SPEECH	Music therapy as a clinical intervention has been demonstrated to improve mood states with a variety of populations, however this has not yet been shown empirically with participants with neurological impairments. This report presents the results of a pilot study examining the effect of music therapy on moods states in patients with acquired and complex neuro-disabilities. Using a single subject design, pre and postsession mood states were measured using the Profile of Mood States (Bipolar form). Analyses examined the main effects of pre/post measures as well as interactions between the specific musical therapeutic intervention, mood state, and diagnosis. Results showed that, in terms of composed-anxious, energetic-tired, and agreeable-hostile mood states, there was a significant difference between pre and post music therapy intervention in a positive direction. Although the study displayed that the benefits of music therapy in treating mood states in this patient group are limited, some of the results were affected by the difficulty of the POMS-BI questionnaire for the subject group. The results are discussed considering methodological improvements and arguing for the inclusion of music therapy as an effective intervention to address negative mood states in neuro-rehabilitation populations.	Royal Hosp Neurodisabil, Mus Therapy Dept, London SW15 3SW, England; Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England	Magee, WL (corresponding author), Royal Hosp Neurodisabil, Mus Therapy Dept, West Hill, London SW15 3SW, England.		Magee, Wendy L./AAP-6839-2020	Magee, Wendy L./0000-0003-4350-1289			Bailey L.M., 1984, MUSIC THER, V4, P5, DOI [DOI 10.1093/MT/4.1.5, 10.1093/mt/4.1.5]; Bruscia K.E., 1987, IMPROVISATIONAL MODE; COHEN NS, 1995, J MUSIC THER, V32, P46, DOI 10.1093/jmt/32.1.46; COHEN NS, 1988, J MUSIC THER, V25, P85, DOI 10.1093/jmt/25.2.85; COHEN NS, 1992, J MUSIC THER, V29, P87, DOI 10.1093/jmt/29.2.102; COHEN NS, 1993, J MUSIC THER, V30, P81, DOI 10.1093/jmt/30.2.81; GERVIN AP, 1991, MUSIC THERAPY PERSPE, V9, P87, DOI DOI 10.1093/MTP/9.1.87; Hanser SB, 1998, J GERONTOL, V49, P265, DOI 10.1093/geronj/49.6.P265; Hurt CP, 1998, J MUSIC THER, V35, P228, DOI 10.1093/jmt/35.4.228; LORR M, 1988, MANUAL PROFILE MOOD; McIntosh GC, 1997, J NEUROL NEUROSUR PS, V62, P22, DOI 10.1136/jnnp.62.1.22; Miller RA, 1996, ELECTROMYOGR MOTOR C, V101, P1, DOI 10.1016/0013-4694(95)00209-X; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Prassas S, 1997, GAIT POSTURE, V6, P218, DOI 10.1016/S0966-6362(97)00010-6; Purdie H, 1997, INT J REHABIL RES, V20, P325, DOI 10.1097/00004356-199709000-00009; THAUT MH, 1989, J MUSIC THER, V26, P155, DOI 10.1093/jmt/26.3.155; Thaut MH, 1999, MOVEMENT DISORD, V14, P808, DOI 10.1002/1531-8257(199909)14:5<808::AID-MDS1014>3.0.CO;2-J; Thaut MH, 1996, MOVEMENT DISORD, V11, P193, DOI 10.1002/mds.870110213; Thaut MH, 1993, NEUROREHABIL NEURAL, V7, P9, DOI DOI 10.1177/136140969300700103	19	53	55	0	32	NATL ASSOC MUSIC THERAPY INC	SILVER SPRING	8455 COLESVILLE RD, STE 1000, SILVER SPRING, MD 20910 USA	0022-2917			J MUSIC THER	J. Music Ther.	SPR	2002	39	1					20	29		10.1093/jmt/39.1.20			10	Music; Rehabilitation	Music; Rehabilitation	553QJ	WOS:000175686700002	12015809				2021-06-18	
J	Delaney, JS; Lacroix, VJ; Gagne, C; Antoniou, J				Delaney, JS; Lacroix, VJ; Gagne, C; Antoniou, J			Concussions among university football and soccer players: A pilot study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; soccer; football; university; symptom duration; risk factors	ATHLETIC HEAD-INJURIES; TRAUMATIC BRAIN INJURY; CEREBRAL CONCUSSION; CONTACT SPORTS; CERVICAL-SPINE; GUIDELINES; RETURN	Objective: A pilot study to examine the incidence and characteristics of concussions for one season of university football and soccer. Design: Retrospective survey. Participants: 60 football and 70 soccer players reporting to 1998 fall training camp. Of these, 44 football and 52 soccer players returned a completed questionnaire. Main Outcome Measures: Based on self-reported symptoms, calculations were made to determine the number of concussions experienced during the previous season, the duration of symptoms, the time for return to play and any associated risk factors for concussions. Results: Of all the athletes who returned completed questionnaires, 34.1% of the football players and 46.2% of the soccer players had experienced symptoms of a concussion during the previous season. Only 16.7% of the concussed football players and 29.2% of the concussed soccer players realized they had suffered a concussion. All of the concussed football players and 75.0% of the concussed soccer players experienced more than one concussion during the season. The symptoms from the concussion lasted for at least 1 day in 28.6% of the football players and 18.1% of the soccer players. Variables that increased the odds of suffering a concussion during the previous season for football and soccer players included a past history of a recognized concussion. Conclusion: More university soccer players than football players may be experiencing sport related concussions. Variables that seem to increase the odds of suffering a concussion during the previous season for football and soccer players include a history of a recognized concussion. Despite being relatively common, many players may not recognize the symptoms of a concussion.	McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, McGill Univ Hlth Ctr, Dept Emergency Med, Montreal, PQ, Canada; McGill Univ, Dept Orthoped Surg, Montreal, PQ, Canada	Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	jdelan2@po-box.mcgill.ca					Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; Cantu RC., 1997, AM COLL SPORTS MED E, P345; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider R., 1973, HEAD NECK INJURIES F; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; 1988, PHYS SPORTSMED, V16, P165	36	53	54	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	OCT	2001	11	4					234	240		10.1097/00042752-200110000-00005			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	491PV	WOS:000172118200005	11753060				2021-06-18	
J	Kim, BT; Raghavendra, VL; Sailor, KA; Bowen, KK; Dempsey, RJ				Kim, BT; Raghavendra, VL; Sailor, KA; Bowen, KK; Dempsey, RJ			Protective effects of glial cell line-derived neurotrophic factor on hippocampal neurons after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						glial cell line-derived neurotrophic factor; neuron death; neuroprotection; traumatic brain injury; rat	CONTROLLED CORTICAL IMPACT; NERVE GROWTH-FACTOR; BARRIER BREAKDOWN; HEAD-INJURY; DEATH; EXPRESSION; ASTROCYTES; RECEPTOR; GDNF; ISCHEMIA	Object. The purpose of this study was to evaluate whether glial cell line-derived neurotrophic factor (GDNF) can protect against hippocampal neuronal death after traumatic brain injury (TBI). Methods. Male Sprague-Dawley rats were subjected to moderate TBI with a controlled cortical impact device while in a state of halothane-induced anesthesia. Then, GDNF or artificial cerebrospinal fluid ([aCSF]; vehicle) was infused into the frontal horn of the left lateral ventricle. In eight brain-injured and eight sham-operated rats, GDNF was infused continuously for 7 days (200 ng/day intracerebroventricularly at a rate of 8.35 ng/0.5 mul/hour). An equal volume of vehicle was infused at the same rate into the remaining eight brain-injured and eight sham-operated rats. Seven days postinjury, all rats were killed. Their brains were sectioned and stained with cresyl violet, and the hippocampal neuronal loss was evaluated in the CA2 and CA3 regions with the aid of microscopy. A parallel set of sections from each brain was subjected to immunoreaction with antibodies against glial fibrillary acidic protein (GFAP; astroglia marker). In the aCSF-treated group, TBI resulted in a significant neuronal loss in the CA2 (60%, p < 0.05) and CA3 regions (68%, p < 0.05) compared with the sham-operated control animals. Compared with control rats infused with aCSF, GDNF infusion significantly decreased the TBI-induced neuronal loss in both the CA2 (58%, p < 0.05) and CA3 regions (51%, P < 0.05). There was no difference in the number of GFAP-positive astroglial cells in the GDNF-infused rats in the TBI and sham-operated groups compared with the respective vehicle-treated groups. Conclusions. The authors found that GDNF treatment following TBI is neuroprotective.	Univ Wisconsin, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA; Soonchunhyang Univ Hosp, Dept Neurosurg, Seoul, South Korea	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, H4-336 CSC,600 Highland Ave, Madison, WI 53792 USA.			Sailor, Kurt/0000-0002-9574-6838			Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Gash DM, 1998, ANN NEUROL, V44, pS121, DOI 10.1002/ana.410440718; Glazner GW, 1998, J COMP NEUROL, V391, P42, DOI 10.1002/(SICI)1096-9861(19980202)391:1<42::AID-CNE4>3.0.CO;2-R; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDSAY RM, 1995, NATURE, V373, P289, DOI 10.1038/373289a0; Lu X, 1997, J COMP NEUROL, V388, P484; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Miyazaki H, 1999, NEUROSCIENCE, V89, P643, DOI 10.1016/S0306-4522(98)00592-2; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Sawada H, 2000, J NEUROCHEM, V74, P1175; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wang Y, 1997, J NEUROSCI, V17, P4341; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Yang SY, 1998, J NEUROSURG, V89, P297, DOI 10.3171/jns.1998.89.2.0297	32	53	58	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2001	95	4					674	679		10.3171/jns.2001.95.4.0674			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	478NQ	WOS:000171352600017	11596962				2021-06-18	
J	Chan, L; Doctor, J; Temkin, N; MacLehose, RF; Esselman, P; Bell, K; Dikmen, S				Chan, L; Doctor, J; Temkin, N; MacLehose, RF; Esselman, P; Bell, K; Dikmen, S			Discharge disposition from acute care after traumatic brain injury: The effect of insurance type	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; health care economics and organizations; health maintenance organizations; Medicaid; patient discharge; rehabilitation; skilled nursing facilities	REHABILITATION; OUTCOMES; STROKE	Objective: To determine if persons with traumatic brain injury (TBI) who are insured by Medicaid or health maintenance organizations (HMOs) are more likely to receive postacute care in skilled nursing facilities (SNFs) than in rehabilitation facilities, compared with persons insured by commercial fee-for-service (FFS) plans. Design: Retrospective cohort study. Setting: County hospital admitting 30% of all Washington State TBI patients. Patients: Patients with moderate to severe TBI discharged to rehabilitation facilities or SNFs between 1992 and 1997 (n = 1271); 56.3% were insured by Medicaid, 26.1% by FFS plans, and 17.6% by HMOs. Interventions: Not applicable. Main Outcome Measures: Disposition on discharge from acute care (rehabilitation facilities vs SNF); adjusted relative risk (RR) and confidence interval (CI) for different insurance types. Results: After accounting for confounding factors, Medicaid patients were 68% more likely (RR = 1.68, 95% CI 1.34-2.11) and HMO patients were 23% more likely (RR = 1.23, 95% CI = .90-1.68) to go to a SNF than FFS patients. However, the latter difference was not statistically significant. Conclusions: An association exists between insurance type and postacute care site. Efforts should be made to determine the effect this relationship has on the cost and outcomes for TBI patients.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Hlth Care Financing Adm, Div Clin Stan & Qual, Reg 10, Seattle, WA USA	Chan, L (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.			Bell, Kathleen/0000-0002-0928-2046			*ASS ADV AUT MED, 1990, ABBR INJ SCAL; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; *HLTH CAR FIN ADM, 1998, HCFA PUBL; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Retchin SM, 1997, JAMA-J AM MED ASSOC, V278, P119; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	8	53	53	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2001	82	9					1151	1154		10.1053/apmr.2001.24892			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	470LR	WOS:000170873900001	11552183				2021-06-18	
J	Milatovic, D; Zivin, M; Gupta, RC; Dettbarn, WD				Milatovic, D; Zivin, M; Gupta, RC; Dettbarn, WD			Alterations in cytochrome c oxidase activity and energy metabolites in response to kainic acid-induced status epilepticus	BRAIN RESEARCH			English	Article						kainic acid; status epilepticus; adenosine triphosphate; phosphocreatine; cytochrome c oxidase; vitamin E; n-tert-butyl-alpha-phenylnitrone; cytochrome c oxidase subunit IV mRNA	TERT-BUTYL-NITRONE; SPIN-TRAPPING AGENTS; NITRIC-OXIDE; ALPHA-TOCOPHEROL; FREE-RADICALS; VITAMIN-E; OXIDATIVE STRESS; INDUCED NEURODEGENERATION; LIPID-PEROXIDATION; NEURONAL INJURY	The effects of kainic acid (KA)-induced limbic seizures have been investigated on cytochrome c oxidase (COx) activity, COx subunit IV mRNA abundance, ATP and phosphocreatine (PCr) levels in amygdala, hippocampus and frontal cortex of rat brain. Rats were killed either 1 h, three days or seven days after the onset of status epilepticus (SE) by CO, and decapitation for the assay of COx activity and by head-focused microwave for the determination of ATP and PCr. Within I h COx activity and COx subunit IV mRNA increased in all brain areas tested between 120% and 130% of control activity, followed by a significant reduction from control, in amygdala and hippocampus on day three and seven, respectively. In amygdala, ATP and PCr levels were reduced to 44% and 49% of control 1 h after seizures. No significant recovery was seen on day three or seven. Pretreatment of rats-with the spin trapping agent N-tert-butyl-alpha -phenylnitrone (PBN, 200 mg kg(-1), i.p.) 30 min before KA administration had no effect on SE, but protected COx activity and attenuated changes in energy metabolites. Pretreatment for three days with the endogenous antioxidant vitamin E (Vit-E, 100 mg/kg, i.p.) had an even greater protective effect than PBN. Both pretreatment regimens attenuated KA-induced neurodegenerative changes, as assessed by histology and prevention of the decrease of COx subunit IV mRNA and COx activity in hippocampus and amygdala, otherwise seen following KA-treatment alone. These findings suggest a close relationship between SE-induced neuronal injury and deficits in energy metabolism due to mitochondrial dysfunction. (C) 2001 Elsevier Science B.V. All rights reserved.	Vanderbilt Univ, Sch Med, Med Ctr S, Dept Pharmacol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Med Ctr S, Dept Neurol, Nashville, TN 37212 USA; Univ Ljubljana, Sch Med, Inst Pathophysiol, Ljubljana 1000, Slovenia; Murray State Univ, Breathitt Vet Ctr, Dept Toxicol, Hopkinsville, KY 42241 USA	Dettbarn, WD (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr S, Dept Pharmacol, 2100 Pierce Ave, Nashville, TN 37212 USA.	wolf-d.dettbarn@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES004597] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES 4597] Funding Source: Medline		Andersen KA, 1996, J APPL PHYSIOL, V80, P862; ANDERSON DE, 1993, BIOCHEM BIOPH RES CO, V193, P878, DOI 10.1006/bbrc.1993.1707; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; BINDOLI A, 1988, FREE RADICAL BIO MED, V5, P247, DOI 10.1016/0891-5849(88)90018-4; BIRKLE DL, 1993, BRAIN RES, V613, P115, DOI 10.1016/0006-8993(93)90461-U; BJORNEBOE A, 1991, J NUTR, V121, P1208; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BOSE R, 1992, TOXICOL LETT, V60, P211, DOI 10.1016/0378-4274(92)90276-P; BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; BRUCE AJ, 1995, FREE RADICAL BIO MED, V18, P993, DOI 10.1016/0891-5849(94)00218-9; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Chow CK, 1999, FREE RADICAL BIO MED, V27, P580, DOI 10.1016/S0891-5849(99)00121-5; Ciani E, 1996, BRAIN RES, V728, P1; COLADO MI, 1995, EUR J PHARMACOL, V280, P343, DOI 10.1016/0014-2999(95)00298-Y; Dettbarn W-D., 2001, INT C ANT, P183; Fallon J, 1997, EXP NEUROL, V144, P193, DOI 10.1006/exnr.1997.6416; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Fredriksson A, 1997, J NEURAL TRANSM, V104, P579, DOI 10.1007/BF01291877; FREEMAN BA, 1982, LAB INVEST, V47, P412; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; Gupta R. C., 1998, TOXICOL SCI, V42, P156; Gupta R.C., 1999, TOXICOL SCI, V48, P188; Gupta RC, 2000, PFLUG ARCH EUR J PHY, V440, pR160, DOI 10.1007/s004240000047; Gupta RC, 2000, HUM EXP TOXICOL, V19, P297, DOI 10.1191/096032700678815927; He QP, 1997, FREE RADICAL BIO MED, V22, P917, DOI 10.1016/S0891-5849(96)00478-9; HEVNER RF, 1990, J NEUROSCI, V10, P1331; KOTEGAWA M, 1993, J MOL CELL CARDIOL, V25, P1067, DOI 10.1006/jmcc.1993.1119; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; Lancelot E, 1997, FREE RADICAL BIO MED, V23, P1031, DOI 10.1016/S0891-5849(97)00128-7; Lehrer-Graiwer JE, 2000, NEUROSCI LETT, V288, P107, DOI 10.1016/S0304-3940(00)01205-2; LUFT R, 1995, BBA-MOL BASIS DIS, V1271, P1, DOI 10.1016/0925-4439(95)00002-L; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MARUBAYASHI S, 1986, SURGERY, V99, P184; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Milatovic D, 2000, FREE RADICAL BIO MED, V28, P597, DOI 10.1016/S0891-5849(99)00270-1; MILATOVIC D, 2001, TOXICOLOGIST, V60, P225; MIYAJIMA T, 1995, BIOCHEM BIOPH RES CO, V215, P114, DOI 10.1006/bbrc.1995.2440; Miyajima T, 1997, FREE RADICAL BIO MED, V22, P463, DOI 10.1016/S0891-5849(96)00391-7; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; Ong WY, 2000, EXP BRAIN RES, V131, P178, DOI 10.1007/s002219900329; Ong WY, 1996, EXP BRAIN RES, V109, P251; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; Punz A, 1998, CLIN NUTR, V17, P85, DOI 10.1016/S0261-5614(98)80311-7; Sack CA, 1996, NEUROSCI LETT, V205, P181, DOI 10.1016/0304-3940(96)12417-4; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Savolainen KM, 1995, TOXICOL LETT, V82-3, P399; Scanlon JM, 1997, EUR J PHARMACOL, V326, P67, DOI 10.1016/S0014-2999(97)00137-4; Schulz JB, 1997, MOL CELL BIOCHEM, V174, P193, DOI 10.1023/A:1006852306789; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SIRINATHSINGHJI DJS, 1990, NEUROSCIENCE, V34, P675, DOI 10.1016/0306-4522(90)90174-3; SMITH MW, 1980, BIOCHIM BIOPHYS ACTA, V618, P192, DOI 10.1016/0005-2760(80)90025-9; SOUSSI B, 1990, ACTA PHYSIOL SCAND, V138, P107, DOI 10.1111/j.1748-1716.1990.tb08822.x; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; Sperlagh B, 1996, SEMIN NEUROSCI, V8, P175, DOI 10.1006/smns.1996.0023; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; TANAKA K, 1994, NEUROCHEM RES, V19, P117, DOI 10.1007/BF00966804; TAYYABA K, 1985, ACTA PHARMACOL TOX, V57, P190, DOI 10.1111/bcpt.1985.57.3.190; Thomas CE, 1997, J NEUROCHEM, V68, P1173; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; VANACKER SABE, 1993, FREE RADICAL BIO MED, V15, P311, DOI 10.1016/0891-5849(93)90078-9; Wharton D., 1967, METHODS ENZYMOL, V10, P245, DOI [10.1016/0076-6879(67)10048-7, DOI 10.1016/0076-6879(67)10048-7]; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3; WONGRILEY MTT, 1976, BRAIN RES, V108, P257, DOI 10.1016/0006-8993(76)90185-2; Yang ZP, 1998, J PHYSIOLOGY-PARIS, V92, P157, DOI 10.1016/S0928-4257(98)80002-8; Yang ZP, 1996, TOXICOL APPL PHARM, V138, P48, DOI 10.1006/taap.1996.0096; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	74	53	54	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 31	2001	912	1					67	78		10.1016/S0006-8993(01)02657-9			12	Neurosciences	Neurosciences & Neurology	477CR	WOS:000171266000008	11520494				2021-06-18	
J	Schmidt, EA; Czosnyka, M; Gooskens, I; Piechnik, SK; Whitfield, PC; Pickard, JD				Schmidt, EA; Czosnyka, M; Gooskens, I; Piechnik, SK; Whitfield, PC; Pickard, JD			Preliminary experience of the estimation of cerebral perfusion pressure using transcranial Doppler ultrasonography	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						cerebral perfusion pressure; transcranial Doppler; non-invasive monitoring	HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; JUGULAR BULB	Objective-The direct calculation of cerebral perfusion pressure (CPP) as the difference between mean arterial pressure and intracranial pressure (ICP) produces a number which does not always adequately describe conditions for brain perfusion. A non-invasive method of CPP measurement has previously been reported based on waveform analysis of blood how velocity measured in the middle cerebral artery (MCA) by transcranial Doppler. This study describes the results of clinical tests of the prototype bilateral transcranial Doppler based apparatus for non-invasive CPP measurement (nCPP). Methods-Twenty five consecutive, paralysed, sedated, and ventilated patients with head injury were studied. Intracranial pressure (ICP) and arterial blood pressure (ABP) were monitored continuously. The left and right MCAs were insonated daily (108 measurements) using a purpose built transcranial Doppler monitor (Neuro Q(TM), Deltex Ltd, Chichester, UK) with software capable of the non-invasive estimation of CPP. Time averaged values of mean and diastolic flow velocities (FVm, FVd) and ABP were calculated, nCPP was then computed as: ABPxFVd/FVm+14. Results-The absolute difference between real CPP and nCPP (daily averages) was less than 10 mm Hg in 89% of measurements and less than 13 mm Hg in 92% of measurements. The 95% confidence range for predictors was no wider than +/-12 mm Hg (n=25) for the CPP, varying from 70 to 95 mm Hg. The absolute value of side to side differences in nCPP was significantly greater (p<0.05) when CT based evidence of brain swelling was present and was also positively correlated (p<0.05) with mean ICP. Conclusion-The device is of potential benefit for intermittent or continuous monitoring of brain perfusion pressure in situations where the direct measurement is not available or its reliability is in question.	Addenbrookes Hosp, Acad Neurosurg & Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; CHRU, Dept Neurosurg, F-63000 Clermont Ferrand, France; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge, England	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg & Wolfson Brain Imaging Ctr, Box 167, Cambridge CB2 2QQ, England.			Piechnik, Stefan K./0000-0002-0268-5221	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Aaslid R, 1986, INTRACRANIAL PRESSUR, VVI, P229; ALRAWI PG, 1997, ACTA NEUROCHIR     S, V71, P255; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1999, J NEUROSURG, V91, P11, DOI 10.3171/jns.1999.91.1.0011; Czosnyka M, 1998, J NEUROSURG, V88, P802, DOI 10.3171/jns.1998.88.5.0802; CZOSNYKA M, 1999, J CEREBRAL BLOOD FLO, V19, pS362; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; Giller CA, 1999, J CEREBR BLOOD F MET, V19, P452, DOI 10.1097/00004647-199904000-00011; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; MARMAROU A, 1991, J NEUROSURG S, V75, pS559; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Miller J D, 1972, Prog Brain Res, V35, P411; Nagai H, 1997, STROKE, V28, P603, DOI 10.1161/01.STR.28.3.603; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schmidtmann ET, 1999, J MED ENTOMOL, V36, P1; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wolfla CE, 1997, J NEUROSURG, V86, P505, DOI 10.3171/jns.1997.86.3.0505; ZURYNSKI Y, 1991, Neurological Research, V13, P248	24	53	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2001	70	2					198	204		10.1136/jnnp.70.2.198			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	395YX	WOS:000166610500011	11160468	Bronze, Green Published			2021-06-18	
J	Goldstein, FC; Levin, HS				Goldstein, FC; Levin, HS			Cognitive outcome after mild and moderate traumatic brain injury in older adults	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; BEHAVIORAL SEQUELAE; AGE; CLASSIFICATION; CONSEQUENCES; PREDICTION; RECOVERY; FALLS; SCALE; RISK	This paper presents findings on the cognitive outcome of older adults sustaining mild traumatic brain injury (TBI). Results indicate that mild TBI patients who are 50 years or older, unlike those with moderate TBI, exhibit cognitive functioning that is comparable to noninjured controls by 1-2-months postinjury. However, these patients continue to report significant anxiety, depression, and somatic preoccupation despite their improvement on objective neuropsychological measures. The lowest postresuscitation Glasgow Coma Scale (GCS) score and the presence of intracranial pathology are more strongly associated with outcome than the durations of posttraumatic amnesia and impaired consciousness, possibly reflecting measurement issues in older persons who are likely to be injured in low velocity falls and to suffer delayed complications. A classification system that considers not only the GCS score but also the presence of intracranial pathology is sensitive to differences in the outcome of older adults, similar to the findings in young patients. The implications of these findings for older TBI patients and directions for research are discussed.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA; Emory Univ, Wesley Woods Ctr, Atlanta, GA 30329 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Goldstein, FC (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMACHER AL, 1987, NEUROSURGERY, V20, P954; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FIELDS RB, 1997, HDB NEUROPSYCHOLOGY, P280; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; GOODMAN H, 1992, PHYSICAL MED REHABIL, P441; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1987, HEAD INJURY; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Libon DJ, 1996, CLIN NEUROPSYCHOL, V10, P237, DOI 10.1080/13854049608406686; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1990, AM J PUBLIC HEALTH, V80, P217, DOI 10.2105/AJPH.80.2.217; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; *OFF POP CENS SURV, 1992, 1991 CENS; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Spreen O., 1998, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P281; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; *US DEP COMM BUR C, 1997, STAT ABSTR US 1997; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231; Vollmer DG, 1991, J NEUROSURG S, V75, P37; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winocur G, 1992, HDB AGING COGNITION, P315; YSEVAGE JA, 1983, J PSYCHIAT RES, V17, P37	69	53	55	1	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					739	753		10.1076/jcen.23.6.739.1028			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200004	11910541				2021-06-18	
J	Engelborghs, K; Haseldonckx, M; Van Reempts, J; Van Rossem, K; Wouters, L; Borgers, M; Verlooy, J				Engelborghs, K; Haseldonckx, M; Van Reempts, J; Van Rossem, K; Wouters, L; Borgers, M; Verlooy, J			Impaired autoregulation of cerebral blood flow in an experimental model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; cerebral blood flow; closed head injury; hypotension; rat; traumatic brain injury	CLOSED-HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBROVASCULAR RESPONSES; ACUTE HYPERTENSION; ANESTHETIZED RATS; AUTO-REGULATION; ISOFLURANE; CATS; HYPOTENSION; CIRCULATION	In order to study the pathophysiology and the intracranial hemodynamics of traumatic brain injury, we have developed a modified closed-head injury model of impact-acceleration that expresses several features of severe head injury in humans, including acute and long-lasting intracranial hypertension, diffuse axonal injury, neuronal necrosis, bleeding, and edema. In view of the clinical relevance of impaired autoregulation of cerebral blood flow after traumatic brain injury, and aiming at further characterization of the model, we investigated the autoregulation efficiency 24 h after experimental closed-head injury. Cortical blood flow was continuously monitored with a laser-Doppler flowmeter, and the mean arterial blood pressure was progressively decreased by controlled hemorrhage. Relative laser-Doppler flow was plotted against the corresponding mean arterial blood pressure, and a two-line segmented model was applied to determine the break point and slopes of the autoregulation curves. The slope of the curve at the right hand of the break point was significantly increased in the closed head injury group (0.751 +/- 0.966%/mm Hg versus -0.104 +/- 0.425%/mm Hg,p = 0.028). The break point tended towards higher values in the closed head injury group (62.2 +/- 20.8 mm Hg versus 46.9 +/- 12.7 mm Hg; mean a SD, p = 0.198). It is concluded that cerebral autoregulation in this modified closed head injury model is impaired 24 h after traumatic brain injury. This finding, in addition to other characteristic features of severe head injury established earlier in this model, significantly contributes to its clinical relevance.	Janssen Res Fdn, Dept Life Sci, B-2340 Beerse, Belgium; Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium	Van Rossem, K (corresponding author), Janssen Res Fdn, Dept Life Sci, Turnhoutseweg 30, B-2340 Beerse, Belgium.	kvrossem@janbe.jnj.com					Bouma G J, 1995, New Horiz, V3, P384; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bullock MR, 1996, J NEUROTRAUM, V13, P711; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FITCH W, 1975, CIRC RES, V37, P550, DOI 10.1161/01.RES.37.5.550; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOLDING EM, 1999, J CEREB BLOOD FLO S1, V19, pS624; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARDEBO JE, 1977, ACTA NEUROL SCAND, V56, P92; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; HEISTAD DD, 1979, CIRC RES, V45, P331, DOI 10.1161/01.RES.45.3.331; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HUDETZ AG, 1995, AM J PHYSIOL-HEART C, V268, pH2202; HUDSON DJ, 1966, J AM STAT ASSOC, V61, P1097, DOI 10.2307/2283203; JOHANSSON BB, 1979, ACTA NEUROL SCAND, V60, P193; LEE JG, 1994, ANESTH ANALG, V79, P58; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL WH, 1959, PHYSIOL REV, V39, P239; MCPHERSON RW, 1988, ANESTHESIOLOGY, V69, P493, DOI 10.1097/00000542-198810000-00008; MILETICH DJ, 1976, ANESTH ANALG, V55, P100; MORITA Y, 1995, ACTA PHYSIOL SCAND, V154, P121, DOI 10.1111/j.1748-1716.1995.tb09894.x; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Preckel MP, 1996, INT J MICROCIRC, V16, P277, DOI 10.1159/000179186; RAICHLE ME, 1971, EUR NEUROL, V6, P1, DOI 10.1159/000114443; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1994, INTRACRANIAL PRESSUR, V9, P222; SCHMIDT JF, 1990, J CARDIOVASC PHARM, V15, P983, DOI 10.1097/00005344-199006000-00017; SEBER GAF, 1989, NONLINEAR REGRESSION, P447; STRAUSS CC, 1992, J ANXIETY DISORD, V6, P89, DOI 10.1016/0887-6185(92)90029-7; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; TOMIDA S, 1989, J CEREBR BLOOD F MET, V9, P79, DOI 10.1038/jcbfm.1989.11; Toyoda K, 1997, J CEREBR BLOOD F MET, V17, P680; TSAI ML, 1989, NEUROPHARMACOLOGY, V28, P1075, DOI 10.1016/0028-3908(89)90120-2; VEHAEGEN MJ, 1993, STROKE, V24, P407; VERHAEGEN MJ, 1992, J CEREBR BLOOD F MET, V12, P230, DOI 10.1038/jcbfm.1992.33; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yamamoto S, 1998, BRAIN RES, V782, P194, DOI 10.1016/S0006-8993(97)01278-X	51	53	53	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					667	677		10.1089/089771500415418			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600004	10972243				2021-06-18	
J	Otto, VI; Heinzel-Pleines, UE; Gloor, SM; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Otto, VI; Heinzel-Pleines, UE; Gloor, SM; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			sICAM-1 and TNF-alpha induce MIP-2 with distinct kinetics in astrocytes and brain microvascular endothelial cells	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; adhesion molecules; chemokines; astrocytes; microvascular endothelial cells	INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; SOLUBLE ICAM-1; PNEUMOCOCCAL MENINGITIS; GENE-EXPRESSION; GLIAL-CELLS; IN-VITRO; CYTOKINES	The dysfunction of the blood-brain barrier (BBB) occurring after traumatic brain injury (TBI) is mediated by intracerebral neutrophil accumulation, chemokine release (e.g., interleukin (IL)-8) and upregulation of adhesion molecules (e.g., intercellular adhesion molecule (ICAM)-1). In patients with severe TBI, we previously found that elevated cerebrospinal fluid (CSF) IL-8 and soluble (s)ICAM-1 correlate with BBB dysfunction, and this prompted us to concomitantly monitor IL-8, sICAM-1 and their stimulator tumor necrosis factor (TNF)-alpha in CSF. Potential mechanisms for upregulation of the IL-8 analogue, murine macrophage inflammatory protein (MIP)-2, and sICAM-1 at the BBB were studied using cultured mouse astrocytes and brain microvascular endothelial cells (MVEC). In CSF of seven patients, IL-8 and sICAM-1 were elevated for 19 days after severe TBI, whereas TNF-alpha exceeded normal values on 9 days. Stimulation of MVEC and astrocytes with TNF-alpha simultaneously induced the release of MIP-2 reaching saturation by 4-8 hr and of sICAM-1 increasing continuously from 2-4 hr to 12 hr. Augmented sICAM-1 production correlated with enhanced membrane-bound (m)ICAM-1 expression in both cell types (r(s) = 0.96 and 0.90, P < 0.0001), but was markedly higher in astrocytes. The release of sICAM-1 was not influenced by IL-8 or MIP-2, although astrocytes and MVEC expressed the IL-8/MIP-2 receptor (CXCR-2) as determined by FAGS analysis. Instead, we found that sICAM-1 strongly induced MIP-2 secretion by both cell types with kinetics differing from those evoked by TNF-alpha. If added together, sICAM-1 and TNF-alpha synergistically induced MIP-2 production suggesting the involvement of two different pathways for MIP-2 regulation. J. Neurosci. Res. 60:733-742, 2000. (C) 2000 Wiley-Liss, Inc.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, Zurich, Switzerland; Univ Tubingen Hosp, Dept Internal Med, Tubingen, Germany; ETH Zentrum, Fed Inst Technol, Inst Biochem, Zurich, Switzerland	Otto, VI (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland.			Otto, Vivianne/0000-0002-1157-0186; Morganti-Kossmann, Cristina/0000-0002-0807-2063			ALOISI F, 1992, J IMMUNOL, V149, P2358; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; BOWMAN PD, 1983, ANN NEUROL, V14, P396, DOI 10.1002/ana.410140403; Budnik A, 1996, EXP HEMATOL, V24, P352; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; HALSTENSEN A, 1993, J INFECT DIS, V167, P471, DOI 10.1093/infdis/167.2.471; HASKARD D, 1986, J IMMUNOL, V137, P2901; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, P699; Ikeda M, 1996, CYTOKINE, V8, P109, DOI 10.1006/cyto.1996.0015; KING PD, 1995, J IMMUNOL, V154, P6080; KOEDEL U, 1995, ANN NEUROL, V37, P313, DOI 10.1002/ana.410370307; Komatsu S, 1997, AM J PATHOL, V151, P205; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KUBY J, 1997, IMMUNOLOGY, P357; Kusterer K, 1998, AM J PHYSIOL-GASTR L, V275, pG377; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lakshminarayanan V, 1997, J BIOL CHEM, V272, P32910, DOI 10.1074/jbc.272.52.32910; LUKACS NW, 1994, BLOOD, V83, P1174; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; MCCABE SM, 1993, CELL IMMUNOL, V150, P364, DOI 10.1006/cimm.1993.1204; MEYER DM, 1995, J IMMUNOL, V155, P3578; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; MullerLadner U, 1996, J NEUROL SCI, V144, P135, DOI 10.1016/S0022-510X(96)00217-1; Paolieri F, 1997, ALLERGY, V52, P521, DOI 10.1111/j.1398-9995.1997.tb02595.x; Perry VH, 1997, MOL MED TODAY, V3, P335, DOI 10.1016/S1357-4310(97)01077-0; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39; Schmal H, 1998, J IMMUNOL, V161, P3685; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHRIKANT P, 1994, J NEUROIMMUNOL, V51, P209, DOI 10.1016/0165-5728(94)90083-3; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Shrikant P, 1996, J IMMUNOL, V157, P1819; SOBEL RA, 1990, AM J PATHOL, V136, P1309; SPELLERBERG B, 1994, ANN MED, V26, P411, DOI 10.3109/07853899409148362; STOCKER R, 1995, INTEGRATED APPROACH, P196; Taub Dennis D., 1996, Cytokine and Growth Factor Reviews, V7, P355, DOI 10.1016/S1359-6101(97)89237-4; Tomita M, 1996, ACT NEUR S, V66, P32; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; Vastag M, 1999, MICROVASC RES, V57, P52, DOI 10.1006/mvre.1998.2115; Wedi B, 1996, ALLERGY, V51, P676; Xiao YQ, 1999, BBA-MOL CELL RES, V1450, P155, DOI 10.1016/S0167-4889(99)00042-7	52	53	54	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUN 15	2000	60	6					733	742		10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X			10	Neurosciences	Neurosciences & Neurology	321TE	WOS:000087470100005	10861785				2021-06-18	
J	Patel, NY; Hoyt, DB; Nakaji, P; Marshall, L; Holbrook, T; Coimbra, R; Winchell, RJ; Mikulaschek, AW				Patel, NY; Hoyt, DB; Nakaji, P; Marshall, L; Holbrook, T; Coimbra, R; Winchell, RJ; Mikulaschek, AW			Traumatic brain injury: Patterns of failure of nonoperative management	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MASSACHUSETTS	Amer Assoc Surgery Trauma			SEVERE HEAD-INJURY; ACUTE EPIDURAL HEMATOMA; ACUTE SUBDURAL-HEMATOMA; INTRACEREBRAL HEMATOMA; EXTRADURAL HEMATOMAS; CONSERVATIVE MANAGEMENT; COMPUTED-TOMOGRAPHY; RAPID RESOLUTION; PATIENT; LESIONS	Objective: The circumstances of failure for nonoperative management of blunt traumatic brain injury have been poorly defined. In this study, all trauma patients identified over a 12-year period with progression of neurologic injury requiring craniotomy were retrospectively reviewed. Methods: Data collected included demographic information, mechanism of injury, field and admission vital signs, and Glasgow Coma Scale score, medications, associated injuries, and coagulopathy. Head computed tomographic scans were reviewed, and anatomic findings were correlated with clinical changes (change in mental status or elevation of intracranial pressure) that led to subsequent CT scan and craniotomy. Results: Of 20,100 patients, there were 852 who had computed tomographic scans with acute intracranial injuries on admission; 462 patients were managed nonoperatively. Fifty-seven patients had progression of neurologic injury (34 < 24 hours = early; 23 > 24 hours = late) that required surgery. Conclusion: Of the variables investigated, only anatomic location of injury was found to be predictive of early failure of nonoperative management. Frontal intraparenchymal hematomas are particularly prone to early failure. Clinical examination and intracranial pressure monitoring are equally important in detecting failure and should be an integral part of nonoperative management.	Univ Calif San Diego, Med Ctr, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Univ Calif San Diego, Med Ctr, Dept Family Med, Div Neurosurg, San Diego, CA 92103 USA	Hoyt, DB (corresponding author), Univ Calif San Diego, Med Ctr, Dept Surg, Div Trauma, 8896,200 W Arbor Dr, San Diego, CA 92103 USA.		Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			Aldrich E F, 1991, Neurosurg Clin N Am, V2, P373; AOKI N, 1988, J NEUROSURG, V68, P149, DOI 10.3171/jns.1988.68.1.0149; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BROWDER J, 1942, N Y STATE J MED, V42, P230; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; CUCCINIELLO B, 1993, ACTA NEUROCHIR, V120, P47, DOI 10.1007/BF02001469; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ERICSON K, 1981, ACTA RADIOL DIAGN, V22, P513, DOI 10.1177/028418518102200501; EVANS JP, 1946, J NEUROSURG, V3, P101, DOI 10.3171/jns.1946.3.2.0101; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; GUILLERMAIN P, 1986, ADV NEUROTRAUMATOLOG, P1; GURGIAN E, 1974, INJURIES BRAIN SPINA, P282; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; JACKSON JJ, 1950, J NEUROSURG, V7, P444; JAMIESON KG, 1972, J NEUROSURG, V37, P528, DOI 10.3171/jns.1972.37.5.0528; Jennett B, 1981, MANAGEMENT HEAD INJU; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; NAGAO T, 1986, NEUROSURGERY, V19, P465, DOI 10.1227/00006123-198609000-00024; PAPO I, 1980, NEUROSURGERY, V7, P337, DOI 10.1227/00006123-198010000-00005; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; POZZATI E, 1984, NEUROSURGERY, V14, P724, DOI 10.1227/00006123-198406000-00012; Rivano C, 1980, J Neurosurg Sci, V24, P77; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TUNCER R, 1993, ACTA NEUROCHIR, V121, P48, DOI 10.1007/BF01405182; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288	37	53	58	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2000	48	3					367	374		10.1097/00005373-200003000-00001			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	295QT	WOS:000085979900001	10744271				2021-06-18	
J	Shohami, E; Kaufer, D; Chen, Y; Seidman, S; Cohen, O; Ginzberg, D; Melamed-Book, N; Yirmiya, R; Soreq, H				Shohami, E; Kaufer, D; Chen, Y; Seidman, S; Cohen, O; Ginzberg, D; Melamed-Book, N; Yirmiya, R; Soreq, H			Antisense prevention of neuronal damages following head injury in mice	JOURNAL OF MOLECULAR MEDICINE-JMM			English	Article						antisense; oligonucleotides; head injury; acetylcholinesterase; emergency medicine	ACETYLCHOLINESTERASE-TRANSGENIC MICE; TRAUMATIC BRAIN INJURY; GENE-EXPRESSION; STRESS; HIPPOCAMPUS; DETERIORATION; STRATEGIES; PATHOLOGY; PROTEIN; CORTEX	Closed head injury (CHI) is an important cause of death among young adults and a prominent risk factor for nonfamilial Alzheimer's disease. Emergency intervention following CHI should therefore strive to improve survival, promote recovery, and prevent delayed neuropathologies. We employed high-resolution nonradioactive in situ hybridization to determine whether a single intracerebroventricular injection of 500 ng 2'-O-methyl RNA-capped antisense oligonucleotide (AS-ODN) against acetylcholinesterase (AChE) mRNA blocks overexpression of the stress-related readthrough AChE (AChE-R) mRNA splicing variant in head-injured mice. Silver-based Golgi staining revealed pronounced dendrite outgrowth in somatosensory cortex of traumatized mice 14 days postinjury that was associated with sites of AChE-R mRNA overexpression and suppressed by anti-AChE AS-ODNs. Furthermore, antisense treatment reduced the number of dead CA3 hippocampal neurons in injured mice, and facilitated neurological recovery as determined by performance in tests of neuromotor coordination. In trauma-sensitive transgenic mice overproducing AChE, antisense treatment reduced mortality from 50% to 20%, similar to that displayed by head-injured control mice. These findings demonstrate the potential of antisense therapeutics in treating acute injury, and suggest antisense prevention of AChE-R overproduction to mitigate the detrimental consequences of various traumatic brain insults.	Hebrew Univ Jerusalem, Fac Social Sci, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Social Sci, Sch Pharm, Dept Pharmacol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Social Sci, Dept Psychol, IL-91904 Jerusalem, Israel	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Fac Social Sci, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.		Yirmiya, Raz/D-1090-2014	Yirmiya, Raz/0000-0002-4009-7316; Soreq, Hermona/0000-0002-0955-526X			Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Beeri R, 1997, J NEUROCHEM, V69, P2441; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; CASCERES A, 1983, J COMP NEUROL, V214, P387; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, P115, DOI 10.1089/oli.1.1998.8.115; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Grifman M, 1997, ANTISENSE NUCLEIC A, V7, P351, DOI 10.1089/oli.1.1997.7.351; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Imai Y, 1998, MOL BRAIN RES, V53, P33, DOI 10.1016/S0169-328X(97)00262-3; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, NEUROSCIENTIST, V5, P173, DOI 10.1177/107385849900500314; Kreutz MR, 1998, J NEUROSCI, V18, P8278; McCarthy MM, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P283; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Morrow BA, 1999, J NEUROSCI, V19, P5666; PERRY E, 2000, IN PRESS EUR J PHARM; Robinson RG, 1997, ANNU REV MED, V48, P217; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Seidman S, 1999, ANTISENSE NUCLEIC A, V9, P333, DOI 10.1089/oli.1.1999.9.333; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOREQ H, 2000, ANTISENSE DRUG TECHN; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	37	53	56	1	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0946-2716			J MOL MED-JMM	J. Mol. Med.		2000	78	4					228	236		10.1007/s001090000104			9	Genetics & Heredity; Medicine, Research & Experimental	Genetics & Heredity; Research & Experimental Medicine	333VH	WOS:000088151100007	10933585				2021-06-18	
J	Stamatakis, EA; Glabus, MF; Wyper, DJ; Barnes, A; Wilson, JTL				Stamatakis, EA; Glabus, MF; Wyper, DJ; Barnes, A; Wilson, JTL			Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study	NEUROIMAGE			English	Article							ARTIFICIAL NEURAL-NETWORK; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; 99TCM-HMPAO SPECT; HEAD-INJURY; QUANTIFICATION; PERFUSION	Simulated abnormalities were introduced in a normal SPECT with known and controllable characteristics (abnormality size and depth) in an attempt to provide validation for the analysis of SPECT lesion studies using SPM. Two simulations were carried out. The first determined the minimum hypoperfusion depth detectable using SPM by altering mean local intensity while keeping the size of the lesion constant. This was done by changing the mean local intensity in percentile increments of 10 down to -100 and up to 50. The second simulation determined the cluster size that SPM can detect by keeping the mean intensity of the lesion constant while altering its size from 4 voxels to 63,000 voxels in a total brain volume of 300,000 voxels. Both simulations determined which method of normalization is most appropriate, what level of grey matter thresholding should be used, and at what statistical probability peak threshold (u) the results should be determined. Proportional scaling was found to be the most appropriate normalization method. ANCOVA was useful where very large abnormalities were present and normalization external to SPM was not available. In those cases, ANCOVA was used in conjunction with measurement of an unaffected part of the brain (in this case medial occipital lobe). For better results statistical probability peak threshold was set to p(u) = 0.01 and grey matter threshold was set to a value below 0.5. SPM produced best results when the abnormality represented a decrease of about -50% from the normal or more and detected other decreases in an acceptable manner. (C) 1999 Academic Press.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Edinburgh, Dept Phys Med, Edinburgh, Midlothian, Scotland; Royal Edinburgh & Associated Hosp, MRC, Brain Metab Unit, Edinburgh, Midlothian, Scotland; So Gen Hosp, NHS Trust, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland	Stamatakis, EA (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.		Wilson, Lindsay/A-3659-2009; Wilson, Lindsay/O-8883-2019	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; barnes, anna/0000-0002-6902-214X			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Acton PD, 1998, EUR J NUCL MED, V25, P663; ADLER RJ, 1996, NEUROLOGY, V46, P278; ARLIG A, 1994, NUCL MED COMMUN, V15, P814; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BUTLER RE, 1995, INT J GERIATR PSYCH, V10, P121, DOI 10.1002/gps.930100207; CHAN KH, 1994, J NUCL MED, V35, P771; CHANG L, 1993, ARCH NEUROL-CHICAGO, V50, P917, DOI 10.1001/archneur.1993.00540090024006; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; Ebmeier KP, 1998, NEUROIMAGE, V7, P199, DOI 10.1006/nimg.1998.0321; Evans, 1994, HUMAN BRAIN MAPPING, V1, P210; FLOYD CE, 1992, INVEST RADIOL, V27, P667, DOI 10.1097/00004424-199209000-00001; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; FRISTON RJ, 1994, FUNCTIONAL NEUROIMAG, P79; GRAY BG, 1992, J NUCL MED, V33, P52; HOUSTON AS, 1994, J NUCL MED, V35, P239; JACOBS A, 1994, J NUCL MED, V35, P942; JACOBS A, 1993, NUCL MED COMMUN, V14, P702, DOI 10.1097/00006231-199308000-00011; JOHNSON KA, 1993, J NUCL MED, V34, P2044; KARBE H, 1994, NEURORADIOLOGY, V36, P1, DOI 10.1007/BF00599183; LONG DT, 1992, MED PHYS, V19, P483, DOI 10.1118/1.596837; LOUFTI I, 1995, INVEST RADIOL, V30, P588; MARKUS HS, 1993, NUCL MED COMMUN, V14, P628, DOI 10.1097/00006231-199308000-00002; MIGNECO O, 1994, COMPUT MED IMAG GRAP, V18, P413, DOI 10.1016/0895-6111(94)90078-7; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Page MPA, 1996, J NUCL MED, V37, P195; PEARLSON GD, 1992, ARCH GEN PSYCHIAT, V49, P402; ROSENTHAL MS, 1995, J NUCL MED, V36, P1489; SYED GMS, 1992, NUCL MED COMMUN, V13, P811, DOI 10.1097/00006231-199211000-00007; TOURASSI GD, 1995, COMPUT BIOMED RES, V28, P257, DOI 10.1006/cbmr.1995.1017; Weeks RA, 1997, J CEREBR BLOOD F MET, V17, P943, DOI 10.1097/00004647-199709000-00003	31	53	53	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT	1999	10	4					397	407		10.1006/nimg.1999.0477			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	243CP	WOS:000082979800005	10493898				2021-06-18	
J	Whalen, MJ; Carlos, TM; Kochanek, PM; Clark, RSB; Heineman, S; Schiding, JK; Franicola, D; Memarzadeh, F; Lo, W; Marion, DW; Dekosky, ST				Whalen, MJ; Carlos, TM; Kochanek, PM; Clark, RSB; Heineman, S; Schiding, JK; Franicola, D; Memarzadeh, F; Lo, W; Marion, DW; Dekosky, ST			Neutrophils do not mediate blood-brain barrier permeability early after controlled cortical impact in rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Xth International Symposium on Intracranial Pressure and Neuromonitoring in Brain Injury	MAY 25-29, 1997	WILLIAMSBURG, VA			neutrophils; blood-brain barrier; inflammation; traumatic brain injury; adhesion	CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL ADHESION MOLECULES; TUMOR-NECROSIS-FACTOR; ISCHEMIC CELL-DAMAGE; EXPERIMENTAL MENINGITIS; MONOCLONAL-ANTIBODY; VESICULAR TRANSPORT; LUNG INJURY; COLD INJURY; HEAD-INJURY	Controlled cortical impact (CCI) produces blood-brain barrier (BBB) permeability and an acute inflammatory response in injured brain, associated with upregulation of cell adhesion molecules and accumulation of neutrophils. Nevertheless, the role of acute inflammation in the pathogenesis of BBB permeability after traumatic brain injury (TBI) is undefined. The purpose of this study was to examine the time course of acute inflammation and BBB permeability after CCI in rats and to determine the effect of neutrophil depletion on BBB permeability early after CCI. In the first protocol, four groups of rats (n = 4-7/group) were subjected to CCI. Expression of endothelial (E)-selectin on cerebrovascular endothelium, accumulation of neutrophils, and BBB permeability were measured in brain at 1, 4, 8, and 24 hours after injury by immunohistochemistry or spectrophotometric quantification of Evans blue. E-selectin upregulation and neutrophil accumulation in injured brain occurred at later times than maximal BBB permeability. In a second protocol, rats made neutropenic with a murine monoclonal IgM antibody (RP-3) specific for rat neutrophils were subjected to CCI, given Evans blue at 3.5 hours, and sacrificed at 4 hours after injury. Neutrophil depletion did not affect BBB permeability at 4 hours after CCI. We conclude that events other than those mediated by neutrophils initiate BBB permeability early after CCI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanek@smtp.anes.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015; Lo, Warren/E-3531-2011	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A21] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		ADELSON P, 1997, P 10 INT S INTR PRES; ARFORS KE, 1987, BLOOD, V69, P338; BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; BEGGS JL, 1976, LAB INVEST, V34, P428; BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHEN H, 1992, NEUROSCI RES COMMUN, V11, P93; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1992, ACTA NEUROPATHOL, V84, P621, DOI 10.1007/BF00227739; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Folkesson HG, 1997, J APPL PHYSIOL, V82, P1743; Gidday J. M., 1998, Society for Neuroscience Abstracts, V24, P254; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; Haring HP, 1996, STROKE, V27, P1386, DOI 10.1161/01.STR.27.8.1386; Hartl R, 1997, ACT NEUR S, V70, P240; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699; Horwitz LD, 1997, AM J PHYSIOL-HEART C, V272, pH618; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOENIG H, 1983, BIOCHEM BIOPH RES CO, V116, P1039, DOI 10.1016/S0006-291X(83)80247-2; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDSBERG PJ, 1995, J NEUROSURG, V82, P269, DOI 10.3171/jns.1995.82.2.0269; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Miller RD, 1996, J NEUROL SCI, V136, P37, DOI 10.1016/0022-510X(95)00309-P; Morikawa E, 1996, STROKE, V27, P951, DOI 10.1161/01.STR.27.5.951; NAWASHIRO H, 1994, ACTA NEUROCHIR, P440; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; QUAGLIARELLO VJ, 1991, J EXP MED, V174, P657, DOI 10.1084/jem.174.3.657; Rodell TC, 1996, IMMUNOPHARMACOLOGY, V33, P279, DOI 10.1016/0162-3109(96)00071-9; ROSOMOFF HL, 1968, ACTA ANAESTH SCAND, VS, P75; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHURER L, 1990, ACT NEUR S, V51, P49; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Soares HD, 1995, J NEUROSCI, V15, P8223; SUZUKI M, 1995, ACTA NEUROPATHOL, V89, P532; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TROUT JJ, 1986, LAB INVEST, V55, P622; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Zhang RL, 1996, J CEREBR BLOOD F MET, V16, P1126, DOI 10.1097/00004647-199611000-00006; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747	67	53	56	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					583	594		10.1089/neu.1999.16.583			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700003	10447070				2021-06-18	
J	Bell, BD; Primeau, M; Sweet, JJ; Lofland, KR				Bell, BD; Primeau, M; Sweet, JJ; Lofland, KR			Neuropsychological functioning in migraine headache, nonheadache chronic pain, and mild traumatic brain injury patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	25th Meeting of the International-Neuropsychological-Society	FEB 05-08, 1997	ORLANDO, FL	Int Neuropsychol Soc			CEREBRAL BLOOD-FLOW; COGNITIVE IMPAIRMENT; EMISSION TOMOGRAPHY; EVOKED-POTENTIALS; MEMORY; SAMPLE; MRI	There are conflicting reports in the literature concerning the neuropsychological functioning of migraine headache patients. The finding in some studies that migraineurs performed more poorly than healthy controls led to the hypothesis that chronic migraine may result in subtle but persistent cerebral dysfunction. Reports describing acute and between-headache neurophysiological disturbances in migraineurs lent support to this hypothesis. To elucidate the cognitive status of these patients, we administered a brief neuropsychological battery to 60 individuals with migraine headache (HA), nonheadache chronic pain (PAIN), or mild traumatic brain injury (MTBI). The PAIN group was included to test the hypothesis that cognitive difficulty in migraineurs might result from the discomfort, depression, medications, etc. often associated with chronic pain, rather than from brain dysfunction. The MTBI patients were considered a useful comparison for the migraineurs because their level of impairment was also expected to be mild, at worst A MANOVA, with three cognitive index scores as the dependent variables, revealed that the three groups differed significantly. Follow-up contrasts demonstrated that the MTBI group was significantly more impaired on the memory index compared to the HA and PAIN groups, which did not differ from each other. The use of two different normative-based cutoffs to identify individuals who were impaired on the test battery revealed that the frequency of impairment within the two groups of pain patients, but not the MTBI patients, was within normal limits. Thus, the results did not support a link between migraine headache and cognitive impairment (C) 1999 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Finch Univ Hlth Sci Chicago Med Sch, N Chicago, IL 60064 USA; Evanston Hosp Corp, Evanston, IL USA; Northwestern Univ, Evanston, IL 60208 USA; Pain & Rehabil Clin Chicago, Chicago, IL USA	Bell, BD (corresponding author), Univ Wisconsin Hosp & Clin, Dept Neurol H4 676, 600 Highland Ave, Madison, WI 53792 USA.						American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ARDILA A, 1988, CEPHALALGIA, V8, P67, DOI 10.1046/j.1468-2982.1988.0802067.x; Benton AL, 1978, MULTILINGUAL APHASIA; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOLTER JF, 1990, MULTIDIGIT MEMORY TE; BORNSTEIN RA, 1988, CLIN NEUROPSYCHOL, V2, P107, DOI DOI 10.1080/13854048808520093; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Burker E, 1989, NEUROPSYCHOLOGY, V3, P61, DOI 10.1037//0894-4105.3.2.61; Cavestri R, 1995, Minerva Med, V86, P257; Cooney BS, 1996, HEADACHE, V36, P616, DOI 10.1046/j.1526-4610.1996.3610616.x; CUETTER AC, 1983, HEADACHE, V23, P195; CULLUM CM, 1990, ARCH CLIN NEUROPSYCH, V5, P23, DOI DOI 10.1093/ARCLIN/5.1.23; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; DEBENEDITTIS G, 1995, HEADACHE, V35, P264; EDMEADS J, 1984, CAN J NEUROL SCI, V11, P363, DOI 10.1017/S0317167100045716; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; GLOVER V, 1989, TRENDS PHARMACOL SCI, V10, P1, DOI 10.1016/0165-6147(89)90089-8; Golden C., 1978, STROOP COLOR WORD TE; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heilbronner R L, 1989, Arch Clin Neuropsychol, V4, P299; HIRSCH AR, 1992, HEADACHE, V32, P233, DOI 10.1111/j.1526-4610.1992.hed3205233.x; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; JAIN S, 1986, HEADACHE, V26, P19, DOI 10.1111/j.1526-4610.1986.hed2601019.x; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; KOEHLER SM, 1991, J CLIN EXP NEUROPSYC, V13, P60; LANCE JW, 1993, NEUROLOGY, V43, P11; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVINE SR, 1987, STROKE, V18, P1164, DOI 10.1161/01.STR.18.6.1164; LIPTON RB, 1993, NEUROLOGY, V43, P6; MAZZUCCHI A, 1988, HEADACHE, V28, P488, DOI 10.1111/j.1526-4610.1988.hed2807488.x; MERSKEY HM, 1986, PAIN S3, V25, pS1; MONTAGNA P, 1995, CEPHALALGIA, V15, P323, DOI 10.1046/j.1468-2982.1995.1504323.x; PUCA F, 1985, MIGRAINE CLIN RES AD, P1; Raskin N, 1988, HEADACHE; Reitan RM, 1979, MANUAL ADM NEUROPSYC; ROBBINS L, 1992, HEADACHE, V32, P507, DOI 10.1111/j.1526-4610.1992.hed3210507.x; ROSE FC, 1988, BASIC MECH HEADACHE, P3; ROTH DL, 1990, J CLIN EXP NEUROPSYC, V12, P834; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan L, 1996, NEUROPSYCHOLOGY, V10, P176, DOI 10.1037/0894-4105.10.2.176; SCHLAKE HP, 1990, HEADACHE, V30, P129, DOI 10.1111/j.1526-4610.1990.hed3003129.x; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; SMITH GE, 1992, J CLIN EXP NEUROPSYC, V14, P211, DOI 10.1080/01688639208402824; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TAGLIATI M, 1995, EVOKED POTENTIAL, V96, P1, DOI 10.1016/0013-4694(94)00211-3; TFELTHANSEN P, 1994, PHARMACOL TOXICOL, V75, P72, DOI 10.1111/j.1600-0773.1994.tb02003.x; Trahan Donald E, 1992, Clin Neuropsychol, V6, P241, DOI 10.1080/13854049208401858; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x	60	53	54	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	1999	14	4					389	399		10.1016/S0887-6177(98)00020-1			11	Psychology, Clinical; Psychology	Psychology	186WP	WOS:000079753900005	14590592	Bronze			2021-06-18	
S	Hall, ED; Kupina, NC; Althaus, JS		Trembly, B; Slikker, W		Hall, ED; Kupina, NC; Althaus, JS			Peroxynitrite scavengers for the acute treatment of traumatic brain injury	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			NITRIC-OXIDE	Recent evidence has suggested that the superoxide and nitric oxide-derived reactive oxygen species peroxynitrite (ONOO-) may play a significant role in the acute pathophysiology of brain injury. One pharmacological mechanism by which ONOO--mediated damage might be interrupted is by the administration of scavenging compounds such as the thiol-containing compound penicillamine. In the present study, we examined the ability of either penicillamine (Pen) or the more brain penetrable penicillamine methyl ester (PenME) (0.01, 0.1, 1.0 or 10.0 mg/kg i.v. 5 min post-injury) to improve the early (1 hr) neurological recovery (grip score) of male CF-1 mice after a severe (900 g-cm; 50 g x 18 cm) injury. Pen produced a dose-related improvement in grip score. At 1.0 mg/kg, a +112% improvement was observed compared to vehicle-treated mice, and at 10.0 mg/kg, the increase was +168% (both, p < 0.05), PenME more potently improved the l-hr grip score, but the magnitude of the optimal effect (+96% at 0.1 mg/kg; p < 0.02) was no greater than that observed with Pen, which largely remains in the cerebral microvasculature. These results are consistent with a role of ONOO- in acute head injury, but suggest that microvascular scavenging may be of primary therapeutic importance during the early post-traumatic period.	Parke Davis Pharmaceut Res, Neurosci Therapeut, Ann Arbor, MI 48105 USA	Hall, ED (corresponding author), Parke Davis Pharmaceut Res, Neurosci Therapeut, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Hall, Edward D/F-8930-2013				ALTHAUS JS, 1994, RES COMMUN CHEM PATH, V83, P243; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; Beckman J. S., 1996, METHODS NITRIC OXIDE, P61; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Coeroli L, 1998, J NEUROCHEM, V70, P2516; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; Hall ED, 1997, NEUROSCIENTIST, V3, P42, DOI 10.1177/107385849700300114; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MESENGE C, IN PRESS EUR J PHARM; Ohnishi S. T., 1995, CENTRAL NERVOUS SYST, P437	10	53	54	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						462	468		10.1111/j.1749-6632.1999.tb08025.x			7	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700042	10668450				2021-06-18	
J	Groom, KN; Shaw, TG; O'Connor, ME; Howard, NI; Pickens, A				Groom, KN; Shaw, TG; O'Connor, ME; Howard, NI; Pickens, A			Neurobehavioral symptoms and family functioning in traumatically brain-injured adults	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PSYCHOSOCIAL ADJUSTMENT; FOLLOW-UP; RELATIVES; STROKE; IMPACT	Traumatic brain injury (TBI) often results in a myriad of symptoms across physical, cognitive, and neurobehavioral domains. Despite inherent limitations associated with physical or cognitive impairments, the extant literature suggests that neurobehavioral symptoms tend to be the most distressing symptoms for the family and are more strongly related to poor outcome for the patient. The Neuropsychology Behavior and Affect Profile (NBAP) along with the General Functioning subscale of the Family Assessment Device (FAD-GF) and the Perceived Stress Scale were administered to 153 family members of persons who had sustained a TBI. The results provide new normative data and statistical support for the NBAP as a promising measure of neurobehavioral symptomatology following TBI. The correlation of .54 (p < .01) between FAD-GF and Full Scale NBAP scores provides powerful support for the hypothesis that family dysfunction is related to the presence of neurobehavioral symptoms in the patient. NBAP domains of Depression, Inappropriateness, Pragnosia, and indifference appear most strongly related to family functioning and also bar a significant relationship to caregiver stress level and patient unemployment, whereas injury severity had little impact on either family functioning or neurobehavioral symptoms. The findings reinforce the significance of neurobehavioral symptoms and fortify their proposed link to family dysfunction post-TBI. (C) 1998 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Tulsa, Tulsa, OK 74104 USA	Groom, KN (corresponding author), 7146 S Braden,Suite 500, Tulsa, OK 74136 USA.						ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO; Alfano D. P., 1987, CLIN NEUROPSYCHOL, V1, P105; Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Bond M R, 1975, Ciba Found Symp, P141; Brooks N., 1984, CLOSED HEAD INJURY P; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; DELORTO A, 1994, HEAD INJURY FAMILY L; DICESARE A, 1990, COGNITIVE REHABILITA, V8, P14; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P508; GRANT I, 1987, NEUROBEHAVIORAL RECO; Groveman A.M., 1985, FAMILY SYST MED, V3, P440, DOI [10.1037/h0089672, DOI 10.1037/H0089672]; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; NOVACK TA, 1987, ARCH PHYS MED REHAB, V68, P729; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PATTERSON JM, 1990, SOC SCI MED, V31, P159, DOI 10.1016/0277-9536(90)90057-Y; RAIT DS, 1992, FAM PROCESS, V31, P383, DOI 10.1111/j.1545-5300.1992.00383.x; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Satz P, 1993, NEUROPSYCHOLOGY, V7, P553; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P1; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	42	53	55	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	1998	13	8					695	711		10.1016/S0887-6177(98)00005-5			17	Psychology, Clinical; Psychology	Psychology	133DY	WOS:000076672200003	14590629	Bronze			2021-06-18	
J	Shafi, S; Gilbert, JC; Loghmanee, F; Allen, JE; Caty, MG; Glick, PL; Carden, S; Azizkhan, RG				Shafi, S; Gilbert, JC; Loghmanee, F; Allen, JE; Caty, MG; Glick, PL; Carden, S; Azizkhan, RG			Impact of bicycle helmet safety legislation on children admitted to a regional pediatric trauma center	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	28th Annual Meeting of the American-Pediatric-Surgical-Association	MAY 18-21, 1997	NAPLES, FLORIDA	Amer Pediat Surg Assoc		injuries; bicycling injuries; injury prevention; legislation; head protective devices; head injuries	HEAD-INJURY; RANDOMIZED TRIAL; UNITED-STATES; USE PATTERNS; PROMOTION; EDUCATION; CAMPAIGN; ONTARIO	Purpose: The regional pediatric trauma center in Buffalo, NY, has been active in pediatric injury prevention programs, including community education and distribution of bicycle helmets, since 1990. Since June 1, 1994, the use of bicycle safety helmets for children under 14 years of age has been mandated by a state law in New York. The authors undertook this study to assess the impact of this legislation on the frequency of helmet use in children involved in bicycle crashes presenting to the regional pediatric trauma center, and to assess the impact of helmet use on the number and severity of head injuries. Methods: Bicycle crash victims (n = 208) admitted to a regional pediatric trauma center from 1993 to 1995 were studied retrospectively. Head injuries were classified as concussion alone, skull fractures, intracranial hemorrhages tie, epidural, subdural, and subarachnoid), cerebral contusions, or diffuse cerebral edema alone (without any other intracranial injury). Helmeted children (HC) were compared with nonhelmeted children (NHC) using chi(2) and Fisher's Exact test. P value less than .05 was considered significant. Results: Only 31 children (15%) wore helmets at the time of the crash. Helmet use increased from 2%, during the period of education alone, to 26% after the legislation went into effect (P < .00001). The proportion of children suffering head injuries was similar in both groups (HC, 68%; NHC, 61%; P = NS). However, the type of head injury was different. HC were more likely to sustain concussion alone (HC, 65%; NHC, 44%; P < .03). HC were less likely to have skull fractures (HC, 0%; NHC, 13%; P < .02), and exhibited a trend toward less intracranial hemorrhages (HC, 0%; NHC, 9%; P = NS), cerebral contusions (HC, 3%; NHC, 5%; P = NS), and cerebral edema (HC, 0%; NHC, 0.6%; P = NS). Excluding the isolated concussions, head injuries were noted in only one HC, compared with 30 NHC (P < .04). None of the three children who died wore helmets at the time of the crash, and all died of multiple head injuries. Conclusions: The bicycle helmet safety law resulted in a 13-fold increase in the use of bicycle helmets among the children admitted to a regional pediatric trauma center after bicycle crashes, but the helmet use remains inadequate. Helmet use reduced the severity of head injuries, and might have prevented deaths caused by head injuries. Copyright (C) 1998 by W.B. Saunders Company.	SUNY Buffalo, Sch Med & Biomed Sci, Div Pediat Surg, Dept Surg, Buffalo, NY 14260 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Pathol, Buffalo, NY 14260 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY 14260 USA; Off Med Examiner, Buffalo, NY USA	Gilbert, JC (corresponding author), Childrens Hosp, Dept Pediat Surg, Kiwanis Pediatr Trauma Ctr, 219 Bryant St, Buffalo, NY 14222 USA.						BENZ G, 1993, EUR J PEDIATR SURG, V3, P259, DOI 10.1055/s-2008-1063555; BJORNSTIG U, 1992, J TRAUMA, V33, P887; BOYLE WE, 1995, PEDIATRICS, V95, P609; CALLAHAN D, 1989, NEW ENGL J MED, V320, P1412, DOI 10.1056/NEJM198905253202110; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; Caplow MP, 1995, AM J PREV MED, V11, P371; *CDC, 1995, J SCH HLTH, V6, P133; COTE TR, 1992, PEDIATRICS, V89, P1216; CUSHMAN R, 1991, PEDIATRICS, V88, P43; CUSHMAN R, 1991, AM J PUBLIC HEALTH, V81, P1044, DOI 10.2105/AJPH.81.8.1044; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P667, DOI 10.2105/AJPH.83.5.667; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P644, DOI 10.2105/AJPH.83.5.644; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Farley C, 1996, AM J PUBLIC HEALTH, V86, P46, DOI 10.2105/AJPH.86.1.46; Finvers KA, 1996, CLIN J SPORT MED, V6, P102, DOI 10.1097/00042752-199604000-00007; FRANK E, 1995, ACAD EMERG MED, V2, P200, DOI 10.1111/j.1553-2712.1995.tb03198.x; HATZIANDREU EJ, 1995, PUBLIC HEALTH REP, V110, P251; HU XH, 1993, CAN J PUBLIC HEALTH, V84, P163; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; MACKNIN ML, 1994, ARCH PEDIAT ADOL MED, V148, P255, DOI 10.1001/archpedi.1994.02170030025005; Mills N J, 1990, Br J Sports Med, V24, P55; MORRIS BAP, 1991, CAN J PUBLIC HEALTH, V82, P92; RIVARA F P, 1983, Pediatrician, V12, P3; RIVARA FP, 1994, PEDIATRICS, V93, P567; RODGERS GB, 1995, ACCIDENT ANAL PREV, V27, P43, DOI 10.1016/0001-4575(94)00044-M; Rodgers GB, 1996, PEDIATRICS, V97, P166; ROWE BH, 1995, CAN J PUBLIC HEALTH, V86, P57; ROWE BH, 1995, CAN MED ASSOC J, V152, P45; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SCHEIBER RA, 1996, ARCH PEDIAT ADOLESC, V150, P707; SCHEIDT PC, 1992, PEDIATRICS, V89, P1248; SPENCE LJ, 1993, J PEDIATR SURG, V28, P214, DOI 10.1016/S0022-3468(05)80278-7; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1388, DOI 10.2105/AJPH.80.11.1388; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; WEISS BD, 1986, PEDIATRICS, V77, P677	39	53	54	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	FEB	1998	33	2					317	320		10.1016/S0022-3468(98)90454-7			4	Pediatrics; Surgery	Pediatrics; Surgery	YX297	WOS:000072026100061	9498409				2021-06-18	
J	Grzybicki, D; Moore, SA; Schelper, R; Glabinski, AR; Ransohoff, RM; Murphy, S				Grzybicki, D; Moore, SA; Schelper, R; Glabinski, AR; Ransohoff, RM; Murphy, S			Expression of monocyte chemoattractant protein (MCP-1) and nitric oxide synthase-2 following cerebral trauma	ACTA NEUROPATHOLOGICA			English	Article						astrocyte; cerebral trauma; chemokine; edema; nitric oxide synthase	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBRILLARY ACIDIC PROTEIN; NADPH-DIAPHORASE ACTIVITY; NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; ACTIVATED ASTROCYTES; MECHANICAL INJURY; INTERLEUKIN-1; MICROGLIA	Traumatic injury to the brain initiates multiple interrelated processes that involve parenchymal, vascular, and infiltrating inflammatory cells. Nitric oxide (NO) and chemokines have been implicated as regulators of the central nervous system ir?jury response, Following a cryogenic lesion of the cerebral cortex in mice, mRNA for NO synthase (NOS)-2 was detected by reverse transcriptase polymerase chain reaction ipsilaterally 12 h after injury and persisted for 2 weeks. While mRNA was also detected contralaterally, the time course of expression was shorter (1 week). By immunohistochemistry, NOS-2 protein was initially detected ipsilaterally 12 h after injury in infiltrating inflammatory cells. Astroglial cells expressed NOS-2 from 24 to 72 h after injury. The expression of monocyte chemoattractant protein (MCP-1) mRNA peaked at 6 h on the lesion side, remained for 24 h and then declined by 48 h. On the unlesioned side, MCP-1 mRNA was expressed to a much lesser extent and had declined by 24 h. The up-regulation of MCP-1 was relatively specific as a closely related mRNA encoding IP-10 was not significantly increased. These findings implicate a role for NOS-2 and MCP-I as potential regulators of cellular events following cryogenic cerebral trauma.	Univ Iowa, Coll Med, Dept Pharmacol, BSB, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA	Murphy, S (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, BSB, Iowa City, IA 52242 USA.			Moore, Steven/0000-0002-6353-7900	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029226] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07294, NS 29226] Funding Source: Medline		BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; FERNAUDESPINOSA I, 1993, GLIA, V8, P277, DOI 10.1002/glia.440080408; FILEP JG, 1993, BRIT J PHARMACOL, V108, P323, DOI 10.1111/j.1476-5381.1993.tb12803.x; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Glabinski AR, 1995, BRAIN BEHAV IMMUN, V9, P315, DOI 10.1006/brbi.1995.1030; Grzybicki D, 1996, J CHEM NEUROANAT, V10, P221, DOI 10.1016/0891-0618(96)00139-1; Grzybicki DM, 1997, J NEUROIMMUNOL, V73, P15, DOI 10.1016/S0165-5728(96)00159-2; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; KITCHENER PD, 1993, NEUROSCIENCE, V53, P613, DOI 10.1016/0306-4522(93)90610-R; Klatzo I, 1980, Adv Neurol, V28, P359; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; LOTAN M, 1994, FASEB J, V8, P1026; Malhotra Sudarshan K., 1994, Biomedical Letters, V49, P273; MCCALL TB, 1992, BIOCHEM BIOPH RES CO, V186, P680, DOI 10.1016/0006-291X(92)90800-Z; MCELHANEY MR, 1994, NEUROSCI LETT, V180, P67, DOI 10.1016/0304-3940(94)90915-6; MURPHY S, 1996, NEUROSCIENTIST, V2, P91; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OURY TD, 1993, J BIOL CHEM, V268, P15394; RANSOHOFF RM, 1993, FASEB J, V7, P592; REGIDOR J, 1993, BRAIN RES, V631, P171, DOI 10.1016/0006-8993(93)91206-8; ROJAS A, 1993, BIOCHEM BIOPH RES CO, V196, P274, DOI 10.1006/bbrc.1993.2245; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SVENSSON M, 1993, J NEUROSCI RES, V35, P373, DOI 10.1002/jnr.490350404; Tani M, 1996, AM J PATHOL, V148, P889; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; WALLACE MN, 1992, NEUROREPORT, V3, P953, DOI 10.1097/00001756-199211000-00001; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMANAKA K, 1995, NEUROSCI LETT, V194, P124, DOI 10.1016/0304-3940(95)11715-9; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	35	53	53	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	JAN	1998	95	1					98	103		10.1007/s004010050770			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	YM855	WOS:000071108400012	9452827				2021-06-18	
J	Hinkle, DA; Baldwin, SA; Scheff, SW; Wise, PM				Hinkle, DA; Baldwin, SA; Scheff, SW; Wise, PM			GFAP and S100 beta expression in the cortex and hippocampus in response to mild cortical contusion	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; glial responses; gene expression; immunocytochemistry; rat; GFAP; S100 beta; mRNA; protein; contusion; reactive astrocyte	FIBRILLARY ACIDIC PROTEIN; GROWTH-FACTOR BFGF; REACTIVE ASTROCYTES; CEREBRAL CONTUSION; NEURITE EXTENSION; MESSENGER-RNA; BRAIN INJURY; CNS INJURY; ADULT-RAT; INTERLEUKIN-1	We studied the acute response of glial fibrillary acidic protein (GFAP) and S100 beta gene expression in the cerebral cortex and hippocampus to mild unilateral cortical contusion. Our goal was to evaluate and compare the expression patterns of each gene in the early stages of the astrocytic response to brain injury. RNA was extracted from the cerebral cortex and hippocampus of male rats at 0, 3, 12, 24, or 96 h after lesion or sham-operation, then quantified using an RNase protection assay. Contusion produced a robust elevation in GFAP mRNA by 12 h in both brain regions on the ipsilateral side to the contusion. In the cortex, but not the hippocampus, this elevation was sustained at 96 h. S100 beta mRNA levels were elevated bilaterally in lesioned animals at 24 h ire both brain regions. However, these data are difficult to interpret because sham mRNA levels decreased with time, making it unclear whether contusion stimulates S100 beta gene expression or whether it mitigates the inhibitory effect of sham. We further analyzed the effect of contusion on GFAP and S100 beta immunoreactive astrocyte density at 96 h postlesion or postsham by double-label immunocytochemistry. All detectable astrocytes under all conditions were S100 beta immunoreactive in both brain regions. Furthermore, all S100 beta immunoreactive astrocytes in the lesioned ipsilateral cortex were also GFAP immunoreactive, whereas only about 11% of S100 beta positive cells were also GFAP labeled in the contralateral lesioned or the ipsilateral sham cortex. In the hippocampus, all S100 beta immunoreactive cells were also GFAP immunoreactive under all conditions. These data correlate with the gene expression data at 96 h, and suggest that, at least in the cortex, resident S100 beta-expressing astrocytes produce GFAP at levels that are undetectable by immunocytochemistry until they are activated in response to injury.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV KENTUCKY,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536	Hinkle, DA (corresponding author), UNIV KENTUCKY,COLL MED,DEPT PHYSIOL,800 ROSE ST,LEXINGTON,KY 40536, USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG02224] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG002224, R37AG002224] Funding Source: NIH RePORTER		AUSUBEL F, 1994, CURRENT PROTCOLS MOL; Baldwin SA, 1996, GLIA, V16, P266; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Duffy PE, 1983, ASTROCYTES NORMAL RE; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1988, CURRENT ISSUES NEURA, P247; ENGELE J, 1991, J NEUROSCI, V11, P3070; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HINKLE DA, 1997, IN PRESS NEUROSCIENC; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; KINDY MS, 1992, MOL BRAIN RES, V13, P199, DOI 10.1016/0169-328X(92)90027-9; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; STEWAD O, 1997, J NEUROSCI, V10, P2373; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TODA M, 1994, J NEUROCHEM, V63, P1975; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; ZIMMER DB, 1989, J CELL BIOL, V108, P141, DOI 10.1083/jcb.108.1.141	39	53	57	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1997	14	10					729	738		10.1089/neu.1997.14.729			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YE057	WOS:A1997YE05700004	9383091				2021-06-18	
J	Stanislav, SW				Stanislav, SW			Cognitive effects of antipsychotic agents in persons with traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; SCHIZOPHRENIC-PATIENTS; MEMORY; EFFORTFUL; CLOZAPINE; DEFICITS; DOPAMINE	Over 1 million survivors of traumatic brain injury receive maintenance pharmacotherapy, of which a substantial number receive antipsychotic agents for the treatment of psychoses, agitation and aggression, and other maladaptive behaviours. In spite of the common clinical uses of antipsychotics, the cognitive risks versus benefits are unclear. The purpose of this study was to assess differences in cognitive functioning before, during, and after discontinuation of antipsychotic agents in inpatients undergoing rehabilitation for traumatic brain injury. Neuropsychiatric tests (Reys Auditory-Verbal Learning, Trail Making A&B, Digit Span Forwards and Backwards) evaluating cognitive skills of verbal ability, visuomotor speed, memory, learning, attention, and spatial ability were administered to each subject at baseline (immediately prior to tapering or discontinuing antipsychotic), when taper reached 50% of baseline dose, 1 week after antipsychotic discontinuation, and 3 weeks after discontinuation. These data suggest that select areas of cognition improve alter antipsychotic discontinuation in subjects with traumatic brain injury. The magnitude of improvement appeared to be greater after discontinuation with thioridazine, a low-potency agent, compared to haloperidol, a high-potency agent. Results, although very preliminary, support the hypothesis or cholinergic involvement in regulating cognitive processes, and this underscores the need for more systematic research in this area.	HEALTHCARE REHABIL CTR, AUSTIN, TX USA	Stanislav, SW (corresponding author), UNIV TEXAS, COLL PHARM, AUSTIN, TX 78712 USA.						BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; BAREGGI SR, 1975, EUR NEUROL, V13, P528, DOI 10.1159/000114709; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; DANIEL DG, 1994, BIOL PSYCHIAT, V35, P667, DOI 10.1016/0006-3223(94)90847-8; Grober E, 1989, J Cogn Neurosci, V1, P327, DOI 10.1162/jocn.1989.1.4.327; HAGGER C, 1993, BIOL PSYCHIAT, V34, P702, DOI 10.1016/0006-3223(93)90043-D; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; NEWMAN RP, 1984, NEUROLOGY, V34, P805, DOI 10.1212/WNL.34.6.805; PARROTT AC, 1987, NEUROPSYCHOBIOLOGY, V17, P53, DOI 10.1159/000118371; PERLICK D, 1986, AM J PSYCHIAT, V143, P230; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SPOHN HE, 1989, J ABNORM PSYCHOL, V98, P367, DOI 10.1037/0021-843X.98.4.367; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SYNDULKO K, 1981, INT J NEUROSCI, V14, P61, DOI 10.3109/00207458108985816; TUNE LE, 1982, AM J PSYCHIAT, V139, P1460; Vogenthaler D R, 1987, Brain Inj, V1, P113; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4	22	53	54	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	1997	11	5					335	341		10.1080/026990597123494			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WW455	WOS:A1997WW45500004	9146839				2021-06-18	
J	Lewen, A; Soderstrom, S; Hillered, L; Ebendal, T				Lewen, A; Soderstrom, S; Hillered, L; Ebendal, T			Expression of serine/threonine kinase receptors in traumatic brain injury	NEUROREPORT			English	Article						activin; ActR-1; ALK; BMPR-II; bone morphogenetic protein; in situ hybridization; mRNA; neuronal plasticity; osteogenic protein; rat; receptors; serine-threonine protein kinase receptors; transforming growth factor beta superfamily; traumatic brain injury	SERINE THREONINE KINASE; NERVE GROWTH-FACTOR; BETA-SUPERFAMILY; MESSENGER-RNA; II RECEPTOR; CLONING; GLUTAMATE; NEURONS; FAMILY; MEMBER	THE aim of this study was to investigate the expression of serine/threonine kinase receptors in the brain following traumatic brain injury. We report here that, the recently cloned and characterized bone morphogenetic protein (BMP) receptor type II (BMPR-II) and the activin receptor type IA (ActR-1) Act: mRNAs were simultaneously up-regulated in neurones in the dentate gyrus 6 h after a mild cerebral contusion injury. This finding was specific for these receptors since other investigated genes (i.e. ActR-II; ActR-IB, trkB and c-fos) showed other temporal patterns. These data suggest that type I and type II receptors act together in signal transduction in vivo and that BMPs may be involved in neuronal plasticity after traumatic brain injury.	UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT DEV NEUROSCI,S-75185 UPPSALA,SWEDEN; BIOMED CTR,S-75185 UPPSALA,SWEDEN			Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Bengtsson H, 1995, NEUROREPORT, V7, P113, DOI 10.1097/00001756-199512000-00027; CUNNINGHAM NS, 1995, GROWTH FACTORS, V12, P99, DOI 10.3109/08977199509028956; HOVDA DA, 1990, ACT NEUR S, V51, P331; KAPHINGST K, 1994, CELL, V78, P437, DOI 10.1016/0092-8674(94)90422-7; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; LAI M, 1995, NEUROSCIENCE, V70, P1013; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEIN P, 1995, NEURON, V15, P597, DOI 10.1016/0896-6273(95)90148-5; LEWEN A, 1996, SOC NEUR ABSTR, V22; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MABLE PC, 1995, SOC NEUR ABSTR, V21; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PREHN JHM, 1993, J NEUROCHEM, V60, P1665, DOI 10.1111/j.1471-4159.1993.tb13389.x; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SODERSTROM S, 1995, DEV BRAIN RES, V85, P96, DOI 10.1016/0165-3806(94)00199-A; SODERSTROM S, 1996, IN PRESS CELL TISSUE; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; WILHERS G, 1995, SOC NEUR ABSTR, V21; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	29	53	55	0	1	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 20	1997	8	2					475	479		10.1097/00001756-199701200-00020			5	Neurosciences	Neurosciences & Neurology	WX340	WOS:A1997WX34000021	9080432				2021-06-18	
J	Ikonomidou, C; Turski, L				Ikonomidou, C; Turski, L			Prevention of trauma-induced neurodegeneration in infant and adult rat brain: Glutamate antagonists	METABOLIC BRAIN DISEASE			English	Article; Proceedings Paper	Symposium on Neuroactive Amino Acids in CNS Disorders, at the 2nd International Congress of the Polish-Neuroscience-Society	SEP 13-16, 1995	KRAKOW, POLAND	Polish Neurosci Soc		traumatic brain injury; glutamate antagonists; AMPA antagonist; NMDA antagonists	METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; ISCHEMIC NEURONAL DEGENERATION; CENTRAL-NERVOUS-SYSTEM; NON-NMDA RECEPTORS; KAINIC-ACID; CEREBRAL-ISCHEMIA; INJURY; NEUROTOXICITY; DAMAGE	The mechanisms of neuronal degeneration following traumatic head injury are not well understood and no adequate treatment is currently available for the prevention of traumatic brain damage in humans. Seven day old rat pups were subjected to mechanical percussion of the head. Cortical damage in infant rats was reduced by pre-treatment with the N-methyl-D-aspartate (NMDA) antagonists dizocilpine (MK-801) or 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate (CPP). The AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX) did not significantly suppress cortical damage in infant rats. In adult rats, traumatic head injury leads to primary (at impact-cortex) and secondary (distant- hippocampus) damage to the brain. Morphometric analysis demonstrated that both cortical and hippocampal damage was mitigated by pre-treatment with either the NMDA antagonist CPP or the non-NMDA antagonist NBQX. Neither treatment prevented primary damage in the cortex when therapy was started after trauma. Delayed treatment of rats with NBQX, but not with CPP, beginning between 1 and 7 h after trauma prevented the hippocampal damage. No protection was seen when therapy with NBQX was started 10 h after trauma. These data indicate that NMDA antagonists may possess better neuroprotective properties against excitotoxic processes triggered by traumatic brain injury in young individuals whereas AMPA antagonists may be more beneficial in adults.	SCHERING AG,RES LABS,D-13342 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,CLIN CHARITE,DEPT PEDIAT NEUROL,D-10098 BERLIN,GERMANY							Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ALBALA BJ, 1984, DEV BRAIN RES, V13, P139, DOI 10.1016/0165-3806(84)90085-3; BENARI Y, 1984, DEV BRAIN RES, V14, P284, DOI 10.1016/0165-3806(84)90314-6; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERNDT RS, 1994, J EXP PSYCHOL LEARN, V20, P977, DOI 10.1037/0278-7393.20.4.977; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; CAMPOCHIARO P, 1978, P NATL ACAD SCI USA, V75, P2025, DOI 10.1073/pnas.75.4.2025; CAVALHEIRO EA, 1983, ELECTROEN CLIN NEURO, V56, P480, DOI 10.1016/0013-4694(83)90232-8; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farber N. B., 1992, Society for Neuroscience Abstracts, V18, P1148; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; GRAFE MR, 1994, BRAIN RES, V653, P161, DOI 10.1016/0006-8993(94)90385-9; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hagberg H., 1992, Biology of the Neonate, V62, P299; HU BR, 1995, J NEUROCHEM, V64, P277; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; IKONOMIDOU C, 1989, Society for Neuroscience Abstracts, V15, P767; IKONOMIDOU C, 1994, NEUROPSYCHOPHARMACOL, V10, pS448; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMAN BA, 1994, PEDIATR ANN, V23, P18, DOI 10.3928/0090-4481-19940101-07; LEHMANN J, 1987, J PHARMACOL EXP THER, V240, P737; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McGeer P, 1978, KAINIC ACID TOOL NEU, P1; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P1; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1991, Society for Neuroscience Abstracts, V17, P184; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OLNEY JW, 1989, J NEUROSCI, V9, P1701; OLNEY JW, 1972, J NEUROPATH EXP NEUR, V31, P464, DOI 10.1097/00005072-197207000-00006; OLNEY JW, 1991, NEUROBIOLOGY NMDA RE, P187; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PEARL TM, 1990, NEW ENGL J MED, V322, P1775; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; Povlishock John T., 1993, P185; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; TEITELBAUM JS, 1990, NEW ENGL J MED, V322, P1781, DOI 10.1056/NEJM199006213222505; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TURSKI L, 1988, NEUROL NEUR, V46, P343; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	56	53	56	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0885-7490			METAB BRAIN DIS	Metab. Brain Dis.	JUN	1996	11	2					125	141		10.1007/BF02069500			17	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	UP556	WOS:A1996UP55600003	8776715				2021-06-18	
J	SempleRowland, SL; Mahatme, A; Popovich, PG; Green, DA; Hassler, G; Stokes, BT; Streit, WJ				SempleRowland, SL; Mahatme, A; Popovich, PG; Green, DA; Hassler, G; Stokes, BT; Streit, WJ			Analysis of TGF-beta 1 gene expression in contused rat spinal cord using quantitative RT-PCR	JOURNAL OF NEUROTRAUMA			English	Article						cytokine; cyclophilin; inflammation; reactive gliosis; regeneration; spinal cord injury; transforming growth factor beta	TRANSFORMING GROWTH FACTOR-BETA-1; INTERLEUKIN-1-BETA MESSENGER-RNA; TRANSIENT FOREBRAIN ISCHEMIA; FACTOR-BETA; DIFFERENTIAL EXPRESSION; MONONUCLEAR PHAGOCYTES; TRAUMATIC INJURY; NERVOUS-SYSTEM; BRAIN; MICROGLIA	We have used northern blot analysis and quantitative reverse transcription polymerase chain reaction (RT-PCR) to determine the postinjury expression profile of the transforming growth factor-beta 1 (TGF-beta 1) gene in the contused rat spinal cord, Spectrophotometric estimates of total sample RNA and quantitative analyses of cyclophilin mRNA using RT-PCR served as controls for comparisons between samples, No changes in cyclophilin gene expression were found at any postinjury survival times, The results of the TGF-beta 1 analyses, which were carried out on spinal cord samples taken at postinjury intervals ranging from 6 h to 10 days, show that the amount of TGF-beta 1 mRNA present in spinal cord increases rapidly following injury, reaching maximum levels 7 days postinjury. Unoperated control samples contained approximately 2 x 10(8) molecules of TGF-beta 1 mRNA/0.5 mu g total RNA. By 1 day postinjury, the amount of TGF-beta 1 mRNA in the cord had increased by a factor of 2.5 to 5 x 10(8) molecules/0.5 mu g total RNA, At 7 days postinjury, there were approximately 15 x 10(8) molecules of TGF-beta 1 mRNA/0.5 mu g total RNA. By 10 days postinjury the amount of TGF-beta 1 mRNA present in the spinal cord had declined to 8 x 10(8) molecules of TGF-beta 1 mRNA/0.5 mu g total RNA, a value similar to that observed at 3 days postinjury, The roles that TGF-beta 1 might play in modifying cellular responses in injured spinal cord are discussed.	OHIO STATE UNIV, COLL MED, SPINAL CORD INJURY RES CTR, DEPT PHYSIOL, COLUMBUS, OH 43210 USA	SempleRowland, SL (corresponding author), UNIV FLORIDA, DEPT NEUROSCI, INST BRAIN, POB 100244 JHMHC, GAINESVILLE, FL 32610 USA.		Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS NS-10165 (BTS), T32 NS07291-05 (PGP)] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007291, P50NS010165] Funding Source: NIH RePORTER		BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1993, BRAIN RES, V632, P314, DOI 10.1016/0006-8993(93)91167-Q; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DING A, 1990, J IMMUNOL, V145, P940; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FONTANA A, 1989, J IMMUNOL, V143, P3230; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HORNER PJ, 1994, NEURAL TRANSPLANTATI, P119; KIEFER R, 1995, INT J DEV NEUROSCI, V13, P331; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; KORSHINAGA M, 1995, J NEUROTRAUM, V12, P209; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MARTINOU JC, 1990, DEV BRAIN RES, V52, P175, DOI 10.1016/0165-3806(90)90233-O; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MERRILL JE, 1991, GLIA, V4, P327, DOI 10.1002/glia.440040311; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NICHOLS NR, 1991, J NEUROSCI RES, V28, P134, DOI 10.1002/jnr.490280114; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; Sambrook J, 1989, MOL CLONING LABORATO; SEMPLEROWLAND SL, 1994, INVEST OPHTH VIS SCI, V35, P2550; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIESSNER C, 1993, ACTA NEUROPATHOL, V86, P439; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	47	53	54	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1003	1014		10.1089/neu.1995.12.1003			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800001	8742129				2021-06-18	
J	NADLER, V; BIEGON, A; BEITYANNAI, E; ADAMCHIK, J; SHOHAMI, E				NADLER, V; BIEGON, A; BEITYANNAI, E; ADAMCHIK, J; SHOHAMI, E			CA-45 ACCUMULATION IN RAT-BRAIN AFTER CLOSED-HEAD INJURY - ATTENUATION BY THE NOVEL NEUROPROTECTIVE AGENT HU-211	BRAIN RESEARCH			English	Article						CALCIUM ACCUMULATION; (45)CALCIUM; CANNABINOID; CLOSED HEAD INJURY; HEAD TRAUMA; HU-211	CALCIUM ACCUMULATION; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; AMINO-ACIDS; NEUROTOXICITY; RECEPTORS; POTASSIUM; BLOCKADE; TRAUMA	Ca-45 accumulation was studied autoradiographically as a marker for lethally injured brain tissue following closed head injury (CHI), and applied to an investigation of the neuroprotective effect of the non-psychoactive cannabinoid(+)-(3S,4S)-7-hydroxy-D-6 tetrahydro-cannabinol 1,1-dimethylheptyl (HU-211). Amassment of Ca-45 in rat brain was examined 24 or 72 h after induction of CHI in the left hemisphere by a weight-drop device. Concentration of Ca-45 within 15 different brain regions was assessed by relative optical density. There was increased Ca-45 accumulation in the hemisphere ipsilateral to the side of the insult as compared with the contralateral hemisphere. The highest density of radioactive labeling was found in the anterior cortex and in the frontal parts of the parietal cortex, with accumulation expanding as a function of time post injury. On the third day following trauma the amount of accumulated Ca-45 was higher than that at 24 h after CHI, with more distant Ca-45-accumulating structures involved: the ventral posterolateral nucleus of the thalamus and the substantia nigra. Histological examination revealed necrotic tissue in the regions accumulating Ca-45. HU-211, a stereoselective inhibitor of the N-methyl-D-aspartate (NMDA) receptor, was injected immediately after induction of trauma. One day after trauma, HU-211 had significantly decreased both the volume of the Ca-45 accumulating zone and the concentration of the amassed radioisotope. In the HU-211 treated rats a considerable reduction in radioactive labeling was also found 72 h after trauma. The ability of HU-211 to decrease Ca-45 accumulation after head trauma is probably due to its ability to attenuate Ca2+ fluxes through the NMDA receptor-mediated calcium channels and to reduce the depolarization evoked Ca2+ fluxes. On the basis of our results, HU-211 seems to be a promising therapeutic agent for head trauma in humans.	HEBREW UNIV JERUSALEM, DEPT PHARMACOL, JERUSALEM, ISRAEL	NADLER, V (corresponding author), PHARMOS LTD, KIRYAT WEIZMANN, IL-76326 REHOVOT, ISRAEL.		Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			ARAKI T, 1990, BRAIN RES, V528, P114, DOI 10.1016/0006-8993(90)90202-M; Bar-Joseph Avi, 1994, Society for Neuroscience Abstracts, V20, P186; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Biegon A., 1993, Society for Neuroscience Abstracts, V19, P1485; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, J NEUROSCI, V10, P2493; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; Eshhar N., 1994, Society for Neuroscience Abstracts, V20, P1046; ESHHAR N, 1994, J NEUROCHEM, V63, pS79; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GRAMSBERGEN JBP, 1988, J NEUROCHEM, V50, P1798, DOI 10.1111/j.1471-4159.1988.tb02481.x; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1994, ACTA NEUROCHIR, P521; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NADLER V, 1993, NEUROSCI LETT, V162, P43, DOI 10.1016/0304-3940(93)90555-Y; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; SAJI M, 1987, SCIENCE, V235, P66, DOI 10.1126/science.3798095; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SMITH DH, 1993, J NEUROSCI, V13, P5383; STEIN DT, 1988, J CEREBR BLOOD F MET, V8, P834, DOI 10.1038/jcbfm.1988.140; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1	36	53	55	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 10	1995	685	1-2					1	11		10.1016/0006-8993(95)00367-Y			11	Neurosciences	Neurosciences & Neurology	RJ201	WOS:A1995RJ20100001	7583233				2021-06-18	
J	ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; BERNTMAN, L; MESSETER, K; RYDING, E				ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH; BERNTMAN, L; MESSETER, K; RYDING, E			EFFECTS OF HYPOTENSIVE TREATMENT WITH ALPHA(2)-AGONIST AND BETA(1)-ANTAGONIST ON CEREBRAL HEMODYNAMICS IN SEVERELY HEAD-INJURED PATIENTS	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						ADRENERGIC ALPHA RECEPTOR AGONISTS; ADRENERGIC BETA RECEPTOR ANTAGONISTS; BRAIN EDEMA; BRAIN INJURIES; CEREBRAL HEMODYNAMICS; CEREBRAL PERFUSION PRESSURE; CLONIDINE; INTRACRANIAL PRESSURE, METOPROLOL	BLOOD-BRAIN-BARRIER; FLOW; CIRCULATION; ANESTHESIA; CLONIDINE; PRESSURE	Therapy of post-traumatic brain oedema often includes preservation of high arterial blood pressure to avoid secondary ischaemic injuries to the brain. This practice can be questioned since high arterial blood pressure may aggravate brain oedema through raised hydrostatic capillary pressure, causing fluid filtration across the damaged blood-brain barrier. This latter view is in agreement with our clinical experience and therefore hypotensive therapy with an alpha(2)-adrenergic agonist (clonidine) and a beta(1)-adrenergic antagonist (metoprolol) has become part of our treatment protocol for severely head injured patients to decrease the post-traumatic brain oedema. The present study is an attempt to analyse whether there are any direct local cerebrovascular effects of the hypotensive agents used, which also might influence intracranial pressure. Severely head injured patients were investigated. Heart rate, mean arterial blood pressure, intracranial pressure, cerebral blood flow and arteriovenous difference in oxygen content were measured before and after a bolus dose of clonidine (six patients) and metoprolol (nine patients). Clonidine decreased mean arterial blood pressure and cerebrovascular resistance without affecting other parameters measured. Metoprolol decreased heart rate and mean arterial pressure, but had no effect on the cerebrovascular parameters. The results show that clonidine and metoprolol have no, or only minor, direct influence on local cerebral haemodynamics in severely brain injured patients. This implies that if there is an intracranial pressure reducing effect of these drugs, as suggested, this must be due to other mechanisms, namely a reduction in capillary hydrostatic pressure secondary to decreased arterial blood pressure and heart rate.	UNIV LUND HOSP,DEPT PHYSIOL & BIOPHYS,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN; UNIV LUND HOSP,DEPT CLIN NEUROPHYSIOL,S-22185 LUND,SWEDEN	ASGEIRSSON, B (corresponding author), UNIV LUND HOSP,DEPT ANAESTHESIA & INTENS CARE,S-22185 LUND,SWEDEN.						ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, IN PRESS INTENSIVE C; ASGEIRSSON B, 1994, 9TH INT S INT PRESS; BOREL C, 1990, CHEST, V98, P180, DOI 10.1378/chest.98.1.180; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; CRIUCKSHANK JM, 1987, LANCET, V2, P585; DAHLGREN N, 1981, J CEREBR BLOOD F MET, V1, P429, DOI 10.1038/jcbfm.1981.47; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; EDVINSSON L, 1978, J PHYSIOL-LONDON, V274, P149, DOI 10.1113/jphysiol.1978.sp012140; EDVINSSON L, 1976, PHARMACOL REV, V2, P275; FENSTERMACHER JD, 1984, EDEMA, P383; HAYASHI Y, 1993, BRIT J ANAESTH, V71, P108, DOI 10.1093/bja/71.1.108; HEISTAD DD, 1983, HDB PHYSL 2, V3, P137; JENSEN K, 1989, BRIT J ANAESTH, V62, P321, DOI 10.1093/bja/62.3.321; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; LASSEN N A, 1987, Nuclear Medicine Communications, V8, P535; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OLESEN J, 1986, CEPHALALGIA, V6, P41, DOI 10.1177/03331024860060S505; PAPPIUS HM, 1989, IMPLICATIONS BLOOD B, V1, P293; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; REID JL, 1981, BRIT J CLIN PHARMACO, V12, P295, DOI 10.1111/j.1365-2125.1981.tb01217.x; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; TODD NV, 1990, ACT NEUR S, V51, P296	28	53	54	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	1995	39	3					347	351		10.1111/j.1399-6576.1995.tb04075.x			5	Anesthesiology	Anesthesiology	RH062	WOS:A1995RH06200014	7793214				2021-06-18	
J	YAZBAK, PA; MCCOMB, JG; RAFFEL, C				YAZBAK, PA; MCCOMB, JG; RAFFEL, C			PEDIATRIC TRAUMATIC INTRACRANIAL ANEURYSMS	PEDIATRIC NEUROSURGERY			English	Article						ANEURYSM, TRAUMATIC INTRACRANIAL	INTERNAL CAROTID-ARTERY; STAB WOUNDS; CHILDHOOD; BRAIN	During the past 17 years, 7 children have been treated at Children's Hospital Los Angeles (CHLA) for traumatic intracranial aneurysms. These patients presented with subarachnoid or intraparenchymal hemorrhage (5 cases), growing fracture (1 case), and behavioral change (1 case). All patients were managed with surgery, and no patient died or was made neurologically worse as a result of such management. The existence of a traumatic aneurysm should be considered when new neurological symptoms develop in a patient with a history of head injury.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV PEDIAT NEUROSURG,LOS ANGELES,CA	YAZBAK, PA (corresponding author), DARTMOUTH HITCHCOCK MED CTR,NEUROSURG SECT,1 MED CTR DR,LEBANON,NH 03756, USA.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ALMEIDA GM, 1977, CHILD BRAIN, V3, P193; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BOUSQUET C, 1989, SURG NEUROL, V31, P319, DOI 10.1016/0090-3019(89)90059-1; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; DIAL DL, 1937, AM J SURG, V35, P2; DUTREVOU MD, 1992, NEUROSURGERY, V31, P905, DOI 10.1227/00006123-199211000-00012; Endo S, 1974, No Shinkei Geka, V2, P329; FELDGES A, 1989, INTENS CARE MED, V15, P400; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FOX JL, 1983, INTRACRANIAL ANEURYS, V3, P1453; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; JUNGMICHEL G, 1932, DTSCH Z GES GERICHTL, V19, P197; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KOMIYAMA M, 1991, SURG NEUROL, V36, P126, DOI 10.1016/0090-3019(91)90230-7; LASSMAN LP, 1974, VASCULAR SURG, V8, P1; LEE JP, 1990, J TRAUMA, V30, P619, DOI 10.1097/00005373-199005000-00017; MENEZES AH, 1974, J NEUROSURG, V40, P544, DOI 10.3171/jns.1974.40.4.0544; MENSCHEL H, 1922, ARZTL SACHVERST ZTG, V28, P13; MORARD M, 1991, NEUROSURGERY, V29, P438, DOI 10.1227/00006123-199109000-00018; NAKSTAD P, 1984, J NEURORADIOLOGY, V11, P3; NOV AA, 1984, J NEURORADIOLOGY, V11, P3; OVERTON MC, 1966, J NEUROSURG, V24, P672, DOI 10.3171/jns.1966.24.3.0672; PATEL AN, 1971, J NEUROSURG, V35, P571, DOI 10.3171/jns.1971.35.5.0571; PAUL GA, 1980, J NEUROSURG, V53, P101, DOI 10.3171/jns.1980.53.1.0101; PIATT JH, 1992, J NEUROSURG, V77, P799, DOI 10.3171/jns.1992.77.5.0799; POZATTI E, 1982, J NEUROSURG, V57, P418; SCHARFETTER F, 1976, ACTA NEUROCHIR, V33, P123, DOI 10.1007/BF01405749; SENEGOR M, 1991, J NEUROSURG, V75, P475, DOI 10.3171/jns.1991.75.3.0475; SHUCART WA, 1974, AM J DIS CHILD, V127, P288, DOI 10.1001/archpedi.1974.02110210138022; SHULMAN K, 1982, PEDIATRIC NEUROSURGE, P617; SMITH KR, 1968, J NEUROSURG, V29, P551, DOI 10.3171/jns.1968.29.5.0551; TEAL JS, 1973, J NEUROSURG, V38, P568, DOI 10.3171/jns.1973.38.5.0568; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163; Tsubokawa T, 1975, No Shinkei Geka, V3, P663; WEINSTEIN JM, 1991, ARCH NEUROL-CHICAGO, V48, P490, DOI 10.1001/archneur.1991.00530170050020; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016	39	53	54	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	JAN	1995	22	1					15	19		10.1159/000121294			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	PY968	WOS:A1995PY96800003	7888388				2021-06-18	
J	ZINK, BJ; WALSH, RF; FEUSTEL, PJ				ZINK, BJ; WALSH, RF; FEUSTEL, PJ			EFFECTS OF ETHANOL IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							HEAD-INJURY; CARDIOCIRCULATORY FUNCTION; VENTILATORY RESPONSES; HEMORRHAGIC-SHOCK; ALCOHOL; INTOXICATION; NALOXONE; HYPERCAPNIA; SEVERITY; HYPOXIA	The effects of ethanol intoxication on brain injury and cerebral blood flow (CBF) were investigated in a porcine fluid-percussion model of traumatic brain injury (TBI). Immature swine, under halothane anesthesia (1%), had a TBI delivered with a fluid-percussion device. The experimental group (n = 10) received ethanol (3.5 gm/kg) via gastric tube followed in 1 h by TBI. Two groups of control animals received normal saline and TBI (n = 10) or ethanol and no TBI (n = 5). Mean arterial blood pressure (MAP), intracranial pressure (ICP), arterial blood gases, and serum lactate were monitored for 3 h after the injury. CBF was measured with radiolabelled 15-micron diameter microspheres. Neuropathologic changes were evaluated and graded after formalin perfusion and brain removal at 3 h postinjury. The ethanol level 60 min post-head injury was 198 +/- 70 (SD) mg/dL in the ethanol + TBI group. At 90 min postinjury and thereafter, ethanol + TBI animals compared with TBI only animals had significantly lower MAP (63 +/- 26 mmHg vs 91 +/- 15 mmHg) and lower cerebral perfusion pressure (50 +/- 25 mmHg vs 78 +/- 15), and at 180 min postinjury, lower CBF (87 +/- 37% vs 62 +/- 79% of preinjury levels). Ethanol + TBI animals had higher blood lactates (28 +/- 11 mg/dL vs 13 +/- 6 mg/dL) than TBI only animals. Ethanol + TBI animals also had significantly longer postinjury apneas (11 +/- 8 min vs 0.6 +/- 0.4 min), with three of ten ethanol-treated animals never recovering spontaneous respiration. Ethanol intoxication produced hemodynamic and respiratory changes, which may have a deleterious effect on outcome and mortality after brain injury.	ALBANY MED COLL,DEPT SURG,A-61,47 NEW SCOTLAND AVE,ALBANY,NY 12208; ALBANY MED COLL,DEPT PEDIAT,ALBANY,NY 12208; UNIV MICHIGAN,MED CTR,DEPT EMERGENCY,ANN ARBOR,MI 48109				Feustel, Paul/0000-0002-6963-4349	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR05394-29] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30303] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR005394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030303] Funding Source: NIH RePORTER		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GORDIS E, 1989, NIAAA ALCOHOL ALERT, V3, P1; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HEYMANN MA, 1977, PROG CARDIOVASC DIS, V20, P55, DOI 10.1016/S0033-0620(77)80005-4; HORTON JW, 1987, CIRC SHOCK, V22, P23; HORTON JW, 1986, SURGERY, V100, P520; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JEHLE D, 1988, ANN EMERG MED, V17, P953, DOI 10.1016/S0196-0644(88)80678-4; KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P2480, DOI 10.1001/jama.1988.03410170018005; KNOTT DH, 1963, NEW ENGL J MED, V269, P292, DOI 10.1056/NEJM196308082690604; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MALT SH, 1971, J TRAUM, V11, P76, DOI 10.1097/00005373-197101000-00007; MANKES RF, 1991, ALCOHOL CLIN EXP RES, V15, P80, DOI 10.1111/j.1530-0277.1991.tb00521.x; MARX J, 1990, Emergency Medicine Clinics of North America, V8, P929; MCCAULEY VB, 1988, AM REV RESPIR DIS, V137, P1406, DOI 10.1164/ajrccm/137.6.1406; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; McQueen J D, 1975, Surg Neurol, V4, P375; MICHIELS TM, 1983, J APPL PHYSIOL, V55, P929; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OVERGAARD J, 1982, HEAD INJURY BASIC CL, P239; POLLACK CV, 1990, J TRAUMA, V30, P888, DOI 10.1097/00005373-199007000-00021; SAHN SA, 1975, CLIN SCI MOL MED, V49, P33, DOI 10.1042/cs0490033; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; STEINBROOK RA, 1984, LIFE SCI, V34, P881, DOI 10.1016/0024-3205(84)90205-4; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; ZINK BJ, 1988, ANN EMERG MED, V17, P15, DOI 10.1016/S0196-0644(88)80496-7; ZINK BJ, 1988, CIRC SHOCK, V24, P19	36	53	55	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1993	10	3					275	286		10.1089/neu.1993.10.275			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	MC021	WOS:A1993MC02100004	8258840				2021-06-18	
J	BEERS, SR				BEERS, SR			COGNITIVE EFFECTS OF MILD HEAD-INJURY IN CHILDREN AND ADOLESCENTS	NEUROPSYCHOLOGY REVIEW			English	Article						NEUROPSYCHOLOGICAL ASSESSMENT; MILD HEAD INJURY; DEVELOPMENT; INFORMATION PROCESSING	NEUROPSYCHOLOGICAL SEQUELAE; INTELLECTUAL ABILITY; REACTION-TIME; TRAUMA; PERFORMANCE; CONCUSSION; RECOVERY; CHILDHOOD; SYMPTOMS; MEMORY	A comprehensive review of recent neuropsychological studies of mild head injury (MHI) involving children and adolescents is presented. The seminal work of Rutter and his colleagues is reviewed. An alternative conceptualization of MHI as proposed by various researchers is elaborated and further research investigating the cognitive sequelae of MHI is reviewed. MHI is discussed within the context of development and information processing models. Finally, the sequelae of MHI are reviewed with respect to academic functioning. Methodological problems inherent in studies of MHI are identified and discussed. The studies reviewed here support the conclusion that both the cognitive and emotional consequences of MHI should receive serious evaluation.	VET ADM MED CTR,PITTSBURGH,PA; WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15261							ADAMS KM, 1991, J CLIN EXP NEUROPSYC, V13, P388, DOI 10.1080/01688639108401053; ADAMS W, 1990, MAY N COAST SOC PED; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ALVS WM, 1985, CENTRAL NERVOUS SYST, P255; ARMSTRONG CL, 1987, NEUROPSYCHOLOGY, V4, P15; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BARTH JT, 1986, J HEAD TRAUMA REHABI, V1, P62; BARTH JT, 1986, J HEAD TRAUMA REHABI, V1, pR9; BARTH JT, 1990, 10TH ANN C NAT AC NE; BARTH JT, 1989, MILD HEAD INJURY, P255; BARTHOLOMEUSZ FDL, 1989, J GASTROEN HEPATOL, V4, P81, DOI 10.1111/j.1440-1746.1989.tb00810.x; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Benton A. L, 1989, MILD HEAD INJURY, P3; BIGLER ED, 1987, J LEARN DISABIL, V20, P516, DOI 10.1177/002221948702000902; BIGLER ED, 1987, J LEARN DISABIL, V20, P454, DOI 10.1177/002221948702000803; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BOLL TJ, 1981, HDB CLIN NEUROPSYCHO, V1, P418; BOLLOK I, 1983, NEUROPEPTIDES, V3, P263; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHADWICK O, 1981, PSYCHOL MED, V11, P46; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P69; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; CONBOY TJ, 1986, REHABIL PSYCHOL, V31, P203, DOI 10.1037//0090-5550.31.4.203; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; DIKMEN S, 1989, REHABIL PSYCHOL, V34, P101; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EAMES P, 1986, LANCET, V2, P164; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FLETCHER JM, 1990, 10TH ANN C NAT AC NE; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENNARELLI TA, 1987, STAPP CAR CRASH C, P49; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; GOUVIER WD, 1986, AM PSYCHOL, V41, P483; GRAHAM P, 1968, BRIT J PSYCHIAT, V114, P581, DOI 10.1192/bjp.114.510.581; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HANNAY HJ, 1988, J CLIN EXPT NEUROPSY, V11, P444; HYND GW, 1990, 10TH ANN C NAT AC NE; HYND GW, 1988, NEUROPSYCHOLOGICAL A, P12; JANE JA, 1982, OUTCOME PATHOLOGY HE, P229; Jennett B, 1978, Practitioner, V221, P77; Jennett B, 1989, MILD HEAD INJURY, P23; KALSBECK WD, 1980, J NEUROSURG, V53, P1931; KANE RL, 1992, NEUROPSYCHOL REV, V2, P281; KAY T, 1986, MINOR HEAD INJURY IN; KLAUBER MR, 1986, PREV MED, V15, P139, DOI 10.1016/0091-7435(86)90084-8; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLVOE H, 1972, SCANDINAVIAN J REHAB, V4, P55; KRAUS JF, 1989, MILD HEAD INJURY, P8; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 1989, MILD HEAD INJURY; LIDVALL HF, 1975, LANCET, V1, P100; Lidvall HF, 1974, ACTA NEUROLOGICA S56, V50, P7; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MARGULIES SS, 1989, J BIOCH ENG, V111, P241; Marshall L. F., 1985, CENTRAL NERVOUS SYST, P45; Marshall LF, 1989, MILD HEAD INJURY, P276; MARTINI DR, 1990, MAY N COAST SOC PED; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Miller WG, 1986, NEUROPSYCHOLOGY HDB, P347; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENTHAL M, 1986, J HEAD TRAUMA REHABI, V1, pR8; Ruff R.M., 1989, MILD HEAD INJURY, P176; Ruff RM, 1986, J HEAD TRAUMA REHAB, V1, P43; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1966, SOC PSYCHIATR, V1, P38, DOI 10.1007/BF00583828; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1982, AM J PSYCHIAT, V139, P21; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; SLATER EJ, 1989, J ADOLESCENT HEALTH, V10, P237, DOI 10.1016/0197-0070(89)90240-4; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SYMONDS C, 1962, LANCET, V1, P1; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; WINOGRON HW, 1984, J CLIN ENUROPSYCHOLO, V6, P268; ZAPPALA G, 1992, ARCH CLIN NEUROPSYCH, V7, P145, DOI 10.1016/0887-6177(92)90008-B	115	53	53	0	6	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU 233 SPRING ST, NEW YORK, NY 10013	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	DEC	1992	3	4					281	320		10.1007/BF01108414			40	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	LE058	WOS:A1992LE05800001	1284851				2021-06-18	
J	SHEPARD, SR; GHAJAR, JBG; GIANNUZZI, R; KUPFERMAN, S; HARIRI, RJ				SHEPARD, SR; GHAJAR, JBG; GIANNUZZI, R; KUPFERMAN, S; HARIRI, RJ			FLUID PERCUSSION BAROTRAUMA CHAMBER - A NEW INVITRO MODEL FOR TRAUMATIC BRAIN INJURY	JOURNAL OF SURGICAL RESEARCH			English	Article							CEREBRAL MISSILE INJURY; HEAD-INJURY; RAT			SHEPARD, SR (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,AITKEN NEUROSURG LAB,1300 YORK AVE,NEW YORK,NY 10021, USA.						BERGREN DR, 1975, J TRAUMA, V15, P336, DOI 10.1097/00005373-197504000-00010; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gennarelli T, 1982, ADV NEUROTRAUMATOLOG, P31; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA, P797; GENNARELLI TA, 1980, APPL NEUROBIOL, V6, P234; GENNARELLI TA, 1985, NIH CENTRAL NERVOUS, P103; GOVONS SR, 1972, EXP NEUROL, V34, P121, DOI 10.1016/0014-4886(72)90193-8; Gurdjian E. S., 1967, MED SCI, V18, P45; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; HARIRI RJ, 1989, J TRAUMA, V29, P1203, DOI 10.1097/00005373-198909000-00003; HAYES RL, 1989, HEAD INJURY; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kobrine A I, 1973, Surg Neurol, V1, P34; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1965, BIOPHYSIK, V3, P320; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1966, HEAD INJURY, P260; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TSUBOKAWA T, 1975, Neurologia Medico-Chirurgica, V15, P57, DOI 10.2176/nmc.15pt1.57	30	53	56	0	1	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0022-4804			J SURG RES	J. Surg. Res.	NOV	1991	51	5					417	424		10.1016/0022-4804(91)90144-B			8	Surgery	Surgery	GK450	WOS:A1991GK45000011	1758175				2021-06-18	
J	SIEGEL, JH; GENS, DR; MAMANTOV, T; GEISLER, FH; GOODARZI, S; MACKENZIE, EJ				SIEGEL, JH; GENS, DR; MAMANTOV, T; GEISLER, FH; GOODARZI, S; MACKENZIE, EJ			EFFECT OF ASSOCIATED INJURIES AND BLOOD-VOLUME REPLACEMENT ON DEATH, REHABILITATION NEEDS, AND DISABILITY IN BLUNT TRAUMATIC BRAIN INJURY	CRITICAL CARE MEDICINE			English	Article						BRAIN INJURIES; BLUNT INJURIES; COST-BENEFIT ANALYSIS; BRAIN DEATH; DISABILITY; REHABILITATION; NEUROLOGIC EXAMINATION; SEVERITY OF ILLNESS INDEX; GLASGOW COMA SCALE	HEAD-INJURY; MULTIPLE TRAUMA; ORGAN INJURY; MANAGEMENT	Objective: To examine the effects of associated injuries on death, disability, rehabilitation needs, and cost in patients with blunt traumatic brain injury. Design: A retrospective case series analysis of 1,709 patients with blunt traumatic brain injury, or 37.2% of 4,590 consecutive blunt trauma patients, was combined with a prospective study of a subset of 202 of the 1,709 brain-injured patients obtained during the same time period with regard to need for rehabilitation services, residual disability, and costs at 1 yr after discharge from the acute trauma center. Setting. A level I regional trauma center that is also the statewide neurotrauma and multiple trauma unit serving a population of more than 3 million persons. Results: Contingency table analysis showed the Glasgow Coma Scale to be highly predictive (p < .0001) of likelihood of mortality, need for postacute inpatient rehabilitation, or discharge home. Of the blunt traumatic brain injury patients, 40.4% (691) had an isolated brain injury and 59.6% (1,018) had brain plus at least one other systemic injury. The mortality rate of the isolated brain injury group was 11.1% compared with 21.8% in all brain plus systemic injury groups (p < .0001). Spine, lung, visceral, pelvis, or extremity injuries in blunt traumatic brain injury all increased mortality rate to > 25% (all simultaneously significant, p < .0001). Analysis of the interaction of brain injury (quantified by Glasgow Coma Scale) with blood replacement in the initial 24 hrs showed that at any Glasgow Coma Scale range, percent mortality increased as the volume of blood increased. Hypovolemic shock increased the mortality rate from 12.8% to 62.1% (p < .0001). The need for postacute inpatient rehabilitation in survivors also increased as blood replacement increased, and shock increased the percent of patients requiring post-acute inpatient rehabilitation from 39.7% to 60.3%. In 202 consecutive surviving brain trauma patients followed for 1 yr, isolated brain-injured patients with moderate brain injuries had a 4% need for posttrauma, postacute inpatient rehabilitation with a total cost per case of $12,489 compared with the brain plus extremity injury group, who had a 23% postacute inpatient rehabilitation rate and a total cost per case of $36,177 at 1 yr. With severe brain injury, isolated brain injury increased postacute inpatient rehabilitation to 29% and 1-yr cost to $59,274, but with the brain plus extremity injury group, postacute inpatient rehabilitation increased to 49% and cost to $84,950. Conclusions: In blunt traumatic brain injury, the addition of major visceral or extremity injuries, with need for blood replacement or shock, increases the risk of death, the need for rehabilitation, and the costs of disability.	UNIV MARYLAND,SCH MED,MARYLAND INST EMERGENCY MED SERVICES SYST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT NEUROSURG,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH PUBL HLTH & HYG,BALTIMORE,MD 21218							ANNEGERS JF, 1979, CENTRAL NERVOUS SYST, P1; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; COOPER PJ, 1987, HEAD INJURY, P1; DALAL SA, 1989, J TRAUMA, V29, P981, DOI 10.1097/00005373-198907000-00012; Dunham C M, 1989, Md Med J, V38, P227; DUNHAM CM, 1991, RESUSCITATION, V21, P207, DOI 10.1016/0300-9572(91)90047-3; Geisler F.H., 1987, TRAUMA EMERGENCY SUR, P919; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Jennett B, 1981, MANAGEMENT HEAD INJU; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; RIVKIND AI, 1989, J TRAUMA, V29, P1398, DOI 10.1097/00005373-198910000-00019; SACHS L, 1982, APPLIED STATISTICS H; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Turney SZ, 1990, MANAGEMENT CARDIOTHO, P229; 1985, ABBREVIATED INJURY S	18	53	53	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	1991	19	10					1252	1265		10.1097/00003246-199110000-00007			14	Critical Care Medicine	General & Internal Medicine	GK390	WOS:A1991GK39000007	1914482				2021-06-18	
J	PHILLIPS, G				PHILLIPS, G			TRAUMATIC EPILEPSY AFTER CLOSED HEAD INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article																BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P348; Eccles J.C., 1953, NEUROPHYSIOLOGICAL B; JEFFERSON G, 1942, GLASGOW MED J, V20, P77; PICKERING GW, 1951, LANCET, V2, P845; RUSSELL WR, 1952, J NEUROL NEUROSUR PS, V15, P93, DOI 10.1136/jnnp.15.2.93; SCA, 1952, COMMUNICATION; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107	8	53	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1954	17	1					1	10		10.1136/jnnp.17.1.1			10	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	YD072	WOS:A1954YD07200001	13131074	Bronze, Green Published			2021-06-18	
J	KUNKLE, EC; MULLER, JC; ODOM, GL				KUNKLE, EC; MULLER, JC; ODOM, GL			TRAUMATIC BRAIN-STEM THROMBOSIS - REPORT OF A CASE AND ANALYSIS OF THE MECHANISM OF INJURY	ANNALS OF INTERNAL MEDICINE			English	Article																ALAJOUANINE T, 1948, REV NEUROL, V80, P321; Alexander L, 1937, ARCH NEURO PSYCHIATR, V38, P1243, DOI 10.1001/archneurpsyc.1937.02260240123010; BAUER W, 1942, DISEASES METABOLISM, P609; Blaine ES, 1925, J AMER MED ASSOC, V85, P1356, DOI 10.1001/jama.1925.02670180012003; Brock S., 1943, INJURIES SKULL BRAIN; Corner EM, 1907, J ANAT PHYSIOL, V41, P149; DEKLEYN A, 1933, DTSCH Z NERVENHEILKD, V132, P157; deKleyn Nieuwenhuyse, 1927, ACTA OTOLARYNG STOCK, V11, P155, DOI 10.3109/00016482709120074; Foix C, 1925, REV NEUROL-FRANCE, V43, P160; FUTCHER TB, 1907, MODERN MED, V1, P808; Grinker RR, 1927, J AMER MED ASSOC, V88, P1140, DOI 10.1001/jama.1927.02680410016007; Hall AJ, 1934, LANCET, V2, P975; MOOLTEN SE, 1949, ARCH INTERN MED, V84, P667, DOI 10.1001/archinte.1949.00230050003001; PERRY TT, 1943, P STAFF M MAYO CLIN, V18, P19; PRATTTHOMAS HR, 1947, JAMA-J AM MED ASSOC, V133, P600, DOI 10.1001/jama.1947.02880090022005; Rigdon RH, 1944, J LAB CLIN MED, V29, P28; Sheehan D, 1937, LANCET, V2, P614; SUGAR O, 1949, AM J ROENTGENOL, V61, P166; Yaskin HE, 1944, ARCH NEURO PSYCHIATR, V51, P271, DOI 10.1001/archneurpsyc.1944.02290270060008; 1937, J A M A, V109, P233	20	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.		1952	36	5					1329	1335		10.7326/0003-4819-36-5-1329			7	Medicine, General & Internal	General & Internal Medicine	UE138	WOS:A1952UE13800016	14924467				2021-06-18	
J	Wang, FF; Wan, H; Ma, ZR; Zhong, YT; Sun, QC; Tian, Y; Qu, LQ; Du, HT; Zhang, MX; Li, LL; Ma, HL; Luo, J; Liang, YY; Li, WJ; Hong, GS; Liu, LQ; Dai, HJ				Wang, Feifei; Wan, Hao; Ma, Zhuoran; Zhong, Yeteng; Sun, Qinchao; Tian, Ye; Qu, Liangqiong; Du, Haotian; Zhang, Mingxi; Li, Lulin; Ma, Huilong; Luo, Jian; Liang, Yongye; Li, Wen Jung; Hong, Guosong; Liu, Lianqing; Dai, Hongjie			Light-sheet microscopy in the near-infrared II window	NATURE METHODS			English	Article							IN-VIVO; FLUORESCENCE MICROSCOPY; 2-PHOTON MICROSCOPY; DEEP; BRAIN; TISSUE; LASER; DYE; NANOPARTICLES; WAVELENGTHS	Non-invasive deep-tissue three-dimensional optical imaging of live mammals with high spatiotemporal resolution is challenging owing to light scattering. We developed near-infrared II (1,000-1,700 nm) light-sheet microscopy with excitation and emission of up to approximately 1,320 nm and 1,700 nm, respectively, for optical sectioning at a penetration depth of approximately 750 mu m through live tissues without invasive surgery and at a depth of approximately 2 mm in glycerol-cleared brain tissues. Near-infrared II light-sheet microscopy in normal and oblique configurations enabled in vivo imaging of live mice through intact tissue, revealing abnormal blood flow and T-cell motion in tumor microcirculation and mapping out programmed-death ligand 1 and programmed cell death protein 1 in tumors with cellular resolution. Three-dimensional imaging through the intact mouse head resolved vascular channels between the skull and brain cortex, and allowed monitoring of recruitment of macrophages and microglia to the traumatic brain injury site.	[Wang, Feifei; Wan, Hao; Ma, Zhuoran; Zhong, Yeteng; Sun, Qinchao; Tian, Ye; Du, Haotian; Dai, Hongjie] Stanford Univ, Dept Chem & BioX, Stanford, CA 94305 USA; [Qu, Liangqiong] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA; [Qu, Liangqiong] Univ N Carolina, BRIC, Chapel Hill, NC USA; [Zhang, Mingxi] Wuhan Univ Technol, State Key Lab Adv Technol Mat Synth & Proc, Wuhan, Hubei, Peoples R China; [Li, Lulin; Luo, Jian] VA Palo Alto Hlth Care Syst, Palo Alto Vet Inst Res, Palo Alto, CA USA; [Ma, Huilong; Liang, Yongye] South Univ Sci & Technol China, Dept Mat Sci & Engn, Shenzhen, Peoples R China; [Luo, Jian] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Li, Wen Jung; Liu, Lianqing] Chinese Acad Sci, Shenyang Inst Automat, State Key Lab Robot, Shenyang, Liaoning, Peoples R China; [Li, Wen Jung] City Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China; [Hong, Guosong] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA	Dai, HJ (corresponding author), Stanford Univ, Dept Chem & BioX, Stanford, CA 94305 USA.	hdai@stanford.edu	Ma, Zhuoran/AAM-6799-2021; Tian, Ye/I-8961-2018; Tian, Ye/AAJ-9782-2021; Liang, Yongye/G-6033-2018; Liang, Yongye/AAH-1981-2020; Hong, Guosong/A-7551-2013; Sun, Qinchao/Y-9302-2019; Luo, Jian/B-8449-2014	Tian, Ye/0000-0002-1833-1807; Tian, Ye/0000-0002-1833-1807; Liang, Yongye/0000-0002-7416-8792; Liang, Yongye/0000-0002-7416-8792; Hong, Guosong/0000-0002-8858-4471; Ma, Zhuoran/0000-0002-1520-2129; Wang, Feifei/0000-0001-7687-3412; Luo, Jian/0000-0002-2064-8467	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1-NS-105737]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [DP1NS105737, R01NS092868] Funding Source: NIH RePORTER	We thank members of the Dai group for discussion. This study was supported by the National Institutes of Health through grant DP1-NS-105737.	Alifu N, 2017, DYES PIGMENTS, V143, P76, DOI 10.1016/j.dyepig.2017.04.017; Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]; Balar AV, 2017, CANCER IMMUNOL IMMUN, V66, P551, DOI 10.1007/s00262-017-1954-6; Bouchard MB, 2015, NAT PHOTONICS, V9, P113, DOI [10.1038/nphoton.2014.323, 10.1038/NPHOTON.2014.323]; Bruns OT, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0056; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Diao S, 2015, ANGEW CHEM INT EDIT, V54, P14758, DOI 10.1002/anie.201507473; Diao S, 2015, NANO RES, V8, P3027, DOI 10.1007/s12274-015-0808-9; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Escobet-Montalban A, 2018, OPT LETT, V43, P5484, DOI 10.1364/OL.43.005484; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Herisson F, 2018, NAT NEUROSCI, V21, P1209, DOI 10.1038/s41593-018-0213-2; Hong G., 2014, NAT COMMUN, V5, P4206, DOI DOI 10.1038/NCOMMS5206; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/NPHOTON.2014.166, 10.1038/nphoton.2014.166]; Hong GS, 2012, NAT MED, V18, P1841, DOI 10.1038/nm.2995; Horton NG, 2013, NAT PHOTONICS, V7, P205, DOI [10.1038/nphoton.2012.336, 10.1038/NPHOTON.2012.336]; Huisken J, 2004, SCIENCE, V305, P1007, DOI 10.1126/science.1100035; Itoh R, 2016, OPT LETT, V41, P5015, DOI 10.1364/OL.41.005015; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Johns M, 2005, OPT EXPRESS, V13, P4828, DOI 10.1364/OPEX.13.004828; Kawakami R, 2015, BIOMED OPT EXPRESS, V6, P891, DOI 10.1364/BOE.6.000891; Keller PJ, 2010, NAT METHODS, V7, P637, DOI [10.1038/NMETH.1476, 10.1038/nmeth.1476]; Lapadula G, 2014, CHEM MATER, V26, P1062, DOI 10.1021/cm404140q; Lee JA, 2013, OPT LETT, V38, P332, DOI 10.1364/OL.38.000332; Liu J, 2015, BIOMED OPT EXPRESS, V6, P1857, DOI 10.1364/BOE.6.001857; Liu TL, 2018, SCIENCE, V360, DOI 10.1126/science.aaq1392; Matthes R, 2000, HEALTH PHYS, V79, P431; Naczynski DJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3199; Ouzounov DG, 2017, NAT METHODS, V14, P388, DOI 10.1038/nmeth.4183; Pediredla AK, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.12.126009; Power RM, 2017, NAT METHODS, V14, P360, DOI 10.1038/nmeth.4224; Rowlands CJ, 2017, LIGHT-SCI APPL, V6, DOI 10.1038/lsa.2016.255; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shi L, 2017, DEEP IMAGING IN TISSUE AND BIOMEDICAL MATERIALS: USING LINEAR AND NONLINEAR OPTICAL METHODS, P1; Shi LY, 2016, J BIOPHOTONICS, V9, P38, DOI 10.1002/jbio.201500192; Song E, 2015, OPT LASER TECHNOL, V73, P69, DOI 10.1016/j.optlastec.2015.03.020; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Tang HD, 2016, CANCER CELL, V29, P285, DOI 10.1016/j.ccell.2016.02.004; Tomer R, 2015, CELL, V163, P1796, DOI 10.1016/j.cell.2015.11.061; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Truong TV, 2011, NAT METHODS, V8, P757, DOI 10.1038/nmeth.1652; VANSTAVEREN HJ, 1991, APPL OPTICS, V30, P4507, DOI 10.1364/AO.30.004507; Wan H, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804956; Wan H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03505-4; WANG LH, 1995, COMPUT METH PROG BIO, V47, P131, DOI 10.1016/0169-2607(95)01640-F; Wang TY, 2018, NAT METHODS, V15, P789, DOI 10.1038/s41592-018-0115-y; Wang WZ, 2018, ADV MATER, V30, DOI 10.1002/adma.201800106; Welsher K, 2011, P NATL ACAD SCI USA, V108, P8943, DOI 10.1073/pnas.1014501108; Welsher K, 2009, NAT NANOTECHNOL, V4, P773, DOI [10.1038/NNANO.2009.294, 10.1038/nnano.2009.294]; Won N, 2012, MOL IMAGING, V11, P338, DOI 10.2310/7290.2011.00057; Zhang MX, 2018, P NATL ACAD SCI USA, V115, P6590, DOI 10.1073/pnas.1806153115; Zhang XD, 2016, ADV MATER, V28, P6872, DOI 10.1002/adma.201600706; Zhong YT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00917-6; Zhu SJ, 2017, P NATL ACAD SCI USA, V114, P962, DOI 10.1073/pnas.1617990114	56	52	54	18	137	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1548-7091	1548-7105		NAT METHODS	Nat. Methods	JUN	2019	16	6					545	+		10.1038/s41592-019-0398-7			11	Biochemical Research Methods	Biochemistry & Molecular Biology	IA3HW	WOS:000469455200024	31086342	Green Accepted			2021-06-18	
J	Jiang, JY; Gao, GY; Feng, JF; Mao, Q; Chen, LG; Yang, XF; Liu, JF; Wang, YH; Qiu, BH; Huang, XJ				Jiang, Ji-Yao; Gao, Guo-Yi; Feng, Jun-Feng; Mao, Qing; Chen, Li-Gang; Yang, Xiao-Feng; Liu, Jin-Fang; Wang, Yu-Hai; Qiu, Bing-Hui; Huang, Xian-Jian			Traumatic brain injury in China	LANCET NEUROLOGY			English	Article							MILD HYPOTHERMIA THERAPY; DECOMPRESSIVE CRANIECTOMY; HEAD TRAUMA; TARGETED MANAGEMENT; EASTERN CHINA; EPIDEMIOLOGY; MULTICENTER; PRESSURE; TRIAL; CRANIOPLASTY	China has more patients with traumatic brain injury (TBI) than most other countries in the world, making this condition a major public health concern. Population-based mortality of TBI in China is estimated to be approximately 13 cases per 100 000 people, which is similar to the rates reported in other countries. The implementation of various measures, such as safety legislation for road traffic, establishment of specialised neurosurgical intensive care units, and the development of evidence-based guidelines, have contributed to advancing prevention and care of patients with TBI in China. However, many challenges remain, which are augmented further by regional differences in TBI care. High-level care, such as intracranial pressure monitoring, is not universally available yet. In the past 30 years, the quality of TBI research in China has substantially improved, as evidenced by an increasing number of clinical trials done. The large number of patients with TBI and specialised trauma centres offer unique opportunities for TBI research in China. Furthermore, the formation and development of research collaborations between China and international groups are considered essential to advancing the quality of TBI care and research in China, and to improve quality of life in patients with this condition.	[Jiang, Ji-Yao; Gao, Guo-Yi; Feng, Jun-Feng; Mao, Qing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Chen, Li-Gang] Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou, Peoples R China; [Yang, Xiao-Feng] Zhejiang Univ, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China; [Liu, Jin-Fang] Southcent Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China; [Wang, Yu-Hai] Wuxi Taihu Hosp, Dept Neurosurg, Wuxi, Peoples R China; [Qiu, Bing-Hui] Southern Med Univ, Southern Hosp, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China; [Huang, Xian-Jian] Shenzhen Univ, Affiliated Hosp 1, Dept Neurosurg, Shenzhen, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81671198, 81771317, 81571883]	The National Natural Science Foundation of China provides financial support to J-YJ (81772058), G-YG (81671198), J-FF (81771317), and QM (81571883) for traumatic brain injury research. J-YJ, G-YG, J-FF, QM, L-GC, X-FY, J-FL, Y-HW, B-HQ, and X-JH declare no competing interests.	Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; CCoN Surgeons, 2009, CHIN J NEUROSURG, V25, P100; Cheng PC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002332; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chinabgao, CHIN REP HALL; Chinese Congress of Neurological Surgeons, 2011, CHIN J NEUROSURG, V27, P1073; Chinese Congress of Neurological Surgeons, 2008, CHIN J NEUROSURG, V24, P723; Chinese Congress of Neurological Surgeons, 2015, CHIN J NEUROSURG, V31, P757; Chinese Congress of Neurological Surgeons, 2018, CHIN J NEUROSURG, V34, P649; Chinese Congress of Neurological Surgeons, 2014, CHIN J NEUROSURG, V30, P840; Chinese Congress of Neurological Surgeons, 2016, CHIN J NEUROSURG, V32, P767; Chinese Congress of Neurological Surgeons, 2017, CHIN J NEUROSURG, V33, P652; Chinese Congress of Neurological Surgeons, 2013, CHIN J NEUROSURG, V29, P967; Clifton GL, 2011, THER HYPOTHERMIA TEM, V1, P3, DOI 10.1089/ther.2010.1500; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Hu J, 2009, CHIN J NEUROSURG DIS, V8, P47; [惠纪元 Hui Jiyuan], 2014, [中华神经外科杂志, Chinese Journal of Neurosurgery], V30, P56; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Jiang JY, 2007, SURG NEUROL, V68, P2, DOI 10.1016/j.surneu.2007.09.016; Jiang JY, 2013, INJURY, V44, P1453, DOI 10.1016/j.injury.2012.08.045; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang RC, 2018, JAMA NEUROL, V75, P1338, DOI 10.1001/jamaneurol.2018.2030; Khor D, 2018, WORLD J SURG, V42, P1727, DOI 10.1007/s00268-017-4373-0; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Lei J, 2015, J NEUROTRAUM, V32, P1584, DOI 10.1089/neu.2014.3768; Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008; [李谷 LI Gu], 2008, [中华神经外科杂志, Chinese Journal of Neurosurgery], V24, P750; Li JL, 2013, J TRAUMA SURG, V15, P492; Li YM, 2017, J CLIN NEUROSCI, V44, P107, DOI 10.1016/j.jocn.2017.05.026; Li YM, 2017, BRAIN INJURY, V31, P1094, DOI 10.1080/02699052.2017.1298004; Lin SQ, 2016, CHIN MED EQUIP, V13, P121; [刘兵 LIU Bing], 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P496; Liu H, 2015, WORLD NEUROSURG, V83, P794, DOI 10.1016/j.wneu.2014.12.040; [刘永 LIU Yong], 2008, [苏州大学学报. 医学版, Suzhou University Journal of Medical Science], V28, P402; Ma JH, 2017, J TRAUMA SURG, V19, P411; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; National Bureau of Statistics of China, NAT DAT; National Health Commission of China, CONT IMPR TRAUM RESC; [倪燕青 Ni Yanqing], 2018, [中华创伤杂志, Chinese Journal of Trauma], V34, P293; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shao JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051634; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Wang HQ, 2013, EPILEPSY RES, V107, P272, DOI 10.1016/j.eplepsyres.2013.10.006; Wang L, 2018, CHIN J DISASTER MED, V6, P485; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Wen L, 2015, BRAIN INJURY, V29, P1654, DOI 10.3109/02699052.2015.1075248; Weng CQ, 2006, FUJIAN MED J, V28, P44; Weng WJ, 2019, J NEUROTRAUM, V36, P1168, DOI 10.1089/neu.2018.5881; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu X, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2045-x; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu HM, 2016, WORLD NEUROSURG, V88, P289, DOI 10.1016/j.wneu.2015.12.028; Yang SZ, 2006, CHIN J NEUROMED, V5, P274; Yang YC, 1987, CHINESE J NEUROSURGE, V3, P23; Yuan Q, 2016, NEUROSURGERY, V78, P361, DOI 10.1227/NEU.0000000000001050; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; [袁强 Yuan Qiang], 2013, [中华神经外科杂志, Chinese Journal of Neurosurgery], V29, P120; Yuan Q, 2012, INJURY, V43, P2094, DOI 10.1016/j.injury.2012.03.028; Zhang QS, 2014, CHIN J PRACT NERV DI, V11, P33; Zhang YiHua, 2015, Journal of Third Military Medical University, V37, P480; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9; Zhou L, 2000, CHIN J TRAUMATOL, V16, P147; Zhu GL, 1989, CHIN J NEUROSURG S, V5, P44; 张玉琪, 2011, [中华神经外科杂志, Chinese Journal of Neurosurgery], V27, P217; 刘敬业, 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P510; 和崇军, 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P236	83	52	75	8	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					286	295		10.1016/S1474-4422(18)30469-1			10	Clinical Neurology	Neurosciences & Neurology	HL2BV	WOS:000458509100020	30784557		Y	N	2021-06-18	
J	Deshpande, SK; Hasegawa, RB; Rabinowitz, AR; Whyte, J; Roan, CL; Tabatabaei, A; Baiocchi, M; Karlawish, JH; Master, CL; Small, DS				Deshpande, Sameer K.; Hasegawa, Raiden B.; Rabinowitz, Amanda R.; Whyte, John; Roan, Carol L.; Tabatabaei, Andrew; Baiocchi, Michael; Karlawish, Jason H.; Master, Christina L.; Small, Dylan S.			Association of Playing High School Football With Cognition and Mental Health Later in Life	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RECURRENT CONCUSSION; REGRESSION ADJUSTMENT; NCAA CONCUSSION; LEAGUE PLAYERS; BIAS; ENCEPHALOPATHY; RECOVERY; METAANALYSIS; PREDICTORS	IMPORTANCE American football is the largest participation sport in US high schools and is a leading cause of concussion among adolescents. Little is known about the long-term cognitive and mental health consequences of exposure to football-related head trauma at the high school level. OBJECTIVE To estimate the association of playing high school football with cognitive impairment and depression at 65 years of age. DESIGN, SETTING, AND PARTICIPANTS A representative sample of male high school students who graduated from high school in Wisconsin in 1957 was studied. In this cohort study using data from the Wisconsin Longitudinal Study, football players were matched between March 1 and July 1, 2017, with controls along several baseline covariates such as adolescent IQ, family background, and educational level. For robustness, 3 versions of the control condition were considered: all controls, those who played a noncollision sport, and those who did not play any sport. EXPOSURES Athletic participation in high school football. MAIN OUTCOMES AND MEASURES A composite cognition measure of verbal fluency and memory and attention constructed from results of cognitive assessments administered at 65 years of age. A modified Center for Epidemiological Studies' Depression Scale score was used to measure depression. Secondary outcomes include results of individual cognitive tests, anger, anxiety, hostility, and heavy use of alcohol. RESULTS Among the 3904 men (mean [SD] age, 64.4 [0.8] years at time of primary outcome measurement) in the study, after matching and model-based covariate adjustment, compared with each control condition, there was no statistically significant harmful association of playing football with a reduced composite cognition score (-0.04 reduction in cognition vs all controls; 97.5% CI, -0.14 to 0.05) or an increased modified Center for Epidemiological Studies' Depression Scale depression score (-1.75 reduction vs all controls; 97.5% CI, -3.24 to -0.26). After adjustment for multiple testing, playing football did not have a significant adverse association with any of the secondary outcomes, such as the likelihood of heavy alcohol use at 65 years of age (odds ratio, 0.68; 95% CI, 0.32-1.43). CONCLUSIONS AND RELEVANCE Cognitive and depression outcomes later in life were found to be similar for high school football players and their nonplaying counterparts from mid-1950s in Wisconsin. The risks of playing football today might be different than in the 1950s, but for current athletes, this study provides information on the risk of playing sports today that have a similar risk of head trauma as high school football played in the 1950s.	[Deshpande, Sameer K.; Hasegawa, Raiden B.; Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, 400 Huntsman Hall,3730 Walnut St, Philadelphia, PA 19104 USA; [Rabinowitz, Amanda R.] Moss Rehabil Res Inst, Brain Injury Neuropsychol Lab, Elkins Pk, PA USA; [Whyte, John] Moss Rehabil Res Inst, TBI Rehabil Res Lab, Elkins Pk, PA USA; [Roan, Carol L.] Univ Wisconsin, Ctr Demog & Ecol, Madison, WI 53706 USA; [Tabatabaei, Andrew] NYU, New York, NY USA; [Baiocchi, Michael] Stanford Univ, Stanford Sch Med, Standard Prevent Res Ctr, Palo Alto, CA 94304 USA; [Karlawish, Jason H.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Karlawish, Jason H.] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA; [Karlawish, Jason H.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Small, DS (corresponding author), Univ Penn, Wharton Sch, Dept Stat, 400 Huntsman Hall,3730 Walnut St, Philadelphia, PA 19104 USA.	dsmall@wharton.upenn.edu		Master, Christina/0000-0002-6717-4270; Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010124] Funding Source: Medline		Anzell AR, 2013, J STRENGTH COND RES, V27, P277, DOI 10.1519/JSC.0b013e31827f4c08; Bachynski KE, 2016, NEW ENGL J MED, V374, P405, DOI 10.1056/NEJMp1513993; Ban VS, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.2.FOCUS15609; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; COCHRAN WG, 1973, SANKHYA SER A, V35, P417; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Der G, 2009, INTELLIGENCE, V37, P573, DOI 10.1016/j.intell.2008.12.002; Everson-Rose SA, 2003, AM J EPIDEMIOL, V158, P1083, DOI 10.1093/aje/kwg263; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hansen BB, 2004, J AM STAT ASSOC, V99, P609, DOI 10.1198/016214504000000647; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hauser R.M., 2008, CRAFT LIFE COURSE RE, P29; Herd P, 2014, INT J EPIDEMIOL, V43, P34, DOI 10.1093/ije/dys194; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miles SH, 2016, AM J BIOETHICS, V16, P6, DOI 10.1080/15265161.2016.1128751; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; National Federation of State High School Associations (NFHS), 2015, NFHS HDB 2015 16; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richards M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8; Rogers MAM, 2009, J GERIATR PSYCH NEUR, V22, P71, DOI 10.1177/0891988708328220; Rosenbaum, 2002, OBSERVATIONAL STUDIE; Rosenbaum PR, 2008, BIOMETRIKA, V95, P248, DOI 10.1093/biomet/asm085; Rosenbaum PR, 2010, SPRINGER SER STAT, P1, DOI 10.1007/978-1-4419-1213-8; ROSENBAUM PR, 1991, J ROY STAT SOC B MET, V53, P597; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; RUBIN DB, 1979, J AM STAT ASSOC, V74, P318, DOI 10.2307/2286330; RUBIN DB, 1973, BIOMETRICS, V29, P185, DOI 10.2307/2529685; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	54	52	52	4	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	AUG	2017	74	8					909	918		10.1001/jamaneurol.2017.1317			10	Clinical Neurology	Neurosciences & Neurology	FD7EB	WOS:000407688300010	28672325	Green Published			2021-06-18	
J	Chang, CF; Wan, JR; Li, Q; Renfroe, SC; Heller, NM; Wang, J				Chang, Che-Feng; Wan, Jieru; Li, Qiang; Renfroe, Stephen C.; Heller, Nicola M.; Wang, Jian			Alternative activation-skewed microglia/macrophages promote hematoma resolution in experimental intracerebral hemorrhage	NEUROBIOLOGY OF DISEASE			English	Article						Intracerebral hemorrhage; Hematoma resolution; Microglia/macrophage polarization; Phagocytosis; Interleukin-10	GAMMA AGONIST ROSIGLITAZONE; HIPPOCAMPAL SLICE CULTURES; TRAUMATIC BRAIN-INJURY; TUFTSIN FRAGMENT 1-3; RECEPTOR-GAMMA; PPAR-GAMMA; MACROPHAGE ACTIVATION; HEME OXYGENASE-1; SPINAL-CORD; NEUROLOGICAL DEFICITS	Microglia/macrophages (MM Phi) are highly plastic phagocytes that can promote both injury and repair in diseased brain through the distinct function of classically activated and alternatively activated subsets. The role of MM Phi polarization in intracerebral hemorrhage (ICH) is unknown. Herein, we comprehensively characterized MM Phi dynamics after ICH in mice and evaluated the relevance of MM Phi polarity to hematoma resolution. MM Phi accumulated within the hematoma territory until at least 14 days after ICH induction. Microglia rapidly reacted to the hemorrhagic insult as early as 1-1.5 h after ICH and specifically presented a "protective" alternatively activated phenotype. Substantial numbers of activated microglia and newly recruited monocytes also assumed an early alternatively activated phenotype, but the phenotype gradually shifted to a mixed spectrum over time. Ultimately, markers of MM Phi classic activation dominated at the chronic stage of ICH. We enhanced MM Phi alternative activation by administering intraperitoneal injections of rosiglitazone, and subsequently observed elevations in CD206 expression on brain-isolated CD11b(+) cells and increases in IL-10 levels in serum and perihematomal tissue. Enhancement of MM Phi alternative activation correlated with hematoma volume reduction and improvement in neurologic deficits. Intraventricular injection of alternative activation signature cytokine IL-10 accelerated hematoma resolution, whereas microglial phagocytic ability was abolished by IL-10 receptor neutralization. Our results suggest that MM Phi respond dynamically to brain hemorrhage by exhibiting diverse phenotypic changes at different stages of ICH. Alternative activation-skewed MM Phi aid in hematoma resolution, and IL-10 signaling might contribute to regulation of MM Phi phagocytosis and hematoma clearance in ICH. (C) 2017 Elsevier Inc. All rights reserved.	[Chang, Che-Feng; Wan, Jieru; Li, Qiang; Heller, Nicola M.; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 367, Baltimore, MD 21205 USA; [Heller, Nicola M.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA; [Chang, Che-Feng; Renfroe, Stephen C.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06511 USA	Heller, NM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 367, Baltimore, MD 21205 USA.	nheller@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Chang, Che-Feng/0000-0002-3211-1739; Heller, Nicola/0000-0001-7247-2021	AHAAmerican Heart Association [13GRNT15730001, R01NS078026, R01AT007317]; MOST/raiwan Grant [105-2917-1-564-082];  [R01 HL124477]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL124477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This work was supported by AHA 13GRNT15730001, R01NS078026, and R01AT007317 OW). NMH was supported by R01 HL124477. CFC was supported by MOST/raiwan Grant 105-2917-1-564-082. We thank Claire Levine, MS, ELS, for editing the manuscript and Dr. Raymond Koehler for insightful input. We thank Dr. Lauren H Sansing for providing laboratory resources for the revision experiments.	Ajmone-Cat MA, 2013, GLIA, V61, P1698, DOI 10.1002/glia.22550; Allahtavakoli M, 2006, CLIN EXP PHARMACOL P, V33, P1052, DOI 10.1111/j.1440-1681.2006.04486.x; Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Avdic S, 2013, J VIROL, V87, P10273, DOI 10.1128/JVI.00912-13; Ballesteros I, 2014, J LEUKOCYTE BIOL, V95, P587, DOI 10.1189/jlb.0613326; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Chang CF, 2015, TRANSL STROKE RES, V6, P384, DOI 10.1007/s12975-015-0399-5; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; De Simoni A, 2006, NAT PROTOC, V1, P1439, DOI 10.1038/nprot.2006.228; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Dziedzic T, 2002, STROKE, V33, P2334, DOI 10.1161/01.STR.0000027211.73567.FA; Egashira Y, 2015, BRAIN RES, V1623, P97, DOI 10.1016/j.brainres.2015.04.003; Fang H, 2014, J IMMUNOL, V192, P5984, DOI 10.4049/jimmunol.1400054; Flores JJ, 2016, NEUROBIOL DIS, V87, P124, DOI 10.1016/j.nbd.2015.12.015; Foerch C, 2008, STROKE, V39, P3397, DOI 10.1161/STROKEAHA.108.517482; Garcia J.A., 2014, CURR PROTOC IMMUNOL, V104; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Gogolla N, 2006, NAT PROTOC, V1, P1165, DOI 10.1038/nprot.2006.168; Gonzales NR, 2013, INT J STROKE, V8, P388, DOI 10.1111/j.1747-4949.2011.00761.x; Hammond MD, 2014, STROKE, V45, P2485, DOI 10.1161/STROKEAHA.114.005551; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Hammond MD, 2012, TRANSL STROKE RES, V3, pS125, DOI 10.1007/s12975-012-0174-9; Hasegawa-Moriyama M, 2012, BIOCHEM BIOPH RES CO, V426, P76, DOI 10.1016/j.bbrc.2012.08.039; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jang E, 2013, J IMMUNOL, V191, P5204, DOI 10.4049/jimmunol.1301637; Katsuki H, 2010, J PHARMACOL SCI, V114, P366, DOI 10.1254/jphs.10R05CR; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kellner CP, 2010, STROKE, V41, pS99, DOI 10.1161/STROKEAHA.110.597476; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Koscso B, 2013, J LEUKOCYTE BIOL, V94, P1309, DOI 10.1189/jlb.0113043; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; LoPresti MA, 2014, J NEUROL SCI, V345, P3, DOI 10.1016/j.jns.2014.06.057; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Mietto BS, 2015, J NEUROSCI, V35, P16431, DOI 10.1523/JNEUROSCI.2119-15.2015; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801; Naito Y, 2014, ARCH BIOCHEM BIOPHYS, V564, P83, DOI 10.1016/j.abb.2014.09.005; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Papatriantafyllou M, 2011, NAT REV IMMUNOL, V11, P158, DOI 10.1038/nri2947; Pelidou SH, 1999, EUR J NEUROL, V6, P437, DOI 10.1046/j.1468-1331.1999.640437.x; Pisanu A, 2014, NEUROBIOL DIS, V71, P280, DOI 10.1016/j.nbd.2014.08.011; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Regnier-Vigouroux A, 2003, INT REV CYTOL, V226, P321, DOI 10.1016/S0074-7696(03)01006-4; Schallner N, 2015, J CLIN INVEST, V125, P2609, DOI 10.1172/JCI78443; Shimada K, 2015, STROKE, V46, P1664, DOI 10.1161/STROKEAHA.114.007722; Shouval DS, 2014, IMMUNITY, V40, P706, DOI 10.1016/j.immuni.2014.03.011; Sonni Shruti, 2014, Curr Treat Options Cardiovasc Med, V16, P277, DOI 10.1007/s11936-013-0277-y; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Toyoda K, 2015, NEUROLOGY, V84, P444, DOI 10.1212/WNL.0000000000001221; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Wan S, 2016, TRANSL STROKE RES, V7, P478, DOI 10.1007/s12975-016-0472-8; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Weis N, 2009, MOL BIOL CELL, V20, P1280, DOI 10.1091/mbc.E08-10-1005; Wu GF, 2016, NEUROL RES, V38, P261, DOI 10.1080/01616412.2015.1105627; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2010, BRAIN RES, V1342, P111, DOI 10.1016/j.brainres.2010.04.033; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Zhang Z., 2016, MOL NEUROBIOL; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2015, J NEUROCHEM, V133, P144, DOI 10.1111/jnc.12974; Zhao XR, 2014, TRANSL STROKE RES, V5, P554, DOI 10.1007/s12975-014-0341-2; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158; Zhou K., 2016, J CEREB BLOOD FLOW M; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423; Ziai WC, 2013, STROKE, V44, pS74, DOI 10.1161/STROKEAHA.111.000662	94	52	56	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUL	2017	103						54	69		10.1016/j.nbd.2017.03.016			16	Neurosciences	Neurosciences & Neurology	EV3TY	WOS:000401683200006	28365213	Green Accepted			2021-06-18	
J	Schwartz, ES; Erdodi, L; Rodriguez, N; Ghosh, JJ; Curtain, JR; Flashman, LA; Roth, RM				Schwartz, Eben S.; Erdodi, Laszlo; Rodriguez, Nicholas; Ghosh, Jyotsna J.; Curtain, Joshua R.; Flashman, Laura A.; Roth, Robert M.			CVLT-II Forced Choice Recognition Trial as an Embedded Validity Indicator: A Systematic Review of the Evidence	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Symptom evaluation; Validity of results; Review; Systematic; Memory deficits; Malingering; Neuropsychology	TRAUMATIC BRAIN-INJURY; LEARNING TEST-II; SYMPTOM VALIDITY; NEUROPSYCHOLOGICAL PERFORMANCE; INVALID PERFORMANCE; CLINICAL NEUROPSYCHOLOGY; AMERICAN ACADEMY; MEMORY; VETERANS; TESTS	Objectives: The Forced Choice Recognition (FCR) trial of the California Verbal Learning Test, 2(nd) edition, was designed as an embedded performance validity test (PVT). To our knowledge, this is the first systematic review of classification accuracy against reference PVTs. Methods: Results from peer-reviewed studies with FCR data published since 2002 encompassing a variety of clinical, research, and forensic samples were summarized, including 37 studies with FCR failure rates (N=7575) and 17 with concordance rates with established PVTs (N=4432). Results: All healthy controls scored >14 on FCR. On average, 16.9% of the entire sample scored 14, while 25.9% failed reference PVTs. Presence or absence of external incentives to appear impaired (as identified by researchers) resulted in different failure rates (13.6% vs. 3.5%), as did failing or passing reference PVTs (49.0% vs. 6.4%). FCR 14 produced an overall classification accuracy of 72%, demonstrating higher specificity (.93) than sensitivity (.50) to invalid performance. Failure rates increased with the severity of cognitive impairment. Conclusions: In the absence of serious neurocognitive disorder, FCR 14 is highly specific, but only moderately sensitive to invalid responding. Passing FCR does not rule out a non-credible presentation, but failing FCR rules it in with high accuracy. The heterogeneity in sample characteristics and reference PVTs, as well as the quality of the criterion measure across studies, is a major limitation of this review and the basic methodology of PVT research in general.	[Schwartz, Eben S.] Waukesha Mem Hosp, Neurosci Ctr, Waukesha, WI USA; [Erdodi, Laszlo; Rodriguez, Nicholas] Univ Windsor, Dept Psychol, Windsor, ON, Canada; [Ghosh, Jyotsna J.; Flashman, Laura A.; Roth, Robert M.] Geisel Sch Med Dartmouth, Neuropsychol Program, Lebanon, NH USA; [Curtain, Joshua R.] Stanford Hlth Care, Dept Neurol & Neurol Sci, Stanford, CA USA	Schwartz, ES (corresponding author), ProHlth Waukesha Mem Hosp, Dept Neurosci, 721 Amer Ave,Suite 406, Waukesha, WI 53188 USA.	eben.schwartz@phci.org					Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Binder LM, 2012, ARCH CLIN NEUROPSYCH, V27, P557, DOI 10.1093/arclin/acs051; Boone K. B., 2013, CLIN PRACTICE FORENS; Clark AL, 2014, CLIN NEUROPSYCHOL, V28, P802, DOI 10.1080/13854046.2014.904928; Clark LR, 2012, CLIN NEUROPSYCHOL, V26, P1201, DOI 10.1080/13854046.2012.728626; Connor D. J., 1997, AM AC NEUR BOST; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2000, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Egeland J, 2015, APPL NEUROPSYCH-ADUL, V22, P215, DOI 10.1080/23279095.2014.910212; Eikeland R, 2012, EUR J NEUROL, V19, P480, DOI 10.1111/j.1468-1331.2011.03563.x; Erdodi L. A., 2016, PSYCHOL ASSESSMENT; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P, 2003, WORD MEMORY TEST WIN; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hanczar B, 2010, BIOINFORMATICS, V26, P822, DOI 10.1093/bioinformatics/btq037; Hand DJ, 2009, MACH LEARN, V77, P103, DOI 10.1007/s10994-009-5119-5; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Jak AJ, 2015, J CLIN EXP NEUROPSYC, V37, P379, DOI 10.1080/13803395.2015.1020769; King PR, 2014, ARCH CLIN NEUROPSYCH, V29, P391, DOI 10.1093/arclin/acu011; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lobo JM, 2008, GLOBAL ECOL BIOGEOGR, V17, P145, DOI 10.1111/j.1466-8238.2007.00358.x; Macher RB, 2012, J CLIN EXP NEUROPSYC, V34, P405, DOI 10.1080/13803395.2011.646957; Maksimovskiy Arkadiy L, 2014, J Alcohol Drug Depend, V2, P144; Marshall P, 2007, CLIN NEUROPSYCHOL, V21, P826, DOI 10.1080/13854040600801001; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morse CL, 2013, CLIN NEUROPSYCHOL, V27, P1395, DOI 10.1080/13854046.2013.832385; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Orff H. J., 2015, J SLEEP DISORDERS TR, V4, P1; Peleikis DE, 2013, ACTA PSYCHIAT SCAND, V127, P455, DOI 10.1111/acps.12041; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schutte C, 2011, CLIN NEUROPSYCHOL, V25, P454, DOI 10.1080/13854046.2010.550635; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2016, APPL NEUROPSYCH-ADUL, V23, P105, DOI 10.1080/23279095.2015.1014557; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Sweet JJ, 2015, CLIN NEUROPSYCHOL, V29, P1069, DOI 10.1080/13854046.2016.1140228; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Yochim BP, 2010, NEUROCASE, V16, P451, DOI 10.1080/13554791003623334	54	52	52	2	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2016	22	8					851	858		10.1017/S1355617716000746			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DX4BU	WOS:000384324800006	27619108				2021-06-18	
J	Burger, N; Lambert, MI; Viljoen, W; Brown, JC; Readhead, C; Hendricks, S				Burger, Nicholas; Lambert, Michael I.; Viljoen, Wayne; Brown, James C.; Readhead, Clint; Hendricks, Sharief			Tackle technique and tackle-related injuries in high-level South African Rugby Union under-18 players: real-match video analysis	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INCIDENT ANALYSIS; MECHANISMS; FOOTBALL; PERFORMANCE; LEAGUE; EPIDEMIOLOGY; CONCUSSIONS; STRATEGIES; CONTACT; SCHOOLS	Background The high injury rate associated with rugby union is primarily due to the tackle, and poor contact technique has been identified as a risk factor for injury. We aimed to determine whether the tackle technique proficiency scores were different in injurious tackles versus tackles that did not result in injury using real-match scenarios in high-level youth rugby union. Methods Injury surveillance was conducted at the under-18 Craven Week tournaments ( 2011-2013). Tackle-related injury information was used to identify injury events in the match video footage and non-injury events were identified for the injured player cohort. Injury and non-injury events were scored for technique proficiency and Cohen's effect sizes were calculated and the Student t test ( p< 0.05) was performed to compare injury versus non-injury scores. Results The overall mean score for front-on ball-carrier proficiency was 7.17+/-1.90 and 9.02+/-2.15 for injury and non-injury tackle events, respectively ( effect size=moderate; p< 0.05). The overall mean score for side/behind ball-carrier proficiency was 4.09+/-2.12 and 7.68+/-1.72 for injury and non-injury tackle events, respectively ( effect size=large; p< 0.01). The overall mean score for front-on tackler proficiency was 7.00 +/- 1.95 and 9.35+/-2.56 for injury and non-injury tackle events, respectively ( effect size=moderate; p< 0.05). The overall mean score for side/behind tackler proficiency was 5.47+/-1.60 and 8.14+/-1.75 for injury and non-injury tackle events, respectively ( effect size=large; p< 0.01). Summary Higher overall mean and criterion-specific tackle-related technique scores were associated with a non-injury outcome. The ability to perform well during tackle events may decrease the risk of injury and may manifest in superior performance.	[Burger, Nicholas; Lambert, Michael I.; Viljoen, Wayne; Brown, James C.; Readhead, Clint; Hendricks, Sharief] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Private Bag X5, ZA-7725 Cape Town, Western Cape, South Africa; [Viljoen, Wayne; Readhead, Clint] South African Rugby Union SARU, SARU House, Cape Town, Western Cape, South Africa	Burger, N (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Human Biol, Div Exercise Sci & Sports Med, Private Bag X5, ZA-7725 Cape Town, Western Cape, South Africa.	burgernick@vodamail.co.za	Brown, James Craig/H-7637-2019; Hendricks, Sharief/U-3278-2019	Brown, James Craig/0000-0002-7778-7783; Hendricks, Sharief/0000-0002-3416-6266; Viljoen, Wayne/0000-0002-9432-6153	National Research Foundation	Funding for NB was provided by the National Research Foundation (Scarce Skills Development Fund Doctoral Scholarship).	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Brown JC, 2012, S AFR J SPORTS MED, V24, P49; Burger N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005556; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gabbett T, 2009, INT J SPORTS SCI COA, V4, P521, DOI 10.1260/174795409790291402; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P625, DOI 10.1519/JSC.0b013e3181635a6a; Gabbett TJ., 2007, INT J SPORTS SCI COA, V2, P467, DOI DOI 10.1260/174795407783359731; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; HENDRICKS S, 2012, S AFR J SPORTS MED, V24, P122, DOI DOI 10.7196/SAJSM.357; Hendricks S, 2014, EUR J SPORT SCI, V14, P753, DOI 10.1080/17461391.2014.905982; Hendricks S, 2014, J SPORT SCI MED, V13, P715; Hendricks S, 2012, SAFETY SCI, V50, P266, DOI 10.1016/j.ssci.2011.08.061; Hendricks S, 2010, INT J SPORTS SCI COA, V5, P117, DOI 10.1260/1747-9541.5.1.117; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; King D, 2012, RES SPORTS MED, V20, P86, DOI 10.1080/15438627.2012.660824; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Nicol A, 2011, J PUBLIC HEALTH-UK, V33, P256, DOI 10.1093/pubmed/fdq047; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Patricios JS, 2014, CURR SPORT MED REP, V13, P326, DOI 10.1249/JSR.0000000000000086; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Viljoen W, 2009, SA RUGBY BOKSMART SA; Wheeler KW, 2010, EUR J SPORT SCI, V10, P237, DOI 10.1080/17461391.2010.482595	34	52	53	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2016	50	15					932	+		10.1136/bjsports-2015-095295			8	Sport Sciences	Sport Sciences	DS7AR	WOS:000380935300011	26781294				2021-06-18	
J	Sun, J; Wang, FY; Ling, ZX; Yu, XC; Chen, WQ; Li, HX; Jin, JT; Pang, MQ; Zhang, HQ; Yu, JJ; Liu, JM				Sun, Jing; Wang, Fangyan; Ling, Zongxin; Yu, Xichong; Chen, Wenqian; Li, Haixiao; Jin, Jiangtao; Pang, Mengqi; Zhang, Huiqing; Yu, Junjie; Liu, Jiaming			Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota	BRAIN RESEARCH			English	Article						Diabetes; Cerebral ischemia/reperfusion; Clostridium butyricum; Apoptosis; Gut microbiota; Butyrate	IRRITABLE-BOWEL-SYNDROME; TRAUMATIC BRAIN-INJURY; SIGNALING PATHWAY; ISCHEMIC-STROKE; AXIS; RATS; PROBIOTICS; APOPTOSIS; MELLITUS; TYPE-2	Diabetes is known to exacerbate cerebral ischemia/reperfusion (I/R) injury. Here, we investigated the effects of Clostridium butyricum on cerebral I/R injury in the diabetic mice subjected to 30 min of bilateral common carotid arteries occlusion (BCCAO). The cognitive impairment, the blood glucose level, neuronal injury, apoptosis, and expressions of Akt, phospho-Akt (p-Akt), and caspase-3 level were assessed. Meanwhile, the changes of gut microbiota in composition and diversity in the colonic feces were evaluated. Our results showed that diabetic mice subjected to BCCAO exhibited worsened cognitive impairment, cell damage and apoptosis. These were all attenuated by C butyricum. Moreover, C butyricum reversed cerebral I/R induced decreases in p-Akt expression and increases in caspase-3 expression, leading to inhibiting neuronal apoptosis. C butyricum partly restored cerebral I/R induced decreases of fecal microbiota diversity, changes of fecal microbiota composition. Together, these findings highlight the important role of bacteria in the bidirectional communication of the gut-brain axis and suggest that certain probiotics might prove to be useful therapeutic adjuncts in cerebral I/R injury with diabetes. (C) 2016 Elsevier B.V. All rights reserved.	[Sun, Jing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurol, 109 Coll West Rd, Wenzhou 325027, Zhejiang, Peoples R China; [Wang, Fangyan] Wenzhou Med Univ, Dept Pathophysiol, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Ling, Zongxin] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis,Collabo, Hangzhou 310003, Zhejiang, Peoples R China; [Yu, Xichong] Wenzhou Med Univ, Sch Pharmaceut Sci, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Chen, Wenqian; Li, Haixiao; Jin, Jiangtao; Pang, Mengqi; Zhang, Huiqing; Yu, Junjie; Liu, Jiaming] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China	Liu, JM (corresponding author), Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China.	wzjiaming_liu@163.com	Ling, Zongxin/M-1657-2018; Ling, Zongxin/AAM-4059-2021	Ling, Zongxin/0000-0001-9662-099X; 	Wenzhou Science and Technology Development Funds [Y20150174]	The research was supported by Wenzhou Science and Technology Development Funds (Y20150174).	Air EL, 2007, DIABETES CARE, V30, P3131, DOI 10.2337/dc06-1537; Asfandiyarova Nailya, 2006, Diab Vasc Dis Res, V3, P57, DOI 10.3132/dvdr.2006.009; Baliga Bantwal Suresh, 2006, Curr Cardiol Rep, V8, P23, DOI 10.1007/s11886-006-0006-1; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Bercik P, 2012, NEUROGASTROENT MOTIL, V24, P405, DOI 10.1111/j.1365-2982.2012.01906.x; Burcelin R, 2011, ACTA DIABETOL, V48, P257, DOI 10.1007/s00592-011-0333-6; Camilleri M, 2006, J CLIN GASTROENTEROL, V40, P264, DOI 10.1097/00004836-200603000-00020; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2009, AM J CLIN NUTR, V90, P1236, DOI 10.3945/ajcn.2009.28095; Chen ZF, 2015, FUTURE MICROBIOL, V10, P1433, DOI 10.2217/fmb.15.66; Chugunova LA, 2006, TERAPEVT ARKH, V78, P21; Cruz-Herranz A, 2015, J DIABETES, V7, P657, DOI 10.1111/1753-0407.12222; Cumbler E, 2015, NEUROHOSPITALIST, V5, P173, DOI 10.1177/1941874415588319; Delzenne NM, 2015, DIABETOLOGIA, V58, P2206, DOI 10.1007/s00125-015-3712-7; Desbonnet L, 2014, MOL PSYCHIATR, V19, P146, DOI 10.1038/mp.2013.65; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; Duan J., 2015, MOL NEUROBIOL; Dutkiewicz J., 2015, J NEURAL TRANSM; El-Sahar AE, 2015, PHARMACOL REP, V67, P901, DOI 10.1016/j.pharep.2015.03.018; Espinera AR, 2013, NEUROSCIENCE, V247, P1, DOI 10.1016/j.neuroscience.2013.04.011; Furie K, 2008, CURR NEUROL NEUROSCI, V8, P12, DOI 10.1007/s11910-008-0004-3; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gomes AC, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-60; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Heckmann JG, 2005, DEUT MED WOCHENSCHR, V130, P291, DOI 10.1055/s-2005-863045; Hill Michael D, 2014, Handb Clin Neurol, V126, P167, DOI 10.1016/B978-0-444-53480-4.00012-6; Hu CY, 2015, PHARMACOL RES, V98, P9, DOI 10.1016/j.phrs.2015.02.006; Kanai T., 2015, J GASTROENTEROL; Kasinska M.A., 2015, POL ARCH MED WEWN; Kim HJ, 2003, ALIMENT PHARM THER, V17, P895, DOI 10.1046/j.1365-2036.2003.01543.x; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kim JS, 2015, J MOV DISORD, V8, P76, DOI 10.14802/jmd.15008; Kootte RS, 2012, DIABETES OBES METAB, V14, P112, DOI 10.1111/j.1463-1326.2011.01483.x; Kumar P, 2014, INT J BIOCHEM CELL B, V53, P302, DOI 10.1016/j.biocel.2014.05.038; Li WY, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00048; Liu AH, 2008, CELL PHYSIOL BIOCHEM, V22, P177, DOI 10.1159/000149795; Liu H, 2015, AM J MED SCI, V350, P204, DOI 10.1097/MAJ.0000000000000540; Liu JM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/412946; Luna RA, 2015, CURR OPIN BIOTECH, V32, P35, DOI 10.1016/j.copbio.2014.10.007; MacFabe Derrick F., 2012, Microbial Ecology in Health and Disease, V23, P19260, DOI 10.3402/mehd.v23i0.19260; Martinez-Sanchez P, 2007, Cerebrovasc Dis, V24 Suppl 1, P143, DOI 10.1159/000107390; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Mendzheritskii A M, 2011, Adv Gerontol, V24, P74; Messaoudi M, 2011, GUT MICROBES, V2, P256, DOI 10.4161/gmic.2.4.16108; Messaoudi M, 2011, BRIT J NUTR, V105, P755, DOI 10.1017/S0007114510004319; Mikelsaar Marika, 2009, Microbial Ecology in Health and Disease, V21, P1, DOI 10.1080/08910600902815561; Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609; Pamenter ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060804; Park S., 2015, EXP BIOL MED; Qu YY, 2015, NEUROCHEM RES, V40, P1, DOI 10.1007/s11064-014-1456-2; Rhee SH, 2009, NAT REV GASTRO HEPAT, V6, P306, DOI 10.1038/nrgastro.2009.35; Savignac HM, 2015, BEHAV BRAIN RES, V287, P59, DOI 10.1016/j.bbr.2015.02.044; Savignac HM, 2014, NEUROGASTROENT MOTIL, V26, P1615, DOI 10.1111/nmo.12427; Shinnoh M, 2013, INT J ONCOL, V42, P903, DOI 10.3892/ijo.2013.1790; Shou J., 2015, J STROKE CEREBROVASC; Stenman LK, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0075-7; STORM T, 1985, BRIT MED J, V291, P1577, DOI 10.1136/bmj.291.6508.1577-a; Sun J, 2016, NEUROSCI LETT, V613, P30, DOI 10.1016/j.neulet.2015.12.047; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Terashima T, 1998, NEUROSURGERY, V43, P900, DOI 10.1097/00006123-199810000-00102; Vanderhoof JA, 1998, J PEDIATR GASTR NUTR, V27, P323, DOI 10.1097/00005176-199809000-00011; Wang GX, 2001, LIFE SCI, V69, P2801, DOI 10.1016/S0024-3205(01)01354-6; Wang XT, 2007, CELL SIGNAL, V19, P1844, DOI 10.1016/j.cellsig.2007.04.005; Wu CR, 2001, J NEUROSCI METH, V107, P101, DOI 10.1016/S0165-0270(01)00356-9; Yadav H, 2013, J BIOL CHEM, V288, P25088, DOI 10.1074/jbc.M113.452516; Yakovlieva M, 2015, BENEF MICROBES, V6, P505, DOI 10.3920/BM2014.0012; Yoo DY, 2015, NEUROL RES, V37, P69, DOI 10.1179/1743132814Y.0000000416; Yu Z, 2015, CELL PHYSIOL BIOCHEM, V37, P67, DOI 10.1159/000430334; Yun SI, 2009, J APPL MICROBIOL, V107, P1681, DOI 10.1111/j.1365-2672.2009.04350.x	69	52	56	3	36	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						180	188		10.1016/j.brainres.2016.03.042			9	Neurosciences	Neurosciences & Neurology	DP7EI	WOS:000378661600021	27037183				2021-06-18	
J	Fralick, M; Thiruchelvam, D; Tien, HC; Redelmeier, DA				Fralick, Michael; Thiruchelvam, Deva; Tien, Homer C.; Redelmeier, Donald A.			Risk of suicide after a concussion	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; EMERGENCY-DEPARTMENT; WEEKEND WARRIOR; POPULATION; MORTALITY; HEALTH; PREVENTION; ONTARIO; SYMPTOMS	Background: Head injuries have been associated with subsequent suicide among military personnel, but outcomes after a concussion in the community are uncertain. We assessed the long-term risk of suicide after concussions occurring on weekends or weekdays in the community. Methods: We performed a longitudinal cohort analysis of adults with diagnosis of a concussion in Ontario, Canada, from Apr. 1, 1992, to Mar. 31, 2012 (a 20-yr period), excluding severe cases that resulted in hospital admission. The primary outcome was the long-term risk of suicide after a weekend or weekday concussion. Results: We identified 235 110 patients with a concussion. Their mean age was 41 years, 52% were men, and most (86%) lived in an urban location. A total of 667 subsequent suicides occurred over a median follow-up of 9.3 years, equivalent to 31 deaths per 100 000 patients annually or 3 times the population norm. Weekend concussions were associated with a one-third further increased risk of suicide compared with weekday concussions (relative risk 1.36, 95% confidence interval 1.14-1.64). The increased risk applied regardless of patients' demographic characteristics, was independent of past psychiatric conditions, became accentuated with time and exceeded the risk among military personnel. Half of these patients had visited a physician in the last week of life. Interpretation: Adults with a diagnosis of concussion had an increased long-term risk of suicide, particularly after concussions on weekends. Greater attention to the long-term care of patients after a concussion in the community might save lives because deaths from suicide can be prevented.	[Fralick, Michael; Redelmeier, Donald A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Fralick, Michael; Thiruchelvam, Deva; Tien, Homer C.; Redelmeier, Donald A.] Sunnybrook Res Inst, Evaluat Clin Sci, Toronto, ON, Canada; [Thiruchelvam, Deva] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tien, Homer C.] Canadian Forces Hlth Serv, Toronto, ON, Canada	Redelmeier, DA (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Redelmeier, DA (corresponding author), Sunnybrook Res Inst, Evaluat Clin Sci, Toronto, ON, Canada.	dar@ices.on.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Aldridge D, 2012, COMPREHENSIVE GUIDE; Alter DA, 2011, HEALTH AFFAIR, V30, P274, DOI 10.1377/hlthaff.2009.0669; [Anonymous], 2014, HLTH TRENDS ONT; [Anonymous], 2012, GLOB HLTH OBS GHO DA; Ardal S, 2012, HLTH ANAL TOOLKIT; Armstrong J.S, 2001, PRINCIPLES FORECASTI; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beghi M, 2013, NEUROPSYCH DIS TREAT, V9, P1725, DOI 10.2147/NDT.S40213; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Bogaert L, 2013, SUICIDE CANADIAN FOR; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Centers for Disease Control and Prevention, 2010, WEB BAS INJ STAT QUE; Chambers A, 2015, AM J PUBLIC HEALTH, V105, P338, DOI 10.2105/AJPH.2014.302223; Colantonio A, 2012, WORK, V43, P195, DOI 10.3233/WOR-2012-1377; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dwiggins George A, 2002, Appl Occup Environ Hyg, V17, P237, DOI 10.1080/10473220252826510; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fallucco EM, 2010, PEDIATRICS, V125, P953, DOI 10.1542/peds.2009-2135; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Festinger L., 1957, THEORY COGNITIVE DIS; Finkelstein Y, 2015, JAMA PSYCHIAT, V72, P570, DOI 10.1001/jamapsychiatry.2014.3188; Fotuhi O, 2013, TOB CONTROL, V22, P52, DOI 10.1136/tobaccocontrol-2011-050139; Fralick M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6196; Freijy T, 2013, BRIT J HEALTH PSYCH, V18, P310, DOI 10.1111/bjhp.12035; Gjertsen F, 2011, J CLIN EPIDEMIOL, V64, P1102, DOI 10.1016/j.jclinepi.2010.12.015; Glazier RH, 2003, CAN J PUBLIC HEALTH, V94, P140, DOI 10.1007/BF03404588; Gonda Xenia, 2007, Ann Gen Psychiatry, V6, P23, DOI 10.1186/1744-859X-6-23; Gosling P, 2006, J PERS SOC PSYCHOL, V90, P722, DOI 10.1037/0022-3514.90.5.722; GRIMBLE S, 1993, ARCH EMERG MED, V10, P203; Haegerich TM, 2014, LANCET, V384, P64, DOI 10.1016/S0140-6736(14)60074-X; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Henry DA, 2012, PAYMENTS ONTARIO PHY; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Improving health care data in Ontario, 2005, IMPR HLTH CAR DAT ON; Iron K., 2008, LIVING DYING ONTARIO; Ivens UI, 1998, AM J IND MED, V33, P182; Juurlink D., 2006, Canadian Institute for Health Information Discharge Abstract Database: a validation study; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Keshavarz Homa, 2013, CMAJ Open, V1, pE159, DOI 10.9778/cmajo.20130030; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kisely S, 2013, CAN MED ASSOC J, V185, pE50, DOI 10.1503/cmaj.121077; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P1076, DOI 10.1001/jama.2013.276547; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Li ZY, 2011, SOC SCI MED, V72, P608, DOI 10.1016/j.socscimed.2010.11.008; Links PS, 2011, CAN MED ASSOC J, V183, P1987, DOI 10.1503/cmaj.111008; Lombardi DA, 2003, J OCCUP ENVIRON MED, V45, P832, DOI 10.1097/01.jom.0000083030.56116.1a; Macpherson A, 2005, INJURIES ONTARIO ICE; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morrish J, 2013, CANADA INJURY COMPAS; Mustard CA, 2010, CAN J PSYCHIAT, V55, P369, DOI 10.1177/070674371005500606; Nishri ED, 2015, INT J CANCER, V136, P639, DOI 10.1002/ijc.29024; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Oquendo MA, 2014, AM J PSYCHIAT, V171, P1259, DOI 10.1176/appi.ajp.2014.14020194; Organisation World Health, 2011, INT STAT CLASS DIS R; Parai JL, 2006, ANN EPIDEMIOL, V16, P805, DOI 10.1016/j.annepidem.2006.01.006; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Pompili M, 2014, WORLD J PSYCHIATR, V4, P141, DOI 10.5498/wjp.v4.i4.141; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Psoinos CM, 2012, J TRAUMA ACUTE CARE, V73, P469, DOI 10.1097/TA.0b013e318258437c; Ramchand R, 2011, WAR PREVENTING SUICI; Ratnasingham S, 2013, CAN J PSYCHIAT, V58, P529; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; Redelmeier DA, 2007, NEW ENGL J MED, V356, P1164, DOI 10.1056/NEJMe068310; Roberts DJ, 2014, CAN J SURG, V57, pE62, DOI 10.1503/cjs.030812; Ronquillo L, 2012, J EMERG MED, V43, P836, DOI 10.1016/j.jemermed.2012.08.015; Ross Lee, 2011, PERSON SITUATION PER; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; Sedgwick Philip, 2010, BMJ CLIN RES ED, V341, DOI [10.1136/bmj.c4804, DOI 10.1136/BMJ.C4804]; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Shuchman M, 2014, CAN MED ASSOC J, V186, pE532, DOI 10.1503/cmaj.109-4897; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Skinner R, 2012, CAN MED ASSOC J, V184, P1029, DOI 10.1503/cmaj.111867; Statistics Canada, 2014, SUIC SUIC RAT SEX AG; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Suokas J, 2001, ACTA PSYCHIAT SCAND, V104, P117, DOI 10.1034/j.1600-0447.2001.00243.x; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; TAYLOR SE, 1990, AM PSYCHOL, V45, P40, DOI 10.1037/0003-066X.45.1.40; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomas KH, 2013, BRIT J CLIN PHARMACO, V76, P145, DOI 10.1111/bcp.12059; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697; Wenzel A, 2011, J AFFECT DISORDERS, V132, P375, DOI 10.1016/j.jad.2011.03.006; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Wilkins R, 1993, Health Rep, V5, P157; Wilkins R, 2004, AUTOMATED GEOGRAPHIC; Williams JI, 1996, PATTERNS HLTH CARE O, V2nd; Wilson A, 2010, DEATH STUD, V34, P625, DOI 10.1080/07481181003761567; World Health Organization, 1997, INT CLASS DIS	106	52	52	0	14	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	APR 19	2016	188	7					497	504		10.1503/cmaj.150790			8	Medicine, General & Internal	General & Internal Medicine	DK3BQ	WOS:000374790500014	26858348	Green Published, Bronze			2021-06-18	
J	Feng, Y; Cui, Y; Gao, JL; Li, MH; Li, R; Jiang, XH; Tian, YX; Wang, KJ; Cui, CM; Cui, JZ				Feng, Yan; Cui, Ying; Gao, Jun-ling; Li, Ming-hang; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia; Wang, Kai-jie; Cui, Chang-meng; Cui, Jian-zhong			Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-kappa B signaling pathway in experimental traumatic brain injury	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						resveratrol; autophagy; traumatic brain injury; Toll-like receptor 4; inflammation	CELL-DEATH; CEREBRAL-ISCHEMIA; INNATE IMMUNITY; DIABETIC MICE; RATS; PATHOPHYSIOLOGY; APOPTOSIS; MODEL; TOLL; CONTRIBUTES	Previous research has demonstrated that traumatic brain injury (TBI) activates autophagy and a neuroinflammatory cascade that contributes to substantial neuronal damage and behavioral impairment, and Toll-like receptor 4 (TLR4) is an important mediator of this cascade. In the present study, we investigated the hypothesis that resveratrol (RV), a natural polyphenolic compound with potent multifaceted properties, alleviates brain damage mediated by TLR4 following TBI. Adult male Sprague Dawley rats, subjected to controlled cortical impact (CCI) injury, were intraperitoneally injected with RV (100 mg/kg, daily for 3 days) after the onset of TBI. The results demonstrated that RV significantly reduced brain edema, motor deficit, neuronal loss and improved spatial cognitive function. Double immunolabeling demonstrated that RV decreased microtubule-associated protein 1 light chain 3 (LC3), TLR4-positive cells co-labeled with the hippocampal neurons, and RV also significantly reduced the number of TLR4-positive neuron-specific nuclear protein (NeuN) cells following TBI. Western blot analysis revealed that RV significantly reduced the protein expression of the autophagy marker proteins, LC3II and Beclin1, in the hippocampus compared with that in the TBI group. Furthermore, the levels of TLR4 and its known downstream signaling molecules, nuclear factor-kappa B (NF-kappa B), and the inflammatory cytokines, interleukin (IL)-1 beta and tumor necrosis factor (TNF)-alpha were also decreased after RV treatment. Our results suggest that RV reduces neuronal autophagy and inflammatory reactions in a rat model of TBI. Thus, we suggest that the neuroprotective effect of RV is associated with the TLR4/NF-kappa B signaling pathway.	[Feng, Yan; Cui, Chang-meng; Cui, Jian-zhong] Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China; [Cui, Ying; Wang, Kai-jie; Cui, Jian-zhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-ling; Li, Ming-hang; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Gao, Jun-ling; Li, Ran; Jiang, Xiao-hua; Tian, Yan-xia] Tangshan Key Lab Preclin & Basic Res Chron Dis, Hebei Key Lab Chron Dis, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alayev A, 2015, J CELL BIOCHEM, V116, P450, DOI 10.1002/jcb.24997; Alayev A, 2014, CELL CYCLE, V13, P371, DOI 10.4161/cc.27355; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Baumgarten G, 2001, J INFECT DIS, V183, P1617, DOI 10.1086/320712; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bursch W, 2000, J CELL SCI, V113, P1189; Chang YP, 2015, J CELL PHYSIOL, V230, P1567, DOI 10.1002/jcp.24903; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Gatson JW, 2013, J TRAUMA ACUTE CARE, V74, P470, DOI 10.1097/TA.0b013e31827e1f51; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han KJ, 2004, J BIOL CHEM, V279, P15652, DOI 10.1074/jbc.M311629200; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li JB, 2015, MOL MED REP, V11, P1120, DOI 10.3892/mmr.2014.2955; Lin CJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.123; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu L, 2014, INT J MOL SCI, V15, P6925, DOI 10.3390/ijms15046925; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Seay MD, 2007, CELL HOST MICROBE, V2, P69, DOI 10.1016/j.chom.2007.07.008; Shao AW, 2014, CNS NEUROSCI THER, V20, P182, DOI 10.1111/cns.12194; Shi RY, 2012, CNS NEUROSCI THER, V18, P250, DOI 10.1111/j.1755-5949.2012.00295.x; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Wang B, 2014, J CELL MOL MED, V18, P1599, DOI 10.1111/jcmm.12312; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Xu Y, 2008, AUTOPHAGY, V4, P110, DOI 10.4161/auto.5225; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Youn HS, 2005, J IMMUNOL, V175, P3339, DOI 10.4049/jimmunol.175.5.3339; Zhang C, 2012, INT J MOL MED, V29, P557, DOI 10.3892/ijmm.2012.885; Zhen L, 2015, ACTA PHARMACOL SIN, V36, P221, DOI 10.1038/aps.2014.131; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	43	52	62	0	8	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	APR	2016	37	4					921	930		10.3892/ijmm.2016.2495			10	Medicine, Research & Experimental	Research & Experimental Medicine	DI4TS	WOS:000373492900006	26936125	Other Gold, Green Published			2021-06-18	
J	Sabirzhanov, B; Stoica, BA; Zhao, Z; Loane, DJ; Wu, J; Dorsey, SG; Faden, AI				Sabirzhanov, B.; Stoica, B. A.; Zhao, Z.; Loane, D. J.; Wu, J.; Dorsey, S. G.; Faden, A. I.			miR-711 upregulation induces neuronal cell death after traumatic brain injury	CELL DEATH AND DIFFERENTIATION			English	Article							SIGNALING PATHWAY; MIRNA PROMOTERS; GENE-EXPRESSION; SEX-DIFFERENCES; PROBE LEVEL; APOPTOSIS; AKT; PROTEINS; NEUROPROTECTION; ACTIVATION	Traumatic brain injury (TBI) is a leading cause of mortality and disability. MicroRNAs (miRs) are small noncoding RNAs that negatively regulate gene expression at post-transcriptional level and may be key modulators of neuronal apoptosis, yet their role in secondary injury after TBI remains largely unexplored. Changes in miRs after controlled cortical impact (CCI) in mice were examined during the first 72 h using miR arrays and qPCR. One selected miR (711) was examined with regard to its regulation and relation to cell death; effects of miR-711 modulation were evaluated after CCI and using in vitro cell death models of primary cortical neurons. Levels of miR-711 were increased in the cortex early after TBI and in vitro models through rapid upregulation of miR-711 transcription (pri-miR-711) rather than catabolism. Increases coincided with downregulation of the pro-survival protein Akt, a predicted target of miR-711, with sequential activation of forkhead box O3 (FoxO3)a/glycogen synthase kinase 3 (GSK3)alpha/beta, pro-apoptotic BH3-only molecules PUMA (Bcl2-binding component 3) and Bim (Bcl2-like 11 (apoptosis facilitator)), and mitochondrial release of cytochrome c and AIF. miR-711 and Akt (mRNA) co-immunoprecipitated with the RNA-induced silencing complex (RISC). A miR-711 hairpin inhibitor attenuated the apoptotic mechanisms and decreased neuronal death in an Akt-dependent manner. Conversely, a miR-711 mimic enhanced neuronal apoptosis. Central administration of the miR-711 hairpin inhibitor after TBI increased Akt expression and attenuated apoptotic pathways. Treatment reduced cortical lesion volume, neuronal cell loss in cortex and hippocampus, and long-term neurological dysfunction. miR-711 changes contribute to neuronal cell death after TBI, in part by inhibiting Akt, and may serve as a novel therapeutic target.	[Sabirzhanov, B.; Stoica, B. A.; Zhao, Z.; Loane, D. J.; Wu, J.; Faden, A. I.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,Room 6-010,BRD,Room 6-015, Baltimore, MD 21201 USA; [Sabirzhanov, B.; Stoica, B. A.; Zhao, Z.; Loane, D. J.; Wu, J.; Faden, A. I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Dorsey, S. G.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Dorsey, S. G.] Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA	Sabirzhanov, B; Stoica, BA (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,Room 6-010,BRD,Room 6-015, Baltimore, MD 21201 USA.	bsabirzhanov@anes.umm.edu; bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503	 [RO1 NS061839];  [R01 NR012686]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839, R01NS096002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012686] Funding Source: NIH RePORTER	This work was supported by grants RO1 NS061839 to AIF and R01 NR012686 to SGD. We thank Taryn Aubrecht and Xiaoyi Lin for technical assistance.	Akhter R, 2014, J BIOL CHEM, V289, P10812, DOI 10.1074/jbc.M113.519355; Ambacher KK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046885; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Engel T, 2010, J NEUROCHEM, V115, P92, DOI 10.1111/j.1471-4159.2010.06909.x; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; He CJ, 2012, NUCLEIC ACIDS RES, V40, P4002, DOI 10.1093/nar/gkr1312; Henshall DC, 2014, CURR OPIN NEUROL, V27, P199, DOI 10.1097/WCO.0000000000000079; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jeong JK, 2012, BIOCHEM BIOPH RES CO, V429, P93, DOI 10.1016/j.bbrc.2012.10.086; Jimenez-Mateos EM, 2013, NEUROSCIENCE, V238, P218, DOI 10.1016/j.neuroscience.2013.02.027; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mohite A, 2011, BIOCHEMISTRY-US, V50, P1691, DOI 10.1021/bi101654w; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sabirzhanov B, 2012, J NEUROCHEM, V123, P542, DOI 10.1111/j.1471-4159.2012.07927.x; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yeh SH, 2011, NUCLEIC ACIDS RES, V39, P5412, DOI 10.1093/nar/gkr161; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zareen N, 2013, CELL DEATH DIFFER, V20, P1719, DOI 10.1038/cdd.2013.128; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Ziu MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014724	57	52	56	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	APR	2016	23	4					654	668		10.1038/cdd.2015.132			15	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	DJ3SP	WOS:000374126800011	26470728	Green Published, Bronze			2021-06-18	
J	Jutzeler, CR; Huber, E; Callaghan, MF; Luechinger, R; Curt, A; Kramer, JLK; Freund, P				Jutzeler, Catherine R.; Huber, Eveline; Callaghan, Martina F.; Luechinger, Roger; Curt, Armin; Kramer, John L. K.; Freund, Patrick			Association of pain and CNS structural changes after spinal cord injury	SCIENTIFIC REPORTS			English	Article							VOXEL-BASED MORPHOMETRY; GRAY-MATTER CHANGES; CHRONIC BACK-PAIN; NEUROPATHIC PAIN; CORTICAL REORGANIZATION; MOTOR CORTEX; NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; SOMATOSENSORY CORTEX; THALAMIC NEURONS	Traumatic spinal cord injury (SCI) has been shown to trigger structural atrophic changes within the spinal cord and brain. However, the relationship between structural changes and magnitude of neuropathic pain (NP) remains incompletely understood. Voxel-wise analysis of anatomical magnetic resonance imaging data provided information on cross-sectional cervical cord area and volumetric brain changes in 30 individuals with chronic traumatic SCI and 31 healthy controls. Participants were clinically assessed including neurological examination and pain questionnaire. Compared to controls, individuals with SCI exhibited decreased cord area, reduced grey matter (GM) volumes in anterior cingulate cortex (ACC), left insula, left secondary somatosensory cortex, bilateral thalamus, and decreased white matter volumes in pyramids and left internal capsule. The presence of NP was related with smaller cord area, increased GM in left ACC and right M1, and decreased GM in right primary somatosensory cortex and thalamus. Greater GM volume in M1 was associated with amount of NP. Below-level NP-associated structural changes in the spinal cord and brain can be discerned from trauma-induced consequences of SCI. The directionality of these relationships reveals specific changes across the neuroaxis (i.e., atrophic changes versus increases in volume) and may provide substrates of underlying neural mechanisms in the development of NP.	[Jutzeler, Catherine R.; Huber, Eveline; Curt, Armin; Kramer, John L. K.; Freund, Patrick] Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland; [Kramer, John L. K.] Univ British Columbia, ICORD, Sch Kinesiol, Fac Educ, Vancouver, BC V5Z 1M9, Canada; [Luechinger, Roger] Univ Zurich, Inst Biomed Engn, Zurich, Switzerland; [Luechinger, Roger] ETH, Zurich, Switzerland; [Freund, Patrick] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Callaghan, Martina F.; Freund, Patrick] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Freund, Patrick] Max Planck Inst Human Cognit & Brain Sci, Dept Neurophys, Leipzig, Germany	Jutzeler, CR (corresponding author), Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland.	cjutzeler@paralab.balgrist.ch	Luechinger, Roger/AAD-5192-2019; Callaghan, Martina F/H-5297-2019; Freund, Patrick/D-4193-2013	Luechinger, Roger/0000-0002-7365-0421; Callaghan, Martina F/0000-0003-0374-1659; Freund, Patrick/0000-0002-4851-2246	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF); Clinical Research Priority Program "Neurorehab" of the University of Zurich, Switzerland; International Foundation for Paraplegia - Zurich	We would like to thank all of the subjects participating in our study, and Jenny Haefeli and Alexandra Schaettin for their support in collecting data. The study was supported by the Swiss National Science Foundation (SNF) and the Clinical Research Priority Program "Neurorehab" of the University of Zurich, Switzerland. John Kramer was supported by postdoctoral funding from the International Foundation for Paraplegia - Zurich.	Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Barnes J, 2010, NEUROIMAGE, V53, P1244, DOI 10.1016/j.neuroimage.2010.06.025; Callaghan MF, 2014, NEUROBIOL AGING, V35, P1862, DOI 10.1016/j.neurobiolaging.2014.02.008; Davis KD, 2008, NEUROLOGY, V70, P153, DOI 10.1212/01.wnl.0000295509.30630.10; Derbyshire SWG, 1999, BIOETHICS, V13, P1, DOI 10.1111/1467-8519.00129; Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; Draganski B, 2006, NEUROIMAGE, V31, P951, DOI 10.1016/j.neuroimage.2006.01.018; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Finnerup NB, 2007, FUND CLIN PHARMACOL, V21, P129, DOI 10.1111/j.1472-8206.2007.00474.x; Finnerup NB, 2004, EUR J NEUROL, V11, P73, DOI 10.1046/j.1351-5101.2003.00725.x; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2013, NEUROSCIENTIST, V19, P116, DOI 10.1177/1073858412449192; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Garcia-Larrea L, 2013, PAIN, V154, pS29, DOI 10.1016/j.pain.2013.09.001; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; HARDY TL, 1979, APPL NEUROPHYSIOL, V42, P160; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Jain N, 1997, NATURE, V386, P495, DOI 10.1038/386495a0; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Knikou M, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/254948; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; LATERRE EC, 1988, J NEUROL NEUROSUR PS, V51, P427, DOI 10.1136/jnnp.51.3.427; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Llinas R, 2005, TRENDS NEUROSCI, V28, P325, DOI 10.1016/j.tins.2005.04.006; LLINAS R, 1982, NATURE, V297, P406, DOI 10.1038/297406a0; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Lotze M, 1999, NAT NEUROSCI, V2, P501, DOI 10.1038/9145; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Lundell H, 2011, NEUROIMAGE, V54, P1254, DOI 10.1016/j.neuroimage.2010.09.009; Lynskey JV, 2008, J REHABIL RES DEV, V45, P229, DOI 10.1682/JRRD.2007.03.0047; Makin TR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2571; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Marino RJ, 2008, J SPINAL CORD MED, V31, P166, DOI 10.1080/10790268.2008.11760707; May A, 2008, PAIN, V137, P7, DOI 10.1016/j.pain.2008.02.034; Mole TB, 2014, NEUROIMAGE-CLIN, V5, P28, DOI 10.1016/j.nicl.2014.05.014; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Papinutto N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118576; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Preissler S, 2013, CEREB CORTEX, V23, P1038, DOI 10.1093/cercor/bhs063; Reulen JPH, 2003, CLIN NEUROPHYSIOL, V114, P556, DOI 10.1016/S1388-2457(02)00405-4; Rocca MA, 2006, STROKE, V37, P1765, DOI 10.1161/01.STR.0000226589.00599.4d; Sarnthein J, 2006, BRAIN, V129, P55, DOI 10.1093/brain/awh631; Schmidt-Wilcke T, 2007, PAIN, V132, pS109, DOI 10.1016/j.pain.2007.05.010; Schmidt-Wilcke T, 2006, PAIN, V125, P89, DOI 10.1016/j.pain.2006.05.004; Schmidt-Wilcke T, 2005, NEUROLOGY, V65, P1483, DOI 10.1212/01.wnl.0000183067.94400.80; Schnitzler A, 2000, J CLIN NEUROPHYSIOL, V17, P592, DOI 10.1097/00004691-200011000-00005; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; Valfre W, 2008, HEADACHE, V48, P109, DOI 10.1111/j.1526-4610.2007.00723.x; van den Berg-Emons RJ, 2007, EUR J PAIN, V11, P587, DOI 10.1016/j.ejpain.2006.09.003; Villiger M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00254; Villiger M, 2013, NEUROREHAB NEURAL RE, V27, P675, DOI 10.1177/1545968313490999; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; WANG T, 1995, J NEUROSCI, V15, P4796; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Wu G, 2002, J NEUROSCI, V22, P7746; Wydenkeller S, 2009, EUR J NEUROSCI, V30, P91, DOI 10.1111/j.1460-9568.2009.06801.x; Yoon EJ, 2013, BRAIN RES, V1540, P64, DOI 10.1016/j.brainres.2013.10.007	72	52	55	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 6	2016	6									10.1038/srep18534			13	Multidisciplinary Sciences	Science & Technology - Other Topics	DB1AQ	WOS:000368240800001	26732942	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Barlow, KM; Crawford, S; Brooks, BL; Turley, B; Mikrogianakis, A				Barlow, Karen M.; Crawford, Susan; Brooks, Brian L.; Turley, Brenda; Mikrogianakis, Angelo			The Incidence of Postconcussion Syndrome Remains Stable Following Mild Traumatic Brain Injury in Children	PEDIATRIC NEUROLOGY			English	Article						mild traumatic brain injury; concussion; postconcussion syndrome; incidence; diagnostic criteria	POST-CONCUSSIVE SYMPTOMS; EMERGENCY-DEPARTMENT; ADOLESCENTS; PREDICTORS; EPIDEMIOLOGY; DURATION; CRITERIA	BACKGROUND: Improving our knowledge about the natural history and persistence of symptoms following mild traumtic brain injury is a vital step in improving the provision of health cares to children with postconcuss ion syndrome. The purposes of this study were to (1) determine the incidence and persistence of symptoms after mild traumatic brain injury and (2) ascertain whether Diagnostic and Statistical. Manual of Mental Disorders, Fourth Edition (DSM-IV), symptom criteria for postconcussion syndrome in adult are appropriate for use in children. METHODS: A tertiary care pediatric emergency department was the setting for this study. This was a prospective observational follow-up cohort study of children (ages 2 to 18 years) with mild traumatic brain injury. Data were collected in person during the acute presentation, and subseqnent follow-up was performed by telephone at 7-10 days and 1, 2, and 3 months postinjury. Postconcussion Symptom Inventory for parents and children was used. The DSM-IV diagnostic criteria for postconcussion syndrome were explored using receiver operating characteristic curve analysis. RESULTS: A total of 467 children (62.5% boys, median age 12.04, range 2.34-18.0) with mild traumatic brain injury participated. The median time until symptom resolution was 29.0 days (95% confidence intervals: 26.09-31.91). Three months after injury, 11.8% of children with mild traumatic brain injury remained symptomatic. Receiver operating curve characteristic analysis of the postconcussion syndrome criteria successfully classified symptomatic participants at three months postinjury; the adolescent receiver operating characteristic curve was excellent with the area under the curve being 0.928 (P < 0.001, standard error 0.019). CONCLUSIONS: Consistent with our previous study, 11.8% of children presenting to the emergency room with a mild traumatic brain injury remain symptomatic at 3 months postinjury. This is the first study to demonstrate stable incidence rates of postconcussion syndrome in children and that modified DSM-IV criteria can be used to successfully classify postconcussion syndrome in children. Although most children report a decay in symptoms over time, 10% of children develop symptoms even though they initially had a good outcome. Caution should be used when using only parent report as a surrogate for childhood outcomes following a concussion.	[Barlow, Karen M.; Brooks, Brian L.; Mikrogianakis, Angelo] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Crawford, Susan] Alberta Hlth Serv, Calgary, AB, Canada; [Brooks, Brian L.; Turley, Brenda] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada	Barlow, KM (corresponding author), Alberta Childrens Prov Gen Hosp, Pediat & Clin Neurosci, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507	Albert Children's Hospital Foundation Grant [10000779]; Psychological Assessment Resources, Inc	Supported by the Albert Children's Hospital Foundation Grant (Project number: 10000779). BLB receives funding from a test publisher (Psychological Assessment Resources, Inc), book royalties from Oxford University Press, and in-kind research support from CNS Vital Signs.	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Babcock L, 2013, PEDIATR EMERG CARE, V29, P458, DOI 10.1097/PEC.0b013e31828a202d; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barlow KM, 2014, J CHILD NEU IN PRESS; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Gioia GA, 2008, J INT NEUROPSYCH SOC, V14, P204; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; GROSS H, 1993, J NEUROPSYCH CLIN N, V5, P224; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Simon R, 2005, J CLIN ONCOL, V23, P7332, DOI 10.1200/JCO.2005.02.8712; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	31	52	52	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	DEC	2015	53	6					491	497		10.1016/j.pediatrneurol.2015.04.011			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CZ2VG	WOS:000366962100005	26421987				2021-06-18	
J	Li, YZ; Bader, M; Tamargo, I; Rubovitch, V; Tweedie, D; Pick, CG; Greig, NH				Li, Yazhou; Bader, Miaad; Tamargo, Ian; Rubovitch, Vardit; Tweedie, David; Pick, Chaim G.; Greig, Nigel H.			Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cAMP-response element binding protein; glucagon-like peptide-1; liraglutide; neuroprotection; traumatic brain injury	GLUCAGON-LIKE PEPTIDE-1; REVERSES BEHAVIORAL IMPAIRMENTS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; GENE-EXPRESSION; ANIMAL-MODEL; HEAD-INJURY; RECEPTOR; GLP-1; EXENDIN-4	Traumatic brain injury (TBI), a brain dysfunction for which there is no present effective treatment, is often caused by a concussive impact to the head and affects an estimated 1.7 million Americans annually. Our laboratory previously demonstrated that exendin-4, a long-lasting glucagon-like peptide 1 receptor (GLP-1R) agonist, has neuroprotective effects in cellular and animal models of TBI. Here, we demonstrate neurotrophic and neuroprotective effects of a different GLP-1R agonist, liraglutide, in neuronal cultures and a mouse model of mild TBI (mTBI). Liraglutide promoted dose-dependent proliferation in SH-SY5Y cells and in a GLP-1R over-expressing cell line at reduced concentrations. Pre-treatment with liraglutide rescued neuronal cells from oxidative stress-and glutamate excitotoxicity-induced cell death. Liraglutide produced neurotrophic and neuroprotective effects similar to those of exendin-4 in vitro. The cAMP/PKA/pCREB pathway appears to play an important role in this neuroprotective activity of liraglutide. Furthermore, our findings in cell culture were well-translated in a weight drop mTBI mouse model. Post-treatment with a clinically relevant dose of liraglutide for 7 days in mice ameliorated memory impairments caused by mTBI when evaluated 7 and 30 days post trauma. These data cross-validate former studies of exendin-4 and suggest that liraglutide holds therapeutic potential for the treatment of mTBI.	[Li, Yazhou; Tamargo, Ian; Tweedie, David; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Bader, Miaad; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel	Li, YZ (corresponding author), Biomed Res Ctr, 251 Bayview Blvd, Baltimore, MD 21224 USA.	liyaz@mail.nih.gov; greign@mail.nih.gov			Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Ari and Regine Aprijaskis Fund at Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (ii) the Ari and Regine Aprijaskis Fund at Tel-Aviv University, and (iii) a grant from the Israel Science Foundation, grant number 108/09. No competing financial interests exist.	Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barger SW, 2004, FRONT BIOSCI-LANDMRK, V9, P3286, DOI 10.2741/1481; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Buse JB, 2013, LANCET, V381, P117, DOI 10.1016/S0140-6736(12)61267-7; Buse JB, 2009, LANCET, V374, P39, DOI 10.1016/S0140-6736(09)60659-0; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Celikyurt IK, 2014, MED SCI MONIT BASIC, V20, P112, DOI 10.12659/MSMBR.891168; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Culmsee Carsten, 2006, Current Alzheimer Research, V3, P269, DOI 10.2174/156720506778249461; DellaValle B, 2014, ANN CLIN TRANSL NEUR, V1, P721, DOI 10.1002/acn3.99; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Dragunow M, 2004, FRONT BIOSCI, V9, P100, DOI 10.2741/1197; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner R. C., 2015, ANN NEUROL, DOI [10.1002/ana.24396, DOI 10.1002/ANA.24396.]; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hakon J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120074; Holscher C, 2014, ALZHEIMERS DEMENT, V10, pS47, DOI 10.1016/j.jalz.2013.12.009; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; Khatri N, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00199; Kim MJ, 2006, J ENDOCRINOL, V188, P623, DOI 10.1677/joe.1.06480; Kinzig KP, 2003, J NEUROSCI, V23, P6163; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Leibson CL, 2012, J NEUROTRAUM, V29, P2038, DOI 10.1089/neu.2010.1713; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mondragon A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104873; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ohtake N, 2014, REGUL PEPTIDES, V190, P1, DOI 10.1016/j.regpep.2014.04.003; Parthsarathy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058784; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scott LJ, 2014, DRUGS, V74, P2161, DOI 10.1007/s40265-014-0321-6; Sharma AN, 2015, METAB BRAIN DIS, V30, P719, DOI 10.1007/s11011-014-9627-z; Sharma MK, 2014, J NEUROCHEM, V128, P459, DOI 10.1111/jnc.12469; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shin S, 2014, MOL METAB, V3, P803, DOI 10.1016/j.molmet.2014.08.001; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Van de Velde S, 2011, P NATL ACAD SCI USA, V108, P16876, DOI 10.1073/pnas.1114228108; Velmurugan K, 2012, ENDOCRINOLOGY, V153, P1116, DOI 10.1210/en.2011-1895; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	82	52	54	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2015	135	6					1203	1217		10.1111/jnc.13169			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CZ6DT	WOS:000367192100014	25982185	Green Accepted, Bronze			2021-06-18	
J	Fu, TS; Jing, RW; McFaull, SR; Cusimano, MD				Fu, Terence S.; Jing, Rowan; McFaull, Steven R.; Cusimano, Michael D.			Management of severe blunt hepatic injury in the era of computed tomography and transarterial embolization: A systematic review and critical appraisal of the literature	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	101st Annual Congress of the Swiss-Society-of-Surgery73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	MAY 21-23, 2014SEP 09-13, 2014	Bern, SWITZERLANDPhiladelphia, PA	Swiss Soc SurgAmer Assoc Surg Trauma			TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POPULATION; TRENDS; EPIDEMIOLOGY; HOSPITALIZATIONS; MORTALITY; VISITS; CARE; AGE		[Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Fu, Terence S.; Jing, Rowan; Cusimano, Michael D.] Univ Toronto, Injury Prevent Res Off, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [McFaull, Steven R.] Publ Hlth Agcy Canada, Ottawa, ON, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Div Neurosurg,Dept Surg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research #TIR-103946, the Ontario Neurotrauma Foundation.	Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Canadian Institute for Health Information, 2012, CIHI DAT QUAL STUD 2; Canadian Institute of Health Information (CIHI), 2006, HEAD INJ CAN DEC CHA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CIHI, 2007, BURD NEUR DIS DIS IN; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Cryer C, 2006, INJURY PREV, V12, P67, DOI 10.1136/ip.2006.011668; Cusimano MD, 2008, INJURY PREV, V14, P113, DOI 10.1136/ip.2007.017533; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fingerhut L, 2002, EXTERNAL CAUSE INJUR; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mayhew D.R., 2005, BEST PRACTICES GRADU; Peloso PM, 2004, J REHABIL MED S43, P2004; Phillips LA, 2009, CAN J NEUROL SCI, V36, P605, DOI 10.1017/S0317167100008118; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Russell KF, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003300.pub3; Simniceanu A, 2014, TRAFFIC INJ PREV, V15, P734, DOI 10.1080/15389588.2013.867483; Solomon R, 2014, CAN PUBLIC POL, V40, P15, DOI 10.3138/cpp.2012-102; Stephenson S, 2004, INJURY PREV, V10, P379, DOI 10.1136/ip.2004.005561; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DKJRC, 1995, STANDARDS SURVEILLAN; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	31	52	52	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2015	79	3					449	455		10.1097/TA.0000000000000733			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	CQ4JV	WOS:000360571900021	26535433	Green Accepted			2021-06-18	
J	Dias, C; Silva, MJ; Pereira, E; Monteiro, E; Maia, I; Barbosa, S; Silva, S; Honrado, T; Cerejo, A; Aries, MJH; Smielewski, P; Paiva, JA; Czosnyka, M				Dias, Celeste; Silva, Maria Joao; Pereira, Eduarda; Monteiro, Elisabete; Maia, Isabel; Barbosa, Silvina; Silva, Sofia; Honrado, Teresa; Cerejo, Antonio; Aries, Marcel J. H.; Smielewski, Peter; Paiva, Jose-Artur; Czosnyka, Marek			Optimal Cerebral Perfusion Pressure Management at Bedside: A Single-Center Pilot Study	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Multimodal brain monitoring; Cerebral perfusion pressure; Cerebrovascular pressure reactivity; Optimal cerebral perfusion pressure	NEAR-INFRARED SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW AUTOREGULATION; CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; VASOMOTOR REACTIVITY; CLASSIFICATION; HYPOXIA; TRIAL	Guidelines recommend cerebral perfusion pressure (CPP) values of 50-70 mmHg and intracranial pressure lower than 20 mmHg for the management of acute traumatic brain injury (TBI). However, adequate individual targets are still poorly addressed, since patients have different perfusion thresholds. Bedside assessment of cerebral autoregulation may help to optimize individual CPP-guided treatment. To assess staff compliance and outcome impact of a new method of autoregulation-guided treatment (CPPopt) based on continuous evaluation of cerebrovascular reactivity (PRx). Prospective pilot study of severe TBI adult patients managed with continuous multimodal brain monitoring in a single Neurocritical Care Unit (NCCU). Every minute CPPopt was automatically estimated, based on the previous 4-h window, as the CPP with the lowest PRx indicating the best cerebrovascular pressure reactivity. Patients were managed with CPPopt targets whenever possible and otherwise CPP was managed following general/international guidelines. In addition, other offline CPPopt estimates were calculated using cerebral oximetry (COx-CPPopt), brain tissue oxygenation (ORxs-CPPopt), and cerebral blood flow (CBFx-CPPopt). Eighteen patients with a total multimodal brain monitoring time of 5,520 h were enrolled. During the total monitoring period, 11 patients (61 %) had a CPPopt U-shaped curve, 5 patients (28 %) had either ascending or descending curves, and only 2 patients (11 %) had no fitted curve. Real CPP correlated significantly with calculated CPPopt (r = 0.83, p < 0.0001). Preserved autoregulation was associated with greater Glasgow coma score on admission (p = 0.01) and better outcome (p = 0.01). We demonstrated that patients with the larger discrepancy (> 10 mm Hg) between real CPP and CPPopt more likely have had adverse outcome (p = 0.04). Comparison between CPPopt and the other estimates revealed similar limits of precision. The lowest bias (-0.1 mmHg) was obtained with COx-CPPopt (NIRS). Targeted individual CPP management at the bedside using cerebrovascular pressure reactivity seems feasible. Large deviation from CPPopt seems to be associated with adverse outcome. The COx-CPPopt methodology using non-invasive CO (NIRS) warrants further evaluation.	[Dias, Celeste; Pereira, Eduarda; Monteiro, Elisabete; Maia, Isabel; Barbosa, Silvina; Silva, Sofia; Honrado, Teresa; Paiva, Jose-Artur] Hosp Sao Joao, Dept Intens Care, Neurocrit Care Unit, Oporto, Portugal; [Silva, Maria Joao] Kings Coll London, Diabet & Nutr Sci Div, London WC2R 2LS, England; [Cerejo, Antonio] Hosp Sao Joao, Neurosurg Dept, Oporto, Portugal; [Aries, Marcel J. H.] Univ Groningen, Univ Med Ctr Groningen, Intens Care Crit Care Unit, Groningen, Netherlands; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England	Dias, C (corresponding author), Hosp Sao Joao, Dept Intens Care, Neurocrit Care Unit, Oporto, Portugal.	mceleste.dias@gmail.com	Dias, Celeste/AAV-3820-2020; Dias, Celeste/L-9901-2014; Paiva, Jose-Artur/AAO-9730-2021; Dias, Celeste/AAD-8711-2019	Dias, Celeste/0000-0003-0340-9808; Dias, Celeste/0000-0003-0340-9808; Smielewski, Peter/0000-0001-5096-3938; Paiva, Jose-Artur/0000-0003-4323-0220; Honrado Santos, Maria Teresa/0000-0001-9416-9971; czosnyka, marek/0000-0003-2446-8006	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986] Funding Source: Medline		Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Cecconi M, 2009, CRIT CARE, V13, DOI 10.1186/cc7129; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Grande PO, 2011, J NEUROSURG ANESTH, V23, P358, DOI 10.1097/01.ana.0000405612.20356.84; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Smielewski P, 2005, ACT NEUR S, V95, P43; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Team RDC, 2012, R LANG ENV STAT COMP; Tzeng YC, 2014, EUR J APPL PHYSIOL, V114, P545, DOI 10.1007/s00421-013-2667-y; Weerakkody RA, 2010, ACTA NEUROCHIR, V152, P1763, DOI 10.1007/s00701-010-0748-9; Zweifel C, 2014, MED ENG PHYS, V36, P638, DOI 10.1016/j.medengphy.2014.03.002; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	42	52	54	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2015	23	1					92	102		10.1007/s12028-014-0103-8			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CN8FJ	WOS:000358674600014	25566826				2021-06-18	
J	Harish, G; Mahadevan, A; Pruthi, N; Sreenivasamurthy, SK; Puttamallesh, VN; Prasad, TSK; Shankar, SK; Bharath, MMS				Harish, Gangadharappa; Mahadevan, Anita; Pruthi, Nupur; Sreenivasamurthy, Sreelakshmi K.; Puttamallesh, Vinuth N.; Prasad, Thottethodi Subrahmanya Keshava; Shankar, Susarla Krishna; Bharath, Muchukunte Mukunda Srinivas			Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion	JOURNAL OF NEUROCHEMISTRY			English	Article						human brain; mitochondria; neurotrauma; oxidative stress; proteomics; synaptic terminal	SUPEROXIDE-DISMUTASE EXPRESSION; FIBRILLARY ACIDIC PROTEIN; HUMAN CEREBROSPINAL-FLUID; HUMAN HEAD-INJURY; OXIDATIVE STRESS; IMMUNOHISTOCHEMICAL EVALUATION; PROTEOMIC IDENTIFICATION; TREATMENT STRATEGIES; YKL-40 EXPRESSION; PERCUSSION INJURY	Traumatic brain injury (TBI) contributes to fatalities and neurological disabilities worldwide. While primary injury causes immediate damage, secondary events contribute to long-term neurological defects. Contusions (Ct) are primary injuries correlated with poor clinical prognosis, and can expand leading to delayed neurological deterioration. Pericontusion (PC) (penumbra), the region surrounding Ct, can also expand with edema, increased intracranial pressure, ischemia, and poor clinical outcome. Analysis of Ct and PC can therefore assist in understanding the pathobiology of TBI and its management. This study on human TBI brains noted extensive neuronal, astroglial and inflammatory changes, alterations in mitochondrial, synaptic and oxidative markers, and associated proteomic profile, with distinct differences in Ct and PC. While Ct displayed petechial hemorrhages, thrombosis, inflammation, neuronal pyknosis, and astrogliosis, PC revealed edema, vacuolation of neuropil, axonal loss, and dystrophic changes. Proteomic analysis demonstrated altered immune response, synaptic, and mitochondrial dysfunction, among others, in Ct, while PC displayed altered regulation of neurogenesis and cytoskeletal architecture, among others. TBI brains displayed oxidative damage, glutathione depletion, mitochondrial dysfunction, and loss of synaptic proteins, with these changes being more profound in Ct. We suggest that analysis of markers specific to Ct and PC may be valuable in the evaluation of TBI pathobiology and therapeutics. We have characterized the primary injury in human traumatic brain injury (TBI). Contusions (Ct) - the injury core displayed hemorrhages, inflammation, and astrogliosis, while the surrounding pericontusion (PC) revealed edema, vacuolation, microglial activation, axonal loss, and dystrophy. Proteomic analysis demonstrated altered immune response, synaptic and mitochondrial dysfunction in Ct, and altered regulation of neurogenesis and cytoskeletal architecture in PC. Ct displayed more oxidative damage, mitochondrial, and synaptic dysfunction compared to PC.	[Harish, Gangadharappa; Bharath, Muchukunte Mukunda Srinivas] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurochem, Bangalore 560029, Karnataka, India; [Mahadevan, Anita; Shankar, Susarla Krishna] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuropathol, Bangalore, Karnataka, India; [Pruthi, Nupur] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India; [Sreenivasamurthy, Sreelakshmi K.; Puttamallesh, Vinuth N.; Prasad, Thottethodi Subrahmanya Keshava] Whitefield, Inst Bioinformat, Bangalore, Karnataka, India; [Sreenivasamurthy, Sreelakshmi K.] Manipal Univ, Manipal, Karnataka, India	Bharath, MMS (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurochem, 2900 Hosur Rd, Bangalore 560029, Karnataka, India.	bharath@nimhans.kar.nic.in	Sreenivasamurthy, Sreelakshmi Kenkere/W-1942-2019; Prasad, Keshava/F-7631-2010	Prasad, Keshava/0000-0002-6206-2384; Sreenivasamurthy, Sreelakshmi K./0000-0002-8891-3714	Indian Council of Medical Research (ICMR) (IRIS) [2009-09910]; DBT, IndiaDepartment of Biotechnology (DBT) India [BT/01/COE/08/05]; University Grants Commission, IndiaUniversity Grants Commission, India	The authors thank all donors and their relatives for tissue samples. These tissues are archived at the Human Brain Bank, NIMHANS, Bangalore, India. This study was supported by the Indian Council of Medical Research (ICMR) (IRIS No. 2009-09910 to MMSB). GH is the senior research fellow of ICMR. TSK and S.K. Shankar are supported by 'DBT Programme Support on Neuroproteomics of Neurological Disorders' by DBT, India (BT/01/COE/08/05). Sreelakshmi K. Sreenivasamurthy is a recipient of Junior Research Fellowship from the University Grants Commission, India. We thank Agilent Technologies for instrumentation support. The authors have no conflicts of interest to declare.	Awasthi D, 2003, NEUROSCI LETT, V345, P29, DOI 10.1016/S0304-3940(03)00497-X; Bagnyukova TV, 2003, J THERM BIOL, V28, P21, DOI 10.1016/S0306-4565(02)00031-1; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bemeur C, 2004, NEUROCHEM INT, V45, P1167, DOI 10.1016/j.neuint.2004.06.010; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bonneh-Barkay D, 2012, BRAIN PATHOL, V22, P530, DOI 10.1111/j.1750-3639.2011.00550.x; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chandana R, 2009, INDIAN J MED RES, V129, P189; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477-3155-5-1; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Galluzzi L, 2008, METHOD ENZYMOL, V442, P355, DOI 10.1016/S0076-6879(08)01418-3; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goel R, 2012, MOL BIOSYST, V8, P453, DOI 10.1039/c1mb05340j; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Harish G, 2013, NEUROPATH APPL NEURO, V39, P298, DOI 10.1111/j.1365-2990.2012.01285.x; Harish G, 2013, NEUROCHEM RES, V38, P186, DOI 10.1007/s11064-012-0907-x; Harish G, 2012, BIOPRESERV BIOBANK, V10, P253, DOI 10.1089/bio.2012.0001; Harish G, 2011, BIOPRESERV BIOBANK, V9, P379, DOI 10.1089/bio.2011.0033; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Jiang XF, 2013, J SURG RES, V184, pE27, DOI 10.1016/j.jss.2013.03.067; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kandasamy K, 2009, NUCLEIC ACIDS RES, V37, pD773, DOI 10.1093/nar/gkn701; KITTO GB, 1967, BIOCHIM BIOPHYS ACTA, V139, P1, DOI 10.1016/0005-2744(67)90107-6; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Liu L, 2012, CHINESE MED J-PEKING, V125, P3831, DOI 10.3760/cma.j.issn.0366-6999.2012.21.016; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Muthusamy B., 2013, CURRENT PROTOCOLS BI, V41, P1; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oli MW, 2009, METHODS MOL BIOL, V566, P293, DOI 10.1007/978-1-59745-562-6_19; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Pawar H, 2011, CANCER BIOL THER, V12, P510, DOI 10.4161/cbt.12.6.16833; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Peluffo H, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-12; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prasad TSK, 2009, METHODS MOL BIOL, V577, P67, DOI 10.1007/978-1-60761-232-2_6; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramadasan-Nair R, 2014, J BIOL CHEM, V289, P485, DOI 10.1074/jbc.M113.493270; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Renjini R, 2012, NEUROCHEM RES, V37, P885, DOI 10.1007/s11064-011-0683-z; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sotgiu S, 2005, EUR NEUROL, V54, P149, DOI 10.1159/000089935; Srere P.A., 1969, METHODS ENZYMOL, P3, DOI 10.1016/ 0076-6879(69)13005-0; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yang XY, 2009, BRAIN INJURY, V23, P830, DOI 10.1080/02699050903196670; Yasha TC, 1997, INDIAN J MED RES, V105, P141; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zupanc GKH, 2007, PROTEOM CLIN APPL, V1, P1362, DOI 10.1002/prca.200700420	88	52	53	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2015	134	1					156	172		10.1111/jnc.13082			17	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CK6WH	WOS:000356368800016	25712633				2021-06-18	
J	Hinzman, JM; DiNapoli, VA; Mahoney, EJ; Gerhardt, GA; Hartings, JA				Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Gerhardt, Greg A.; Hartings, Jed A.			Spreading depolarizations mediate excitotoxicity in the development of acute cortical lesions	EXPERIMENTAL NEUROLOGY			English	Article						Spreading depression; Stroke; Middle cerebral artery occlusion	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; EXTRACELLULAR GLUTAMATE; ANOXIC DEPOLARIZATION; RAT STRIATUM; IN-VIVO; ARTERY OCCLUSION; AMINO-ACIDS; INTRACEREBRAL MICRODIALYSIS	Spreading depolarizations (SD) are mass depolarizations of neurons and astrocytes that occur spontaneously in acute brain injury and mediate time-dependent lesion growth. Glutamate excitotoxicity has also been extensively studied as a mechanism of neuronal injury, although its relevance to in vivo pathology remains unclear. Here we hypothesized that excitotoxicity in acute lesion development occurs only as a consequence of SD. Using glutamate-sensitive microelectrodes, we found that SD induced by KCl in normal rat cortex elicits increases in extracellular glutamate (11.6 +/- 1.3 mu M) that are synchronous with the onset, sustainment, and resolution of the extracellular direct-current shift of SD. Inhibition of glutamate uptake with D,L-threo-beta-benzyloxyaspartate (TBOA, 0.5 and 1 mM) significantly prolonged the duration of the direct-current shift (148% and 426%, respectively) and the glutamate increase (167% and 374%, respectively) in a dose-dependent manner (P < 0.05). These prolonged events produced significant cortical lesions as indicated by Fluoro-Jade staining (P < 0.05), while no lesions were observed after SD in control conditions or after cortical injection of 1 mM glutamate (extracellular increase: 243 +/- 50.8 mu M) or 0.5 mM TBOA (glutamate increase: 8.5 +/- 1.6 mu M) without SD. We then used an embolic focal ischemia model to determine whether glutamate elevations occur independent of SD in the natural evolution of a cortical lesion. In both the ischemic core and penumbra, glutamate increased only in synchrony with anoxic terminal SD (6.1 +/- 1.1 mu M) and transient SDs (11.8 +/- 2.4 mu M), and not otherwise. Delayed terminal SDs were also observed in two animals at 98 and 150 min after ischemic onset and induced similar glutamate elevations. Durations of SDs and glutamate increases were significantly correlated in both normal and ischemic animals (P < 0.05). These data suggest that pathologically prolonged SDs are a required mechanism of acute cortical lesion development and that glutamate elevations and the mass electrochemical changes of SD and are merely different facets of the same pathophysiologic process. (C) 2015 Elsevier Inc. All rights reserved.	[Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Coll Med, Cincinnati, OH 45267 USA; [Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Hartings, Jed A.] UC Neurosci Inst, Neurotrauma Ctr, Cincinnati, OH 45267 USA; [DiNapoli, Vince A.; Hartings, Jed A.] Mayfield Clin, Cincinnati, OH USA; [Gerhardt, Greg A.] Univ Kentucky, Morris K Udall Parkinsons Dis Res Ctr Excellence, Ctr Microelectrode Technol,Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr,Chandler Med C, Lexington, KY USA	Hinzman, JM (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com		Hartings, Jed/0000-0001-8583-3471	Mayfield Education and Research Foundation	This work was funded by the Mayfield Education and Research Foundation.	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Canals S, 2008, J CEREBR BLOOD F MET, V28, P1835, DOI 10.1038/jcbfm.2008.71; CHOI DW, 1987, J NEUROSCI, V7, P369; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; GILL R, 1987, J NEUROSCI, V7, P3343; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1984, AN ACAD BRAS CIENC, V56, P457; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70085-6; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hayashi T, 1954, KEIJO J MED, V3, P192, DOI [DOI 10.2302/KJM.3.183, 10.2302/kjm.3.183]; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; Hemandez-Caceres J., 1987, BRAIN RES, V437, P360; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jeffcote T, 2014, NEUROCRIT CARE, V20, P21, DOI 10.1007/s12028-013-9938-7; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Kunimatsu T, 1999, BRAIN RES, V831, P273, DOI 10.1016/S0006-8993(99)01481-X; Landolt H, 1998, J CLIN NEUROSCI, V5, P193, DOI 10.1016/S0967-5868(98)90037-6; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lindquist BE, 2014, J CEREBR BLOOD F MET, V34, P1779, DOI 10.1038/jcbfm.2014.146; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Muller M, 2000, J NEUROPHYSIOL, V83, P735, DOI 10.1152/jn.2000.83.2.735; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Nallet H, 1999, BRAIN RES, V842, P148, DOI 10.1016/S0006-8993(99)01859-4; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; Obrenovitch TP, 1997, BRIT J PHARMACOL, V122, P372, DOI 10.1038/sj.bjp.0701372; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Raiteri L, 2007, J NEUROCHEM, V103, P952, DOI 10.1111/j.1471-4159.2007.04784.x; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Sanchez-Porras R, 2014, NEUROPHARMACOLOGY, V84, P52, DOI 10.1016/j.neuropharm.2014.04.018; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; Satoh M, 1999, BRAIN RES, V822, P142, DOI 10.1016/S0006-8993(99)01141-5; Shimamoto K, 1998, MOL PHARMACOL, V53, P195; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; UEDA Y, 1992, STROKE, V23, P253, DOI 10.1161/01.STR.23.2.253; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; WAHL F, 1994, J NEUROCHEM, V63, P1003; Zhang H, 2009, J NEUROSCI METH, V179, P191, DOI 10.1016/j.jneumeth.2009.01.023; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	85	52	54	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						243	253		10.1016/j.expneurol.2015.03.014			11	Neurosciences	Neurosciences & Neurology	CH1AZ	WOS:000353754800023	25819105				2021-06-18	
J	Lu, CH; Petzold, A; Topping, J; Allen, K; Macdonald-Wallis, C; Clarke, J; Pearce, N; Kuhle, J; Giovannoni, G; Fratta, P; Sidle, K; Fish, M; Orrell, R; Howard, R; Greensmith, L; Malaspina, A				Lu, Ching-Hua; Petzold, Axel; Topping, Jo; Allen, Kezia; Macdonald-Wallis, Corrie; Clarke, Jan; Pearce, Neil; Kuhle, Jens; Giovannoni, Gavin; Fratta, Pietro; Sidle, Katie; Fish, Mark; Orrell, Richard; Howard, Robin; Greensmith, Linda; Malaspina, Andrea			Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SUBUNIT PNF-H; CEREBROSPINAL-FLUID; AXONAL DAMAGE; LIGHT LEVELS; ALS; CSF; SERUM; BIOMARKERS; ANTIBODIES	Objective To investigate the role of longitudinal plasma neurofilament heavy chain protein ( NfH) levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis ( ALS). Methods A cross-sectional study involving 136 clinically heterogeneous patients with ALS and 104 healthy and neurological controls was extended to include a prospective analysis of 74 of these ALS cases, with samplings at approximately 3-month intervals in a follow-up period of up to 3 years. We analysed the correlation between longitudinal NfH-phosphoform levels and disease progression. Temporal patterns of NfH changes were evaluated using multilevel linear regression. Results Baseline plasma NfH levels were higher than controls only in patients with ALS with short disease duration to baseline sampling. Compared with controls, fast-progressing patients with ALS, particularly those with a short diagnostic latency and disease duration, had higher plasma NfH levels at an early stage and lower levels closer to end-stage disease. Lower NfH levels between visits were associated with rapid functional deterioration. We also detected antibodies against NfH, NfH aggregates and NfH cleavage products. Conclusions Disease progression in ALS involves defined trajectories of plasma NfH levels, reflecting speed of neurological decline and survival. Intervisit plasma NfH changes are also indicative of disease progression. This study confirms that longitudinal measurements of NfH plasma levels are more informative than cross-sectional studies, where the time of sampling may represent a bias in the interpretation of the results. Autoantibodies against NfH aggregates and NfH cleavage products may explain the variable expression of plasma NfH with disease progression.	[Lu, Ching-Hua; Topping, Jo; Kuhle, Jens; Giovannoni, Gavin; Malaspina, Andrea] Queen Mary Univ London, Ctr Neurosci & Trauma, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England; [Lu, Ching-Hua; Greensmith, Linda] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England; [Petzold, Axel] UCL Inst Neurol, Dept Neuroinflammat, London, England; [Allen, Kezia; Malaspina, Andrea] Basildon & Thurrock Univ Hosp NHS Fdn Trust, Basildon, Essex, England; [Macdonald-Wallis, Corrie; Howard, Robin] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Clarke, Jan; Orrell, Richard] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Pearce, Neil] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England; [Fratta, Pietro] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Sidle, Katie] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Fish, Mark] Musgrove Pk Hosp, Clin Trial Unit, Taunton, Somerset, England; [Orrell, Richard] UCL Inst Neurol, Dept Clin Neurosci, London, England; [Greensmith, Linda] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England; [Malaspina, Andrea] North East London & Essex MND Care & Res Ctr, London, England	Malaspina, A (corresponding author), Queen Mary Univ London, Ctr Neurosci & Trauma, Blizard Inst, Barts & London Sch Med & Dent, 4 Newark St, London E1 2AT, England.	a.malaspina@qmul.ac.uk	Fratta, Pietro/G-1296-2019; Petzold, Axel/C-1090-2009	Fratta, Pietro/0000-0002-8762-8188; Petzold, Axel/0000-0002-0344-9749; Pearce, Neil/0000-0002-9938-7852	Motor Neurone Disease Association [Malaspina/Apr13/6097]; Barts and The London Charities [468/1714]; Brain Research Trust; European CommunityEuropean Commission; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K000608/1, G1000287, MR/M008606/1] Funding Source: researchfish; Motor Neurone Disease Association [Fratta/Jan15/946-795] Funding Source: researchfish	This project was funded by The Motor Neurone Disease Association (Malaspina/Apr13/6097) and Barts and The London Charities (468/1714). LG is the Graham Watts Senior Research Fellow, funded by The Brain Research Trust and the European Community's Seventh Framework Programme (FP7/2007-2013).	Abou-Donia Mohamed B, 2013, J Toxicol Environ Health A, V76, P363, DOI 10.1080/15287394.2013.765369; Bowser R, 2011, NAT REV NEUROL, V7, P631, DOI 10.1038/nrneurol.2011.151; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Boylan KB, 2013, J NEUROL NEUROSUR PS, V84, P467, DOI 10.1136/jnnp-2012-303768; Brettschneider J, 2006, NEUROLOGY, V66, P852, DOI 10.1212/01.wnl.0000203120.85850.54; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Cellura E, 2012, CLIN NEUROL NEUROSUR, V114, P550, DOI 10.1016/j.clineuro.2011.11.026; Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P310, DOI 10.3109/17482960802566824; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Couratier P, 1998, J NEUROL SCI, V154, P137, DOI 10.1016/S0022-510X(97)00219-0; De Carvalho M, 2009, AMYOTROPH LATERAL SC, V10, P53, DOI 10.1080/17482960802521126; Fialova L, 2010, EUR J NEUROL, V17, P562, DOI 10.1111/j.1468-1331.2009.02853.x; Fialova L, 2013, J NEUROIMMUNOL, V259, P81, DOI 10.1016/j.jneuroim.2013.03.009; Ganesalingam J, 2011, J NEUROCHEM, V117, P528, DOI 10.1111/j.1471-4159.2011.07224.x; Iwasaki Y, 2002, CLIN NEUROL NEUROSUR, V104, P87, DOI 10.1016/S0303-8467(01)00188-3; Leckie G, 2013, J STAT SOFTW, V52, P1; Lu CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040998; Lu CH, 2011, J NEUROSCI METH, V195, P143, DOI 10.1016/j.jneumeth.2010.11.026; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Petzold A, 2010, ANN NEUROL, V68, P806, DOI 10.1002/ana.22169; Puentes F, 2014, J NEUROL NEUROSUR PS, V85, P274, DOI [10.1136/jnnp-2013-305494, 10.1136/jnnp-2013-307454]; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Stevenson L, 2014, AAPS J, V16, P83, DOI 10.1208/s12248-013-9542-y; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Touloumi G, 1999, STAT MED, V18, P1215; Turner MR, 2010, J NEUROL SCI, V294, P81, DOI 10.1016/j.jns.2010.03.028; Zetterberg H, 2007, EUR J NEUROL, V14, P1329, DOI 10.1111/j.1468-1331.2007.01972.x; Zoing MC, 2006, J CLIN NEUROSCI, V13, P78, DOI 10.1016/j.jocn.2004.04.011	35	52	53	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2015	86	5					565	573		10.1136/jnnp-2014-307672			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	CF8BR	WOS:000352780800018	25009280	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Zhang, JJ; Cheah, CC				Zhang, Juanjuan; Cheah, Chien Chern			Passivity and Stability of Human-Robot Interaction Control for Upper-Limb Rehabilitation Robots	IEEE TRANSACTIONS ON ROBOTICS			English	Article						Adaptive control; human-robot interaction; rehabilitation robotics	STROKE PATIENTS; THERAPY; EXOSKELETON	Each year, stroke and traumatic brain injury leave millions of survivors with motion control loss, which results in great demand for recovery training. The great labor intensity in traditional human-based therapies has recently boosted the research on rehabilitation robotics. Existing controllers for rehabilitative robotics cannot solve the closed-loop system stability with uncertain nonlinear dynamics and conflicting human-robot interactions. This paper presents a theoretical framework that establishes the passivity of the closed-loop upper-limb rehabilitative robotic systems and allows rigorous stability analysis of human-robot interaction. Position-dependent stiffness and position-dependent desired trajectory are employed to resolve the possible conflicts in motions between patient and robot. The proposed method also realizes the "assist-as-needed" strategy. In addition, it handles human-robot interactions in such a way that correct movements are encouraged and incorrect ones are suppressed to make the training process more effective. While guaranteeing these properties, the proposed controller allows parameter adjustment to provide flexibility for therapists to adjust and fine tune depending on the conditions of the patients and the progress of their recovery. Simulation and experiment results are presented to illustrate the performance of the method.	[Zhang, Juanjuan] Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA; [Zhang, Juanjuan; Cheah, Chien Chern] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore	Zhang, JJ (corresponding author), Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA.	juanjuaz@andrew.cmu.edu; ecccheah@ntu.edu.sg	Cheah, Chien-Chern/A-5024-2011	Zhang, Juanjuan/0000-0002-3833-487X; Cheah, Chien Chern/0000-0003-3728-9277			Aguirre-Ollinger G, 2012, IEEE T NEUR SYS REH, V20, P68, DOI 10.1109/TNSRE.2011.2176960; Arimoto S., 1996, CONTROL THEORY NONLI; Banala SK, 2007, INT C REHAB ROBOT, P401, DOI 10.1109/ICORR.2007.4428456; Cai LL, 2006, J NEUROSCI, V26, P10564, DOI 10.1523/JNEUROSCI.2266-06.2006; Cheah CC, 2003, IEEE T ROBOTIC AUTOM, V19, P692, DOI 10.1109/TRA.2003.814517; Fasse E. D., 1996, ROB RES INT S, P28; Finley MA, 2005, J REHABIL RES DEV, V42, P683, DOI 10.1682/JRRD.2004.12.0153; Freud S., 2001, STANDARD EDITION COM, V1, P283; Haddadin S, 2010, INT J SOC ROBOT, V2, P235, DOI 10.1007/s12369-010-0053-z; Hallett M, 1999, NEUROSCIENTIST, V5, P324, DOI 10.1177/107385849900500518; Hanneton S, 1997, BIOL CYBERN, V77, P381, DOI 10.1007/s004220050398; HOGAN N, 1985, J DYN SYST-T ASME, V107, P1, DOI 10.1115/1.3140702; Hogan N., 1992, Proceedings. IEEE International Workshop on Robot and Human Communication (Cat. No.92TH0469-7), P161, DOI 10.1109/ROMAN.1992.253895; Hogan N., 2005, ROBOTICS AUTOMATION, P1901; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Kazerooni H, 2005, IEEE INT CONF ROBOT, P4353; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Marchal-Crespo L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-20; Masiero S, 2011, J REHABIL RES DEV, V48, P355, DOI 10.1682/JRRD.2010.04.0063; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Saglia JA, 2010, IEEE INT CONF ROBOT, P2221, DOI 10.1109/ROBOT.2010.5509883; Sawicki GS, 2009, J EXP BIOL, V212, P21, DOI 10.1242/jeb.017269; SHATZ CJ, 1992, SCI AM, V267, P61, DOI 10.1038/scientificamerican0992-60; SLOTINE JJE, 1987, INT J ROBOT RES, V6, P49, DOI 10.1177/027836498700600303; Slotine JJE., 1991, APPL NONLINEAR CONTR; Stienen AHA, 2010, IEEE T BIO-MED ENG, V57, P728, DOI 10.1109/TBME.2009.2018628; TAKEGAKI M, 1981, J DYN SYST-T ASME, V103, P119, DOI 10.1115/1.3139651; Vitiello N, 2013, IEEE T ROBOT, V29, P220, DOI 10.1109/TRO.2012.2211492; Zhang JJ, 2013, IEEE INT CONF ROBOT, P2201, DOI 10.1109/ICRA.2013.6630873	30	52	54	4	95	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1552-3098	1941-0468		IEEE T ROBOT	IEEE Trans. Robot.	APR	2015	31	2					233	245		10.1109/TRO.2015.2392451			13	Robotics	Robotics	CF2EV	WOS:000352361300001					2021-06-18	
J	Huang, YL; Kuo, YS; Tseng, YC; Chen, DYT; Chiu, WT; Chen, CJ				Huang, Yen-Lin; Kuo, Ying-Sheng; Tseng, Ying-Chi; Chen, David Yen-Ting; Chiu, Wen-Ta; Chen, Chi-Jen			Susceptibility-weighted MRI in mild traumatic brain injury	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; CEREBRAL MICROBLEEDS; GRADIENT-ECHO; HEMORRHAGE; CHILDREN; ESWAN; PHASE	Objective:To compare the frequency of microbleeds identified by susceptibility-weighted MRI (SWMRI) in patients with mild traumatic brain injury (mTBI) and normal controls, and correlate these findings with neuropsychological tests.Methods:Research ethics committee approval and patient written informed consents were obtained. One hundred eleven patients with mTBI without parenchymal hemorrhage on CT and conventional MRI received SWMRI as well as a digit span and continuous performance test. One hundred eleven healthy volunteers without history of traumatic brain injury were enrolled as the control group and received conventional MRI with additional SWMRI study. We analyzed the number and location of microbleeds in both groups.Results:Twenty-six patients with mTBI and 12 control subjects presented microbleeds on SWMRI (p = 0.0197). Sixty microbleeds were found in 26 patients with mTBI and 15 microbleeds in 12 control subjects. The mTBI group showed notably more microbleeds in the cortex/subcortical region (52 microbleeds, 86.7%, vs 3 microbleeds, 20%; p < 0.0001). Conversely, the control group showed more microbleeds in the central brain (9 microbleeds, 60%, vs 3 microbleeds, 5%; p < 0.0001). There was no statistical difference in number of microbleeds in the cerebellum and brainstem (p = 0.2598 and p = 0.4932, respectively). Patients with mTBI who had detected microbleeds had lower digit span scores than the patients with negative SWMRI findings (p = 0.017).Conclusion:Presence of mTBI-related microbleeds showed a neuropsychological defect on short-term memory function, indicating that the presence of microbleeds could be a possible severity biomarker for mTBI. Addition of the SWMRI technique to the MRI protocol for patients with mTBI is recommended.	[Huang, Yen-Lin; Kuo, Ying-Sheng; Tseng, Ying-Chi; Chen, David Yen-Ting; Chen, Chi-Jen] Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan	Chen, CJ (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Diagnost Radiol, Taipei, Taiwan.	08889@shh.org.tw					Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Boeckh-Behrens T, 2012, EUR J RADIOL, V81, P1238, DOI 10.1016/j.ejrad.2011.02.057; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chen CJ, 2012, RADIOLOGY, V264, P844, DOI 10.1148/radiol.12112154; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12287; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Guo LF, 2013, CLIN NEURORADIOL, V23, P197, DOI 10.1007/s00062-012-0196-4; Guo LF, 2013, CLIN NEURORADIOL, V23, P121, DOI 10.1007/s00062-012-0185-7; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hodel J, 2014, EUR RADIOL, V24, P762, DOI 10.1007/s00330-013-3061-1; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Pittella JEH, 2003, J FORENSIC SCI, V48, P626; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Shoamanesh A, 2011, CEREBROVASC DIS, V32, P528, DOI 10.1159/000331466; Tatsumi S, 2008, CEREBROVASC DIS, V26, P142, DOI 10.1159/000139661; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	31	52	55	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 10	2015	84	6					580	585		10.1212/WNL.0000000000001237			6	Clinical Neurology	Neurosciences & Neurology	CC6VT	WOS:000350507800013	25576634				2021-06-18	
J	Hayes, JP; Miller, DR; Lafleche, G; Salat, DH; Verfaellie, M				Hayes, Jasmeet P.; Miller, Danielle R.; Lafleche, Ginette; Salat, David H.; Verfaellie, Mieke			The nature of white matter abnormalities in blast-related mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Fractional anisotropy; PTSD; Diffusion tensor imaging; OEF/OIF; Loss of consciousness	POSTTRAUMATIC-STRESS-DISORDER; OEF/OIF VETERANS; IRAQI FREEDOM; SELF-REPORT; PTSD; CONCUSSION; INTEGRITY; SYMPTOMS; DEFICITS; AFGHANISTAN	Blast-related traumatic brain injury (TBI) has been a common injury among returning troops due to the widespread use of improvised explosive devices in the Iraq and Afghanistan Wars. As most of the TBIs sustained are in the mild range, brain changes may not be detected by standard clinical imaging techniques such as CT. Furthermore, the functional significance of these types of injuries is currently being debated. However, accumulating evidence suggests that diffusion tensor imaging (DTI) is sensitive to subtle white matter abnormalities and may be especially useful in detecting mild TBI (mTBI). The primary aim of this study was to use DTI to characterize the nature of white matter abnormalities following blast-related mTBI, and in particular, examine the extent to which mTBI-related white matter abnormalities are region-specific or spatially heterogeneous. In addition, we examined whether mTBI with loss of consciousness (LOC) was associated with more extensive white matter abnormality than mTBI without LOC, as well as the potential moderating effect of number of blast exposures. A second aim was to examine the relationship between white matter integrity and neurocognitive function. Finally, a third aim was to examine the contribution of PTSD symptom severity to observed white matter alterations. One hundred fourteen OEF/OIF veterans underwent DTI and neuropsychological examination and were divided into three groups including a control group, blast-related mTBI without LOC (mTBI-LOC) group, and blast-related mTBI with LOC (mTBI + LOC) group. Hierarchical regression models were used to examine the extent to which mTBI and PTSD predicted white matter abnormalities using two approaches: 1) a region-specific analysis and 2) a measure of spatial heterogeneity. Neurocognitive composite scores were calculated for executive functions, attention, memory, and psychomotor speed. Results showed that blast-related mTBI + LOC was associated with greater odds of having spatially heterogeneous white matter abnormalities. Region-specific reduction in fractional anisotropy (FA) in the left retrolenticular part of the internal capsule was observed in the mTBI + LOC group as the number of blast exposures increased. A mediation analysis revealed that mTBI + LOC indirectly influenced verbal memory performance through its effect on white matter integrity. PTSD was not associated with spatially heterogeneous white matter abnormalities. However, there was a suggestion that at higher levels of PTSD symptom severity, LOC was associated with reduced FA in the left retrolenticular part of the internal capsule. These results support postmortem reports of diffuse axonal injury following mTBI and suggest that injuries with LOC involvement may be particularly detrimental to white matter integrity. Furthermore, these results suggest that LOC-associatedwhitematter abnormalities in turn influence neurocognitive function. Published by Elsevier Inc.	[Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Hayes, Jasmeet P.; Lafleche, Ginette; Verfaellie, Mieke] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Hayes, Jasmeet P.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA; [Miller, Danielle R.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Miller, Danielle R.; Lafleche, Ginette; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA; [Salat, David H.] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02115 USA; [Salat, David H.] Harvard Univ, Sch Med, Boston, MA USA	Hayes, JP (corresponding author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, 150 S Huntington Ave, Boston, MA 02130 USA.	jphayes@bu.edu	Hayes, Jasmeet/AAN-4150-2020	Hayes, Jasmeet/0000-0002-5157-0666; Verfaellie, Mieke/0000-0001-5535-4584; Sullivan, Danielle R./0000-0002-0141-5887	VA Merit ReviewUS Department of Veterans Affairs [822-MR-18176]; NIH grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23MH084013]; National Center for PTSD; VA Clinical Science Research and Development Service; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH084013] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000216] Funding Source: NIH RePORTER	This work was supported by VA Merit Review 822-MR-18176 (awarded to M.V.), NIH grant K23MH084013 (awarded to J.P.H.), the National Center for PTSD, and the VA Clinical Science Research and Development Service.	Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Bruce ML, 2010, ANN NY ACAD SCI, V1208, P98, DOI 10.1111/j.1749-6632.2010.05697.x; Calabrese E, 2014, J NEUROTRAUM, V31, P938, DOI 10.1089/neu.2013.3144; Cercignani M, 2003, AM J NEURORADIOL, V24, P638; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hayes A. F., 2014, BRIT J MATH STAT PSY; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kanagaratnam P, 2007, J ANXIETY DISORD, V21, P510, DOI 10.1016/j.janxdis.2006.06.008; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Taber K. H., 2015, J HEAD TRAUMA REHABI; Tombaugh TN, 1996, TEST MEMORY MALINGER; Ursano RJ, 2010, ANN NY ACAD SCI, V1208, P72, DOI 10.1111/j.1749-6632.2010.05721.x; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Watts R, 2014, RADIOLOGY, V272, P217, DOI 10.1148/radiol.14131856; Weathers F., 1991, PTSD CHECKLIST MILIT; Wechsler D., 2001, WECHSLER TEST ADULT; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	45	52	53	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	8						148	156		10.1016/j.nicl.2015.04.001			9	Neuroimaging	Neurosciences & Neurology	DI0LE	WOS:000373187100016	26106539	DOAJ Gold, Green Published			2021-06-18	
J	Solanki, N; Alkadhi, I; Atrooz, F; Patki, G; Salim, S				Solanki, Naimesh; Alkadhi, Isam; Atrooz, Fatin; Patki, Gaurav; Salim, Samina			Grape powder prevents cognitive, behavioral, and biochemical impairments in a rat model of posttraumatic stress disorder	NUTRITION RESEARCH			English	Article						single-prolonged stress; PTSD; depression; anxiety; cognition; grape powder	ANXIETY-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; NEUROTROPHIC FACTOR; MEMORY IMPAIRMENT; SEED EXTRACT; BDNF GENE; EPIGENETIC REGULATION; SOCIAL DEFEAT	Previously, using the single-prolonged stress (SPS) rat model of posttraumatic stress disorder, we reported that moderate treadmill exercise, via modulation of oxidative stress-related mechanisms, rescued anxiety- and depression-like behaviors and reversed SPS-induced memory impairment. In this study using the SPS model (2-hour restrain, 20-minute forced swimming, 15-minute rest, and 1-2 minute diethyl ether exposure), we hypothesized that antioxidant rich grape powder (GP) prevents SPS-induced behavioral and memory impairment in rats. Male Sprague Dawley rats were randomly assigned into control (CON) (provided tap water), SPS (provided tap water), GP-SPS (provided 15 g/L GP in tap water for 3 weeks followed by SPS), or GP-CON (3 weeks of GP followed by CON exposure). Anxiety- and depression-like behaviors were significantly greater in SPS rats, when compared with CON- or GP-treated rats, and GP reversed these behavioral deficits. Single-prolonged stress rats made significantly more errors in both short- and long-term memory tests compared with CON- or GP-treated rats, which were prevented in GP-SPS rats. Grape powder prevented SPS-induced increase in plasma corticosterone level. Furthermore, brain-derived neurotrophic factor levels were significantly decreased in amygdala of SPS rats but not in GP-SPS rats compared with CON or GP-CON rats. In addition, GP significantly increased acetylated histone 3 and histone deacetylase 5 in hippocampus and amygdala of SPS rats as compared with CON or GP-CON rats. In conclusion, we suggest protective role of GP in SPS-induced behavioral, cognitive, and biochemical impairments in rats. Perhaps, epigenetic regulation of brain-derived neurotrophic factor enables GP-mediated prevention of SPS-induced deficits in rats. Published by Elsevier Inc.	[Solanki, Naimesh; Alkadhi, Isam; Atrooz, Fatin; Patki, Gaurav; Salim, Samina] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77251 USA	Salim, S (corresponding author), Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77251 USA.	ssalim@uh.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R15 G103327]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R15MH093918] Funding Source: NIH RePORTER	Funding for this research was provided by National Institutes of Health R15 G103327 grant awarded to Samina Salim.	Allam F, 2013, J NUTR, V143, P835, DOI 10.3945/jn.113.174649; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Balu M, 2006, BRAIN RES BULL, V68, P469, DOI 10.1016/j.brainresbull.2005.10.007; Beck CT, 2011, ARCH PSYCHIAT NURS, V25, P1, DOI 10.1016/j.apnu.2010.05.005; Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004; Bert B, 2002, NEUROBIOL LEARN MEM, V78, P11, DOI 10.1006/nlme.2001.4040; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Bouayed J, 2007, EUR J PHARMACOL, V564, P146, DOI 10.1016/j.ejphar.2007.02.055; Boulle F, 2012, MOL PSYCHIATR, V17, P584, DOI 10.1038/mp.2011.107; Calvo N, 2011, NEUROSCIENCE, V183, P81, DOI 10.1016/j.neuroscience.2011.03.046; Carpagnano GE, 2003, CHEST, V124, P1386, DOI 10.1378/chest.124.4.1386; Cougle JR, 2009, BEHAV RES THER, V47, P1012, DOI 10.1016/j.brat.2009.07.014; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; de Assis MA, 2008, CLINICS, V63, P473, DOI 10.1590/S1807-59322008000400010; de Oliveira MR, 2007, NEUROTOXICOLOGY, V28, P1191, DOI 10.1016/j.neuro.2007.07.008; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Devi SA, 2006, MED SCI MONITOR, V12, pBR124; El-Alfy AT, 2005, PHARMACOL RES, V52, P264, DOI 10.1016/j.phrs.2005.04.003; Fuchikami M, 2010, PSYCHIAT INVEST, V7, P251, DOI 10.4306/pi.2010.7.4.251; Fuchikami M, 2009, INT J NEUROPSYCHOPH, V12, P73, DOI 10.1017/S1461145708008997; Fuhrman B, 2005, J NUTR, V135, P722; Gingrich JA, 2005, NAT MED, V11, P1281, DOI 10.1038/nm1205-1281; Halliwell B, 2005, AM J CLIN NUTR, V81, p268S, DOI 10.1093/ajcn/81.1.268S; Hovatta I, 2010, NEUROSCI RES, V68, P261, DOI 10.1016/j.neures.2010.08.007; Hwang IK, 2004, LIFE SCI, V75, P1989, DOI 10.1016/j.lfs.2004.05.013; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Janle EM, 2010, J MED FOOD, V13, P926, DOI 10.1089/jmf.2009.0157; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kohda K, 2007, NEUROSCIENCE, V148, P22, DOI 10.1016/j.neuroscience.2007.05.041; Lee BH, 2010, PSYCHIAT INVEST, V7, P231, DOI 10.4306/pi.2010.7.4.231; Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9; Masood A, 2008, J PHARMACOL EXP THER, V326, P369, DOI 10.1124/jpet.108.137208; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Narita K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014575; Patki G, 2013, BRAIN RES, VS0006-8993; Patki G, 2013, BRAIN RES, V1539, P73, DOI 10.1016/j.brainres.2013.09.033; Patki G, 2014, PHYSIOL BEHAV, V130, P135, DOI 10.1016/j.physbeh.2014.04.011; Patki G, 2014, PHYSIOL BEHAV, V130, P47, DOI 10.1016/j.physbeh.2014.03.016; Patki G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074522; Pezzuto JM, 2008, J AGR FOOD CHEM, V56, P6777, DOI 10.1021/jf800898p; Pezzuto JM, 2009, J NUTR, V139, p1783S, DOI 10.3945/jn.109.107458; Pinent M, 2004, ENDOCRINOLOGY, V145, P4985, DOI 10.1210/en.2004-0764; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Salim S, 2010, BRAIN RES, V1359, P178, DOI 10.1016/j.brainres.2010.08.093; Salim S, 2010, BEHAV BRAIN RES, V208, P545, DOI 10.1016/j.bbr.2009.12.039; Shukitt-Hale B, 2006, NUTRITION, V22, P295, DOI 10.1016/j.nut.2005.07.016; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thomas P, 2009, MUTAT RES-FUND MOL M, V661, P25, DOI 10.1016/j.mrfmmm.2008.10.016; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Virgili M, 2000, NEUROSCI LETT, V281, P123, DOI 10.1016/S0304-3940(00)00820-X; Vislocky LM, 2013, NUTR TODAY, V48, P47, DOI DOI 10.1097/NT.0B013E31823DB374; Vollert C, 2011, BEHAV BRAIN RES, V224, P233, DOI 10.1016/j.bbr.2011.05.010; Wang YJ, 2009, NEUROTOX RES, V15, P3, DOI 10.1007/s12640-009-9000-x; Wilson CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076146; Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629; YEHUDA R, 1993, BIOL PSYCHIAT, V33, P479, DOI 10.1016/0006-3223(93)90001-T; Yoshii T, 2008, NEUROSCIENCE, V156, P466, DOI 10.1016/j.neuroscience.2008.07.049; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zhuang H, 2003, ANN NY ACAD SCI, V993, P87	64	52	52	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0271-5317			NUTR RES	Nutr. Res.	JAN	2015	35	1					65	75		10.1016/j.nutres.2014.11.008			11	Nutrition & Dietetics	Nutrition & Dietetics	AY7MX	WOS:000347745200009	25533441	Green Accepted			2021-06-18	
J	Clausen, BH; Degn, M; Martin, NA; Couch, Y; Karimi, L; Ormhoj, M; Mortensen, MLB; Gredal, HB; Gardiner, C; Sargent, IIL; Szymkowski, DE; Petit, GH; Deierborg, T; Finsen, B; Anthony, DC; Lambertsen, KL				Clausen, Bettina Hjelm; Degn, Matilda; Martin, Nellie Anne; Couch, Yvonne; Karimi, Leena; Ormhoj, Maria; Mortensen, Maria-Louise Bergholdt; Gredal, Hanne Birgit; Gardiner, Chris; Sargent, Ian I. L.; Szymkowski, David E.; Petit, Geraldine H.; Deierborg, Tomas; Finsen, Bente; Anthony, Daniel Clive; Lambertsen, Kate Lykke			Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia	JOURNAL OF NEUROINFLAMMATION			English	Article						SolTNF and tmTNF; Granulocytes; Behavior; Acute phase response; Microvesicle; Inflammation	TUMOR-NECROSIS-FACTOR; MICROGLIAL-MACROPHAGE SYNTHESIS; TRAUMATIC BRAIN-INJURY; FACTOR-ALPHA; CHRONIC STROKE; ETANERCEPT; MODEL; MICE; EXPRESSION; PROTECTS	Background: The innate immune system contributes to the outcome after stroke, where neuroinflammation and post-stroke systemic immune depression are central features. Tumor necrosis factor (TNF), which exists in both a transmembrane (tm) and soluble (sol) form, is known to sustain complex inflammatory responses associated with stroke. We tested the effect of systemically blocking only solTNF versus blocking both tmTNF and solTNF on infarct volume, functional outcome and inflammation in focal cerebral ischemia. Methods: We used XPro1595 (a dominant-negative inhibitor of solTNF) and etanercept (which blocks both solTNF and tmTNF) to test the effect of systemic administration on infarct volume, functional recovery and inflammation after focal cerebral ischemia in mice. Functional recovery was evaluated after one, three and five days, and infarct volumes at six hours, 24 hours and five days after ischemia. Brain inflammation, liver acute phase response (APR), spleen and blood leukocyte profiles, along with plasma microvesicle analysis, were evaluated. Results: We found that both XPro1595 and etanercept significantly improved functional outcomes, altered microglial responses, and modified APR, spleen T cell and microvesicle numbers, but without affecting infarct volumes. Conclusions: Our data suggest that XPro1595 and etanercept improve functional outcome after focal cerebral ischemia by altering the peripheral immune response, changing blood and spleen cell populations and decreasing granulocyte infiltration into the brain. Blocking solTNF, using XPro1595, was just as efficient as blocking both solTNF and tmTNF using etanercept. Our findings may have implications for future treatments with anti-TNF drugs in TNF-dependent diseases.	[Clausen, Bettina Hjelm; Martin, Nellie Anne; Couch, Yvonne; Karimi, Leena; Ormhoj, Maria; Mortensen, Maria-Louise Bergholdt; Gredal, Hanne Birgit; Finsen, Bente; Anthony, Daniel Clive; Lambertsen, Kate Lykke] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, DK-5000 Odense, Denmark; [Degn, Matilda] Glostrup Cty Hosp, Dept Diagnost, Mol Sleep Lab, DK-2600 Glostrup, Denmark; [Couch, Yvonne; Anthony, Daniel Clive] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; [Gardiner, Chris; Sargent, Ian I. L.] Univ Oxford, Nuffield Dept Obstet & Gynecol, Oxford OX1 3QT, England; [Petit, Geraldine H.; Deierborg, Tomas] Lund Univ, Dept Clin Sci, Neuronal Survival Unit, Lab Expt Med Sci, S-22100 Lund, Sweden; [Szymkowski, David E.] Xencor Inc, Monrovia, CA 91016 USA; [Gredal, Hanne Birgit] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet Clin & Anim Sci, DK-1870 Frederiksberg, Denmark	Lambertsen, KL (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, JB Winsloewsvej 21, DK-5000 Odense, Denmark.	klambertsen@health.sdu.dk	Deierborg, Tomas/P-6345-2015; Gardiner, Chris/F-1178-2011; Anthony, Daniel C/F-7765-2010; Lambertsen, Kate L./I-8676-2014	Deierborg, Tomas/0000-0002-3651-3444; Gardiner, Chris/0000-0002-2318-0062; Anthony, Daniel C/0000-0003-1380-6655; Ormhoj, Maria/0000-0002-0997-8262; Degn, Matilda/0000-0003-3093-3525; Lambertsen, Kate L./0000-0001-9276-4902; Szymkowski, David/0000-0002-8934-7902; Finsen, Bente/0000-0002-8323-9329; Clausen, Bettina Hjelm/0000-0003-3302-2022; Gredal, Hanne/0000-0001-5582-1816	Lundbeck Foundation, Copenhagen, DenmarkLundbeckfonden [R54-A5539, R67-A6383]; Novo Nordisk Foundation, Hellerup, DenmarkNovo Nordisk Foundation [R153-A-12550, R168-A14120]; Carlsberg Foundation, Copenhagen, DenmarkCarlsberg Foundation [2007_01_0176]; Fonden til Laegevidenskabens Fremme; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/J003360/1] Funding Source: researchfish	We acknowledge skilled technical help from technicians Louise Lykkemark, Dorte Lyholmer, Signe Marie Andersen and Sussanne Petersen. This work was supported by research grants from the Lundbeck Foundation, Copenhagen, Denmark (KLL (R54-A5539) and BHC (R67-A6383)), the Novo Nordisk Foundation, Hellerup, Denmark (R153-A-12550 and R168-A14120) and the Carlsberg Foundation, Copenhagen, Denmark (KLL, 2007_01_0176). Fonden til Laegevidenskabens Fremme is also acknowledged for their financial support.	Alexopoulou L, 2006, EUR J IMMUNOL, V36, P2768, DOI 10.1002/eji.200635921; Azevedo Luciano C P, 2007, Recent Pat Cardiovasc Drug Discov, V2, P41, DOI 10.2174/157489007779606121; Barnum CJ, 2014, J PARKINSON DIS, V4, P349, DOI 10.3233/JPD-140410; Bautista LE, 2005, J HUM HYPERTENS, V19, P149, DOI 10.1038/sj.jhh.1001785; Boettger MK, 2008, ARTHRITIS RHEUM-US, V58, P2368, DOI 10.1002/art.23608; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Couch Y, 2013, BRAIN BEHAV IMMUN, V29, P136, DOI 10.1016/j.bbi.2012.12.017; Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Johansen Flemming Fryd, 2003, J Stroke Cerebrovasc Dis, V12, P97; King MD, 2013, NEUROSCI LETT, V542, P92, DOI 10.1016/j.neulet.2013.02.051; Lambertsen KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047744; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Li K, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/901420; Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006; Nielsen HH, 2011, AM J PATHOL, V179, P2028, DOI 10.1016/j.ajpath.2011.06.006; Novrup HG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0159-6; Olleros ML, 2009, J INFECT DIS, V199, P1053, DOI 10.1086/597204; Petit GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060691; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ruuls SR, 2001, IMMUNITY, V15, P533, DOI 10.1016/S1074-7613(01)00215-1; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Scheinfeld N, 2004, J Dermatolog Treat, V15, P280; Shen C, 2005, CLIN IMMUNOL, V115, P250, DOI 10.1016/j.clim.2005.01.007; Simak J, 2006, J THROMB HAEMOST, V4, P1296, DOI 10.1111/j.1538-7836.2006.01911.x; Soriano SG, 1999, STROKE, V30, P134, DOI 10.1161/01.STR.30.1.134; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Sumbria RK, 2012, J CEREBR BLOOD F MET, V32, P1933, DOI 10.1038/jcbfm.2012.97; Taylor PC, 2009, NAT REV RHEUMATOL, V5, P578, DOI 10.1038/nrrheum.2009.181; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tobinick E, 2011, CNS DRUGS, V25, P145, DOI 10.2165/11588400-000000000-00000; Tyring S, 2006, LANCET, V367, P29, DOI 10.1016/S0140-6736(05)67763-X; Venegas-Pont M, 2010, HYPERTENSION, V56, P643, DOI 10.1161/HYPERTENSIONAHA.110.157685; Verderio C, 2012, ANN NEUROL, V72, P610, DOI 10.1002/ana.23627; Yu NC, 1998, NEUROIMMUNOMODULAT, V5, P42, DOI 10.1159/000026325; Zalevsky J, 2007, J IMMUNOL, V179, P1872, DOI 10.4049/jimmunol.179.3.1872	45	52	52	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 12	2014	11								203	10.1186/s12974-014-0203-6			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AY2NH	WOS:000347426400001	25498129	DOAJ Gold, Green Published			2021-06-18	
J	Takematsu, M; Hoffman, RS; Nelson, LS; Schechter, JM; Moran, JH; Wiener, SW				Takematsu, M.; Hoffman, R. S.; Nelson, L. S.; Schechter, J. M.; Moran, J. H.; Wiener, S. W.			A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid	CLINICAL TOXICOLOGY			English	Article						Synthetic cannabinoid; Ischemic stroke; XLR-11; JWH-018; Marijuana; Acute kidney injury	QUANTITATIVE MEASUREMENT; METABOLITES; JWH-018	Objective. Synthetic cannabinoids are increasingly used in the United States as marijuana substitutes. However, reports of severe toxicity, resulting from their use, are limited. We present the case of acute cerebral infarction following synthetic cannabinoid inhalation. Case report. A 33-year-old man with no significant medical history presented at the emergency department with right-sided weakness and aphasia. He had smoked a synthetic cannabinoid (SC) product called "WTF" prior to the onset of symptoms. Physical examination showed right hemiparesis, dysarthria, and aphasia. Laboratory evaluation, electrocardiography, and computed tomography (CT) of the head were unremarkable. Following administration of intravenous tissue plasminogen activator, his symptoms improved. A repeat head CT showed acute infarction in the left insular cortex. His hypercoagulability panel was unremarkable, and the patient was discharged neurologically intact. Urine toxicology results were unremarkable. Analysis of the product by gas chromatography-mass spectrometry (GC-MS) procedure confirmed the presence of a synthetic cannabinoid known as XLR-11. Conclusion. XLR-11 has previously been associated with acute kidney injury in humans. However, there are no reports of it causing acute cerebral ischemic events. The close temporal association between XLR-11 inhalation and his stroke is concerning. Acute cerebral infarction may occur after XLR-11 use in healthy patients.	[Takematsu, M.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Emergency Med, Div Med Toxicol, New York, NY 10467 USA; [Hoffman, R. S.; Nelson, L. S.] NYU, Sch Med, Dept Emergency Med, Div Med Toxicol, New York, NY USA; [Nelson, L. S.] New York City Poison Control Ctr, New York, NY USA; [Schechter, J. M.; Wiener, S. W.] Suny Downstate Med Ctr, Dept Emergency Med, Brooklyn, NY 11203 USA; [Schechter, J. M.; Wiener, S. W.] Kings Cty Hosp, Dept Emergency Med, New York, NY USA; [Moran, J. H.] Arkansas Dept Hlth, Arkansas Publ Hlth Lab, Little Rock, AR 72205 USA	Takematsu, M (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Emergency Med, Div Med Toxicol, 111 E210 St, New York, NY 10467 USA.	mtakemat@montefiore.org		Hoffman, Robert/0000-0002-0091-9573; Nelson, Lewis/0000-0001-9551-3922			BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brust JCM, 2013, NEUROLOGY, V81, P2064, DOI 10.1212/01.wnl.0000437310.96160.fa; Chimalakonda KC, 2011, ANAL CHEM, V83, P6381, DOI 10.1021/ac201377m; Freeman MJ, 2013, NEUROLOGY, V81, P2090, DOI 10.1212/01.wnl.0000437297.05570.a2; Hillebrand J, 2010, SUBST USE MISUSE, V45, P330, DOI 10.3109/10826080903443628; Lapoint J, 2011, CLIN TOXICOL, V49, P760, DOI 10.3109/15563650.2011.609822; Mir A, 2011, PEDIATRICS, V128, pE1622, DOI 10.1542/peds.2010-3823; Moran CL, 2011, ANAL CHEM, V83, P4228, DOI 10.1021/ac2005636; Murphy TD, 2013, MMWR-MORBID MORTAL W, V62, P93; Patton AL, 2013, ANAL CHEM, V85, P9390, DOI 10.1021/ac4024704; Schneir AB, 2011, J EMERG MED, V40, P296, DOI 10.1016/j.jemermed.2010.10.014; Seely KA, 2011, MOL INTERV, V11, P36, DOI 10.1124/mi.11.1.6; Simmons JR, 2011, ANN EMERG MED, V57, P187, DOI 10.1016/j.annemergmed.2010.08.039	13	52	52	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	NOV	2014	52	9					973	975		10.3109/15563650.2014.958614			3	Toxicology	Toxicology	AS6FH	WOS:000344359400010	25241766				2021-06-18	
J	Dada, T; Rosenzweig, JM; Al Shammary, M; Firdaus, W; Al Rebh, S; Borbiev, T; Tekes, A; Zhang, JY; Alqahtani, E; Mori, S; Pletnikov, MV; Johnston, MV; Burd, I				Dada, Tahani; Rosenzweig, Jason M.; Al Shammary, Mofeedah; Firdaus, Wance; Al Rebh, Shorouq; Borbiev, Talaibek; Tekes, Aylin; Zhang, Jiangyang; Alqahtani, Eman; Mori, Susumu; Pletnikov, Mikhail V.; Johnston, Michael V.; Burd, Irina			Mouse model of intrauterine inflammation: Sex-specific differences in long-term neurologic and immune sequelae	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Intrauterine inflammation; Preterm birth; Mouse model; Lipopolysaccharide; Brain damage; MRI; Behavior	TRAUMATIC BRAIN-INJURY; INDUCED PRETERM BIRTH; GESTATIONAL-AGE; CEREBRAL-PALSY; RISK-FACTOR; FETAL; CHORIOAMNIONITIS; MICROGLIA; LIPOPOLYSACCHARIDE; INFECTION	Preterm infants, especially those that are exposed to prenatal intrauterine infection or inflammation, are at a major risk for adverse neurological outcomes, including cognitive, motor and behavioral disabilities. We have previously shown in a mouse model that there is an acute fetal brain insult associated with intrauterine inflammation. The objectives of this study were: (1) to elucidate long-term (into adolescence and adulthood) neurological outcomes by assessing neurobehavioral development, MRI, immunohistochemistry and flow cytometry of cells of immune origin and (2) to determine whether there are any sex-specific differences in brain development associated with intrauterine inflammation. Our results have shown that prenatal exposure appeared to lead to changes in MRI and behavior patterns throughout the neonatal period and during adulthood. Furthermore, we observed chronic brain inflammation in the offspring, with persistence of microglial activation and increased numbers of macrophages in the brain, ultimately resulting in neuronal loss. Moreover, our study highlights the sex-specific differences in long-term sequelae. This study, while extending the growing literature of adverse neurologic outcomes following exposure to inflammation during early development, presents novel findings in the context of intrauterine inflammation. (C) 2014 Elsevier Inc. All rights reserved.	[Dada, Tahani; Rosenzweig, Jason M.; Al Shammary, Mofeedah; Firdaus, Wance; Al Rebh, Shorouq; Borbiev, Talaibek; Burd, Irina] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Integrated Res Ctr Fetal Med, Baltimore, MD 21205 USA; [Tekes, Aylin; Zhang, Jiangyang; Alqahtani, Eman; Mori, Susumu] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA; [Pletnikov, Mikhail V.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Johnston, Michael V.; Burd, Irina] Kennedy Krieger Inst, Dept Neurosci, Baltimore, MD USA; [Burd, Irina] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Burd, I (corresponding author), Johns Hopkins Univ Hosp, Dept Gynecol & Obstet, Integrated Res Ctr Fetal Med, Phipps 228,600 North Wolfe St, Baltimore, MD 21287 USA.	iburd@jhmi.edu	Pletnikov, Mikhail V/G-8709-2012	Burd, Irina/0000-0001-7256-7784; Zhang, Jiangyang/0000-0003-4146-8163; Zhang, Jiangyang/0000-0003-0740-2662	Aramco Services Company Fellowship Fund; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073315]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS28208]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 EB003543]; Brain Science Institute, Johns Hopkins; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD074593, K08HD073315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB003543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH094268, R01MH083728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS028208] Funding Source: NIH RePORTER	This work was supported by Aramco Services Company Fellowship Fund (W.F., J.M.R.), NICHD K08HD073315 (I.B.), NINDS NS28208 (M.J.), NIH RO1 EB003543 (S.M.), and a grant support from Brain Science Institute, Johns Hopkins (SM).	Ashdown H, 2006, MOL PSYCHIATR, V11, P47, DOI 10.1038/sj.mp.4001748; Ayhan Y, 2011, MOL PSYCHIATR, V16, P293, DOI 10.1038/mp.2009.144; Balakrishnan B, 2013, DEV NEUROSCI-BASEL, V35, P396, DOI 10.1159/000353156; Beloosesky R, 2006, AM J OBSTET GYNECOL, V194, P268, DOI 10.1016/j.ajog.2005.06.082; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Burd I., 2010, AM J OBSTET GYNECOL, V202, pe1; Burd I, 2012, AM J REPROD IMMUNOL, V67, P287, DOI 10.1111/j.1600-0897.2012.01110.x; Burd I, 2011, REPROD SCI, V18, P900, DOI 10.1177/1933719111398498; Burd I, 2009, AM J OBSTET GYNECOL, V201, pS3, DOI 10.1016/j.ajog.2009.10.018; Burd I, 2010, J NEUROSCI RES, V88, P1872, DOI 10.1002/jnr.22368; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Cheng Y, 2011, NEUROIMAGE, V56, P1027, DOI 10.1016/j.neuroimage.2011.02.022; Dammann O, 2008, CLIN PERINATOL, V35, P643, DOI 10.1016/j.clp.2008.07.011; de Vries LS, 2009, ANN NEUROL, V66, P127, DOI 10.1002/ana.21761; Elovitz MA, 2003, AM J PATHOL, V163, P2103, DOI 10.1016/S0002-9440(10)63567-5; Elovitz MA, 2011, INT J DEV NEUROSCI, V29, P663, DOI 10.1016/j.ijdevneu.2011.02.011; Glass H.C., 2009, J PEDIAT, V154, pe1; Hagberg H, 2005, CURR OPIN NEUROL, V18, P117, DOI 10.1097/01.wco.0000162851.44897.8f; Hamilton BE, 2013, PEDIATRICS, V131, P548, DOI 10.1542/peds.2012-3769; Hill Joanna M., 2008, V39, P131, DOI 10.1007/978-1-60327-099-1_10; Hsiao EY, 2012, P NATL ACAD SCI USA, V109, P12776, DOI 10.1073/pnas.1202556109; Hsiao EY, 2011, BRAIN BEHAV IMMUN, V25, P604, DOI 10.1016/j.bbi.2010.12.017; Johnson S, 2010, J AM ACAD CHILD PSY, V49, P453, DOI 10.1016/j.jaac.2010.02.002; Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041; Johnston MV, 2007, DEV MED CHILD NEUROL, V49, P74, DOI 10.1017/S0012162207000199; Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162; Kapellou O, 2006, PLOS MED, V3, P1382, DOI 10.1371/journal.pmed.0030265; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Lieblein-Boff JC, 2013, J NEUROSCI, V33, P16334, DOI 10.1523/JNEUROSCI.0708-13.2013; Linnet KM, 2006, ARCH DIS CHILD, V91, P655, DOI 10.1136/adc.2005.088872; Malaeb S, 2009, J CHILD NEUROL, V24, P1119, DOI 10.1177/0883073809338066; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Saadani-Makki F, 2009, J CHILD NEUROL, V24, P1179, DOI 10.1177/0883073809338213; Schendel D, 2008, PEDIATRICS, V121, P1155, DOI 10.1542/peds.2007-1049; Schwarz JM, 2012, J NEUROCHEM, V120, P948, DOI 10.1111/j.1471-4159.2011.07630.x; Sharma J, 2011, ASN NEURO, V3, DOI 10.1042/AN20100032; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Williamson LL, 2013, BRAIN BEHAV IMMUN, V30, P186, DOI 10.1016/j.bbi.2013.01.077; Williamson LL, 2011, J NEUROSCI, V31, P15511, DOI 10.1523/JNEUROSCI.3688-11.2011; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Yoon BH, 2000, AM J OBSTET GYNECOL, V182, P675, DOI 10.1067/mob.2000.104207	45	52	52	1	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2014	38						142	150		10.1016/j.bbi.2014.01.014			9	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	AF8RU	WOS:000334984100016	24486323	Green Accepted			2021-06-18	
J	Depue, BE; Olson-Madden, JH; Smolker, HR; Rajamani, M; Brenner, LA; Banich, MT				Depue, B. E.; Olson-Madden, J. H.; Smolker, H. R.; Rajamani, M.; Brenner, L. A.; Banich, M. T.			Reduced Amygdala Volume Is Associated with Deficits in Inhibitory Control: A Voxel- and Surface-Based Morphometric Analysis of Comorbid PTSD/Mild TBI	BIOMED RESEARCH INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; HIPPOCAMPAL VOLUME; NEUROCIRCUITRY MODELS; BASOLATERAL AMYGDALA; FUNCTIONAL MRI; METAANALYSIS; SYMPTOMS; VETERANS	A significant portion of previously deployed combat Veterans from Operation Enduring Freedom and Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) are affected by comorbid posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI). Despite this fact, neuroimaging studies investigating the neural correlates of cognitive dysfunction within this population are almost nonexistent, with the exception of research examining the neural correlates of diagnostic PTSD or TBI. The current study used both voxel-based and surface-based morphometry to determine whether comorbid PTSD/mTBI is characterized by altered brain structure in the same regions as observed in singular diagnostic PTSD or TBI. Furthermore, we assessed whether alterations in brain structures in these regions were associated with behavioral measures related to inhibitory control, as assessed by the Go/No-go task, self-reports of impulsivity, and/or PTSD or mTBI symptoms. Results indicate volumetric reductions in the bilateral anterior amygdala in our comorbid PTSD/mTBI sample as compared to a control sample of OEF/OIF Veterans with no history of mTBI and/or PTSD. Moreover, increased volume reduction in the amygdala predicted poorer inhibitory control as measured by performance on the Go/No-go task, increased self-reported impulsivity, and greater symptoms associated with PTSD. These findings suggest that alterations in brain anatomy in OEF/OIF/OND Veterans with comorbid PTSD/mTBI are associated with both cognitive deficits and trauma symptoms related to PTSD.	[Depue, B. E.; Smolker, H. R.; Banich, M. T.] Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA; [Depue, B. E.; Banich, M. T.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Olson-Madden, J. H.; Rajamani, M.; Brenner, L. A.] VISN, Mental Illness Res Educ & Clin Ctr 19, Denver, CO 80220 USA; [Olson-Madden, J. H.; Brenner, L. A.] Univ Colorado Denver, Aurora, CO 80045 USA	Depue, BE (corresponding author), Univ Colorado, Inst Cognit Sci, Boulder, CO 80309 USA.	depue@colorado.edu	Brenner, Lisa A./AAG-2442-2019	BANICH, MARIE/0000-0001-9373-9194	Colorado Traumatic Brain Injury Trust Fund Program	Support for this project was provided by the Colorado Traumatic Brain Injury Trust Fund Program.	Allen L.M., 1997, CARB 97 MANUAL COMPU; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bonne O, 2001, AM J PSYCHIAT, V158, P1248, DOI 10.1176/appi.ajp.158.8.1248; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Briere J., 1996, TRAUMA SYMPTOM INVEN; Bryant RA, 2011, J CLIN PSYCHIAT, V72, P233, DOI 10.4088/JCP.09r05072blu; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; De Bellis MD, 2001, BIOL PSYCHIAT, V50, P305, DOI 10.1016/S0006-3223(01)01105-2; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Epstein JN, 2007, J CHILD PSYCHOL PSYC, V48, P899, DOI 10.1111/j.1469-7610.2007.01761.x; Etkin A, 2004, NEURON, V44, P1043, DOI 10.1016/j.neuron.2004.12.006; Falconer E., 2008, J PSYCHIATR NEUROSCI, V33, P413; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Good CD, 2001, NEUROIMAGE, V14, P685, DOI 10.1006/nimg.2001.0857; Gopal A, 2013, PSYCHIAT RES-NEUROIM, V211, P24, DOI 10.1016/j.pscychresns.2012.10.010; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Hastie T., 2009, LINEAR METHODS REGRE; Hedges DW, 2010, COGN BEHAV NEUROL, V23, P124, DOI 10.1097/WNN.0b013e3181e1cbe1; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Hoge C. W., 2008, US ARMY MED DEP J; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Imielinska C., 2006, INFORM VISUAL, V5, P279, DOI DOI 10.1057/PALGRAVE.IVS.9500137; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Lanius RA, 2001, AM J PSYCHIAT, V158, P1920, DOI 10.1176/appi.ajp.158.11.1920; Lui S., 2013, J PSYCHIATR NEUROSCI, V38; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mollica RF, 2009, ARCH GEN PSYCHIAT, V66, P1221, DOI 10.1001/archgenpsychiatry.2009.127; Morey RA, 2009, J PSYCHIATR RES, V43, P809, DOI 10.1016/j.jpsychires.2008.10.014; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Royer S, 1999, J NEUROSCI, V19, P10575; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102; Spitzer R. l., 1995, STRUCTURED CLIN INTE; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Whalen PJ, 2001, EMOTION, V1, P70, DOI 10.1037/1528-3542.1.1.70; Winstanley CA, 2004, J NEUROSCI, V24, P4718, DOI 10.1523/JNEUROSCI.5606-03.2004; Winter H, 2004, AM J PSYCHIAT, V161, P2194, DOI 10.1176/appi.ajp.161.12.2194; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Zachary R. A., 1986, SHIPLEY I LIVING SCA	75	52	52	1	12	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2014	2014								691505	10.1155/2014/691505			11	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	AD0MY	WOS:000332929700001	24724093	DOAJ Gold, Green Published			2021-06-18	
J	Ryu, J; Horkayne-Szakaly, I; Xu, L; Pletnikova, O; Leri, F; Eberhart, C; Troncoso, JC; Koliatsos, VE				Ryu, Jiwon; Horkayne-Szakaly, Iren; Xu, Leyan; Pletnikova, Olga; Leri, Francesco; Eberhart, Charles; Troncoso, Juan C.; Koliatsos, Vassilis E.			The problem of axonal injury in the brains of veterans with histories of blast exposure	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Traumatic brain injury; Diffuse axonal injury; APP; Axon bulbs; Opiate; Microglia	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; POSTCONCUSSIVE SYMPTOMS; EXPERIMENTAL-MODELS; HEAD-INJURY; BETA-APP; MILD; ACCUMULATION; DEGENERATION	Introduction: Blast injury to brain, a hundred-year old problem with poorly characterized neuropathology, has resurfaced as health concern in recent deployments in Iraq and Afghanistan. To characterize the neuropathology of blast injury, we examined the brains of veterans for the presence of amyloid precursor protein (APP)-positive axonal swellings typical of diffuse axonal injury (DAI) and compared them to healthy controls as well as controls with opiate overdose, anoxic-ischemic encephalopathy, and non-blast TBI (falls and motor vehicle crashes). Results: In cases with blast history, we found APP (+) axonal abnormalities in several brain sites, especially the medial dorsal frontal white matter. In white matter, these abnormalities were featured primarily by clusters of axonal spheroids or varicosities in a honeycomb pattern with perivascular distribution. Axonal abnormalities colocalized with IBA1 (+) reactive microglia and had an appearance that was distinct from classical DAI encountered in TBI due to motor vehicle crashes. Opiate overdose cases also showed APP (+) axonal abnormalities, but the intensity of these lesions was lower compared to cases with blast histories and there was no clear association of such lesions with microglial activation. Conclusions: Our findings demonstrate that many cases with history of blast exposure are featured by APP (+) axonopathy that may be related to blast exposure, but an important role for opiate overdose, antemortem anoxia, and concurrent blunt TBI events in war theater or elsewhere cannot be discounted.	[Ryu, Jiwon; Xu, Leyan; Pletnikova, Olga; Eberhart, Charles; Troncoso, Juan C.; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Horkayne-Szakaly, Iren] Def Hlth Agcy, Joint Pathol Ctr, Dept Neuropathol & Ophthalm Pathol, Silver Spring, MD 20910 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Leri, Francesco] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada	Koliatsos, VE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA.	koliat@jhmi.edu		Ryu, Jiwon/0000-0003-0251-7858	Johns Hopkins Alzheimer's Disease Research Center [RFA AG-09-001]; Kate Sidran Family Foundation; Sam and Sheila Giller family	This work was supported from the Johns Hopkins Alzheimer's Disease Research Center grant RFA AG-09-001 and generous gifts from the Kate Sidran Family Foundation and Sam and Sheila Giller family. The antibodies against phosphorylated tau; PHF1, CP13 and MC1, were generous gift from Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI 10.1111/j.1365-2990.2010.01131.x; Buttner A, 2006, ADDICTION, V101, P1339, DOI 10.1111/j.1360-0443.2006.01505.x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Department of Defense, 2012, DOD WORLDW NUMB TRAU; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Engel M., 2007, PARENTS BLAME VA FAT; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Goldstein LE, SCI TRANSL MED; Griffin John W., 1995, P375; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HEDREEN JC, 1994, J NEUROPATH EXP NEUR, V53, P663, DOI 10.1097/00005072-199411000-00013; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mac DC, 2013, PLOS ONE, V8, DOI 10.1371/journalpone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mott FW, 1916, LANCET, V1, P331; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Omalu B, 2011, NEUROSURG FOCUS, V31, pF3, DOI [10.3171/2011.91CKUS11178, DOI 10.3171/2011.91CKUS11178]; Pakaski M, 2005, IMIPRAMINE CITALOPRA; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; Zoroya G, 2008, US TODAY	56	52	52	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2014	2								153	10.1186/s40478-014-0153-3			14	Neurosciences	Neurosciences & Neurology	V9K3A	WOS:000422389300119	25422066	DOAJ Gold, Green Published			2021-06-18	
J	Sorg, SF; Delano-Wood, L; Luc, N; Schiehser, DM; Hanson, KL; Nation, DA; Lanni, E; Jak, AJ; Lu, K; Meloy, MJ; Frank, LR; Lohr, JB; Bondi, MW				Sorg, Scott F.; Delano-Wood, Lisa; Luc, Norman; Schiehser, Dawn M.; Hanson, Karen L.; Nation, Daniel A.; Lanni, Elisa; Jak, Amy J.; Lu, Kun; Meloy, M. J.; Frank, Lawrence R.; Lohr, James B.; Bondi, Mark W.			White Matter Integrity in Veterans With Mild Traumatic Brain Injury: Associations With Executive Function and Loss of Consciousness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; diffusion tensor imaging; white matter; executive functions	DIFFUSION-TENSOR; POSTCONCUSSIVE SYMPTOMS; FRACTIONAL ANISOTROPY; VERBAL FLUENCY; BLAST; MODERATE; MILITARY; PERFORMANCE; CONCUSSION; MECHANISMS	Objective: We investigated using diffusion tensor imaging (DTI) and the association between white matter integrity and executive function (EF) performance in postacute mild traumatic brain injury (mTBI). In addition, we examined whether injury severity, as measured by loss of consciousness (LOC) versus alterations in consciousness (AOC), is related to white matter microstructural alterations and neuropsychological outcome. Participants: Thirty Iraq and Afghanistan War era veterans with a history of mTBI and 15 healthy veteran control participants. Results: There were no significant overall group differences between control and mTBI participants on DTI measures. However, a subgroup of mTBI participants with EF decrements (n = 13) demonstrated significantly decreased fractional anisotropy of prefrontal white matter, corpus callosum, and cingulum bundle structures compared with mTBI participants without EF decrements (n = 17) and control participants. Participants having mTBI with LOC were more likely to evidence reduced EF performances and disrupted ventral prefrontal white matter integrity when compared with either mTBI participants without LOC or control participants. Conclusions: Findings suggest that altered white matter integrity contributes to reduced EF in subgroups of veterans with a history of mTBI and that LOC may be a risk factor for reduced EF as well as associated changes to ventral prefrontal white matter.	[Sorg, Scott F.] San Diego State Univ Univ Calif San Diego Joint D, San Diego, CA USA; [Delano-Wood, Lisa; Luc, Norman; Schiehser, Dawn M.; Hanson, Karen L.; Nation, Daniel A.; Lanni, Elisa; Jak, Amy J.; Meloy, M. J.; Frank, Lawrence R.; Lohr, James B.; Bondi, Mark W.] VASDHS, San Diego, CA USA; [Delano-Wood, Lisa; Schiehser, Dawn M.; Hanson, Karen L.; Jak, Amy J.; Frank, Lawrence R.; Lohr, James B.; Bondi, Mark W.] VASDHS, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Delano-Wood, Lisa; Schiehser, Dawn M.; Hanson, Karen L.; Jak, Amy J.; Meloy, M. J.; Lohr, James B.; Bondi, Mark W.] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA; [Lu, Kun; Frank, Lawrence R.] Univ Calif San Diego, Sch Med, Dept Radiol, San Diego, CA 92103 USA	Delano-Wood, L (corresponding author), VA San Diego Healthcare Syst 151B, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	ldelano@ucsd.edu	Nation, Daniel/AAD-1019-2019	Lu, Quin/0000-0001-9526-1614	Veterans Affairs (Career Development Awards)US Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH); National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH096100-01]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH096100] Funding Source: NIH RePORTER	This work was supported by grants awarded by the Veterans Affairs (Career Development Awards [CDA]: L.D.-W., D.S.) as well as the Department of Defense (Investigator-Initiated Research Grant [IIRG]: L.D.-W.). This material is further supported with resources of the Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH: L.D.-W., A.J.J., K.L.H) and a National Institute of Health grant awarded to Dr Lawrence Frank (R01 MH096100-01). The coauthors report no conflicts of interest.	Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Casscells SW., 2007, TRAUMATIC BRAIN INJU; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fox RJ, 2012, AM J NEURORADIOL, V33, P695, DOI 10.3174/ajnr.A2844; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; Gelman N, 2001, MAGNET RESON MED, V45, P71, DOI 10.1002/1522-2594(200101)45:1<71::AID-MRM1011>3.0.CO;2-2; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Heaton R. K, 1981, WISCONSIN CARD SORTI; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kongs SK, 2000, WISCONSIN CARD SORTI; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P327; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madler B, 2008, MAGN RESON IMAGING, V26, P874, DOI 10.1016/j.mri.2008.01.047; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Pfefferbaum A, 2003, J MAGN RESON IMAGING, V18, P427, DOI 10.1002/jmri.10377; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Weathers F. W., 1993, ANN M INT SOC TRAUM; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zakzanis K. K., 1999, NEUROPSYCHOLOGICAL D, P163; Zakzanis KK, 2011, J CLIN EXP NEUROPSYC, V33, P785, DOI 10.1080/13803395.2011.558496	70	52	53	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2014	29	1					21	32		10.1097/HTR.0b013e31828a1aa4			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH1OC	WOS:000335889400006	23640539	Green Accepted			2021-06-18	
J	Sullivan, GM; Mierzwa, AJ; Kijpaisalratana, N; Tang, HY; Wang, Y; Song, SK; Selwyn, R; Armstrong, RC				Sullivan, Genevieve M.; Mierzwa, Amanda J.; Kijpaisalratana, Naruchorn; Tang, Haiying; Wang, Yong; Song, Sheng-Kwei; Selwyn, Reed; Armstrong, Regina C.			Oligodendrocyte Lineage and Subventricular Zone Response to Traumatic Axonal Injury in the Corpus Callosum	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Axonal damage; Corpus callosum; Diffusion tensor imaging; Oligodendrocyte progenitor; Redundant myelin; Regeneration	BRAIN-INJURY; EXPERIMENTAL DEMYELINATION; MULTIPLE-SCLEROSIS; HEAD-INJURY; MYELIN; WHITE; MATTER; REPAIR; REMYELINATION; DIAGNOSIS	Traumatic brain injury frequently causes traumatic axonal injury (TAI) in white matter tracts. Experimental TAI in the corpus callosum of adult mice was used to examine the effects on oligodendrocyte lineage cells and myelin in conjunction with neuroimaging. The injury targeted the corpus callosum over the subventricular zone, a source of neural stem/progenitor cells. Traumatic axonal injury was produced in the rostral body of the corpus callosum by impact onto the skull at the bregma. During the first week after injury, magnetic resonance diffusion tensor imaging showed that axial diffusivity decreased in the corpus callosum and that corresponding regions exhibited significant axon damage accompanied by hypertrophic microglia and reactive astrocytes. Oligodendrocyte progenitor proliferation increased in the subventricular zone and corpus callosum. Oligodendrocytes in the corpus callosum shifted toward upregulation of myelin gene transcription. Plp/CreER(T):R26IAP reporter mice showed normal reporter labeling of myelin sheaths 0 to 2 days after injury but labeling was increased between 2 and 7 days after injury. Electron microscopy revealed axon degeneration, demyelination, and redundant myelin figures. These findings expand the cell types and responses to white matter injuries that inform diffusion tensor imaging evaluation and identify pivotal white matter changes after TAI that may affect axon vulnerability vs. recovery after brain injury.	[Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Mol & Cell Biol, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Mierzwa, Amanda J.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Mierzwa, Amanda J.; Kijpaisalratana, Naruchorn; Tang, Haiying; Selwyn, Reed; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Tang, Haiying; Selwyn, Reed] Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA; [Wang, Yong; Song, Sheng-Kwei] Washington Univ, Dept Radiol, St Louis, MO USA; [Kijpaisalratana, Naruchorn] Chulalongkorn Univ, Fac Med, Dept Internal Med, Bangkok 10330, Thailand	Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021	Sullivan, Genevieve/0000-0002-3561-223X	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS047592]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG 4549A4/1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047592] Funding Source: NIH RePORTER	This work was funded by the Department of Defense in the Center for Neuroscience and Regenerative Medicine (RCA), National Institute of Health R01-NS047592 (S-KS), and National Multiple Sclerosis Society RG 4549A4/1 (SKS).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Badea TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007859; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Doerflinger NH, 2003, GENESIS, V35, P63, DOI 10.1002/gene.10154; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gallo V, 2008, CURR OPIN NEUROL, V21, P278, DOI 10.1097/WCO.0b013e3282fd1875; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kuo LW, 2008, NEUROIMAGE, V41, P7, DOI 10.1016/j.neuroimage.2008.02.016; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Mason JL, 2007, NEUROPATHOL APPL NEU, V27, P50; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McMahon PJ, 2013, J NEUROTRAUMA; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nait-Oumesmar B, 2007, P NATL ACAD SCI USA, V104, P4694, DOI 10.1073/pnas.0606835104; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Pierpaoli C., 2010, ISMRM 18 ANN M STOCK, P1597; Powers BE, 2013, P NATL ACAD SCI USA, V110, P4075, DOI 10.1073/pnas.1210293110; Rasmussen S, 2011, ANN NEUROL, V69, P878, DOI 10.1002/ana.22299; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simons M, 2012, BBA-MOL CELL BIOL L, V1821, P1146, DOI 10.1016/j.bbalip.2012.01.011; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; White RE, 2011, J NEUROSCI, V31, P15173, DOI 10.1523/JNEUROSCI.3441-11.2011; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhou YX, 2012, NEUROBIOL DIS, V45, P196, DOI 10.1016/j.nbd.2011.08.004	60	52	56	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2013	72	12					1106	1125		10.1097/NEN.0000000000000009			20	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	299ZC	WOS:000330433200001	24226267	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Sun, CR; Sun, H; Wu, S; Lee, CC; Akamatsu, Y; Wang, RKK; Kernie, SG; Liu, JL				Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Wang, Ruikang K.; Kernie, Steven G.; Liu, Jialing			Conditional Ablation of Neuroprogenitor Cells in Adult Mice Impedes Recovery of Poststroke Cognitive Function and Reduces Synaptic Connectivity in the Perforant Pathway	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL NEUROGENESIS; GENERATED NEURONS; PROGENITOR CELLS; GAIT IMPAIRMENT; DENTATE GYRUS; STROKE; CIRCUITRY; MEMORIES; ISCHEMIA	The causal relationship between neurogenesis and the recovery of poststroke cognitive function has not been properly explored. The current study aimed to determine whether depleting neuroprogenitor cells (NPCs) affects poststroke functional outcome in nestin-delta-HSV-TK-EGFP transgenic mice, in which the expression of a truncated viral thymidine kinase gene and EGFP was restricted to nestin-expressing NPCs. Ganciclovir (GCV; 200 mg/kg/d) or saline was continuously administered via osmotic pumps in mice for 4 weeks before the induction of experimental stroke. Both baseline and stroke-induced type 1 and type 2 NPCs were conditionally ablated. GCV eliminated NPCs in a duration-dependent fashion, but it did not attenuate the genesis of astroglia or oligodendrocytes in the peri-infarct cortex, nor did it affect infarct size or cerebral blood reperfusion after stroke. Transgenic stroke mice given GCV displayed impaired spatial learning and memory in the Barnes maze test compared with saline control or wild-type stroke mice given GCV, suggesting a contributing role of stroke-induced neurogenesis in the recovery of cognitive function. However, there was no significant difference in poststroke motor function between transgenic mice treated with GCV and those treated with vehicle, despite a significant ablation of NPCs in the subventricular zone of the former. Furthermore, nestin-delta-HSV-TK-EGFP mice treated with GCV had fewer retrogradely labeled neurons in the entorhinal cortex (EC) when injected with the polysynaptic viral marker PRV614 in the dentate gyrus (DG), suggesting that there might be reduced synaptic connectivity between the DG and EC following ablation of NPCs, which may contribute to impaired poststroke memory function.	[Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA; [Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Sun, Chongran] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Sun, Hui] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurol Surg, Shanghai 201101, Peoples R China; [Akamatsu, Yosuke] Tohoku Univ, Grad Sch Med, Dept Neurol Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; [Kernie, Steven G.] Columbia Univ, Dept Pediat, New York, NY 10032 USA; [Kernie, Steven G.] Columbia Univ, Dept Pathol, New York, NY 10032 USA; [Kernie, Steven G.] Columbia Univ, Dept Cell Biol, New York, NY 10032 USA	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Wang, Ruikang K./L-3889-2019; Kernie, Steven/AAT-9912-2020; Liu, Jialing/A-8627-2012	Wang, Ruikang K./0000-0001-5169-8822; Liu, Jialing/0000-0003-4420-4382; Kernie, Steven/0000-0003-1371-0549	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS071050]; AHA EIAAmerican Heart Association [0940065N]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192, R01NS071050] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R01 NS071050 (J.L.) and AHA EIA 0940065N (J.L.). We thank Dr. Lin An for his technical assistance in the analysis of blood perfusion by optical coherence tomography.	Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; An L, 2010, OPT EXPRESS, V18, P8220, DOI 10.1364/OE.18.008220; Arruda-Carvalho M, 2011, J NEUROSCI, V31, P15113, DOI 10.1523/JNEUROSCI.3432-11.2011; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BRAGIN A, 1995, J NEUROSCI, V15, P47; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jia YL, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3432654; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim ES, 2002, J NEUROTRAUM, V19, P787, DOI 10.1089/08977150260139156; Lee JW, 2000, J COMP NEUROL, V418, P484; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Pendlebury Sarah T, 2009, Cerebrovasc Dis, V27 Suppl 3, P1, DOI 10.1159/000209260; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Rafuse VF, 2005, NEUROSCIENCE, V131, P899, DOI 10.1016/j.neuroscience.2004.11.048; Rinaman L, 2000, J NEUROSCI, V20, P2731; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santra M, 2006, NEUROSCIENCE, V142, P739, DOI 10.1016/j.neuroscience.2006.06.065; Song J, 2012, DEV NEUROBIOL, V72, P1032, DOI 10.1002/dneu.22014; Sun H, 2011, NEUROBIOL DIS, V44, P73, DOI 10.1016/j.nbd.2011.06.006; Toni N, 2011, EUR J NEUROSCI, V33, P1062, DOI 10.1111/j.1460-9568.2011.07604.x; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663; Wang Y. B. B., 2011, AM J NEUROPROTECTION, V3, P66; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009	37	52	52	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	OCT 30	2013	33	44					17314	17325		10.1523/JNEUROSCI.2129-13.2013			12	Neurosciences	Neurosciences & Neurology	246BB	WOS:000326509800009	24174664	Green Published, Bronze			2021-06-18	
J	Brooks, BL; McKay, CD; Mrazik, M; Barlow, KM; Meeuwisse, WH; Emery, CA				Brooks, Brian L.; McKay, Carly D.; Mrazik, Martin; Barlow, Karen M.; Meeuwisse, Willem H.; Emery, Carolyn A.			Subjective, but not Objective, Lingering Effects of Multiple Past Concussions in Adolescents	JOURNAL OF NEUROTRAUMA			English	Article						baseline; concussion; cumulative; lingering; mild traumatic brain injury; pediatric	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; WORKING-MEMORY; BODY CHECKING; NOVEMBER 2008; PLAYERS; IMPACT	The existing literature on lingering effects from concussions in children and adolescents is limited and mixed, and there are no clear answers for patients, clinicians, researchers, or policy makers. The purpose of this study was to examine whether there are lingering effects of past concussions in adolescent athletes. Participants in this study included 643 competitive Bantam and Midget hockey players (most elite 20% by division of play) between 13 and 17 years of age (mean age = 15.5, SD = 1.2). Concussion history at baseline assessment was retrospectively documented using a pre-season questionnaire (PSQ), which was completed at home by parents and players in advance of baseline testing. Players with English as a second language, self-reported attention or learning disorders, a concussion within 6 months of baseline, or suspected invalid test profiles were excluded from these analyses. Demographically adjusted standard scores for the five composites/domains and raw symptom ratings from the brief Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) computerized battery were analyzed. Adolescent athletes with one or two or more prior concussions did not have significantly worse neurocognitive functioning on ImPACT than did those with no previous concussions. There were significantly more symptoms reported in those with two or more prior concussions than in those with no or one prior concussion. Adolescents with multiple previous concussions had higher levels of baseline symptoms, but there were not group differences in neurocognitive functioning using this brief computerized battery.	[Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Neurosci Brain Injury & Rehabil Programs, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst Child & Mat Hlth, Calgary, AB T3B 6A8, Canada; [McKay, Carly D.; Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Mrazik, Martin] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2E1, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Emery, Carolyn/AAI-2761-2020; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	McKay, Carly/0000-0001-7664-3211; Barlow, Karen/0000-0003-2612-8507	Calgary; ImPACTEuropean Commission; International Olympic Committee; Alberta Innovates Health Solutions (AIHS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI)	The authors thank the following people for their help with data collection (in alphabetical order): Tracy Blake, Andrea Jubinville, Nicole Lemke, Maria Romiti, and Kathryn Schneider. The authors thank Emily Tam for assistance with data management, and Dr. Helen Carlson for her help with data management, entering the demographically adjusted normative scores for this entire sample, and formatting the manuscript. The authors also thank Hockey Calgary, Girls Hockey Calgary, Hockey Edmonton, Edmonton Girls Hockey, the Edge School (Calgary), the team designates, research assistants, coaches, families, and the players who participated in this study. Computerized cognitive testing in this study was funded in Calgary by the McCarthy Tetrault award (administered by the Alberta Children's Hospital Research Institute for Child & Maternal Health) to Dr. Brooks (computers, test credits) and in Edmonton by funding provided to and in-kind support by ImPACT to Dr. Mrazik. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. Drs. Meeuwisse and Emery acknowledge funding from Alberta Innovates Health Solutions (AIHS), Canadian Institutes of Health Research (CIHR), and the Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI; Professorship in pediatric rehabilitation for Dr. Emery).	[Anonymous], 1999, JAMA, V282, P974; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Blake T.A., 2012, CLIN J SPORT MED, V22, P307; Brooks B.L., 2013, ARCH CLIN NEUROPSYCH; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKay C, 2012, CLIN J SPORT MED, V22, P307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider K., 2010, CLIN J SPORT MED, V20, P232; Schneider K.J., 2012, CLIN J SPORT MED, V22, P307; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Talavage TM, 2013, J NEUROTRAUMA; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967	46	52	52	0	68	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1469	1475		10.1089/neu.2012.2720			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800001	23560947	Green Published			2021-06-18	
J	Fait, P; Swaine, B; Cantin, JF; Leblond, J; McFadyen, BJ				Fait, Philippe; Swaine, Bonnie; Cantin, Jean-Francois; Leblond, Jean; McFadyen, Bradford J.			Altered Integrated Locomotor and Cognitive Function in Elite Athletes 30 Days Postconcussion: A Preliminary Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						athletes; clinical testing; concussion; divided attention; neuropsychological tests; return to play	TRAUMATIC BRAIN-INJURY; CONTROL FOLLOWING CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; CLOSED-HEAD INJURY; POSTURAL STABILITY; NCAA CONCUSSION; ATTENTION; RECOVERY; DEFICITS	Objective: To begin to understand changes in locomotor navigation in elite athletes following concussion. Methods: Clinical measures and gait analysis were undertaken on average 37.33 days (SD = 4.8) postconcussion for 6 athletes as well as for a control group of athletes matched for age, sex, and team. The locomotor task consisted of walking at a self-selected speed along an unobstructed or obstructed path with and without a visual interference task. The trends for 4 dependent variables were described (2 for gait behavior and 2 for cognitive behavior). A principal component analysis was used to reduce data to root sources of variance among these variables. General group differences were tested with Wilcoxon matched-pairs tests on factorial scores. Results: Athletes with concussion were symptom free at the time of testing and their neuropsychological test results were not different from those of athletes in the control group. However, when the laboratory data between paired groups were compared, descriptive analyses suggested potential group differences in navigating the obstacle. The simultaneous Stroop task appeared to present difficulty for both groups. A significant group effect was found on the component of the factorial analysis that was highly loaded with both gait and cognitive variables (minimum clearance, Stroop task errors, and cognitive dual-task costs), generally supporting the descriptive analyses by suggesting that athletes with concussion do not navigate the targeted complex environments like the control group. Conclusions: Athletes with concussion appear to still show navigational deficits in environments well after being considered fully recovered according to current return-to-play protocols. Although still preliminary and requiring further study, the present findings suggest that functional assessment within complex environment contexts could be considered before sending athletes back to play following a concussion, even in the absence of postconcussion symptoms or with normal clinical outcomes.	[Fait, Philippe; McFadyen, Bradford J.] Univ Laval, Quebec City, PQ, Canada; [Cantin, Jean-Francois] Quebec Rehabil Inst, Quebec City, PQ, Canada; [Fait, Philippe; Leblond, Jean; McFadyen, Bradford J.] Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 2S8, Canada; [Swaine, Bonnie] Univ Montreal, Montreal, PQ, Canada	McFadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Boul Hamel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927; Fait, Philippe/0000-0002-2554-9273	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Ontario Neurotrauma Foundation-Quebec Rehabilitation Network	The authors thank Guy St-Vincent for his technical assistance, Eric Huard and Janick Bisson for their consultation and development of the Stroop presentation program, and the TBI unit of the IRDPQ, This study was partially funded by the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada (to Dr McFadyen) and partial Ontario Neurotrauma Foundation-Quebec Rehabilitation Network stipend (to Dr Fait).	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Gerin-Lajoie M, 2005, MOTOR CONTROL, V9, P242, DOI 10.1123/mcj.9.3.242; Gerin-Lajoie M, 2006, GAIT POSTURE, V24, P364, DOI 10.1016/j.gaitpost.2005.11.001; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Golden C., 1978, STROOP COLOR WORD TE; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller E, 2002, CALCAP CALIFORNIA CO; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2001, J ATHL TRAINING, V36, P288; Robertson I. H., 1994, TEST EVERYDAY ATTENT; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Smith A., 1982, SYMBOL DIGIT MODALIT; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Thompson JWG, 2006, FDN SPORT RELATED BR; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wai-Hang JL, 2002, ARE YOU LEFT HANDED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	45	52	53	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					293	301		10.1097/HTR.0b013e3182407ace			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900007	22495102				2021-06-18	
J	Silverberg, ND; Hallam, BJ; Rose, A; Underwood, H; Whitfield, K; Thornton, AE; Whittal, ML				Silverberg, Noah D.; Hallam, Bradley J.; Rose, Alice; Underwood, Heather; Whitfield, Kevin; Thornton, Allen E.; Whittal, Maureen L.			Cognitive-Behavioral Prevention of Postconcussion Syndrome in At-Risk Patients: A Pilot Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; cognitive-behavioral therapy; postconcussion syndrome; randomized controlled trial; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; WHIPLASH-ASSOCIATED DISORDERS; POST-CONCUSSION SYMPTOMS; TASK-FORCE; HOSPITAL ANXIETY; QUESTIONNAIRE; THERAPY; RULE	Objective: To examine the tolerability and estimate the treatment effect of cognitive-behavioral therapy (CBT) delivered soon after mild traumatic brain injury to patients at risk for chronic postconcussion syndrome (PCS). Setting: Tertiary rehabilitation center. Participants: Twenty-eight patients with uncomplicated mild traumatic brain injury, determined to be at risk for chronic PCS based on a published algorithm that incorporates subacute postconcussion symptoms and maladaptive illness beliefs (recovery expectations and perceived consequences). They were enrolled within 6 weeks postinjury. Design: Open-label, parallel-group, randomized controlled trial, with masked outcome assessment 3 months after enrolment. Interventions were (1) treatment as usual (education, reassurance, and symptom management strategies) from an occupational therapist, or (2) treatment as usual plus CBT delivered by a psychologist. Main Measures: Rivermead Postconcussion Symptoms Questionnaire. Results: Four participants (2:2) withdrew. Treatment credibility and satisfaction ratings were high in the CBT group. Treatment effect sizes were moderate for postconcussion symptoms (Cohen d = 0.74) and moderate-large for most secondary outcome measures (Cohen d = 0.62-1.61). Fewer participants receiving CBT had a diagnosis of PCS at follow-up (54% vs 91%, P < .05). Conclusion: Our preliminary data suggest that CBT delivered soon after mild traumatic brain injury is well tolerated and may facilitate recovery in patients who are at risk for chronic PCS. A definitive clinical trial is warranted.	[Silverberg, Noah D.; Hallam, Bradley J.; Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Silverberg, Noah D.; Underwood, Heather] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.; Hallam, Bradley J.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada; [Whittal, Maureen L.] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Whittal, Maureen L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Whitfield, Kevin; Thornton, Allen E.] Simon Fraser Univ, Human Neuropsychol Lab, Burnaby, BC V5A 1S6, Canada	Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Thornton, Allen/0000-0002-9942-0122	BC Rehab Foundation; Vancouver Coastal Health Research Institute	A William G. Fraser Rehabilitation Research Award from the BC Rehab Foundation provided operational funds for this study. The principal investigator (N.D.S) received salary support from the Vancouver Coastal Health Research Institute.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Barsky A, 2003, MANAGING MED SYMPTOM; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cote P, 2011, SPINE, V36, pS275, DOI 10.1097/BRS.0b013e3182388d32; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Greenberg RP, 2006, CLIN PSYCHOL REV, V26, P657, DOI 10.1016/j.cpr.2005.03.002; HOLDEN G, 1991, SOC WORK HEALTH CARE, V16, P53; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; NSW Government Motor Accidents Authority, 2008, GUID MILD TRAUM BRAI; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silverberg ND, 2013, 41 ANN M INT NEUR SO; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; SPITZER WO, 1995, SPINE, V20, pS1; Stallard N, 2012, STAT MED, V31, P1031, DOI 10.1002/sim.4357; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Taylor S., 2004, TREATING HLTH ANXIET; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	52	52	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					313	322		10.1097/HTR.0b013e3182915cb5			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900009	23640544				2021-06-18	
J	Bryan, CJ				Bryan, Craig J.			Repetitive Traumatic Brain Injury (or Concussion) Increases Severity of Sleep Disturbance among Deployed Military Personnel	SLEEP			English	Article						Insomnia; military; multiple TBI; sleep; TBI; traumatic brain injury	INSOMNIA; PREVALENCE; DISORDERS; COMPLAINTS; SOLDIERS; CONTEXT; IRAQ	Study Objectives: Considerable research indicates that sleep disturbances and insomnia are more common and severe among individuals following a traumatic brain injury (TBI). It remains unclear, however, how the experience of multiple TBIs affect sleep disturbances and insomnia. The current study investigated the incidence and severity of insomnia and sleep complaints among active-duty military personnel who have sustained multiple TBIs. Design and Setting: Upon intake at a military TBI clinic located in Iraq, 150 male military patients completed standardized self-report measures and clinical interviews. Measurements and Results: Patients were categorized into three groups according to history of TBI: zero TBIs (n = 18), single TBI (n = 54), multiple TBIs (n = 78). Rates of clinical insomnia significantly increased across TBI groups (P < 0.001): 5.6% for no TBIs, 20.4% for single TBI, and 50.0% for multiple TBIs. Insomnia severity significantly increased across TBI groups even when controlling for depression, posttraumatic stress disorder, and concussion symptom severity (B = 1.134, standard error = 0.577, P = 0.049). Conclusions: Multiple TBIs are associated with increased risk for and severity of sleep disturbance among male military personnel.	Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA	Bryan, CJ (corresponding author), Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Bryan, Craig/0000-0002-9714-0733			[Anonymous], 2005, SLEEP, V28, P1049; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blount TH, 2010, ANN M ASS BEH COGN T; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; CelestHealth Solutions, 2008, CLIN REP MAN COLL CO; Def. Veterans Brain Inj. Cent, 2007, MIL AC CONC EV MACE; Department of Veterans Affairs, 2009, CLIN PRACT GUID MAN; DOD/VA Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Medical Surveillance Monthly Report, 2010, MED SURV MONTHLY REP, V17, P12; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Taylor DJ, 2007, HDB PSYCHOL ASSESSME, V1, P674; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F. W., 1993, ANN M INT SOC TRAUM; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	28	52	52	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	JUN 1	2013	36	6					941	946		10.5665/sleep.2730			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	155HX	WOS:000319739700021	23729938	Bronze, Green Published			2021-06-18	
J	Atif, F; Yousuf, S; Sayeed, I; Ishrat, T; Hua, F; Stein, DG				Atif, Fahim; Yousuf, Seema; Sayeed, Iqbal; Ishrat, Tauheed; Hua, Fang; Stein, Donald G.			Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: The role of BDNF/TrkB/Erk1/2 signaling in neuroprotection	NEUROPHARMACOLOGY			English	Article						Cerebral ischemia; Combination treatment; Progesterone; Vitamin D; BDNF/TrkB/Erk1/2 signaling	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; MEDROXYPROGESTERONE ACETATE; NEUROTROPHIC FACTOR; INFLAMMATORY RESPONSE; INFARCT VOLUME; D DEFICIENCY; RATS; EXPRESSION; BDNF	We investigated whether combinatorial post-injury treatment with progesterone (P4) and vitamin D hormone (VDH) would reduce ischemic injury more effectively than P4 alone in an oxygen glucose deprivation (OGD) model in primary cortical neurons and in a transient middle cerebral artery occlusion (tMCAO) model in rats. In the OGD model, P4 and VDH each showed neuroprotection individually, but combination of the "best" doses did not show substantial efficacy; instead, the lower dose of VDH in combination with P4 was the most effective. In the tMCAO model, P4 and VDH were given alone or in combination at different times post-occlusion for 7 days. In vivo data confirmed the in vitro findings and showed better infarct reduction at day 7 and functional outcomes (at 3, 5 and 7 days post-occlusion) after combinatorial treatment than when either agent was given alone. VDH, but not P4, upregulated heme oxygenase-1, suggesting a pathway for the neuroprotective effects of VDH differing from that of P4. The combination of P4 and VDH activated brain-derived neurotrophic factor and its specific receptor, tyrosine kinase receptor-B. Under specific conditions VDH potentiates P4's neuroprotective efficacy and should be considered as a potential partner of P4 in a low-cost, safe and effective combinatorial treatment for stroke. (c) 2012 Elsevier Ltd. All rights reserved.	[Atif, Fahim; Yousuf, Seema; Sayeed, Iqbal; Ishrat, Tauheed; Hua, Fang; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, 1365B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020		BHR Pharmaceuticals; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER	DG Stein is entitled to royalties from products of BHR Pharmaceuticals Ltd related to the use of P4 in TBI and stroke, and may receive research funding from BHR Pharmaceuticals, which is developing products related to this research. In addition, he serves as a consultant to BHR Pharmaceuticals and receives compensation for these services. The terms of this arrangement have been reviewed and approved by Emory University, which receives the largest share of fees in accordance with its conflict of interest policies.; This research was supported by NIH grant RO1 HD061971. The authors would like to thank Leslie McCann for invaluable editorial assistance.	Abe K, 1997, BRAIN RES, V776, P230, DOI 10.1016/S0006-8993(97)01041-X; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Balden R, 2012, ENDOCRINOLOGY, V153, P2420, DOI 10.1210/en.2011-1783; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Coughlan T, 2009, INT J NEUROSCI, V119, P1718, DOI 10.1080/00207450903116430; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jodhka PK, 2009, ENDOCRINOLOGY, V150, P3162, DOI 10.1210/en.2008-1247; Kojima G, 2012, STROKE, V43, P2163, DOI 10.1161/STROKEAHA.112.651752; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2010, ENDOCRINOLOGY, V151, P5782, DOI 10.1210/en.2010-0005; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Makariou S.E., 2012, CURR VASC PHARM; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Oermann E, 2004, J CHEM NEUROANAT, V28, P225, DOI 10.1016/j.jchemneu.2004.07.003; Pilz S, 2008, J CLIN ENDOCR METAB, V93, P3927, DOI 10.1210/jc.2008-0784; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Shi QD, 2009, NEUROSCI LETT, V465, P220, DOI 10.1016/j.neulet.2009.08.049; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Sun Q, 2012, STROKE, V43, P1470, DOI 10.1161/STROKEAHA.111.636910; Wang JP, 2011, MOL MED REP, V4, P319, DOI 10.3892/mmr.2011.418; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zeng Y, 2011, J NEUROSCI, V31, P17800, DOI 10.1523/JNEUROSCI.3878-11.2011	43	52	53	0	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						78	87		10.1016/j.neuropharm.2012.10.004			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400010	23154302	Green Accepted			2021-06-18	
J	Lincoln, AE; Caswell, SV; Almquist, JL; Dunn, RE; Hinton, RY				Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.			Video Incident Analysis of Concussions in Boys' High School Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; head injury; concussion; sports; boys' lacrosse; video analysis	TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; SPORTS; GAME; MECHANISMS; FOOTBALL; EPIDEMIOLOGY; GIRLS	Background: Boys' lacrosse has one of the highest rates of concussion among boys' high school sports. A thorough understanding of injury mechanisms and game situations associated with concussions in boys' high school lacrosse is necessary to target injury prevention efforts. Purpose: To characterize common game-play scenarios and mechanisms of injury associated with concussions in boys' high school lacrosse using game video. Study Design: Descriptive epidemiological study. Methods: In 25 public high schools of a single school system, 518 boys' lacrosse games were videotaped by trained videographers during the 2008 and 2009 seasons. Video of concussion incidents was examined to identify game characteristics and injury mechanisms using a lacrosse-specific coding instrument. Results: A total of 34 concussions were captured on video. All concussions resulted from player-to-player bodily contact. Players were most often injured when contact was unanticipated or players were defenseless (n = 19; 56%), attempting to pick up a loose ball (n = 16; 47%), and/or ball handling (n = 14; 41%). Most frequently, the striking player's head (n = 27; 79%) was involved in the collision, and the struck player's head was the initial point of impact in 20 incidents (59%). In 68% (n = 23) of cases, a subsequent impact with the playing surface occurred immediately after the initial impact. A penalty was called in 26% (n = 9) of collisions. Conclusion: Player-to-player contact was the mechanism for all concussions. Most commonly, injured players were unaware of the pending contact, and the striking player used his head to initiate contact. Further investigation of preventive measures such as education of coaches and officials and enforcement of rules designed to prevent intentional head-to-head contact is warranted to reduce the incidence of concussions in boys' lacrosse.	[Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.] MedStar Sports Med Res Ctr, Baltimore, MD USA	Lincoln, AE (corresponding author), Care of Camire L, MedStar Union Mem Orthopaed, 3333 North Calvert St,Suite 400, Baltimore, MD 21218 USA.	lyn.camire@medstar.net			National Operating Committee on Standards for Athletic Equipment (NOCSAE); US Lacrosse Sports Science & Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: Funded in part by a grant from the National Operating Committee on Standards for Athletic Equipment (NOCSAE) and from the US Lacrosse Sports Science & Safety Committee.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Appleby B, 2002, J SCI MED SPORT, V5, P129, DOI 10.1016/S1440-2440(02)80034-2; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Carter EA, 2010, INT J INJ CONTROL SA, V17, P111, DOI 10.1080/17457300903524888; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Caswell SV, 2010, MED SCI SPORT EXER, V42, P813, DOI 10.1249/01.MSS.0000386513.75340.cb; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; ESPN, OUTS LIN; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2012, INJURY RES THEORIES, P397; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; National Federation of State High School Associations, 2012 BOYS LACR RUL C; National Football League, DEF DEF PLAYER; National Hockey League, BOARD GOV APPR CHANG; NCAA Men's Lacrosse Rules Committee, 2011 2012 APPR RUL C; Olsen E, 1997, Science and football III, V3rd, P209; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; US Lacrosse, 2012 RUL BOYS YOUTH; US Lacrosse, 2010, 2010 PART SURV	29	52	52	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2013	41	4					756	761		10.1177/0363546513476265			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	135NR	WOS:000318295500014	23413274				2021-06-18	
J	Sareen, J; Erickson, J; Medved, MI; Asmundson, GJG; Enns, MW; Stein, M; Leslie, W; Doupe, M; Logsetty, S				Sareen, Jitender; Erickson, Julie; Medved, Maria I.; Asmundson, Gordon J. G.; Enns, Murray W.; Stein, Murray; Leslie, William; Doupe, Malcolm; Logsetty, Sarvesh			RISK FACTORS FOR POST-INJURY MENTAL HEALTH PROBLEMS	DEPRESSION AND ANXIETY			English	Article						injury; burns; risk factor; posttraumatic stress; adjustment; anxiety; biopsychosocial; mental health	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MAJOR BURN INJURY; BODY-IMAGE DISSATISFACTION; MOTOR-VEHICLE ACCIDENTS; SPINAL-CORD-INJURY; PSYCHIATRIC MORBIDITY; HEART-RATE; FOLLOW-UP; FUNCTIONAL OUTCOMES	Serious nonfatal physical injuries and burns are common occurrences that can have substantial implications for personal, social, and occupational functioning. Such injuries are frequently associated with significant mental health issues, and compromised quality of life and well-being. The purpose of this review is to summarize the current literature on physical, psychological, and social risk factors for mental health issues post-injury and to contextualize findings using Engel's biopsychosocial framework. We distinguish between pre-injury, injury-related, and post-injury risk factors for mental health problems. Female sex, history of mental health problems or trauma, type of injury, and level of pain are among the strong risk factors for mental health problems post-injury. We highlight inconsistent findings in the literature, identify directions for future research, and explore the implications of the risk factors identified for treatment and prevention.	[Sareen, Jitender; Enns, Murray W.] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; [Sareen, Jitender; Erickson, Julie; Medved, Maria I.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada; [Sareen, Jitender; Doupe, Malcolm] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Asmundson, Gordon J. G.] Univ Regina, Dept Psychol, Regina, SK S4S 0A2, Canada; [Stein, Murray] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Leslie, William; Logsetty, Sarvesh] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada	Sareen, J (corresponding author), PZ430-771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada.	sareen@cc.umanitoba.ca		Enns, Murray/0000-0002-8375-0151; Leslie, William/0000-0002-1056-1691	Manitoba Medical Services Foundation; Health Sciences Foundation; Manitoba Health Research Council Chair; Manitoba Health Research Council Chair award	Contract grant sponsors: Manitoba Medical Services Foundation, Health Sciences Foundation, Manitoba Health Research Council Chair.; Preparation of this article was supported by grants from Manitoba Medical Services Foundation, Health Sciences Foundation, and Manitoba Health Research Council Chair award.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Association AP, 1994, DIAGN STAT MAN MENT; Birmes P, 2003, AM J PSYCHIAT, V160, P1337, DOI 10.1176/appi.ajp.160.7.1337; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Blaszczynski A, 1998, COMPR PSYCHIAT, V39, P111, DOI 10.1016/S0010-440X(98)90069-4; Breslau Naomi, 2002, J Gend Specif Med, V5, P34; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P923, DOI 10.4088/JCP.v69n0606; Cairns DM, 1996, ARCH PHYS MED REHAB, V77, P329, DOI 10.1016/S0003-9993(96)90079-9; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Cloitre M, 2009, J TRAUMA STRESS, V22, P399, DOI 10.1002/jts.20444; Collimore KC, 2010, DEPRESS ANXIETY, V27, P1017, DOI [10.1002/da.20728, 10.1002/da.20771, 10.1002/da.20759]; Duckworth MP, 2005, CLIN J PAIN, V21, P251, DOI 10.1097/00002508-200505000-00008; Dyster-Aas J, 2008, J TRAUMA, V64, P1349, DOI 10.1097/TA.0b013e318047e005; Edwards RR, 2007, ARCH PHYS MED REHAB, V88, pS36, DOI 10.1016/j.apmr.2007.05.031; ENGEL GL, 1981, J MED PHILOS, V6, P101, DOI 10.1093/jmp/6.2.101; Esselman PC, 2007, ARCH PHYS MED REHAB, V88, pS50, DOI 10.1016/j.apmr.2007.09.009; Fauerbach JA, 2001, J BURN CARE REHABIL, V22, P26, DOI 10.1097/00004630-200101000-00007; Fauerbach JA, 2000, PSYCHOSOM MED, V62, P576, DOI 10.1097/00006842-200007000-00017; Fauerbach JA, 2000, J NERV MENT DIS, V188, P510, DOI 10.1097/00005053-200008000-00006; Fauerbach JA, 2007, PSYCHOSOM MED, V69, P473, DOI 10.1097/psy.0b013e31806bf393; Friedman MJ, 2004, J NERV MENT DIS, V192, P42, DOI 10.1097/01.nmd.0000105999.57129.ee; Gill JM, 2009, PERSPECT PSYCHIATR C, V45, P262, DOI 10.1111/j.1744-6163.2009.00229.x; Han PP, 2011, J TRAUMA, V70, P923, DOI 10.1097/TA.0b013e31820cf03e; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Information CIfH, 2006, NAT TRAUM REG REP MA; Kendler KS, 1997, BRIT J PSYCHIAT, V170, P541, DOI 10.1192/bjp.170.6.541; Kessler RC, 2005, NEW ENGL J MED, V352, P2515, DOI 10.1056/NEJMsa043266; Klein MB, 2007, J BURN CARE RES, V28, P84, DOI 10.1097/BCR.0b013E31802C888E; Klose M, 2004, Arch Womens Ment Health, V7, P133, DOI 10.1007/s00737-004-0047-7; Koenen KC, 2003, J CONSULT CLIN PSYCH, V71, P980, DOI 10.1037/0022-006X.71.6.980; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; McLaughlin KA, 2012, BRIT J PSYCHIAT, V200, P290, DOI 10.1192/bjp.bp.111.101253; McNally RJ, 2003, BIOL PSYCHIAT, V53, P779, DOI 10.1016/S0006-3223(02)01663-3; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; Norton PJ, 2004, PAIN, V111, P218, DOI 10.1016/j.pain.2004.06.018; O'Donnell ML, 2008, CLIN PSYCHOL REV, V28, P387, DOI 10.1016/j.cpr.2007.07.008; O'Donnell ML, 2007, PSYCHOSOM MED, V69, P256, DOI 10.1097/PSY.0b013e3180417d04; O'Donnell ML, 2010, J TRAUMA, V69, P627, DOI 10.1097/TA.0b013e3181bc0923; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Oakley PA, 2004, INJURY, V35, P379, DOI 10.1016/S0020-1383(03)00096-2; Ozer E. J., 2008, PSYCHOL TRAUMA-US, P3, DOI [DOI 10.1037/1942-9681.S.1.3, 10.1037/1942-9681.S.1.3]; Pagura J, 2010, J PSYCHIATR RES, V44, P1190, DOI 10.1016/j.jpsychires.2010.04.016; Park SY, 2008, BURNS, V34, P24, DOI 10.1016/j.burns.2007.03.012; Pole Nnamdi, 2005, Cultur Divers Ethnic Minor Psychol, V11, P144, DOI 10.1037/1099-9809.11.2.144; Richter JC, 2006, PSYCHOSOMATICS, V47, P223, DOI 10.1176/appi.psy.47.3.223; Roberts NP, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007944.pub2; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Smith MT, 2008, PAIN, V138, P497, DOI 10.1016/j.pain.2008.01.028; Stein MB, 2000, BEHAV RES THER, V38, P619, DOI 10.1016/S0005-7967(99)00098-4; Stein MB, 2002, JAMA-J AM MED ASSOC, V288, P1513, DOI 10.1001/jama.288.12.1513; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Street AE, 2005, J TRAUMA STRESS, V18, P245, DOI 10.1002/jts.20026; Suliman S, 2009, COMPR PSYCHIAT, V50, P121, DOI 10.1016/j.comppsych.2008.06.006; Sutherland AG, 2003, CYTOKINE, V24, P219, DOI 10.1016/j.cyto.2003.09.004; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; ter Smitten MH, 2011, BURNS, V37, P753, DOI 10.1016/j.burns.2010.12.018; Thombs BD, 2007, GEN HOSP PSYCHIAT, V29, P14, DOI 10.1016/j.genhosppsych.2006.09.002; Thombs BD, 2006, GEN HOSP PSYCHIAT, V28, P494, DOI 10.1016/j.genhosppsych.2006.08.010; Van Loey NEE, 2008, BURNS, V34, P1082, DOI 10.1016/j.burns.2008.01.012; Van Loey NEE, 2003, AM J CLIN DERMATOL, V4, P245, DOI 10.2165/00128071-200304040-00004; Wiechman SA, 2004, BRIT MED J, V329, P391, DOI 10.1136/bmj.329.7462.391; Wiechman SA, 2001, J BURN CARE REHABIL, V22, P417, DOI 10.1097/00004630-200111000-00012; Wisely JA, 2010, BURNS, V36, P183, DOI 10.1016/j.burns.2009.08.008; Young E, 2010, MOL PSYCHIATR, V15, P23, DOI 10.1038/mp.2009.94; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642	79	52	55	0	24	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety	APR	2013	30	4					321	327		10.1002/da.22077			7	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	126GJ	WOS:000317600800006	23408506				2021-06-18	
J	Piazza-Gardner, AK; Gaffud, TJB; Barry, AE				Piazza-Gardner, Anna K.; Gaffud, Timothy J. B.; Barry, Adam E.			The impact of alcohol on Alzheimer's disease: A systematic review	AGING & MENTAL HEALTH			English	Article						Alzheimer's disease; alcohol; drinking; dementia	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; COGNITIVE DECLINE; BEVERAGE PREFERENCE; TOBACCO CONSUMPTION; METABOLIC SYNDROME; VASCULAR DEMENTIA; WHITE WINE; DRINKING; HEALTH	Currently, there is discrepancy regarding alcohol's impact on Alzheimer's disease (AD). Consequently, the purpose of this systematic review was to determine whether alcohol serves as a protective agent against the development of AD, as well as whether protective effects are influenced by quantity and/or frequency of drinking. Adapted versions of the Matrix Method and PRISMA guidelines were used in order to identify, organize, and synthesize relevant research. Overall, there is no consensus regarding alcohol's impact on AD. Specifically, seven articles suggested drinking alcohol decreases the risk of AD, three studies found drinking led to an increased risk of AD, and yet another nine reported alcohol had no impact on AD. Validity and consistency of both alcohol and AD measures across studies represents a severe limitation. Prior to the development of standards and/or clinical recommendations, more investigations into the association between alcohol and AD are necessary. Considering the current evidence base, alcohol should not be used as a means to decrease risk of developing AD.	[Piazza-Gardner, Anna K.; Gaffud, Timothy J. B.; Barry, Adam E.] Univ Florida, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA	Barry, AE (corresponding author), Univ Florida, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA.	aebarry@ufl.edu		Barry, Adam/0000-0001-6527-6866			Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angevaren M, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005381.pub3, 10.1002/14651858.CD005381.pub2]; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Bachman DL, 2003, NEUROLOGY, V60, P1372, DOI 10.1212/01.WNL.0000058751.43033.4D; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Chiu E, 2008, AGE AGEING, V37, P493, DOI 10.1093/ageing/afn157; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Del Boca FK, 2003, ADDICTION, V98, P1, DOI 10.1046/j.1359-6357.2003.00586.x; Deng J, 2006, CLIN NEUROL NEUROSUR, V108, P378, DOI 10.1016/j.clineuro.2005.06.005; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Garcia AM, 2010, J ALZHEIMERS DIS, V20, P577, DOI 10.3233/JAD-2010-1399; Garrard J, 1999, HLTH SCI LIT REV MAD; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Gronbaek M, 2009, J INTERN MED, V265, P407, DOI 10.1111/j.1365-2796.2009.02082.x; Grossberg GT, 2003, J CLIN PSYCHIAT, V64, P3; Hall W, 2012, DRUG ALCOHOL REV, V31, P194, DOI 10.1111/j.1465-3362.2011.00345.x; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Harwood DG, 2010, INT J GERIATR PSYCH, V25, P511, DOI 10.1002/gps.2372; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holland D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042325; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Jensen MK, 2002, EPIDEMIOLOGY, V13, P127, DOI 10.1097/00001648-200203000-00005; Khachaturian Zaven S, 2005, Alzheimers Dement, V1, P93, DOI 10.1016/j.jalz.2005.09.001; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Kuntsche E, 2006, ALCOHOL ALCOHOLISM, V41, P566, DOI 10.1093/alcalc/agl046; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lopez OL, 2000, NEUROLOGY, V55, P1854, DOI 10.1212/WNL.55.12.1854; Luchsinger JA, 2004, J AM GERIATR SOC, V52, P540, DOI 10.1111/j.1532-5415.2004.52159.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mitchell AJ, 2009, J PSYCHIATR RES, V43, P411, DOI 10.1016/j.jpsychires.2008.04.014; Moher D., 2009, BRIT MED J, V339, pb2700; Murphy S, 2012, NATL VITAL STAT REP, V60, P1; Naimi TS, 2007, AM J PREV MED, V33, P188, DOI 10.1016/j.amepre.2007.04.026; National Institute on Alcohol Abuse and Alcoholism, 2003, NAT COUNC ALC AB ALC; Neafsey EJ, 2011, NEUROPSYCH DIS TREAT, V7, P465, DOI 10.2147/NDT.S23159; Ogunniyi A, 2006, METAB BRAIN DIS, V21, P235, DOI 10.1007/s11011-006-9017-2; Panza F, 2009, J ALZHEIMERS DIS, V17, P7, DOI 10.3233/JAD-2009-1009; Peele S, 2000, DRUG ALCOHOL DEPEN, V60, P221, DOI 10.1016/S0376-8716(00)00112-5; Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095; Piazza-Gardner AK, 2012, DRUG ALCOHOL REV, V31, P198, DOI 10.1111/j.1465-3362.2011.00415.x; Pinder RM, 2004, J PSYCHOPHARMACOL, V18, P449, DOI 10.1177/0269881104047272; Puddey IB, 2006, CLIN EXP PHARMACOL P, V33, P847, DOI 10.1111/j.1440-1681.2006.04452.x; Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x; Richard F, 2012, J ALZHEIMERS DIS, V32, P765, DOI 10.3233/JAD-2012-121012; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSEN J, 1993, BRIT J PSYCHIAT, V163, P358, DOI 10.1192/bjp.163.3.358; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Siegel MB, 2011, AM J PREV MED, V40, P419, DOI 10.1016/j.amepre.2010.12.011; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Thakker KD, 1998, ALCOHOL CLIN EXP RES, V22, p285S, DOI 10.1111/j.1530-0277.1998.tb04381.x; Tsolaki M, 1997, Int Psychogeriatr, V9, P327, DOI 10.1017/S104161029700447X; Tyas SL, 2000, STAT MED, V19, P1685, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1685::AID-SIM454>3.0.CO;2-#; Vogel RA, 2003, J AM COLL CARDIOL, V41, P479, DOI 10.1016/S0735-1097(02)02825-5; Weyerer S, 2011, AGE AGEING, V40, P456, DOI 10.1093/ageing/afr007; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Yaffe K, 2007, CURR ALZHEIMER RES, V4, P123, DOI 10.2174/156720507780362191; Yaffe K, 2007, ALZ DIS ASSOC DIS, V21, P167, DOI 10.1097/WAD.0b013e318065bfd6; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	77	52	54	2	47	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1360-7863	1364-6915		AGING MENT HEALTH	Aging Ment. Health	MAR 1	2013	17	2					133	146		10.1080/13607863.2012.742488			14	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	100ED	WOS:000315677700001	23171229				2021-06-18	
J	Shultz, SR; Bao, F; Weaver, LC; Cain, DP; Brown, A				Shultz, Sandy R.; Bao, Feng; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur			Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion	JOURNAL OF NEUROINFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; LONG-EVANS RAT; PROFESSIONAL FOOTBALL PLAYERS; FLUID-PERCUSSION INJURY; ELEVATED PLUS-MAZE; HEAD-INJURY; RECURRENT CONCUSSION; ANIMAL-MODEL; BEHAVIORAL IMPAIRMENTS; REACTIVE ASTROCYTES	Background: Concussions account for the majority of traumatic brain injuries (TBI) and can result in cumulative damage, neurodegeneration, and chronic neurological abnormalities. The underlying mechanisms of these detrimental effects remain poorly understood and there are presently no specific treatments for concussions. Neuroinflammation is a major contributor to secondary damage following more severe TBI, and recent findings from our laboratory suggest it may be involved in the cumulative properties of repeated concussion. We previously found that an anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and adhesion molecule interaction following severe experimental TBI reduces neuroinflammation, oxidative activity, and tissue damage, and improves functional recovery. As similar processes may be involved in repeated concussion, here we studied the effects of the anti-CD11d treatment in a rat model of repeated concussion. Methods: Rats were treated 2 h and 24 h after each of three repeated mild lateral fluid percussion injuries with either the CD11d antibody or an isotype-matched control antibody, 1B7. Injuries were separated by a five-day inter-injury interval. After the final treatment and either an acute (24 to 72 h post-injury) or chronic (8 weeks post-injury) recovery period had elapsed, behavioral and pathological outcomes were examined. Results: The anti-CD11d treatment reduced neutrophil and macrophage levels in the injured brain with concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein accumulation, and neuronal loss. The anti-CD11d treatment also improved outcome on tasks of cognition, sensorimotor ability, and anxiety. Conclusions: These findings demonstrate that reducing inflammation after repeated mild brain injury in rats leads to improved behavioral outcomes and that the anti-CD11d treatment may be a viable therapy to improve post-concussion outcomes.	[Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada; [Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C2, Canada; [Bao, Feng; Weaver, Lynne C.; Brown, Arthur] Univ Western Ontario, Schulich Sch Med, Robarts Res Inst, London, ON N6A 5K8, Canada	Brown, A (corresponding author), Univ Western Ontario, Schulich Sch Med, Robarts Res Inst, 100 Perth Dr St, London, ON N6A 5K8, Canada.	abrown@robarts.ca	Weaver, Lynne C/K-8491-2013; Brown, Arthur/K-8328-2013; Brown, Arthur/K-6837-2013	Brown, Arthur/0000-0002-8725-3195; Shultz, Sandy/0000-0002-2525-8775	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported the Canadian Institutes of Health Research (LCW and AB) and the Natural Sciences and Engineering Research Council of Canada (DPC).	Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Geremia NM, 2012, J NEUROTRAUM, V29, P539, DOI 10.1089/neu.2011.1976; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gris P, 2009, J NEUROIMMUNOL, V209, P104, DOI 10.1016/j.jneuroim.2009.02.002; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44	45	52	52	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 15	2013	10								26	10.1186/1742-2094-10-26			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	100RM	WOS:000315719200001	23414334	DOAJ Gold, Green Published			2021-06-18	
J	Olthof, DC; Joosse, P; van der Vlies, CH; de Haan, RJ; Goslings, JC				Olthof, Dominique C.; Joosse, Pieter; van der Vlies, Cornelis H.; de Haan, Rob J.; Goslings, J. Carel			Prognostic factors for failure of nonoperative management in adults with blunt splenic injury: A systematic review	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Nonoperative management; failure; prognostic factors; blunt splenic injury	SOLID-ORGAN INJURIES; PREDICTIVE FACTORS; BURN PATIENTS; TRAUMA; SPLEEN; METAANALYSIS; SPLENECTOMY; MULTICENTER; MORTALITY; CRITERIA	BACKGROUND: Contradictory findings are reported in the literature concerning prognostic factors for failure of nonoperative management (NOM) in the treatment of adults with blunt splenic injury. The objective of this systematic review was to identify prognostic factors for failure of NOM, with or without angiography and embolization. METHODS: MEDLINE, Embase, and the Cochrane Library databases were searched. Prospective or retrospective cohort studies addressing failure of nonoperative treatment, with and/or without angiography and embolization, of blunt abdominal injuries were included. Methodological quality of the studies was assessed. RESULTS: A total of 335 titles and abstracts were screened, of which 31 fulfilled the inclusion criteria. No randomized controlled trials were found. Ten articles were qualified as high-quality articles and used for data extraction (best-evidence synthesis). A total of 25 prognostic factors were investigated, of which 14 were statistically significant in one or more studies. Strong evidence exists that age of 40 years or above, Injury Severity Score (ISS) of 25 or greater, and splenic injury grade of 3 or greater are prognostic factors for failure of NOM. Moderate evidence was found for a splenic Abbreviated Injury Scale score of 3 or greater, trauma and ISS of less than 0.80, the presence of an intraparenchymal contrast blush, as well as transfusion of 1 unit of packed red blood cells or more. Limited evidence was found for large hemoperitoneum, lower Revised Trauma Score, lower Glasgow Coma Scale score, lower systolic blood pressure, male sex, the presence of traumatic brain injury, and splenic embolization as protective factor for failure of NOM. CONCLUSION: Awareness for failure ofNOMis required in patients aged 40 years or older, in patients with an ISS of 25 or higher or those with splenic injury grade 3 or higher. The prognostic factors for failure that we identified should be confirmed in future prospective cohort studies or meta-analyses using individual patient data. (J Trauma Acute Care Surg. 2013;74: 546-557. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Olthof, Dominique C.; Joosse, Pieter; Goslings, J. Carel] Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands; [de Haan, Rob J.] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands; [van der Vlies, Cornelis H.] Maasstad Ziekenhuis Rotterdam, Rotterdam, Netherlands	Goslings, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl					Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; Barone JE, 1999, J TRAUMA, V46, P87, DOI 10.1097/00005373-199901000-00014; Bee TK, 2001, J TRAUMA, V50, P230, DOI 10.1097/00005373-200102000-00007; Bhangu A, 2012, INJURY, V43, P1337, DOI 10.1016/j.injury.2011.09.010; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; Cocanour CS, 2000, J TRAUMA, V48, P606, DOI 10.1097/00005373-200004000-00005; Cohn SM, 2009, AM SURGEON, V75, P133; Demetriades D, 2012, J TRAUMA ACUTE CARE, V72, P229, DOI 10.1097/TA.0b013e31823fe0b6; Duchesne JC, 2008, J TRAUMA, V65, P1346, DOI 10.1097/TA.0b013e31818c29ea; Fu CY, 2010, WORLD J SURG, V34, P2745, DOI 10.1007/s00268-010-0723-x; Galvan DA, 2006, CURR OPIN CRIT CARE, V12, P590, DOI 10.1097/MCC.0b013e328010d4ad; Gaunt WT, 1999, AM SURGEON, V65, P689; Germann G, 1997, BURNS, V23, P195, DOI 10.1016/S0305-4179(96)00112-X; Gonzalez M, 2008, J CHIR-PARIS, V145, P561, DOI 10.1016/S0021-7697(08)74687-8; Haan JM, 2005, J TRAUMA, V58, P492, DOI 10.1097/01.TA.0000154575.49388.74; Hashemzadeh SH, 2010, MINERVA CHIR, V65, P267; Jeremitsky E, 2011, AM SURGEON, V77, P215; Lehman R, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d8158; Lievense AM, 2002, ARTHRIT RHEUM-ARTHR, V47, P556, DOI 10.1002/art.10660; McIntyre LK, 2005, ARCH SURG-CHICAGO, V140, P563, DOI 10.1001/archsurg.140.6.563; Meguid AA, 2003, AM SURGEON, V69, P238; MRC Clinical Trials Unit, 2012, IND PAT DAT MET; Nix JA, 2001, J TRAUMA, V50, P835, DOI 10.1097/00005373-200105000-00010; O'Connor D, 2008, COCHRANE HDB SYSTEMA; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Post B, 2007, MOVEMENT DISORD, V22, P1839, DOI 10.1002/mds.21537; Renzulli P, 2010, BRIT J SURG, V97, P1696, DOI 10.1002/bjs.7203; Schroeppel TJ, 2007, CURR OPIN CRIT CARE, V13, P399, DOI 10.1097/MCC.0b013e32825a6a32; SCHURR MJ, 1995, J TRAUMA, V39, P507; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SMITH DL, 1994, J TRAUMA, V37, P655, DOI 10.1097/00005373-199410000-00021; Smith J, 2008, J TRAUMA, V64, P656, DOI 10.1097/TA.0b013e3181650fb4; Velmahos GC, 2000, ARCH SURG-CHICAGO, V135, P674, DOI 10.1001/archsurg.135.6.674; Velmahos GC, 2008, AM SURGEON, V74, P297; Velmahos GC, 2010, ARCH SURG-CHICAGO, V145, P456, DOI 10.1001/archsurg.2010.58; Watson GA, 2006, J TRAUMA, V61, P1113, DOI 10.1097/01.ta.0000241363.97619.d6	36	52	53	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					546	557		10.1097/TA.0b013e31827d5e3a			12	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UH	WOS:000316321200044	23354249				2021-06-18	
J	Choo, AM; Miller, WJ; Chen, YC; Nibley, P; Patel, TP; Goletiani, C; Morrison, B; Kutzing, MK; Firestein, BL; Sul, JY; Haydon, PG; Meaney, DF				Choo, Anthony M.; Miller, William J.; Chen, Yung-Chia; Nibley, Philip; Patel, Tapan P.; Goletiani, Cezar; Morrison, Barclay, III; Kutzing, Melinda K.; Firestein, Bonnie L.; Sul, Jai-Yoon; Haydon, Philip G.; Meaney, David F.			Antagonism of purinergic signalling improves recovery from traumatic brain injury	BRAIN			English	Article						neuroprotection; calcium waves; in vivo imaging; MRS 2179; astrocytes	INTERCELLULAR CALCIUM WAVES; SYNAPTIC-TRANSMISSION; GLUTAMATE EXOCYTOSIS; REACTIVE ASTROCYTES; EXTRACELLULAR ATP; PYRAMIDAL NEURONS; CLINICAL-TRIALS; CREB SHUTOFF; RECEPTORS; P2Y(1)	The recent public awareness of the incidence and possible long-term consequences of traumatic brain injury only heightens the need to develop effective approaches for treating this neurological disease. In this report, we identify a new therapeutic target for traumatic brain injury by studying the role of astrocytes, rather than neurons, after neurotrauma. We use in vivo multiphoton imaging and show that mechanical forces during trauma trigger intercellular calcium waves throughout the astrocytes, and these waves are mediated by purinergic signalling. Subsequent in vitro screening shows that astrocyte signalling through the 'mechanical penumbra' affects the activity of neural circuits distant from the injury epicentre, and a reduction in the intercellular calcium waves within astrocytes restores neural activity after injury. In turn, the targeting of different purinergic receptor populations leads to a reduction in hippocampal cell death in mechanically injured organotypic slice cultures. Finally, the most promising therapeutic candidate from our in vitro screen (MRS 2179, a P2Y1 receptor antagonist) also improves histological and cognitive outcomes in a preclinical model of traumatic brain injury. This work shows the potential of studying astrocyte signalling after trauma to yield new and effective therapeutic targets for treating traumatic brain injury.	[Choo, Anthony M.; Miller, William J.; Chen, Yung-Chia; Nibley, Philip; Patel, Tapan P.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Goletiani, Cezar; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Kutzing, Melinda K.; Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ USA; [Sul, Jai-Yoon] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Haydon, Philip G.] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, Suite 240,Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Firestein, Bonnie/0000-0002-1679-3565; Meaney, David/0000-0002-0954-4122; Patel, Tapan/0000-0001-8959-6645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 35712, HS 41699]; Department of DefenseUnited States Department of Defense [W911NF-10-1-0526]; State of New Jersey [10-3209-BIR-E-3]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER	National Institutes of Health (NS 35712, HS 41699); Department of Defense (W911NF-10-1-0526); the State of New Jersey (10-3209-BIR-E-3).	Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Charles A, 1998, GLIA, V24, P39, DOI 10.1002/(SICI)1098-1136(199809)24:1<39::AID-GLIA5>3.0.CO;2-W; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Deng P, 2011, J NEUROTRAUM, V28, P1173, DOI 10.1089/neu.2010.1683; Ding S, 2007, J NEUROSCI, V27, P10674, DOI 10.1523/JNEUROSCI.2001-07.2007; Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Franklin K.P.G., 1996, MOUSE BRAIN STEREOTA; Gordon GRJ, 2009, NEURON, V64, P391, DOI 10.1016/j.neuron.2009.10.021; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; HOWARD CV, 1998, UNBIASED STEREOLOGY; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jayaraman V, 2007, FRONT NEURAL CIRCUIT, V1, DOI [10.3389/neuro.04/003.2007, 10.3389/neuro.04.003.2007]; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Kuboyama K, 2011, J CEREBR BLOOD F MET, V31, P1930, DOI 10.1038/jcbfm.2011.49; Kunapuli SP, 2003, CURR PHARM DESIGN, V9, P2303, DOI 10.2174/1381612033453947; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mendoza-Fernandez V, 2000, J PHARMACOL EXP THER, V293, P172; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Newman EA, 2001, J NEUROSCI, V21, P2215; Oliveira-da-Silva A, 2010, NEUROSCIENCE, V167, P163, DOI 10.1016/j.neuroscience.2010.01.060; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Peden M., 2004, WORLD REPORT ROAD TR; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rodrigues RJ, 2005, J NEUROSCI, V25, P6286, DOI 10.1523/JNEUROSCI.0628-05.2005; Rodriguez-Zayas AE, 2012, J MOL NEUROSCI, V46, P167, DOI 10.1007/s12031-011-9567-6; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Tian GF, 2006, ADV DRUG DELIVER REV, V58, P773, DOI 10.1016/j.addr.2006.07.001; Tonazzini I, 2007, EUR J NEUROSCI, V26, P890, DOI 10.1111/j.1460-9568.2007.05697.x; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Van Hedel HJA, 2006, J NEUROTRAUM, V23, P1621, DOI 10.1089/neu.2006.23.1621; Venance L, 1997, J NEUROSCI, V17, P1981; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	58	52	52	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2013	136		1				65	80		10.1093/brain/aws286			16	Clinical Neurology; Neurosciences	Neurosciences & Neurology	089KR	WOS:000314909900007	23293266	Green Published, Bronze			2021-06-18	
J	Fabbri, A; Servadei, F; Marchesini, G; Bronzoni, C; Montesi, D; Arietta, L				Fabbri, Andrea; Servadei, Franco; Marchesini, Giulio; Bronzoni, Carolina; Montesi, Danilo; Arietta, Luca		Soc Italiana Med Emergenza Urgenza	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; MODERATE HEAD-INJURY; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; EUROPEAN-SOCIETY; RISK-FACTORS; TASK-FORCE; PROGRESSION; VALIDATION	Introduction: Pre-injury antithrombotic therapy might influence the outcome of subjects with head injuries and positive computed tomography (CT) scans. We aimed to determine the potential risk of pre-injury antiplatelet drug use on short-and long-term outcome of head injured subjects admitted to emergency departments (EDs) in Italy for extended observation. Methods: A total of 1,558 adult subjects with mild, moderate and severe head injury admitted to Italian EDs were studied. In multivariable logistic regression analyses, the short-term outcome was assessed by an evaluation of head CT scan at 6 to 24 hours after trauma and the long-term outcome by the Glasgow outcome scale (GOS) at six months. Results: Head CT scan comparisons showed that 201 subjects (12.9%) worsened. The risk of worsening was increased two fold by the use of antiplatelet drugs (106, 19.7% treated versus 95, 9.3% untreated; relative risk (RR) 2.09, 95% CI 1.63 to 2.71). The risk was particularly high in subjects on clopidogrel (RR 5.76, 95% CI 3.88 to 8.54), independent of the association with aspirin. By logistic regression, 5 of 14 items were independently associated with worsening (Glasgow coma scale (GCS), Marshall category, antiplatelet therapy, intraventricular hemorrhage, number of lesions). After six months, only 4 of 14 items were predictors of unfavorable outcome (GOS 1 to 3) (GCS score, Marshall category, age in decades, intracerebral hemorrhage/contusion). The risk increased by 50% in the group treated with antiplatelet therapy (RR 1.58, 95% CI 1.28 to 1.95; P < 0.001). Conclusions: Antithrombotic therapy (in particular clopidogrel) is a risk factor for both short-term and long-term unfavorable outcome in subjects with head injury, increasing the risk of progression and death, permanent vegetative state and severe disability.	[Fabbri, Andrea] Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, Azienda Unita Sanit Locale Forli, I-40121 Forli, Italy; [Servadei, Franco; Bronzoni, Carolina] Univ Parma, Azienda Osped, Dipartimento Emergenza Urgenza, I-43126 Parma, Italy; [Marchesini, Giulio] Univ Bologna, Dipartimento Sci Med & Chirurg, I-40138 Bologna, Italy; [Montesi, Danilo; Arietta, Luca] Univ Bologna, Dipartimento Informat Sci & Ingn, I-40127 Bologna, Italy	Fabbri, A (corresponding author), Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, Azienda Unita Sanit Locale Forli, Via Forlanini 34, I-40121 Forli, Italy.	dr.andrea.fabbri@gmail.com	Fabbri, Andrea/K-9994-2016; Vercelli, Alessandro/A-1926-2012	Marchesini, Giulio/0000-0003-2407-9860; Vercelli, Alessandro/0000-0002-5909-2128; Servadei, Franco/0000-0002-3595-3464; MONTESI, DANILO/0000-0002-4748-6867; Fabbri, Andrea/0000-0002-9837-4638			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; DEROSA M, 2007, COLLANA RAPPORTI ARN, V11, P1; Donze J, 2012, AM J MED, V125, P773, DOI 10.1016/j.amjmed.2012.01.033; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FABBRI A, J NEUROL NEUROSURG P, V81, P1275; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Giannoudis PV, 2009, INJURY, V40, P362, DOI 10.1016/j.injury.2008.10.016; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; *ISS AIFA, 2008, US FARM IT, P36; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martini SR, 2012, NEUROLOGY, V79, P2275, DOI 10.1212/WNL.0b013e318276896f; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patrono C, 2004, EUR HEART J, V25, P166, DOI 10.1016/j.ehj.2003.10.013; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2000, NEUROSURGERY, V46, P70; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAN MSP, 2006, INTRO DATA MINING, P1; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Visca A, 2006, BRIT J NEUROSURG, V20, P82, DOI 10.1080/02688690600682416; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	40	52	52	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	2							R53	10.1186/cc12575			11	Critical Care Medicine	General & Internal Medicine	264OG	WOS:000327887300018	23514619	DOAJ Gold, Green Published			2021-06-18	
J	Aries, MJH; Czosnyka, M; Budohoski, KP; Kolias, AG; Radolovich, DK; Lavinio, A; Pickard, JD; Smielewski, P				Aries, Marcel J. H.; Czosnyka, Marek; Budohoski, Karol P.; Kolias, Angelos G.; Radolovich, Danila K.; Lavinio, Andrea; Pickard, John D.; Smielewski, Peter			Continuous Monitoring of Cerebrovascular Reactivity Using Pulse Waveform of Intracranial Pressure	NEUROCRITICAL CARE			English	Article						Brain injuries; Intracranial pressure; Physiological adaptation; Outcome assessment; Wavelet analysis	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; AUTOREGULATION; DYNAMICS	Guidelines for the management of traumatic brain injury (TBI) call for the development of accurate methods for assessment of the relationship between cerebral perfusion pressure (CPP) and cerebral autoregulation and to determine the influence of quantitative indices of pressure autoregulation on outcome. We investigated the relationship between slow fluctuations of arterial blood pressure (ABP) and intracranial pressure (ICP) pulse amplitude (an index called PAx) using a moving correlation technique to reflect the state of cerebral vasoreactivity and compared it to the index of pressure reactivity (PRx) as a moving correlation coefficient between averaged values of ABP and ICP. A retrospective analysis of prospective 327 TBI patients (admitted on neurocritical care unit of a university hospital in the period 2003-2009) with continuous ABP and ICP monitoring. PAx was worse in patients who died compared to those who survived (-0.04 +/- A 0.15 vs. -0.16 +/- A 0.15, chi(2) = 28, p < 0.001). In contrast to PRx, PAx was able to differentiate between fatal and non-fatal outcome in a group of 120 patients with ICP levels below 15 mmHg (-0.04 +/- A 0.16 vs. -0.14 +/- A 0.16, chi(2) = 6, p = 0.01). PAx is a new modified index of cerebrovascular reactivity which performs equally well as established PRx in long-term monitoring in severe TBI patients, but importantly is potentially more robust at lower values of ICP. In view of establishing an autoregulation-oriented CPP therapy, continuous determination of PAx is feasible but its value has to be evaluated in a prospective controlled trail.	[Aries, Marcel J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Aries, Marcel J. H.; Czosnyka, Marek; Budohoski, Karol P.; Kolias, Angelos G.; Pickard, John D.; Smielewski, Peter] Univ Cambridge, Dept Clin Neurosci, Acad Neurosurg Unit, Cambridge, England; [Radolovich, Danila K.] Univ Hosp Pavia, Dept Intens Care, Pavia, Italy; [Lavinio, Andrea] Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England	Aries, MJH (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	m.j.h.aries@umcg.nl	Lavinio, Andrea/M-1778-2016	Smielewski, Peter/0000-0001-5096-3938; Kolias, Angelos/0000-0003-3992-0587	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development; European Federation of Neurological Societies (EFNS); Royal College of Surgeons of England; National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G0001237, G0001354B, G0600986, G9439390, G0001354] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Marcel JH Aries is supported by the Netherlands Organisation for Health Research and Development and a fellowship of the European Federation of Neurological Societies (EFNS). Angelos G. Kolias is supported by a Royal College of Surgeons of England Research Fellowship, a National Institute for Health Research (NIHR) Academic Clinical Fellowship and a Raymond and Beverly Sackler Studentship. John D. Pickard is a NIHR senior investigator and is a principal investigator (PI) within the NIHR Biomedical Research Centre (Cambridge University Hospital Foundation Trust) and lead PI for the Medical Research Council (MRC) 'Acute Brain Injury Programme' grant.	AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Bentsen G, 2008, CRIT CARE MED, V36, P2414, DOI 10.1097/CCM.0b013e318180fe04; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Eide PK, 2006, ACTA NEUROCHIR, V148, P1267, DOI 10.1007/s00701-006-0908-0; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Mahfoud F, 2010, ACTA NEUROCHIR, V152, P443, DOI 10.1007/s00701-009-0520-1; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Radolovich DK, 2011, NEUROCRIT CARE, V15, P379, DOI 10.1007/s12028-011-9553-4; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Zweifel C, 2010, J NEUROTRAUM, V27, P1951, DOI 10.1089/neu.2010.1388; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	24	52	52	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					67	76		10.1007/s12028-012-9687-z			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000009	22477613				2021-06-18	
J	Bouwes, A; Robillard, LBM; Binnekade, JM; de Pont, ACJM; Wieske, L; den Hartog, AW; Schultz, MJ; Horn, J				Bouwes, Aline; Robillard, Laure B. M.; Binnekade, Jan M.; de Pont, Anne-Cornelie J. M.; Wieske, Luuk; den Hartog, Alexander W.; Schultz, Marcus J.; Horn, Janneke			The influence of rewarming after therapeutic hypothermia on outcome after cardiac arrest	RESUSCITATION			English	Article						Cardiac arrest; Hypothermia; Rewarming; Fever; Outcome	EMERGENCY CARDIOVASCULAR CARE; TRAUMATIC BRAIN-INJURY; CARDIOPULMONARY-RESUSCITATION; MODERATE HYPOTHERMIA; FEVER CONTROL; HYPERTHERMIA; DAMAGE; RATS; ISCHEMIA	Introduction: Treatment with hypothermia has been shown to improve outcome after cardiac arrest (CA). Current consensus is to rewarm at 0.25-0.5 degrees C/h and avoid fever. The aim of this study was to investigate whether active rewarming, the rate of rewarming or development of fever after treatment with hypothermia after CA was correlated with poor outcome. Methods: This retrospective cohort study included adult patients treated with hypothermia after CA and admitted to the intensive care unit between January 2006 and January 2009. The average rewarming rate from end of hypothermia treatment (passive rewarming) or start active rewarming until 36 degrees C was dichotomized in a high (>= 0.5 degrees C/h) or normal rate (<0.5 degrees C/h). Fever was defined as >38 degrees C within 72 h after admission. Poor outcome was defined as death, vegetative state, or severe disability after 6 months. Results: From 128 included patients, 56% had a poor outcome. Actively rewarmed patients (38%) had a higher risk for poor outcome, OR 2.14 (1.01-4.57), p < 0.05. However, this effect disappeared after adjustment for the confounders age and initial rhythm, OR 1.51 (0.64-3.58). A poor outcome was found in 15/21 patients (71%) with a high rewarming rate, compared to 54/103 patients (52%) with a normal rewarming rate, OR 2.61 (0.88-7.73), p = 0.08. Fever was not associated with outcome, OR 0.64 (0.31-1.30), p = 0.22. Conclusions: This study showed that patients who needed active rewarming after therapeutic hypothermia after CA did not have a higher risk for a poor outcome. In addition, neither speed of rewarming, nor development of fever had an effect on outcome. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Bouwes, Aline; Robillard, Laure B. M.; Binnekade, Jan M.; de Pont, Anne-Cornelie J. M.; Wieske, Luuk; den Hartog, Alexander W.; Schultz, Marcus J.; Horn, Janneke] Acad Med Ctr, Dept Intens Care, NL-1100 DD Amsterdam, Netherlands; [Wieske, Luuk] Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands; [Schultz, Marcus J.] Acad Med Ctr, LEICA, NL-1100 DD Amsterdam, Netherlands	Bouwes, A (corresponding author), Acad Med Ctr, Dept Intens Care, Room C3-423,POB 22660, NL-1100 DD Amsterdam, Netherlands.	a.bouwes@amc.uva.nl	Schultz, Marcus J/K-6147-2012; Wieske, Luuk/AAF-1899-2020		Dutch Heart FoundationNetherlands Heart Foundation [2007B039]	Part of this work was previously presented as a poster at the 3rd International Hypothermia Symposium, Lund, Sweden, September 2009. Dr. Bouwes, Mrs. Robillard, Dr. Binnekade, Dr. de Pont, Dr. Wieske, Dr. den Hartog and Dr. Schultz report no conflicts of interest. Dr. Horn received a research grant from the Dutch Heart Foundation (2007B039).	Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Badjatia N, 2009, CRIT CARE MED, V37, pS250, DOI 10.1097/CCM.0b013e3181aa5e8d; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bouwes A, 2012, ANN NEUROL, V71, P206, DOI 10.1002/ana.22632; Chester JG, 2011, J AM MED DIR ASSOC, V12, P337, DOI 10.1016/j.jamda.2010.04.009; De Tanti A, 2005, BRAIN INJURY, V19, P1277, DOI 10.1080/02699050500309270; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Gordan ML, 2010, PERFUSION-UK, V25, P349, DOI 10.1177/0267659110377946; Grigore AM, 2002, ANESTH ANALG, V94, P4, DOI 10.1097/00000539-200201000-00002; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Suffoletto B, 2009, RESUSCITATION, V80, P1365, DOI 10.1016/j.resuscitation.2009.08.020; Takasu A, 2001, RESUSCITATION, V49, P273, DOI 10.1016/S0300-9572(00)00360-9; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	32	52	56	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	AUG	2012	83	8					996	1000		10.1016/j.resuscitation.2012.04.006			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	009TL	WOS:000309048000026	22521448				2021-06-18	
J	Bennett, TD; Riva-Cambrin, J; Keenan, HT; Korgenski, EK; Bratton, SL				Bennett, Tellen D.; Riva-Cambrin, Jay; Keenan, Heather T.; Korgenski, E. Kent; Bratton, Susan L.			Variation in Intracranial Pressure Monitoring and Outcomes in Pediatric Traumatic Brain Injury	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							CRITICALLY-ILL CHILDREN; GLASGOW COMA SCALE; SEVERITY SCORE; YOUNG-CHILDREN; UNITED-STATES; CARE; THERAPY; VOLUME; MORTALITY; HOSPITALIZATIONS	Objectives: To describe between-hospital and patient-level variation in intracranial pressure (ICP) monitoring and to evaluate ICP monitoring in association with hospital features and outcome in children with traumatic brain injury (TBI). Design: Retrospective cohort study. Setting: Children's hospitals participating in the Pediatric Health Information System database (January 2001 to June 2011). Participants: Children (aged <18 years) with TBI and head Abbreviated Injury Scale scores of at least 3 who were ventilated for at least 96 consecutive hours or who died in the first 4 days after hospital admission. Main Outcome Measures: Monitoring of ICP. Results: A total of 4667 children met the study criteria. Hospital mortality was 41% (n=1919). Overall, 55% of patients (n=2586) received ICP monitoring. Expected hospital ICP monitoring rates after adjustment for patient age, cardiac arrest, inflicted injury, craniotomy or craniectomy, head Abbreviated Injury Scale score, and Injury Severity Score were 47% to 60%. Observed hospital ICP monitoring rates were 14% to 83%. Hospitals with more observed ICP monitoring, relative to expected, and hospitals with higher patient volumes had lower rates of mortality or severe disability. After adjustment for between-hospital variation and patient severity of injury, ICP monitoring was independently associated with age 1 year and older (odds ratio, 3.1; 95% CI, 2.5-3.8) vs age younger than 1 year. Conclusions: There was significant between-hospital variation in ICP monitoring that cannot be attributed solely to differences in case mix. Hospitals that monitor ICP more frequently and hospitals with higher patient volumes had better patient outcomes. Infants with TBI are less likely to receive ICP monitoring than are older children.	[Bennett, Tellen D.; Korgenski, E. Kent] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA	Bennett, TD (corresponding author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	tell.bennett@hsc.utah.edu		Bratton, Susan/0000-0002-4605-8078; Bennett, Tellen/0000-0003-1483-4236	National Cancer Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1KM1CA156723]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [KM1CA156723] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001067] Funding Source: NIH RePORTER	Dr Bennett is partially supported by the Mentored Scholars Program for Translational Comparative Effectiveness Research grant 1KM1CA156723 from the National Cancer Institute, National Institutes of Health.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; American College of Surgeons Committee on Traum, VER TRAUM CTR; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Conway PH, 2009, J PEDIATR-US, V154, P789, DOI 10.1016/j.jpeds.2009.01.010; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Di Gennaro JL, 2010, DEV NEUROSCI-BASEL, V32, P420, DOI 10.1159/000322083; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; *EXP GROUP INJ SEV, DISC DOC INJ SEV MEA; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Goldin AB, 2007, PEDIATRICS, V119, P905, DOI 10.1542/peds.2006-2040; Goodman DC, 2009, PEDIATR CLIN N AM, V56, P745, DOI 10.1016/j.pcl.2009.05.007; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2006, PEDIAT CRITICAL CARE, P1596; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McLeod L, 2011, ARCH PEDIAT ADOL MED, V165, P857, DOI 10.1001/archpediatrics.2011.132; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Odetola FO, 2006, PEDIATRICS, V117, P1893, DOI 10.1542/peds.2005-2179; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Tepas JJ, 2009, J TRAUMA, V67, P185, DOI 10.1097/TA.0b013e3181a5f03c; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Tilford JM, 2000, PEDIATRICS, V106, P289, DOI 10.1542/peds.106.2.289; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Tri-Analytics Inc. and The Johns Hopkins University, 1997, ICDMAP 90 SOFTW US G; US Health Care Financing Administration, 2007, INT CLASS DIS; Weiss PF, 2009, J PEDIAT, V155, P812; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	44	52	54	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2012	166	7					641	647					7	Pediatrics	Pediatrics	967HJ	WOS:000305897200011	22751878	Green Accepted, Bronze			2021-06-18	
J	Lange, RT; Iverson, GL; Brubacher, JR; Madler, B; Heran, MK				Lange, Rael T.; Iverson, Grant L.; Brubacher, Jeffrey R.; Maedler, Burkhard; Heran, Manraj K.			Diffusion Tensor Imaging Findings Are Not Strongly Associated With Postconcussional Disorder 2 Months Following Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						corpus callosum; diffusion tensor imaging; mild traumatic brain injury; postconcussion symptoms	GOOD OLD DAYS; CORPUS-CALLOSUM; AXONAL INJURY; BASE RATES; MODERATE; ABNORMALITIES; SYMPTOMS; PERFORMANCE; ETIOLOGY	Objective: To examine the relation between diffusion tensor imaging (DTI) of the corpus callosum and postconcussion symptom reporting following mild traumatic brain injury (MTBI). Participants: Sixty patients with MTBI and 34 patients with orthopedic/soft-tissue injuries (Trauma Controls) prospectively enrolled from consecutive admissions to a level 1 trauma center. Procedure: Diffusion tensor imaging of the corpus callosum was undertaken using a Phillips 3T scanner at 6 to 8 weeks postinjury. Participants also completed a postconcussion symptom checklist. The MTBI group was divided into 2 subgroups based on the International Classification of Diseases, Tenth Revision symptom criteria for postconcussion disorder (PCD): PCD Present (n = 21), PCD Absent (n = 39). Main Outcome Measures: Measures of fractional anisotropy and mean diffusivity for the genu, body, and splenium of the corpus callosum. Participants also completed the British Columbia Post-Concussion Symptom Inventory. Results: The MTBI group reported more postconcussion symptoms than the trauma controls. There were no significant differences between MTBI and trauma control groups on all DTI measures. In the MTBI sample, there were no significant differences on all DTI measures between those who did and did not meet the International Classification of Diseases, Tenth Revision research criteria for postconcussion disorder. Conclusions: These data do not support an association between white matter integrity in the corpus callosum and self-reported postconcussion syndrome 6 to 8 weeks post-MTBI.	[Lange, Rael T.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Lange, Rael T.; Iverson, Grant L.; Brubacher, Jeffrey R.; Maedler, Burkhard; Heran, Manraj K.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Brubacher, Jeffrey R.; Heran, Manraj K.] Vancouver Gen Hosp, Vancouver, BC, Canada; [Brubacher, Jeffrey R.] Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	Lange, RT (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B207,6900 Georgia Ave NW, Washington, DC 20307 USA.	rlange@dvbic.org		Brubacher, Jeffrey/0000-0002-4866-4231; Iverson, Grant/0000-0001-7348-9570	Alcohol Beverage Medical Research Foundation; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-89374]	This study was supported, in part, by a research grant from the Alcohol Beverage Medical Research Foundation and the Canadian Institutes of Health Research (MOP-89374).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J, 1998, STAT POWER ANAL BEHA; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sosin DM, 1996, BRAIN INJURY, V10, P47; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	47	52	52	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					188	198		10.1097/HTR.0b013e318217f0ad			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500007	21642855				2021-06-18	
J	Yamada, KH; Kozlowski, DA; Seidl, SE; Lance, S; Wieschhaus, AJ; Sundivakkam, P; Tiruppathi, C; Chishti, I; Herman, IM; Kuchay, SM; Chishti, AH				Yamada, Kaori H.; Kozlowski, Dorothy A.; Seidl, Stacey E.; Lance, Steven; Wieschhaus, Adam J.; Sundivakkam, Premanand; Tiruppathi, Chinnaswamy; Chishti, Imran; Herman, Ira M.; Kuchay, Shafi M.; Chishti, Athar H.			Targeted Gene Inactivation of Calpain-1 Suppresses Cortical Degeneration Due to Traumatic Brain Injury and Neuronal Apoptosis Induced by Oxidative Stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MU-CALPAIN; CROSS-TALK; CLEAVAGE; ACTIVATION; INHIBITOR; CASPASE; CALCIUM; PROTEIN; IMPACT	Calpains are calcium-regulated cysteine proteases that have been implicated in the regulation of cell death pathways. Here, we used our calpain-1 null mouse model to evaluate the function of calpain-1 in neural degeneration following a rodent model of traumatic brain injury. In vivo, calpain-1 null mice show significantly less neural degeneration and apoptosis and a smaller contusion 3 days post-injury than wild type littermates. Protection from traumatic brain injury corroborated with the resistance of calpain-1 neurons to apoptosis induced by oxidative stress. Biochemical analysis revealed that caspase-3 activation, extracellular calcium entry, mitochondrial membrane permeability, and release of apoptosis-inducing factor from mitochondria are partially blocked in the calpain-1 null neurons. These findings suggest that the calpain-1 knock-out mice may serve as a useful model system for neuronal protection and apoptosis in traumatic brain injury and other neurodegenerative disorders in which oxidative stress plays a role.	[Yamada, Kaori H.; Wieschhaus, Adam J.; Herman, Ira M.; Chishti, Athar H.] Tufts Univ, Sch Med, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA; [Wieschhaus, Adam J.; Chishti, Athar H.] Univ Illinois, Coll Med, Sackler Sch Program Physiol, Chicago, IL 60612 USA; [Wieschhaus, Adam J.; Chishti, Imran] Univ Illinois, Coll Med, Sackler Sch Program Pharmacol, Chicago, IL 60612 USA; [Wieschhaus, Adam J.; Chishti, Imran] Univ Illinois, Coll Med, Sackler Sch Program Microbiol, Chicago, IL 60612 USA; [Yamada, Kaori H.; Wieschhaus, Adam J.; Sundivakkam, Premanand; Tiruppathi, Chinnaswamy; Chishti, Imran; Kuchay, Shafi M.; Chishti, Athar H.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; [Kozlowski, Dorothy A.; Seidl, Stacey E.; Lance, Steven] Depaul Univ, Dept Biol Sci, Chicago, IL 60614 USA	Chishti, AH (corresponding author), Tufts Univ, Sch Med, Dept Mol Physiol & Pharmacol, Boston, MA 02111 USA.	athar.chishti@tufts.edu		Yamada, Kaori/0000-0003-4075-9866	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL089517, HL095050, HL051445]; DePaul University Research Council; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL051445, R56HL051445, R01HL095050, R01HL089517] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants HL089517, HL095050, and HL051445 (to A. H. C.). This work was also supported by DePaul University Research Council (to D. A. K.).	Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Badugu R, 2008, J BIOL CHEM, V283, P3409, DOI 10.1074/jbc.M706851200; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bertipaglia I., 2007, V45, P29; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Clark RSB, 1999, FASEB J, V13, P813; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dipolo R, 2006, PHYSIOL REV, V86, P155, DOI 10.1152/physrev.00018.2005; Dixon C. E., 1996, FLUID PERCUSSION COR, P1337; Fedrizzi L, 2011, BIOFACTORS, V37, P189, DOI 10.1002/biof.157; Gafni J, 2009, J BIOL CHEM, V284, P25441, DOI 10.1074/jbc.M109.038174; Gao G, 2000, J CELL BIOCHEM, V80, P53; Geddes JW, 2010, EXP NEUROL, V226, P6, DOI 10.1016/j.expneurol.2010.07.025; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Harper AGS, 2007, CELL CALCIUM, V41, P169, DOI 10.1016/j.ceca.2006.05.008; Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321; Horiguchi K, 2006, J CELL BIOL, V174, P425, DOI 10.1083/jcb.200604031; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kuchay SM, 2007, MOL CELL BIOL, V27, P6038, DOI 10.1128/MCB.00522-07; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kuwako K, 2002, MOL BRAIN RES, V107, P166, DOI 10.1016/S0169-328X(02)00489-8; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Ray SK, 2003, J CHEM NEUROANAT, V26, P119, DOI 10.1016/S0891-0618(03)00044-9; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sareen D, 2007, MOL PHARMACOL, V72, P1466, DOI 10.1124/mol.107.039040; Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sundivakkam PC, 2009, AM J PHYSIOL-CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Volbracht C, 2001, NEUROREPORT, V12, P3645, DOI 10.1097/00001756-200112040-00008; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Waters SL, 1997, J PHARMACOL EXP THER, V283, P1177; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	57	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2012	287	16					13182	13193		10.1074/jbc.M111.302612			12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	927JO	WOS:000302903700056	22367208	Green Published, Other Gold			2021-06-18	
J	Cheyuo, C; Jacob, A; Wu, RQ; Zhou, MA; Qi, L; Dong, WF; Ji, YX; Chaung, WW; Wang, HC; Nicastro, J; Coppa, GF; Wang, P				Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Wang, Haichao; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping			Recombinant human MFG-E8 attenuates cerebral ischemic injury: Its role in anti-inflammation and anti-apoptosis	NEUROPHARMACOLOGY			English	Article						MFG-E8; Cerebral ischemia; Inflammation; Apoptosis; Neuroprotection	FACTOR-VIII; PROTEIN; RATS; REPERFUSION; STROKE; INFARCTION; DOMAINS; DISEASE; MICE; INFILTRATION	Excessive inflammation and apoptosis contribute to the pathogenesis of ischemic stroke. MFG-E8 is a 66-kDa glycoprotein that has shown tissue protection in various models of organ injury. However, the potential role of MFG-E8 in cerebral ischemia has not been investigated. We found that levels of MFG-E8 protein in the brain were reduced at 24 h after cerebral ischemia. To assess the potential role of MFG-E8 in cerebral ischemia, adult male Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion (MCAO). At 1 h post-stroke onset, an intravenous administration of 1 ml saline as vehicle or 160 mu g/kg BW recombinant human MFG-E8 (rhMFG-E8) as treatment was given. The optimal dose of rhMFG-E8 was obtained from previous dose response organ protection in rat sepsis studies. Neurological scores were determined at 24 h and 48 h post-MCAO. Rats were sacrificed thereafter and brains rapidly removed and analyzed for infarct size, histopathology, and markers of inflammation and apoptosis. Compared with saline vehicle, rhMFG-E8 treatment led to significant decreases in sensorimotor and vestibulomotor deficits, and infarct size at 24 h and 48 h post-MCAO. Measures associated with improved outcome included reduced microglial inflammatory cytokine secretion, adhesion molecules and neutrophil influx, cleaved caspase-3, and upregulation of peroxisome proliferator activated receptor-gamma (PPAR-gamma), and Bcl-2/Bax ratio leading to decreased apoptosis. Thus, rhMFG-E8 treatment is neuroprotective against cerebral ischemia through suppression of inflammation and apoptosis. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.	[Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Wang, Haichao; Wang, Ping] Elmezzi Grad Sch Mol Med, Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA; [Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping] N Shore Univ Hosp, Dept Surg, Manhasset, NY USA; [Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping] Long Isl Jewish Med Ctr, Manhasset, NY USA	Wang, P (corresponding author), Elmezzi Grad Sch Mol Med, Feinstein Inst Med Res, Ctr Immunol & Inflammat, 350 Community Dr, Manhasset, NY 11030 USA.	pwang@nshs.edu	ji, youxin/F-3802-2014; Wu, Rongqian/I-3614-2012; Cheyuo, Cletus/AAM-5785-2021; Varghese, Asha/AAK-4922-2021; Wang, Haichao/K-6310-2012; Qi, Lei/A-2980-2009; ji, youxin/F-3802-2014	ji, youxin/0000-0003-2895-4730; Wu, Rongqian/0000-0003-0993-4531; Wang, Haichao/0000-0002-0211-9000; Wang, Ping/0000-0002-1557-0394; Qi, Lei/0000-0002-9525-9132; ji, youxin/0000-0003-2303-8784	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL076179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM053008, R01GM057468] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL076179, R01 HL076179-05A1] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM053008-15, R01 GM057468-13, R01 GM053008, R01 GM057468] Funding Source: Medline		Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Antonsson B, 2004, MOL CELL BIOCHEM, V256, P141, DOI 10.1023/B:MCBI.0000009865.70898.36; Aziz MM, 2009, J IMMUNOL, V182, P7222, DOI 10.4049/jimmunol.0803711; Boddaert J, 2007, AM J PATHOL, V170, P921, DOI 10.2353/ajpath.2007.060664; Boscia F, 2009, STROKE, V40, P3608, DOI 10.1161/STROKEAHA.109.557439; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Cheyuo C, 2011, SHOCK, V35, P258, DOI 10.1097/SHK.0b013e3181f48a37; Collins C, 1997, GENOMICS, V39, P117; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Cui TP, 2010, AM J RESP CRIT CARE, V181, P238, DOI 10.1164/rccm.200804-625OC; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fuller AD, 2008, J NEUROIMMUNE PHARM, V3, P246, DOI 10.1007/s11481-008-9118-2; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hofmeijer J, 2004, BRAIN RES, V1013, P74, DOI 10.1016/j.brainres.2004.03.057; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Kozak W, 2008, J PHARMACOL EXP THER, V326, P773, DOI 10.1124/jpet.108.139618; Kranich J, 2010, J EXP MED, V207, P2271, DOI 10.1084/jem.20092401; LAROCCA D, 1991, CANCER RES, V51, P4994; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Leonardi-Essmann F, 2005, J NEUROIMMUNOL, V160, P92, DOI 10.1016/j.jneuroim.2004.11.012; Lu C, 2010, J CEREBR BLOOD F MET, V30, P1972, DOI 10.1038/jcbfm.2010.59; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Miksa M, 2006, SHOCK, V25, P586, DOI 10.1097/01.shk.0000209533.22941.d0; Noda M, 2011, J BIOL CHEM, V286, P2308, DOI 10.1074/jbc.M110.169839; Ozden H, 2011, BRAIN RES, V1370, P185, DOI 10.1016/j.brainres.2010.11.045; Qiang XL, 2011, INT J MOL MED, V28, P1071, DOI 10.3892/ijmm.2011.782; Raymond AS, 2010, MOL REPROD DEV, V77, P550, DOI 10.1002/mrd.21189; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Shah KG, 2012, INTENS CARE MED, V38, P128, DOI 10.1007/s00134-011-2353-7; Shao C, 2008, J BIOL CHEM, V283, P7230, DOI 10.1074/jbc.M705195200; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wiessner R, 2009, TRANSPL P, V41, P3622, DOI 10.1016/j.transproceed.2009.05.039; Wu JS, 2009, CIRCULATION, V119, P1124, DOI 10.1161/CIRCULATIONAHA.108.812537; Wu RQ, 2009, ANN SURG, V250, P126, DOI 10.1097/SLA.0b013e3181ad85d6; Yu JH, 2008, INT J BIOCHEM CELL B, V40, P677, DOI 10.1016/j.biocel.2007.10.007; Zeng HK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-153; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zimmerman SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017256	45	52	55	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	FEB	2012	62	2					890	900		10.1016/j.neuropharm.2011.09.018			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	909FZ	WOS:000301549300037	21964436	Green Accepted			2021-06-18	
J	Egea-Guerrero, JJ; Revuelto-Rey, J; Murillo-Cabezas, F; Munoz-Sanchez, MA; Vilches-Arenas, A; Sanchez-Linares, P; Dominguez-Roldan, JM; Leon-Carrion, J				Egea-Guerrero, J. J.; Revuelto-Rey, J.; Murillo-Cabezas, F.; Munoz-Sanchez, M. A.; Vilches-Arenas, A.; Sanchez-Linares, P.; Dominguez-Roldan, J. M.; Leon-Carrion, J.			Accuracy of the S100 beta protein as a marker of brain damage in traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; S100 beta protein; CT scan; biomarkers; brain damage	MINOR HEAD-INJURY; NEURON-SPECIFIC ENOLASE; COMPUTED-TOMOGRAPHY; S100B LEVELS; SERUM S100B; S-100B; BIOMARKER; ELIMINATION; MANAGEMENT; TAU	Introduction: This study tested the hypothesis that S100 beta is a useful screening tool for detecting intracranial lesion (IL) in patients with a normal level of consciousness after traumatic brain injury (TBI). Methods: One hundred and forty-three post-TBI patients without a decrease in consciousness (GCS = 15) and with at least one neurological symptom (e.g. transitory loss of consciousness, amnesia, headache, dizziness or vomiting) were prospectively included. A blood sample was drawn at 6-hours post-TBI. A routine CT scan was obtained within 24 hours post-injury. Diagnostic properties of S100 beta for IL prediction in CT scan findings were tested using ROC-analysis. Results: A total of 15 patients (10.5%) had IL. Serum levels were significantly higher in these patients. Significant differences were found between S100 beta levels and CT scan findings (p = 0.007). ROC-analysis showed that S100 beta is a useful tool for detecting the presence of IL in CT scans (p = 0.007). In this series, the best cut-off for S100 beta is 0.130 mu g L(-1), with 100% sensitivity and 32.81% specificity. Conclusion: Within the first 6 hours post-TBI, serum S100 beta seems to be an effective biochemical indicator of IL in patients without a decrease in consciousness. These results indicate that higher S100 beta cut-off values substantially improve the clinical relevance of this protein.	[Egea-Guerrero, J. J.; Revuelto-Rey, J.; Murillo-Cabezas, F.; Dominguez-Roldan, J. M.] Virgen Rocio Univ Hosp, NeuroCrit Care Unit, Seville 41013, Spain; [Munoz-Sanchez, M. A.] Virgen Rocio Univ Hosp, Emergency Dept, Seville 41013, Spain; [Vilches-Arenas, A.] Univ Seville, Dept Stat, Seville, Spain; [Sanchez-Linares, P.] Virgen Rocio Univ Hosp, Dept Med Biochem, Seville 41013, Spain; [Leon-Carrion, J.] Univ Seville, Human Neuropsychol Lab, Seville, Spain; [Leon-Carrion, J.] Ctr Brain Injury Rehabil CRECER, Seville, Spain	Egea-Guerrero, JJ (corresponding author), Virgen Rocio Univ Hosp, NeuroCrit Care Unit, Avda Manuel Siurot S-N, Seville 41013, Spain.	juanj.egea.sspa@juntadeandalucia.es	Dominguez-Roldan, Jose-Maria/M-1728-2016; IBIS, NEUROCRITICOS/C-1805-2016; Vilches-Arenas, Angel/C-1167-2015; Murillo-Cabezas, Francisco/AAO-3348-2021; Egea-Guerrero, Juan Jose/P-5080-2014	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Vilches-Arenas, Angel/0000-0003-2197-3760; Egea-Guerrero, Juan Jose/0000-0002-4166-313X; Revuelto-Rey, Jaume/0000-0001-8350-9555			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	23	52	56	0	19	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2012	26	1					76	82		10.3109/02699052.2011.635360			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900008	22149446				2021-06-18	
J	Fried-Oken, M; Beukelman, DR; Hux, K				Fried-Oken, Melanie; Beukelman, David R.; Hux, Karen			Current and Future AAC Research Considerations for Adults with Acquired Cognitive and Communication Impairments	ASSISTIVE TECHNOLOGY			English	Article						acquired disabilities; aphasia; augmentative and alternative communication (AAC); cognition; dementia; primary progressive aphasia; traumatic brain injury	PROGRESSIVE APHASIA; 3 VARIANTS; INTERFACE; PEOPLE; ACCESS; IMPACT; ICF	Adults with acquired language impairments secondary to stroke, traumatic brain injury, and neurodegenerative diseases are candidates for communication supports outside of the traditional restoration-based approaches to intervention. Recent research proves repeatedly that augmentative and alternative communication (AAC) provides a means for participation, engagement, conversation, and message transfer when individuals can no longer expect full return of pre-morbid communication skills and that inclusion of communication supports should begin early. We discuss current research and future directions for integrated systems of technical supports that include low-technology, high tech, and partner-dependent strategies for adults with severe and chronic aphasia, cognitive-communication problems resulting from traumatic brain injuries, and primary progressive aphasia.	[Fried-Oken, Melanie] Oregon Hlth & Sci Univ, CDRC, Portland, OR 97239 USA; [Beukelman, David R.; Hux, Karen] Univ Nebraska, Lincoln, NE USA	Fried-Oken, M (corresponding author), Oregon Hlth & Sci Univ, CDRC, POB 574, Portland, OR 97239 USA.	friedm@ohsu.edu	Hux, Karen/AAQ-2078-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD047754] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD047754] Funding Source: Medline		American Speech-Language-Hearing Association, 2005, ROL SPEECH LANG PATH; Beukelman D, 1985, COMMUNICATION AUGMEN; Beukelman DR, 2007, AUGMENT ALTERN COMM, V23, P230, DOI 10.1080/07434610701553668; Burke R, 2008, AUGMENT ALTERN COMM, V24, P56, DOI 10.1080/07434610701421015; Chapey R., 2001, LANGUAGE INTERVENTIO, P246; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cress C., 1999, AUGMENTATIVE ALTERNA, V15, P248, DOI [10.1080/07434619912331278785, DOI 10.1080/07434619912331278785]; DeRuyter F, 1995, Assist Technol, V7, P3; DeRuyter F., 1987, AUGMENTATIVE ALTERNA, V3, P18, DOI DOI 10.1080/07434618712331274209; DERUYTER F, 1989, AUGMENTATIVE ALTERNA, V5, P49, DOI DOI 10.1080/07434618912331274966; Dietz A, 2009, APHASIOLOGY, V23, P1053, DOI 10.1080/02687030802635832; Doyle M, 2000, AUG ALTER COMMUN SER, P271; Duffy JR, 2019, MOTOR SPEECH DISORDE; Fager S, 2006, AUGMENT ALTERN COMM, V22, P37, DOI 10.1080/07434610500243990; Fager S., 2007, AUGMENTATIVE COMMUNI, P59; Fager S., 2011, ASSISTING SURVIVORS, P227; Fager S, 2012, ASSIST TECHNOL, V24, P25, DOI 10.1080/10400435.2011.648712; Fox L., 2000, AUGMENTATIVE ALTERNA, P3; Fox LE, 2001, APHASIOLOGY, V15, P171, DOI 10.1080/02687040042000133; Fried-Oken M, 1995, ASHA AAC SPECIAL INT, V4, P3; Fried-Oken M., 2008, PERSPECTIVES AUGMENT, V17, P99; Fried-Oken M, 1992, J HEAD TRAUMA REHAB, V7, P59, DOI DOI 10.1097/00001199-199209000-00008; Garrett K. L., 1989, AUGMENTATIVE ALTERNA, V5, P55, DOI DOI 10.1080/07434618912331274976; Garrett KL, 2002, APHASIOLOGY, V16, P523, DOI 10.1080/02687030244000149; Garrett KL, 1995, CLIN APHASIOL, V23, P237; Gibbons C., 2010, PERSPECTIVES NEUROPH, V20, P21, DOI DOI 10.1044/nnsld20.1.21; Gorno-Tempini ML, 2004, ANN NEUROL, V55, P335, DOI 10.1002/ana.10825; HELMESTABROOKS N, 2001, CLQT COGNITIVE LINGU; Higginbotham DJ, 2012, ASSIST TECHNOL, V24, P14, DOI 10.1080/10400435.2011.648714; Hodges J R, 1996, J Int Neuropsychol Soc, V2, P511; Hux K., 2011, ASSISTING SURVIVORS, P121; Hux K., 2008, LANGUAGE INTERVENTIO, V5, P814; Hux K, 2010, APHASIOLOGY, V24, P643, DOI 10.1080/02687030902869299; Johnson RK, 2008, AUGMENT ALTERN COMM, V24, P269, DOI 10.1080/07434610802463957; Kagan A, 2008, APHASIOLOGY, V22, P258, DOI 10.1080/02687030701282595; Keenan J, 1993, AUGMENTATIVE ALTERNA, V9, P184, DOI DOI 10.1080/07434619312331276591; Kimberly MHA, 2005, AUGMENT ALTERN COMM, V21, P218, DOI 10.1080/07434610400016694; KING J, 1995, AUGMENTATIVE ALTERNA, V11, P187, DOI DOI 10.1080/07434619512331277309; LaPointe L., 2005, APHASIA RELATED NEUR, P1; Laska AC, 2001, J INTERN MED, V249, P413, DOI 10.1046/j.1365-2796.2001.00812.x; Lasker J., 2005, AUGMENTATIVE ALTERNA, P467; Lasker J., 1997, AUGMENT ALTERN COMM, V13, DOI [10.1080/07434619712331277908, DOI 10.1080/07434619712331277908]; Lasker J., 2007, AUGMENTATIVE COMMUNI, P163; Lasker JP, 2005, APHASIOLOGY, V19, P399, DOI 10.1080/02687030444000840; Light J., 1988, AUGMENTATIVE ALTERNA, V4, P2, DOI DOI 10.1080/07434618812331274557; LYON JG, 1995, APHASIOLOGY, V9, P84, DOI 10.1080/02687039508248694; LYON JG, 1995, APHASIOLOGY, V9, P33, DOI 10.1080/02687039508248687; McKelvey ML, 2010, AM J SPEECH-LANG PAT, V19, P22, DOI 10.1044/1058-0360(2009/08-0021); McNeil MR, 2001, APHASIOLOGY, V15, P901, DOI 10.1080/02687040143000276; Mesulam MM, 2001, ANN NEUROL, V49, P425, DOI 10.1002/ana.91.abs; MESULAM MM, 1982, ANN NEUROL, V11, P592, DOI 10.1002/ana.410110607; Murray LL, 1998, APHASIOLOGY, V12, P651, DOI 10.1080/02687039808249564; National Aphasia Association, 2009, APH FREQ ASK QUEST; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Raghavendra P, 2007, AUGMENT ALTERN COMM, V23, P349, DOI 10.1080/07434610701650928; Rogers MA, 2000, AUG ALTER COMMUN SER, P305; Rogers MA, 1998, APHASIOLOGY, V12, P635, DOI 10.1080/02687039808249563; Rowland C, 2012, AUGMENT ALTERN COMM, V28, P21, DOI 10.3109/07434618.2012.654510; Shane HC, 2012, ASSIST TECHNOL, V24, P3, DOI 10.1080/10400435.2011.648716; Simmons-Mackie Nina, 2007, Seminars in Speech and Language, V28, P244, DOI 10.1055/s-2007-986521; Simms NJ, 2001, EUR FED CORR PUBL, P246; Trautman J., 2002, PATIENTS CLIN PATHWA; Wallace SE, 2010, AUGMENT ALTERN COMM, V26, P242, DOI 10.3109/07434618.2010.521895; Wilson SM, 2010, BRAIN, V133, P2069, DOI 10.1093/brain/awq129; World Health Organization, 2001, INT CLASS FUNCT DIS; Yorkston KM, 2000, AUG ALTER COMMUN SER, P55	66	52	52	0	87	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1040-0435	1949-3614		ASSIST TECHNOL	Assist. Technol.		2012	24	1			SI		56	66		10.1080/10400435.2011.648713			11	Rehabilitation	Rehabilitation	957QD	WOS:000305176800007	22590800	Green Published, Green Accepted			2021-06-18	
J	Gallun, FJ; Diedesch, AC; Kubli, LR; Walden, TC; Folmer, RL; Lewis, MS; McDermott, DJ; Fausti, SA; Leek, MR				Gallun, Frederick J.; Diedesch, Anna C.; Kubli, Lina R.; Walden, Therese C.; Folmer, Robert L.; Lewis, M. Samantha; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.			Performance on tests of central auditory processing by individuals exposed to high-intensity blasts	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						audiometric evaluation; auditory dysfunction; auditory processing disorder; blast; central auditory processing; evoked potential; hearing loss; rehabilitation; traumatic brain injury; Veterans	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; HEARING-LOSS; DYSFUNCTION; COCHLEAR; WAR	Thirty-six blast-exposed patients and twenty-nine non-blast-exposed control subjects were tested on a battery of behavioral and electrophysiological tests that have been shown to be sensitive to central auditory processing deficits. Abnormal performance among the blast-exposed patients was assessed with reference to normative values established as the mean performance on each test by the control subjects plus or minus two standard deviations. Blast-exposed patients performed abnormally at rates significantly above that which would occur by chance on three of the behavioral tests of central auditory processing: the Gaps-In-Noise, Masking Level Difference, and Staggered Spondaic Words tests. The proportion of blast-exposed patients performing abnormally on a speech-in-noise test (Quick Speech-In-Noise) was also significantly above that expected by chance. These results suggest that, for some patients, blast exposure may lead to difficulties with hearing in complex auditory environments, even when peripheral hearing sensitivity is near normal limits	[Gallun, Frederick J.; Diedesch, Anna C.; Folmer, Robert L.; Lewis, M. Samantha; McDermott, Daniel J.; Fausti, Stephen A.; Leek, Marjorie R.] Portland Dept Vet Affairs Med Ctr, NCRAR, Portland, OR USA; [Gallun, Frederick J.; Folmer, Robert L.; Lewis, M. Samantha; Fausti, Stephen A.; Leek, Marjorie R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kubli, Lina R.; Walden, Therese C.] Walter Reed Natl Mil Med Ctr, Audiol & Speech Ctr, Sci & Clin Studies Sect, Bethesda, MD USA	Gallun, FJ (corresponding author), VA RR&D Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	Frederick.Gallun@va.gov	Gallun, Frederick J./G-3792-2012; Folmer, Robert L/E-3105-2010	Gallun, Frederick J./0000-0002-4145-2199; 	VA Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B5067R, C7755I]; Senior Research Career Scientist award [C4042L]; VA Career Development II awards [C4963W, C7067W]; VA Rehabilitation Research and Development NCRAR (Center of Excellence) [C4844C]; Veterans AffairsUS Department of Veterans Affairs [I01RX000536] Funding Source: NIH RePORTER	This material was based on work supported by the VA Rehabilitation Research and Development Service (Merit Review awards B5067R [PIs: Leek, Fausti] and C7755I [PIs: Gallun, Leek]), a Senior Research Career Scientist award (grant C4042L [PI: Leek]), VA Career Development II awards (grants C4963W [PI: Gallun] and C7067W [PI: Lewis]), and the VA Rehabilitation Research and Development NCRAR (Center of Excellence award C4844C).	Alberti A, 2001, HEADACHE, V41, P579, DOI 10.1046/j.1526-4610.2001.041006579.x; ARNST DJ, 1983, EAR HEARING, V4, P243, DOI 10.1097/00003446-198309000-00004; Bamiou DE, 2006, NEUROLOGY, V67, P614, DOI 10.1212/01.wnl.0000230197.40410.db; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chandler CDW, 2006, ASHA LEAD, V11, P8, DOI DOI 10.1044/LEADER.FTR4.11092006.8; Chermak GD, 1997, CENTRAL AUDITORY PRO; Department of Veterans Affairs, 1991, SPEECH REC ID MAT CO; Department of Veterans Affairs Office of Patient Care Services Office of Rehabilitation Services, 2011, TBI COMPR EV SUMM RE; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1059, DOI 10.1682/JRRD.2010.09.0166; Hall J, 2006, HDB CENTRAL AUDITORY, V1, P287; Helfer TM, 2011, AM J AUDIOL, V20, P33, DOI 10.1044/1059-0889(2011/10-0033); HENDLER T, 1990, EAR HEARING, V11, P403, DOI 10.1097/00003446-199012000-00002; Humes L E, 1996, J Am Acad Audiol, V7, P419; JERGER J, 1984, ARCH OTOLARYNGOL, V110, P290; Katz J., 1998, SSW TEST MANUAL; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; MUELLER H G, 1987, Seminars in Hearing, V8, P267, DOI 10.1055/s-0028-1091377; Musiek F E, 1992, J Am Acad Audiol, V3, P5; Musiek FE, 2005, EAR HEARING, V26, P608, DOI 10.1097/01.aud.0000188069.80699.41; MUSIEK FE, 1983, EAR HEARING, V4, P79, DOI 10.1097/00003446-198303000-00002; MUSIEK FE, 1989, AM J OTOL, V10, P343; MUSIEK FE, 1987, AUDIOLOGY, V26, P79; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2004, AM J FOREN MED PATH, V25, P270, DOI 10.1097/01.paf.0000136642.17300.8b; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; RAPPAPORT JM, 1994, J OTOLARYNGOL, V23, P307; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Turner L, 1966, THESIS U KANSAS LAWR; Wilson Richard H, 2003, J Am Acad Audiol, V14, P1, DOI 10.3766/jaaa.14.1.2	33	52	53	1	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2012	49	7					1005	1024		10.1682/JRRD.2012.03.0038			20	Rehabilitation	Rehabilitation	149EZ	WOS:000319303100006	23341276	Bronze			2021-06-18	
J	Hsieh, MY; Ponsford, J; Wong, D; Schonberger, M; Taffe, J; Mckay, A				Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; Schoenberger, Michael; Taffe, John; Mckay, Adam			Motivational interviewing and cognitive behaviour therapy for anxiety following traumatic brain injury: A pilot randomised controlled trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Anxiety; Motivational interviewing; Cognitive behaviour therapy; Traumatic brain injury	SCHEDULED TELEPHONE INTERVENTION; CASE EXPERIMENTAL-DESIGN; PSYCHIATRIC-DISORDERS; DEPRESSION SCALE; HOSPITAL ANXIETY; STRESS-DISORDER; 1ST YEAR; PROGRAM; PSYCHOTHERAPY; RECOVERY	Although cognitive-behavioural therapy (CBT) is the treatment of choice for anxiety, its delivery needs to be adapted for individuals with traumatic brain injury (TBI). It also requires clients' active engagement for maximum benefit. This study was a pilot randomised controlled trial involving an anxiety treatment programme adapted for people with TBI, based on CBT and motivational interviewing (MI). Twenty-seven participants with moderate/severe TBI (aged 21-73 years, 78% males) recruited from a brain injury rehabilitation hospital were randomly allocated to receive MI + CBT (n = 9), non-directive counselling (NDC) + CBT (n = 10) and treatment-as-usual (TAU) (n = 8). CBT and MI were manualised and delivered in 12 weekly individual sessions. Primary outcome was self-reported anxiety symptoms assessed at baseline, at the end of NDC/MI and immediately following CBT. Assessment was conducted by assessors blinded to group assignment. Intention-to-treat analyses showed that the two active treatment groups demonstrated significantly greater anxiety reduction than TAU. Participants receiving MI showed greater response to CBT, in terms of reduction in anxiety, stress and non-productive coping, compared to participants who received NDC. The results provided preliminary support for the adapted CBT programme, and the potential utility of MI as treatment prelude. Longer follow-up data are required to evaluate the maintenance of treatment effects.	[Hsieh, Ming-Yun; Ponsford, Jennie; Wong, Dana; Taffe, John; Mckay, Adam] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Hsieh, Ming-Yun; Ponsford, Jennie] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Mckay, Adam] Epworth Med Fdn, Melbourne, Vic, Australia; [Hsieh, Ming-Yun] Arbias, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, Freiburg, Germany	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Wong, Dana/AAD-3410-2020; McKay, Adam JD/M-6003-2017	McKay, Adam JD/0000-0002-0479-7681; Wong, Dana/0000-0001-9619-1929	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Monash UniversityMonash University; Victorian Brain Injury Recovery Association (Australia)	This study was supported in part by grants from the National Health and Medical Research Council and Monash University, and a scholarship from the Victorian Brain Injury Recovery Association (Australia). The funding sources had no role in study design and analysis of data. The authors alone were responsible for the content and writing of the paper. A portion of the preliminary findings of this paper was presented at the International Congress of Applied Psychology conference in Melbourne, 2010.	Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Buckner JD, 2009, BEHAV RES THER, V47, P710, DOI 10.1016/j.brat.2009.04.009; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Coughlin A, 2007, MEMORY INFORM PROCES; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dahm J, 2009, APS ANN C PERTH AUST; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; DEVILLY GJ, 2005, CLINTOOLS SOFTWARE W; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; First M.B., 2007, STRUCTURED CLIN INTE; Fleming JM, 1996, BRAIN INJURY, V10, P1; Friedli K, 1997, LANCET, V350, P1662, DOI 10.1016/S0140-6736(97)05298-7; Frydenberg E., 1996, COPING SCALE ADULTS; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hox J. J., 2010, MULTILEVEL ANAL TECH; Hsieh M.-Y., NEUROPSYCHO IN PRESS, DOI [10.1080/09602011.2012.676284, DOI 10.1080/09602011.2012.676284]; Hsieh MY, 2012, BRAIN INJURY, V26, P126, DOI 10.3109/02699052.2011.635365; Hsieh MY, 2012, DISABIL REHABIL, V34, P408, DOI 10.3109/09638288.2011.607219; Lane-Brown A, 2010, J HEAD TRAUMA REHAB, V25, P459, DOI 10.1097/HTR.0b013e3181d98e1d; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Lundahl BW, 2010, RES SOCIAL WORK PRAC, V20, P137, DOI 10.1177/1049731509347850; Madson MB, 2005, PSYCHOL ADDICT BEHAV, V19, P303, DOI 10.1037/0893-164X.19.3.303; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Merlo Lisa J., 2010, Cognitive Behaviour Therapy, V39, P24, DOI 10.1080/16506070902831773; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Moyers T.B, 2007, Revised global scales: Motivational interviewing treatment integrity 3.0 (MITI 3.0); Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Perna R, 2006, J HEAD TRAUMA REHAB, V21, P82, DOI 10.1097/00001199-200601000-00009; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Shallice, 1997, HAYLING BRIXTON TEST; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; StataCorp, 2009, STAT STAT SOFTW REL; Tate R. L., 2010, COMPENDIUM TESTS SCA; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Vickery CD, 2006, REHABIL PSYCHOL, V51, P30, DOI 10.1037/0090-5550.51.1.30; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WESTRA HA, 2003, MOTIVATIONAL I UNPUB; Westra HA, 2006, COGNITIVE THER RES, V30, P481, DOI 10.1007/s10608-006-9016-y; Westra HA, 2010, TREATMENT RESISTANT ANXIETY DISORDERS: RESOLVING IMPASSES TO SYMPTOM REMISSION, P199; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Wilson, 1991, NATL ADULT READING T; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wood Angela M, 2004, Clin Trials, V1, P368; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zwarenstein M, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2390	65	52	52	1	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	4					585	608		10.1080/09602011.2012.678860			24	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	995SC	WOS:000308031600007	22632385				2021-06-18	
J	Scheibel, RS; Newsome, MR; Troyanskaya, M; Lin, XD; Steinberg, JL; Radaideh, M; Levin, HS				Scheibel, Randall S.; Newsome, Mary R.; Troyanskaya, Maya; Lin, Xiaodi; Steinberg, Joel L.; Radaideh, Majdi; Levin, Harvey S.			Altered Brain Activation in Military Personnel with One or More Traumatic Brain Injuries Following Blast	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain concussion; Brain mapping; Executive function; fMRI; Post-concussion syndrome; PTSD	POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-CONTROL; FUNCTIONAL MRI; HEAD-INJURY; VETERANS; MEMORY; IRAQ; CONCUSSION; SYMPTOMS; SCALE	Explosive blast is a frequent cause of traumatic brain injury (TBI) among personnel deployed to Afghanistan and Iraq. Functional magnetic resonance imaging (fMRI) with an event-related stimulus-response compatibility task was used to compare 15 subjects with mild, chronic blast-related TBI with 15 subjects who had not experienced a TBI or blast exposure during deployment. Six TBI subjects reported multiple injuries. Relative to the control group, TBI subjects had slightly slower responses during fMRI and increased somatic complaints and symptoms of post-traumatic stress disorder (PTSD) and depression. A between-group analysis indicated greater activation during stimulus-response incompatibility in TBI subjects within the anterior cingulate gyrus, medial frontal cortex, and posterior cerebral areas involved in visual and visual-spatial functions. This activation pattern was more extensive after statistically controlling for reaction time and symptoms of PTSD and depression. There was also a negative relationship between symptoms of PTSD and activation within posterior brain regions. These results provide evidence for increased task-related activation following mild, blast-related TBI and additional changes associated with emotional symptoms. Limitations of this study include no matching for combat exposure and different recruitment strategies so that the control group was largely a community-based sample, while many TBI subjects were seeking services. (JINS, 2012, 18, 89-100)	[Scheibel, Randall S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Scheibel, Randall S.; Newsome, Mary R.; Troyanskaya, Maya; Lin, Xiaodi; Radaideh, Majdi; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Steinberg, Joel L.] Univ Texas Houston, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX 77225 USA; [Radaideh, Majdi] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA	Scheibel, RS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	scheibel@bcm.tmc.edu			Department of Veterans Affairs Center of ExcellenceUS Department of Veterans Affairs [B6812C]; Department of Veterans AffairsUS Department of Veterans Affairs [B4596R]	The authors report no conflicts of interest. This work was supported by a Department of Veterans Affairs Center of Excellence grant (H. S. L., grant number B6812C), Neurorehabilitation: Neurons to Networks Center for Rehabilitation Research; and by a Department of Veterans Affairs Merit Review grant (H. S. L., grant number B4596R). The Michael E. DeBakey Veterans Affairs Medical Center in Houston, TX, and the South Central Mental Illness Research, Education, and Clinical Center (MIRECC) provided access to equipment and facilities used for the analysis of the image data. We thank Xiaoqi Li for assisting with statistical analysis and Drs. Helene K. Henson and David P. Graham for assisting with the screening and recruitment of subjects.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Galati G, 2010, EXP BRAIN RES, V206, P109, DOI 10.1007/s00221-010-2168-8; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kleinbaum D., 1998, APPL REGRESSION ANAL; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Morey RA, 2008, PSYCHIAT RES-NEUROIM, V162, P59, DOI 10.1016/j.pscychresns.2007.07.007; Orban GA, 2004, TRENDS COGN SCI, V8, P315, DOI 10.1016/j.tics.2004.05.009; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware J., 2004, SCORE VERSION 2 SF 1	46	52	52	0	31	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2012	18	1					89	100		10.1017/S1355617711001433			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	874LL	WOS:000298958800009	22132942				2021-06-18	
J	Greco, T; Shafer, J; Fiskum, G				Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary			Sulforaphane inhibits mitochondrial permeability transition and oxidative stress	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Mitochondria; Calcium; Thiol; Nrf2; Sulforaphane; Antioxidant; Permeability transition pore; Redox state; Oxidative stress; Free radicals	TRAUMATIC BRAIN-INJURY; CYCLOPHILIN-D; RAT-LIVER; MOLECULAR-MECHANISM; REPERFUSION INJURY; REDUCTION STATE; CELL-DEATH; PORE; RELEASE; HEPATOCYTES	Exposure of mitochondria to oxidative stress and elevated Ca2+ promotes opening of the mitochondrial permeability transition pore (PTP), resulting in membrane depolarization, uncoupling of oxidative phosphorylation, and potentially cell death. This study tested the hypothesis that treatment of rats with sulforaphane (SFP), an activator of the Nrf2 pathway of antioxidant gene expression, increases the resistance of liver mitochondria to redox-regulated PTP opening and elevates mitochondrial levels of antioxidants. Rats were injected with SFP or drug vehicle and liver mitochondria were isolated 40 h later. Respiring mitochondria actively accumulated added Ca2+, which was then released through PIP opening induced by agents that either cause an oxidized shift in the mitochondrial redox state or directly oxidize protein thiol groups. SFP treatment of rats inhibited the rate of pro-oxidant-induced mitochondrial Ca2+ release and increased expression of the glutathione peroxidase/reductase system, thioredoxin, and malic enzyme. These results are the first to demonstrate that SFP treatment of animals increases liver mitochondrial antioxidant defenses and inhibits redox-sensitive PIP opening. This novel form of preconditioning could protect against a variety of pathologies that include oxidative stress and mitochondrial dysfunction in their etiologies. (C) 2011 Elsevier Inc. All rights reserved.	[Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Shafer, Jonathan] Univ Maryland Baltimore Cty, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS34152]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER	This study was supported by NIH RO1NS34152.	Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bianchi G, 1997, HEPATO-GASTROENTEROL, V44, P784; Burwell LS, 2009, J MOL CELL CARDIOL, V46, P804, DOI 10.1016/j.yjmcc.2009.02.026; DEVI BG, 1994, ALCOHOL CLIN EXP RES, V18, P1436, DOI 10.1111/j.1530-0277.1994.tb01447.x; Dinkova-Kostova AT, 2008, MOL NUTR FOOD RES, V52, pS128, DOI 10.1002/mnfr.200700195; Dinkova-Kostova AT, 2010, ARCH BIOCHEM BIOPHYS, V501, P116, DOI 10.1016/j.abb.2010.03.019; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; FISKUM G, 1986, CANCER RES, V46, P3459; Gogvadze V, 2010, INT J CANCER, V127, P1823, DOI 10.1002/ijc.25204; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Halestrap AP, 2010, BIOCHEM SOC T, V38, P841, DOI 10.1042/BST0380841; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Koehler CM, 2006, ANTIOXID REDOX SIGN, V8, P813, DOI 10.1089/ars.2006.8.813; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; KUKIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P377, DOI 10.1006/abbi.1994.1127; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; LIU SL, 1995, HEPATOLOGY, V22, P1474, DOI 10.1016/0270-9139(95)90155-8; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; MOORE M, 1985, J BIOL CHEM, V260, P3035; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Norberg E, 2008, CELL DEATH DIFFER, V15, P1857, DOI 10.1038/cdd.2008.123; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad; PONSODA X, 1995, TOXICOL IN VITRO, V9, P439, DOI 10.1016/0887-2333(95)00035-7; Ramachandran A, 2011, FREE RADICAL RES, V45, P156, DOI 10.3109/10715762.2010.520319; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SHIGESAWA T, 1992, J GASTROEN HEPATOL, V7, P7, DOI 10.1111/j.1440-1746.1992.tb00926.x; Stravitz RT, 2009, NAT REV GASTRO HEPAT, V6, P542, DOI 10.1038/nrgastro.2009.127; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; Thimmulappa RK, 2002, CANCER RES, V62, P5196; THORNILEY MS, 1995, HEPATOLOGY, V21, P1602, DOI 10.1002/hep.1840210619; Toman J, 2011, J BIOENERG BIOMEMBR, V43, P3, DOI 10.1007/s10863-011-9337-8; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422; VERCESI AE, 1984, BIOCHEM BIOPH RES CO, V119, P305, DOI 10.1016/0006-291X(84)91652-8; Yamamoto Y, 1998, BIOCHEM BIOPH RES CO, V247, P166, DOI 10.1006/bbrc.1998.8752; Zhu H, 2008, CARDIOVASC TOXICOL, V8, P115, DOI 10.1007/s12012-008-9020-4	49	52	57	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC 15	2011	51	12					2164	2171		10.1016/j.freeradbiomed.2011.09.017			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	860PK	WOS:000297960000005	21986339	Green Accepted			2021-06-18	
J	Kurtz, P; Fitts, V; Sumer, Z; Jalon, H; Cooke, J; Kvetan, V; Mayer, SA				Kurtz, Pedro; Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary; Cooke, Joseph; Kvetan, Vladimir; Mayer, Stephan A.			How Does Care Differ for Neurological Patients Admitted to a Neurocritical Care Unit Versus a General ICU?	NEUROCRITICAL CARE			English	Article						Neurocritical care; Outcomes research	ILL PATIENTS; IMPACT; MORTALITY; OUTCOMES; NEUROINTENSIVIST; TRACHEOSTOMY; PROTOCOL	Neurological patients have lower mortality and better outcomes when cared for in specialized neurointensive care units than in general ICUs. However, little is known about how the process of care differs between these types of units. The Greater New York Hospital Association conducted a city-wide 24-h ICU prevalence survey on March 15th, 2007. Data was collected on all patients admitted to 143 ICUs in 69 different hospitals. Of 1,906 ICU patients surveyed, 231 had a primary neurological diagnosis. Of these, 52 (22%) were admitted to one of 9 neuro-ICU's in NY and 179 (78%) to a medical or surgical ICU. Neurological patients in neuro-ICUs were more likely to have been transferred from an outside hospital (37% vs. 11%, P < 0.0001). Hemorrhagic stroke was more frequent in neuro-ICUs (46% vs. 16%, P < 0.0001), whereas traumatic brain injury (2% vs. 24%, P < 0.0001) and ischemic stroke (0% vs. 19%, P = 0.001) were less common. Despite a lower rate of mechanical ventilation (39% vs. 50%, P = 0.15), ICU length of stay was longer in neuro-ICU patients (a parts per thousand yen10 days, 40% vs. 17%, P < 0.0001). More neuro-ICU patients had undergone tracheostomy (35% vs. 15%, P = 0.04), invasive hemodynamic monitoring (40% vs. 20%, P = 0.002), and invasive intracranial pressure monitoring (29% vs. 9%, P < 0.001) than patients cared for in general ICUs. Intravenous sedation was less prevalent in neuro-ICUs (12% vs. 30%, P = 0.009) and more patients were receiving nutritional support compared to general ICUs (67% vs. 39%, P < 0.001). Neurological patients cared for in specialty neuro-ICUs underwent more invasive intracranial and hemodynamic monitoring, tracheostomy, and nutritional support, and received less IV sedation than patients in general ICUs. These differences in care may explain previously observed disparities in outcome between neurocritical care and general ICUs.	[Mayer, Stephan A.] Neurol Inst, Div Neurocrit Care, New York, NY 10032 USA; [Kurtz, Pedro; Mayer, Stephan A.] Columbia Univ, Dept Neurol, New York, NY USA; [Kurtz, Pedro; Mayer, Stephan A.] Columbia Univ, Dept Neurosurg, New York, NY USA; [Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary] GNYHA, New York, NY USA; [Cooke, Joseph] Weill Cornell Med Ctr, Dept Med, New York, NY USA; [Kvetan, Vladimir] Montefiore Med Ctr, Div Crit Care Med, Bronx, NY USA; [Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary] UHF, New York, NY USA	Mayer, SA (corresponding author), Neurol Inst, Div Neurocrit Care, Milstein Hosp Bldg,Suite 8-300 Ctr,177 Ft Washing, New York, NY 10032 USA.	sam14@columbia.edu			Greater New York Hospital Association/United Hospital	The authors wish to thank the many physicians and nurses who participated in the Greater New York Hospital Association/United Hospital Fund ICU Survey. GNYHA, a trade association representing 150 hospitals throughout New York State, New Jersey, Connecticut, Pennsylvania, and Rhode Island, and UHF, a private not-for-profit health services research and philanthropic organization, formed a partnership in 2005 to support hospitals' quality improvement efforts. This survey was part of the initiatives they partner on in the area of critical care.	Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Clarke J, 2005, LANCET, V365, P764; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rincon F, 2007, CURR OPIN CRIT CARE, V13, P115, DOI 10.1097/MCC.0b013e32808255c6; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21	17	52	55	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					477	480		10.1007/s12028-011-9539-2			4	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400018	21519958				2021-06-18	
J	Xiong, Y; Zhang, YL; Mahmood, A; Meng, YL; Qu, CS; Chopp, M				Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Chopp, Michael			Erythropoietin Mediates Neurobehavioral Recovery and Neurovascular Remodeling Following Traumatic Brain Injury in Rats by Increasing Expression of Vascular Endothelial Growth Factor	TRANSLATIONAL STROKE RESEARCH			English	Article						Angiogenesis; Erythropoietin; Neurogenesis; Traumatic brain injury; Vascular endothelial growth factor	FUNCTIONAL RECOVERY; ENHANCES NEUROGENESIS; PROGENITOR CELLS; SPATIAL MEMORY; ANGIOGENESIS; RECEPTOR; STROKE; VEGF; PROTECTION; NEUROPROTECTION	Erythropoietin (EPO) improves functional recovery after traumatic brain injury (TBI). Here, we investigated the role of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) on EPO-induced therapeutic efficacy in rats after TBI. Young male Wistar rats were subjected to unilateral controlled cortical impact injury and then infused intracerebroventricularly with either a potent selective VEGFR2 inhibitor SU5416 or vehicle dimethyl sulfoxide. Animals from both groups received delayed EPO treatment (5,000 U/kg in saline) administered intraperitoneally daily at 1, 2, and 3 days post-injury. TBI rats treated with saline administered intraperitoneally daily at 1, 2, and 3 days post-injury served as EPO treatment controls. 5-Bromo-2'-deoxyuridine was administered to label dividing cells. Spatial learning and sensorimotor function were assessed using a modified Morris water maze test and modified neurological severity score, respectively. Animals were sacrificed at 4 days post-injury for measurement of VEGF and VEGFR2 or 35 days post-injury for evaluation of cell proliferation, angiogenesis, and neurogenesis. EPO treatment promoted sensorimotor and cognitive functional recovery after TBI. EPO treatment increased brain VEGF expression and phosphorylation of VEGFR2. EPO significantly increased cell proliferation, angiogenesis, and neurogenesis in the dentate gyrus after TBI. Compared to the vehicle, SU5416 infusion significantly inhibited phosphorylation of VEGFR2, cell proliferation, angiogenesis, and neurogenesis as well as abolished functional recovery in EPO-treated TBI rats. These findings indicate the VEGF/VEGFR2 activation plays an important role in EPO-mediated neurobehavioral recovery and neurovascular remodeling after TBI.	[Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Xiong, Y (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS023393]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS023393] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS62002 to Y. Xiong and PO1 NS023393 to M. Chopp. Special thanks to Ms. Susan MacPhee-Gray for editorial assistance.; This study was financially supported by NINDS grants RO1 NS62002 (Ye Xiong) and PO1 NS023393 (Michael Chopp).	Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Cotena S, 2008, PANMINERVA MED, V50, P185; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Fong TAT, 1999, CANCER RES, V59, P99; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Grasso G, 2009, NEUROSURGERY, V65, P763, DOI 10.1227/01.NEU.0000347475.73347.5F; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Hansen TM, 2008, CURR NEUROVASC RES, V5, P236, DOI 10.2174/156720208786413433; Itokawa T, 2002, MOL CANCER THER, V1, P295; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li L, 2007, BRAIN RES, V1132, P185, DOI 10.1016/j.brainres.2006.10.098; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Liu ZW, 2011, STROKE, V42, P740, DOI 10.1161/STROKEAHA.110.607226; Liu ZW, 2009, STROKE, V40, P2546, DOI 10.1161/STROKEAHA.109.547265; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	74	52	55	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2011	2	4			SI		619	632		10.1007/s12975-011-0120-2			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	943YJ	WOS:000304163700019	22707988	Green Accepted			2021-06-18	
J	Mena, JH; Sanchez, AI; Rubiano, AM; Peitzman, AB; Sperry, JL; Gutierrez, MI; Puyana, JC				Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Rubiano, Andres M.; Peitzman, Andrew B.; Sperry, Jason L.; Isabel Gutierrez, Maria; Puyana, Juan Carlos			Effect of the Modified Glasgow Coma Scale Score Criteria for Mild Traumatic Brain Injury on Mortality Prediction: Comparing Classic and Modified Glasgow Coma Scale Score Model Scores of 13	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Glasgow Coma Scale; Mortality; Prediction	MODERATE HEAD-INJURY; NEW-ORLEANS CRITERIA; INTERRATER RELIABILITY; PROGNOSTIC-FACTORS; PRACTICAL SCALE; HOSPITALIZATION; MANAGEMENT; HYPOTHERMIA; VALIDATION; ADMISSION	Background: The Glasgow Coma Scale (GCS) classifies traumatic brain injuries (TBIs) as mild (14-15), moderate (9-13), or severe (3-8). The Advanced Trauma Life Support modified this classification so that a GCS score of 13 is categorized as mild TBI. We investigated the effect of this modification on mortality prediction, comparing patients with a GCS score of 13 classified as moderate TBI (classic model) to patients with GCS score of 13 classified as mild TBI (modified model). Methods: We selected adult TBI patients from the Pennsylvania Outcome Study database. Logistic regressions adjusting for age, sex, cause, severity, trauma center level, comorbidities, and isolated TBI were performed. A second evaluation included the time trend of mortality. A third evaluation also included hypothermia, hypotension, mechanical ventilation, screening for drugs, and severity of TBI. Discrimination of the models was evaluated using the area under receiver operating characteristic curve (AUC). Calibration was evaluated using the Hosmer-Lemershow goodness of fit test. Results: In the first evaluation, the AUCs were 0.922 (95% CI, 0.917-0.926) and 0.908 (95% CI, 0.903-0.912) for classic and modified models, respectively. Both models showed poor calibration (p < 0.001). In the third evaluation, the AUCs were 0.946 (95% CI, 0.943-0.949) and 0.938 (95% CI, 0.934-0.940) for the classic and modified models, respectively, with improvements in calibration (p = 0.30 and p = 0.02 for the classic and modified models, respectively). Conclusion: The lack of overlap between receiver operating characteristic curves of both models reveals a statistically significant difference in their ability to predict mortality. The classic model demonstrated better goodness of fit than the modified model. A GCS score of 13 classified as moderate TBI in a multivariate logistic regression model performed better than a GCS score of 13 classified as mild.	[Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Peitzman, Andrew B.; Sperry, Jason L.; Puyana, Juan Carlos] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Isabel Gutierrez, Maria] Univ Valle, CISALVA Inst, Cali, Colombia; [Rubiano, Andres M.] Neiva Univ Hosp, Neiva City, Colombia	Mena, JH (corresponding author), IROQU 400 4C Pittsburgh Off, Dept Emergency Med Off, Pittsburgh, PA USA.	jhm26@pitt.edu	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43 TW007560, 1 D43 TW007560 05, D43 TW007560-05] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007560] Funding Source: NIH RePORTER		Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Elliott M, 1996, J Neurosci Nurs, V28, P213; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; JENNETT B, 1975, LANCET, V1, P480; JONES C, 1979, AM J NURS, V79, P1551; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Matis G, 2008, ACTA NEUROL BELG, V108, P75; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Rosner B., 2006, FUNDAMENTALS BIOSTAT; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Santrucek M, 1978, Cas Lek Cesk, V117, P225; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Strachan R D, 1989, Brain Inj, V3, P51, DOI 10.3109/02699058909008073; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Ting HW, 2010, J CHIN MED ASSOC, V73, P139, DOI 10.1016/S1726-4901(10)70028-9; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Wang HE, 2005, CRIT CARE MED, V33, P1296, DOI 10.1097/01.CCM.0000165965.31895.80; Yanagawa Y, 2007, AM J EMERG MED, V25, P757, DOI 10.1016/j.ajem.2006.12.006; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	49	52	54	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1185	1192		10.1097/TA.0b013e31823321f8			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600022	22071923	Green Accepted			2021-06-18	
J	Raz, E; Jensen, JH; Ge, Y; Babb, JS; Miles, L; Reaume, J; Grossman, RI; Inglese, M				Raz, E.; Jensen, J. H.; Ge, Y.; Babb, J. S.; Miles, L.; Reaume, J.; Grossman, R. I.; Inglese, M.			Brain Iron Quantification in Mild Traumatic Brain Injury: A Magnetic Field Correlation Study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							MULTIPLE-SCLEROSIS; UNITED-STATES; IMMATURE RAT; PATHOPHYSIOLOGY; METABOLISM	BACKGROUND AND PURPOSE: Experimental studies have suggested a role for iron accumulation in the pathology of TBI. Magnetic field correlation MR imaging is sensitive to the presence of non-heme iron. The aims of this study are to 1) assess the presence, if any, and the extent of iron deposition in the deep gray matter and regional white matter of patients with mTBI by using MFC MR imaging; and 2) investigate the association of regional brain iron deposition with cognitive and behavioral performance of patients with mTBI. MATERIALS AND METHODS: We prospectively enrolled 28 patients with mTBI. Eighteen healthy subjects served as controls. The subjects were administered the Stroop color word test, the Verbal Fluency Task, and the Post-Concussion Symptoms Scale. The MR imaging protocol (on a 3T imager) consisted of conventional brain imaging and MFC sequences. After the calculation of parametric maps, MFC was measured by using a region of interest approach. MFC values across groups were compared by using analysis of covariance, and the relationship of MFC values and neuropsychological tests were evaluated by using Spearman correlations. RESULTS: Compared with controls, patients with mTBI demonstrated significant higher MFC values in the globus pallidus (P = .002) and in the thalamus (P = .036). In patients with mTBI, Stroop test scores were associated with the MFC value in frontal white matter (r = -0.38, P = .043). CONCLUSIONS: MFC values were significantly elevated in the thalamus and globus pallidus of patients with mTBI, suggesting increased accumulation of iron. This supports the hypothesis that deep gray matter is a site of injury in mTBI and suggests a possible role for iron accumulation in the pathophysiological events after mTBI.	[Inglese, M.] Mt Sinai Sch Med, Dept Neurol & Radiol, New York, NY 10029 USA; [Raz, E.; Jensen, J. H.; Ge, Y.; Babb, J. S.; Miles, L.; Reaume, J.; Grossman, R. I.] NYU, Sch Med, Dept Radiol, New York, NY USA; [Raz, E.] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy	Inglese, M (corresponding author), Mt Sinai Sch Med, Dept Neurol, Annenberg 14-89,Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	matilde.inglese@mssm.edu	Jensen, Jens H/A-8334-2009; Ge, Yulin/D-9060-2019; Inglese, Matilde/AAH-3189-2020; Ge, Yulin/L-7052-2019	Jensen, Jens H/0000-0003-3219-4287; Ge, Yulin/0000-0002-2320-6031; Inglese, Matilde/0000-0002-9610-0297; Babb, James/0000-0003-1798-1186	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS039135, R01 NS051323]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This study was supported by the National Institute of Health grants R01 NS039135 and R01 NS051323.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Campbell A, 2001, BRAIN RES BULL, V55, P125, DOI 10.1016/S0361-9230(01)00455-5; Connor JR, 2001, PEDIATR NEUROL, V25, P118, DOI 10.1016/S0887-8994(01)00303-4; CRAELIUS W, 1982, ARCH PATHOL LAB MED, V106, P397; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Ge Y, 2007, AM J NEURORADIOL, V28, P1639, DOI 10.3174/ajnr.A0646; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Haber SN, 2009, BRAIN RES BULL, V78, P69, DOI 10.1016/j.brainresbull.2008.09.013; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jensen JH, 2006, MAGN RESON MED, V55, P1350, DOI 10.1002/mrm.20907; Jensen JH, 2009, MAGN RESON MED, V61, P481, DOI 10.1002/mrm.21823; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lull N, 2010, NEUROLOGIA, V25, P174; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sipe JC, 2002, DEV NEUROSCI-BASEL, V24, P188, DOI 10.1159/000065701; Sukstanskii AL, 2003, J MAGN RESON, V163, P236, DOI 10.1016/S1090-7807(03)00131-9; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO	32	52	52	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV	2011	32	10					1851	1856		10.3174/ajnr.A2637			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	859PM	WOS:000297888300017	21885717	Green Published, Other Gold, Green Accepted			2021-06-18	
J	Larson, MJ; Forrer, TJ; Clayson, PE				Larson, Michael J.; Forrer, Thomas J.; Clayson, Peter E.			Cognitive control in mild traumatic brain injury: Conflict monitoring and conflict adaptation	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						N450; Conflict SP; Concussion; Mild TBI; Event-related potential; Sequential trial	ANTERIOR CINGULATE CORTEX; POST-CONCUSSION SYMPTOMS; ERROR-RELATED NEGATIVITY; EVENT-RELATED POTENTIALS; STROOP TASK; DIFFUSION-TENSOR; HEAD-INJURY; PERSISTENT SYMPTOMS; SEVERE TBI; DYSFUNCTION	Recent studies suggest that individuals who have experienced a concussion or mild traumatic brain injury (TBI) show deficits in cognitive control. We tested the hypothesis that behavioral (response time [RT] and error rate) and electrophysiological (N450 and conflict SP components of the event-related potential [ERP]) reflections of conflict monitoring and conflict adaptation would be attenuated in 29 individuals with mild TBI compared to 36 control participants. Groups did not differ in age, sex, years of education, or neuropsychological test performance. Conflict monitoring and conflict adaptation can be seen when behavioral and ERP indices are reduced following high-conflict trials relative to low-conflict trials. Participants completed a Stroop task with 50% congruent and 50% incongruent trials. Behaviorally, both groups showed statistically significant conflict adaptation effects for RTs and error rates; these effects did not differ as a function of group. For ERPs, both groups showed more negative N450 and more positive conflict SP amplitudes on incongruent trials relative to congruent trials. Groups significantly differed in level of conflict adaptation for the conflict SP; controls showed significant conflict adaptation, whereas individuals with mild TBI did not. ERP amplitudes did not correlate with indices of injury severity or time since injury. Findings replicate and extend previous work that suggests the conflict SP is sensitive to conflict adaptation in healthy individuals, but is decreased in individuals across the range of TB! severity. Findings also suggest that mild TBI is associated with intact conflict monitoring, but altered conflict adaptation and adjustment processes. (C) 2011 Elsevier B.V. All rights reserved.	[Larson, Michael J.; Forrer, Thomas J.; Clayson, Peter E.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Clayson, Peter/AAC-9207-2019; Larson, Michael J/C-8543-2012; Clayson, Peter E/F-5438-2011	Clayson, Peter/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter E/0000-0003-4437-6598; Farrer, Thomas J./0000-0001-8092-6214			Beck A. T., 1996, BECK DEPRESSION INVE, VII; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benton A., 1976, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carroll JFX., 2001, MENTAL HLTH SCREENIN; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dai Q, 2011, CLIN NEUROPHYSIOL, V122, P52, DOI 10.1016/j.clinph.2010.05.025; Danielmeier C, 2009, PSYCHOPHYSIOLOGY, V46, P1288, DOI 10.1111/j.1469-8986.2009.00860.x; di Pellegrino G, 2007, J COGNITIVE NEUROSCI, V19, P275, DOI 10.1162/jocn.2007.19.2.275; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Forster SE, 2011, J COGNITIVE NEUROSCI, V23, P923, DOI 10.1162/jocn.2010.21458; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Hanslmayr S, 2008, J COGNITIVE NEUROSCI, V20, P215, DOI 10.1162/jocn.2008.20020; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Holmes AJ, 2008, NEUROPSYCHOLOGIA, V46, P2904, DOI 10.1016/j.neuropsychologia.2008.05.028; Hommel B, 2004, PSYCHOL RES-PSYCH FO, V68, P1, DOI 10.1007/s00426-003-0132-y; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROPSYCHOLOGIA, V47, P663, DOI 10.1016/j.neuropsychologia.2008.11.013; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; Mayr U, 2009, PSYCHOL RES-PSYCH FO, V73, P794, DOI 10.1007/s00426-008-0191-1; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sarno S, 2006, FUNCT NEUROL, V21, P21; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sivak S, 2008, BRAIN INJURY, V22, P193, DOI 10.1080/02699050801895431; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Speilberger CD., 1970, MANUAL STATE TRAIT A; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Ullsperger M, 2005, COGN AFFECT BEHAV NE, V5, P467, DOI 10.3758/CABN.5.4.467; Vanderhasselt MA, 2009, BIOL PSYCHOL, V81, P169, DOI 10.1016/j.biopsycho.2009.03.009; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2005, CORTEX, V41, P570, DOI 10.1016/S0010-9452(08)70197-7; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]; Yeung N, 2007, COGN AFFECT BEHAV NE, V7, P347, DOI 10.3758/CABN.7.4.347	82	52	56	1	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		69	78		10.1016/j.ijpsycho.2011.02.018			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600008	21392543				2021-06-18	
J	Siopi, E; Cho, AH; Homsi, S; Croci, N; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Siopi, Eleni; Cho, Angelo H.; Homsi, Shadi; Croci, Nicole; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Minocycline Restores sAPP alpha Levels and Reduces the Late Histopathological Consequences of Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						astrogliosis; atrophy; minocycline; sAPP alpha; traumatic brain injury; white matter	AMYLOID-PRECURSOR-PROTEIN; CLOSED-HEAD-INJURY; HIPPOCAMPAL-NEURONS; PROGRESSIVE ATROPHY; SECRETED FORMS; ACTIVATION; MODEL; RECEPTOR; WHITE; RATS	Traumatic brain injury (TBI) induces both focal and diffuse lesions that are concurrently responsible for the ensuing morbidity and mortality and for which no established treatment is available. It has been recently reported that an endogenous neuroprotector, the soluble form alpha of the amyloid precursor protein (sAPP alpha), exerts neuroprotective effects following TBI. However, the emergent post-traumatic neuroinflammatory environment compromises sAPP alpha production and may promote neuronal degeneration and consequent brain atrophy. Hence, the aim of this study was to examine the effects of the anti-inflammatory drug minocycline on sAPP alpha levels, as well as on long-term histological consequences post-TBI. The weight-drop model was used to induce TBI in mice. Minocycline or its vehicle were administered three times: at 5 min (90mg/ kg, i.p.) and at 3 and 9 h (45 mg/kg, i.p.) post-TBI. The levels of sAPP alpha, the extent of brain atrophy, and reactive gliosis were evaluated by ELISA, cresyl violet, and immunolabeling of GFAP and CD11b, respectively. Our results revealed a post-TBI sAPP alpha decrease that was significantly attenuated by minocycline. Additionally, corpus callosum and striatal atrophy, ventriculomegaly, astrogliosis, and microglial activation were observed at 3 months post-TBI. All the above consequences were significantly reduced by minocycline. In conclusion, inhibition of the acute phase of post-TBI neuroinflammation was associated with the sparing of sAPP alpha and the protection of brain tissue in the long-term, emphasizing the potential role of minocycline as an effective treatment for TBI.	[Siopi, Eleni; Cho, Angelo H.; Homsi, Shadi; Croci, Nicole; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, F-75006 Paris, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, 4 Ave Observ, F-75006 Paris, France.	mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	nonprofit organization Fondation des Gueules Cassees	This work was supported by the nonprofit organization Fondation des Gueules Cassees (grants to E.S. and M.J.T.).	Antonenko YN, 2010, J BIOENERG BIOMEMBR, V42, P151, DOI 10.1007/s10863-010-9271-1; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Claasen AM, 2009, NEUROSCI LETT, V460, P92, DOI 10.1016/j.neulet.2009.05.040; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Czeiter E, 2009, MOLECULES, V14, P5115, DOI 10.3390/molecules14125115; Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gunther A, 2005, EUR J NEUROSCI, V21, P3189, DOI 10.1111/j.1460-9568.2005.04151.x; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; KOSTRZEWA RM, 1994, BRAIN RES BULL, V34, P161, DOI 10.1016/0361-9230(94)90013-2; Kovesdi E, 2010, INT J MOL SCI, V11, P1253, DOI 10.3390/ijms11041253; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lesne S, 2005, J NEUROSCI, V25, P9367, DOI 10.1523/JNEUROSCI.0849-05.2005; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Magara F, 2000, NEUROSCI BIOBEHAV R, V24, P45, DOI 10.1016/S0149-7634(99)00051-2; Mahmood A., 2009, NEUROSURGERY, V65, P191, DOI DOI 10.1227/01.NEU.0000343540.24780.D6; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081; Matute C, 2010, CELL CALCIUM, V47, P150, DOI 10.1016/j.ceca.2009.12.004; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Miller Janet M, 2007, Cerebrospinal Fluid Res, V4, P5, DOI 10.1186/1743-8454-4-5; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Osuka S, 2010, J NEUROSURG, V112, P832, DOI 10.3171/2009.7.JNS09550; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Verger K, 2001, BRAIN INJURY, V15, P211; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	61	52	52	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2135	2143		10.1089/neu.2010.1738			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500014	21770756				2021-06-18	
J	Kurowski, BG; Taylor, HG; Yeates, KO; Walz, NC; Stancin, T; Wade, SL				Kurowski, Brad G.; Taylor, H. Gerry; Yeates, Keith Owen; Walz, Nicolay C.; Stancin, Terry; Wade, Shari L.			Caregiver Ratings of Long-term Executive Dysfunction and Attention Problems After Early Childhood Traumatic Brain Injury: Family Functioning Is Important	PM&R			English	Article							DEFICIT HYPERACTIVITY DISORDER; OUTCOME 30 MONTHS; YOUNG-CHILDREN; HEAD-INJURY; DEFICIT/HYPERACTIVITY DISORDER; ASSESSMENT DEVICE; BEHAVIOR PROBLEMS; FOLLOW-UP; PREDICTORS; RECOVERY	Objective: To evaluate the relationship of family and parenting factors to long-term executive dysfunction and attention problems after early childhood traumatic brain injury (TBI). We hypothesized that the magnitude of executive dysfunction and attention problems would be moderated by family and parenting factors. Design: A multicenter, prospective cohort study that included an orthopedic injury (01) reference group. Setting: Three tertiary academic children's hospital medical centers and one general medical center. Participants: Children, ages 3-7 years, hospitalized for 01, moderate TBI, or severe TBI. Methods and Outcome Measurements: Parental ratings of family functioning and parenting styles were obtained 18 months after the injury occurred. The main outcome measurements, which were parental ratings of children's executive function and attention, were performed at least 24 months after the injury occurred (mean, 39 months; range, 25-63 months). Analysis: Group comparisons were conducted with use of t-tests, chi(2) analysis, analysis of variance, and Pearson and Spearman correlations. Regression analysis was used to examine associations of the outcomes with family functioning and parenting styles and to test moderating effects of these factors on group differences. Results: Participants with severe TBI demonstrated increased executive dysfunction and attention problems compared with those who sustained moderate TBI or OI. Lower levels of family dysfunction were associated with better executive function and attention across groups but did not moderate group differences. However, attention deficits after severe TBI were exacerbated under conditions of more permissive parenting relative to attention deficits after OIs. Conclusions: Executive function and attention problems persisted on a long-term basis (>24 months) after early childhood TBI, and positive global family functioning and nonpermissive parenting were associated with better outcomes. Better characterization of the optimal family environment for recovery from early childhood TBI could help target future interventions. PM R 2011;3:836-845	[Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH USA; [Kurowski, Brad G.; Walz, Nicolay C.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Psychiat, Div Pediat Psychol, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human Development, Rehabilitation Medicine Scientist Training Program (RMSTP) [R01 HD42729, 7K12 H0001097-14]; United States Public Health Service National Institutes of HealthUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; Trauma Research grants from State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729, K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	Funding for this study was provided through grant R01 HD42729 from the National Institute of Child Health and Human Development, Rehabilitation Medicine Scientist Training Program (RMSTP) grant 7K12 H0001097-14, in part by United States Public Health Service National Institutes of Health grant M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services.	Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; BAUMRIND D, 1966, CHILD DEV, V37, P887, DOI 10.1111/j.1467-8624.1966.tb05416.x; BAUMRIND D, 1967, GENET PSYCHOL MONOGR, V75, P43; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Faul M, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia G. A., 2003, BRIEF P BEHAV RATING; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Stancin T, 2010, J DEV BEHAV PEDIATR, V31, P317, DOI 10.1097/DBP.0b013e3181dbaf32; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	56	52	52	1	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	SEP	2011	3	9					836	845		10.1016/j.pmrj.2011.05.016			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	961BE	WOS:000305438100008	21944301	Green Accepted			2021-06-18	
J	Kharlamov, EA; Lepsveridze, E; Meparishvili, M; Solomonia, RO; Lu, B; Miller, ER; Kelly, KM; Mtchedlishvili, Z				Kharlamov, Elena A.; Lepsveridze, Eka; Meparishvili, Maia; Solomonia, Revaz O.; Lu, Bo; Miller, Eric R.; Kelly, Kevin M.; Mtchedlishvili, Zakaria			Alterations of GABA(A) and glutamate receptor subunits and heat shock protein in rat hippocampus following traumatic brain injury and in posttraumatic epilepsy	EPILEPSY RESEARCH			English	Article						Controlled cortical impact; Epileptogenesis; Hippocampus; Traumatic brain injury; Posttraumatic epilepsy; Western blot	CONTROLLED CORTICAL IMPACT; D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; NR2B-CONTAINING NMDA RECEPTORS; SUBCELLULAR STRESS-RESPONSE; TRANSIENT GLOBAL-ISCHEMIA; FLUID-PERCUSSION INJURY; DENTATE GYRUS; KINASE-II; SYNAPTIC PLASTICITY	Traumatic brain injury (TBI) can result in the development of posttraumatic epilepsy (PTE). Recently, we reported differential alterations in tonic and phasic GABA(A) receptor (GABA(A)R) currents in hippocampal dentate granule cells 90 days after controlled cortical impact (CCI) (Mtchedlishvili et al., 2010). In the present study, we investigated long-term changes in the protein expression of GABA(A)R alpha 1, alpha 4, gamma 2, and delta subunits, NMDA (NR2B) and AMPA (GluR1) receptor subunits, and heat shock proteins (HSP70 and HSP90) in the hippocampus of Sprague-Dawley rats evaluated by Western blotting in controls, CC-injured animals without PTE (CCI group), and CCI-injured animals with PTE (PTE group). No differences were found among all three groups for alpha 1 and alpha 4 subunits. Significant reduction of gamma 2 protein was observed in the PTE group compared to control. CCI caused a 194% and 127% increase of delta protein in the CCI group compared to control (p < 0.0001), and PTE (p < 0.0001) groups, respectively. NR2B protein was increased in CCI and PTE groups compared to control (p = 0.0001, and p = 0.011, respectively). GluR1 protein was significantly decreased in CCI and PTE groups compared to control (p = 0.003, and p = 0.001, respectively), and in the PTE group compared to the CCI group (p = 0.036). HSP70 was increased in CCI and PTE groups compared to control (p = 0.014, and p = 0.005, respectively); no changes were found in HSP90 expression. These results provide for the first time evidence of long-term alterations of GABA(A) and glutamate receptor subunits and a HSP following CCI. (c) 2011 Elsevier B.V. All rights reserved.	[Kharlamov, Elena A.; Lepsveridze, Eka; Lu, Bo; Miller, Eric R.; Kelly, Kevin M.; Mtchedlishvili, Zakaria] Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Neurosci Res, Pittsburgh, PA 15212 USA; [Kharlamov, Elena A.; Kelly, Kevin M.; Mtchedlishvili, Zakaria] Drexel Univ, Coll Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kelly, Kevin M.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; [Lepsveridze, Eka; Meparishvili, Maia; Solomonia, Revaz O.] Ilia State Univ, Inst Biol Chem, Tbilisi, Georgia; [Lepsveridze, Eka; Meparishvili, Maia; Solomonia, Revaz O.] I Beritashvili Inst Physiol, Tbilisi, Georgia	Kharlamov, EA (corresponding author), Allegheny Gen Hosp, Allegheny Singer Res Inst, Ctr Neurosci Res, 320 East North Ave,9J1 S Tower, Pittsburgh, PA 15212 USA.	ekharlam@wpahs.org			Health Research Formula Fund [RFA 01-07-26]; Pennsylvania Department of Health; Epilepsy Foundation; Georgian National Science Scholars Program	The study was supported by Health Research Formula Fund RFA 01-07-26, Pennsylvania Department of Health, and a Research Grant from the Epilepsy Foundation to ZM and a grant from the Georgian National Science Scholars Program (EL). We thank Teresa M. Hentosz for assistance in the preparation of the manuscript.	Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003; Alldred MJ, 2005, J NEUROSCI, V25, P594, DOI 10.1523/JNEUROSCI.4011-04.2005; ARAKI T, 1993, MOL BRAIN RES, V20, P263, DOI 10.1016/0169-328X(93)90050-Y; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Belelli D, 2009, J NEUROSCI, V29, P12757, DOI 10.1523/JNEUROSCI.3340-09.2009; Bencsits E, 1999, J BIOL CHEM, V274, P19613, DOI 10.1074/jbc.274.28.19613; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; Blair RE, 2008, EUR J PHARMACOL, V588, P64, DOI 10.1016/j.ejphar.2008.04.021; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Bush PC, 1999, J NEUROPHYSIOL, V82, P1748; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Cendes F, 2005, CURR OPIN NEUROL, V18, P173, DOI 10.1097/01.wco.0000162860.49842.90; Chen Q, 2007, J NEUROSCI, V27, P542, DOI 10.1523/JNEUROSCI.3607-06.2007; Clayton DA, 2002, J NEUROSCI, V22, P3628; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; D'Souza SM, 1998, CELL STRESS CHAPERON, V3, P188, DOI 10.1379/1466-1268(1998)003<0188:CEOHSP>2.3.CO;2; DeBlas AL, 1996, MOL NEUROBIOL, V12, P55, DOI 10.1007/BF02740747; Delgado JY, 2007, J NEUROSCI, V27, P13210, DOI 10.1523/JNEUROSCI.3056-07.2007; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; Didelot C, 2006, HANDB EXP PHARM, V172, P171; Dingledine R, 1999, PHARMACOL REV, V51, P7; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dittmer A, 2006, ELECTROPHORESIS, V27, P2844, DOI 10.1002/elps.200500785; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Ekimova IV, 2010, J NEUROCHEM, V115, P1035, DOI 10.1111/j.1471-4159.2010.06989.x; Emond MR, 2010, J PHYSIOL-LONDON, V588, P1929, DOI 10.1113/jphysiol.2010.187229; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Eugene E, 2007, J NEUROSCI, V27, P14108, DOI 10.1523/JNEUROSCI.2618-07.2007; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Foster KA, 2010, J NEUROSCI, V30, P2676, DOI 10.1523/JNEUROSCI.4022-09.2010; Fritschy JM, 2008, FRONT MOL NEUROSCI, V1, DOI 10.3389/neuro.02.005.2008; Fritschy JM, 1999, NEUROCHEM INT, V34, P435, DOI 10.1016/S0197-0186(99)00040-6; Frugier G, 2007, J BIOL CHEM, V282, P3819, DOI 10.1074/jbc.M608910200; Gallagher MJ, 2007, P NATL ACAD SCI USA, V104, P12999, DOI 10.1073/pnas.0700163104; Gallagher MJ, 2005, J BIOL CHEM, V280, P37995, DOI 10.1074/jbc.M508305200; GALLAGHER S, 2008, CURR PROTOC IMMUNOL, pCH8; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GASS P, 1995, NEUROSCIENCE, V65, P27, DOI 10.1016/0306-4522(95)92049-P; GASS P, 1994, NEUROSCI LETT, V182, P188, DOI 10.1016/0304-3940(94)90794-3; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; Goebel SM, 2005, MOL BRAIN RES, V142, P65, DOI 10.1016/j.molbrainres.2005.09.012; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Groc L, 2006, P NATL ACAD SCI USA, V103, P18769, DOI 10.1073/pnas.0605238103; Gutierrez A, 1996, MOL BRAIN RES, V35, P91, DOI 10.1016/0169-328X(95)00187-W; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hellier JL, 2009, NEUROPHARMACOLOGY, V56, P414, DOI 10.1016/j.neuropharm.2008.09.009; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Hota SK, 2010, FREE RADICAL BIO MED, V49, P178, DOI 10.1016/j.freeradbiomed.2010.03.027; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; IZUMOTO S, 1993, J NEUROSCI RES, V35, P20, DOI 10.1002/jnr.490350104; JONAS P, 1995, NEURON, V15, P987, DOI 10.1016/0896-6273(95)90087-X; Joshi S, 2009, NEUROSCIENCE, V164, P507, DOI 10.1016/j.neuroscience.2009.08.008; KAPUR J, 1989, J NEUROPHYSIOL, V61, P427; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kharlamov EA, 2007, BRAIN RES, V1127, P151, DOI 10.1016/j.brainres.2006.09.107; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Korpi ER, 2002, NEUROSCIENCE, V109, P733, DOI 10.1016/S0306-4522(01)00527-9; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lagrange Andre, 2005, Epilepsy Curr, V5, P91, DOI 10.1111/j.1535-7511.2005.05304.x; Lagrange AH, 2007, J PHYSIOL-LONDON, V578, P655, DOI 10.1113/jphysiol.2006.122135; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lee HK, 2007, MOL CELL NEUROSCI, V36, P86, DOI 10.1016/j.mcn.2007.06.003; Lee HK, 2010, J NEUROPHYSIOL, V103, P479, DOI 10.1152/jn.00835.2009; Liu FY, 2007, BIOCHEM BIOPH RES CO, V358, P825, DOI 10.1016/j.bbrc.2007.05.010; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lively S, 2008, J NEUROCHEM, V107, P1335, DOI 10.1111/j.1471-4159.2008.05696.x; Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9; Loup F, 2009, BRAIN, V132, P2449, DOI 10.1093/brain/awp178; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luo WJ, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-24; Luscher B, 2004, PHARMACOL THERAPEUT, V102, P195, DOI 10.1016/j.pharmthera.2004.04.003; MacDonald John F., 2006, Critical Reviews in Neurobiology, V18, P71; Macdonald RL, 2010, J PHYSIOL-LONDON, V588, P1861, DOI 10.1113/jphysiol.2010.186999; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mallouk Y, 1999, INT J MOL MED, V4, P463; Mangan PS, 2005, MOL PHARMACOL, V67, P775, DOI 10.1124/mol.104.007385; Martel MA, 2009, NEUROSCIENCE, V158, P334, DOI 10.1016/j.neuroscience.2008.01.080; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; Meng FJ, 2003, BRAIN RES, V967, P161, DOI 10.1016/S0006-8993(02)04267-1; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Miranda JD, 1997, J BIOL CHEM, V272, P16288, DOI 10.1074/jbc.272.26.16288; Moddel G, 2005, BRAIN RES, V1046, P10, DOI 10.1016/j.brainres.2005.03.042; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mony L, 2009, BRIT J PHARMACOL, V157, P1301, DOI 10.1111/j.1476-5381.2009.00304.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Nusser Z, 2002, J NEUROPHYSIOL, V87, P2624, DOI 10.1152/jn.2002.87.5.2624; Pal S, 2000, CELL CALCIUM, V28, P181, DOI 10.1054/ceca.2000.0146; Park CS, 2008, NEUROSCIENCE, V151, P43, DOI 10.1016/j.neuroscience.2007.09.075; Peng Z, 2002, J COMP NEUROL, V446, P179, DOI 10.1002/cne.10210; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PorteraCailliau C, 1996, J NEUROCHEM, V66, P692, DOI 10.1046/j.1471-4159.1996.66020692.x; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Powers MV, 2009, CELL CYCLE, V8, P518, DOI 10.4161/cc.8.4.7583; Pratt WB, 2006, HANDB EXP PHARM, V172, P111; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prenosil GA, 2006, J NEUROPHYSIOL, V96, P846, DOI 10.1152/jn.01199.2006; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rakhade SN, 2008, J NEUROSCI, V28, P7979, DOI 10.1523/JNEUROSCI.1734-08.2008; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Raveendran R, 2009, J NEUROCHEM, V110, P92, DOI 10.1111/j.1471-4159.2009.06108.x; Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101; Rebola N, 2010, J PHYSIOL-LONDON, V588, P93, DOI 10.1113/jphysiol.2009.179382; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; ROGERS SW, 1991, J NEUROSCI, V11, P2713; RUANO D, 1991, J PHARMACOL EXP THER, V256, P902; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Schweizer C, 2003, MOL CELL NEUROSCI, V24, P442, DOI 10.1016/S1044-7431(03)00202-1; Scimemi A, 2005, J NEUROSCI, V25, P10016, DOI 10.1523/JNEUROSCI.2520-05.2005; SHARP FR, 1993, STROKE, V24, pI72; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Sieghart W, 2006, ADV PHARMACOL, V54, P231, DOI 10.1016/S1054-3589(06)54010-4; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Solomonia R, 2010, NEUROSCI LETT, V468, P277, DOI 10.1016/j.neulet.2009.11.012; Solomonia RO, 2005, J PHYSIOL-LONDON, V569, P643, DOI 10.1113/jphysiol.2005.098012; Spigelman I, 2003, J NEUROPHYSIOL, V90, P903, DOI 10.1152/jn.01022.2002; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Sun CS, 2004, BRAIN RES, V1029, P207, DOI 10.1016/j.brainres.2004.09.056; Toth Z, 1997, J NEUROSCI, V17, P8106; Tretter V, 1997, J NEUROSCI, V17, P2728; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Wei WZ, 2003, J NEUROSCI, V23, P10650; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yang TT, 2008, ACTA NEUROPATHOL, V115, P219, DOI 10.1007/s00401-007-0297-3; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zara V, 2009, BIOCHEM J, V419, P369, DOI 10.1042/BJ20082270; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	168	52	56	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUN	2011	95	1-2					20	34		10.1016/j.eplepsyres.2011.02.008			15	Clinical Neurology	Neurosciences & Neurology	788GV	WOS:000292434300003	21439793				2021-06-18	
J	de Witt, BW; Ehrenberg, KM; McAloon, RL; Panos, AH; Shaw, KE; Raghavan, PV; Skidmore, ER; Kline, AE				de Witt, Benjamin Wells; Ehrenberg, Kathryn M.; McAloon, Rose L.; Panos, Amanda H.; Shaw, Kaitlyn E.; Raghavan, Priya V.; Skidmore, Elizabeth R.; Kline, Anthony E.			Abbreviated Environmental Enrichment Enhances Neurobehavioral Recovery Comparably to Continuous Exposure After Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						controlled cortical impact; environmental enrichment; functional recovery; galantamine; learning and memory; Morris water maze	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; CONTROLLED CORTICAL IMPACT; 5-HT1A RECEPTOR; COGNITIVE DEFICITS; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; VOLUNTARY EXERCISE; TREATMENT REGIMEN; UNITED-STATES; GROWTH	Background. Environmental enrichment (EE) is a complex living milieu that has been shown to enhance functional recovery versus standard (STD) housing after experimental traumatic brain injury (TBI) and therefore may be considered a rodent correlate of rehabilitation. However, the typical EE paradigm consists of continuous exposure to enrichment after TBI, which is inconsistent with the limited time frame in clinical rehabilitation. Objective. To determine whether abbreviated EE (ie, rehabilitation-relevant dose response) confers benefits similar to typical EE after TBI. Methods. Adult male rats received either a controlled cortical impact (2.8 mm depth at 4 m/s) or sham injury and were then randomly assigned to TBI + EE, TBI + EE (2 hours), TBI + EE (4 hours), TBI + EE (6 hours), TBI + STD, and respective sham controls. Motor (beam balance/beam walk) and cognitive (Morris water maze) performance was assessed on postoperative days 1 to 5 and 14 to 19, respectively. Results. The TBI + EE (2 hours) and TBI + EE (4 hours) groups were not statistically different from the TBI + STD group in any behavioral assessment. In contrast, the TBI + EE (6 hours) group exhibited significant enhancement of motor and cognitive performance when compared with the TBI + STD group, as well as the TBI + EE (2 hours) and TBI + EE (4 hours) groups (P < .003), and did not differ from the TBI + EE (typical) group. Conclusions. These data demonstrate that abbreviated EE (6 hours) produces motor and cognitive benefits similar to continuous EE after TBI and thus may be considered a dose-relevant rehabilitation paradigm.	[de Witt, Benjamin Wells; Ehrenberg, Kathryn M.; McAloon, Rose L.; Panos, Amanda H.; Shaw, Kaitlyn E.; Raghavan, Priya V.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005, K12 HD055931]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055931, R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This work was supported, in part, by National Institutes of Health grants HD046700 and NS060005 awarded to AEK and K12 HD055931 (ERS).	BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	50	52	52	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2011	25	4					343	350		10.1177/1545968310390520			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	742KJ	WOS:000288940900005	21186330	Green Accepted			2021-06-18	
J	Akin, FW; Murnane, OD				Akin, Faith W.; Murnane, Owen D.			Head Injury and Blast Exposure: Vestibular Consequences	OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA			English	Article						Dizziness; Traumatic brain injury; Blast injuries; Vestibular function tests; Saccule and utricle; Postural balance; Vestibular labyrinth	TRAUMATIC BRAIN-INJURY; MILD HEAD; POSTURAL STABILITY; EVOKED-POTENTIALS; OTOLITH DISORDERS; DIZZINESS; EAR; IMPAIRMENT; VERTIGO; DUTY	Young adults are more likely to suffer blast injury and traumatic brain injury (TBI) than other age groups. This article reviews the literature on the vestibular consequences of blast exposure and TBI and concussion. In addition, the vestibular test findings obtained from 31 veterans with a history of blast exposure and/or mild TBI are presented. The authors discuss loss of horizontal semicircular canal function and postural instability related to head injury. Preliminary data suggest the novel theory that otolith organs are uniquely vulnerable to head injury and blast exposure.	[Akin, Faith W.; Murnane, Owen D.] E Tennessee State Univ, Dept Audiol & Speech Pathol, Johnson City, TN 37614 USA; [Akin, Faith W.; Murnane, Owen D.] Vet Affairs Med Ctr, Audiol Serv, Vestibular Balance Lab, Mountain Home, TN 37684 USA	Akin, FW (corresponding author), E Tennessee State Univ, Dept Audiol & Speech Pathol, Johnson City, TN 37614 USA.	faith.akin@va.gov			Auditory and Vestibular Dysfunction Research Enhancement Award Program; Merit Review grants; Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, DCUS Department of Veterans Affairs	This work was supported by the Merit Review grants and by the Auditory and Vestibular Dysfunction Research Enhancement Award Program. All funding was sponsored by the Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, DC.	BARANY R, 1967, NOBEL LECT PHYSL MED; BARBER H O, 1964, Laryngoscope, V74, P891; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Basta D, 2005, HUM MOVEMENT SCI, V24, P268, DOI 10.1016/j.humov.2005.04.002; Basta D, 2008, GAIT POSTURE, V28, P397, DOI 10.1016/j.gaitpost.2008.01.006; Bohmer A, 1999, J VESTIBUL RES-EQUIL, V9, P413; CAVENESS W F, 1961, N Y State J Med, V61, P871; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clarke AH, 2001, ACTA OTO-LARYNGOL, P84; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; COLEBATCH JG, 1992, NEUROLOGY, V42, P1635, DOI 10.1212/WNL.42.8.1635; Colebatch JG, 2001, CURR OPIN NEUROL, V14, P21, DOI 10.1097/00019052-200102000-00004; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Waele C, 1999, AM J OTOL, V20, P223; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; DIETERICH M, 1993, ANN NEUROL, V33, P292, DOI 10.1002/ana.410330311; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; HALMAGYI G, 2007, VESTIBULAR REHABILIT, P144; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kisilevski V, 2001, Int Tinnitus J, V7, P118; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Lachman J, 1955, ACTA MED ORIENT, V14, P44; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PALOSKI WH, 1993, AM J OTOL, V14, P9; PROCTOR B, 1956, Laryngoscope, V66, P16; RUBIN AM, 1995, AM J OTOL, V16, P216; SANNA M, 1983, ORL J OTO-RHINO-LARY, V45, P216, DOI 10.1159/000275645; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, P7; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; WETZIG J, 1990, ACTA ASTRONAUT, V21, P519, DOI 10.1016/0094-5765(90)90070-2; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; YLIKOSKI J, 1982, AM J OTOL, V3, P343	51	52	53	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0030-6665			OTOLARYNG CLIN N AM	Otolaryngol. Clin. N. Am.	APR	2011	44	2					323	+		10.1016/j.otc.2011.01.005			13	Otorhinolaryngology	Otorhinolaryngology	757ZH	WOS:000290128000006	21474007				2021-06-18	
J	Heffernan, DS; Vera, RM; Monaghan, SF; Thakkar, RK; Kozloff, MS; Connolly, MD; Gregg, SC; Machan, JT; Harrington, DT; Adams, CA; Cioffi, WG				Heffernan, Daithi S.; Vera, Roberto M.; Monaghan, Sean F.; Thakkar, Rajan K.; Kozloff, Matthew S.; Connolly, Michael D.; Gregg, Shea C.; Machan, Jason T.; Harrington, David T.; Adams, Charles A., Jr.; Cioffi, William G.			Impact of Socioethnic Factors on Outcomes Following Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Socioethnic factors; Traumatic brain injury; Race; Income; Insurance	SOCIOECONOMIC-STATUS; ETHNIC DISPARITIES; RACIAL-DIFFERENCES; MEDICAL ADVICE; RISK-FACTORS; REHABILITATION; RACE; MORTALITY; ALCOHOL; CARE	Background: Ethnic minorities and low income families tend to be in poorer health and have worse outcomes for a spectrum of diseases. Health care provider bias has been reported to potentially affect the distribution of care away from poorer communities, minorities, and patients with a history of substance abuse. Trauma is perceived as a disease of the poor and medically underserved. Minorities are overrepresented in low income populations and are also less likely to possess health insurance leading to a potential overlapping effect. Traumatic brain injury (TBI) is a predominant cause of mortality and long-term morbidity, which imposes a considerable social and financial burden. We therefore sought to determine the independent effect on outcome after TBI from race, insurance status, intoxication on presentation, and median income. Methods: A 5-year retrospective chart review of admitted trauma patients aged 18 years and older to a Level I trauma center. Zip code of residency was a surrogate marker for socioeconomic status, because median income for each zip code is available from the US Census. Charts review included race, insurance status, mechanisms of trauma, and injuries sustained. Outcomes were placement of tracheostomy, hospital length of stay (HLOS), leaving Against Medical Advice (AMA), and discharge to home versus rehabilitation and mortality. Results: A total of 3,101 TBI patients were included in the analyses. Multivariable logistic and proportional hazard regression analyses were undertaken adjusting for age, gender, Injury Severity Score, and mechanism. Rates of tracheostomy placement were unaffected by race, median income, or insurance status. Race and median income did not affect HLOS, but private insurance was associated with shorter HLOS and intoxication was associated with longer HLOS. Neither race nor intoxication affected rates of AMA, but higher income and private insurance was associated with lower rates of AMA. Non-Caucasian race and lack of insurance had significantly lower likelihood of placement in a rehabilitation center. Mortality was unaffected by race, increased in intoxicated patients, was variably affected by median income, and was lowest in patients with private insurance. Conclusions: An extremely complex interplay exists between socioethnic factors and outcomes after TBI. Few physicians would claim overt discrimination. Tracheostomy, the factor most directed by the surgeon, was unbiased by race, income, or insurance status. The likelihood of placement in a rehabilitation center was significantly impacted by both race and insurance status. Future prospective studies are needed to better address causation.	[Heffernan, Daithi S.; Vera, Roberto M.; Monaghan, Sean F.; Thakkar, Rajan K.; Kozloff, Matthew S.; Connolly, Michael D.; Gregg, Shea C.; Machan, Jason T.; Harrington, David T.; Adams, Charles A., Jr.; Cioffi, William G.] Brown Univ, Alpert Med Sch, Dept Surg, Div Trauma & Surg Crit Care,Rhode Isl Hosp, Providence, RI 02903 USA	Heffernan, DS (corresponding author), Brown Univ, Alpert Med Sch, Dept Surg, Div Trauma & Surg Crit Care,Rhode Isl Hosp, 435 APC Bldg,4th Floor,593 Eddy St, Providence, RI 02903 USA.	dheffernan@brown.edu	Machan, Jason T/D-3897-2013	Machan, Jason T/0000-0003-2048-4914			Alban RF, 2010, AM SURGEON, V76, P1108; Anis AH, 2002, CAN MED ASSOC J, V167, P633; Armenian SH, 1999, DRUG ALCOHOL DEPEN, V56, P1, DOI 10.1016/S0376-8716(99)00027-7; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Braver ER, 2003, ACCIDENT ANAL PREV, V35, P295, DOI 10.1016/S0001-4575(01)00106-3; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Cooper L. A., 2003, PATIENT PROVIDER COM; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Girasek DC, 2010, TRAFFIC INJ PREV, V11, P151, DOI 10.1080/15389580903531598; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Green AR, 2007, J GEN INTERN MED, V22, P1231, DOI 10.1007/s11606-007-0258-5; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; HERTZMAN C, 1999, POPULATION HLTH HUMA; Kressin NR, 2001, ANN INTERN MED, V135, P352, DOI 10.7326/0003-4819-135-5-200109040-00012; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lim HJ, 2007, J TRAUMA, V63, P902, DOI 10.1097/01.ta.0000240110.14909.71; Lu N, 2004, J HEALTH CARE POOR U, V15, P618, DOI 10.1353/hpu.2004.0053; Lurie N, 2005, CIRCULATION, V111, P1264, DOI 10.1161/01.CIR.0000157738.12783.71; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Nirula R, 2009, J TRAUMA, V66, P255, DOI 10.1097/TA.0b013e31815ede46; NOORDZIJ PC, 1988, ERGONOMICS, V31, P663, DOI 10.1080/00140138808966708; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Reutter LI, 2009, QUAL HEALTH RES, V19, P297, DOI 10.1177/1049732308330246; Saitz R, 1999, AM J MED, V107, P507, DOI 10.1016/S0002-9343(99)00262-4; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Taylor SL, 2006, ANN THORAC SURG, V81, P531, DOI 10.1016/j.athoracsur.2005.08.004; Voas RB, 2009, ACCIDENT ANAL PREV, V41, P522, DOI 10.1016/j.aap.2009.02.004; Weingart SN, 1998, J GEN INTERN MED, V13, P568, DOI 10.1046/j.1525-1497.1998.00169.x; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	37	52	53	2	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2011	70	3					527	533		10.1097/TA.0b013e31820d0ed7			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	732PU	WOS:000288201200007	21610339				2021-06-18	
J	Kovacech, B; Novak, M				Kovacech, B.; Novak, M.			Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Tau truncation; Alzheimer's disease; neurofibrillary degeneration; tau transition	PAIRED HELICAL FILAMENTS; ACTIVATED NEUTRAL PROTEINASE; TRAUMATIC BRAIN-INJURY; CASPASE-CLEAVAGE; HYPERPHOSPHORYLATED-TAU; AMYLOID-BETA; IN-VITRO; ABNORMAL PHOSPHORYLATION; SENILE PLAQUES; FRONTOTEMPORAL DEMENTIA	Deposits of the misfolded neuronal protein tau are major hallmarks of neurodegeneration in Alzheimer's disease (AD) and other tauopathies. The etiology of the transformation process of the intrinsically disordered soluble protein tau into the insoluble misordered aggregate has attracted much attention. Tau undergoes multiple modifications in AD, most notably hyperphosphorylation and truncation. Hyperphosphorylation is widely regarded as the hottest candidate for the inducer of the neurofibrillary pathology. However, the true nature of the impetus that initiates the whole process in the human brains remains unknown. In AD, several site-specific tau cleavages were identified and became connected to the progression of the disease. In addition, western blot analyses of tau species in AD brains reveal multitudes of various truncated forms. In this review we summarize evidence showing that tau truncation alone is sufficient to induce the complete cascade of neurofibrillary pathology, including hyperphosphorylation and accumulation of misfolded insoluble forms of tau. Therefore, proteolytical abnormalities in the stressed neurons and production of aberrant tau cleavage products deserve closer attention and should be considered as early therapeutic targets for Alzheimer's disease.	[Kovacech, B.; Novak, M.] Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Bratislava 84510, Slovakia; [Kovacech, B.; Novak, M.] Axon Neurosci GmbH, Vienna, Austria	Novak, M (corresponding author), Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Dubravska Cesta 9, Bratislava 84510, Slovakia.	michal.novak@savba.sk	Kovacech, Brnislav/ABD-3254-2020		VEGAVedecka grantova agentura MSVVaS SR a SAV (VEGA)European Commission [2/6183/26, 2/0162/10, APVV 0631-07, APVV 0621-07, APVV 603-06, LPP-0326-06]	This work was supported by research grants VEGA 2/6183/26 and 2/0162/10, APVV 0631-07, APVV 0621-07, APVV 603-06 and LPP-0326-06.	Abraha A, 2000, J CELL SCI, V113, P3737; Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, J BIOL CHEM, V276, P37967; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Alonso AD, 2006, P NATL ACAD SCI USA, V103, P8864, DOI 10.1073/pnas.0603214103; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Burack MA, 1996, NEUROSCIENCE, V72, P167, DOI 10.1016/0306-4522(95)00546-3; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Canu N, 1998, J NEUROSCI, V18, P7061; Cataldo AM, 1996, J NEUROSCI, V16, P186; CENTE M, 2009, J ALZHEIMERS DIS; Cente M, 2006, EUR J NEUROSCI, V24, P1085, DOI 10.1111/j.1460-9568.2006.04986.x; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Csokova N, 2006, PROTEIN PEPTIDE LETT, V13, P941, DOI 10.2174/092986606778256180; Dawson HN, 2001, J CELL SCI, V114, P1179; Delobel P, 2008, AM J PATHOL, V172, P123, DOI 10.2353/ajpath.2008.070627; Deng YQ, 2009, AM J PATHOL, V175, P2089, DOI 10.2353/ajpath.2009.090157; Ding HP, 2006, J BIOL CHEM, V281, P19107, DOI 10.1074/jbc.M511697200; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Fasulo L, 1998, ALZHEIMERS REP, V1, P25; Fasulo L, 2005, J ALZHEIMERS DIS, V7, P3; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Filipcik P, 2009, CELL MOL NEUROBIOL, V29, P895, DOI 10.1007/s10571-009-9372-8; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Garcia-Sierra F, 2008, J ALZHEIMERS DIS, V14, P401; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; GARVER TD, 1994, J NEUROCHEM, V63, P2279; Gastard MC, 2003, ANN NEUROL, V54, P393, DOI 10.1002/ana.10680; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; HANEMAAIJER R, 1991, J NEUROSCI RES, V30, P163, DOI 10.1002/jnr.490300117; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hrnkova M, 2007, BRAIN RES, V1130, P206, DOI 10.1016/j.brainres.2006.10.085; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Iqbal K, 2006, Bratisl Lek Listy, V107, P341; Iqbal Khalid, 2005, Current Alzheimer Research, V2, P335, DOI 10.2174/1567205054367810; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; IWAMOTO N, 1991, BRAIN RES, V561, P177, DOI 10.1016/0006-8993(91)90766-O; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Ko LW, 1999, BRAIN RES, V830, P301, DOI 10.1016/S0006-8993(99)01415-8; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Koson P, 2008, EUR J NEUROSCI, V28, P239, DOI 10.1111/j.1460-9568.2008.06329.x; Kovac A, 2009, J ALZHEIMERS DIS, V18, P897, DOI 10.3233/JAD-2009-1197; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; Ledesma MD, 1996, MOL CHEM NEUROPATHOL, V27, P249, DOI 10.1007/BF02815107; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEDESMA MD, 1995, J NEUROCHEM, V65, P1658; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mena R, 1996, ACTA NEUROPATHOL, V91, P633, DOI 10.1007/s004010050477; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; NOVAK M, 1994, ACTA VIROL, V38, P173; Novak M, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P281; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Novak M, 1989, Prog Clin Biol Res, V317, P755; NOVAK M, 1991, P NATL ACAD SCI USA, V88, P5837, DOI 10.1073/pnas.88.13.5837; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Pevalova M, 2006, Bratisl Lek Listy, V107, P346; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Quintanilla RA, 2009, J BIOL CHEM, V284, P18754, DOI 10.1074/jbc.M808908200; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Reynolds MR, 2006, J NEUROSCI, V26, P10636, DOI 10.1523/JNEUROSCI.2143-06.2006; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sevcik J, 2007, FEBS LETT, V581, P5872, DOI 10.1016/j.febslet.2007.11.067; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; Skrabana R, 2006, ANAL BIOCHEM, V359, P230, DOI 10.1016/j.ab.2006.09.031; Smith MA, 1996, BRAIN RES, V717, P99, DOI 10.1016/0006-8993(95)01473-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Sun Q, 2009, BIOCHEMISTRY-US, V48, P6002, DOI 10.1021/bi900602h; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Tucholski J, 1999, J NEUROCHEM, V73, P1871; Ugolini G, 1997, NEUROREPORT, V8, P3709, DOI 10.1097/00001756-199712010-00010; Vechterova L, 2003, NEUROREPORT, V14, P87, DOI 10.1097/00001756-200301200-00017; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yin HS, 2006, FEBS LETT, V580, P211, DOI 10.1016/j.febslet.2005.11.077; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013; Zilka N, 2009, ACTA NEUROPATHOL, V118, P71, DOI 10.1007/s00401-009-0499-y	122	52	52	1	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	DEC	2010	7	8					708	716		10.2174/156720510793611556			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	692UZ	WOS:000285182300008	20678071				2021-06-18	
J	Liu, YR; Cardamone, L; Hogan, RE; Gregoire, MC; Williams, JP; Hicks, RJ; Binns, D; Koe, A; Jones, NC; Myers, DE; O'Brien, TJ; Bouilleret, V				Liu, Ying R.; Cardamone, Lisa; Hogan, R. Edward; Gregoire, Marie-Claude; Williams, John P.; Hicks, Rod J.; Binns, David; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane			Progressive Metabolic and Structural Cerebral Perturbations After Traumatic Brain Injury: An In Vivo Imaging Study in the Rat	JOURNAL OF NUCLEAR MEDICINE			English	Article						traumatic brain injury; rat; F-18-FDG PET; MRI; anxiety	TEMPORAL-LOBE EPILEPSY; TIME-COURSE; MRI; HIPPOCAMPUS; PET; MODEL; DIFFUSION	Traumatic brain injury (TBI) has a high incidence of long-term neurologic and neuropsychiatric morbidity. Metabolic and structural changes in rat brains were assessed after TBI using serial F-18-FDG PET and 3-dimensional MRI in vivo. Methods: Rats underwent lateral fluid percussion injury (FPI; n = 16) or a sham procedure (n = 11). PET and MR images were acquired at 1 wk and at 1, 3, and 6 mo after injury. Morphologic changes were assessed using MRI-based regions of interest, and hippocampal shape changes were assessed with large-deformation high-dimensional mapping. Metabolic changes were assessed using region-of-interest analysis and statistical parametric mapping with the flexible factorial analysis. Anxiety-like behavior and learning were assessed at 1, 3, and 6 mo after injury. Results: PET analyses showed widespread hypometabolism in injured rats, in particular involving the ipsilateral cortex, hippocampus, and amygdalae, present at 1 wk after FPI, most prominent at 1 mo, and then decreasing. Compared with the sham group, rats in the FPI group had decreased structural volume which progressively increased over 3-6 mo, occurring in the ipsilateral cortex, hippocampus, and ventricles after FPI (P < 0.05). Large-deformation high-dimensional mapping showed evolving hippocampal shape changes across the 6 mo after FPI. Injured rats displayed increased anxiety-like behavior (P < 0.05), but there were no direct correlations between the severity of the behavior abnormalities and functional or structural imaging changes. Conclusion: In selected brain structures, FPI induces early hypometabolism and delayed progressive atrophic changes that are dynamic and continue to evolve for months. These findings have implications for the understanding of the pathophysiology and evolution of long-term neurologic morbidity following TBI, and indicate an extended window for targeted neuroprotective interventions.	[Bouilleret, Viviane] UNCE, CHU Bicetre, AP HP, Dept Neurophysiol & Epilepsy, F-94275 Le Kremlin Bicetre, France; [Liu, Ying R.; Cardamone, Lisa; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic 3010, Australia; [Hogan, R. Edward] Washington Univ, Dept Neurol, St Louis, MO USA	Bouilleret, V (corresponding author), UNCE, CHU Bicetre, AP HP, Dept Neurophysiol & Epilepsy, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	viviane.bouilleret@bct.aphp.fr	Myers, Damian E/L-5302-2013; O'Brien, Terence J/L-8102-2013; Jones, Nigel C/K-7773-2012; Bouilleret, viviane/AAQ-5878-2021	O'Brien, Terence/0000-0002-7198-8621; Jones, Nigel/0000-0002-1080-8439; Myers, Damian/0000-0002-7569-9907; Hicks, Rodney/0000-0002-0758-0824; Hogan, Robert/0000-0003-2272-5005	Victorian Government Transport Accident Commission (TAC) [DP0023]; Australian NHMRCNational Health and Medical Research Council of Australia [400088]	We thank Prof. Gary Egan and the staff of the Small Animal MRI Facility, Howard Florey Institute, for assistance with MRI scanning. We also thank the radiochemistry staff of the Peter MacCallum Cancer Centre for assistance with <SUP>18</SUP>F-FDG PET. This work was supported by the Victorian Government Transport Accident Commission (TAC) in the form of a Victorian Neurotrauma Initiative Project grant (DP0023) and a project grant from the Australian NHMRC (400088).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Casteels C, 2006, J NUCL MED, V47, P1858; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Chassoux F, 2004, BRAIN, V127, P164, DOI 10.1093/brain/awh014; Csernansky JG, 1998, P NATL ACAD SCI USA, V95, P11406, DOI 10.1073/pnas.95.19.11406; Etkin A, 2009, ARCH GEN PSYCHIAT, V66, P1361, DOI 10.1001/archgenpsychiatry.2009.104; Hogan RE, 2008, J NEUROL NEUROSUR PS, V79, P636, DOI 10.1136/jnnp.2007.123406; Hogan RE, 2006, AM J NEURORADIOL, V27, P2149; Hogan RE, 2009, J MAGN RESON IMAGING, V29, P1027, DOI 10.1002/jmri.21766; Hogan RE, 2004, BRAIN, V127, P1731, DOI 10.1093/brain/awh197; IGARDNER R, 2005, CLIN ANAT, V18, P481; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Jones NC, 2009, BEHAV BRAIN RES, V203, P81, DOI 10.1016/j.bbr.2009.04.023; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jupp B, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2007.01245.x; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LOBKR H, 2006, Carr Alzheimer Res, V3, P327; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Posener JA, 2003, AM J PSYCHIAT, V160, P83, DOI 10.1176/appi.ajp.160.1.83; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ryvlin P, 1998, BRAIN, V121, P2067, DOI 10.1093/brain/121.11.2067; Soto-Montenegro M, 2009, MOL IMAGING BIOL, V11, P94, DOI 10.1007/s11307-008-0179-7; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Kuyck K, 2007, NEUROIMAGE, V35, P214, DOI 10.1016/j.neuroimage.2006.12.009; YARNAKI T, 1996, J TRAUMA, V40, P50; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	38	52	54	0	11	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	NOV	2010	51	11					1788	1795		10.2967/jnumed.110.078626			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	674RQ	WOS:000283766000047	21051651	Bronze			2021-06-18	
J	Omoto, S; Ueno, M; Mochio, S; Takai, T; Yamashita, T				Omoto, Shusaku; Ueno, Masaki; Mochio, Soichiro; Takai, Toshiyuki; Yamashita, Toshihide			Genetic Deletion of Paired Immunoglobulin-Like Receptor B Does Not Promote Axonal Plasticity or Functional Recovery after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD-INJURY; NOGO-66 RECEPTOR; CORTICOSPINAL TRACT; NEURITE OUTGROWTH; SENSORIMOTOR DYSFUNCTION; STROKE RECOVERY; STAIRCASE TEST; REGENERATION; INHIBITION	The rewiring of neural networks is a fundamental step in recovering behavioral functions after brain injury. However, there is limited potential for axonal plasticity in the adult CNS. The myelin-associated proteins Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp) are known to inhibit axonal plasticity, and thus targeting the inhibitory pathways they participate in is a potential means of promoting plasticity and functional recovery. Each of Nogo, MAG, and OMgp interacts with both the Nogo receptor (NgR) and paired immunoglobulin-like receptor B (PirB). Here, we determined whether blocking PirB activity enhances axonal reorganization and functional recovery after cortical injury. We found that axons of the contralesional corticospinal tract sprouted into the denervated side of the cervical spinal cord after unilateral injury of the motor cortex. The extent to which this axonal reorganization occurred was far greater in mice lesioned during early postnatal days than in mice lesioned at an age when myelin had begun to form. This suggests that myelin-associated proteins might limit axonal remodeling in vivo. However, the number of sprouting fibers within either the corticospinal or corticorubral tract was not enhanced in PirB(-/-) mice. Blocking PirB signaling also failed to enhance functional recovery with three motor tests. Our results suggest that blocking the function of PirB is not sufficient to promote axonal reorganization or functional recovery after cortical injury.	[Omoto, Shusaku; Ueno, Masaki; Yamashita, Toshihide] Osaka Univ, Grad Sch Med, Dept Mol Neurosci, Suita, Osaka 5650871, Japan; [Omoto, Shusaku; Mochio, Soichiro] Jikei Univ, Sch Med, Dept Neurol, Minato Ku, Tokyo 1058461, Japan; [Takai, Toshiyuki] Tohoku Univ, Inst Dev Aging & Canc, Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol Program, Sendai, Miyagi 9808575, Japan; [Takai, Toshiyuki] Tohoku Univ, Dept Expt Immunol, Sendai, Miyagi 9808575, Japan	Yamashita, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Ueno, Masaki/J-1216-2019	Yamashita, Toshihide/0000-0003-4559-7018	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21700381] Funding Source: KAKEN	This work was supported by a Grant-in-Aid for Young Scientists (S) from Japan Society for the Promotion of Science. We thank Yuka Nakamura, Yuki Fujita, and Sachiko Lee for the helpful advice and technical support they provided during the course of this study.	AKINTUNDE A, 1992, BRAIN RES, V586, P208, DOI 10.1016/0006-8993(92)91629-S; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Baird AL, 2001, BRAIN RES BULL, V54, P243, DOI 10.1016/S0361-9230(00)00457-3; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Benson MD, 2005, P NATL ACAD SCI USA, V102, P10694, DOI 10.1073/pnas.0504021102; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fujita N, 1998, J NEUROSCI, V18, P1970; Giger RJ, 2008, RESTOR NEUROL NEUROS, V26, P97; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; JORDAN C, 1989, J NEUROSCI, V9, P248; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; KUANG RZ, 1990, J COMP NEUROL, V302, P461, DOI 10.1002/cne.903020304; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Low K, 2008, J NEUROSCI, V28, P1099, DOI 10.1523/JNEUROSCI.4906-07.2008; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Moreau-Fauvarque C, 2003, J NEUROSCI, V23, P9229; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; ONO K, 1990, BRAIN DEV-JPN, V12, P226, DOI 10.1016/S0387-7604(12)80330-5; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Pronichev I V, 1998, Neurosci Behav Physiol, V28, P80, DOI 10.1007/BF02461916; REINOSO BS, 1989, EXP BRAIN RES, V74, P387; Schnaar RL, 2009, J NEUROSCI RES, V87, P3267, DOI 10.1002/jnr.21992; SCHWAB ME, 1989, J NEUROCYTOL, V18, P161, DOI 10.1007/BF01206659; Schwab ME, 1996, PHYSIOL REV, V76, P319; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Syken J, 2006, SCIENCE, V313, P1795, DOI 10.1126/science.1128232; Takahashi M, 2009, EUR J NEUROSCI, V30, P1878, DOI 10.1111/j.1460-9568.2009.06989.x; Takai T, 2005, IMMUNOLOGY, V115, P433, DOI 10.1111/j.1365-2567.2005.02177.x; Takai T, 2001, IMMUNOL REV, V181, P215, DOI 10.1034/j.1600-065X.2001.1810118.x; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Ujike A, 2002, NAT IMMUNOL, V3, P542, DOI 10.1038/ni801; Vanek P, 1998, EUR J NEUROSCI, V10, P45, DOI 10.1046/j.1460-9568.1998.00018.x; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wu CY, 2006, J HISTOCHEM CYTOCHEM, V54, P997, DOI 10.1369/jhc.5A6901.2006; Yamashita T, 2005, MOL NEUROBIOL, V32, P105, DOI 10.1385/MN:32:2:105; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zai LL, 2009, J NEUROSCI, V29, P8187, DOI 10.1523/JNEUROSCI.0414-09.2009; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102	57	52	59	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 29	2010	30	39					13045	13052		10.1523/JNEUROSCI.3228-10.2010			8	Neurosciences	Neurosciences & Neurology	659MY	WOS:000282571800015	20881122	Green Published, Bronze			2021-06-18	
J	Blyth, BJ; Bazarian, JJ				Blyth, Brian J.; Bazarian, Jeffrey J.			Traumatic Alterations in Consciousness: Traumatic Brain Injury	EMERGENCY MEDICINE CLINICS OF NORTH AMERICA			English	Article						Concussion; Trauma; Brain; Injury	POSTTRAUMATIC-STRESS-DISORDER; FIBRILLARY ACIDIC PROTEIN; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; RISK-FACTORS; 2ND IMPACT; PHARMACOLOGICAL-TREATMENT; PSYCHIATRIC-DISORDERS; INTRACRANIAL INJURY	Mild traumatic brain injury (mTBI) refers to the clinical condition of transient alteration of consciousness as a result of traumatic injury to the brain The priority of emergency care is to identify and facilitate the treatment of rare but potentially life-threatening intracranial injuries associated with mTBI through the judicious application of appropriate imaging studies and neurosurgical consultation. Although post-mTBI symptoms quickly and completely resolve in the vast majority of cases, a significant number of patients will complain of lasting problems that may cause significant disability Simple and early interventions such as patient education and appropriate referral can reduce the likelihood of chronic symptoms Although definitive evidence is lacking, mTBI is likely to be related to significant long-term sequelae such as Alzheimer disease and other neurode-generative processes.	[Blyth, Brian J.; Bazarian, Jeffrey J.] Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Dept Emergency Med, Rochester, NY 14642 USA	Blyth, BJ (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Dept Emergency Med, 601 Elmwood Ave,Box 645, Rochester, NY 14642 USA.				National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HD051865-03]; Jahnigen Career Development Scholars Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051865] Funding Source: NIH RePORTER	This work was supported by Grant No 5R01HD051865-03 from the National Institutes of Health (J.J.B and B J B) and a Jahnigen Career Development Scholars Award (B J B)	Adams R. D., 1997, PRINCIPLES NEUROLOGY; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J. David, 2004, Journal of Rehabilitation Medicine Supplement, P28; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; *CONC MTBI WORK GR, VA DOD CLIN PRACT GU; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; Hain TC, 2005, NEUROL CLIN, V23, P831, DOI 10.1016/j.ncl.2005.01.012; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; Hayes RL, 1989, MILD HEAD INJURY, P54; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; IOM, 2009, GULF WAR HLTH, V7; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; IVERSON GL, 2007, POSTCONCUSSIVE DISOR; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; KATAYAMA Y, 1984, BRAIN RES, V299, P348, DOI 10.1016/0006-8993(84)90717-0; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Missler U, 1999, CLIN CHEM, V45, P138; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPA L, 2009, CRIT CARE MED, V38, P318; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; PYYKKO I, 1988, ACTA OTO-LARYNGOL, P77; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sagduyu K, 2002, J CLIN PSYCHIAT, V63, P594, DOI 10.4088/JCP.v63n0710a; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P35; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Singer R B, 2001, J Insur Med, V33, P42; Sosin DM, 1996, BRAIN INJURY, V10, P47; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; VANDUIJN CM, 1994, GENET EPIDEMIOL, V11, P539, DOI 10.1002/gepi.1370110609; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; ZEE DS, 1985, ARCH OTOLARYNGOL, V111, P609	134	52	52	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8627	1558-0539		EMERG MED CLIN N AM	Emerg. Med. Clin. N. Am.	AUG	2010	28	3					571	+		10.1016/j.emc.2010.03.003			26	Emergency Medicine	Emergency Medicine	649AN	WOS:000281737700010	20709244	Green Accepted			2021-06-18	
J	Bonneh-Barkay, D; Zagadailov, P; Zou, HC; Niyonkuru, C; Figley, M; Starkey, A; Wang, GJ; Bissel, SJ; Wiley, CA; Wagner, AK				Bonneh-Barkay, Dafna; Zagadailov, Pavel; Zou, Huichao; Niyonkuru, Christian; Figley, Matthew; Starkey, Adam; Wang, Guoji; Bissel, Stephanie J.; Wiley, Clayton A.; Wagner, Amy K.			YKL-40 Expression in Traumatic Brain Injury: An Initial Analysis	JOURNAL OF NEUROTRAUMA			English	Article						chitinase; controlled cortical impact; cytokine; gliosis; neuroinflammation; traumatic brain injury; YKL-40	CEREBROSPINAL-FLUID; GROWTH-FACTOR; MODERATE HYPOTHERMIA; HEAD-INJURY; CHILDREN; INTERLEUKIN-10; IL-6; CYTOKINE; MARKER; TISSUE	YKL-40 (chitinase 3-like protein 1) is expressed in a broad spectrum of inflammatory conditions and cancers. We have previously reported that YKL-40 levels are elevated in the cerebrospinal fluid (CSF) of macaques and humans with lentiviral encephalitis, as well as multiple sclerosis (MS). The current study assessed temporal CSF YKL-40 levels in subjects with severe traumatic brain injury (TBI; Glasgow Coma Scale [GCS] score <= 8). We also evaluated temporal expression of YKL-40 after parasagittal controlled cortical impact (CCI) injury over the parietal cortex (2.8 mm deep, 4 m/sec). We demonstrate that CSF YKL-40 levels are elevated after acute TBI, and that YKL-40 levels are higher in patients who died following injury than in patients who survived. YKL-40 levels significantly correlate with CSF levels of inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), as well as the inflammatory marker C-reactive protein (CRP). After CCI, in situ hybridization (ISH) showed that YKL-40 transcription is primarily associated with reactive astrocytes in peri-contusional cortex. Tissue YKL-40 transcription time course analysis after CCI showed that YKL40 transcription in astrocytes began 1 day after injury, remained elevated for several days, and then declined by day 12. Similarly to our temporal CSF measurements in humans, YKL-40 induction after CCI is coincident with IL-1 beta expression. Taken together these findings demonstrate that YKL-40 is induced in astrocytes during acute neuroinflammation, is temporally related to inflammatory mediator expression, and may be a useful biomarker for understanding secondary injury and for patient prognosis.	[Bonneh-Barkay, Dafna; Figley, Matthew; Starkey, Adam; Wang, Guoji; Bissel, Stephanie J.; Wiley, Clayton A.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Zagadailov, Pavel; Zou, Huichao; Niyonkuru, Christian; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Zagadailov, Pavel; Zou, Huichao; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Bonneh-Barkay, D (corresponding author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	bonnehbarkayd@upmc.edu	Zou, Huichao/D-4094-2011	Zagadailov, Pavel/0000-0002-5433-1118; Figley, Matthew/0000-0003-2125-829X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; Pittsburgh Foundation;  [DODW81XWH-071-0701];  [CDCR 49 CCR323155-03];  [K24 MH01717];  [RO1 MH071151]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH001717, R01MH071151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	We thank Arlene Carbone-Wiley, Jonette Werley, and Mark Stauffer for valuable technical assistance. We thank the Brain Trauma Research Center (National Institutes of Health grant no. 5P01NS030318-16) for assistance with subject recruitment and sample collection. This work was supported by grants DODW81XWH-071-0701 and CDCR 49 CCR323155-03 to A. K. W.; K24 MH01717 and RO1 MH071151 to C. A. W.; and Pittsburgh Foundation Emmerling funds to D.B.-B.	Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bonneh-Barkay D, 2008, AM J PATHOL, V173, P130, DOI 10.2353/ajpath.2008.080045; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; JENNETT B, 1975, LANCET, V1, P480; Johansen JS, 2006, DAN MED BULL, V53, P172; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Waje-Andreassen U, 2005, ACTA NEUROL SCAND, V111, P360, DOI 10.1111/j.1600-0404.2005.00416.x; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	25	52	54	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1215	1223		10.1089/neu.2010.1310			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100006	20486806	Green Published			2021-06-18	
J	Bansal, V; Costantini, T; Ryu, SY; Peterson, C; Loomis, W; Putnam, J; Elicieri, B; Baird, A; Coimbra, R				Bansal, Vishal; Costantini, Todd; Ryu, Seok Yong; Peterson, Carrie; Loomis, William; Putnam, James; Elicieri, Brian; Baird, Andrew; Coimbra, Raul			Stimulating the Central Nervous System to Prevent Intestinal Dysfunction After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Intestinal permeability; Vagus nerve; TNF-alpha	INFLAMMATORY RESPONSE; SEVERITY; SURVIVAL; ALPHA; BLOOD; RATS; GUT	Background: Traumatic brain injury (TBI) causes gastrointestinal dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system. We hypothesize that vagal nerve stimulation prevents an increase in intestinal permeability after TBI. Methods: Balb/c mice underwent a weight drop TBI. Selected mice had electrical stimulation of the cervical vagus nerve before TBI. Intestinal permeability to 4.4 kDa FITC-Dextran was measured 6 hours after injury. Ileum was harvested and intestinal tumor necrosis factor-alpha and glial fibrillary acidic protein (GFAP), a marker of glial activity, were measured. Results: TBI increased intestinal permeability compared with sham, 6 hours after injury (98.5 mu g/mL +/- 12.5 vs. 29.5 mu g/mL +/- 5.9 mu g/mL; p < 0.01). Vagal stimulation prevented TBI-induced intestinal permeability (55.8 +/- 4.8 mu g/mL vs. 98.49 mu g/mL +/- 12.5; p < 0.02). TBI animals had an increase in intestinal tumor necrosis factor-alpha 6 hours after injury compared with vagal stimulation + TBI (45.6 +/- 8.6 pg/mL vs. 24.1 +/- 1.4 pg/mL; p < 0.001). TBI increased intestinal GFAP 6.2-fold higher than sham at 2 hours and 11.5-fold higher at 4 hours after injury (p < 0.05). Intestinal GFAP in vagal stimulation + TBI animals was also 6.7-fold higher than sham at 2 hours, however, intestinal GFAP was 18.0-fold higher at 4 hours compared with sham and 1.6-fold higher than TBI alone (p < 0.05). Conclusion: In a mouse model of TBI, vagal stimulation prevented TBI-induced intestinal permeability. Furthermore, vagal stimulation increased enteric glial activity and may represent the pathway for central nervous system regulation of intestinal permeability.	[Bansal, Vishal; Costantini, Todd; Peterson, Carrie; Loomis, William; Putnam, James; Elicieri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Sanggye Paik Hosp, Dept Emergency Med, Gyeongnam, South Korea	Coimbra, R (corresponding author), Dept Surg, Div Trauma, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Peterson, Carrie/AAF-8586-2021; Coimbra, Raul/AAP-3019-2020	Peterson, Carrie/0000-0002-8448-4633; Coimbra, Raul/0000-0002-3759-6851; Baird, Andrew/0000-0003-0027-9905	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM078421, P20 GM078421-05] Funding Source: Medline		Ammori JB, 2008, SURGERY, V144, P159, DOI 10.1016/j.surg.2008.03.008; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; BANSAL V, 2009, J NEUROTRAUMA   0406; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; Berthoud HR, 2004, NEUROGASTROENT MOTIL, V16, P28, DOI 10.1111/j.1743-3150.2004.00471.x; Borovikova LV, 2000, NATURE, V405, P458; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Enderson BL, 2007, J TRAUMA, V62, P33; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Kemp CD, 2008, AM SURGEON, V74, P866; Luyer MD, 2005, J EXP MED, V202, P1023, DOI 10.1084/jem.20042397; Ma B, 2007, ANAT HISTOL EMBRYOL, V36, P62, DOI 10.1111/j.1439-0264.2006.00741.x; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Todd SR, 2008, CURR OPIN CRIT CARE, V14, P690, DOI 10.1097/MCC.0b013e3283196562; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	26	52	55	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2010	68	5					1059	1064		10.1097/TA.0b013e3181d87373			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	595MQ	WOS:000277615200007	20453760	Green Accepted			2021-06-18	
J	Campbell, JD; Yoon, DP; Johnstone, B				Campbell, James D.; Yoon, Dong Phil; Johnstone, Brick			Determining Relationships Between Physical Health and Spiritual Experience, Religious Practices, and Congregational Support in a Heterogeneous Medical Sample	JOURNAL OF RELIGION & HEALTH			English	Article						Health; Spiritual belief; Religious practices; Congregational support; Psychoneuroimmunological models	QUALITY-OF-LIFE; CONSTRUCT-VALIDITY; STYLE DISRUPTIONS; CANCER-PATIENTS; MENTAL-HEALTH; OUTCOMES; STROKE; REHABILITATION; INTERVENTION; DISABILITIES	Previous research indicates that increased religiosity/spirituality is related to better health, but the specific nature of these relationships is unclear. The purpose of this study was to determine the relationships between physical health and spiritual belief, religious practices, and congregational support using the Brief Multidimensional Measure of Religiousness/Spirituality and the Medical Outcomes Scale Shortform-36. A total of 168 participants were surveyed with the following medical disorders: Cancer, Spinal Cord Injury, Traumatic Brain Injury, and Stroke, plus a healthy sample from a primary care setting. The results show that individuals with chronic medical conditions do not automatically turn to religious and spiritual resources following onset of their disorder. Physical health is positively related to frequency of attendance at religious services, which may be related to better health leading to increased ability to attend services. In addition, spiritual belief in a loving, higher power, and a positive worldview are associated with better health, consistent with psychoneuroimmunological models of health. Practical implications for health care providers are discussed.	[Campbell, James D.; Yoon, Dong Phil; Johnstone, Brick] Univ Missouri, Dept Family & Community Med, Columbia, MO 65212 USA	Campbell, JD (corresponding author), Univ Missouri, Dept Family & Community Med, MA306 Med Sci Bldg, Columbia, MO 65212 USA.	campbellj@health.missouri.edu; yond@missouri.edu; johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649			Astin John A, 2004, Adv Mind Body Med, V20, P14; Baskin TW, 2004, J COUNS DEV, V82, P79, DOI 10.1002/j.1556-6678.2004.tb00288.x; Berges IM, 2007, EXP AGING RES, V33, P1, DOI 10.1080/03610730601005893; Brillhart Barbara, 2005, Rehabil Nurs, V30, P31; Cohen L, 2001, PSYCHOSOM MED, V63, P951, DOI 10.1097/00006842-200111000-00014; COLANTONIO A, 1993, J GERONTOL, V48, pS261, DOI 10.1093/geronj/48.5.S261; Devins GM, 2006, PSYCHO-ONCOLOGY, V15, P221, DOI 10.1002/pon.940; Devins GM, 2001, MED CARE, V39, P1097, DOI 10.1097/00005650-200110000-00007; Ellis MR, 2002, J FAM PRACTICE, V51, P249; Faull K, 2006, DISABIL REHABIL, V28, P729, DOI 10.1080/09638280500265946; Fetzer Institute & National Institute on Aging Working Group, 1999, MULT MEAS REL SPIR U; Fitchett G, 1999, REHABIL PSYCHOL, V44, P333, DOI 10.1037//0090-5550.44.4.333; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; George LK, 2000, J SOC CLIN PSYCHOL, V19, P102, DOI 10.1521/jscp.2000.19.1.102; George LK, 2002, PSYCHOL INQ, V13, P190, DOI 10.1207/S15327965PLI1303_04; Giaquinto S, 2007, STROKE, V38, P993, DOI 10.1161/01.STR.0000257996.26950.59; GOLDMAN N, 1995, SOC SCI MED, V40, P1717, DOI 10.1016/0277-9536(94)00281-W; Haley KC, 2001, J RELIG HEALTH, V40, P305, DOI 10.1023/A:1012561909054; Idler EL, 2003, RES AGING, V25, P327, DOI 10.1177/0164027503025004001; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; JOHNSTONE B, J RELIG HLT IN PRESS; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kendler KS, 2003, AM J PSYCHIAT, V160, P496, DOI 10.1176/appi.ajp.160.3.496; Kim J, 2000, REHABIL PSYCHOL, V45, P365, DOI 10.1037/0090-5550.45.4.365; Koenig H.G., 2001, HDB RELIG HLTH; Koenig T, 2002, GERONTOLOGIST, V42, P92, DOI 10.1093/geront/42.suppl_3.20; Lee BY, 2005, ZYGON, V40, P443, DOI 10.1111/j.1467-9744.2005.00674.x; MAGYARRUSSELL GM, 2005, THESIS B GREEN STATE; McCullough ME, 2000, HEALTH PSYCHOL, V19, P211, DOI 10.1037//0278-6133.19.3.211; Mokuau N, 2001, Pac Health Dialog, V8, P407; Moreira-Almeida A, 2006, REV BRAS PSIQUIATR, V28, P242, DOI 10.1590/S1516-44462006000300018; Moreira-Almeida A, 2006, SOC SCI MED, V63, P843, DOI 10.1016/j.socscimed.2006.03.001; Mulligan Thomas, 2005, Consult Pharm, V20, P1025, DOI 10.4140/TCP.n.2005.1025; Neff JA, 2006, J SCI STUD RELIG, V45, P449, DOI 10.1111/j.1468-5906.2006.00318.x; NISSIM EN, 2003, THESIS F DICKINSON U; NOREAU L, 1996, CANADIAN J REHABILIT, V10, P81; Pargament KennethI, 1999, RELIG SPIRITUAL COPI, P43; Pargament KI, 2000, J CLIN PSYCHOL, V56, P519, DOI 10.1002/(SICI)1097-4679(200004)56:4<519::AID-JCLP6>3.3.CO;2-T; Pargament KI, 1998, LAWS LIF SYMP SER, V1, P59; Piedmont R. L., 2006, RES SOCIAL SCI STUDY, V17, P177; Powell LH, 2003, AM PSYCHOL, V58, P36, DOI 10.1037/0003-066X.58.1.36; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Rippentrop AE, 2005, PAIN, V116, P311, DOI 10.1016/j.pain.2005.05.008; *SF 36, 2006, SF 36 HLTH SURV; Sherman AC, 2001, PSYCHO-ONCOLOGY, V10, P436, DOI 10.1002/pon.523; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Thoresen C E, 1999, J Health Psychol, V4, P291, DOI 10.1177/135910539900400314; Thoresen CE, 2002, ANN BEHAV MED, V24, P3, DOI 10.1207/S15324796ABM2401_02; Treloar LL, 2002, J ADV NURS, V40, P594, DOI 10.1046/j.1365-2648.2002.02417.x; Underwood LG, 2002, ANN BEHAV MED, V24, P22, DOI 10.1207/S15324796ABM2401_04; Van Ness PH, 2003, J GERONTOL B-PSYCHOL, V58, pS21, DOI 10.1093/geronb/58.1.S21; Yoon DP, 2005, J HUM BEHAV SOC ENVI, V10, P191, DOI 10.1300/J137v10n01_05	53	52	52	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4197	1573-6571		J RELIG HEALTH	J. Relig. Health	MAR	2010	49	1					3	17		10.1007/s10943-008-9227-5			15	Public, Environmental & Occupational Health; Religion	Public, Environmental & Occupational Health; Religion	556YP	WOS:000274631200002	20162451				2021-06-18	
J	Holmes, MD; Tucker, DM; Quiring, JM; Hakimian, S; Miller, JW; Ojemann, JG				Holmes, Mark D.; Tucker, Don M.; Quiring, Jason M.; Hakimian, Shahin; Miller, John W.; Ojemann, Jeffrey G.			Comparing Noninvasive Dense Array and Intracranial Electroencephalography for Localization of Seizures	NEUROSURGERY			English	Article						Dense array electroencephalography; Epilepsy surgery; Intracranial electroencephalography; Refractory seizures; Source localization	SCALP EEG; DISCHARGES	OBJECTIVE: To compare the localization of the seizure onset zone estimated from ictal recordings with high spatial resolution, 256-channel scalp dense array electroencephalographic video long-term monitoring (LTM) with the aid of source analysis with that obtained from subsequent intracranial ictal recordings. METHODS: Ten patients with medically refractory epilepsy, all surgical candidates, underwent intracranial LTM after standard noninvasive evaluation failed to provide adequate localizing information regarding ictal origins. Before invasive studies, all patients underwent dense array electroencephalographic LTM in which habitual clinical seizures were recorded for each patient. Source analysis was applied to ictal onsets. Intracranial electrode placement followed conventional guidelines, although the neurosurgeon was aware of the dense array electroencephalographic results. Patients ranged in age from 10 to 49 years (mean age, 24 y); 7 were male. Identified risk factors included closed head injury in 1 patient and childhood meningitis in another. No focal neurological signs were found in any patient. Magnetic resonance imaging findings were normal in 6 patients; 1 patient had cerebellar hypoplasia, 1 had right frontoparietal dysplasia, 1 had bilateral nonspecific white matter abnormalities, and 1 had bilateral cavernous angiomas. RESULTS: Ictal onsets, based on invasive recordings, were in the mesiotemporal lobe (3 patients), lateroparietal (2 patients), mesioparietal (1 patient), laterofrontal (1 patient), superolateral frontocentral (11 patient), frontopolar (1 patient), and posteroinferior temporo-occipital neocortex (1 patient). Dense array electroencephalography localized ictal onsets to the same region as intracranial monitoring in 8 of 10 cases; invasive studies disclosed an additional ictal focus in 2 of these patients. Surgical resections were based only on intracranial electroencephalographic findings. CONCLUSION: Dense array electroencephalography has the potential to assist in the noninvasive localization of epileptic seizures and to guide the placement of invasive electrodes for localizing seizure onset.	[Holmes, Mark D.] Univ Washington, Harborview Med Ctr, Reg Epilepsy Ctr, Dept Neurol, Seattle, WA 98104 USA; [Miller, John W.; Ojemann, Jeffrey G.] Univ Washington, Dept Neurol Surg, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [Tucker, Don M.; Quiring, Jason M.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA; [Tucker, Don M.; Quiring, Jason M.] Elect Geodes Inc, Eugene, OR USA	Holmes, MD (corresponding author), Univ Washington, Harborview Med Ctr, Reg Epilepsy Ctr, Dept Neurol, 325 9th Ave, Seattle, WA 98104 USA.	mdholmes@u.washington.edu		Ojemann, Jeffrey/0000-0001-7580-8934			Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Engel Jerome Jr., 1993, P609; Ferree TC, 2001, CLIN NEUROPHYSIOL, V112, P536, DOI 10.1016/S1388-2457(00)00533-2; Freeman WJ, 2006, CLIN NEUROPHYSIOL, V117, P1228, DOI 10.1016/j.clinph.2006.03.012; Freeman WJ, 2003, CLIN NEUROPHYSIOL, V114, P1053, DOI 10.1016/S1388-2457(03)00045-2; Holmes M, 2006, EPILEPSY SURG PRINCI, P247; Holmes MD, 2005, EPILEPSIA, V46, P136; Holmes MD, 2004, EPILEPSIA, V45, P1568, DOI 10.1111/j.0013-9580.2004.23204.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lantz G, 2003, CLIN NEUROPHYSIOL, V114, P63, DOI 10.1016/S1388-2457(02)00337-1; Liu AK, 2002, HUM BRAIN MAPP, V16, P47, DOI 10.1002/hbm.10024; LUU P, 2008, EEG SENSOR ELECT ATT; Menendez RGD, 2004, NEUROIMAGE, V21, P527, DOI 10.1016/j.neuroimage.2003.09.051; Michel CM, 2001, BRAIN RES REV, V36, P108, DOI 10.1016/S0165-0173(01)00086-8; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; Miller JW, 2007, NEUROIMAGE, V35, P583, DOI 10.1016/j.neuroimage.2006.12.018; MORRELL F, 1989, J NEUROSURG, V70, P231, DOI 10.3171/jns.1989.70.2.0231; Nunez P.L., 2006, ELECT FIELDS BRAIN N, V2nd; PERRIN F, 1987, ELECTROEN CLIN NEURO, V66, P75, DOI 10.1016/0013-4694(87)90141-6; Plummer C, 2008, EPILEPSIA, V49, P201, DOI 10.1111/j.1528-1167.2007.01381.x; RAMON C, 2007, AM EP ANN M NOV 30 D; Russell GS, 2005, CLIN NEUROPHYSIOL, V116, P1130, DOI 10.1016/j.clinph.2004.12.022; Thompson Paul, 2008, Am J Electroneurodiagnostic Technol, V48, P93; Tucker D, 1994, HUM BRAIN MAPP, V1, P134, DOI [DOI 10.1002/HBM.460010206, DOI 10.1002/hbm.460010206]; Tucker DM, 2004, EPILEPSIA, V45, P71; Tucker DM, 2007, EPILEPSY BEHAV, V11, P546, DOI 10.1016/j.yebeh.2007.04.023; Vanhatalo S, 2003, NEUROLOGY, V60, P1098, DOI 10.1212/01.WNL.0000052993.37621.CC; Worrell GA, 2004, BRAIN, V127, P1496, DOI 10.1093/brain/awh149	28	52	53	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2010	66	2					354	362		10.1227/01.NEU.0000363721.06177.07			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	546RV	WOS:000273829400036	20087136				2021-06-18	
J	Lee, V; Ford, RL; Xing, W; Bunce, C; Foot, B				Lee, V.; Ford, R. L.; Xing, W.; Bunce, C.; Foot, B.			Surveillance of traumatic optic neuropathy in the UK	EYE			English	Article						TON; optic neuropathy; optic nerve injury; head injury; orbital fracture; BOSU	CONTROLLED-TRIAL; INDIRECT INJURY; NERVE TRAUMA; METHYLPREDNISOLONE; MANAGEMENT; CHILDREN; THERAPY	Aims The aim of this study is to provide epidemiological data on the incidence, aetiology, management, and visual outcome in traumatic optic neuropathy (TON) in the UK. Methods Patients with TON were identified prospectively by population-based active surveillance through the British Ophthalmic Surveillance Unit over a 2-year period with data obtained from an incident questionnaire and follow-up questionnaire sent to positive reporters. Results Incident and follow-up data were available on 121 and 97 (80%) patients, respectively. The minimum estimated incidence was 1.005 per million. Leading causes included falls (25.6%), road traffic accidents (RTAs) (21.5%), and assaults (20.7%). The median age was 31 years. There were 95 (78.5%) men. Presenting visual acuity (VA) was 6/60 or worse in 85 (70%) patients, with 43 patients (36%) with no perception of light. Associated injuries included 47 (39%) orbital wall fractures, 37 (31%) closed globe injuries, 23 (19%) ocular adnexal injuries, 23 (19%) skull fractures, and 18 (16%) intracranial bleeding. Sixty-five percent (75/116) received no acute treatment and 35% (41/116) received steroids and/or surgery. Of the treated group, 24% (8/33) and of the untreated group 20% (11/56) improved three lines or more of VA (P = 0.61). Prompt ophthalmic examination (P = 0.002), orbital fracture (P = 0.046), high Glasgow Coma Scale (GCS) score (P = 0.023), and poor initial VA (P = 0.009) were associated with increased likelihood of treatment. Poor initial VA (P < 0.001), orbital fracture (P = 0.004), and significant head injury (P = 0.038) were associated with poor visual outcome. Conclusions This study suggested that young men were at greatest risk of TON. We detected a trend towards conservative management of this condition in the UK. TON was associated with significant ocular, orbital, and head injuries that highlighted the need for multidisciplinary management. Eye (2010) 24, 240-250; doi: 10.1038/eye.2009.79; published online 1 May 2009	[Lee, V.; Ford, R. L.] Cent Middlesex Hosp, Cent Eye Serv, NW London NHS Trust, London NW10 7NS, England; [Xing, W.; Bunce, C.] Moorfields Eye Hosp NHS Fdn Trust, Dept Res & Dev, London, England; [Foot, B.] Royal Coll Ophthalmologists, London, England	Lee, V (corresponding author), Cent Middlesex Hosp, Cent Eye Serv, NW London NHS Trust, Acton Lane, London NW10 7NS, England.	vickielee@mac.com		Ford, Rebecca/0000-0001-6392-3097; Bunce, Catey/0000-0002-0935-3713; Lee, Vickie/0000-0002-2963-5742	British Ophthalmic Surveillance Unit; Central Middlesex Hospital Eye Clinic Fund	We are grateful for the support of the British Ophthalmic Surveillance Unit. The work was supported by a grant from the Central Middlesex Hospital Eye Clinic Fund. We thank the following ophthalmologists who have reported cases to this study: Mr J Acheson, Miss D AhKine, Mr S Ahmed, Mr RWAllchin, Mr ED Allen, Mr S Armstrong, Mr S Ataullah, Mr HR Atta, Mr HF Bacon, Mr R Bates, Miss K Belfer, Mr PD Black, Mrs T Blamires, Mr CR Bentley, Mr AK Brahma, Mr F Bremner, Mr MC Briggs, Mr MA Burdon, Miss SEP Burgess, Mr R Caesar, Mr IG Calder, Mr A Cassels-Brown, Mr JKT Chan, Mr PR Chaudhuri, Mr S Chawdhury, Mrs JK Chhina, Mr JR Clarke, Mr MD Cole, Mr A Coombes, Dr M Cooper, Mr R Dagres, Mr RB Dapling, Mr K Davey, Mr DV De Alwis, Mr JA Dunne, Miss O Earley, Miss BE Enoch, Dr J Ellis, Mr D Etchells, Mr MG Falcon, Mrs V Ferguson, Mr J Ferris, Mr DW Flanagan, Professor JV Forrester, Mr PD Fox, Mr DG Frazer, Mr LB Freeman, Mrs H Gaston, Dr ND George, Mr RA Gibson, Mr JT Gillow, Mr RHB Grey, Dr DJ Grierson, Mr PG Griffiths, Mr C Hammond, Miss J Harcourt, Mr R Haslett, Mr JM Hayward, Dr DJ Huggan, Mr C Illingworth, Mr A Jacks, Mr JSH Jacob, Miss CA Jones, Mr A Kamal, Mr WSS Karwatowski, Mr VV Kayarkar, Mr J Keenan, Miss G Larkin, Mr N Lee, Mr NP Litvin, Mr M Logendran, Mr V Long, Mr J Luck, Mr G Mackingtosh, Dr JR Mackinnon, Dr DC Manfield, Miss R Manners, Miss DC Mather, Mr BK McLeod, Mr JE Morgan, Mr SJ Morgan, Mr AP Moriarty, Mr CD Morsman, Mrs CE Morton, Mr G Naylor, Dr J Olsen, Mr V Pai, Dr S Patterson-Brown, Dr R Paul, Mr JC Pauw, Mrs I Pepper, Mr W Poon, Mr M Potts, Mr AP Plumb, Mr A Quinn, Mr C Rene, Mr P Riordan-Eva, Dr STD Roxburgh, Mr NJ Sarkies, Mr S Scotcher, Mr C Scott, Dr JA Scott, Mr RAH Scott, Mr PR Simcock, Mr DL Smerdon, Mr R Smith, Mr L Stevenson, Mr G Sturrock, Miss S Vickers, Mr AN Tadros, Mr A Tekriwal, Mr DM Tole, Mr A Toufeeq, Mr JM Twomey, Mr V Vampali, Mr AJ Vivian, Mr IMJ Wearne, Ms S Webber, Mr ST White, Dr Whittle, and Mr YF Yang.	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P291; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CHADWICK J, 1950, MED WORKS HIPPOCRATE, P260; Chou PI, 1996, NEURO-OPHTHALMOLOGY, V16, P325, DOI 10.3109/01658109609044636; Cook MW, 1996, ARCH OTOLARYNGOL, V122, P389; CROMPTON M R, 1970, Brain Behavior and Evolution, V93, P785, DOI 10.1093/brain/93.4.785; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; EDMUND J, 1963, ACTA OPHTHALMOL, V41, P693; Edwards P, 2005, LANCET, V365, P1957; Foot B, 2003, EYE, V17, P9, DOI 10.1038/sj.eye.6700233; FUJITANI T, 1986, JPN J OPHTHALMOL, V30, P125; Goldenberg-Cohen N, 2004, J AAPOS, V8, P20, DOI 10.1016/j.jaapos.2003.08.009; GROSS CE, 1981, J NEUROSURG, V55, P963, DOI 10.3171/jns.1981.55.6.0963; HALL ED, 1984, J NEUROSURG, V61, P805; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1; LEVIN LA, 1994, OPHTHALMOLOGY, V101, P566; Levin LA, 2003, J NEURO-OPHTHALMOL, V23, P72, DOI 10.1097/00041327-200303000-00013; MAHAPATRA AK, 1993, PEDIATR NEUROSURG, V19, P34, DOI 10.1159/000120698; MAURIELLO JA, 1992, BRIT J OPHTHALMOL, V76, P349, DOI 10.1136/bjo.76.6.349; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Rajiniganth MG, 2003, ARCH OTOLARYNGOL, V129, P1203, DOI 10.1001/archotol.129.11.1203; SEIFF SR, 1990, OPHTHALMIC SURG LAS, V21, P389; Spencer Matthew T, 2003, Ann Emerg Med, V41, P410, DOI 10.1067/mem.2003.84; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; STEINSAPIR KD, 2005, COMP OPHTHALMOL UPDA, V6, P11; Steinsapir KDGR, 1998, WALSH HOYTS CLIN NEU, P715; TAKEHARA S, 1994, NEURORADIOLOGY, V36, P512, DOI 10.1007/BF00593510; TEASDALE G, 1974, LANCET, V2, P81; THACKER SB, 1986, AM J PREV MED, V2, P345; VOGT RL, 1983, AM J PUBLIC HEALTH, V73, P795, DOI 10.2105/AJPH.73.7.795; Wang BH, 2001, PLAST RECONSTR SURG, V107, P1655, DOI 10.1097/00006534-200106000-00003; Yang WG, 2004, ANN PLAS SURG, V52, P36, DOI 10.1097/01.sap.0000096442.82059.6d; Yu-Wai-Man P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005024.pub3; Yu-Wai-Man P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006032.pub2	43	52	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-222X	1476-5454		EYE	Eye	FEB	2010	24	2					240	250		10.1038/eye.2009.79			11	Ophthalmology	Ophthalmology	553WQ	WOS:000274397900006	19407847	Bronze			2021-06-18	
J	White, BD; Nathe, RJ; Maris, DO; Nguyen, NK; Goodson, JM; Moon, RT; Horner, PJ				White, Bryan D.; Nathe, Ryan J.; Maris, Don O.; Nguyen, Nghi K.; Goodson, Jamie M.; Moon, Randall T.; Horner, Philip J.			beta-Catenin Signaling Increases in Proliferating NG2+Progenitors and Astrocytes during Post-Traumatic Gliogenesis in the Adult Brain	STEM CELLS			English	Article						Wnt; Neural stem cell; Gliosis; Brain injury; Spinal cord injury	SPINAL-CORD-INJURY; EMBRYONIC STEM-CELLS; UP-REGULATES STAT3; NG2 PROTEOGLYCAN; SELF-RENEWAL; STEM/PROGENITOR CELLS; SUBVENTRICULAR ZONE; REACTIVE GLIOSIS; PROGENITOR CELLS; NERVOUS-SYSTEM	Wnt/beta-catenin signaling can influence the proliferation and differentiation of progenitor populations in the hippocampus and subventricular zone, known germinal centers in the adult mouse brain. It is not known whether beta-catenin signaling occurs in quiescent glial progenitors in cortex or spinal cord, nor is it known whether beta-catenin is involved in the activation of glial progenitor populations after injury. Using a beta-catenin reporter mouse (BATGAL mouse), we show that beta-catenin signaling occurs in NG2 chondroitin sulfate proteoglycan+ (NG2) progenitors in the cortex, in subcallosal zone (SCZ) progenitors, and in subependymal cells surrounding the central canal. Interestingly, cells with beta-catenin signaling increased in the cortex and SCZ following traumatic brain injury (TBI) but did not following spinal cord injury. Initially after TBI, beta-catenin signaling was predominantly increased in a subset of NG2+ progenitors in the cortex. One week following injury, the majority of beta-catenin signaling appeared in reactive astrocytes but not oligodendrocytes. Bromodeoxyuridine (BrdU) paradigms and Ki-67 staining showed that the increase in beta-catenin signaling occurred in newly born cells and was sustained after cell division. Dividing cells with beta-catenin signaling were initially NG21; however, by four days after a single injection of BrdU, they were predominantly astrocytes. Infusing animals with the mitotic inhibitor cytosine arabinoside prevented the increase of beta-catenin signaling in the cortex, confirming that the majority of beta-catenin signaling after TBI occurs in newly born cells. These data argue for manipulating the Wnt/beta-catenin pathway after TBI as a way to modify post-traumatic gliogenesis. STEM CELLS 2010;28:297-307	[Nathe, Ryan J.; Maris, Don O.; Horner, Philip J.] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA 98109 USA; [White, Bryan D.] Univ Washington, Sch Med, Program Neurobiol & Behav, Seattle, WA 98109 USA; [White, Bryan D.; Moon, Randall T.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98109 USA; [White, Bryan D.; Nguyen, Nghi K.; Goodson, Jamie M.; Moon, Randall T.] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98109 USA	Horner, PJ (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Inst Stem Cell & Regenerat Med, Box 358056,815 Mercer St, Seattle, WA 98109 USA.	rtmoon@u.washington.edu; phorner@u.washington.edu	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019; Horner, Philip J./AAF-7012-2021	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Goodson, Jamie/0000-0002-9091-8362	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 GM073887, NSO46724, NIG5 T32GM07108]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073887, T32GM007108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046724] Funding Source: NIH RePORTER	We wish to thank Denise Inman, Kathy Davidson, Andy Chien, Richard James, and Nathan Camp for helpful comments on the manuscript; Ramona Hicks and Andy Fink for initial discussions and assistance with TBI procedure; William Stallcup for the gift of anti-NG2 antibody. This work was supported by NIH RO1 GM073887 (R. T. M.), NIH NSO46724 (P. J. H.), and NIH NIG5 T32GM07108 (B. D. W). R. T. M is an Investigator of the HHMI.	Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007-0177; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Gulacsi AA, 2008, NAT NEUROSCI, V11, P1383, DOI 10.1038/nn.2226; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766; Ito M, 2009, J NEUROTRAUM, V26, P41, DOI 10.1089/neu.2008.0646; Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Lytle JM, 2009, GLIA, V57, P270, DOI 10.1002/glia.20755; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Sellers DL, 2009, J NEUROSCI, V29, P6722, DOI 10.1523/JNEUROSCI.4538-08.2009; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shimizu T, 2005, DEV BIOL, V282, P397, DOI 10.1016/j.ydbio.2005.03.020; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; YE F, 2009, NATURE NEUROSCI; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Zhu XQ, 2008, NEURON GLIA BIOL, V4, P19, DOI 10.1017/S1740925X09000015	51	52	55	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2010	28	2					297	307		10.1002/stem.268			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	562NK	WOS:000275058400014	19960516	Green Accepted, Bronze			2021-06-18	
J	Chevignard, M; Toure, H; Brugel, DG; Poirier, J; Laurent-Vannier, A				Chevignard, M.; Toure, H.; Brugel, D. G.; Poirier, J.; Laurent-Vannier, A.			A comprehensive model of care for rehabilitation of children with acquired brain injuries	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						assessment of outcome; childhood disability; model of care; multidisciplinary; rehabilitation; traumatic brain injury	OF-THE-SCIENCE; EXECUTIVE FUNCTION; PEDIATRIC TRAUMA; YOUNG-CHILDREN; HEAD-INJURY; OUTCOMES; TBI; SERVICES; PROGRAM; STROKE	Background Acquired brain injury (ABI) is a leading cause of death and lifelong acquired disability in children and remains a significant public health issue. Deficits may only become fully apparent when developmental demands increase and once cognitive processes are expected to be fully developed. It is therefore necessary to provide organized long-term follow-up for children post ABI. Despite these recommendations, it has been shown that only a small proportion of children received specialized rehabilitation and adequate follow-up after ABI. Aims The aims are: (i) to describe a comprehensive model of care devoted to children with acquired brain injuries; and (ii) to provide descriptive data analysing the characteristics of children followed up, the type/amount of services provided and general outcomes. Programme description The programme features an in- and outpatient rehabilitation facility, where multidisciplinary rehabilitation and specialized schooling are provided. The ultimate goal of the programme is to promote each child's successful reintegration in school and in the community. Adequate preparation of discharge is essential, long-term follow-up is organized, and an outreach programme has been developed to deal with the complex delayed psychosocial issues. Results Overall outcome, as measured by the Glasgow Outcome Scale, improved dramatically between admission (3.3; SD = 0.45) and discharge (2.15; SD = 0.74). Most of the children were discharged home with an adequate personalized plan for ongoing rehabilitation and school adaptations. Analysis of the outreach programme underlines the more challenging issues arising in late adolescence-early adulthood. Conclusion Given the specificities of childhood ABI, long-term specific care must be organized and co-ordinated, regardless of injury severity.	[Chevignard, M.; Toure, H.; Brugel, D. G.; Laurent-Vannier, A.] Hop Natl St Maurice, Phys Med & Rehabil Dept Children Acquired Neurol, St Maurice, France; [Chevignard, M.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Chevignard, M.] Univ Paris 06, UMR S 731, Paris, France; [Toure, H.; Brugel, D. G.; Poirier, J.; Laurent-Vannier, A.] Hop Natl St Maurice, Ctr Suivi & Insert, Outreach Program, St Maurice, France	Chevignard, M (corresponding author), INR A Hop Natl St Maurice, 14 Rue Val Osne, F-94415 St Maurice, France.	m.chevignard@hopital-saint-maurice.fr			Hopital National de Saint Maurice' (France); France-Traumatisme Crnien-SOFMER; SFERHE	This work was conducted in a clinical setting, and was therefore supported by the 'Hopital National de Saint Maurice' (France), where the study was performed. It was also supported by a grant of 'France-Traumatisme Crnien-SOFMER' and a grant from SFERHE. We thank Dr Pascale Pradat-Diehl, Dr Cheryl Soo and Associate Professor Cathy Catroppa for their helpful advice about the article and for the English corrections. We wish to acknowledge the whole team for their active work in this network of care.	Aitken ME, 2005, ARCH PHYS MED REHAB, V86, P175, DOI 10.1016/j.apmr.2004.02.026; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; AUBERT S, 2007, DEV NEUROREHABIL, V10, P275; Bettger JAP, 2007, ARCH PHYS MED REHAB, V88, P1526, DOI 10.1016/j.apmr.2007.06.768; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Callu D, 2008, DEV NEUROREHABIL, V11, P16, DOI 10.1080/17518420701419227; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chung B, 2004, PEDIATRICS, V114, P206; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Cullen N, 2007, J HEAD TRAUMA REHAB, V22, P214, DOI 10.1097/01.HTR.0000281836.54602.6d; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Emanuelson I, 2003, INT J REHABIL RES, V26, P257, DOI 10.1097/00004356-200312000-00002; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Gillett J, 2004, NEUROREHABILITATION, V19, P207; GIROUD M, 1995, J CLIN EPIDEMIOL, V48, P1343, DOI 10.1016/0895-4356(95)00039-9; Glang A, 2004, NEUROREHABILITATION, V19, P219; Gordon AL, 2002, J CHILD NEUROL, V17, P429, DOI 10.1177/088307380201700606; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Gregg J, 1999, LANCET, V354, pS28; Grill J, 2004, J NEUROSURG, V101, P152, DOI 10.3171/ped.2004.101.2.0152; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hartel C, 2004, EUR J NEUROL, V11, P431, DOI 10.1111/j.1468-1331.2004.00861.x; Heinemann AW, 2007, AM J PHYS MED REHAB, V86, P869, DOI 10.1097/PHM.0b013e31815840b3; Hoofien D, 2001, BRAIN INJURY, V15, P189; *INSEE, 2004, INSEE DIV ENQ ET DEM, P2004; Javouhey E, 2006, EUR J PEDIATR, V165, P519, DOI 10.1007/s00431-006-0118-z; JENNETT B, 1975, LANCET, V1, P480; Kieffer V, 2007, ARCH PEDIATRIE, V14, P1282, DOI 10.1016/j.arcped.2007.08.009; Kieffer-Renaux V, 2005, PEDIATR BLOOD CANCER, V45, P814, DOI 10.1002/pbc.20329; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; LAURENTVANNIER A, 2008, BRAIN INJURY S1, V22, P206; LAURENTVANNIER A, 2005, ANN READAPTATION MED, V48, P481; LAURENTVANNIER A, 1998, ANN READAPTATION MED, V41, P93; Lexell J, 2007, J HEAD TRAUMA REHAB, V22, P229, DOI 10.1097/01.HTR.0000281838.00344.03; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McDougall J, 2006, BRAIN INJURY, V20, P1189, DOI 10.1080/02699050600975541; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Nyein K, 2007, J HEAD TRAUMA REHAB, V22, P239, DOI 10.1097/01.HTR.0000281840.85096.1f; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rickert CH, 1997, CHILD NERV SYST, V13, P507, DOI 10.1007/s003810050127; Rosenbaum P, 2006, DEV MED CHILD NEUROL, V48, P4, DOI 10.1017/S001216226000028; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; Tomlin P, 2002, DEV MED CHILD NEUROL, V44, P828; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; *VICT PAED REH SER, 2007, VICT PAED REH SERV M; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	74	52	52	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1862	1365-2214		CHILD CARE HLTH DEV	Child Care Health Dev.	JAN	2010	36	1					31	43		10.1111/j.1365-2214.2009.00949.x			13	Psychology, Developmental; Pediatrics	Psychology; Pediatrics	536BF	WOS:000273016400004	19438875				2021-06-18	
J	Metting, Z; Rodiger, LA; Stewart, RE; Oudkerk, M; De Keyser, J; van der Naalt, J				Metting, Zwany; Rodiger, Lars A.; Stewart, Roy E.; Oudkerk, Matthijs; De Keyser, Jacques; van der Naalt, Joukje			Perfusion Computed Tomography in the Acute Phase of Mild Head Injury: Regional Dysfunction and Prognostic Value	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; POSITRON EMISSION TOMOGRAPHY; GLASGOW OUTCOME SCALE; ACUTE STROKE; TECHNETIUM-99M-HMPAO SPECT; SUBARACHNOID HEMORRHAGE; DYNAMIC CT; DISABILITY; ISCHEMIA	Objective: Traumatic brain injury is a major Cause of disability and death. Most patients sustain a mild head injury with a subgroup that experiences disabling symptoms interfering with return to work. Brain imaging in the acute phase is not predictive of outcome, as 20% of noncontrast computed tomographic (CT) scans on admission is normal in patients with a suboptimal Outcome. The aim of this study was to perform perfusion CT imaging in the acute phase of mild head injury in patients without intracranial abnormalities on the noncontrast CT, to assess whether these patients had cerebral perfusion abnormalities. Furthermore, the relation between perfusion CT parameters and severity of head injury and Outcome was evaluated. Methods: In patients with mild head injury and normal noncontrast CT, perfusion CT was performed directly after admission. The perfusion data were compared with data of 25 healthy control subjects. Outcome was determined 6 months after injury with the extended Glasgow Coma Outcome Scale score and return to work. Results: Seventy-six patients were included. In patients with a decreased Glasgow Coma Scale score, a significant decrease of cerebral blood flow and cerebral blood volume was detected in the frontal and occipital gray matter. In logistic regression analyses, decreased cerebral blood flow and cerebral blood volume in the Frontal lobes predicted worse outcome according to the extended Glasgow Coma Outcome Scale score. CT perfusion parameters did not predict return to work. Interpretation: In the acute phase of mild head injury, disturbed cerebral perfusion is seen in patients with normal noncontrast CT correlating with severity Of injury and Outcome. Ann Neurol 2009;66:809-816	[Metting, Zwany; De Keyser, Jacques; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Rodiger, Lars A.; Oudkerk, Matthijs] Univ Med Ctr Groningen, Dept Radiol, NL-9700 RB Groningen, Netherlands; [Stewart, Roy E.] Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 RB Groningen, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@neuro.umcg.nl	De Keyser, Jacques/D-3725-2013; De Keyser, Jacques/AAA-8721-2021	De Keyser, Jacques/0000-0002-3394-7757; De Keyser, Jacques/0000-0002-3394-7757; Oudkerk, Matthijs/0000-0003-2800-4110	ZonMw, Den Haag, the NetherlandsNetherlands Organization for Health Research and DevelopmentNetherlands Government	This Study was Supported by ZonMw, Den Haag, the Netherlands.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Audenaert K., 2003, MED SCI MONITOR, V9, P112; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Eastwood JD, 2002, RADIOLOGY, V222, P227, DOI 10.1148/radiol.2221010471; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Esteban JM, 2004, NEURORADIOLOGY, V46, P705, DOI 10.1007/s00234-004-1235-x; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Klotz E, 1999, EUR J RADIOL, V30, P170, DOI 10.1016/S0720-048X(99)00009-1; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; Mayer TE, 2000, AM J NEURORADIOL, V21, P1441; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Muizelaar JP, 1997, STROKE, V28, P1998, DOI 10.1161/01.STR.28.10.1998; Nariai T, 2001, J NEUROTRAUM, V18, P1323, DOI 10.1089/08977150152725623; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; POWERS WJ, 1985, STROKE, V16, P361, DOI 10.1161/01.STR.16.3.361; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROLAND PE, 1987, J NEUROSCI, V7, P2373; SAKAS DE, 1995, J NEUROSURG, V83, P277, DOI 10.3171/jns.1995.83.2.0277; Soustiel JF, 2008, NEURORADIOLOGY, V50, P189, DOI 10.1007/s00234-007-0337-7; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Schaaf I, 2006, NEUROLOGY, V66, P1533, DOI 10.1212/01.wnl.0000216272.67895.d3; van der Schaaf I, 2006, STROKE, V37, P409, DOI 10.1161/01.STR.0000198831.69035.43; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wintermark M, 2005, PEDIATR EMERG CARE, V21, P149; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2002, ANN NEUROL, V51, P417, DOI 10.1002/ana.10136	47	52	54	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	DEC	2009	66	6					809	816		10.1002/ana.21785			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	540FX	WOS:000273317800014	20035508				2021-06-18	
J	Norris, CM; Scheff, SW				Norris, Christopher M.; Scheff, Stephen W.			Recovery of Afferent Function and Synaptic Strength in Hippocampal CA1 following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical contusion injury; deafferentation; excitatory postsynaptic potential; fiber volley; Schaffer collaterals	LONG-TERM POTENTIATION; FLUID PERCUSSION INJURY; NMDA RECEPTORS; AREA CA1; RAT; ACTIVATION; MECHANISMS; DEPRESSION; PLASTICITY; NITRATION	Cortical contusion injury can result in the partial loss of ipsilateral CA3 neurons within 48 h, leading to a proportional reduction in the number of afferent fibers to CA1 stratum radiatum. While the loss of afferent input to CA1 exhibits a remarkable, albeit incomplete, recovery over the next few weeks, little is known about the functional status of presynaptic afferents during the depletion and recovery phases following injury. Here, we prepared hippocampal slices from adult Sprague Dawley rats at 2, 7, and 14 days after lateral cortical contusion injury and measured fiber volley (FV) amplitudes extracellularly in CA1 stratum radiatum. Field excitatory postsynaptic potentials (EPSPs) were also measured and plotted as a function of FV amplitude to assess relative synaptic strength of residual and/or regenerated synaptic contacts. At 2 days post-injury, FV amplitude and synaptic strength were markedly reduced in the ipsilateral, relative to the contralateral, hippocampus. FV amplitude in ipsilateral CA1 showed a complete recovery by 7 days, indicative of a post-injury sprouting response. Synaptic strength in ipsilateral CA1 also showed a dramatic recovery over this time; however, EPSP-to-FV curves remained slightly suppressed at both the 7 and 14 day time points. Despite these deficits, ipsilateral slices retained the capacity to express long-term potentiation, indicating that at least some mechanisms for synaptic plasticity remain intact, or are compensated for. These results are in agreement with anatomical evidence showing a profound deafferentation, followed by a remarkable re-enervation, of ipsilateral CA1 in the first few weeks after traumatic brain injury. Although plasticity mechanisms appear to remain intact, synaptic strength deficits in CA1 could limit information throughput in the hippocampus, leading to persistent memory dysfunction.	[Norris, Christopher M.; Scheff, Stephen W.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Scheff, Stephen W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA	Norris, CM (corresponding author), 131 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	cnorr2@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; Kentucky Spinal Cord; Head Injury Trust; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981, R01AG027297] Funding Source: NIH RePORTER	This work was supported by NIH grant AG21981 and an award from the Kentucky Spinal Cord and Head Injury Trust.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Campbell LW, 1996, J NEUROSCI, V16, P6286; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; FOSTER TC, 1991, NEUROBIOL AGING, V12, P441, DOI 10.1016/0197-4580(91)90071-Q; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nakazawa K, 2003, NEURON, V38, P305, DOI 10.1016/S0896-6273(03)00165-X; Norris CM, 1998, J NEUROSCI, V18, P3171; Norris CM, 1996, J NEUROSCI, V16, P5382; NORRIS CM, 2008, NEUROBIOLOGY, DOI DOI 10.1016/J.NEUROBIOLAGING.2008.03.026; Paxinos G., 2004, RAT NERVOUS SYSTEM, VThird; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shankar S, 1998, J NEUROPHYSIOL, V79, P334; Shetty AK, 2002, HIPPOCAMPUS, V12, P534, DOI 10.1002/hipo.10031; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	35	52	53	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2269	2278		10.1089/neu.2009.1029			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200014	19604098	Green Accepted, Green Published			2021-06-18	
J	Zhang, YL; Xiong, Y; Mahmood, A; Meng, YL; Qu, CS; Schallert, T; Chopp, M				Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Schallert, Timothy; Chopp, Michael			Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit	BRAIN RESEARCH			English	Article						Angiogenesis; Erythropoietin; Hemodilution; Neurogenesis; Traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; MITOCHONDRIAL DYSFUNCTION; ENHANCES NEUROGENESIS; NEUROBLAST MIGRATION; SPATIAL MEMORY; EPOETIN-ALPHA; BLOOD-FLOW; STROKE; ANEMIA; NEURONS	Erythropoietin (EPO) provides neuroprotection and neurorestoration after traumatic brain injury (TBI). The EPO doses used for treatment of TBI significantly increase hematocrit, which may affect the efficacy of EPO therapy for TBI. The aim of this study was to investigate whether normalization of hematocrit would affect EPO efficacy for treatment of TBI. Young adult male Wistar rats were randomly divided into four groups: (1) Sham group (n = 6); (2) TBI+saline group (n = 6); (3) TBI+EPO group (n = 6); and (4) TBI+EPO+hemodilution group (n = 7). TBI was induced by controlled cortical impact over the left parietal cortex. EPO (5,000 U/kg) or saline was administered intraperitoneally at days 1, 2, and 3 postinjury. Neurological function was assessed using a modified neurological severity score (mNSS), footfault and the Morris water maze (MWM) tests. Animals were sacrificed 35 days after injury, and brain sections were stained for immunohistochemistry. Compared to the saline treatment, EPO treatment significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved sensorimotor functional outcome (lowered mNSS and foot faults) and spatial learning (MWM test). Normovolemic hemodilution effectively normalized the hematocrit and did not significantly affect the histological and functional outcome of EPO therapy for TBI. These data for the first time demonstrate that increased hematocrit does not affect therapeutic effects of EPO on histological and long-term functional outcomes in rats after TBI and also suggest that neuroprotection and neurorestoration of EPO treatment are independent of hematocrit. (C) 2009 Elsevier B.V. All rights reserved.	[Zhang, Yanlu; Xiong, Ye; Mahmood, Asim; Meng, Yuling; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS 62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS 62002 and PO1 NS42345.	Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Cheung W, 2001, EUR J CLIN PHARMACOL, V57, P411, DOI 10.1007/s002280100324; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; Ge YL, 2007, ACTA ANAESTH SCAND, V51, P1331, DOI 10.1111/j.1399-6576.2007.01448.x; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Li M, 2006, J NEUROSURG ANESTH, V18, P125, DOI 10.1097/00008506-200604000-00006; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lindenblatt N, 2007, ARTERIOSCL THROM VAS, V27, P1191, DOI 10.1161/ATVBAHA.107.141580; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; Milano M, 2007, CRIT REV ONCOL HEMAT, V62, P119, DOI 10.1016/j.critrevonc.2006.11.011; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rosenzweig MQ, 2004, J PAIN SYMPTOM MANAG, V27, P185, DOI 10.1016/j.jpainsymman.2003.06.010; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shibata J, 2003, BLOOD, V101, P4416, DOI 10.1182/blood-2002-09-2814; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wish JB, 2009, ADV CHRONIC KIDNEY D, V16, P101, DOI 10.1053/j.ackd.2008.12.005; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2009, NEUROL RES, V31, P496, DOI 10.1179/174313208X353703; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2009, J CEREBR BLOOD F MET, V29, P1240, DOI 10.1038/jcbfm.2009.55; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	59	52	53	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 6	2009	1294						153	164		10.1016/j.brainres.2009.07.077			12	Neurosciences	Neurosciences & Neurology	504ZZ	WOS:000270658500016	19646970	Green Accepted			2021-06-18	
J	King, DR; Ogilvie, MP; Pereira, BMT; Chang, YC; Manning, RJ; Conner, JA; Schulman, CI; McKenney, MG; Proctor, KG				King, David R.; Ogilvie, Michael P.; Pereira, Bruno M. T.; Chang, Yuchiao; Manning, Ronald J.; Conner, Jeffrey A.; Schulman, Carl I.; McKenney, Mark G.; Proctor, Kenneth G.			Heart Rate Variability as a Triage Tool in Patients With Trauma During Prehospital Helicopter Transport	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	22nd Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 13-17, 2009	Lake Buena Vista, FL	Eastern Assoc Surg Trauma		Combat casualty care; Base deficit; Vital sign monitor	BRAIN-INJURY; MORTALITY; ASSOCIATION; COMPLEXITY; PREDICTOR; INTERVAL; DEATH	Background: Prehospital triage of patients with trauma is routinely challenging, but more so in mass casualty situations and military operations. The purpose of this study was to prospectively test whether heart rate variability (HRV) could be used as a triage tool during helicopter transport of civilian patients with trauma. Methods: After institutional review board approval and waiver of informed consent, 75 patients with trauma requiring prehospital helicopter transport to our level I center (from December 2007 to November 2008) were prospectively instrumented with a 2-Channel SEER Light recorder (GE Healthcare, Milwaukee, WI). HRV was analyzed with a Mars Holter monitor system and proprietary software. SDNN (standard deviation [SD] of the normal-to-normal R-R interval), as an index of HRV, was correlated with prehospital trauma triage criteria, base deficit, seriousness Of injury, operative interventions, outcome, and other data extracted from the patients' medical records. There were no interventions or medical decisions based on HRV. Data were excluded only if there was measurement artifact or technical problems with the recordings. Results: The demographics were mean age 47 years, 63% men, 88% blunt, 25% traumatic brain injury, 9% mortality. Prehospital SDNN predicted patients with base excess <=-6, those defined as seriously injured and benefiting front trauma center care, as well as patients requiring a life-saving procedure in the operating room. No other available data, including prehospital en-route vital signs, predicted any of these. The sensitivity, specificity, positive predictive value, and negative predictive value were 80%, 75%, 33%, 96%, respectively, with and an overall accuracy of 76% for predicting a life-saving intervention in the operating room. Conclusions: This, is the first demonstration that prehospital HRV (specifically SDNN) predicts base excess and operating room life-saving opportunities. HRV triages and discriminates severely injured patients better than routine trauma criteria or en-route prehospital vital signs. HRV may be a useful civilian or military triage tool to avoid unnecessary helicopter evacuation for minimally injured patients. A prospective, randomized trial in a larger patient population is indicated.	[King, David R.; Ogilvie, Michael P.; Pereira, Bruno M. T.; Manning, Ronald J.; Conner, Jeffrey A.; Schulman, Carl I.; McKenney, Mark G.; Proctor, Kenneth G.] Univ Miami, Miller Sch Med, Daughtry Family Dept Surg, Div Trauma & Surg Crit Care, Miami, FL 33136 USA; [King, David R.; Chang, Yuchiao] Harvard Univ, Massachusetts Gen Hosp, Sch Med,,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02141 USA; [Conner, Jeffrey A.] GE Healthcare Diagnost Cardiol, Marquette, MI USA	King, DR (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambrige St,Suite 810, Boston, MA 02141 USA.	Dking3@partners.org	Schulman, Carl/AAE-7448-2021; Pereira, Bruno M/D-4542-2015	Pereira, Bruno M/0000-0003-3763-1749; Schulman, Carl/0000-0001-8899-4350; King, David/0000-0003-1028-1478			Batchinsky AL, 2007, J TRAUMA, V63, P512, DOI 10.1097/TA.0b013e318142d2f0; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Buchman Timothy G, 2002, Curr Opin Crit Care, V8, P311, DOI 10.1097/00075198-200208000-00007; Cancio LC, 2008, J TRAUMA, V65, P813, DOI 10.1097/TA.0b013e3181848241; Cooke WH, 2006, J TRAUMA, V60, P363, DOI 10.1097/01.ta.0000196623.48952.0e; Godin PJ, 1996, CRIT CARE MED, V24, P1107, DOI 10.1097/00003246-199607000-00008; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Grogan EL, 2005, J TRAUMA, V58, P7, DOI 10.1097/01.TA.0000151179.74839.98; Grogan EL, 2004, ANN SURG, V240, P547, DOI 10.1097/01.sla.0000137143.65540.9c; Henry MC, 1996, ACAD EMERG MED, V3, P992, DOI 10.1111/j.1553-2712.1996.tb03340.x; Kann SH, 2007, ACTA ANAESTH SCAND, V51, P1172, DOI 10.1111/j.1399-6576.2007.01354.x; King ML, 1997, BRAIN INJURY, V11, P445; Ko SH, 2008, DIABETIC MED, V25, P1171, DOI 10.1111/j.1464-5491.2008.02567.x; Leach SR, 2008, PREHOSP EMERG CARE, V12, P467, DOI 10.1080/10903120802290836; Maule S, 2008, HYPERTENS RES, V31, P2003, DOI 10.1291/hypres.31.2003; MORRIS JA, 2006, ANN SURG, V243, P812; Morris JA, 2006, J TRAUMA, V60, P1165, DOI 10.1097/01.ta.0000220384.04978.3b; Morris John A Jr, 2005, Adv Surg, V39, P77, DOI 10.1016/j.yasu.2005.04.004; Norris PR, 2008, SHOCK, V30, P17, DOI 10.1097/SHK.0b013e318164e4d0; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Norris PR, 2005, J SURG RES, V129, P122, DOI 10.1016/j.jss.2005.04.024; Proctor KG, 2007, J TRAUMA, V63, P33, DOI 10.1097/01.ta.0000251593.32396.df; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; Stein PK, 2001, CRIT CARE MED, V29, P1738, DOI 10.1097/00003246-200109000-00014; Thompson EC, 2005, J TRAUMA, V58, P12; Tiamfook-Morgan TO, 2008, PREHOSP EMERG CARE, V12, P443, DOI 10.1080/10903120802290794; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	30	52	52	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2009	67	3					436	440		10.1097/TA.0b013e3181ad67de			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	493IL	WOS:000269729900003	19741382				2021-06-18	
J	Lindstrom, B; Roding, J; Sundelin, G				Lindstrom, Britta; Roding, Jenny; Sundelin, Gunnevi			POSITIVE ATTITUDES AND PRESERVED HIGH LEVEL OF MOTOR PERFORMANCE ARE IMPORTANT FACTORS FOR RETURN TO WORK IN YOUNGER PERSONS AFTER STROKE: A NATIONAL SURVEY	JOURNAL OF REHABILITATION MEDICINE			English	Article						questionnaire; rehabilitation; stroke; work; young adults	TRAUMATIC BRAIN-INJURY; PATIENTS EXPERIENCES; QUALITY REGISTER; RECOVERY	Objective: Significant numbers of younger persons with stroke should be given the opportunity to return to work. The aim of this study was to investigate factors of importance for return to work among persons after first ever stroke, in the age range 18-55 years. Methods: A questionnaire was sent to all persons who had experienced a first ever stroke, 18-55 years of age, registered in the Swedish national quality register for stroke care, Riks-Stroke. Of the 1068 who answered the questionnaire, 855 (539 men and 316 women) were in paid employment before their stroke, and were included in this study. Results: Sixty-five percent returned to work and, of these, an equal proportion were men and women. Significant factors associated with return to work were the perceived importance of work (odds ratio (OR) 5.10), not perceiving themselves as a burden on others (OR 3.33), support from others for return to work (OR 3.66), retaining the ability to run a short distance (OR 2.77), and higher socioeconomic codes (OR 2.12). A negative association was found between those rehabilitated in wards intended for younger persons and return to work (OR 0.37). Conclusion: External support from others, and positive attitudes towards return to work, were factors associated with successful return to work after stroke. Contrary to what was expected, independence in personal activities of daily living and cognitive factors were not associated with return to work to the same extent as persistent higher level of physical functions, such as ability to run a short distance.	[Lindstrom, Britta; Roding, Jenny; Sundelin, Gunnevi] Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden; [Roding, Jenny] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden	Lindstrom, B (corresponding author), Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden.	britta.lindstrom@physiother.umu.se		Sundelin, Gunnevi/0000-0002-0198-7033	Norrlandska Strokefonden	Ellinor Flink and Helena Forsen are gratefully acknowledged for assistance in data collection and preparation. We also thank Norrlandska Strokefonden for financial Support and Riks-Stroke for access to the national quality register.	Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Asplund K, 2003, CEREBROVASC DIS, V15, P5, DOI 10.1159/000068203; Eriksson M, 2007, STROKE, V38, P1384, DOI 10.1161/01.STR.0000260102.97954.9c; Glader EL, 2003, STROKE, V34, P1970, DOI 10.1161/01.STR.0000083534.81284.C5; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Hamedani AG, 2001, STROKE, V32, P687, DOI 10.1161/01.STR.32.3.687; Hofgren C, 2007, ACTA NEUROL SCAND, V115, P73, DOI 10.1111/j.1600-0404.2006.00768.x; MAHONEY F I, 1965, Md State Med J, V14, P61; Medin J, 2006, DISABIL REHABIL, V28, P1051, DOI 10.1080/09638280500494819; Neau JP, 1998, CEREBROVASC DIS, V8, P296, DOI 10.1159/000015869; Puolakka K, 2008, EUR SPINE J, V17, P386, DOI 10.1007/s00586-007-0552-2; Roding J, 2003, DISABIL REHABIL, V25, P867, DOI 10.1080/0963828031000122276; Roding J, 2009, DISABIL REHABIL, V31, P1092, DOI 10.1080/09638280802510965; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; Saeki Satoru, 2004, Journal of UOEH, V26, P41; *SCB, REG ARB RAMS STAT SW; *SCB, UND LEV ULF; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; *SOC, RAPP RIKS STROK 2006; *SOC, LIVSS IV AR EFT STRO; *SVENSKT NAR, CONF SWED ENT; Treger I, 2007, DISABIL REHABIL, V29, P1397, DOI 10.1080/09638280701314923; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568; Wozniak MA, 2002, NEUROEPIDEMIOLOGY, V21, P159, DOI 10.1159/000059516	26	52	54	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2009	41	9					714	718		10.2340/16501977-0423			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	510PK	WOS:000271102200004	19774303	DOAJ Gold			2021-06-18	
J	Xu, G; Bayly, PV; Taber, LA				Xu, Gang; Bayly, Philip V.; Taber, Larry A.			Residual stress in the adult mouse brain	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Biomechanics; Morphogenesis; Cortical folding; Axon; Stiffness	IN-VIVO; MECHANICAL-PROPERTIES; WHITE-MATTER; TISSUE; GROWTH; MODEL; NEURONS; TENSION; CYTOMECHANICS; HYDROCEPHALUS	This work provides direct evidence that sustained tensile stress exists in white matter of the mature mouse brain. This finding has important implications for the mechanisms of brain development, as tension in neural axons has been hypothesized to drive cortical folding in the human brain. In addition, knowledge of residual stress is required to fully understand the mechanisms behind traumatic brain injury and changes in mechanical properties due to aging and disease. To estimate residual stress in the brain, we performed serial dissection experiments on 500-mum thick coronal slices from fresh adult mouse brains and developed finite element models for these experiments. Radial cuts were made either into cortical gray matter, or through the cortex and the underlying white matter tract composed of parallel neural axons. Cuts into cortical gray matter did not open, but cuts through both layers consistently opened at the point where the cut crossed the white matter. We infer that the cerebral white matter is under considerable tension in the circumferential direction in the coronal cerebral plane, parallel to most of the neural fibers, while the cerebral cortical gray matter is in compression. The models show that the observed deformation after cutting can be caused by more growth in the gray matter than in the white matter, with the estimated tensile stress in the white matter being on the order of 100-1,000 Pa.	[Xu, Gang; Bayly, Philip V.; Taber, Larry A.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Bayly, Philip V.] Washington Univ, Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA	Taber, LA (corresponding author), Washington Univ, Dept Biomed Engn, 1 Brookings Dr,Campus Box 1097, St Louis, MO 63130 USA.	lat@wustl.edu	Xu, Gang/C-7118-2013	Bayly, Philip/0000-0003-4303-0704	National Science FoundationNational Science Foundation (NSF) [DMS-0540701]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB005834] Funding Source: NIH RePORTER	We gratefully acknowledge technical assistance from Edward Kim, William McCarran, and Christine McDonald in harvesting the mouse brains used in this work. We also thank Paul Bridgman, Krikor Dikranian, Jeffrey Neil, and David Van Essen for their helpful discussions and suggestions. This work was supported by the National Science Foundation ( grant #DMS-0540701).	Alexander GM, 2000, J NEUROCHEM, V74, P1666, DOI 10.1046/j.1471-4159.2000.0741666.x; Chada S, 1997, J CELL SCI, V110, P1179; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Drapaca CS, 2006, J ELASTICITY, V85, P65, DOI 10.1007/s10659-006-9071-3; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Faisal AA, 2005, CURR BIOL, V15, P1143, DOI 10.1016/j.cub.2005.05.056; Fung Y., 1993, BIOMECHANICS MECH PR; FUNG YC, 1998, BIOMECHANICS MOTION; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Hilgetag CC, 2005, ANAT EMBRYOL, V210, P411, DOI 10.1007/s00429-005-0041-5; Hilgetag CC, 2006, PLOS COMPUT BIOL, V2, P146, DOI 10.1371/journal.pcbi.0020022; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kioussi C, 2007, BRAIN RES BULL, V74, P439, DOI 10.1016/j.brainresbull.2007.07.024; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; Lamoureux P, 2002, J CELL BIOL, V159, P499, DOI 10.1083/jcb.200207174; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; Larvaron P, 2007, NMR BIOMED, V20, P413, DOI 10.1002/nbm.1082; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nordahl CW, 2007, J NEUROSCI, V27, P11725, DOI 10.1523/JNEUROSCI.0777-07.2007; Olivares R, 2001, BRAIN BEHAV EVOLUT, V57, P98, DOI 10.1159/000047229; Porter BE, 2002, ARCH NEUROL-CHICAGO, V59, P361, DOI 10.1001/archneur.59.3.361; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RICHMAN DP, 1975, SCIENCE, V189, P18; RODRIGUEZ EK, 1994, J BIOMECH, V27, P455, DOI 10.1016/0021-9290(94)90021-3; Sallet PC, 2003, AM J PSYCHIAT, V160, P1606, DOI 10.1176/appi.ajp.160.9.1606; Taber LA, 2001, ANNU REV BIOMED ENG, V3, P1, DOI 10.1146/annurev.bioeng.3.1.1; Taber LA, 2000, J ELASTICITY, V61, P165, DOI 10.1023/A:1011082712497; Taber LA, 2008, BIOMECH MODEL MECHAN, V7, P427, DOI 10.1007/s10237-007-0106-x; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; TODD PH, 1982, J THEOR BIOL, V97, P529, DOI 10.1016/0022-5193(82)90380-0; Toro R, 2005, CEREB CORTEX, V15, P1900, DOI 10.1093/cercor/bhi068; VALVERDE F, 2004, GOLGI ATLAS POSTNATA; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Welker W, 1990, CEREB CORTEX, P3, DOI DOI 10.1007/978-1-4615-3824-0; Zamir EA, 2004, J BIOMECH ENG-T ASME, V126, P276, DOI 10.1115/1.1695573; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	48	52	53	0	18	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2009	8	4					253	262		10.1007/s10237-008-0131-4			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	476XF	WOS:000268479400001	18651186	Green Accepted			2021-06-18	
J	Hayashi, T; Kaneko, Y; Yu, S; Bae, E; Stahl, CE; Kawase, T; van Loveren, H; Sanberg, PR; Borlongan, CV				Hayashi, Takuro; Kaneko, Yuji; Yu, SeongJin; Bae, EunKyung; Stahl, Christine E.; Kawase, Takeshi; van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.			Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats	BRAIN RESEARCH			English	Article						Head injury; MMP-9; Cortex; Immunohistochemistry; Quantitative real-time PCR	CONTROLLED CORTICAL IMPACT; EXPRESSION; MATRIX-METALLOPROTEINASE-9; SYNAPTOGENESIS; THERAPY; DEATH; MICE	Recent laboratory evidence implicates matrix metalloproteinases (MMPs) as playing a pivotal role in ischemic and traumatic brain injuries (TBI). Here, quantitative real-time PCR analyses revealed that brains from TBI rats displayed significantly elevated MMP-9 expression at 24 h post-TBI, which remained upregulated at least until 48 h after injury. Immunohistochemical analyses similarly revealed significantly increased MMP-9 immunoreactivity at 24 and 48 h post-TBI. These results demonstrate that alterations in MMPs (i.e., MMP-9) commenced immediately after TBI, suggesting that treatment strategies designed to maintain MMP integrity should be initiated in the acute phase of injury. (C) 2009 Elsevier B.V. All rights reserved.	[Hayashi, Takuro; Kaneko, Yuji; Yu, SeongJin; Bae, EunKyung; van Loveren, Harry; Sanberg, Paul R.; Borlongan, Cesar V.] Univ S Florida, Dept Neurosurg, 12906 Bruce B Downs Blvd MDC78, Tampa, FL 33612 USA; [Stahl, Christine E.] Dwight D Eisenhower Army Med Ctr, Dept Internal Med, Ft Gordon, GA 30905 USA; [Kawase, Takeshi] Keio Univ, Dept Neurosurg, Shinjuku Ku, Tokyo 1608582, Japan	Borlongan, CV (corresponding author), Univ S Florida, Dept Neurosurg, 12906 Bruce B Downs Blvd MDC78, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782			Chuck Y, 2008, MILD TRAUMATIC BRAIN; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Hu SL, 2008, ACTA NEUROCHIR SUPPL, V105, P191; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LEE H, 2009, NEUROBIOL DIS   0106; MAMMIS A, 2008, SURG NEUROL     0910; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	25	52	54	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 14	2009	1280						172	177		10.1016/j.brainres.2009.05.040			6	Neurosciences	Neurosciences & Neurology	469OS	WOS:000267909800020	19464272				2021-06-18	
J	Yu, Z; Graudejus, O; Tsay, C; Lacour, SP; Wagner, S; Morrison, B				Yu, Zhe; Graudejus, Oliver; Tsay, Candice; Lacour, Stephanie P.; Wagner, Sigurd; Morrison, Barclay, III			Monitoring Hippocampus Electrical Activity In Vitro on an Elastically Deformable Microelectrode Array	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; in vitro studies; outcome measures; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SOURCE DENSITY ANALYSIS; STRETCH-INDUCED INJURY; SLICE CULTURES; MULTIELECTRODE ARRAY; INTEGRATED-CIRCUITS; RECORDINGS; STIMULATION; ELASTOMER; POLYIMIDE	Interfacing electronics and recording electrophysiological activity in mechanically active biological tissues is challenging. This challenge extends to recording neural function of brain tissue in the setting of traumatic brain injury (TBI), which is caused by rapid (within hundreds of milliseconds) and large (greater than 5% strain) brain deformation. Interfacing electrodes must be biocompatible on multiple levels and should deform with the tissue to prevent additional mechanical damage. We describe an elastically stretchable microelectrode array (SMEA) that is capable of undergoing large, biaxial, 2-D stretch while remaining functional. The new SMEA consists of elastically stretchable thin metal films on a silicone membrane. It can stimulate and detect electrical activity from cultured brain tissue (hippocampal slices), before, during, and after large biaxial deformation. We have incorporated the SMEA into a well-characterized in vitro TBI research platform, which reproduces the biomechanics of TBI by stretching the SMEA and the adherent brain slice culture. Mechanical injury parameters, such as strain and strain rate, can be precisely controlled to generate specific levels of damage. The SMEA allowed for quantification of neuronal function both before and after injury, without breaking culture sterility or repositioning the electrodes for the injury event, thus enabling serial and long-term measurements. We report tests of the SMEA and an initial application to study the effect of mechanical stimuli on neuron function, which could be employed as a high-content, drug-screening platform for TBI.	[Yu, Zhe; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Graudejus, Oliver; Tsay, Candice; Wagner, Sigurd] Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; [Lacour, Stephanie P.] Univ Cambridge, Dept Engn, Cambridge CB2 1PZ, England	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Yu, Zhe/K-6180-2013; Lacour, Stephanie/AAR-2213-2020; Morrison, Barclay/B-7132-2008; Lacour, Stephanie P/E-6375-2010	Yu, Zhe/0000-0002-1401-2294; Lacour, Stephanie/0000-0001-9075-4022; Morrison, Barclay/0000-0001-7676-0864; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS R21 052794]; New Jersey Commission on Science and Technology; University Research Fellowship	The authors would like to acknowledge the assistance of J. Jones. This work was supported by NIH (NINDS R21 052794), the New Jersey Commission on Science and Technology, and a University Research Fellowship from the Royal Society (S.P.L.).	Beggs JM, 2003, J NEUROSCI, V23, P11167; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Cao Q, 2008, NATURE, V454, P495, DOI 10.1038/nature07110; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cheung KC, 2007, BIOSENS BIOELECTRON, V22, P1783, DOI 10.1016/j.bios.2006.08.035; CHIU SL, 1994, J APPL PHYS, V76, P5136, DOI 10.1063/1.357227; Christensen TA, 2000, NAT NEUROSCI, V3, P927, DOI 10.1038/78840; DEADWYLER SA, 1995, SCIENCE, V270, P1316, DOI 10.1126/science.270.5240.1316; Diogo ACM, 2003, J NEUROSCI, V23, P3881; Doetsch GS, 2000, PHYSIOL BEHAV, V69, P187, DOI 10.1016/S0031-9384(00)00201-8; Egert U, 1998, BRAIN RES PROTOC, V2, P229, DOI 10.1016/S1385-299X(98)00013-0; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Harris KD, 2003, NATURE, V424, P552, DOI 10.1038/nature01834; Heuschkel MO, 2002, J NEUROSCI METH, V114, P135, DOI 10.1016/S0165-0270(01)00514-3; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kim DH, 2008, SCIENCE, V320, P507, DOI 10.1126/science.1154367; Kim YT, 2004, BIOMATERIALS, V25, P2229, DOI 10.1016/j.biomaterials.2003.09.010; Kralik JD, 2001, METHODS, V25, P121, DOI 10.1006/meth.2001.1231; Lacour SP, 2003, APPL PHYS LETT, V82, P2404, DOI 10.1063/1.1565683; Lacour SP, 2004, IEEE ELECTR DEVICE L, V25, P179, DOI 10.1109/LED.2004.825190; Li T, 2004, APPL PHYS LETT, V85, P3435, DOI 10.1063/1.1806275; Liu WF, 2001, IEEE T COMPON PACK T, V24, P520, DOI 10.1109/6144.946501; Madou M.J., 2002, FUNDAMENTALS MICROFA, V2nd ed; Meacham KW, 2008, BIOMED MICRODEVICES, V10, P259, DOI 10.1007/s10544-007-9132-9; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; NISCH W, 1994, BIOSENS BIOELECTRON, V9, P737, DOI 10.1016/0956-5663(94)80072-3; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; PASHLEY DW, 1960, PROC R SOC LON SER-A, V255, P218, DOI 10.1098/rspa.1960.0064; Ray AM, 2003, J NEUROSCI, V23, P10146; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Rousche PJ, 2001, IEEE T BIO-MED ENG, V48, P361, DOI 10.1109/10.914800; Sanchez JC, 2006, EXP NEUROL, V198, P31, DOI 10.1016/j.expneurol.2005.10.031; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shimono K, 2002, J NEUROSCI METH, V120, P193, DOI 10.1016/S0165-0270(02)00202-9; Spaepen F, 2000, ACTA MATER, V48, P31, DOI 10.1016/S1359-6454(99)00286-4; Sun YG, 2006, NAT NANOTECHNOL, V1, P201, DOI 10.1038/nnano.2006.131; TAMAI T, 1982, IEEE T COMPON HYBR, V5, P56, DOI 10.1109/TCHMT.1982.1135954; TAUBE JS, 1988, J NEUROSCI, V8, P1645; Thiebaud P, 1999, BIOSENS BIOELECTRON, V14, P61, DOI 10.1016/S0956-5663(98)00098-0; van Bergen A, 2003, BRAIN RES PROTOC, V11, P123, DOI 10.1016/S1385-299X(03)00024-2; Warren DJ, 2001, NEUROSCIENCE, V105, P19, DOI 10.1016/S0306-4522(01)00174-9; Williams JC, 1999, BRAIN RES PROTOC, V4, P303, DOI 10.1016/S1385-299X(99)00034-3; Yu Z, 2007, NANO LETT, V7, P2188, DOI 10.1021/nl070291a; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	57	52	52	1	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1135	1145		10.1089/neu.2008.0810			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500018	19594385	Green Published			2021-06-18	
J	Zlotnik, A; Gruenbaum, SE; Artru, AA; Rozet, I; Dubilet, M; Tkachov, S; Brotfain, E; Klin, Y; Shapira, Y; Teichberg, VI				Zlotnik, Alexander; Gruenbaum, Shaun E.; Artru, Alan A.; Rozet, Irene; Dubilet, Michael; Tkachov, Sergey; Brotfain, Evgeny; Klin, Yael; Shapira, Yoram; Teichberg, Vivian I.			The Neuroprotective Effects of Oxaloacetate in Closed Head Injury in Rats is Mediated by its Blood Glutamate Scavenging Activity Evidence From the Use of Maleate	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain injury; glutamate; maleate; oxaloacetate; neurologic outcome; rat	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; CEREBROSPINAL-FLUID; CLINICAL-TRIALS; PYRUVATE; RELEASE; METABOLISM; RECEPTORS; BARRIER; EFFLUX	Introduction: Treatment with oxaloacetate after traumatic brain injury has been shown to decrease blood glutamate levels and protect against the neurtotoxic effects of glutamate oil the brain. A number of potential mechanisms have been Suggested to explain oxaloacetate-induced neuroprotection. We hypothesize that the primary mechanism by which intravenous oxaloacetate provides neuroprotection is by activation of the blood glutamate-scavenging enzyme glutamate-oxaloacetate transaminase, increasing thereby the driving force for the efflux of excess glutamate from brain interstitial fluids into blood. If so, coadministration of maleate, a glutamate-oxaloacetate transaminase-blocker is expected to prevent the neuroprotective effects of oxaloacetate. Materials and Methods: A neurological severity score (NSS) was measured 1 hour after closed head injury (CHI) in rats. Then, rats received 30 mu L/min/100 g infusion of saline, or 1 mmol/100 g Solution of oxaloacetate, maleate, or a Mixture of oxaloacetate and maleate. NSS was reassessed at 24 and 48 hour after CHI. Blood glutamate and glucose levels were measured at 0, 60, 90, and 120 minutes. Results: NSS improved significantly at 24 hour (P < 0.001) and 48 hour (P < 0.001) only in the rats treated with oxaloacetate. Blood glutamate decreased significantly in the oxaloacetate-treated group at 90 Minute (at the conclusion of oxaloacetate administration) (P < 0.00001), but not in the control, maleate or oxaloacetate+maleate groups. A strong correlation r(2) = 0.86 Was found to exist between the percent decrease in blood glutamate levels and percent improvement in NSS. Discussion: The results of this study demonstrate that the primary mechanism by which oxaloacetate provides neuroprotective activity after CHI is related to its blood glutamate scavenging activity. Management of blood glutamate concentration may have important implications in the treatment of acute brain conditions, including CHI and stroke.	[Artru, Alan A.; Rozet, Irene] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Zlotnik, Alexander; Gruenbaum, Shaun E.; Dubilet, Michael; Tkachov, Sergey; Brotfain, Evgeny; Shapira, Yoram] Ben Gurion Univ Negev, Soroka Med Ctr, Dept Anesthesiol & Crit Care, IL-84105 Beer Sheva, Israel; [Klin, Yael; Teichberg, Vivian I.] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Artru, AA (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	artruaa@u.washington.edu					BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BERL S, 1961, J NEUROCHEM, V7, P186, DOI 10.1111/j.1471-4159.1961.tb13503.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Crestanello JA, 1998, SURGERY, V124, P92, DOI 10.1016/S0039-6060(98)70080-7; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Desagher S, 1997, J NEUROSCI, V17, P9060; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; GRAHAM LT, 1966, ANAL BIOCHEM, V15, P487, DOI 10.1016/0003-2697(66)90110-2; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hosoya K, 1999, J NEUROCHEM, V73, P1206, DOI 10.1046/j.1471-4159.1999.0731206.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnston MV, 2001, PEDIATR RES, V49, P735, DOI 10.1203/00006450-200106000-00003; Koura SS, 1998, ACT NEUR S, V71, P244; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Richards DA, 2003, PHARMACOL RES, V48, P101, DOI 10.1016/S1043-6618(03)00081-1; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sattler R, 2001, MOL NEUROBIOL, V24, P107, DOI 10.1385/MN:24:1-3:107; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Teichberg VI, 2009, NEUROSCIENCE, V158, P301, DOI 10.1016/j.neuroscience.2008.02.075; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; VELICK SF, 1962, J BIOL CHEM, V237, P2109; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang H, 2001, CLIN CHEM, V47, P1458; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021	36	52	53	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2009	21	3					235	241		10.1097/ANA.0b013e3181a2bf0b			7	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	464KF	WOS:000267503100009	19543002				2021-06-18	
J	Yang, H; Cheng, XP; Li, JW; Yao, Q; Ju, G				Yang, Hao; Cheng, Xi-Ping; Li, Jing-Wen; Yao, Qin; Ju, Gong			De-differentiation Response of Cultured Astrocytes to Injury Induced by Scratch or Conditioned Culture Medium of Scratch-Insulted Astrocytes	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Astrocyte; De-differentiation; Rat; Nestin; GFAP	NEURAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; RAT SPINAL-CORD; RADIAL-GLIA; NERVOUS-SYSTEM; SUBVENTRICULAR ZONE; REACTIVE ASTROCYTES; PROGENITOR CELLS; MULLER CELLS	Our previous reports indicated that astrocytes (ASTs) in injured adult rat spinal cord underwent a process of de-differentiation, and may acquire the potential of neural stem cells (NSCs). However, the AST de-differentiation and transitional rejuvenation process following injury is still largely unclear. The aim of the present study was to determine whether injured in vitro ASTs can re-enter the multipotential-like stem cell pool and regain NSC characteristics, and to further understand the mechanism of AST de-differentiation. We used an in vitro scratch-wound model to evoke astrocytic response to mechanical injury. GFAP and nestin double-labeled indirect immunofluorescence were carried out to characterize these scratched cells at various periods. Western-blot analysis was used to determine the changes of GFAP and nestin expression following injury. Furthermore, the rate of proliferation was determined by immunocytochemical detection of BrdU incorporating cells. These scratch-wound ASTs were cultured with stem cells medium to explore their ability to generate neurospheres and examine the self-renewal and multi-potency of such neurospheres. Moreover, scratched AST culture supernatant as conditioned cultured medium (ACM) was used to investigate if some diffusible factors derived from injured ASTs could induce de-differentiation of AST. The results showed: (1) the nestin positivity first appeared in GFAP-positive cells at the edge of the scratch, subsequently, disseminated into un-insulted zone. The expression of nestin in AST was increased with longer culture, while that of GFAP was decreased. Furthermore, these nestin-immunoreactive ASTs could generate neurospheres, which showed self-renewal and could be differentiated into neurons, ASTs and oligodendrocytes. (2) Scratched ASTs culture supernatant can induce astrocytic proliferation and de-differentiation. These results reveal that the in vitro injured ASTs can de-differentiate into nestin-positive stem/precursor cells, the process of de-differentiation may arise from direct injury or some diffusible factors released from injured ASTs.	[Yang, Hao; Cheng, Xi-Ping; Li, Jing-Wen; Yao, Qin; Ju, Gong] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi, Peoples R China	Ju, G (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi, Peoples R China.	jugong@fmmu.edu.cn			National Basic Research Program of ChinaNational Basic Research Program of China [2003CB515301]; Chinese PLA national scientific technological project [06G089]	We thank Dr. Gautam Hebbar and Dr. Zhe Liang from Emory University for critical reading of the manuscript. This work was supported by the National Basic Research Program of China (2003CB515301) and Chinese PLA national scientific technological project (06G089).	AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Bonfanti L, 2007, PROG NEUROBIOL, V83, P24, DOI 10.1016/j.pneurobio.2006.11.002; Bottai D, 2003, J HEMATOTH STEM CELL, V12, P655, DOI 10.1089/15258160360732687; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; ChalmersRedman RME, 1997, NEUROSCIENCE, V76, P1121, DOI 10.1016/S0306-4522(96)00386-7; Chang ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x; Chen J, 2005, EUR J NEUROSCI, V22, P1895, DOI 10.1111/j.1460-9568.2005.04348.x; Diez del Corral R, 2003, NEURON, V40, P65; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fischer AJ, 2002, J NEUROSCI, V22, P9387; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Hung CH, 2006, BIOMATERIALS, V27, P5901, DOI 10.1016/j.biomaterials.2006.08.009; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kohno H, 2006, GRAEF ARCH CLIN EXP, V244, P90, DOI 10.1007/s00417-005-0030-7; Lang B, 2004, NEUROSCIENCE, V128, P775, DOI 10.1016/j.neuroscience.2004.06.033; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; Lee J, 2003, DEV BIOL, V253, P84, DOI 10.1006/dbio.2002.0868; Lepore AC, 2006, NEUROSCIENCE, V142, P285, DOI 10.1016/j.neuroscience.2005.12.068; Liu Y, 2004, BIOL CELL, V96, P279, DOI 10.1016/j.biolcel.2004.02.001; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Monnin J, 2007, NEUROSCI LETT, V421, P22, DOI 10.1016/j.neulet.2007.04.073; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006; Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101; PHIFER CB, 1986, PHYSIOL BEHAV, V38, P887, DOI 10.1016/0031-9384(86)90058-2; Pillai R, 2006, EXP CELL RES, V312, P2336, DOI 10.1016/j.yexcr.2006.03.031; Rao MS, 1999, ANAT RECORD, V257, P137; Raymond PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-36; Rowitch DH, 2002, TRENDS NEUROSCI, V25, P417, DOI 10.1016/S0166-2236(02)02201-4; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Schmid RS, 2003, P NATL ACAD SCI USA, V100, P4251, DOI 10.1073/pnas.0630496100; Sergent-Tanguy S, 2003, J NEUROSCI METH, V129, P73, DOI 10.1016/S0165-0270(03)00210-3; Sergent-Tanguy S, 2006, J NEUROSCI RES, V83, P1515, DOI 10.1002/jnr.20846; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Steindler DA, 2003, GLIA, V43, P62, DOI 10.1002/glia.10242; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Timiras PS, 2005, MECH AGEING DEV, V126, P3, DOI 10.1016/j.mad.2004.09.020; Yang H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4; Yu T, 2006, J CELL BIOCHEM, V99, P1096, DOI 10.1002/jcb.20979; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	53	52	54	0	12	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUN	2009	29	4					455	473		10.1007/s10571-008-9337-3			19	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	457IH	WOS:000266921200005	19130217				2021-06-18	
J	Makley, MJ; Johnson-Greene, L; Tarwater, PM; Kreuz, AJ; Spiro, J; Rao, V; Celnik, PA				Makley, Michael J.; Johnson-Greene, Lisa; Tarwater, Patrick M.; Kreuz, Andrew J.; Spiro, J.; Rao, V.; Celnik, Pablo A.			Return of Memory and Sleep Efficiency Following Moderate to Severe Closed Head Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Memory; Sleep disturbance; Brain injury; Rehabilitation	EXCESSIVE DAYTIME SLEEPINESS; POSTTRAUMATIC NARCOLEPSY; GALVESTON ORIENTATION; RATING-SCALE; AMNESIA; DISTURBANCE; IMPAIRMENT; COGNITION; CHILDREN; LIFE	Objective. Sleep disturbance is common in the subacute recovery phase following brain injury. A previous study from the authors' group found 68% of patients with closed head injury (CHI) had disrupted sleep on a rehabilitation unit. In the present study, the authors investigated whether improvement in sleep efficiency correlates with duration of posttraumatic amnesia (PTA) after CHI. Methods. Fourteen CHI patients were enrolled and followed prospectively. Mechanism of injury included motor vehicle accident, fall, and blunt assault. An actigraph was placed on each subject's wrist within 72 hours of admission to the rehabilitation unit and recorded data for the duration of their stay. A minimum of 7 days of continuous actigraphy data was obtained on all subjects. PTA was measured daily using the Orientation Log (O-LOG). Results. Seventy-eight percent of subjects had mean week-1 sleep efficiency scores of <= 63%. Patients admitted having already cleared PTA had significantly better week-1 sleep efficiency scores than those with ongoing amnesia (P=.032). For those patients admitted with ongoing PTA, each 10-unit increase in sleep efficiency score correlated with 1 unit increase in O-LOG score (P=.056). Conclusions. Disrupted sleep is common in the postacute stage following CHI. Improved sleep efficiency correlates with resolution of PTA. Decreased sleep efficiency may negatively affect memory return after traumatic brain injury. Actigraphy is uniquely suited to study the sleep patterns of these patients.	[Makley, Michael J.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Johnson-Greene, Lisa] Kernan Hosp, Dept Neuropsychol, Baltimore, MD USA; [Tarwater, Patrick M.] Texas Tech Univ, Hlth Sci Ctr, Div Biostat & Epidemiol, Paul L Foster Sch Med, El Paso, TX USA; [Kreuz, Andrew J.] Stevenson Univ, Dept Biol, Stevenson, MD USA; [Spiro, J.; Rao, V.] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD USA; [Celnik, Pablo A.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Dept Neurol, Baltimore, MD USA	Makley, MJ (corresponding author), Univ Maryland, Kernan Hosp, Brain Injury Unit, 2200 Kernan Dr, Baltimore, MD 21207 USA.	mmakley@kernan.umm.edu					Ahmed S, 2000, BRAIN INJURY, V14, P765; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Borak J, 1996, J SLEEP RES, V5, P123, DOI 10.1046/j.1365-2869.1996.d01-60.x; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cohen SD, 2007, CLIN J AM SOC NEPHRO, V2, P919, DOI 10.2215/CJN.00820207; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Drubach DA, 1994, J NEUROL REHABIL, V8, P92; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; DUYCKAERTS C, 1985, ANN NEUROL, V18, P314, DOI 10.1002/ana.410180307; Feeney DM, 1997, ADV NEUROL, V73, P383; Feuerstein C, 1997, ACTA NEUROL BELG, V97, P96; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; Franck LS, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e62; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; GORNY S, 1997, ANN M ASS PROF SLEEP; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Moore BE, 1944, NEW ENGL J MED, V230, P445, DOI 10.1056/NEJM194404132301501; NAEGELE B, 1995, SLEEP, V18, P43; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ohayon MM, 2004, SLEEP, V27, P1255, DOI 10.1093/sleep/27.7.1255; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RempelClower NL, 1996, J NEUROSCI, V16, P5233; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; ROWLAND LP, 1989, MERRITTS TXB NEUROLO, P904; SADEH A, 1991, PEDIATRICS, V87, P494; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SERIES F, 1994, AM J RESP CRIT CARE, V150, P481, DOI 10.1164/ajrccm.150.2.8049833; Singer C, 2003, SLEEP, V26, P893, DOI 10.1093/sleep/26.7.893; Spira AP, 2008, J AM GERIATR SOC, V56, P45, DOI 10.1111/j.1532-5415.2007.01506.x; Stepanski EJ, 2002, SLEEP, V25, P268, DOI 10.1093/sleep/25.3.268; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; TEASDALE G, 1974, LANCET, V2, P81; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Wei JL, 2007, ARCH OTOLARYNGOL, V133, P974, DOI 10.1001/archotol.133.10.974; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	52	53	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2009	23	4					320	326		10.1177/1545968308325268			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	428UJ	WOS:000264876100002	19171947				2021-06-18	
J	Bee, TK; Magnotti, LJ; Croce, MA; Maish, GO; Minard, G; Schroeppel, TJ; Zarzaur, BL; Fabian, TC				Bee, Tiffany K.; Magnotti, Louis J.; Croce, Martin A.; Maish, George O.; Minard, Gayle; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.			Necessity of Repeat Head CT and ICU Monitoring in Patients With Minimal Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Minimal brain injury; Repeat head CT; Traumatic head injury; Brain trauma; Intensive care monitoring; Traumatic brain injury	COMPUTED-TOMOGRAPHY; EXTRADURAL HEMATOMA; MANAGEMENT; ADMISSION; UTILITY	Background: Recent publications have dismissed the need for routine repeat computed tomography (CT) scans in patients with minimal brain injury (MBI) (Glasgow Coma Scale score 13-15 with positive initial CT) unless physical examination changes. In an attempt to better allocate scarce resources, we hypothesized that not only was repeat head CT unnecessary but also routine intensive care unit (ICU) monitoring of these patients with MBI and stable examinations were unnecessary. Methods: All blunt injured patients admitted to a level I trauma center from January 2005 through December 2007 who met our criteria for MBI (Glasgow Coma Scale score 14-15 with positive initial CT) were reviewed. All patients had ICU monitoring and repeat CT done (at 12-24 hours) regardless of clinical examination. Patients with skull fractures, facial fractures needing urgent repair, those requiring immediate neurosurgical intervention and those with other injuries requiring ICU monitoring were excluded. Data including demographics, initial brain injury, follow-up CT scan results, changes in clinical examination, neurosurgical interventions, and ICU days were recorded. Results: Two hundred seven patients met criteria. Fifty-eight patients (28%) developed worsening findings on follow-up CT or examination. Eighteen required invasive neurosurgicai intervention (6 intracranial pressure [ICP] monitors, 12 craniotomies) and I died (stroke). Those requiring ICP monitors had worsening intracranial hemorrhages (IPHs) with clinical examination changes or examination changes only, whereas those requiring craniotomy had worsening subaralmoid hemorrhage (2 patient), epidural hematoma (1 patient), and subdural hematoma (8 patients). Five of the subdural hematoma patients remained asymptomatic before craniotomy. ICU days were significantly increased in those patients with worsening CT findings who did not require neurosurgical intervention compared with those patients with unchanged or improved CT scans (5 days vs. 2.7 days, p <= 0002). Conclusions Routine follow-up CT scans are beneficial in those patients with MBI and may lead to higher levels of medical management or neurosurgical intervention in patients with worsening CT findings. These patients should be kept in an ICU setting until head CT has stabilized. With these dissimilar results from previous studies, a prospectively randomized multicentered trial would be beneficial.	[Bee, Tiffany K.; Magnotti, Louis J.; Croce, Martin A.; Maish, George O.; Minard, Gayle; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.] Univ Tennessee, Dept Gen Surg, Crit Care Trauma Div, Memphis, TN 38163 USA	Bee, TK (corresponding author), Univ Tennessee, Dept Gen Surg, Crit Care Trauma Div, Memphis, TN 38163 USA.	tbee@utmem.edu	Zarzaur, Ben/S-6572-2019				BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; KRAUPS KL, 2004, J TRAUMA, V56, P475; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d	11	52	52	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2009	66	4					1015	1018		10.1097/TA.0b013e31819adbc8			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	431KI	WOS:000265059800013	19359908				2021-06-18	
J	Kanno, H; Ozawa, H; Sekiguchi, A; Itoi, E				Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Itoi, Eiji			The role of autophagy in spinal cord injury	AUTOPHAGY			English	Article						autophagy; spinal cord injury; Beclin 1; apoptosis; autophagic cell death	PROGRAMMED CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; UP-REGULATION; APOPTOSIS; BECLIN-1; RAPAMYCIN; PROTEINS; MICE; NEURODEGENERATION	Previous studies have indicated that autophagy has an important function, not only in many neurodegenerative diseases, but also in traumatic and ischemic brain injury. However, no study has previously shown the contribution of autophagy to neural tissue damage after spinal cord injury. We recently investigated the alterations in Beclin 1 expression and the involvement of autophagy and autophagic cell death after spinal cord injury using a spinal cord hemisection model in mice. The results showed that the expression of Beclin 1 dramatically increased in the damaged neural tissue and induced autophagic cell death after a spinal cord injury. These observations suggested that the increased expression of Beclin 1 activates autophagy, while mediating a novel cell death mechanism at the lesion site in response to spinal cord injury. Here we discuss several unsolved issues and review the evidence in related articles regarding the role of autophagy and its contribution to the mechanism of cell death in spinal cord injury.	[Kanno, Haruo] Nishitaga Natl Hosp, Dept Orthopaed Surg, Sendai, Miyagi, Japan; [Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Itoi, Eiji] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Sendai, Miyagi 9808574, Japan	Kanno, H (corresponding author), Tohoku Univ, Sch Med, Dept Orthoped Surg, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.	kanno-h@isis.ocn.ne.jp	Kanno, Haruo/AAA-2187-2020	Kanno, Haruo/0000-0003-1985-2257	Health Labour Sciences Research [19591712]; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Japan Orthopaedics and Traumatology Foundation, Inc. [0138]; The General Insurance Association of Japan	This work was supported by a Health Labour Sciences Research Grant, by a Grant-in-Aid for Scientific Research (19591712) from the Japan Society for the Promotion of Science, by the Japan Orthopaedics and Traumatology Foundation, Inc., (No. 0138), and by a Grant in 2007 from The General Insurance Association of Japan.	Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Matsui Y, 2008, AUTOPHAGY, V4, P409, DOI 10.4161/auto.5638; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Suzuki C, 2008, BIOCHEM BIOPH RES CO, V368, P100, DOI 10.1016/j.bbrc.2008.01.059; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	39	52	56	0	5	LANDES BIOSCIENCE	AUSTIN	1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA	1554-8627			AUTOPHAGY	Autophagy	APR 1	2009	5	3					390	392		10.4161/auto.5.3.7724			3	Cell Biology	Cell Biology	439KP	WOS:000265626300017	19158496	Bronze			2021-06-18	
J	Hopkins, RO; Jackson, JC				Hopkins, Ramona O.; Jackson, James C.			Short- and Long-Term Cognitive Outcomes in Intensive Care Unit Survivors	CLINICS IN CHEST MEDICINE			English	Article						Cognitive impairments; Critical illness; Critical care outcomes	QUALITY-OF-LIFE; MECHANICALLY VENTILATED PATIENTS; PREDICT FUNCTIONAL DECLINES; EXECUTIVE FUNCTION; INFORMANT QUESTIONNAIRE; MEDICATION ADHERENCE; CLINICAL PREDICTORS; ELDERLY-PATIENTS; OLDER-ADULTS; RISK-FACTORS	Evidence increasingly suggests that cognitive impairment is common in intensive care unit survivors, although the nature, severity, and natural history remain unclear. Although the cognitive impairments improve over time in some individuals, they often fail to completely abate. While the functional correlates of these impairments are under-studied, cognitive impairments may adversely impact quality of life, ability to return to work or to work at previously established levels, and ability to function effectively in emotional and interpersonal domains. The potential etiologies of cognitive impairments in intensive care unit survivors are not fully understood and are likely heterogeneous and vary widely across patients. The contributions of these many factors may be particularly significant in patients with pre-existing vulnerabilities for the development of cognitive impairments, such as mild cognitive impairment, dementia, prior traumatic brain injury, or other comorbid disorders, as well as predisposing genetic factors.	[Hopkins, Ramona O.] Intermt Med Ctr, Murray, UT 84107 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] LIDS Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT USA; [Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA; [Jackson, James C.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37212 USA	Hopkins, RO (corresponding author), Intermt Med Ctr, 5121 S Cottonwood St, Murray, UT 84107 USA.	ramona.hopkins@imail.org					Allen SC, 2003, AGE AGEING, V32, P299, DOI 10.1093/ageing/32.3.299; ALSAIDI F, 2003, AM J RESP CRIT CARE, V167, pA737; [Anonymous], 1988, LANCET, V2, P349; Biederman J, 2006, AM J PSYCHIAT, V163, P1730, DOI 10.1176/appi.ajp.163.10.1730; Boyle PA, 2004, CLIN NEUROPSYCHOL, V18, P75, DOI 10.1080/13854040490507172; Boyle PA, 2002, INT J GERIATR PSYCH, V17, P164, DOI 10.1002/gps.539; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; BRODY MP, 1969, GERONTOLOGIST, V9, P179; Burton CL, 2006, CLIN NEUROPSYCHOL, V20, P432, DOI 10.1080/13854040590967063; Cahn-Weiner Deborah A, 2002, Appl Neuropsychol, V9, P187, DOI 10.1207/S15324826AN0903_8; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Christie JD, 2006, J CRIT CARE, V21, P125, DOI 10.1016/j.jcrc.2005.11.004; Dolan MM, 2000, J GERONTOL A-BIOL, V55, pM527, DOI 10.1093/gerona/55.9.M527; Eikelenboom P, 1999, DEMENT GERIATR COGN, V10, P319, DOI 10.1159/000017162; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Evans JD, 2004, SCHIZOPHR RES, V70, P331, DOI 10.1016/j.schres.2004.01.011; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Galanakis P, 2001, INT J GERIATR PSYCH, V16, P349, DOI 10.1002/gps.327; Galvin JE, 2006, NEUROLOGY, V67, P1942, DOI 10.1212/01.wnl.0000247042.15547.eb; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; Griffiths RD, 2007, CURR OPIN CRIT CARE, V13, P508, DOI 10.1097/MCC.0b013e3282efae05; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; Hinkin CH, 2002, NEUROLOGY, V59, P1944, DOI 10.1212/01.WNL.0000038347.48137.67; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; HOPKINS RO, 2005, INT NEUR LOG SOC M S; Hopkins RO, 2005, P AM THORAC SOC, V2, pA36; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Insel K, 2006, J GERONTOL B-PSYCHOL, V61, pP102, DOI 10.1093/geronb/61.2.P102; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, ARCH CLIN NEUROPSYCH, V18, P688; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2006, INTENS CARE MED, V32, P923, DOI 10.1007/s00134-006-0112-y; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; KOPONEN H, 1989, ACTA PSYCHIAT SCAND, V79, P579, DOI 10.1111/j.1600-0447.1989.tb10306.x; KOPONEN H, 1989, J NERV MENT DIS, V177, P226, DOI 10.1097/00005053-198904000-00006; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee TA, 2005, J ALZHEIMERS DIS, V7, P319; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; MATA GV, 1992, CRIT CARE MED, V20, P1257, DOI 10.1097/00003246-199209000-00012; McCusker J, 2001, CAN MED ASSOC J, V165, P575; McGurk SR, 2006, ADM POLICY MENT HLTH, V33, P598, DOI 10.1007/s10488-006-0070-2; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; NYGARD L, 2003, ACTA NEUROL SCAND, V179, P542; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Rahkonen T, 2001, INT J GERIATR PSYCH, V16, P415, DOI 10.1002/gps.356; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Rockwood K, 1999, AGE AGEING, V28, P551, DOI 10.1093/ageing/28.6.551; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Royall DR, 2000, J GERONTOL A-BIOL, V55, pM541, DOI 10.1093/gerona/55.9.M541; Royall DR, 1998, J AM GERIATR SOC, V46, P1519, DOI 10.1111/j.1532-5415.1998.tb01536.x; Shephard R J, 2001, J Cardiopulm Rehabil, V21, P189, DOI 10.1097/00008483-200107000-00001; Spinella M, 2004, INT J NEUROSCI, V114, P1323, DOI 10.1080/00207450490476011; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; SUCHYTA MR, 2005, P AM THORAC SOC, V2, pA46; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teunissen CE, 2003, J NEUROIMMUNOL, V134, P142, DOI 10.1016/S0165-5728(02)00398-3; Udekwu P, 2001, J AM COLL SURGEONS, V193, P245, DOI 10.1016/S1072-7515(01)00994-2; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Van Wielingen LE, 2004, AGING MENT HEALTH, V8, P374, DOI 10.1080/13607860410001709728; VANDIXHOORN J, 1989, AM HEART J, V118, P545, DOI 10.1016/0002-8703(89)90271-8; Wadley VG, 2007, J AM GERIATR SOC, V55, P1192, DOI 10.1111/j.1532-5415.2007.01245.x; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7	80	52	54	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0272-5231	1557-8216		CLIN CHEST MED	Clin. Chest Med.	MAR	2009	30	1					143	+		10.1016/j.ccm.2008.11.001			12	Respiratory System	Respiratory System	413MH	WOS:000263796700010	19186286				2021-06-18	
J	Xiong, YQ; Hall, ED				Xiong, Yiqin; Hall, Edward D.			Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Tempol; Peroxynitrite; Spinal cord injury; Oxidative damage; Protein nitration; Lipid peroxidation; Mitochondrial dysfunction; Cytoskeletal breakdown	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; NERVOUS-SYSTEM TRAUMA; NITRIC-OXIDE; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; NITROXIDE RADICALS; DEPENDENT TOXICITY; CYTOTOXIC PATHWAY; MOUSE MODEL	Evidence suggests that the reactive oxygen species peroxynitrite (PN) is an important player in the pathophysiology of acute spinal cord injury (SCI). In the present study. we examined the ability of tempol, a catalytic scavenger of PN-derived free radicals, to alleviate oxidative damage, mitochondrial dysfunction and cytoskeletal degradation following a severe contusion (200 kdyn force) SCI in female Sprague-Dawley rats. PN-mediated oxidative damage in spinal cord tissue, including protein nitration, protein oxidation and lipid peroxidation was significantly reduced by acute tempol treatment (300 mg/kg, i.p. within 5 min post-injury). Injury-induced mitochondrial respiratory dysfunction, measured after 24 h in isolated mitochondria, was partially reversed by tempol along with an attenuation of oxidative damage to mitochondrial proteins. Mitochondrial dysfunction disrupts intracellular Ca(2+) homeostasis contributing to calpain-mediated axonal cytoskeletal protein (alpha-spectrin, 280 kD) degradation. Increased levels of alpha-spectrin breakdown proteins (SBDP 145 kD and 150 kD) were significantly decreased at 24 h in tempol-treated rats indicative of spinal axonal protection, However, a therapeutic window analysis showed that the axonal cytoskeletal protective effects require tempol dosing within the first hour after injury. Nevertheless, these findings are the first to support the concept that PN is an important neuroprotective target in early secondary SCI, and that there is a mechanistic link between PN-mediated oxidative compromise of spinal cord mitochondrial function, loss of intracellular Ca(2+) homeostasis and calpain-mediated proteolytic axonal damage. (C) 2008 Elsevier Inc. All rights reserved.	[Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Xiong, Yiqin/H-1710-2012; Hall, Edward D/F-8930-2013		Kentucky Spinal Cord and Head Injury Research Trust; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	This study was supported by a grant from the Kentucky Spinal Cord and Head Injury Research Trust and by NIH 1P30 NS051220.	Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Alvarez MN, 2002, METHOD ENZYMOL, V359, P353; Banik NL, 2000, METH MOL B, V144, P195; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crow JP, 1996, ADV EXP MED BIOL, V387, P147; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kruman I, 1997, J NEUROSCI, V17, P5089; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; MIURA Y, 1993, ARCH BIOCHEM BIOPHYS, V300, P148, DOI 10.1006/abbi.1993.1021; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Stewart VC, 2002, EUR J NEUROSCI, V15, P458, DOI 10.1046/j.0953-816x.2001.01878.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Valdez LB, 2000, FREE RADICAL BIO MED, V29, P349, DOI 10.1016/S0891-5849(00)00301-4; Vicente S, 2006, J NEUROSCI RES, V84, P78, DOI 10.1002/jnr.20853; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Zeltcer G, 1997, FREE RADICAL RES, V27, P627, DOI 10.3109/10715769709097866; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341	54	52	56	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					105	114		10.1016/j.expneurol.2008.11.025			10	Neurosciences	Neurosciences & Neurology	413UK	WOS:000263817800013	19111721	Green Accepted			2021-06-18	
J	Frechede, B; McIntosh, AS				Frechede, Bertrand; McIntosh, Andrew S.			Numerical Reconstruction of Real-Life Concussive Football Impacts	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD; RIGID BODY; MODEL; CONCUSSION; INJURY; TOLERANCE	RISK COMPENSATION; HEAD IMPACTS; INJURY; BIOMECHANICS; SPORT; SIDE	FRECHEDE, B., and A. S. MCINTOSH. Numerical Reconstruction of Real-Life Concussive Football Impacts. Med. Sci. Sports Exerc., Vol. 41, No. 2, pp. 390-398, 2009. Purpose: To present a protocol of numerical reconstructions of concussive events in football using MADYMO. To refine the knowledge of the dynamics associated with these events. Methods: Twenty-seven cases of concussive head impacts involving unhelmeted Australian football and rugby players were simulated Using MADYMO. The cases had been previously analyzed using a video analysis protocol and were fully reconstructed for the purpose of this study. The reliability of these reconstructions had been previously assessed using a sensitivity analysis of the influence of several independent variables on the dynamical outputs. The use of a complete human model enabled consideration for morphometry, initial movements of the players, and an accurate estimate of the effective masses involved in the impacts. Results: Mean peak values for concussion were found to be 103g for the head center of gravity linear acceleration, 8022 rad.s(-2) for the head angular acceleration, and 359 for the head impact criterion. An estimate of the average effective energy transferred to the head was 47 J. With the severity grading used in this study, the head impact power was found to be the best predictor of concussion severity. Conclusions: These biomechanical results compare well with other studies. They should contribute to the identification of the energy levels at which concussive impacts occur in football for the purpose of a better evaluation of protective devices in these sports.	[Frechede, Bertrand; McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia	Frechede, B (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	b.frechede@unsw.edu.au	FRECHEDE, Bertrand/H-3091-2018	FRECHEDE, Bertrand/0000-0002-9292-3544			ABEL J, 1978, P 22 STAPP CAR CRASH, V33; BAUMGARTNER D, 2001, P 2001 INT IRCOBI C, P353; BEUSENBERG M, 2001, P 2001 IRCOBI C BIOM, P295; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Cheng HM, 1996, PROCEEDINGS OF THE 1996 FIFTEENTH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE, P251, DOI 10.1109/SBEC.1996.493162; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; FRECHEDE B, 2007, P 21 ESV C 2007 JUN, P1; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Gilchrist A, 1996, ACCIDENT ANAL PREV, V28, P525, DOI 10.1016/0001-4575(96)00030-9; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hodgson V.R., 1969, P 13 STAPP CAR CRASH, P18; King A.I., 2003, IRCOBI C LISB PORT, P1; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; MILLER RT, 1998, P 42 STAPP CAR CRASH, P155; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; NEWMAN JA, 2000, P INT RES C BIOM IMP, P223; NEWMAN JA, 2000, STAPP CAR CRASH J, V44, P362; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; ONO K, 1980, P 24 STAPP CAR CRASH, P379; ONO K, 2002, P IRCOBI C 2002 SEP, P235; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Ruan J. S., 1993, P 37 STAPP CAR CRASH, P69, DOI DOI 10.4271/933114; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; *TNO, 2005, MADYMO HUM MOD MAN V, P219; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; ZHANG L, 2003, P IRCOBI C 2003 SEP, P27; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	40	52	52	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2009	41	2					390	398		10.1249/MSS.0b013e318186b1c5			9	Sport Sciences	Sport Sciences	396OO	WOS:000262601200018	19127185				2021-06-18	
J	Itoh, T; Satou, T; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Hiroyuki			Expression of amyloid precursor protein after rat traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Amyloid precursor protein; traumatic brain injury; Alzheimer's disease; dystrophic neurites; APP overexpression	ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROFIBRILLARY TANGLES; LEVELS DECREASE; HIPPOCAMPUS; DEPOSITION; IMMUNOREACTIVITY; PROLIFERATION; NEURONS; CELLS	Objective: Previous reports have demonstrated that some focal brain injuries increase amyloid precursor protein (APP) immunoreactivity in the region surrounding the injury in the cerebral cortex. However, the chronologic changes in APP expression have not been evaluated after traumatic brain injury (TBI). Methods: In this study, we immunohistochemically and biologically investigated chronologic changes in cellular sources and levels of APP production after rat TBI. Results: In the present report, we show that traumatic brain injury increased the expression of APP in the neuronal perikarya and in damaged dystrophic neurites from 1 to 90 days after injury. Moreover, 7 days after injury, some macrophages/microglia also were co-localized with APP, which was overproduced by the neuronal perikarya and APP-positive dystrophic neurites after injury and then APP were phagocytosed by macrophages/microglia during this phase. However, astroglia did not express APP immunopositivity after brain injury. Discussion: These results suggested that long-term overexpression of APP was confirmed by immunohistochemical and biologic technique after TBI. This may be related to the induction of Alzheimer type dementia and it is a very important risk factor for this disease. [Neurol Res 2009; 31: 103-109]	[Itoh, Tatsuki; Satou, Takao; Ito, Hiroyuki] Kinki Univ, Dept Pathol, Sch Med, Osakasayama City, Osaka 5898511, Japan; [Satou, Takao] Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Inst Life Sci, Div Sports Med, Osakasayama City, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osakasayama City, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Dept Pathol, Osaka, Japan	Itoh, T (corresponding author), Kinki Univ, Dept Pathol, Sch Med, 377-2 Ohnohigashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20500472] Funding Source: KAKEN		Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Itoh T, 2005, NEUROL RES, V27, P429, DOI 10.1179/016164105X18476; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1988, LANCET, V2, P1456; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Xie YY, 2003, J NEUROSCI RES, V73, P557, DOI 10.1002/jnr.10667; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	30	52	54	0	4	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	FEB	2009	31	1					103	109		10.1179/016164108X323771			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	415BA	WOS:000263908100014	19228461				2021-06-18	
J	Bergquist, T; Gehl, C; Mandrekar, J; Lepore, S; Hanna, S; Osten, A; Beaulieu, W				Bergquist, Thomas; Gehl, Carissa; Mandrekar, Jay; Lepore, Susan; Hanna, Sherrie; Osten, Angela; Beaulieu, William			The effect of internet-based cognitive rehabilitation in persons with memory impairments after severe traumatic brain injury	BRAIN INJURY			English	Article						Cognitive rehabilitation; telemedicine	SELF-AWARENESS; TELEREHABILITATION; TELETHERAPY; OUTCOMES	Primary objective: The current study examined whether cognitive rehabilitation delivered over the Internet was associated with improvements in functioning. Research design: A total of 14 individuals with medically documented traumatic brain injury completed this study. Participants completed 30 sessions of an active calendar acquisition intervention and 30 sessions of a control diary intervention in a cross-over study design for a total of 60 online sessions. All sessions were completed using an instant messaging system via the Internet. Measures of cognitive functioning, ratings of memory and mood and frequency of use of common memory and cognitive compensation techniques were gathered from participants and family members. Main outcomes and results: There were no significant differences between the active and control conditions on the primary outcome measure of memory functioning. However, significant improvements in use of compensatory strategies as well as family reports of improved memory and mood were observed following completion of all sessions. Individuals with less use of compensatory strategies at baseline were significantly less likely to complete the study. Conclusions: These results suggest that the Internet may be an effective delivering mechanism for compensatory cognitive rehabilitation, particularly among individuals who are already utilizing some basic compensatory strategies.	[Bergquist, Thomas; Gehl, Carissa; Mandrekar, Jay; Lepore, Susan; Hanna, Sherrie; Osten, Angela; Beaulieu, William] Mayo Clin, Coll Med, Rochester, MN 55905 USA	Bergquist, T (corresponding author), Mayo Clin, Coll Med, Rochester, MN 55905 USA.	bergquist.thomas@mayo.edu			National Institute for Disability and Rehabilitation Research (NIDRR)	This research was supported by a TBI Model System grant from the National Institute for Disability and Rehabilitation Research (NIDRR).	Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Day J. C., 2005, COMPUTER INTERNET US; Diamond BJ, 2003, NEUROREHABILITATION, V18, P171; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Kupachi A., 2002, LONG TERM USE COMPEN; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Man DWK, 2006, BRAIN INJURY, V20, P959, DOI 10.1080/02699050600909789; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Randolph C., 1998, RBANS MANUAL REPEATA; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schoenberg MR, 2008, PROF PSYCHOL-RES PR, V39, P169, DOI 10.1037/0735-7028.39.2.169; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Wade SL, 2005, REHABIL PSYCHOL, V50, P323, DOI 10.1037/0090-5550.50.4.323; WILKINSON RT, 1993, WIDE RANGE ACHIEVEME; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	22	52	52	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	10					790	799	PII 914076410	10.1080/02699050903196688			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	485SP	WOS:000269144600002	19697167				2021-06-18	
J	Maggiore, U; Picetti, E; Antonucci, E; Parenti, E; Regolisti, G; Mergoni, M; Vezzani, A; Cabassi, A; Fiaccadori, E				Maggiore, Umberto; Picetti, Edoardo; Antonucci, Elio; Parenti, Elisabetta; Regolisti, Giuseppe; Mergoni, Mario; Vezzani, Antonella; Cabassi, Aderville; Fiaccadori, Enrico			The relation between the incidence of hypernatremia and mortality in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							POSTTRAUMATIC INTRACRANIAL HYPERTENSION; HYPERTONIC SALINE THERAPY; INTENSIVE-CARE-UNIT; MEDICAL COMPLICATIONS; SODIUM-CHLORIDE; CRITICALLY-ILL; SUBARACHNOID HEMORRHAGE; DIABETES-INSIPIDUS; HEAD-INJURY; PRESSURE	Introduction The study was aimed at verifying whether the occurrence of hypernatremia during the intensive care unit (ICU) stay increases the risk of death in patients with severe traumatic brain injury (TBI). We performed a retrospective study on a prospectively collected database including all patients consecutively admitted over a 3-year period with a diagnosis of TBI (post-resuscitation Glasgow Coma Score <= 8) to a general/neurotrauma ICU of a university hospital, providing critical care services in a catchment area of about 1,200,000 inhabitants. Methods Demographic, clinical, and ICU laboratory data were prospectively collected; serum sodium was assessed an average of three times per day. Hypernatremia was defined as two daily values of serum sodium above 145 mmol/l. The major outcome was death in the ICU after 14 days. Cox proportional-hazards regression models were used, with time-dependent variates designed to reflect exposure over time during the ICU stay: hypernatremia, desmopressin acetate (DDAVP) administration as a surrogate marker for the presence of central diabetes insipidus, and urinary output. The same models were adjusted for potential confounding factors. Results We included in the study 130 TBI patients (mean age 52 years (standard deviation 23); males 74%; median Glasgow Coma Score 3 (range 3 to 8); mean Simplified Acute Physiology Score II 50 (standard deviation 15)); all were mechanically ventilated; 35 (26.9%) died within 14 days after ICU admission. Hypernatremia was detected in 51.5% of the patients and in 15.9% of the 1,103 patient-day ICU follow-up. In most instances hypernatremia was mild (mean 150 mmol/l, interquartile range 148 to 152). The occurrence of hypernatremia was highest (P = 0.003) in patients with suspected central diabetes insipidus (25/130, 19.2%), a condition that was associated with increased severity of brain injury and ICU mortality. After adjustment for the baseline risk, the incidence of hypernatremia over the course of the ICU stay was significantly related with increased mortality (hazard ratio 3.00 (95% confidence interval: 1.34 to 6.51; P = 0.003)). However, DDAVP use modified this relation (P = 0.06), hypernatremia providing no additional prognostic information in the instances of suspected central diabetes insipidus. Conclusions Mild hypernatremia is associated with an increased risk of death in patients with severe TBI. In a proportion of the patients the association between hypernatremia and death is accounted for by the presence of central diabetes insipidus.	[Maggiore, Umberto; Antonucci, Elio; Parenti, Elisabetta; Regolisti, Giuseppe; Cabassi, Aderville; Fiaccadori, Enrico] Univ Parma, Dipartimento Clin Med Nefrol & Sci Prevenz, I-43100 Parma, Italy; [Picetti, Edoardo; Mergoni, Mario; Vezzani, Antonella] Univ Parma, Azienda Osped, Serv Anestesia & Rianimaz 1, I-43100 Parma, Italy	Fiaccadori, E (corresponding author), Univ Parma, Dipartimento Clin Med Nefrol & Sci Prevenz, Via Gramsci 14, I-43100 Parma, Italy.	enrico.fiaccadori@unipr.it	Regolisti, Giuseppe/AAH-4766-2021	Regolisti, Giuseppe/0000-0002-9976-5681; Maggiore, Umberto/0000-0002-7468-9600	Italian Ministry of UniversityMinistry of Education, Universities and Research (MIUR) [20074TCLB8]	The authors would like to warmly thank Nino Stocchetti MD for his insightful suggestions, and Luca Longhi MD for comments. Financial support was from the Italian Ministry of University Grant PRIN 20074TCLB8.	Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boughey JC, 2004, AM SURGEON, V70, P500; *BRAIN TRAUM FDN I, 2003, GUID MAN SEV TRAUM B; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; EDWARDS OM, 1986, MEDICINE, V65, P281; Forsyth LL, 2008, PHARMACOTHERAPY, V28, P469, DOI 10.1592/phco.28.4.469; Froelich M, 2008, CRIT CARE MED, V36, P642, DOI 10.1097/CCM.0B013E3181629821; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Guesde R, 1998, LANCET, V352, P1178, DOI 10.1016/S0140-6736(98)05456-7; Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017; Hartl R, 1997, ACT NEUR S, V70, P126; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hoorn EJ, 2008, NEPHROL DIAL TRANSPL, V23, P1562, DOI 10.1093/ndt/gfm831; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hosmer DW, 1999, APPL SURVIVAL ANAL; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kraft MD, 2005, AM J HEALTH-SYST PH, V62, P1663, DOI 10.2146/ajhp040300; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lindner G, 2007, AM J KIDNEY DIS, V50, P952, DOI 10.1053/j.ajkd.2007.08.016; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Muizelaar JP, 2009, CRIT CARE MED, V37, P1521, DOI 10.1097/CCM.0b013e31819d3ea0; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; O'Quigley J, 2005, STAT MED, V24, P479, DOI 10.1002/sim.1946; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Petit L, 2006, ANN FR ANESTH, V25, P828, DOI 10.1016/j.annfar.2006.04.005; Phongsamran Paula V, 2004, Prog Transplant, V14, P105; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 1999, CRIT CARE MED, V27, P1105, DOI 10.1097/00003246-199906000-00029; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Royston P, 2007, STATA J, V7, P376, DOI 10.1177/1536867X0700700305; Royston P, 2006, STATA J, V6, P83, DOI 10.1177/1536867X0600600105; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; Stelfox HT, 2008, CRIT CARE, V12, DOI 10.1186/cc7162; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEASDALE G, 1974, LANCET, V2, P81; Tisdall M, 2006, J NEUROSURG ANESTH, V18, P57, DOI 10.1097/01.ana.0000191280.05170.0f; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Valadka AB, 2000, CRIT CARE MED, V28, P1245, DOI 10.1097/00003246-200004000-00069; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; 2000, J NEUROTRAUMA, V17, P457	60	52	57	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	4							R110	10.1186/cc7953			9	Critical Care Medicine	General & Internal Medicine	525OL	WOS:000272225600007	19583864	DOAJ Gold, Green Published			2021-06-18	
J	Muscara, F; Catroppa, C; Eren, S; Anderson, V				Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki			The impact of injury severity on long-term social outcome following paediatric traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; EARLY-CHILDHOOD; CHILDREN; RECOVERY; BEHAVIOR; FAMILY; ADOLESCENCE; INTEGRATION; COMPETENCE; PREDICTORS	Despite suggestions that paediatric traumatic brain injury (TBI) disrupts social skill development, few studies have investigated long-term social outcome following the transition into adulthood. The current study aimed to investigate long-term social outcome, in a sample of 36 survivors who suffered a mild, moderate or severe TBI between 8 and 12 years of age. At 7-10 years post-injury, the age of participants ranged between 16 and 22 years. Social outcome was assessed using a number of self-rated and parent-rated questionnaires, in order to obtain self-and other-rated accounts of the groups' current social functioning. Predictors of long-term social outcome were also explored, with findings suggesting that young people who suffered mild TBI during childhood tended to be functioning at a higher level on some measures of social functioning, compared to those that suffered a moderate and severe injury. Further, results suggested that pre-injury adaptive functioning and socio-economic status predicted long-term functioning for some measures of social outcome. Finally, social problem-solving skills predicted the success of social reintegration post-TBI. These preliminary findings indicate that there is a risk of social difficulties following paediatric TBI continuing into adulthood, and that a number of demographic, social, and neuropsychological variables continue to predict social outcome even at this late stage post-injury.	[Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia	Muscara, F (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	frank.muscara@mcri.edu.au					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Daniel A. E., 1983, POWER PRIVILEGE PRES; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DZURILLA TJ, 1998, MANUAL SOCIAL PROBLE; Gioia G.A., 2000, BEHAV RATING INVENTO; Gresham F. M., 1990, SOCIAL SKILLS RATING; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Noller P, 1988, ICPS FAMILY FUNCTION; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Sparrow S., 1984, VINELAND ADAPTIVE BE; Tabachnick B., 2001, USING MULTIVARIATE S; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V6, P555; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D, 1991, MANUAL WECHSLER SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	48	52	52	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	4					541	561		10.1080/09602010802365223			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	539EJ	WOS:000273236100003	18839384				2021-06-18	
J	Greenberg, G; Mikulis, DJ; Ng, K; DeSouza, D; Green, RE				Greenberg, Gahl; Mikulis, David J.; Ng, Kevin; DeSouza, Danielle; Green, Robin E.			Use of Diffusion Tensor Imaging to Examine Subacute White Matter Injury Progression in Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Follow-up studies; Magnetic resonance imaging; Rehabilitation	AXONAL INJURY; HEAD-INJURY; FIBER TRACKING; MR; RECOVERY; EXPERIENCE; CONTUSIONS; APOPTOSIS; FEATURES; ATROPHY	Objective: To demonstrate subacute progression of white matter (WM) injury (4.5mo-2.5y postinjury) in patients with traumatic brain injury using diffusion-tensor imaging. Design: Prospective, repeated-measures, within-subjects design. Setting: Inpatient neurorehabilitation program and teaching hospital MRI department. Participants: Brain-injured adults (N=13) with a mean Glasgow Coma Scale score of 7.67 +/- 4.16. Interventions: Not applicable. Main Outcome Measures: :Fractional anisotropy (FA) values were measured at 4.5 and 29 months postinjury in right and left frontal and temporal deep WM tracts and the anterior and posterior corpus callosum. Results: FA significantly decreased in frontal and temporal tracts: right frontal (.38 +/-.06 to.30 +/-.06; P<.005), left frontal (.37 +/-.06 to.32 +/-.06; P<.05), right temporal (.28 +/-.05 to .22 +/-.018; P<.005), and left temporal (.28 +/-.05 to .24 +/-.02; P<.05). No significant changes were in the corpus callosum. Conclusions: Preliminary results demonstrate progression of WM damage as evidenced by interval changes in diffusion anisotropy. Future research should examine the relationship between decreased FA and long-term clinical outcome.	[DeSouza, Danielle; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Mikulis, David J.] Univ Hlth Network, Res Inst, Div Brain Imaging & Behav Syst, Toronto Western Div, Toronto, ON, Canada; [Greenberg, Gahl; Mikulis, David J.; Ng, Kevin] Univ Hlth Network, Dept Med Imaging, Div Neuroradiol, Toronto, ON, Canada; [DeSouza, Danielle; Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	Green, RE (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehah.on.ca	Mikulis, David J/H-5167-2019; DeSouza, Danielle/J-9821-2019	DeSouza, Danielle/0000-0001-6861-5691; Mikulis, David/0000-0003-3956-0892; Green, Robin/0000-0001-9451-3963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Incorporated; Ontario Mental Health Foundation [MOP-67072, 05-50, 2005-ABI-392]	Supported by the Canadian Institutes of Health Research, the Physicians' Services Incorporated, and the Ontario Mental Health Foundation (grant nos. MOP-67072, 05-50, 2005-ABI-392).	ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gean A, 1994, IMAGING HEAD TRAUMA; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MACKENZIE JD, 2002, AM J NEURORADIOL, V23, P1442; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Watts R, 2003, MENT RETARD DEV D R, V9, P168, DOI 10.1002/mrdd.10077; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zhang XP, 2006, J NEUROTRAUM, V23, P1583, DOI 10.1089/neu.2006.23.1583	48	52	53	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S45	S50		10.1016/j.apmr.2008.08.211			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400006	19081441				2021-06-18	
J	Deguise, E; LeBlanc, J; Feyz, M; Meyer, K; Duplantie, J; Thomas, H; Abouassaly, M; Champoux, MC; Couturier, C; Lin, H; Lu, L; Robinson, C; Roger, E				deGuise, Elaine; LeBlanc, Joanne; Feyz, Mitra; Meyer, Kim; Duplantie, Jennifer; Thomas, Harle; Abouassaly, Michel; Champoux, Marie-Claude; Couturier, Celine; Lin, Howell; Lu, Lucy; Robinson, Cathlyn; Roger, Eric			Long-term outcome after severe traumatic brain injury: The McGill Interdisciplinary Prospective Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; functional; multidisciplinary; outcome; physical; psychosocial; traumatic brain injury	SEVERE HEAD-INJURY; FOLLOW-UP; ACUTE PREDICTORS; VARIABLES; SCALE; DISABILITY; MODERATE	Objective: To obtain a comprehensive understanding of long-term outcome after severe traumatic brain injury (sTBI). Participants: Forty-six patients with sTBI. Design: Comparison of interdisciplinary evaluation results at discharge from acute care and at 2 to 5 year follow-up. Main Measures: Extended Glasgow Outcome Scale, the FIM (TM) instrument, and the Neurobehavioral Rating Scale-Revised. Results: Significant improvement was observed on the FIM (TM) instrument, the Extended Glasgow Outcome Scale, and on 3 factors of the Neurobehavioral Rating Scale-Revised. These measures at discharge were significant predictors of outcome. Conclusion: Patients with sTBI 2 to 5 years postinjury showed relatively good physical and functional outcome but poorer cognitive and emotional outcome.	[deGuise, Elaine; LeBlanc, Joanne; Feyz, Mitra; Meyer, Kim; Duplantie, Jennifer; Thomas, Harle; Abouassaly, Michel; Champoux, Marie-Claude; Couturier, Celine; Lin, Howell; Robinson, Cathlyn] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; [Roger, Eric] SUNY Buffalo, Buffalo, NY 14260 USA	LeBlanc, J (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Local D13-124,1650 Ave, Montreal, PQ H3G 1A4, Canada.	joanne.leblanc@mcgill.ca					Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	29	52	54	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2008	23	5					294	303		10.1097/01.HTR.0000336842.53338.f4			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	357GN	WOS:000259834400004	18815506				2021-06-18	
J	Halpern, CH; Reilly, PM; Turtz, AR; Stein, SC				Halpern, Casey H.; Reilly, Patrick M.; Turtz, Alan R.; Stein, Sherman C.			Traumatic coagulopathy: The effect of brain injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	56th Annual Meeting of the Congress-of-Neurological-Surgeons	OCT 07-12, 2006	Chicago, IL	Congress Neurol Surg		disseminated intravascular coagulation; prothrombin time; tissue factor; trauma; traumatic brain injury	DISSEMINATED INTRAVASCULAR COAGULATION; TISSUE FACTOR; HEAD-INJURY; HEMORRHAGE; BARRIER; PATIENT; ABNORMALITIES; DYSFUNCTION; EXPRESSION; DISORDERS	Traumatic coagulopathy has several possible mechanisms. In traumatic brain injury (TBI), the principal process involves the release of tissue factor (TF). There is no agreement how common this mechanism is following general trauma. Furthermore, when TF-induced coagulopathy occurs, it is unknown whether the source of TF (TBI or extracranial trauma) influences the course of coagulopathy. We undertook this investigation to address both questions. The temporal course of prothrombin times (PTs) were recorded in a group (n = 441) with isolated TBI (head Abbreviated Injury Scale [AIS] >= 3, non-head AIS < 3) and a group (n = 101) with extracranial trauma (non-TBI; non-head AIS >= 3; head AIS < 3). Data were arranged according to preset time intervals after injury. The PT values in both groups were elevated and not significantly different for the first 12 h after trauma. Values then fell to normal in TBI patients, but remained elevated in non-TBI injury. Traumatic coagulopathy can be explained at least in part by TF release into the general circulation with activation of the coagulation cascade in both TBI and non-TBI. We hypothesize that the different time courses of coagulopathy represented by PT values in these populations were due to reconstitution of the blood-brain barrier, although further investigation is warranted. Peripheral hematologic studies may not reflect persistent coagulopathy in cerebral circulation.	[Halpern, Casey H.; Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Reilly, Patrick M.] Hosp Univ Penn, Div Trauma & Surg Crit Care, Philadelphia, PA 19104 USA; [Turtz, Alan R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp Univ Med Ctr, Dept Surg Neurosurg, Camden, NJ 08103 USA	Halpern, CH (corresponding author), Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St,3rd Floor,Silverstein Pavil, Philadelphia, PA 19104 USA.	casey.halpern@uphs.upenn.edu					Adelson PD, 1998, ACT NEUR S, V71, P104; Anderson CA, 2002, NURS OUTLOOK, V50, P85, DOI 10.1067/mno.2002.125271; ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Beaumont A, 2002, ACT NEUR S, V81, P217; BREDBACKA S, 1992, J NEUROSURG ANESTH, V4, P128, DOI 10.1097/00008506-199204000-00008; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; CLARK JA, 1980, J NEUROSURG, V52, P266, DOI 10.3171/jns.1980.52.2.0266; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; DeLoughery TG, 2004, CRIT CARE CLIN, V20, P13, DOI 10.1016/S0749-0704(03)00089-7; DRAKE TA, 1989, AM J PATHOL, V134, P1087; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Gando S, 1997, CRIT CARE MED, V25, P1820, DOI 10.1097/00003246-199711000-00019; Gando S, 2006, SEMIN THROMB HEMOST, V32, P48, DOI 10.1055/s-2006-933340; Gando S, 2001, SEMIN THROMB HEMOST, V27, P585, DOI 10.1055/s-2001-18864; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Gando S, 1999, ANN SURG, V229, P121, DOI 10.1097/00000658-199901000-00016; Garrison JR, 1996, J TRAUMA, V40, P923, DOI 10.1097/00005373-199606000-00010; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Ho AMH, 2005, AM J SURG, V190, P479, DOI 10.1016/j.amjsurg.2005.03.034; Holcomb JB, 2005, MIL MED, V170, P287, DOI 10.7205/MILMED.170.4.287; HOOTS WK, 1996, NEUROTRAUMA, P673; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; ORDOG GJ, 1985, ANN EMERG MED, V14, P650, DOI 10.1016/S0196-0644(85)80881-7; Osterud B, 1997, THROMB HAEMOSTASIS, V78, P755; Osterud B, 2001, SEMIN THROMB HEMOST, V27, P605, DOI 10.1055/s-2001-18866; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schreiber MA, 2005, CURR OPIN CRIT CARE, V11, P590, DOI 10.1097/01.ccx.0000186374.49320.ab; Spahn DR, 2005, BRIT J ANAESTH, V95, P130, DOI 10.1093/bja/aei169; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; Utter GH, 2002, J TRAUMA, V52, P1071, DOI 10.1097/00005373-200206000-00008; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357	44	52	64	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					997	1001		10.1089/neu.2008.0548			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700005	18687038				2021-06-18	
J	Theodoros, D; Hill, A; Russell, T; Ward, E; Wootton, R				Theodoros, Deborah; Hill, Anne; Russell, Trevor; Ward, Elizabeth; Wootton, Richard			Assessing acquired language disorders in adults via the internet	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article							TELEREHABILITATION; SPEECH	Aphasia, a language disturbance, frequently occurs following acquired brain impairment in adults. Because management of aphasia is often long-term, provision of ongoing and equitable access to treatment creates a significant challenge to speech-language pathologists (SLPs). This study aimed to determine the validity and reliability of assessing aphasia using standardized language assessments via an Internet-based videoconferencing system using a bandwidth of 128 kbits/sec. Thirty-two participants with aphasia due to stroke or traumatic brain injury were assessed simultaneously in either a face-to-face or online-led environment by two SLPs. Short forms of the Boston Diagnostic Aphasia Examination (BDAE-3) and the Boston Naming Test (BNT, 2nd edition) were administered. An eight-item participant satisfaction questionnaire was completed by 15 participants assigned to the online-led assessment. Results failed to identify any significant differences between the 24 subtest scores of the BDAE-3 and the BNT scores obtained in the online and face-to-face test environments (p > 0.01). Weighted kappa statistics indicated moderate to very good agreement (0.59-1.00) between the two assessors for the 24 subtests and eight rating scales of the BDAE-3, the BNT, and for aphasia diagnosis. Good to very good inter- and intra-rater reliability for the online assessment was found across the majority of assessment tasks. Participants reported high overall satisfaction, comfort level, and audio and visual quality in the online environment. This study supports the validity and reliability of delivering standardized assessments of aphasia online and provides a basis for ongoing development of telerehabilitation as an alternate mode of service delivery to persons with aphasia.	[Theodoros, Deborah; Hill, Anne; Ward, Elizabeth] Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; [Russell, Trevor] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia; [Wootton, Richard] Univ Queensland, Ctr Online Hlth, Brisbane, Qld 4072, Australia	Theodoros, D (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	d.theodoros@uq.edu.au	Wootton, Richard/F-7609-2014; Ward, Elizabeth/F-9652-2010; Theodoros, Deborah/F-1362-2010; Russell, Trevor/F-6888-2010; Russell, Trevor/AAS-2590-2020; Hill, Anne/F-4106-2010	Wootton, Richard/0000-0002-2666-3596; Ward, Elizabeth/0000-0002-2680-8978; Russell, Trevor/0000-0002-9732-6167; Russell, Trevor/0000-0002-9732-6167; Hill, Anne/0000-0003-3907-8369	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [401604]; National Health and Medical Research Council of Australia Public Health Postgraduate ScholarshipNational Health and Medical Research Council of Australia [ID: 351649]	This research was made possible with funding from the National Health and Medical Research Council of Australia Project Grant No. 401604, and a National Health and Medical Research Council of Australia Public Health Postgraduate Scholarship ID: 351649. The authors acknowledge the assistance of Roy Andersen in the software development of the assessment application, Monique Waite in data collection, and the Princess Alexandra Hospital, The Royal Brisbane and Womens' Hospital, Queen Elizabeth II Jubilee Hospital, the School of Health and Rehabilitation Sciences Clinic, and the University of Queensland Aphasia Registry for assistance in participant recruitment.	*AM HEART ASS, HEART DIS STROK STAT; Biddle A., 2002, AHRQ PUBLICATION, V02-E010; BOROD J C, 1980, Journal of Clinical Neuropsychology, V2, P209, DOI 10.1080/01688638008403793; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; BROOKSHIRE RH, 2007, INTRO NEUROGENIC COM, P445; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Duffy JR, 2005, MOTOR SPEECH DISORDE, P3; Enderby PM, 1995, DOES SPEECH LANGUAGE; FINLAYSON MAJ, 1994, BRAIN INJURY REHABIL, P3; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Fratalli C., 2000, NEUROGENIC COMMUNICA; Georgeadis AC, 2004, APHASIOLOGY, V18, P639, DOI 10.1080/02687030444000075; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; HAYES JM, MICROSOFT NETMEETING; Kaplan E., 2001, Boston naming test; Kraus JF, 1993, HEAD INJURY, P1; LANDIS JR, 1977, BIOMETRICS, V33, P174; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; Palsbo SE, 2007, J TELEMED TELECARE, V13, P40, DOI 10.1258/135763307779701121; Pickering M, 1998, AM J SPEECH-LANG PAT, V7, P5, DOI 10.1044/1058-0360.0704.05; Savard L, 2003, NEUROREHABILITATION, V18, P93	22	52	56	0	19	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED J E-HEALTH	Telemed. J. e-Health	AUG	2008	14	6					552	559		10.1089/tmj.2007.0091			8	Health Care Sciences & Services	Health Care Sciences & Services	347GN	WOS:000259128700044	18729754				2021-06-18	
J	Vanhaudenhuyse, A; Laureys, S; Perrin, F				Vanhaudenhuyse, Audrey; Laureys, Steven; Perrin, Fabien			Cognitive event-related potentials in comatose and post-comatose states	NEUROCRITICAL CARE			English	Article						coma; vegetative state; minimally conscious state; ERPs; N100; MMN; P300; N400	AUDITORY-EVOKED-POTENTIALS; MINIMALLY CONSCIOUS STATE; TRAUMATIC BRAIN-INJURY; PERSISTENT VEGETATIVE STATE; MEDIAL TEMPORAL-LOBE; SUBJECTS OWN NAME; MISMATCH NEGATIVITY; INTRACEREBRAL POTENTIALS; PROGNOSTIC VALUE; PREDICTIVE-VALUE	We review the interest of cognitive event-related potentials (ERPs) in comatose, vegetative, or minimally conscious patients. Auditory cognitive ERPs are useful to investigate residual cognitive functions, such as echoic memory (MMN), acoustical and semantic discrimination (P300), and incongruent language detection (N400). While early ERPs (such as the absence of cortical responses on somatosensory-evoked potentials) predict bad outcome, cognitive ERPs (MMN and P300) are indicative of recovery of consciousness. In coma-survivors, cognitive potentials are more frequently obtained when using stimuli that are more ecologic or have an emotional content (such as the patient's own name) than when using classical sine tones.	[Perrin, Fabien] Univ Lyon 1, CNRS, UMR Neurosci Sensorielles Comportement Cognit 502, Lyon 07, France; [Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, Liege, Belgium; [Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Liege, Dept Neurol, Liege, Belgium	Perrin, F (corresponding author), Univ Lyon 1, CNRS, UMR Neurosci Sensorielles Comportement Cognit 502, 50 Ave Tony Garnier, Lyon 07, France.	Fabien.Perrin@univ-lyonl.fr	Laureys, Steven/AAN-2097-2021; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; 			ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Celsis P, 1999, NEUROIMAGE, V9, P135, DOI 10.1006/nimg.1998.0389; CONNOLLY JF, 1990, BRAIN LANG, V39, P302, DOI 10.1016/0093-934X(90)90016-A; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; Dehaene S, 2004, COGNITIVE NEUROSCIEN; Fischer C, 1988, Agressologie, V29, P359; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Fischer C, 2006, CRIT CARE MED, V34, P1520, DOI 10.1097/01.CCM.0000215823.36344.99; Fischer C., 2001, EVALUATION NEUROPHYS, P169; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIORGIANNI R, 1997, EEG J, V103, P149; Glass I, 1998, CLIN ELECTROENCEPHAL, V29, P19, DOI 10.1177/155005949802900109; GOODIN DS, 1984, BRAIN, V107, P241, DOI 10.1093/brain/107.1.241; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Hagoort P, 1996, BRAIN, V119, P627, DOI 10.1093/brain/119.2.627; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; HARRIS DP, 1990, EAR HEARING, V11, P340, DOI 10.1097/00003446-199010000-00004; HILLYARD SA, 1973, SCIENCE, V182, P177, DOI 10.1126/science.182.4108.177; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kotchoubey B, 2003, NEUROSCI LETT, V352, P129, DOI 10.1016/j.neulet.2003.08.045; Kotchoubey B, 2001, NEUROSCI LETT, V310, P93, DOI 10.1016/S0304-3940(01)02057-2; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Kutas M, 1989, J Cogn Neurosci, V1, P38, DOI 10.1162/jocn.1989.1.1.38; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2005, CURR OPIN NEUROL, V18, P726, DOI 10.1097/01.wco.0000189874.92362.12; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; LIEGEOISCHAUVEL C, 1994, ELECTROEN CLIN NEURO, V92, P204, DOI 10.1016/0168-5597(94)90064-7; LITSCHER G, 1995, EVOKED POTENTIAL, V96, P413, DOI 10.1016/0168-5597(95)00045-T; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; MAROSI M, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90914-3; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; Naatanen R, 1997, NATURE, V385, P432, DOI 10.1038/385432a0; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Naatanen R., 1992, ATTENTION BRAIN FUNC; Naccache L, 2005, CLIN NEUROPHYSIOL, V116, P988, DOI 10.1016/j.clinph.2004.10.009; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Perrin F, 2003, COGNITIVE BRAIN RES, V17, P36, DOI 10.1016/S0926-6410(03)00078-8; Perrin F, 1999, CLIN NEUROPHYSIOL, V110, P2153, DOI 10.1016/S1388-2457(99)00177-7; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Plum F., 1983, DIAGNOSIS STUPOR COM; POLICH J, 1989, J CLIN NEUROPHYSIOL, V6, P277, DOI 10.1097/00004691-198907000-00003; Prevec T., 1993, ELECTROENCEPHALOGR C, V87, pS130; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rees G, 2002, NEUROCASE, V8, P387, DOI 10.1093/neucas/8.5.387; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; SCHERG M, 1985, ELECTROEN CLIN NEURO, V62, P32, DOI 10.1016/0168-5597(85)90033-4; Schoenle PW, 2004, NEUROREHABILITATION, V19, P329; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; Signorino M, 1997, J PSYCHOPHYSIOL, V11, P59; SMITH ME, 1986, ELECTROEN CLIN NEURO, V63, P145, DOI 10.1016/0013-4694(86)90008-8; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; VERLEGER R, 1988, BIOL PSYCHOL, V27, P45, DOI 10.1016/0301-0511(88)90004-X; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O	78	52	58	0	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2008	8	2					262	270		10.1007/s12028-007-9016-0			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	270KE	WOS:000253718900007	17990124				2021-06-18	
J	Carlsson, E; Paterson, BL; Scott-Findlay, S; Ehnfors, M; Ehrenberg, A				Carlsson, Eva; Paterson, Barbara L.; Scott-Findlay, Shannon; Ehnfors, Margareta; Ehrenberg, Anna			Methodological issues in interviews involving people with communication impairments after acquired brain damage	QUALITATIVE HEALTH RESEARCH			English	Article						communication impairment; qualitative research; interviewing; informed consent; fatigue	INFORMED-CONSENT; APHASIA; STROKE; PARTICIPANTS; EXPERIENCES; SELF; CONVERSATIONS; CHILDREN; VOICE	Qualitative research has made a significant contribution to the body of knowledge related to how people experience living with various chronic diseases and disabilities; however, the voices of certain vulnerable populations, particularly those with impairments that affect their ability to communicate, are commonly absent. In recent years, a few researchers have attempted to explore the most effective ways to ensure that the voices of people with communication impairments from acquired brain damages can be captured in qualitative research interviews; yet several methodological issues related to including this population in qualitative research remained unexamined. In this article, the authors draw on insights derived from their research on the experiences of adult survivors of stroke and traumatic brain injury to describe methodological issues related to sampling, informed consent, and fatigue in participant and researcher while also making some recommendations for conducting qualitative interviews with these populations.	Univ Orebro, Dept Hlth Sci, Orebro, Sweden; Univ New Brunswick, Tier 1 Canada Res Chair, Fredericton, NB, Canada; Univ Alberta, Dept Pediat, Edmonton, AB, Canada	Carlsson, E (corresponding author), Univ Orebro, Dept Hlth Sci, Orebro, Sweden.			Carlsson, Eva/0000-0002-0714-0167			Adams J, 2005, QUAL HEALTH RES, V15, P1293, DOI 10.1177/1049732305281761; Albrecht TL, 2005, CURR OPIN ONCOL, V17, P336, DOI 10.1097/01.cco.0000166654.23169.a2; Arscott K, 1999, PSYCHOL MED, V29, P1367, DOI 10.1017/S0033291799008715; Bargh JA, 2002, J SOC ISSUES, V58, P33, DOI 10.1111/1540-4560.00247; Beukelman D.R., 1998, AUGMENTATIVE ALTERNA; BEUKELMAN DR, 1985, ARCH PHYS MED REHAB, V66, P675; BLOCH S, 1999, UNDERSTANDING TROUBL; Burton CR, 2000, J ADV NURS, V32, P301, DOI 10.1046/j.1365-2648.2000.01477.x; Camp DL, 2002, SOC SCI MED, V55, P823, DOI 10.1016/S0277-9536(01)00205-2; Carlsson E, 2004, J CLIN NURS, V13, P825, DOI 10.1111/j.1365-2702.2004.01023.x; DIKEMAN K, 1998, STROKE ENHANCING QUA, P103; Dockrell J, 2004, BRIT J LEARN DISABIL, V32, P161; Flory J, 2004, JAMA-J AM MED ASSOC, V292, P1593, DOI 10.1001/jama.292.13.1593; Goldsmith M., 1996, HEARING VOICE PEOPLE; Goodson IF, 2001, LIFE HIST RES ED SET; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; HAMILTON I, 2000, THESIS LARAHOGSKOLAN; Hamilton RJ, 2006, QUAL HEALTH RES, V16, P821, DOI 10.1177/1049732306287599; Jimison HB, 1998, J AM MED INFORM ASSN, V5, P245, DOI 10.1136/jamia.1998.0050245; JOHNSTON JR, 1993, J SPEECH HEAR RES, V36, P973, DOI 10.1044/jshr.3605.973; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Killick J., 2001, COMMUNICATION CARE P; Kralik D, 2006, J ADV NURS, V53, P213, DOI 10.1111/j.1365-2648.2006.03717.x; Kvale S, 1996, INTERVIEWS INTRO QUA; Lemieux L, 2001, SEX DISABIL, V19, P253, DOI 10.1023/A:1017953308761; Lewis A., 2004, BRIT J LEARN DISABIL, V32, P191, DOI DOI 10.1111/J.1468-3156.2004.00313.X; Lyketsos CG, 2004, ALZ DIS ASSOC DIS, V18, P171; MCCOLL MA, 2002, DISABILITY REHABILIT, V22, P555; MCDOUGALL G, 2000, GERIATRIC NURSING RE, P322; Mead G., 1972, MIND SELF SOC; Mishler E, 1986, RES INTERVIEWING CON; Montgomery JW, 2000, J SPEECH LANG HEAR R, V43, P293, DOI 10.1044/jslhr.4302.293; Moore TF, 2003, NURS SCI QUART, V16, P163, DOI 10.1177/0894318403251793251793; Moyle W, 2002, J ADV NURS, V39, P266, DOI 10.1046/j.1365-2648.2002.02273.x; Murphy J, 2005, HEALTH SOC CARE COMM, V13, P95, DOI 10.1111/j.1365-2524.2005.00528.x; MURPHY J, 2000, BRIT J THERAPY REHAB, V7, P454, DOI DOI 10.12968/BJTR.2000.7.11.13835; *NAT LIB MED, 2006, MED SUBJ HEAD; NEWBORN B, 1998, STROKE ENHANCING QUA, P189; Nilsson I, 1997, J ADV NURS, V25, P953, DOI 10.1046/j.1365-2648.1997.1997025953.x; Palmer BW, 2005, ARCH GEN PSYCHIAT, V62, P726, DOI 10.1001/archpsyc.62.7.726; Parr S, 2001, FOLIA PHONIATR LOGO, V53, P266, DOI 10.1159/000052681; Parr S., 1997, TALKING APHASIA LIVI; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; PATERSON B, 2001, REHABILITATION NURSI, V2, P48; Paterson B.L., 2001, META STUDY QUALITATI; Perry L, 2003, INT J NURS STUD, V40, P185, DOI 10.1016/S0020-7489(02)00060-3; Philpin SM, 2005, J ADV NURS, V50, P299, DOI 10.1111/j.1365-2648.2005.03393.x; Piamjariyakul U, 2006, WESTERN J NURS RES, V28, P602, DOI 10.1177/0193945906288582; SAMO MT, 1998, STROKE ENHANCING QUA, P189; SARNO MT, 1993, APHASIOLOGY, V7, P321, DOI 10.1080/02687039308249514; Simmons-Mackie NN, 2003, AM J SPEECH-LANG PAT, V12, P144, DOI 10.1044/1058-0360(2003/061); *SUBC BRAIN BEH SC, 1991, NTIS PUBL; Thorne S, 1997, RES NURS HEALTH, V20, P169; Thorne S, 2002, QUAL HEALTH RES, V12, P437, DOI 10.1177/104973202129120007; Yorkston KM, 2001, AM J SPEECH-LANG PAT, V10, P126, DOI 10.1044/1058-0360(2001/013); Young A. F., 2006, BR J LEARN DISABIL, V34, P11	56	52	52	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	DEC	2007	17	10					1361	1371		10.1177/1049732307306926			11	Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	234BD	WOS:000251134800007	18000075				2021-06-18	
J	Hollingworth, W; Vavilala, MS; Jarvik, JG; Chaudhry, S; Johnston, BD; Layman, S; Tontisirin, N; Muangman, SL; Wang, MC				Hollingworth, William; Vavilala, Monica S.; Jarvik, Jeffrey G.; Chaudhry, Sidhartha; Johnston, Brian D.; Layman, Sarah; Tontisirin, Nuj; Muangman, Saipin L.; Wang, Marjorie C.			The use of repeated head computed tomography in pediatric blunt head trauma: Factors predicting new and worsening brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injuries; radiograph computed tomography; pediatrics; critical care; intracranial pressure; traumatic brain hemorrhage	GLASGOW COMA SCALE; CHILDREN; CT; PROGRESSION; HEMORRHAGE; MORTALITY; HEMATOMA; MODERATE; SCORE	Objective: Opinion is divided on the value of repeat head computed tomography for guiding clinical management of pediatric patients with blunt head trauma. This study describes the prevalence of worsening brain injury on repeat computed tomography, predictors of worsening computed tomography findings, and the frequency of neurosurgical intervention after the repeat computed tomography. Design: Retrospective cohort study. Setting: All patients were admitted to a level I pediatric trauma center between 1994 and 2003. Patients: Children < 15 yrs old with two or more head computed tomographies following hospital admission for blunt head trauma. Interventions: None. Measurements and Main Results: We reviewed the imaging reports to determine injury progression. Potential predictors of worsening computed tomography findings and neurosurgical intervention were recorded by chart review. Logistic regression and recursive partitioning were used to identify predictors. Twenty percent (50 of 257) of patients with mild head injury had worsening computed tomography findings, and three patients (1%) had subsequent neurosurgical intervention. Patients with moderate and severe head injuries were more likely to have worsening computed tomography findings (107 of 248; 43%) and to have neurosurgical intervention (15 of 248; 6%). In most surgical patients, repeat computed tomography was preceded by rapid decline in neurologic status or elevated intracranial pressure. Stratification based on four clinical factors (initial head injury severity, any intraparenchymal finding on initial computed tomography, normal findings on initial computed tomography, coagulopathy) identified 100% of the surgical patients and 89% of patents with worsening brain injuries on the repeat computed tomography. Conclusions: Repeat head computed tomography imaging is frequently used. About 30% of repeated computed tomographies showed new or worsening brain injury. However, worsening brain injury on repeat computed tomography rarely resulted in neurosurgical intervention. Patients with moderate or severe head injury and intraparenchymal injuries were more likely to show worsening brain injury and undergo neurosurgical intervention.	Univ Washington, Dept Radiol, Sch Publ Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Hollingworth, W (corresponding author), Univ Washington, Dept Radiol, Sch Publ Hlth, Seattle, WA 98195 USA.	willh@u.washington.edu	Jarvik, Jeffrey/AAL-4292-2021	Hollingworth, William/0000-0002-0840-6254			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Boone JM, 2003, RADIOLOGY, V228, P352, DOI 10.1148/radiol.2282020471; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; FARINGER PD, 1993, J TRAUMA, V34, P481, DOI 10.1097/00005373-199304000-00002; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Holmes JF, 2001, PEDIATR EMERG CARE, V17, P324, DOI 10.1097/00006565-200110000-00002; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ostir GV, 2000, AM J PHYS MED REHAB, V79, P565, DOI 10.1097/00002060-200011000-00017; Paterson A, 2001, AM J ROENTGENOL, V176, P297, DOI 10.2214/ajr.176.2.1760297; Shafi S, 2005, J TRAUMA, V59, P1081, DOI 10.1097/01.ta.0000188647.03665.fd; Slovis TL, 2002, RADIOLOGY, V223, P5, DOI 10.1148/radiol.2231012100; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WANG MC, IN PRESS J TRAUMA	37	52	52	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2007	8	4					348	356		10.1097/01.PCC.0000270837.66217.3B			9	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	190MK	WOS:000248062800006	17545925				2021-06-18	
J	McEwen, ML; Sullivan, PG; Springer, JE				McEwen, Melanie L.; Sullivan, Patrick G.; Springer, Joe E.			Pretreatment with the cyclosporin derivative, NIM811, improves the function of synaptic mitochondria following spinal cord contusion in rats	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; mitochondria; permeability transition; reactive oxygen species; spinal cord injury	PERMEABILITY TRANSITION PORE; INTERMEMBRANE JUNCTIONAL COMPLEXES; TRAUMATIC BRAIN-INJURY; P-GLYCOPROTEIN; CYCLOPHILIN-D; THERAPEUTIC TARGET; COMPRESSION TRAUMA; AXONAL DAMAGE; CELL-DEATH; BLOOD	Trauma to the spinal cord causes a cascade of secondary events, such as mitochondrial dysfunction, which disrupts cellular functions and ultimately leads to cell death. Cyclosporin A (CsA) is a potent immunosuppressant that promotes mitochondrial function by inhibiting mitochondrial permeability transition (mPT). Clinical trials examining CsA in traumatic brain injury are currently underway, but CsA is potentially neurotoxic. NIM811 is a non-immunosuppressive CsA derivative that inhibits mPT at nanomolar concentrations and with significantly less cytotoxicity than CsA. In the present study, we investigated the effects of NIM811 treatment on mitochondrial bioenergetics and the production of reactive oxygen species following spinal cord injury (SCI) in rats. Rats were pre-treated with NIM811 or vehicle, and after 15 min the rats received a "mild/moderate" spinal cord contusion. After 24 h, the spinal cords were rapidly removed and synaptosomal mitochondria were isolated. NIM811 pretreatment significantly improved mitochondrial respiratory control ratios, and the maximal electron transport capacity of complex I and II, as well as their ATP-producing capacity. Consistent with the improvements in mitochondrial function, NIM811 pretreatment significantly decreased free radical production in isolated mitochondria. These studies are the first to demonstrate the therapeutic potential of CsA derivatives in a model of SCI, and support the need for continued investigation of compounds like NIM811 as an acute treatment for human SCI.	Univ Kentucky, Ctr Med, Dept Phys Med & Rehabil, Lexington, KY 40536 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	McEwen, ML (corresponding author), Univ Kentucky, Ctr Med, Dept Phys Med & Rehabil, 800 Rose St,MN225, Lexington, KY 40536 USA.	mlmcew2@uky.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS46380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046380] Funding Source: NIH RePORTER		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHOI DW, 1987, J NEUROSCI, V7, P369; Crompton M, 2003, CURR MED CHEM, V10, P1473, DOI 10.2174/0929867033457197; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Faden A I, 1997, Adv Neurol, V72, P377; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Ibarra A, 2003, BRAIN RES, V979, P165, DOI 10.1016/S0006-8993(03)02898-1; Jemmerson R, 2005, ANTIOXID REDOX SIGN, V7, P1158, DOI 10.1089/ars.2005.7.1158; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; LAI JCK, 1976, BIOCHEM J, V154, P423, DOI 10.1042/bj1540423; LEMAIRE M, 1988, J PHARMACOL EXP THER, V244, P740; LEONG SF, 1984, J NEUROCHEM, V42, P1306, DOI 10.1111/j.1471-4159.1984.tb02788.x; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Liu XZ, 1997, J NEUROSCI, V17, P5395; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEDERBERGER W, 1983, TRANSPLANT P, V15, P2419; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nukala VN, 2006, J NEUROSCI METH, V152, P48, DOI 10.1016/j.jneumeth.2005.08.017; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Peng TI, 1998, MOL PHARMACOL, V53, P974; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rolfe DFS, 1997, BIOSCIENCE REP, V17, P9, DOI 10.1023/A:1027327015957; RYFFEL B, 1991, J RECEPTOR RES, V11, P675, DOI 10.3109/10799899109066435; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAKATA A, 1994, BIOCHEM PHARMACOL, V48, P1989, DOI 10.1016/0006-2952(94)90601-7; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, J BIOL CHEM, V279, P20699, DOI 10.1074/jbc.M313579200; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; WAGNER O, 1987, J PHARMACOL EXP THER, V244, P740; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	95	52	55	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					613	624		10.1089/neu.2006.9969			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000004	17439345				2021-06-18	
J	Tisdall, MM; Tachtsidis, I; Leung, TS; Elwell, CE; Smith, M				Tisdall, Martin M.; Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin			Near-infrared spectroscopic quantification of changes in the concentration of oxidized cytochrome c oxidase in the healthy human brain during hypoxemia	JOURNAL OF BIOMEDICAL OPTICS			English	Article						cytochrome c oxidase; near infrared spectroscopy; cerebral monitoring	CARDIOPULMONARY BYPASS; REDOX STATE; ADULT BRAIN; REDUCTION; TISSUE; OXYGENATION; DYSFUNCTION; SURGERY	The near-IR cytochrome c oxidase (CCO) signal has potential as a clinical marker of changes in mitochondrial oxygen utilization. We examine the CCO signal response to reduced oxygen delivery in the healthy human brain. We induced a reduction in arterial oxygen saturation from baseline levels to 80% in eight healthy adult humans, while minimizing changes in end tidal carbon dioxide tension. We measured changes in the cerebral concentrations of oxidized CCO (Delta[oxCCO], oxyhemoglobin (Delta[HbO(2)]), and deoxyhemoglobin bin (Delta[HHb]) using broadband near-IR spectroscopy (NIRS), and estimated changes in cerebral oxygen delivery (ecDO(2)) using pulse oximetry and transcranial Doppler ultrasonography. Results are presented as median (interquartile range). At the nadir of hypoxemia ecDO2 decreased by 9.2 (5.4 to 12.1)% (p< 0.0001), Delta[oxCCO] decreased by 0.24 (0.06 to 0.28) micromoles/l (p < 0.01), total hemoglobin concentration increased by 2.83 (2.27 to 4.46) micromoles/I (p < 0.0001), and change in hemoglobin difference concentration (Delta[Hbdiff] = Delta[HbO(2)]- Delta[HHb]) decreased by 12.72 (11.32 to 16.34) micromoles/I (p < 0.0001). Change in ecDO(2) correlated with Delta[oxCCO] (r=0.78, p < 0.001), but not with either change in total hemoglobin concentration or Delta[Hbdiff]. This is the first description of cerebral Delta[oxCCO] during hypoxemia in healthy adults. Studies are ongoing to investigate the clinical relevance of this signal in patients with traumatic brain injury. (C) 2007 Society of Photo-Optical Instrumentation Engineers.	Natl Hosp Neurol & Neurosurg, Dept Neuroanesthesia & Neurocrit Care, London WC1N 3BG, England; UCL, Dept Med Phys & Bioengn, London WC1E 6BT, England	Tisdall, MM (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuroanesthesia & Neurocrit Care, Queen Sq, London WC1N 3BG, England.	m.tisdall@ion.ucl.ac.uk	Smith, Martin/B-2616-2009; Tachtsidis, Ilias/N-2747-2018	Tachtsidis, Ilias/0000-0002-8125-0313; Elwell, Clare/0000-0002-7281-7234; Tisdall, Martin/0000-0001-8880-8386			BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P273, DOI 10.1016/S0005-2728(05)80109-4; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; Cooper CE, 1999, J CEREBR BLOOD F MET, V19, P27, DOI 10.1097/00004647-199901000-00003; Cooper CE, 1998, BIOCHEM J, V332, P627, DOI 10.1042/bj3320627; Cooper CE, 1997, PHILOS T R SOC B, V352, P669, DOI 10.1098/rstb.1997.0048; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; DRABKIN DL, 1951, PHYSIOL REV, V31, P345; EDWARDS AD, 1991, J APPL PHYSIOL, V71, P1907; FERRARI M, 1990, AM J PHYSIOL, V258, pH1706; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Kakihana Y, 2002, EUR J CARDIO-THORAC, V21, P434, DOI 10.1016/S1010-7940(01)01139-3; Kirkpatrick PJ, 1998, J NEUROSURG, V89, P389, DOI 10.3171/jns.1998.89.3.0389; MATCHER SJ, 1995, ANAL BIOCHEM, V227, P54, DOI 10.1006/abio.1995.1252; MATCHER SJ, 1994, PHYS MED BIOL, V39, P177, DOI 10.1088/0031-9155/39/1/011; McGown AD, 2003, SLEEP, V26, P710; NOLLERT G, 1995, THORAC CARDIOV SURG, V43, P260, DOI 10.1055/s-2007-1013224; Quaresima V, 1998, BBA-BIOENERGETICS, V1366, P291, DOI 10.1016/S0005-2728(98)00129-7; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; Sakamoto T, 2001, PEDIATR RES, V49, P770, DOI 10.1203/00006450-200106000-00010; SKOV L, 1994, PHYSIOL MEAS, V15, P447, DOI 10.1088/0967-3334/15/4/006; Springett R, 2000, AM J PHYSIOL-HEART C, V279, pH2202; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Stingele R, 1996, AM J PHYSIOL-HEART C, V271, pH579; TSUJI M, 1995, PEDIATR RES, V37, P253, DOI 10.1203/00006450-199503000-00001; Uludag K, 2004, NEUROIMAGE, V22, P109, DOI 10.1016/j.neuroimage.2003.09.053; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929	26	52	52	1	5	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	MAR-APR	2007	12	2							024002	10.1117/1.2718541			7	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	173FW	WOS:000246859900018	17477717				2021-06-18	
J	Amirjamshidi, A; Abouzari, M; Eftekhar, B; Rashidi, A; Rezaii, J; Esfandiari, K; Shirani, A; Asadollahi, M; Aleali, H				Amirjamshidi, A.; Abouzari, M.; Eftekhar, B.; Rashidi, A.; Rezaii, J.; Esfandiari, K.; Shirani, A.; Asadollahi, M.; Aleali, H.			Outcomes and recurrence rates in chronic subdural haematoma	BRITISH JOURNAL OF NEUROSURGERY			English	Article						chronic subdural haematoma; Glasgow Coma Scale; Glasgow Outcome Scale; recurrence	CLOSED-SYSTEM DRAINAGE; POSTOPERATIVE RECURRENCE; SURGICAL-TREATMENT; TRIAL	The object of this study was to determine the relationship between outcome (assessed by Glasgow Outcome Scale) and recurrence in chronic subdural haematoma (CSDH). Eighty-two consecutive patients who underwent surgery for CSDH were included in this study. The relationship between the following variables and CSDH recurrence was studied: sex; age; history of trauma; Glasgow Coma Scale (GCS) at the time of admission (stage 1: GCS > 12, stage 2: GCS: 8-12, stage 3: GCS < 8); interval between head injury ( when a history of trauma was present) and surgery; presence of a midline shift on CT scans; presence of intracranial air 7 days after surgery; haematoma density; haematoma width; presence of brain atrophy; and Glasgow Outcome Scale (GOS, both quantitative and non-quantitative) at the time of discharge. Throughout the analysis, p < 0.05 was considered statistically significant. The results showed lower GCS (p50.001), higher GOS ( p50.001), presence of intracranial air 7 days after surgery (p = 0.002), and a high density haematoma (p50.001) were significantly associated with recurrence of CSDH. It was concluded that GOS is related with recurrence in CSDH.	Univ Tehran Med Sci, Sinai Hosp, Tehran, Iran; Amir Alam Hosp, Tehran, Iran; Shahid Beheshti Univ Med Sci, Tehran, Iran	Abouzari, M (corresponding author), 17 Allaei Alley,Ard E Iran St, Tehran, Iran.	maboozari@yahoo.com		Abouzari, Mehdi/0000-0002-3585-698X; Rashidi, Armin/0000-0002-9384-272X			AMIRJAMSHIDI A, 2007, IN PRESS J CLIN NEUR; Amirjamshidi A, 2007, CLIN NEUROL NEUROSUR, V109, P152, DOI 10.1016/j.clineuro.2006.07.007; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; CAMERON MM, 1978, J NEUROL NEUROSUR PS, V41, P834, DOI 10.1136/jnnp.41.9.834; El-Kadi H, 2000, NEUROSURG CLIN N AM, V11, P553, DOI 10.1016/S1042-3680(18)30122-0; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; FOELHOLM R, 1975, J NEUROSURG, V42, P43; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024; Fukuhara T, 1996, SURG NEUROL, V45, P570, DOI 10.1016/0090-3019(95)00471-8; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KOTWICA Z, 1991, British Journal of Neurosurgery, V5, P461, DOI 10.3109/02688699108998474; KRUPP WF, 1995, BRIT J NEUROSURG, V9, P619, DOI 10.1080/02688699550040909; LABADIE EL, 1976, J NEUROSURG, V45, P382, DOI 10.3171/jns.1976.45.4.0382; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; Nakaguchi H, 2000, J NEUROSURG, V93, P791, DOI 10.3171/jns.2000.93.5.0791; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Nakajima H, 2002, SURG NEUROL, V58, P385, DOI 10.1016/S0090-3019(02)00921-7; Oishi M, 2001, NEUROL MED-CHIR, V41, P382, DOI 10.2176/nmc.41.382; OKU Y, 1984, J NEUROSURG, V61, P269, DOI 10.3171/jns.1984.61.2.0269; PROBST C, 1988, J NEUROSURG, V68, P908, DOI 10.3171/jns.1988.68.6.0908; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; Tsutsumi K, 1997, J NEUROSURG, V87, P870, DOI 10.3171/jns.1997.87.6.0870; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217	29	52	53	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2007	21	3					272	275		10.1080/02688690701272232			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	191QS	WOS:000248146700008	17612917				2021-06-18	
J	Huber, M; Kirchler, E; Karner, M; Pycha, R				Huber, M.; Kirchler, E.; Karner, M.; Pycha, R.			Delusional parasitosis and the dopamine transporter. A new insight of etiology?	MEDICAL HYPOTHESES			English	Article							BASAL GANGLIA; IN-VIVO; COCAINE; BRAIN; RAT; EXPRESSION; DISEASE; SYSTEM; HALLUCINATIONS; TRANSMISSION	Delusional parasitosis (DP) is a psychotic condition in which a person has the unshakeable and mistaken belief (delusion) and/or aberrant perception (hallucination) of being infested with parasites. The disorder will be usually classified in a primary DP-group without a detectable cause (so-called pure forms), while secondary DP-groups are associated with general organic conditions, psychiatric illnesses and drugs (substance induced). Etiology and pathophysiology of DP remain however unknown. In the present paper we hypothesize for the first time a decreased striatal. dopamine transporter (DAT)-functioning (corresponding with an increased extracellular dopamine-level) as etiologic condition for DP (primary and secondary groups). The DAT as key regulator of the dopamine-reuptake in the human brain is well known (regulation of the extracellular dopamine concentration). It is a presynaptic plasma membrane protein highly dense represented in the striatum. The hypothesis of a decreased DAT-functioning as etiologic condition by DP is revealed in case reports which show that DAT-inhibitors, such as cocaine, pemoline, methylphenidate and other amphetamine-derivatives can induce the clinical expression of DP. Several other associated causes of secondary DP-groups (medications, parkinson, chorea huntington, multiple system atrophy, diabetes, cerebrovascular diseases, alcoholism, traumatic brain injury, hyperuricemia, human immunodeficiency virus, iron deficiency, schizophrenia, depression) suggest that the clinical expression of DID may be related to a decreased striatal DAT-functioning (blocking, reduced ligand binding, reduced density, reduced activity). Our examined DP-cases (2-females) show means of magnetic resonance imaging a structurally damaged striatum. Furthermore, we presume that by the primary DP-group, the physiologically age-related decline of the DAT-density is pathologically elevated. Based on this hypothesis we show in the present paper the relation between DP and decreased striatal DAT-functioning, trying to give a new insight into the pathophysiologically mechanism involved. The hypothesis provides supporting evidence that increased levels of extracellular dopamine in the striatum of DP-patients is likely to be the result of decreased DAT-functioning and not increased rates of release. The hypothesis can be investigated simply by dopamine transporter imaging in patients with DP. (C) 2006 Elsevier Ltd. AR rights reserved.	Gen Hosp SB Bruneck, Dept Psychiat, I-39031 Brunico, Italy; Gen Hosp SB Bruneck, Dept Radiol, I-39031 Brunico, Italy	Huber, M (corresponding author), Gen Hosp SB Bruneck, Dept Psychiat, Spitalstr 4, I-39031 Brunico, Italy.	markus.huber@sb-bruneck.it			Austrian Science Fund FWFAustrian Science Fund (FWF) [P 19925] Funding Source: Medline		Abi-Dargham A, 2004, INT J NEUROPSYCHOPH, V7, pS1, DOI 10.1017/S1461145704004110; Amancio EJ, 2002, ARQ NEURO-PSIQUIAT, V60, P155, DOI 10.1590/S0004-282X2002000100029; ANDREWS E, 1986, J CLIN PSYCHIAT, V47, P188; Baker Glen B., 1992, Journal of Psychiatry and Neuroscience, V17, P206; Bannon MJ, 2005, TOXICOL APPL PHARM, V204, P355, DOI 10.1016/j.taap.2004.08.013; Czyrak A, 2003, POL J PHARMACOL, V55, P667; DAMIANI JT, 1990, J AM ACAD DERMATOL, V22, P312, DOI 10.1016/S0190-9622(08)80767-0; Demaria JE, 2000, ENDOCRINOLOGY, V141, P366, DOI 10.1210/en.141.1.366; Eisenhofer G, 2001, PHARMACOL THERAPEUT, V91, P35, DOI 10.1016/S0163-7258(01)00144-9; El Fakhri G, 2006, EUR J NUCL MED MOL I, V33, P87, DOI 10.1007/s00259-005-1920-y; Elliott JM, 2005, CURR OPIN PHARMACOL, V5, P94, DOI 10.1016/j.coph.2004.09.005; Elmer MKB, 2000, J AM ACAD DERMATOL, V43, P683, DOI 10.1067/mjd.2000.106510; ELPERN DJ, 1988, CUTIS, V42, P273; Erikson KM, 2000, J NUTR, V130, P2831; Erixon-Lindroth N, 2005, PSYCHIAT RES-NEUROIM, V138, P1, DOI 10.1016/j.pscychresns.2004.09.005; Figlewicz DP, 1996, BRAIN RES, V736, P54, DOI 10.1016/S0006-8993(96)00727-5; Freudenmann RW, 2002, FORTSCHR NEUROL PSYC, V70, P531, DOI 10.1055/s-2002-34666; Fujita M, 1996, J NUCL MED, V37, P1214; Geng Yu, 2005, J Zhejiang Univ Sci B, V6, P22, DOI 10.1631/jzus.2005.B0022; Gorelick DA, 2004, DRUGS, V64, P1547, DOI 10.2165/00003495-200464140-00004; Gross-Tsur V, 2004, NEUROLOGY, V63, P753, DOI 10.1212/01.WNL.0000134656.93147.F1; Hernandez-Albujar S, 1996, An Med Interna, V13, P549; Ichikawa H, 2001, Rinsho Shinkeigaku, V41, P423; Izzo E, 2005, PHARMACOL BIOCHEM BE, V81, P701, DOI 10.1016/j.pbb.2005.04.017; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kahlig KM, 2003, EUR J PHARMACOL, V479, P153, DOI 10.1016/j.ejphar.2003.08.065; Kapur Shitij, 2006, NeuroRx, V3, P10, DOI 10.1016/j.nurx.2005.12.003; KING BH, 1990, PHARMACOPSYCHIATRY, V23, P85, DOI 10.1055/s-2007-1014488; Krauseneck T, 2005, PSYCHOPATHOLOGY, V38, P103, DOI 10.1159/000085352; Laakso A, 2001, SCHIZOPHR RES, V52, P115, DOI 10.1016/S0920-9964(00)00095-5; Lanczik M, 1999, PSYCHOPATHOLOGY, V32, P277, DOI 10.1159/000029100; Laruelle M, 1998, Q J NUCL MED, V42, P211; Laruelle M, 1999, BIOL PSYCHIAT, V46, P56, DOI 10.1016/S0006-3223(99)00067-0; Lorberboym M, 2004, J NUCL MED, V45, P1688; Lorenzo CR, 2004, AM J CLIN DERMATOL, V5, P339, DOI 10.2165/00128071-200405050-00007; LYNCH PJ, 1993, SEMIN DERMATOL, V12, P39; MARNEROS A, 1988, PSYCHOPATHOLOGY, V21, P267, DOI 10.1159/000284569; MARSCHALL MA, 1991, PLAST RECONSTR SURG, V88, P328, DOI 10.1097/00006534-199108000-00027; Mateos JJ, 2005, PSYCHOPHARMACOLOGY, V181, P401, DOI 10.1007/s00213-005-2250-2; Meehan WJ, 2006, ARCH DERMATOL, V142, P352, DOI 10.1001/archderm.142.3.352; Melikian HE, 1999, J NEUROSCI, V19, P7699; MELTZER HY, 1983, PSYCHIAT RES, V9, P285, DOI 10.1016/0165-1781(83)90002-1; Mendez I, 2004, LUPUS, V13, P45, DOI 10.1191/0961203304lu487oa; Meng SZ, 2000, PEDIATR NEUROL, V22, P115, DOI 10.1016/S0887-8994(99)00126-5; Meng SZ, 1999, BRAIN RES, V843, P136, DOI 10.1016/S0006-8993(99)01933-2; Meyer JH, 2001, NEUROREPORT, V12, P4121, DOI 10.1097/00001756-200112210-00052; MITCHELL J, 1991, J PSYCHOL, V125, P301, DOI 10.1080/00223980.1991.10543294; MOLINA VA, 1981, ARCH INT PHARMACOD T, V251, P66; Mozley PD, 1996, J NUCL MED, V37, P1965; Narumoto J, 2006, PROG NEURO-PSYCHOPH, V30, P737, DOI 10.1016/j.pnpbp.2005.11.029; Ngai LY, 2005, J NEUROENDOCRINOL, V17, P424, DOI 10.1111/j.1365-2826.2005.01321.x; OLIANAS MC, 1988, EUR J PHARMACOL, V150, P389, DOI 10.1016/0014-2999(88)90025-8; Owens WA, 2005, J NEUROCHEM, V94, P1402, DOI 10.1111/j.1471-4159.2005.03289.x; Petrisic MS, 1997, J NEUROCHEM, V68, P2435; Raasch W, 1999, ANN NY ACAD SCI, V881, P313, DOI 10.1111/j.1749-6632.1999.tb09376.x; Repo E, 1999, PSYCHOPHARMACOLOGY, V147, P314, DOI 10.1007/s002130051173; Robinson DL, 2005, ALCOHOL CLIN EXP RES, V29, P746, DOI 10.1097/01.ALC.0000164362.21484.14; Schenk James O, 2002, Prog Drug Res, V59, P111; Silkis IG, 2005, ZH VYSSH NERV DEYAT+, V55, P592; Slaughter JR, 1998, PSYCHOSOMATICS, V39, P491, DOI 10.1016/S0033-3182(98)71281-2; Smagin GN, 2004, PSYCHONEUROENDOCRINO, V29, P1223, DOI 10.1016/j.psyneuen.2004.02.004; Suzuki M, 2001, SYNAPSE, V41, P329, DOI 10.1002/syn.1089; TAKEDA M, 1985, ACTA PSYCHIAT SCAND, V72, P470, DOI 10.1111/j.1600-0447.1985.tb02641.x; TRABERT W, 1995, PSYCHOPATHOLOGY, V28, P238, DOI 10.1159/000284934; van den Buuse M, 2005, NEUROSCI LETT, V380, P6, DOI 10.1016/j.neulet.2005.01.009; van Dyck CH, 2002, AM J GERIAT PSYCHIAT, V10, P36, DOI 10.1176/appi.ajgp.10.1.36; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Volkow ND, 1996, J NUCL MED, V37, P554; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V20, P424, DOI 10.1016/S0893-133X(98)00108-0; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269; Weintraub D, 2005, J NUCL MED, V46, P227; Wong DF, 1996, P NATL ACAD SCI USA, V93, P5539, DOI 10.1073/pnas.93.11.5539; Zhou CY, 2006, J PHARMACOL EXP THER, V317, P1155, DOI 10.1124/jpet.106.101923	76	52	54	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2007	68	6					1351	1358		10.1016/j.mehy.2006.07.061			8	Medicine, Research & Experimental	Research & Experimental Medicine	168QV	WOS:000246540000028	17134847				2021-06-18	
J	Segalowitz, SJ; Mahaney, P; Santesso, DL; MacGregor, L; Dywan, J; Willer, B				Segalowitz, Sidney J.; Mahaney, Patrick; Santesso, Diane L.; MacGregor, Leslie; Dywan, Jane; Willer, Barry			Retest reliability in adolescents of a computerized neuropsychological battery used to assess recovery from concussion	NEUROREHABILITATION			English	Article							SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; BRAIN-INJURY; MANAGEMENT; DIAGNOSIS; DISCHARGE	We examined in a group of 15-year-old adolescents the retest reliability over one week of 7 subscales of the Automated Neuropsychological Metrics (ANAM), a computerized battery based on standard neuropsychological test measures that is one of several such batteries available to assess concussion effects. Since the principle behind these computerized batteries is to assess athletes before injury and after injury to determine the level of deficit and whether the individual is safe to return to play, it is critical that such batteries have excellent retest reliability. Retest reliability of the ANAM was good, especially for the aggregate of throughput scores, reaching 0.87, but lower for individual subtests, especially for those measuring only speed of processing. Thus, the ANAM aggregated score appears to have robust reliability for cognitive measures involving memory and attention in 15-year-olds. Limitations related to assessing return-to-baseline after concussion in adolescents are discussed.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada; Harvard Univ, Dept Psychol, Affect Neurosci Lab, Cambridge, MA 02138 USA; SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA	Segalowitz, SJ (corresponding author), Brock Univ, Dept Psychol, 500 Glenridge Ave, St Catharines, ON L2S 3A1, Canada.	sid.segalowitz@brocku.ca					Barth J T, 2000, Dent Clin North Am, V44, P67; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yaghi HM, 1997, J EDUC COMPUT RES, V16, P237, DOI 10.2190/X668-LXE1-4X00-PARW	29	52	52	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					243	251					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800010	17917174				2021-06-18	
J	Yard, EE; Comstock, RD				Yard, Ellen Elizabeth; Comstock, R. Dawn			Injuries sustained by pediatric ice hockey, lacrosse, and field hockey athletes presenting to United States emergency departments, 1990-2003	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; athletic injuries; protective equipment	WOMENS LACROSSE; NECK INJURIES; HEAD-INJURIES; EYE INJURIES; FACE MASKS; PLAYERS; FOOTBALL; EPIDEMIOLOGY; SPORTS; SOCCER	Context. Ice hockey, lacrosse, and field hockey are increasingly popular sports among US youth athletes, but no authors to date have compared injuries in male and female pediatric (ages 2 through 18 years) participants. Objective: To compare patterns of injury among pediatric ice hockey, lacrosse, and field hockey players. Design: A descriptive analysis of all pediatric (ages 2 through 18 years) ice hockey, lacrosse, and field hockey injuries captured by the US Consumer Product Safety Commission's National Electronic Injury Surveillance System. Setting: US Consumer Product Safety Commission's National Electronic Injury Surveillance System. Patients or Other Participants: Children with ice hockey, lacrosse, or field hockey injuries presenting to emergency departments participating in the National Electronic Injury Surveillance System. Main Outcome Measure(s): We reviewed all ice hockey, lacrosse, and field hockey injuries captured by the National Electronic Injury Surveillance System and categorized them by sex, age, injury site, and injury diagnosis. Results: An estimated 321237 pediatric participants in ice hockey, lacrosse, and field hockey presented to US emergency departments from 1990 through 2003. The injured were primarily male (74.4%) and aged 10 through 18 years (95.4%). Ice hockey accounted for more injuries (53.6%) than lacrosse (26.5%) or field hockey (19.9%). Children aged 2 through 9 years sustained twice the proportion of head and face injuries (53.1%) as children aged 10 through 18 years (23.2%) (incidence rate ratio [IRR] = 2.25, 95% confidence interval [CI] 1.94 to 2.62). Males incurred a higher proportion of shoulder and upper arm injuries (14.1%) than females (3.1%) (IRR = 4.51, 95% Cl = 3.07 to 6.62). The proportion of concussion was higher in ice hockey players (3.9%) than in field hockey players (1.4%) (IRR = 2.75, 95% Cl = 1.17 to 6.46). Females in lacrosse had twice the proportion of facial injuries (20.9%) as males (10.5%) (IRR = 1.95, 95% Cl = 1.46 to 2.60). In all sports, the ball or puck caused a greater proportion of face injuries in females than in males (IRR = 2.48, 95% Cl = 2.03 to 3.05). Facial injuries from falls occurred in higher proportions in ice hockey players (10.6%) than in lacrosse (2.4%) (IRR = 4.32, 95% Cl = 1.53 to 12.18) and field hockey (0.4%) players (IRR = 28.38, 95% Cl = 6.71 to 120.01). Conclusions: Pediatric ice hockey, lacrosse, and field hockey injuries differed by age and sport and, within each sport, by sex. An understanding of sport-specific patterns of injury should assist coaches and certified athletic trainers in developing targeted preventive interventions.	Childrens Hosp, Ctr Injury Res & Policy, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA	Yard, EE (corresponding author), Childrens Hosp, Ctr Injury Res & Policy, Columbus Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	YardE@ccri.net					Anderson AJ, 2000, PEDIATRICS, V105, P657; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Bolhuis J H, 1987, Br J Sports Med, V21, P174; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Delaney JS, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.015735; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; DELOES M, 1988, INT J SPORTS MED, V9, P461, DOI 10.1055/s-2007-1025052; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Dryden DM, 2000, MED SCI SPORT EXER, V32, P1378, DOI 10.1097/00005768-200008000-00004; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Hostetler SG, 2004, PEDIATRICS, V114, pE661, DOI 10.1542/peds.2004-1565; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; Marchie A, 2003, CAN MED ASSOC J, V169, P124; Matz SO, 2004, AM J SPORT MED, V32, P608, DOI 10.1177/0363546503262172; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MURRAY TM, 1995, PEDIATRICS, V95, P419; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; *NAT FED STAT HIGH, NFHS 2003 04 HIGH SC; National Federation of State High School Associations, PART FIG HIST; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Stevenson MR, 2000, BRIT J SPORT MED, V34, P188, DOI 10.1136/bjsm.34.3.188; *US CENS BUR, NAT POP DAT; *US CONS PROD SAF, 1997, NEISS SAMPL DES IMPL; *US FIELD HOCK, US FIELD HOCK FACT S; *US HOCK, US HOCK 2003 2004 FI; *US LACR, 2004, US LACR PART SURG; Waicus KM, 2002, CLIN J SPORT MED, V12, P24, DOI 10.1097/00042752-200201000-00008; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004	30	52	52	0	18	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2006	41	4					441	449					9	Sport Sciences	Sport Sciences	124QU	WOS:000243385800016	17273471				2021-06-18	
J	Zazryn, T; Cameron, P; McCrory, P				Zazryn, T.; Cameron, P.; McCrory, P.			A prospective cohort study of injury in amateur and professional boxing	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							RUGBY-LEAGUE; FOOTBALL; BOXERS; HEAD; EPIDEMIOLOGY; CONCUSSIONS; STATE; ELITE	Background: There is concern over the potential for a high incidence of injury in boxing. This is despite a lack of prospective data evaluating the risk for modern day participants. Updated, reliable data with a focus on potential exposure to injury for both amateur and, especially, professional boxers is required. Aim: To determine the epidemiology of injury and exposure of amateur and professional boxers in Victoria, Australia. Methods: A prospective cohort study with one year follow up was carried out over 2004 - 2005. Thirty three amateur and 14 active professional boxers registered with either Boxing Victoria Inc ( amateurs) or the Professional Boxing and Combat Sports Board of Victoria ( professionals) volunteered. Exposure at training and competition was measured, and any injuries sustained during this participation were recorded. Results: Twenty one injuries were sustained by the cohort during the follow up period. Most were to the head region (71%; 95% confidence interval 23.7 to 89.4), with concussion being the most common (33%). An overall injury rate of 2.0 injuries per 1000 hours of boxing was calculated. Conclusion: The high exposure experienced by the boxers ( as a result of considerable training time) indicated that boxing has acute injury rates comparable to, and often lower than, those found in other contact and non-contact sports. Further, acute injuries during training appear to be less common and severe than those sustained in bouts.	Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; Univ Melbourne, Brain Res Inst, Melbourne, Vic, Australia	Cameron, P (corresponding author), Monash Univ, Cent & Eastern Clin Sch, Alfred Hosp, Dept Epidemiol & Prevent Med, Commercial Rd, Melbourne, Vic 3004, Australia.	peter.cameron@med.monash.edu.au	McCrory, Paul/Q-8688-2019	Cameron, Peter/0000-0002-1443-557X			Boxing Jordan B, 1996, EPIDEMIOLOGY SPORTS, P113; Braham R, 2004, J SCI MED SPORT, V7, P96, DOI 10.1016/S1440-2440(04)80048-3; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CANTU R, 1995, BOXING MED; Carson JD, 1999, CLIN J SPORT MED, V9, P75, DOI 10.1097/00042752-199904000-00006; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; Critchley GR, 1999, BRIT J SPORT MED, V33, P174, DOI 10.1136/bjsm.33.3.174; deLoes M, 1997, SPORTS MED, V24, P172, DOI 10.2165/00007256-199724030-00005; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; Finch C, 2002, AUST NZ J PUBL HEAL, V26, P462, DOI 10.1111/j.1467-842X.2002.tb00348.x; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; Gabbe B, 2002, J SCI MED SPORT, V5, P149, DOI 10.1016/S1440-2440(02)80036-6; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; Gissane C, 2003, OCCUP MED-OXFORD, V53, P512, DOI 10.1093/occmed/kqg103; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN B, 1993, MED ASPECTS BOXING, P4; JORDAN BD, 1990, PHYSICIAN SPORTSMED, V18, P81, DOI 10.1080/00913847.1990.11709974; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1992, J NEUROIMAGING, V2, P181; JORDAN BD, 1993, MED ASPECTS BOXING, P177; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Kolt GS, 1999, BRIT J SPORT MED, V33, P312, DOI 10.1136/bjsm.33.5.312; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; Morgan BE, 2001, AM J SPORT MED, V29, P426, DOI 10.1177/03635465010290040701; Orchard J, 1998, J SCI MED SPORT, V1, P82; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; *PROF BOX COMB SPO, 2002, RUL SCOR KICKB BOX C; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; SCOTT I, 2001, COUNTING INJURIES OU; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Shawdon A, 1994, Aust J Sci Med Sport, V26, P59; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; WELCH MJ, 1986, PHYSICIAN SPORTSMED, V14, P81, DOI 10.1080/00913847.1986.11709169; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	40	52	56	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2006	40	8					670	674		10.1136/bjsm.2006.025924			5	Sport Sciences	Sport Sciences	066BW	WOS:000239205600005	16807306	Green Published			2021-06-18	
J	Kobori, N; Clifton, GL; Dash, PK				Kobori, Nobuhide; Clifton, Guy L.; Dash, Pramod K.			Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: Implications for prefrontal dysfunction	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; dopamine; norepinephrine; prefrontal cortex; tyrosine hydroxylase; working memory	TYROSINE-HYDROXYLASE PHOSPHORYLATION; CORTICAL IMPACT MODEL; WORKING-MEMORY; COGNITIVE FUNCTION; CHROMAFFIN CELLS; FRONTAL-CORTEX; ACTIVATION; DEFICITS; KINASE; BIOSYNTHESIS	Traumatic brain injury (TBI)-induced dysfunction of the prefrontal cortex causes many high-level cognitive deficits, including working memory (WM) dysfunction. WM lies at the core of many high-level functions, yet the cellular and molecular mechanisms underlying its dysfunction are poorly understood. Lesion and pharmacological studies in rodents have implicated the medial prefrontal cortex (mPFC), which includes the prelimbic/infralimbic (PL/IL) cortices, in WM tasks. These studies have shown that optimal levels of catecholamine neurotransmission are critical for normalcy of WM function, suggesting that alterations in their synthesis may play a role in WM dysfunction. Using the cortical impact injury model of traumatic brain injury which reproducibly causes working memory deficits in rodents, we have measured the protein levels and activity of tyrosine hydroxylase (TH), the rate-limiting enzyme for catecholamine biosynthesis, and tissue dopamine (DA) and norepinephrine (NE) levels in microdissected PL/IL tissues. Our results show that TBI increases TH protein levels, its activity and tissue DA and NE content in the PL/IL. These findings suggest that altered catecholamine signaling within the PL/IL may contribute to impaired PFC function, and may have implications in the design and implementation of strategies to alleviate prefrontal dysfunction in brain injury patients.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Dept Neurobiol & Anat, POB 20708,MSB 7-160, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, NS049160, NS0523] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R01NS035457] Funding Source: NIH RePORTER		Arnsten AFT, 1998, ARCH GEN PSYCHIAT, V55, P362, DOI 10.1001/archpsyc.55.4.362; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Betarbet R, 1997, J NEUROSCI, V17, P6761; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRITO GNO, 1990, BEHAV BRAIN RES, V36, P127, DOI 10.1016/0166-4328(90)90167-D; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Delatour B, 2000, BEHAV BRAIN RES, V109, P113, DOI 10.1016/S0166-4328(99)00168-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; Goldman-Rakic PS, 2000, BRAIN RES REV, V31, P295, DOI 10.1016/S0165-0173(99)00045-4; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYCOCK JW, 1993, NEUROCHEM RES, V18, P15, DOI 10.1007/BF00966919; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2004, J BIOL CHEM, V279, P2182, DOI 10.1074/jbc.M310734200; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LEVINE RA, 1984, ANAL BIOCHEM, V143, P205, DOI 10.1016/0003-2697(84)90577-3; Lew JY, 1999, MOL PHARMACOL, V55, P202; Lindgren N, 2002, EUR J NEUROSCI, V15, P769, DOI 10.1046/j.1460-9568.2002.01901.x; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Runyan JD, 2005, LEARN MEMORY, V12, P103, DOI 10.1101/lm.89405; Salvatore MF, 2004, J NEUROCHEM, V90, P245, DOI 10.1111/j.1471-4159.2004.02496.x; Salvatore MF, 2001, J NEUROCHEM, V79, P349, DOI 10.1046/j.1471-4159.2001.00593.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Toska K, 2002, J NEUROCHEM, V83, P775, DOI 10.1046/j.1471-4159.2002.01172.x; WAYMIRE JC, 1991, J NEUROCHEM, V57, P1313, DOI 10.1111/j.1471-4159.1991.tb08296.x; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.neuro.12.1.415	41	52	53	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2006	23	7					1094	1102		10.1089/neu.2006.23.1094			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069UG	WOS:000239473200005	16866622				2021-06-18	
J	Liu-Snyder, P; Ben Borgens, R; Shi, R				Liu-Snyder, Peishan; Ben Borgens, Richard; Shi, Riyi			Hydralazine rescues PC12 cells from acrolein-mediated death	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acrolein; secondary injury; neurotrauma; hydralazine	SPINAL-CORD-INJURY; LIPID-PEROXIDATION PRODUCT; OXIDATIVE STRESS; CYTOTOXICITY; DISRUPTION; ALDEHYDE; ACID	Acrolein, a major lipid peroxidation product, has been associated with both CNS trauma and neurodegenerative diseases. Because of its long half-life, acrolein is a potent endogenous toxin capable of killing healthy cells during the secondary injury process. Traditionally, attempts to intervene in the process of progressive cell death after the primary injury have included scavenging reactive oxygen species (so-called free radicals). The animal data supporting such an approach have generally been positive, but all human clinical trials attempting a similar outcome in human CNS injury have failed. New drugs that might reduce toxicity by scavenging the products of lipid peroxidation present a promising, and little investigated, therapeutic approach. Hydralazine, a well-known treatment for hypertension, has been reported to react with acrolein, forming hydrazone in cell-free systems. In the companion paper, we have established an acrolein-mediated cell injury model using PC12 cells in vitro. Here we test the hypothesis that the formation of hydrazone adducts with acrolein is able to reduce acrolein toxicity and spare a significant percentage of the population of PC12 cells from death. Concentrations of approximately 1 mM of this aldehyde scavenger can rescue over 80% of the population of PC12 cells. This study provides a basis for a new pharmacological treatment to reduce the effects of secondary injury in the damaged and/or diseased nervous system. In particular, we describe the need for new drugs that possess aldehyde scavenging properties but do not interfere with the regulation of blood pressure. (c) 2006 Wiley-Liss, Inc.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Shi, R (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Sci, 408 S Univ St, W Lafayette, IN 47907 USA.	riyi@purdue.edu					Burcham PC, 2000, REDOX REP, V5, P47, DOI 10.1179/rer.2000.5.1.47; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; Harper ME, 2004, ACTA PHYSIOL SCAND, V182, P321, DOI 10.1111/j.1365-201X.2004.01370.x; JAESCHKE H, 1987, BIOCHEM PHARMACOL, V36, P51, DOI 10.1016/0006-2952(87)90381-9; LALICH JJ, 1974, EXP MOL PATHOL, V21, P29, DOI 10.1016/0014-4800(74)90076-8; Lucas JH, 2002, J NEUROTRAUM, V19, P763, DOI 10.1089/08977150260139138; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; NORDQUIST JE, 2002, THESIS UPPSALA U; Norton ND, 1997, TOXICOLOGY, V122, P111, DOI 10.1016/S0300-483X(97)00086-3; Picklo MJ, 2001, BBA-MOL BASIS DIS, V1535, P145, DOI 10.1016/S0925-4439(00)00093-4; Rudra PK, 1999, ANTICANCER RES, V19, P461; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P403, DOI 10.3748/wjg.v11.i3.403; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tanel A, 2005, BBA-MOL CELL RES, V1743, P255, DOI 10.1016/j.bbamcr.2004.11.007; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Vasan S, 2003, ARCH BIOCHEM BIOPHYS, V419, P89, DOI 10.1016/j.abb.2003.08.016; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4; Zhang DQ, 1999, NEUROSCI LETT, V272, P57, DOI 10.1016/S0304-3940(99)00455-3; ZOLLNER H, 1973, BIOCHEM PHARMACOL, V22, P1171, DOI 10.1016/0006-2952(73)90234-7	25	52	53	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2006	84	1					219	227		10.1002/jnr.20862			9	Neurosciences	Neurosciences & Neurology	061UD	WOS:000238897400020	16619236				2021-06-18	
J	Singh, M				Singh, M			Progesterone-induced neuroprotection	ENDOCRINE			English	Article						progestins; progesterone; neuroprotection; signal transduction	TRAUMATIC BRAIN-INJURY; SPRAGUE-DAWLEY RATS; MEDROXYPROGESTERONE ACETATE; BINDING PROTEIN; MEMBRANE; EXPRESSION; ESTROGEN; STEROIDS; RECEPTOR; CELL	Estrogen and progesterone are two steroid hormones whose biology has been greatly studied within the confines of reproductive function. As a consequence, the effects of these hormones on the brain have focused primarily on the hypothalamus. Growing evidence, however, forces us to recognize that various extrahypothalamic brain regions, including the cerebral cortex and hippocampus, are equally important targets of these hormones. As such, hormones are involved in numerous aspects of brain function, and elicit effects ranging from the regulation of mood and cognition to the regulation of neuronal survival. While estrogen exerts neuroprotective effects in various experimental models, the potential for progesterone as a protective agent has, until recently, been greatly understudied. Here, we review the data from various laboratories including our own that support the protective role of progesterone and describe the multiplicity of mechanisms by which progesterone elicits these protective effects. Finally, we contrast the neurobiology of progesterone with that of the clinically used progestin, medroxyprogesterone acetate (MPA), and suggest that the "natural" progesterone may be the better choice when considering which progestin to use for future therapeutic/palliative purposes in CNS-related disorders.	Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Singh, M (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	msingh@hsc.unt.edu		Singh, Meharvan/0000-0002-8072-1769	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 22550, AG 23330] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022550, R03AG023330] Funding Source: NIH RePORTER		Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BELLHORNER C, 2004, 34 ANN SOC NEUR M SA; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; COLLADO ML, 1985, PHARMACOL BIOCHEM BE, V23, P501, DOI 10.1016/0091-3057(85)90408-3; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; DEUTSCH SI, 1992, CLIN NEUROPHARMACOL, V15, P352, DOI 10.1097/00002826-199210000-00002; Falkenstein E, 1998, CELL MOL BIOL, V44, P571; GAMBRELL RD, 1986, CLIN OBSTET GYNAECOL, V13, P695; Goodman YD, 1996, J NEUROCHEM, V66, P1836; HIRVONEN E, 1996, MATURITAS S, V23, P13; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; KAUR P, 2004, 34 ANN SOC NEUR M SA; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; Krebs CJ, 2000, P NATL ACAD SCI USA, V97, P12816, DOI 10.1073/pnas.97.23.12816; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Meyer C, 1996, EUR J BIOCHEM, V239, P726, DOI 10.1111/j.1432-1033.1996.0726u.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Min L, 2004, MOL CELL ENDOCRINOL, V215, P143, DOI 10.1016/j.mce.2003.11.025; Miyagawa K, 1997, AM J PHYSIOL-HEART C, V272, pH2645; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rosano GMC, 2000, J AM COLL CARDIOL, V36, P2154, DOI 10.1016/S0735-1097(00)01007-X; Sakamoto H, 2004, NEUROSCIENCE, V126, P325, DOI 10.1016/j.neuroscience.2004.04.003; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; Vasan R., 2003, 33 ANN SOC NEUR M NE; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	35	52	53	1	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0969-711X			ENDOCRINE	Endocrine	APR	2006	29	2					271	274		10.1385/ENDO:29:2:271			4	Endocrinology & Metabolism	Endocrinology & Metabolism	050LM	WOS:000238088900010	16785602				2021-06-18	
J	Narotam, PK; Budonrappa, SC; Raynor, SC; Rao, M; Taylon, C				Narotam, PK; Budonrappa, SC; Raynor, SC; Rao, M; Taylon, C			Cerebral oxygenation in major pediatric trauma: its relevance to trauma severity and outcome	JOURNAL OF PEDIATRIC SURGERY			English	Article						brain tissue oxygenation (PbtO(2)); Pediatric Trauma Score; Injury Severity Score; Revised Trauma Score; traumatic brain injury	SEVERE HEAD-INJURY; BRAIN-TISSUE OXYGENATION; PERFUSION-PRESSURE; HEMORRHAGIC-SHOCK; COMATOSE PATIENTS; INSPIRED OXYGEN; TENSION; SCORE; EXPERIENCE; MANAGEMENT	Introduction: Trauma is the commonest cause of death in the pediatric population, which is prone to diffuse primary brain injury aggravated by secondary insults (eg, hypoxia, hypotension). Standard monitoring involves intracranial pressure (ICP) and cerebral perfusion pressure, which do not reflect true cerebral oxygenation (oxygen delivery [Do,]). We explore the merits of a brain tissue oxygen-directed critical care guide. Methods: Sixteen patients with major trauma (Injury Severity Score, > 16/Pediatric Trauma Score [PTS], < 7) had partial pressure of brain tissue oxygen (PbtO(2)) monitor (Licox; Integra Neurosciences, Plainsboro, NJ) placed under local anesthesia using twist-drill craniostomy and definitive management of associated injuries. PbtO(2) levels directed therapy intensity level (ventilator management, inotrops, blood transfusion, and others). Patient demographics, short-term physiological parameters, PbtO(2), ICP, Glasgow Coma Score, trauma scores, and outcomes were analyzed to identify the patients at risk for low DO2. Results: There were 10 males and 6 females (mean age, 14 years) sustaining motor vehicle accident (14), falls (1), and assault (1), with a mean Injury Severity Score of 36 (16-59); PTS, 3 (0-7); and Revised Trauma Score, 5.5 (4-11). Eleven patients (70%) had low DO2 (PbtO(2), < 20 mm Hg) on admission despite undergoing standard resuscitation affected by fraction of inspired oxygen, PaO2, and cerebral perfusion pressure (P=.001). Eubaric hyperoxia improved cerebral oxygenation in the low-DO2 group (P=.044). The Revised Trauma Score (r = 0.65) showed moderate correlation with PbtO(2) and was a significant predictor for low DO2 (P=-001) In patients with PbtO(2) of less than 20 mm Hg, PTS correlated with cerebral oxygenation (r = 0.671, P =.033). The mean 2-hour PbtO(2) and the final PbtO(2) in survivors were significantly higher than deaths (21.6 vs 7.2 mm Hg [P =.009] and 25 vs 11 mm Hg [P =.01]). Although 4 of 6 deaths were from uncontrolled high ICP, PTS and 2-hour low DO2 were significant for roots for mortality. Conclusions: PbtO(2) monitoring allows for early recognition of low-Do, situations, enabling appropriate therapeutic intervention. (c) 2006 Elsevier Inc. All rights reserved.	Creighton Univ, Med Ctr, Div Neurosurg, Div Neurosurg & Trauma, Omaha, NE 68131 USA	Narotam, PK (corresponding author), Creighton Univ, Med Ctr, Div Neurosurg, Div Neurosurg & Trauma, Omaha, NE 68131 USA.	narotam@creighton.edu		Burjonrappa, Sathyaprasad/0000-0002-4743-4047			Bardt TF, 1998, ACT NEUR S, V71, P153; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P1053, DOI 10.1016/S0196-0644(89)80930-8; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; Filippi R, 2000, NEUROSURG REV, V23, P94; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Jodicke A, 2003, J NEUROSURG, V98, P515, DOI 10.3171/jns.2003.98.3.0515; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; McKinley Bruce A, 2003, Curr Opin Crit Care, V9, P292, DOI 10.1097/00075198-200308000-00007; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAYDUCH DA, 1991, J TRAUMA, V31, P452, DOI 10.1097/00005373-199104000-00003; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAMENOFSKY ML, 1988, J TRAUMA, V28, P1038, DOI 10.1097/00005373-198807000-00021; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Stocchetti N, 1998, ACT NEUR S, V71, P162; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	41	52	53	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	MAR	2006	41	3					505	513		10.1016/j.jpedsurg.2005.11.069			9	Pediatrics; Surgery	Pediatrics; Surgery	026FU	WOS:000236325600009	16516625				2021-06-18	
J	Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME				Williams, G; Robertson, V; Greenwood, K; Goldie, P; Morris, ME			The concurrent validity and responsiveness of the High-Level Mobility Assessment Tool for measuring the mobility limitations of people with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	International Symposium on Measurement and Evaluation of Outcomes in Rehabilitation	SEP 27-28, 2004	Stockholm, SWEDEN			brain injuries; gait disorders, neurologic; rehabilitation; reproducibility of results; running	FUNCTIONAL INDEPENDENCE MEASURE; RIVERMEAD MOTOR-ASSESSMENT; STROKE PATIENTS; REHABILITATION; RELIABILITY; OUTCOMES; SCALABILITY; INSTRUMENTS; IMPAIRMENT; DISABILITY	Objective: To investigate the concurrent validity and responsiveness of the High-Level Mobility Assessment Tool (HiMAT) in people after traumatic brain injury (TBI). Design: This study compared the concurrent validity and responsiveness of the motor subsection of the FIM instrument and the gross function component of the Riverinead Motor Assessment (RMA) with the HiMAT, a new measure of highlevel mobility developed for use in TBI. Setting: A major rehabilitation hospital. Participants: A convenience sample of 103 participants with TBI were recruited from a major rehabilitation hospital. Interventions: Not applicable. Main Outcome Measures: HiMAT, motor FIM, and the gross function RMA. Results: The correlation between the HiMAT and motor FIM Was moderate (r=.53, P <.001), largely because of a ceiling effect in the motor FIM. The correlation between the HiMAT and gross function RMA was strong (r=.87, P <.001), yet the gross function RMA was also susceptible to a ceiling effect. with 51.5% of subjects achieving the maximum score. The HiMAT was more responsive than the motor FIM and the gross function RMA on all indices. Conclusions: The HiMAT is a new unidimensional scale with moderate concurrent validity for measuring high-level mobility. The HiMAT is more responsive and has less of a ceiling effect than either the motor FIM or the gross function RMA.	Epworth Med Fdn, Richmond, Vic 3121, Australia; La Trobe Univ, Sch Physiotherapy, Bundoora, Vic, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; Univ Melbourne, Sch Physiotherapy, Melbourne, Vic, Australia	Williams, G (corresponding author), Epworth Med Fdn, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Morris, Meg/0000-0002-0114-4175; Williams, Gavin/0000-0003-2758-7473			Adams SA, 1997, CLIN REHABIL, V11, P52, DOI 10.1177/026921559701100108; Adams SA, 1997, CLIN REHABIL, V11, P42, DOI 10.1177/026921559701100107; Beaton DE, 2001, J CLIN EPIDEMIOL, V54, P1204, DOI 10.1016/S0895-4356(01)00407-3; Brock KA, 2002, ARCH PHYS MED REHAB, V83, P92, DOI 10.1053/apmr.2002.27348; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Collen F M, 1991, Int Disabil Stud, V13, P50; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Davidson M, 2002, PHYS THER, V82, P8, DOI 10.1093/ptj/82.1.8; Dillon H, 2000, EAR HEARING, V21, p2S, DOI 10.1097/00003446-200008001-00002; Fisher K, 2002, CLIN REHABIL, V16, P871, DOI 10.1191/0269215502cr554oa; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Granger CV, 1983, GUIDE USE UNIFORM DA; Guttman L, 1944, AM SOCIOL REV, V9, P139, DOI 10.2307/2086306; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KAZIS LE, 1989, MED CARE S, V27, P178; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lincoln N, 1979, Physiotherapy, V65, P48; Ponte-Allan M, 1999, AM J OCCUP THER, V53, P646, DOI 10.5014/ajot.53.6.646; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WILLIAMS G, IN PRESS PHYS THER; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	28	52	52	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2006	87	3					437	442		10.1016/j.apmr.2005.10.028			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	021XZ	WOS:000236020500020	16500181	Green Published			2021-06-18	
J	Lister, JP; Tonkiss, J; Blatt, GJ; Kemper, TL; DeBassio, WA; Galler, JR; Rosene, DL				Lister, James P.; Tonkiss, John; Blatt, Gene J.; Kemper, Thomas L.; DeBassio, William A.; Galler, Janina R.; Rosene, Douglas L.			Asymmetry of neuron numbers in the hippocampal formation of prenatally malnourished and normally nourished rats: A stereological investigation	HIPPOCAMPUS			English	Article						CA1; cerebral dominance; hippocampus; nutrition; stereology; subiculum	TRAUMATIC BRAIN-INJURY; PROTEIN-MALNUTRITION; POSTNATAL-DEVELOPMENT; PYRAMIDAL CELLS; AGED RATS; CA1; MEMORY; ESTIMATORS; FEMALE; REGION	There is considerable evidence for lateralization of hippocampal function and hemispheric asymmetry in humans. In the rat, studies have reported asymmetries in the thicknesses of layers, the volumes of hippocampal subfields, and the density of cells at specific points along the septotemporal axis. To determine if there is an asymmetry of neuron numbers and whether prenatal malnutrition affects any asymmetries, 90-day old male Sprague-Dawley rats that were either normally nourished or malnourished prenatally were perfused with 4% paraformaldehyde and the brains cut into 30-mu m sections. One interrupted series of sections through the entire hippocampus was analyzed stereologically to estimate the total number of neurons in the hilus of the dentate gyrus, the CA3/CA2 stratum pyramidale (SP), the CA1 SP, and the SP of the prosubiculum/subiculum of both hemispheres. Significant asymmetries (P < 0.05) were found in the CA1 and CA3/CA2 subfields, with the right hemisphere containing 21 and 6% fewer neurons, respectively. Malnutrition reduced neuron numbers in the CA1 subfield by 12%, but did not alter the hemispheric asymmetry. Our findings agree with previous reports of left dominant asymmetries in the rat brain and suggest that this may result from differences in total numbers of neurons. (c) 2006 Wiley-Liss, Inc.	Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Behav Dev & Mental Retardat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Lister, JP (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, 715 Albany St W701, Boston, MA 02118 USA.	listerj@bu.edu	Rosene, Douglas L/G-1973-2015	Kemper, Thomas/0000-0002-4623-4094; Tonkiss, John/0000-0002-6498-7815; DeBassio, William/0000-0002-0073-5627; Rosene, Douglas/0000-0001-8719-1441	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD022539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH069686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG000001] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01-AG00001] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01-HD22539] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1R01-MH069686] Funding Source: Medline		BAYER SA, 1974, J COMP NEUROL, V158, P55, DOI 10.1002/cne.901580105; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; Bronzino JD, 1997, EXP NEUROL, V148, P317, DOI 10.1006/exnr.1997.6653; CINTRA L, 1990, BRAIN RES, V532, P271, DOI 10.1016/0006-8993(90)91769-D; Cintra L, 1997, HIPPOCAMPUS, V7, P184, DOI 10.1002/(SICI)1098-1063(1997)7:2<184::AID-HIPO5>3.0.CO;2-N; Cintra L, 1997, HIPPOCAMPUS, V7, P192, DOI 10.1002/(SICI)1098-1063(1997)7:2<192::AID-HIPO6>3.0.CO;2-P; DIAMOND MC, 1983, EXP NEUROL, V81, P1, DOI 10.1016/0014-4886(83)90153-X; DIAMOND MC, 1982, EXP NEUROL, V76, P553, DOI 10.1016/0014-4886(82)90124-8; DIAZCINTRA S, 1991, J COMP NEUROL, V310, P356, DOI 10.1002/cne.903100306; DIAZCINTRA S, 1994, BRAIN RES, V662, P117, DOI 10.1016/0006-8993(94)90803-6; GALLER JR, 1991, J NUTR, V121, P762; GALLER JR, 1996, NUTR PEDIAT, P196; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Granados-Rojas L, 2002, BRAIN RES, V933, P164, DOI 10.1016/S0006-8993(02)02314-4; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Halpern ME, 2003, TRENDS NEUROSCI, V26, P308, DOI 10.1016/S0166-2236(03)00129-2; Hedreen JC, 1998, ANAT REC, V250, P366; JENNRICH R, 1988, BMDP STAT SOFTWARE M, P485; Kawakami R, 2003, SCIENCE, V300, P990, DOI 10.1126/science.1082609; KOLB B, 1982, EXP NEUROL, V78, P348, DOI 10.1016/0014-4886(82)90053-X; Lister JP, 2005, HIPPOCAMPUS, V15, P393, DOI 10.1002/hipo.20065; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Milner B, 1972, Clin Neurosurg, V19, P421; Morgane PJ, 2002, NEUROSCI BIOBEHAV R, V26, P471, DOI 10.1016/S0149-7634(02)00012-X; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; Ragbetli MC, 2002, INT J NEUROSCI, V112, P81, DOI 10.1080/00207450212016; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; ROSENE DL, 1986, J HISTOCHEM CYTOCHEM, V34, P1301, DOI 10.1177/34.10.3745909; Rosene DL., 1987, CEREB CORTEX, P345, DOI [10.1007/978-1-4615-6616-8_9, DOI 10.1007/978-1-4615-6616-8_9]; SLOMIANKA L, 1987, BRAIN RES, V436, P69, DOI 10.1016/0006-8993(87)91557-5; Slomianka L, 2005, NEUROSCIENCE, V136, P757, DOI 10.1016/j.neuroscience.2005.06.086; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; STOKES KA, 1981, PHYSIOL BEHAV, V26, P163, DOI 10.1016/0031-9384(81)90005-6; Tang AC, 2003, ASYMMETRICAL BRAIN, P37; Toga AW, 2003, NAT REV NEUROSCI, V4, P37, DOI 10.1038/nrn1009; TONKISS J, 1993, ANN NY ACAD SCI, V678, P215; TONKISS J, 1990, BEHAV BRAIN RES, V40, P95, DOI 10.1016/0166-4328(90)90002-V; Tuunanen J, 2000, EPILEPSY RES, V39, P171, DOI 10.1016/S0920-1211(99)00123-0; VALDES JJ, 1981, PHYSIOL BEHAV, V27, P381, DOI 10.1016/0031-9384(81)90284-5; VANEDEN CG, 1984, DEV BRAIN RES, V12, P146, DOI 10.1016/0165-3806(84)90186-X; VANGROEN T, 1990, J COMP NEUROL, V302, P515, DOI 10.1002/cne.903020308; Verstynen T, 2001, NEUROREPORT, V12, P3019, DOI 10.1097/00001756-200110080-00008; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	45	52	52	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1050-9631	1098-1063		HIPPOCAMPUS	Hippocampus		2006	16	11					946	958		10.1002/hipo.20221			13	Neurosciences	Neurosciences & Neurology	102SL	WOS:000241833500005	16983649				2021-06-18	
J	Itoh, T; Satou, T; Hashimoto, S; Ito, H				Itoh, T; Satou, T; Hashimoto, S; Ito, H			Isolation of neural stem cells from damaged rat cerebral cortex after traumatic brain injury	NEUROREPORT			English	Article						culture; nestin; neural stem cell; neurosphere; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; CORTICAL IMPACT INJURY; ADULT-RAT; PROLIFERATION; EXPRESSION; NESTIN; NEUROGENESIS; ASTROCYTES; NEURONS	Nestin-positive cells were seen around the damaged area at 24 h, 72 In and 7 days after rat traumatic brain injury. Tissue was isolated from around the damaged area at 72 h after injury and spheres were cultured with basic fibroblast growth factor and epidermal growth factor. These spheres could not be isolated at 24 h and 7 days after injury. Isolated spheres consisted of nestin-positive neural stem cells. Neurospheres differentiated into Tujl-positive, glial fibrillary acidic protein-positive and O4-positive cells after 4 days in culture without basic fibroblast growth factor and epidermal growth factor. These results indicate that isolated and cultured neurospheres can differentiate into neurons and glia. An increase in nestin-positive cells around a cerebral cortical damaged area might contribute to neurogenesis and neuroplasticity.	Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan; Kinki Univ, Sch Med, Div Hosp Pathol, Osaka, Japan; Kinki Univ, Div Sports Med, Inst Life Sci, Osaka, Japan; PL Hosp, Div Pathol, Osaka, Japan	Itoh, T (corresponding author), 377-2,Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp					Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Johansson CB, 2002, J NEUROSCI RES, V69, P784, DOI 10.1002/jnr.10376; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Magavi SS, 2000, NATURE, V405, P951; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798; Yanagisawa M, 2000, J NEUROCHEM, V74, P1498, DOI 10.1046/j.1471-4159.2000.0741498.x	17	52	70	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	OCT 17	2005	16	15					1687	1691		10.1097/01.wnr.0000183330.44112.ab			5	Neurosciences	Neurosciences & Neurology	981FW	WOS:000233073900015	16189478				2021-06-18	
J	Hadjigeorgiou, GM; Paterakis, K; Dardiotis, E; Dardioti, M; Aggelakis, K; Tasiou, A; Xiromerisiou, G; Komnos, A; Zintzaras, E; Scarmeas, N; Papadimitriou, A; Karantanas, A				Hadjigeorgiou, GM; Paterakis, K; Dardiotis, E; Dardioti, M; Aggelakis, K; Tasiou, A; Xiromerisiou, G; Komnos, A; Zintzaras, E; Scarmeas, N; Papadimitriou, A; Karantanas, A			IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury	NEUROLOGY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN-ENDOTHELIAL-CELLS; SEVERE HEAD-INJURY; MULTIPLE-SCLEROSIS; HUMAN MONOCYTES; INNATE IMMUNE; ASSOCIATION; DISEASE; INFLAMMATION; COAGULATION	Objective: To investigate the association of (variable number tandem repeat) interleukin (IL) 1RN and (-511) IL-1B gene polymorphisms with brain hemorrhagic events after traumatic brain injury (TBI). Methods: Data from brain CT, Glasgow Coma Scale (GCS) at admission, and 6-month Glasgow Outcome Scale (GOS) and modified Rankin Scale (mRS) were collected for 151 prospectively recruited patients with TBI. IL-1RN and IL-1B genotypes were determined using standard methods. Presence vs absence of any type of brain hemorrhage was the main outcome. Type of brain hemorrhage, GCS at admission, and 6-month GOS and mRS were secondary outcomes. Odd ratios (ORs) and corresponding 95% CI were calculated using logistic regression analyses. In adjusted models, the associations were controlled for age, gender, diffuse brain edema, volume of intracranial hematoma, neurosurgical intervention, and GCS at admission. p values less than 0.01 were considered significant. Results: Compared with noncarriers, IL-1RN allele 2 carriers had higher odds of having cerebral hemorrhages after TBI ( adjusted OR = 4.57; 95% CI = 1.67 to 12.96; p = 0.004). The associations for (-511) IL-1B polymorphism were not significant. Conclusion: There is an association between the presence of interleukin-1RN allele 2 and posttraumatic brain hemorrhage.	Univ Thessaly, Sch Med, Dept Neurol, Neurogenet Unit, Larisa 41222, Greece; Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Neurosurg, Larisa 41222, Greece; Univ Thessaly, Sch Med, ICU, Larisa 41222, Greece; Univ Thessaly, Sch Med, CT & MRI Unit, Gen Hosp Larissa, Larisa 41222, Greece; Univ Thessaly, Sch Med, Dept Biomath, Larisa 41222, Greece; Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA; Columbia Univ, Med Ctr, Taub Inst, New York, NY USA	Hadjigeorgiou, GM (corresponding author), Univ Thessaly, Sch Med, Dept Neurol, Neurogenet Unit, Papakyriazi 22 St, Larisa 41222, Greece.	gmhadji@med.uth.gr	Scarmeas, Nikolaos/AAD-2517-2020; Paterakis, Konstantinos/AAH-4554-2019; Karantanas, Apostolos/AAE-6820-2020; Scarmeas, Nikolaos/AAD-2512-2020	Scarmeas, Nikolaos/0000-0001-6453-8908; Karantanas, Apostolos/0000-0002-0927-2403; Scarmeas, Nikolaos/0000-0001-6453-8908; Dardiotis, Efthimios/0000-0003-2957-641X; Xiromerisiou, Georgia/0000-0001-7162-3588			Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Bird TD, 2001, NEUROLOGY, V57, P1153, DOI 10.1212/WNL.57.7.1153; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303; DEHAAN R, 1995, STROKE, V26, P2027, DOI 10.1161/01.STR.26.11.2027; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dewberry R, 2000, ARTERIOSCL THROM VAS, V20, P2394, DOI 10.1161/01.ATV.20.11.2394; Di Giovine F. S., 1992, Human Molecular Genetics, V1, P450; Esmon CT, 2004, TRENDS IMMUNOL, V25, P536, DOI 10.1016/j.it.2004.08.003; Francis SE, 1999, CIRCULATION, V99, P861, DOI 10.1161/01.CIR.99.7.861; Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRAMSE M, 1986, BIOCHEM BIOPH RES CO, V139, P720, DOI 10.1016/S0006-291X(86)80050-X; Hall SK, 2004, ARTHRITIS RHEUM-US, V50, P1976, DOI 10.1002/art.20310; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; JENNETT B, 1975, LANCET, V1, P480; Joseph L, 2002, BLOOD COAGUL FIBRIN, V13, P105, DOI 10.1097/00001721-200203000-00005; Kantarci OH, 2000, J NEUROIMMUNOL, V106, P220, DOI 10.1016/S0165-5728(00)00202-2; Kastrati A, 2000, J AM COLL CARDIOL, V36, P2168, DOI 10.1016/S0735-1097(00)01014-7; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lawton MT, 2005, NEUROSURGERY, V56, P485, DOI 10.1227/01.NEU.0000153924.67360.EA; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; Mann CLA, 2002, J NEUROIMMUNOL, V129, P197, DOI 10.1016/S0165-5728(02)00181-9; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McGeer PL, 2002, NEUROSCI LETT, V326, P67, DOI 10.1016/S0304-3940(02)00300-2; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Opal SM, 2003, CRIT CARE, V7, P23, DOI 10.1186/cc1854; Osnes LTN, 1996, CYTOKINE, V8, P822, DOI 10.1006/cyto.1996.0110; Ott J, 2004, NEUROLOGY, V63, P955, DOI 10.1212/WNL.63.6.955; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Paterniti S, 1998, ACTA NEUROCHIR, V140, P953, DOI 10.1007/s007010050198; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Rhodes Jonathan K J, 2003, Curr Opin Crit Care, V9, P86; Santtila S, 1998, SCAND J IMMUNOL, V47, P195; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; SCHORER AE, 1989, THROMB RES, V56, P515, DOI 10.1016/0049-3848(89)90235-1; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Stein Deborah M, 2004, Curr Opin Crit Care, V10, P520, DOI 10.1097/01.ccx.0000144770.96342.65; TARLOW JK, 1993, HUM GENET, V91, P403; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; WEIR BS, 1996, DATA ANAL, V2; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; Worrall BB, 2003, STROKE, V34, P790, DOI 10.1161/01.STR.0000057815.79289.EC	59	52	55	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 11	2005	65	7					1077	1082		10.1212/01.wnl.0000178890.93795.0e			6	Clinical Neurology	Neurosciences & Neurology	972RF	WOS:000232470200020	16217062				2021-06-18	
J	Stiefel, MF; Tomita, Y; Marmarou, A				Stiefel, MF; Tomita, Y; Marmarou, A			Secondary ischemia impairing the restoration of ion homeostasis following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; ischemia; ion-selective electrode; potassium; sodium; rat	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; TRANSIENT FOREBRAIN ISCHEMIA; COMA DATA-BANK; EXTRACELLULAR POTASSIUM; RAT-BRAIN; PHOSPHATE-METABOLISM; IN-VIVO; HYPOXIA; EDEMA	Object. It is well established that posttraumatic secondary ischemia contributes to poor outcome. Ion dysfunction leading to cytotoxic edema is a primary force in the formation of ischemic brain edema and is a principal component of traumatic brain swelling. Because cell swelling is the result of net ion and water movement, it is crucial to have a thorough understanding of these transient phenomena. The purpose of this study was to characterize the effects of secondary ischemia following traumatic brain injury (TBI) on the ability to restore ion homeostasis. Methods. Twenty-four Sprague-Dawley rats were divided into four groups of six animals each. The rats underwent transient forebrain ischemia via bilateral carotid artery occlusion combined with hypotension: 15 minutes of forebrain ischemia (Group 1); 60 minutes of forebrain ischemia (Group 2); impact acceleration/TBI (Group 3); and impact acceleration/TBI followed by 15 minutes of ischemia (Group 4). Ischemia resulted in a rapid accumulation of [K+](e): 41.94 +/- 13.65 and 66.33 +/- 6.63 mM, respectively, in Groups I and 2, with a concomitant decrease of (Na+],: 64 +/- 18 mM and 72 +/- 11 mM in Groups I and 2. Traumatic brain injury resulted in a less severe although identical trend in ion dysfunction ([K+](e) 30.42 +/- 11.67 mM and [Na+](e) 63 +/- 33 mM). Secondary ischemia resulted in prolonged and sustained ion dysfunction with a concomitant elevation of intracranial pressure (ICP). Conclusions. Analysis of these results indicates that ischemia and TBI are sublethal in isolation; however, when TBI is associated with secondary ischemia, ion dysfunction is sustained and is associated with elevated ICP.	Virginia Commonwealth Univ, Dept Neurosurg, Hlth Syst, Richmond, VA 23298 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Hlth Syst, POB 980508,1001 E Broad St,Old City Hall, Suite 5, Richmond, VA 23298 USA.	marmarou@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587] Funding Source: NIH RePORTER		ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Chappell JE, 1996, J TRAUMA, V41, P781, DOI 10.1097/00005373-199611000-00003; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; HANSEN AJ, 1980, PFLUG ARCH EUR J PHY, V389, P1, DOI 10.1007/BF00587921; HANSEN AJ, 1977, ACTA PHYSIOL SCAND, V101, P438, DOI 10.1111/j.1748-1716.1977.tb06027.x; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P438, DOI 10.1038/jcbfm.1984.63; HOSSMANN KA, 1977, STROKE, V8, P77, DOI 10.1161/01.STR.8.1.77; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1991, BRAIN RES, V568, P294, DOI 10.1016/0006-8993(91)91412-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KITA H, 1994, ACTA NEUROCHIR, P452; LJUNGGREN B, 1974, BRAIN RES, V73, P291, DOI 10.1016/0006-8993(74)91050-6; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; PULSINELLI WA, 1982, ANN NEUROL, V11, P499, DOI 10.1002/ana.410110510; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; Stiefel MF, 2002, J NEUROSURG, V97, P97, DOI 10.3171/jns.2002.97.1.0097; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WALZ W, 1983, PROG NEUROBIOL, V20, P133, DOI 10.1016/0301-0082(83)90013-8; WALZ W, 1984, J CEREBR BLOOD F MET, V4, P301, DOI 10.1038/jcbfm.1984.42; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yamamoto T, 1997, ACT NEUR S, V70, P71; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751	51	52	52	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2005	103	4					707	714		10.3171/jns.2005.103.4.0707			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	971LG	WOS:000232385000019	16266054				2021-06-18	
J	Goldstrohm, SL; Arffa, S				Goldstrohm, SL; Arffa, S			Preschool children with mild to moderate traumatic brain injury: An exploration of immediate and post-acute morbidity	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						traumatic brain injury; brain injury; head injury; pediatric neuropsychology; preschool children; TBI	CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; SEVERITY; ADOLESCENTS; PREDICTORS; PERFORMANCE; RECOVERY; MEMORY; ADULTS; OLDER	This study explored premorbid, neurocognitive, behavioral, and familial factors in preschoolers, ages 3-6, who experienced a mild to moderate traumatic brain injury (TBI). Twenty-nine children with TBI, 33 children with mild to moderate injuries to other body regions, and 34 non-injured children participated in the study. Neuropsychological assessments and behavioral measures were administered at the time of hospitalization and 6 months later. In comparison to the non-injury children, preschool-aged children with TBI had higher rates of premorbid behavior difficulties, lower premorbid cognitive functioning, and poorer development of pre-academic skills. In addition, parents of children with TBI reported greater situational issues and life stressors than parents of children in the non-injured group. Some neurocognitive recovery was evident in the TBI group, but no differences were recognized in behavioral and family measures at the 6-month follow-up. This study emphasizes the relative effects of premorbid characteristics in later practice of preschool children who sustain TBI. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, Pittsburgh, PA 15213 USA; Watson Inst, Pittsburgh, PA 15143 USA	Goldstrohm, SL (corresponding author), Univ Pittsburgh, Western Psychiat Inst & Clin, Med Ctr, 3811 Ohara St, Pittsburgh, PA 15213 USA.	goldstrohmsl@upmc.edu					Abidin RR., 1995, PARENTING STRESS IND; Achenbach T. M., 1986, CHILD BEHAV CHECKLIS; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ARFFA S, 1995, HEAD INJURY THROUGH; ARFFA S, 1998, PEDIAT NEUROPSYCHIAT; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Bracken B. A., 1984, BRACKEN BASIC CONCEP; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, PSYCHOL MED, V11, P1227; Conners CK, 1997, CONNERS GLOBAL INDEX; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P279; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GOTSCHALL CS, 1993, PEDIAT TRAUMA PREVEN, P16; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kolb B., 1995, BRAIN PLASTICITY BEH; KORKMAN M, 1997, NEPSY; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1979, CHILD BRAIN, V5, P281; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MATHENY AP, 1987, ANN PROGR CHILD PSYC; McCarney SB, 1995, ATTENTION DEFICIT DI; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; RUTTER M, 1983, HEAD INJURY DEV NEUR; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; SHAFFER D, 1975, OUTCOME SEVERE DAMAG, P191; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; TAYLOR HG, 1995, TRAUMATIC HEAD INJUR; Thorndike RL., 1986, STANFORD BINET INTEL, V4; TRICKETT PK, 1991, DEV PSYCHOL, V27, P148, DOI 10.1037/0012-1649.27.1.148; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	57	52	52	1	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2005	20	6					675	695		10.1016/j.acn.2005.02.005			21	Psychology, Clinical; Psychology	Psychology	950HW	WOS:000230849200001	15967630	Bronze			2021-06-18	
J	Martin, I; McDonald, S				Martin, I; McDonald, S			Evaluating the causes of impaired irony comprehension following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; FRONTAL-LOBE; LINGUISTIC HUMOR; MIND; COMMUNICATION; CHILDREN; ABILITY; ADOLESCENTS; DEFICITS	Background: Individuals with traumatic brain injury (TBI) are known to have difficulty in understanding non-literal language devices such as irony. There are at least two possible explanations for poor irony comprehension following TBI; first, deficits might be caused by a specific impairment to theory of mind (ToM) and, second, deficits could be attributed to more general impairment in executive functioning (EF). Aims: This study aimed to evaluate the role of ToM and EF in the ability to comprehend non-literal ironic jokes. Methods & Procedures: Participants were 16 individuals who had sustained a TBI and 16 age- and demographic-matched controls. The ability to make inferences about mental states was compared to inferential reasoning capacity more generally. Participants were also assessed on other aspects of EF thought to contribute to inference making (working memory, concept formation, and fluency). The extent to which scores on theses tasks were associated with participants' ability to comprehend ironic jokes was assessed using correlational and regression analyses. Outcomes & Results: Participants with TBI were significantly impaired on tasks measuring both ToM and EF. ToM was not significantly associated with irony comprehension. Instead, inferential reasoning, more broasdly defined, demonstrated the strongest association. None of the component EF tasks were associated with irony comprehension. Conclusion: The results of this study do not support the theory that a specific impairment to ToM causes poor irony comprehension in TBI. In contrast, general inferential reasoning was a strong and significant predictor.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMOVICH BLB, 1991, COGNITIVE REHABILITA; Bach K., 1998, PRAGMATICS CRITICAL, P712; Bach K., 1994, FDN SPEECH ACT THEOR, P267; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Courtin C, 1998, PSYCHOLOGICAL PERSPECTIVES ON DEAFNESS, VOL 2, P79; DAVIS HL, 1995, AUST J PSYCHOL, V47, P25, DOI 10.1080/00049539508258765; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Gibbs RW, 1999, BRAIN LANG, V68, P466, DOI 10.1006/brln.1999.2123; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; Joanette Y., 1990, DISCOURSE ABILITY BR; Keenan T, 1998, NEW ZEAL J PSYCHOL, V27, P36; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Levinson S.C., 1983, PRAGMATICS; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Martin I, 2004, J AUTISM DEV DISORD, V34, P311, DOI 10.1023/B:JADD.0000029553.52889.15; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 2003, NEUROPSYCHOL REHABIL, V14, P285; MENNEL HD, 1997, SEVERE HEAD INJURIES, P19; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Perkins MR, 1998, J PRAGMATICS, V29, P291, DOI 10.1016/S0378-2166(97)00055-6; Peterson CC, 1999, PSYCHOL SCI, V10, P126, DOI 10.1111/1467-9280.00119; Peterson CC, 2000, MIND LANG, V15, P123, DOI 10.1111/1468-0017.00126; PRIGATANO GP, 1986, NEUROPSYCHOGICAL REH; Russell J, 1999, J CHILD PSYCHOL PSYC, V40, P859, DOI 10.1111/1469-7610.00504; Russell J, 1997, AUTISM EXECUTIVE DIS, P256, DOI DOI 10.1093/MED:PSYCH/9780198523499.003.0008; Russell J, 1997, AUTISM EXECUTIVE DIS; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; SPERBER D, 1987, BEHAV BRAIN SCI, V10, P697, DOI 10.1017/S0140525X00055345; Sperber D., 1986, RELEVANCE COMMUNICAT; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1993, DEMENTIA, V4, P220, DOI 10.1159/000107326; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1997, WAIS 3 ADM SCORING M; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x	66	52	54	1	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	AUG	2005	19	8					712	730		10.1080/02687030500172203			19	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	963NT	WOS:000231811700002					2021-06-18	
J	Ratcliff, G; Colantonio, A; Escobar, M; Chase, S; Vernich, L				Ratcliff, G; Colantonio, A; Escobar, M; Chase, S; Vernich, L			Long-term survival following traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; mortality; standardized mortality ratio; death rate; long-term survival	HEAD INJURIES; UNITED-STATES; ASSOCIATION; SEVERITY; TRENDS; DEATH	Purpose. The study used a retrospective cohort design to establish long-term mortality rates and predictors of mortality for persons after moderate to severe traumatic brain injury (TBI). Method. Consecutive records of persons with moderate to severe TBI who were discharged from a large rehabilitation hospital in Pittsburgh, Pennsylvania in the years 1974 - 1984, 1988 and 1989 were reviewed. Results. Six hundred and forty-two eligible individuals were identified and mortality was ascertained up to 24 years post injury. One hundred and twenty-eight of these individuals were found to be deceased. Poisson regression analyses revealed at least a 2-fold increased risk for mortality compared to the general population. Pre-injury characteristics and levels of disability at discharge from in- patient rehabilitation were among the strongest predictors of mortality. Conclusions. These data constitute evidence for premature death in the post-acute TBI population following a moderate to severe head injury and are discussed in relation to other research in the area.	Neuropsychol HealthSouth Harmarville Rehabil Hosp, Pittsburgh, PA 15240 USA; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Working Order, Pittsburgh, PA USA	Ratcliff, G (corresponding author), Neuropsychol HealthSouth Harmarville Rehabil Hosp, POB 11460 Guys Run Rd, Pittsburgh, PA 15240 USA.			Colantonio, Angela/0000-0003-2094-4765; Escobar, Michael/0000-0001-9055-4709	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33AG005856] Funding Source: NIH RePORTER		Agresti A., 1996, INTRO CATEGORICAL DA; Baguley I, 2000, BRAIN INJURY, V14, P505; Breslow N.E., 1980, STAT METHODS CANC RE, V1; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; *COUNC CLIN CLASS, 1980, INT CLASS DIS 9 REV; Das-Gupta R, 2002, DISABIL REHABIL, V24, P654, DOI 10.1080/09638280110109282; Dischinger PC, 2001, J TRAUMA, V51, P877, DOI 10.1097/00005373-200111000-00009; FAHY TJ, 1967, LANCET, V2, P475; KINGMA J, 1992, 9201; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; *PA DEP HLTH BUR H, 1996, PENNS VIT STAT TABL; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; *SAS I INC, 1994, SAS STAT SOFTW REL 6; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	25	52	54	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1464-5165			DISABIL REHABIL	Disabil. Rehabil.	MAR	2005	27	6					305	314		10.1080/09638280400018338			10	Rehabilitation	Rehabilitation	920CL	WOS:000228666400003	16040532				2021-06-18	
J	Runyan, JD; Moore, AN; Dash, PK				Runyan, JD; Moore, AN; Dash, PK			A role for prefrontal calcium-sensitive protein phosphatase and kinase activities in working memory	LEARNING & MEMORY			English	Article							LONG-TERM POTENTIATION; TRAUMATIC BRAIN INJURY; DOPAMINE-RECEPTORS; C ACTIVATION; D-1; CORTEX; PHOSPHORYLATION; INDUCTION; DEFICITS; NEURONS	The prefrontal cortex is involved in the integration and interpretation of information for directing thoughts and planning action. Working memory is defined as the active maintenance of information in mind and is thought to lie at the core of many prefrontal functions. Although dopamine and other neurotransmitters have been implicated, the intracellular events activated by their receptors that influence working memory are poorly understood. We demonstrate that working memory involves transient changes in prefrontal G(q/11)-signaling and in calcium-dependent intracellular protein phosphatase and kinase activity. Interestingly, inhibition of the calcium activated phosphatase calcineurin impaired, while calcium/calmodulin dependent kinase II (CaMKII) and calcium-dependent protein kinase C (PKC) enhanced, working memory. Our findings suggest that the active maintenance of information required for working memory involves transient changes in the balance of these enzymes' activities.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 35457, R01 NS035457] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER		ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; Arthur JM, 1999, AM J PHYSIOL-RENAL, V276, pF528; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Baeg EH, 2003, NEURON, V40, P177, DOI 10.1016/S0896-6273(03)00597-X; Birnbaum SG, 2004, SCIENCE, V306, P882, DOI 10.1126/science.1100021; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Camodeca N, 1999, NEUROPHARMACOLOGY, V38, P1597, DOI 10.1016/S0028-3908(99)00093-3; Castner SA, 2000, SCIENCE, V287, P2020, DOI 10.1126/science.287.5460.2020; d'Alcantara P, 2003, EUR J NEUROSCI, V17, P2521, DOI 10.1046/j.1460-9568.2003.02693.x; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Day M, 2002, J NEUROPHYSIOL, V87, P2490, DOI 10.1152/jn.00843.2001; Edagawa Y, 2000, EUR J NEUROSCI, V12, P1391, DOI 10.1046/j.1460-9568.2000.00007.x; Egorov AV, 2002, NATURE, V420, P173, DOI 10.1038/nature01171; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Goldman-Rakic PS, 2000, BRAIN RES REV, V31, P295, DOI 10.1016/S0165-0173(99)00045-4; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; HYTTEL J, 1983, EUR J PHARMACOL, V91, P153, DOI 10.1016/0014-2999(83)90381-3; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Kozlov A P, 2001, Neurosci Behav Physiol, V31, P405, DOI 10.1023/A:1010488612338; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Margrie TW, 1998, NAT NEUROSCI, V1, P378; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Robbins TW, 2000, SCIENCE, V290, P2275, DOI 10.1126/science.290.5500.2275; Roeper J, 1997, J NEUROSCI, V17, P3379; Runyan JD, 2004, J NEUROSCI, V24, P1288, DOI 10.1523/JNEUROSCI.4880-03.2004; Runyan JD, 2004, NEUROBIOL LEARN MEM, V82, P65, DOI 10.1016/j.nlm.2004.04.006; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Sawaguchi T, 2001, NEUROSCI RES, V41, P115, DOI 10.1016/S0168-0102(01)00270-X; Seamans JK, 1998, J NEUROSCI, V18, P1613; SIBLEY DR, 1982, LIFE SCI, V31, P637, DOI 10.1016/0024-3205(82)90764-0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Taylor AM, 1999, J CARDIOV MAGN RESON, V1, P23, DOI 10.3109/10976649909080830; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ungerleider LG, 1998, P NATL ACAD SCI USA, V95, P883, DOI 10.1073/pnas.95.3.883; UYLINGS HBM, 1990, PROG BRAIN RES, V85, P31; Waters NS, 1997, BEHAV BRAIN RES, V84, P23, DOI 10.1016/S0166-4328(96)00130-1; Young CE, 2004, J NEUROSCI, V24, P8, DOI 10.1523/JNEUROSCI.1650-03.2004; YULE DI, 1992, J BIOL CHEM, V267, P13830; Zahrt J, 1997, J NEUROSCI, V17, P8528	56	52	53	0	0	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1072-0502	1549-5485		LEARN MEMORY	Learn. Mem.	MAR-APR	2005	12	2					103	110		10.1101/lm.89405			8	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	912KV	WOS:000228077800006	15805309	Green Published, Bronze			2021-06-18	
J	Boockvar, JA; Schouten, J; Royo, N; Millard, M; Spangler, Z; Castelbuono, D; Snyder, E; O'Rourke, D; McIntosh, T				Boockvar, JA; Schouten, J; Royo, N; Millard, M; Spangler, Z; Castelbuono, D; Snyder, E; O'Rourke, D; McIntosh, T			Experimental traumatic brain injury modulates the survival migration, and terminal phenotype of transplanted epidermal growth factor receptor-activated neural stem cells	NEUROSURGERY			English	Article						epidermal growth factor receptor; epidermal growth factor receptor vIII; neural stem cells; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD INJURY; PROGENITOR CELLS; RAT-BRAIN; ADULT-RAT; MAGNETIC-RESONANCE; IN-VIVO; PROLIFERATION; ASTROCYTES; INFUSION	OBJECTIVE: We have previously shown that constitutively active epidermal growth factor receptor signaling enhances the survival and motility of engrafted neural stem cells (NSCs) when transplanted into normal adult brain. In the present study, using the C17.2 NSC line stably transfected with the constitutively active epidermal growth factor receptor vIII, we sought to evaluate the phenotype of INKS after engraftment into the milieu of traumatic head injury. METHODS: We performed intracerebral NSC transplantation with C17.2 NSCs overexpressing the active epidermal growth factor receptor vIII receptor into the ipsilateral (n = 17) or contralateral (n = 19) corpus Callosum at 48 hours after severe experimental traumatic brain injury (TBI) or after sham injury (n = 12) in rats. RESULTS: All sham-injured animals (100%) showed NSC graft survival, compared with 65% of brain-injured animals receiving ipsilateral NSC transplants, and only 10% of brain-injured animals had surviving transplants after engraftment into the contralateral uninjured corpus callosum. A marked elevation of nerve growth factor (pg/mg protein) was observed at 72 hours after injury in the injured hemisphere (x = 80 +/- 10 pg/mg) compared with the contralateral uninjured hemisphere (35 +/- 0 pg/mg) (P < 0.05), and this elevation of nerve growth factor may have contributed to enhanced survival of engrafted NSCs. In uninjured control animals, NSC transplants proliferated actively, as evidenced by incorporation of bromodeoxyuridine. After TBI, however, transplanted NSCs failed to proliferate, regardless of the site of implantation. Morphologically, NSCs transplanted into the injured brain showed extensive process formation suggestive of a more differentiated phenotype, in contrast to INKS engrafted into uninjured brain that appear undifferentiated, with round soma and no processes. NSCs transplanted into the corpus callosum of brain-injured animals also expressed NG2, a pro-oligodendrocyte marker that was not seen in cells transplanted into uninjured brain. Although migration of NSCs was much more pronounced in the uninjured brain, 2 weeks after TBI, NSCs transplanted into the ipsilateral corpus callosum were found to have migrated to the injury cavity. Moreover, NSCs transplanted into the corpus callosum contralateral to the site of injury were observed crossing the corpus callosum by 2 weeks after transplantation. CONCLUSION: Our results suggest that the environment associated with acute experimental TBI can significantly modulate the phenotype and migratory patterns of the engrafted NSC. These findings have particularly important implications for transplantation of NSCs into the traumatically injured nervous system.	Weill Cornell Med Coll, Dept Neurosurg, New York, NY 10021 USA; Univ Penn, Head Injury Ctr, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Burnham Inst, Program Dev & Regenerat Cell Biol, La Jolla, CA 92037 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Boockvar, JA (corresponding author), Weill Cornell Med Coll, Dept Neurosurg, 1300 York Ave, New York, NY 10021 USA.	jab2029@med.cornell.edu	O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01-CA90586] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-40978] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [N508803, F32-044750] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA090586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978] Funding Source: NIH RePORTER		Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Englund U, 2002, EXP NEUROL, V173, P1, DOI 10.1006/exnr.2001.7750; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Lee VMY, 2000, PROG BRAIN RES, V128, P299; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lynch WP, 1999, J VIROL, V73, P6841, DOI 10.1128/JVI.73.8.6841-6851.1999; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rosario CM, 1997, DEVELOPMENT, V124, P4213; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Snyder EY, 1996, CURR OPIN NEUROL, V9, P126, DOI 10.1097/00019052-199604000-00013; Snyder EY, 2002, NAT MED, V8, P928, DOI 10.1038/nm0902-928; SNYDER EY, 1992, SEMIN PERINATOL, V16, P106; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Tanaka K, 2001, NEUROREPORT, V12, P2169, DOI 10.1097/00001756-200107200-00025; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Vescovi AL, 1999, BRAIN PATHOL, V9, P569, DOI 10.1111/j.1750-3639.1999.tb00542.x; Wagner J, 1999, NAT BIOTECHNOL, V17, P653; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Wu JP, 2000, NEUROSCI LETT, V292, P203, DOI 10.1016/S0304-3940(00)01472-5; Yip S, 2003, CANCER J, V9, P189, DOI 10.1097/00130404-200305000-00007	41	52	56	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2005	56	1					163	171		10.1227/01.NEU.0000145866.25433.FF			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	884FD	WOS:000226069300049	15617599				2021-06-18	
J	Hurley, RA; McGowan, JC; Arfanakis, K; Taber, KH				Hurley, RA; McGowan, JC; Arfanakis, K; Taber, KH			Traumatic axonal injury: Novel insights into evolution and identification	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							NEURON-SPECIFIC ENOLASE; BRAIN-INJURY; HEAD-INJURY; SERUM; DAMAGE; RELEASE; S-100B; SPECTROSCOPY; PREDICTION; PATHOLOGY		Salisbury Vet Affairs Med Ctr, Mental Hlth Serv Line, Salisbury, NC USA; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; IIT, Pritzker Inst Biomed Sci & Engn, Chicago, IL 60616 USA; Univ Texas, Hlth Sci Ctr, Sch Hlth Informat Sci, Houston, TX USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Hurley, RA (corresponding author), Hefner VA Med Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA.	Robin.Hurley@med.va.gov	Arfanakis, Konstantinos/AAN-3148-2021; Taber, Katherine H/B-8260-2011	Arfanakis, Konstantinos/0000-0001-9705-597X; Taber, Katherine H/0000-0001-7382-6151			Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; ARFANAKIS K, 2002, AM J NEURORADIOL, V97, P568; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Hurley Robin A., 2002, Curr Treat Options Neurol, V4, P59, DOI 10.1007/s11940-002-0005-5; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Kuzma BB, 2000, SURG NEUROL, V53, P400; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZI L, 2003, AM J PHYS MED REHABI, V82, P556	36	52	57	0	1	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2004	16	1					1	7		10.1176/appi.neuropsych.16.1.1			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	777PM	WOS:000189186800001	14990753				2021-06-18	
J	Heep, A; Stoffel-Wagner, B; Bartmann, P; Benseler, S; Schaller, C; Groneck, P; Obladen, M; Felderhoff-Mueser, U				Heep, A; Stoffel-Wagner, B; Bartmann, P; Benseler, S; Schaller, C; Groneck, P; Obladen, M; Felderhoff-Mueser, U			Vascular endothelial growth factor and transforming growth factor-beta 1 are highly expressed in the cerebrospinal fluid of premature infants with posthemorrhagic hydrocephalus	PEDIATRIC RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; FACTOR-BETA; SUBARACHNOID HEMORRHAGE; PRETERM INFANTS; IN-VIVO; SERUM; TGF-BETA-1; COLLAGEN; IL-6; ERYTHROPOIETIN	The expression of specific growth factors such as vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) is of importance during brain development and in the pathogenesis of neurodegenerative disorders. VEGF and TGF-beta1 was studied in the cerebrospinal fluid (CSF) of neonates with posthemorrhagic hydrocephalus (PHHC) and nonhemorrhagic hydrocephalus. For determining the interference of inflammatory cytokine interaction with the expression of VEGF and TGF-beta1, IL-6 and IL-10 CSF concentrations were measured. Eighteen neonates who had PHHC and underwent serial reservoir puncture and nine neonates who had congenital nonhemorrhagic hydrocephalus (CHC) and underwent first shunt surgery were included in the study. CSF samples of 11 neonates with lumbar puncture for the exclusion of meningitis served as control subjects. VEGF, TGF-beta1, IL-6, and IL-10 concentrations in the CSF were measured by ELISA technique. VEGF concentrations in the CSF of patients with PHHC were significantly higher (median: 377 pg/mL; range: 101-1301 pg/mL) when compared with patients with CHC (median: 66 pg/mL; range: 3-1991; p < 0.001) and control subjects (median: 2 pg/mL; range: 0-12 pg/mL; p < 0.0001). TGF-beta1 CSF concentrations did not differ from control infants in all groups. Median IL-6 and IL-10 concentrations in the CSF were found to be low in all patient groups. Increased release of VEGF in the CSF of neonates with PHHC and nonhemorrhagic hydrocephalus may serve as an indicator of brain injury from progressive ventricular dilation. TGF-beta1 CSF concentrations are not elevated in the phase of acute fibroproliferative reactions in patients with PHHC.	Univ Bonn, Dept Neonatol, D-53113 Bonn, Germany; Univ Bonn, Dept Clin Biochem, D-53105 Bonn, Germany; Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany; Cologne Childrens Hosp, Dept Neonatol, D-50735 Cologne, Germany; Free Univ Berlin, Med Ctr, Dept Neonatol, D-13353 Berlin, Germany	Heep, A (corresponding author), Univ Bonn, Dept Neonatol, Adenauerallee 19, D-53113 Bonn, Germany.	a.heep@uni-bonn.de	Felderhoff-Muser, Ursula/AAU-9682-2020				Arai Y, 1998, PEDIATR NEUROL, V19, P45, DOI 10.1016/S0887-8994(98)00018-6; Baumeister FAM, 2000, INFECTION, V28, P234, DOI 10.1007/s150100070043; Bell MJ, 1997, ACT NEUR S, V70, P96; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bocker-Meffert S, 2002, INVEST OPHTH VIS SCI, V43, P2021; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Cai ZW, 2000, PEDIATR RES, V47, P64, DOI 10.1203/00006450-200001000-00013; Cai ZW, 2003, BRAIN RES, V975, P37, DOI 10.1016/S0006-8993(03)02545-9; Cheng SY, 1997, P NATL ACAD SCI USA, V94, P12081, DOI 10.1073/pnas.94.22.12081; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Flood C, 2001, J CEREBR BLOOD F MET, V21, P157, DOI 10.1097/00004647-200102000-00007; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; Heep A., 2000, Biology of the Neonate, V78, P153; Heep A, 2004, EUR J PEDIATR, V163, P44, DOI 10.1007/s00431-003-1333-5; Heep A, 2002, ARCH DIS CHILD-FETAL, V87, pF34, DOI 10.1136/fn.87.1.F34; Heep A, 2001, CHILD NERV SYST, V17, P47, DOI 10.1007/s003810000363; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Ilzecka J, 2002, CYTOKINE, V20, P239, DOI 10.1006/cyto.2002.2005; JOHNSON MD, 1992, LAB INVEST, V67, P360; Jones KL, 2003, PEDIATRICS, V111, P358, DOI 10.1542/peds.111.2.358; KIM RC, 1989, NEUROSURGERY, V24, P771, DOI 10.1227/00006123-198905000-00022; KITAZAWA K, 1994, STROKE, V25, P1400, DOI 10.1161/01.STR.25.7.1400; Koehne P, 2002, CHILD NERV SYST, V18, P137, DOI 10.1007/s00381-002-0567-2; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; Leviton A, 2002, NEUROPEDIATRICS, V33, P281, DOI 10.1055/s-2002-37089; Maskin B, 2001, MEDICINA-BUENOS AIRE, V61, P573; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; Moinuddin SM, 2000, NEUROL RES, V22, P215, DOI 10.1080/01616412.2000.11741064; Nakazato F, 2002, NEUROL MED-CHIR, V42, P151, DOI 10.2176/nmc.42.151; Paneth N, 1999, J PEDIATR-US, V134, P527, DOI 10.1016/S0022-3476(99)70231-3; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rollnik JD, 1997, ACTA NEUROL SCAND, V96, P101; Savman K, 1998, PEDIATR RES, V43, P746; Scheufler KM, 2003, J CEREBR BLOOD F MET, V23, P99, DOI 10.1097/01.WCB.0000037547.46809.83; Schromm AB, 1998, J IMMUNOL, V161, P5464; Segura I, 2002, FASEB J, V16, DOI 10.1096/fj.01-0819com; Slevin M, 2000, STROKE, V31, P1863, DOI 10.1161/01.STR.31.8.1863; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Takizawa T, 2001, NEUROL RES, V23, P724, DOI 10.1179/016164101101199243; Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Volpe JJ, 2001, NEUROLOGY NEWBORN, P428; Whitelaw A, 1999, PEDIATR RES, V46, P576, DOI 10.1203/00006450-199911000-00014; XIAO L, 2002, HUMAN YI KE DA XUE X, V28, P123; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002	46	52	60	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	NOV	2004	56	5					768	774		10.1203/01.PDR.0000141524.32142.53			7	Pediatrics	Pediatrics	864WD	WOS:000224662800017	15319463	Bronze			2021-06-18	
J	Maxwell, WL; Pennington, K; MacKinnon, MA; Smith, DH; McIntosh, TK; Wilson, JTL; Graham, DI				Maxwell, WL; Pennington, K; MacKinnon, MA; Smith, DH; McIntosh, TK; Wilson, JTL; Graham, DI			Differential responses in three thalamic nuclei in moderately disabled, severely disabled and vegetative patients after blunt head injury	BRAIN			English	Article						human thalamus; stereology; traumatic brain injury; thalamus; loss of neurons	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; ALZHEIMERS-DISEASE; CORTICAL ATROPHY; DEGENERATION; CELLS; HIPPOCAMPUS; ABLATION; NEURONS; PROTEIN	In vivo imaging techniques have indicated for many years that there is loss of white matter after human traumatic brain injury (TBI) and that the loss is inversely related to cognitive outcome. However, correlated, quantitative evidence for loss of neurons from either the cerebral cortex or the diencephalon is largely lacking. There is some evidence in models of TBI that neuronal loss occurs within the thalamus, but no systematic studies of such loss have been undertaken in the thalamus of humans after blunt head injury. We have undertaken a stereological analysis of changes in numbers of neurons within the dorsomedial, ventral posterior and lateral posterior thalamic nuclei in patients assessed by the Glasgow Outcome Scale as moderately disabled (n = 9), severely disabled (n = 12) and vegetative (n = 10) head-injured patients who survived between 6 h and 3 years, and controls (n = 9). In histological sections at the level of the lateral geniculate body, the cross-sectional area of each nucleus and the number and the mean size of neurons within each nucleus was quantified. A statistically significant loss of cross-sectional area and number of neurons occurred in the dorsomedial nucleus in moderately disabled, and both the dorsomedial and ventral posterior thalamic nuclei in severely disabled and vegetative head-injured patients. However, there was no change in neuronal cell size. In the lateral posterior nucleus, despite a reduction in mean cell size, there was not a significant change in either nuclear area or number of neurons in cases of moderately disabled, severely disabled or vegetative patients. We posit, although detailed neuropsychological outcome for the patients included within this study was not available, that neuronal loss in the dorsomedial thalamus in moderately and severely disabled and vegetative patients may be the structural basis for the clinical assessment in the Glasgow Outcome Scale. In severely disabled and vegetative pati-ents, loss of neurons from the ventral posterior thalamic nucleus may also reflect loss of response to afferent stimuli.	Univ Glasgow, Inst Biomed & Life Sci, Lab Human Anat, Glasgow G12 8QQ, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Penn, Div Neurosurg, Head Injury Res Ctr, Philadelphia, PA 19104 USA	Maxwell, WL (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Lab Human Anat, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	w.maxwell@bio.gla.ac.uk	Wilson, Lindsay/O-8883-2019; Ritter, Stefanie L/D-9312-2012; Wilson, Lindsay/A-3659-2009; smith, douglas/A-1321-2007	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328; Pennington, Kyla/0000-0002-4323-606X			Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CARRERAS M, 1969, ARCH ITAL BIOL, V107, P570; CHMIELOWSKA J, 1995, J COMP NEUROL, V360, P377, DOI 10.1002/cne.903600302; Conti AC, 1998, J NEUROSCI, V18, P5663; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HOWARD CV, 1998, UNBIASED STEREOLOGY; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jennett B., 1997, HEAD INJURY, P439; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Jones E.G., 1985, THALAMUS; Juhasz C, 1999, NEUROLOGY, V53, P2037, DOI 10.1212/WNL.53.9.2037; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MOUTON PR, 2002, PRINCIPLES PRACTICES; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RAUSELL E, 1992, J NEUROSCI, V12, P4088; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stamatakis EA, 2002, J NUCL MED, V43, P476; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; WONGRILEY MT, 1972, J COMP NEUROL, V146, P519, DOI 10.1002/cne.901460407; XUEREB JH, 1991, BRAIN, V114, P1363	45	52	53	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2004	127		11				2470	2478		10.1093/brain/awh294			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	865LD	WOS:000224703700010	15456707	Bronze			2021-06-18	
J	Jiang, JF; Borisenko, GG; Osipov, A; Martin, I; Chen, RW; Shvedova, AA; Sorokin, A; Tyurina, YY; Potapovich, A; Tyurin, VA; Graham, SH; Kagan, VE				Jiang, JF; Borisenko, GG; Osipov, A; Martin, I; Chen, RW; Shvedova, AA; Sorokin, A; Tyurina, YY; Potapovich, A; Tyurin, VA; Graham, SH; Kagan, VE			Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells	JOURNAL OF NEUROCHEMISTRY			English	Article						carbon-centered radical formation; cyclo-oxygenase-2 inhibitor; cyclo-oxygenase-2 transfection; PC12 cells; phosphatidylserine oxidation; radical spin-trapping	PROSTAGLANDIN-H SYNTHASE-2; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD NEURONS; OXIDATIVE STRESS; OXYGEN RADICALS; ISCHEMIC BRAIN; CYTOCHROME-C; INDUCIBLE CYCLOOXYGENASE	Cyclo-oxygenase-2 (COX-2) is believed to induce neuronal oxidative stress via production of radicals. While oxygen radicals are not directly involved in COX-2-catalytic cycle, superoxide anion radicals have been repeatedly reported to play a critical role in COX-2-associated oxidative stress. To resolve the controversy, we characterized production of free radicals in PC12 cells in which COX-2 expression was manipulated either genetically or by direct protein transfection and compared them with those generated by a recombinant COX-2 in a cell-free system. Using spin-traps alpha-(4-pyridyl-1-oxide)-N-t-butylnitrone, 5,5-dimethyl-1-pyrroline-N-oxide and 4-((9-acridinecarbonyl) amino)-2,2,6,6- tetramethylpiperidine-1-oxyl (Ac-Tempo), we observed arachidonic acid (AA)-dependent production of carbon-centered radicals by heme-reconstituted recombinant COX-2. No oxygen radicals or thiyl radicals have been detected. COX-2 also catalyzed AA-dependent one-electron co-oxidation of ascorbate to ascorbate radicals. Next, we used two different approaches of COX-2 expression in cells, PCXII cells which express isopropyl-1-thio-beta-D-galactopyranoside inducible COX-2, and PC12 cells transfected with COX-2 using a protein delivery reagent, Chariot. In both models, COX-2-dependent AA-induced generation of carbon-centered radicals was documented using spin-traps and Ac-Tempo. No oxygen radical formation was detected in COX-2-transfected cells by either spin-traps or fluorogenic probe, dihydroethidium. In the presence of ascorbate, AA-induced COX-2-dependent ascorbate radicals were detected. AA caused a significant and selective oxidation of one of the major phospholipids, phosphatidylserine (PS). PS was not a direct substrate for COX-2 but was co-oxidized in the presence of AA. The radical generation and PS oxidation were inhibited by COX-2 inhibitors, niflumic acid, nimesulide, or NS-398. Thus, COX-2 generated carbon-centered radicals but not oxygen radicals or thiyl radicals are responsible for oxidative stress in AA-challenged PC12 cells overexpressing COX-2.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.	kagan+@pitt.edu		Tyurin, Vladimir/0000-0002-3474-1697; Tyurina, Yulia/0000-0003-0287-2091; Kagan, Valerian E./0000-0002-7245-1885; Sorokin, Andrey/0000-0002-5660-0190	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, NS 37459, R01 NS037459-07, R01 NS037459, F05 NS 43922] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, R01NS037459, P50NS030318, P20NS030318, R56NS037459, F05NS043922] Funding Source: NIH RePORTER		Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4; Armstead WM, 2003, ANESTHESIOLOGY, V98, P1378, DOI 10.1097/00000542-200306000-00012; ARMSTEAD WM, 1988, AM J PHYSIOL, V255, pH401; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; BLOUGH NV, 1988, J AM CHEM SOC, V110, P1915, DOI 10.1021/ja00214a041; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUSIJA DW, 1998, PHARM CEREBRAL ISCHE, P237; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Candelario-Jalil E, 2002, EUR J PHARMACOL, V453, P189, DOI 10.1016/S0014-2999(02)02422-6; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garrido R, 2001, J NEUROCHEM, V76, P1395, DOI 10.1046/j.1471-4159.2001.00135.x; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Horakova L, 1997, NEUROPHARMACOLOGY, V36, P177, DOI 10.1016/S0028-3908(96)00165-7; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jiang JF, 2003, FREE RADICAL BIO MED, V35, P814, DOI 10.1016/S0891-5849(03)00429-5; Kagan V E, 1998, Methods Mol Biol, V108, P71; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kinouchi H, 1999, J NEUROSURG, V91, P1005, DOI 10.3171/jns.1999.91.6.1005; Kirkland RA, 2002, NEUROSCIENCE, V115, P587, DOI 10.1016/S0306-4522(02)00512-2; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LI Y, 1995, AM J PATHOL, V146, P1045; Love S, 1999, BRAIN PATHOL, V9, P119; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Marnett LJ, 2000, CURR OPIN CHEM BIOL, V4, P545, DOI 10.1016/S1367-5931(00)00130-7; MASON RP, 1980, J BIOL CHEM, V255, P5019; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; MCGOWAN JE, 1994, BIOL NEONATE, V66, P367; Mishra OP, 1999, BRAIN RES BULL, V48, P233, DOI 10.1016/S0361-9230(98)00170-1; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; Nogawa S, 1997, J NEUROSCI, V17, P2746; NOGAWA S, 2002, ACTA NEUROPATHOL, V104, P601; O'Brien PJ, 1978, BIOCHEM SOC T, V6, P1169, DOI 10.1042/bst0061169; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; Rice ME, 1998, NEUROSCIENCE, V82, P1213; SCHREIBER J, 1986, ARCH BIOCHEM BIOPHYS, V249, P126, DOI 10.1016/0003-9861(86)90567-9; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Takadera T, 2002, NEUROSCI LETT, V317, P61, DOI 10.1016/S0304-3940(01)02449-1; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; TSUNAWAKI S, 1986, J EXP MED, V164, P1319, DOI 10.1084/jem.164.4.1319; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Tyurina YY, 2004, J BIOL CHEM, V279, P6056, DOI 10.1074/jbc.M309929200; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	73	52	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2004	90	5					1036	1049		10.1111/j.1471-4159.2004.02577.x			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	847CN	WOS:000223366500002	15312159	Bronze			2021-06-18	
J	Hu, BR; Liu, CL; Bramlett, T; Sick, TJ; Alonso, TF; Chen, SY; Dietrich, WD				Hu, BR; Liu, CL; Bramlett, T; Sick, TJ; Alonso, TF; Chen, SY; Dietrich, WD			Changes in TrkB-ERK1/2-CREB/Elk-1 pathways in hippocampal mossy fiber organization after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; mossy fiber; seizure and epilepsy; hippocampus; TrkB-ERK1/2-CREB/Elk-1	SEIZURE-INDUCED ACTIVATION; SIGNAL-REGULATED KINASE; ELEMENT-BINDING PROTEIN; LONG-TERM POTENTIATION; FLUID PERCUSSION; NEUROTROPHIC FACTOR; DENTATE GYRUS; IMMUNOHISTOCHEMICAL EVIDENCE; CEREBRAL-ISCHEMIA; ADULT HIPPOCAMPUS	Traumatic brain injury (TBI) leads to mossy fiber reorganization, which is considered to be a causative factor in the development of temporal lobe epilepsy. However, the underlying mechanism is not fully understood. Emerging evidence suggests that TrkB-ERK1/2-CREB/Elk-1 pathways are highly related to synaptic plasticity. This study used the rat fluid-percussion injury model to investigate activation of TrkB-ERK1/2-CREB/Elk-1 signaling pathways after TBI. Rats were subjected to 2.0-atm parasagittal TBf followed by 30 minutes, 4 hours, 24 hours, and 72 hours of recovery. After TBI, striking activation of TrkB-ERK 1/2-CREB/Elk-1 signaling pathways in mossy fiber organization were observed with confocal microscopy and Western blot analysis. ERK1/2 was highly phosphorylated predominantly in hippocampal mossy fibers, whereas TrkB was phosphorylated both in the mossy fibers and the dentate gyrus region at 30 minutes and 4 hours of recovery after TBI. CREB was also activated at 30 minutes, peaked at 24 hours of recovery, and returned to the control level at 72 hours of recovery in dentate gyrus granule cells. Elk-1 phosphorylation was seen in CA3 neurons at 4 hours after TBI. The results suggest that the signaling pathways of TrkBERK1/2-CREB/Elk-1 are highly activated in mossy fiber organization, which may contribute to mossy fiber reorganization seen after TBI.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Hu, BR (corresponding author), Univ Miami, Sch Med, Dept Neurol, POB 16960, Miami, FL 33136 USA.	bhu@med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36810, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS036810, R56NS036810, R29NS036810] Funding Source: NIH RePORTER		Bender RA, 2001, EUR J NEUROSCI, V13, P679, DOI 10.1046/j.1460-9568.2001.01432.x; Binder DK, 1999, J NEUROSCI, V19, P4616; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cavazos JE, 2003, J COMP NEUROL, V458, P272, DOI 10.1002/cne.10581; Croll SD, 1999, NEUROSCIENCE, V93, P1491, DOI 10.1016/S0306-4522(99)00296-1; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Ernfors P, 2003, TRENDS NEUROSCI, V26, P171, DOI 10.1016/S0166-2236(03)00064-X; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Golarai G, 2001, J NEUROSCI, V21, P8523; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; He XP, 2002, J NEUROSCI, V22, P7502; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li S, 2003, NEUROSCIENCE, V119, P1147, DOI 10.1016/S0306-4522(03)00239-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mazzucchelli C, 2000, CELL MOL LIFE SCI, V57, P604, DOI 10.1007/PL00000722; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Ouyang YB, 2001, NEUROSCI LETT, V298, P159, DOI 10.1016/S0304-3940(00)01721-3; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Povlishock J T, 1992, Hum Cell, V5, P345; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scharfman HE, 1999, J NEUROSCI, V19, P5619; Scharfman HE, 2002, J COMP NEUROL, V454, P424, DOI 10.1002/cne.10449; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Thiels E, 2002, J NEUROSCI, V22, P2054, DOI 10.1523/JNEUROSCI.22-06-02054.2002; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wenzel HJ, 2000, HIPPOCAMPUS, V10, P244, DOI 10.1002/1098-1063(2000)10:3<244::AID-HIPO5>3.0.CO;2-7; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	52	52	59	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2004	24	8					934	943		10.1097/01.WCB.0000125888.56462.A1			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	844CA	WOS:000223133600012	15362724	Bronze			2021-06-18	
J	Moseley, AM; Lanzarone, S; Bosman, JM; van Loo, MA; de Bie, RA; Hassett, L				Moseley, AM; Lanzarone, S; Bosman, JM; van Loo, MA; de Bie, RA; Hassett, L			Ecological validity of walking speed assessment after traumatic brain injury - A pilot study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult; brain injuries; functional assessment; gait; physical therapy; walking	GAIT CHARACTERISTICS; OLDER PEDESTRIANS; RELIABILITY; STREET; TASKS; SEX	Objective: To assess the ecological validity of walking speed measurement after traumatic brain injury (FBI). Participants: Ten people with TBI who could walk independently and were participating in a rehabilitation program. Design: Walking speed on 3 clinical gait tests (comfortable and fast pace over a 10-m distance and a 6-minute walk test) in 3 "natural" environments (a corridor in a brain injury rehabilitation unit, a car park of a metropolitan shopping center, and inside a metropolitan shopping center). Normative data were collected for 275 able-bodied pedestrians as they walked in the 3 natural environments. Results: For subjects with TBI, agreement between the speeds used in the clinical gait tests and the natural environments was poor (intraclass correlation coefficient [ICC] values ranged from -0.24 to 0.63). The closest speed match was the comfortable paced 10-m walk test and walking in a corridor of a brain injury rehabilitation unit (ICC 0.63). Able-bodied pedestrians walked at significantly faster speeds than did subjects with TBI in all 3 natural environments. Conclusions: Comfortable walking speed appears to have the highest ecological validity of the clinical gait tests investigated. Practice in natural and more complex environments should be incorporated into walking rehabilitation programs for people with TBI.	Univ Sydney, Fac Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Univ Maastricht, Maastricht, Netherlands; Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Moseley, AM (corresponding author), Univ Sydney, Fac Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amoseley@mail.usyd.edu.au		Hassett, Leanne/0000-0002-3546-1822			Carr J. H., 2003, STROKE REHABILITATIO; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dean CM, 2001, CLIN REHABIL, V15, P415, DOI 10.1191/026921501678310216; DELISA JA, 1998, REHABILITATION MED P; EKEOKORO ST, 1984, J HUM MOVEMENT STUD, V10, P107; FINLAY O, 1993, PHYSIOTHERAPY, V79, P845; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gifford R, 1977, J HUM MOVEMENT STUD, V3, P66; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Hangland A, 1997, PERCEPT MOTOR SKILL, V85, P845, DOI 10.2466/pms.1997.85.3.845; HOXIE RE, 1994, J AM GERIATR SOC, V42, P241, DOI 10.1111/j.1532-5415.1994.tb01745.x; Langlois JA, 1997, AM J PUBLIC HEALTH, V87, P393, DOI 10.2105/AJPH.87.3.393; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; ROBINETT CS, 1988, PHYS THER, V68, P1371, DOI 10.1093/ptj/68.9.1371; Sheperd, 2000, MOVEMENT SCI FDN PHY, P111; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sun J, 1996, ERGONOMICS, V39, P677, DOI 10.1080/00140139608964489; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; VANLOO MA, 2004, BRAIN INJURY, P18; Wade DT, 1992, MEASUREMENT NEUROLOG; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E; Watson M.J., 2002, PHYSIOTHERAPY, P386, DOI DOI 10.1016/S0031-9406(05)61264-3; WELKOWITZ J, 1972, INTRO STAT BEHAV SCI, P112	25	52	52	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2004	19	4					341	348		10.1097/00001199-200407000-00008			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	839CB	WOS:000222759800008	15263861				2021-06-18	
J	Dimopoulou, I; Tsagarakis, S; Theodorakopoulou, M; Douka, E; Zervou, M; Kouyialis, AT; Thalassinos, N; Roussos, C				Dimopoulou, I; Tsagarakis, S; Theodorakopoulou, M; Douka, E; Zervou, M; Kouyialis, AT; Thalassinos, N; Roussos, C			Endocrine abnormalities in critical care patients with moderate-to-severe head trauma: incidence, pattern and predisposing factors	INTENSIVE CARE MEDICINE			English	Article						head trauma; cortisol hyporesponsiveness; hypogonadism; partial growth hormone deficiency; hypothyroidism; Marshall Computerized Tomographic Classification	SEVERE CRANIOCEREBRAL TRAUMA; BRAIN-INJURY; AXONAL INJURY; HYPOPITUITARISM; HORMONE; INSUFFICIENCY; DYSFUNCTION; PROGNOSIS; AXIS	Objective. To investigate the incidence and type of endocrine abnormalities in critical care patients with traumatic brain injury (TBI) and to examine their relationships to possible predisposing factors. Design. Prospective study. Setting. General intensive care unit in a university hospital. Patients and participants. Thirty-four TBI patients (27 men, 7 women), having a mean age of 37+/-16 years, were studied after weaning from mechanical ventilation. Interventions. Baseline endocrine assessment was carried out by measuring cortisol, corticotropin, dehydroepiandrosterone sulfate, free thyroxine, thyrotropin (TSH), testosterone, oestradiol, follicle stimulating hormone (FSH), luteinizing hormone, prolactin, growth hormone and insulin-like growth factor I. Dynamic evaluation was performed by human corticotropin releasing hormone and growth hormone releasing hormone in all patients. Male patients underwent additional investigation with gonadotropin-releasing hormone. Severity of neurological derangement was graded according to Glasgow Coma Scale (GCS), Marshall Computerized Tomographic Classification and intracranial pressure (ICP) levels. Measurements and results. Eighteen of the 34 patients (53%) had an abnormal result in at least one hormonal axis tested, with cortisol hyporesponsiveness and gonadal dysfunction being equally common, affecting 24% of patients. Endocrine abnormalities were associated with a higher brain CT-scan classification score (p=0.02). The GCS on admission correlated positively with baseline FSH (r=0.37, p=0.03), peak FSH (r=0.41, p=0.03), testosterone (r=0.44, p=0.02) and TSH (r=0.39, p=0.03). There were no relations between ICPmax and any baseline or dynamic hormone measurements. Conclusions. Patients with TBI receiving critical care show changes in their neuroendocrine responses, which depend upon clinical and radiological measures of head injury severity. Most common abnormalities include cortisol hyporesponsiveness and hypogonadism.	Natl & Kapodistrian Univ Athens, Sch Med, Evangelismos Hosp, Dept Crit Care Med, Athens, Greece; Natl & Kapodistrian Univ Athens, Sch Med, Evangelismos Hosp, Dept Diabet Endocrinol & Metab, Athens, Greece	Dimopoulou, I (corresponding author), 2 Pesmazoglou St, Athens 14561, Greece.	idimo@otenet.gr					BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Dimopoulou I, 2004, INTENS CARE MED, V30, P298, DOI 10.1007/s00134-003-2058-7; EDWARDS OM, 1986, MEDICINE, V65, P281; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Pittella JEH, 2003, J FORENSIC SCI, V48, P626; Sassolas G, 1999, EUR J ENDOCRINOL, V141, P595, DOI 10.1530/eje.0.1410595; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; Segal-Lieberman G, 2000, Pituitary, V3, P181, DOI 10.1023/A:1011407910913; TEASDALE G, 1974, LANCET, V2, P81; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Webb SM, 1999, J CLIN ENDOCR METAB, V84, P3696, DOI 10.1210/jc.84.10.3696; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	27	52	55	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2004	30	6					1051	1057		10.1007/s00134-004-2257-x			7	Critical Care Medicine	General & Internal Medicine	825BF	WOS:000221730300009	15069597				2021-06-18	
J	Hoffman, R; Al'Absi, M				Hoffman, R; Al'Absi, M			The effect of acute stress on subsequent neuropsychological test performance (2003)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neuropsychology; cortisol; memory; attention; cardiovascular	TRAUMATIC BRAIN-INJURY; CORTISOL REACTIVITY; ADRENOCORTICAL RESPONSES; POSTCONCUSSIVE SYMPTOMS; MENTAL STRESS; HEAD-INJURY; ANXIETY; TASK; MEMORY; SEX	Acute mental stressors have been implicated as variables that may deleteriously affect neuropsychological test performance by increasing distractibility and decreasing working memory function. This study examined 25 subjects with no known neurological or psychiatric impairment on a brief battery of neuropsychological measures on alternate days following either rest or induced mental stress in a counterbalanced design. The test battery consisted of the Rey Auditory-Verbal Learning Test, the Rey Complex Figure, and three Wechsler Memory Scale-III subtests (Logical Memory, Digit Span, and Visual Memory Span). The Ss average age was 24.8 years (S.D. = 10.1) and average education was 15.0 years (S.D. = 1.6). The mental stressor employed was a videotaped public-speaking exercise that has been shown in previous work to induce negative mood, cardiovascular reactivity, and perceived mental stress. Ss demonstrated statistically significant (P < .05) increases in negative mood, heart rate, diastolic blood pressure, and systolic blood pressure as well as elevated cortisol concentration following induced stress, suggesting substantially increased adrenocortical reactivity and cardiovascular stress response. There were, however, no statistically significant differences in any of the neuropsychological measures when stress versus rest days were compared. The results suggest that acute mental stressors may have no measurable effect on subsequent performance on selected neuropsychological tests in a normal population. Further work is suggested to determine whether pre-existing anxiety-related psychopathology or pre-existing neurological compromise might interact with induced mental stress to cause decrements in neuropsychological test performance. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Minnesota, Dept Behav Sci, Sch Med, Duluth, MN 55812 USA	Hoffman, R (corresponding author), Univ Minnesota, Dept Behav Sci, Sch Med, 10 Univ Dr, Duluth, MN 55812 USA.	rhoffman@d.umn.edu					Al'Absi M, 2002, PSYCHOPHYSIOLOGY, V39, P95, DOI 10.1017/S0048577202001543; al'Absi M, 1998, PSYCHOSOM MED, V60, P521, DOI 10.1097/00006842-199807000-00021; ALABSI M, 1994, PSYCHOSOM MED, V56, P245, DOI 10.1097/00006842-199405000-00011; BOHNEN N, 1990, BIOL PSYCHOL, V31, P107, DOI 10.1016/0301-0511(90)90011-K; BOHNEN N, 1991, J PSYCHOSOM RES, V35, P141, DOI 10.1016/0022-3999(91)90068-Y; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BUCKELEW SP, 1986, PERCEPT MOTOR SKILL, V63, P711, DOI 10.2466/pms.1986.63.2.711; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHAVEZ EL, 1983, PERCEPT MOTOR SKILL, V56, P923, DOI 10.2466/pms.1983.56.3.923; COCKBURN J, 1994, BRIT J PSYCHOL, V85, P273, DOI 10.1111/j.2044-8295.1994.tb02523.x; DABSI M, 1997, PSYCHOPHYSIOLOGY, V34, P266; DRESSENDORFER RA, 1992, J STEROID BIOCHEM, V43, P683, DOI 10.1016/0960-0760(92)90294-S; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P192; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Holdwick DJ, 1999, ARCH CLIN NEUROPSYCH, V14, P273, DOI 10.1016/S0887-6177(98)00021-3; KING GD, 1978, J CONSULT CLIN PSYCH, V46, P375, DOI 10.1037/0022-006X.46.2.375; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; McEwen BS, 2002, PSYCHIAT CLIN N AM, V25, P469, DOI 10.1016/S0193-953X(01)00009-0; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McEwen BS, 2000, BRAIN RES, V886, P172, DOI 10.1016/S0006-8993(00)02950-4; Meyers J., 1995, CLIN NEUROPSYCHOL, V9, P63, DOI [DOI 10.1080/13854049508402059, 10.1080/13854049508402059]; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; TAYLOR L, 1979, FUNCTIONAL NEUROSURG; Taylor L B, 1969, Clin Neurosurg, V16, P269; VINGERHOETS G, 1995, CLIN NEUROPSYCHOL, V9, P198, DOI 10.1080/13854049508401603; Waldstein SR, 1997, ARCH CLIN NEUROPSYCH, V12, P567; Zielinski CM, 1991, **DROPPED REF**, V4, P110	30	52	57	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2004	19	4					497	506		10.1016/j.acn.2003.07.005			10	Psychology, Clinical; Psychology	Psychology	830DL	WOS:000222101700004	15163451				2021-06-18	
J	Yue, HF; Strauss, KI; Borenstein, MR; Barbe, MF; Rossi, LJ; Jansen, SA				Yue, HF; Strauss, KI; Borenstein, MR; Barbe, MF; Rossi, LJ; Jansen, SA			Determination of bioactive eicosanoids in brain tissue by a sensitive reversed-phase liquid chromatographic method with fluorescence detection	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						eicosanoids	ARACHIDONIC-ACID; CARBOXYLIC-ACIDS; P-450 METABOLITES; CYTOCHROME-P-450; EPOXYGENASE; DERIVATIZATION; ULTRAVIOLET; INJURY	Arachidonic acid (AA) is metabolized to prostaglandins (PGs) via cyclooxygenases (COX) catalysis, and to epoxyeicosatrienoic acids (EETs), dihydroxyeicosatrienoic acids (DiHETrEs), and hydroxyeicosatetraenoic acids (HETEs) via cytochrome P450 (CYP450) enzymes. A reliable and robust fluorescence based HPLC method for these eicosanoids was developed. A new selective reverse-phase solid phase extraction (SPE) procedure was developed for PG, DiHETrEs, HETE, and EETs of interest from rat cortical brain tissue. The eicosanoids were derivatized with 2-(2,3-naphthalimino)ethyl-trifluoromethanesulphonate (NE-OTf), followed by separation and quantification at high sensitivity using reverse-phase HPLC with fluorescent detection, and further identified via LC/MS. The derivatization was studied and optimized to obtain reproducible reactions. Various PGs, DiHETrEs, HETEs, EETs, and AA were sensitively detected and baseline resolved simultaneously. LC/MS under positive electrospray ionization selected ion monitoring (SIM) mode was developed to further identify the peaks of these eicosanoids in cortical brain tissue. The method was applied in the traumatic brain injured rat brain. (C) 2004 Elsevier B.V. All rights reserved.	Temple Univ, Dept Chem, Philadelphia, PA 19122 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA; Temple Univ, Dept Phys Therapy, Philadelphia, PA 19140 USA; Temple Univ, Dept Anat & Cell Biol, Philadelphia, PA 19140 USA; US FDA, Philadelphia, PA 19106 USA	Jansen, SA (corresponding author), Temple Univ, Dept Chem, 1901 N 13th St, Philadelphia, PA 19122 USA.	suebee@unix.temple.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654-03] Funding Source: Medline		Beare-Rogers J, 2001, PURE APPL CHEM, V73, P685, DOI 10.1351/pac200173040685; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Cunico RL, 1998, BASIC HPLC CE BIOMOL; Davis BB, 2002, P NATL ACAD SCI USA, V99, P2222, DOI 10.1073/pnas.261710799; DEYL Z, 1998, ADV CHROMATOGRAPHIC, P315; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; GOPEZ JJ, 2003, IN PRESS J NEUROSCIE; Hampson AJ, 2002, J NEUROSCI, V22, P257, DOI 10.1523/JNEUROSCI.22-01-00257.2002; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; Maier KG, 2000, AM J PHYSIOL-HEART C, V279, pH863; Mukherjee PS, 1996, BIOMED CHROMATOGR, V10, P193, DOI 10.1002/(SICI)1099-0801(199609)10:5<193::AID-BMC591>3.3.CO;2-2; Nithipatikom K, 2000, AM J PHYSIOL-HEART C, V279, pH857; Nithipatikom K, 2001, ANAL BIOCHEM, V298, P327, DOI 10.1006/abio.2001.5395; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; OHKURA Y, 1994, J CHROMATOGR B, V659, P85, DOI 10.1016/0378-4347(94)00125-1; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; TOYOOKA T, 1995, J CHROMATOGR B, V671, P91, DOI 10.1016/0378-4347(94)00559-N; VanderNoot VA, 2002, ANAL CHEM, V74, P5859, DOI 10.1021/ac025909+; YASAKA Y, 1990, J CHROMATOGR, V508, P133, DOI 10.1016/S0021-9673(00)91246-9; YASAKA Y, 1994, J CHROMATOGR B, V659, P139, DOI 10.1016/S0378-4347(94)80126-6; YUE H, 2002, P 224 ACS M BOST AUG	26	52	55	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	APR 25	2004	803	2					267	277		10.1016/j.jchromb.2003.12.027			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	809MG	WOS:000220640200012	15063335				2021-06-18	
J	Nagdyman, N; Fleck, T; Barth, S; Abdul-Khaliq, H; Stiller, B; Ewert, P; Huebler, M; Kuppe, H; Lange, PE				Nagdyman, N; Fleck, T; Barth, S; Abdul-Khaliq, H; Stiller, B; Ewert, P; Huebler, M; Kuppe, H; Lange, PE			Relation of cerebral tissue oxygenation index to central venous oxygen saturation in children	INTENSIVE CARE MEDICINE			English	Article						near-infrared spectroscopy; tissue oxygenation index; cerebral oxygenation; central venous oxygen saturation; congenital heart defects; children	NEAR-INFRARED SPECTROSCOPY; HYPOTHERMIC CIRCULATORY ARREST; EXTRACRANIAL BLOOD OXYGENATION; CLOSED-HEAD INJURY; BULB OXIMETRY; SURGERY; SPECTROPHOTOMETRY; INFANTS; BYPASS	Objective: To evaluate the relationship between the cerebral tissue oxygenation index measured by near-infrared spectroscopy and central venous oxygen saturation (SvO(2)) after corrective surgery of congenital heart defects in children. Design: Prospective observational clinical study. Setting: A tertiary neonatal and paediatric intensive care unit for paediatric cardiology. Patients: Neonates and children consecutively admitted to the paediatric cardiology intensive care unit after corrective surgery of non-cyanotic congenital heart defects. Measurements and results: Forty-three children were studied. Cerebral tissue oxygenation index, measured non-invasively by near-infrared spectroscopy, was compared to SvO(2), measured by a catheter placed in the right atrium, and to haemodynamic and respiratory parameters. Pearson's correlation coefficients and p values were calculated. Simultaneously measured values for SvO(2) (62.2+/-9.8%, 39.8-80.4%) and cerebral tissue oxygenation index (56.7+/-8.8%, 35.8-71.2%) showed a significant correlation (r=0.52, p<0.001). Conclusion: Cerebral tissue oxygenation index and SvO(2) are not interchangeable parameters, but cerebral tissue oxygenation index reflects the haemodynamic influence on cerebral oxygenation after cardiovascular surgery. Further work is necessary to confirm the clinical role of continuous non-invasive measurement of cerebral tissue oxygenation index with regard to the variations of global systemic oxygen consumption after cardiac surgery in children.	German Heart Inst, Dept Intens Care & Paediat Cardiol, D-13353 Berlin, Germany; German Heart Inst, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany; German Heart Inst, Dept Anaesthesiol, D-13353 Berlin, Germany	Nagdyman, N (corresponding author), German Heart Inst, Dept Intens Care & Paediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	nagdyman@dhzb.de	huebler, michael/AAS-4063-2020; Fleck, Thilo Pierre Karl/H-9073-2019	Fleck, Thilo Pierre Karl/0000-0003-4531-5930			Abdul-Khaliq H, 2002, THORAC CARDIOV SURG, V50, P77, DOI 10.1055/s-2002-26698; Abdul-Khaliq H, 2000, BIOMED TECH, V45, P328, DOI 10.1515/bmte.2000.45.11.328; Adcock LM, 1999, CLIN PERINATOL, V26, P893; Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Ali MS, 2001, CAN J ANAESTH, V48, P497, DOI 10.1007/BF03028317; Ali MS, 2001, ANAESTHESIA, V56, P24; Chan MTV, 1997, ANAESTHESIA, V52, P705; Daubeney PEF, 1996, ANN THORAC SURG, V61, P930, DOI 10.1016/0003-4975(95)01186-2; Du Plessis Adre J., 1995, Current Opinion in Pediatrics, V7, P632; Fearn SJ, 1997, ANAESTHESIA, V52, P704; Fortune PM, 2001, INTENS CARE MED, V27, P1401, DOI 10.1007/s001340100994; GERMON TJ, 1995, J NEUROL NEUROSUR PS, V58, P477, DOI 10.1136/jnnp.58.4.477; Grubhofer G, 1997, ANAESTHESIA, V52, P116, DOI 10.1111/j.1365-2044.1997.20-az020.x; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MATCHER SJ, 1995, P SOC PHOTO-OPT INS, V2359, P486; MILLER HC, 1974, BRIT HEART J, V36, P446; Nollert G, 1998, THORAC CARDIOV SURG, V46, P167, DOI 10.1055/s-2007-1010220; Nollert G, 2000, THORAC CARDIOV SURG, V48, P247, DOI 10.1055/s-2000-6895; Quaresima V, 2000, J BIOMED OPT, V5, P201, DOI 10.1117/1.429987; Rigg CD, 1997, ANAESTHESIA, V52, P356, DOI 10.1111/j.1365-2044.1997.98-az0094a.x; Schulz G, 2002, INTENS CARE MED, V28, P184, DOI 10.1007/s00134-001-1182-5; Suzuki S, 1999, P SOC PHOTO-OPT INS, V3579, P144; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Tweddell James S, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P187; VONSIEBENTHAL K, 1992, BRAIN DEV-JPN, V14, P135; Wahr JA, 1996, J CARDIOTHOR VASC AN, V10, P406, DOI 10.1016/S1053-0770(96)80107-8; Weiss M, 2002, CAN J ANAESTH, V49, P824, DOI 10.1007/BF03017416	29	52	52	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2004	30	3					468	471		10.1007/s00134-003-2101-8			4	Critical Care Medicine	General & Internal Medicine	780GQ	WOS:000189364300018	14722637				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Recovery and predictors of language skills two years following pediatric traumatic brain injury	BRAIN AND LANGUAGE			English	Article						traumatic brain injury; children; language; recovery	CLOSED-HEAD-INJURY; CHILDREN; ADOLESCENTS; FAMILY; PERFORMANCE; CHILDHOOD; DISCOURSE	Subtle language processing difficulties may adversely affect scholastic performance, as well as communication and social skills. It is therefore crucial that language skills are monitored following traumatic brain injury (TBI) in childhood. The present study examined language skills in a group of 68 children who had sustained a mild, moderate or severe TBI. Results indicated that during the acute stage a dose-response relationship was evident, where severe TBI was associated with poorest performance and mild TBI with least deficits. By 24 months post-TBI, it was clear that for some language functions, the severe TBI group showed substantial recovery, and at times performed better than the moderate TBI group. Predictors of language and literacy skills at 24 months post TBI included pre-injury communication skills, socio-economic status, age at injury, and Vocabulary, as measured by the Wechsler Intelligence Scale for Children (WISC-111). (C) 2003 Elsevier Science (USA). All rights reserved.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	catroppc@cryptic.rch.unimelb.edu.au					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; Didus E, 1999, Pediatr Rehabil, V3, P177; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; GADDES WH, 1973, RES MONOGRAPH U VICT, V25; GARDNER M, 1979, MANUAL EXPRESSIVE ON; Goldstein FC, 1992, COGNITIVE DISORDERS; Goldstone BP, 2001, READ TEACH, V55, P362; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hallett T L, 1997, Pediatr Rehabil, V1, P219; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; MARQUARDT TP, 1988, J LEARN DISABIL, V21, P340, DOI 10.1177/002221948802100605; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Morse S, 1999, Pediatr Rehabil, V3, P139; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; RIVARA JMB, 1995, ARCH PHYSICAL MED RE, V77, P754; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1992, MANUAL WECHSLER INTE; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	37	52	52	1	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JAN	2004	88	1					68	78		10.1016/S0093-934X(03)00159-7			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	766CB	WOS:000188326900007	14698732				2021-06-18	
J	Gan, BK; Lim, JHG; Ng, IHB				Gan, BK; Lim, JHG; Ng, IHB			Outcome of moderate and severe traumatic brain injury amongst the elderly in Singapore	ANNALS ACADEMY OF MEDICINE SINGAPORE			English	Article						geriatric; Glasgow Outcome Score; Glasgow Coma Score; moderate and severe traumatic brain injury	SEVERE HEAD-INJURY; COMA-DATA-BANK; SUBARACHNOID HEMORRHAGE; CLINICAL COURSE; MORTALITY; AGE; CLASSIFICATION; TOMOGRAPHY; PROGNOSIS; VARIABLES	Introduction: In line with other established protocols, our unit has instituted a standardised protocol for the management of moderate and severe traumatic brain injury since 1996 in our neurointensive care unit. Materials and Methods: We reviewed the outcomes, at 6 months' postinjury, in an elderly group aged greater than or equal to64 years (73.86 +/- 8.0 years) and compared them to a younger group aged 20 to 40 years (29.2 +/- 5.7 years) in a cohort of 324 patients. Outcome was dichotomised as favourable (mild and moderate disability but independent; Glasgow Outcome Score [GOS] 4 and 5), unfavourable (severe disability and persistent vegetative state; GOS 2 and 3) and death (GOS 1). Results: In the elderly group, the mortality (55.4%) was slightly more than double that of the younger group (20.9%); 21.5% had an unfavourable outcome (14.2% in the younger group) and only 23% had a favourable outcome (compared to 64.9% in the younger group). The final outcomes were significantly worse in all levels in the elderly group. This was in spite of data showing that the mechanism of injury was of a higher impact in the younger group, with a higher incidence of polytrauma and cervical spine injury. On admission, the mean Glasgow Coma Score (GCS) was 8.3 +/- 3.91 for the elderly group and 8.59 +/- 4.05 for the younger group (P = 0.763). Computed tomography scan showed that the elderly had a higher incidence of mass lesions (extradural haematoma and subdural haematoma) and traumatic subarachnoid haemorrhage. A subgroup (29.2%) of elderly patients had no surgical intervention based on poor clinical/ neurological status, premorbid functional status and pre-existing medical conditions, with their family's consent. The GCS of less than or equal to8, on admission, was significant (P <0.001) in predicting mortality in the elderly. In the elderly group, the female gender had a higher mortality rate (70.4%) than the males (44.7%) (P = 0.19). Conclusion: Age must be considered an independent factor in outcome prediction in the elderly with moderate and severe traumatic brain injury. A more conservative approach in the management of an elderly patient with severe head injury may be reasonable given its dismal outcomes after careful dialogue with the relatives.	Natl Inst Neurosci, Dept Neurosurg, Sect Neurotrauma, Singapore 308433, Singapore	Ng, IHB (corresponding author), Natl Inst Neurosci, Dept Neurosurg, Sect Neurotrauma, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	Ivan_Ng@ttsh.com.sg					AMACHER AL, 1987, NEUROSURGERY, V20, P954; Baltas I, 1998, J Neurosurg Sci, V42, P85; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; *BRAUN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1982, NEUROLOGICAL DISORDE, P202; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V1, pS287; *MIN HLTH, 2002, HLTH FACTS SING 2002; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P789; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; ZWIMPFER TJ, 1993, CRIT CARE CLIN, V9, P727	38	52	56	0	5	ACAD MEDICINE SINGAPORE	REPUBLIC SINGAPORE	142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE	0304-4602			ANN ACAD MED SINGAP	Ann. Acad. Med. Singap.	JAN	2004	33	1					63	67					5	Medicine, General & Internal	General & Internal Medicine	776DD	WOS:000189100700013	15008565				2021-06-18	
J	Evered, L; Ruff, R; Baldo, J; Isomura, A				Evered, L; Ruff, R; Baldo, J; Isomura, A			Emotional risk factors and postconcussional disorder	ASSESSMENT			English	Article						mild traumatic brain injury (MTBI); postconcussional disorder (PCD); emotional factors; forensic evaluation	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; MILD; SYMPTOMS; MODERATE; SPECTRUM	Emotional risk factors were examined in 129 litigant and nonlitigant patients diagnosed with Postconcussional Disorder (PCD) following Mild Traumatic Brain Injury (MTBI). According to Millon Clinical Multiaxial Inventorv (MCMI) criteria, four subgroups emerged: (a) 14.7% met criteria for an Axis I disorder, (b) 24.8% for an Axis II disorder (c) threshold for 24.0% for bout Axis I and II disorders, and (d) 36.4% fell below psychopathology. Thus, 63.5% endorsed emotional pathology. Of the four groups, those with both Axis I and II psychopathology presented the greatest number of emotional complaints in a clinical interview and manifested the lowest neurocognitive test scores. Motor skills. verbal abilities, memory functioning, and IQ were primarily affected. With the exception of post-morbid emotional complaints, no significant differences were identified between litigants and nonlitigants. Our analysis suggests that the combination of both Axis I and II psychopathology is associated with greater impairment following MTBI.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Scripps Coll, Claremont, CA 91711 USA; Brown Univ, Providence, RI 02912 USA							ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baser C A, 1987, Arch Clin Neuropsychol, V2, P13, DOI 10.1016/0887-6177(87)90031-X; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Groth-Marnat G, 1997, HDB PSYCHOL ASSESSME; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LUCAS JA, 1998, CLIN NEUROPSYCHOLOGY, P243; Millon T., 1996, DISORDERS PERSONALIT; MILLON T, 1987, MCMI 2 MANUAL; MILLON T, 1997, MANUAL MILLON CLIN M, V3; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; *NIH, 2000, NIH CONS STAT REH PE; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUFF R, IN PRESS RUFF NEUROB; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUFF RM, 1991, HDB CLIN TRIALS NEUR, P89; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tombaugh TN, 1996, TEST MEMORY MALINGER; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	36	52	52	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	DEC	2003	10	4					420	427		10.1177/1073191103259539			8	Psychology, Clinical	Psychology	750GU	WOS:000186983600013	14682488				2021-06-18	
J	van Loo, M; Moseley, AM; Bosman, JM; de Bie, RA; Hassett, L				van Loo, M; Moseley, AM; Bosman, JM; de Bie, RA; Hassett, L			Inter-rater reliability and concurrent validity of walking speed measurement after traumatic brain injury	CLINICAL REHABILITATION			English	Article							HEMIPLEGIC GAIT; STROKE	Objective: To assess the inter-rater reliability and concurrent validity of walking speed measurement after traumatic brain injury. Design: Twelve subjects each completed five comfortably paced and five fast-paced walking trials. Walking speed was measured simultaneously by five observers using a stopwatch (clinical procedure) and by infrared timing gates (gold standard). Setting: Brain injury rehabilitation unit. Subjects: People with traumatic brain injury who could walk independently and were participating in a rehabilitation programme. Main outcome measures: Walking speed over a 10-metre distance. Results: The inter-rater reliability of walking speed measured using a stopwatch was very high, with an intraclass correlation coefficient of at least 0.998 for both comfortable and fast-paced tests. Concurrent validity was excellent for comfortable and fast tests, with perfect correlations between the stopwatch and infrared timing gate measurement procedures. Conclusions: Physiotherapists can use a stopwatch as a reliable and valid measurement tool to quantify walking speed over a short distance at both comfortable and fast paces in people who have sustained traumatic brain injuries.	Univ Sydney, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Moseley, AM (corresponding author), Univ Sydney, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.			Hassett, Leanne/0000-0002-3546-1822			BRANDSTATER ME, 1983, ARCH PHYS MED REHAB, V64, P583; Datta D, 1996, CLIN REHABIL, V10, P227, DOI DOI 10.1177/026921559601000307; EKEOKORO ST, 1994, J HUM MOVEMENT STUD, V10, P107; Evans MD, 1997, ARCH PHYS MED REHAB, V78, P725, DOI 10.1016/S0003-9993(97)90080-0; Gifford R, 1977, J HUM MOVEMENT STUD, V3, P66; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Marks R, 1994, Arthritis Care Res, V7, P50, DOI 10.1002/art.1790070111; MAYERSON NH, 1984, ARCH PHYS MED REHAB, V65, P92; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wade DT, 1992, MEASUREMENT NEUROLOG	11	52	53	0	4	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	OCT	2003	17	7					775	779		10.1191/0269215503cr677oa			5	Rehabilitation	Rehabilitation	736CC	WOS:000186152000012	14606745				2021-06-18	
J	Burnett, DM; Kolakowsky-Hayner, SA; Slater, D; Stringer, A; Bushnik, T; Zafonte, R; Cifu, DX				Burnett, DM; Kolakowsky-Hayner, SA; Slater, D; Stringer, A; Bushnik, T; Zafonte, R; Cifu, DX			Ethnographic analysis of traumatic brain injury patients in the national model systems database	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						accidents; traffic; automobiles; brain injuries; demography; rehabilitation	SPINAL-CORD INJURY; HISPANICS; ETHNICITY; IMPACT	Objective: To compare demographics, injury characteristics, therapy service and intensity, and outcome in minority versus nonminority patients with traumatic brain injury (TBI). Design: Retrospective analysis. Setting: Twenty medical centers. Participants: Two thousand twenty patients (men, n=1518; women, n=502; nonminority, n=1168; minority, n=852) with TBI enrolled in the Traumatic Brain Injury Model Systems database. Interventions: Not applicable. Main Outcome Measures: Age, gender, marital status, education, employment status, injury severity (based on Glasgow Coma Scale [GCS] admission score, length of posttraumatic amnesia, duration of unconsciousness), intensity (hours) of therapy rendered, rehabilitation length of stay (LOS), rehabilitation charges, discharge disposition, postinjury employment status, FIMTM instrument change scores, and FIM efficiency scores. Independent sample t tests were used to analyze continuous variables; chi-square analyses were used to evaluate categorical data. Results: Demographics: overall, minorities were found to be mostly young men who were single, unemployed, and less well educated, with a longer work week if employed when injured. Etiology: motor vehicle crashes (MVCs) predominated as the cause of injury for both groups; however, minorities were more likely to sustain injury from acts of violence and auto-versuspedestrian crashes. Minorities also had higher GCS scores on admission and shorter LOS. Rehabilitation services: significant differences were found in the types and intensity of rehabilitation services provided; these included physical therapy, occupational therapy, and speech-language pathology, but not psychology. Conclusions: Minority patients who sustain TBI generally tend to be young men with less social responsibility. Although MVCs predominate as the primary etiology, acts of violence and auto-versus-pedestrian incidents are more common in the minority population. Minorities tend to have higher GCS scores at admission. Also, the type and intensity of rehabilitation services provided differed significantly for the various interdisciplinary subspecialties. Rehabilitation charges, discharge disposition, and postinjury employment status were similar for the 2 groups, even though LOS is typically 3 to 4 days shorter for the minority group. A more detailed investigation is warranted to explain these findings.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Emory Univ, Dept Rehabil Med, Atlanta, GA USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Burnett, DM (corresponding author), Lester Schneider Hosp, 9048 Sugar Estates Rd, St Thomas, VI 00802 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387; Bushnik, Tamara/0000-0003-3328-257X			Burnett DM, 2000, BRAIN INJURY, V14, P713; FAIR GW, 1980, J SCHOOL HEALTH, V50, P275, DOI 10.1111/j.1746-1561.1980.tb07769.x; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HOWARD G, 1994, STROKE, V25, P120; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Krause JS, 1999, ARCH PHYS MED REHAB, V80, P1492; RINTALA R, 1998, TOP SPINAL CORD INJ, V4, P2; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; SACCO RL, 1991, STROKE, V22, P305, DOI 10.1161/01.STR.22.3.305; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245; 1983, WEBSTERS 9 NEW COLLE, P757	12	52	52	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					263	267		10.1053/apmr.2003.50091			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700017	12601659				2021-06-18	
J	Masson, F; Thicoipe, M; Mokni, T; Aye, P; Erny, P; Dabadie, P				Masson, F; Thicoipe, M; Mokni, T; Aye, P; Erny, P; Dabadie, P		Aquitaine Grp Severe Brain Injury	Epidemiology of traumatic comas: a prospective population-based study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURIES; BRAIN INJURY; UNITED-STATES; OLDER ADULTS; MORTALITY; DEATHS; GUIDELINES; FALLS; CARE; PREVENTION	Objective: Most studies on patients with severe brain injury (SBI) are based on data from specialized centres. This prospective epidemiologic study included all patients in a defined region with a coma lasting more than 24 hours or leading to a death. Methods: All patients with a SBI admitted to an emergency department in the region were included during a 1-year period. A data form was completed with initial neurological state, CT scan lesions and associated injuries. Outcome at the end of acute hospitalization was assessed from medical notes. Results: Two hundred and forty-eight patients were registered. Annual incidence was 8.5/100 000 population. Median age was 41 years. Traffic crashes were the most frequent cause (59%). Falls occurred in 30% (16% from a high level, 14% from one level). Initial GCS was above 8 in 31%, and patients with a neurological deterioration were older ( 52 vs 32 years). Death occurred in 52% of the cohort. Outcome was related to CT scan diagnosis, delay before eye opening and delay before obeying commands. Conclusion. This population-based cohort of patients with SBI was different from patients selected in trauma centres. The patients were older, more often injured in falls and their mortality rate remained very high.	Univ Hosp Bordeaux, Dept Anesthesia, Bordeaux, France; Univ Hosp Bordeaux, Dept Emergency, Bordeaux, France; Hosp Bayonne, Dept Emergency, Bayonne, France; Hosp Pau, Dept Emergency, Pau, France	Masson, F (corresponding author), Hop Pellegrin, Serv Reanimat, F-33076 Bordeaux, France.						American Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Baethmann A, 2002, EUR SURG RES, V34, P42, DOI 10.1159/000048886; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; Bruder N, 1997, ANN FR ANESTH, V16, P227, DOI 10.1016/S0750-7658(97)86405-2; Carter ND, 2001, SPORTS MED, V31, P427, DOI 10.2165/00007256-200131060-00003; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; Gentleman D, 1999, BRIT MED BULL, V55, P910, DOI 10.1258/0007142991902718; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Gubler KD, 1996, J TRAUMA, V41, P952, DOI 10.1097/00005373-199612000-00002; Hannan EL, 2001, J TRAUMA, V50, P1117, DOI 10.1097/00005373-200106000-00023; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2001, J CLIN EPIDEMIOL, V54, P597, DOI 10.1016/S0895-4356(00)00346-2; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LAVECCHIA C, 1994, SOZ PRAVENTIV MED, V39, P150, DOI 10.1007/BF01299659; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MacKenzie E J, 1989, Md Med J, V38, P725; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MCKENZIE EJ, 1988, J TRAUMA, V28, P281; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; *OBS NAT INT SEC R, 1997, BIL ANN STAT COMM AN, P1; Piek J, 1998, INTENS CARE MED, V24, P1221, DOI 10.1007/s001340050748; Rzepka SG, 2001, J CLIN EPIDEMIOL, V54, P627, DOI 10.1016/S0895-4356(00)00337-1; SALMI LR, 1989, ACCIDENT ANAL PREV, V6, P589; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	45	52	56	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	4					279	293		10.1080/0269905021000030805			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	660MP	WOS:000181837200002	12637181				2021-06-18	
J	Pavone, A; Cardile, T				Pavone, A; Cardile, T			An in vitro study of new antiepileptic drugs and astrocytes	EPILEPSIA			English	Article						AEDs; epilepsy; glial cells; rat	GLUTAMINE-SYNTHETASE ACTIVITY; RAT ASTROCYTES; NITRIC-OXIDE; DNA-DAMAGE; RELEASE; QUANTITATION; TIAGABINE; PROTEINS; CULTURES; STRESS	Purpose: The aim of our research was to study some biochemical modifications elicited in primary rat astrocyte cultures by treatment with gabapentin (GBP), carbamazepine (CBZ), lamotrigine (LTG), topiramate (TPM), oxcarbazepine (OXC), tiagabine (TGB), and levetiracetam (LEV), commonly used in the treatment of epilepsy. We investigated the biologic effects of these anticonvulsants (AEDs) at concentrations of 1, 10, 50, and 100 mug/ml. Methods: The study was performed by examining cell viability (MTT assay), cell toxicity [lactate dehydrogenase (LDH) release in the medium], glutamine synthetase (GS) activity, reactive oxygen species (ROS) production, lipoperoxidation level (malondialdehyde; MDA), and DNA fragmentation (COMET assay). The level of the expression of 70-kDa heat-shock protein (HSP70) and inducible nitric oxide synthase (iNOS) as oxidative stress-modulated genes also was determined. Results: Our experiments indicate that CBZ, TPM, and OXC induce stress on astrocytes at all concentrations. GBP, LTG, TGB, and LEV, at low concentrations, do not significantly change the metabolic activities examined and do not demonstrate toxic actions on astrocytes. They do so at higher concentrations. Conclusions: Most AEDs have effects on glial cells and, when used at an appropriate cell-specific (concentrations, may be well tolerated by cortical astrocytes. However, at higher concentrations, GBP, LTG, TGB, and LEV seem to be better tolerated than are CBZ, TPM, and OXC. These findings may reveal novel ways of producing large numbers of new AEDs capable of reducing the extent of inflammation, neuronal damage, and death under pathological conditions such as epilepsy and/or traumatic brain injury.	Univ Catania, Dept Physiol Sci, I-95125 Catania, Italy; Garibaldi Hosp, Dept Neurol, Catania, Italy	Cardile, T (corresponding author), Univ Catania, Dept Physiol Sci, Vle A Doria 6, I-95125 Catania, Italy.	cardile@mbox.unict.it		CARDILE, Venera/0000-0001-9902-3736			Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; AIRD RB, 1989, EPILEPSY RES, V3, P77, DOI 10.1016/0920-1211(89)90071-5; ALTAR AC, 1996, NEURODEGENERATION NE, P116; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardile V, 1996, BRAIN RES, V715, P98, DOI 10.1016/0006-8993(95)01564-7; Cardile V, 2001, NEUROSCI LETT, V306, P17, DOI 10.1016/S0304-3940(01)01836-5; Cardile V, 2000, NEUROSCI LETT, V288, P49, DOI 10.1016/S0304-3940(00)01206-4; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; DING AH, 1988, J IMMUNOL, V141, P2407; Fraser CM, 1999, BRIT J PHARMACOL, V126, P1634, DOI 10.1038/sj.bjp.0702472; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loscher W, 2002, J PHARMACOL EXP THER, V301, P7, DOI 10.1124/jpet.301.1.7; McGeer EG, 1997, MOVEMENT DISORD, V12, P855, DOI 10.1002/mds.870120604; McNaught KSP, 2000, NEUROSCI LETT, V285, P61, DOI 10.1016/S0304-3940(00)00982-4; Miyamae Y, 1998, Mutat Res, V415, P229, DOI 10.1016/S1383-5718(97)00192-7; Moller P, 2000, CANCER EPIDEM BIOMAR, V9, P1005; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nicolson A, 2001, CNS DRUGS, V15, P955, DOI 10.2165/00023210-200115120-00005; Renis M, 1998, BRAIN RES, V783, P143, DOI 10.1016/S0006-8993(97)01321-8; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; Sills Graeme J., 1998, Epilepsia, V39, P40; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; WELCH WJ, 1992, PHYSIOL REV, V72, P1063	26	52	55	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2003	44			10			34	39		10.1046/j.1528-1157.44.s10.5.x			6	Clinical Neurology	Neurosciences & Neurology	733YK	WOS:000186028100007	14511393	Bronze			2021-06-18	
J	Mussack, T; Biberthaler, P; Kanz, KG; Heckl, U; Gruber, R; Linsenmaier, U; Mutschler, W; Jochum, M				Mussack, T; Biberthaler, P; Kanz, KG; Heckl, U; Gruber, R; Linsenmaier, U; Mutschler, W; Jochum, M			Immediate S-100B and neuron-specific enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients	SHOCK			English	Article						traumatic brain injury; minor head injury; S-100B; NSE; cerebral computed tomography; ROC analysis; alcohol intoxication; screening test	COMPUTED-TOMOGRAPHY; NEUROBIOCHEMICAL MARKERS; TEMPORAL PROFILE; SERUM LEVELS; TRAUMA; MANAGEMENT; PROTEIN; S100-BETA; SEVERITY; RELEASE	The neuroproteins S-100B and neuron-specific enolase (NSE) released into the circulation are suggested to be reliable markers for primary brain damage. However, safe identification of relevant post-traumatic complications after minor head injury (MHI) is often hampered by acute intoxication of the patients. The objective of this study was to determine the diagnostic validity of immediate plasma measurements of S-100B and NSE in comparison with neurological examinations and cerebral computed tomography (CCT) findings in alcohol-intoxicated MHI patients. One hundered thrity-nine MHI individuals were enrolled in this prospective study during Munich's Oktoberfest 2000. Plasma levels of S-100B and NSE as well as serum alcohol and glucose values were determined by fully automated assays immediately after admission. The results were compared with Glasgow Coma Scale score, a brief neurological examination, and the CCT findings. Without being influenced by alcohol, median S-100B levels of the CCT+ group were significantly increased compared with those of the CCT- group (P < 0.001). NSE, alcohol, and glucose levels showed no significant group differences. As calculated by the ROC analysis, a cutoff value of 0.21 ng/mL with an area under the curve of 0.864 clearly differentiates between CCT+ and CCT- patients at a sensitivity of 100%, a specificity of 50.0%, and a positive likelihood ratio of 2.0. Although acute alcohol intoxication did not confound plasma measurements of S-100B and NSE, only S-100B levels below the cutoff level of 0.21 ng/mL seem to indicate absence of primary brain damage. Thus, in addition to routine neurological examinations, S-100B measurements immediately after admission might help to reduce CCT scans in alcohol-intoxicated patients early after MHI.	Klinikum Univ Munich, Chirurg Klin & Poliklin Innenstadt, D-80336 Munich, Germany; Klinikum Univ Munich, Med Klin & Poliklin Innenstadt, Munich, Germany; Klinikum Univ Munich, Inst Klin Radiol, Munich, Germany; Klinikum Univ Munich, Abt Klin Chem & Klin Biochem, Munich, Germany	Mussack, T (corresponding author), Klinikum Univ Munich, Chirurg Klin & Poliklin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.						Baethmann A, 1999, ACT NEUR S, V73, P93; Baethmann A, 1998, ACT NEUR S, V71, P107; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Griner P F, 1981, Ann Intern Med, V94, P557; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hammon JW, 2000, J THORAC CARDIOV SUR, V119, P130, DOI 10.1016/S0022-5223(00)70227-3; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; KAHN HJ, 1991, MODERN PATHOL, V4, P698; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	36	52	58	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	NOV	2002	18	5					395	400		10.1097/00024382-200211000-00002			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	617VW	WOS:000179382400002	12412616				2021-06-18	
J	Randolph, LC; Takacs, M; Davis, KA				Randolph, LC; Takacs, M; Davis, KA			Resuscitation in the pediatric trauma population: Admission base deficit remains an important prognostic indicator	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	32nd Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2002	WHISTLER-BLACKCOMBE, CANADA	Western Trauma Assoc		post-traumatic shock; outcome	OXYGEN DEBT; RISK; PREDICTORS; CLEARANCE; MORTALITY; SHOCK	Background: Base deficit (BD), as an endpoint for trauma resuscitation, has been extensively studied in the adult trauma patient but not in the pediatric population. We proposed that admission BD would correlate with outcomes after trauma in a pediatric population. Methods: This study was a retrospective review of all patients admitted to the pediatric intensive care unit in an adult trauma center with pediatric commitment in whom an admission BD was available, over the 5-year period ending June 2001. Results: A total of 65 patients formed the study population. Overall mortality was 20%. Patients who died were younger (6 +/- 5 vs. 9 +/- 5 years; p = 0.009), had lower Glasgow Coma Scale scores at admission (7 +/- 5 vs. 10 +/- 5; p < 0.0001), had higher Injury Severity Scores (24 +/- 14 vs. 14 +/- 9; p < 0.0001), and had lower Pediatric Trauma Scores (7 +/- 4 vs. 10 +/- 2; p < 0.0001). No patient with a BD less negative than -5 died, whereas 13 of 37 patients with a BD of -5 or higher died (37%) (p < 0.0001). Of the 13 patients who died, 8 never cleared their BD and died within 33 +/- 18 hours of admission. Failure to clear BD was associated with 100% mortality. Five patients who normalized their BD died of isolated closed head injuries (time to death, 37 +/- 18 hours; p = not significant). All surviving patients normalized their BD within 43 +/- 41 hours of admission. Seventy-five percent of patients who survived (39 of 52) had a normal BD within 48 hours of admission. Conclusion: Admission BD in the pediatric trauma patient is a strong indicator of posttraumatic shock. An admission BD of less than or equal to -5 is predictive of severe injury and of poor outcome, with a 37% mortality in this series. Failure to clear BD is an extremely poor prognostic indicator.	Loyola Univ, Med Ctr, Div Trauma Surg Crit Care & Burns, Dept Surg, Maywood, IL 60153 USA	Davis, KA (corresponding author), Loyola Univ, Med Ctr, Div Trauma Surg Crit Care & Burns, Dept Surg, 2160 S 1st Ave,Bldg 110,Room 3272, Maywood, IL 60153 USA.	kdavis3@lumc.edu		Takacs, Michael/0000-0001-6783-2192			ABOUKHALIL B, 1994, CRIT CARE MED, V22, P633, DOI 10.1097/00003246-199404000-00020; ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Chang MC, 1997, J TRAUMA, V42, P577, DOI 10.1097/00005373-199704000-00001; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; Davis JW, 1998, J TRAUMA, V44, P114, DOI 10.1097/00005373-199801000-00014; DAVIS JW, 1991, SURG GYNECOL OBSTET, V173, P473; Davis JW, 1998, J TRAUMA, V45, P873, DOI 10.1097/00005373-199811000-00005; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; Eichelberger M, 1993, PEDIAT TRAUMA PREVEN; Foreman John, 1997, P127; GOODWIN CW, 1997, COMPLICATONS SURG TR, P126; Kincaid EH, 2001, J TRAUMA, V51, P332, DOI 10.1097/00005373-200108000-00018; Porter JM, 1998, J TRAUMA, V44, P908, DOI 10.1097/00005373-199805000-00028; ROGERS MC, 1996, PEDIAT INTENSIVE CAR; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SHOEMAKER WC, 1971, SURG GYNECOL OBSTETR, V132, P1033; Siegel JH, 1997, J TRAUMA, V42, P199, DOI 10.1097/00005373-199702000-00005	20	52	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2002	53	5					838	842		10.1097/00005373-200211000-00006			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	618DV	WOS:000179403900006	12435932				2021-06-18	
J	Gorrie, C; Oakes, S; Duflou, J; Blumbergs, P; Waite, PME				Gorrie, C; Oakes, S; Duflou, J; Blumbergs, P; Waite, PME			Axonal injury in children after motor vehicle crashes: Extent, distribution, and size of axonal swellings using beta-APP immunohistochemistry	JOURNAL OF NEUROTRAUMA			English	Article						beta-APP; axons diameter; axonal injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; TRAUMATIC BRAIN INJURY; CORPUS-CALLOSUM; DAMAGE; TRANSPORT; HUMANS; MARKER; MODEL; NEUROPATHOLOGY	The brains of 32 children (3 months to 16 years) who died as a result of motor vehicle collisions were examined for axonal injury using,beta-APP immunohistochemistry. The extent and distribution of axonal injury was assessed and quantified throughout the forebrain, brainstem and cerebellum. The mean diameter of immunoreactive axons in the corpus callosum was measured for this pediatric group and, for comparison, a small adult sample. beta-APP immunoreactivity was seen in 14 pediatric cases (survival 35 mins to 87 h), most frequently in the parasagittal white matter (12/14), the corpus callosum (11/14), the brainstem (10/14) and cerebellum (9/14). In 2 cases, axon swelling was visualized in the internal capsule after only 35-45-min survival, earlier than has previously been reported. No immunoreactivity was seen in the remaining 18 cases who died within I h. The extent and distribution of axonal injury throughout the brain showed a rapid early increase with increasing survival time and then a slower progression. The diameter of individual callosal axons increased with increasing survival times, rapidly over the first 24 h and then more slowly. There was no statistical difference (p < 0.05) for callosal axon diameters at different survival times between the children and the adults sampled here. The extent and distribution of axonal injury throughout the brain appears to be similar in children to that previously reported in adults. The spatial and temporal spread of axonal damage suggests there may be therapeutic potential for the process to be arrested or slowed in its early stages.	Univ New S Wales, Sch Med Sci, Neural Injury Res Unit, Sydney, NSW 2052, Australia; Sydney Cent Area Hlth Serv, Dept Forens Med, Sydney, NSW, Australia; Inst Med & Vet Sci, Neuropathol Lab, Adelaide, SA 5000, Australia	Gorrie, C (corresponding author), Univ New S Wales, Sch Biomed Sci, Dept Anat, Neural Injury Res Unit, Wallace Wurth Bldg, Sydney, NSW 2052, Australia.		Gorrie, Catherine/S-6591-2019; Duflou, Johan/AAK-2331-2020	Gorrie, Catherine/0000-0001-5934-2492; Oakes, Samantha/0000-0003-1838-2310; Duflou, Johan/0000-0001-5863-635X			ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Blumbergs PC, 1998, J CLIN NEUROSCI, V5, P123, DOI 10.1016/S0967-5868(98)90026-1; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRODY BA, 1987, J NEUROPATH EXP NEUR, V46, P283, DOI 10.1097/00005072-198705000-00005; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Finnie J, 1999, J CLIN NEUROSCI, V6, P38, DOI 10.1016/S0967-5868(99)90601-X; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gorrie C, 1999, CHILD NERV SYST, V15, P322, DOI 10.1007/s003810050403; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; POLITIS MJ, 1979, BRAIN RES, V166, P221, DOI 10.1016/0006-8993(79)90209-9; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RUSS JC, 1994, IMAGE PROCESSING HDB; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Slazinski T, 1994, J Neurosci Nurs, V26, P151; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; TEMPLETON JM, 1993, PEDIAT TRAUMA PREVEN, P20; VIANCOUR TA, 1993, BRAIN RES, V628, P209, DOI 10.1016/0006-8993(93)90957-O; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	52	52	54	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2002	19	10					1171	1182		10.1089/08977150260337976			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	605MJ	WOS:000178681400006	12427326				2021-06-18	
J	Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG				Saljo, A; Bao, F; Shi, JS; Hamberger, A; Hansson, HA; Haglid, KG			Exposure to short-lasting impulse noise causes neuronal c-Jun expression and induction of apoptosis in the adult rat brain	JOURNAL OF NEUROTRAUMA			English	Article						acoustic energy; apoptosis; brain damage; closed head injury; immediate early gene; impulse noise; pressure waves	PROGRAMMED CELL-DEATH; SPINAL-CORD INJURY; INDUCIBLE TRANSCRIPTION FACTORS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; METHYL-D-ASPARTATE; PARKINSONS-DISEASE; DNA FRAGMENTATION; SUBSTANTIA-NIGRA; SENSORY NEURONS	Exposure to impulse noise, above a certain intensity, is harmful to auditory function. Effects of impulse noise on the central nervous system (CNS) are largely unexplored, and there is little information on critical threshold values and time factors. We have recently shown that neurofilament proteins are affected in the cerebral cortex and the hippocampus. Now we show that impulse noise induces expression of the immediate early gene c-Jun products, proposed to play a role in the initiation of neuronal death, and apoptosis as revealed by TUNEL staining. Rat brains were investigated immunohistochemically 2 h to 21 days after exposure to impulse noise of 198 dB or 202 dB. c-Jun was expressed in neuronal perikarya in layers II-VI of the temporal cortex, the cingulate and the piriform cortices at 2 h to 21 days after both exposure levels. Granule neurons of the dentate gyrus and the CA1-3 in the hippocampus pyramidal neurons were similarly affected. The elevated expression of c-Jun products remained high at all postexposure times. TUNEL staining was positive among the same nerve cell populations 6 h after exposure and persisted even at 7 days at both exposure levels.	Univ Gothenburg, Dept Anat & Cell Biol, SE-40530 Gothenburg, Sweden; China Med Univ, Inst Brain Res, Shenyang, Peoples R China; Zunyi Med Coll, Dept Pharmacol, Zunyi, Peoples R China	Saljo, A (corresponding author), Univ Gothenburg, Dept Anat & Cell Biol, POB 420, SE-40530 Gothenburg, Sweden.	annette.saljo@anatcell.gu.se					BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; Cheung NS, 1998, J NEUROSCI RES, V52, P69, DOI 10.1002/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.3.CO;2-L; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COHEN JJ, 1984, J IMMUNOL, V132, P38; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dancer A, 1998, SCAND AUDIOL, V27, P123; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HERDEGEN T, 1991, NEUROSCIENCE, V45, P413, DOI 10.1016/0306-4522(91)90237-I; HERDEGEN T, 1992, MOL BRAIN RES, V14, P155, DOI 10.1016/0169-328X(92)90170-G; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124; Houle JD, 1998, EXP NEUROL, V154, P602, DOI 10.1006/exnr.1998.6954; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; *ISO, 1992, 317 ISO; JENKINS R, 1993, NEUROSCIENCE, V53, P447, DOI 10.1016/0306-4522(93)90208-W; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; JOHNSON EM, 1995, J NEUROTRAUM, V12, P843, DOI 10.1089/neu.1995.12.843; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XZ, 1997, J NEUROSCI, V17, P5395; Messina A, 1996, J COMP NEUROL, V372, P544, DOI 10.1002/(SICI)1096-9861(19960902)372:4<544::AID-CNE4>3.0.CO;2-4; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Pittman S, 1997, LEUKEMIA RES, V21, P491, DOI 10.1016/S0145-2126(97)00038-6; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Smith BJ, 1997, IEEE DES TEST COMPUT, V14, P7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Wullner U, 1999, ACTA NEUROPATHOL, V97, P408, DOI 10.1007/s004010051005; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F	57	52	53	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					985	991		10.1089/089771502320317131			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800008	12225658				2021-06-18	
J	Dunham, CM; Sosnowski, C; Porter, JM; Siegal, J; Kohli, C				Dunham, CM; Sosnowski, C; Porter, JM; Siegal, J; Kohli, C			Correlation of noninvasive cerebral oximetry with cerebral perfusion in the severe head injured patient: A pilot study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-13, 2001	TARPON SPRINGS, FL	Eastern Assoc Surg Trauma			BRAIN-TISSUE PO2; VENOUS OXYGEN-SATURATION; JUGULAR BULB; PRESSURE; ISCHEMIA	Background: Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in trauma patients. Cerebral perfusion pressure (CPP) directed ICU management is recommended for patients with severe TBI. It, however, requires an invasive device to measure intracranial pressure (ICP). Transcranial cerebral oximetry is a noninvasive method utilizing near-infrared technology to indirectly measure cerebral saturation (Stco(2)). Methods: A prospective observational study was performed at a Level I trauma center. Data were collected hourly for the first 6 days on four patients with severe TBI. Each patient had ICP monitoring and Stco(2) (INVOS, Somanetics) assessed from each frontal lobe. CPP directed care was used. Results: Four patients with TBI, with admission GCS scores of 4. 4. 7, and 8. all had subdural hematomas and contusions; three had subarachnoid hemorrhage (SAH); one had an epidural hematoma (the only death; day 6); two had craniotomies. In the first 48 hours when CPP 70, Stco2 was 71 +/- 9, while it was 61 9 when CPP < 70 (p < 0.0001). This relationship was constant for all study days, with p < 0.0001. Moreover, CPP < 70 correlated with Stco(2) with r = 0.81 and r(2) = 0.66. Stco(2) greater than or equal to75 was associated with CPP greater than or equal to 70 96.4% of the time (95% CL, 94.3-98.5%). Stco2 < 55 was associated with CPP < 70 68.2% of the time (95% CL, 57-79.4%). Also, 13.4% of observations with CPP ? 70 had Stco(2) < 60, suggesting the potential of cerebral ischemia in the face of ''normal'' CPP. The Stco(2) patches were user-friendly and not technically finicky. Conclusion: In this pilot study, Stco(2) correlated significantly with CPP. A Stco2 75 suggests that CPP is adequate, while < 55 suggests an inadequate CPP. Although these results should be confirmed in a larger study, Stco(2) may serve as a noninvasive measurement of cerebral perfusion in the patient with a TBI or, at the very least, a sensitive indicator for the need to begin monitoring the ICP.	Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Surg, Trauma Crit Care Serv,St Elizabeth Hlth Ctr, Youngstown, OH 44501 USA	Dunham, CM (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Surg, Trauma Crit Care Serv,St Elizabeth Hlth Ctr, 1044 Belmont Ave, Youngstown, OH 44501 USA.	michael_dunham@hmis.org					Bruzzone P, 1998, ACT NEUR S, V71, P111; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gupta AK, 1998, HOSP MED, V59, P704; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1998, ACT NEUR S, V71, P172; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; MCCORMICK PW, 1991, STROKE, V22, P596, DOI 10.1161/01.STR.22.5.596; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Samra SK, 1999, J NEUROSURG ANESTH, V11, P1, DOI 10.1097/00008506-199901000-00001; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Savers S, 2000, J NEUROTRAUM, V17, P507; SCHELL RM, 1992, ANESTH ANALG, V74, P627; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; The Brain Trauma Foundation American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; WILLIAMS IM, 1993, SURGERY STROKE, P129; 2000, J NEUROTRAUMA, V17, P453	25	52	58	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2002	52	1					40	46		10.1097/00005373-200201000-00009			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	514PF	WOS:000173449700009	11791050				2021-06-18	
J	Regan, RF; Kumar, N; Gao, F; Guo, Y				Regan, RF; Kumar, N; Gao, F; Guo, Y			Ferritin induction protects cortical astrocytes from heme-mediated oxidative injury	NEUROSCIENCE			English	Article						brain injury; free radical; glia; hemoglobin; iron; mouse	MESSENGER-RNA TRANSLATION; TRAUMATIC BRAIN INJURY; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; IRON-UPTAKE; IN-VITRO; OXYGENASE-1 EXPRESSION; CELLULAR-DISTRIBUTION; HEMOGLOBIN TOXICITY; FENTON REAGENT	Hemin is released from hemoglobin after CNS hemorrhage and may contribute to its cytotoxic effect. In a prior study, we demonstrated that heme oxygenase-1 induction protected murine cortical astrocytes from hemoglobin toxicity. Since heme metabolism releases iron, this observation suggested that these cells are able to effectively sequester and detoxify free iron. In this study, we tested the hypotheses that astrocytes increased ferritin synthesis after exposure to heme-bound iron, and that this induction protected cells from subsequent exposure to toxic concentrations of hemin. Incubation with low micromolar concentrations of hemin, hemoglobin, or ferrous sulfate increased ferritin expression, as detected on immunoblots stained with a polyclonal antibody that was raised against horse spleen ferritin. Time course studies demonstrated an increase in ferritin levels within 2 h. Weak and scattered cellular staining was detected by immunohistochemistry in control, untreated cultures, while diffuse immunoreactivity was observed in cultures exposed to heme-bound iron. An enhanced ferritin band was detected on immunoblots from cultures that were treated with purified apoferritin, consistent with astrocytic ferritin uptake. Immunoreactivity after apoferritin treatment was not altered by concomitant treatment with cycloheximide. Pretreatment with apoferritin protected astrocytes from hemin toxicity in a concentration-dependent fashion between 1 and 4 mg/ml. At the highest concentration, cell death due to a 6-h exposure to 30 muM hemin was decreased by about 85%. A protective effect was also produced by induction of endogenous ferritin with nontoxic concentrations of ferrous sulfate, hemoglobin, or hemin. These results suggest that cortical astrocytes respond to exogenous heme-bound or free iron by rapidly increasing ferritin synthesis. The combined action of heme oxygenase-1 and ferritin may be a primary astrocytic defense against heme-mediated injury. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Surg, 1020 Sansom St,239 Thompson Bldg, Philadelphia, PA 19107 USA.	raymond.f.regan@mail.tju.edu					ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ADAMS PC, 1990, HEPATOLOGY, V11, P805, DOI 10.1002/hep.1840110514; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BALLA G, 1991, LAB INVEST, V64, P648; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BLIGHT GD, 1983, BRIT J HAEMATOL, V55, P59, DOI 10.1111/j.1365-2141.1983.tb01224.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Castellani RJ, 2000, ANTIOXID REDOX SIGN, V2, P137, DOI 10.1089/ars.2000.2.1-137; Cheepsunthorn P, 1998, J COMP NEUROL, V400, P73; CHOI DW, 1987, J NEUROSCI, V7, P357; CONNOR JR, 1990, J NEUROSCI RES, V27, P595, DOI 10.1002/jnr.490270421; CONNOR JR, 1995, J NEUROCHEM, V65, P717; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Double KL, 1998, J NEUROCHEM, V70, P2492; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gelvan D, 1996, BLOOD, V88, P3200, DOI 10.1182/blood.V88.8.3200.bloodjournal8883200; Goessling LS, 1998, J BIOL CHEM, V273, P12555, DOI 10.1074/jbc.273.20.12555; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; Halliwell B, 1989, FREE RADICALS BIOL M; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HULCRANTZ R, 1987, EXP CELL RES, V171, P203; Hulet SW, 2000, J NEUROSCI RES, V61, P52, DOI 10.1002/1097-4547(20000701)61:1<52::AID-JNR6>3.3.CO;2-K; Hulet SW, 1999, J NEUROCHEM, V72, P868, DOI 10.1046/j.1471-4159.1999.720868.x; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KAJIKAWA H, 1979, Neurologia Medico-Chirurgica, V19, P61, DOI 10.2176/nmc.19.61; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; MAINES MD, 1988, FASEB J, V2, P2557; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Mehindate K, 2001, J NEUROCHEM, V77, P1386, DOI 10.1046/j.1471-4159.2001.00354.x; MOSS D, 1992, J INORG BIOCHEM, V47, P219, DOI 10.1016/0162-0134(92)84067-W; PUPPO A, 1988, BIOCHEM J, V249, P185, DOI 10.1042/bj2490185; Regan RF, 1999, BRAIN RES, V817, P145, DOI 10.1016/S0006-8993(98)01252-9; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; REIF DW, 1988, ARCH BIOCHEM BIOPHYS, V264, P84322; Robb SJ, 1998, BRAIN RES, V788, P125, DOI 10.1016/S0006-8993(97)01543-6; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; SCHAICH KM, 1992, LIPIDS, V27, P209, DOI 10.1007/BF02536181; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; SCHIPPER HM, 1995, ANN NEUROL, V37, P758, DOI 10.1002/ana.410370609; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	56	52	54	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	113	4					985	994	PII S0306-4522(02)00243-9	10.1016/S0306-4522(02)00243-9			10	Neurosciences	Neurosciences & Neurology	592ZL	WOS:000177966700022	12182902				2021-06-18	
J	Green, A; Felmingham, K; Baguley, IJ; Slewa-Younan, S; Simpson, S				Green, A; Felmingham, K; Baguley, IJ; Slewa-Younan, S; Simpson, S			The clinical utility of the Beck Depression Inventory after traumatic brain injury	BRAIN INJURY			English	Article							COMPONENTS; MOOD	Primary objective: To examine the psychometric properties of the Beck Depression Inventory (BDI) in traumatic brain injury (TBI) and to determine the relative endorsement of somatic-performance and cognitive-affective items in this group. Research design: Prospective 2 year follow up assessment. Methods: 117 patients discharged from an inpatient TBI rehabilitation service completed the BDI as part of a 24 month follow up assessment. Demographic and injury related data were obtained from patient files and significant others. Main outcomes: A principal components analysis revealed three factors describing affective and performance items, negative attitudes towards oneself and somatic disturbance. The reliability estimate was high (coefficient alpha =0.92). A dependent sample t-test revealed higher endorsement of the cognitive-affective subscale with more clients classified as at least moderately depressed using the cognitive-affective rather than the total BDI score. Conclusion: This study provides preliminary evidence suggesting that the BDI may be an effective screening tool for self reported depression in TBI.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia	Green, A (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.	alisag@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Beck A. T., 1979, COGNITIVE THERAPY DE; BECK AT, 1973, J PSYCHOL, V85, P257, DOI 10.1080/00223980.1973.9915655; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; CHRISTENSEN BK, 1995, J INT NEUROPSYCH SOC, V1, P122; CLARK CD, 1984, J NERV MENT DIS, V171, P705; CLARK CD, 1984, J NERV MENT DIS, V173, P482; COAKES JS, 1997, SPSS ANAL ANGUISH; DEGAGNEBROWN A, 1998, JOEM, V40, P862; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOWELL CD, 1997, STAT METHODS PSYCHOL; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; PIOTROWSKI C, 1985, J PERS ASSESS, V49, P115, DOI 10.1207/s15327752jpa4902_1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; ROSS ED, 1981, ARCH GEN PSYCHIAT, V54, P343; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; *SPSS, 1999, SPSS BASE 9 0 US GUI; STARTUP M, 1992, J AFFECT DISORDERS, V26, P251, DOI 10.1016/0165-0327(92)90103-D; STEER RA, 1987, J PSYCHOPATHOL BEHAV, V9, P327, DOI 10.1007/BF00964561; WILLIAMS ACD, 1993, PAIN, V55, P259, DOI 10.1016/0304-3959(93)90155-I; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	25	52	52	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2001	15	12					1021	1028		10.1080/02699050110074187			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	493CM	WOS:000172204500001	11712948				2021-06-18	
J	Cernak, I; O'Connor, C; Vink, R				Cernak, I; O'Connor, C; Vink, R			Activation of cyclo-oxygenase-2 contributes to motor and cognitive dysfunction following diffuse traumatic brain injury in rats	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the Australasian-Society-of-Clinical-and-Experimental-Pharmacologists-and-Toxicologists	DEC 03-06, 2000	NEWCASTLE, AUSTRALIA	Australasian Soc Clin & Exptl Pharmacologists & Toxicologists		diffuse axonal injury; neurological outcome; neurotrauma; nimesulide	CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; CYCLOOXYGENASE-2; DAMAGE; INHIBITION; INDOMETHACIN; HIPPOCAMPUS; EXPRESSION; INDUCTION; MODEL	1. Post-traumatic inflammation may play a significant role in the development of delayed secondary brain damage following traumatic brain injury. 2. During post-traumatic inflammation, metabolic products of arachidonic acid, known as prostanoids (prostaglandins and thromboxanes) are released and aggravate the injury process. Prostanoid synthesis is regulated by the enzyme cyclo-oxygenase (COX), which is present in at least two isoforms, COX-1 (the constitutive form) and COX-2 (the inducible form). 3. In the present study, we examine the temporal and spatial profiles of COX-2 expression and the effects of the COX-2 inhibitor nimesulide on motor and cognitive outcome following diffuse traumatic brain injury in rats. 4. Adult male Sprague-Dawley rats were injured using the 2 m impact acceleration model of diffuse traumatic brain injury. At preselected time points after injury, animals were killed and the expression of COX-2 was measured in the cortex and hippocampus by western blotting techniques. 5. Increased expression of COX-2 was found in the cortex at 3 days and in the hippocampus as early as 3 h postinjury and this persisted for at least 12 days. 6. Administration of nimesulide (6 mg/kg, i.p.) at 30 min after injury and daily over a 10 day post-traumatic neurological assessment period resulted in a significant improvement compared with vehicle (2% dimethylsulphoxide diluted in isotonic saline)-treated controls in cognitive deficits, as assessed by the Barnes circular maze. There was also a significant improvement in motor dysfunction as assessed by the rotarod test on days 1 and 2 post-trauma compared with vehicle-treated controls. 7. These results implicate the involvement of COX-2 in cognitive and motor dysfunction following diffuse traumatic brain injury.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia	Cernak, I (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bld Room EP04,3970 Reservoir Rd NW, Washington, DC 20001 USA.	ifc@georgetown.edu	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019; Cernak, Ibolja/A-6399-2008	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Buccellati C, 1998, NEUROSCI LETT, V257, P123, DOI 10.1016/S0304-3940(98)00745-9; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; Parsadaniantz SM, 2000, J NEUROENDOCRINOL, V12, P766, DOI 10.1046/j.1365-2826.2000.00517.x; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wakita H, 1999, NEUROREPORT, V10, P1461, DOI 10.1097/00001756-199905140-00013; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	24	52	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	NOV	2001	28	11					922	925		10.1046/j.1440-1681.2001.03549.x			4	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	548PA	WOS:000175396000014	11703397				2021-06-18	
J	Marklund, N; Lewander, T; Clausen, F; Hillered, L				Marklund, N; Lewander, T; Clausen, F; Hillered, L			Effects of the nitrone radical scavengers PBN and S-PBN on in vivo trapping of reactive oxygen species after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						4-hydroxybenzoic acid; nitrone PBN radical; rats; reactive oxygen species; S-PBN; traumatic brain injury	TERT-BUTYL-NITRONE; COMPRESSION CONTUSION TRAUMA; FOCAL CEREBRAL-ISCHEMIA; FLUID PERCUSSION INJURY; NERVOUS-SYSTEM TRAUMA; NITRIC-OXIDE SYNTHASE; ALPHA-PHENYLNITRONE; LIPID-PEROXIDATION; OXIDATIVE STRESS; SUPEROXIDE-PRODUCTION	In previous studies, the authors showed that the nitrone radical scavenger alpha -phenyl-N-tert-butyl nitrone (PBN) and its sulfo-derivative, 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN), attenuated cognitive disturbance and reduced tissue damage after traumatic brain injury (TBI) in rats. In the current study, the production of reactive oxygen species (ROS) after TBI was monitored with microdialysis and the 4-hydroxybenzoic acid (4-HBA) trapping method. A single dose of PBN (30 mg/kg) or an equimolar dose of S-PBN (47 mg/kg) was administered intravenously 30 minutes before a controlled cortical contusion injury in rats. Plasma and brain tissue drug concentrations were analyzed at the end of the microdialysis experiment (3 hours after injury) and, in a separate experiment with S-PBN, at 30 and 60 minutes after injury. Traumatic brain injury caused a significant increase in ROS formation that lasted for 60 minutes after the injury as evidenced by increased 3,4-dihydroxybenzoic acid (3,4-DHBA) concentrations in the dialysate. PBN and S-PBN equally and significantly attenuated the posttraumatic increase in 3,4-DHBA formation. High PBN concentrations were found bilaterally in brain tissue up to 3 hours after injury. In contrast, S-PBN was rapidly cleared from the circulation and was not detectable in brain at 30 minutes after injury or at any later time point. The results suggest that scavenging of ROS after TBI may contribute to the neuroprotective properties observed with nitrone spin-trapping agents. S-PBN, which remained undetectable even in traumatized brain tissue, reduced ROS production to the same extent as PBN that readily crossed the blood-brain barrier. This finding supports an important role for ROS production at the blood-endothelial interface in TBI.	Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Psychiat, Ulleraker, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden.			Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			Althaus JS, 2000, FREE RADICAL BIO MED, V29, P1085, DOI 10.1016/S0891-5849(00)00350-6; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDERSON DE, 1993, BIOCHEM BIOPH RES CO, V193, P878, DOI 10.1006/bbrc.1993.1707; Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741; Beckman JS, 1996, ADV NEUROL, V71, P339; BETZ AL, 1985, J NEUROCHEM, V44, P574, DOI 10.1111/j.1471-4159.1985.tb05451.x; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Floyd RA, 1999, LIFE SCI, V65, P1893, DOI 10.1016/S0024-3205(99)00443-9; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; Gahm C, 2000, NEUROSURGERY, V46, P169; Gidday JM, 1999, J NEUROTRAUM, V16, P27, DOI 10.1089/neu.1999.16.27; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOULD TJ, 1994, BRAIN RES, V660, P333, DOI 10.1016/0006-8993(94)91308-0; GRAMMAS P, 1993, FREE RADICAL BIO MED, V14, P553, DOI 10.1016/0891-5849(93)90113-9; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; JOSEPH JA, 1995, BRAIN RES, V671, P73, DOI 10.1016/0006-8993(94)01320-H; Kawamata T, 1997, ACT NEUR S, V70, P191; Keller JN, 1998, J NEUROSCI, V18, P687; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1987, AM REV RESPIR DIS, V136, P474, DOI 10.1164/ajrccm/136.2.474; Kotake Y, 1998, BBA-MOL CELL RES, V1448, P77, DOI 10.1016/S0167-4889(98)00126-8; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MARKLUND N, 2001, IN PRESS J NEUROTRAU; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIYAJIMA T, 1995, BIOCHEM BIOPH RES CO, V215, P114, DOI 10.1006/bbrc.1995.2440; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Pazos AJ, 1999, BRAIN RES, V846, P186, DOI 10.1016/S0006-8993(99)02010-7; Peeling J, 1998, BRAIN RES, V795, P63, DOI 10.1016/S0006-8993(98)00253-4; POGREBNIAK HW, 1992, SURGERY, V112, P130; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; SCHINETTI ML, 1989, CARDIOVASC RES, V23, P76, DOI 10.1093/cvr/23.1.76; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHULZ JB, 1995, J CEREBR BLOOD F MET, V15, P948, DOI 10.1038/jcbfm.1995.120; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SteMarie L, 1996, ANAL BIOCHEM, V241, P67, DOI 10.1006/abio.1996.0379; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Whalen MJ, 1998, ACT NEUR S, V71, P212; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; YOSHIKAWA T, 1996, FREE RADICALS BRAIN, P45	66	52	53	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2001	21	11					1259	1267		10.1097/00004647-200111000-00002			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	491AZ	WOS:000172087000002	11702041	Bronze			2021-06-18	
J	Belayev, L; Alonso, OF; Liu, YT; Chappell, AS; Zhao, WH; Ginsberg, MD; Busto, R				Belayev, L; Alonso, OF; Liu, YT; Chappell, AS; Zhao, WH; Ginsberg, MD; Busto, R			Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						histopathology; neuroprotection; talampanel; traumatic brain injury	REDUCES HISTOPATHOLOGICAL DAMAGE; RECEPTOR-MEDIATED EXCITOTOXICITY; HIPPOCAMPAL CULTURES; CALCIUM; PERMEABILITY; HYPOTHERMIA; LY-300164; DIAZEPAM; ISCHEMIA; CHANNELS	Talampanel {(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3] benzodiazepine} is an orally active noncompetitive antagonist of the AMPA subtype of glutamate excitatory amino acid receptors. The purpose of this study was to determine whether treatment with talampanel would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, a fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and a balance of oxygen; mechanically ventilated and physiologically regulated; and subjected to right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). The agent (talampanel, bolus infusion of 4 mg/kg followed by infusion of 4 mg/kg/h over 72 h) or vehicle was administered i.v. starting at either 30 min or 3 h after trauma. Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas were measured. Treatment with talampanel, when instituted 30 min after trauma, significantly reduced total contusion area compared to vehicle-treated rats (0.54 +/- 0.25 vs. 1.79 +/- 0.42 mm(2), respectively). When talampanel treatment was begun at 3 h, the neuroprotective effect of the drug was lost. In addition, treatment with talampanel starting at 30 min significantly attenuated neuronal damage in all three subsectors of the hippocampal CAI sector compared to vehicle-treated rats (normal-neuron counts, right (ipsilateral) medial CAI: 80.3 +/- 2.0 [talampanel] vs. 66.3 +/- 2.1 [vehicle] (mean SEM); middle CAI: 71.5 +/- 2.0 vs. 60.3 +/- 2.2; lateral CAI: 74.5 +/- 3.0 vs. 63.0 +/- 3.2, respectively). By contrast, when talampanel treatment was begun at 3 h, normal pyramidal-neuron counts were almost identical in both groups. Our findings document that talampanel therapy instituted 30 min after trauma significantly reduces histological damage.	Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Belayev, L (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Neurotrauma Res Ctr, POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820, NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, P01NS005820, P50NS005820] Funding Source: NIH RePORTER		Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Borowicz KK, 1999, EUR J PHARMACOL, V380, P67, DOI 10.1016/S0014-2999(99)00541-5; Borowicz KK, 1999, POL J PHARMACOL, V51, P103; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN AM, 1993, STROKE, V24, pI148; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; Lodge D, 1996, NEUROPHARMACOLOGY, V35, P1681, DOI 10.1016/S0028-3908(96)00155-4; MAY PC, 1993, NEUROSCI LETT, V152, P169, DOI 10.1016/0304-3940(93)90510-R; May PC, 1999, NEUROSCI LETT, V262, P219, DOI 10.1016/S0304-3940(99)00084-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; RAINES A, 1990, EPILEPSIA, V31, P313, DOI 10.1111/j.1528-1157.1990.tb05381.x; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; TARNAWA I, 1989, EUR J PHARMACOL, V167, P193, DOI 10.1016/0014-2999(89)90579-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	27	52	52	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					1031	1038		10.1089/08977150152693728			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000006	11686490				2021-06-18	
J	Hermanns, S; Reiprich, P; Muller, HW				Hermanns, S; Reiprich, P; Muller, HW			A reliable method to reduce collagen scar formation in the lesioned rat spinal cord	JOURNAL OF NEUROSCIENCE METHODS			English	Article						spinal cord injury; collagen scar; 2,2 '-bipyridine; axonal regeneration; [2,2 '-bipyridine]-5,5 '-dicarboxylic acid; connective tissue growth factor	TISSUE GROWTH-FACTOR; NEURITE OUTGROWTH; AXONAL REGENERATION; BASAL LAMINA; ADULT-RAT; CNS AXONS; INJURY; BRAIN; PROTEOGLYCANS; INHIBITORS	Following traumatic injury, the formation of a glial scar and deposition of extracellular matrix (ECM) contributes to the regeneration failure in the adult mammalian central nervous system (CNS). Using a postcommissural fornix transection as a brain lesion model in rat, we have previously shown that the collagenous basement membrane (BM) at the lesion site is a major impediment for axon regeneration. Deposition of BM in this lesion model can be delayed by administration of the iron chelator 2,2'-bipyridine (BPY), an inhibitor of prolyl 4-hydroxylase (PH), a key enzyme of collagen biosynthesis. To examine whether this potential therapeutic approach is transferable to other CNS regions, we have chosen the mechanically lesioned rat spinal cord to investigate the effects of BPY administration on BM formation. Due to the close proximity of the lesion zone to meningeal fibroblasts, a cell-type secreting large amounts of collagen IV, BM deposition was much more extensive in the spinal cord than in the brain lesion. Neither immediate injections nor continuous application of BPY resulted in a detectable reduction of BM formation in the spinal cord. Only a combination of anti-scarring treatments including (i) injection of the more potent PH inhibitor [2,2'-bipyridine]-5,5'-dicarboxylic acid (BPY-DCA), (ii) selective inhibition of fibroblast proliferation and ECM production by S-Br-cAMP, and (iii) continuous application of BPY-DCA, reduced the lesion-induced BM significantly. The present results clearly demonstrate, that the exclusive application of BPY according to a protocol designed for treatment of brain lesions is not sufficient to reduce BM formation in the lesioned adult rat spinal cord. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Dusseldorf, Dept Neurol, Mol Neurobiol Lab, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Physiol, D-40225 Dusseldorf, Germany	Muller, HW (corresponding author), Univ Dusseldorf, Dept Neurol, Mol Neurobiol Lab, Moorenstr 5, D-40225 Dusseldorf, Germany.		Luhmann, Heiko J./N-8797-2019	Luhmann, Heiko J./0000-0002-7934-8661			Becker T, 2000, GLIA, V29, P330, DOI 10.1002/(SICI)1098-1136(20000215)29:4<330::AID-GLIA4>3.0.CO;2-L; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Bovolenta P, 1997, EUR J NEUROSCI, V9, P977, DOI 10.1111/j.1460-9568.1997.tb01448.x; Bradbury EJ, 1999, EUR J NEUROSCI, V11, P3873, DOI 10.1046/j.1460-9568.1999.00809.x; Duncan MR, 1999, FASEB J, V13, P1774; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grill R, 1997, J NEUROSCI, V17, P5560; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GUTH L, 1980, J NEUROSURG, V52, P73, DOI 10.3171/jns.1980.52.1.0073; HALES NJ, 1993, J MED CHEM, V36, P3853, DOI 10.1021/jm00076a014; Hermanns S, 2001, BRAIN RES PROTOC, V7, P162, DOI 10.1016/S1385-299X(01)00059-9; IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; KOWALSKI TF, 1979, ANN NEUROL, V6, P78, DOI 10.1002/ana.410060121; KUHL U, 1984, DIFFERENTIATION, V28, P164, DOI 10.1111/j.1432-0436.1984.tb00279.x; MATINIAN LA, 1973, ENZYME THERAPY ORGAN, P94; Moon LDF, 2000, EXP NEUROL, V161, P49, DOI 10.1006/exnr.1999.7230; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Shen YJ, 1998, MOL CELL NEUROSCI, V12, P79, DOI 10.1006/mcne.1998.0700; SMITH AL, 1995, J NEUROSCI METH, V60, P211, DOI 10.1016/0165-0270(95)00014-L; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Weidner N, 1999, EXP NEUROL, V160, P40, DOI 10.1006/exnr.1999.7200	29	52	53	1	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2001	110	1-2					141	146		10.1016/S0165-0270(01)00427-7			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	482VM	WOS:000171598000017	11564534				2021-06-18	
J	Klonoff, PS; Lamb, DG; Henderson, SW				Klonoff, PS; Lamb, DG; Henderson, SW			Outcomes from milieu-based neurorehabilitation at up to 11 years post-discharge	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; FOLLOW-UP; WORK; EMPLOYMENT; RETURN; REHABILITATION; PREDICTION; STABILITY	Outcome in patients with brain injury after milieu-based day treatment neurorehabilitation was examined at up to 11 years post-discharge. Follow-up data in this cross-sectional study were sought from all admissions since May 1986 to May 1998 at 3 months, 1, 3, 5, 7, 9, and 11 year intervals. The 164 participants who responded had heterogeneous brain injury aetiologies and represented 73.9% of all patients who were successfully discharged from the programme. Rates of productivity (defined as gainful employment, school, and/or volunteer work) and employment (defined as work for pay) were examined in this follow-up sample. The results demonstrate that 83.5% of patients were productive up to 11 years post-discharge, with 67.1% engaged in work or school, and no decline in productivity was seen over time from discharge. Better vocational/school outcomes were associated with younger age, male gender, and higher staff working alliance ratings of patients and their families.	Barrow Neurol Inst, ADHNR, Catholic Healthcare W, Phoenix, AZ 85013 USA	Klonoff, PS (corresponding author), Barrow Neurol Inst, ADHNR, St Joseph Hosp & Med Ctr, 222 W Thomas Rd,Suite 115, Phoenix, AZ 85013 USA.						Ashley MJ, 1997, BRAIN INJURY, V11, P677; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1995, BRAIN INJURY, V10, P631; Evans RW, 1997, ARCH PHYS MED REHAB, V78, pS17, DOI 10.1016/S0003-9993(97)90151-9; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hillier SL, 1997, BRAIN INJURY, V11, P661; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Klonoff P S, 1997, Appl Neuropsychol, V4, P107, DOI 10.1207/s15324826an0402_3; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; KLONOFF PS, 1997, CLIN NEUROPSYCHOLOGY, P219; Klonoff PS, 2000, INT HDB NEUROPSYCHOL, P195; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Sherer M, 1999, BRAIN INJURY, V13, P973; Wall JR, 1998, BRAIN INJURY, V12, P215; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177	30	52	52	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2001	15	5					413	428		10.1080/02699050010005968			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	431TW	WOS:000168648700004	11350655				2021-06-18	
J	Miller, LJ; Donders, J				Miller, LJ; Donders, J			Subjective symptomatology after traumatic head injury	BRAIN INJURY			English	Article							MMPI-2 VALIDITY SCALES; FAKE BAD SCALE; BRAIN-INJURY; IMPAIRMENT; RECOVERY	Background: Controversy persists regarding the reasons for persistent subjective complaints after mild traumatic head injury (THI). Statement of purpose: To evaluate the influence of injury severity, psychological factors, and financial contingencies on symptomatology after THI. Methods: Subjective complaints about cognitive, emotional, and somatic symptoms, as assessed by a standardized self-report inventory (Minnesota Multiphasic Personality Inventory-2; MMPI-2) were evaluated in 150 patients with THI. Results: Individuals with mild THI demonstrated paradoxically greater symptomatology on the MMPI-2 than patients with moderate-to-severe THI. Furthermore, specific actuarial criteria for possible symptom magnification (Fake Bad Scale) were met about twice as often in patients with mild THI who were seeking financial compensation for alleged acquired dysfunction than in patients with mild THI without such external contingencies. Conclusion: The evaluation of persistent subjective complaints after THI should consider injury severity in concert with psychological and financial/motivational factors. Great caution should be taken in attributing persistent symptomatology after mild THI to cerebral dysfunction.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BUTCHER J, 1989, MINNESOTA MULTIPHASI, V2; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GASS CS, 2000, CLIN GUIDE NEUROPSYC, P55; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Millis Scott R., 1996, P481; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOUNGQUIST RC, 1984, OPT LETT, V9, P177, DOI 10.1364/OL.9.000177	30	52	52	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2001	15	4					297	304		10.1080/026990501750111238			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000002	11299131				2021-06-18	
J	Struchen, MA; Hannay, HJ; Contant, CF; Robertson, CS				Struchen, MA; Hannay, HJ; Contant, CF; Robertson, CS			The relation between acute physiological variables and outcome on the Glasgow outcome scale and disability rating scale following severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral perfusion pressure; intracranial pressure; jugular venous oxygen saturation; mean arterial pressure; outcome; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; INTRACRANIAL HYPERTENSION; CEREBRAL OXYGENATION; AGGRESSIVE TREATMENT; VENOUS DESATURATION; MANAGEMENT; EXPERIENCE; PROGNOSIS; COMA	The relation between outcome and duration of adverse physiological events was studied, using suggested critical physiological values, Subjects were 184 patients with severe traumatic brain injury who received continuous monitoring of intracranial pressure (ICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP), and jugular venous oxygen satuation, Longer durations of adverse physiological events were significantly related to Glasgow Outcome Scale (GOS) scores and Disability Rating Scale (DRS) scores for all variables at all timepoints postinjury, When analyses excluded patients who died, the relation between adverse physiological events and GOS was nonsignificant; however, duration of ICP, MAP, and CPP still accounted for a significant portion of the variance in DRS scalres, The relative sensitivity of the GOS and DRS is discussed.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX USA	Struchen, MA (corresponding author), Brain Injury Res Ctr, 4007EE Bellaire Blvd, Houston, TX 77025 USA.	strucm@tirr.tmc.edu		Hannay, H. Julia/0000-0001-7023-912X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CONTANT CF, 1993, J NEUROTRAUMA S1, V10, pS57; CROUCH JD, 1991, P 8 INT S INTR PRESS; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; EDDY VA, 1995, AM SURGEON, V61, P24; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Jane J, 1996, NEUROTRAUMA, P793; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1981, MANAGEMENT HEAD INJU, P47; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kanter M J, 1990, Intensive Care World, V7, P16; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LANGFITT TW, 1972, INTRACRANIAL PRESSUR, P361; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEWIS SB, 1995, ANAESTH INTENS CARE, V23, P307, DOI 10.1177/0310057X9502300307; MACCAULEY S, 2000, IN PRESS J INT NEURO; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1987, HEAD INJURY, P159; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller JD, 1987, CEREBRAL BLOOD FLOW, P119; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; *SPSS, 1994, SPSS PCPLUS VERS 6 1; STRUCHEN MA, 1994, THESIS U HOUSTON; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1989, INTRACRANIAL PRESSUR, V7, P567; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	58	52	54	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2001	18	2					115	125		10.1089/08977150150502569			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	402PW	WOS:000166998200001	11229706				2021-06-18	
J	McCarron, MO; Muir, KW; Nicoll, JAR; Stewart, J; Currie, Y; Brown, K; Bone, I				McCarron, MO; Muir, KW; Nicoll, JAR; Stewart, J; Currie, Y; Brown, K; Bone, I			Prospective study of apolipoprotein E genotype and functional outcome following ischemic stroke	ARCHIVES OF NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; E EPSILON-2 ALLELE; CEREBROVASCULAR-DISEASE; E POLYMORPHISM; APOE GENOTYPE; CEREBRAL INFARCTION; ALZHEIMERS-DISEASE; NEURONAL DAMAGE; GLOBAL-ISCHEMIA; ANIMAL-MODELS	Background: The apolipoprotein E (APOE) epsilon 4 allele is a marker of adverse outcome following head injury and intracerebral hemorrhage. Transgenic animal data in a focal cerebral ischemia model suggest that the epsilon 4 allele increases infarct size and functional impairment. Objective: To determine if APOE genotype is associated with functional recovery from ischemic stroke. Design: Prospective study. Setting: Stroke service at a university teaching hospital. Patients: Patients with clinical and neuroimaging findings (computed tomography or magnetic resonance imaging) compatible with an acute ischemic stroke. Main Outcome: Functional outcome by Barthel index (BI) and modifed Rankin scale (mRS) was compared fur epsilon 3/epsilon 3 patients vs epsilon 4 carriers and vs epsilon 2 carriers at 1 and 3 months. Univariate predictors of 3-month outcome were examined in a multivariate analysis. Results: One hundred eighty nine patients were enrolled: 100 women, 89 men (mean+/-SD age, 69.4+/-11.0 years). There were 25 epsilon 2 alleles (frequency, 0.07), 292 epsilon 3 alleles (0.77), and 61 epsilon 4 alleles (0.16). Baseline National Institutes of Health Stroke Scale scores and Oxfordshire Community Stroke Project classifications were similar in all groups (epsilon 3/epsilon 3. epsilon 4, and epsilon 2 carriers). One-month (BI, P=.64; mRS, P=.59) and 3-month (BI, P=.87; mRS, P=.73) outcomes were not associated with possession of either epsilon 4 or the epsilon 2 allele. Baseline National Institutes of Health Stroke Scale scores (P<.001) and age (P=.002) were significant predictors of 3-month BI and mRS outcomes in multivariate analyses. Conclusions: Although there: is a robust influence of APOE polymorphism on functional recovery after some types of brain injury in humans, it does not exert a major influence on injury severity or functional recovery following ischemic stroke.	So Gen Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland	Muir, KW (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.		Muir, Keith W/A-7670-2011; Nicoll, James/I-9253-2017	Muir, Keith W/0000-0001-9535-022X; Nicoll, James/0000-0002-9444-7246			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CORIA F, 1995, STROKE, V26, P2375; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Ferrucci L, 1997, STROKE, V28, P2410, DOI 10.1161/01.STR.28.12.2410; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fullerton SM, 1998, EXP NEUROL, V153, P156, DOI 10.1006/exnr.1998.6872; Hachinski V, 1996, ARCH NEUROL-CHICAGO, V53, P303, DOI 10.1001/archneur.1996.00550040031011; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kessler C, 1997, ARTERIOSCL THROM VAS, V17, P2880, DOI 10.1161/01.ATV.17.11.2880; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; MAHIEUX F, 1990, STROKE, V21, P1; MAHONEY F I, 1965, Md State Med J, V14, P61; Margaglione M, 1998, STROKE, V29, P399, DOI 10.1161/01.STR.29.2.399; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; Meyer MR, 1998, NAT GENET, V19, P321; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Muller W, 1998, BRAIN PATHOL, V8, P641; Nakata Y, 1997, AM J HYPERTENS, V10, P1391, DOI 10.1016/S0895-7061(97)90510-0; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; RANKIN J, 1957, Scott Med J, V2, P200; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOMIMOTO H, 1995, ACTA NEUROPATHOL, V90, P608; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WIEBERS DO, 1990, STROKE, V21, P1; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250	44	52	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2000	57	10					1480	1484		10.1001/archneur.57.10.1480			5	Clinical Neurology	Neurosciences & Neurology	363EB	WOS:000089821200011	11030801	Bronze			2021-06-18	
J	Isaki, E; Turkstra, L				Isaki, E; Turkstra, L			Communication abilities and work re-entry following traumatic brain injury	BRAIN INJURY			English	Article							SUPPORTED EMPLOYMENT; RETURN; REHABILITATION; PREDICTION; OUTCOMES	This exploratory study was completed to determine if communication measures could discriminate employed from unemployed individuals with traumatic brain injury (TBI). Twenty adults with TBI participated, 10 employed and 10 unemployed; subjects in both groups were 1-4 years post-injury, with comparable severity of injury and type of work. Subjects were administered communication tests measuring auditory processing, effects of speaking under time pressure, production of oral language, and functional verbal reasoning ability. An aphasia test and a functional outcome measure were also administered. Results revealed that a combination of three tests, one test of functional verbal reasoning and two tests of auditory processing, correctly classified 85% of subjects as employed or unemployed. Tasks that were impairment- and disability-based appear to be more related to outcome than impairment-level tasks alone. Impairment and disability level communication tasks may provide functional and practical information, which could assist in work re-entry.	Nat Ctr Neurogen Commun Disorders, Tucson, AZ USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Isaki, E (corresponding author), Univ Hawaii, Div SPA, 1410 Lower Campus Rd, Honolulu, HI 96822 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-01409, DC-00163] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER		BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CONBOY TJ, 1986, REHABIL PSYCHOL, V31, P203, DOI 10.1037//0090-5550.31.4.203; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DENCKLA M B, 1974, Cortex, V10, P186; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GLOSSER G, 1990, BRAIN LANG, V6, P271; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hartley L. L., 1995, COGNITIVE COMMUNICAT; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; KEITH RW, 1994, SCANA TEST AUDITORY; Kertesz A, 1982, W APHASIA BATTERY TE; MACDONALD S, IN PRESS FUNCTIONAL; MURRAY LL, 1995, DISS ABSTR INT, V56, P2592; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1987, NEUROPSYCHOLOGICAL R; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spreen O., 1991, COMPENDIUM NEUROPSYC; *STAT CORP, 1997, STAT 5 0 COMP SOFTW; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 1980, INT CLASS IMP DIS HA; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P239, DOI 10.1055/s-2008-1064200; 1988, ASHA, V30, P79	33	52	52	0	8	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2000	14	5					441	453					13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	316MQ	WOS:000087171500005	10834339				2021-06-18	
J	Adelson, PD; Dixon, CE; Kochanek, PM				Adelson, PD; Dixon, CE; Kochanek, PM			Long-term dysfunction following diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	15th Annual Meeting of the Neurotrauma-Society	OCT 24-25, 1997	NEW ORLEANS, LOUISIANA	Neurotrauma Soc		cognitive; functional recovery; immature; Morris Water Maze; rats; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; HEAD-INJURY; HIPPOCAMPAL-LESIONS; DEFICITS; CHILDREN; ADOLESCENTS; IMPAIRMENT; MEMORY; MOTOR	Children often suffer sustained cognitive dysfunction after severe diffuse traumatic brain injury (TBI), To study the effects of diffuse injury in the immature brain, we developed a model of severe diffuse impact (DI) acceleration TBI in immature rats and previously described the early motor and cognitive dysfunction posttrauma. In the present study, we investigated the long-term functional ability after DI (150 gm/2 m) compared to sham in the immature (PND 17) rat. Beam balance and inclined plane latencies were measured daily for 10 days after injury to assess gross vestibulomotor function. The Morris water maze (MWM) paradigm was evaluated monthly up to 3 months after DI and sham injuries. Reduced latencies on the balance beam and inclined plane were observed in DI rats (p < 0.05 vs. sham [n = 10 per group]) at 24 h and persisted for 10 days postinjury, DI produced sustained MWM performance deficits (p < 0.05 vs, sham) as indicated by the greater latencies to find the hidden platform remarkably through 90 days after injury. Lastly, the brain and body weights of the injured animals were less than sham (p < 0.05) after 3 months. We conclude that a diffuse TBI in the immature rat: (a) created a consistent, marked, but reversible motor deficit up to 10 days following injury; (b) produced a long-term, sustained performance deficit in the MWM up to 3 months posttrauma; and (c) affected body and brain weight gain in the developing rat through 3 months after injury. This TBI model should be useful for the testing of novel therapies and their effect on long-term outcome and development in the immature rat.	Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, Pittsburgh, PA 15213 USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA	Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 33150, NS 30318, K08 NS01809] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS033150, K08NS001809, P20NS030318, P01NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ADELSON PD, 1996, J NEUROSURG, V85, P134; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BOKSA P, 1995, PEDIATR RES, V37, P489, DOI 10.1203/00006450-199504000-00018; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; JOHNSTON MV, 1983, ANN NEUROL, V13, P511, DOI 10.1002/ana.410130507; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER E, 1993, J NEUROSCI, V13, P3916; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WINICK M, 1983, MED CLIN N AM, V54, P1413; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	36	52	54	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					273	282		10.1089/neu.2000.17.273			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500002	10776912				2021-06-18	
J	Mackenzie, C				Mackenzie, C			Adult spoken discourse: the influences of age and education	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						communication; discourse; elderly	CONNECTED SPEECH SAMPLES; TRAUMATIC BRAIN INJURY; SPONTANEOUS LANGUAGE; OLDER ADULTS; PERFORMANCE; COMMUNICATION; POPULATION; APHASIA	Spoken discourse is regarded as an important component of communication assessment, but data on the discourse characteristics of the adult population, and in particular those who fall into the fastest growing section of the population (those aged over 75), are scant. Therefore, detection of deficit is commonly dependent on the assessor's opinion as to what constitutes normal performance. To determine the effects of age, education and gender on spoken discourse, the conversational interaction and picture description skills of 189 neurologically normal adults were examined. Conversation was appraised with reference to five parameters (initiation, topic maintenance, verbosity, turn taking, reference). Picture description was assessed for relevant content, length, efficiency and the inclusion of extraneous information Level of education did not affect conversational interaction but in picture description those not educated beyond minimal school leaving produced shorter and less complete descriptions. Picture description content and length were not affected by advancing age but the older elderly (aged 75 +) conveyed information with reduced efficiency. Conversational interaction style altered with advancing age, with some suggestion of change in the young elderly (age 60-74), but highly significant differences in respect of the old elderly. Gender had no effect on the parameters of conversation and no significant picture description differences were present in males and females though there were trends towards longer and higher content descriptions in females. The results have important diagnostic implications for those concerned with establishing whether pathology such as stroke has affected communication. On a wider scale, awareness of the effects of advancing age and limited education may facilitate successful communication for all who communicate with the public in a professional capacity.	Univ Strathclyde, Dept Speech & Langauge Therapy, Glasgow G13 1PP, Lanark, Scotland	Mackenzie, C (corresponding author), Univ Strathclyde, Dept Speech & Langauge Therapy, Glasgow G13 1PP, Lanark, Scotland.						ARMSTRONG L, 1994, EUR J DISORDER COMM, V29, P371; BLOOM RL, 1992, BRAIN LANG, V42, P153, DOI 10.1016/0093-934X(92)90122-U; BODEN D, 1983, HUM DEV, V26, P308, DOI 10.1159/000272892; BODEN D, 1986, LANG COMMUN, V6, P73, DOI 10.1016/0271-5309(86)90007-8; BROOKSHIRE R, 1992, INTRO NEUROGENIC COM; BURNS MS, 1985, CLIN MANAGEMENT RIGH; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; Ceccaldi M, 1996, BRAIN LANG, V54, P75, DOI 10.1006/brln.1996.0061; CHAFETZ P K, 1988, Seminars in Speech and Language, V9, P177, DOI 10.1055/s-0028-1082463; Coates Jennifer, 1986, WOMEN MEN LANGUAGE; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; COHEN G, 1979, COGNITIVE PSYCHOL, V11, P412, DOI 10.1016/0010-0285(79)90019-7; COOPER PV, 1990, J GERONTOL B-PSYCHOL, V45, P210; COUPLAND N, 1991, LANGUAGE SOC ELDERLY; CRAIG HK, 1993, APHASIOLOGY, V7, P155, DOI 10.1080/02687039308249503; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; EMERY OB, 1985, LANGUAGE AGEING MONO, V11; Giles E, 1996, APHASIOLOGY, V10, P395, DOI 10.1080/02687039608248419; Glosser G., 1992, J GERONTOL B-PSYCHOL, V47, P266; GOLD D, 1988, J GERONTOL, V43, P27; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Goren AR, 1996, EUR J DISORDER COMM, V31, P153; GOULET P, 1994, J SPEECH HEAR RES, V37, P629, DOI 10.1044/jshr.3703.629; Grice Paul, 1975, SYNTAX SEMANTICS, V3; GRUNDY E., 1998, BROCKLEHURSTS TXB GE, P1; HALPER AS, 1996, CLIN MANAGEMENT RIGH; HENWOOD M, 1992, 14 KINGS FUND I; KAUSLER DH, 1988, COMMUNICATION BEHAVI, P79; Kemper S., 1989, ANNU REV APPL LINGUI, V10, P37, DOI DOI 10.1017/S0267190500001203; KENNEDY MRT, 1994, CLIN APHASIOL, V22, P67; Lesser R., 1997, CONVERSATION ANAL PR; Levinson S.C., 1983, PRAGMATICS; MACKENZIE C, 1997, RIGHT HEMISPHERE STR; MAXIM J, 1994, LANGUAGE ELDERLY CLI; MENN L, 1994, APHASIOLOGY, V8, P343, DOI 10.1080/02687039408248664; Myers Penelope S., 1979, CLIN APHASIOLOGY C P, P38; Myers Penelope S, 1994, LANGUAGE INTERVENTIO, P514; NEILS J, 1995, J SPEECH HEAR RES, V38, P1143, DOI 10.1044/jshr.3805.1143; NORTH AJ, 1986, INT J AGING HUM DEV, V23, P267, DOI 10.2190/BPF0-2BWD-BGNQ-HWCW; Obler L. K., 1994, DISCOURSE ANAL APPL, P15; OBLER LK, 1980, LANG COMMUN, P75; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OLSHANSKY SJ, 1993, SCI AM           APR, P18; PAYNE J, 1997, ADULT NEUROGENIC LAN; PERKINS L, 1993, FOUNDATIONS OF APHASIA REHABILITATION, P211; Perkins L Whitworth A Lesser R, 1997, CONVERSATION ANAL PR; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; RYAN EB, 1986, LANG COMMUN, V6, P1, DOI 10.1016/0271-5309(86)90002-9; RYAN EB, 1995, DEMENTIA COMMUNICATI, P84; RYFF CD, 1989, PSYCHOL AGING, V4, P195, DOI 10.1037/0882-7974.4.2.195; SCHAIE KW, 1980, LANG COMMUN, P7; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; SHADDEN BB, 1988, COMMUNICATION BEHAV, P3; SHEWAN CM, 1988, J COMMUN DISORD, V21, P139, DOI 10.1016/0021-9924(88)90002-0; SHEWAN CM, 1988, J COMMUN DISORD, V21, P103, DOI 10.1016/0021-9924(88)90001-9; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; STOVER SE, 1989, CLIN LINGUIST PHONET, V3, P137, DOI 10.3109/02699208908985277; SWIHART AA, 1988, NEUROPSYCHOLOGICAL S, P1; TOMPKINS CA, 1993, CLIN APHASIOLOGY, V21, P113; Ulatowska H. K., 1991, HDB GERIATRIC COMMUN, P21; ULATOWSKA HK, 1986, BRAIN LANG, V28, P24, DOI 10.1016/0093-934X(86)90088-X; ULATOWSKA HK, 1995, AGEING BRAIN COMMUNI; WEEKS DJ, 1988, ANOMALOUS SENTENCES; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	64	52	57	1	14	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	1368-2822			INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	APR-JUN	2000	35	2					269	285		10.1080/136828200247188			17	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	304PE	WOS:000086492000006	10912255				2021-06-18	
J	Simpson, G; Mohr, R; Redman, A				Simpson, G; Mohr, R; Redman, A			Cultural variations in the understanding of traumatic brain injury and brain injury rehabilitation	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; BEHAVIORAL LIMITATIONS; RELATIVES VIEW; AWARENESS; FAMILIES; SERVICES; PATTERNS; PACIFIC; MODEL	Little is known about how people from different cultures experience and understand traumatic brain injury (TBI) and the process of brain injury rehabilitation. The Brain Injury Rehabilitation Unit (BIRU) undertook a qualitative project to research cultural variations in the understanding of TBI and the rehabilitation process, interviewing 39 people with TBI and family members from Italian, Lebanese and Vietnamese backgrounds. The focus was on the reporting of sequelae of the TBI; valued qualities of service providers; barriers to effective communication; the role of the families in the rehabilitation process; and the experience of social stigma. Findings suggest there is a universal experience of TBI that transcends individual cultures. Study participants valued attentiveness, friendliness and guidance from rehabilitation staff. Family support was not always available to the person with TBI due to family conflict. Generally, people with TBI and family members valued the assistance of health interpreters facilitating their communication with rehabilitation staff People with TBI from all three cultures experienced problems of stigma and social isolation. The findings have a number of implications for how brain injury rehabilitation staff can approach service provision to people from diverse cultural backgrounds.	Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; Univ Wollongong, Fac Law, Wollongong, NSW, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Mohr, Richard/0000-0003-2127-0440			BRANNON E, 1986, MULTI CULTURAL COUNS; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; DIKENGIL A, 1993, J COGNITIVE REHABILI, V11, P10; DYCK I, 1992, AM J OCCUP THER, V46, P696, DOI 10.5014/ajot.46.8.696; Fitzgerald M. H., 1997, AUSTR OCCUPATIONAL T, V44, P1, DOI DOI 10.1111/J.1440-1630.1997.TB00749.X; FITZGERALD MH, 1992, J REHABIL, V58, P38; FITZGERALD MH, 1993, WESTERN J MED, V159, P50; Gregory RJ, 1996, DISABIL REHABIL, V18, P47, DOI 10.3109/09638289609167089; KAKAKIOS M, 1995, HLTH SERVICE CULTURA; KLEINMAN A, 1978, SOC SCI MED-MED ANTH, V12, P85, DOI 10.1016/0160-7987(78)90014-5; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Miles M.B., 1994, QUALITATIVE DATA ANA; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOSELEY A, 1995, BRAIN INJURY, V9, P355, DOI 10.3109/02699059509005775; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Patton MQ., 1990, QUALITATIVE EVALUATI; PAUWELS A, 1995, CROSS CULTURAL COMMU; PONSFORD JL, 1995, 2 INT NEUR SOC ASSBI; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; *S W SYDN AR HLTH, 1995, HLTH PLAN NONENGL SP; SMART JF, 1992, J REHABIL, V58, P29; Sue D.W., 1990, COUNSELLING CULTURAL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; VASQUEZ C, 1991, HOSP COMMUNITY PSYCH, V42, P163; Williams DE, 1991, REV COMPUTATIONAL CH, P219; YAMAMOTO J, 1986, ETHNIC PSYCHIAT, P89	34	52	52	0	13	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					125	140		10.1080/026990500120790			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000003	10695569				2021-06-18	
J	Sweet, JJ; Wolfe, P; Sattlberger, E; Numan, B; Rosenfeld, JP; Clingerman, S; Nies, KJ				Sweet, JJ; Wolfe, P; Sattlberger, E; Numan, B; Rosenfeld, JP; Clingerman, S; Nies, KJ			Further investigation of traumatic brain injury versus insufficient effort with the California Verbal Learning Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	17th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 10-13, 1997	LAS VEGAS, NEVADA	Natl Acad Neuropsychol			RECOGNITION MEMORY TEST; MALINGERED HEAD-INJURY; NEUROPSYCHOLOGICAL EVALUATION; IMPAIRMENT; IDENTIFICATION; VALIDATION	The present study replicates and attemps to extend previous research using the California Verbal Learning Test (CVLT) to identify malingerers. Documented moderate and severe traumatic brain injury patients (n = 42) were compared with clinical malingerers identified by criteria other than the CVLT (n = 21), malingering simulators instructed in realistic potential injury sequelae (n = 25), and normal controls (n = 21). Results of discriminant function analyses for high and low base rates are reported, showing similar results. Also, the four individual cutoff scores (Recognition Hits, Discriminability, Total Words Recalled, Long Delay Cued Recall) from Millis, Putnam, Adams, and Ricker (1995) were evaluated with these groups. Similar specificity rates were found with all four variables, while sensitivity rates were slightly lower than that of Millis. Adjusted cutoffs derived from the new samples resulted in slightly improved overall classification rates. Overall, present findings support those of Millis et al. (1995) with regard to the use of the CVLT in detection of malingering. Exploratory use of Total Instructions and Recognition Hits Compared to Long Delay Free Recall was not promising. Simulators were found to be fairly comparable in performance to actual malingerers, affirming their use in malingering research. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Northwestern Univ, Evanston Hosp, Neuropsychol Serv, Sch Med, Evanston, IL 60201 USA; IIT, Evanston Hosp, Chicago, IL 60616 USA; Cook Cty Hosp, Chicago, IL 60612 USA	Sweet, JJ (corresponding author), Northwestern Univ, Evanston Hosp, Neuropsychol Serv, Sch Med, 2650 Ridge Ave, Evanston, IL 60201 USA.						Ben-Porath Y. S., 1994, PSYCHOL ASSESSMENT, V6, P14; BERRY DTR, 1994, PSYCHOL ASSESSMENT, V6, P16; DELIS D, 1987, CALIFORNIA VERBAL LE; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; MILLIS S, 1997, J INT NEUROPSYCH SOC, V3, P225; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; REYNOLDS C, 1998, DETECTION MALINGERED; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580	21	52	53	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2000	15	2					105	113		10.1016/S0887-6177(98)00153-X			9	Psychology, Clinical; Psychology	Psychology	276WD	WOS:000084900600002	14590555	Bronze			2021-06-18	
J	Whalen, MJ; Carlos, TM; Dixon, CE; Robichaud, P; Clark, RSB; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Dixon, CE; Robichaud, P; Clark, RSB; Marion, DW; Kochanek, PM			Reduced brain edema after traumatic brain injury in mice deficient in P-selectin and intercellular adhesion molecule-1	JOURNAL OF LEUKOCYTE BIOLOGY			English	Article						controlled cortical impact; inflammation; neutrophil; head injury; platelet	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; COLONY-STIMULATING FACTOR; DOUBLE MUTANT MICE; NEUTROPHIL ACCUMULATION; ISCHEMIA-REPERFUSION; BACTERIAL-MENINGITIS; ACUTE-INFLAMMATION; CELL-ADHESION; IMMATURE RAT	Platelet (P-) selectin and intercellular adhesion molecule-1 (ICAM-1) mediate accumulation of neutrophils in brain. How-ever, the mechanisms regulating neutrophil accumulation and damage after traumatic brain injury (TBI) are poorly defined. We hypothesized that mice deficient in both P-selectin and ICAM-1 (-/-) would have decreased brain neutrophil accumulation and edema, and improved functional and histopathological outcome after TBI compared with wild-type (+/+), In Protocol I, neutrophils and brain water content were quantified at 24 b after TBI, No difference in brain neutrophil accumulation was observed between groups; however, brain edema was decreased in dual P-selectin and ICAM-1 -/- (P < 0.05 vs. +/+ mice). In Protocol II, after TBI, tests of motor and memory function and histopathology were assessed over 21 days. No difference in motor or memory function or histopathological damage was observed between +/+ and -/- mice, A role for adhesion molecules in the pathogenesis of brain edema independent of leukocyte accumulation in brain is suggested.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanck@smtp.anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		Adelson PD, 1998, ACT NEUR S, V71, P104; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; CARDEN DL, 1993, J APPL PHYSIOL, V75, P2529; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Doerschuk CM, 1996, J IMMUNOL, V157, P4609; Gibbs SAL, 1996, SURGERY, V119, P652, DOI 10.1016/S0039-6060(96)80189-9; Goussev AV, 1998, J NEUROL SCI, V161, P16, DOI 10.1016/S0022-510X(98)00262-7; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KING PD, 1995, J IMMUNOL, V154, P6080; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kyriakides C, 1999, FASEB J, V13, pA21; LINDSBERG PJ, 1995, J NEUROSURG, V82, P269, DOI 10.3171/jns.1995.82.2.0269; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Mizgerd JP, 1998, J LEUKOCYTE BIOL, V64, P291; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SINZ EH, 1997, J NEUROTRAUM, V14, P769; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Soares HD, 1995, J NEUROSCI, V15, P8223; Squadrito F, 1997, BRIT J PHARMACOL, V120, P333, DOI 10.1038/sj.bjp.0700904; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Subramaniam M, 1996, BLOOD, V87, P1238, DOI 10.1182/blood.V87.4.1238.bloodjournal8741238; SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277; Sun XM, 1997, AM J PHYSIOL-GASTR L, V273, pG56; Suzuki H, 1999, NEUROSCI LETT, V265, P163, DOI 10.1016/S0304-3940(99)00229-3; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; Tomita M, 1996, ACT NEUR S, V66, P32; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Weiser MR, 1996, SHOCK, V5, P402, DOI 10.1097/00024382-199606000-00003; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; Whalen M, 1999, CRIT CARE MED, V27, pA103, DOI 10.1097/00003246-199901001-00262; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; YEO EL, 1994, BLOOD, V83, P2498	61	52	61	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0741-5400	1938-3673		J LEUKOCYTE BIOL	J. Leukoc. Biol.	FEB	2000	67	2					160	168					9	Cell Biology; Hematology; Immunology	Cell Biology; Hematology; Immunology	307AH	WOS:000086630800003	10670575				2021-06-18	
J	Assaf, Y; Holokovsky, A; Berman, E; Shapira, Y; Shohami, E; Cohen, Y				Assaf, Y; Holokovsky, A; Berman, E; Shapira, Y; Shohami, E; Cohen, Y			Diffusion and perfusion magnetic resonance imaging following closed head injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; diffusion and perfusion MRI; head trauma; MRI; rat brain	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; CEREBRAL-ISCHEMIA; EDEMA; MRI; SPECTROSCOPY; METABOLISM; MECHANISMS; LACTATE; STROKE	Diffusion-, perfusion-, T-1-, and T-2-weighted magnetic resonance imaging (MRI) were performed at 1-2 h, 24 h, and 1 week following closed head injury (CHI) in rats, and data was compared with hematoxylin and eosin histology, At 1-2 h, large areas of low perfusion in the damaged hemisphere overestimate the histological damage, In the first 2 h, the histological damage seems to be a superposition of abnormalities in the T1- and diffusion-weighted images, In areas with more than 10% reduction in the apparent diffusion coefficients (ADCs), reduced regional cerebral blood volume (r-CBV) was also observed. The decrease in ADCs and rCBV correlated with r = 0.78. Changes in the MRI parameters revealed the following: (a) Further reduction in ADC occurred from 83 +/- 15% at 1-2 h after trauma to 69 +/- 9% at 24 h, and 1 week later a marked elevation in the ADC values is observed. (b) Blood perfusion measurements performed 1-2 h posttrauma revealed a pronounced reduction in r-CBV (53 +/- 18%) in the damaged hemisphere in all rats, At 24 h postimpact, areas of hyper- and hypoperfusion were observed, One week later, similar perfusion was found in both hemispheres of all rats, (c) T-2 hyperintensity at 24 h overestimated the histological damage found at 1 week. At one week following the trauma, the T-2 hyperintensity underestimated the histological damage. It is concluded that CHI, which is a heterogeneous insult, should be studied by a combination of MRI techniques, The superposition of the abnormalities seen on T-1 and on the diffusion-weighted MR images at early time point represents best the histological damage. Both T-2 and rCBV images are less informative in terms of actual histological damage.	Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, IL-69978 Tel Aviv, Israel; Kaplan Hosp, Dept Anesthesiol, IL-76100 Rehovot, Israel; Soroka Med Hosp, Dept Anesthesiol, Beer Sheva, Israel; Hadassah Univ Hosp, Human Biol Res Ctr, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Cohen, Y (corresponding author), Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, IL-69978 Tel Aviv, Israel.	ycohen@ccsg.tau.ac.il		assaf, yaniv/0000-0001-6828-7595			Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRANTZAWADZKI M, 1987, AM J ROENTGENOL, V148, P579, DOI 10.2214/ajr.148.3.579; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; DECANNIERE C, 1995, MAGNET RESON MED, V34, P343, DOI 10.1002/mrm.1910340311; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRAHM J, 1986, MAGNET RESON MED, V3, P321, DOI 10.1002/mrm.1910030217; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gomori J M, 1988, Radiographics, V8, P427; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOSSMANN KA, 1995, CEREBROVAS BRAIN MET, V7, P187; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Le Bihan D, 1995, DIFFUSION PERFUSION; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1981, BRAIN EDEMA, P99; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Pierce AR, 1997, J CEREBR BLOOD F MET, V17, P183, DOI 10.1097/00004647-199702000-00008; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; STARK DD, 1992, MAGNETIC RESONANCE I; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983	36	52	52	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1165	1176		10.1089/neu.1999.16.1165			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400004	10619195				2021-06-18	
J	McMahon, CG; Yates, DW; Campbell, FM; Hollis, S; Woodford, M				McMahon, CG; Yates, DW; Campbell, FM; Hollis, S; Woodford, M			Unexpected contribution of moderate traumatic brain injury to death after major trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEMORRHAGIC-SHOCK; SEVERITY SCORE; CARE; SUPPRESSION; ENGLAND; ALCOHOL; RATS	Background: The cardiovascular reflex responses to injury and simple hemorrhage are coordinated in the central nervous system. Coincidental brain injury, which is present in 64% of trauma patients who die, could impair these homeostatic responses. The occurrence of hemorrhagic shock in the patient with head injury is also known to increase mortality. Therefore, there is a potential bidirectional interaction between traumatic brain injury and peripheral injury, which would result in an increased mortality when these two injuries coexist. Our objective was to test the hypothesis that moderate traumatic brain injury is an independent predictor of outcome in patients with multisystem trauma. Methods: We carried out an analysis of the UK Trauma Audit and Research Network Database. Moderate traumatic brain injury was defined as an Abbreviated Injury Scale score of 3, The study population included 2,717 patients with multisystem injury: 378 patients had a moderate brain injury with peripheral injury, and 2,339 patients had extracranial injury alone, Mortality rates for both groups were compared at increasing injury severity. Results: Moderate brain injury alone was associated with a mortality rate of 4.2%. However, when combined with extracranial injury, the risk of death was double that attributable to extracranial injury alone (odds ratio, 2.08; 95% confidence interval, 1.57-2.77). Conclusion: This study confirms that the coexistence of moderate traumatic brain injury with extracranial injury is associated with a doubling of the predicted mortality rate throughout the injury severity ranges studied.	Univ Lancaster, Lancaster LA1 4YW, England; Univ Manchester, Hope Hosp, Salford M6 8HD, Lancs, England	McMahon, CG (corresponding author), Univ Manchester, Hope Hosp, Clin Sci Bldg, Salford M6 8HD, Lancs, England.		McMahon, C Geraldine/M-8684-2019	McMahon, C Geraldine/0000-0002-9870-3104			ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; ANDERSON ID, 1990, J TRAUMA, V30, P974, DOI 10.1097/00005373-199008000-00005; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barcroft H, 1944, LANCET, V1, P489; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULL JP, 1991, INJURY, V21, P127; Campbell FM, 1996, THESIS U MANCHESTER; FLAMM ES, 1977, J TRAUMA, V47, P328; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; HOLLIS S, 1995, J TRAUMA, V38, P766; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; MCMAHON G, 1997, J ACCID EMERG MED, V14, P130; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; *ROYAL COLL SURG E, 1988, MAN PAT MAJ INJ REP; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; *SPSS, 1996, STAT PACK SOC SCI WI; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; YATES DW, 1987, J ROY SOC MED, V80, P486, DOI 10.1177/014107688708000810; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	23	52	55	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	1999	47	5					891	895		10.1097/00005373-199911000-00013			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	254QM	WOS:000083623700013	10568718				2021-06-18	
J	Allen, JW; Knoblach, SM; Faden, AI				Allen, JW; Knoblach, SM; Faden, AI			Combined mechanical trauma and metabolic impairment in vitro induces NMDA receptor-dependent neuronal cell death and caspase-3-dependent apoptosis	FASEB JOURNAL			English	Article						neuronal injury; ischemia; caspases; 3-nitropropionic acid	BRAIN INJURY; 3-NITROPROPIONIC ACID; CEREBRAL-ISCHEMIA; CASPASE-3-LIKE PROTEASE; IN-VITRO; MODEL; ACTIVATION; CULTURES; RAT; INHIBITION	Neuronal necrosis and apoptosis occur after traumatic brain injury (TBI) in animals and contribute to subsequent neurological deficits. In contrast, relatively little apoptosis is found after mechanical injury in vitro, Because in vivo trauma models and clinical head injury have associated cerebral ischemia and/or metabolic impairment, we transiently impaired cellular metabolism after mechanical trauma of neuronal-glial cultures by combining 5-nitropropionic acid treatment with concurrent glucose deprivation, This produced greater neuronal cell death than mechanical trauma alone. Such injury was attenuated by the NMDA receptor antagonist dizocilpine (MK801), In addition, this injury significantly increased the number of apoptotic cells over that accruing from mechanical injury alone. This apoptotic cell. death was accompanied by DNA fragmentation, attenuated by cycloheximide, and associated with an increase in caspase-3-like but not caspase-1-like activity, Cell death was reduced by the pan-caspase inhibitor BAF or the caspase-3 selective inhibitor z-DEVD-fmk, whereas the caspase-1 selective inhibitor z-YVAD-fmk had no effect; z-DEVD-fmk also reduced the number of apoptotic cells after combined injury. Moreover, cotreatment with MK801 and BAF resulted in greater neuroprotection than either drug alone. Thus, in vitro trauma with concurrent metabolic inhibition parallels in vivo TBI, showing both NMDA-sensitive necrosis and caspase-3-dependent apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA	Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arden S. R., 1997, Society for Neuroscience Abstracts, V23, P2294; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CIESLA Z, 1974, MOL GEN GENET, V135, P339, DOI 10.1007/BF00271148; Clark R. S. B., 1998, Society for Neuroscience Abstracts, V24, P251; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HASSEL B, 1995, J NEUROCHEM, V65, P1184; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MIRSA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1998, J NEUROCHEM, V71, P186; Pang Z, 1997, J NEUROSCI, V17, P3064; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; RINK A, 1995, AM J PATHOL, V147, P1575; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIEGEL JH, 1995, TRAUMATIC BRAIN INJU, P85; Sonnewald U, 1996, NEUROCHEM RES, V21, P987, DOI 10.1007/BF02532408; Varming T, 1996, J NEUROSCI RES, V44, P40, DOI 10.1002/(SICI)1097-4547(19960401)44:1<40::AID-JNR5>3.0.CO;2-I; VERITY MA, 1991, MOL CHEM NEUROPATHOL, V15, P217; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	52	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1875	1882					8	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	WOS:000083063400024	10506592				2021-06-18	
J	Leker, RR; Shohami, E; Abramsky, O; Ovadia, H				Leker, RR; Shohami, E; Abramsky, O; Ovadia, H			Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						stroke; ischemia; dexanabinol; TNF alpha; nitric oxide synthase	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; BRAIN INJURY; NITRIC-OXIDE; FACTOR-ALPHA; TNF-ALPHA; HU-211; RATS; INFLAMMATION; ANTAGONIST	The permanent middle cerebral artery occlusion (PMCAO) model was used to investigate the cerebroprotective effects of the synthetic cannabinoid, dexanabinol (HU-211). Dexanabinol is a noncompetitive N-methyl-D-aspartate antagonist, with antioxidant and anti-TNF alpha properties. Twenty hypertensive rats were subjected to PMCAO. Eight were given 4 mg/kg dexanabinol, i.v., 1 h after PMCAO, eight received vehicle and four were not injected. Five rats underwent sham surgery. Infaret volumes were assessed, as well as TNF alpha oconcentrations and NOS activity in brain homogenates. Dexanabinol significantly decreased infarct volumes. It also significantly lowered TNFa levels in the ipsilateral hemisphere although not to the level of sham operated rats. No effect could be demonstrated on NOS activity. In conclusion, dexanabinol may be a pluripotent cerebroprotective agent. (C) 1999 Elsevier Science B.V. All rights reserved.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Leker, RR (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Neurol, IL-91010 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334			Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BELAYEV L, 1995, MOL CHEM NEUROPATHOL, V25, P19, DOI 10.1007/BF02815084; Biegon A, 1995, Ann N Y Acad Sci, V765, P314, DOI 10.1111/j.1749-6632.1995.tb16597.x; BIEGON A, 1997, J NEUROTRAUM, V17, P758; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; BUCE AJ, 1997, NATURE MED, V7, P788; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Dalkara T, 1997, INT REV NEUROBIOL, V40, P319; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Margaill I, 1997, BRIT J PHARMACOL, V120, P160, DOI 10.1038/sj.bjp.0700889; MCCULLOCH J, 1994, J NEURAL TRANSM-SUPP, P71; Meistrell ME, 1997, SHOCK, V8, P341; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Olesen SP, 1997, ACTA NEUROL SCAND, V95, P219, DOI 10.1111/j.1600-0404.1997.tb00102.x; Sadoshima S, 1997, BRAIN RES, V744, P246, DOI 10.1016/S0006-8993(96)01063-3; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; WITYK RJ, 1994, CRIT CARE MED, V22, P1278, DOI 10.1097/00003246-199408000-00012; ZHAI QH, 1997, J NEUROL SCI, V152, P1119	29	52	57	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JAN 15	1999	162	2					114	119		10.1016/S0022-510X(98)00301-3			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	177UB	WOS:000079228500002	10202976				2021-06-18	
J	Joashi, UC; Greenwood, K; Taylor, DL; Kozma, M; Mazarakis, ND; Edwards, AD; Mehmet, H				Joashi, UC; Greenwood, K; Taylor, DL; Kozma, M; Mazarakis, ND; Edwards, AD; Mehmet, H			Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; brain; caspase; diaschisis; hypoxia; ischaemia	ISCHEMIC BRAIN INJURY; INTERLEUKIN-1-BETA CONVERTING-ENZYME; APOPTOTIC CELL-DEATH; HYPOXIA-ISCHEMIA; MAGNETIC-RESONANCE; CEREBRAL-ISCHEMIA; INFANT RAT; INHIBITION; ACTIVATION; DIASCHISIS	Transient unilateral forebrain hypoxia-ischaemia (HI) in 14-day-old rats produces infarction and delayed neuronal death in the frontal cortex. Cell death can also be observed in regions distant from the primary injury, a phenomenon known as diaschisis. While apoptosis is involved in selective neuronal death, its role in infarction and diaschisis remains poorly understood, Here, we have investigated the proteolytic cleavage of poly(ADP ribose) polymerase (PARP) and the occurrence of apoptosis in the hippocampus and the cerebellum following either HI or traumatic brain injury. We demonstrate that: (i) in vitro, PARP is cleaved during apoptosis but not necrosis in cultured neuronal (N1E) cells and Swiss 3T3 fibroblasts; (ii) following HI, apoptotic cells can be detected by 4h after injury in the hippocampus; (iii) in the ipsilateral hippocampus the appearance of cells with apoptotic morphology is preceded by a dramatic increase in PARR cleavage in the same region, starting immediately following HI and persisting for 24 h; (iv) HI also induces apoptosis in the cerebellum and, as in the hippocampus, the appearance of cells with apoptotic morphology is preceded by PARP cleavage that is greater on the side Ipsilateral to forebrain injury; and (v) similarly, traumatic brain injury to the forebrain leads to PARR cleavage and apoptosis in the cerebellum. We conclude that HI injury or traumatic injury to the developing rat forebrain leads to PARP cleavage in directly affected areas and in sites distant from the primary injury that precedes the appearance of cells with apoptotic morphology. Our results are consistent with a role for apoptotic cell death in infarction and in diaschisis resulting from forebrain injury to the developing brain.	Hammersmith Hosp, Imperial Coll, Sch Med, Weston Lab,Div Paediat Obstet & Gynaecol, London W12 0NN, England	Mehmet, H (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Weston Lab,Div Paediat Obstet & Gynaecol, Du Cane Rd, London W12 0NN, England.	hmehmet@rpms.ac.uk		Edwards, Anthony David/0000-0003-4801-7066	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ANSARI B, 1993, J PATHOL, V179, P1; Beilharz Erica J., 1995, Molecular Brain Research, V29, P1, DOI 10.1016/0169-328X(94)00217-3; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Edwards AD, 1997, PEDIATR RES, V42, P684, DOI 10.1203/00006450-199711000-00022; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Evan Gerard I., 1994, Trends in Cell Biology, V4, P191, DOI 10.1016/0962-8924(94)90134-1; FERRER I, 1994, BRAIN PATHOL, V4, P115, DOI 10.1111/j.1750-3639.1994.tb00821.x; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; FUKUDA K, 1993, AM J PATHOL, V142, P935; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; GOTO K, 1990, BRAIN RES, V534, P299, DOI 10.1016/0006-8993(90)90144-Z; HAMANO S, 1993, PEDIATR NEUROL, V9, P435, DOI 10.1016/0887-8994(93)90022-5; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada J, 1997, BRAIN RES, V753, P251, DOI 10.1016/S0006-8993(97)00011-5; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HOCKENBERY D, 1995, AM J PATHOL, V146, P16; INFELD B, 1995, STROKE, V26, P90, DOI 10.1161/01.STR.26.1.90; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; LI Y, 1995, AM J PATHOL, V146, P1045; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARLANGUE CC, 1996, J CEREB BLOOD FLOW M, V16, P186; MAZARAKIS ND, 1997, ARCH DIS CHILD, V77, P165; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MEHMET H, 1994, NEUROSCI LETT, V181, P121, DOI 10.1016/0304-3940(94)90574-6; MEYER JS, 1993, NEUROL RES, V15, P362; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROSENBAUM DM, 1994, ANN NEUROL, V36, P864, DOI 10.1002/ana.410360610; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Smolders I, 1997, EUR J PHARMACOL, V319, P21, DOI 10.1016/S0014-2999(96)00830-8; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.ne.15.030192.002155; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; WILLIAMS CE, 1992, ANN NEUROL, V31, P14, DOI 10.1002/ana.410310104; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; WYLLIE AH, 1992, OXFORD TXB PATHOLOGY, P141	50	52	54	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JAN	1999	11	1					91	100		10.1046/j.1460-9568.1999.00409.x			10	Neurosciences	Neurosciences & Neurology	155NY	WOS:000077954300009	9987014				2021-06-18	
J	Mahalick, DM; Carmel, PW; Greenberg, JP; Molofsky, W; Brown, JA; Heary, RF; Marks, D; Zampella, E; Hodosh, R; von der Schmidt, E				Mahalick, DM; Carmel, PW; Greenberg, JP; Molofsky, W; Brown, JA; Heary, RF; Marks, D; Zampella, E; Hodosh, R; von der Schmidt, E			Psychopharmacologic treatment of acquired attention disorders in children with brain injury	PEDIATRIC NEUROSURGERY			English	Article						attention; children; traumatic brain injury; head injury; closed head injury; psychostimulant; ritalin; methylphenidate; neuropsychological assessment	CLOSED-HEAD-INJURY; ADOLESCENTS; DEFICIT	This investigation examined the efficacy of psychostimulant therapy in alleviating neurobehavioral dysfunction attendant to pediatric brain injury. The most commonly reported neurobehavioral sequelae associated with head injury in the pediatric population involve deficits along the attentional matrix. This is also the most common objectively documented neurobehavioral finding among children as well as adults. There are several investigations in the adult literature which have employed the use of psychostimulants in treating both psychiatric and neuropsychological residua associated with head injury. Overall, the results of these studies are equivocal, but suggest a beneficial impact on general functioning. The present prospective investigation utilized a double-blind, placebo-controlled, cross-over experimental design to examine the efficacy of methylphenidate in treating children with acquired attentional disorders secondary to brain injury. A cohort of 14 children with varying degrees of head injury were recruited for participation. As expected, differences between drug and placebo conditions uniformly achieved statistical significance, Additionally, there were no differences in performance between baseline and placebo conditions on neurobehavioral tasks of attention and concentration. Current findings suggest that methylphenidate (and probably other psychostimulants such as Cylert, Adderal, Wellbutrin and dextroamphetamine sulfate) is an extremely effective agent in treating attentional disorders secondary to brain injury in children.	UMDNJ, Dept Surg, Neurosurg Sect, Sch Med, Newark, NJ USA; UMDNJ, Dept Psychiat, Sch Med, Newark, NJ USA; UMDNJ, Dept Pediat, Sch Med, Newark, NJ USA; UMDNJ, Dept Neurosci, Sch Med, Newark, NJ USA; Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ USA; Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ USA; Robert Wood Johnson Med Sch, Dept Surg Neurosurg, New Brunswick, NJ USA; Neurobehav Inst NJ, Somerville, NJ USA; Beth Israel Hosp, New York, NY USA	Mahalick, DM (corresponding author), Univ Med & Dent New Jersey, Sch Med, Div Neurol Surg, Doctors Off Ctr, 90 Bergen St,Suite 7300, Newark, NJ 07103 USA.						ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, V3, P219; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DOUGLAS VI, 1995, J AM ACAD CHILD PSY, V34, P877, DOI 10.1097/00004583-199507000-00011; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; GORDON M, 1982, GORDON DIAGNOSTIC SY; GORDON M, 1983, UNPUB ASSESSMENT ADD; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Luria A. R., 1966, HIGHER CORTICAL FUNC; MAHALICK DM, 1996, TRAUMA, V38, P39; MESULAM MM, 1985, PRINCIPLES BEHAVIORA, P1; MESULAM MM, 1985, PRINCIPLES BEHAV NEU, P124; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; Woodcock R. W., 1990, WOODCOCK JOHNSON PSY	27	52	52	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	SEP	1998	29	3					121	126		10.1159/000028705			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	148RD	WOS:000077545000004	9838263				2021-06-18	
